{
  "analysis_mode": "HISTORICAL_ONLY",
  "symbol": "AVCT.L",
  "generated_at": "2026-02-12T21:57:56.725965Z",
  "top_card": {
    "ticker": "AVCT.L",
    "company_name": "Avacta Group Plc",
    "sector": "Healthcare",
    "market_cap_gbp": 256015415,
    "days_active": 1459,
    "apex_score_100": 61,
    "confidence_score_100": 50,
    "ai_final_score_25": 11,
    "ai_strength": "MODERATE",
    "timing_regime": "EARLY_BUILD",
    "action": "WATCH",
    "thesis_one_liner": "WATCH - EARLY_BUILD timing with 61/100 opportunity score"
  },
  "enrichment": {
    "company_info": {
      "name": "Avacta Group Plc",
      "sector": "Healthcare",
      "industry": "Biotechnology",
      "exchange": "LSE",
      "market": "AIM",
      "currency": "GBP",
      "risk_tier": "High Risk",
      "current_market_cap": 256015415,
      "current_close_price": 58.5
    },
    "basics": {
      "ticker": "AVCT.L",
      "current_price": 58.5,
      "ath": 291.7038,
      "atl": 12.6128,
      "ath_date": "2021-04-20",
      "atl_date": "2020-03-17",
      "week_52_high": 84.0,
      "week_52_low": 26.0,
      "week_52_high_date": "2025-12-17",
      "week_52_low_date": "2025-05-27",
      "drawdown_from_ath_pct": 79.95,
      "data_start": "2020-01-02",
      "data_end": "2026-02-12",
      "total_bars": 1545
    },
    "latest_signal": {
      "date": "2022-02-14",
      "scan_date": "2026-01-26",
      "signal_type": "CRASH ZONE BOTTOM",
      "signal_color": "YELLOW",
      "price": 50.9832,
      "drawdown_pct": 82.52,
      "ai_score": 9.0,
      "rsi": 35.6,
      "cycle_position": 0.0118,
      "holding_period_days": 1459,
      "current_pnl_pct": 14.74,
      "rally_state": "pulling_back",
      "distance_from_high_pct": -71.3,
      "Rally_Count": 8,
      "days_since_last_high": 20,
      "last_high_date": "2026-01-06",
      "lock_in_reached": true,
      "lock_in_date": "2023-02-08",
      "best_rally_pct": 262.86
    },
    "best_historical_signal": {
      "signal_date": "2022-02-14",
      "signal_type": "CRASH ZONE BOTTOM",
      "signal_color": "YELLOW",
      "entry_price": 50.9832,
      "peak_price": 187.98,
      "peak_date": "2023-02-08",
      "rally_pct": 268.71,
      "days_to_peak": 359,
      "ai_score": 9.0
    },
    "all_historical_signals": [
      {
        "signal_id": "AVCT.L_2022-02-14",
        "signal_date": "2022-02-14",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 50.9832,
        "current_price": 53.0877,
        "current_return_pct": 4.13,
        "best_rally_pct": 262.86,
        "best_rally_date": "2023-02-08",
        "rally_state": "pulling_back",
        "Rally_Count": 8,
        "distance_from_high_pct": -71.3,
        "days_since_last_high": 20,
        "lock_in_reached": true,
        "age_days": 1442,
        "status": "historical"
      }
    ],
    "stats": {
      "total_signals": 1,
      "win_rate_pct": 100.0,
      "avg_rally_pct": 268.71,
      "median_rally_pct": 268.71,
      "best_rally_pct": 268.71,
      "worst_rally_pct": 268.71
    },
    "splits": [],
    "split_risk": {
      "split_detected": false,
      "risk_level": "NONE",
      "confidence": "HIGH"
    },
    "data_quality": {
      "price_reliability": "RELIABLE",
      "pnl_reliability": "RELIABLE",
      "overall_confidence": "HIGH"
    },
    "risk_flags": [],
    "last_updated": "2026-02-12 20:04:26 UTC",
    "volatility": {
      "atr_normalized": 6.43,
      "stddev_20d": 1.0397
    },
    "trends": {
      "intelligence_signal": "DOWNTREND"
    }
  },
  "decision_summary": {
    "why_it_matters": [
      "APEX 61/100 indicates strong opportunity quality",
      "Timing regime: EARLY_BUILD",
      "Historical profile: 8 rallies, 263% best run"
    ],
    "main_risk": "Confidence 50/100 - full data loaded",
    "watch_next": [
      "RNS catalysts (funding/operational updates)",
      "Volume expansion confirmation",
      "Timing regime change signals"
    ]
  },
  "triangulation": {
    "rns": {
      "has_data": true,
      "ticker": "AVCT.L",
      "latest": [
        {
          "title": "Appointment of CSO",
          "announcement_date": "9th Feb 2026",
          "release_time": "7:00 am",
          "source": "RNS",
          "content": "9 Feb 2026 07:00\nRNS Number : 1433S\nAvacta Group PLC\n09 February 2026\nAvacta appoints Francis Wilson as Chief Scientific Officer\nLONDON and PHILADELPHIA\n- February 9, 2026 - Avacta Therapeutics (AIM: AVCT, \"the Company\", \"Avacta\"), a clinical stage biopharmaceutical company developing pre|CISION\u00ae,\u00a0a tumor-activated oncology delivery platform, has appointed Francis Wilson as its Chief Scientific Officer.\nSince joining Avacta in September 2022 as Vice President of Chemistry, Francis has demonstrated his extensive expertise and experience in the chemistry field, particularly in the development of the Company's pre|CISION\u00ae platform. Francis has been instrumental in the development of novel intellectual property around the pre|CISION\u00ae mechanism, notably the sustained release mechanism that forms the backbone of the FAP-Exd (AVA6103) program that is anticipated to begin clinical testing in the near term. He has also established himself as an industry leader in medicinal chemistry, a valued external speaker for the Company, and a strong team leader within the Avacta organization.\nBefore Avacta, Francis held various positions across the medicinal chemistry sector, including being a Research Scientist at Roche Discovery Welwyn from 1990-2001, Head of Chemistry at Xenova (2001-2003), Director of Chemistry at Cellzome (2003-2007) and Director of Chemistry at Summit Therapeutics (2007-2022) where he led multiple programs from discovery into clinical development.\nFrancis has a chemistry degree and holds a Doctor of Philosophy degree from Oxford University and is a Chartered Chemist and Fellow of the Royal Society of Chemistry.\nAlong with this leadership change, former CSO Michelle Morrow will be leaving Avacta to pursue another opportunity. The Company thanks her for her contributions and wishes her success in the future.\nChristina Coughlin, CEO of Avacta Therapeutics commented,\n\"\nFrancis is the ideal person to take us forward, both internally and across our industry, given his deep knowledge of the working of our unique pre|CISION\n\u00ae\nplatform. Francis has demonstrated his keen ability to foster an environment of innovation, and this has been instrumental in developing significant advances in the options for our pre|CISION\n\u00ae\nplatform to be used in the clinic. As Avacta enters a period of potentially significant preclinical development and intellectual property generation, we look forward to leveraging Francis' expertise and leadership in the drug development arena.\"\n\"In addition to his leadership internally, he has also been a key member of the team positioning our business across the international drug development sector. Francis is a well-known leader in medicinal chemistry externally and we are looking forward to forging the next chapter of pre|CISION\n\u00ae\nwith his scientific leadership and expertise. We also extend our well wishes to Michelle in the next chapter of her career and thank her for her contributions to Avacta.\"\nFrancis Wilson, CSO of Avacta added:\n\"I am thrilled to step into this role and look forward to partnering with Chris and the Management Team to move Avacta forward to our next chapter. Seeing AVA6103 - the molecule we invented - move to the clinic is a huge success for the Company. We will learn more about this program in the clinic and apply that as we continue to develop novel intellectual property around our highly successful pre|CISION\n\u00ae\nplatform.\"\n-Ends-\nFor further information from Avacta, please contact:\nAvacta Group plc\nChristina Coughlin, Chief Executive Officer\nhttps://avacta.com/\nvia Cohesion Bureau\nStrand Hanson Limited (Nominated Adviser)\nJames Harris / Chris Raggett / James Dance\nwww.strandhanson.co.uk\nZeus (Broker)\nJames Hornigold / George Duxberry / Dominic King\nwww.zeuscapital.co.uk\nCohesion Bureau (Communications)\nRichard Jarvis / Chris Maggos\navacta@cohesionbureau.com\nAbout Avacta\n-\nhttps://avacta.com/\nAvacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION\u00ae platform. pre|CISION\u00ae is a proprietary payload delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate highly potent payloads in the tumor microenvironment while sparing normal tissues.\nOur innovative pipeline consists of pre|CISION\u00ae peptide drug conjugates (PDC) or Affimer\u00ae drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates.\nThe pre|CISION\u00ae platform comprises an anticancer payload conjugated to a proprietary peptide that is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The pre|CISION\u00ae platform harnesses this tumor specific protease to cleave pre|CISION\u00ae peptide drug conjugates and pre|CISION\u00ae antibody/Affimer\u00ae drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity, allowing dosing to be optimized to deliver the best outcomes for patients.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nBOAFLFFRFIITIIR",
          "rns_number": "RNS Number : 1433S"
        },
        {
          "title": "Faridoxorubicin Program Clinical Updates",
          "announcement_date": "3rd Feb 2026",
          "release_time": "7:00 am",
          "source": "RNS",
          "content": "3 Feb 2026 07:00\nRNS Number : 4824R\nAvacta Group PLC\n03 February 2026\nAvacta announces two key clinical updates to its faridoxorubicin program\nCardiac dosing limit removed and path forward to dose selection identified\nLONDON and PHILADELPHIA\n- February 3, 2026 - Avacta Therapeutics (AIM: AVCT, \"the Company\", \"Avacta\"), a clinical stage biopharmaceutical company developing pre|CISION\u00ae,\u00a0a tumor-activated oncology delivery platform, has published two key clinical updates to its faridoxorubicin (AVA6000) clinical program.\nAgreed updates to the trial protocol include the removal of the maximum dosing limit and to allow flexibility in dosing levels. These two developments underscore the growing confidence from investigators and regulators in the tolerability profile of faridoxorubicin and should support a smooth transition to future efficacy studies.\nThe historic maximum dosing limit which is based on the patient's exposure to released (free) doxorubicin, has been removed in the clinical trial following the collection of highly favorable safety data from the faridoxorubicin program and observation of patients receiving the highest cumulative doses for prolonged periods. Dosing in the Phase 1 clinical trial escalated to a dose of nearly 4x the conventional dose of doxorubicin and the maximum cumulative exposure of released doxorubicin was increased to 550 mg/m2 during the trial with no severe cardiac toxicity observed.\nOne of the key advantages of the pre|CISION\u00ae platform is that its unique delivery mechanism allows patients to receive the drug for longer and at higher doses due to improved tolerability, with the potential to extend the progression free survival endpoint in trials.\nThe Company's second significant update relates to the determination of the dose for the study in efficacy trials. The final cohorts of patients with the selected indications in Phase 1b will be enrolled, enabling two dose levels to be compared in order to determine the optimal biologic dose in future trials.\nUpdates to the clinical program will appear in the National Library of Medicine's clinicaltrials.gov entry for Faridoxorubicin (AVA6000) under the trial designation, ID Number NCT04969835.\nChristina Coughlin, CEO of Avacta Therapeutics commented,\n\"These two critical steps in the development of our faridoxorubicin (AVA6000) program and by extension the proprietary pre|CISION\u00ae platform demonstrate growing recognition by regulators of the safety of this platform.\n\"Highly favorable cardiac safety data for faridoxorubicin enable patients to be treated longer, as opposed to stopping the drug for a theoretical risk of cardiac toxicity which is the usual practice with doxorubicin therapy. Despite dosing to nearly 4x the standard dose of doxorubicin as well as to a higher lifetime maximum exposure, we have not seen a single case of severe cardiac toxicity.\nFurthermore, identifying the path forward to the selection of the optimal biologic dose will enable a smooth transition to efficacy studies with faridoxorubicin program and allows the Company to implement these approaches in the platform currently in Phase 1b, facilitating the development across pre|CISION\u00ae medicines.\"\n-Ends-\nFor further information from Avacta, please contact:\nAvacta Group plc\nChristina Coughlin, Chief Executive Officer\nhttps://avacta.com/\nvia ICR Healthcare\nStrand Hanson Limited (Nominated Adviser)\nJames Harris / Chris Raggett / James Dance\nwww.strandhanson.co.uk\nZeus (Broker)\nJames Hornigold / George Duxberry / Dominic King\nwww.zeuscapital.co.uk\nICR Healthcare\nMary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert\navacta@icrhealthcare.com\nInvestor Contact\nRenee Leck\nTHRUST Strategic Communications\nrenee@thrustsc.com\nMedia Contact\nCarly Scaduto\nTHRUST Strategic Communications\ncarly@thrustsc.com\nAbout Avacta\n-\nhttps://avacta.com/\nAvacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION\u00ae platform. pre|CISION\u00ae is a proprietary payload delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate highly potent payloads in the tumor microenvironment while sparing normal tissues.\nOur innovative pipeline consists of pre|CISION\u00ae peptide drug conjugates (PDC) or Affimer\u00ae drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates.\nThe pre|CISION\u00ae platform comprises an anticancer payload conjugated to a proprietary peptide that is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The pre|CISION\u00ae platform harnesses this tumor specific protease to cleave pre|CISION\u00ae peptide drug conjugates and pre|CISION\u00ae antibody/Affimer\u00ae drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity, allowing dosing to be optimized to deliver the best outcomes for patients.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nMSCGLGDDLBGDGLX",
          "rns_number": "RNS Number : 4824R"
        },
        {
          "title": "FDA Clearance of IND Application for AVA6103",
          "announcement_date": "21st Jan 2026",
          "release_time": "7:00 am",
          "source": "RNS",
          "content": "Today 07:00\nRNS Number : 6789P\nAvacta Group PLC\n21 January 2026\nAvacta Announces U.S. Food and Drug Administration Clearance of the Investigational New Drug (IND) Application for the Second pre|CISION\n\u00ae\nMedicine, FAP-Exatecan (AVA6103)\nThe Phase 1 clinical study of FAP-Exd (AVA6103) is anticipated to begin later in Q1 2026\nLONDON and PHILADELPHIA\n- January 21, 2026 - Avacta Therapeutics (AIM: AVCT, \"the Company\", \"Avacta\"), a clinical stage biopharmaceutical company developing pre|CISION\u00ae,\u00a0a\ntumor-activated oncology delivery platform, is pleased to announce U.S. Food and Drug Administration (FDA) clearance of the Investigational New Drug (IND) application for the Company's second program FAP-Exd (AVA6103), the first pre|CISION\u00ae peptide drug conjugate based on the highly potent topoisomerase I inhibitor, exatecan.\nThe IND approval is an important step in the development of AVA6103 as this is the point where the program moves from the lab into human testing. The Phase 1 clinical trial will evaluate the safety and potential efficacy of FAP-Exd and seek to identify a dose for further clinical development in patients with four solid tumors, pancreatic cancer, cervical cancer, gastric cancer and small cell lung cancer. The selection of these tumor types was based on an AI approach investigating a sensitivity marker for topoisomerase I inhibitors and FAP expression as part of the strategic collaboration with Tempus AI.\nAdult participants will be enrolled in the dose-escalation part of the trial with two parallel arms investigating two schedules of administration (every two weeks, Q2W and every three weeks, Q3W) with preliminary data from this trial anticipated in the second half of 2026.\nChristina Coughlin, MD, PhD,\nChief Executive Officer at Avacta Therapeutics commented,\n\"Taking FAP-Exd into the clinic is a critical milestone for the pre|CISION\n\u00ae\nplatform and for the Company. In moving the FAP-Exd program forward from inception to a cleared IND in just 24 months, our team has exceeded industry standard timelines. The sustained release mechanism of FAP-Exd, invented by Avacta, is expected to enable greater efficacy in the clinic while limiting the toxicities that were observed with exatecan in its original clinical development. We are very excited to move this program forward for patients and shareholders alike.\"\nDavid Liebowitz, MD, PhD,\nChief Medical Officer at Avacta Therapeutics added,\n\"Our FAP-Exd program in the clinic will very soon provide a greater understanding of the new chemistry of the pre|CISION\n\u00ae\nplatform and also validate the potential to move forward with varied payloads based on our novel capping group and linker technologies. This new program will support a greater understanding of our technology's broad applicability and validate our ability to design molecules that maximize the exposure of our payloads in the tumor in patients.\"\nAlexander Spira MD, PhD, FACP, FASCO,\nCo-Director, Virginia Cancer Specialists (VCS) Research Institute; Director, VCS Thoracic and Phase 1 Program; Chief Scientific Officer, NEXT Oncology; and Clinical Assistant Professor, Johns Hopkins also commented:\n\"I am thrilled to work with Avacta on this exciting new drug. The ability to concentrate a potent topoisomerase I inhibitor directly in the tumor while protecting normal tissues from harmful effects is the next stage of how we should be treating cancer. We are looking forward to participating in this second pre|CISION\n\u00ae\nPhase 1 trial and helping the Company to drive this pioneering technology forward.\"\n-Ends-\nFor further information from Avacta, please contact:\nAvacta Group plc\nChristina Coughlin, Chief Executive Officer\nhttps://avacta.com/\nvia ICR Healthcare\nStrand Hanson Limited (Nominated Adviser)\nJames Harris / Chris Raggett / James Dance\nwww.strandhanson.co.uk\nZeus (Broker)\nJames Hornigold / George Duxberry / Dominic King\nwww.zeuscapital.co.uk\nICR Healthcare\nMary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert\navacta@icrhealthcare.com\nInvestor Contact\nRenee Leck\nTHRUST Strategic Communications\nrenee@thrustsc.com\nMedia Contact\nCarly Scaduto\nCarly Scaduto Consulting\nCarly@carlyscadutoconsulting.com\nAbout Avacta\n-\nhttps://avacta.com/\nAvacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION\u00ae platform. pre|CISION\u00ae is a proprietary payload delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate highly potent payloads in the tumor microenvironment while sparing normal tissues.\nOur innovative pipeline consists of pre|CISION\u00ae peptide drug conjugates (PDC) or Affimer\u00ae drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates.\nThe pre|CISION\u00ae platform comprises an anticancer payload conjugated to a proprietary peptide that is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The pre|CISION\u00ae platform harnesses this tumor specific protease to cleave pre|CISION\u00ae peptide drug conjugates and pre|CISION\u00ae antibody/Affimer\u00ae drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity, allowing dosing to be optimized to deliver the best outcomes for patients.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nREABMMLTMTITBPF",
          "rns_number": "RNS Number : 6789P"
        },
        {
          "title": "Year-end trading update",
          "announcement_date": "20th Jan 2026",
          "release_time": "7:01 am",
          "source": "RNS",
          "content": "20 Jan 2026 07:01\nRNS Number : 5121P\nAvacta Group PLC\n20 January 2026\nAvacta Group plc\n(\"Avacta\", the \"Group\" or the \"Company\")\nYear-end trading update\nLONDON and PHILADELPHIA\n- January 20, 2026 - Avacta Therapeutics (AIM: AVCT), a clinical stage biopharmaceutical company developing pre|CISION\u00ae,\u00a0a tumor-activated oncology delivery platform, has published a trading update for the year ended December 31, 2025.\nThe Company made excellent progress during 2025, developing its unique industry-leading technology platform, pre|CISION\u00ae, with two programs anticipated to be in clinical development in 2026. The Company raised \u00a322.5m in equity during 2025 to support the investment in its programs.\nHighlights\nResearch and Development\n\u00b7\nFaridoxorubicin (AVA6000) program\no\nIn December 2025 Avacta reported highly encouraging efficacy and safety data from the cohort of patients enrolled with salivary gland cancer where a disease control rate of 90% is maintained in the full cohort (\nlink\n)\no\nProgram continued to enroll patients in the Phase 1b expansion cohorts, to assess the efficacy of faridoxorubicin in more homogenous, defined patient populations to better predict the magnitude of efficacy anticipated in larger Phase 2/3 trials.\n\u00b7\nFAP-Exd (AVA6103) program\no\nIn December 2025 Avacta reported new pharmacology data in support of the IND process and the design of the Phase 1 trial was published in parallel (\nlink\n)\no\nClinical testing expected to initiate in Q1 2026, subject to clearance by regulators. Multiple U.S. specialty oncology centers are expected to open with key investigators of different specialties to enroll the four selected tumor types: pancreatic cancer, gastric cancer, small cell lung cancer and cervical cancer.\n\u00b7\nIntellectual property (IP) portfolio continued to grow and gain momentum measured by increased IP filings. These include two important advances in the pre|CISION\u00ae IP estate:\no\nthe sustained release mechanism of payload delivery, piloted in the AVA6103 program, which is anticipated to begin clinical testing in Q1 2026;\no\nand the dual payload mechanism of delivery allowing the precise delivery of two payloads to the tumor with all of the benefits of the pre|CISION\u00ae technology.\nFinancial\n\u00b7\nThe Company successfully raised \u00a322.5m in new equity during 2025 from a broad range of existing and new investors to support R&D programs and also renegotiated the terms of the convertible bond (\nlink\n)\n\u00b7\nUnaudited cash and cash equivalents as of December 31, 2025: \u00a316.9m providing a runway into Q3 2026 supporting the planned spend on the Group's two clinical stage programs and preclinical pipeline to key value inflection points.\nOutlook for 2026\n\u00b7\nFaridoxorubicin (AVA6000) program. Multiple data updates in both patient groups, with salivary gland cancers and with triple negative breast cancer updates expected in H1 2026.\n\u00b7\nBeginning of the FAP-Exd (AVA6103) clinical testing expected in Q1 2026. A group of U.S. clinical trial specialty centers are expected to open imminently with key investigators of different specialties to enroll the four selected tumor types: pancreatic cancer, gastric cancer, small cell lung cancer and cervical cancer. Preliminary data from this trial is anticipated in the second half of 2026.\n\u00b7\nContinued active interaction with potential partners regarding both faridoxorubicin (AVA6000) and FAP-Exd (AVA6103). The survival data in the SGC indication continues to mature, allowing planning of the next stage of development with potential partners (\nlink\n). The initiation of the FAP-Exd clinical trial continues to be of interest in the market.\nChristina Coughlin MD, PhD, CEO of Avacta, commented\n:\n\"We gained real traction with our R&D programs, based on our unique industry leading technology, pre|CISION\u00ae, during 2025. There are no other technologies that can deliver cancer treatment drugs directly into the tumor at the concentrations that our payloads enable without causing highly toxic side effects.\n\"Our sustained release mechanism piloted in the FAP-Exd (AVA6103) program is anticipated to begin clinical testing this quarter, a significant milestone achievement, just 24 months after the beginning of the program. This program continues to garner significant interest from global pharmaceutical companies; however, the Company's strategy remains to retain 100% of AVA6103 until we begin to see readouts from the Phase 1a clinical trial. Importantly, the trial has been designed to rapidly deliver clinical data in this program.\n\"We are developing further IP around the pre|CISION\u00ae platform. Drug development isn't just about science, it is about strategy and protecting our innovation. Our IP estate is the most valuable asset we have. To further this IP estate, we also raised over \u00a322m to support our research and development programs, which gives us a runway into Q3 2026. These funds allow the Company to initiate the AVA6103 clinical trial and we anticipate the initial data in the AVA6103 program in the second half of 2026.\n\"The unique nature of the dual payload program is also generating interest and we are exploring opportunities with multiple potential partners with a view to investigating the wide utility of this novel technology.\n\"We continue to have multiple conversations with global pharmaceutical companies regarding our full pipeline. We are incredibly excited for the year ahead, which the board believes will be a transformative period for the Company, patients and our shareholders.\"\nOperational update\nFaridoxorubicin (AVA6000)\n\u00b7\nHighly encouraging data were presented last month describing the efficacy observed in the patients treated in the Phase 1b expansion cohort, which appears highly similar to the data observed in the Phase 1a patient population (\nlink\n).\n-\nThe larger numbers of patients treated in this cohort are important to inform the design and size of a subsequent trial in this indication. Importantly, the prolonged PFS observed in the Phase 1a cohort of patients indicates a prolonged PFS in the Phase 1b cohort.\n-\nAlthough these data can take time to collect, the Company is encouraged by the extended survival observations in the trial. Attention to this stage of development is designed to derisk later stages of clinical trials.\n\u00b7\nThe data in the Phase 1a portion of the trial were updated at ESMO (\nlink\n), where the PFS was reported as highly encouraging when compared with benchmark data in this indication. As the data in the Phase 1b expansion cohort are preliminary, the Company continues to collect the data. The estimates of the PFS and overall survival (OS) will be used to design the randomized study in this indication.\n\u00b7\nIn addition, the Company expects to release data in the TNBC cohort in H1 2026. Further development of faridoxorubicin will be undertaken subject to a partner being secured. The Company continues to engage with multiple partners as the data matures.\nFAP-Exd (AVA6103)\nRecent pharmacology data (\nlink\n) have been released demonstrating several key aspects of the FAP-Exd (AVA6103) program, including:\n\u00b7\nRobust efficacy in a broad range of patient-derived cancer models with deep complete responses observed with only three doses of FAP-Exd, even in settings of low FAP expression. In an encouraging parallel, the durability of the responses in the preclinical setting with FAP-Exd match those observed among patients with salivary gland cancers, treated with faridoxorubicin even in the setting of low FAP expression (\nlink\n).\n\u00b7\nTumor and plasma exposure studies have demonstrated that FAP-Exd rapidly penetrates the tumor microenvironment (TME), is held intact for over five days in the tumor and releases exatecan, with an observed high maximal concentration (Cmax) in the tumor within minutes and very low exposure in the bloodstream which is undetectable within two hours.\nThe FAP-Exd Phase 1 trial design has been released (\nlink\n) and includes the following aspects to optimize the execution of this study:\n\u00b7\nThe trial will enroll patients with a selected set of four cancer indications predicted by AI (in our strategic collaboration with Tempus AI) to be the most sensitive among solid tumor indications. These include pancreatic cancer, small cell lung cancer, gastric cancer and cervical cancer. Importantly, each of these four disease settings has a favorable regulatory path forward and the group includes both large tumor types as well as potential orphan indications.\n\u00b7\nClinical trial sites in the U.S. and the trial investigators have been selected based on their deep experience with these indications. The Company has enjoyed strong interest among clinical trial sites and investigators in the study.\n\u00b7\nThe trial design has two key features to optimize the rapid collection of data:\n-\nTwo independent arms investigating two schedules with every two weeks dosing (Q2W) and every three weeks dosing (Q3W) are anticipated to enroll in parallel, and;\n-\nThe trial will use the Bayesian Optimal Interval (BOIN) design, a modern statistical method for oncology Phase 1 trials. BOIN combines the simplicity of the traditional 3+3 enrollment method, where small groups of patients are treated at increasing doses, with efficient dose exploration and flexible enrollment into cohorts to optimize data collection over the course of the trial. This approach has been shown to enable the trial to handle complex findings and rapidly identify the optimal dose range.\nDual Payload Technology (AVA6207)\n\u00b7\nThe work in the AVA6103 program to better define the self-immolative linker technology led to the invention of the dual payload technology (\nlink\n). The dual payload platform is enabled by the insertion of two payload attachment points in the linker, ensuring the independent release of both payloads with a single FAP cleavage event.\n\u00b7\nThe release of two payloads in one pre|CISION\u00ae medicine has three key advantages:\n-\nCombination therapy is the mainstay of how patients are treated in oncology. The challenge is the toxicities with each individual drug. With a single pre|CISION\u00ae medicine, a simple monotherapy trial is needed and both payloads have the benefits of the pre|CISION\u00ae technology: concentration in the TME and minimal exposure in normal tissues.\n-\nThe release of dual payloads is accomplished without the need for a biologic arm (e.g. an antibody, Fc region or Affimer) which greatly simplifies the manufacturing of these medicines. Indeed, all pre|CISION\u00ae medicines are small molecules, meaning short and chemical-based manufacturing that is more cost-efficient than biologics.\n-\nBecause the size of the molecule is small, rapid and efficient tumor penetration of two payloads is anticipated based on the data presented with FAP-Exd, where tumor cells will see both payloads in parallel. The design of the first program combines a topoisomerase I inhibitor with a second payload that can overcome a key resistance mechanism, namely the DNA Damage Repair pathway (DDR). Preclinical data presented at the AACR-NCI-EORTC International Conference on Molecular Targets\u00a0and\u00a0Cancer Therapeutics\u00a0(October, 2025) demonstrates preliminary synergy of this combination (\nlink\n).\n\u00b7\nThe Company has committed to the selection of the payloads for the AVA6207 program in 2026.\nFinancial update\nThe Company raised \u00a322.5m in equity (gross) to support its investment programs during the year and also realized just over \u00a315m from the disposal of the non-core diagnostics businesses.\nThe Company renegotiated the terms of the convertible bond with the Quarterly Convertible Bond repayments and interest in January 2026 and April 2026 payment dates deferred until October 2027. In addition, the bondholder has the right to accelerate the satisfaction of the deferred repayments based on agreed conditions and the conversion price of the convertible bond is reset at 75.0p. All conditions of the bond renegotiation are reported here (\nlink\n).\nUnaudited cash and cash equivalents at as December 31, 2025, were \u00a316.9m, providing the Company with a runway into Q3 2026 to support its research and development activities.\n-Ends-\nFor further information from Avacta, please contact:\nAvacta Group plc\nChristina Coughlin, Chief Executive Officer\nhttps://avacta.com/\nvia ICR Healthcare\nStrand Hanson Limited (Nominated Adviser)\nJames Harris / Chris Raggett / James Dance\nwww.strandhanson.co.uk\nZeus (Broker)\nJames Hornigold / George Duxberry / Dominic King\nwww.zeuscapital.co.uk\nICR Healthcare\nMary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert\navacta@consilium-comms.com\nInvestor Contact\nRenee Leck\nTHRUST Strategic Communications\nrenee@thrustsc.com\nMedia Contact\nCarly Scaduto\nTHRUST Strategic Communications\ncarly@thrustsc.com\nAbout Avacta\n-\nwww.avacta.com\nAvacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION\u00ae platform. pre|CISION\u00ae is a proprietary payload delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate highly potent payloads in the tumor microenvironment while sparing normal tissues.\nOur innovative pipeline consists of pre|CISION\u00ae peptide drug conjugates (PDC) or Affimer\u00ae drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates.\nThe pre|CISION\u00ae platform comprises an anticancer payload conjugated to a proprietary peptide that is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The pre|CISION\u00ae platform harnesses this tumor specific protease to cleave pre|CISION\u00ae peptide drug conjugates and pre|CISION\u00ae antibody/Affimer\u00ae drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity, allowing dosing to be optimized to deliver the best outcomes for patients.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nTSTEAFFNFLEKEAA",
          "rns_number": "RNS Number : 5121P"
        },
        {
          "title": "Appointment of Nominated Adviser & TVR",
          "announcement_date": "20th Jan 2026",
          "release_time": "7:00 am",
          "source": "RNS",
          "content": "20 Jan 2026 07:00\nRNS Number : 5119P\nAvacta Group PLC\n20 January 2026\nAppointment of Nominated Adviser\nTotal Voting Rights Update\nLONDON and PHILADELPHIA\n- January 20, 2026 - Avacta Therapeutics (AIM: AVCT, \"the Company\", \"Avacta\"), a clinical stage biopharmaceutical company developing pre|CISION\u00ae,\u00a0a\ntumor-activated oncology delivery platform, announces the appointment of Strand Hanson Limited as the Company's Nominated Adviser, with immediate effect.\nCorrection to Total Voting Rights\nThe Company's issued ordinary share capital is 440,415,495 Ordinary Shares. This figure may be used by holders of Ordinary Shares as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.\nAdditional information is disclosed below under Schedule Two, paragraph (g) of the AIM Rules for Companies.\n-Ends-\nFor further information from Avacta, please contact:\nAvacta Group plc\nChristina Coughlin, Chief Executive Officer\nhttps://avacta.com/\nvia ICR Healthcare\nStrand Hanson Limited (Nominated Adviser)\nJames Harris / Chris Raggett / James Dance\nwww.strandhanson.co.uk\nZeus (Broker)\nJames Hornigold / George Duxberry / Dominic King\nwww.zeuscapital.co.uk\nICR Healthcare\nMary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert\navacta@consilium-comms.com\nInvestor Contact\nRenee Leck\nTHRUST Strategic Communications\nrenee@thrustsc.com\nMedia Contact\nCarly Scaduto\nTHRUST Strategic Communications\ncarly@thrustsc.com\nAIM Rule 17 Updates\nIn addition to the disclosures made in the announcement of Richard Hughes's appointment to the Board on 28 May 2025, Richard Hughes was:\nappointed a director of Trafford Finance Limited on 28 October 2009, a company incorporated in England and Wales. The company was placed into administration on 21 April 2010 and was subsequently dissolved on 19 September 2013, with an estimated \u00a35.4 million owed to creditors;\nappointed a director of Procurasell International (Packaging) Ltd on 30 October 2007, a company incorporated in England and Wales. The company was placed into administration on 8 January 2009 and was subsequently dissolved on 23 September 2010, with approximately \u00a30.1 million owing to creditors; and\nappointed a director of Holyrood Leisure Limited on 26 April 2007, a company incorporated in England and Wales. The company was placed into administration on 28 June 2018 and was subsequently dissolved on 25 February 2020, with approximately \u00a30.5 million owing to creditors.\nAbout Avacta\n-\nwww.avacta.com\nAvacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION\u00ae platform. pre|CISION\u00ae is a proprietary payload delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate highly potent payloads in the tumor microenvironment while sparing normal tissues.\nOur innovative pipeline consists of pre|CISION\u00ae peptide drug conjugates (PDC) or Affimer\u00ae drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates.\nThe pre|CISION\u00ae platform comprises an anticancer payload conjugated to a proprietary peptide that is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The pre|CISION\u00ae platform harnesses this tumor specific protease to cleave pre|CISION\u00ae peptide drug conjugates and pre|CISION\u00ae antibody/Affimer\u00ae drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity, allowing dosing to be optimized to deliver the best outcomes for patients.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nAPPFFFVLLDIALIR",
          "rns_number": "RNS Number : 5119P"
        }
      ],
      "themes": [
        "operations"
      ]
    },
    "social": {
      "has_data": true,
      "buzz_level": "HIGH",
      "post_count": 2703,
      "sentiment_breakdown": {
        "positive": 0.0,
        "neutral": 100.0,
        "negative": 0.0
      }
    },
    "trends": {
      "has_data": true,
      "current_interest": 0,
      "momentum_score": 0,
      "trend_direction": "flat",
      "intelligence_signal": "DOWNTREND"
    },
    "volatility": {
      "atr_normalized": 6.43,
      "stddev_20d": 1.0397
    },
    "risk_flags": {
      "split_risk_level": "NONE",
      "halt_risk": "NONE",
      "penny_stock_risk": "NONE"
    },
    "all_events": [
      {
        "event_id": "RNS-20th Jan 2026-year-end",
        "event_type": "rns_announcement",
        "date": "2026-01-21T03:29:59.777498Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Year-end trading update",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/AVCT/year-end-trading-update-63xrambu5i622u5.html",
          "rns_number": "RNS Number : 5121P",
          "full_content": "20 Jan 2026 07:01\nRNS Number : 5121P\nAvacta Group PLC\n20 January 2026\nAvacta Group plc\n(\"Avacta\", the \"Group\" or the \"Company\")\nYear-end trading update\nLONDON and PHILADELPHIA\n- January 20, 2026 - Avacta Therapeutics (AIM: AVCT), a clinical stage biopharmaceutical company developing pre|CISION\u00ae,\u00a0a tumor-activated oncology delivery platform, has published a trading update for the year ended December 31, 2025.\nThe Company made excellent progress during 2025, developing its unique industry-leading technology platform, pre|CISION\u00ae, with two programs anticipated to be in clinical development in 2026. The Company raised \u00a322.5m in equity during 2025 to support the investment in its programs.\nHighlights\nResearch and Development\n\u00b7\nFaridoxorubicin (AVA6000) program\no\nIn December 2025 Avacta reported highly encouraging efficacy and safety data from the cohort of patients enrolled with salivary gland cancer where a disease control rate of 90% is maintained in the full cohort (\nlink\n)\no\nProgram continued to enroll patients in the Phase 1b expansion cohorts, to assess the efficacy of faridoxorubicin in more homogenous, defined patient populations to better predict the magnitude of efficacy anticipated in larger Phase 2/3 trials.\n\u00b7\nFAP-Exd (AVA6103) program\no\nIn December 2025 Avacta reported new pharmacology data in support of the IND process and the design of the Phase 1 trial was published in parallel (\nlink\n)\no\nClinical testing expected to initiate in Q1 2026, subject to clearance by regulators. Multiple U.S. specialty oncology centers are expected to open with key investigators of different specialties to enroll the four selected tumor types: pancreatic cancer, gastric cancer, small cell lung cancer and cervical cancer.\n\u00b7\nIntellectual property (IP) portfolio continued to grow and gain momentum measured by increased IP filings. These include two important advances in the pre|CISION\u00ae IP estate:\no\nthe sustained release mechanism of payload delivery, piloted in the AVA6103 program, which is anticipated to begin clinical testing in Q1 2026;\no\nand the dual payload mechanism of delivery allowing the precise delivery of two payloads to the tumor with all of the benefits of the pre|CISION\u00ae technology.\nFinancial\n\u00b7\nThe Company successfully raised \u00a322.5m in new equity during 2025 from a broad range of existing and new investors to support R&D programs and also renegotiated the terms of the convertible bond (\nlink\n)\n\u00b7\nUnaudited cash and cash equivalents as of December 31, 2025: \u00a316.9m providing a runway into Q3 2026 supporting the planned spend on the Group's two clinical stage programs and preclinical pipeline to key value inflection points.\nOutlook for 2026\n\u00b7\nFaridoxorubicin (AVA6000) program. Multiple data updates in both patient groups, with salivary gland cancers and with triple negative breast cancer updates expected in H1 2026.\n\u00b7\nBeginning of the FAP-Exd (AVA6103) clinical testing expected in Q1 2026. A group of U.S. clinical trial specialty centers are expected to open imminently with key investigators of different specialties to enroll the four selected tumor types: pancreatic cancer, gastric cancer, small cell lung cancer and cervical cancer. Preliminary data from this trial is anticipated in the second half of 2026.\n\u00b7\nContinued active interaction with potential partners regarding both faridoxorubicin (AVA6000) and FAP-Exd (AVA6103). The survival data in the SGC indication continues to mature, allowing planning of the next stage of development with potential partners (\nlink\n). The initiation of the FAP-Exd clinical trial continues to be of interest in the market.\nChristina Coughlin MD, PhD, CEO of Avacta, commented\n:\n\"We gained real traction with our R&D programs, based on our unique industry leading technology, pre|CISION\u00ae, during 2025. There are no other technologies that can deliver cancer treatment drugs directly into the tumor at the concentrations that our payloads enable without causing highly toxic side effects.\n\"Our sustained release mechanism piloted in the FAP-Exd (AVA6103) program is anticipated to begin clinical testing this quarter, a significant milestone achievement, just 24 months after the beginning of the program. This program continues to garner significant interest from global pharmaceutical companies; however, the Company's strategy remains to retain 100% of AVA6103 until we begin to see readouts from the Phase 1a clinical trial. Importantly, the trial has been designed to rapidly deliver clinical data in this program.\n\"We are developing further IP around the pre|CISION\u00ae platform. Drug development isn't just about science, it is about strategy and protecting our innovation. Our IP estate is the most valuable asset we have. To further this IP estate, we also raised over \u00a322m to support our research and development programs, which gives us a runway into Q3 2026. These funds allow the Company to initiate the AVA6103 clinical trial and we anticipate the initial data in the AVA6103 program in the second ",
          "content_length": 14722
        },
        "ingested_at": "2026-01-21T03:29:59.777542Z"
      },
      {
        "event_id": "RNS-20th Jan 2026-appointm",
        "event_type": "rns_announcement",
        "date": "2026-01-21T03:29:59.777570Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Appointment of Nominated Adviser & TVR",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/AVCT/appointment-of-nominated-adviser-tvr-8ltrhg8tmlond3k.html",
          "rns_number": "RNS Number : 5119P",
          "full_content": "20 Jan 2026 07:00\nRNS Number : 5119P\nAvacta Group PLC\n20 January 2026\nAppointment of Nominated Adviser\nTotal Voting Rights Update\nLONDON and PHILADELPHIA\n- January 20, 2026 - Avacta Therapeutics (AIM: AVCT, \"the Company\", \"Avacta\"), a clinical stage biopharmaceutical company developing pre|CISION\u00ae,\u00a0a\ntumor-activated oncology delivery platform, announces the appointment of Strand Hanson Limited as the Company's Nominated Adviser, with immediate effect.\nCorrection to Total Voting Rights\nThe Company's issued ordinary share capital is 440,415,495 Ordinary Shares. This figure may be used by holders of Ordinary Shares as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.\nAdditional information is disclosed below under Schedule Two, paragraph (g) of the AIM Rules for Companies.\n-Ends-\nFor further information from Avacta, please contact:\nAvacta Group plc\nChristina Coughlin, Chief Executive Officer\nhttps://avacta.com/\nvia ICR Healthcare\nStrand Hanson Limited (Nominated Adviser)\nJames Harris / Chris Raggett / James Dance\nwww.strandhanson.co.uk\nZeus (Broker)\nJames Hornigold / George Duxberry / Dominic King\nwww.zeuscapital.co.uk\nICR Healthcare\nMary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert\navacta@consilium-comms.com\nInvestor Contact\nRenee Leck\nTHRUST Strategic Communications\nrenee@thrustsc.com\nMedia Contact\nCarly Scaduto\nTHRUST Strategic Communications\ncarly@thrustsc.com\nAIM Rule 17 Updates\nIn addition to the disclosures made in the announcement of Richard Hughes's appointment to the Board on 28 May 2025, Richard Hughes was:\nappointed a director of Trafford Finance Limited on 28 October 2009, a company incorporated in England and Wales. The company was placed into administration on 21 April 2010 and was subsequently dissolved on 19 September 2013, with an estimated \u00a35.4 million owed to creditors;\nappointed a director of Procurasell International (Packaging) Ltd on 30 October 2007, a company incorporated in England and Wales. The company was placed into administration on 8 January 2009 and was subsequently dissolved on 23 September 2010, with approximately \u00a30.1 million owing to creditors; and\nappointed a director of Holyrood Leisure Limited on 26 April 2007, a company incorporated in England and Wales. The company was placed into administration on 28 June 2018 and was subsequently dissolved on 25 February 2020, with approximately \u00a30.5 million owing to creditors.\nAbout Avacta\n-\nwww.avacta.com\nAvacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION\u00ae platform. pre|CISION\u00ae is a proprietary payload delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate highly potent payloads in the tumor microenvironment while sparing normal tissues.\nOur innovative pipeline consists of pre|CISION\u00ae peptide drug conjugates (PDC) or Affimer\u00ae drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates.\nThe pre|CISION\u00ae platform comprises an anticancer payload conjugated to a proprietary peptide that is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The pre|CISION\u00ae platform harnesses this tumor specific protease to cleave pre|CISION\u00ae peptide drug conjugates and pre|CISION\u00ae antibody/Affimer\u00ae drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity, allowing dosing to be optimized to deliver the best outcomes for patients.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nAPPFFFVLLDIALIR",
          "content_length": 4647
        },
        "ingested_at": "2026-01-21T03:29:59.777586Z"
      },
      {
        "event_id": "RNS-18th Dec 2025-avactare",
        "event_type": "rns_announcement",
        "date": "2026-01-21T03:29:59.777601Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Avacta reports new AVA6103 pharmacology data",
          "category": "RNS-R",
          "url": "https://www.lse.co.uk/rns/AVCT/avacta-reports-new-ava6103-pharmacology-data-pbsp081aip6odfc.html",
          "rns_number": "RNS Number : 0258M",
          "full_content": "18 Dec 2025 07:00\nRNS Number : 0258M\nAvacta Group PLC\n18 December 2025\nAvacta reports new pharmacology data for FAP-Exd (AVA6103)\nMultiple patient-derived xenograft models with prolonged complete responses associated with sustained release of the exatecan payload within the tumor over five days\nLONDON and PHILADELPHIA\n- December 18, 2025 - Avacta Therapeutics (AIM: AVCT), a clinical stage biopharmaceutical company developing pre|CISION\u00ae,\u00a0a tumor-activated oncology delivery platform, today announced new pharmacology data with its second asset, FAP-Exd (AVA6103) which is anticipated to begin Phase 1 testing in Q1 2026.\nFAP-Exd (AVA6103) is a pre|CISION\u00ae peptide drug conjugate comprised of the proprietary FAP-cleavable peptide linked to a highly potent topoisomerase I (topo I) inhibitor, a key antitumor mechanism useful in many human solid tumor types.\nToday's new data include the following observations:\n\u00b7\nPotent tumor-specific and broad-spectrum cytotoxicity: FAP-Exd (pre|CISION exatecan) is a potent peptide drug conjugate designed to produce sustained release of active exatecan directly in the tumor via the pre|CISION bystander effect\n\u00b7\nSustained release mechanism in the tumor is highly effective: The sustained release mechanism produces a maximum concentration (Cmax) of released exatecan, with exposure duration of over five days in the tumor, with plasma exposure gone in two hours\n\u00b7\nHigh levels of antitumor activity of FAP-Exd: Multiple patient-derived xenograft models demonstrate robust antitumor activity with deeper and more durable responses than achieved with conventional exatecan\n\u00b7\nFAP-Exd has the potential to reach a broad patient population with high unmet need: Exatecan is the most potent topoisomerase I inhibitor that has been tested in the clinic and as a pre|CISION medicine delivers exatecan directly to the tumor with the potential to address multiple indications with high unmet need\n\u00b7\nFaster and more robust Phase 1 development using AI: The clinical development of FAP-Exd was designed using an AI approach, querying a large database to identify those cancer indications with the highest likelihood of response to the drug through co-expression of FAP and SLFN11\nChristina Coughlin MD, PhD, CEO of Avacta, commented:\n\"These data are key to support the clinical development of FAP-Exd (AVA6103) and the profile of this second pre|CISION medicine in the preclinical setting is tremendous. The sustained release mechanism developed by Avacta scientists results in a robust concentration of active drug in the tumor over five days with the disappearance from the bloodstream in only two hours. This is the exact profile needed to achieve better efficacy with this highly potent topo I inhibitor.\n\"Our AI collaboration has led to several key insights into the patient population for the FAP-Exd program and has helped to drive a smarter and faster clinical trial. We are eagerly anticipating the next steps for this exciting program in 2026.\"\n-Ends-\nFor further information from Avacta, please contact:\nAvacta Group plc\nChristina Coughlin, Chief Executive Officer\nhttps://avacta.com/\nvia ICR Healthcare\nZeus (Joint Broker)\nJames Hornigold / George Duxberry / Dominic King\nwww.zeuscapital.co.uk\nICR Healthcare\nMary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert\navacta@icrhealthcare.com\nInvestor Contact\nRenee Leck\nTHRUST Strategic Communications\nrenee@thrustsc.com\nMedia Contact\nCarly Scaduto\nTHRUST Strategic Communications\ncarly@thrustsc.com\nmailto:Carly@carlyscadutoconsulting.com\nAbout Avacta\n-\nwww.avacta.com\nAvacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION\u00ae platform. pre|CISION\u00ae is a proprietary payload delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate highly potent payloads in the tumor microenvironment while sparing normal tissues.\nOur innovative pipeline consists of pre|CISION\u00ae peptide drug conjugates (PDC) or Affimer\u00ae drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates.\nThe pre|CISION\u00ae platform comprises an anticancer payload conjugated to a proprietary peptide that is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The pre|CISION\u00ae platform harnesses this tumor specific protease to cleave pre|CISION\u00ae peptide drug conjugates and pre|CISION\u00ae antibody/Affimer\u00ae drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity, allowing dosing to be optimized to deliver the best outcomes for patients.\nThis information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may ap",
          "content_length": 5496
        },
        "ingested_at": "2026-01-21T03:29:59.777617Z"
      },
      {
        "event_id": "RNS-17th Dec 2025-faridoxo",
        "event_type": "rns_announcement",
        "date": "2026-01-21T03:29:59.777631Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Faridoxorubicin Phase 1b SGC data",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/AVCT/faridoxorubicin-phase-1b-sgc-data-dsqw83n4nn3h7m4.html",
          "rns_number": "RNS Number : 8417L",
          "full_content": "17 Dec 2025 07:00\nRNS Number : 8417L\nAvacta Group PLC\n17 December 2025\nFaridoxorubicin\n(AVA6000)\nPhase 1b cohort demonstrates clinically meaningful tumor shrinkage in patients with salivary gland cancers\nPreliminary Phase 1b data is in line with Phase 1a data reported at the European Society of Medical Oncology in September 2025\nCombined disease control rate of 90% across both Phase 1a and Phase 1b patients with confirmed partial and minor responses observed\nLONDON and PHILADELPHIA\n- December 17, 2025 - Avacta Therapeutics (AIM: AVCT), a clinical stage biopharmaceutical company developing pre|CISION\u00ae,\u00a0a tumor-activated oncology delivery platform, today announced compelling new data in patients with salivary gland cancer (SGC) enrolled in the ongoing Phase 1b trial of faridoxorubicin (AVA6000). The data show confirmed partial and minor responses, consistent with data previously reported from the Phase 1a part of the study.\nFaridoxorubicin is the first peptide drug conjugate (PDC) in Avacta's pipeline. It consists of doxorubicin conjugated with Avacta's proprietary pre|CISION\u00ae peptide and is specifically cleaved (released) by fibroblast activation protein-alpha (FAP), which is over-expressed in the tumor microenvironment, enabling targeted release of the doxorubicin payload.\nSGC accounts for 6-8% of head and neck cancers, with approximately 2,500 cases diagnosed in the U.S. each year.\n1\nSGC is a disease that does not respond to chemotherapy, has no standard therapy defined in the metastatic setting and a five-year survival rate of approximately 42%2 in advanced stage disease.\nAvacta's recent data demonstrate continued robust and meaningful tumor shrinkage in patients with SGCs and a combined disease control rate of 90% across Phase 1a and Phase 1b patients.\nBased on the preliminary favorable efficacy and safety data observed in the Phase 1b cohort in this part of the trial,\nenrollment will continue in this cohort with further data updates across the Phase 1a and Phase 1b cohorts expected in 1H 2026.\nChristina Coughlin MD, PhD, CEO of Avacta, commented:\n\"These data continue to reinforce our belief in the transformative potential of our pre|CISION\u00ae peptide drug conjugates\nto expand\nthe therapeutic index and increase the efficacy of highly potent therapeutics and further strengthens our confidence across our broader pipeline.\n\"SGC cancer is a devastating disease with no established standard of care treatment options. The clinically meaningful tumor shrinkage and prolonged progression free survival we have observed in the study highlight faridoxorubicin's potential as an important new treatment option for patients with SGC and other solid tumors. The Phase 1b data will mature as we continue to collect the survival data in this cohort.\n\"Translational data collected from this population continue to demonstrate the power of our pre|CISION\u00ae\nplatform, with optimal payload release observed even at the lowest levels of FAP expression. This supports a broad market opportunity for all pre|CISION\u00ae medicines across our pipeline.\"\nFaridoxorubicin (AVA6000) -\nClinical data observations in SGC\nThese data demonstrate ongoing evidence of durable anti-tumor activity in patients with SGC (both treatment-na\u00efve and those who have failed earlier lines of therapy), that is supported by ongoing RECIST3 responses (both partial and minor responses) and continued observation of a robust disease control rate and strong progression-free survival (PFS) data. The trial enrolled both a Phase 1a cohort (n=11) and Phase 1b cohort to date (n=19 evaluable for efficacy) for a total of 30 patients with SGC.\nOf the 30 patients with SGC treated at the dose of 250 mg/m2 and above and evaluable for efficacy, nine experienced clinically meaningful disease shrinkage, including two confirmed partial responses (PR,\n>\n30% tumor shrinkage) and seven minor responses (MR,\n>\n10% and <30% tumor shrinkage) using RECISTv1.1 criteria. PFS in the Phase 1b cohort has not been reached with a median follow up exceeding 15 weeks at the data cutoff.\nThese data include the following:\n\u00b7\nNineteen patients in the Phase 1b arm of the trial are evaluable for efficacy. Safety findings (n=22) are in line with those data reported in the Phase 1a cohort. Three patients enrolled were not evaluable for efficacy at the data cutoff (2 patients not eligible and 1 patient not having reached an initial follow up scan) but having received one dose of drug are considered evaluable for safety\n\u00b7\nThe baseline characteristics of the patients enrolled in the Phase 1b are in line with the patients in Phase 1a. In Phase 1b, the median number of prior therapy regimens in the metastatic setting is 1 with a range of 0-2. Seven patients in Phase 1b had not received prior systemic therapy\n\u00b7\nAmong the total of 30 patients evaluable for efficacy treated at the dose of 250 mg/m2 and above in Phase 1a and 1b, 27 patients demonstrated partial or minor responses or stable disease, resulting in a disease cont",
          "content_length": 9056
        },
        "ingested_at": "2026-01-21T03:29:59.777646Z"
      },
      {
        "event_id": "RNS-8th Dec 2025-prelimin",
        "event_type": "rns_announcement",
        "date": "2026-01-21T03:29:59.777660Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Preliminary Data in Faridoxorubicin Phase 1b Trial",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/AVCT/preliminary-data-in-faridoxorubicin-phase-1b-trial-z2pvwyt8vwe1obc.html",
          "rns_number": "RNS Number : 6167K",
          "full_content": "8 Dec 2025 07:00\nRNS Number : 6167K\nAvacta Group PLC\n08 December 2025\nAvacta Group plc\n(\"Avacta\", the \"Group\" or the \"Company\")\nAvacta Announces the Preliminary Clinical Data in the Faridoxorubicin Phase 1b Trial in the Salivary Gland Cancer Cohort\nLONDON and PHILADELPHIA\n- December 8, 2025 - Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor,\u00a0expects to announce initial Faridoxorubicin Phase 1b data in the salivary gland cancer indication on December 17, 2025. A presentation will be made available via the Investor Meet Platform on December 17, 2025, at 10:00 AM GMT. The link to view the presentation is below. Investors can register for the webinar and submit questions through the platform link below at any time before the presentation.\nhttps://www.investormeetcompany.com/avacta-group-plc/register\n-Ends-\nFor further information from Avacta, please contact:\nAvacta Group plc\nChristina Coughlin, Chief Executive Officer\nhttps://avacta.com/\nvia ICR Healthcare\nPeel Hunt (Nomad and Joint Broker)\nJames Steel / Chris Golden\nwww.peelhunt.com\nZeus (Joint Broker)\nJames Hornigold / George Duxberry\nDominic King\nwww.zeuscapital.co.uk\nICR Healthcare (Europe/UK media and investors)\nMary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert\navacta@icrhealthcare.com\nInvestor Contact\nRenee Leck\nTHRUST Strategic Communications\nrenee@thrustsc.com\nMedia Contact\nCarly Scaduto\nTHRUST Strategic Communications\ncarly@thrustsc.com\nA\nbout Avacta\u00a0-\nwww.avacta.com\nAvacta is a clinical stage life sciences company developing an innovative proprietary drug delivery peptide drug conjugate (PDC) platform, pre|CISION\u00ae. The pre|CISION\u00ae platform uniquely enables the repurposing of a range of oncology drugs as PDC payloads with the goal to significantly reduce toxicity and side effects for patients by concentrating the drug directly in the tumor.\nAbout pre|CISION\u00ae\nThe key aspect of pre|CISION\u00ae is its peptide drug conjugates (PDC) technology. The combination of the cancer drug and the proprietary cleavable peptide (the PDC) is inert and incapable of entering cells and killing them until the peptide is specifically released within the tumor. The active payload in the pre|CISION\u00ae PDC is released when the PDC comes into contact with the common tumor-associated protein, known as fibroblast activation protein (FAP), in the tumor. The release of the payload from the pre|CISION\u00ae product directly in the tumor results in higher concentration of the drug at the tumor and lower blood and healthy tissue levels than standard systemic administration, offering the potential to improve efficacy and patient tolerability.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nMSCBCBDDUUGDGUR",
          "content_length": 3511
        },
        "ingested_at": "2026-01-21T03:29:59.777673Z"
      },
      {
        "event_id": "RNS-3rd Nov 2025-completi",
        "event_type": "rns_announcement",
        "date": "2026-01-21T03:29:59.777687Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Completion of Placing and TVR",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/AVCT/completion-of-placing-and-tvr-yuvz7fqyppuu72h.html",
          "rns_number": "RNS Number : 8646F",
          "full_content": "3 Nov 2025 08:24\nRNS Number : 8646F\nAvacta Group PLC\n03 November 2025\nAvacta Group plc\n(\"Avacta\" or the \"Group\" or the \"Company\")\nCompletion of Placing and TVR\nLONDON and PHILADELPHIA\n- November 3, 2025\n- Avacta Therapeutics (AIM: AVCT, 'Avacta', 'the Company'),\na clinical stage biopharmaceutical company developing pre|CISION\n\u00ae,\na tumor-activated oncology delivery platform\n, today confirms that following Admission earlier today of the 25,396,806 Placing Shares, the Amendments to the Convertible Bond as set out in the Placing Announcement have taken effect.\nThe Company's enlarged issued ordinary share capital is 436,445,681 Ordinary Shares. This figure may be used by holders of Ordinary Shares as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.\nCapitalized terms in this announcement shall, unless the context demands otherwise, bear the meanings given to such terms in the Placing Announcement issued on 20 October 2025.\n-Ends-\nFor further information from Avacta, please contact:\nAvacta Group plc\nChristina Coughlin, Chief Executive Officer\nhttps://avacta.com/\nvia ICR Healthcare\nPeel Hunt (Nomad and Joint Broker)\nJames Steel / Chris Golden\nwww.peelhunt.com\nPanmure Liberum (Joint Broker)\nEmma Earl / Will Goode / Mark Rogers\nZeus (Joint Broker)\nJames Hornigold / George Duxberry\nDominic King\nwww.panmureliberum.com\nwww.zeuscapital.co.uk\nICR Healthcare (Europe/UK media and investors)\nMary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert\navacta@icrhealthcare.com\nInvestor Contact\nRenee Leck\nTHRUST Strategic Communications\nrenee@thrustsc.com\nMedia Contact\nCarly Scaduto\nTHRUST Strategic Communications\ncarly@thrustsc.com\nAbout Avacta\u00a0-\nwww.avacta.com\nAvacta is a clinical stage life sciences company developing an innovative proprietary drug delivery peptide drug conjugate (PDC) platform, pre|CISION\u00ae. The pre|CISION\u00ae platform uniquely enables the repurposing of a range of oncology drugs as PDC payloads with the goal to significantly reduce toxicity and side effects for patients by concentrating the drug directly in the tumor.\nAbout pre|CISION\u00ae\nThe key aspect of pre|CISION\u00ae is its peptide drug conjugates (PDC) technology. The combination of the cancer drug and the proprietary cleavable peptide (the PDC) is inert and incapable of entering cells and killing them until the peptide is specifically released within the tumor. The active payload in the pre|CISION\u00ae PDC is released when the PDC comes into contact with the common tumor-associated protein, known as fibroblast activation protein (FAP), in the tumor. The release of the payload from the pre|CISION\u00ae product directly in the tumor results in higher concentration of the drug at the tumor and lower blood and healthy tissue levels than standard systemic administration, offering the potential to improve efficacy and patient tolerability.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nMSCFLLLBEFLLFBE",
          "content_length": 3817
        },
        "ingested_at": "2026-01-21T03:29:59.777700Z"
      },
      {
        "event_id": "RNS-27th Oct 2025-blocklis",
        "event_type": "rns_announcement",
        "date": "2026-01-21T03:29:59.777713Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Block Listing Six Monthly Return",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/AVCT/block-listing-six-monthly-return-dmo3jkx5wbu5byi.html",
          "rns_number": "RNS Number : 0074F",
          "full_content": "27 Oct 2025 17:39\nRNS Number : 0074F\nAvacta Group PLC\n27 October 2025\nAvacta Group plc\n(\"Avacta\" or \"the Group\" or \"the Company\")\nBlock Listing Six Monthly Return\nLONDON\u00a0AND\u00a0PHILADELPHIA\n-\u00a0October 27, 2025\u00a0Avacta Therapeutics (AIM: AVCT, 'the Company'), a clinical stage biopharmaceutical company developing pre|CISION\n\u00ae,\na tumor-activated oncology delivery platform, today\nmakes the following notification pursuant to Schedule Six of the AIM Rules for Companies regarding its existing block admission arrangements:\nName of\napplicant\n:\nAvacta Group plc\nName of scheme:\nEMI scheme\nPeriod of return:\nFrom:\n28 April 2025\n27 October 2025\nBalance of unallotted securities under scheme(s) from previous return:\n228,380\nPlus:\nThe amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):\nnil\nLess:\nNumber of\nsecurities\nissued/allotted under scheme(s) during period (see LR3.5.7G):\n103,822\nEquals:\nBalance under scheme(s) not yet issued/allotted at end of period:\n124,558\nName of\napplicant\n:\nAvacta Group plc\nName of scheme:\nLTIP/ESOS scheme\nPeriod of return:\nFrom:\n28 April 2025\n27 October 2025\nBalance of unallotted securities under scheme(s):\n1,546,375\nPlus:\nThe amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):\n6,500,000\nLess:\nNumber of\nsecurities\nissued/allotted under scheme(s) during period (see LR3.5.7G):\n6,862,713\nEquals:\nBalance under scheme(s) not yet issued/allotted at end of period:\n1,183,662\nName of contact:\nBrian Hahn, Company Secretary\nTelephone number of contact:\n+ 44 (0)\n1904 217070\nEnds-\nFor further information from Avacta Group plc, please contact:\nAvacta Group plc\nChristina Coughlin, Chief Executive Officer\nhttps://avacta.com/\nvia ICR Healthcare\nPeel Hunt (Nomad and Joint Broker)\nJames Steel / Chris Golden\nwww.peelhunt.com\nPanmure Liberum (Joint Broker)\nEmma Earl / Will Goode / Mark Rogers\nZeus (Joint Broker)\nJames Hornigold / George Duxberry\nDominic King\nwww.panmureliberum.com\nwww.zeuscapital.co.uk\nICR Healthcare (Europe/UK media and investors)\nMary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert\navacta@icrhealthcare.com\nInvestor Contact\nRenee Leck\nTHRUST Strategic Communications\nrenee@thrustsc.com\nMedia Contact\nCarly Scaduto\nTHRUST Strategic Communications\ncarly@thrustsc.com\nAbout pre|CISION\u00ae\nThe key aspect of pre|CISION\u00ae is its peptide drug conjugates (PDC) technology. The combination of the cancer drug and the proprietary cleavable peptide (the PDC) is inert and incapable of entering cells and killing them until the peptide is specifically released within the tumor. The active payload in the pre|CISION\u00ae PDC is released when the PDC comes into contact with the common tumor-associated protein, known as fibroblast activation protein (FAP), in the tumor. The release of the payload from the pre|CISION\u00ae product directly in the tumor results in higher concentration of the drug at the tumor and lower blood and healthy tissue levels than standard systemic administration, offering the potential to improve efficacy and patient tolerability.\nAbout Avacta\u00a0-\nwww.avacta.com\nAvacta is a clinical stage life sciences company developing an innovative proprietary drug delivery peptide drug conjugate (PDC) platform, pre|CISION\u00ae. The pre|CISION\u00ae platform uniquely enables the repurposing of a range of oncology drugs as PDC payloads with the goal to significantly reduce toxicity and side effects for patients by concentrating the drug directly in the tumor.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nBLRPPGMPUUPAGMM",
          "content_length": 4325
        },
        "ingested_at": "2026-01-21T03:29:59.777726Z"
      },
      {
        "event_id": "RNS-27th Oct 2025-avactapr",
        "event_type": "rns_announcement",
        "date": "2026-01-21T03:29:59.777739Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Avacta presents preclinical data at AACR-NCI-EORTC",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/AVCT/avacta-presents-preclinical-data-at-aacr-nci-eortc-b36bqabrh7wlo98.html",
          "rns_number": "RNS Number : 8541E",
          "full_content": "27 Oct 2025 07:00\nRNS Number : 8541E\nAvacta Group PLC\n27 October 2025\nAvacta presents first preclinical data from dual payload pre|CISION\u00ae medicines at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets\nFirst-in-class dual payload peptide drug conjugate delivers two complementary therapies from a single molecule with potential to overcome resistance and maximize tumor control\nLONDON and PHILADELPHIA\n- October 27, 2025\n- Avacta Therapeutics (AIM: AVCT, 'Avacta', 'the Company'),\na clinical stage biopharmaceutical company developing pre|CISION\n\u00ae,\na tumor-activated oncology delivery platform\n, announces it presented preclinical data demonstrating its novel first-in-class dual payload pre|CISION\u00ae technology (AVA6207) at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics on October 25, 2025 in Boston, Massachusetts.\nThe data presented showcase the Company's innovative approach to delivering two distinct therapeutic payloads simultaneously to the tumor microenvironment (TME) through a single fibroblast activation protein (FAP)-mediated cleavage event. Avacta is the first company to develop dual payload peptide drug conjugates (PDCs), circumventing resistance mechanisms that cancer cells develop against single-drug therapies while maximizing therapeutic effect through targeted combination delivery. This approach has the potential to address several critical challenges in cancer therapy.\nThe Company's dual payload pipeline currently comprises two strategic approaches: combination of microtubule inhibition and topoisomerase I inhibition (MMAE and exatecan), representing two distinct anti-cancer mechanisms with established clinical activity; and DNA damage response (DDR) agents (ATR or PARP inhibitors) combined with exatecan, where inhibition of DNA repair potentiates the cytotoxic effect of exatecan.\nChristina Coughlin, M.D., Ph.D., Chief Executive Officer of Avacta, commented:\n\"The first dual payload peptide drug conjugate marks an important step forward in oncology therapy, significantly extending the potential of our pre|CISION\u00ae platform by implementing combination cancer therapy in a single small molecule medicine. The synergistic enhancement in anti-tumor activity observed with our exatecan-DDR inhibitor combinations highlights the potential of targeting the tumor with a potent cytotoxic drug while attacking the known resistance mechanisms. We believe this technology has the potential to markedly improve outcomes for cancer patients, particularly those with highly-resistant tumors.\n\"The pre|CISION\u00ae platform has been validated by compelling clinical data with faridoxorubicin (AVA6000, FAP-Dox), demonstrating a tumor-to-plasma payload concentration of 100:1 and a significant reduction in off-target toxicities despite dosing up to approximately 4x the dose of conventional doxorubicin. The new dual payload intellectual property extends the platform to release two drugs from one pre|CISION\u00ae molecule, targeting highly-resistant cancers by addressing key resistance mechanisms.\"\nKey Preclinical Findings:\nThe pre|CISION\u00ae dual payload technology demonstrated robust FAP-selective delivery and potent anti-tumor activity across multiple complementary payload combinations:\n\u00b7\nValidated dual payload release mechanism:\nBiologic and biochemical analyses confirmed simultaneous release of two independent payloads from a single FAP cleavage event. Modifications to the self-immolative linkers enabled tunable payload delivery kinetics, providing flexibility to optimize therapeutic profiles for different payload combinations. Strategic modifications of linker and capping group structures enabled optimization of compound activity.\n\u00b7\nFAP-selective tumor cell killing with maintained potency:\nDual payload compounds achieved potent cytotoxic activity comparable to free payloads in the presence of FAP (IC50 values of 2-9 nM), while demonstrating minimal activity without FAP (IC50 >100 nM), confirming excellent tumor selectivity in 2D and 3D tumor spheroid models over the course of seven days.\n\u00b7\nConfirmed dual mechanism biomarker modulation:\nTarget-specific biomarkers for both payloads were modulated only in the presence of FAP. FAP-Exd/MMAE compounds induced decreased TOP1 levels, DNA damage markers (\u03b3H2AX, pCHK1), tubulin depolymerization, M-phase arrest, and characteristic S-phase and G2/M cell cycle arrest patterns, confirming both mechanisms of action were operational.\n\u00b7\nEnhanced synergistic activity addressing resistance mechanisms:\nFAP-Exd/PARPi and FAP-Exd/ATRi compounds demonstrated 4-5 fold greater FAP-dependent tumor cell killing compared to exatecan alone, directly addressing the known DDR-mediated resistance pathway to topoisomerase I inhibitors. FAP-dependent biomarker modulation confirmed payload release (reduced TOP1, PAR, and pCHK1 levels) alongside elevated DNA damage and apoptosis markers (\u03b3H2AX, cleaved PARP), with synergistically increased \u03b3H2AX demonstrating enhanc",
          "content_length": 9210
        },
        "ingested_at": "2026-01-21T03:29:59.777756Z"
      },
      {
        "event_id": "RNS-23rd Oct 2025-noticeof",
        "event_type": "rns_announcement",
        "date": "2026-01-21T03:29:59.777770Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Notice of Investor Presentation",
          "category": "RNS-R",
          "url": "https://www.lse.co.uk/rns/AVCT/notice-of-investor-presentation-ozti0bop10owllm.html",
          "rns_number": "RNS Number : 6352E",
          "full_content": "23 Oct 2025 17:00\nRNS Number : 6352E\nAvacta Group PLC\n23 October 2025\nNotice of Investor Presentation\nLONDON and PHILADELPHIA\n- October 23, 2025 - Avacta Therapeutics (AIM: AVCT, 'Avacta', 'the Company'),\na clinical stage biopharmaceutical company developing pre|CISION\n\u00ae,\na unique oncology delivery platform\n, announces the team will present the published data of the platform innovation, the pre|CISION\u00ae dual payload peptide drug conjugate (PDC) delivery system, following their return from the 2025 AACR-NCI-EORTC International Molecular Targets Congress.\nChristina Coughlin, Chief Executive Officer, David Liebowitz, Chief Medical Officer, Francis Wilson, VP Chemistry and Ruairidh Edwards, Translational Scientist will deliver a presentation via Investor Meet Company at 16:00 BST on Wednesday October 29, 2025.\nThe presentation is open to all existing and potential shareholders.\nInvestors can sign up to Investor Meet Company for free and add to meet AVACTA GROUP PLC\nhere\n.\nInvestors who already follow Avacta on the Investor Meet Company platform will automatically be invited.\nQuestions can be submitted pre-event via the Investor Meet Company dashboard up until October 28 09:00 BST, or at any time during the recorded presentation.\n-Ends-\nFor further information from Avacta, please contact:\nAvacta Group plc\nChristina Coughlin (CEO), Brian Hahn (CFO)\nhttps://avacta.com/\nPeel Hunt (Nomad and Broker)\nJames Steel / Chris Golden\nwww.peelhunt.com\nPanmure Liberum (Joint Broker)\nEmma Earl / Will Goode / Mark Rogers\nZeus (Joint Broker)\nJames Hornigold / George Duxberry\nDominic King\nwww.panmureliberum.com\nwww.zeuscapital.co.uk\nICR Healthcare\nMary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert\navacta@icrhealthcare.com\nInvestor Contact\nRenee Leck\nTHRUST Strategic Communications\nrenee@thrustsc.com\nMedia Contact\nCarly Scaduto\nTHRUST Strategic Communications\ncarly@thrustsc.com\nAbout Avacta\n-\nwww.avacta.com\nAvacta is a clinical stage life sciences company developing an innovative proprietary drug delivery peptide drug conjugate (PDC) platform, pre|CISION\u00ae. The pre|CISION\u00ae platform uniquely enables the repurposing of a range of oncology drugs as PDC payloads with the goal to significantly reduce toxicity and side effects for patients by concentrating the drug directly in the tumor.\nAbout pre|CISION\u00ae\nThe key aspect of pre|CISION\u00ae is its peptide drug conjugates (PDC) technology. The combination of the cancer drug and the proprietary cleavable peptide (the PDC) is inert and incapable of entering cells and killing them until the peptide is specifically released within the tumor. The active payload in the pre|CISION\u00ae PDC is released when the PDC comes into contact with the common tumor-associated protein, known as fibroblast activation protein (FAP), in the tumor. The release of the payload from the pre|CISION\u00ae product directly in the tumor results in higher concentration of the drug at the tumor and lower blood and healthy tissue levels than standard systemic administration, offering the potential to improve efficacy and patient tolerability.\nThis information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nNRAFZMZGKFRGKZM",
          "content_length": 3791
        },
        "ingested_at": "2026-01-21T03:29:59.777783Z"
      },
      {
        "event_id": "RNS-20th Oct 2025-equityfu",
        "event_type": "rns_announcement",
        "date": "2026-01-21T03:29:59.777797Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Equity fundraise of \u00a316 million",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/AVCT/equity-fundraise-of-16316-million-3lc5yfsa7q8xqtu.html",
          "rns_number": "RNS Number : 9983D",
          "full_content": "20 Oct 2025 07:01\nRNS Number : 9983D\nAvacta Group PLC\n20 October 2025\nTHIS ANNOUNCEMENT AND THE INFORMATION CONTAINED IN IT, IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. PLEASE SEE THE IMPORTANT NOTICE IN THIS ANNOUNCEMENT.\nTHIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF THE MARKET ABUSE REGULATION (EU) 596 / 2014 WHICH FORMS PART OF\u00a0UK\u00a0LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 (AS AMENDED) (\"MAR\").\nAvacta Group plc\n(\"Avacta\" or the \"Group\" or the \"Company\")\nEquity fundraise of \u00a316 million\nLONDON and PHILADELPHIA - 20 October 2025 - Avacta (AIM: AVCT),\na clinical stage biopharmaceutical company developing pre|CISION\n\u00ae,\na unique oncology delivery platform, is pleased to announce that it has raised gross proceeds of approximately \u00a316 million from institutional and high net worth investors by way of a conditional oversubscribed placing of 25,396,806 new ordinary shares of 10 pence each in the Company (the \"Placing Shares\") at a price of 63 pence per share (the \"Issue Price\"), with Zeus Capital Limited acting as sole bookrunner (the \"Placing\").\nThe net proceeds of the Placing provide additional working capital to progress the Company's R&D programs into 2H 2026 including progressing the faridoxorubicin Phase 1b trial and planned initiation of the FAP-EXd Phase Ia trial. Completion of the Placing will satisfy the remaining conditions to the Amendments to the Convertible Bond terms, as announced on 29 August 2025 (as defined in RNS No. 1385X) (the \"Bond Amendments RNS\"). The Company therefore confirms that the quarterly repayment and interest of the Convertible Bond (as defined in the Bond Amendments RNS) due today will be paid in cash.\nThe following Amendments to the Convertible Bond will take effect upon completion of the Placing (with capitalised terms having the definitions given in the Bond Amendments RNS):\n\u00b7\nQuarterly Convertible Bond repayments and interest in respect of 20 January 2026 and 20 April 2026 payment dates will be deferred until 20 October 2027 (together, the \"Deferred Repayments\").\n\u00b7\nUpon the earlier of (i) the date on which the Company publishes the data readouts of its Phase 1b trials of faridoxorubicin (FAP-Dox, AVA6000) in triple negative breast cancer and (ii) 30 June 2026, the Bondholder will have the right to accelerate the satisfaction (in cash or shares) of one of both the Deferred Repayments and in addition, from 1 October 2026, at any time accelerate the satisfaction of the quarterly repayments on the Convertible Bond, subject to a maximum of one acceleration per quarter.\n\u00b7\nThe conversion price of the Convertible Bond is to be set at 75.0 pence having previously been set at 88.72 pence under the terms of the reset conversion price as announced on 22 April 2024. The relevant share settlement price in relation to the quarterly repayments and interest remains calculatable based on the then prevailing VWAP.\nThe Company will continue to progress faridoxorubicin (AVA6000) into 2026, and expects to progress FAP-EXd (AVA6103) into a Phase 1 trial (subject to receipt of an IND from the US Food & Drug Administration) and advance the development of the Company's Dual Payload Technology (AVA6207) with the net proceeds of the Placing extending the Company's cash runway into H2 2026.\nChristina Coughlin, CEO of Avacta commented:\n\"The Board's decision to raise funds enables Avacta to retain 100% ownership of our highly promising programs based on our proprietary pre|CISION\u00ae\u00a0technology and provide us with a cash runway into H2 2026. Completion of the raise also enables us to meet the terms of the Heights convertible loan note deferment. We believe this decision to be in the long-term interest of shareholders.\n\"We are continuing to make good progress across all our programs. Our faridoxorubicin trial is gaining momentum, with Phase 1a data presented this weekend at the European Society for Medical Oncology (ESMO) meeting demonstrating a disease control rate in patients treated of 91%.\n\"Meanwhile, the FAP-EXd (AVA6103) asset is advancing towards clinical development. Our recently revealed dual payload platform is also pioneering how peptide drug conjugates (PDCs) can be utilized for dual payload peptide drug delivery.\n\"FAP-EXd is on track to enter clinical development in Q1 2026 and is generating interest from a number of potential partners. Importantly, the funds raised allow Avacta to maintain control of this promising asset, allowing us to maximize potential value, while supporting our broader pipeline of programs.\n\"Avacta continues to focus on building its IP estate, based on our unique pre|CISION\u00ae\u00a0technology, as we seek to seek to maximize, in the long term, value for the benefit of patients and shareholders.\"\n-Ends-\nFor further ",
          "content_length": 24467
        },
        "ingested_at": "2026-01-21T03:29:59.777812Z"
      },
      {
        "event_id": "RNS-20th Oct 2025-avactapr",
        "event_type": "rns_announcement",
        "date": "2026-01-21T03:29:59.777825Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Avacta Presents Phase 1a Data for Faridoxorubicin",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/AVCT/avacta-presents-phase-1a-data-for-faridoxorubicin-u75gyyolhik7qkn.html",
          "rns_number": "RNS Number : 9980D",
          "full_content": "20 Oct 2025 07:00\nRNS Number : 9980D\nAvacta Group PLC\n20 October 2025\nAvacta Therapeutics presents compelling Phase 1a data for faridoxorubicin and the pre|CISION\n\u00ae\nplatform at the European Society of Medical Oncology Annual Congress\nMedian progression free survival (PFS) has not been reached in the cohort of patients with salivary gland cancer with PFS follow up suggesting a more than doubling of the benchmark PFS and a disease control rate of 91%\nNo maximum tolerated dose reached despite dosing up to 385 mg/m\u00b2 (approximately 4x conventional doxorubicin dose) with no severe cardiac toxicity observed even at cumulative doses up to 550 mg/m\u00b2\nLONDON and PHILADELPHIA\n- October 20, 2025 - Avacta Therapeutics (AIM: AVCT, 'Avacta', 'the Company'),\na clinical stage biopharmaceutical company developing pre|CISION\n\u00ae,\na unique oncology delivery platform\n, today announces further development updates in the Phase 1a clinical trial with its lead program, faridoxorubicin (FAP-Dox, AVA6000) were presented at the 2025 European Society of Medical Oncology Annual Congress in Berlin, Germany on October 19, 2025.\nFaridoxorubicin treatment data demonstrate favorable safety and tolerability across both the every three weeks and every two weeks dosing regimens. The trial data also demonstrate a robust reduction in toxicities associated with conventional doxorubicin therapy, with preliminary efficacy in patients with salivary gland cancers and soft tissue sarcomas. Cardiac safety data in patients treated above the standard cumulative dose demonstrate no severe toxicity observed either in treatment stage or in follow up and no severe cardiac adverse events were reported in the trial, regardless of the cumulative dose level.\nMedian progression-free survival (PFS) has not been reached in the previously-reported cohort of patients with salivary gland cancers, indicating a durable response. The follow up data to-date suggest a duration of PFS that is more than double the duration of that reported in benchmark data in this patient population of pretreated patients in Phase 1a (median duration of PFS follow-up of 41 weeks).\nChristina Coughlin,\nCEO Avacta commented\n:\n\"We are delighted to confirm the observations first published in April of this year with exciting efficacy in patients with salivary gland cancers. These data continue to demonstrate the power of pre|CISION\n\u00ae\nto generate meaningful PFS data in a patient population with limited therapeutic options and importantly with no FAP on the tumor cells.\n\"Given the extension of PFS, we are excited to be moving this program forward. The very strong cardiac safety data out to the cumulative maximum dose of 550 mg/m2 validates the safety implications of the platform and has the potential to open up a new avenue of treatment options for patients.\n\"These data highlight three important findings for the pre|CISION\n\u00ae\nplatform: first, the elimination of the cardiac signal even at higher cumulative doses demonstrates that pre|CISION\n\u00ae\nis capable of protecting normal tissues from toxicity. Second, the activity in a tumor type without FAP on the tumor cells confirms the bystander effect of pre|CISION\n\u00ae\nand third, the tumor concentration data even at low FAP expression opens up an even greater number of cancer types to the platform.\n\"This development, combined with the recent update on our first dual payload peptide drug conjugate, underscores the tremendous potential of our proprietary pre|CISION\n\u00ae\ntechnology pipeline to deliver meaningful benefits for patients.\"\nFaridoxorubicin (AVA6000, FAP-Dox) Clinical Highlights (ESMO Developmental Therapeutics Poster Session, October 19, 2025)\nFaridoxorubicin is a FAP-activated form of doxorubicin designed to reduce the systemic side effects of conventional chemotherapy and concentrate the active payload in the tumor microenvironment. Prior reports (\nAACR Annual Meeting, April 2025\n) have demonstrated favorable preliminary safety and early efficacy data in a subset of patients with salivary gland cancers.\nClinical data with faridoxorubicin\nIn the Phase 1a dose-escalation study, faridoxorubicin was well-tolerated across both every-three-week (Q3W) and every-two-week (Q2W) dosing regimens (N-63 patients). No maximum tolerated dose (MTD) was reached despite dosing up to 385 mg/m\u00b2 every three weeks. In addition, no events of severe cardiac toxicity were observed even to maximum cumulative exposure consistent with the anthracycline dose of 550 mg/m2, further supporting a markedly improved safety profile over conventional doxorubicin.\nIn patients with salivary gland cancers (SGC, n=11) treated at or above the dose level of 250 mg/m2, faridoxorubicin demonstrated multiple confirmed partial and minor responses with a disease control rate of 91%. Median progression-free survival (PFS) has not yet been reached, with an absolute median PFS follow-up of approximately 41 weeks (range 8 to 76 weeks). Multiple patients demonstrate durable disease stabilization despite disco",
          "content_length": 12529
        },
        "ingested_at": "2026-01-21T03:29:59.777842Z"
      },
      {
        "event_id": "RNS-13th Oct 2025-avactato",
        "event_type": "rns_announcement",
        "date": "2026-01-21T03:29:59.777856Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Avacta to present data at EORTC-NCI-AACR",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/AVCT/avacta-to-present-data-at-eortc-nci-aacr-ikflbewo2m5ybuf.html",
          "rns_number": "RNS Number : 0780D",
          "full_content": "13 Oct 2025 07:00\nRNS Number : 0780D\nAvacta Group PLC\n13 October 2025\nAvacta to Present First Dual Payload\npre|CISION\u00ae Medicines Data\nat the 2025 EORTC-NCI-AACR International Conference on Molecular Targets Symposium\nGroundbreaking oncology development with the first dual payload peptide drug conjugate platform, establishing Avacta as a leader in combination therapy innovation\nLONDON and PHILADELPHIA\n- October 13, 2025\n- Avacta Therapeutics (AIM: AVCT, 'Avacta', 'the Company'),\na clinical stage biopharmaceutical company developing pre|CISION\n\u00ae,\na unique oncology delivery platform\n, today announces that the Company will present data on its first dual-payload peptide drug conjugate (PDC) at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston on October 25.\nThe data highlights the Company's proprietary development enabling two\ncomplementary\ndrugs to be delivered via a single\npre|CISION\u00ae medicine,\nrepresenting the first dual payload PDC in the field\n.\nData presented will be\nin vitro\nproof of mechanism for this platform innovation.\nDrug combinations are commonly used in cancer therapy to improve outcomes and mitigate against resistance. This novel approach extends the pre|CISION\u00ae technology to allow for the selective and controlled release of two cancer-targeting payloads directly in the tumor, from a single molecule via\nfibroblast activation protein (FAP)\ncleavage.\nPreviously, development of the\npre|CISION\u00ae\nplatform focused on optimizing the delivery of single payloads to the tumor microenvironment leveraging the cleavage event by FAP, expressed in more than 90% of solid tumors.\nThe new dual payload innovation expands the platform's versatility, opening potential for more complex and effective oncology treatments.\nChristina Coughlin, M.D., Ph.D., Chief Executive Officer of Avacta, said:\n\"The development of the first dual payload peptide drug conjugate platform marks a major leap forward in oncology therapy. This significantly extends the potential of our innovative pre|CISION\u00ae platform by implementing combination cancer therapy in a single medicine.\n\"This new IP builds on the success of our FAP-EXd (AVA6103) program, where we invented a sustained release delivery mechanism with the platform. Our novel implementation of the platform extends this observation to now release two drugs from one pre|CISION\u00ae molecule. The key factor here is our ability to target the tumor with a cytotoxic drug and attack the known resistance mechanism all in one cancer medicine. By building on the prior knowledge, we have now extended the reach to highly-resistant cancers by targeting key resistance mechanisms.\nThis drug combination approach demonstrates the value we are building in our proprietary pre|CISION\u00ae technology by further underlining its flexibility and unique potential to expand into novel oncology therapeutic approaches.\nWe look forward to presenting the full data at the 2025 EORTC-NCI-AACR Symposium later this month.\"\nEvent details are below and are available online on the\n2025 EORTC-NCI-AACR Symposium\nwebsite.\nTitle:\nDiscovery and characterization of novel pre|CISION\u00ae technology compounds delivering complementary dual payloads to the tumor microenvironment following FAP cleavage\nAuthors:\nTom Clough, Alexa Kennedy,\nEllen Watts, Iva Zlatareva, Folake Orafidiya, Hanna Buist, Jannah Jeon, Sophie Brown, Doug Sammon, Victoria Juskaite, David Jones, Dave Liebowitz, Michelle Morrow, Francis Wilson\nSpeaker:\nFrancis Wilson\nSession:\nPoster Session C\nDate and Time\n: Saturday, October 25, 12:30-4pm\n-Ends-\nFor further information from Avacta, please contact:\nAvacta Group plc\nChristina Coughlin, Chief Executive Officer\nhttps://avacta.com/\nvia ICR Healthcare\nPeel Hunt (Nomad and Joint Broker)\nJames Steel / Chris Golden\nwww.peelhunt.com\nPanmure Liberum (Joint Broker)\nEmma Earl / Will Goode / Mark Rogers\nZeus (Joint Broker)\nJames Hornigold / George Duxberry\nDominic King\nwww.panmureliberum.com\nwww.zeuscapital.co.uk\nICR Healthcare (Europe/UK media and investors)\nMary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert\navacta@icrhealthcare.com\nInvestor Contact\nRenee Leck\nTHRUST Strategic Communications\nrenee@thrustsc.com\nMedia Contact\nCarly Scaduto\nTHRUST Strategic Communications\ncarly@thrustsc.com\nAbout Avacta\u00a0-\nwww.avacta.com\nAvacta is a clinical stage life sciences company developing an innovative proprietary drug delivery peptide drug conjugate (PDC) platform, pre|CISION\u00ae. The pre|CISION\u00ae platform uniquely enables the repurposing of a range of oncology drugs as PDC payloads with the goal to significantly reduce toxicity and side effects for patients by concentrating the drug directly in the tumor.\nAbout pre|CISION\u00ae\nThe key aspect of pre|CISION\u00ae is its peptide drug conjugates (PDC) technology. The combination of the cancer drug and the proprietary cleavable peptide (the PDC) is inert and incapable of entering cells and killing them until the peptide is specifically released within the tu",
          "content_length": 6257
        },
        "ingested_at": "2026-01-21T03:29:59.777870Z"
      },
      {
        "event_id": "RNS-30th Sep 2025-interimh",
        "event_type": "rns_announcement",
        "date": "2026-01-21T03:29:59.777883Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Interim Half Year Results 2025",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/AVCT/interim-half-year-results-2025-xtgyescwh7u4pla.html",
          "rns_number": "RNS Number : 2945B",
          "full_content": "30 Sep 2025 07:00\nRNS Number : 2945B\nAvacta Group PLC\n30 September 2025\nAvacta Group plc\n(\"Avacta\" or the \"Company\")\nInterim Results for the six months to June 30, 2025\nLONDON and PHILADELPHIA\n- September 30, 2025 - Avacta Therapeutics (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs, announces the publication of the interim results for the six months ended June 30, 2025 (\"H1 25\").\nHighlights - pre|CISION\u00ae medicine pipeline\n\u00b7\nClinical stage programs continue to advance with enrolment ongoing in Phase 1b expansion cohorts in the faridoxorubicin1 (FAP-Dox, AVA6000) program. The initial clinical activity observed in Phase 1b is highly encouraging.\n\u00b7\nFAP-EXd (AVA6103) remains on track to dose the first patient in Q1 2026.\n\u00b7\nClinical data with faridoxorubicin (FAP-Dox, AVA6000), FAP-EXd (AVA6103) and translational work in FAP pre|CISION\u00ae programs was presented in April 2025 at American Association of Cancer Research Annual Meeting (AACR, 2025).\n\u00b7\nAvacta to present the final faridoxorubicin Phase 1a dose escalation data at ESMO 2025 in Berlin, October 2025, with longer term cardiac safety data and updated efficacy data.\nFinancial and operational - including post period end\n\u00b7\nPeriod end cash and cash-equivalent balances were \u00a312.65 million (30 June 2024: \u00a328.56 million; 31 December 2024: \u00a312.87 million).\n\u00b7\nCash outflow from operations and working capital movements were \u00a312.14 million (H1 2024: \u00a312.60 million; FY 2024: \u00a326.05 million) and cash inflow from investing activities were \u00a38.77 million reflecting the proceeds of the sale of Launch Diagnostics (H1 2024: outflow of \u00a30.80 million; FY 2024: outflow of \u00a31.43 million).\n\u00b7\nRenegotiated terms of Heights Convertible Bond (the \"Bond\") and raised \u00a36.5 million (gross) to fund two quarterly cash payments of the Bond. Year to date bond settlement was\n\u00a35.1 million, 30 June 2025 bond balance is \u00a325.5 million reducing to \u00a322.95 million by 30 September 2025.\nChristina Coughlin, MD, PhD, CEO of Avacta, said,\n\"We have continued to make strong progress with our R&D pipeline, seeing a number of advances in our clinical programs. Notably the activity we are seeing in the faridoxorubicin Phase 1b trial has further increased our confidence in the value and utility of the pre|CISION\u00ae platform. Further, we continue to see increasing industry interest in our innovative platform.\n\"Raising \u00a36.5 million to fund the July and October bond payments and renegotiating the terms of the convertible bond reflect the progress and growing confidence in our R&D pipeline.\n\"We anticipate multiple pipeline updates in the last quarter of 2025, including the data from the first expansion cohort (salivary gland cancer) in the faridoxorubicin program. We look forward to continuing to update on our progress across our programs and exploiting our unique technology.\"\n1\nfaridoxorubicin: generic nomenclature assigned to the AVA6000 program by the World Health Organization (WHO)\n-Ends-\nFor further information from Avacta, please contact:\nAvacta\nChristina Coughlin (CEO) /\nBrian Hahn (CFO)\nhttps://avacta.com\nPeel Hunt (Nomad and Joint Broker)\nJames Steel / Chris Golden\nwww.peelhunt.com\nPanmure Liberum (Joint Broker)\nEmma Earl / Will Goode / Mark Rogers\nZeus (Joint Broker)\nJames Hornigold / George Duxberry\nDominic King\nwww.panmureliberum.com\nwww.zeuscapital.co.uk\nICR Healthcare (Europe/UK media and investors)\nMary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert\navacta@icrhealthcare.com\nInvestor Contact\nRenee Leck\nTHRUST Strategic Communications\nrenee@thrustsc.com\nMedia Contact\nCarly Scaduto\nCarly Scaduto Consulting\nCarly@carlyscadutoconsulting.com\nAbout Avacta\n-\nwww.avacta.com\nAvacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION\u00ae platform. pre|CISION\u00ae is a proprietary payload delivery system\nbased on a tumor-specific protease (fibroblast activation protein or FAP)\u00a0that is designed to concentrate highly potent payloads in the tumor microenvironment while sparing normal tissues. Our innovative pipeline consists of pre|CISION\u00ae peptide drug conjugates (PDC) or Affimer\u00ae drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates.\nAbout the pre|CISION\u00ae Platform\nThe pre|CISION\u00ae platform comprises an anticancer payload conjugated to a proprietary peptide that is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The pre|CISION\u00ae platform harnesses this tumor specific protease to cleave pre|CISION\u00ae peptide drug conjugates and pre|CISION\u00ae antibody/Affimer\u00ae drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity, allowing dosing to be optimized to deliver the best outcomes for patients.\nInterim report\nStrategic overview\nWe are making excellent progress in the",
          "content_length": 44953
        },
        "ingested_at": "2026-01-21T03:29:59.777897Z"
      },
      {
        "event_id": "RNS-15th Sep 2025-noticeof",
        "event_type": "rns_announcement",
        "date": "2026-01-21T03:29:59.777910Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Notice of Interim Results",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/AVCT/notice-of-interim-results-0o5n8rr03clkcm6.html",
          "rns_number": "RNS Number : 3046Z",
          "full_content": "15 Sep 2025 07:00\nRNS Number : 3046Z\nAvacta Group PLC\n15 September 2025\nNotice of Interim Results and Investor Presentation\nChange of Date, Time and Location of ESMO Abstract Presentation\nLONDON AND PHILADELPHIA\n- September 15, 2025 -\nAvacta Group plc (AIM: AVCT) a life sciences company developing innovative, targeted oncology drugs, confirms it will announce its unaudited interim results for the six months ended June 30, 2025 (\"HY25\"), on September 30, 2025.\nChristina Coughlin, Chief Executive Officer and Brian Hahn, Chief Financial Officer will also deliver a live presentation via Investor Meet Company at 14:00 BST on the day.\nThe presentation is open to all existing and potential shareholders.\nInvestors can sign up to Investor Meet Company for free and add to meet AVACTA GROUP PLC via:\nAVCT - AVACTA GROUP PLC | Investor Meet Company\nInvestors who already follow Avacta on the Investor Meet Company platform will automatically be invited.\nQuestions can be submitted pre-event via the Investor Meet Company dashboard up until September 30 09:00 BST, or at any time during the live presentation.\nThe Company will also post the results presentation on its website at the following page:\nhttps://avacta.com/investors/investor-resources/\n.\nESMO Congress Update\nThe Company confirms that the date, time and location of the abstract being presented at the European Society for Medical Oncology (ESMO) Congress, taking place from October 17-21, 2025, has changed. The updated details are included below:\nTitle:\nA Phase I trial of FAP-Dox (AVA6000), a Fibroblast Activation Protein (FAP)-released and tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with FAP-positive solid tumors\nSession Title\n: Developmental Therapeutics\nSession Date and Time:\n19 October, 12.00-12.45\nLocation:\nHall 25\nAbstract Presentation Number:\n964P\nSpeaker:\nWilliam D. Tap\n-Ends-\nFor further information from Avacta, please contact:\nPeel Hunt (Nomad and Joint Broker)\nJames Steel / Chris Golden\nwww.peelhunt.com\nPanmure Liberum (Joint Broker)\nEmma Earl / Will Goode / Mark Rogers\nZeus (Joint Broker)\nJames Hornigold / George Duxberry\nDominic King\nwww.panmureliberum.com\nwww.zeuscapital.co.uk\nICR Healthcare (Europe/UK media and investors)\nMary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert\navacta@icrhealthcare.com\nInvestor Contact\nRenee Leck\nTHRUST Strategic Communications\nrenee@thrustsc.com\nMedia Contact\nCarly Scaduto\nCarly Scaduto Consulting\nCarly@carlyscadutoconsulting.com\nAbout Avacta\n-\nhttps://avacta.com/\nAvacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION\u00ae\u00a0platform. pre|CISION\u00ae\u00a0is a\u00a0proprietary payload delivery system\nbased on a tumor-specific protease (fibroblast activation protein or FAP)\u00a0that is designed to concentrate highly potent payloads in the tumor microenvironment while sparing normal tissues. Our innovative pipeline consists of pre|CISION\u00ae\u00a0peptide drug conjugates (PDC) or Affimer\u00ae\u00a0drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates.\nAbout the pre|CISION\u00ae Platform\nThe pre|CISION\u00ae platform comprises an anticancer payload conjugated to a proprietary peptide that is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The pre|CISION\u00ae platform harnesses this tumor specific protease to cleave pre|CISION\u00ae peptide drug conjugates and pre|CISION\u00ae antibody/Affimer\u00ae drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity, allowing dosing to be optimized to deliver the best outcomes for patients.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nNORUSSKRVRUKAAR",
          "content_length": 4567
        },
        "ingested_at": "2026-01-21T03:29:59.777923Z"
      },
      {
        "event_id": "RNS-9th Sep 2025-shortlis",
        "event_type": "rns_announcement",
        "date": "2026-01-21T03:29:59.777936Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Shortlisted for AIM Awards Technology of the Year",
          "category": "RNS-R",
          "url": "https://www.lse.co.uk/rns/AVCT/shortlisted-for-aim-awards-technology-of-the-year-0hi9arpmvrf5xb0.html",
          "rns_number": "RNS Number : 5693Y",
          "full_content": "9 Sep 2025 07:00\nRNS Number : 5693Y\nAvacta Group PLC\n09 September 2025\nAvacta's pre|CISION\n\u00ae\nPlatform Shortlisted for the Technology of the Year Award at the AIM Awards\nLONDON AND PHILADELPHIA\n- September 9, 2025 -\nAvacta Group plc (AIM: AVCT) a life sciences company developing innovative, targeted oncology drugs, is pleased to announce today that its pre|CISION\u00ae platform has been shortlisted for the AIM Technology of the Year Award. The AIM Awards\nis the flagship event for AIM and is held annually, in London, to celebrate success and achievement amongst the world's fastest growing publicly quoted companies. The Awards identify the quoted companies and entrepreneurs who have harnessed AIM to help them fulfil their ambition and growth potential in the last twelve months. The Awards will be distributed at the event on October 1, 2025.\nChristina Coughlin, CEO of Avacta commented:\n\"We are delighted to be on the shortlist for Technology of the Year among companies listed on the AIM market. Our pre|CISION\u00ae technology changes the way that potent cancer therapies are delivered to patients, where the drug is silent in the bloodstream yet active in the tumor, allowing cancer cells to be targeted while preserving patient vitality. We look forward to the event next month.\"\n-Ends-\nFor further information from Avacta, please contact:\nPeel Hunt (Nomad and Joint Broker)\nJames Steel / Chris Golden\nwww.peelhunt.com\nPanmure Liberum (Joint Broker)\nEmma Earl / Will Goode / Mark Rogers\nZeus (Joint Broker)\nJames Hornigold / George Duxberry\nDominic King\nwww.panmureliberum.com\nwww.zeuscapital.co.uk\nICR Healthcare (Europe/UK media and investors)\nMary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert\navacta@icrhealthcare.com\nInvestor Contact\nRenee Leck\nTHRUST Strategic Communications\nrenee@thrustsc.com\nMedia Contact\nCarly Scaduto\nCarly Scaduto Consulting\nCarly@carlyscadutoconsulting.com\nAbout Avacta\n-\nwww.avacta.com\nAvacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION\u00ae\u00a0platform. pre|CISION\u00ae\u00a0is a\u00a0proprietary payload delivery system\nbased on a tumor-specific protease (fibroblast activation protein or FAP)\u00a0that is designed to concentrate highly potent payloads in the tumor microenvironment while sparing normal tissues. Our innovative pipeline consists of pre|CISION\u00ae\u00a0peptide drug conjugates (PDC) or Affimer\u00ae\u00a0drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates.\nAbout the pre|CISION\u00ae Platform\nThe pre|CISION\u00ae platform comprises an anticancer payload conjugated to a proprietary peptide that is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The pre|CISION\u00ae platform harnesses this tumor specific protease to cleave pre|CISION\u00ae peptide drug conjugates and pre|CISION\u00ae antibody/Affimer\u00ae drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity, allowing dosing to be optimized to deliver the best outcomes for patients.\nThis information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nNRAEKLBBEKLZBBZ",
          "content_length": 3892
        },
        "ingested_at": "2026-01-21T03:29:59.777949Z"
      },
      {
        "event_id": "RNS-1st Sep 2025-avactaco",
        "event_type": "rns_announcement",
        "date": "2026-01-21T03:29:59.777962Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Avacta completes sale of Coris Bioconcept",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/AVCT/avacta-completes-sale-of-coris-bioconcept-ndefxph88xtfs1u.html",
          "rns_number": "RNS Number : 3732X",
          "full_content": "1 Sep 2025 07:00\nRNS Number : 3732X\nAvacta Group PLC\n01 September 2025\nAvacta Announces Completion of the Sale of Coris Bioconcept SRL\nLONDON AND PHILADELPHIA\n- September 1, 2025 -\nFurther to the announcement on July 28, 2025, Avacta Group plc (AIM: AVCT) a life sciences company developing innovative, targeted oncology drugs, today announces that all closing conditions to the sale of the entire issued share capital of Coris Bioconcept SRL to\n3B BlackBio Dx Ltd\nhave been satisfied and the completion of the sale took place on Friday August 29, 2025\n.\n-Ends-\nFor further information from Avacta, please contact:\nPeel Hunt (Nomad and Joint Broker)\nJames Steel / Chris Golden\nwww.peelhunt.com\nPanmure Liberum (Joint Broker)\nEmma Earl / Will Goode / Mark Rogers\nZeus (Joint Broker)\nJames Hornigold / George Duxberry\nDominic King\nwww.panmureliberum.com\nwww.zeuscapital.co.uk\nICR Healthcare (Europe/UK media and investors)\nMary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert\navacta@icrhealthcare.com\nInvestor Contact\nRenee Leck\nTHRUST Strategic Communications\nrenee@thrustsc.com\nMedia Contact\nCarly Scaduto\nCarly Scaduto Consulting\nCarly@carlyscadutoconsulting.com\nAbout Avacta\n-\nwww.avacta.com\nAvacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION\u00ae\u00a0platform. pre|CISION\u00ae\u00a0is a\u00a0proprietary payload delivery system\nbased on a tumor-specific protease (fibroblast activation protein or FAP)\u00a0that is designed to concentrate highly potent payloads in the tumor microenvironment while sparing normal tissues. Our innovative pipeline consists of pre|CISION\u00ae\u00a0peptide drug conjugates (PDC) or Affimer\u00ae\u00a0drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates.\nAbout the pre|CISION\u00ae Platform\nThe pre|CISION\u00ae platform comprises an anticancer payload conjugated to a proprietary peptide that is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The pre|CISION\u00ae platform harnesses this tumor specific protease to cleave pre|CISION\u00ae peptide drug conjugates and pre|CISION\u00ae antibody/Affimer\u00ae drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity, allowing dosing to be optimized to deliver the best outcomes for patients.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nDISDZGFRLMKGKZM",
          "content_length": 3228
        },
        "ingested_at": "2026-01-21T03:29:59.777975Z"
      },
      {
        "event_id": "RNS-29th Aug 2025-amendmen",
        "event_type": "rns_announcement",
        "date": "2026-01-21T03:29:59.777988Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Amendments to Convertible Bond + equity fundraise",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/AVCT/amendments-to-convertible-bond-equity-fundraise-2jriwu98ir7pj3q.html",
          "rns_number": "RNS Number : 1385X",
          "full_content": "29 Aug 2025 07:00\nRNS Number : 1385X\nAvacta Group PLC\n29 August 2025\nTHIS ANNOUNCEMENT AND THE INFORMATION CONTAINED IN IT, IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. PLEASE SEE THE IMPORTANT NOTICE IN THIS ANNOUNCEMENT.\nTHIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF THE MARKET ABUSE REGULATION (EU) 596 / 2014 WHICH FORMS PART OF\u00a0UK\u00a0LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 (\"MAR\").\nAvacta Group plc\n(\"Avacta\" or the \"Group\" or the \"Company\")\nAmendments to the Convertible Bond and equity fundraise of \u00a33.25 million\nLONDON AND PHILADELPHIA -August 29 2025 - Avacta Therapeutics (AIM: AVCT),\na life sciences company developing innovative, targeted oncology drugs, is pleased to announce conditional amendments to the Convertible Bond including deferral of several payments alongside raising gross proceeds of \u00a33.25 million from high net worth investors introduced by Zeus Capital Limited by way of an oversubscribed conditional placing of 6,500,000 new ordinary shares of 10 pence each in the Company (the \"Placing Shares\") at a price of 50 pence per share (the \"Issue Price\"), (the \"Placing\").\nThe net proceeds of approximately \u00a33.1 million from the Placing will be used to settle the October quarterly repayment of the unsecured convertible bond which is due to be paid on 20 October 2025.\nAmendment to the Convertible Bond\nThe Company is pleased to announce that it has agreed to the following amendments to the unsecured convertible bond issued by Avacta Finance Jersey Limited and guaranteed by the Company (as announced on\n18 October 2022\n(the \"Convertible Bond\")) (the \"Amendments\"):\n\u00b7\nThe October 2025 quarterly repayment and interest on the Convertible Bond will be paid in cash;\n\u00b7\nQuarterly Convertible Bond repayments and interest in respect of 20 January 2026 and 20 April 2026 payment dates will be deferred until 20 October 2027 (together, the \"Deferred Repayments\")\n\u00b7\nUpon the earlier of (i) the date on which the Company publishes the data readouts of its Phase 1b trials of FAP-Dox (AVA6000) in triple negative breast cancer and (ii) 30 June 2026, the Bondholder will have the right to accelerate the satisfaction (in cash or shares) of one of both the Deferred Repayments and in addition, from 1 October 2026, at any time accelerate the satisfaction of the quarterly repayments on the Convertible Bond, subject to a maximum of one acceleration per quarter\n\u00b7\nThe conversion price of the Convertible Bond is to be set at 75.0 pence, previously set at 88.72 pence under the terms of the reset conversion price as announced on 22 April 2024. The relevant share settlement price in relation to the quarterly repayments and interest remains calculatable based on the then prevailing VWAP.\nThe Amendments are subject to the following conditions having been satisfied by 15 January 2026 (the \"Long Stop Date\"):\n\u00b7\nAvacta completing a fundraise of, or receiving gross proceeds of at least \u00a313,000,000 in aggregate on or prior to the Long Stop Date by way of:\no\nEntering into any partnership or other agreements in respect of its pharmaceutical products; and/or\no\nAny strategic investment into the Company; and/or;\no\nAn equity fundraise\nChristina Coughlin, CEO of Avacta commented:\n\"I am very pleased Avacta has been able to raise the necessary funds to pay off the October instalment of the convertible bond ahead of schedule and also reach an agreement with the Bondholder to amend the terms of the convertible bond.\n\"The amendment to the terms of the convertible bond is representative of the excellent progress our pre|CISION\u00ae platform continues to make in the clinic and our laboratories, and its terms demonstrate our confidence in Avacta's ability to partner pre|CISION\u00ae across a number of modalities as well as our ability to source additional funding. The initial clinical activity observed in Phase 1b of the FAP-Dox trial is highly encouraging and has further increased our confidence in the utility of our pre|CISION\u00ae platform to transform how we treat cancer.\"\nAdmission and Total Voting Rights\nApplication will be made to the London Stock Exchange for the admission to trading on AIM of the 6,500,000 Placing Shares resulting from the Placing, which is expected to occur at or around 8.00 am on 12 September 2025 (\"Admission\"). The Placing Shares will rank\npari passu\nwith the existing ordinary shares of 10 pence each (\"Ordinary Shares\") of the Company.\nFollowing Admission, the Company's enlarged issued share capital will be 411,048,875. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial ",
          "content_length": 23151
        },
        "ingested_at": "2026-01-21T03:29:59.778004Z"
      },
      {
        "event_id": "RNS-30th Jul 2025-avactato",
        "event_type": "rns_announcement",
        "date": "2026-01-21T03:29:59.778018Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Avacta to Present at ESMO Congress",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/AVCT/avacta-to-present-at-esmo-congress-u6jnp2dn669m5io.html",
          "rns_number": "RNS Number : 1598T",
          "full_content": "30 Jul 2025 07:00\nRNS Number : 1598T\nAvacta Group PLC\n30 July 2025\nAvacta to Present New FAP Dox (AVA6000) Data at the European Society for Medical Oncology (ESMO) Congress\nLONDON AND PHILADELPHIA\n- July 30, 2025 -\nAvacta Therapeutics (AIM: AVCT, 'the Company'), a life sciences company developing innovative, targeted oncology drugs, today announces that the Company will present an updated data analysis from the Phase 1a trial of FAP-Dox (AVA6000) at the 2025 European Society for Medical Oncology (ESMO) Congress, in Berlin, Germany, taking place from October 17-21, 2025.\nAVA6000 is a peptide drug conjugate consisting of doxorubicin conjugated with a peptide moiety that is specifically cleaved by FAP in the tumor microenvironment.\nThe poster presentation will be based on the most recent data analysis from the Phase 1a trial of FAP-Dox (AVA6000) in patients with Fibroblast Activation Protein (FAP)-positive solid tumors. Avacta completed the Phase 1a enrollment dose escalation portion of the clinical trial in late 2024, with patient enrollment ongoing in multiple dose expansion cohorts of a Phase 1b study.\nAbstract details are listed below and available online on the ESMO website.\nAvacta will hold an investor event shortly after the ESMO presentation. Further details will be made available nearer the time.\nTitle:\nA Phase I trial of FAP-Dox (AVA6000), a Fibroblast Activation Protein (FAP)-released and tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with FAP-positive solid tumors\nSession Title\n: Developmental Therapeutics\nSession Date and Time:\n17 October, 19:40 - 20:00\nLocation:\nBerlin Auditorium - Hub 27\nAbstract Presentation Number:\n964P\nSpeaker:\nWilliam D. Tap\n-Ends-\nFor further information from Avacta, please contact:\nAvacta Group plc\nMichael Vinegrad, Group Communications\nDirector\nhttps://avacta.com/\nPeel Hunt (Nomad and Joint Broker)\nJames Steel / Chris Golden\nwww.peelhunt.com\nPanmure Liberum (Joint Broker)\nEmma Earl / Will Goode / Mark Rogers\nZeus (Joint Broker)\nJames Hornigold / George Duxberry\nDominic King\nwww.panmureliberum.com\nwww.zeuscapital.co.uk\nICR Healthcare (Europe/UK media and investors)\nMary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert\navacta@icrhealthcare.com\nInvestor Contact\nRenee Leck\nTHRUST Strategic Communications\nrenee@thrustsc.com\nMedia Contact\nCarly Scaduto\nCarly Scaduto Consulting\nCarly@carlyscadutoconsulting.com\nAbout Avacta\n-\nwww.avacta.com\nAvacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION\u00ae\u00a0platform. pre|CISION\u00ae\u00a0is a\u00a0proprietary payload delivery system\nbased on a tumor-specific protease (fibroblast activation protein or FAP)\u00a0that is designed to concentrate highly potent payloads in the tumor microenvironment while sparing normal tissues. Our innovative pipeline consists of pre|CISION\u00ae\u00a0peptide drug conjugates (PDC) or Affimer\u00ae\u00a0drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates.\nAbout the pre|CISION\u00ae Platform\nThe pre|CISION\u00ae platform comprises an anticancer payload conjugated to a proprietary peptide that is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The pre|CISION\u00ae platform harnesses this tumor specific protease to cleave pre|CISION\u00ae peptide drug conjugates and pre|CISION\u00ae antibody/Affimer\u00ae drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity, allowing dosing to be optimized to deliver the best outcomes for patients.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nMSCRMMATMTJJMLA",
          "content_length": 4482
        },
        "ingested_at": "2026-01-21T03:29:59.778031Z"
      },
      {
        "event_id": "RNS-28th Jul 2025-agreemen",
        "event_type": "rns_announcement",
        "date": "2026-01-21T03:29:59.778044Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Agreement to Sell Coris Bioconcept SRL",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/AVCT/agreement-to-sell-coris-bioconcept-srl-uw286sbv1ibhsp0.html",
          "rns_number": "RNS Number : 7789S",
          "full_content": "28 Jul 2025 07:48\nRNS Number : 7789S\nAvacta Group PLC\n28 July 2025\nAvacta Announces Agreement to Sell Coris Bioconcept SRL\nCompletes transition to a pure-play therapeutics business\nLONDON AND PHILADELPHIA\n- July 28, 2025 -\nAvacta Therapeutics (AIM: AVCT, 'the Company'), a life sciences company developing innovative, targeted oncology drugs, today announced the sale of\nCoris Bioconcept SRL (\"\nCoris\n\")\nto\n3B BlackBio Dx Ltd\nfor an upfront cash consideration of \u00a3\n2\n.\n15\nMillion (including net cash & customary working capital adjustments) with an additional earn-out based on future business performance of up to \u00a3\n0\n.\n615\nMillion. Completion of the sale is expected in August 2025, subject to customary closing conditions.\nThis sale follows the divestment of Launch Diagnostics completed in\nMarch 2025\nand is the important final step in the Company's goal of becoming a pure-play therapeutics business. The sale proceeds will be used to further Avacta's pre|CISION\n\u00ae\nplatform.\nCoris\nreported unaudited revenue of \u20ac5.22 Million for the financial year ended 31 December 2024 (\"FY24\"), primarily driven by sales from non-COVID products. In FY24\nCoris\nrecorded negative EBITDA of \u20ac0.215 Million and its net assets at the year-end stood at \u20ac4.14 Million.\nFollowing the sale of Coris, the Company's cash runway will extend further into Q1 2026.\nIn the year ending 31 December 2024, the Group reported a noncash impairment charge of \u00a3\n6\n.\n8\nMillion as a result of this disposal.\nChristina Coughlin, M.D., Ph.D., Chief Executive Officer of Avacta, said:\n\"This disposal marks the pivotal final step in Avacta's transition to a pure-play therapeutics company. We are now fully focused on advancing\nour promising peptide drug conjugate pipeline powered by our innovative pre|CISION\n\u00ae\ntechnology, which is delivering\nprecision oncology treatments that have the potential to make a meaningful impact on patient outcomes.\"\n-Ends-\nFor further information from Avacta, please contact:\nAvacta Group plc\nMichael Vinegrad, Group Communications\nDirector\nhttps://avacta.com/\nPeel Hunt (Nomad and Joint Broker)\nJames Steel / Chris Golden\nwww.peelhunt.com\nPanmure Liberum (Joint Broker)\nEmma Earl / Will Goode / Mark Rogers\nZeus (Joint Broker)\nJames Hornigold / George Duxberry\nDominic King\nwww.panmureliberum.com\nwww.zeuscapital.co.uk\nICR Healthcare (Europe/UK media and investors)\nMary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert\navacta@icrhealthcare.com\nInvestor Contact\nRenee Leck\nTHRUST Strategic Communications\nrenee@thrustsc.com\nMedia Contact\nCarly Scaduto\nCarly Scaduto Consulting\nCarly@carlyscadutoconsulting.com\nAbout Avacta\n-\nwww.avacta.com\nAvacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION\u00ae\u00a0platform. pre|CISION\u00ae\u00a0is a\u00a0proprietary payload delivery system\nbased on a tumor-specific protease (fibroblast activation protein or FAP)\u00a0that is designed to concentrate highly potent payloads in the tumor microenvironment while sparing normal tissues. Our innovative pipeline consists of pre|CISION\u00ae\u00a0peptide drug conjugates (PDC) or Affimer\u00ae\u00a0drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates.\nAbout the pre|CISION\u00ae Platform\nThe pre|CISION\u00ae platform comprises an anticancer payload conjugated to a proprietary peptide that is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The pre|CISION\u00ae platform harnesses this tumor specific protease to cleave pre|CISION\u00ae peptide drug conjugates and pre|CISION\u00ae antibody/Affimer\u00ae drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity, allowing dosing to be optimized to deliver the best outcomes for patients.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nAGRQVLBLEDLZBBE",
          "content_length": 4670
        },
        "ingested_at": "2026-01-21T03:29:59.778056Z"
      },
      {
        "event_id": "RNS-21st Jul 2025-paymento",
        "event_type": "rns_announcement",
        "date": "2026-01-21T03:29:59.778069Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Payment of Convertible Bond Installment",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/AVCT/payment-of-convertible-bond-installment-xyu013gswwk8jed.html",
          "rns_number": "RNS Number : 8230R",
          "full_content": "21 Jul 2025 07:00\nRNS Number : 8230R\nAvacta Group PLC\n21 July 2025\nAvacta Group plc\n(\"Avacta\" or the \"Group\" or the \"Company\")\nPayment of Convertible Bond Installment\nLONDON and PHILADELPHIA - 21 July 2025 - Avacta (AIM: AVCT),\na life sciences company developing innovative, targeted oncology drugs, confirms that further to the announcement of the \u00a33.25m equity financing on 17 July 2025 (the \"Placing\"), it has settled the quarterly principal of \u00a32.55 million and interest repayment of c.\u00a30.414 million in respect of the Company's unsecured convertible bond in cash. The Placing is due to complete on 24 July 2025.\nAfter settlement of the quarterly repayment, the principal remaining under the convertible bond will be reduced by \u00a32.55 million to \u00a322.95 million.\n-Ends-\nFor further information from Avacta Group plc, please contact:\nAvacta Group plc\nMichael Vinegrad, Group Communications\nDirector\nhttps://avacta.com/\nPeel Hunt (Nomad and Joint Broker)\nJames Steel / Chris Golden\nwww.peelhunt.com\nPanmure Liberum (Joint Broker)\nEmma Earl / Will Goode / Mark Rogers\nZeus (Joint Broker)\nJames Hornigold / George Duxberry\nDominic King\nICR Healthcare\nMary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert\nhttps://panmureliberum.com/\nwww.zeuscapital.co.uk\navacta@icrhealthcare.com\nInvestor Contact\nRenee Leck\nTHRUST Strategic Communications\nrenee@thrustsc.com\nMedia Contact\nCarly Scaduto\nCarly Scaduto Consulting\nCarly@carlyscadutoconsulting.com\nAbout Avacta\n-\nwww.avacta.com\nAvacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION\u00ae platform. pre|CISION\u00ae is a\u00a0proprietary warhead delivery system\nbased on a tumor-specific protease (fibroblast activation protein or FAP)\u00a0that is designed to concentrate highly potent warheads in the tumor microenvironment while sparing normal tissues. Our innovative pipeline consists of pre|CISION\u00ae\u00a0peptide drug conjugates (PDC) or Affimer\u00ae\u00a0drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates.\nAbout the pre|CISION\u00ae Platform\nThe pre|CISION\u00ae platform comprises an anticancer payload conjugated to a proprietary peptide that is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The pre|CISION\u00ae platform harnesses this tumor specific protease to cleave pre|CISION\u00ae peptide drug conjugates and pre|CISION\u00ae antibody/Affimer\u00ae drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity, allowing dosing to be optimized to deliver the best outcomes for patients.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nMSCVBLFLEDLBBBZ",
          "content_length": 3506
        },
        "ingested_at": "2026-01-21T03:29:59.778081Z"
      },
      {
        "event_id": "RNS-17th Jul 2025-equityfu",
        "event_type": "rns_announcement",
        "date": "2026-01-21T03:29:59.778095Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Equity fundraise of \u00a33.25 million",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/AVCT/equity-fundraise-of-163325-million-f166wsff5zuc63c.html",
          "rns_number": "RNS Number : 4628R",
          "full_content": "17 Jul 2025 07:00\nRNS Number : 4628R\nAvacta Group PLC\n17 July 2025\nTHIS ANNOUNCEMENT AND THE INFORMATION CONTAINED IN IT, IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. PLEASE SEE THE IMPORTANT NOTICE IN THIS ANNOUNCEMENT.\nTHIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF THE MARKET ABUSE REGULATION (EU) 596 / 2014 WHICH FORMS PART OF\u00a0UK\u00a0LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 (\"MAR\").\nAvacta Group plc\n(\"Avacta\" or the \"Group\" or the \"Company\")\nEquity fundraise of \u00a33.25 million\nLONDON and PHILADELPHIA - 17 July 2025 - Avacta (AIM: AVCT),\na life sciences company developing innovative, targeted oncology drugs, is pleased to announce that it has raised gross proceeds of \u00a33.25 million from long term, high net worth investors introduced by Zeus Capital Limited by way of a conditional placing of 10,833,333 new ordinary shares of 10 pence each in the Company (the \"Placing Shares\") at a price of 30 pence per share (the \"Issue Price\"), together (the \"Placing\").\nThe net proceeds of approximately \u00a33.1 million from the Placing will effectively be used to settle the July quarterly repayment of the unsecured convertible bond which is due to be paid on 21 July 2025.\nThe Issue Price of the Placing Shares represents a lower level of dilution to Avacta's shareholders than would have been the case through the share-based payment route under the terms of the bond.\nApplication has been made to the London Stock Exchange for the admission to trading on AIM of the 10,833,333 Placing Shares resulting from the Placing, which is expected to occur at or around 8.00 am on 24 July 2025 (\"Admission\"). The Placing Shares will rank\npari passu\nwith the existing ordinary shares of 10 pence each (\"Ordinary Shares\") of the Company.\nFollowing Admission, the Company's enlarged issued share capital will be 404,548,875 Ordinary Shares. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.\nChristina Coughin, CEO of Avacta commented:\n\"This placing for July's convertible bond repayment presents us with greater funding solution optionality, as we enter a pivotal period commercially with multiple catalysts over the coming months. I am very confident our strengthened Board and management team will ensure we are well positioned to capitalize on the multiple opportunities our pre|CISION\n\u00ae\ntechnology is enabling\"\n.\nFurther details of the Placing can be found below.\n-Ends-\nFor further information from Avacta Group plc, please contact:\nAvacta Group plc\nMichael Vinegrad, Group Communications\nDirector\nwww.avacta.com\nPeel Hunt (Nomad and Joint Broker)\nJames Steel / Chris Golden\nwww.peelhunt.com\nPanmure Liberum (Joint Broker)\nEmma Earl / Will Goode / Mark Rogers\nZeus (Joint Broker)\nJames Hornigold / George Duxberry\nDominic King\nICR Healthcare\nMary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert\nwww.panmureliberum.com\nwww.\nzeuscapital.co.uk\navacta@icrhealthcare.com\nInvestor Contact\nRenee Leck\nTHRUST Strategic Communications\nrenee@thrustsc.com\nMedia Contact\nCarly Scaduto\nCarly Scaduto Consulting\nCarly@carlyscadutoconsulting.com\nAbout Avacta\n-\nwww.avacta.com\nAvacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION\u00ae platform. pre|CISION\u00ae is a\u00a0proprietary warhead delivery system\nbased on a tumor-specific protease (fibroblast activation protein or FAP)\u00a0that is designed to concentrate highly potent warheads in the tumor microenvironment while sparing normal tissues. Our innovative pipeline consists of pre|CISION\u00ae\u00a0peptide drug conjugates (PDC) or Affimer\u00ae\u00a0drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates.\nBackground to the fundraise\nThe Placing has been conducted by Zeus Capital Limited (\"Zeus\") as sole bookrunner and Turner Pope Investments (TPI) Limited (\"Turner Pope\") as placing agent (the \"Placing Agent\").\nThe Placing\nThe Placing comprises\nthe issue of 10,833,333 Placing Shares at the Issue Price to conditionally raise approximately \u00a33.25 million before expenses for the Company.\nThe Placing Shares will represent approximately 2.7 per cent of the enlarged share capital of the Company (as enlarged by the Placing Shares) and will rank\npari passu\nwith the existing Ordinary Shares.\nThe Company, Zeus and Turner Pope have entered into a placing agreement (the \"Placing Agreement\"). Pursuant to the terms of the Placing Agreement, Zeus and Turner Pope, as agents for the C",
          "content_length": 22514
        },
        "ingested_at": "2026-01-21T03:29:59.778129Z"
      },
      {
        "event_id": "RNS-2nd Jul 2025-resultof",
        "event_type": "rns_announcement",
        "date": "2026-01-21T03:29:59.778144Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Result of AGM",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/AVCT/result-of-agm-mf559qysuc4d3aw.html",
          "rns_number": "RNS Number : 4867P",
          "full_content": "2 Jul 2025 17:00\nRNS Number : 4867P\nAvacta Group PLC\n02 July 2025\nAvacta Group plc\n(\"Avacta\" or the \"Group\" or the \"Company\")\nResult of AGM\nLONDON and\nPHILADELPHIA\n- July, 2 2025 -\nAvacta Group plc (AIM: AVCT),\na life sciences company developing innovative, targeted oncology drugs,\ntoday announces that at the Annual General Meeting (AGM) held this morning, all resolutions were duly passed by shareholders (with the exception of Resolution 3 which was not put to the meeting).\nThe results of the voting at the AGM are outlined in the table below and\nthe presentation materials are available\non the Company's website\nhere\n.\nFor\nAgainst\nWithheld\nResolution\nVotes\n%\nVotes\n%\nVotes\n1\n69,286,714\n99.84%\n111,935\n0.16%\n2,231,336\n2\n52,723,506\n77.25%\n15,527,142\n22.75%\n3,379,337\n3\nSee above\n-\nSee above\n-\nSee above\n4\n70,378,158\n99.32%\n482,896\n0.68%\n768,931\n5\n68,687,888\n98.79%\n843,416\n1.21%\n2,098,681\n6\n68,241,916\n97.50%\n1,747,126\n2.50%\n1,640,943\n7\n70,242,593\n99.58%\n293,323\n0.42%\n1,094,069\n8\n61,988,039\n90.99%\n6,139,673\n9.01%\n3,502,273\n9\n64,805,029\n98.71%\n850,095\n1.29%\n5,974,861\n10\n65,957,356\n97.83%\n1,462,237\n2.17%\n4,210,392\n11\n64,414,344\n96.66%\n2,229,203\n3.34%\n4,986,438\n12\n64,418,047\n96.71%\n2,189,948\n3.29%\n5,021,990\n13\n67,217,793\n99.14%\n580,188\n0.86%\n3,832,004\nAlthough all the resolutions were passed, the Board of Avacta notes that more than 20% of votes were cast against Resolution 2. The Board will continue to engage with shareholders in the periods ahead and remains committed to open and constructive dialogue in order to understand shareholders' views. To this end, shareholders who voted against resolution 2 can email any views to\navacta@icrhealthcare.com\n.\n-Ends -\nFor further information from Avacta Group plc, please contact:\nAvacta Group plc\nMichael Vinegrad,\nGroup Communications Director\nhttps://avacta.com/\nPeel Hunt (Nomad and Joint Broker)\nJames Steel / Chris Golden\nwww.peelhunt.com\nPanmure Liberum (Joint Broker)\nEmma Earl / Will Goode / Mark Rogers\nZeus (Joint Broker)\nJames Hornigold / George Duxberry\nDominic King\nICR Healthcare\nMary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert\nwww.panmureliberum.com\nwww.zeuscapital.co.uk\navacta@icrhealthcare.com\nInvestor Contact\nRenee Leck\nTHRUST Strategic Communications\nrenee@thrustsc.com\nMedia Contact\nCarly Scaduto\nCarly Scaduto Consulting\nCarly@carlyscadutoconsulting.com\nAbout Avacta\n-\nhttps://avacta.com/\nAvacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION\u00ae\u00a0platform. pre|CISION\u00ae\u00a0is a\u00a0proprietary warhead delivery system\nbased on a tumor-specific protease (fibroblast activation protein or FAP)\u00a0that is designed to concentrate highly potent warheads in the tumor microenvironment while sparing normal tissues. Our innovative pipeline consists of pre|CISION\u00ae\u00a0peptide drug conjugates (PDC) or Affimer\u00ae\u00a0drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nRAGEASXAESASEFA",
          "content_length": 3782
        },
        "ingested_at": "2026-01-21T03:29:59.778156Z"
      },
      {
        "event_id": "RNS-2nd Jul 2025-q22025bu",
        "event_type": "rns_announcement",
        "date": "2026-01-21T03:29:59.778169Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Q2 2025 Business Update",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/AVCT/q2-2025-business-update-4ultkn5e1ed41ys.html",
          "rns_number": "RNS Number : 3813P",
          "full_content": "2 Jul 2025 07:00\nRNS Number : 3813P\nAvacta Group PLC\n02 July 2025\nAvacta Provides Q2 2025 Business Update\nOutlining Progress Against Strategic Objectives\nAVA6000 Phase 1b expansion cohorts continue to enroll with encouraging initial signals of efficacy\nAvacta strengthens the Executive Management Team and Board of Directors with multiple additions\nLONDON AND PHILADELPHIA\n- July 2, 2025 -\nAvacta Therapeutics (AIM: AVCT, 'the Company'), a life sciences company developing innovative, targeted oncology drugs, today provides a business update ahead of the Annual General Meeting of Shareholders outlining progress against its strategic objectives for 2025 and a review of upcoming milestones.\nChristina Coughlin, M.D., Ph.D., Chief Executive Officer of Avacta, said:\n\"The Company is focused on advancing our promising peptide drug conjugate pipeline with our innovative pre|CISION\n\u00ae\ntechnology. We are making strong progress with the clinical development of FAP-Dox (AVA6000), with patient enrollment ongoing in multiple dose expansion cohorts of our ongoing Phase 1b study, including triple negative breast cancer.\n\"The data continue to show a favorable tolerability profile and increasingly durable responses in salivary gland cancers.\nThe AVA6103 program is progressing towards the start of a Phase 1 trial early next year, reflecting efforts to develop a new class of medicines aimed at improving drug delivery and patient outcomes. These advances in pre|CISION\n\u00ae\nwill continue to drive value in the Company for shareholders.\"\npre|CISION\u00ae Medicine Pipeline\n\u25cf\nFAP-Dox (AVA6000), a pre|CISION\u00ae-enabled form of doxorubicin chemotherapy, continues to progress in Phase 1b studies.\nDuring the second quarter, patient\nenrollment\ncontinued across the expansion cohorts, with early signs of efficacy observed, including a robust partial response in a patient with salivary gland cancer, with a nearly 50% reduction in tumor diameters. We remain on track to release the initial data in salivary gland cancer in late 2025 and in triple negative breast cancer in H1 2026.\n\u25cf\nFAP-EXd (AVA6103),\na pre|CISION\u00ae-enabled PDC comprised of the pre|CISION\u00ae peptide linked to exatecan, continues preclinical development\n. AVA6103 is currently in investigational new drug (IND)-enabling studies with a Phase 1 trial anticipated to begin in the first quarter of 2026.\n\u25cf\nMultiple Data Presentations at the American Association for Cancer Research (AACR) Annual Congress.\nIn April\nAvacta presented three posters at the\nAACR Annual Meeting, showcasing continued progress across its pipeline. These included an update from the salivary gland cancer cohort of the Phase 1a trial of\nFAP-Dox (AVA6000),\nwith sustained durable responses observed in multiple patients. Notably, median progression free survival (PFS) had not yet been reached after a follow-up of 5.9 months, nearly double that reported in published benchmark data (Licitra et a. ESMO 2024). The two additional presentations featured preclinical data from Avacta's second agent, FAP-EXd (AVA6103), along with translational work with the proprietary pre|CISION\u00ae\u00a0platform. Further updates on the next generation peptide drug conjugates (PDCs) are expected later in 2025.\n\u25cf\nWe continue to engage with third parties across a range of commercial opportunities reflecting the breadth of the pre|CISION\u00ae platform and progressing these discussions remains a top priority. We are also discussing\nFAP-Dox\nwith a range of parties who are keen to assess additional data which is due later this year and in H1 2026.\nChanges to Board and Executive Management Team\n\u25cf\nChanges to the Board of Directors.\nTwo directors, Richard Hughes, founder of Zeus Capital with deep UK capital markets experience, and David Bryant, with\nextensive commercial industry knowledge and networks, have joined the Avacta Board of Directors\n. Darlene Deptula-Hicks has resigned with immediate effect from the Board to enable her to focus on other business interests.\n\u25cf\nStrengthened Executive Management Team and Business Development.\nDavid Liebowitz was named Chief Medical Officer on July 1, 2025. David joins Avacta with deep clinical development experience and publicly traded company experience. Avacta has also appointed Yulii Bogatyrenko as a consultant in the business development team on July 1, 2025, with a focus on supporting the Company's commercial partnership strategy. Yulii brings long experience of overseeing commercial deals in multiple senior level positions in large pharmaceutical companies in the US.\nAddition of Broker to the Company\n\u25cf\nZeus Capital was appointed a joint broker to the Company, along with Peel Hunt as Nomad and joint broker and Panmure Liberum as joint broker. The Company continues to develop traction with a range of investors as it assesses options to extend the Group's cash runway and to further build value in the pre|CISION\n\u00ae\nplatform.\n-Ends-\nFor further information from Avacta, please contact:\nAvacta Group plc\nMichael Vinegrad, Group Communications\nD",
          "content_length": 7636
        },
        "ingested_at": "2026-01-21T03:29:59.778184Z"
      },
      {
        "event_id": "RNS-1st Jul 2025-manageme",
        "event_type": "rns_announcement",
        "date": "2026-01-21T03:29:59.778197Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Management Team Appointments",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/AVCT/management-team-appointments-t5jii5nuq7ltlr6.html",
          "rns_number": "RNS Number : 0880P",
          "full_content": "1 Jul 2025 07:00\nRNS Number : 0880P\nAvacta Group PLC\n01 July 2025\nAvacta Group plc\n(\"Avacta\" or the \"Group\" or the \"Company\")\nAvacta Appoints David Liebowitz, M.D., Ph.D. as Chief Medical Officer and Yulii Bogatyrenko as Advisor in Business Development\nLONDON and\nPHILADELPHIA\n- July 1, 2025 -\nAvacta Group plc (AIM: AVCT),\na life sciences company developing innovative, targeted oncology drugs,\ntoday announces the appointment of\nDavid Liebowitz, M.D., Ph.D.\nas\nChief Medical Officer (CMO) and Yulii Bogatyrenko as an advisor in business development\n. Dr. Liebowitz will lead the Company's clinical strategy and execution as it continues to advance its pipeline of targeted cancer therapies and Mr. Bogatyrenko will add additional strength to the Group's business development strategy.\nDr. Liebowitz is a seasoned hematologist-oncologist and drug development leader with more than 30 years of experience across academia and industry and has contributed to the successful filing of more than 25 Investigational New Drug (IND) applications. He joins Avacta from Inovio Pharmaceuticals (Nasdaq: INO), where he served as Senior Vice President of early-stage clinical development, overseeing the clinical strategy for DNA-based vaccines and immunotherapies. Prior to that, he held senior roles at Xencor, Vaxart, and Amgen, with a consistent focus on oncology, immunotherapy, and translational science. At Vaxart, Dr. Liebowitz led the acquisition and execution of a significant BARDA contract as principal investigator, culminating in successful completion of the award. Earlier in his career, he held key R&D leadership roles at Amgen, where he directed oncology and vascular biology drug discovery at the company's Washington research site.\nDr. Liebowitz began his academic career at the University of Chicago, where he served as Assistant Professor of Medicine and Virology and Director of the Bone Marrow Transplantation Program. He later became an associate investigator at the University of Pennsylvania's Abramson Cancer Institute, where he led immunotherapy and cellular therapy programs focused on cancer and chronic viral diseases, and was a recipient of a Bill & Melinda Gates Foundation grant. Dr. Liebowitz holds MD and PhD. degrees from the University of Chicago and BS and MS degrees from Emory University.\nMr. Bogatyrenko is a Principal at Biopharma C&I, a biotechnology consulting firm that works with private and public companies in business development, corporate strategy, commercialization, launch readiness and R&D strategy. Previously, he held senior level positions in business development and commercial strategy, including leading multiple global commercial drug launches and numerous industry partnerships at Pfizer/Wyeth, Bayer Healthcare and Teva Specialty Pharmaceuticals.\nChristina Coughlin, MD, PhD, CEO of Avacta, commented:\n\"We are thrilled to welcome David and Yulii at this pivotal time for Avacta. David's deep expertise in oncology, coupled with a successful track record of advancing innovative therapies into the clinic, will be instrumental as we continue to execute on our clinical development strategy and progress our pre|CISION\u2122 platform and pipeline of targeted cancer therapies.\nYulii's deep experience across commercial strategy, global drug launches, and industry partnerships at leading pharma organizations will be invaluable as we advance our pipeline and corporate growth strategy.\"\n\"We look forward to benefiting from their insights and strategic perspective as we remain focused on driving value for both patients and shareholders.\"\n-Ends -\nFor further information from Avacta Group plc, please contact:\nAvacta Group plc\nMichael Vinegrad,\nGroup Communications Director\nhttps://avacta.com/\nPeel Hunt (Nomad and Joint Broker)\nJames Steel / Chris Golden\nwww.peelhunt.com\nPanmure Liberum (Joint Broker)\nEmma Earl / Will Goode / Mark Rogers\nZeus (Joint Broker)\nJames Hornigold / George Duxberry\nDominic King\nICR Healthcare\nMary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert\nwww.panmureliberum.com\nwww.zeuscapital.co.uk\navacta@icrhealthcare.com\nInvestor Contact\nRenee Leck\nTHRUST Strategic Communications\nrenee@thrustsc.com\nMedia Contact\nCarly Scaduto\nCarly Scaduto Consulting\nCarly@carlyscadutoconsulting.com\nAbout Avacta\n-\nwww.avacta.com\nAvacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION\u00ae\u00a0platform. pre|CISION\u00ae\u00a0is a\u00a0proprietary warhead delivery system\nbased on a tumor-specific protease (fibroblast activation protein or FAP)\u00a0that is designed to concentrate highly potent warheads in the tumor microenvironment while sparing normal tissues. Our innovative pipeline consists of pre|CISION\u00ae\u00a0peptide drug conjugates (PDC) or Affimer\u00ae\u00a0drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates.\nThis information is provided by RNS, the news service of the London Stock Exchange. ",
          "content_length": 5695
        },
        "ingested_at": "2026-01-21T03:29:59.778213Z"
      },
      {
        "event_id": "RNS-30th Jun 2025-appointm",
        "event_type": "rns_announcement",
        "date": "2026-01-21T03:29:59.778226Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Appointment of Zeus Capital as Joint Broker",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/AVCT/appointment-of-zeus-capital-as-joint-broker-jymd35b10nfa9zv.html",
          "rns_number": "RNS Number : 0314P",
          "full_content": "30 Jun 2025 15:00\nRNS Number : 0314P\nAvacta Group PLC\n30 June 2025\nAvacta Group plc\n(\"Avacta\" or the \"Group\" or the \"Company\")\nAppointment of Zeus Capital as Joint Broker to Avacta Group plc\nLONDON and PHILADELPHIA - June 30, 2025 - Avacta Therapeutics (AIM: AVCT),\na life sciences company developing innovative, targeted oncology drugs, today announces\nthe appointment of Zeus Capital as a joint broker to the Company with immediate effect.\nPeel Hunt and Panmure Liberum both continue in their respective roles as NOMAD and Joint Broker and Joint Broker to the Company.\nRelated Party Transaction\nRichard Hughes, a Director of the Company, is an associate of Zeus Capital as defined under the AIM Rules. Zeus Capital\u00a0is therefore a related party of the Company pursuant to the AIM Rules and the appointment of Zeus Capital including a \u00a375,000 annual retainer due to Zeus Capital is a related party transaction. The Directors (other than Richard Hughes who is an associate of Zeus Capital) consider, having consulted with the Company's nominated adviser\u00a0Peel Hunt, that the appointment of Zeus Capital including the annual retainer are fair and reasonable insofar as Shareholders are concerned.\n-Ends-\nFor further information from Avacta Group plc, please contact:\nAvacta Group plc\nMichael Vinegrad, Group Communications\nDirector\nhttps://avacta.com/\nPeel Hunt (Nomad and Joint Broker)\nJames Steel / Chris Golden\nwww.peelhunt.com\nPanmure Liberum (Joint Broker)\nEmma Earl / Will Goode / Mark Rogers\nZeus (Joint Broker)\nJames Hornigold / George Duxberry\nDominic King\nICR Healthcare\nMary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert\nhttps://panmureliberum.com/\nwww.zeuscapital.co.uk\navacta@icrhealthcare.com\nInvestor Contact\nRenee Leck\nTHRUST Strategic Communications\nrenee@thrustsc.com\nMedia Contact\nCarly Scaduto\nCarly Scaduto Consulting\nCarly@carlyscadutoconsulting.com\nAbout Avacta\n-\nwww.avacta.com\nAvacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION\u00ae platform. pre|CISION\u00ae is a\u00a0proprietary warhead delivery system\nbased on a tumor-specific protease (fibroblast activation protein or FAP)\u00a0that is designed to concentrate highly potent warheads in the tumor microenvironment while sparing normal tissues. Our innovative pipeline consists of pre|CISION\u00ae\u00a0peptide drug conjugates (PDC) or Affimer\u00ae\u00a0drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nMSCEADKEDLSSEFA",
          "content_length": 3308
        },
        "ingested_at": "2026-01-21T03:29:59.778239Z"
      },
      {
        "event_id": "RNS-19th Jun 2025-newrespo",
        "event_type": "rns_announcement",
        "date": "2026-01-21T03:29:59.778252Z",
        "source": "LSE_RNS",
        "data": {
          "title": "New Response in Phase 1b Trial",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/AVCT/new-response-in-phase-1b-trial-d1xrfy7uzfxbsbz.html",
          "rns_number": "RNS Number : 5471N",
          "full_content": "19 Jun 2025 07:00\nRNS Number : 5471N\nAvacta Group PLC\n19 June 2025\nAvacta Group plc\n(\"Avacta\" or the \"Group\" or the \"Company\")\nNew Response in the FAP-Dox (AVA6000) Phase 1b Trial\nLONDON and PHILADELPHIA - June 19, 2025 - Avacta Therapeutics (AIM: AVCT),\na life sciences company developing innovative, targeted oncology drugs, today announces\na new partial response observed in a patient with salivary gland cancer (SGC) in the dose expansion phase of the FAP-Dox (AVA6000) Phase 1b trial.\nThis further signal of antitumor activity in this disease setting is encouraging as the expansion cohort continues to enroll in the indication of salivary gland cancer. This patient is a 69-year-old male with metastatic salivary gland cancer. His prior therapy includes surgery and radiation with no prior systemic therapy. His combined tumor diameter was reduced at the first scan by almost 50%, qualifying as a partial response.\nRecent data presented by the Company at the American Association of Cancer Research (AACR) annual meeting in April 2025 described the Phase 1a cohort of patients with one confirmed partial response and multiple minor responses with a disease control rate of 91%. At the time of the data cutoff, the median progression free survival had not been reached and the data are trending to a doubling of the benchmark PFS in this pretreated setting. Recent benchmark data were published at ESMO in 2024 (Licitra\net al.\nESMO Annual Congress 2024). The unmet need in this rare tumor type is very high, with metastatic salivary gland cancer having no preferred standard therapy.\nThe Company plans to publish the final data from the AVA6000 Phase 1a in the second half of 2025. Further, the Company will provide a business update on the date of the Annual General Meeting, on July 2, 2025.\nChristina Coughlin, CEO Avacta commented:\n\"We are thrilled to see the antitumor activity of FAP-Dox (AVA6000) in this disease with no preferred standard therapy. The high unmet need in this indication underscores the potential for FAP-Dox to have a meaningful impact to patients. We are encouraged by this response and remain focused on delivering further updates in this setting later in 2025.\"\n-Ends-\nFor further information from Avacta Group plc, please contact:\nAvacta Group plc\nMichael Vinegrad, Group Communications\nDirector\nwww.avacta.com\nPeel Hunt (Nomad and Joint Broker)\nJames Steel / Chris Golden\nwww.peelhunt.com\nPanmure Liberum (Joint Broker)\nEmma Earl / Will Goode / Mark Rogers\nICR Healthcare\nMary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert\nwww.panmureliberum.com\navacta@icrhealthcare.com\nInvestor Contact\nRenee Leck\nTHRUST Strategic Communications\nrenee@thrustsc.com\nMedia Contact\nCarly Scaduto\nCarly Scaduto Consulting\nCarly@carlyscadutoconsulting.com\nAbout Avacta\n-\nwww.avacta.com\nAvacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION\u00ae platform. pre|CISION\u00ae is a\u00a0proprietary warhead delivery system\nbased on a tumor-specific protease (fibroblast activation protein or FAP)\u00a0that is designed to concentrate highly potent warheads in the tumor microenvironment while sparing normal tissues. Our innovative pipeline consists of pre|CISION\u00ae\u00a0peptide drug conjugates (PDC) or Affimer\u00ae\u00a0drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nMSCGUGDLRXBDGUC",
          "content_length": 4210
        },
        "ingested_at": "2026-01-21T03:29:59.778265Z"
      },
      {
        "event_id": "RNS-9th Jun 2025-postingo",
        "event_type": "rns_announcement",
        "date": "2026-01-21T03:29:59.778278Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Posting of Annual Report and Revised Notice of AGM",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/AVCT/posting-of-annual-report-and-revised-notice-of-agm-4aa16hp9tfoi9bk.html",
          "rns_number": "RNS Number : 0774M",
          "full_content": "9 Jun 2025 17:15\nRNS Number : 0774M\nAvacta Group PLC\n09 June 2025\nAvacta Group plc\n(\"Avacta\" or the \"Group\" or the \"Company\")\nPosting of Annual Report and Revised Notice of AGM\nLONDON and PHILADELPHIA - June 9, 2025 - Avacta Therapeutics (AIM: AVCT),\na life sciences company developing innovative, targeted oncology drugs, today announces\nthat its Annual Report and Accounts for the year ended\u00a0December 31, 2024 and the Notice of Annual General Meeting (\"AGM\") are available on the Company's website at\nhttps://avacta.com/investors/investor-resources/\n.\nCopies of the Annual Report and Accounts and the Notice of AGM will be posted today to registered shareholders who have elected to receive them in paper form.\nThe Company had intended to hold the AGM on Monday, June 30, 2025 however due to some logistical considerations and investor feedback on the prior date, the Company will now convene the AGM for Wednesday, July 2, 2025 at 9:00 am BST. The meeting will be held at the offices of Peel Hunt LLP, 7th Floor, 100 Liverpool Street, London EC2M 2AT (the \"Venue\").\nThe Venue has a capacity of approximately 120 people. Registered shareholders have a right to attend the AGM. In addition, the current expectation is that the chair of the AGM will, at their discretion, permit beneficial shareholders to attend in person. Shareholders (registered or beneficial) who propose to attend the AGM in person are requested to pre-register their interest and, to assist the Company in its preparation for the AGM, prove their shareholding by emailing their letter of representation to ICR at\navacta@icrhealthcare.com\nby Friday,\nJune 27, 2025. Any failure to pre-register will not, of itself, preclude a registered shareholder from attending the AGM in person (or by proxy).\nOnly registered shareholders who attend in person or by proxy will be able to vote on the day. Details of how to submit a proxy vote are contained in the Notice of the AGM.\nThe Company will provide a business update following the AGM, which will be recorded and uploaded on the Company's website for shareholders who are not able to attend in person. All presentation materials will be made available on the website at the end of the day and no new material information will be provided.\nEarly pre-registration to attend the AGM in person is recommended as the venue's capacity is limited (as referred to above) and, for non-registered shareholders, registrations will be dealt with on a first come, first served basis. Those attending in person are also recommended to arrive around 30 minutes before the start of the meeting to ensure that the venue's admission procedures can be adhered to.\n-Ends-\nFor further information from Avacta Group plc, please contact:\nAvacta Group plc\nMichael Vinegrad, Group Communications\nDirector\nhttps://avacta.com/\nPeel Hunt (Nomad and Joint Broker)\nJames Steel / Chris Golden\nwww.peelhunt.com\nPanmure Liberum (Joint Broker)\nEmma Earl / Will Goode / Mark Rogers\nICR Healthcare\nMary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert\nhttps://panmureliberum.com/\navacta@icrhealthcare.com\nInvestor Contact\nRenee Leck\nTHRUST Strategic Communications\nrenee@thrustsc.com\nMedia Contact\nCarly Scaduto\nCarly Scaduto Consulting\nCarly@carlyscadutoconsulting.com\nAbout Avacta\n-\nwww.avacta.com\nAvacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION\u00ae platform. pre|CISION\u00ae is a\u00a0proprietary warhead delivery system\nbased on a tumor-specific protease (fibroblast activation protein or FAP)\u00a0that is designed to concentrate highly potent warheads in the tumor microenvironment while sparing normal tissues. Our innovative pipeline consists of pre|CISION\u00ae\u00a0peptide drug conjugates (PDC) or Affimer\u00ae\u00a0drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nACSBLGDLUBGDGUC",
          "content_length": 4687
        },
        "ingested_at": "2026-01-21T03:29:59.778291Z"
      },
      {
        "event_id": "RNS-6th Jun 2025-prelimin",
        "event_type": "rns_announcement",
        "date": "2026-01-21T03:29:59.778304Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Preliminary Full Year 2024 Results",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/AVCT/preliminary-full-year-2024-results-aylqbxprkek22hn.html",
          "rns_number": "RNS Number : 7780L",
          "full_content": "6 Jun 2025 07:00\nRNS Number : 7780L\nAvacta Group PLC\n06 June 2025\nAvacta Group plc\n(\"Avacta\", the \"Group\" or the \"Company\")\nPreliminary Results for the Year Ended December 31, 2024\nLONDON and PHILADELPHIA\n- June 6, 2025 - Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor,\u00a0has published its unaudited preliminary results for the 12 months ended December 31, 2024\u00a0(\"FY24\").\nHighlights\n\u25cf\nPositioned the business as a pure play oncology biopharmaceutical company focused on the Company's proprietary pre|CISION\u00ae peptide drug conjugate platform\n\u25cf\nFAP-Dox (AVA6000) - first pre|CISION\u00ae program\n\u25cf\nCompleted Phase 1a enrollment dose escalation portion of clinical trial\n\u25cf\nOpening of the Phase 1b expansion cohorts in salivary gland cancers, triple negative breast cancer and high-grade soft tissue sarcoma\n\u25cf\nAnticipate releasing the initial data in salivary gland cancer in late 2025 and in triple negative breast cancer in H1 2026.\n\u25cf\nPhase 2 trials in these indications planned for H1 2026\n\u25cf\nFAP-EXd (AVA6103)\n\u25cf\nClinical candidate selection enables move toward clinical testing, by advancing to Investigational New Drug (IND)-enabling studies and Good Manufacturing Practices (GMP) manufacturing process development to support initiation of the Phase 1 clinical trial in Q1 2026\n\u25cf\nEntered into a strategic collaboration with Tempus,\nleveraging AI to capture full market opportunity in both wholly owned and partnered medicines and drive smarter trials\n\u25cf\nCash and short-term deposit balances at December 31, 2024 of \u00a312.9 million (31 December 2023: \u00a316.6 million). As of April 30, 2025, \u00a317.3 million following the divestment of Launch Diagnostics extending the Company's cash runway into Q1 2026.\n\u25cf\nBoard and management strengthened - new Chief Financial Officer and Chief Scientific Officer plus two Non-Executive Directors appointed.\nChristina Coughlin, MD, PhD, CEO of Avacta, said,\n\"Over the past year, we have transformed the business into a dedicated therapeutics company focused on our unique pre|CISION\u00ae\nplatform. We are pioneering a novel, differentiated class of medicines, which has the potential to revolutionize drug delivery.\n\"This unique platform has the potential to treat up to\n90% of solid tumors by repurposing a range of effective oncology drugs to significantly reduce toxicity and side effects. This represents a potential breakthrough for patients and a major opportunity for Avacta.\n\"With our first program in the clinic, we expect to release the initial data in salivary gland cancer for FAP-Dox (AVA6000) towards the end of 2025 and in triple negative breast cancer in H1 2026 with potential for Phase 2 trials in H1 2026.\n\"FAP-EXd (AVA6103) has advanced into IND-enabling work this year and we plan to initiate the Phase 1 trial in early 2026. In parallel, we are actively pursuing a number of commercial opportunities.\n\"Overall, 2025 and 2026 are set to be a transformative for Avacta, driven by a number of catalysts to drive shareholder value.\"\n-Ends-\nFor further information, please contact:\nAvacta Group plc\nMichael Vinegrad, Group Communications\nDirector\nhttps://avacta.com/\nPeel Hunt (Nomad and Broker)\nJames Steel / Chris Golden\nwww.peelhunt.com\nPanmure Liberum (Joint Broker)\nEmma Earl / Will Goode / Mark Rogers\nwww.panmureliberum.com\nICR Healthcare\nMary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert\navacta@icrhealthcare.com\nInvestor Contact\nRenee Leck\nTHRUST Strategic Communications\nrenee@thrustsc.com\nMedia Contact\nCarly Scaduto\nCarly Scaduto Consulting\nCarly@carlyscadutoconsulting.com\nAbout Avacta\n-\nwww.avacta.com\nAvacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION\u00ae\u00a0platform. pre|CISION\u00ae\u00a0is a\u00a0proprietary warhead delivery system\u00a0based on a tumor-specific protease (fibroblast activation protein or FAP)\u00a0that is designed to concentrate highly potent warheads in the tumor microenvironment while sparing normal tissues. Our innovative pipeline consists of pre|CISION\u00ae\u00a0peptide drug conjugates (PDC) or Affimer\u00ae\u00a0drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates.\nAbout the pre|CISION\u00ae Platform\nThe pre|CISION\u00ae platform comprises an anticancer payload conjugated to a proprietary peptide that is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The pre|CISION\u00ae platform harnesses this tumor specific protease to cleave pre|CISION\u00ae peptide drug conjugates and pre|CISION\u00ae antibody/Affimer\u00ae drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity, allowing dosing to be optimized to deliver the best outcomes for patients.\nChairman's statement\nThe Group has undergone significant transform",
          "content_length": 72964
        },
        "ingested_at": "2026-01-21T03:29:59.778319Z"
      },
      {
        "event_id": "RNS-4th Jun 2025-avactach",
        "event_type": "rns_announcement",
        "date": "2026-01-21T03:29:59.778332Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Avacta Change in Prelim Date Part 2",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/AVCT/avacta-change-in-prelim-date-part-2-rpawkftvglg81ip.html",
          "rns_number": "RNS Number : 3736L",
          "full_content": "4 Jun 2025 07:00\nRNS Number : 3736L\nAvacta Group PLC\n04 June 2025\nAvacta Group plc\n(\"Avacta\" or the \"Group\" or the \"Company\")\nUpdate on timing of preliminary results announcement\nLONDON and PHILADELPHIA\n- June 4, 2025 - Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor,\u00a0today announces that the preliminary results for year ended December 31, 2024 will now be published on June 6, 2025 as the Group's auditors very recently requested some additional time to finalise their audit work.\nThere is no impact to Avacta's financial position and cash runway.\nChristina Coughlin, Chief Executive Officer and Brian Hahn, Chief Financial Officer will now deliver the planned live presentation via Investor Meet Company at 11:00 BST on June 6, 2025.\nThe presentation is open to all existing and potential shareholders.\nInvestors can sign up to Investor Meet Company for free and add to meet AVACTA GROUP PLC via:\nhttps://www.investormeetcompany.com/avacta-group-plc/register-investor\n.\nInvestors who already follow Avacta on the Investor Meet Company platform will automatically be invited.\nQuestions can be submitted pre-event via the Investor Meet Company dashboard up until June 6 at 09:00 BST, or at any time during the live presentation.\nThe Company will also post the results presentation on its website at the following page:\nhttps://avacta.com/investors/investor-resources/\n.\n-Ends -\nFor further information from Avacta Group plc, please contact:\nAvacta Group plc\nMichael Vinegrad, Group Communications\nDirector\nwww.avacta.com\nPeel Hunt (Nomad and Joint Broker)\nJames Steel / Chris Golden\nwww.peelhunt.com\nPanmure Liberum (Joint Broker)\nEmma Earl / Will Goode / Mark Rogers\nICR Healthcare\nMary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert\nwww.panmureliberum.com\navacta@icrhealthcare.com\nInvestor Contact\nRenee Leck\nTHRUST Strategic Communications\nrenee@thrustsc.com\nMedia Contact\nCarly Scaduto\nCarly Scaduto Consulting\nCarly@carlyscadutoconsulting.com\nAbout Avacta\n-\nwww.avacta.com\nAvacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION\u00ae\u00a0platform. pre|CISION\u00ae\u00a0is a\u00a0proprietary warhead delivery system\u00a0based on a tumor-specific protease (fibroblast activation protein or FAP)\u00a0that is designed to concentrate highly potent warheads in the tumor microenvironment while sparing normal tissues. Our innovative pipeline consists of pre|CISION\u00ae\u00a0peptide drug conjugates (PDC) or Affimer\u00ae\u00a0drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates.\nAbout the pre|CISION\u00ae Platform\nThe pre|CISION\u00ae platform comprises an anticancer payload conjugated to a proprietary peptide that is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The pre|CISION\u00ae platform harnesses this tumor specific protease to cleave pre|CISION\u00ae peptide drug conjugates and pre|CISION\u00ae antibody/Affimer\u00ae drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity, allowing dosing to be optimized to deliver the best outcomes for patients.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nMSCUSAVRVUUNRRR",
          "content_length": 4142
        },
        "ingested_at": "2026-01-21T03:29:59.778344Z"
      },
      {
        "event_id": "RNS-28th May 2025-boardapp",
        "event_type": "rns_announcement",
        "date": "2026-01-21T03:29:59.778357Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Board appointments",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/AVCT/board-appointments-583c0iopsre0lyk.html",
          "rns_number": "RNS Number : 3082K",
          "full_content": "28 May 2025 07:00\nRNS Number : 3082K\nAvacta Group PLC\n28 May 2025\nAvacta Group plc\n(\"Avacta\" or the \"Group\" or the \"Company\")\nBoard appointments\nLONDON and PHILADELPHIA\n- May 28, 2025 - Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor,\u00a0today announces the appointments of David Bryant and Richard Hughes as Non-Executive Directors with immediate effect.\nDavid Bryant is a highly experienced international pharmaceutical executive with over 35 years in the industry. He has a strong track record in commercial leadership roles at GSK and Pfizer and was one of the original management team at Clinigen Group, from its 2012 IPO on AIM to its sale for $1.6bn in 2022. David is currently an Advisor to Healthcare Royalty (HCRx), a US-based healthcare focused private investment business.\nRichard Hughes has had a long and successful career in UK capital markets with over 30 years' corporate finance experience, including IPOs, equity capital raising and M&A for both public and private companies. He was previously a founder shareholder and a director of boohoo.com and a majority shareholder of Crawford Healthcare,\na UK-based advanced wound care and dermatology company, which was acquired by Acelity in June 2018\n. He is a shareholder and director of numerous private companies operating across a range of sectors. Richard founded Zeus Capital, an independent financial services group, in 2003 and is a director of Zeus Group.\nShaun Chilton,\nNon-Executive Chairman, commented:\n\"As Avacta completes its transformation into a dedicated pure play therapeutics company, focused on advancing our unique preCISION\n\u00ae\nplatform for the benefit of patients, it needs seasoned and expert guidance. David and Richard have many years' experience and proven track records in pharmaceutical development and commercialization and capital markets respectively. Their collective expertise will significantly enhance the Board's capabilities as we focus on the strategic opportunities within our innovative pipeline to build long-term shareholder value.\"\nDavid Bryant\ncommented:\n\"I am looking forward to working closely with the executive management team on Avacta's exciting technology and leveraging my commercial expertise. With the recent advances from the pre|CISION platform just published and the second program entering the clinic soon, the timing is ideal for me to join the Board.\"\nRichard Hughes\nadded\n:\n\"I am delighted to be appointed as a Director. The business has a proprietary delivery platform in pre|CISION\n\u00ae\nthat I believe will have a significant impact on the standard of care across a range of therapeutics, whilst limiting the harmful side effects that so many patients experience. I look forward to utilizing my experience in both fundraising and the scaling of businesses to assist the executive management team in delivering value for all shareholders.\"\n-Ends -\nFor further information from Avacta Group plc, please contact:\nAvacta Group plc\nMichael Vinegrad, Group Communications\nDirector\nhttps://avacta.com/\nPeel Hunt (Nomad and Joint Broker)\nJames Steel / Chris Golden\nwww.peelhunt.com\nPanmure Liberum (Joint Broker)\nEmma Earl / Will Goode / Mark Rogers\nICR Healthcare\nMary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert\nhttps://panmureliberum.com/\navacta@icrhealthcare.com\nInvestor Contact\nRenee Leck\nTHRUST Strategic Communications\nrenee@thrustsc.com\nMedia Contact\nCarly Scaduto\nCarly Scaduto Consulting\nCarly@carlyscadutoconsulting.com\nAbout Avacta\n-\nhttps://avacta.com/\nAvacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION\u00ae\u00a0platform. pre|CISION\u00ae\u00a0is a\u00a0proprietary warhead delivery system\u00a0based on a tumor-specific protease (fibroblast activation protein or FAP)\u00a0that is designed to concentrate highly potent warheads in the tumor microenvironment while sparing normal tissues. Our innovative pipeline consists of pre|CISION\u00ae\u00a0peptide drug conjugates (PDC) or Affimer\u00ae\u00a0drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates.\nAbout the pre|CISION\u00ae Platform\nThe pre|CISION\u00ae platform comprises an anticancer payload conjugated to a proprietary peptide that is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The pre|CISION\u00ae platform harnesses this tumor specific protease to cleave pre|CISION\u00ae peptide drug conjugates and pre|CISION\u00ae antibody/Affimer\u00ae drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity, allowing dosing to be optimized to deliver the best outcomes for patients.\nAppendix 1: Further disclosures regarding David Bryant\nAvacta also discloses the following information in accordance with Schedule 2(g) ",
          "content_length": 10138
        },
        "ingested_at": "2026-01-21T03:29:59.778371Z"
      },
      {
        "event_id": "RNS-27th May 2025-updateon",
        "event_type": "rns_announcement",
        "date": "2026-01-21T03:29:59.778384Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Update on timing of preliminary results",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/AVCT/update-on-timing-of-preliminary-results-algwopm302080da.html",
          "rns_number": "RNS Number : 1215K",
          "full_content": "27 May 2025 07:00\nRNS Number : 1215K\nAvacta Group PLC\n27 May 2025\nAvacta Group plc\n(\"Avacta\" or the \"Group\" or the \"Company\")\nUpdate on timing of preliminary results announcement\nLONDON and PHILADELPHIA\n- May 27, 2025 - Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor,\u00a0today announces that the preliminary results for year ended December 31, 2024 will now be published on June 4, 2025 as the Group's auditors have been unable to finalise the audit work connected to the disposal of Launch Diagnostics, which completed post period end, by the originally planned date of May, 29 2025. The Group was notified of this development on May 23, 2025.\nThere is no impact to Avacta's financial position and cash runway.\nChristina Coughlin, Chief Executive Officer and Brian Hahn, Chief Financial Officer will now deliver the planned live presentation via Investor Meet Company at 11:00 BST on June 4, 2025.\nThe presentation is open to all existing and potential shareholders.\nInvestors can sign up to Investor Meet Company for free and add to meet AVACTA GROUP PLC via:\nhttps://www.investormeetcompany.com/avacta-group-plc/register-investor\n.\nInvestors who already follow Avacta on the Investor Meet Company platform will automatically be invited.\nQuestions can be submitted pre-event via the Investor Meet Company dashboard up until June 4 at 09:00 BST, or at any time during the live presentation.\nThe Company will also post the results presentation on its website at the following page:\nhttps://avacta.com/investors/investor-resources/\n.\n-Ends -\nFor further information from Avacta Group plc, please contact:\nAvacta Group plc\nMichael Vinegrad, Group Communications\nDirector\nhttps://avacta.com/\nPeel Hunt (Nomad and Joint Broker)\nJames Steel / Chris Golden\nwww.peelhunt.com\nPanmure Liberum (Joint Broker)\nEmma Earl / Will Goode / Mark Rogers\nICR Healthcare\nMary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert\nwww.panmureliberum.com\navacta@icrhealthcare.com\nInvestor Contact\nRenee Leck\nTHRUST Strategic Communications\nrenee@thrustsc.com\nMedia Contact\nCarly Scaduto\nCarly Scaduto Consulting\nCarly@carlyscadutoconsulting.com\nAbout Avacta\n-\nwww.avacta.com\nAvacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION\u00ae\u00a0platform. pre|CISION\u00ae\u00a0is a\u00a0proprietary warhead delivery system\u00a0based on a tumor-specific protease (fibroblast activation protein or FAP)\u00a0that is designed to concentrate highly potent warheads in the tumor microenvironment while sparing normal tissues. Our innovative pipeline consists of pre|CISION\u00ae\u00a0peptide drug conjugates (PDC) or Affimer\u00ae\u00a0drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates.\nAbout the pre|CISION\u00ae Platform\nThe pre|CISION\u00ae platform comprises an anticancer payload conjugated to a proprietary peptide that is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The pre|CISION\u00ae platform harnesses this tumor specific protease to cleave pre|CISION\u00ae peptide drug conjugates and pre|CISION\u00ae antibody/Affimer\u00ae drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity, allowing dosing to be optimized to deliver the best outcomes for patients.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nNORDGGDUUXDDGUL",
          "content_length": 4306
        },
        "ingested_at": "2026-01-21T03:29:59.778396Z"
      },
      {
        "event_id": "RNS-15th May 2025-noticeof",
        "event_type": "rns_announcement",
        "date": "2026-01-21T03:29:59.778409Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Notice of Results",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/AVCT/notice-of-results-rzxfylxym8awwc7.html",
          "rns_number": "RNS Number : 7116I",
          "full_content": "15 May 2025 07:00\nRNS Number : 7116I\nAvacta Group PLC\n15 May 2025\nNotice of Results\nInvestor Presentation via Investor Meet Company\nLONDON and PHILADELPHIA\n- May 15, 2025 - Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, will announce its audited preliminary results for year ended December 31, 2024 (\"FY24\") on May 29, 2025.\nChristina Coughlin, Chief Executive Officer and Brian Hahn, Chief Financial Officer will also deliver a live presentation via Investor Meet Company at 11:00 BST on the day.\nThe presentation is open to all existing and potential shareholders.\nInvestors can sign up to Investor Meet Company for free and add to meet AVACTA GROUP PLC via:\nhttps://www.investormeetcompany.com/avacta-group-plc/register-investor\n.\nInvestors who already follow Avacta on the Investor Meet Company platform will automatically be invited.\nQuestions can be submitted pre-event via the Investor Meet Company dashboard up until May 29 09:00 BST, or at any time during the live presentation.\nThe Company will also post the results presentation on its website at the following page:\nhttps://avacta.com/investors/investor-resources/\n.\n-Ends-\nFor further information from Avacta, please contact:\nAvacta Group plc\nMichael Vinegrad, Group Communications\nDirector\nhttps://avacta.com/\nPeel Hunt (Nomad and Joint Broker)\nJames Steel / Chris Golden\nwww.peelhunt.com\nPanmure Liberum (Joint Broker)\nEmma Earl / Will Goode / Mark Rogers\nwww.panmureliberum.com\nICR Healthcare\nMary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert\navacta@icrhealthcare.com\nInvestor Contact\nRenee Leck\nTHRUST Strategic Communications\nrenee@thrustsc.com\nMedia Contact\nCarly Scaduto\nCarly Scaduto Consulting\nCarly@carlyscadutoconsulting.com\nAbout Avacta\n-\nwww.avacta.com\nAvacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION\u00ae\u00a0platform. pre|CISION\u00ae\u00a0is a\u00a0proprietary warhead delivery system\nbased on a tumor-specific protease (fibroblast activation protein or FAP)\u00a0that is designed to concentrate highly potent warheads in the tumor microenvironment while sparing normal tissues. Our innovative pipeline consists of pre|CISION\u00ae\u00a0peptide drug conjugates (PDC) or Affimer\u00ae\u00a0drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates.\nAbout the pre|CISION\u00ae Platform\nThe pre|CISION\u00ae platform comprises an anticancer payload conjugated to a proprietary peptide that is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The pre|CISION\u00ae platform harnesses this tumor specific protease to cleave pre|CISION\u00ae peptide drug conjugates and pre|CISION\u00ae antibody/Affimer\u00ae drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity, allowing dosing to be optimized to deliver the best outcomes for patients.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nNORSFLFMLEISESI",
          "content_length": 3895
        },
        "ingested_at": "2026-01-21T03:29:59.778421Z"
      },
      {
        "event_id": "RNS-12th May 2025-investor",
        "event_type": "rns_announcement",
        "date": "2026-01-21T03:29:59.778434Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Investor Webinar",
          "category": "RNS-R",
          "url": "https://www.lse.co.uk/rns/AVCT/investor-webinar-6rb6m4zq1kdvvrm.html",
          "rns_number": "RNS Number : 2880I",
          "full_content": "12 May 2025 12:00\nRNS Number : 2880I\nAvacta Group PLC\n12 May 2025\nInvestor Webinar\nLONDON and PHILADELPHIA\n- May 12, 2025 - Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor,\nis pleased to announce that Dr Christina Coughlin, Chief Executive Officer, and Michelle Morrow, Chief Scientific Officer, will be presenting at a webinar on 15 May 2025 at 6.00 pm (BST)\n.\nThe webinar is open to all existing and potential investors and will focus on the Company's recent data presentations on its proprietary pre|CISION\u00ae candidates FAP-Dox (AVA6000) and FAP-EXd (AVA6103) at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, USA.\nThe Company welcomes investor interaction so there will be a Q&A session after the presentation and questions can be submitted pre-event as part of the registration process.\nThe webinar will be hosted by Turner Pope Investments.\nInvestors can register for the event by using the following link:\nhttps://www.turnerpope.com/register/\n-Ends-\nFor further information from Avacta, please contact:\nAvacta Group plc\nMichael Vinegrad, Group Communications\nDirector\nhttps://avacta.com/\nPeel Hunt (Nomad and Joint Broker)\nJames Steel / Chris Golden\nwww.peelhunt.com\nPanmure Liberum (Joint Broker)\nEmma Earl / Will Goode / Mark Rogers\nwww.panmureliberum.com\nICR Healthcare\nMary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert\navacta@icrhealthcare.com\nInvestor Contact\nRenee Leck\nTHRUST Strategic Communications\nrenee@thrustsc.com\nMedia Contact\nCarly Scaduto\nCarly Scaduto Consulting\nCarly@carlyscadutoconsulting.com\nAbout Avacta\n-\nhttps://avacta.com/\nAvacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION\u00ae\u00a0platform. pre|CISION\u00ae\u00a0is a\u00a0proprietary warhead delivery system\nbased on a tumor-specific protease (fibroblast activation protein or FAP)\u00a0that is designed to concentrate highly potent warheads in the tumor microenvironment while sparing normal tissues. Our innovative pipeline consists of pre|CISION\u00ae\u00a0peptide drug conjugates (PDC) or Affimer\u00ae\u00a0drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates.\nAbout the pre|CISION\u00ae Platform\nThe pre|CISION\u00ae platform comprises an anticancer payload conjugated to a proprietary peptide that is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The pre|CISION\u00ae platform harnesses this tumor specific protease to cleave pre|CISION\u00ae peptide drug conjugates and pre|CISION\u00ae antibody/Affimer\u00ae drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity, allowing dosing to be optimized to deliver the best outcomes for patients.\nThis information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nNRAPKBBKKBKDOPD",
          "content_length": 3687
        },
        "ingested_at": "2026-01-21T03:29:59.778447Z"
      },
      {
        "event_id": "RNS-8th May 2025-blocklis",
        "event_type": "rns_announcement",
        "date": "2026-01-21T03:29:59.778460Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Block Listing Application to AIM",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/AVCT/block-listing-application-to-aim-s8n4hvw0jjn342c.html",
          "rns_number": "RNS Number : 8570H",
          "full_content": "8 May 2025 07:30\nRNS Number : 8570H\nAvacta Group PLC\n08 May 2025\nAvacta Group plc\n(\"Avacta\" or the \"Group\" or the \"Company\")\nBlock Listing Application to AIM\nLONDON and PHILADELPHIA - May 8, 2025 - Avacta Therapeutics (AIM: AVCT),\na life sciences company developing innovative, targeted oncology drugs, today announces an application has been made to AIM for a block listing of 6,500,000 ordinary shares of 10 pence each in the Company (\"Ordinary Shares\"). This will be used to facilitate the admission of shares to trading following the exercise of options granted under the Group's LTIP/ESOS Scheme.\nThe Ordinary Shares will be issued from time to time pursuant to the Company's existing plans including outstanding options already issued but not yet exercised to the employees of the Company. New Ordinary Shares issued following option exercises and admitted to trading under the block admission will rank pari passu in all respects with the existing Ordinary Shares.\nThe block listing is expected to become effective on 14 May 2025. The Company will continue to make six-monthly announcements of the utilisation of the block admission, in line with its obligations under AIM Rule 29.\nAt the time of this announcement, Avacta has 389,788,205 Ordinary Shares in issue. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.\nFor further information from Avacta Group plc, please contact:\nAvacta Group plc\nMichael Vinegrad, Group Communications\nDirector\nhttps://avacta.com/\nPeel Hunt (Nomad and Joint Broker)\nJames Steel / Chris Golden\nwww.peelhunt.com\nPanmure Liberum (Joint Broker)\nEmma Earl / Will Goode / Mark Rogers\nICR Healthcare\nMary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert\nwww.panmureliberum.com\navacta@icrhealthcare.com\nInvestor Contact\nRenee Leck\nTHRUST Strategic Communications\nrenee@thrustsc.com\nMedia Contact\nCarly Scaduto\nCarly Scaduto Consulting\nCarly@carlyscadutoconsulting.com\nAbout Avacta\n-\nhttps://avacta.com/\nAvacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION\u00ae platform. pre|CISION\u00ae is a\u00a0proprietary warhead delivery system\nbased on a tumor-specific protease (fibroblast activation protein or FAP)\u00a0that is designed to concentrate highly potent warheads in the tumor microenvironment while sparing normal tissues. Our innovative pipeline consists of pre|CISION\u00ae\u00a0peptide drug conjugates (PDC) or Affimer\u00ae\u00a0drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nALSUPUPGAUPAUQR",
          "content_length": 3591
        },
        "ingested_at": "2026-01-21T03:29:59.778473Z"
      },
      {
        "event_id": "RNS-29th Apr 2025-boardcha",
        "event_type": "rns_announcement",
        "date": "2026-01-21T03:29:59.778486Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Board change",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/AVCT/board-change-wrgf2kjhuz5e404.html",
          "rns_number": "RNS Number : 5158G",
          "full_content": "29 Apr 2025 07:00\nRNS Number : 5158G\nAvacta Group PLC\n29 April 2025\nAvacta Group plc\n(\"Avacta\" or the \"Group\" or the \"Company\")\nBoard change\nLONDON and PHILADELPHIA - April 29, 2025 - Avacta Therapeutics (AIM: AVCT),\na life sciences company developing innovative, targeted oncology drugs, today announces that Dr. Trevor Nicholls, one of the Group's non-executive directors, is retiring from the Board with effect from April 30, 2025.\nMark Goldberg will take over as the Board's Chair of the Remuneration Committee\nShaun Chilton,\nnon-executive Chairman commented:\n\"On behalf of the Avacta Board, I would like to thank Trevor for his valued contribution and dedication to the Company since his appointment in 2013 and wish him all the best for the future.\n\"As Avacta transitions to a pure-play biotechnology company, we have initiated the process of appointing an independent non-executive director with relevant international commercial experience and expertise. A further announcement will be made in due course.\"\nFor further information from Avacta Group plc, please contact:\nAvacta Group plc\nMichael Vinegrad, Group Communications\nDirector\nwww.avacta.com\nPeel Hunt (Nomad and Joint Broker)\nJames Steel / Chris Golden\nwww.peelhunt.com\nPanmure Liberum (Joint Broker)\nEmma Earl / Will Goode / Mark Rogers\nICR Healthcare\nMary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert\nwww.panmureliberum.com\navacta@icrhealthcare.com\nInvestor Contact\nRenee Leck\nTHRUST Strategic Communications\nrenee@thrustsc.com\nMedia Contact\nCarly Scaduto\nCarly Scaduto Consulting\nCarly@carlyscadutoconsulting.com\nAbout Avacta\n-\nwww.avacta.com\nAvacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION\u00ae platform. pre|CISION\u00ae is a\u00a0proprietary warhead delivery system\nbased on a tumor-specific protease (fibroblast activation protein or FAP)\u00a0that is designed to concentrate highly potent warheads in the tumor microenvironment while sparing normal tissues. Our innovative pipeline consists of pre|CISION\u00ae\u00a0peptide drug conjugates (PDC) or Affimer\u00ae\u00a0drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nBOAPPUACCUPAGBR",
          "content_length": 3023
        },
        "ingested_at": "2026-01-21T03:29:59.778498Z"
      },
      {
        "event_id": "RNS-28th Apr 2025-blocklis",
        "event_type": "rns_announcement",
        "date": "2026-01-21T03:29:59.778511Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Block Listing Six Monthly Return",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/AVCT/block-listing-six-monthly-return-my8zwwh0cl3ljaq.html",
          "rns_number": "RNS Number : 5059G",
          "full_content": "28 Apr 2025 17:52\nRNS Number : 5059G\nAvacta Group PLC\n28 April 2025\nAvacta Group plc\n(\"Avacta\" or \"the Group\" or \"the Company\")\nBlock Listing Six Monthly Return\nLONDON\u00a0AND\u00a0PHILADELPHIA\n-\u00a0April 28, 2025,\u00a0Avacta Therapeutics (AIM: AVCT, 'the Company'), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, today\nmakes the following notification pursuant to Schedule Six of the AIM Rules for Companies regarding its existing block admission arrangements:\nName of\napplicant\n:\nAvacta Group plc\nName of scheme:\nEMI scheme\nPeriod of return:\nFrom:\n28 October 2024\n27 April 2025\nBalance of unallotted securities under scheme(s) from previous return:\n275,380\nPlus:\nThe amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):\nnil\nLess:\nNumber of\nsecurities\nissued/allotted under scheme(s) during period (see LR3.5.7G):\n47,000\nEquals:\nBalance under scheme(s) not yet issued/allotted at end of period:\n228,380\nName of\napplicant\n:\nAvacta Group plc\nName of scheme:\nLTIP/ESOS scheme\nPeriod of return:\nFrom:\n28 October 2024\n27 April 2025\nBalance of unallotted securities under scheme(s):\n5,913,257\nPlus:\nThe amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):\nnil\nLess:\nNumber of\nsecurities\nissued/allotted under scheme(s) during period (see LR3.5.7G):\n4,366,882\nEquals:\nBalance under scheme(s) not yet issued/allotted at end of period:\n1,546,375\nName of contact:\nBrian Hahn, Company Secretary\nTelephone number of contact:\n+ 44 (0)\n1904 217070\nEnds-\nFor further information from Avacta Group plc, please contact:\nAvacta Group plc\nMichael Vinegrad, Group Communications\nDirector\nhttps://avacta.com/\nPeel Hunt (Nomad and Joint Broker)\nJames Steel / Chris Golden\nwww.peelhunt.com\nPanmure Liberum (Joint Broker)\nEmma Earl / Will Goode / Mark Rogers\nICR Healthcare\nMary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert\nwww.panmureliberum.com\navacta@icrhealthcare.com\nInvestor Contact\nRenee Leck\nTHRUST Strategic Communications\nrenee@thrustsc.com\nMedia Contact\nCarly Scaduto\nCarly Scaduto Consulting\nCarly@carlyscadutoconsulting.com\nAbout Avacta\n-\nhttps://avacta.com/\nAvacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION\u00ae platform. pre|CISION\u00ae is a\u00a0proprietary warhead delivery system\nbased on a tumor-specific protease (fibroblast activation protein or FAP)\u00a0that is designed to concentrate highly potent warheads in the tumor microenvironment while sparing normal tissues. Our innovative pipeline consists of pre|CISION\u00ae\u00a0peptide drug conjugates (PDC) or Affimer\u00ae\u00a0drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nBLRPPUGACUPAGQR",
          "content_length": 3691
        },
        "ingested_at": "2026-01-21T03:29:59.778523Z"
      },
      {
        "event_id": "RNS-28th Apr 2025-avactapr",
        "event_type": "rns_announcement",
        "date": "2026-01-21T03:29:59.778537Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Avacta presents preclinical data at AACR",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/AVCT/avacta-presents-preclinical-data-at-aacr-j36wguf6n2vaqhs.html",
          "rns_number": "RNS Number : 3962G",
          "full_content": "28 Apr 2025 07:01\nRNS Number : 3962G\nAvacta Group PLC\n28 April 2025\nAvacta Therapeutics Presents Preclinical and Translational Data from pre|CISION\u00ae Platform Candidates at 2025 AACR Annual Meeting\nFAP-EXd (AVA6103) demonstrates tumor growth inhibition and durable complete responses in multiple therapy-resistant preclinical models\nLONDON and PHILADELPHIA\n- April 28, 2025 - Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, today announced preclinical results from its second pre|CISION\u00ae candidate FAP-EXd (AVA6103) and new analyses around the potential of the pre|CISION\u00ae platform at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, IL.\nThe pre|CISION\u00ae programs are designed to target fibroblast activation protein-alpha (FAP\u03b1), the protease that forms the basis of the platform. FAP is consistently overexpressed across a broad range of solid tumors and enriched at the tumor-stroma interface, making it an ideal target for tumor-localized drug activation. Avacta's proprietary pre|CISION\u00ae chemistry leverages this tumor-specific biology to activate potent drugs selectively at the tumor site, enhancing efficacy while minimizing systemic toxicity.\n\"The encouraging results we are showcasing at this year's AACR Annual Meeting highlight the versatility of our pre|CISION\u00ae platform,\" said Michelle Morrow, CSO of Avacta Therapeutics. \"Our data presented today demonstrate that the platform can deliver potent payloads like exatecan with remarkable tumor selectivity and our novel sustained release mechanism. Together, these programs reinforce the broad potential of our pipeline to transform outcomes for patients and generate long-term value for shareholders.\"\nAVA6103 (FAP-EXd) Preclinical Candidate Highlights (Abstract 3139, 28 April 2025)\nAvacta presented preclinical data from its second clinical candidate, AVA6103, a novel FAP-activated pre|CISION\u00ae PDC delivering the topoisomerase I inhibitor exatecan directly to the tumor-stroma interface. This mechanism minimizes systemic toxicity while ensuring precise delivery of the cytotoxic agent directly to the tumor with a sustained release mechanism that optimizes the pharmacokinetics of the released payload. Importantly, despite a very short half-life of 9 hours with conventional exatecan, FAP-EXd (AVA6103) is capable of delivering high tumor concentration vs. plasma with exposures of more than 60 hours projected with a single dose. Additionally, FAP-EXd's bystander effect enables exatecan to induce cytotoxicity in surrounding FAP-negative cancer cells, enhancing its therapeutic impact.\nThe compound has demonstrated significant tumor growth inhibition and durable complete responses in multiple patient-derived xenograft models, including those that are resistant to topoisomerase I inhibition. These results reinforce the potential of FAP-EXd to deliver effective, targeted treatment with minimal off-target effects. The investigational new drug (IND) submission is anticipated in December 2025 and initiation of the first-in-human study in the first quarter of 2026.\nAbstract Number and Title:\n#3139: The novel PDC AVA6103 is a FAP-enabled pre|CISION\u00ae\u00a0medicine which targets exatecan, a topoisomerase I inhibitor, to the tumor microenvironment following FAP cleavage\n\u00b7\nSession Category\n: Experimental and Molecular Therapeutics\n\u00b7\nSession Title:\nTherapeutic Approach to Attack the Tumor Microenvironment\n\u00b7\nSession Date and Time:\nMonday, April 28, 2025,\u00a02:00 - 5:00 p.m. CT\nFAP Targeting Approach with pre|CISION\u00ae medicines (Abstract 2699, 28 April 2025)\nFAP is overexpressed across a wide range of solid tumors, with estimated frequency of over 90% of patients with evidence of FAP expression. This expression is spatially enriched at the tumor-stroma interface, demonstrating the effective nature of the pre|CISION\u00ae mechanism to deliver highly potent payloads directly to the tumor. Given the broad expression of FAP in human solid tumors and correlation of the protein and RNA levels of FAP, an AI-based approach to this target was employed with the Avacta strategic collaboration with Tempus.\nAvacta's work with Tempus has demonstrated several key aspects of the pre|CISION\n\u00ae\nplatform, namely (1) FAP expression remains consistent across lines of therapy and in pre- and post-tumor samples, and (2) co-expression of genes associated with sensitivity to the payload and FAP identify the optimal patient populations for pre|CISION\n\u00ae\nmedicines including FAP-EXd. These data reinforce the potential of Avacta's pre|CISION\u00ae platform to deliver potent therapies across multiple solid tumor indications with broad clinical utility.\nAbstract Number and Title\n: #2699: Investigating fibroblast activation protein alpha (FAP\u03b1) as a therapeutic target for delivery of pre|CISION\u00ae\u00a0cancer medicines: Expression, spatial localization and functional insights\n\u00b7\nSession Category\n: Tumor",
          "content_length": 7779
        },
        "ingested_at": "2026-01-21T03:29:59.778551Z"
      },
      {
        "event_id": "RNS-28th Apr 2025-avactapr",
        "event_type": "rns_announcement",
        "date": "2026-01-21T03:29:59.778565Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Avacta presents data from lead candidate at AACR",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/AVCT/avacta-presents-data-from-lead-candidate-at-aacr-9gxnayixe2wcacr.html",
          "rns_number": "RNS Number : 3960G",
          "full_content": "28 Apr 2025 07:00\nRNS Number : 3960G\nAvacta Group PLC\n28 April 2025\nAvacta Therapeutics Presents Data from Lead pre|CISION\u00ae Candidate FAP-Dox (AVA6000) at the 2025 AACR Annual Meeting\nCompelling Phase 1 safety and efficacy data for FAP-Dox (AVA6000) with preliminary evidence of efficacy in salivary gland cancers and no severe cardiac toxicity\nProgression free survival (PFS) data to date represents a near doubling of the benchmarking data in this patient population without reaching median PFS\nLONDON and PHILADELPHIA\n- April 28, 2025 - Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, today announced Phase 1 data from its lead program FAP-Dox (AVA6000), that were presented alongside preclinical pharmacokinetic results from its second pre|CISION\u00ae candidate AVA6103 (FAP-EXd) at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, IL.\nBoth programs are designed to target fibroblast activation protein-alpha (FAP\u03b1), the protease that forms the basis of the pre|CISION\u00ae platform. FAP is consistently overexpressed across a broad range of solid tumors and enriched at the tumor-stroma interface, making it an ideal target for tumor-localized drug activation. Avacta's proprietary pre|CISION\u00ae chemistry leverages this tumor-specific biology to activate potent drugs selectively at the tumor site, enhancing efficacy while minimizing systemic toxicity.\n\"Today's clinical results mark the achievement of a proof-of-concept milestone with our proprietary pre|CISION\u00ae platform demonstrating meaningful activity,\" said Christina Coughlin, CEO of Avacta Therapeutics. \"With AVA6000 demonstrating strong early signs of efficacy in a specific patient population of salivary gland cancers and a differentiated safety profile, we are not only validating a tumor-targeted approach to cytotoxics delivery - we are establishing a foundation for this new class of precision oncology therapeutics. These data underscore the tremendous potential of our pipeline to deliver meaningful benefits for patients and drive sustained value creation for our key stakeholders.\"\nAVA6000 (FAP-Dox) Clinical Highlights (Abstract #CT15, Apil 29, 2025)\nAVA6000 is a FAP-activated form of doxorubicin designed to reduce the systemic side effects of conventional chemotherapy. In the Phase 1a dose-escalation study, AVA6000 was well-tolerated across both every-three-week (Q3W) and every-two-week (Q2W) dosing regimens. No maximum tolerated dose (MTD) was reached despite dosing up to 385 mg/m\u00b2 every three weeks.\nIn patients with salivary gland cancers (SGC, n=11) treated at or above the dose level of 250 mg/m2, AVA6000 demonstrated multiple confirmed responses and a disease control rate of 91%. Median progression-free survival (PFS) has not yet been reached, with median follow-up exceeding 25 weeks (25.3 weeks, 5.9 months). These FAP-Dox PFS results compare favorably to recent benchmarking data in this patient population presented at ESMO 2024, with a reported PFS of 3.5 months (15 weeks) in a large cohort (n=54) in a similar setting of pretreated patients with SGC (Licitra et al. ESMO 2024).\nDespite dosing up to 4x the dose of conventional doxorubicin, the exposure of released doxorubicin in plasma and normal tissues is lower than that observed with conventional dose doxorubicin (75 mg/m2 Q3W) and the median tumor to plasma ratio is 100:1. In addition, no severe cardiac toxicity was observed, further supporting a markedly improved safety profile over conventional doxorubicin. The lack of toxicity is explained by the limited tissue distribution as well as limited first pass effect exposure of released doxorubicin.\nThe full Phase 1a data across all patients (n=63), including a full assessment of the cardiac safety data with long-term follow-up are expected in the second half of 2025.\nAvacta continues to enroll patients in three Phase 1b expansion cohorts in salivary gland cancer, triple negative breast cancer and high-grade soft tissue sarcoma with data anticipated by the end of 2025.\nAbstract Number and Title\n: #CT15: Comparative pharmacokinetics and tumor activation of fibroblast activation protein (FAP)-enabled pre|CISION\u00ae\u00a0peptide drug conjugates\n\u00b7\nSession Title\n: First-in-Human Phase I Clinical Trials 2\n\u00b7\nSession Date and Time:\nTuesday, April 29, 2025,\u00a09:00 a.m. - 12:00 p.m. CT\n-Ends-\nFor further information from Avacta, please contact:\nAvacta Group plc\nMichael Vinegrad, Group Communications\nDirector\nwww.avacta.com\nPeel Hunt (Nomad and Broker)\nJames Steel / Chris Golden\nwww.peelhunt.com\nPanmure Liberum (Joint Broker)\nEmma Earl / Will Goode / Mark Rogers\nwww.panmureliberum.com\nICR Healthcare\nMary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert\navacta@icrhealthcare.com\nInvestor Contact\nRenee Leck\nTHRUST Strategic Communications\nrenee@thrustsc.com\nMedia Contact\nCarly Scaduto\nCarly Scaduto Consulting\nCarly@carlyscadutoconsulti",
          "content_length": 7067
        },
        "ingested_at": "2026-01-21T03:29:59.778580Z"
      },
      {
        "event_id": "RNS-23rd Apr 2025-issueofe",
        "event_type": "rns_announcement",
        "date": "2026-01-21T03:29:59.778593Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Issue of Equity and Total Voting Rights",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/AVCT/issue-of-equity-and-total-voting-rights-sjrp9nqig3mpcvv.html",
          "rns_number": "RNS Number : 8271F",
          "full_content": "23 Apr 2025 07:00\nRNS Number : 8271F\nAvacta Group PLC\n23 April 2025\nAvacta Group plc\n(\"Avacta\" or the \"Group\" or the \"Company\")\nIssue of Equity and Total Voting Rights\nLONDON and PHILADELPHIA - 23 April 2025 - Avacta Therapeutics (AIM:AVCT),\na life sciences company developing innovative, targeted oncology drugs, today announces it has issued and allotted a total of 9,384,366 new ordinary shares of 10 pence each in the Company (\"New Ordinary Shares\").\nThe New Ordinary Shares are being issued in settlement of the quarterly principal of \u00a32.55 million and interest repayment of c. \u00a30.456 million in respect of the Company's unsecured convertible bond.\nAfter settlement of the quarterly repayment, the principal remaining under the convertible bond will be reduced by \u00a32.55 million to \u00a325.5 million.\nAs communicated previously, the Company originally issued the unsecured convertible bond in October 2022 to fund the acquisition of a diagnostic business, provide additional funding for a diagnostics roll-up strategy and provide working capital for the Group.\nAvacta is on the pathway to becoming a pure play biotechnology company and focuses all its resources on its drug development activities. Maintaining an appropriate level of cash is fundamental for biotechnology companies at Avacta's stage of development and is a key factor in the Board's decision as to whether to make quarterly repayments in cash or through the issue of new Ordinary Shares.\nThe Board carefully considers each payment as it arises and took the following additional factors into account when determining to settle this quarterly payment via the issue of New Ordinary Shares: the Company's cash runway in the context of the funding requirements to advance the Company's R&D pipeline and value creation opportunities and the recent increased volatility in equity markets including biotechnology stocks.\nThe Board is focused on the effective delivery of the Company's strategic goals and whilst issuance of shares for the bond settlement is regrettable, the level of dilution from each conversion event depends on the prevailing share price, which has been adversely impacted by market volatility.\nThe Board continues to actively explore all available options to finance its clinical therapeutics programs as well as reviewing the terms of the Company's unsecured convertible bond. These include partnering, attracting global specialist biotechnology investors and potentially a NASDAQ dual listing.\n.\nApplication has been made to AIM for the admission to trading of the 9,384,366 New Ordinary Shares resulting from the conversion, which is expected to occur at or around 8.00 am on 24 April 2025 (\"Admission\"). The New Ordinary Shares will rank pari passu with the existing Ordinary Shares of the Company.\nFollowing Admission, the Company's enlarged issued share capital will be 386,868,205. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.\nFor further information from Avacta Group plc, please contact:\nAvacta Group plc\nMichael Vinegrad, Group Communications\nDirector\nwww.avacta.com\nPeel Hunt (Nomad and Joint Broker)\nJames Steel / Chris Golden\nwww.peelhunt.com\nPanmure Liberum (Joint Broker)\nEmma Earl / Will Goode / Mark Rogers\nICR Healthcare\nMary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert\nwww.panmureliberum.com\navacta@icrhealthcare.com\nInvestor Contact\nRenee Leck\nTHRUST Strategic Communications\nrenee@thrustsc.com\nMedia Contact\nCarly Scaduto\nCarly Scaduto Consulting\nCarly@carlyscadutoconsulting.com\nAbout Avacta\n-\nwww.avacta.com\nAvacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION\u00ae platform. pre|CISION\u00ae is a\u00a0proprietary warhead delivery system\nbased on a tumor-specific protease (fibroblast activation protein or FAP)\u00a0that is designed to concentrate highly potent warheads in the tumor microenvironment while sparing normal tissues. Our innovative pipeline consists of pre|CISION\u00ae\u00a0peptide drug conjugates (PDC) or Affimer\u00ae\u00a0drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis wit",
          "content_length": 5202
        },
        "ingested_at": "2026-01-21T03:29:59.778607Z"
      },
      {
        "event_id": "RNS-31st Mar 2025-avactaqu",
        "event_type": "rns_announcement",
        "date": "2026-01-21T03:29:59.778620Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Avacta Quarterly Update",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/AVCT/avacta-quarterly-update-gfz1vx3abcn47xc.html",
          "rns_number": "RNS Number : 8729C",
          "full_content": "31 Mar 2025 07:00\nRNS Number : 8729C\nAvacta Group PLC\n31 March 2025\nAvacta Provides Business Update for the First Quarter of 2025 Outlining Progress Against Strategic Objectives\nAVA6000 Phase 1b expansion cohorts enrolling with data targeted for later in 2025\nAVA6103 IND-enabling studies underway with a Phase 1 trial anticipated to begin in the first quarter of 2026\nMultiple presentations at the AACR Annual Meeting highlight the promise of the pre|CISION\u00ae platform\nTransformation into a pure-play therapeutics company prioritizes proprietary pre|CISION\n\u00ae\nplatform and extends cash runway into Q1 2026\nLONDON AND PHILADELPHIA\n- March 31, 2025 Avacta Therapeutics (AIM: AVCT, 'the Company'), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, today provides a business update on progress for the first three months of 2025 and a review of upcoming milestones.\nChristina Coughlin, M.D., Ph.D., Chief Executive Officer of Avacta, said:\n\"We made a strong start to 2025, continuing to make excellent progress against all of our strategic objectives. We are very encouraged by the Phase 1 data from FAP-Dox (AVA60000) so far, which continue to show an excellent tolerability profile and increasingly durable responses in salivary gland cancers. We are now enrolling in multiple dose expansion cohorts, including triple negative breast cancer with preliminary data targeted for later in 2025.\n\"Our pre|CISION\u00ae-enabled exatecan program (FAP-EXd, AVA6103) also continues to progress toward a Phase 1 trial initiation early next year, underscoring our deep commitment to pioneering a novel, differentiated class of medicines to revolutionize drug delivery mechanisms. We are enthusiastic about the promise of a potent topoisomerase I inhibitor delivered in this mechanism.\"\npre|CISION\u00ae Medicine Pipeline\nFAP-Dox (AVA6000), a\npre|CISION\n\u00ae\n-enabled form of doxorubicin chemotherapy,\nadvances to Phase 1b dose expansion.\nDuring the first quarter, Avacta completed\nthe Phase 1a dose escalation portion of the trial, demonstrating promising early efficacy and a favorable safety profile. As of the most recent data cut-off\n,\nAVA6000 continues to show improved tolerability compared to conventional dose doxorubicin, with no observed events of severe cardiac toxicity. Encouraging progression-free survival (PFS) data has also been observed in patients with salivary gland cancers. The Company has begun enrolling patients in the Phase 1b expansion cohorts, including salivary gland cancer, triple negative breast cancer and high-grade soft tissue sarcoma and plans to report updates from these trials later in 2025. For more details see announcement from 07 March 2025\nhere.\n\u00b7\nAVA6103,\na pre|CISION\u00ae-enabled PDC comprised of the pre|CISION peptide linked to the potent topo I inhibitor exatecan, continues preclinical development\n. AVA6103 is currently in investigational new drug (IND)-enabling studies with a Phase 1 trial anticipated to begin in the first quarter of 2026.\n\u00b7\nUpcoming Data Presentations at AACR.\nAvacta is presenting three posters at the\nAmerican Association for Cancer Research\u00a0(AACR) Annual Meeting from\u00a0April 25-30, 2025\u00a0in\u00a0Chicago, IL. The presentations will feature data from the Company's\u00a0proprietary pre|CISION\u00ae\u00a0platform and pipeline of next generation peptide drug conjugates (PDCs), including clinical data on AVA6000 and\u00a0preclinical pharmacology highlights for\u00a0AVA6103. For more details see announcement from 26 March 2025\nhere\n.\n\u00b7\nNovel data from our strategic collaboration with Tempus AI\ncontinues to be reported, including at the AACR Annual Meeting in Chicago.\nExecutive Leadership Team Addition\n.\n\u00b7\nStrengthened management team.\nIn January Avacta strengthened the management team with the appointment of Brian Hahn as Chief Financial Officer (\"CFO\"). Brian is a seasoned CFO with over 25 years' biopharma financial and operational experience. He spent 15 years as CFO and Senior Vice President of GlycoMimetics, Inc., where he led the company's 2014 initial public offering (\"IPO\") on Nasdaq.\nNotice of 2024 Preliminary Results\nAvacta expects to report its Preliminary Results for the 12 months ended 31 December 2024 during May 2025.\n-Ends-\nFor further information from Avacta, please contact:\nAvacta Group plc\nMichael Vinegrad, Group Communications\nDirector\nwww.avacta.com\nPeel Hunt (Nomad and Joint Broker)\nJames Steel / Chris Golden\nwww.peelhunt.com\nPanmure Liberum (Joint Broker)\nEmma Earl / Will Goode / Mark Rogers\nwww.panmureliberum.com\nICR Healthcare\nMary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert\navacta@icrhealthcare.com\nInvestor Contact\nRenee Leck\nTHRUST Strategic Communications\nrenee@thrustsc.com\nMedia Contact\nCarly Scaduto\nCarly Scaduto Consulting\nCarly@carlyscadutoconsulting.com\nAbout Avacta\n-\nwww.avacta.com\nAvacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION\u00ae\u00a0platform. p",
          "content_length": 6882
        },
        "ingested_at": "2026-01-21T03:29:59.778634Z"
      },
      {
        "event_id": "RNS-26th Mar 2025-avactaan",
        "event_type": "rns_announcement",
        "date": "2026-01-21T03:29:59.778647Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Avacta Announces Presentations at AACR",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/AVCT/avacta-announces-presentations-at-aacr-7b4807it8cvqada.html",
          "rns_number": "RNS Number : 1477C",
          "full_content": "26 Mar 2025 07:00\nRNS Number : 1477C\nAvacta Group PLC\n26 March 2025\nAvacta Therapeutics Announces Presentations at 2025 AACR Annual Meeting\nLONDON and PHILADELPHIA\n- March 26, 2025 - Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, today announced that the Company will have three presentations at the American Association for Cancer Research (AACR) Annual Meeting from April 25-30, 2025 in Chicago, IL.\nThe poster presentations will feature data from the Company's\nproprietary pre|CISION\u00ae\u00a0platform and pipeline of next generation peptide drug conjugates (PDCs)\n, including AVA6000\n, a PDC consisting of doxorubicin conjugated with a peptide moiety that is specifically cleaved by FAP in the tumor microenvironment via a pharmacokinetics and clinical presentation, and\npreclinical pharmacology highlights for\nAVA6103\n, a PDC comprised of the pre|CISION\u00ae peptide linked to exatecan. The third presentation will describe detailed analysis of the target fibroblast activation protein-alpha (FAP\u03b1), the protease that forms the basis of the pre|CISION\u00ae platform.\nDetails for Avacta's poster presentations are below and can be found on the\nAACR website\n:\nAbstract Number and Title:\n#3139: The novel PDC AVA6103 is a FAP-enabled pre|CISION\u00ae\u00a0medicine which targets exatecan, a topoisomerase I inhibitor, to the tumor microenvironment following FAP cleavage\n\u00b7\nSession Category\n: Experimental and Molecular Therapeutics\n\u00b7\nSession Title:\nTherapeutic Approach to Attack the Tumor Microenvironment\n\u00b7\nSession Date and Time:\nMonday, April 28, 2025, 2:00 - 5:00 p.m. CT\nAbstract Number and Title\n: #2699: Investigating fibroblast activation protein alpha (FAP\u03b1) as a therapeutic target for delivery of pre|CISION\u00ae\u00a0cancer medicines: Expression, spatial localization and functional insights\n\u00b7\nSession Category\n: Tumor Biology\n\u00b7\nSession Title\n: Targeting the Tumor Microenvironment: A Brave New World\n\u00b7\nSession Date and Time\n: Monday, April 28, 2025, 2:00 - 5:00 p.m. CT\nAbstract Number and Title\n: #CT15: Comparative pharmacokinetics and tumor activation of fibroblast activation protein (FAP)-enabled pre|CISION\u00ae\u00a0peptide drug conjugates\n\u00b7\nSession Title\n: First-in-Human Phase I Clinical Trials 2\n\u00b7\nSession Date and Time:\nTuesday, April 29, 2025, 9:00 a.m. - 12:00 p.m. CT\n-Ends-\nFor further information from Avacta, please contact:\nAvacta Group plc\nMichael Vinegrad, Group Communications\nDirector\nhttps://avacta.com/\nPeel Hunt (Nomad and Broker)\nJames Steel / Chris Golden\nwww.peelhunt.com\nPanmure Liberum (Joint Broker)\nEmma Earl / Will Goode / Mark Rogers\nwww.panmureliberum.com\nICR Healthcare\nMary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert\navacta@icrhealthcare.com\nInvestor Contact\nRenee Leck\nTHRUST Strategic Communications\nrenee@thrustsc.com\nMedia Contact\nCarly Scaduto\nCarly Scaduto Consulting\nCarly@carlyscadutoconsulting.com\nAbout Avacta\n-\nhttps://avacta.com/\nAvacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION\u00ae\u00a0platform. pre|CISION\u00ae\u00a0is a\u00a0proprietary warhead delivery system\nbased on a tumor-specific protease (fibroblast activation protein or FAP)\u00a0that is designed to concentrate highly potent warheads in the tumor microenvironment while sparing normal tissues. Our innovative pipeline consists of pre|CISION\u00ae\u00a0peptide drug conjugates (PDC) or Affimer\u00ae\u00a0drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates.\nAbout the pre|CISION\u00ae Platform\nThe pre|CISION\u00ae platform comprises an anticancer payload conjugated to a proprietary peptide that is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The pre|CISION\u00ae platform harnesses this tumor specific protease to cleave pre|CISION\u00ae peptide drug conjugates and pre|CISION\u00ae antibody/Affimer\u00ae drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity, allowing dosing to be optimized to deliver the best outcomes for patients.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nE",
          "content_length": 5018
        },
        "ingested_at": "2026-01-21T03:29:59.778661Z"
      },
      {
        "event_id": "RNS-25th Mar 2025-avactaco",
        "event_type": "rns_announcement",
        "date": "2026-01-21T03:29:59.778675Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Avacta Completes Launch Diagnostics Sale",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/AVCT/avacta-completes-launch-diagnostics-sale-tq2slvv76w8pibp.html",
          "rns_number": "RNS Number : 9659B",
          "full_content": "25 Mar 2025 07:00\nRNS Number : 9659B\nAvacta Group PLC\n25 March 2025\nAvacta Announces Completion of the Sale of Launch Diagnostics\nLONDON AND PHILADELPHIA - 25 March 2025 - Further to the announcement made on 7 March 2025, Avacta Group plc (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, is pleased to announce that all closing conditions to the sale of the entire issued share capital of Launch Diagnostics Holdings Limited and its subsidiaries, its UK-headquartered and largest diagnostics unit, to Duomed Belgium NV, a subsidiary of Palex Healthcare Group S.L.U, have been satisfied and completion of the sale took place yesterday.\n-Ends-\nFor further information from Avacta, please contact:\nAvacta Group plc\nMichael Vinegrad, Group Communications\nDirector\nhttps://avacta.com/\nPeel Hunt (Nomad and Broker)\nJames Steel / Chris Golden\nwww.peelhunt.com\nPanmure Liberum (Joint Broker)\nEmma Earl / Will Goode / Mark Rogers\nwww.panmureliberum.com\nICR Healthcare\nMary-Jane Elliott / Jessica Hodgson / Max Bennett\navacta@icrhealthcare.com\nInvestor Contact\nRenee Leck\nTHRUST Strategic Communications\nrenee@thrustsc.com\nMedia Contact\nCarly Scaduto\nCarly Scaduto Consulting\nCarly@carlyscadutoconsulting.com\nAbout Avacta\n-\nhttps://avacta.com/\nAvacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION\u00ae\u00a0platform. pre|CISION\u00ae\u00a0is a\u00a0proprietary payload delivery system\nbased on a tumor-specific protease (fibroblast activation protein or FAP)\u00a0that is designed to concentrate highly potent payloads in the tumor microenvironment while sparing normal tissues. Our innovative pipeline consists of pre|CISION\u00ae\u00a0peptide drug conjugates (PDC) or Affimer\u00ae\u00a0drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates.\nAbout the pre|CISION\u00ae Platform\nThe pre|CISION\u00ae platform comprises an anticancer payload conjugated to a proprietary peptide that is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The pre|CISION\u00ae platform harnesses this tumor specific protease to cleave pre|CISION\u00ae peptide drug conjugates and pre|CISION\u00ae antibody/Affimer\u00ae drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity, allowing dosing to be optimized to deliver the best outcomes for patients.\nAbout Palex\nHealthcare Group S.L.U\n-\npalexhealth.com\nPalex is the European benchmark for advanced solutions in the healthcare sector, with over 70 years of experience providing tailored technological innovations to healthcare professionals and researchers. Its purpose is to improve lives by introducing cutting-edge technology to hospitals, laboratories, and research centers. Palex's approach ranges from selecting state-of-the-art products to offering technical support and specialized training for healthcare and research professionals. The company operates across various fields, including surgery, diagnostics, laboratory and critical care, ensuring solutions adapted to each client's needs. With a presence in multiple countries, Palex remains strongly committed to quality, innovation, and sustainability in the healthcare sector. Through its own brands and strategic partnerships with internationally renowned manufacturers, Palex positions itself as a key partner in the evolution of the medical-scientific sector, contributing to improved efficiency and safety in healthcare.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nFURDDGDXSDDDGUS",
          "content_length": 4458
        },
        "ingested_at": "2026-01-21T03:29:59.778687Z"
      },
      {
        "event_id": "RNS-10th Mar 2025-avactato",
        "event_type": "rns_announcement",
        "date": "2026-01-21T03:29:59.778700Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Avacta to Present at Leerink Healthcare Conference",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/AVCT/avacta-to-present-at-leerink-healthcare-conference-8b0jtj2czgtq9xe.html",
          "rns_number": "RNS Number : 8864Z",
          "full_content": "10 Mar 2025 07:00\nRNS Number : 8864Z\nAvacta Group PLC\n10 March 2025\nAvacta Therapeutics to Present at the 2025 Leerink Global Healthcare Conference\nLONDON and PHILADELPHIA\n- March 10, 2025 - Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, today announced that the Company will present at the Leerink Global Healthcare Conference on Wednesday, March 12, 2025, at 10:00 a.m. ET in Miami.\nA live webcast of the presentation will be available in the investors section of the Company's website at https://avacta.com/investors. The webcast will be archived for at least 30 days following the presentation.\n-Ends-\nFor further information from Avacta, please contact:\nAvacta Group plc\nMichael Vinegrad, Group Communications\nDirector\navacta.com\nPeel Hunt (Nomad and Broker)\nJames Steel / Chris Golden / Patrick Birkholm\nwww.peelhunt.com\nPanmure Liberum (Joint Broker)\nEmma Earl / Will Goode / Mark Rogers\nwww.panmureliberum.com\nICR Healthcare\nMary-Jane Elliott / Jessica Hodgson / Max Bennett\navacta@icrhealthcare.com\nInvestor Contact\nRenee Leck\nTHRUST Strategic Communications\nrenee@thrustsc.com\nMedia Contact\nCarly Scaduto\nCarly Scaduto Consulting\nCarly@carlyscadutoconsulting.com\nAbout Avacta\n-\navacta.com\nAvacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION\u00ae\u00a0platform. pre|CISION\u00ae\u00a0is a\u00a0proprietary warhead delivery system\nbased on a tumor-specific protease (fibroblast activation protein or FAP)\u00a0that is designed to concentrate highly potent warheads in the tumor microenvironment while sparing normal tissues. Our innovative pipeline consists of pre|CISION\u00ae\u00a0peptide drug conjugates (PDC) or Affimer\u00ae\u00a0drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates.\nAbout the pre|CISION\u00ae Platform\nThe pre|CISION\u00ae platform comprises an anticancer payload conjugated to a proprietary peptide that is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The pre|CISION\u00ae platform harnesses this tumor specific protease to cleave pre|CISION\u00ae peptide drug conjugates and pre|CISION\u00ae antibody/Affimer\u00ae drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity, allowing dosing to be optimized to deliver the best outcomes for patients.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nMSCBLGDXUSGDGUR",
          "content_length": 3358
        },
        "ingested_at": "2026-01-21T03:29:59.778713Z"
      },
      {
        "event_id": "RNS-7th Mar 2025-avactaan",
        "event_type": "rns_announcement",
        "date": "2026-01-21T03:29:59.778726Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Avacta announces data update for AVA6000",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/AVCT/avacta-announces-data-update-for-ava6000-z52geps9dk63a1m.html",
          "rns_number": "RNS Number : 8110Z",
          "full_content": "7 Mar 2025 08:40\nRNS Number : 8110Z\nAvacta Group PLC\n07 March 2025\nAvacta Announces\nPromising Early Efficacy and Safety Data for AVA6000 in the\nPhase 1a Dose Escalation and Ongoing Enrollment in the Phase 1b Expansion Cohorts\nEncouraging Progression Free Survival (PFS) data observed in patients with salivary gland cancers compared to conventional treatments\nLONDON AND PHILADELPHIA - 07 March 2025 - Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, is pleased to announce that the lead program of the Company, AVA6000, the first clinical stage asset which is a pre|CISION\n\u00ae\n-enabled form of doxorubicin, has completed the Phase 1a dose escalation with encouraging PFS data in patients with salivary gland cancers.\nThe Company has initiated enrollment in the Phase 1b expansion cohorts with multiple patients treated.\nPromising early efficacy and safety signals are observed in the Phase 1a trial. As of the most recent data cut-off, the favorable safety profile continues to be observed when compared with conventional dose doxorubicin, including no observed events of severe cardiac toxicity, which are associated with conventional doxorubicin.\nAmong patients in the dose-escalation portion, 11 patients with salivary gland cancers have been treated with AVA6000 at or above the dose of 250 mg/m2 and above. Among these 11 patients, one patient experienced a confirmed partial response as best response (greater than -30% reduction in tumor diameters by RECIST criteria), four patients had minor responses (-10 to -29% reduction by RECIST criteria), and only one patient had disease progression for a disease control rate of 91%. These responses have been durable to date. Importantly, the median PFS has not yet been reached, as five patients remain on AVA6000 treatment and 9 of the 11 patients are without progression and remain in follow-up. The median time of follow-up in this cohort is approximately 5 months. These data compare very favorably to published PFS reports (with conventional anti-cancer therapy) in this setting of pre-treated SGC, is reported at approximately 3.5 months. It is anticipated that PFS would be the primary endpoint in the registrational trial of AVA6000 in this indication, which is characterized by low response rates and high unmet need.\nAvacta also announces patient dosing in the AVA6000 Phase 1b expansion cohorts with multiple patients treated in this portion of the trial, which include three indications: (1) salivary gland cancer, (2) triple negative breast cancer and (3) high grade soft tissue sarcoma. Each arm of the Phase 1b expansion cohort will enroll 20-30 patients by the following criteria.\n\u00b7\nSalivary gland cancers\n: patients with advanced or metastatic salivary gland cancers of any histologic subtype. Patients may have received up to 1 prior line of therapy in the metastatic or advanced setting.\n\u00b7\nTriple negative breast cancer\n: patients with advanced or metastatic triple negative breast cancer with up to 2 prior lines of therapy in the metastatic or advanced setting\n\u00b7\nHigh grade soft tissue sarcomas:\npatients with undifferentiated pleomorphic sarcoma or dedifferentiated liposarcoma and patients may have received 0 or 1 prior line of therapy in the metastatic or advanced setting\nThe Company anticipates providing a further update from the Phase 1a dose escalation data in 2Q 2025 and Phase 1b dose expansion cohort data at the end of 2025. The full Phase 1a data will be presented in 2H 2025, including a full assessment of the cardiac safety data with long-term follow up. The data will allow the Company to plan for the registration study of AVA6000.\nAlan Ho, MD\nPhD,\u00a0Chief of the Head and Neck Oncology Service,\nMemorial Sloan Kettering Cancer Center and member, Avacta Scientific Advisory Board, commented:\n\"We are very excited to move the development of AVA6000 to the next level\u00a0to generate\u00a0data that demonstrates\u00a0clinically meaningful efficacy and durability of response in patients with previously treated salivary gland cancers. It is important to note the high degree of unmet need in this disease where few agents have shown efficacy. I am happy to participate in the trials of AVA6000 in this disease setting going forward.\"\nChristina Coughlin, CEO of Avacta Therapeutics\ncommented:\n\"We are very pleased to advance to the expansion cohorts in the AVA6000 trial in these three indications with high unmet need. Our development of AVA6000 is proceeding according to plans and today's new data demonstrate the durability of the responses we have observed in the SGC indication. We believe that AVA6000 has an important role to play in the clinic, given our preliminary efficacy data and the large commercial market size of conventional doxorubicin\"\n-Ends-\nFor further information from Avacta, please contact:\nAvacta Group plc\nMichael Vinegrad, Group Communications\nDirector\nwww.avacta.com\nPeel ",
          "content_length": 7500
        },
        "ingested_at": "2026-01-21T03:29:59.778739Z"
      },
      {
        "event_id": "RNS-7th Mar 2025-avactato",
        "event_type": "rns_announcement",
        "date": "2026-01-21T03:29:59.778752Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Avacta to sell Launch Diagnostics",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/AVCT/avacta-to-sell-launch-diagnostics-0u1kkxfd9rtm4iz.html",
          "rns_number": "RNS Number : 8027Z",
          "full_content": "7 Mar 2025 07:42\nRNS Number : 8027Z\nAvacta Group PLC\n07 March 2025\nTHIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE\u00a0UK\u00a0VERSION OF REGULATION (EU) NO 596/2014 WHICH IS PART OF\u00a0UK\u00a0LAW BY VIRTUE OF THE\u00a0EUROPEAN UNION\u00a0(WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN\nAvacta Announces Agreement to Sell Launch Diagnostics and a Corporate Update\nLONDON AND PHILADELPHIA - 07 March 2025 - Avacta Therapeutics (AIM: AVCT, 'the Company'), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, announces that it has agreed to sell Launch Diagnostics Holdings Limited (\"Launch Diagnostics\") and its subsidiaries, its UK-based and largest diagnostics unit, for \u00a312.9 million in cash to Duomed Belgium NV, a subsidiary of Palex Healthcare Group S.L.U. Completion of the sale is expected by the end of April 2025, subject to customary closing conditions. The sale proceeds will be used to further Avacta's pre|CISION\n\u00ae\nplatform.\nThis disposal is a significant step towards delivering a key Board objective of the Company becoming a pure-play biotechnology company. In order to complete the divestment of its diagnostics business operations, Avacta is also in discussions regarding the sale of its remaining and much smaller Belgian-headquartered diagnostics unit, Coris BioConcept SRL.\nLaunch Diagnostics delivered audited revenues of \u00a317.9 million and profit after tax of \u00a30.38 million in the year ended 31 December 2023 and has traded in line with the Board's expectations during the year ended 31 December 2024. As at 30 June 2024 Launch Diagnostics had unaudited net assets of \u00a313.65 million.\nFollowing the divestment of Launch Diagnostics, the Company's cash runway will extend into Q1 2026.\nIn the year ending 31 December 2025, the Group expects to report a non-cash loss as a result of this disposal.\nShaun Chilton,\nNon-Executive Chairman commented:\n\"The diversification into diagnostics over the last two years has been very disappointing. However, this disposal is a critical and necessary step forward in our corporate strategy to become a pure-play therapeutics company.\n\"This disposal, which followed an extensive auction process, realizes cash to support our growing R&D investment program and also enables the management to focus on the development of our\u00a0unique proprietary pre|CISION\n\u00ae\ntechnology platform.\"\nCorporate Update\nAvacta Therapeutics has made strong progress, presenting the R&D pipeline, adding critical experience to the management team, formalizing the strategic partnership with Tempus and achieving previously stated development milestones.\nAVA6000\nThe Company has today also separately announced an update on its lead program, AVA6000, the first clinical stage asset which is a pre|CISION\n\u00ae\n-enabled form of doxorubicin.\nInitial proof of concept data with AVA6000 in the clinic have demonstrated the broad potential of the pre|CISION\n\u00ae\nplatform and data from our strategic collaboration with Tempus AI have demonstrated the broad addressable patient populations that could be targeted with pre|CISION\n\u00ae\n-enabled medicines.\nImportantly, in the clinic AVA6000 has demonstrated the profile of a pre|CISION\n\u00ae\nmedicine with three key findings: (1) a significant reduction in the observed toxicities associated with conventional doxorubicin, (2) the capacity to shrink tumors with multiple, durable responses observed in different disease settings with sensitivity to doxorubicin and (3) the profound concentration of the active payload (doxorubicin) in the tumor versus the plasma. Together, these findings in the clinic underscore the potential for the next assets in the pipeline to be highly differentiated and have potential for enhanced activity compared with traditional oncology therapeutics.\nAVA6103\nAVA6103, the Company's second program, is a pre|CISION\n\u00ae\n-enabled PDC comprised of the pre|CISION peptide linked to exatecan, the most potent topoisomerase I (topo I) inhibitor in clinical development. The AVA6103 program has completed candidate selection and is in the pre-IND preparation stage with GMP manufacturing ongoing for the Phase 1 trial. The Phase 1 trial of AVA6103 is anticipated to begin early in 2026.\nThe Company has seen a dramatic increase in therapeutic index in preclinical models, suggesting that AVA6103 could have an unprecedented safety profile in the clinic. AVA6103 has the potential to treat hundreds of thousands of patients with the broad use of the topo I drug class and over 90% of solid tumors expressing FAP.\nOther strategic initiatives\nThe Company continues to explore the possibility of attaining a dual listing on NASDAQ. Any definitive decision on if or when to dual list on NASDAQ will depend on a range of factors including the Group's clinical data package, SEC approval and wide",
          "content_length": 8990
        },
        "ingested_at": "2026-01-21T03:29:59.778766Z"
      },
      {
        "event_id": "RNS-4th Feb 2025-appointm",
        "event_type": "rns_announcement",
        "date": "2026-01-21T03:29:59.778779Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Appointment of Joint Broker",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/AVCT/appointment-of-joint-broker-4i7g6phz20ly50n.html",
          "rns_number": "RNS Number : 7481V",
          "full_content": "4 Feb 2025 07:00\nRNS Number : 7481V\nAvacta Group PLC\n04 February 2025\nAvacta Group plc\n(\"Avacta\" or the \"Group\" or the \"Company\")\nAppointment of Joint Broker\nLONDON and PHILADELPHIA\n- February 4, 2025 - Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, today announced the appointment of Panmure Liberum Limited (\"Panmure Liberum\") as its joint broker with immediate effect. Panmure Liberum will work alongside Peel Hunt, the Company's Nominated Adviser and existing corporate broker.\n-Ends-\nFor further information from Avacta, please contact:\nAvacta Group plc\nMichael Vinegrad, Group Communications\nDirector\navacta.com\nPeel Hunt (Nomad and Joint Broker)\nJames Steel / Chris Golden / Patrick Birkholm\nwww.peelhunt.com\nPanmure Liberum (Joint Broker)\nEmma Earl, Will Goode, Mark Rogers\nDavid Cox (Healthcare Specialist Sales)\nwww.panmureliberum.com\nICR Healthcare\nMary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert\navacta@consilium-comms.com\nInvestor and Communications Contact\nRenee Leck\nTHRUST Strategic Communications\nwww.thruststrategiccommunications.com\nMedia Contact\nCarly Scaduto\nCarly Scaduto Consulting\nCarly@carlyscadutoconsulting.com\nAbout Avacta\n-\nhttp://avacta.com/\nAvacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION\u00ae\u00a0platform. pre|CISION\u00ae\u00a0is a\u00a0proprietary warhead delivery system\nbased on a tumor-specific protease (fibroblast activation protein or FAP)\u00a0that is designed to concentrate highly potent warheads in the tumor microenvironment while sparing normal tissues. Our innovative pipeline consists of pre|CISION\u00ae\u00a0peptide drug conjugates (PDC) or Affimer\u00ae\u00a0drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nAPPSSWESDEISEFE",
          "content_length": 2713
        },
        "ingested_at": "2026-01-21T03:29:59.778792Z"
      },
      {
        "event_id": "RNS-21st Jan 2025-issueofe",
        "event_type": "rns_announcement",
        "date": "2026-01-21T03:29:59.778805Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Issue of Equity and Total Voting Rights",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/AVCT/issue-of-equity-and-total-voting-rights-9hlapfxf3pz6hol.html",
          "rns_number": "RNS Number : 1685U",
          "full_content": "21 Jan 2025 15:09\nRNS Number : 1685U\nAvacta Group PLC\n21 January 2025\nAvacta Group plc\n(\"Avacta\" or the \"Group\" or the \"Company\")\nIssue of Equity and Total Voting Rights\nLONDON and PHILADELPHIA - Jan 21 2025 - Avacta Therapeutics (AIM:AVCT),\na life sciences company developing innovative, targeted oncology drugs, today announces it has issued and allotted a total of 6,663,568 new ordinary shares of 10 pence each in the Company (\"New Ordinary Shares\").\nThe New Ordinary Shares are being issued in settlement of the quarterly principal of \u00a32.55 million and interest repayment of \u00a30.50 million in respect of the Company's unsecured convertible bond.\nAfter settlement of the quarterly repayment, the principal remaining under the convertible bond will be reduced by \u00a32.55 million to \u00a328.05 million.\nAs communicated previously the Company originally issued the unsecured convertible bond in October 2022 to fund the acquisition of a diagnostic business, provide additional funding for a diagnostics roll-up strategy and provide working capital for the Group. More recently the Board has also consistently communicated its strategy to become a pure play biotechnology company and focus its resources on its drug development activities. Maintaining an appropriate level of cash on the balance sheet is fundamental for biotechnology companies at Avacta's stage of development.\nThe Board carefully considers each payment separately as it arises and took the following additional factors into account when determining to settle this quarterly payment via the issue of New Ordinary Shares: the stage of the process to divest of the Group's Diagnostics Division (which continues to progress) and shareholder dilution.\nThe Avacta management team and Board continue to explore all available pathways to provide optionality for financing its clinical therapeutics programs over the longer term, including divestment of the Diagnostics Division, partnering, attracting global specialist biotechnology investors and potentially a NASDAQ dual listing, on which further updates will be provided in the coming months.\nApplication has been made to AIM for the admission to trading of the 6,663,568 New Ordinary Shares resulting from the conversion, which is expected to occur at or around 8.00 am on 23 January 2025 (\"Admission\"). The New Ordinary Shares will rank pari passu with the existing Ordinary Shares of the Company.\nFollowing Admission, the Company's enlarged issued share capital will be 376,216,957. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.\nFor further information from Avacta Group plc, please contact:\nAvacta Group plc\nMichael Vinegrad, Group Communications\nDirector\nwww.avacta.com\nPeel Hunt (Nomad and Broker)\nJames Steel / Chris Golden / Patrick Birkholm\nwww.peelhunt.com\nICR Healthcare\nMary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert\navacta@icrhealthcare.com\nInvestor Contact\nRenee Leck\nTHRUST Strategic Communications\nrenee@thrustsc.com\nMedia Contact\nCarly Scaduto\nCarly Scaduto Consulting\nCarly@carlyscadutoconsulting.com\nAbout Avacta\n-\nwww.avacta.com\nAvacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION\u00ae platform. pre|CISION\u00ae is a\u00a0proprietary warhead delivery system\nbased on a tumor-specific protease (fibroblast activation protein or FAP)\u00a0that is designed to concentrate highly potent warheads in the tumor microenvironment while sparing normal tissues. Our innovative pipeline consists of pre|CISION\u00ae\u00a0peptide drug conjugates (PDC) or Affimer\u00ae\u00a0drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nIOEBUGDBIGDDGUB",
          "content_length": 4749
        },
        "ingested_at": "2026-01-21T03:29:59.778817Z"
      },
      {
        "event_id": "RNS-16th Jan 2025-avactaan",
        "event_type": "rns_announcement",
        "date": "2026-01-21T03:29:59.778830Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Avacta Announces Data from AVA6000 Phase 1 trial",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/AVCT/avacta-announces-data-from-ava6000-phase-1-trial-4xr8168hppkd6bd.html",
          "rns_number": "RNS Number : 5772T",
          "full_content": "16 Jan 2025 07:00\nRNS Number : 5772T\nAvacta Group PLC\n16 January 2025\nAvacta Announces Positive New Data from the AVA6000 Phase 1 trial Demonstrating Clinically Meaningful Tumor Shrinkage in Patients with Salivary Gland Cancers\nMeaningful tumor shrinkage observed in five out of 10 patients with partial and minor responses and 90% disease control rate in patients with salivary gland cancers\nPhase 1b expansion cohorts screening patients in triple negative breast cancer, soft tissue sarcoma and salivary gland cancer\nLONDON and PHILADELPHIA\n- January 16, 2025 - Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, today announced compelling new data in patients with\nsalivary gland cancer (SGC)\nfrom the ongoing\nPhase 1a trial of AVA6000 in patients with\nFAP-positive solid tumors.\nThe data demonstrates robust and meaningful tumor shrinkage in patients with salivary gland cancers, a disease with no standard therapy defined in the metastatic setting.\nAVA6000 is the first peptide drug conjugate in Avacta's pipeline and consists of doxorubicin conjugated with Avacta's proprietary pre|CISION\u00ae peptide, that is specifically cleaved by fibroblast activation protein-alpha (FAP) in the tumor microenvironment.\nThe key findings include:\n\u00b7\nAmong 10 patients treated at the dose of 250 mg/m2 and above, five patients demonstrate tumor shrinkage (one partial and four minor responses)\n\u00b7\nSix of these 10 patients are continuing treatment and an additional two patients, who have reached maximum cycles, are still in follow up for progression free survival\n\u00b7\nThe safety profile of AVA6000 continues to demonstrate a robust reduction in severe hematologic and cardiac toxicities that are associated with conventional dose doxorubicin\nBased on this favorable efficacy and safety data observed in the Phase 1a trial, Avacta\nhas initiated three Phase 1b expansion cohorts in triple negative breast cancer, soft tissue sarcoma and salivary gland cancer in the first and second line setting. Patients are screening and the first patients to be treated in these expansions are expected imminently in the US.\nChristina Coughlin MD, PhD, CEO of Avacta\n, commented,\n\"These data highlight the transformative potential of our pre|CISION\u00ae peptide drug conjugates\nin expanding\nthe efficacy of highly potent therapeutics and support our growing optimism in this program.\n\"Salivary gland cancer is a devastating disease with no established standard of care treatment options. AVA6000 demonstrated a clinically meaningful tumor shrinkage in SGC patients, highlighting its potential as an important new treatment option for patients with SGC and other solid tumors.\n\"We look forward to continuing to work with our investigators and the broader community to explore its potential in SGC and other cancers. We are thrilled to begin enrollment in the expansion cohorts, and this part of the trial will also be conducted in less heavily pretreated patients which will allow us to better understand the potential of AVA6000 in these disease settings with high unmet need.\"\nThese results demonstrate preliminary evidence of durable antitumor activity in patients with SGC, supported by ongoing RECIST1 responses (both partial and minor responses) in a disease setting with no standard of care.\nSGC accounts for 6-8% of head and neck cancers in the US, with approximately 2,500 cases diagnosed in the US each year2. There is no standard of care for SGC once patients have developed distant metastasis, with a five year survival rate of approximately 43%.\nClinical data observations:\nOut of 10 patients with SGC treated at the dose of 250 mg/m2 and above, 5 patients experienced clinically meaningful disease shrinkage, including a confirmed partial response (PR, 45% tumor shrinkage) and four minor responses (MR, 10-19.5% tumor shrinkage) using RECIST criteria.1 These data include the following cases:\n\u00b7\nA durable, confirmed PR was observed at 12 weeks in a 79-year-old male patient. The response is ongoing despite patient discontinuation due to reaching lifetime maximum of doxorubicin exposure. This patient began their treatment with AVA6000 in October 2023 following one line of therapy which he experienced disease progression prior to enrolling in the AVA6000 clinical trial.\n\u00b7\nRapid and complete regression of large skin and visceral metastasis was observed in a 74-year-old male patient experiencing a MR, despite low to mid-level FAP expression in the cancer-associated fibroblasts alone. A 15% reduction in parotid and lymph nodal lesions continues at the12 weeks post scan. This patient began treatment in September 2024 following two prior lines of therapy to which he experienced disease progression with both therapies prior to enrolling in the AVA6000 trial.\nAlthough these data are reported early in the treatment course of most patients, it is notable that six patients (of the 10 patie",
          "content_length": 8884
        },
        "ingested_at": "2026-01-21T03:29:59.778844Z"
      },
      {
        "event_id": "RNS-13th Jan 2025-avactaap",
        "event_type": "rns_announcement",
        "date": "2026-01-21T03:29:59.778857Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Avacta Appoints Chief Financial Officer",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/AVCT/avacta-appoints-chief-financial-officer-nouecb72wuoe9x6.html",
          "rns_number": "RNS Number : 0551T",
          "full_content": "13 Jan 2025 07:00\nRNS Number : 0551T\nAvacta Group PLC\n13 January 2025\nAvacta Appoints Brian Hahn as Chief Financial Officer\n-\nBrian brings 25 years' senior financial and operational experience, including leading GlycoMimetics' Nasdaq IPO and financial operations\nLONDON and PHILADELPHIA - Jan 13, 2025 - Avacta Therapeutics (AIM: AVCT)\n,\na life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, today announced the appointment of Brian Hahn as Chief Financial Officer\n(CFO).\nMr Hahn brings more than 25 years of\nsenior financial and operations experience in the biopharmaceutical industry, including a 15-year tenure as CFO and Senior Vice President of GlycoMimetics, Inc., where he led the company's 2014 initial public offering (IPO) on Nasdaq and the build-out of its finance, accounting, investor relations and corporate affairs functions.\nHe has worked with life science companies from early stages through product launch, has significant experience in dealing with US healthcare investors, having been involved in multiple IPOs and has raised over $700 million in capital. He has broad experience in developing strategic plans, business development deals, building strong organizations and establishing strong accounting and control systems which ensure Sarbanes-Oxley compliance.\nMr Hahn currently serves as co-chairman of the BIO Finance and Tax Committee, as a co-chairman of the Steering Committee of the Washington, DC chapter of the Association for Bio Financial Officers (ABFO) and has also served on the Securities and Exchange Commissions' Advisory Committee on Small and Emerging Companies.\nPrior to his 15-year tenure at GlycoMimetics, Mr. Hahn held roles of increasing financial leadership responsibility, including Executive Director of Finance at MiddleBrook Pharmaceuticals (formerly Advancis Pharmaceutical), and earlier, Senior Accountant with Bering Truck Corporation.\nHe received a B.B.A. in Accounting from Shenandoah University and an M.B.A. from the University of Maryland.\n\"Brian brings the ideal combination of deep public company experience and understanding of the biotechnology sector that Avacta needs at this transformative stage,\"\nsaid\nChristina Coughlin, M.D., Ph.D., Chief Executive Officer of Avacta.\n\"His strategic insight and track record of successful financial leadership in clinical-stage companies will be essential as we advance our promising pipeline and prepare for our next phase of growth, including our\npotential dual listing on the Nasdaq exchange.\n\"\n\"\nWhat drew me to Avacta was not just the company's innovative technology platforms. It also has a clear vision for revolutionizing cancer treatment through targeted therapies that improve outcomes for patients and their families,\"\ncommented\nBrian Hahn\n. \"\nThe company has built a strong foundation with its pre|CISION\u00ae and Affimer\u00ae platforms, and I look forward to leveraging my experience to help accelerate Avacta's growth and strengthen its position in both the U.K. and U.S. capital markets.\"\n-Ends-\nFor further information from Avacta, please contact:\nAvacta Group plc\nMichael Vinegrad, Group Communications\nDirector\nwww.avacta.com\nPeel Hunt (Nomad and Broker)\nJames Steel / Chris Golden / Patrick Birkholm\nwww.peelhunt.com\nICR Healthcare\nMary-Jane Elliott / Jessica Hodgson / Max Bennett\navacta@consilium-comms.com\nInvestor Contact\nRenee Leck\nTHRUST Strategic Communications\nrenee@thrustsc.com\nMedia Contact\nCarly Scaduto\nCarly Scaduto Consulting\nCarly@carlyscadutoconsulting.com\nAbout Avacta\n-\nwww.avacta.com\nAvacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION\u00ae platform. pre|CISION\u00ae is a\u00a0proprietary warhead delivery system\nbased on a tumor-specific protease (fibroblast activation protein or FAP)\u00a0that is designed to concentrate highly potent warheads in the tumor microenvironment while sparing normal tissues. Our innovative pipeline consists of pre|CISION\u00ae\u00a0peptide drug conjugates (PDC) or Affimer\u00ae\u00a0drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nBOAGZG",
          "content_length": 5009
        },
        "ingested_at": "2026-01-21T03:29:59.778871Z"
      },
      {
        "event_id": "RNS-12th Dec 2024-completi",
        "event_type": "rns_announcement",
        "date": "2026-01-21T03:29:59.778884Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Completion of Dose Escalation and RDE Arms",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/AVCT/completion-of-dose-escalation-and-rde-arms-4tfwmou9njc2fwf.html",
          "rns_number": "RNS Number : 7701P",
          "full_content": "12 Dec 2024 07:00\nRNS Number : 7701P\nAvacta Group PLC\n12 December 2024\nAvacta Group plc\n(\"Avacta\" or \"the Group\" or \"the Company\")\nDose Escalation and Recommended Dose for Expansion (RDE) Arms of the AVA6000 Phase 1a Trial complete and Phase 1b Disease Specific Expansion Cohorts Open for Enrolment\nLONDON - Dec. 12, 2024 - Avacta Therapeutics (AIM: AVCT)\n, a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, today announces the completion of the enrollment in the AVA6000 Phase 1a Dose Escalation and Recommended Dose for Expansion (RDE) cohort, and the opening of the Phase 1b disease-specific expansion cohorts\nin the trial. Patient screening has commenced.\nThe Phase 1b expansion cohorts follow the encouraging preliminary results in the trial reported earlier in 2024 demonstrating a favorable safety profile and significant antitumor activity in patients with salivary gland cancers (a subset of head and neck cancer) and high-grade soft tissue sarcoma.\nThe Phase 1b cohorts will enroll patients in three disease-specific cohorts including: (1) triple negative breast cancer; (2) salivary gland cancer and (3) high grade soft tissue sarcoma.\nUpdated data for the Phase 1 dose escalation cohorts and the recommended dose for expansion cohort will be presented in the first half of 2025.\nChristina Coughlin, MD PhD, CEO of Avacta, commented:\n\"We are encouraged by the anti-tumor activity observed in the Phase 1 dose escalation and RDE cohorts of the trial and the expansion cohorts are designed to build on that knowledge. Opening of the expansion cohorts represents a significant milestone in the development of FAP-Doxorubicin (AVA6000) in that we will now be able to assess the activity in specific indications to better plan Phase 2 development\n.\"\nFor further information from Avacta Group plc, please contact:\nAvacta Group plc\nMichael Vinegrad, Group Communications Director\nhttps://avacta.com/\nPeel Hunt (Nomad and Broker)\nJames Steel / Chris Golden / Patrick Birkholm\nwww.peelhunt.com\nICR Healthcare\nMary-Jane Elliott / Jessica Hodgson / Sukaina Virji\navacta@consilium-comms.com\nAbout the pre|CISION\n\u00ae\nPlatform\nThe pre|CISION\n\u00ae\nplatform comprises an anticancer payload conjugated to a proprietary peptide that is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The pre|CISION\n\u00ae\nplatform harnesses this tumor specific protease to cleave pre|CISION\n\u00ae\npeptide drug conjugates and pre|CISION\n\u00ae\nantibody/Affimer\u00ae\u00a0drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity, allowing dosing to be optimized to deliver the best outcomes for patients.\nAbout AVA6000: FAP-enabled doxorubicin\nThe lead pre|CISION\n\u00ae\nprogram AVA6000, a peptide drug conjugate form of doxorubicin, is in Phase 1 studies. It has shown an improvement in safety and tolerability in clinical trials to date compared with standard doxorubicin and preliminary signs of clinical activity in multiple patients.To register for news alerts by email go to\nhttps://avacta.com/investors/investor-news-email-alerts/\n.\nAbout Avacta Group plc -\nhttps://avacta.com/\nAvacta Group\u00a0is a\u00a0UK-based life sciences company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics. Its clinical stage oncology biotech division Avacta Therapeutics is harnessing the proprietary pre|CISION\n\u00ae\nplatform technology to develop novel, highly targeted cancer drugs. Avacta Diagnostics\u00a0focuses on supporting healthcare professionals and broadening access to diagnostics. To register for news alerts by email go to\nhttps://avacta.com/investors/investor-news-email-alerts/\n.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nMSCGPGQGPUPCPGG",
          "content_length": 4593
        },
        "ingested_at": "2026-01-21T03:29:59.778897Z"
      },
      {
        "event_id": "RNS-30th Oct 2024-r&dspotl",
        "event_type": "rns_announcement",
        "date": "2026-01-21T03:29:59.778910Z",
        "source": "LSE_RNS",
        "data": {
          "title": "R&D Spotlight focusing on pipeline advances",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/AVCT/rd-spotlight-focusing-on-pipeline-advances-xx6z132fr1yb5dx.html",
          "rns_number": "RNS Number : 1323K",
          "full_content": "30 Oct 2024 07:00\nRNS Number : 1323K\nAvacta Group PLC\n30 October 2024\nAvacta Group plc\n(\"Avacta\" or \"the Group\" or \"the Company\")\nR&D Spotlight focusing on pre|CISION\n\u00ae\ntechnology and pipeline advances\nLONDON - Oct. 30, 2024 -\nAvacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful antitumor payloads directly to the tumor, is today hosting a live R&D Spotlight: \"Next Generation of pre|CISION\u00ae Medicines\" in London.\nAvacta's unique proprietary technology allows for targeted delivery of cytotoxic drugs (the \"payload\") in the tumor microenvironment (TME). The presentations will cover the Company's next generation of follow-on candidates with their unique features and patient populations.\nAvacta will highlight in this event the novel pre|CISION\u00ae candidates in the evolving pipeline, details of which were presented at the EORTC-NCI-AACR Triple Meeting in Barcelona last week and provide further detail on their properties and patient populations.\nAvacta's AVA6000, AVA6103, and AVA7100 programs are highly differentiated pipeline assets, addressing large markets. The presentation will also address these programs' near-term milestones.\nAvacta will highlight the franchise it has developed in breast cancer and how these therapies in this indication will move forward.\nThe Company confirms that the process to divest the revenue-generating diagnostics division is ongoing and it continues to actively explore opportunities for a potential dual listing on NASDAQ. No additional financial information will be disclosed.\nThis event is open to both analysts and investors, further details are provided on the Company website and a recording of the event will be made available in due course.\nFor further information from Avacta Group plc, please contact:\nAvacta Group plc\nMichael Vinegrad, Group Communications Director\nhttps://avacta.com/\nPeel Hunt (Nomad and Broker)\nJames Steel / Chris Golden / Patrick Birkholm\nwww.peelhunt.com\nICR Healthcare\nMary-Jane Elliott / Jessica Hodgson / Sukaina Virji\navacta@consilium-comms.com\nAbout the pre|CISION\n\u00ae\nPlatform\nThe pre|CISION\n\u00ae\nplatform comprises an anticancer payload conjugated to a proprietary peptide that is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The pre|CISION\n\u00ae\nplatform harnesses this tumor specific protease to cleave pre|CISION\n\u00ae\npeptide drug conjugates and pre|CISION\n\u00ae\nantibody/Affimer\u00ae\u00a0drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity, allowing dosing to be optimized to deliver the best outcomes for patients.\nAbout AVA6000: FAP-enabled doxorubicin\nThe lead pre|CISION\n\u00ae\nprogram AVA6000, a peptide drug conjugate form of doxorubicin, is in Phase 1 studies. It has shown an improvement in safety and tolerability in clinical trials to date compared with standard doxorubicin and preliminary signs of clinical activity in multiple patients. To register for news alerts by email go to\nhttps://avacta.com/investors/investor-news-email-alerts/\n.\nAVA6103: FAP-enabled PDC targeting Topoisomerase I\nAVA6103 is a pre|CISION-enabled PDC comprised of the pre|CISION peptide linked to exatecan, the most potent topoisomerase I inhibitor in clinical development. Exatecan has demonstrated clinical activity in breast, gastric, lung and pancreatic cancers; however, it is associated with severe dose-limiting toxicities and a short half-life in patients that led to discontinuation of its monotherapy development. AVA6103 is designed to enable patients to obtain the therapeutic benefit associated with exatecan, while limiting the systemic exposure associated with its poor tolerability.\nAVA7100: pre|CISION\n\u00ae\nFAP Affimer Drug Conjugate (AffDC)\nAVA7100 is a pre|CISION\u00ae-enabled Affimer\u00ae\u00a0drug conjugate, a new class of therapies being developed by Avacta with potential applications in a variety of cancer types, including those with lower levels of FAP in the tumor. Affimer\u00ae\u00a0molecules are small proteins that are engineered to bind to a target molecule in the same way that an antibody does, but with several advantages, including smaller molecule size and a broad range of binding affinity. AVA7100 consists of a novel FAP-Affimer conjugated to a pre|CISION\n\u00ae\n-peptide linker with multiple options for the payload.\nAbout Avacta Group plc -\nhttps://avacta.com/\nAvacta Group\u00a0is a\u00a0UK-based life sciences company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics. Its clinical stage oncology biotech division Avacta Therapeutics is harnessing the proprietary pre|CISION\n\u00ae\nplatform technology to develop novel, highly targeted cancer drugs. Avacta Diagnostics\u00a0focuses on supporting healthcare professionals and broadening access to diagnostics. To register for news alerts by email go to\nhttps://avacta.com/investors/investor-news-email-alerts/\n.\n",
          "content_length": 5779
        },
        "ingested_at": "2026-01-21T03:29:59.778923Z"
      },
      {
        "event_id": "RNS-28th Oct 2024-blocklis",
        "event_type": "rns_announcement",
        "date": "2026-01-21T03:29:59.778936Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Block Listing Six Monthly Return",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/AVCT/block-listing-six-monthly-return-x2s0yfrlp1e4a0c.html",
          "rns_number": "RNS Number : 7700J",
          "full_content": "28 Oct 2024 07:00\nRNS Number : 7700J\nAvacta Group PLC\n28 October 2024\n28 October 2024\nAvacta Group plc\n(\"Avacta\" or \"the Group\" or \"the Company\")\nBlock Listing Six Monthly Return\nAvacta Group plc\u00a0(AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, today\nmakes the following notification pursuant to Schedule Six of the AIM Rules for Companies regarding its existing block admission arrangements:\nName of\napplicant\n:\nAvacta Group plc\nName of scheme:\nEMI scheme\nPeriod of return:\nFrom:\n28 April 2024\n27 October 2024\nBalance of unallotted securities under scheme(s) from previous return:\n803,006\nPlus:\nThe amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):\nnil\nLess:\nNumber of\nsecurities\nissued/allotted under scheme(s) during period (see LR3.5.7G):\n527,626\nEquals:\nBalance under scheme(s) not yet issued/allotted at end of period:\n275,380\nName of\napplicant\n:\nAvacta Group plc\nName of scheme:\nLTIP scheme\nPeriod of return:\nFrom:\n28 April 2024\n27 October 2024\nBalance of unallotted securities under scheme(s):\n9,719,257\nPlus:\nThe amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):\nnil\nLess:\nNumber of\nsecurities\nissued/allotted under scheme(s) during period (see LR3.5.7G):\n3,806,000\nEquals:\nBalance under scheme(s) not yet issued/allotted at end of period:\n5,913,257\nName of contact:\nJames Heseltine, Company Secretary\nTelephone number of contact:\n+ 44 (0)\n1904 217070\nEnds-\nFor further information from\u00a0Avacta Group plc, please contact:\nAvacta Group plc\nMichael Vinegrad, Group Communications Director\nhttps://avacta.com/\nPeel Hunt (Nomad and Broker)\nJames Steel\u00a0/\u00a0Chris Golden\u00a0/\u00a0Patrick Birkholm\nwww.peelhunt.com\nICR Healthcare\nMary-Jane Elliott\u00a0/\u00a0Jessica Hodgson\u00a0/\u00a0Sukaina Virji\navacta@consilium-comms.com\nAbout the pre|CISION\n\u00ae\nPlatform\nThe pre|CISION\n\u00ae\nplatform comprises an anticancer payload conjugated to a proprietary peptide that is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The pre|CISION\n\u00ae\nplatform harnesses this tumor specific protease to cleave pre|CISION\n\u00ae\npeptide drug conjugates and pre|CISION\n\u00ae\nantibody/Affimer\n\u00ae\ndrug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity, allowing dosing to be optimized to deliver the best outcomes for patients.\nAbout AVA6000: FAP-enabled doxorubicin\nThe lead pre|CISION\n\u00ae\nprogram AVA6000, a peptide drug conjugate form of doxorubicin, is in Phase 1 studies. It has shown an improvement in safety and tolerability in clinical trials to date compared with standard doxorubicin and preliminary signs of clinical activity in multiple patients.To register for news alerts by email go to\nhttps://avacta.com/investors/investor-news-email-alerts/\n.\nAVA6103: FAP-enabled PDC targeting Topoisomerase I\nAVA6103 is a pre|CISION-enabled PDC comprised of the pre|CISION peptide linked to exatecan, the most potent topoisomerase I inhibitor in clinical development. Exatecan has demonstrated clinical activity in breast, gastric, lung and pancreatic cancers; however, it is associated with severe dose-limiting toxicities and a short half-life in patients that led to discontinuation of its monotherapy development. AVA6103 is designed to enable patients to obtain the therapeutic benefit associated with exatecan, while limiting the systemic exposure associated with its poor tolerability.\nAVA7100: pre|CISION\n\u00ae\nFAP Affimer Drug Conjugate (AffDC)\nAVA7100 is a pre|CISION\n\u00ae\n-enabled Affimer\n\u00ae\ndrug conjugate, a new class of therapies being developed by\u00a0Avacta\u00a0with potential applications in a variety of cancer types, including those with lower levels of FAP in the tumor. Affimer\n\u00ae\nmolecules are small proteins that are engineered to bind to a target molecule in the same way that an antibody does, but with several advantages, including smaller molecule size and a broad range of binding affinity. AVA7100 consists of a novel FAP-Affimer conjugated to a pre|CISION-peptide linker with multiple options for the payload.\nAbout\u00a0Avacta Group plc\u00a0-\nhttps://avacta.com/\nAvacta Group\u00a0is a\u00a0UK-based life sciences company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics. Its clinical stage oncology biotech division Avacta Therapeutics is harnessing the proprietary pre|CISION\n\u00ae\nplatform technology to develop novel, highly targeted cancer drugs. Avacta Diagnostics\u00a0focuses on supporting healthcare professionals and broadening access to diagnostics. To register for news alerts by email go to\nhttps://avacta.com/investors/investor-news-email-alerts/\n.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to",
          "content_length": 5642
        },
        "ingested_at": "2026-01-21T03:29:59.778950Z"
      },
      {
        "event_id": "RNS-21st Jan 2026-fdaclear",
        "event_type": "rns_announcement",
        "date": "2026-01-21T22:39:53.628630Z",
        "source": "LSE_RNS",
        "data": {
          "title": "FDA Clearance of IND Application for AVA6103",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/AVCT/fda-clearance-of-ind-application-for-ava6103-530mmd5nxalilur.html",
          "rns_number": "RNS Number : 6789P",
          "full_content": "Today 07:00\nRNS Number : 6789P\nAvacta Group PLC\n21 January 2026\nAvacta Announces U.S. Food and Drug Administration Clearance of the Investigational New Drug (IND) Application for the Second pre|CISION\n\u00ae\nMedicine, FAP-Exatecan (AVA6103)\nThe Phase 1 clinical study of FAP-Exd (AVA6103) is anticipated to begin later in Q1 2026\nLONDON and PHILADELPHIA\n- January 21, 2026 - Avacta Therapeutics (AIM: AVCT, \"the Company\", \"Avacta\"), a clinical stage biopharmaceutical company developing pre|CISION\u00ae,\u00a0a\ntumor-activated oncology delivery platform, is pleased to announce U.S. Food and Drug Administration (FDA) clearance of the Investigational New Drug (IND) application for the Company's second program FAP-Exd (AVA6103), the first pre|CISION\u00ae peptide drug conjugate based on the highly potent topoisomerase I inhibitor, exatecan.\nThe IND approval is an important step in the development of AVA6103 as this is the point where the program moves from the lab into human testing. The Phase 1 clinical trial will evaluate the safety and potential efficacy of FAP-Exd and seek to identify a dose for further clinical development in patients with four solid tumors, pancreatic cancer, cervical cancer, gastric cancer and small cell lung cancer. The selection of these tumor types was based on an AI approach investigating a sensitivity marker for topoisomerase I inhibitors and FAP expression as part of the strategic collaboration with Tempus AI.\nAdult participants will be enrolled in the dose-escalation part of the trial with two parallel arms investigating two schedules of administration (every two weeks, Q2W and every three weeks, Q3W) with preliminary data from this trial anticipated in the second half of 2026.\nChristina Coughlin, MD, PhD,\nChief Executive Officer at Avacta Therapeutics commented,\n\"Taking FAP-Exd into the clinic is a critical milestone for the pre|CISION\n\u00ae\nplatform and for the Company. In moving the FAP-Exd program forward from inception to a cleared IND in just 24 months, our team has exceeded industry standard timelines. The sustained release mechanism of FAP-Exd, invented by Avacta, is expected to enable greater efficacy in the clinic while limiting the toxicities that were observed with exatecan in its original clinical development. We are very excited to move this program forward for patients and shareholders alike.\"\nDavid Liebowitz, MD, PhD,\nChief Medical Officer at Avacta Therapeutics added,\n\"Our FAP-Exd program in the clinic will very soon provide a greater understanding of the new chemistry of the pre|CISION\n\u00ae\nplatform and also validate the potential to move forward with varied payloads based on our novel capping group and linker technologies. This new program will support a greater understanding of our technology's broad applicability and validate our ability to design molecules that maximize the exposure of our payloads in the tumor in patients.\"\nAlexander Spira MD, PhD, FACP, FASCO,\nCo-Director, Virginia Cancer Specialists (VCS) Research Institute; Director, VCS Thoracic and Phase 1 Program; Chief Scientific Officer, NEXT Oncology; and Clinical Assistant Professor, Johns Hopkins also commented:\n\"I am thrilled to work with Avacta on this exciting new drug. The ability to concentrate a potent topoisomerase I inhibitor directly in the tumor while protecting normal tissues from harmful effects is the next stage of how we should be treating cancer. We are looking forward to participating in this second pre|CISION\n\u00ae\nPhase 1 trial and helping the Company to drive this pioneering technology forward.\"\n-Ends-\nFor further information from Avacta, please contact:\nAvacta Group plc\nChristina Coughlin, Chief Executive Officer\nhttps://avacta.com/\nvia ICR Healthcare\nStrand Hanson Limited (Nominated Adviser)\nJames Harris / Chris Raggett / James Dance\nwww.strandhanson.co.uk\nZeus (Broker)\nJames Hornigold / George Duxberry / Dominic King\nwww.zeuscapital.co.uk\nICR Healthcare\nMary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert\navacta@icrhealthcare.com\nInvestor Contact\nRenee Leck\nTHRUST Strategic Communications\nrenee@thrustsc.com\nMedia Contact\nCarly Scaduto\nCarly Scaduto Consulting\nCarly@carlyscadutoconsulting.com\nAbout Avacta\n-\nhttps://avacta.com/\nAvacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION\u00ae platform. pre|CISION\u00ae is a proprietary payload delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate highly potent payloads in the tumor microenvironment while sparing normal tissues.\nOur innovative pipeline consists of pre|CISION\u00ae peptide drug conjugates (PDC) or Affimer\u00ae drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates.\nThe pre|CISION\u00ae platform comprises an anticancer payload conjugated to a proprietary peptide that is a highly specific substrate for fibroblast activation protein (FAP) wh",
          "content_length": 6204
        },
        "ingested_at": "2026-01-21T22:39:53.628664Z"
      },
      {
        "event_id": "SOCIAL-Today0749-Bella653--2241640",
        "event_type": "social_post",
        "date": "2026-01-22T22:02:42.325388",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "And some wonder how shorters get their shares....sites like these and your broker sites... 'We lend shares from your portfolio to borrowers and receive interest in exchange. We split all interest equally with you. Share lending is fully automatic and will never cause delays when selling. You still get paid dividends in full.'",
          "sentiment": 0.0,
          "engagement": "6,741",
          "price_at_post": "55.50",
          "thread_title": "RE: Avct & T212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=4D59A380-8A24-424C-A087-DA0FAA8B5786"
        },
        "ingested_at": "2026-01-22T22:02:42.341373+00:00"
      },
      {
        "event_id": "SOCIAL-Today0754-Livedata-25917773",
        "event_type": "social_post",
        "date": "2026-01-22T22:02:42.324592",
        "source": "LSE_CHAT",
        "data": {
          "author": "Livedataaccount",
          "content": "How good were avactas 6103 pre clinical results amd does anyone know what they are aiming to replicate in humans I'm looking at tumour shrinkage thank you in advance",
          "sentiment": 0.0,
          "engagement": "2,951",
          "price_at_post": "55.00",
          "thread_title": "Ava6103",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D0FF62CB-42BA-4C76-A490-A0F2D765A919"
        },
        "ingested_at": "2026-01-22T22:02:42.341341+00:00"
      },
      {
        "event_id": "SOCIAL-Today0757-BuenaVis-70388198",
        "event_type": "social_post",
        "date": "2026-01-22T22:02:42.323798",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Https://www.londonstockexchange.com/news-article/AVCT/year-end-trading-update/17421159",
          "sentiment": 0.0,
          "engagement": "5,713",
          "price_at_post": "55.50",
          "thread_title": "RE: Ava6103",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D0FF62CB-42BA-4C76-A490-A0F2D765A919"
        },
        "ingested_at": "2026-01-22T22:02:42.341322+00:00"
      },
      {
        "event_id": "SOCIAL-Today0802-HarChris--2796106",
        "event_type": "social_post",
        "date": "2026-01-22T22:02:42.323023",
        "source": "LSE_CHAT",
        "data": {
          "author": "HarChris",
          "content": "'Or a deal might not' Sure, but with 6103 trial already having begun there's an argument to be had that the realistic worst case over the coming months is a runway extending placing at 50p to get us through to 2027... yet you're selling at 53p with all the potential upside options on the table to protect against a small downside risk? Terrible R/R at this stage.",
          "sentiment": 0.0,
          "engagement": "15,811",
          "price_at_post": "55.50",
          "thread_title": "RE: For Chris",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=204FD580-E2F8-4E01-9636-04251DFD3A79"
        },
        "ingested_at": "2026-01-22T22:02:42.341303+00:00"
      },
      {
        "event_id": "SOCIAL-Today0808-BuenaVis-84061268",
        "event_type": "social_post",
        "date": "2026-01-22T22:02:42.322263",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "And another fool steps forward to continue the engagement.",
          "sentiment": 0.0,
          "engagement": "5,713",
          "price_at_post": "55.00",
          "thread_title": "RE: For Chris",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=204FD580-E2F8-4E01-9636-04251DFD3A79"
        },
        "ingested_at": "2026-01-22T22:02:42.341278+00:00"
      },
      {
        "event_id": "SOCIAL-Today0824-Thornogs-88186001",
        "event_type": "social_post",
        "date": "2026-01-22T22:02:42.321667",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Loveable, would it not be more reasonable to expect a deal first on a Pre|Cision platform that is clinically proven to work before anyone is going to do a deal on the dual platform? Walking and running? Avacta aren't doing a deal on FAP-EXD until they can extract maximum value from it, once (if) this happens then a dual deal might follow. I agree RE a 'bridging raise' Chris but with the SP at 55p today it would do well to get away at 50p the way the markets tend to walk down the SP prior to a raise.",
          "sentiment": 0.0,
          "engagement": "8,580",
          "price_at_post": "55.00",
          "thread_title": "RE: For Chris",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=204FD580-E2F8-4E01-9636-04251DFD3A79"
        },
        "ingested_at": "2026-01-22T22:02:42.341250+00:00"
      },
      {
        "event_id": "SOCIAL-Today0912-Aldebara--8342842",
        "event_type": "social_post",
        "date": "2026-01-22T22:02:42.320955",
        "source": "LSE_CHAT",
        "data": {
          "author": "Aldebaran",
          "content": "Last raise was 8% discount only. Hughes and his mates. Its pennies for them who have all done well. If any bridging financing is required im sure they'll take care of it and it won't be open to retail.",
          "sentiment": 0.0,
          "engagement": "3,862",
          "price_at_post": "54.00",
          "thread_title": "RE: For Chris",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=204FD580-E2F8-4E01-9636-04251DFD3A79"
        },
        "ingested_at": "2026-01-22T22:02:42.341221+00:00"
      },
      {
        "event_id": "SOCIAL-Today0917-Thornogs-78749872",
        "event_type": "social_post",
        "date": "2026-01-22T22:02:42.320268",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Always good to be certain what's going to happen on AIM, never goes wrong.",
          "sentiment": 0.0,
          "engagement": "8,580",
          "price_at_post": "54.00",
          "thread_title": "RE: For Chris",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=204FD580-E2F8-4E01-9636-04251DFD3A79"
        },
        "ingested_at": "2026-01-22T22:02:42.341201+00:00"
      },
      {
        "event_id": "SOCIAL-Today0918-Aldebara--7051438",
        "event_type": "social_post",
        "date": "2026-01-22T22:02:42.319742",
        "source": "LSE_CHAT",
        "data": {
          "author": "Aldebaran",
          "content": "With Hughesy getting 6103 and BC data plus knowing what exactly those talks with Novartis and others are all about i Would absolutely not rule out a premium final placing also. Just bridging if necessary. Ultimately I think anyone sensible has done the sums on 500m shares in issue at the takeover point and you get a hefty return whichever way you calculate the buyout price. This hole talk of funding is nonsense at this stage. Its FUD. What avacta have achieved is truly groundbreaking and will rewrite the rules on oncology.",
          "sentiment": 0.0,
          "engagement": "3,862",
          "price_at_post": "54.00",
          "thread_title": "RE: For Chris",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=204FD580-E2F8-4E01-9636-04251DFD3A79"
        },
        "ingested_at": "2026-01-22T22:02:42.341171+00:00"
      },
      {
        "event_id": "SOCIAL-Today0925-HarChris--7869454",
        "event_type": "social_post",
        "date": "2026-01-22T22:02:42.319076",
        "source": "LSE_CHAT",
        "data": {
          "author": "HarChris",
          "content": "Never possible to be certain until after the fact, the skill is in discernment and recognising what companies are well supported and what companies  can be wiped out by a need for funding. The worst case scenario over the coming three or four months isn\u2019t all that bad, the best case is excellent.",
          "sentiment": 0.0,
          "engagement": "15,811",
          "price_at_post": "54.00",
          "thread_title": "RE: For Chris",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=204FD580-E2F8-4E01-9636-04251DFD3A79"
        },
        "ingested_at": "2026-01-22T22:02:42.341151+00:00"
      },
      {
        "event_id": "SOCIAL-Today0932-Aldebara--8787312",
        "event_type": "social_post",
        "date": "2026-01-22T22:02:42.318300",
        "source": "LSE_CHAT",
        "data": {
          "author": "Aldebaran",
          "content": "You seem pretty certain in your views Thorn. Im just providing a bit of balance ;-)",
          "sentiment": 0.0,
          "engagement": "3,862",
          "price_at_post": "54.00",
          "thread_title": "RE: For Chris",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=204FD580-E2F8-4E01-9636-04251DFD3A79"
        },
        "ingested_at": "2026-01-22T22:02:42.341112+00:00"
      },
      {
        "event_id": "SOCIAL-Today0938-LovableL-74328180",
        "event_type": "social_post",
        "date": "2026-01-22T22:02:42.317531",
        "source": "LSE_CHAT",
        "data": {
          "author": "LovableLumax",
          "content": "Gap filled from yesterday morning.",
          "sentiment": 0.0,
          "engagement": "2,695",
          "price_at_post": "54.00",
          "thread_title": "RE: For Chris",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=204FD580-E2F8-4E01-9636-04251DFD3A79"
        },
        "ingested_at": "2026-01-22T22:02:42.341062+00:00"
      },
      {
        "event_id": "SOCIAL-Today0941-avctIPma-72425586",
        "event_type": "social_post",
        "date": "2026-01-22T22:02:42.316752",
        "source": "LSE_CHAT",
        "data": {
          "author": "avctIPmatters",
          "content": "Note   Avacta   Tempus expert   Ruairidh Edwards liked  this Tempus update  : https://www.tempus.com/news/pr/tempus-announces-the-launch-of-paige-predict/?utm_source=linkedin&utm_medium=organic-social&utm_campaign=paige-predict-jan&utm_term=january-2026&utm_content=learn-more Getting patient tissue clinical trial data  treatment results key part of the trials . All helps speed up the process : ---------------------------------- View Ryan Fukushima\u2019s  graphic link Ryan FukushimaRyan Fukushima \u2022 3rd+Premium \u2022 3rd+ CEO Data & Apps at Tempus AICEO Data & Apps at Tempus AI View my newsletter 16h \u2022 Edited \u2022  16 hours ago \u2022 Edited \u2022 Visible to anyone on or off LinkedIn Follow The bottleneck in precision medicine isn't sequencing speed or capacity. It's tissue scarcity. But too often, physicians hear three words: \"Quantity Not Sufficient.\" Everything stops. Limited options. Delayed decisions. This is the hidden crisis in precision oncology. Today we launched Paige Predict to address this QNS issue: AI that predicts 123 biomarkers across 16 cancer types from a single H&E pathology slide. Here's the main change: When tissue is scarce, every test is a bet. Which biomarker do you prioritize when you only get one shot? Paige Predict tells you which biomarkers are likely present before you run confirmatory tests. Now you can maximize your odds of getting actionable results before tissue runs out. This isn't benchmarks on ppt slides. This is deployed in clinical care today. Built on Paige's foundation model. Validated on the largest multimodal oncology dataset. Built for industrial scale. The lesson matters beyond this product: Healthcare AI spent years proving it could match human performance. Table stakes. The next decade? Solving real clinical problems to ensure that every actionable biomarker is found for every patient. This is what we're laser focused on in Data & Apps. Foundation models + multimodal data + workflow integration = value physicians actually use to be superhuman. We acquired Paige because we saw this coming. Their foundation model. Our datasets. Integrated deployment. All three. The future of precision medicine isn't choosing between AI and molecular testing. It's using AI to make every molecule of tissue count. Link: https://lnkd.in/g_ku5RX3 hashtag#PrecisionMedicine hashtag#HealthcareAI hashtag#DigitalPathology hashtag#FoundationModels hashtag#DrugDevelopment Gmcc",
          "sentiment": 0.0,
          "engagement": "717",
          "price_at_post": "54.00",
          "thread_title": "Tempus Announces the Launch of Paige Predict",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=11121BA4-FF09-4D71-81D5-EC789DA2AC8E"
        },
        "ingested_at": "2026-01-22T22:02:42.341026+00:00"
      },
      {
        "event_id": "SOCIAL-Today0958-avctIPma-13813302",
        "event_type": "social_post",
        "date": "2026-01-22T22:02:42.315670",
        "source": "LSE_CHAT",
        "data": {
          "author": "avctIPmatters",
          "content": "Not seen yet any formal clinical trial register record for AVA6103   - Suppose first patient dosed  would  count as an inflection point . Anyway at least one new clinic involved . ( Adult participants will be enrolled in the dose-escalation part of the trial with two parallel arms investigating two schedules of administration (every two weeks, Q2W and every three weeks, Q3W) with preliminary data from this trial anticipated in the second half of 2026.\" https://nextoncology.com/ \" NEXT Oncology, an Avacare businessNEXT Oncology, an Avacare business 3,214 followers3,214 followers 16h \u2022  16 hours ago \u2022 Visible to anyone on or off LinkedIn Follow Congratulations to our colleagues at Avacta Therapeutics for this exciting hashtag#IND clearance from the hashtag#FDA. Avacta TherapeuticsAvacta Therapeutics 8,063 followers8,063 followers 1d \u2022  1 day ago \u2022 Visible to anyone on or off LinkedIn Avacta is pleased to announce U.S. FDA clearance of the IND application for the Company\u2019s second program FAP-Exd (AVA6103), the first pre|CISION peptide drug conjugate based on the highly potent topoisomerase I inhibitor, exatecan. https://lnkd.in/g9sndmAy \u2026more Avacta Announces U.S. Food and Drug Administration Clearance of the Investigational New Drug (IND) Application for the Second pre|CISION\u00ae Medicine, FAP-Exatecan (AVA6103) | Avacta Therapeutics avacta.com Gmcc",
          "sentiment": 0.0,
          "engagement": "717",
          "price_at_post": "53.50",
          "thread_title": "NEXT Oncology",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=5126192A-5F35-4AD6-B07D-1551DA973BA1"
        },
        "ingested_at": "2026-01-22T22:02:42.340990+00:00"
      },
      {
        "event_id": "SOCIAL-Today1012-avctIPma-46086759",
        "event_type": "social_post",
        "date": "2026-01-22T22:02:42.314736",
        "source": "LSE_CHAT",
        "data": {
          "author": "avctIPmatters",
          "content": "Courtesy  Stonks thanks Two AffyXell patents published this morning in the US citing #AVCT's Affimer tech https://x.com/JStonker/status/2014275561762299995 https://x.com/JStonker/status/2014275561762299995/photo/1 https://x.com/JStonker/status/2014275561762299995/photo/2 Gmcc",
          "sentiment": 0.0,
          "engagement": "717",
          "price_at_post": "54.00",
          "thread_title": "AffyXell Therapeutics",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=1703BB40-302C-467E-9C31-59942566D4E1"
        },
        "ingested_at": "2026-01-22T22:02:42.340954+00:00"
      },
      {
        "event_id": "SOCIAL-Today1039-Matml74-20284060",
        "event_type": "social_post",
        "date": "2026-01-22T22:02:42.313950",
        "source": "LSE_CHAT",
        "data": {
          "author": "Matml74",
          "content": "Thought the fud crew said Affyxell was a fraud. \ud83e\udd21",
          "sentiment": 0.0,
          "engagement": "2,529",
          "price_at_post": "54.00",
          "thread_title": "RE: AffyXell Therapeutics",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=1703BB40-302C-467E-9C31-59942566D4E1"
        },
        "ingested_at": "2026-01-22T22:02:42.340918+00:00"
      },
      {
        "event_id": "SOCIAL-Today1040-steviebo-58589087",
        "event_type": "social_post",
        "date": "2026-01-22T22:02:42.313156",
        "source": "LSE_CHAT",
        "data": {
          "author": "stevieboro",
          "content": "Morning all, i was wondering if anyone had any clarity on as to why investing.com, https://www.investing.com/equities/avacta-group-plc , has Avacta as 'strong sell' in its technical analysis yet 'buy' on technical sentiment? Struggling to see how this could be judged a 'strong sell' share with what's going on in the background. Yes time frames are further down the road than we had hoped but surely that wouldn't be a reason to sell your holding? Just wondered, LTH so mine is going no where GLA",
          "sentiment": 0.5,
          "engagement": "289",
          "price_at_post": "54.00",
          "thread_title": "Buy or Sell",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=91C612D8-4488-4CDE-B1DC-E363D8AAABB4"
        },
        "ingested_at": "2026-01-22T22:02:42.340883+00:00"
      },
      {
        "event_id": "SOCIAL-Today1050-Thornogs-98176742",
        "event_type": "social_post",
        "date": "2026-01-22T22:02:42.312318",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "I actually said that I was disappointed that in the recent Trading Update they chose to talk almost exclusively about FAP-EXD when, in theory at least, the company is working on several other important things. It's difficult to know how much these affect your potential investment return/risk if month on month and year on year they're never mentioned. That's surely a minimum that investors in a company would expect?",
          "sentiment": 0.0,
          "engagement": "8,580",
          "price_at_post": "54.00",
          "thread_title": "RE: AffyXell Therapeutics",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=1703BB40-302C-467E-9C31-59942566D4E1"
        },
        "ingested_at": "2026-01-22T22:02:42.340851+00:00"
      },
      {
        "event_id": "SOCIAL-Today1052-wyndrum--1099859",
        "event_type": "social_post",
        "date": "2026-01-22T22:02:42.311489",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "Not sure steve. My view on the chart is its on a support but in a downtrend so the question is: will the support hold so maybe the supoort suggests sentiment will  move up from here as it has done previously. Or, technically until the downtrend is reversed technically it expects further falls. If you are a new potential stock holder and want to buy, you tend to wait for a support as an entry point (particularly in an uptrend), but still now for instance, as a good entry point if you think the fall is likely to be over. If you are already a holder you may wait for the support to be broken before selling. All buyers (and sellers) have to make a decision at some stage and pull the trigger. No one knows what will happen so its the individual has to have their own plan/strategy as to when to make a decision and when that criteria is fulfilled, react. The scale of their decision and confidence in the future outcome then comes into risk/reward. What must be eliminated is any emotion in the process, otherwise whats the point of looking at a chart if all you are waiting for is confirmation bias?",
          "sentiment": 0.0,
          "engagement": "12,186",
          "price_at_post": "54.00",
          "thread_title": "RE: Buy or Sell",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=91C612D8-4488-4CDE-B1DC-E363D8AAABB4"
        },
        "ingested_at": "2026-01-22T22:02:42.340815+00:00"
      },
      {
        "event_id": "SOCIAL-Today1054-Yorkshir-59407668",
        "event_type": "social_post",
        "date": "2026-01-22T22:02:42.310644",
        "source": "LSE_CHAT",
        "data": {
          "author": "Yorkshirepragma",
          "content": "Commercial focus in recent RNS\u2019s gives strong message. Not often these \u2018signals\u2019 given . GLA",
          "sentiment": 0.0,
          "engagement": "1,800",
          "price_at_post": "54.00",
          "thread_title": "RE: Buy or Sell",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=91C612D8-4488-4CDE-B1DC-E363D8AAABB4"
        },
        "ingested_at": "2026-01-22T22:02:42.340778+00:00"
      },
      {
        "event_id": "SOCIAL-Today1107-Thornogs-72232521",
        "event_type": "social_post",
        "date": "2026-01-22T22:02:42.309997",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "And it would be nice to be able to see the promised Q&As from said meeting too.",
          "sentiment": 0.0,
          "engagement": "8,580",
          "price_at_post": "54.00",
          "thread_title": "RE: AffyXell Therapeutics",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=1703BB40-302C-467E-9C31-59942566D4E1"
        },
        "ingested_at": "2026-01-22T22:02:42.340740+00:00"
      },
      {
        "event_id": "SOCIAL-Today1138-cj62--2658747",
        "event_type": "social_post",
        "date": "2026-01-22T22:02:42.309569",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "This program continues to garner significant interest from global pharmaceutical companies; however, the Company's strategy remains to retain 100% of AVA6103 until we begin to see readouts from the Phase 1a clinical trial. Importantly, the trial has been designed to rapidly deliver clinical data in this program. If the above statement doesnt give you any assurances regarding commercial partnership i dont know what will. I for one can wait another 6-9 months.",
          "sentiment": 0.0,
          "engagement": "4,265",
          "price_at_post": "54.00",
          "thread_title": "RE: Buy or Sell",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=91C612D8-4488-4CDE-B1DC-E363D8AAABB4"
        },
        "ingested_at": "2026-01-22T22:02:42.340703+00:00"
      },
      {
        "event_id": "SOCIAL-Today1302-Icecool--6795580",
        "event_type": "social_post",
        "date": "2026-01-22T22:02:42.309129",
        "source": "LSE_CHAT",
        "data": {
          "author": "Icecool",
          "content": "Let\u2019s stop overcomplicating this. AIM says Avacta is worth \u00a3240m. That valuation only makes sense if nothing works, and they are still developing. AVA6000 has already proven the platform works in humans. AVA6103 now has FDA IND clearance and enters the clinic this quarter. Same delivery tech, stronger payload, broader applicability. That\u2019s no longer binary science risk. That\u2019s execution and scale. IND clearance isn\u2019t just a rubber stamp. The FDA has signed off the chemistry, linker, payload and trial design. This is a platform moving through humans, not a lab university experiment. Yet AIM still prices it like a speculative punt, not a validated oncology delivery engine. That disconnect won\u2019t be fixed by traders or sentiment. It gets fixed when partners price the asset properly. If AVA6103 even partially replicates preclinical signals in humans, today\u2019s market cap looks absurd in hindsight. I suggest anyone that\u2019s interested to do research on ADC deals and compare even the most basic ones to Avacta 240m market cap. That\u2019s the opportunity here. \ud83d\udcaf\ud83d\udc4d",
          "sentiment": 0.0,
          "engagement": "8,808",
          "price_at_post": "54.00",
          "thread_title": "AIM Disconnect is real",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=736218C9-3E99-4D78-999F-C98074689712"
        },
        "ingested_at": "2026-01-22T22:02:42.340662+00:00"
      },
      {
        "event_id": "SOCIAL-Today1316-avctIPma--3065573",
        "event_type": "social_post",
        "date": "2026-01-22T22:02:42.308612",
        "source": "LSE_CHAT",
        "data": {
          "author": "avctIPmatters",
          "content": "Avacta https://x.com/search?q=%23AVCT&src=typeahead_click&f=live Avacta @avacta \u00b7 42m Our 2nd pre|CISION medicine is heading to the clinic! With FDA clearance of the IND for AVA6103, we\u2019re one step closer to a new approach for cancer treatment. We\u2019re honored to have Dr. Alexander Spira and team joining us on this journey. Phase 1 begins later this quarter. #AVCT Gmcc",
          "sentiment": 0.0,
          "engagement": "717",
          "price_at_post": "54.00",
          "thread_title": "RE: NEXT Oncology",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=5126192A-5F35-4AD6-B07D-1551DA973BA1"
        },
        "ingested_at": "2026-01-22T22:02:42.340626+00:00"
      },
      {
        "event_id": "SOCIAL-Today1319-Thornogs-30640175",
        "event_type": "social_post",
        "date": "2026-01-22T22:02:42.308045",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "No ICE, not the same 'delivery tech'. Improved (longer half life) 'delivery tech'. It's 'Fundamental' as to why AVA6000 has to why AVA6000 has NOT proven that the platform works in humans, at least in the practical sense that Pharma wants to see: improved chemotherapy deposition in tumours with improved trial outcome data in a head to head trial of the same chemo agent delivered to the same tumour/patient group on with and one without the platform. That hasn't happened, the platform has NOT been proved, hence no Pharma deals. That's rather basic.",
          "sentiment": 0.0,
          "engagement": "8,580",
          "price_at_post": "54.00",
          "thread_title": "RE: AIM Disconnect is real",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=736218C9-3E99-4D78-999F-C98074689712"
        },
        "ingested_at": "2026-01-22T22:02:42.340590+00:00"
      },
      {
        "event_id": "SOCIAL-Today1322-Watching--4131108",
        "event_type": "social_post",
        "date": "2026-01-22T22:02:36.891981",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "Just won  on bet Fred that a clown bot would follow ice lol Where the hell do there plonkers come from in the world !",
          "sentiment": 0.0,
          "engagement": "9,200",
          "price_at_post": "54.00",
          "thread_title": "RE: AIM Disconnect is real",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=736218C9-3E99-4D78-999F-C98074689712"
        },
        "ingested_at": "2026-01-22T22:02:42.340554+00:00"
      },
      {
        "event_id": "SOCIAL-Today1326-cj62--8449438",
        "event_type": "social_post",
        "date": "2026-01-22T22:02:36.891473",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "Oh Thorn you are whipping yourself into a frenzy. How many sets of crayons have you gone through today ? You must have written ava6000 doesn't work and half life a million times recently, if you have used your brown crayons first can you over write with other colours because iam really worried you will run out of wall space and that will definitely send out nurse bothering again and we don't want that now do we.",
          "sentiment": 0.0,
          "engagement": "4,265",
          "price_at_post": "54.00",
          "thread_title": "RE: AIM Disconnect is real",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=736218C9-3E99-4D78-999F-C98074689712"
        },
        "ingested_at": "2026-01-22T22:02:42.340516+00:00"
      },
      {
        "event_id": "SOCIAL-Today1337-Thornogs-20351500",
        "event_type": "social_post",
        "date": "2026-01-22T22:02:36.891022",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "And yet the majority still post as if AVA6000 has been a great success and 'proved the platform'. The failure of AVA6000 to take on and beat Soft Tissue Sarcoma says it all, it hasn't worked. An SP of heading down below Dr Smith's own placing price of 50p after nearly 5 years of a 'data rich' clinical trial surely tells you that Pharma need more? We await FAP-EXD. We start again.",
          "sentiment": 0.0,
          "engagement": "8,580",
          "price_at_post": "54.00",
          "thread_title": "RE: AIM Disconnect is real",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=736218C9-3E99-4D78-999F-C98074689712"
        },
        "ingested_at": "2026-01-22T22:02:42.340473+00:00"
      },
      {
        "event_id": "SOCIAL-Today1401-Toukanka--4842295",
        "event_type": "social_post",
        "date": "2026-01-22T22:02:36.890578",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "And still the deluded Poms Poms wail that no one understands Avacta like they do. All the BP scientists and the institutional investors are all thick as mince. Only the \u201cheroes\u201d on here understand the truth. And to make it worse their tribal zombies cheer them on   Heaping insults and character assassinations on those of us that try to explain: I\u2019ll make it as easy as possible;;; AVA6000 is now truly overshadowed by AVA6103. Hopefully the next cycle of AVA6000 P1 results will secure a licence deal. Regarding AVA6103: progress looks on track to deliver initial results sometime around June which will be pivotal one way or another. In the meantime expect the SP to at best track sideways at current levels. So get over it and be patient.",
          "sentiment": 0.0,
          "engagement": "4,434",
          "price_at_post": "54.00",
          "thread_title": "RE: AIM Disconnect is real",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=736218C9-3E99-4D78-999F-C98074689712"
        },
        "ingested_at": "2026-01-22T22:02:42.340437+00:00"
      },
      {
        "event_id": "SOCIAL-Today1403-LiveLong--4320042",
        "event_type": "social_post",
        "date": "2026-01-22T22:02:36.890127",
        "source": "LSE_CHAT",
        "data": {
          "author": "LiveLongnProsper",
          "content": "Most \u2018sins of past\u2019 undone (but not forgiven). Dx disposal (more-or-less given away, but necessary for the \u2018play book\u2019 \u2013 you know the one). CLN sorted (albeit \u2018parked\u2019 for now), and some short-term funding \u2013 credit to BH and RH. Progress with science / pipeline / trials truly brilliant \u2013 credit CC (in R&D and CMO roles), and fantastic scientists. Great setup for AVA6103 trials \u2013 thankyou CC and 'involved' team. Now CC (as CEO) and (so far, invisible) BD team \u2013 SB and YB (plus maybe DB), really need to demonstrate their \u2018contribution\u2019 with a significant commercial deal. GLA Ps \u2013 Novartis, just \u2018fill that gap\u2019 in your pipeline, you know it makes sense, and waiting will cost.",
          "sentiment": 0.0,
          "engagement": "1,833",
          "price_at_post": "54.00",
          "thread_title": "RE: AIM Disconnect is real",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=736218C9-3E99-4D78-999F-C98074689712"
        },
        "ingested_at": "2026-01-22T22:02:42.340400+00:00"
      },
      {
        "event_id": "SOCIAL-Today1406-avctIPma--6770004",
        "event_type": "social_post",
        "date": "2026-01-22T22:02:36.889642",
        "source": "LSE_CHAT",
        "data": {
          "author": "avctIPmatters",
          "content": "Obviously Dr Spira   not put off   by our resident  LSE  no life expert  . \"NEXT Oncology Names Dr. Alex Spira Chief Scientific Officer\" https://nextoncology.com/next-oncology-names-dr-alex-spira-chief-scientific-officer/ \"\u201cWe are committed to offering hope when conventional treatments fall short\u2014and that\u2019s what being the NEXT Option is all about,\u201d said Dr. Tolcher. \u201cDr. Spira is a respected leader in the oncology community, and his expertise will be instrumental as we expand our Phase 1 trial capabilities and scientific leadership.\u201d About NEXT Oncology NEXT Oncology is dedicated to the development of new anticancer agents for patients whose current cancer therapy is no longer working to benefit them and are looking for their next option. NEXT Oncology is partnered with  Texas Oncology, the largest private oncology practice in the United States with more than 400 referring medical oncologists. Texas Oncology is a practice within The US Oncology Network, a network of independent, community-based oncologists in the U.S. This formidable size and reach provide NEXT Oncology unprecedented opportunities to transform what has come to be expected from clinical trials of new agents.\"",
          "sentiment": 0.0,
          "engagement": "717",
          "price_at_post": "54.00",
          "thread_title": "RE: NEXT Oncology",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=5126192A-5F35-4AD6-B07D-1551DA973BA1"
        },
        "ingested_at": "2026-01-22T22:02:42.340362+00:00"
      },
      {
        "event_id": "SOCIAL-Today1409-D-Geeman-93058612",
        "event_type": "social_post",
        "date": "2026-01-22T22:02:36.889087",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "'won on bet Fred ' Was it an accumulator? No need to thank me.",
          "sentiment": 0.0,
          "engagement": "5,837",
          "price_at_post": "54.00",
          "thread_title": "RE: AIM Disconnect is real",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=736218C9-3E99-4D78-999F-C98074689712"
        },
        "ingested_at": "2026-01-22T22:02:42.340326+00:00"
      },
      {
        "event_id": "SOCIAL-Today1414-Icecool-77343926",
        "event_type": "social_post",
        "date": "2026-01-22T22:02:36.888648",
        "source": "LSE_CHAT",
        "data": {
          "author": "Icecool",
          "content": "Touk, was that a ChatGPT special or did you write it yourself? \ud83e\udd23\ud83d\ude2d Either way, do yourself a favour, use AI properly and spend an hour looking at ADC topo -1 deal comps and how assets get valued at IND  early clinical when the mechanism is credible. Then come back and explain, without handwaving, how a \u00a3240m AIM market cap makes sense for a company with. Human-validated platform (AVA6000) IND-cleared AVA6103 entering clinic this quarter. A payload class (topo-1) that pharma already pays through the nose for. Plus dual-payload IP on top. Look forward to seeing the response. \ud83e\udd23\ud83d\udc4d\ud83d\udcaf",
          "sentiment": 0.0,
          "engagement": "8,808",
          "price_at_post": "54.00",
          "thread_title": "RE: AIM Disconnect is real",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=736218C9-3E99-4D78-999F-C98074689712"
        },
        "ingested_at": "2026-01-22T22:02:42.340289+00:00"
      },
      {
        "event_id": "SOCIAL-Today1419-Watching-50382496",
        "event_type": "social_post",
        "date": "2026-01-22T22:02:36.888040",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "We are alll doomed They\u2019ve switched on BOT Geeman too ! I\u2019m keeping my head down until its battery goes dead lol",
          "sentiment": 0.0,
          "engagement": "9,200",
          "price_at_post": "54.00",
          "thread_title": "RE: AIM Disconnect is real",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=736218C9-3E99-4D78-999F-C98074689712"
        },
        "ingested_at": "2026-01-22T22:02:42.340252+00:00"
      },
      {
        "event_id": "SOCIAL-Today1419-Thornogs-33660895",
        "event_type": "social_post",
        "date": "2026-01-22T22:02:36.887502",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Only one answer ICE. Is the Market (still) as thick as mince?",
          "sentiment": 0.0,
          "engagement": "8,580",
          "price_at_post": "54.00",
          "thread_title": "RE: AIM Disconnect is real",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=736218C9-3E99-4D78-999F-C98074689712"
        },
        "ingested_at": "2026-01-22T22:02:42.340215+00:00"
      },
      {
        "event_id": "SOCIAL-Today1422-BuenaVis-24637878",
        "event_type": "social_post",
        "date": "2026-01-22T22:02:36.886999",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "As DanGB has so succintly said (15 Jan 2026 @ 16:35): \"Half-life is not an issue with AVA6000/DOX. \"It is an issue with exatecan. \"It might be an issue with other payloads. \"Down talking AVA6000 based on half-life is FUD. \"And, although yet to be proven in clinic, Avacta now has the ability to tailor half-life to the payload if required.\" - - - - - Really, nothing more needs to be said.  Nothing.",
          "sentiment": 0.0,
          "engagement": "5,713",
          "price_at_post": "54.00",
          "thread_title": "RE: AIM Disconnect is real",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=736218C9-3E99-4D78-999F-C98074689712"
        },
        "ingested_at": "2026-01-22T22:02:42.340178+00:00"
      },
      {
        "event_id": "SOCIAL-Today1426-Thornogs--9176688",
        "event_type": "social_post",
        "date": "2026-01-22T22:02:36.886514",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "And Dan's qualifications to issue this unsubstantiated statement of fact in the face of the indifference of the entire multi-billion pound Pharmaceutical industry is BV? Or just a well meaning shareholder with a contrary opinion perhaps.",
          "sentiment": 0.0,
          "engagement": "8,580",
          "price_at_post": "54.00",
          "thread_title": "RE: AIM Disconnect is real",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=736218C9-3E99-4D78-999F-C98074689712"
        },
        "ingested_at": "2026-01-22T22:02:42.340141+00:00"
      },
      {
        "event_id": "SOCIAL-Today1429-BuenaVis--5481112",
        "event_type": "social_post",
        "date": "2026-01-22T22:02:36.885923",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Anyone know the price of fish?",
          "sentiment": 0.0,
          "engagement": "5,713",
          "price_at_post": "54.00",
          "thread_title": "RE: AIM Disconnect is real",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=736218C9-3E99-4D78-999F-C98074689712"
        },
        "ingested_at": "2026-01-22T22:02:42.340090+00:00"
      },
      {
        "event_id": "SOCIAL-Today1447-yeboha--2853879",
        "event_type": "social_post",
        "date": "2026-01-22T22:02:36.885050",
        "source": "LSE_CHAT",
        "data": {
          "author": "yeboha",
          "content": "Countless shares have performed badly or gone sideways for years on Aim,  that have gone on to be sold for multiple billions! Avacta will be one of those shares 100%",
          "sentiment": 0.0,
          "engagement": "947",
          "price_at_post": "54.00",
          "thread_title": "RE: AIM Disconnect is real",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=736218C9-3E99-4D78-999F-C98074689712"
        },
        "ingested_at": "2026-01-22T22:02:42.340053+00:00"
      },
      {
        "event_id": "SOCIAL-Today1503-NFTs--8916591",
        "event_type": "social_post",
        "date": "2026-01-22T22:02:36.884211",
        "source": "LSE_CHAT",
        "data": {
          "author": "NFTs",
          "content": "we all know who is going to be the winner hence why he hides behind thornogson because he knows he is going to be destroyed more than an pizza delivery boy hiding \ud83d\ude48 in his shack in north wales the tension between tom winnifrith (of *************) and the duo of myles mcnulty and avacta is one of the longest-running \"civil wars\" in the uk aim market. it isn\u2019t just about the stock; it is a clash of two very different investment philosophies. here is the breakdown of why there is so much \"vengeance\" in this particular feud: 1. the philosophical clash (fundamentals vs. future) \u2022 winnifrith\u2019s view: tom operates on a \"show me the money\" basis. he is a fundamentalist who focuses on cash burn, dilution, and revenue. he sees avacta as a \"lifestyle business\" that has spent years burning investor cash without delivering a commercial blockbuster (especially after the covid-19 lateral flow test hype failed to materialize in the way many hoped). \u2022 mcnulty\u2019s view: myles mcnulty is widely seen as the primary bull and research lead for the private investor community on avacta. he focuses on the biotech science (specifically the pre|cision platform and ava6000). he views avacta as a generational opportunity in oncology that requires patience and high r&d spend. 2. the \"credibility\" war the vengeance stems from the fact that both men\u2019s reputations are tied to this stock: \u2022 the \"mcnulty effect\": when avacta\u2019s share price rises, it validates myles's deep-dive research. winnifrith views this as \"pumping\" and often attacks the followers of myles as being part of a \"cult.\" \u2022 the \"winnifrith bear raid\": when the price drops or there is a funding round (dilution), tom uses it to claim he was right all along about the company's financial instability. he views myles\u2019s optimism as dangerous to retail investors. 3. past grievances: the covid era much of the current vitriol is a carry-over from the 2020\u20132021 period. \u2022 avacta was a \"covid darling\" that saw its share price rocket on the promise of their lateral flow tests. \u2022 tom was relentlessly bearish during this peak, calling the tests \"jam tomorrow.\" \u2022 when the government contracts didn't materialize and the share price crashed from the highs, tom felt vindicated. myles and the avacta bulls, however, shifted focus to the cancer pipeline (ava6000), which tom dismisses as just another excuse for more \"cash-grabbing\" placements. 4. recent friction: the convertible bond & cash runway as of this week (january 2026), the feud has reignited because: \u2022 tom points to the q3 2026 cash runway and the high interest on convertible bonds as proof that the company is a \"zombie\" heading for a massive dilutive rescue. \u2022 myles and the bulls point to the fda clearance for ava6103 (yesterday) as proof that the science is working and the company is being built for a multi-billion dollar buyout. summary of the hostility in short: it is personal because if the cancer data (ava6000/6103) is",
          "sentiment": 0.0,
          "engagement": "817",
          "price_at_post": "54.00",
          "thread_title": "Thornogson your time is running out hiding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B0CABD0D-9525-4145-B85F-56AAF275F036"
        },
        "ingested_at": "2026-01-22T22:02:42.340025+00:00"
      },
      {
        "event_id": "SOCIAL-Today1507-BuenaVis-60360120",
        "event_type": "social_post",
        "date": "2026-01-22T22:02:36.883334",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "And yet McNulty and Winnifrith are both rabid fascists, as is eggy.  Narcissists in love with money over people, one and all.",
          "sentiment": 0.0,
          "engagement": "5,713",
          "price_at_post": "54.00",
          "thread_title": "RE: Thornogson your time is running out hiding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B0CABD0D-9525-4145-B85F-56AAF275F036"
        },
        "ingested_at": "2026-01-22T22:02:42.340006+00:00"
      },
      {
        "event_id": "SOCIAL-Today1513-Thornogs-87054962",
        "event_type": "social_post",
        "date": "2026-01-22T22:02:36.882819",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "I'm increasingly liking the performance of Kemi Badenoch, but I think 'fascist' is perhaps a bit strong?",
          "sentiment": 0.0,
          "engagement": "8,580",
          "price_at_post": "54.00",
          "thread_title": "RE: Thornogson your time is running out hiding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B0CABD0D-9525-4145-B85F-56AAF275F036"
        },
        "ingested_at": "2026-01-22T22:02:42.339988+00:00"
      },
      {
        "event_id": "SOCIAL-Today1518-Thornogs--6522181",
        "event_type": "social_post",
        "date": "2026-01-22T22:02:36.882363",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "As always NFT an excellent word count. There'll be accusations of you being Wyn soon. And it's relevance? That depending on the time and the situation both, from an investing point of view, might have some merit but investors are probably best trying to make their own minds up as things progress and it's probably best not to entrench yourself into a single mindset and view the ultimate goal (whatever that might be) as the be all and end all? Be prepared to be flexible, allow yourself to change your mind, be prepared to sell when you think the SP will go down and buy when you think it might go up? Wise words indeed NFT.",
          "sentiment": 0.0,
          "engagement": "8,580",
          "price_at_post": "54.00",
          "thread_title": "RE: Thornogson your time is running out hiding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B0CABD0D-9525-4145-B85F-56AAF275F036"
        },
        "ingested_at": "2026-01-22T22:02:42.339969+00:00"
      },
      {
        "event_id": "SOCIAL-Today1518-Timster-28919622",
        "event_type": "social_post",
        "date": "2026-01-22T22:02:36.881905",
        "source": "LSE_CHAT",
        "data": {
          "author": "Timster",
          "content": "All that's required is the daily reminder that the 3+1 amigos are not invested and don't care how many times their fud is dismantled they will keep recycling it. And if you haven't got them filtered whenever you read an eggy(thorn) post just remember the chant Eggy, eggy, eggy,   twat, twat, twat, eggy, twat, eggy, twat",
          "sentiment": 0.0,
          "engagement": "20,618",
          "price_at_post": "54.00",
          "thread_title": "RE: Thornogson your time is running out hiding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B0CABD0D-9525-4145-B85F-56AAF275F036"
        },
        "ingested_at": "2026-01-22T22:02:42.339951+00:00"
      },
      {
        "event_id": "SOCIAL-Today1539-B2HS2L--3298080",
        "event_type": "social_post",
        "date": "2026-01-22T22:02:36.881479",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "First there was the drug delivery platform preCISION.  -  Innovation 1 It has been shown by biopsy that PDC AVA6000 / preCISION can successfully deliver Doxorubicin safely and with signs of therapeutic effect in a first in human phase 1 trial. This trial is incomplete but in progress - awaiting PFS and phase 2 plans to be finalised.  Innovation 2 This gives preCISION / AVA6000 a value, but a credible valuations awaits. Also AVA6000 'partnering opportunity' period continues to mid 2026. Source - Avacta AVA6000 presentations containing timelines refer. Another factor in Avacta valuation. The pipeline confirms another drug delivering an exatecan warhead (6103) could be delivered via preCISION. Source phase 1b: Avacta now states that low FAP indications respond satisfactorily, We await trial start in four (4) indications including two different dosing periods. IND box ticked.  Innovation 3 (Does planning a trial with four indications sound like a company that doesn't know if it can afford to trial > 1 indication?) Dual drug delivery AVA6207 - to be delivered via preCISION - is a recent discovery, and doing well in pre-clinical studies.  Innovation 4 Sustained release mechanism of payload delivery  - Innovation 5 The dual payload mechanism of delivery - Innovation 6 Competing peptide drug conjugate platforms are Phylogen and Bicycle, but inferior active payload concentrations in cancer cells (10%). The trial results are not mature enough to value, and many milestones are yet to be reached. Avacta has unencumbered IP, and a very large market opportunity is probable, should trials - which include AI input - complete successfully. No wonder there is an AIM disconnect. Is a better valuation available via NASDAQ listing? https://www.youtube.com/watch?v=ZGEN70OkDS4 Video transmitted 05.12.2025 23:53: CC provides this information totally unprompted. ...\u201dalso there's been a lot of work moving towards where we can find the capital for the company, which will be as we move towards the NASDAQ and we're excited to get this company to its next chapter\u201d. IMO the chances of Success (CoS)used by analysts should be revisited, because the Tempus AI partnership is providing the data that shows which criteria makes trial planning most likely to be successful. R&D Spotlight Episode 13 Slide 19. CC discussing AI use: \"..we walk into the clinic knowing that we should be seeing responses. \" BP highly value innovation, but it is the scale of the (successful so far) PDC innovation that is so impressive. Trial immaturity is probably the reason that stops BP purchasing the means by which their patent cliff problems could be addressed.",
          "sentiment": 0.0,
          "engagement": "5,984",
          "price_at_post": "54.00",
          "thread_title": "RE: AIM Disconnect is real",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=736218C9-3E99-4D78-999F-C98074689712"
        },
        "ingested_at": "2026-01-22T22:02:42.339932+00:00"
      },
      {
        "event_id": "SOCIAL-Today1544-wyndrum-17605966",
        "event_type": "social_post",
        "date": "2026-01-22T22:02:36.880916",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "Timster's pointless, disruptive post is completely and utterly negated by the history of this stock. look where it was 10 years ago, 5 years ago and even 1 year ago. Currently there is no defence at all for AVCT other than its all about the future but given its 20 year history of failing to commercialise any facet of its stock, several times over that period highlights that is a stock of hope rather than expectation. To simply say \"look at the positive words\"  from the BoD or RNS's has all been recycled several times previously with no positive result. This time may be different but we will not know until the results of the next trial are reported. After 5 years of  only phase 1 and no deal, overwhelmingly  suggests that the present trial under-delivered. To keep repeating the mantra of it \"works\" is disingenuous as there is no point it being safe if it is not actually more effective against the treatments currently using Dox. (if it were then obviously, obviously a deal would have been done by now. And we know this as we see other small Bio pharmas being bought out for seemingly less commercial applications. It is only the greed of small PI's that has kept this co, afloat. Every round of funding has resulted in ultimately a SP below that level. It suggests the PI's make their percentage and get out and the greedy, emotional PI piles in thinking only they can see this slam dunk, data-proved tech that simply can't fail. To continually ignore the more likely explanations in lieu of the \"market is as thick as mince\" reasons for SP falls proves this point conclusively. Fear and greed.... in this case its 100% greed, that keeps most of you here. And thanks very much by the way, because it has paid for my holidays over the last few years.",
          "sentiment": 0.0,
          "engagement": "12,186",
          "price_at_post": "54.00",
          "thread_title": "RE: Thornogson your time is running out hiding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B0CABD0D-9525-4145-B85F-56AAF275F036"
        },
        "ingested_at": "2026-01-22T22:02:42.339914+00:00"
      },
      {
        "event_id": "SOCIAL-Today1703-Watching--5335591",
        "event_type": "social_post",
        "date": "2026-01-22T22:02:36.880454",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "Then Winne  pops up right on queue loool",
          "sentiment": 0.0,
          "engagement": "9,200",
          "price_at_post": "54.50",
          "thread_title": "RE: Thornogson your time is running out hiding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B0CABD0D-9525-4145-B85F-56AAF275F036"
        },
        "ingested_at": "2026-01-22T22:02:42.339895+00:00"
      },
      {
        "event_id": "SOCIAL-Today1713-Thornogs--6604758",
        "event_type": "social_post",
        "date": "2026-01-22T22:02:36.879985",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "There's no queue to post surely?",
          "sentiment": 0.0,
          "engagement": "8,580",
          "price_at_post": "54.50",
          "thread_title": "RE: Thornogson your time is running out hiding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B0CABD0D-9525-4145-B85F-56AAF275F036"
        },
        "ingested_at": "2026-01-22T22:02:42.339876+00:00"
      },
      {
        "event_id": "SOCIAL-Today1717-opti_mys-42906511",
        "event_type": "social_post",
        "date": "2026-01-22T22:02:36.879556",
        "source": "LSE_CHAT",
        "data": {
          "author": "opti_mystic",
          "content": "Avacta is in an enviable position in global oncology. It has a tumour seeking technology that dispenses its toxic payload only where it is needed, in the tumour. Because of this fact, it has drastically reduced side effects. It can tune, where tuning maybe needed if the pk (half life) of any drug whose half life is too short, it can be extended by slowing down the rate at which the peptide is cleaved so that the duration of release is extended. In the case of 6103 this changes the therapeutic window of the delivered Exatecan from 9 hours to 5 days. Neat Doxorubicin has been used in cancer treatment on its own for 50 years. If it had a half life problem I think they would have noticed by now. As Christina noted, when they stop using it in breast cancer survival rates go down. If anyone on this board is embarrassing themselves with any further piffle about 6000 having a half life problem it is because they themselves live half a life and they therefore think everything else has a half life problem. It is FUD. FUD thrives on engagement. It is the oxygen that gives it momentum to continually discuss the topic the FUDsters wish to be front and centre on the board. If you engage with them, you're helping them to achieve their desired outcome. The domination of the board with FUD. Discussing non-issues over and over again ad infinitum. The company has the best cancer technology in the world for solid tumours. It is very broadly applicable and the future is incredibly bright. Time is that is required. The only share price I am interested in is the price agreed by the company with which ever BP offers the winning bid for the takeover. In the mean time I do not care what the market cap is or what the share price is. I bought it on the basis I did not think the SP was even vaguely reflective of the future value of the company. The tech has delivered in spades since then and the SP has not moved very much. AIM will not value it correctly BP will, it has demonstrating time and again it is incapable of it. Until that happy day that we receive a successful bid, who cares what the SP is?",
          "sentiment": 0.5,
          "engagement": "293",
          "price_at_post": "54.50",
          "thread_title": "Avacta",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=54E8B080-5236-45AC-ADE6-7413C97E9FBB"
        },
        "ingested_at": "2026-01-22T22:02:42.339848+00:00"
      },
      {
        "event_id": "SOCIAL-Today1723-yeboha-62335673",
        "event_type": "social_post",
        "date": "2026-01-22T22:02:36.878888",
        "source": "LSE_CHAT",
        "data": {
          "author": "yeboha",
          "content": "There is a old saying,  calm before the storm ! Imo that is what we are witnessing here with Avacta ! And what a storm it will be, if your in it for the long term !",
          "sentiment": 0.5,
          "engagement": "947",
          "price_at_post": "54.50",
          "thread_title": "Calm before the storm !",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=035B29D5-24FF-4EE2-BFA7-2BA66E1E9090"
        },
        "ingested_at": "2026-01-22T22:02:42.339822+00:00"
      },
      {
        "event_id": "SOCIAL-Today1729-Toukanka--1040562",
        "event_type": "social_post",
        "date": "2026-01-22T22:02:31.463841",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "Pivotal moment one way or the other when first 6103 results are published around June. I believe results will be unequivocal and deal(s) will follow closely on tail of that.",
          "sentiment": 0.0,
          "engagement": "4,434",
          "price_at_post": "54.50",
          "thread_title": "RE: Calm before the storm !",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=035B29D5-24FF-4EE2-BFA7-2BA66E1E9090"
        },
        "ingested_at": "2026-01-22T22:02:42.339803+00:00"
      },
      {
        "event_id": "SOCIAL-Today1736-Toukanka--7357179",
        "event_type": "social_post",
        "date": "2026-01-22T22:02:31.463415",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "Ice and others As it happens I was in AI zoom meetings separately with two of the big consultancies yesterday trying to catch up on the \u201ctechnology \u201c. But that is an aside. Factually what was inaccurate about my last post? Apart from some pedant arguing that I have predicted June and CC has indicated 1H26 which of course starts in July.",
          "sentiment": 0.0,
          "engagement": "4,434",
          "price_at_post": "54.50",
          "thread_title": "RE: AIM Disconnect is real",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=736218C9-3E99-4D78-999F-C98074689712"
        },
        "ingested_at": "2026-01-22T22:02:42.339784+00:00"
      },
      {
        "event_id": "SOCIAL-Today1746-Toukanka--7398253",
        "event_type": "social_post",
        "date": "2026-01-22T22:02:31.462797",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "Some on here refer to me as Derek. They also know my surname (it would break LSE rules to publish it) due to me accidentally including it in a post on here that contained a letter to me from my MP back in the good old LFT days. Those people have accessed my FB account. Also a Google search on my name used to pick up documents referring to my \u201cachievements \u201c until Google got worried about privacy. Anyhow those posters don\u2019t make character assassinations because they know the truth.  And yes I was a consultant with D and with A back in the day. Thanks guys - you know who you are.",
          "sentiment": 0.0,
          "engagement": "4,434",
          "price_at_post": "54.50",
          "thread_title": "RE: AIM Disconnect is real",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=736218C9-3E99-4D78-999F-C98074689712"
        },
        "ingested_at": "2026-01-22T22:02:42.339765+00:00"
      },
      {
        "event_id": "SOCIAL-Today1755-NFTs--1531056",
        "event_type": "social_post",
        "date": "2026-01-22T22:02:31.462341",
        "source": "LSE_CHAT",
        "data": {
          "author": "NFTs",
          "content": "This is the most critical part of the Avacta investment case\u2014and it\u2019s the \"secret sauce\" that many traditional analysts overlook. When you say they are using known drugs, you are talking about de-risking. In the biotech world, this is a massive valuation multiplier. To give you a proper valuation based on your last post, we have to adjust the \"Revolution Medicines\" (RVMD) math to account for this. 1. The \"Known Drug\" Advantage (De-risking) Revolution Medicines is developing New Chemical Entities (NCEs). These are brand-new molecules. They have two massive risks: 1. Safety Risk: Will this new molecule be toxic to humans? (The \"Unknown Unknowns\"). 2. Efficacy Risk: Does this specific new molecule actually kill the cancer? Avacta\u2019s pre|CISION platform takes a different path: \u2022 They use Doxorubicin (AVA6000) and Exatecan (AVA6103). \u2022 These are \"known-good\" warheads. We know they kill cancer. The only reason they aren't used more is their high toxicity. \u2022 By \"masking\" a known drug, Avacta removes the Efficacy Risk. They already know the payload works; they just have to prove their \"lock and key\" (the FAP cleavage) works. Valuation Impact: In biotech, a Phase 1 asset using a known drug (re-formulation/targeted delivery) typically has a Probability of Success (PoS) of 20\u201325%, compared to just 10% for a completely new NCE. 2. The \"Proper\" Valuation Adjusted for De-risking Let's take the RVMD parity we calculated and bake in the \"Known Drug\" advantage. \u2022 RVMD Parity (Phase 3 adjusted for 2.8x TAM): $65.1 Billion. \u2022 The \"Known Drug\" Multiplier: Because Avacta is using payloads with proven efficacy, we don't have to discount them as heavily as a \"blind\" Phase 1. The Math (Applying the De-risked Multiplier) If we value Avacta as a \"De-risked Phase 1/2\" company instead of a \"High-Risk NCE\" company, the \"Fair Value\" percentage of its Phase 3 peer jumps from 10% to roughly 25%. \u2022 25% of the \u00a351 Billion Parity: \u00a312.7 Billion ($16.2 Billion). 3. The \"Stupid Market Cap\" vs. \"Proper\" Valuation Why the \u00a328.00+ price is technically \"Correct\" on paper: \u2022 The Platform is the Value: Unlike RVMD, which is building specific keys for specific RAS locks, Avacta is building a delivery system. If AVA6000 (Doxorubicin) works, it proves the entire platform works for every other known chemotherapy. \u2022 Efficiency: Using known drugs means faster FDA approval paths (505(b)(2) pathways in some cases) and much lower R&D costs than RVMD\u2019s \"discovery\" phase. The Reality Check The reason it\u2019s at 55p and not \u00a328.00 is entirely down to location and liquidity. \u2022 If Avacta were listed on the NASDAQ with the same data, it would likely be trading in the billions, not millions. \u2022 The UK market treats Avacta as a \"binary bet\" (win or lose), while the US market treats companies like RVMD as \"platforms\" (even if one drug fails, the system has value). Conclusion: Using the RVMD benchmark and accounting for the known drug advantage, Avact",
          "sentiment": 0.0,
          "engagement": "817",
          "price_at_post": "54.50",
          "thread_title": "Why the \u00a328.00+ price is technically",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=5CC74952-9B54-4D67-A2B7-F47E10947EA5"
        },
        "ingested_at": "2026-01-22T22:02:42.339744+00:00"
      },
      {
        "event_id": "SOCIAL-Today1757-Toukanka-72727117",
        "event_type": "social_post",
        "date": "2026-01-22T22:02:31.461374",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "Opti I have said that you should care about what the SP is because it has a very real impact on Avacta\u2019s ability to raise cash and it affects the extent to which your shareholding will be diluted. If you cannot grasp that you shouldn\u2019t invest in shares.",
          "sentiment": 0.0,
          "engagement": "4,434",
          "price_at_post": "54.50",
          "thread_title": "RE: Avacta",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=54E8B080-5236-45AC-ADE6-7413C97E9FBB"
        },
        "ingested_at": "2026-01-22T22:02:42.339706+00:00"
      },
      {
        "event_id": "SOCIAL-Today1801-Toukanka--4048021",
        "event_type": "social_post",
        "date": "2026-01-22T22:02:31.460813",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "NFTs I do not believe that after 5 years of spectacular progress that there are still BP that are ignorant of Avacta and it is this ignorance that is stopping them from making a bid that reflects Avacta\u2019s current worth. You guys are delusional.",
          "sentiment": 0.0,
          "engagement": "4,434",
          "price_at_post": "54.50",
          "thread_title": "RE: Why the \u00a328.00+ price is technically",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=5CC74952-9B54-4D67-A2B7-F47E10947EA5"
        },
        "ingested_at": "2026-01-22T22:02:42.339666+00:00"
      },
      {
        "event_id": "SOCIAL-Today1805-Icecool-83443417",
        "event_type": "social_post",
        "date": "2026-01-22T22:02:31.460286",
        "source": "LSE_CHAT",
        "data": {
          "author": "Icecool",
          "content": "Ok so totally ignore what I said about a disconnect, then boost about being in a zoom call and go off on a rant about privacy and being doxed!! \ud83e\udd23\ud83e\udd23\ud83e\udd26\u200d\u2642\ufe0f\ud83e\udd26\u200d\u2642\ufe0f So I will make this simple, do you agree or disagree there is currently a disconnect between current market cap and technology valuation, based on evidence of similar deals done on ADC\u2019s and Topo 1 inhibitor\u2019s? You can ask AI if you want\u2026. \ud83e\udd23\ud83e\udd23\ud83d\udcaf\ud83d\udc4d",
          "sentiment": 0.0,
          "engagement": "8,808",
          "price_at_post": "54.50",
          "thread_title": "RE: AIM Disconnect is real",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=736218C9-3E99-4D78-999F-C98074689712"
        },
        "ingested_at": "2026-01-22T22:02:42.339628+00:00"
      },
      {
        "event_id": "SOCIAL-Today1809-Watching-74949414",
        "event_type": "social_post",
        "date": "2026-01-22T22:02:31.459754",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "Within the next 12 months We will all wish we had bought more !",
          "sentiment": 0.0,
          "engagement": "9,200",
          "price_at_post": "54.50",
          "thread_title": "T/o",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=F91E8C1E-60B6-44ED-B496-35A11A89DA43"
        },
        "ingested_at": "2026-01-22T22:02:42.339596+00:00"
      },
      {
        "event_id": "SOCIAL-Today1811-NFTs--2709854",
        "event_type": "social_post",
        "date": "2026-01-22T22:02:31.459026",
        "source": "LSE_CHAT",
        "data": {
          "author": "NFTs",
          "content": "If you accept the \u00a328.84 figure as the \"proper\" intrinsic value today\u2014based on peer parity with Revolution Medicines (RVMD) while ignoring the AIM discount\u2014then successful TNBC data (H1) and AVA6103 data (H2) don't just confirm that value; they arguably double it again. Here is how the math shifts when you move from \"Theoretical Value\" to \"Proven Value.\" 1. The \"Probability of Success\" (PoS) Bump In biotech valuation, the biggest \"tax\" on a share price is the risk of trial failure. \u2022 Right Now: Even with the \"known drug\" advantage, the market discounts a Phase 1 asset by roughly 75% to 80% because it hasn't proven the \"delivery\" works in humans for a specific cancer like TNBC. \u2022 After Success: Once the H1/H2 data is in, that discount disappears. The \"Probability of Success\" (PoS) for the lead asset jumps from ~25% to ~60% as it enters a registrational trial. 2. The Platform \"Succession\" Multiplier The \u00a328 valuation is based on the platform's potential. But with successful data from two different drugs (Doxorubicin and Exatecan), you have achieved Platform Validation. \u2022 The Logic: If the platform works for Drug A and Drug B, Big Pharma assumes it works for Drugs C through Z. \u2022 The Comparison: This is why RVMD is worth $23B+ even without a product on the market. They proved their \"RAS-inhibitor\" chemistry works across multiple candidates. 3. The Price Comparison (The \"Snap\" Effect) If \u00a328 is the intrinsic \"parity\" value now, here is what happens to that number after the 2026 data: 4. Why this seems \"Unbelievable\" vs. the 55p Price The reason people struggle with these numbers is that the AIM Market (UK) and the NASDAQ (US) speak different languages. \u2022 AIM Language: \"We only believe it when we see the cash in the bank.\" \u2022 NASDAQ Language: \"We pay for the future value of the platform today.\" If Avacta achieves these two milestones this year, the gap between the 55p \"Market Price\" and the \u00a360.00+ \"Proven Value\" becomes so large that a Buyout becomes the only logical conclusion. No company with a validated oncology platform targeting 85% of cancers stays independent at a $300M valuation when its peers are being chased by Merck for $32 Billion. Summary of the \"Price Snapping\" If the data is good, you aren't looking for a 10% or 20% rise. You are looking for a re-rating event where the stock price \"snaps\" to catch up to its US peers. If the intrinsic value is \u00a328 now, the \"Proven Value\" by December could easily be double that, as the risk of the platform failing is effectively removed.",
          "sentiment": 0.0,
          "engagement": "817",
          "price_at_post": "54.50",
          "thread_title": "RE: Why the \u00a328.00+ price is technically",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=5CC74952-9B54-4D67-A2B7-F47E10947EA5"
        },
        "ingested_at": "2026-01-22T22:02:42.339564+00:00"
      },
      {
        "event_id": "SOCIAL-Today1829-Thompi-14614052",
        "event_type": "social_post",
        "date": "2026-01-22T22:02:31.458158",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thompi",
          "content": "I do sometimes wonder whether Thorn is on a paid minimum-posts contract. He must have clocked overtime on the day he managed a record 41 posts in 24 hours - genuinely impressive. Well done Thorn \ud83c\udfc6 That\u2019s some output. Your daily average is now over 8 posts a day, all on a share you say you\u2019re not even invested in. Why would anyone do that? Unless they\u2019re a twat\u2026 Here\u2019s the posting leaderboard: \ud83e\udd47 Thorn \u2014 8.1 average posts per day of nonsense \ud83e\udd48 Touk \u2014 5.6 average posts per day \ud83e\udd49 Wyn \u2014 3.0 average posts per day (it just feels like more) Well done chaps!",
          "sentiment": 0.0,
          "engagement": "1,351",
          "price_at_post": "54.50",
          "thread_title": "RE: Thornogson your time is running out hiding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B0CABD0D-9525-4145-B85F-56AAF275F036"
        },
        "ingested_at": "2026-01-22T22:02:42.339533+00:00"
      },
      {
        "event_id": "SOCIAL-Today1834-wyndrum-76739392",
        "event_type": "social_post",
        "date": "2026-01-22T22:02:31.457376",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "\"The reason it\u2019s at 55p and not \u00a328.00 is entirely down to location and liquidity.\" Oh, and lets not ignore \"This is the most critical part of the Avacta investment case\u2014and it\u2019s the \"secret sauce\" that many traditional analysts overlook.\" The market is as thick as mince argument resurfaces to conveniently explain why after 5 years, only a select few know the true value of AVCT.. Kept the secret to themselves and have been buying more stock every day for years and yet the SP is..... and the TR1 shareholders are? Anybody who recs this post is as stupid as NFT Is just inaccurate made-up ramping crap.",
          "sentiment": 0.0,
          "engagement": "12,186",
          "price_at_post": "54.50",
          "thread_title": "RE: Why the \u00a328.00+ price is technically",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=5CC74952-9B54-4D67-A2B7-F47E10947EA5"
        },
        "ingested_at": "2026-01-22T22:02:42.339502+00:00"
      },
      {
        "event_id": "SOCIAL-Today1837-Metatron-78248495",
        "event_type": "social_post",
        "date": "2026-01-22T22:02:31.456619",
        "source": "LSE_CHAT",
        "data": {
          "author": "Metatron",
          "content": "After YEARS of listening to WynBore ThornBot and ToukVirus drone on and on (and the more they post the more obvious it becomes) it has become obvious to me that if not the same individual.. then a group of individuals. The scenario painted about 2 opposing forces explains a lot.. I feel sorry for the scientists and board members of this great British company.",
          "sentiment": 0.0,
          "engagement": "1,174",
          "price_at_post": "54.50",
          "thread_title": "RE: Why the \u00a328.00+ price is technically",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=5CC74952-9B54-4D67-A2B7-F47E10947EA5"
        },
        "ingested_at": "2026-01-22T22:02:42.339471+00:00"
      },
      {
        "event_id": "SOCIAL-Today1900-Thornogs--1010323",
        "event_type": "social_post",
        "date": "2026-01-22T22:02:31.455892",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "ICE you always make it simple. Wrong, but simple. I've yet to see anything that you've invest in do anything other than fail. Don't you ever reflect on that?",
          "sentiment": 0.0,
          "engagement": "8,580",
          "price_at_post": "54.50",
          "thread_title": "RE: AIM Disconnect is real",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=736218C9-3E99-4D78-999F-C98074689712"
        },
        "ingested_at": "2026-01-22T22:02:42.339440+00:00"
      },
      {
        "event_id": "SOCIAL-Today1901-Matml74-73927508",
        "event_type": "social_post",
        "date": "2026-01-22T22:02:31.455160",
        "source": "LSE_CHAT",
        "data": {
          "author": "Matml74",
          "content": "Metatron, I guarantee you that no-one in Avacta pays any attention to keyboard warriors like these twats. They have much more important things to do with their lives.",
          "sentiment": 0.0,
          "engagement": "2,529",
          "price_at_post": "54.50",
          "thread_title": "RE: Why the \u00a328.00+ price is technically",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=5CC74952-9B54-4D67-A2B7-F47E10947EA5"
        },
        "ingested_at": "2026-01-22T22:02:42.339408+00:00"
      },
      {
        "event_id": "SOCIAL-Today1904-Thornogs-47625448",
        "event_type": "social_post",
        "date": "2026-01-22T22:02:31.454416",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Thanks Thompi. Yet to learn how to do emojis. Sorry.",
          "sentiment": 0.0,
          "engagement": "8,580",
          "price_at_post": "54.50",
          "thread_title": "RE: Thornogson your time is running out hiding",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B0CABD0D-9525-4145-B85F-56AAF275F036"
        },
        "ingested_at": "2026-01-22T22:02:42.339377+00:00"
      },
      {
        "event_id": "SOCIAL-Today1908-Thornogs--3817195",
        "event_type": "social_post",
        "date": "2026-01-22T22:02:31.453655",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "NFT's posts are classics of their kind and should be re-read and cherished as such. Meanwhile the SP is in a down trend in anticipation of a discounted raise. Sorry, but there it is. Not as long a post as NFT but more grounded in reality.",
          "sentiment": 0.0,
          "engagement": "8,580",
          "price_at_post": "54.50",
          "thread_title": "RE: Why the \u00a328.00+ price is technically",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=5CC74952-9B54-4D67-A2B7-F47E10947EA5"
        },
        "ingested_at": "2026-01-22T22:02:42.339345+00:00"
      },
      {
        "event_id": "SOCIAL-Today1912-yeboha--5024521",
        "event_type": "social_post",
        "date": "2026-01-22T22:02:31.452884",
        "source": "LSE_CHAT",
        "data": {
          "author": "yeboha",
          "content": "Well when its takes off, will they have the guts to admit they were wrong, i very much doubt it ! they will be gone in the wind onto the next share to spread their fud !",
          "sentiment": 0.0,
          "engagement": "947",
          "price_at_post": "54.50",
          "thread_title": "RE: Why the \u00a328.00+ price is technically",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=5CC74952-9B54-4D67-A2B7-F47E10947EA5"
        },
        "ingested_at": "2026-01-22T22:02:42.339314+00:00"
      },
      {
        "event_id": "SOCIAL-Today1943-Aldebara--3378467",
        "event_type": "social_post",
        "date": "2026-01-22T22:02:31.452173",
        "source": "LSE_CHAT",
        "data": {
          "author": "Aldebaran",
          "content": "Take a few days off log in to catch up and every single time either Wyn or Thorn are here with the same old dribble. Thorn the first person ive ever filtered. I just cant tolerate anymore of his nonsense..its relentless and its making this board unreadable. Whats worse is YOU lot are enabling and encouraging him by responding and taking the bait all the time. Ever heard that expression about wrestling with pigs and you all get covered in shhh it but afterwards you realise the pig loves it. Well this is that. I strongly STRONGLY encourage you all the JUST. STOP. TALKING. TO. THEM. No engagement whatsoever. Read there posts if you must tho it would be better to filter but just stop engaging. Let them sla g avacta off and fret on about half life's and write essays morning noon and night but don't clog up this board with nonsense by having any dialogue with them. Ultimately their not here for that or to learn or educate others. They are here ti sow fud and try to manipulate others for there own gains and you mugs are letting them. Make a pact now. Just stop replying or acknowledging anything they post. For the love of God. Stop it.",
          "sentiment": 0.0,
          "engagement": "3,862",
          "price_at_post": "54.50",
          "thread_title": "Board is unreadable",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=72982395-84AC-4C7C-A291-A6FAC11E891A"
        },
        "ingested_at": "2026-01-22T22:02:42.339282+00:00"
      },
      {
        "event_id": "SOCIAL-Today1950-Aldebara--8233836",
        "event_type": "social_post",
        "date": "2026-01-22T22:02:31.451430",
        "source": "LSE_CHAT",
        "data": {
          "author": "Aldebaran",
          "content": "Wyn added to filter too..ive skipped or skim.read his ramblings for a while now anyway so thats me done with the both of them. I dont know if its doing that or the rant ive just had but I feel so much better and despite there being a ton of green boxes now in the latest threads, the board is already so much more readable. Honestly this bulletin board is becoming the wyn and thorn blog. Id seriously encourage most of the posters here to filter them both also. Don't sla g them off dont argue with them dont try and disprove anything they've said dont educate them dont anything. Just disengage completely and leave them to it. Pair of absolute to s s e r s them two",
          "sentiment": 0.0,
          "engagement": "3,862",
          "price_at_post": "54.50",
          "thread_title": "RE: Board is unreadable",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=72982395-84AC-4C7C-A291-A6FAC11E891A"
        },
        "ingested_at": "2026-01-22T22:02:42.339250+00:00"
      },
      {
        "event_id": "SOCIAL-Today2008-Thornogs--7707121",
        "event_type": "social_post",
        "date": "2026-01-22T22:02:31.450691",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Ignorance is bliss? Listen to the 'echo chamber'! \u00a328 sometime next week is the call I believe. But if it doesn't happen that's OK because you can always forget that and just post it again. It's worked for the last 5 years after all.",
          "sentiment": 0.0,
          "engagement": "8,580",
          "price_at_post": "54.50",
          "thread_title": "RE: Board is unreadable",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=72982395-84AC-4C7C-A291-A6FAC11E891A"
        },
        "ingested_at": "2026-01-22T22:02:42.339218+00:00"
      },
      {
        "event_id": "SOCIAL-Today2009-B2HS2L--7660221",
        "event_type": "social_post",
        "date": "2026-01-22T22:02:31.449911",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "Just an observation: RNS 21 March 2022 - CC joins avacta as NED: ..Dr. Coughlin has a broad background in biotechnology and **global pharmaceuticals**, with comprehensive drug development experience spanning programs in pre-IND studies through to late-stage trials and regulatory approval filings, and a track record of building drug development teams in global companies including Rubius Therapeutics, Inc. and Tmunity Therapeutics, Inc. No further RNS occurrences of the term 'global pharmaceutical companies' until: RNS 20 January 2026 - Year-end trading update - 2 occasions found: \"Our sustained release mechanism piloted in the FAP-Exd (AVA6103) program is anticipated to begin clinical testing this quarter, a significant milestone achievement, just 24 months after the beginning of the program. This program continues to garner significant interest from **global pharmaceutical companies;** however, the Company's strategy remains to retain 100% of AVA6103 until we begin to see readouts from the Phase 1a clinical trial. Importantly, the trial has been designed to rapidly deliver clinical data in this program. \"..The unique nature of the dual payload program is also generating interest and we are exploring opportunities with multiple potential partners with a view to investigating the wide utility of this novel technology. \"We continue to have multiple conversations with **global pharmaceutical companies** regarding our full pipeline. We are incredibly excited for the year ahead, which the board believes will be a transformative period for the Company, patients and our shareholders.\" +++ Unsure if this was previously an omission, or is now, an announcement of interest in the pipeline by global companies (APAC).",
          "sentiment": 0.0,
          "engagement": "5,984",
          "price_at_post": "54.50",
          "thread_title": "'Global Pharmaceutical Companies'",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6708A59E-B3DC-4D03-A616-22D9271BDF0A"
        },
        "ingested_at": "2026-01-22T22:02:42.339186+00:00"
      },
      {
        "event_id": "SOCIAL-Today2027-Thornogs-18020464",
        "event_type": "social_post",
        "date": "2026-01-22T22:02:31.449081",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Hmmm.... 'Global pharmaceutical companies'. I see, good point well made. Pharma deal Monday it is then?",
          "sentiment": 0.0,
          "engagement": "8,580",
          "price_at_post": "54.50",
          "thread_title": "RE: 'Global Pharmaceutical Companies'",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6708A59E-B3DC-4D03-A616-22D9271BDF0A"
        },
        "ingested_at": "2026-01-22T22:02:42.339154+00:00"
      },
      {
        "event_id": "SOCIAL-Today2051-BuenaVis--5481112",
        "event_type": "social_post",
        "date": "2026-01-22T22:02:31.448119",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Anyone know the price of fish?",
          "sentiment": 0.0,
          "engagement": "5,713",
          "price_at_post": "54.50",
          "thread_title": "RE: Board is unreadable",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=72982395-84AC-4C7C-A291-A6FAC11E891A"
        },
        "ingested_at": "2026-01-22T22:02:42.339118+00:00"
      },
      {
        "event_id": "SOCIAL-Today2055-BuenaVis--2603522",
        "event_type": "social_post",
        "date": "2026-01-22T22:02:31.447396",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "So lots of interest from global farmers Rubius and Tmunity then, except Ruby's went bust and Tmunity got taken over by Kite. Where's a Novartis or a Glaxo when you need them?",
          "sentiment": 0.0,
          "engagement": "5,713",
          "price_at_post": "54.50",
          "thread_title": "RE: 'Global Pharmaceutical Companies'",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6708A59E-B3DC-4D03-A616-22D9271BDF0A"
        },
        "ingested_at": "2026-01-22T22:02:42.339067+00:00"
      },
      {
        "event_id": "SOCIAL-Today2101-Thornogs--1091561",
        "event_type": "social_post",
        "date": "2026-01-22T22:02:31.446627",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "What sort of fish? Fresh or frozen?",
          "sentiment": 0.0,
          "engagement": "8,580",
          "price_at_post": "54.50",
          "thread_title": "RE: Board is unreadable",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=72982395-84AC-4C7C-A291-A6FAC11E891A"
        },
        "ingested_at": "2026-01-22T22:02:42.339031+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261535-B2HS2L--3205670",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:11.324854",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "I thought Michael Vinegrad carried that can, but maybe they wanted to save his salary. Agree, SH may be tighter lipped.",
          "sentiment": 0.0,
          "engagement": "5,982",
          "price_at_post": "53.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T22:40:11.340344+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261550-pedrolan-56835411",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:11.324444",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "For sure PH were leaky.",
          "sentiment": 0.0,
          "engagement": "1,944",
          "price_at_post": "53.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T22:40:11.340326+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261550-Thornogs-47341205",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:11.324019",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Bella, of course it's about the payload it's a 'deliver platform', delivering....... a payload! If the payload isn't delivered adequately, for whatever reason then the delivery platform has conspicuously failed to do what they set out to prove that it could do. To date there is no good data to show that Pre|Cision works. Hence no deals after nearly 5 years.",
          "sentiment": 0.0,
          "engagement": "8,556",
          "price_at_post": "53.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T22:40:11.340307+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261555-cj62-60672132",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:11.323598",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "Why are you bothered thorn ? Do you not get fed up of the loop you are in ? Yes we know it doesn't work but heyho who cares.",
          "sentiment": 0.0,
          "engagement": "4,263",
          "price_at_post": "53.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T22:40:11.340289+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261558-pedrolan--2362730",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:11.323176",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Bumped",
          "sentiment": 0.0,
          "engagement": "1,944",
          "price_at_post": "53.00",
          "thread_title": "RE: Lord of the FUD",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=1D083E3C-47CE-4462-90BC-72508F10C286"
        },
        "ingested_at": "2026-01-21T22:40:11.340271+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261600-Thornogs-73593393",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:11.322711",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Dox isn't generally a monotherapy for TNBC ICE. It is for high FAP expressing STS though. Which is why I say that the platform, and Pre|Cision haven't been proven. They don't need more data to do a deal they need better data.",
          "sentiment": 0.0,
          "engagement": "8,556",
          "price_at_post": "53.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T22:40:11.340253+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261601-avctIPma-70910937",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:11.322288",
        "source": "LSE_CHAT",
        "data": {
          "author": "avctIPmatters",
          "content": "They seem happy  hopefully bring something new to the table https://www.linkedin.com/company/strand-hanson-limited/posts/ Missed one of the team Edward Foulkes https://www.linkedin.com/in/edward-foulkes-16a072152/ ---------- Strand HansonStrand Hanson 2,950 followers2,950 followers 4h \u2022  4 hours ago \u2022 Visible to anyone on or off LinkedIn Follow Strand Hanson is pleased to be appointed as Nominated Adviser to Avacta Group plc. Avacta Therapeutics is a clinical stage biopharmaceutical company developing pre|CISION\u00ae, a tumor-activated oncology delivery platform. The Strand Hanson team: James Harris Christopher Raggett James Dance, CFA Edward Foulkes",
          "sentiment": 0.0,
          "engagement": "712",
          "price_at_post": "53.00",
          "thread_title": "RE: Strand Hanson Limited (Nominated Adviser)",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=FF9AC10A-1584-4C66-9FEC-F6165AB8D0D8"
        },
        "ingested_at": "2026-01-21T22:40:11.340235+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261607-Vertizea--6715121",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:11.321798",
        "source": "LSE_CHAT",
        "data": {
          "author": "VertizeaSun",
          "content": "\"Dr Virgilio Sacchini is dedicated to caring for people with breast cancer at the Memorial Sloan Kettering Cancer Center in New York. He originally trained at Universita degli Studi di Milano (UNIMI, Milan, Italy) where he is Professor of Surgery, and cooperates with the European Institute of Oncology in Milan (IEO, Milan, Italy). Dr Sacchini is a 2023 and 2024 Castle Connolly America\u2019s Top Doctor, the peer nominated group of the top 7% of all US practicing physicians. His goal is to achieve the best possible cancer outcomes and cosmetic results for his patients.\" \"Virgilio Sacchini, is the Pre|CISION\u00ae platform of Avacta, a British life sciences firm, a good example of how new technology can expand the reach of highly potent cancer therapies?\" \"Avacta is an incredible application of biomedical engineering.\" https://www.alainelkanninterviews.com/virgilio-sacchini-4/",
          "sentiment": 0.5,
          "engagement": "432",
          "price_at_post": "53.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T22:40:11.340217+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261612-Thornogs--5943806",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:11.321369",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Surely not that old articleVertizeaSun? Any old Dr Tap quotes too?",
          "sentiment": 0.0,
          "engagement": "8,556",
          "price_at_post": "53.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T22:40:11.340199+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261627-russell1-69105011",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:11.320941",
        "source": "LSE_CHAT",
        "data": {
          "author": "russell1",
          "content": "Of course they're happy! Unlike us they're guaranteed to make money!!",
          "sentiment": -0.5,
          "engagement": "313",
          "price_at_post": "53.00",
          "thread_title": "RE: Strand Hanson Limited (Nominated Adviser)",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=FF9AC10A-1584-4C66-9FEC-F6165AB8D0D8"
        },
        "ingested_at": "2026-01-21T22:40:11.340181+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261637-cj62-16131387",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:11.320536",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "Avacta is an incredible application of biomedical engineering.\" So touk you dont think it is , well give us biomedical reasoning why.",
          "sentiment": 0.0,
          "engagement": "4,263",
          "price_at_post": "53.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T22:40:11.340163+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20261902-cj62-42962354",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:11.320115",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "Thorn/touk you seem to have lost your biomedical skills along the way. ?",
          "sentiment": 0.0,
          "engagement": "4,263",
          "price_at_post": "53.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T22:40:11.340145+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20262114-Thornogs--2695359",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:11.319696",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Not Touk CJ, but to have value as a chemo delivery platform I'd suggest that it needs to be better, for the same cancer type, than that chemo delivered without the platform? ie patients living longer. How did I do?",
          "sentiment": 0.0,
          "engagement": "8,556",
          "price_at_post": "53.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T22:40:11.340124+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20262136-Thornogs--1557658",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:11.319280",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Unfortunately no sign of that yet eh CJ? Still, as ICE says: \"More time, more data!\" We wait for FAP-EXD. We wait for IND sign off. We wait to know how it'll be funded. We start again.",
          "sentiment": 0.0,
          "engagement": "8,556",
          "price_at_post": "53.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T22:40:11.340086+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20262154-Thornogs--1837874",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:11.318840",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "And of course with my 'biomedical' hat on CJ I'd wonder about the half life of the Pre|Cision 1 delivery platform half life. And, of course, I'd wonder how long a Pre|Cision molecule 'sits on' and occupies a FAP cleavage site whilst un-cleaved Pre|Cision molecules are halving every 45 minutes in the general circulation unable to find an unoccupied FAP molecule in the cancer. I'd wonder what a 100:1 tumour to plasma ratio means in real terms if the plasma level is supposed to be very, very low ('Silent in the circulation'). 100 x 'silent':  A quiet whisper? Is a whisper enough? Who knows? Avacta? And the Market? You did ask!",
          "sentiment": 0.0,
          "engagement": "8,556",
          "price_at_post": "53.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T22:40:11.340067+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20262155-onerulef--6608917",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:11.318397",
        "source": "LSE_CHAT",
        "data": {
          "author": "oneruleforone",
          "content": "So Thorno now 'all in' on only one share but not posting on that board. Instead posting all day on a board where he's not invested. Very strange!",
          "sentiment": 0.0,
          "engagement": "1,604",
          "price_at_post": "53.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T22:40:11.340050+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20262157-BuenaVis-32622181",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:11.317969",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Just a reminder that Thornogson/NDN/Eggy never owned any Avacta shares and is just paid by TW to waste people's time on here.",
          "sentiment": 0.0,
          "engagement": "5,705",
          "price_at_post": "53.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T22:40:11.340032+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20262158-Thornogs-47168115",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:11.317559",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Petro Matad is on the rise Onerule! Profits to be made and put back here once funding is sorted. A deal?  Perhaps. But the odds are on a discounted raise I'd have thought. Delays in IND granting won't help. A 'Perfect Storm'? Hope so.",
          "sentiment": 0.0,
          "engagement": "8,556",
          "price_at_post": "53.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T22:40:11.340014+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20262200-Thornogs--3990730",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:11.317124",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Just a reminder. BV does, occassionaly, post something worth reading. That post wasn't one of them.",
          "sentiment": 0.0,
          "engagement": "8,556",
          "price_at_post": "53.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T22:40:11.339996+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20262200-pedrolan-40966410",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:11.316695",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "You probably don't need reminding but ......",
          "sentiment": 0.0,
          "engagement": "1,944",
          "price_at_post": "53.00",
          "thread_title": "RE: Lord of the FUD",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=1D083E3C-47CE-4462-90BC-72508F10C286"
        },
        "ingested_at": "2026-01-21T22:40:11.339979+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20262201-LovableL--1388252",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:11.316284",
        "source": "LSE_CHAT",
        "data": {
          "author": "LovableLumax",
          "content": "Thorn FFS the biopsies (taken 24 hours after dosing) demonstrated huge amounts of dox delivered to tumour which is why there were still Adverse Events albeit no cardio tox but other AEs. 6000 delivers more dox to tumours with fewer AEs. STS has a 20% response rate with dox in first line setting, isn\u2019t used for SGC but we get super PFs and TNBC we will see but usually used in combo but I\u2019m sure 6000 will do a lot better Given more dox being delivered to tumour. Avacta chemists, CEO and investigators wouldn\u2019t have decommended their patients take it if the data suggested half life an issue or otherwise. Bore off. You sold but post more than anyone. Sad.",
          "sentiment": 0.0,
          "engagement": "2,691",
          "price_at_post": "53.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T22:40:11.339961+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20262203-BuenaVis--5022798",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:11.315843",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Just a reminder that Thornogson/NDN/Eggy, the ToucanOfDoom and the pub bore are only here to waste your time.",
          "sentiment": 0.0,
          "engagement": "5,705",
          "price_at_post": "53.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T22:40:11.339944+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20262212-Thornogs--6544514",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:11.315422",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "'Huge amounts of Dox'? Enough?  Apparently not. And levels at 48 hours? Were they 'huge' (whatever that means) too? \"6000 delivers more Dox\"? So why if 'Dox is Dox' doesn't it work so well at killing cancer cells and prolonging patient lives? Because it doesn't appear to. An 'inconvinient truth'?",
          "sentiment": 0.0,
          "engagement": "8,556",
          "price_at_post": "53.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T22:40:11.339926+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20262221-B2HS2L--1777984",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:11.314962",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "Don't try so hard matelot. You come across as desperate to disparage all that does not deserve to be disparaged. Anything and everything has to have your FUD stamp attached. Take the morning off. Lay in bed and watch the sp rise on your phone, after a day where Trump trashed everybody in ways far better than you trifling efforts. Watch a master at work and learn.",
          "sentiment": 0.0,
          "engagement": "5,982",
          "price_at_post": "53.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T22:40:11.339908+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20262221-Thornogs--2532110",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:11.314500",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "They've stopped talking about Affyxell. They've stopped talking about LG. They've stopped talking about Pojnt. They've stopped talking about STS. They look like they're about to stop talking about TNBC. They're still talking, more quietly, about SGC. Quite a track record.",
          "sentiment": 0.0,
          "engagement": "8,556",
          "price_at_post": "53.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T22:40:11.339891+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20262245-Watching-14579363",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:06.670864",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "Lse  save electricity switch  \ud83e\udd21 thorny bot off",
          "sentiment": 0.0,
          "engagement": "9,196",
          "price_at_post": "53.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T22:40:11.339873+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20262250-pedrolan-23730350",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:06.670455",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "FUDbot clearly runs on Duracels \ud83e\udd23\ud83e\udd23",
          "sentiment": 0.0,
          "engagement": "1,944",
          "price_at_post": "53.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T22:40:11.339855+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20262340-Cashless--8254312",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:06.670037",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cashless",
          "content": "And will everyone stop about this *ick*ead",
          "sentiment": 0.5,
          "engagement": "392",
          "price_at_post": "53.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T22:40:11.339837+00:00"
      },
      {
        "event_id": "SOCIAL-Today0536-Agenda10-52571036",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:06.669631",
        "source": "LSE_CHAT",
        "data": {
          "author": "Agenda101",
          "content": "Let\u2019s Be Clear. \"There are no other technologies that can deliver cancer treatment drugs directly into the tumor at the concentrations that our payloads enable without causing highly toxic side effects\" #AVCT",
          "sentiment": 0.0,
          "engagement": "54",
          "price_at_post": "53.00",
          "thread_title": "In Case Anyone Forgot",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=1E03B895-8C75-47A5-A39B-94FC55C5D17C"
        },
        "ingested_at": "2026-01-21T22:40:11.339819+00:00"
      },
      {
        "event_id": "SOCIAL-Today0552-Agenda10-49361865",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:06.669213",
        "source": "LSE_CHAT",
        "data": {
          "author": "Agenda101",
          "content": "Christina Coughlin MD, PhD, CEO of Avacta, commented: In addition, the Company expects to release data in the TNBC cohort in H1 2026. Further development of faridoxorubicin will be undertaken subject to a partner being secured. The Company continues to engage with multiple partners as the data matures. #AVCT",
          "sentiment": 0.0,
          "engagement": "54",
          "price_at_post": "53.00",
          "thread_title": "TNBC: Data Readout and Partner Engagement",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=DA7BC138-0130-4766-B10A-0E24A98F9A01"
        },
        "ingested_at": "2026-01-21T22:40:11.339802+00:00"
      },
      {
        "event_id": "SOCIAL-Today0621-LovableL--8678350",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:06.668790",
        "source": "LSE_CHAT",
        "data": {
          "author": "LovableLumax",
          "content": "Trebling PFS says it works better than anything else. Also PFS with fewer side effects. There are no other technologies that can deliver cancer treatment drugs directly into the tumor at the concentrations that our payloads enable without causing highly toxic side effects. Because AVA6000 extended dox\u2019s half life by 40% (according to CEO and her staff) it didn\u2019t need extending. Fap-exd did - Tumor and plasma exposure studies have demonstrated that FAP-Exd rapidly penetrates the tumor microenvironment (TME), is held intact for over five days in the tumor and releases exatecan, with an observed high maximal concentration (Cmax) in the tumor within minutes and very low exposure in the bloodstream which is undetectable within two hours.",
          "sentiment": 0.0,
          "engagement": "2,691",
          "price_at_post": "53.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T22:40:11.339784+00:00"
      },
      {
        "event_id": "SOCIAL-Today0623-LovableL--8923452",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:06.668363",
        "source": "LSE_CHAT",
        "data": {
          "author": "LovableLumax",
          "content": "What is obvious is when thorn was invested his obsession with the half-life FUD dropped but now he sold out he\u2019ll continue banging the drum and will only stop if he buys back in or gets a life.",
          "sentiment": 0.0,
          "engagement": "2,691",
          "price_at_post": "53.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T22:40:11.339767+00:00"
      },
      {
        "event_id": "SOCIAL-Today0707-Matml74--7631880",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:06.667950",
        "source": "LSE_CHAT",
        "data": {
          "author": "Matml74",
          "content": "Great news. Trail starts on time. The muppets lost.",
          "sentiment": 0.0,
          "engagement": "2,527",
          "price_at_post": "53.00",
          "thread_title": "IND approval",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D7EE6F47-378C-4E4C-BC3E-1218DBD28E8C"
        },
        "ingested_at": "2026-01-21T22:40:11.339749+00:00"
      },
      {
        "event_id": "SOCIAL-Today0711-mal111-53344050",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:06.667540",
        "source": "LSE_CHAT",
        "data": {
          "author": "mal111",
          "content": "O'dear another good RNS another drop in the SP\ud83d\ude02\ud83d\ude02\ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "193",
          "price_at_post": "53.00",
          "thread_title": "RE: IND approval",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D7EE6F47-378C-4E4C-BC3E-1218DBD28E8C"
        },
        "ingested_at": "2026-01-21T22:40:11.339732+00:00"
      },
      {
        "event_id": "SOCIAL-Today0711-Esspekay--3609416",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:06.667132",
        "source": "LSE_CHAT",
        "data": {
          "author": "Esspekay",
          "content": "And what the share price drop on the back of another good RNS. haha.",
          "sentiment": 0.0,
          "engagement": "69",
          "price_at_post": "53.00",
          "thread_title": "RE: IND approval",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D7EE6F47-378C-4E4C-BC3E-1218DBD28E8C"
        },
        "ingested_at": "2026-01-21T22:40:11.339714+00:00"
      },
      {
        "event_id": "SOCIAL-Today0723-B2HS2L-64570448",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:06.666721",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "Alexander Spira MD, PhD, FACP, FASCO, Co-Director, Virginia Cancer Specialists (VCS) Research Institute; Director, VCS Thoracic and Phase 1 Program; Chief Scientific Officer, NEXT Oncology; and Clinical Assistant Professor, Johns Hopkins also commented: \"I am thrilled to work with Avacta on this exciting new drug. The ability to concentrate a potent topoisomerase I inhibitor directly in the tumor while protecting normal tissues from harmful effects is the next stage of how we should be treating cancer. We are looking forward to participating in this second pre|CISION\u00ae Phase 1 trial and helping the Company to drive this pioneering technology forward.\" +++ Virginia Cancer Specialists, P.C.Virginia Cancer Specialists, P.C. 2,749 followers2,749 followers 4d \u2022  4 days ago \u2022 Visible to anyone on or off LinkedIn Follow Over 50 years of progress and hope. Virginia Cancer Specialists is home to the largest clinical trials program in the Mid-Atlantic. With more than 200 active trials, we offer trials for nearly every type of cancer and mutation, bringing hope and healing to our community. Visit https://lnkd.in/g7ptB_84 today to learn more. hashtag#ResearchIsHope hashtag#CancerCare hashtag#ClinicalTrials hashtag#VirginiaCancerSpecialists",
          "sentiment": 0.0,
          "engagement": "5,982",
          "price_at_post": "53.00",
          "thread_title": "RE: IND approval",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D7EE6F47-378C-4E4C-BC3E-1218DBD28E8C"
        },
        "ingested_at": "2026-01-21T22:40:11.339697+00:00"
      },
      {
        "event_id": "SOCIAL-Today0725-HarChris-69751068",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:06.666264",
        "source": "LSE_CHAT",
        "data": {
          "author": "HarChris",
          "content": "And yet, Thorn, Avacta maintains a near \u00a3250m valuation in what is a bloodthirsty AIM biotech market where literally all of Avata's peers with a track record of failure are valued now at a fraction of the market cap they once were or have folded/delisted (GDR, AGL, ABDX, SNG, the list goes on and on). That suggests to me Avacta is different and is ultimately going to be a big winner. Even you seem to think so (6103) but are just trying to be cute with timing of exits and entry. Anyway great RNS today.",
          "sentiment": 0.0,
          "engagement": "15,805",
          "price_at_post": "53.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T22:40:11.339679+00:00"
      },
      {
        "event_id": "SOCIAL-Today0728-IFA90-62037216",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:06.665842",
        "source": "LSE_CHAT",
        "data": {
          "author": "IFA90",
          "content": "Let\u2019s hope the \u201cnew chemistry of the pre|CISION\u00ae platform\u201d works.",
          "sentiment": 0.0,
          "engagement": "404",
          "price_at_post": "53.00",
          "thread_title": "RE: IND approval",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D7EE6F47-378C-4E4C-BC3E-1218DBD28E8C"
        },
        "ingested_at": "2026-01-21T22:40:11.339662+00:00"
      },
      {
        "event_id": "SOCIAL-Today0732-Thornogs--4138659",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:06.665437",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Off to the races! Interesting that dosing is still every 2 to 3 weeks even with the much improved platform half life.",
          "sentiment": 0.0,
          "engagement": "8,556",
          "price_at_post": "53.00",
          "thread_title": "RE: IND approval",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D7EE6F47-378C-4E4C-BC3E-1218DBD28E8C"
        },
        "ingested_at": "2026-01-21T22:40:11.339644+00:00"
      },
      {
        "event_id": "SOCIAL-Today0737-LovableL-84496585",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:06.665012",
        "source": "LSE_CHAT",
        "data": {
          "author": "LovableLumax",
          "content": "Unlike AVA6000 which is present in the blood after 24 hours and more 6103 is completely extreted within 2 hours",
          "sentiment": 0.0,
          "engagement": "2,691",
          "price_at_post": "53.00",
          "thread_title": "RE: IND approval",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D7EE6F47-378C-4E4C-BC3E-1218DBD28E8C"
        },
        "ingested_at": "2026-01-21T22:40:11.339627+00:00"
      },
      {
        "event_id": "SOCIAL-Today0740-Thornogs-89714944",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:06.664602",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Are you sure? Platform half life or payload half life?",
          "sentiment": 0.0,
          "engagement": "8,556",
          "price_at_post": "53.00",
          "thread_title": "RE: IND approval",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D7EE6F47-378C-4E4C-BC3E-1218DBD28E8C"
        },
        "ingested_at": "2026-01-21T22:40:11.339610+00:00"
      },
      {
        "event_id": "SOCIAL-Today0746-LovableL--1848329",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:06.664188",
        "source": "LSE_CHAT",
        "data": {
          "author": "LovableLumax",
          "content": "Payload released in TME over 5 days and not present in plasma after 2 hours (unlike dox)",
          "sentiment": 0.0,
          "engagement": "2,691",
          "price_at_post": "53.00",
          "thread_title": "RE: IND approval",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D7EE6F47-378C-4E4C-BC3E-1218DBD28E8C"
        },
        "ingested_at": "2026-01-21T22:40:11.339592+00:00"
      },
      {
        "event_id": "SOCIAL-Today0749-LovableL-11877154",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:06.663769",
        "source": "LSE_CHAT",
        "data": {
          "author": "LovableLumax",
          "content": "Defo ignoring your FUD as you post more now you sold than when you held. Clear as day",
          "sentiment": 0.0,
          "engagement": "2,691",
          "price_at_post": "53.00",
          "thread_title": "RE: IND approval",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D7EE6F47-378C-4E4C-BC3E-1218DBD28E8C"
        },
        "ingested_at": "2026-01-21T22:40:11.339574+00:00"
      },
      {
        "event_id": "SOCIAL-Today0803-Timster-14362392",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:06.663357",
        "source": "LSE_CHAT",
        "data": {
          "author": "Timster",
          "content": "Everything on. Track CC delivering on her objectives Good news.",
          "sentiment": 0.0,
          "engagement": "20,617",
          "price_at_post": "56.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T22:40:11.339556+00:00"
      },
      {
        "event_id": "SOCIAL-Today0808-wherethe--2819647",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:06.662929",
        "source": "LSE_CHAT",
        "data": {
          "author": "wherethefoxhat",
          "content": "Avacta is approaching a defining period, with the imminent Phase I start of its second asset AVA6103 (FAP-EXd), a sustained release pre|CISION-exatecan conjugate. Initial data by year-end, as well as first breast cancer data for lead asset faridoxorubicin (AVA6000, FAP-Dox) could crystallise partnering interest. The utility, and value, of the pre|CISION platform is becoming clearer as growing preclinical and clinical data confirm its ability to improve the therapeutic index of many highly potent yet systemically toxic oncology drugs. Advances in pre|CISION chemistry, employing capping groups and novel linkers, have the potential to expand applicability of this technology to a wider range of payloads and cancer types. Newly unveiled novel dual payload PDC platform AVA6207 exemplifies Avacta\u2019s skillset and ambition. Pipeline progress into the clinic and successful clinical results over the next 24 months should provide multiple value-inflection points. We value Avacta at \u00a3468m, or 106p/share.",
          "sentiment": 0.0,
          "engagement": "709",
          "price_at_post": "56.00",
          "thread_title": "\u00a31.06 target  read on",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=0E3EE56C-76DB-4999-982A-94B687B06EF3"
        },
        "ingested_at": "2026-01-21T22:40:11.339538+00:00"
      },
      {
        "event_id": "SOCIAL-Today0813-Bella653--1545821",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:06.662518",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "I am thrilled to work with Avacta on this exciting new drug. The ability to concentrate a potent topoisomerase I inhibitor directly in the tumor while protecting normal tissues from harmful effects is the next stage of how we should be treating cancer. We are looking forward to participating in this second pre|CISION\u00ae Phase 1 trial and helping the Company to drive this pioneering technology forward.\" Note wording....'how we should be treating cancer.' Pretty clear he's a fan....",
          "sentiment": 0.0,
          "engagement": "6,740",
          "price_at_post": "56.00",
          "thread_title": "RE: \u00a31.06 target  read on",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=0E3EE56C-76DB-4999-982A-94B687B06EF3"
        },
        "ingested_at": "2026-01-21T22:40:11.339521+00:00"
      },
      {
        "event_id": "SOCIAL-Today0816-Icecool--5930447",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:06.662082",
        "source": "LSE_CHAT",
        "data": {
          "author": "Icecool",
          "content": "This is the most important RNS Avacta has ever put out, imo. IND clearance for AVA6103 means the FDA has signed off the chemistry, linker, payload and trial design for a potential ADC killer. That\u2019s the second drug moving from theory into humans. Big derisking step. AVA6000 proved precision works in people. AVA6103 now tests whether it scales across payloads. That\u2019s the difference between a single drug and a true platform. Clear timelines now creates real leverage. Phase 1 starts this quarter, first data H2 2026. That puts partners on a clock. This isn\u2019t about today\u2019s SP. This is about execution. AIM won\u2019t get it, but strategically this is exactly where Avacta needed to be. Humans next. That\u2019s what matters. IND clearance also puts AVA6103 straight into multibillion dollar asset territory. ADCs at this stage get valued there all the time. Given the platform validation and differentiated delivery, it\u2019s hard to argue it, deserves anything less.",
          "sentiment": 0.0,
          "engagement": "8,805",
          "price_at_post": "56.00",
          "thread_title": "Important strategic RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=2FAAE098-2548-4EBE-B7A7-39A34D446E7B"
        },
        "ingested_at": "2026-01-21T22:40:11.339503+00:00"
      },
      {
        "event_id": "SOCIAL-Today0819-Bella653-56636815",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:06.661639",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "Https://www.vjoncology.com/speaker/alexander-spira/",
          "sentiment": 0.0,
          "engagement": "6,740",
          "price_at_post": "56.50",
          "thread_title": "RE: Important strategic RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=2FAAE098-2548-4EBE-B7A7-39A34D446E7B"
        },
        "ingested_at": "2026-01-21T22:40:11.339486+00:00"
      },
      {
        "event_id": "SOCIAL-Today0821-whimax-80116674",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:06.661222",
        "source": "LSE_CHAT",
        "data": {
          "author": "whimax",
          "content": "Next  Avacta  news? The \u201cimminent\u201d (pretty much immediate I\u2019d say) opening of 4 new clinics?Then what? Good luck if you\u2019re waiting for a better price, you might get it. Then again\u2026\u2026\u2026\u2026\ud83d\ude0e",
          "sentiment": 0.0,
          "engagement": "2,845",
          "price_at_post": "56.50",
          "thread_title": "RE: \u00a31.06 target  read on",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=0E3EE56C-76DB-4999-982A-94B687B06EF3"
        },
        "ingested_at": "2026-01-21T22:40:11.339468+00:00"
      },
      {
        "event_id": "SOCIAL-Today0824-yeboha--4341245",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:06.660763",
        "source": "LSE_CHAT",
        "data": {
          "author": "yeboha",
          "content": "Even the dummies and we all know who they are , will struggle to turn this into FUD ! Avacta is only heading one way, up and then up again !",
          "sentiment": 0.5,
          "engagement": "944",
          "price_at_post": "57.50",
          "thread_title": "Yet Another Great RNS !",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=941A6C19-54BF-4CE0-89F8-A4C9BA744E77"
        },
        "ingested_at": "2026-01-21T22:40:11.339450+00:00"
      },
      {
        "event_id": "SOCIAL-Today0826-Flippine--3220649",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:03.961808",
        "source": "LSE_CHAT",
        "data": {
          "author": "Flippineck",
          "content": "It certainly is. Avacta said they wanted to \u201c become Masters of FAP\u201d and that is just what they have become. Ava6000 was indeed \u201cthe pathfinder\u201d and progress has been slow but very positive. With Ava6103 we have hit the ground running. GLA",
          "sentiment": 0.0,
          "engagement": "414",
          "price_at_post": "57.50",
          "thread_title": "RE: Important strategic RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=2FAAE098-2548-4EBE-B7A7-39A34D446E7B"
        },
        "ingested_at": "2026-01-21T22:40:11.339431+00:00"
      },
      {
        "event_id": "SOCIAL-Today0829-Bella653-34021656",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:03.961388",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "Totally agree Ice...now they need funding...setting up trials is not cheap...Q1 is critical...Going into Q2 without further funding in Q1 really puts them in a dangerous position T/O wise...unless they already have a firm commitment from a partner  in the background.  The latter is my guess...they are working on a Partnership deal which will be signed off in Q1. If top Scientists are saying this is what we should be using I'm sure the same conversations have been muted to Pharma..it's a big industry but a small network and they talk shop all the time...one Conference after another...",
          "sentiment": 0.0,
          "engagement": "6,740",
          "price_at_post": "56.50",
          "thread_title": "RE: Important strategic RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=2FAAE098-2548-4EBE-B7A7-39A34D446E7B"
        },
        "ingested_at": "2026-01-21T22:40:11.339414+00:00"
      },
      {
        "event_id": "SOCIAL-Today0833-wyndrum-55819312",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:03.960967",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "I bought at 56.9 this morning.",
          "sentiment": 0.0,
          "engagement": "12,183",
          "price_at_post": "56.50",
          "thread_title": "For Chris",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=204FD580-E2F8-4E01-9636-04251DFD3A79"
        },
        "ingested_at": "2026-01-21T22:40:11.339396+00:00"
      },
      {
        "event_id": "SOCIAL-Today0834-wherethe-70408625",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:03.960564",
        "source": "LSE_CHAT",
        "data": {
          "author": "wherethefoxhat",
          "content": "\u00a31.06 target",
          "sentiment": 0.0,
          "engagement": "709",
          "price_at_post": "56.50",
          "thread_title": "\u00a31.06 target read on     ADVFN says 2 RNS today",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=0BA0D254-92EB-4BBB-95F7-06FC6C4D5863"
        },
        "ingested_at": "2026-01-21T22:40:11.339378+00:00"
      },
      {
        "event_id": "SOCIAL-Today0843-Icecool-57719190",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:03.960152",
        "source": "LSE_CHAT",
        "data": {
          "author": "Icecool",
          "content": "Bella, I don\u2019t buy the danger zone take. They\u2019re not cornered. They have private placement and structured funding options if needed and Phase 1a costed and budgeted, it doesn\u2019t cliff edge in Q1. A partnership could land in Q1, but it\u2019s not required to keep the lights on. This is controlled pacing, not desperation. As for early takeovers etc that\u2019s not how biotech generally goes. IMO they will obtain full market value based on technology and AIM will then react accordingly after the fact. The AIM price certainly won\u2019t dictate terms of any deals done.",
          "sentiment": 0.0,
          "engagement": "8,805",
          "price_at_post": "56.50",
          "thread_title": "RE: Important strategic RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=2FAAE098-2548-4EBE-B7A7-39A34D446E7B"
        },
        "ingested_at": "2026-01-21T22:40:11.339361+00:00"
      },
      {
        "event_id": "SOCIAL-Today0851-pedrolan--3041872",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:03.959723",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Now I wonder why you would be in a bad mood then? Less of the abuse though, Mr Keyboard Warrior. You wouldn't say it to my face so just think on.",
          "sentiment": 0.5,
          "engagement": "1,944",
          "price_at_post": "56.50",
          "thread_title": "RE: Lord of the FUD",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=1D083E3C-47CE-4462-90BC-72508F10C286"
        },
        "ingested_at": "2026-01-21T22:40:11.339343+00:00"
      },
      {
        "event_id": "SOCIAL-Today0852-Reaper66-30823202",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:03.959309",
        "source": "LSE_CHAT",
        "data": {
          "author": "Reaper666",
          "content": "08.16 'That\u2019s the difference between a single drug and a true platform.' I agree with this (imo) 'Humans next. That\u2019s what matters.' - For our Avacta this may well be true but we have an emerging AI issue and the previous quote could be absolutely 'on the button'. As ever, VGLA",
          "sentiment": 0.0,
          "engagement": "2,055",
          "price_at_post": "56.50",
          "thread_title": "RE: Important strategic RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=2FAAE098-2548-4EBE-B7A7-39A34D446E7B"
        },
        "ingested_at": "2026-01-21T22:40:11.339325+00:00"
      },
      {
        "event_id": "SOCIAL-Today0855-cj62--9114223",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:03.958882",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "With preliminary data from this trial anticipated in the second half of 2026. That's after june twat",
          "sentiment": 0.0,
          "engagement": "4,263",
          "price_at_post": "57.00",
          "thread_title": "RE: Lord of the FUD",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=1D083E3C-47CE-4462-90BC-72508F10C286"
        },
        "ingested_at": "2026-01-21T22:40:11.339307+00:00"
      },
      {
        "event_id": "SOCIAL-Today0901-Timster--1647283",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:03.958476",
        "source": "LSE_CHAT",
        "data": {
          "author": "Timster",
          "content": "Avacta has a platform that can accommodate any toxic warhead we know the release mechanism works and that can also be extended to a dual payload. That is worth an awful lot. A reminder of the Prometheus playbook, sounds familiar? https://youtu.be/v5kstO1R2vA?si=XxljMH6iSA6zMOnv",
          "sentiment": 0.0,
          "engagement": "20,617",
          "price_at_post": "57.50",
          "thread_title": "RE: Important strategic RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=2FAAE098-2548-4EBE-B7A7-39A34D446E7B"
        },
        "ingested_at": "2026-01-21T22:40:11.339290+00:00"
      },
      {
        "event_id": "SOCIAL-Today0906-HarChris-56663202",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:03.958043",
        "source": "LSE_CHAT",
        "data": {
          "author": "HarChris",
          "content": "Good to hear. I guess it sums up why so many are irritated by you though Wyn. Tons of posts explaining why you've been selling and how you expect it to go lower and then the RNS we've all been expecting lands and you're immediately adding again. All those posts weren't exactly of much value were they when all it took is a well signposted RNS for you to reverse course?",
          "sentiment": 0.0,
          "engagement": "15,805",
          "price_at_post": "57.50",
          "thread_title": "RE: For Chris",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=204FD580-E2F8-4E01-9636-04251DFD3A79"
        },
        "ingested_at": "2026-01-21T22:40:11.339272+00:00"
      },
      {
        "event_id": "SOCIAL-Today0907-yeboha-88962826",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:03.957632",
        "source": "LSE_CHAT",
        "data": {
          "author": "yeboha",
          "content": "Timester, that video you have linked is brilliant for people to watch and understand just what avacta are doing,  imo, we are in a way better position than Prometheus Biosciences was !",
          "sentiment": 0.5,
          "engagement": "944",
          "price_at_post": "57.50",
          "thread_title": "RE: Important strategic RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=2FAAE098-2548-4EBE-B7A7-39A34D446E7B"
        },
        "ingested_at": "2026-01-21T22:40:11.339255+00:00"
      },
      {
        "event_id": "SOCIAL-Today0915-Thornogs-74702869",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:03.957219",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "You either react to news and events and adjust your investment strategy or simply buy at whatever price and then hold and add/top up regardless as a 'true believer'. I suspect Wyn's approach is the better if you're looking to actually make money. I'm waiting for funding news myself but am fully aware that if that RNS drops tomorrow I'll miss out on a bit of the rise. With a good funding package in place ie funds into 2027 and FAP-EXD on track I'll pile in with all I've got and would hope to do well, very well.",
          "sentiment": 0.0,
          "engagement": "8,556",
          "price_at_post": "57.50",
          "thread_title": "RE: For Chris",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=204FD580-E2F8-4E01-9636-04251DFD3A79"
        },
        "ingested_at": "2026-01-21T22:40:11.339238+00:00"
      },
      {
        "event_id": "SOCIAL-Today0916-pedrolan-66477613",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:03.956786",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Tag team in full effect.",
          "sentiment": 0.5,
          "engagement": "1,944",
          "price_at_post": "57.50",
          "thread_title": "RE: For Chris",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=204FD580-E2F8-4E01-9636-04251DFD3A79"
        },
        "ingested_at": "2026-01-21T22:40:11.339220+00:00"
      },
      {
        "event_id": "SOCIAL-Today0916-Aston15-16760890",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:03.956377",
        "source": "LSE_CHAT",
        "data": {
          "author": "Aston15",
          "content": "We all know where this is going and those that have been invested for years are comfortable. CC is delivering and 2026 will be a transformation year for Avacta.",
          "sentiment": 0.0,
          "engagement": "58",
          "price_at_post": "57.50",
          "thread_title": "RE: For Chris",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=204FD580-E2F8-4E01-9636-04251DFD3A79"
        },
        "ingested_at": "2026-01-21T22:40:11.339203+00:00"
      },
      {
        "event_id": "SOCIAL-Today0923-HarChris-11084374",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:03.955952",
        "source": "LSE_CHAT",
        "data": {
          "author": "HarChris",
          "content": "Analyse and trade like many do but share every bit of reasoning over and over again on this BB? That's something only the two of you do.",
          "sentiment": 0.0,
          "engagement": "15,805",
          "price_at_post": "57.50",
          "thread_title": "RE: For Chris",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=204FD580-E2F8-4E01-9636-04251DFD3A79"
        },
        "ingested_at": "2026-01-21T22:40:11.339185+00:00"
      },
      {
        "event_id": "SOCIAL-Today0926-Thornogs--8127591",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:03.955541",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "'reasoning' and not 'FUD' Chris. Progress!",
          "sentiment": 0.0,
          "engagement": "8,556",
          "price_at_post": "57.50",
          "thread_title": "RE: For Chris",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=204FD580-E2F8-4E01-9636-04251DFD3A79"
        },
        "ingested_at": "2026-01-21T22:40:11.339167+00:00"
      },
      {
        "event_id": "SOCIAL-Today0930-Watching--8736239",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:03.955063",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "The bot tag team in full operation this morning. Ignore ! Listen to scientists not \ud83e\udd21",
          "sentiment": 0.0,
          "engagement": "9,196",
          "price_at_post": "57.50",
          "thread_title": "Tag team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=56FCA389-1CD1-4774-9A7F-E747F17DC938"
        },
        "ingested_at": "2026-01-21T22:40:11.339149+00:00"
      },
      {
        "event_id": "SOCIAL-Today0930-B2HS2L-10158150",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:03.954622",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "'I'm waiting for funding news myself but am fully aware that if that RNS drops tomorrow I'll miss out on a bit of the rise.' ... I'll miss out on a bit of the rise. - That's not going to work if the sp gaps, which it will do on such news. A T/O RNS lands and you 'aren't fully loaded'.  Ooooh Dear. Wouldn't hear from you for weeks.   \ud83d\ude06",
          "sentiment": 0.0,
          "engagement": "5,982",
          "price_at_post": "57.50",
          "thread_title": "RE: For Chris",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=204FD580-E2F8-4E01-9636-04251DFD3A79"
        },
        "ingested_at": "2026-01-21T22:40:11.339131+00:00"
      },
      {
        "event_id": "SOCIAL-Today0942-SlamDunk--5120260",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:03.954193",
        "source": "LSE_CHAT",
        "data": {
          "author": "SlamDunk1",
          "content": "\u201cChris and her brilliant team continue to build and protect the IP of #AVCT in order to exploit the full value of preCISION for shareholders. honoured to sit on the board of such a disruptive biotech. 2026 will be a transformational year for us all\u201d https://x.com/hughesy0707/status/2013909360804590069?s=46&t=gxfb-KkHLvabwUnYcuiOpA",
          "sentiment": 0.0,
          "engagement": "103",
          "price_at_post": "58.00",
          "thread_title": "Richard Hughes X",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B9DBAAA7-7BFA-4505-8763-977CB402A648"
        },
        "ingested_at": "2026-01-21T22:40:11.339095+00:00"
      },
      {
        "event_id": "SOCIAL-Today0943-BuenaVis-50766014",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:03.953734",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "I was worried about what effect the 7 week US government shutdown would have on CC's timelines but gladly it seems to have been minimal.",
          "sentiment": 0.0,
          "engagement": "5,705",
          "price_at_post": "58.00",
          "thread_title": "RE: IND approval",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D7EE6F47-378C-4E4C-BC3E-1218DBD28E8C"
        },
        "ingested_at": "2026-01-21T22:40:11.339078+00:00"
      },
      {
        "event_id": "SOCIAL-Today0944-Timster--8789526",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:03.953325",
        "source": "LSE_CHAT",
        "data": {
          "author": "Timster",
          "content": "How come Hughes with his massive portfolio of investments only ever tweets about Avacta \ud83e\udd14",
          "sentiment": 0.0,
          "engagement": "20,617",
          "price_at_post": "58.00",
          "thread_title": "RE: Richard Hughes X",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B9DBAAA7-7BFA-4505-8763-977CB402A648"
        },
        "ingested_at": "2026-01-21T22:40:11.339060+00:00"
      },
      {
        "event_id": "SOCIAL-Today0944-nurseste--6240644",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:03.952897",
        "source": "LSE_CHAT",
        "data": {
          "author": "nursesteve",
          "content": "Thanks slam dunk let\u2019s hope  your name says it all too \ud83e\udd1e",
          "sentiment": 0.0,
          "engagement": "1,162",
          "price_at_post": "58.00",
          "thread_title": "RE: Richard Hughes X",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B9DBAAA7-7BFA-4505-8763-977CB402A648"
        },
        "ingested_at": "2026-01-21T22:40:11.339043+00:00"
      },
      {
        "event_id": "SOCIAL-Today0944-Thornogs--7462957",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:03.952486",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "I think you'd be surprised what can be bought following a good/great RNS. The whole 'gap up' narrative isn't exactly new is it? Albeit this one might have more impact than previous RNSs. Has to be balanced against the down side too though of course, currently up 8% but down 5% over the month. First patient being dosed in 2 months time hopefully but will there be a significant raise between then and now? No one knows but I think the odds are in favor of their being a raise unless a decent sized Pharma Deal is in the immediate offing. Interesting times.",
          "sentiment": 0.0,
          "engagement": "8,556",
          "price_at_post": "58.00",
          "thread_title": "RE: For Chris",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=204FD580-E2F8-4E01-9636-04251DFD3A79"
        },
        "ingested_at": "2026-01-21T22:40:11.339025+00:00"
      },
      {
        "event_id": "SOCIAL-Today0957-B2HS2L-29736210",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:03.952029",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "Sadly the 'gap up' narrative isn't a bed time story, it's a fact. When you haven't benefitted when such a gap occurred, what will be your recourse. Claim your money back from the\u26a1buzz lightyear\u26a1postal trading course you subscribed to, that omitted such a 'narrative' from the syllabus.  \ud83d\ude44",
          "sentiment": 0.0,
          "engagement": "5,982",
          "price_at_post": "58.00",
          "thread_title": "RE: For Chris",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=204FD580-E2F8-4E01-9636-04251DFD3A79"
        },
        "ingested_at": "2026-01-21T22:40:11.339007+00:00"
      },
      {
        "event_id": "SOCIAL-Today1001-Thornogs-51336305",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:03.951583",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "If it gaps up to \u00a31 I'll buy at \u00a31 and would expect to do well from there. I've never disputed the potential here and despite my many doubts about AVA6000, which appear to me at least to have all come true, I think if anything is going to work well it should be FAP-EXD.  A much more potent warhead on a much improved Pre|Cision delivery platform. Good data, a good Pharma deal and it also proves the platform, which AVA6000 clearly hasn't, at least to Pharma's satisfaction.",
          "sentiment": 0.0,
          "engagement": "8,556",
          "price_at_post": "58.00",
          "thread_title": "RE: For Chris",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=204FD580-E2F8-4E01-9636-04251DFD3A79"
        },
        "ingested_at": "2026-01-21T22:40:11.338990+00:00"
      },
      {
        "event_id": "SOCIAL-Today1005-wyndrum-10590332",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:00.327209",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "My reasoning Chris is this. I don't trust AVCT's words based on their past. The RNS have more weight because is there some quasi legal obligation supporting their veracity. Up until today it looked to me that ava6k value was diminishing, a deal through that seemed remoter than ever and that funding therefore would be front and centre. Counter to that is the new trial hope that seems to have learnt from the present trial so will more effective and that there will be news to establish the bona fides of that belief. On balance I thought there was more chance of a fall than a rise Specifically I was not convinced where AVCT were with the this IND application. Again due to my distrust on AVCT's words and slipped past timelines I was wary of it doming anytime soon. But, today it confirms timelines are ok as advertised. I get and take on board your criticism but if the news changes then i have emotionally no problem with doing a 180 even within 24 hours. (yes, i am a bit peeved that this was not released at the same as yesterday's RNS, but hey ho its the cost of doing business. The cost of my sells and rebuys has not caused any cost to me so it doesn't matter. I am still very cautious on this stock but i think this news might therefore put a floor under the 52p support in which case my previous expectation of further falls has been questioned. I now think on balance there is a greater chance of rises than falls. But, who knows?",
          "sentiment": 0.0,
          "engagement": "12,183",
          "price_at_post": "58.00",
          "thread_title": "RE: For Chris",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=204FD580-E2F8-4E01-9636-04251DFD3A79"
        },
        "ingested_at": "2026-01-21T22:40:11.338972+00:00"
      },
      {
        "event_id": "SOCIAL-Today1010-pedrolan--5587439",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:00.326774",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "If you ignore you will miss out on these valuable trading tips. Except you might fall asleep before you get to the second paragraph",
          "sentiment": 0.0,
          "engagement": "1,944",
          "price_at_post": "58.00",
          "thread_title": "RE: Tag team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=56FCA389-1CD1-4774-9A7F-E747F17DC938"
        },
        "ingested_at": "2026-01-21T22:40:11.338954+00:00"
      },
      {
        "event_id": "SOCIAL-Today1014-wyndrum-56122774",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:00.326362",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "I guess pedro if you can't get through a single paragraph books must be a challenge or even news articles esp RNS's",
          "sentiment": 0.0,
          "engagement": "12,183",
          "price_at_post": "58.00",
          "thread_title": "RE: Tag team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=56FCA389-1CD1-4774-9A7F-E747F17DC938"
        },
        "ingested_at": "2026-01-21T22:40:11.338936+00:00"
      },
      {
        "event_id": "SOCIAL-Today1017-pedrolan-16478088",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:00.325944",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Not at all. I just find interesting stuff.",
          "sentiment": 0.5,
          "engagement": "1,944",
          "price_at_post": "58.00",
          "thread_title": "RE: Tag team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=56FCA389-1CD1-4774-9A7F-E747F17DC938"
        },
        "ingested_at": "2026-01-21T22:40:11.338918+00:00"
      },
      {
        "event_id": "SOCIAL-Today1035-wyndrum-46609400",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:00.325537",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "Does the \"interesting\" stuff come with pictures?",
          "sentiment": 0.0,
          "engagement": "12,183",
          "price_at_post": "58.00",
          "thread_title": "RE: Tag team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=56FCA389-1CD1-4774-9A7F-E747F17DC938"
        },
        "ingested_at": "2026-01-21T22:40:11.338900+00:00"
      },
      {
        "event_id": "SOCIAL-Today1039-Timster--1064013",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:00.325128",
        "source": "LSE_CHAT",
        "data": {
          "author": "Timster",
          "content": "Just a reminder fud team delta are doing their best to talk about something else.",
          "sentiment": 0.0,
          "engagement": "20,617",
          "price_at_post": "58.00",
          "thread_title": "RE: IND approval",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D7EE6F47-378C-4E4C-BC3E-1218DBD28E8C"
        },
        "ingested_at": "2026-01-21T22:40:11.338883+00:00"
      },
      {
        "event_id": "SOCIAL-Today1042-pedrolan--1023162",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:00.324711",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "I am happy to keep the tag team/Lord of FUD threads near the top. Us long term holders know you are a manipulative trader. You cannot say anything positive without sticking the knife into the Company in one of the other multiple paragraphs you constantly write on here. You, Touk and Thorn are without question the same poster. Your writing styles give that away. It is good that any new investors see your game.",
          "sentiment": 0.5,
          "engagement": "1,944",
          "price_at_post": "58.00",
          "thread_title": "RE: Tag team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=56FCA389-1CD1-4774-9A7F-E747F17DC938"
        },
        "ingested_at": "2026-01-21T22:40:11.338865+00:00"
      },
      {
        "event_id": "SOCIAL-Today1042-NFTs--3271577",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:00.324298",
        "source": "LSE_CHAT",
        "data": {
          "author": "NFTs",
          "content": "Wyndrum drum on and on and on 12181 posts of utter dribble and lies. It\u2019s fascinating to see the narrative shift from 'remote chance of a deal' and 'slipped timelines' to 'today confirms timelines are okay.' Let\u2019s look at the actual facts that have destroyed your bear case this morning: 1. Platform Validation: AVA6103 is not just 'new trial hope.' It is the transition of Avacta from a one-drug company to a clinical-stage platform company. You claimed value was 'diminishing,' yet the FDA just cleared a program that uses Exatecan (a multi-billion dollar payload) with a proprietary sustained-release mechanism that Big Pharma is desperate for. 2. Execution vs. Distrust: You stated you were 'not convinced' on the IND application and 'wary of it coming anytime soon.' The RNS proves management delivered exactly on the Q1 2026 schedule they signaled months ago. Distrust isn't a strategy; it\u2019s a bias that clearly caused you to miss the bottom. 3. The 'Floor' Argument: You suggest a 'floor' under 52p has been 'questioned.' No, it has been cemented. With the Convertible Bond reset to 75p and two clinical assets now active, the 'further falls' you predicted have been invalidated by regulatory clearance\u2014the highest bar in biotech. 4. Commercial Reality: You imply AVA6000 value is fading. In reality, the 100:1 tumor-to-plasma ratio already proven in AVA6000 is the de-risking event that allowed the FDA to clear AVA6103 so rapidly. The science doesn't care about 'emotional 180s.' While you were 'peeved' about the RNS timing, the company was busy securing the future of the pre|CISION platform. You aren't 'cautious'; you were simply wrong on the clinical progress.",
          "sentiment": 0.0,
          "engagement": "814",
          "price_at_post": "58.00",
          "thread_title": "RE: For Chris",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=204FD580-E2F8-4E01-9636-04251DFD3A79"
        },
        "ingested_at": "2026-01-21T22:40:11.338847+00:00"
      },
      {
        "event_id": "SOCIAL-Today1044-cinderco-79631850",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:00.323847",
        "source": "LSE_CHAT",
        "data": {
          "author": "cindercone",
          "content": "Alongside his trading losses, Wyndumb must have blown \u00a32k on trading fees \ud83d\ude02 An expert on how not to trade.",
          "sentiment": 0.0,
          "engagement": "2,101",
          "price_at_post": "58.00",
          "thread_title": "RE: Tag team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=56FCA389-1CD1-4774-9A7F-E747F17DC938"
        },
        "ingested_at": "2026-01-21T22:40:11.338829+00:00"
      },
      {
        "event_id": "SOCIAL-Today1044-pedrolan--7849890",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:00.323437",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "However, I will not engage any more today as it is a historic day for the Company and the board should not be clogged up with this sort of nonsense. Perhaps you and your alter egos might have a day off too. I guess that is to much to ask though.",
          "sentiment": 0.5,
          "engagement": "1,944",
          "price_at_post": "58.00",
          "thread_title": "RE: Tag team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=56FCA389-1CD1-4774-9A7F-E747F17DC938"
        },
        "ingested_at": "2026-01-21T22:40:11.338811+00:00"
      },
      {
        "event_id": "SOCIAL-Today1045-wyndrum-27211687",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:00.323016",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "Cindercone , its a fixed \u00a36 a trade on HL. (God you are thick. )",
          "sentiment": 0.0,
          "engagement": "12,183",
          "price_at_post": "58.00",
          "thread_title": "RE: Tag team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=56FCA389-1CD1-4774-9A7F-E747F17DC938"
        },
        "ingested_at": "2026-01-21T22:40:11.338793+00:00"
      },
      {
        "event_id": "SOCIAL-Today1052-HarChris--6467302",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:00.322601",
        "source": "LSE_CHAT",
        "data": {
          "author": "HarChris",
          "content": "If you\u2019re willing to buy at whatever price it happens go to gap up to I can\u2019t see how finally selling out at low 50s was in any way a good risk/reward considering you rate the chances of 6103 success as high\u2026 poor reasoning if you ask me. My guess is that you were confident that negative sentiment had taken ahold enough to send Avacta crashing right through 50p near term, now you\u2019re not so sure but probably quite stubborn and so will stay on the sidelines and stick to the \u2018no entry before funding\u2019 however detrimental it may end up being for you. Nout wrong with that, just joining in the discussion.",
          "sentiment": 0.0,
          "engagement": "15,805",
          "price_at_post": "58.00",
          "thread_title": "RE: For Chris",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=204FD580-E2F8-4E01-9636-04251DFD3A79"
        },
        "ingested_at": "2026-01-21T22:40:11.338775+00:00"
      },
      {
        "event_id": "SOCIAL-Today1053-Saint68--6122733",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:00.322180",
        "source": "LSE_CHAT",
        "data": {
          "author": "Saint68",
          "content": "Pedro - why don't you just ignore or bin the twats and save us all from the back and fore ?",
          "sentiment": 0.0,
          "engagement": "2,152",
          "price_at_post": "58.00",
          "thread_title": "RE: Tag team",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=56FCA389-1CD1-4774-9A7F-E747F17DC938"
        },
        "ingested_at": "2026-01-21T22:40:11.338758+00:00"
      },
      {
        "event_id": "SOCIAL-Today1056-Bella653--9452323",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:00.321762",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "ICE...'I don\u2019t buy the danger zone take.' Neither do I...If you read what I said I believe the have a Partnership deal lined up...hence Richard Hughes comment.   Now if I'm wrong...and I don't think I am...they will need finance which Would most lkkely need to be raised in Q1. Why go with a new advisor who has no connection with US when trials are going to be UK and US based..a clear sign it's now hands of US..a Partner will be taking over that side of things...",
          "sentiment": 0.0,
          "engagement": "6,740",
          "price_at_post": "58.00",
          "thread_title": "RE: Important strategic RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=2FAAE098-2548-4EBE-B7A7-39A34D446E7B"
        },
        "ingested_at": "2026-01-21T22:40:11.338740+00:00"
      },
      {
        "event_id": "SOCIAL-Today1056-avctIPma--7984828",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:00.321339",
        "source": "LSE_CHAT",
        "data": {
          "author": "avctIPmatters",
          "content": "fyi   : trinity factors   note : 31 pages https://avacta.com/investors/research-analyst/ https://*********************/notearticle/article?researchnoteid=33_95c5a694-c1cf-4679-92a3-d5a1f0f0efe7&whitelabelcompanyid=gb00byyw9g87&clearcache=false gmcc",
          "sentiment": 0.0,
          "engagement": "712",
          "price_at_post": "58.00",
          "thread_title": "RE: \u00a31.06 target read on     ADVFN says 2 RNS today",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=0BA0D254-92EB-4BBB-95F7-06FC6C4D5863"
        },
        "ingested_at": "2026-01-21T22:40:11.338722+00:00"
      },
      {
        "event_id": "SOCIAL-Today1058-Thornogs--2103390",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:00.320902",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Because if there's a big dilutative raise I'll do better Chris and whatever downside there is, other than clinical failure obviously, will have been removed. I don't see any SP catalysts now until 3 months into FAP-EXD. I'm out so near term downside is nil with the likelihood of buying lower at the raise with downside well and truly minimised. Might be a Pharma deal for AVA6000 is suppose but the RNS didn't make that appear either likely or large/company making. Happy here watching for now, 8% up with 7% spread. I think the price will now start to drift until funding sorted, each to their own.",
          "sentiment": 0.0,
          "engagement": "8,556",
          "price_at_post": "58.00",
          "thread_title": "RE: For Chris",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=204FD580-E2F8-4E01-9636-04251DFD3A79"
        },
        "ingested_at": "2026-01-21T22:40:11.338704+00:00"
      },
      {
        "event_id": "SOCIAL-Today1103-NFTs--2389317",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:00.320474",
        "source": "LSE_CHAT",
        "data": {
          "author": "NFTs",
          "content": "To suggest there are 'no SP catalysts' for 3 months is a complete fabrication of the current clinical timeline. You are either ignoring or haven't read the Year-End Trading Update from yesterday (Jan 20) and today's FDA RNS: 1. The TNBC Catalyst: The company explicitly confirmed that Triple Negative Breast Cancer (TNBC) cohort data is expected in H1 2026. That is a massive near-term readout for a multi-billion dollar indication, not a '3-month wait.' 2. The SGC Survival Data: Management also confirmed survival data in Salivary Gland Cancer (SGC) continues to mature, with updates expected alongside TNBC in H1. This is the 'mature data' Big Pharma requires for the Phase 2 partnership you claim is unlikely. 3. Dosing Milestone: Today's FDA clearance isn't just paper; it triggers First Patient Dosed in Q1 2026 for AVA6103. That is a concrete operational milestone happening now, not in 3 months. 4. The Funding Myth: You\u2019re calling for a 'dilutative raise' while ignoring the \u00a316.9m cash balance and the \u00a322m raised in 2025 which provides a runway into Q3 2026. They have the cash to hit the TNBC and SGC value inflection points before needing further funding. 5. Partnership Interest: The CEO stated today that AVA6103 is already 'garnering significant interest from global pharmaceutical companies.' Clearing the IND is the specific 'de-risking' event that moves those talks from the 'if' to the 'when.' The 'drift' narrative only works if you pretend the H1 clinical data doesn't exist. The science is moving faster than your Bear thesis.",
          "sentiment": 0.0,
          "engagement": "814",
          "price_at_post": "58.00",
          "thread_title": "RE: For Chris",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=204FD580-E2F8-4E01-9636-04251DFD3A79"
        },
        "ingested_at": "2026-01-21T22:40:11.338686+00:00"
      },
      {
        "event_id": "SOCIAL-Today1108-Bella653-90888069",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:00.320021",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "Product-based partnerships: partnering or out-licensing deals with large pharma/biotech companies that have clinical and/or commercial expertise in certain therapeutic areas, or geographies, could help accelerate development of either existing or new product candidates. We note that Avacta is actively seeking a deal for AVA6000, ahead of starting Phase II development in H126; and Technology-based collaborations: to date, such alliances for either the pre|CISION and Affimer platforms have typically been outside Avacta\u2019s core area of focus, with current collaborations covering the application of pre|CISION technology in FAP-activated radiopharmaceuticals (POINT Biopharma/Eli Lilly) and the development of Affimer-based therapeutics (through the AffyXell joint venture with Daewoong Pharmaceuticals, and a separate multi-product deal with LG Chem Life Sciences).",
          "sentiment": 0.0,
          "engagement": "6,740",
          "price_at_post": "58.00",
          "thread_title": "THEN AND NOW...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=A234F3F6-D21D-4818-A1AA-54BE0C4DC43A"
        },
        "ingested_at": "2026-01-21T22:40:11.338668+00:00"
      },
      {
        "event_id": "SOCIAL-Today1110-Bella653--2738170",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:00.319607",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "That was from Trinity note last year... https://www.trinitydelta.org/research-notes/beneath-the-tip-of-the-precision-iceberg/",
          "sentiment": 0.0,
          "engagement": "6,740",
          "price_at_post": "58.00",
          "thread_title": "RE: THEN AND NOW...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=A234F3F6-D21D-4818-A1AA-54BE0C4DC43A"
        },
        "ingested_at": "2026-01-21T22:40:11.338650+00:00"
      },
      {
        "event_id": "SOCIAL-Today1118-HarChris-39457297",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:00.319191",
        "source": "LSE_CHAT",
        "data": {
          "author": "HarChris",
          "content": "In other words in the low 50s in case there was a big dilutive raise and no other catalysts materialising you were willing to give up 100%+ potential gains to protect against a potential 20% or so drop? And even then every chance the raise would land at the same price as Alastair\u2019s ie barely any drop from that price you eventually sold out. Again, I repeat, just from a trading perspective that is terrible R/R unless you can persuasively argue that the chance of no left field news landing over the coming months ending up in a sub 50p raise is sort of 80%+. I\u2019m sure most agree just from a trading perspective that looks poorly thought out\u2026 Wyn seems to agree hence the correcting course today.",
          "sentiment": 0.0,
          "engagement": "15,805",
          "price_at_post": "58.00",
          "thread_title": "RE: For Chris",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=204FD580-E2F8-4E01-9636-04251DFD3A79"
        },
        "ingested_at": "2026-01-21T22:40:11.338628+00:00"
      },
      {
        "event_id": "SOCIAL-Today1121-Thornogs-20144086",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:00.318753",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "\u00a31 is rather a figure plucked from the air Chris. The point is that at \u00a31 there may well be considerable upside still with risk greatly reduced and in the meantime I can wait to see what happens and might do better, but even what might turn out to be the worse option isn't a bad option. All my options are currently open and they're all good ones.",
          "sentiment": 0.0,
          "engagement": "8,556",
          "price_at_post": "58.00",
          "thread_title": "RE: For Chris",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=204FD580-E2F8-4E01-9636-04251DFD3A79"
        },
        "ingested_at": "2026-01-21T22:40:11.338610+00:00"
      },
      {
        "event_id": "SOCIAL-Today1127-HarChris--2631197",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:00.318331",
        "source": "LSE_CHAT",
        "data": {
          "author": "HarChris",
          "content": "Others\u2019 options are completely open too, with the added benefit of being able to sell right now at higher than you did if they so choose. Don\u2019t pretend that being out is the only thing that gives a trader and investor control, it\u2019s not. Only suspension or a big holding relative to daily volume locks someone out. Again that\u2019s the market but as you share your positions and the thought behind them so vocally it\u2019s reasonable to evaluate that strategy too.",
          "sentiment": 0.0,
          "engagement": "15,805",
          "price_at_post": "58.00",
          "thread_title": "RE: For Chris",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=204FD580-E2F8-4E01-9636-04251DFD3A79"
        },
        "ingested_at": "2026-01-21T22:40:11.338591+00:00"
      },
      {
        "event_id": "SOCIAL-Today1209-Trickyma-32124211",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:00.317900",
        "source": "LSE_CHAT",
        "data": {
          "author": "Trickymatters",
          "content": "Exciting. IND came in on time. Both treatments progressing to next stage clinical trials. Results will be out this year. Avacta always release interim results. TR1s will be getting in sooner than later. All this progress in the US with a British company. Bodes well. We must have something extraordinary. Nothing is going to get in the way of a potential cancer treatment like this. Too late I fear for my brother. Which is breaking my heart. But will change the game for millions. Well done Avacta!",
          "sentiment": 0.5,
          "engagement": "4,343",
          "price_at_post": "58.00",
          "thread_title": "Great RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=24B6DB7B-C3BF-4112-B481-85FB99D14452"
        },
        "ingested_at": "2026-01-21T22:40:11.338573+00:00"
      },
      {
        "event_id": "SOCIAL-Today1218-pedrolan--6658627",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:00.317483",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Very sorry to hear about you brother. My father in law dies at 56 from Pancreatic Cancer which, I believe, has the lowest recovery rate of nearly all cancers. So this is close to my heart.",
          "sentiment": 0.5,
          "engagement": "1,944",
          "price_at_post": "58.00",
          "thread_title": "RE: Great RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=24B6DB7B-C3BF-4112-B481-85FB99D14452"
        },
        "ingested_at": "2026-01-21T22:40:11.338551+00:00"
      },
      {
        "event_id": "SOCIAL-Today1240-DaProphe--4686536",
        "event_type": "social_post",
        "date": "2026-01-21T22:40:00.317025",
        "source": "LSE_CHAT",
        "data": {
          "author": "DaProphet",
          "content": "I'm personally not brave enough to sell now on the unknown speculation of raise at a lower price.. Imagine holding for years only to see a licence deal or TO appear Out of nowhere..we are not in the old narcissistic era of AS anymore.. Plenty of options now \" Some neghead just wrote this \"Might be a Pharma deal for AVA6000 is suppose but the RNS didn't make that appear either likely or large/company making\" Quite sure they mentioned recently talks are ongoing on the commercial basis with numerous pharma companies Anyway glad you've sold out and you can move on to ither ventures ..now please shut the door behind you.. there's a good chap\ud83d\udc4d",
          "sentiment": 0.0,
          "engagement": "4,837",
          "price_at_post": "57.50",
          "thread_title": "RE: For Chris",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=204FD580-E2F8-4E01-9636-04251DFD3A79"
        },
        "ingested_at": "2026-01-21T22:40:11.338516+00:00"
      },
      {
        "event_id": "SOCIAL-Today1253-Bella653--1193238",
        "event_type": "social_post",
        "date": "2026-01-21T22:39:57.429115",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "Product-based partnerships: partnering or out-licensing deals with large pharma/biotech companies that have clinical and/or commercial expertise in certain therapeutic areas, or geographies, could help accelerate development of either existing or new product candidates. We note that Avacta is actively seeking a deal for AVA6000, ahead of starting Phase II development in H126; Note wording 'clinical...expertise in certain therapeutic areas'   treatment, therapy, or drug  - AVA6000/Dox??? ;or geographies'   so why do we no longer have an advisor represented in the US???? 'Avacta is actively seeking a deal for AVA6000, ahead of starting Phase II development in H126' ..what has happened since end June 2025???  Would all these actions have taken place if a Partner seriously call the shorts...you need to do this you need to do that etc etc...deals don't just happen, they take a long time to sort out especially if big money is involved and a third party like Healthcare Royalty...",
          "sentiment": 0.0,
          "engagement": "6,740",
          "price_at_post": "57.50",
          "thread_title": "RE: THEN AND NOW...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=A234F3F6-D21D-4818-A1AA-54BE0C4DC43A"
        },
        "ingested_at": "2026-01-21T22:40:11.338490+00:00"
      },
      {
        "event_id": "SOCIAL-Today1255-Bella653--3774828",
        "event_type": "social_post",
        "date": "2026-01-21T22:39:57.428679",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "Sorry should have read Would all these actions have taken place if a Partner/future Financier wasn't seriously calling the shots...you need to do this, you need to do that etc etc..",
          "sentiment": 0.0,
          "engagement": "6,740",
          "price_at_post": "57.50",
          "thread_title": "RE: THEN AND NOW...",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=A234F3F6-D21D-4818-A1AA-54BE0C4DC43A"
        },
        "ingested_at": "2026-01-21T22:40:11.338472+00:00"
      },
      {
        "event_id": "SOCIAL-Today1259-Bella653--5226085",
        "event_type": "social_post",
        "date": "2026-01-21T22:39:57.428265",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "DaProphet...'Quite sure they mentioned recently talks are ongoing on the commercial basis with numerous pharma companies'... I'd be extremely worried if they weren't...",
          "sentiment": 0.0,
          "engagement": "6,740",
          "price_at_post": "57.00",
          "thread_title": "RE: For Chris",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=204FD580-E2F8-4E01-9636-04251DFD3A79"
        },
        "ingested_at": "2026-01-21T22:40:11.338454+00:00"
      },
      {
        "event_id": "SOCIAL-Today1332-steviebo-90192045",
        "event_type": "social_post",
        "date": "2026-01-21T22:39:57.427844",
        "source": "LSE_CHAT",
        "data": {
          "author": "stevieboro",
          "content": "It most certainly is, the beast will be a different animal with any luck. Really looking forward to seeing what this year brings. LTH should be well rewarded. As always GLA",
          "sentiment": 0.0,
          "engagement": "288",
          "price_at_post": "55.50",
          "thread_title": "RE: Yet Another Great RNS !",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=941A6C19-54BF-4CE0-89F8-A4C9BA744E77"
        },
        "ingested_at": "2026-01-21T22:40:11.338436+00:00"
      },
      {
        "event_id": "SOCIAL-Today1332-Thornogs-86572208",
        "event_type": "social_post",
        "date": "2026-01-21T22:39:57.427437",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "When haven't they been 'talking to Pharma'? I'd put 'talking to Pharma' some way behind 'Deals in the not too distant future', indeed if that was happening I'd have expected to have heard 'deals are imminent' or worst case 'Deals are continuing to progress'? I'm not holding my breath on that one.",
          "sentiment": 0.0,
          "engagement": "8,556",
          "price_at_post": "55.50",
          "thread_title": "RE: For Chris",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=204FD580-E2F8-4E01-9636-04251DFD3A79"
        },
        "ingested_at": "2026-01-21T22:40:11.338418+00:00"
      },
      {
        "event_id": "SOCIAL-Today1348-Livedata--8185203",
        "event_type": "social_post",
        "date": "2026-01-21T22:39:57.427011",
        "source": "LSE_CHAT",
        "data": {
          "author": "Livedataaccount",
          "content": "Its very encouraging and good to see avacta using the BOIN design for the 6103 trial will hopefully speed things up compared to three 3+3 design 6000 used",
          "sentiment": 0.0,
          "engagement": "2,950",
          "price_at_post": "55.50",
          "thread_title": "RE: Yet Another Great RNS !",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=941A6C19-54BF-4CE0-89F8-A4C9BA744E77"
        },
        "ingested_at": "2026-01-21T22:40:11.338399+00:00"
      },
      {
        "event_id": "SOCIAL-Today1352-Kagefc--1005929",
        "event_type": "social_post",
        "date": "2026-01-21T22:39:57.426598",
        "source": "LSE_CHAT",
        "data": {
          "author": "Kagefc",
          "content": "Thorn, \"all my options are currently open \" well ,apart from the one of buying shares in this company below 40p, or even 30p (6 months ago) those options are gone forever. Never mind.",
          "sentiment": 0.0,
          "engagement": "256",
          "price_at_post": "55.50",
          "thread_title": "RE: For Chris",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=204FD580-E2F8-4E01-9636-04251DFD3A79"
        },
        "ingested_at": "2026-01-21T22:40:11.338379+00:00"
      },
      {
        "event_id": "SOCIAL-Today1408-D-Geeman--5864339",
        "event_type": "social_post",
        "date": "2026-01-21T22:39:57.426187",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "Will the trials all be in the US? (Relative is having 'whipple procedure' carried out shortly. I'd like to keep them informed.)",
          "sentiment": 0.0,
          "engagement": "5,836",
          "price_at_post": "55.50",
          "thread_title": "RE: Yet Another Great RNS !",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=941A6C19-54BF-4CE0-89F8-A4C9BA744E77"
        },
        "ingested_at": "2026-01-21T22:40:11.338344+00:00"
      },
      {
        "event_id": "SOCIAL-Today1504-BuenaVis-62150031",
        "event_type": "social_post",
        "date": "2026-01-21T22:39:57.425767",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "The BOIN (Bayesian Optimal Interval) design is a model-assisted, adaptive statistical method for early-phase oncology trials, used primarily to find the Maximum Tolerated Dose (MTD) by comparing the observed dose-limiting toxicity (DLT) rate with pre-set escalation and de-escalation boundaries, offering a simple, efficient, and statistically sound alternative to older methods like the 3+3 design. It's known for its transparency, operational simplicity, and strong performance in guiding dose escalation/de-escalation to safely identify the optimal dose level for further study. Primarily used in Phase I oncology trials to find the MTD or the Recommended Phase II Dose (RP2D). Key Advantages \u2022 Simplicity & Efficiency: Easier for clinicians to use than complex model-based designs, while being more adaptive and faster than traditional methods. \u2022 Improved Safety: Better overdose control, reducing patient exposure to overly toxic doses. \u2022 Flexibility: Can handle various scenarios, including drug combinations, late-onset toxicity, and different endpoints. \u2022 Strong Performance: High probability of correctly identifying the true MTD. There is a series of complex (as in involving strange mathematical symbols) decision criteria.  More details here: An overview of the BOIN design and its current extensions for novel early-phase oncology trials ( https://www.sciencedirect.com/science/article/pii/S2451865422000606 )",
          "sentiment": 0.0,
          "engagement": "5,705",
          "price_at_post": "56.00",
          "thread_title": "The BOIN clinical trial design",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=8CC8CA55-C5AB-4A6E-AEB2-099C950F44E1"
        },
        "ingested_at": "2026-01-21T22:40:11.338309+00:00"
      },
      {
        "event_id": "SOCIAL-Today1518-cj62--4124674",
        "event_type": "social_post",
        "date": "2026-01-21T22:39:57.425313",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "Cancer Type\tUSA (Annual Cases)\tEurope (Annual Cases) Pancreatic\t~67,000\t~145,000 Gastric (Stomach)\t~31,500\t~161,000 Lung (overall)\t~226,650 (~29,500 small-cell)\t~435,000 (~56,000 small-cell) Cervical\t~14,000\u201315,000\t~58,000 I have to say that its a huge addressable market and if AVA 6103 is successful I would find it impossible to put a value to it.",
          "sentiment": 0.0,
          "engagement": "4,263",
          "price_at_post": "56.00",
          "thread_title": "Annual Cases",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=519B7F4A-BC51-4841-8F9F-D2E4AB6E56EF"
        },
        "ingested_at": "2026-01-21T22:40:11.338286+00:00"
      },
      {
        "event_id": "SOCIAL-Today1536-Thornogs--1656680",
        "event_type": "social_post",
        "date": "2026-01-21T22:39:57.424876",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Google thinks not for what it's worth 'D'.",
          "sentiment": 0.0,
          "engagement": "8,556",
          "price_at_post": "56.00",
          "thread_title": "RE: Yet Another Great RNS !",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=941A6C19-54BF-4CE0-89F8-A4C9BA744E77"
        },
        "ingested_at": "2026-01-21T22:40:11.338268+00:00"
      },
      {
        "event_id": "SOCIAL-Today1548-D-Geeman-68602452",
        "event_type": "social_post",
        "date": "2026-01-21T22:39:57.424466",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "Cheers Thorn. I will still mention to him and his wife. They can ask the surgeon later on. Maybe surgery alone will work. If nothing else it will show to the team that they are looking into trials.",
          "sentiment": 0.0,
          "engagement": "5,836",
          "price_at_post": "56.00",
          "thread_title": "RE: Yet Another Great RNS !",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=941A6C19-54BF-4CE0-89F8-A4C9BA744E77"
        },
        "ingested_at": "2026-01-21T22:40:11.338250+00:00"
      },
      {
        "event_id": "SOCIAL-Today1604-pedrolan--5598529",
        "event_type": "social_post",
        "date": "2026-01-21T22:39:57.424051",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Cheers BV. I thought it was something to do with West Bromwich Albion \ud83e\udd23",
          "sentiment": 0.5,
          "engagement": "1,944",
          "price_at_post": "56.00",
          "thread_title": "RE: The BOIN clinical trial design",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=8CC8CA55-C5AB-4A6E-AEB2-099C950F44E1"
        },
        "ingested_at": "2026-01-21T22:40:11.338232+00:00"
      },
      {
        "event_id": "SOCIAL-Today1728-Thompi-78709793",
        "event_type": "social_post",
        "date": "2026-01-21T22:39:57.423631",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thompi",
          "content": "Thorn has ADD - Avacta Deficit Order: \u2022\tCompulsive posting (41 posts in 24hrs is his record so far) \u2022\tZero shareholding \u2022\tChronic fixation on one company \u2022\tSymptoms worsen after data releases Sadly, there\u2019s no approved treatment: \u2022\tData doesn\u2019t help \u2022\tClarification doesn\u2019t help \u2022\tSilence helps a bit, but relapse is common What a prize plonker!",
          "sentiment": 0.0,
          "engagement": "1,350",
          "price_at_post": "55.50",
          "thread_title": "RE: Lord of the FUD",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=1D083E3C-47CE-4462-90BC-72508F10C286"
        },
        "ingested_at": "2026-01-21T22:40:11.338215+00:00"
      },
      {
        "event_id": "SOCIAL-Today1733-BuenaVis--1304425",
        "event_type": "social_post",
        "date": "2026-01-21T22:39:57.423180",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "I suspect the trial will, of necessity, need to start at a sub-toxic dose level as a precaution, as was the case with AVA6000 at 80mg/m\u00b2 \u2261 54mg/m\u00b2 (90% of the  clinical 60 to 75mg/m\u00b2 dose of) straight doxorubicin.  Hopefully though the doses can escalate rapidly based on uptake, side-effects and PK experience gained in the trial.",
          "sentiment": 0.0,
          "engagement": "5,705",
          "price_at_post": "55.50",
          "thread_title": "RE: The BOIN clinical trial design",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=8CC8CA55-C5AB-4A6E-AEB2-099C950F44E1"
        },
        "ingested_at": "2026-01-21T22:40:11.338198+00:00"
      },
      {
        "event_id": "SOCIAL-Today1735-Agenda10-69725003",
        "event_type": "social_post",
        "date": "2026-01-21T22:39:57.422765",
        "source": "LSE_CHAT",
        "data": {
          "author": "Agenda101",
          "content": "It\u2019s nuts how many posters are filtered here, yet still keep posting despite getting hardly any ticks on their comments. Compare that to posts with genuine engagement, surely at some point self-awareness has to kick in?",
          "sentiment": 0.0,
          "engagement": "54",
          "price_at_post": "55.50",
          "thread_title": "Recommend Ticks!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=8AE1789C-AF8C-4584-B91C-609C71676579"
        },
        "ingested_at": "2026-01-21T22:40:11.338180+00:00"
      },
      {
        "event_id": "SOCIAL-Today1751-Thompi-52545895",
        "event_type": "social_post",
        "date": "2026-01-21T22:39:57.422354",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thompi",
          "content": "Sorry, correction to post - Thorn\u2019s ADD is Avacta Deficit Disorder. It would be good if LSE gave the option to edit a post - even if it\u2019s just 10 minutes to make a correction.",
          "sentiment": 0.0,
          "engagement": "1,350",
          "price_at_post": "55.50",
          "thread_title": "RE: Lord of the FUD",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=1D083E3C-47CE-4462-90BC-72508F10C286"
        },
        "ingested_at": "2026-01-21T22:40:11.338162+00:00"
      },
      {
        "event_id": "SOCIAL-Today1836-B2HS2L-47903826",
        "event_type": "social_post",
        "date": "2026-01-21T22:39:57.421928",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "I've ordered him a strait jacket, but had to guess the size. XXXL to assure he can be got into it, - it should stop him using a keyboard!   \u2328\ufe0f Brian Blessed has volunteered to 'squeeze him into it'.  \ud83d\udddc\ufe0f\ud83d\udddc\ufe0f\ud83d\udddc\ufe0f What's the postcode?",
          "sentiment": 0.0,
          "engagement": "5,982",
          "price_at_post": "55.50",
          "thread_title": "RE: Lord of the FUD",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=1D083E3C-47CE-4462-90BC-72508F10C286"
        },
        "ingested_at": "2026-01-21T22:40:11.338144+00:00"
      },
      {
        "event_id": "SOCIAL-Today1938-D-Geeman--1968580",
        "event_type": "social_post",
        "date": "2026-01-21T22:39:57.421507",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "\u2018 posters are filtered \u2026.  getting hardly any ticks on their comments\u2019 You can see the number of ticks on filtered posts? That\u2019s new to me.",
          "sentiment": 0.0,
          "engagement": "5,836",
          "price_at_post": "55.50",
          "thread_title": "RE: Recommend Ticks!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=8AE1789C-AF8C-4584-B91C-609C71676579"
        },
        "ingested_at": "2026-01-21T22:40:11.338124+00:00"
      },
      {
        "event_id": "SOCIAL-Today2007-B2HS2L-62010324",
        "event_type": "social_post",
        "date": "2026-01-21T22:39:57.421079",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "...End-June 2025 cash and equivalents were \u00a312.6m (vs \u00a312.9m at end-December 2004), with a \u00a316.9m cash balance at end-2025. In H225, Avacta completed two equity raises for a total of \u00a36.5m gross (c \u00a36.2m net) to fund the July and October 2025 convertible bond (CB) repayments, sold Coris for \u00a32.15m in cash, and completed a \u00a316m gross (we assume c \u00a315.1m net) equity raise. This extended the cash runway into Q326, beyond key data read outs, allowing management to progress its pipeline through to the next inflection points. For the purposes of our model, we include \u00a330m of cash inflows in FY26e (as illustrative short-term debt) to address the H226 funding shortfall. This could come from a variety of sources, such as potential licensing deals or collaborations, and debt and/or equity funding which could include the potential for dual listing on AIM and NASDAQ. Here's a simplified version of the above provided by Grok: At the end of June 2025, Avacta had \u00a312.6 million in cash (slightly down from \u00a312.9 million at the end of 2024). By the end of 2025, the cash balance reached \u00a316.9 million. During the second half of 2025, the company: Raised \u00a36.5 million gross (~\u00a36.2 million net) through two small equity placings \u2192 used to repay convertible bonds in July and October 2025 Sold Coris for \u00a32.15 million in cash Raised \u00a316 million gross (~\u00a315.1 million net) in another equity placing These moves extended the cash runway into Q3 2026 \u2014 long enough to cover important upcoming data readouts and reach the next key milestones in the pipeline. For modelling purposes, we assume an extra \u00a330 million of cash inflows in 2026 (treated as short-term debt for now) to cover any remaining funding needs in the second half of 2026. This could come from licensing deals, partnerships, more debt, additional equity raises, or possibly a dual listing on AIM and NASDAQ. +++ So Trinity Delta, - who would routinely OK text within this report with Avacta prior to publishing, - are assuming \u00a330 million of cash inflows in 2026. This could come from licensing deals, partnerships, more debt, additional equity raises, or possibly a dual listing on AIM and NASDAQ. Does that line display, in order of appearance, the source of this \u00a330M funding in the most likely order. I'm assuming these are all the sources of funds the company would consider.",
          "sentiment": 0.0,
          "engagement": "5,982",
          "price_at_post": "55.50",
          "thread_title": "Today's Trinity Delta research report",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=1C83398D-57C7-4E09-83D8-C9F29FA3FE4A"
        },
        "ingested_at": "2026-01-21T22:40:11.338085+00:00"
      },
      {
        "event_id": "SOCIAL-Today2011-Bella653-40500784",
        "event_type": "social_post",
        "date": "2026-01-21T22:39:57.420588",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "Was the AVA6000 low starting dose more to do with the Dox element or PreCision or both... Could the AVA6000 trial data allow for a higher starting dose since no MTD was attained at the very high dose levels...",
          "sentiment": 0.0,
          "engagement": "6,740",
          "price_at_post": "55.50",
          "thread_title": "RE: The BOIN clinical trial design",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=8CC8CA55-C5AB-4A6E-AEB2-099C950F44E1"
        },
        "ingested_at": "2026-01-21T22:40:11.338067+00:00"
      },
      {
        "event_id": "SOCIAL-Today2013-Bella653--3726599",
        "event_type": "social_post",
        "date": "2026-01-21T22:39:57.420166",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "21-Jan-26\t17:10:18\t55.50\t15,000\tUnknown*\t8,325\tO 21-Jan-26\t11:11:56\t58.00\t100,000\tUnknown*\t58.00k\tO 21-Jan-26\t16:25:53\t55.75\t370\tBuy*\t206.28\tO",
          "sentiment": 0.0,
          "engagement": "6,740",
          "price_at_post": "55.50",
          "thread_title": "DELAYED TRADE",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=2A1C3661-AEB0-49B1-9144-AC38977B6038"
        },
        "ingested_at": "2026-01-21T22:40:11.338048+00:00"
      },
      {
        "event_id": "SOCIAL-Today2022-BuenaVis-88934862",
        "event_type": "social_post",
        "date": "2026-01-21T22:39:57.419741",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "I suspect the low initial AVA6000 dose, 90% of the 60mg/m\u00b2 standard doxorubicin dose, was partly to protect the patients in case all the doxorubicin got dumped in the bloodstream in one go and partly in case AVA6000 had some toxicity for the patients - remember that this was a first in human study. I suspect it will be similar for AVA6103 as that chemical has never been in humans before either.",
          "sentiment": 0.0,
          "engagement": "5,705",
          "price_at_post": "55.50",
          "thread_title": "RE: The BOIN clinical trial design",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=8CC8CA55-C5AB-4A6E-AEB2-099C950F44E1"
        },
        "ingested_at": "2026-01-21T22:40:11.338029+00:00"
      },
      {
        "event_id": "SOCIAL-Today2109-D-Geeman-24389912",
        "event_type": "social_post",
        "date": "2026-01-21T22:39:57.419328",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "AI probably quite good for this sort of thing: \u2018 The starting dose in a Phase 1 drug trial is a critically calculated low level, derived from preclinical (animal) toxicity data (like the No Observed Adverse Effect Level - NOAEL), scaled to humans, and then reduced by a significant safety factor (often 10x) to ensure patient safety, aiming to avoid toxicity while being high enough for potential biological activity, balancing risk and efficiency. Regulatory guidance (FDA, EMA) provides frameworks, but the exact dose is unique, using methods like the \"Maximum Recommended Starting Dose\" (MRSD) calculation, often involving human equivalent dose (HED) conversion and safety margins. Key Factors in Determining the Starting Dose: Preclinical Data: The NOAEL from the most sensitive animal species is a primary input. Species Scaling: The NOAEL is converted to a Human Equivalent Dose (HED) using specific scaling factors, often based on body surface area. Safety Factor: A safety margin (e.g., 10x) is applied to the HED to get the MRSD, ensuring the initial dose is far below predicted toxicity. Drug Type: Different rules apply to small molecules (often escalating by ~100% or half-log) versus biologics (often half-log or 3x increments). Trial Goals: While safety is paramount, the dose shouldn't be so low as to be sub-therapeutic, minimizing unnecessary exposure to ineffective doses. \u2019",
          "sentiment": 0.0,
          "engagement": "5,836",
          "price_at_post": "55.50",
          "thread_title": "RE: The BOIN clinical trial design",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=8CC8CA55-C5AB-4A6E-AEB2-099C950F44E1"
        },
        "ingested_at": "2026-01-21T22:40:11.338010+00:00"
      },
      {
        "event_id": "SOCIAL-Today2220-gidrae-65581802",
        "event_type": "social_post",
        "date": "2026-01-21T22:39:57.418849",
        "source": "LSE_CHAT",
        "data": {
          "author": "gidrae",
          "content": "Avct is now tradeable on Trading 212",
          "sentiment": 0.5,
          "engagement": "263",
          "price_at_post": "55.50",
          "thread_title": "Avct & T212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=4D59A380-8A24-424C-A087-DA0FAA8B5786"
        },
        "ingested_at": "2026-01-21T22:40:11.337988+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20260745-Reaper66-10830705",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:18.664856",
        "source": "LSE_CHAT",
        "data": {
          "author": "Reaper666",
          "content": "07.33 - Regarding this poster I had to reach for my trusty  kaleidoscope glasses (as earlier today). The posting histories reveal a sea of colour. So, in a nutshell, the posts represent rubbish - but, surely. the genuine here know that DYOR. VGLA",
          "sentiment": 0.0,
          "engagement": "2,054",
          "price_at_post": "55.50",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T03:30:18.692693Z"
      },
      {
        "event_id": "SOCIAL-20Jan20260752-Runner-R--4896024",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:18.664449",
        "source": "LSE_CHAT",
        "data": {
          "author": "Runner-Runner",
          "content": "\"Wow! That\u2019s the most positive trading update in company history\" You're kidding right? I don't like the tone in this RNS. The \"multiple conversation\" carot's have been dangling for years. Effectively mothballing AVA6000 due to lack of funds. I expect an already jaded market to lose even more enthusiasm. There are only so many upbeat comments they can make with zero follow through. We will see and I hope I am proved wrong. I don't expect a positive remainder of the week as far as SP is concerned.",
          "sentiment": 0.0,
          "engagement": "697",
          "price_at_post": "55.50",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T03:30:18.692666Z"
      },
      {
        "event_id": "SOCIAL-20Jan20260752-B2HS2L-88318391",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:18.664009",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "Are we expecting another RNS with the (Links) inserted.",
          "sentiment": 0.0,
          "engagement": "5,977",
          "price_at_post": "55.50",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T03:30:18.692640Z"
      },
      {
        "event_id": "SOCIAL-20Jan20260804-Shannon4--8777155",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:18.663601",
        "source": "LSE_CHAT",
        "data": {
          "author": "Shannon4",
          "content": "James Dance Strand Harrison head of mergers and acquisitions?",
          "sentiment": 0.0,
          "engagement": "23",
          "price_at_post": "58.50",
          "thread_title": "Strand Harrison",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=9EEC28F0-6AB6-4C4B-87B3-470D103C85BF"
        },
        "ingested_at": "2026-01-21T03:30:18.692614Z"
      },
      {
        "event_id": "SOCIAL-20Jan20260806-emilly1k--1051484",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:18.663185",
        "source": "LSE_CHAT",
        "data": {
          "author": "emilly1katie",
          "content": "How little faith you have.",
          "sentiment": 0.0,
          "engagement": "87",
          "price_at_post": "58.50",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T03:30:18.692587Z"
      },
      {
        "event_id": "SOCIAL-20Jan20260814-seethree-35840534",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:18.662756",
        "source": "LSE_CHAT",
        "data": {
          "author": "seethreeIPO",
          "content": "No I\u2019m not kidding, show me a more positive trading update? I\u2019ve been here since 2019 and I can absolutely say there has never been a more positive update, maybe the sp will drop, maybe it will go ballistic, I\u2019m not sure but I stand by what I said. Avacta has at may times been a very frustrating hold. I\u2019m very excited for this year, with Q1 just being the start of true value delivery for shareholders.",
          "sentiment": 0.5,
          "engagement": "1,842",
          "price_at_post": "57.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T03:30:18.692561Z"
      },
      {
        "event_id": "SOCIAL-20Jan20260817-seethree--6160468",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:18.662341",
        "source": "LSE_CHAT",
        "data": {
          "author": "seethreeIPO",
          "content": "The links are in the original, it\u2019s just the LSE republished one hasn\u2019t coped them over https://avacta.com/year-end-trading-update/",
          "sentiment": 0.5,
          "engagement": "1,842",
          "price_at_post": "57.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T03:30:18.692536Z"
      },
      {
        "event_id": "SOCIAL-20Jan20260818-CrudeTra-56120169",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:18.661916",
        "source": "LSE_CHAT",
        "data": {
          "author": "CrudeTrader",
          "content": "Always the same: -> Running out of cash in less than 6 months -> Clearly no Nasdaq listing, when appointing tiny local broker as NOMAD -> Partnership discussion sounds uber dull",
          "sentiment": 0.0,
          "engagement": "460",
          "price_at_post": "57.00",
          "thread_title": "Jam tomorrow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=53FD148E-604E-4CB6-BA57-5482DA3F76C1"
        },
        "ingested_at": "2026-01-21T03:30:18.692510Z"
      },
      {
        "event_id": "SOCIAL-20Jan20260819-Icecool--6339430",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:18.661495",
        "source": "LSE_CHAT",
        "data": {
          "author": "Icecool",
          "content": "Let me simplify this because some people are overthinking it. More data equals more leverage and better longterm outcomes. That\u2019s it. End of story. Avacta isn\u2019t here to do a rushed AIM style panic deal just to soothe the SP for a week and appease impatient gambling junkies. Every extra patient, every extra PFS datapoint, every cohort that matures strengthens their hand in negotiations. That\u2019s how you get better economics. AVA6000 has already done the hard part. Human validation Safety Targeted payload release Durability PFS signal At this point, selling it early would be bad strategy unless you\u2019re desperate. They\u2019re clearly not. They\u2019re letting the data compound. AVA6103 is even more obvious. The preclinical data is ridiculous, but the real value unlock happens the moment human data starts landing. As soon as Phase 1a shows signal, the clock starts ticking for pharma. Avacta knows this, which is why they\u2019re not giving anything away cheap. If you want instant gratification, AIM biotechs aren\u2019t for you. From a longterm holder perspective this was extremely bullish imo, just what we wanted to hear! \ud83d\udcaf\ud83d\udc4d",
          "sentiment": 0.0,
          "engagement": "8,802",
          "price_at_post": "56.50",
          "thread_title": "Thoughts \ud83d\udcad",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=300150EA-38A1-4B63-8B76-B30DB2951F02"
        },
        "ingested_at": "2026-01-21T03:30:18.692484Z"
      },
      {
        "event_id": "SOCIAL-20Jan20260823-Aston15--3932505",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:18.661025",
        "source": "LSE_CHAT",
        "data": {
          "author": "Aston15",
          "content": "Crude 'Trader' = Poor 'Investor'",
          "sentiment": 0.0,
          "engagement": "57",
          "price_at_post": "56.50",
          "thread_title": "RE: Jam tomorrow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=53FD148E-604E-4CB6-BA57-5482DA3F76C1"
        },
        "ingested_at": "2026-01-21T03:30:18.692458Z"
      },
      {
        "event_id": "SOCIAL-20Jan20260824-Pollack-74428135",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:18.660612",
        "source": "LSE_CHAT",
        "data": {
          "author": "Pollack",
          "content": "Great post Ice",
          "sentiment": 0.0,
          "engagement": "740",
          "price_at_post": "56.00",
          "thread_title": "SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=73B0163A-F877-45F9-B690-0FD139C3FAAA"
        },
        "ingested_at": "2026-01-21T03:30:18.692432Z"
      },
      {
        "event_id": "SOCIAL-20Jan20260831-Hurst10-26680286",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:18.660206",
        "source": "LSE_CHAT",
        "data": {
          "author": "Hurst10",
          "content": "Agree, What is important is what the CEO did NOT say and it is very clear, it is a question of WHEN  not IF . If you can hold on, you will be rewarded!",
          "sentiment": 0.5,
          "engagement": "2,634",
          "price_at_post": "54.00",
          "thread_title": "RE: Thoughts \ud83d\udcad",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=300150EA-38A1-4B63-8B76-B30DB2951F02"
        },
        "ingested_at": "2026-01-21T03:30:18.692407Z"
      },
      {
        "event_id": "SOCIAL-20Jan20260840-Bella653-67139450",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:18.659774",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "'Continued active interaction with potential partners regarding both faridoxorubicin (AVA6000) and FAP-Exd (AVA6103).' As has been said before...they will need funds in their bank within next three months either from a fundraise or upfront deal payment(s) or from partner(s) who take on all the trial work/ costs and Avacta just does R&D work for a Royalty later. Now why no US connection from our new advisor...me thinks a commercial deal will come with Healthcare Royalty financial support.  They and the one we do deal with will be US based and will take care of all things US based...allowing Avacta to look East... Read the RNS again...it's all about what's not said and 'wording'...",
          "sentiment": 0.0,
          "engagement": "6,729",
          "price_at_post": "54.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T03:30:18.692381Z"
      },
      {
        "event_id": "SOCIAL-20Jan20260840-hamsters-34109554",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:18.659357",
        "source": "LSE_CHAT",
        "data": {
          "author": "hamsters18",
          "content": "Glad PH are gone..",
          "sentiment": 0.0,
          "engagement": "3,671",
          "price_at_post": "54.00",
          "thread_title": "RE: Thoughts \ud83d\udcad",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=300150EA-38A1-4B63-8B76-B30DB2951F02"
        },
        "ingested_at": "2026-01-21T03:30:18.692355Z"
      },
      {
        "event_id": "SOCIAL-20Jan20260843-Bella653-65957803",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:18.658937",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "Why did Avacta manage to get the loan payments deferred...but if a deal falls through then what?.read the wording...",
          "sentiment": 0.0,
          "engagement": "6,729",
          "price_at_post": "54.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T03:30:18.692330Z"
      },
      {
        "event_id": "SOCIAL-20Jan20260847-oldtrade--7367921",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:18.658531",
        "source": "LSE_CHAT",
        "data": {
          "author": "oldtrader2",
          "content": "Market does not believe at the moment",
          "sentiment": 0.0,
          "engagement": "647",
          "price_at_post": "54.00",
          "thread_title": "Share price",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=0B699608-554F-4B63-B443-95C787C21CE9"
        },
        "ingested_at": "2026-01-21T03:30:18.692304Z"
      },
      {
        "event_id": "SOCIAL-20Jan20260848-Bella653-20632212",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:18.658112",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "Why no mention of AVA6000 p2...?",
          "sentiment": 0.0,
          "engagement": "6,729",
          "price_at_post": "54.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T03:30:18.692278Z"
      },
      {
        "event_id": "SOCIAL-20Jan20260850-Thornogs--6432157",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:18.657695",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "\"More data equals more leverage\" ICE. It's that 'simple' is it? More leverage with the STS cohort?  Not even mentioned! )Along with LG and Affyxel - again)! More data with TNBC?  Perhaps but they're not exactly 'bigging up' the data to date are they? More data with SGC? Ib data very similar to 1a data they say so in what way does that help? I note that data to date is still 'highly encouraging', gosh as good as that! Did anyone else notice how long FAP-EXD is held, unaltered, in the tumour?  If that happens to FAP-DOX whilst the remaining AVA6000 is being washed away then much would be explained, I wonder why they haven't told us? Also after 2 days (with a longer half lifr) FAP-EXD can't be detected in the plasma, nothing! Puts the 100:1 Dox ratio stat into perspective doesn't it? 100x virtually nothing = not a lot? And what's there sits on the FAP (perhaps) for too long whilst the rest is flushed away un-cleaved. Q1 FAP-EXD is good though, but 'pending regulatory approval', hmm. We wait for FAP. We start again.",
          "sentiment": 0.0,
          "engagement": "8,545",
          "price_at_post": "54.00",
          "thread_title": "RE: Thoughts \ud83d\udcad",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=300150EA-38A1-4B63-8B76-B30DB2951F02"
        },
        "ingested_at": "2026-01-21T03:30:18.692253Z"
      },
      {
        "event_id": "SOCIAL-20Jan20260852-Icecool-45563237",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:18.657225",
        "source": "LSE_CHAT",
        "data": {
          "author": "Icecool",
          "content": "Bella, as expected, Avacta has no intention of taking AVA6000 into Phase 2 on its own. It\u2019s done exactly what it was meant to do, prove the platform works in humans, derisk the technology, and generate clinically meaningful data. From here, the rational path is licensing. Pushing multiple Phase 2 studies internally would be capital inefficient when the asset is already attractive to partners. Once the TNBC data lands, AVA6000 becomes a package, not a project, and I\u2019d fully expect interest in the entire program rather than single indications.",
          "sentiment": 0.0,
          "engagement": "8,802",
          "price_at_post": "54.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T03:30:18.692227Z"
      },
      {
        "event_id": "SOCIAL-20Jan20260855-Yorkshir-79476541",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:18.656791",
        "source": "LSE_CHAT",
        "data": {
          "author": "Yorkshirepragma",
          "content": "Declared Global pharma interests\u2026.that\u2019ll do",
          "sentiment": 0.0,
          "engagement": "1,799",
          "price_at_post": "54.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T03:30:18.692201Z"
      },
      {
        "event_id": "SOCIAL-20Jan20260856-JRDC-74345545",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:18.656376",
        "source": "LSE_CHAT",
        "data": {
          "author": "JRDC",
          "content": "Is quite telling that after 5 years, CCs ginger stepchild ava6k is still merely described as 'encouraging', whilst her baby 6103 which isn't even in the clinic has been called 'the beast' for about a year. Doesn't inspire much confidence that we'll get cracking value for 6k, basically worded that it's not worth our time taking it forwards without someone else funding it, please take it off our hands or we'll abandon it, and if pharma are just waiting for early p1 readout for 6103, then they'll just snap everything up cheaply. Even an unrealistic 200% premium to SP at the time will probably be far less than \u00a32. So possibly a profit, but not the life changing amounts that looked possible back during the infamous 'holy grail' pitch. Right horse, wrong time for us LTHs.",
          "sentiment": 0.0,
          "engagement": "868",
          "price_at_post": "54.00",
          "thread_title": "RE: Thoughts \ud83d\udcad",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=300150EA-38A1-4B63-8B76-B30DB2951F02"
        },
        "ingested_at": "2026-01-21T03:30:18.692175Z"
      },
      {
        "event_id": "SOCIAL-20Jan20260858-Metatron-77638175",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:18.655936",
        "source": "LSE_CHAT",
        "data": {
          "author": "Metatron",
          "content": "Looks to me like ThornogsonBot is having a breakdown \ud83e\udd2a He's starting again.",
          "sentiment": 0.0,
          "engagement": "1,172",
          "price_at_post": "54.00",
          "thread_title": "RE: Thoughts \ud83d\udcad",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=300150EA-38A1-4B63-8B76-B30DB2951F02"
        },
        "ingested_at": "2026-01-21T03:30:18.692150Z"
      },
      {
        "event_id": "SOCIAL-20Jan20260902-Bella653-74372784",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:18.655514",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "Ice...agree and that's the point...AVA6000 proves PreCision works...several companies could easilit licence it now for use with their own single warhead with an option for other PreCision products already developed or bring developed by Avacta.",
          "sentiment": 0.0,
          "engagement": "6,729",
          "price_at_post": "54.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T03:30:18.692123Z"
      },
      {
        "event_id": "SOCIAL-20Jan20260911-Thornogs-21197029",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:18.655082",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Why would they license AVA6000 for their 'single warhead'? AVA6000 has shown, beyond doubt that for Dox against it's usual target, STS, that it doesn't work. It'll be a tough sell, don't expect much, particularly if FAP-EXD is as good as hoped. Like buying the rights off Kodac for a film based photography package as digital really took off.",
          "sentiment": 0.0,
          "engagement": "8,545",
          "price_at_post": "54.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T03:30:18.692086Z"
      },
      {
        "event_id": "SOCIAL-20Jan20260930-Thornogs--1838008",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:18.654631",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "To enable first patient dosing of FAP-EXD in Q1. Why?  They've been lining this up for 2 years and already have it manufactured. Is this the first hint of a bit of slippage on the time line? And funding steams appear OK for the time being but by the time the first patient is dosed in FAP-EXD there'll be about 3 months monies left, I can't see them settling for that situation, first trial data will be several months down the line from that point. Deal(s) for FAP-DOX might buy enough time, otherwise a raise at less than Dr Smith's 50p?",
          "sentiment": 0.0,
          "engagement": "8,545",
          "price_at_post": "54.00",
          "thread_title": "'Pending regulatory approval'?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=5D594FA5-A489-492F-8942-1CE3BFF6B2D6"
        },
        "ingested_at": "2026-01-21T03:30:18.692061Z"
      },
      {
        "event_id": "SOCIAL-20Jan20260930-Toukanka-43362597",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:14.623312",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "Can\u2019t you read? CC has repeated her assertion that the extra data on 6000 is required in order to command an acceptable deal which will then fund further development Regarding 6103: the RNS supports my earlier prediction of initial data being released in June. Therefore IMHO no deal until after June.",
          "sentiment": 0.0,
          "engagement": "4,427",
          "price_at_post": "54.00",
          "thread_title": "RE: My opinion is",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=53B570CF-DF6D-4A07-A8F0-00C9BD609ABE"
        },
        "ingested_at": "2026-01-21T03:30:18.692035Z"
      },
      {
        "event_id": "SOCIAL-20Jan20260937-B2HS2L-71934816",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:14.622877",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "\u00b7 Unaudited cash and cash equivalents as of December 31, 2025: \u00a316.9m providing a runway into Q3 2026 supporting the planned spend on the Group's two clinical stage programs and preclinical pipeline to key value inflection points. AVA7100 (pre-clinical - being developed for FAP low cancers), must be history months ago to have this much left in the tank (Q3 2026). AVA6000 ph1b results are showing FAP low cancers being treated just fine.",
          "sentiment": 0.0,
          "engagement": "5,977",
          "price_at_post": "54.00",
          "thread_title": "RE: My opinion is",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=53B570CF-DF6D-4A07-A8F0-00C9BD609ABE"
        },
        "ingested_at": "2026-01-21T03:30:18.692009Z"
      },
      {
        "event_id": "SOCIAL-20Jan20260937-Toukanka-34340425",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:14.622459",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "IceCool Few weeks back peeps laughed when I posted about focus now would be entirely on 6103. I even asked whether Avacta would take 6000 into P2. Now here it is in black and white. CC has said that 6000 will only be developed in a partnership. However I was wrong about needing a fund raise yet. That is a relief.",
          "sentiment": 0.0,
          "engagement": "4,427",
          "price_at_post": "54.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T03:30:18.691984Z"
      },
      {
        "event_id": "SOCIAL-20Jan20260941-cj62-34256201",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:14.622023",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "Why are you concerned thorn as i believe you sold up waiting until funding is sorted?",
          "sentiment": 0.0,
          "engagement": "4,261",
          "price_at_post": "54.00",
          "thread_title": "RE: 'Pending regulatory approval'?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=5D594FA5-A489-492F-8942-1CE3BFF6B2D6"
        },
        "ingested_at": "2026-01-21T03:30:18.691957Z"
      },
      {
        "event_id": "SOCIAL-20Jan20260943-pedrolan-82501378",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:14.621610",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Maybe he forgot he told us he'd sold. Must be confusing switching between logins all the time. I really feel for him. Bless.",
          "sentiment": 0.0,
          "engagement": "1,936",
          "price_at_post": "54.00",
          "thread_title": "RE: 'Pending regulatory approval'?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=5D594FA5-A489-492F-8942-1CE3BFF6B2D6"
        },
        "ingested_at": "2026-01-21T03:30:18.691931Z"
      },
      {
        "event_id": "SOCIAL-20Jan20260944-Toukanka--4011577",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:14.621195",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "JRDC This is only clarification of what CC said in December. I had already set my sites on June anyway. Good news is that the money lasts until then. Not sure whether the accounts will be able to be signed off on a \u201cgoing concern \u201c basis though.",
          "sentiment": 0.0,
          "engagement": "4,427",
          "price_at_post": "54.00",
          "thread_title": "RE: Thoughts \ud83d\udcad",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=300150EA-38A1-4B63-8B76-B30DB2951F02"
        },
        "ingested_at": "2026-01-21T03:30:18.691906Z"
      },
      {
        "event_id": "SOCIAL-20Jan20260944-BuenaVis--3522594",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:14.620758",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "An excellent summary of the state of play - with links to full details. If, after thoroughly digesting this RNS and linked information, 'concerned' shareholders don't understand the enormous value of what they hold and have been spooked by those who make their living spreading fear, uncertainty and doubt, then they should sell and move on; the lengthy time and many hurdles of biopharma progress isn't for you. Just be aware that share-boosting news could arrive now at any time.",
          "sentiment": 0.0,
          "engagement": "5,701",
          "price_at_post": "54.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T03:30:18.691880Z"
      },
      {
        "event_id": "SOCIAL-20Jan20260946-Toukanka-46930705",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:14.620344",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "Pedrol CJ62 It is so predictable now that whenever you don\u2019t have an answer you switch back to insults or character assassination.",
          "sentiment": 0.0,
          "engagement": "4,427",
          "price_at_post": "54.00",
          "thread_title": "RE: 'Pending regulatory approval'?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=5D594FA5-A489-492F-8942-1CE3BFF6B2D6"
        },
        "ingested_at": "2026-01-21T03:30:18.691854Z"
      },
      {
        "event_id": "SOCIAL-20Jan20260947-B2HS2L-32008863",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:14.619918",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "30.09.2025 https://www.investormeetcompany.com/meetings/interim-results-491 Q/A tab Investormeet: How much do you expect phase two Faridoxorubicin to cost Avacta? How will you fund this if a partnership doesn't materialize? CC: So, we're very confident in the maturing data and the phase 1B of Faridoxorubicin and we think that this will support the long-term value of this asset. Salivary gland cancers, you know, high unmet need and we continue to collect data in the various cohorts. We have committed that we won't start the further development activities in the absence of a partnership. WE HAVE COMMITTED THAT WE WON'T START THE FURTHER DEVELOPMENT ACTIVITIES IN THE ABSENCE OF A PARTNERSHIP However, as I've said, the maturing data set in phase 1B is providing us with ample confidence that precision is working exactly as we designed it to work. The development in the expansion cohorts is well underway. We believe the preliminary data here will provide that natural inflection point for the program. It's also going to provide clarity on accelerated approval pathways that we might be able to seek. Also there's really an opportunity for the overall market to digest essentially the commercial potential for the program and the platform. As I mentioned, we'll have that pipeline update, platform update. And so we're really excited about the fourth quarter for the company.",
          "sentiment": 0.0,
          "engagement": "5,977",
          "price_at_post": "54.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T03:30:18.691828Z"
      },
      {
        "event_id": "SOCIAL-20Jan20260948-pedrolan--7727258",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:14.619463",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "It was to Thorn, Touk Oh wait.......",
          "sentiment": 0.0,
          "engagement": "1,936",
          "price_at_post": "54.00",
          "thread_title": "RE: 'Pending regulatory approval'?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=5D594FA5-A489-492F-8942-1CE3BFF6B2D6"
        },
        "ingested_at": "2026-01-21T03:30:18.691802Z"
      },
      {
        "event_id": "SOCIAL-20Jan20260948-Thornogs-54068701",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:14.619039",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "I have an opinion when I'm in and an opinion when I'm out, I like to think that my take on the science is broadly the same. I've grown increasingly doubtful of AVA6000's ability to 'prove the platform' and the data increasing now shows this. I've always thought that FAP-EXD is the future (potentially) but funding it was clearly important and now remains my biggest doubt, particularly if there's slippage in the clinical program time line. And as always I'm a little cross that in a Company update they  haven't mentioned anything other than the FAP programmes! Affyxell? LG? Point radio-ligands? It's an investor update not a corporate brainwashing and misinformation opportunity.",
          "sentiment": 0.0,
          "engagement": "8,545",
          "price_at_post": "54.00",
          "thread_title": "RE: 'Pending regulatory approval'?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=5D594FA5-A489-492F-8942-1CE3BFF6B2D6"
        },
        "ingested_at": "2026-01-21T03:30:18.691777Z"
      },
      {
        "event_id": "SOCIAL-20Jan20260949-BuenaVis-25468446",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:14.618604",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Bella wrote: \"Why no mention of AVA6000 p2...?\" I can only suggest you re-read the RNS and then list the several mentions of faridox Phase 2 plans here for us.",
          "sentiment": 0.0,
          "engagement": "5,701",
          "price_at_post": "54.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T03:30:18.691751Z"
      },
      {
        "event_id": "SOCIAL-20Jan20260951-cj62--6464037",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:14.618196",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "Come back when funding is sorted as no one cares for you thoughts",
          "sentiment": 0.0,
          "engagement": "4,261",
          "price_at_post": "54.00",
          "thread_title": "RE: 'Pending regulatory approval'?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=5D594FA5-A489-492F-8942-1CE3BFF6B2D6"
        },
        "ingested_at": "2026-01-21T03:30:18.691725Z"
      },
      {
        "event_id": "SOCIAL-20Jan20260953-wyndrum-21883921",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:14.617780",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "Just fore Chris: I have sold down quite a bit this morning (53.7p) to leave a small rump. Not sure where this is going now. AVA6k has gone like all the rest of the AVCT stable: great promise but in the end fails to live up to the hype. Which in turn puts doubts over the next trial because again at this stage its all words so the outcome is hardly guaranteed. Are timelines slipping? Not sure but when have they not? Is there enough money? No Is a deal imminent? well, it can always come out of the blue but I think AVA6k has disappointed with the  extra data (take note ice), so if there ever was a not to distant deal, that seems to have receeded or disappeared altogether. Which only further confirms my original thoughts that a RI and more dilution comes next. Trouble is now, where will the SP be for that likely raise? And overlaying all of this is the direction of travel in a broader sense and it is vaccines, again, my analogy is that AVCT are improving the combustion engine while the industry goes electric. And although I presume there will be a market for chemo going forward, but for how long? The more alternatives come to market the less value long term will AVCT tech have. For instance I can't see 10 years ahead in this science, can anyone? So, the risks now have increased for me. How long I will keep this stock at all will probably be determined over the next few months. (I may trade of course if the opportunity presents itself but I agree the likely best scenario is likely to be a relatively low take out price. (hence why I still have some stock holding) imo dyor etc",
          "sentiment": 0.0,
          "engagement": "12,177",
          "price_at_post": "54.00",
          "thread_title": "RE: My opinion is",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=53B570CF-DF6D-4A07-A8F0-00C9BD609ABE"
        },
        "ingested_at": "2026-01-21T03:30:18.691699Z"
      },
      {
        "event_id": "SOCIAL-20Jan20260954-Icecool--9185516",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:14.617323",
        "source": "LSE_CHAT",
        "data": {
          "author": "Icecool",
          "content": "\u201cNow here it is in black and white. CC has said that 6000 will only be developed in a partnership.\u201d That\u2019s been clear since the 19th of December. It makes the most strategic sense. Package up the Asset and license it off. That\u2019s a massive boost to the LTH as running an orphan phase 2 solo indication, would be a complete waste of resources!!",
          "sentiment": 0.0,
          "engagement": "8,802",
          "price_at_post": "54.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T03:30:18.691673Z"
      },
      {
        "event_id": "SOCIAL-20Jan20261003-pedrolan-50177285",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:14.616898",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Literally nobody cares about your opinion Wyn.",
          "sentiment": 0.0,
          "engagement": "1,936",
          "price_at_post": "54.00",
          "thread_title": "RE: My opinion is",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=53B570CF-DF6D-4A07-A8F0-00C9BD609ABE"
        },
        "ingested_at": "2026-01-21T03:30:18.691648Z"
      },
      {
        "event_id": "SOCIAL-20Jan20261008-Livedata--6731231",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:14.616492",
        "source": "LSE_CHAT",
        "data": {
          "author": "Livedataaccount",
          "content": "I will accept your apology in the form of flowers chocolates or craft beer thank you",
          "sentiment": 0.0,
          "engagement": "2,949",
          "price_at_post": "54.00",
          "thread_title": "RE: Update  on 6103 please",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=A2B46A78-CAF6-42A7-B164-63C36C75DBEB"
        },
        "ingested_at": "2026-01-21T03:30:18.691622Z"
      },
      {
        "event_id": "SOCIAL-20Jan20261009-pedrolan--6874297",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:14.616068",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Just a reminder that Wyn/Touk/Thorn are the same poster who is not invested. He is just here to sow doubt on this Company.",
          "sentiment": 0.5,
          "engagement": "1,936",
          "price_at_post": "54.00",
          "thread_title": "Lord of the FUD",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=1D083E3C-47CE-4462-90BC-72508F10C286"
        },
        "ingested_at": "2026-01-21T03:30:18.691596Z"
      },
      {
        "event_id": "SOCIAL-20Jan20261015-Thompi--3750154",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:14.615655",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thompi",
          "content": "Touk, I think you\u2019re over-crediting your Mystic Meg abilities here. \u201cAvacta won\u2019t take 6000 into P2 \u2013 probably no one will\u201d is a judgement on AVA6000\u2019s viability as a Phase 2 asset. Management saying they would look to take it into Phase 2 with a partner is a funding and risk-sharing strategy. Those are different positions, and conflating them after the fact is rewriting the meaning of your original post. Which incidentally was the 20th December - fecking hell you don\u2019t half post a lot, it took some scrolling through.",
          "sentiment": 0.0,
          "engagement": "1,348",
          "price_at_post": "54.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T03:30:18.691570Z"
      },
      {
        "event_id": "SOCIAL-20Jan20261024-13thmonk--1739295",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:14.615244",
        "source": "LSE_CHAT",
        "data": {
          "author": "13thmonkey",
          "content": "So why are you asking here? The last update it could be inferred that they have submitted IND, until then there is nothing. So I ask are you confused about where you are and who you are talking to?",
          "sentiment": 0.0,
          "engagement": "2,494",
          "price_at_post": "54.00",
          "thread_title": "RE: Update  on 6103 please",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=A2B46A78-CAF6-42A7-B164-63C36C75DBEB"
        },
        "ingested_at": "2026-01-21T03:30:18.691543Z"
      },
      {
        "event_id": "SOCIAL-20Jan20261029-D-Geeman-43958244",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:14.614825",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "Morning Pedrolancaster, I personally know that your two recent posts are untrue so despite the recs I shall always take your opinions with a large pinch of salt.",
          "sentiment": 0.0,
          "engagement": "5,829",
          "price_at_post": "54.00",
          "thread_title": "RE: My opinion is",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=53B570CF-DF6D-4A07-A8F0-00C9BD609ABE"
        },
        "ingested_at": "2026-01-21T03:30:18.691518Z"
      },
      {
        "event_id": "SOCIAL-20Jan20261035-pedrolan-72717510",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:14.614408",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Morning D-G That is entirely your prerogative and I have no problem with that. What I will say is that even if they are not the same poster, they seem to be very highly connected, with a clear agenda and I have seen nothing to suggest otherwise.",
          "sentiment": 0.0,
          "engagement": "1,936",
          "price_at_post": "54.00",
          "thread_title": "RE: My opinion is",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=53B570CF-DF6D-4A07-A8F0-00C9BD609ABE"
        },
        "ingested_at": "2026-01-21T03:30:18.691492Z"
      },
      {
        "event_id": "SOCIAL-20Jan20261036-D-Geeman-31684294",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:14.613980",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "Fair enough Pedro. Good luck :-)",
          "sentiment": 0.0,
          "engagement": "5,829",
          "price_at_post": "54.00",
          "thread_title": "RE: My opinion is",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=53B570CF-DF6D-4A07-A8F0-00C9BD609ABE"
        },
        "ingested_at": "2026-01-21T03:30:18.691466Z"
      },
      {
        "event_id": "SOCIAL-20Jan20261037-Runner-R--7207320",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:14.613565",
        "source": "LSE_CHAT",
        "data": {
          "author": "Runner-Runner",
          "content": "\u201cThat\u2019s been clear since the 19th of December. It makes the most strategic sense. Package up the asset and license it off.\u201d Yes, that really is the nub of it. If they can do that, it would demonstrate a meaningful level of commercial nous. I would like to believe they are capable of executing something along those lines, although I am starting to waver. The key question for me is timing. How long do you think they realistically have to secure a deal of that nature to keep things moving forward? Six months? A year? Longer? Or is it simply a case of raising dilutive cash for as long as necessary while discussions continue? Apologies to the board if this comes across as sour. It is not intended that way. But at some point, promise, words, and \u201congoing discussions\u201d do need to translate into something tangible. After ten years invested in Avacta, my own time and risk tolerance is inevitably thinner than it once was. Others will be in a different position, which is entirely fair. We live in hope.",
          "sentiment": 0.0,
          "engagement": "697",
          "price_at_post": "54.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T03:30:18.691438Z"
      },
      {
        "event_id": "SOCIAL-20Jan20261042-pedrolan-66322768",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:14.613093",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Runner-Runner - I think that is how a lot of us feel, especially those that have been in that long (I am in that camp sadly!)",
          "sentiment": 0.0,
          "engagement": "1,936",
          "price_at_post": "54.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T03:30:18.691412Z"
      },
      {
        "event_id": "SOCIAL-20Jan20261050-BuenaVis-30619007",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:10.126657",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Crude 'Trader' = Rainbow 'Trader' = Rainbow Chaser https://www.lse.co.uk/profiles/crudetrader/",
          "sentiment": 0.0,
          "engagement": "5,701",
          "price_at_post": "54.00",
          "thread_title": "RE: Jam tomorrow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=53FD148E-604E-4CB6-BA57-5482DA3F76C1"
        },
        "ingested_at": "2026-01-21T03:30:18.691386Z"
      },
      {
        "event_id": "SOCIAL-20Jan20261051-wyndrum--3493328",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:10.126245",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "Pedo, how is what RR says different in essence (maybe tone for sure), to what I have said? You agree with him that you live in hope on this stock. That is not an investment strategy. My posts come from that direction. Will I make money by buying this stock? could I better returns elsewhere? Those are the only questions, after your research, that should be asked and answered. One fine day you will get it that to continually question the risks the individual takes by running their own portfolio without likely any training or experience in doing so is prudent and is not Fud, or any other invented idea you have to try and discredit views you don't agree with. The absurdity of your position is that you continually attack the character rather than the thoughts of the poster.",
          "sentiment": 0.0,
          "engagement": "12,177",
          "price_at_post": "54.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T03:30:18.691360Z"
      },
      {
        "event_id": "SOCIAL-20Jan20261052-Icecool--1469796",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:10.125806",
        "source": "LSE_CHAT",
        "data": {
          "author": "Icecool",
          "content": "TNBC data and maturing PFS are the leverage points. That\u2019s it. That\u2019s what sets deal value for AVA6000. If Avacta needs to raise more cash to reach those inflection points, so be it. Dilution to secure better terms later beats panic selling AVA6000 cheap now. The science works. The platform is validated in humans. That debate is over. What we\u2019re watching now is value maximisation, not scientific risk. People losing patience because deals aren\u2019t landing on their preferred timeline are confusing frustration with failure. AVA6000 is doing exactly what it was designed to do, let\u2019s be clear it hasn\u2019t failed or underperformed. It\u2019s perfectly packaged for a partnership. That is now the correct strategy moving forward.",
          "sentiment": 0.0,
          "engagement": "8,802",
          "price_at_post": "54.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T03:30:18.691334Z"
      },
      {
        "event_id": "SOCIAL-20Jan20261056-pedrolan--4692500",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:10.125378",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "I will not engage with you Wyn other than to say he is a genuine investor and you are a manipulative trader. That's why I can identify with a lot of his post. You and your cohorts will be wasting your time trying to goad me further. I have no doubt you will all continue to try though. All part of your modus operandi.",
          "sentiment": 0.0,
          "engagement": "1,936",
          "price_at_post": "54.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T03:30:18.691308Z"
      },
      {
        "event_id": "SOCIAL-20Jan20261057-Matml74--6484789",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:10.124956",
        "source": "LSE_CHAT",
        "data": {
          "author": "Matml74",
          "content": "There is only ever one reason to invest in a biotech company and that is for the huge returns that M&A can produce in this sector. It is never a quick process and your capital will always be tied up for an extended period of time. Avacta has a strong hand with it\u2019s tech now proven in human and a strong pipeline following ava6000. The hard work is done. The company will be bought out. Simple.",
          "sentiment": 0.0,
          "engagement": "2,526",
          "price_at_post": "54.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T03:30:18.691282Z"
      },
      {
        "event_id": "SOCIAL-20Jan20261059-Timster-75619777",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:10.124543",
        "source": "LSE_CHAT",
        "data": {
          "author": "Timster",
          "content": "100% runner-rumner",
          "sentiment": 0.0,
          "engagement": "20,613",
          "price_at_post": "54.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T03:30:18.691256Z"
      },
      {
        "event_id": "SOCIAL-20Jan20261106-BuenaVis--4867607",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:10.124136",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Peel Hunt seems to have been dropped as both nomad and broker.  New nomad is Strand Hanson: https://www.strandhanson.co.uk/about I don't know what this means but I am impressed with the layout and clarity of today's year-end trading update (see here for RNS with active links: https://www.londonstockexchange.com/news-article/AVCT/year-end-trading-update/17421159 ). And I only noticed one typo, in the very last sentence!",
          "sentiment": 0.0,
          "engagement": "5,701",
          "price_at_post": "54.00",
          "thread_title": "New nomad",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=829C4218-D6AF-422B-A1D4-DAD3159CCA3A"
        },
        "ingested_at": "2026-01-21T03:30:18.691231Z"
      },
      {
        "event_id": "SOCIAL-20Jan20261121-avctIPma-18978035",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:10.123702",
        "source": "LSE_CHAT",
        "data": {
          "author": "avctIPmatters",
          "content": "Good RNS  update   No real surprises     interesting choice of  Nominated Adviser https://www.strandhanson.co.uk/ ( Maybe move AVCT to LSE main market as first step ?) Avacta   management   keeping   a tight  hold of the IP assets  :  OK by me ,  just as well not in any rush for an investment return. \"U.S. clinical trial specialty centers are expected to open imminently\"   next  inflection point . Review position in June ,  meantime  life goes on . Good luck everyone Gmcc \" Outlook for 2026 \u00b7 Faridoxorubicin (AVA6000) program. Multiple data updates in both patient groups, with salivary gland cancers and with triple negative breast cancer updates expected in H1 2026. \u00b7 Beginning of the FAP-Exd (AVA6103) clinical testing expected in Q1 2026. A group of U.S. clinical trial specialty centers are expected to open imminently with key investigators of different specialties to enroll the four selected tumor types: pancreatic cancer, gastric cancer, small cell lung cancer and cervical cancer. Preliminary data from this trial is anticipated in the second half of 2026. \u00b7 Continued active interaction with potential partners regarding both faridoxorubicin (AVA6000) and FAP-Exd (AVA6103). The survival data in the SGC indication continues to mature, allowing planning of the next stage of development with potential partners (link). The initiation of the FAP-Exd clinical trial continues to be of interest in the market.\"",
          "sentiment": 0.0,
          "engagement": "711",
          "price_at_post": "53.00",
          "thread_title": "Outlook for 2026",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=CFDC72F5-21C6-43AF-9CCD-B90BDBA0D9D2"
        },
        "ingested_at": "2026-01-21T03:30:18.691205Z"
      },
      {
        "event_id": "SOCIAL-20Jan20261131-HarChris-53475936",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:10.123247",
        "source": "LSE_CHAT",
        "data": {
          "author": "HarChris",
          "content": "It's worth remembering on a day like today that the vast majority of shares are down as the markets wobble over Trump's ever more erratic world domination threats. Today's update could well have wrestled the price back in the positive direction if it wasn't delivered into such a market.",
          "sentiment": 0.0,
          "engagement": "15,784",
          "price_at_post": "53.00",
          "thread_title": "RE: New nomad",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=829C4218-D6AF-422B-A1D4-DAD3159CCA3A"
        },
        "ingested_at": "2026-01-21T03:30:18.691179Z"
      },
      {
        "event_id": "SOCIAL-20Jan20261134-Viking.R-49909701",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:10.122823",
        "source": "LSE_CHAT",
        "data": {
          "author": "Viking.Raider",
          "content": "So the never ending trial for AV6k continues after 5 years get the company sold and let\u2019s all move on.",
          "sentiment": 0.0,
          "engagement": "413",
          "price_at_post": "53.00",
          "thread_title": "Jam tomorrow",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=75A618AF-C5E2-4F1A-ADB4-25B1BA51736D"
        },
        "ingested_at": "2026-01-21T03:30:18.691153Z"
      },
      {
        "event_id": "SOCIAL-20Jan20261136-Thornogs--1085056",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:10.122418",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "The 'three Amigo's' take on things is broadly similar, so what? Do we suggest that Tim, ICE, Watching and Sheppy are the same person? The accusation says more about the insecurity of the poster than anything else?",
          "sentiment": 0.0,
          "engagement": "8,545",
          "price_at_post": "53.00",
          "thread_title": "RE: My opinion is",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=53B570CF-DF6D-4A07-A8F0-00C9BD609ABE"
        },
        "ingested_at": "2026-01-21T03:30:18.691126Z"
      },
      {
        "event_id": "SOCIAL-20Jan20261137-wyndrum--8056738",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:10.121987",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "No pedro, you always have your little get-out clause to any inconvenient post \"I won't engage\". Well, fine so stop posting lies and insults about me. If you would stop engaging then the whole BB  would benefit. But you won't of course because all you want to do is disrupt. Your hypocrisy is monumental",
          "sentiment": 0.0,
          "engagement": "12,177",
          "price_at_post": "53.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T03:30:18.691083Z"
      },
      {
        "event_id": "SOCIAL-20Jan20261140-Biggi--1876856",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:10.121569",
        "source": "LSE_CHAT",
        "data": {
          "author": "Biggi",
          "content": "I don't partake in this broad largely as a result of you Wyn. You have very little faith in AVCT and you suggest you can make more money elsewhere, yet here you are, always... It's total nonsense and a waste of time.  You either can't follow your own advice or you're a complete wind up. Either way you always seem to be here and it's just really sad to watch. Bye for another few weeks.",
          "sentiment": 0.0,
          "engagement": "41",
          "price_at_post": "53.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T03:30:18.691057Z"
      },
      {
        "event_id": "SOCIAL-20Jan20261146-Bella653-51095778",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:10.121164",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "'program continued to enroll patients in the phase 1b expansion cohorts, to assess the efficacy of faridoxorubicin in more ****genous, defined patient populations to better predict the magnitude of efficacy anticipated in larger phase 2/3 trials. ' imo...they have a partner....they are still too confident re funding.  us is now hands off...deferred payments of loan with clause which basically allows reversal if a deal falls through...bryant was brought in to help close such a deal...",
          "sentiment": 0.0,
          "engagement": "6,729",
          "price_at_post": "53.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T03:30:18.691031Z"
      },
      {
        "event_id": "SOCIAL-20Jan20261149-PL75-30867322",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:10.120737",
        "source": "LSE_CHAT",
        "data": {
          "author": "PL75",
          "content": "The RNS was in line with my expectations as that's what I said, nowt until H2.  They'll want the beast in the clinic and evidence it's working before flogging off ava6k as the worst case is that the beast flops and they're left with little.  They'll raise again with the group of chums and then we really find out what big farmer thinks and hopefully won't look back.  It comes down to the science, they have unique valuable tech.  They're not flogging it too early, they're still following the Prometheus playbook and that works for me.",
          "sentiment": 0.0,
          "engagement": "11,223",
          "price_at_post": "53.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T03:30:18.691005Z"
      },
      {
        "event_id": "SOCIAL-20Jan20261152-D-Geeman-50857634",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:10.120328",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "'they have a partner' is very important SP changing news that they'd have to release, which they haven't done.",
          "sentiment": 0.0,
          "engagement": "5,829",
          "price_at_post": "53.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T03:30:18.690980Z"
      },
      {
        "event_id": "SOCIAL-20Jan20261159-Cashless-17902815",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:10.119905",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cashless",
          "content": "YET!!!",
          "sentiment": 0.0,
          "engagement": "392",
          "price_at_post": "53.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T03:30:18.690954Z"
      },
      {
        "event_id": "SOCIAL-20Jan20261202-B2HS2L--6661791",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:10.119499",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "Bella, The RNS also contains this: \"There are no other technologies that can deliver cancer treatment drugs directly into the tumor at the concentrations that our payloads enable without causing highly toxic side effects.\" This is a come on directly from the CEO, to enter or progress discussions with Avacta Business Developers, and not necessary if they had a chosen suitor.",
          "sentiment": 0.0,
          "engagement": "5,977",
          "price_at_post": "53.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T03:30:18.690928Z"
      },
      {
        "event_id": "SOCIAL-20Jan20261208-wyndrum-52176033",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:10.119067",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "My \"faith\" biggi, does not affect my investment decisions. I have traded this stock successfully for over 4 years (it took about 6 months for me to realise a: it was in fact tradeable and b:that results did not match the BoD's hype. Thats why i have stayed here. I make money on this stock. Also I find it illuminating into this part of the human psyche the thoughts and reasoning of posters here.",
          "sentiment": 0.0,
          "engagement": "12,177",
          "price_at_post": "53.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T03:30:18.690900Z"
      },
      {
        "event_id": "SOCIAL-20Jan20261227-HarChris--4109317",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:10.118644",
        "source": "LSE_CHAT",
        "data": {
          "author": "HarChris",
          "content": "You might not be losing as much as long term holders stubbornly holding through thick and thin but i'm struggling to see where your recent successes are coming from? I remember you were averaging up all the way through to those p1b results and now you've been selling down as it falls whilst still holding on to a portion. These last few months can't have been particularly profitable for you? No dig just curious. I assume many sold out after Christina's uncharacteristic presentation on the 17th December but that felt at the time the pivot/change of momentum if anything, not 6 weeks later and 30% lower.",
          "sentiment": 0.0,
          "engagement": "15,784",
          "price_at_post": "53.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T03:30:18.690874Z"
      },
      {
        "event_id": "SOCIAL-20Jan20261246-Knotagai-37972219",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:10.118228",
        "source": "LSE_CHAT",
        "data": {
          "author": "Knotagain",
          "content": "Another great RNS, another SP fall, another day of FUD. Cc - \"We are incredibly excited for the year ahead which the board believes will be a transformative period for the Company, patients and our shareholders\" It's very simple, you either believe her or you don't. Ignore the FUD.",
          "sentiment": 0.0,
          "engagement": "447",
          "price_at_post": "53.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T03:30:18.690848Z"
      },
      {
        "event_id": "SOCIAL-20Jan20261258-wyndrum--1217729",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:10.117788",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "Chris, Just the very brief highlights: I bought heavily when the SP(years ago was 102p and stated that) and with a bit of trading in between ended up with 77000 shares which I sold down from 256p ( I almost always hold a portion in case of the mythical RNS drop.) When it collapsed into the 40's I bought there and more in the 50's and 60's and sold down from 100p with the last tranche in the 70s. Most recently I bought again at 32p and added in the 40s again with some trading in between and have been selling down from the 70's and 50's. I have been very, very active at various times in this stock and not all successfully, obviously, however I have ended up with a success rate of around 60/70% correct calls. Some with just a few thou on the table sometimes tens of thousands. (Its not always that much, \u00a310% of \u00a35k is only \u00a3500 profit) I never bet the house in one trade and in this stock I invariably keep some in hand although last year for a while I was completely out. I can see that happening again. Every trade I make stands on its own. I don't care if when I sell I have made, after costs only a few %. I try to avoid losses as much as possible. Often when there is a pull back if it gets close to my buy in, I bank the profit however small. keeping my capital intact as much as I can given the risk is my paramount aim. I see the year as successful if after everything in every trade in every stock (and there are many!), I am up by more than 5% as that is roughly the alternative in a savings account, so my ambition is small, but the strategy has provided more than that over the years. The less I care about big wins and keep scalping here and there, helps remove the emotional attachment and therefore aids me in my decision making. As you can read here I have gotten under the skin (unfortunately) of what seems to be the majority here and that is due not to me (a stranger) but the individuals emotional attachment to their own decision making. (That emotional anger needs venting and releasing and it has to go somewhere!) (Thats why social media is such a cess pit imo, there are a lot of unhappy people with their lives and decisions, and take it out on others because there is no comeback. Do you know any happy people who routinely spout bile and insults at strangers without even having the facts or correct info?) (I guess i am doing a social service to people here on the board? :0))",
          "sentiment": 0.0,
          "engagement": "12,177",
          "price_at_post": "53.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T03:30:18.690822Z"
      },
      {
        "event_id": "SOCIAL-20Jan20261307-cj62--5283732",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:10.117334",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "Bravo wyndrone you appear to be the next Warren B. Now you narcissistic half wit  can you go elsewhere. I bought nvidia at $56 and sold them $1220 and I had a lot of them Am I better than you ?",
          "sentiment": 0.0,
          "engagement": "4,261",
          "price_at_post": "53.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T03:30:18.690796Z"
      },
      {
        "event_id": "SOCIAL-20Jan20261314-Thornogs-14832023",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:10.116899",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "One by one the 'well informed' pillars of knowledge and reassurance crumble to dust? 'It Works!' - hmm perhaps in a rather limited sort of way? '\u00a3200 ex-Chinar!' - hmm, clearly not yet. 'Holy Grail!' and 'Vesicant!'  - again sadly not. Even the old standby 'Thick as mince' appears to apply more to them now than the wider Market and Investment community.. Time for a re-think perhaps. We wait for FAP-EXD. We wait to see how it'll be paid for. We start again.",
          "sentiment": 0.0,
          "engagement": "8,545",
          "price_at_post": "53.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T03:30:18.690770Z"
      },
      {
        "event_id": "SOCIAL-20Jan20261315-avctIPma-25592000",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:10.116428",
        "source": "LSE_CHAT",
        "data": {
          "author": "avctIPmatters",
          "content": "Strand Hanson Limited (Nominated Adviser) James Harris / Chris Raggett / James Dance Meet the new team page 13 ------Seem to be well versed in M & A. -------------------- https://cdn.prod.website-files.com/6703111b1e323aa38a8950bb/6836481d9188f66f12405c1b_StrandHanson-Brochure%20_%20May%202025_spreads.pdf James Harris Director, Head of Corporate James has over 25 years investment banking experience, having worked at Robert Fleming, Soci\u00e9t\u00e9 G\u00e9n\u00e9rale and Arbuthnot Securities, before joining the corporate finance team at Strand Hanson in 2004. James acts as lead adviser to a broad range of domestic and international clients, covering IPOs and secondary fund raisings, restructurings and Mergers & Acquisitions Christopher Raggett Director, Corporate Finance Christopher has over 15 years of experience in energy and corporate finance. Prior to joining Strand Hanson, Christopher was CEO of UK based incubator fund, Green House Capital Group. Until September 2023, he sat on the executive committee of finnCap Group plc \u2013 an AIM quoted financial services firm incorporating capital markets, M&A, private capital and debt advisory services \u2013 where he was also Head of Energy and Natural Resources and Co-Head of Corporate Finance. Prior to joining finnCap, Christopher was a solicitor at a multinational US-based law firm. In September 2022, Christopher was appointed to the board of net-zero energy consultancy, Energise Ltd. James Dance Director, Head of Mergers & Acquisitions James graduated from Bristol University, in June 2006, with a BSc Honours in Biochemistry. After graduation, James joined Smith & Williamson where he qualified as a chartered accountant in 2009. He then moved into Transaction Services, gaining experience in financial modelling and valuation, followed by two years in the Corporate Finance department. James is a CFA charterholder and a member of the CFA Society United Kingdom. James joined Strand Hanson in December 2012.\" Gmcc",
          "sentiment": 0.0,
          "engagement": "711",
          "price_at_post": "53.00",
          "thread_title": "Strand Hanson Limited (Nominated Adviser)",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=FF9AC10A-1584-4C66-9FEC-F6165AB8D0D8"
        },
        "ingested_at": "2026-01-21T03:30:18.690745Z"
      },
      {
        "event_id": "SOCIAL-20Jan20261315-HarChris-17594532",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:06.093651",
        "source": "LSE_CHAT",
        "data": {
          "author": "HarChris",
          "content": "Fab results Wyn! I only ask because I like to keep tabs on how you\u2019re doing. You said things like \u2018\u2019the fact that I have been buying all the way up from 32p\u2019 on Nov 14th as AVCT hit 80p made me think you were also buying far higher and following the trend (instead of trading) but obviously not. Or when you said \u2018I did top up at just under 79p on Friday\u2019 17th Nov, it again suggested you weren\u2019t trading but averaging up and up as you were predicting 106p. I\u2019ve got loads more but I won\u2019t bother sharing because they were obviously trades and you made money form most of them - again well done, it ain\u2019t easy making money on this atm, I\u2019m sure you\u2019re one of the most successful!!!",
          "sentiment": 0.0,
          "engagement": "15,784",
          "price_at_post": "53.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T03:30:18.690719Z"
      },
      {
        "event_id": "SOCIAL-20Jan20261343-pedrolan--2348729",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:06.093232",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Don't be spoiling his fantasy trading game with facts now Chris. That won't do at all!",
          "sentiment": 0.0,
          "engagement": "1,936",
          "price_at_post": "53.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T03:30:18.690693Z"
      },
      {
        "event_id": "SOCIAL-20Jan20261344-wyndrum--4874727",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:06.092812",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "You are right chris I  did buy (top up) (\u00a32k) at 79p and  got out with less than 3% loss. (I said I have 3-4 losses in every 10) Over all that tranche of buying was successful. However you are very sceptical of my record so I don't think there is much point continuing this point. I have done fine with AVCT, you don't believe. I really don't care.  (And nor does anybody else.)  But it was you that asked, not me.",
          "sentiment": 0.0,
          "engagement": "12,177",
          "price_at_post": "53.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T03:30:18.690667Z"
      },
      {
        "event_id": "SOCIAL-20Jan20261348-Livedata-15546689",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:06.092392",
        "source": "LSE_CHAT",
        "data": {
          "author": "Livedataaccount",
          "content": "Wyndrum I hope your trades have gone well as I do for all on this board however I did a little faith in you when you pretended to  be getting a plane a while back i must admin i found that behaviour very odd",
          "sentiment": 0.0,
          "engagement": "2,949",
          "price_at_post": "53.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T03:30:18.690641Z"
      },
      {
        "event_id": "SOCIAL-20Jan20261352-D-Geeman--2265435",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:06.091964",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "Hi Wyn, I've read HC's post a few times and I think he's being geniune, except he has 9 recs which seams unlikey if he's he's really pleased for you..",
          "sentiment": 0.0,
          "engagement": "5,829",
          "price_at_post": "53.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T03:30:18.690615Z"
      },
      {
        "event_id": "SOCIAL-20Jan20261355-Icecool-67074460",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:06.091551",
        "source": "LSE_CHAT",
        "data": {
          "author": "Icecool",
          "content": "Oh yeah the \u2708\ufe0f incident where Thorn replied as Wyn accidentally on the wrong account absolutely hilarious, that\u2019s when I had dumb and dumber off Green. \ud83e\udd23\ud83e\udd23",
          "sentiment": 0.0,
          "engagement": "8,802",
          "price_at_post": "53.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T03:30:18.690589Z"
      },
      {
        "event_id": "SOCIAL-20Jan20261358-Thornogs-86172062",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:06.091143",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Nonsense upon nonsense ICE. I'd focus on the 'fundamentals here if I were you. They look to be changing all the time. Not a great feature in 'fundamentals'.",
          "sentiment": 0.0,
          "engagement": "8,545",
          "price_at_post": "53.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T03:30:18.690563Z"
      },
      {
        "event_id": "SOCIAL-20Jan20261407-wyndrum--3602828",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:06.090710",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "LDA, I don't know what you are referring to? (I fly out 2-3 times a year on holiday.) I'm not sure why you use the word \"pretend\", but as I say I don't know what you are talking about. As for ice he is simply an idiot if he thinks I have any multiple accounts. This whole \"multiple account\" thing is a very convenient way of trying to discredit views others disagree with. I am not Thorn or DG or anyone else. I have only ever had 1 account. If any wish to perpetuate this then its your problem not mine. (I seem to recall Thorn was incredibly bullish until recently, yet I remained cautious all the way through. His writing style is completely different, so different views, different styles plus I know for a fact I am right and you are wrong about multiple log-ins, but wait... hold the front page...none of that will change a single mind here which is a testement to the narrow-minded, myopic view and reasoning of so many here.)",
          "sentiment": 0.0,
          "engagement": "12,177",
          "price_at_post": "53.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T03:30:18.690537Z"
      },
      {
        "event_id": "SOCIAL-20Jan20261408-D-Geeman--7957741",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:06.090275",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "In a major diplomatic coup that should keep almost everyone happy I sold 30% of my AVCT (set a sell order at 7.35am for 50p) and it went through at 55p just after 8am. And then I put most into Wood Group for a more-or-less guaranteed 13% so long I stick with it.",
          "sentiment": 0.0,
          "engagement": "5,829",
          "price_at_post": "53.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T03:30:18.690510Z"
      },
      {
        "event_id": "SOCIAL-20Jan20261416-wyndrum--2730517",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:06.089852",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "CH, is D right? Did I read sarcasm in your post  when you were congratulating my trading record incorrectly?",
          "sentiment": 0.0,
          "engagement": "12,177",
          "price_at_post": "53.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T03:30:18.690483Z"
      },
      {
        "event_id": "SOCIAL-20Jan20261417-Toukanka-69408548",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:06.089440",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "I\u2019m not as downbeat as Wyndrum because it\u2019s been on the cards since 2Q25 when there was a huge shift towards 6103. Little news then leading up to what was supposed to be pivotal announcements before year end and CC\u2019s terrible presentation appearing to kick the can down the road on 6000 yet again. For me that confirmed my prediction of June at earliest for 6000 results that would secure an acceptable deal alongside initial 6103 results that will be the pivotal moment. So I had already resigned myself to a 6 months wait during which there will probably be ample opportunity to buy more shares if I want to. But seriously now I don\u2019t think I will buy any more the risk reward balance has changed due to today\u2019s RNS. GOOD LUCK ALL",
          "sentiment": 0.0,
          "engagement": "4,427",
          "price_at_post": "53.00",
          "thread_title": "RE: My opinion is",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=53B570CF-DF6D-4A07-A8F0-00C9BD609ABE"
        },
        "ingested_at": "2026-01-21T03:30:18.690457Z"
      },
      {
        "event_id": "SOCIAL-20Jan20261418-Bella653-34808230",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:06.089008",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "D-Geeman...'they have a partner' is very important SP changing news that they'd have to release, which they haven't done'   They only have to announce once the deal is signed.",
          "sentiment": 0.0,
          "engagement": "6,729",
          "price_at_post": "53.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T03:30:18.690431Z"
      },
      {
        "event_id": "SOCIAL-20Jan20261423-D-Geeman-78285888",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:06.088601",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "Bella, my computer is very slow today so I won't scroll back but I think you wrote 'imo.. they have a partner'. We are led to believe by CC herself that they are talking to multiple potential partners (wouldn't mean much on a dating site) but if they HAVE a partner then CC would presumably be breaking disclosure rules by keeping it quiet. That's what I meant.",
          "sentiment": 0.0,
          "engagement": "5,829",
          "price_at_post": "53.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T03:30:18.690404Z"
      },
      {
        "event_id": "SOCIAL-20Jan20261430-Bella653--7929554",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:06.088186",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "B2...they want a Partner for AVA6000 and the rest of the pipeline will be Licence deals.  They've proved PreCision works...that's all they needed to do with AVA6000.  It's not about the payload, it's about Precision.   Avacta is a small R&D company...they want to develop new pipeline products...secure the IP etc...they want to create value through product development and licencing.  The big bucks only come into play when a Big Pharma looks at the R&D/pipeline work to date and sees long term big bucks for themselves and means full blown T/O not buying or Licencing the odd product.",
          "sentiment": 0.0,
          "engagement": "6,729",
          "price_at_post": "53.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T03:30:18.690378Z"
      },
      {
        "event_id": "SOCIAL-20Jan20261432-Bella653--7558788",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:06.087764",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "Knotagain...the markets only see the money side...cash runway into Q3 just doesn't look good right now. Why didn't they opt for a bigger fundraise last time round if it was over subscribed????",
          "sentiment": 0.0,
          "engagement": "6,729",
          "price_at_post": "53.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T03:30:18.690352Z"
      },
      {
        "event_id": "SOCIAL-20Jan20261438-Icecool--4513131",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:06.087349",
        "source": "LSE_CHAT",
        "data": {
          "author": "Icecool",
          "content": "\u201cWhy didn't they opt for a bigger fundraise last time round if it was over subscribed???\u201d Expect more small, private raises imo. That\u2019s not weakness, it\u2019s strategy. Raise the absolute minimum, extend runway, collect more data, increase leverage. Rinse, repeat. The goal is not to pump the AIM share price. The goal is to force better commercial terms. Data is leverage, dilution without leverage is stupidity. Long term, this is exactly how you maximise value. Short term, it\u2019s going to be volatile as hell and anyone obsessing over daily ticks is going to suffer big time. \ud83e\udd23\ud83e\udd23\ud83d\udcaf",
          "sentiment": 0.0,
          "engagement": "8,802",
          "price_at_post": "52.50",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T03:30:18.690326Z"
      },
      {
        "event_id": "SOCIAL-20Jan20261447-Bella653--3523995",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:06.086914",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "I guess Zeus brought SHL to the table...see Enwell Energy, Jersey OIl & Gas, Metal Tiger....both rep these companies.",
          "sentiment": 0.0,
          "engagement": "6,729",
          "price_at_post": "52.50",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T03:30:18.690300Z"
      },
      {
        "event_id": "SOCIAL-20Jan20261455-wyndrum-74632305",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:06.086503",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "\"Data is leverage, dilution without leverage is stupidity. Long term, this is exactly how you maximise value. Short term, it\u2019s going to be volatile as hell and anyone obsessing over daily ticks is going to suffer big time. \ud83e\udd23\ud83e\udd23\ud83d\udcaf\" Why would the SP be volatile in the short term as more data is released as its the data that is  going to maximise value? Surely the SP should just carry on rising. Like today for instance. Surely the volatility will only be produced directly because of ambiguous and uncertain data? And also, how long is long term (AVCT as a plc is 20 years old)? 1 year ago the SP was 50p 5 yrs ago the SP was 150p 10 years ago it was 125p All that data, all that volatility in between, and this now trading close to all time lows. But yeah, its the market that been wrong for 20 years with  their short-term outlook and not understanding the data",
          "sentiment": 0.0,
          "engagement": "12,177",
          "price_at_post": "53.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T03:30:18.690274Z"
      },
      {
        "event_id": "SOCIAL-20Jan20261503-pedrolan--5900599",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:06.086037",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Yes, it would appear there was an appetite for the last raise so that would seem to be the strategy Ice. Only raise small amounts if needed. Makes sense, if there is something on the horizon.",
          "sentiment": 0.0,
          "engagement": "1,936",
          "price_at_post": "53.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T03:30:18.690248Z"
      },
      {
        "event_id": "SOCIAL-20Jan20261526-Icecool-29907310",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:06.085626",
        "source": "LSE_CHAT",
        "data": {
          "author": "Icecool",
          "content": "\ud83e\udd14\ud83e\udd14 If Avacta is now positioning the entire AVA6000 program for licensing rather than cherry picking one or two indications, that actually makes perfect strategic sense. Any serious pharma buyer will want to see early TNBC data first before a deal is struck. TNBC is dox sensitive, commercially meaningful, and acts as the anchor indication. Once that box is ticked, the rest of the program gets valued as a package, not just on an orphan indication\u2019s. This pivot doesn\u2019t happen unless management is confident in the platform. You don\u2019t move to a whole asset sale if you\u2019re unsure the engine works. Yes, if negotiations drag, expect a small bridging raise as I suggested last post. That\u2019s just leverage management. But the long term funding path is clear, monetise AVA6000 fully sell that asset, fund the platform, and move forward.",
          "sentiment": 0.0,
          "engagement": "8,802",
          "price_at_post": "53.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T03:30:18.690222Z"
      },
      {
        "event_id": "SOCIAL-20Jan20261526-BuenaVis--3144945",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:06.085189",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Maybe Peel Hunt have been ditched because they are leaky and SH engaged to be tighter-lipped for any placings.",
          "sentiment": 0.0,
          "engagement": "5,701",
          "price_at_post": "53.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T03:30:18.690196Z"
      },
      {
        "event_id": "SOCIAL-20Jan20261535-wyndrum-18049108",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:06.084759",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "Pedro, how about this as an alternative, seeing as RH is pretty savvy, he says to his pals \"ask for more stock,, You wont get it but it lwill allow us to say it is over subscribed which increases the chances for you for a spike in the SP so you make more money? (Given the SP has fallen way below the offer price of last year suggests to me there is little appetite currently in this stock.) Some of you can't wait to say how I try and manipulate the stock which with all our piddling amounts we can't even if we wanted to, but the big players get a free pass from you as though they are only paragons of virtue. It was the head of AVCT (AS at the time) who smiled and said don't worry about finding. You all seemed to be shocked after the event yet none of you saw it coming? You seem to go out of your way for positive bias. Where has it got you? Do you ever learn from experience?",
          "sentiment": 0.0,
          "engagement": "12,177",
          "price_at_post": "53.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T03:30:18.690170Z"
      },
      {
        "event_id": "SOCIAL-20Jan20261535-B2HS2L-70900703",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:06.084330",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "I thought Michael Vinegrad carried that can, but maybe they wanted to save his salary. Agree, SH may be tighter lipped.",
          "sentiment": 0.0,
          "engagement": "5,977",
          "price_at_post": "53.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T03:30:18.690144Z"
      },
      {
        "event_id": "SOCIAL-20Jan20261550-pedrolan-80456155",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:06.083891",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "For sure PH were leaky.",
          "sentiment": 0.0,
          "engagement": "1,936",
          "price_at_post": "53.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T03:30:18.690108Z"
      },
      {
        "event_id": "SOCIAL-20Jan20261550-Thornogs-15130829",
        "event_type": "social_post",
        "date": "2026-01-21T03:30:06.083454",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Bella, of course it's about the payload it's a 'deliver platform', delivering....... a payload! If the payload isn't delivered adequately, for whatever reason then the delivery platform has conspicuously failed to do what they set out to prove that it could do. To date there is no good data to show that Pre|Cision works. Hence no deals after nearly 5 years.",
          "sentiment": 0.0,
          "engagement": "8,545",
          "price_at_post": "53.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6809BF29-D21C-45CA-BAAE-BDADFA8E17A9"
        },
        "ingested_at": "2026-01-21T03:30:18.690070Z"
      },
      {
        "event_id": "SOCIAL-23Jan20262219-Thornogs--7790267",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.801399",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Anything new there? 'Expected' Q1? No, nothing new, just 'same old'.",
          "sentiment": 0.0,
          "engagement": "8,596",
          "price_at_post": "54.50",
          "thread_title": "RE: Bioconjugate Insights",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0DCD83D9-A17D-43E1-842E-1C922D520A76"
        },
        "ingested_at": "2026-01-24T02:51:17.818917+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20262212-avctIPma-45844743",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.801859",
        "source": "LSE_CHAT",
        "data": {
          "author": "avctIPmatters",
          "content": "Again courtesy of Stonks -  Finds  new coverage  Avacta related   many thanks . https://cdn.insights.bio/uploads/attachments/BCI%20Industry%20Insights.pdfAvacta Therapeutics reported new preclinical pharmacology data for FAP-Exd peptide drug conjugate [25] \"Avacta Therapeutics announced new preclinical pharmacology data for FAP-Exd (AVA6103), its second asset derived from the pre|CISION\u00ae tumor-activated delivery platform, which is expected to enter Phase 1 testing in Q1 2026. FAP-Exd is a fibroblast activation protein\u2013cleavable peptide-drug linking a proprietary peptide to a topoisomerase I inhibitor payload. The data demonstrated tumor-specific cytotoxicity, sustained intratumoral release of active exatecan with limited systemic exposure, and robust antitumor activity across multiple patient-derived xenograft models. Avacta also reported that artificial intelligence\u2013guided analysis was used to prioritize clinical indications based on co-expression of FAP and SLFN11.\" Gmcc",
          "sentiment": 0.0,
          "engagement": "720",
          "price_at_post": "54.50",
          "thread_title": "Bioconjugate Insights",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0DCD83D9-A17D-43E1-842E-1C922D520A76"
        },
        "ingested_at": "2026-01-24T02:51:17.818954+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20262210-Thornogs--6785083",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.802303",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Avacta does its thing regardless of what's posted here. Get over yourselves, self appointed \"Guardian's of the truth\"! And if you must wear your underpants on the outside do at least please ensure that  they're better laundered?",
          "sentiment": 0.0,
          "engagement": "8,596",
          "price_at_post": "54.50",
          "thread_title": "The reality?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=D8CC0643-0047-4DA0-A21A-3E0ECC3BD17C"
        },
        "ingested_at": "2026-01-24T02:51:17.818988+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20262154-BuenaVis-89696675",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.802718",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "I had Firefox nicely set up with AdBlock so that all ads were wiped out but had to 'repair' Firefox today (as tabs were crashing) and then reload an AdBlock extension but I now keep getting these annoying messages from LSE about ads that I never used to get.  Can't remember what I did before to permanently remove those messages.  Can anyone offer advice on how they've solved this?",
          "sentiment": 0.0,
          "engagement": "5,722",
          "price_at_post": "54.50",
          "thread_title": "Off-topic - removing ads on Firefox",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=9BE707F4-9555-444A-A3C8-1254E00A3443"
        },
        "ingested_at": "2026-01-24T02:51:17.819007+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20262109-Knotagai--1743631",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.803142",
        "source": "LSE_CHAT",
        "data": {
          "author": "Knotagain",
          "content": "All day every day...",
          "sentiment": 0.0,
          "engagement": "448",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-01-24T02:51:17.819025+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261944-Agenda10-63750034",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.803559",
        "source": "LSE_CHAT",
        "data": {
          "author": "Agenda101",
          "content": "Brilliant! The never ending Twats.. they are all green boxed here\u2026 But I\u2019m hearing you Sheepy! Exactly right.",
          "sentiment": 0.0,
          "engagement": "55",
          "price_at_post": "54.50",
          "thread_title": "RE: Frankly pathetic",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B36E2695-D07A-4E60-838B-02C995994856"
        },
        "ingested_at": "2026-01-24T02:51:17.819043+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261943-BuenaVis--8036670",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.803971",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Lighten up Thompi.  It's the best comedy show in town.",
          "sentiment": 0.0,
          "engagement": "5,722",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-01-24T02:51:17.819061+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261940-Thompi--2279869",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.804413",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thompi",
          "content": "Because, Touk, Thorn talks total twaddle and inundates this board with spam. It\u2019s made the board virtually unreadable. Even blocking him doesn\u2019t really help, because all I then see are green boxes and other people replying to his posts. I probably add to the noise at times too - but I\u2019ve genuinely had enough of one person commandeering the board with the same malicious rubbish, day after day. Post after post after post. It wears people down. It stops being discussion and just becomes disruption.",
          "sentiment": 0.0,
          "engagement": "1,355",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-01-24T02:51:17.819079+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261848-Toukanka--7164647",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.804832",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "Cj62 How can it be utter garbage when it\u2019s generally been predicting what is happening to Avacta. But the pond poms utter garbage of \u201ctakeover tomorrow \u201c, \u201cmarket thick as mince\u201d etc etc ad infinitum even though they\u2019ve been entirely wrong for years. Well that\u2019s fine clogging up the board with that garbage",
          "sentiment": 0.0,
          "engagement": "4,436",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-01-24T02:51:17.819114+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261845-BuenaVis--2470013",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.805254",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "6am to midnight but with a two hour evening break to neck a bottle of whisky.",
          "sentiment": 0.0,
          "engagement": "5,722",
          "price_at_post": "54.50",
          "thread_title": "RE: Frankly pathetic",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B36E2695-D07A-4E60-838B-02C995994856"
        },
        "ingested_at": "2026-01-24T02:51:17.819139+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261844-Toukanka--3332192",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.805661",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "You\u2019re right Thompi. You never do say much more than joining your mates and flinging the insults. Why not talk about Avacta rather the other posters on here?",
          "sentiment": 0.0,
          "engagement": "4,436",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-01-24T02:51:17.819157+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261841-sheppy-73758656",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.806079",
        "source": "LSE_CHAT",
        "data": {
          "author": "sheppy",
          "content": "Wyn, Thorn, Touk , DG same poster numerous aliases. Hourly paid hired help disrupter. Regardless of that what sort of sad, moronic halfwit would spend 7 days a week starting each day at 6 am and continuing after midnight posting negative comments about a share they are allegedly not invested in? Regardless of their reason what a total waste of one\u2019s life on this earth . What a pathetic pitiful existence arguing with anonymous people on an anonymous bb. I actually pity their sad, lonely unfulfilled existence. And before the poster tells me they live a very fulfilled life doing lots of other meaningful things ask yourself how this is possible with so many never ending  daily boring transparent attempts at disruption. Sad twat and a weirdo",
          "sentiment": 0.0,
          "engagement": "563",
          "price_at_post": "54.50",
          "thread_title": "Frankly pathetic",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B36E2695-D07A-4E60-838B-02C995994856"
        },
        "ingested_at": "2026-01-24T02:51:17.819175+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261831-cj62-47187837",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.806499",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "Anything you post Thorn is utter garbage. How many crayons have you done today ?",
          "sentiment": 0.0,
          "engagement": "4,270",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-01-24T02:51:17.819193+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261820-Thornogs--4236461",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.806924",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "And what did you say? Anything worth hearing? Anything about Avacta and what's going well and what isn't and thoughts about why? No, thought not. Shame.",
          "sentiment": 0.0,
          "engagement": "8,596",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-01-24T02:51:17.819211+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261755-Thompi-44370981",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.807357",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thompi",
          "content": "Pedro, if I add your 67 posts over the last 30 days to my 20, plus Tim\u2019s 43 and Watching\u2019s 39, the grand combined total is 169 posts. That\u2019s four people combined. Compared to Thorn\u2019s 253 posts on his own. The figures speak for themselves.",
          "sentiment": 0.0,
          "engagement": "1,355",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-01-24T02:51:17.819228+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261754-wyndrum--7962070",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.807774",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "And i see my requests to get NFT to respond have been deleted but the insults to me remain. But yes, its the LSE moderators allowing me to post that is the problem here. Where are you NFT, want to answer my queries so you can justify the remarks in your post?",
          "sentiment": 0.0,
          "engagement": "12,198",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-01-24T02:51:17.819247+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261737-pedrolan-90763508",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.808191",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Make that 29 to go",
          "sentiment": 0.0,
          "engagement": "1,948",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-01-24T02:51:17.819265+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261719-Thompi--8710725",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.808620",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thompi",
          "content": "Avacta posts over the last 30 days: 253 Thorn \ud83e\udd47 43 Timster 39 Watching Not much else to say really Thorn.",
          "sentiment": 0.0,
          "engagement": "1,355",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-01-24T02:51:17.819284+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261708-Thornogs-83598788",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.809052",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "And the two posters below your post Thompi? Watching 9,000 and Tim 20,000! All on only Avacta and all 100% content free 'jokes' or 'bile'. But to comment on that would be to show a consistent approach to this sort of thing wouldn't it? Be honest, it's not the number or posts, it's the fact that you might have to consider things that you don't want to consider. Fine, your choice, 5 years in and AVA6000 limping along to a possible low-ball deal and FAP-EXD entering the 'Last Chance Saloon' in the next 2-3 months. Everything that you've been predicting for the last 5 years, why would you need to hear a contrary opinion when you've clearly been smashing it all this time? Well up I dare say on your investment are we?",
          "sentiment": 0.0,
          "engagement": "8,596",
          "price_at_post": "54.00",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-01-24T02:51:17.819302+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261644-Thompi--4521118",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.809483",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thompi",
          "content": "To be fair Tim, Thorn\u2019s only posted 11 times so far today. He\u2019s got another 30 to go before he equals his personal best of 41 posts in 24 hours. By my reckoning, if he manages around 4.3 posts per hour between now and midnight (17:00\u201312:00am), he might just be in with a chance of beating it. Bless his selfless little heart.",
          "sentiment": 0.0,
          "engagement": "1,355",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-01-24T02:51:17.819321+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261537-Watching-41295331",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.809893",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "24/7. He keeps churning out verbal \ud83d\udca9",
          "sentiment": 0.0,
          "engagement": "9,201",
          "price_at_post": "54.50",
          "thread_title": "RE: CC interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=F5A9F3B7-45F7-4EC2-B1FD-1ACB3A2D2E18"
        },
        "ingested_at": "2026-01-24T02:51:17.819339+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261535-Timster--1743631",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.810318",
        "source": "LSE_CHAT",
        "data": {
          "author": "Timster",
          "content": "All day every day...",
          "sentiment": 0.0,
          "engagement": "20,620",
          "price_at_post": "54.50",
          "thread_title": "To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-01-24T02:51:17.819357+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261529-cj62--1306059",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.810731",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "Shall we have a 'Spot the idiot' competition? You win it thorn, no competition !!!",
          "sentiment": 0.0,
          "engagement": "4,270",
          "price_at_post": "54.50",
          "thread_title": "RE: CC interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=F5A9F3B7-45F7-4EC2-B1FD-1ACB3A2D2E18"
        },
        "ingested_at": "2026-01-24T02:51:17.819375+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261517-Thornogs-35935254",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.811159",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Of course we don't BV, and the industry experts who know these things currently value Avacta at 50 odd pence a share. NFT and the 28 odd who ticked up his posts think \u00a328 is more accurate. Shall we have a 'Spot the idiot' competition?",
          "sentiment": 0.0,
          "engagement": "8,596",
          "price_at_post": "54.50",
          "thread_title": "RE: CC interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=F5A9F3B7-45F7-4EC2-B1FD-1ACB3A2D2E18"
        },
        "ingested_at": "2026-01-24T02:51:17.819394+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261515-cj62-54700456",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.811569",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "That's theoretical of course. Thorn its like 99% of the other gibberish you post twat.",
          "sentiment": 0.0,
          "engagement": "4,270",
          "price_at_post": "54.50",
          "thread_title": "RE: CC interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=F5A9F3B7-45F7-4EC2-B1FD-1ACB3A2D2E18"
        },
        "ingested_at": "2026-01-24T02:51:17.819412+00:00"
      },
      {
        "event_id": "SOCIAL-Today1236-Watching--6287304",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.595387",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "Let\u2019s have a day where know one engages with the Fudders A watch them argue with themselves \ud83d\ude0a",
          "sentiment": 0.0,
          "engagement": "9,213",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-01-29T12:41:41.864458+00:00"
      },
      {
        "event_id": "SOCIAL-Today1207-D-Geeman-55292494",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.595837",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "Evan Davis discussing mergers and acquisitions on Radio 4 right now.",
          "sentiment": 0.0,
          "engagement": "5,844",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-01-29T12:41:41.864500+00:00"
      },
      {
        "event_id": "SOCIAL-Today1050-D-Geeman--5579422",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.596300",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "Many of the most useful posts are green boxes to others. That's fine. I really don't care if **** doesn't read ****'s post as long as I can. Please, everyone who doesn't like ****'s posts filter and then the people who do read them can do so in peace.",
          "sentiment": 0.0,
          "engagement": "5,844",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-01-29T12:41:41.864536+00:00"
      },
      {
        "event_id": "SOCIAL-Today1034-Thornogs-87172490",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.596741",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Happy to sit on the sidelines to watch the emergence of all this deep research and intelligent discussion on the company's 'fundamentals'. Of course if it isn't accurate or realistic I presume there's the right to point this out? Otherwise it's just a meaningless Echo Chamber. Over to you, the self proclaimed 'well informed'. Let's see what quality posting looks like!",
          "sentiment": 0.0,
          "engagement": "8,655",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-01-29T12:41:41.864574+00:00"
      },
      {
        "event_id": "SOCIAL-Today1032-BuenaVis-25668122",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.597214",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "As Runner-Runner wrote... It's simple. 1. DO NOT ENGAGE 2. DO NOT ASK IT A QUESTION 3. DO NOT ANSWER ITS QUESTIONS 4. DO NOT MOAN ABOUT ITS POSTS 5. DO NOT ARGUE WITH IT 6. If you must do something. Mock it with reference only to its stupidity and nothing else. ------------------------------------------------------ If you're not part of the solution, you're part of the problem",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-01-29T12:41:41.864612+00:00"
      },
      {
        "event_id": "SOCIAL-Today1025-pedrolan-60728321",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.597761",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Ok, as one of the offenders ( I did it mainly to remind people of their/his agenda) I will pledge to now ignore them/him going forward. We really need everyone to do that though.",
          "sentiment": 0.5,
          "engagement": "1,972",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-01-29T12:41:41.864650+00:00"
      },
      {
        "event_id": "SOCIAL-Today1022-Aston15-67345974",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.598209",
        "source": "LSE_CHAT",
        "data": {
          "author": "Aston15",
          "content": "People do understand the only reason then come on here to spout sh*t is because others give them an audience? Its not difficult..  Green Box them and focus the chat on the company, not their trading agendas.",
          "sentiment": 0.0,
          "engagement": "61",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-01-29T12:41:41.864689+00:00"
      },
      {
        "event_id": "SOCIAL-Today1005-IFA90--5409507",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.598630",
        "source": "LSE_CHAT",
        "data": {
          "author": "IFA90",
          "content": "More posts than trades, never a good sign.",
          "sentiment": 0.0,
          "engagement": "408",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-01-29T12:41:41.864725+00:00"
      },
      {
        "event_id": "SOCIAL-Today0954-Aldebara-88741076",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.599061",
        "source": "LSE_CHAT",
        "data": {
          "author": "Aldebaran",
          "content": "Anyone engaging with them is part of the problem. I'll soon be adding them to my filter list if all the want to do is talk smack and try to score points against them. It's a waste of everyone's time, least not their own yet they persist. Sad. We could use this bb once again to discuss avacta but only if the engagement with FUDsters ends. Its nothing more than a digital playground otherwise. Filter. Them.",
          "sentiment": 0.0,
          "engagement": "3,894",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-01-29T12:41:41.864765+00:00"
      },
      {
        "event_id": "SOCIAL-Today0948-Watching-68227205",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.599520",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "Let\u2019s have a day where know one engages with the Fudders And watch them argue with there selves \ud83d\ude0a",
          "sentiment": 0.0,
          "engagement": "9,213",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-01-29T12:41:41.864803+00:00"
      },
      {
        "event_id": "SOCIAL-Today0932-Thornogs--6515083",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.599949",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "And on a day to day basis is there actually much new to talk about with Avacta? Tumbleweed City now until the next RNS, whatever that might be for.",
          "sentiment": 0.0,
          "engagement": "8,655",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-01-29T12:41:41.864838+00:00"
      },
      {
        "event_id": "SOCIAL-Today0924-wyndrum-14606935",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.600402",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "But Jane this was all caused by BV\u2019s non AVCT post. He deliberately provokes with his insults and lies. Non of this would have happened today without his non AVCT related post. Remember that would you",
          "sentiment": 0.0,
          "engagement": "12,217",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-01-29T12:41:41.864874+00:00"
      },
      {
        "event_id": "SOCIAL-Today0918-Watching-11901331",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.601027",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "Let\u2019s have a day where know one engages with the Fudders And watch them argue with themselves \ud83d\ude2c",
          "sentiment": 0.0,
          "engagement": "9,213",
          "price_at_post": "54.00",
          "thread_title": "Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-01-29T12:41:41.864912+00:00"
      },
      {
        "event_id": "SOCIAL-Today0917-pedrolan-28181981",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.601613",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "A seamless switch between users there Eggy Bravo",
          "sentiment": 0.0,
          "engagement": "1,972",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-29T12:41:41.864947+00:00"
      },
      {
        "event_id": "SOCIAL-Today0916-Thornogs-43174259",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.602292",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "To be fair Live account it's very easy to judge someone who repeatedly posts nonsense like you just have. And Pedro and BV joining in the: 'Look at us, we're idiots' gang.",
          "sentiment": 0.0,
          "engagement": "8,655",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-29T12:41:41.864978+00:00"
      },
      {
        "event_id": "SOCIAL-Today0902-wyndrum--5690534",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.603136",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "Sadly you have the memory of a goldfish but not its intellect. Again bv starts and contributes to the disruption. All we wait for now is the \u201cooh I can see all these green boxes\u201dposts add up my posts and add up all the rest and you quickly see who the paid disrupters are",
          "sentiment": 0.0,
          "engagement": "12,217",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-29T12:41:41.865011+00:00"
      },
      {
        "event_id": "SOCIAL-Today0859-BuenaVis-75888289",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.603939",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "\ud83e\udd14 Today's 'wyndrum' sounds even more petty and whiny than the 'Thornogson' account.",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-29T12:41:41.865046+00:00"
      },
      {
        "event_id": "SOCIAL-Today0858-pedrolan--8040025",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.604745",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "BV - he is doing it to fool us into thinking it is not one account. I nearly fell for it because I have the memory of a goldfish.",
          "sentiment": 0.5,
          "engagement": "1,972",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-29T12:41:41.865078+00:00"
      },
      {
        "event_id": "SOCIAL-Today0853-wyndrum--1161119",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.605571",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "It\u2019s snowing pretty hard here so it\u2019s not really the smoking gun you claim is it? Plus the fact you think I have multiple accounts only reinforces your mistaken analysis. (And see how many posts have been generated by bv These are the cause of the disruption. Not the posters who try to discuss the disconnect between AVCT results and the sp over the last 5 years",
          "sentiment": 0.0,
          "engagement": "12,217",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-29T12:41:41.865130+00:00"
      },
      {
        "event_id": "SOCIAL-Today0850-BuenaVis--7114746",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.606369",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Why is Thornogson/NDN/Eggy using the wyndrum account today?",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-29T12:41:41.865163+00:00"
      },
      {
        "event_id": "SOCIAL-Today0847-Livedata--3122699",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.607182",
        "source": "LSE_CHAT",
        "data": {
          "author": "Livedataaccount",
          "content": "With respect wyndrum its difficult not to judge someone who pretends to go on holiday and occasionally logs on with another alias replying to himself",
          "sentiment": 0.0,
          "engagement": "2,956",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-29T12:41:41.865200+00:00"
      },
      {
        "event_id": "SOCIAL-Today0835-BuenaVis-49228434",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.607959",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Wyn Shakespeare has swallowed a whole bag of question marks.",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-29T12:41:41.865237+00:00"
      },
      {
        "event_id": "SOCIAL-Today0831-pedrolan-73971452",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.608744",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Keep it up BV - people do need reminding. I see user Wyn Shakespeare is on the early shift.",
          "sentiment": 0.5,
          "engagement": "1,972",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-29T12:41:41.865275+00:00"
      },
      {
        "event_id": "SOCIAL-Today0826-wyndrum--2875272",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.609574",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "Thanks for reminding us dad, it must only be the 20th time you have posted this. Still at least your post s don\u2019t disrupt the board It\u2019s a great service you do, giving up your time to treat everyone here like morons by constantly reposting. Is it your new rule now that you must be shareholder to post and also be a genuine one at that? How do you intend to police your rules? Or is it just petty personal vendetta you are boring us all with?",
          "sentiment": 0.0,
          "engagement": "12,217",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-29T12:41:41.865321+00:00"
      },
      {
        "event_id": "SOCIAL-Today0750-BuenaVis--2850039",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.610363",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Just a reminder that Thornogson/NDN/Eggy isn't invested and is only here to argue, disrupt and try to waste our time.",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-29T12:41:41.865361+00:00"
      },
      {
        "event_id": "SOCIAL-Today0746-BuenaVis-40826983",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.904033",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Say what you see \ud83c\udf77\ud83c\udf77\ud83c\udf77",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "54.00",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-01-29T12:41:41.865402+00:00"
      },
      {
        "event_id": "SOCIAL-Today0733-Unbreade-33295251",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.904514",
        "source": "LSE_CHAT",
        "data": {
          "author": "Unbreaded",
          "content": "I love green boxes in the morning! Time for a coffee and catch up on the news.",
          "sentiment": 0.0,
          "engagement": "22",
          "price_at_post": "54.00",
          "thread_title": "Green Boes",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=F7E09828-40CF-45D7-8337-5F0A79C87685"
        },
        "ingested_at": "2026-01-29T12:41:41.865441+00:00"
      },
      {
        "event_id": "SOCIAL-Today0035-Thornogs--2001544",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.904967",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Sujood & Icecool. Similar content but I think ICE probably ahead on presentation. Both deeply underwater but talking a good game. Of course the SP matters, the only data that might be maturing is SGC 1b, which might secure a small deal. We've been told nothing about TNBC and STS is written off. We wait for FAP-EXD, we start again.",
          "sentiment": 0.0,
          "engagement": "8,655",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-29T12:41:41.865482+00:00"
      },
      {
        "event_id": "SOCIAL-Today0005-Toukanka--4571271",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.905422",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "Pivotal news in the Summer. Where have I heard that before? Oh yeah, it was me and I duly got panned by the Pom Pom girls for suggesting it would take thst long. \ud83e\udd23\ud83e\udd23\ud83e\udd23",
          "sentiment": 0.0,
          "engagement": "4,451",
          "price_at_post": "54.00",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-01-29T12:41:41.865522+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262359-Toukanka-37666046",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.905891",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "Work for ever????",
          "sentiment": 0.0,
          "engagement": "4,451",
          "price_at_post": "54.00",
          "thread_title": "RE: This will haunt you or please you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=8AE0FBBC-C14D-49F3-85C3-E6BED1BD66ED"
        },
        "ingested_at": "2026-01-29T12:41:41.865562+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262324-IFA90--2620308",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.906405",
        "source": "LSE_CHAT",
        "data": {
          "author": "IFA90",
          "content": "Thanks Andy",
          "sentiment": 0.0,
          "engagement": "408",
          "price_at_post": "54.00",
          "thread_title": "RE: This will haunt you or please you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=8AE0FBBC-C14D-49F3-85C3-E6BED1BD66ED"
        },
        "ingested_at": "2026-01-29T12:41:41.865600+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262322-BuenaVis--7357512",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.906824",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Thanks Thompi",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-29T12:41:41.865640+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262302-Sujood-13910484",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.907374",
        "source": "LSE_CHAT",
        "data": {
          "author": "Sujood",
          "content": "A multi billion dollar company in the making. It will haunt you if you dont position yourself Will please you, if you do the write thing. Learn about the company and do what you know is the right move to make. Nobody every wants to work forever. Keep this message We will talk again soon.",
          "sentiment": 0.5,
          "engagement": "1,260",
          "price_at_post": "54.00",
          "thread_title": "This will haunt you or please you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=8AE0FBBC-C14D-49F3-85C3-E6BED1BD66ED"
        },
        "ingested_at": "2026-01-29T12:41:41.865680+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262258-Icecool--2291348",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.907813",
        "source": "LSE_CHAT",
        "data": {
          "author": "Icecool",
          "content": "Commercial deals will come, and they\u2019ll be welcomed when they do. I\u2019m not in a rush though. If the data continues to strengthen and Avacta can leverage that science into materially better terms, I\u2019m perfectly happy for it to take longer. Time spent increasing leverage isn\u2019t wasted time, it\u2019s how you avoid bad deals and maximise value. \ud83d\ude0a Waiting could be the difference between a few billion and tens of billions. \ud83d\ude0a\ud83e\udd14",
          "sentiment": 0.0,
          "engagement": "8,824",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-29T12:41:41.865718+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262250-Thompi--7463239",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.908255",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thompi",
          "content": "You may find BV this tweet on X interesting on AVA6103 and BOIN design. AND https://x.com/sandyradders/status/2012950578595258664?s=61&t=BBb2UcjLDTXOFIzJM-vM6A",
          "sentiment": 0.0,
          "engagement": "1,357",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-29T12:41:41.865756+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262144-Knotagai--8132891",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.908887",
        "source": "LSE_CHAT",
        "data": {
          "author": "Knotagain",
          "content": "We're all fixated on the SP Icecool, it's just a matter of time frames. I've been invested for over five years and would love to see  some commercial news. Nothing wrong with that.",
          "sentiment": 0.0,
          "engagement": "451",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-29T12:41:41.865796+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262118-Icecool-51295289",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.909330",
        "source": "LSE_CHAT",
        "data": {
          "author": "Icecool",
          "content": "That\u2019s only a concern if you\u2019re fixated on the SP. AIM has never been able to price Avacta properly and it won\u2019t until there\u2019s either a takeover (and suspension) or a move to a serious exchange. The day to day price action is noise. What actually matters is what\u2019s happening behind the scenes with the science, the data, and the strategic discussions. That\u2019s where the real value is being built. \ud83d\udcaf\ud83d\udc4d",
          "sentiment": 0.0,
          "engagement": "8,824",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-29T12:41:41.865835+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262058-Knotagai--3277213",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.909883",
        "source": "LSE_CHAT",
        "data": {
          "author": "Knotagain",
          "content": "Totally agree Icecool, but only third party validation will move the share price. Hopefully it will happen sometime soon.",
          "sentiment": 0.0,
          "engagement": "451",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-29T12:41:41.865875+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262032-Icecool-11382097",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.910560",
        "source": "LSE_CHAT",
        "data": {
          "author": "Icecool",
          "content": "The FDA won\u2019t drag this out. AVA6000 proved the platform in humans, AVA6103 builds on that. Phase 1 is about safety and speed. This trial is designed to surface signals quickly with regulatory alignment, not waste years. AVA6000 data will have done a load of heavy lifting already.",
          "sentiment": 0.0,
          "engagement": "8,824",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-29T12:41:41.865914+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261954-BuenaVis--1773246",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.910984",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "I've got to say I was concerned that the AVA6103 trial with such a toxic agent as exatecan would start at a very low dose and take a long, long time if the step increases were to mimic those in the AVA6000 trial (seven dose levels! - three steps of 40 from 80 to 200, and then three 25% increases to 385) so very pleased to hear about all the benefits of the BOIN design.",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-29T12:41:41.865952+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261946-Icecool--1822887",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.911503",
        "source": "LSE_CHAT",
        "data": {
          "author": "Icecool",
          "content": "I would also point out that when Thorn bought in he\u2019s also a mega ramping twat!!! Flip/Flop. \ud83d\udcaf\ud83e\udd23\ud83e\udd23 best on filter \ud83d\udc4d",
          "sentiment": 0.0,
          "engagement": "8,824",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-29T12:41:41.865990+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261937-HarChris-19693264",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.912044",
        "source": "LSE_CHAT",
        "data": {
          "author": "HarChris",
          "content": "Going back to the trial design I thought this overview could be useful: Key Comparisons Accuracy in MTD Selection: BOIN generally outperforms 3+3 by more accurately identifying the true MTD. In simulations across various scenarios BOIN achieves a 12-16% higher percentage of correct selection (PCS) of the MTD, and in cases where the MTD is at higher doses, it can nearly triple the PCS compared to 3+3. Efficiency and Patient Allocation: BOIN is more efficient, often resulting in shorter trial durations and lower costs by adapting in real-time and allocating more patients to the MTD (especially at higher doses or with higher target DLT rates). The 3+3 design can prolong trials due to its conservative escalation and fixed cohort requirements, leading to fewer patients treated at effective doses. Safety and Risk Management: While 3+3 minimizes overdose risk by being overly cautious (e.g., lower chance of assigning >60% of patients above the MTD), it increases under-dosing, where many patients receive suboptimal doses. BOIN balances this better with built-in overdose controls and dynamic adjustments, reducing under-dosing without significantly raising overdose risks, thus improving ethical standards by minimising patient exposure to ineffective or overly toxic doses. Simplicity and Flexibility: Both are relatively easy to implement\u2014BOIN requires no complex programming or simulations beyond basic setup, making it accessible like 3+3. However, BOIN offers more flexibility, such as variable cohort sizes (e.g., 4 patients) and adjustable target toxicity rates, whereas 3+3 is fixed to cohorts of 3 (or 3+3) and standard targets. In summary, BOIN represents an evolution over 3+3, providing better performance across most metrics while maintaining ease of use. The 3+3 design is still widely used for its familiarity and safety focus in conservative settings but is increasingly seen as outdated for not fully utilising trial data.",
          "sentiment": 0.0,
          "engagement": "15,865",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-29T12:41:41.866028+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261812-Cashless--5739381",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.912567",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cashless",
          "content": "Been out all day, so just logged on.....and what a pleasure to see a sea of green and pretty much all informative posts...I LOVE GREEN...not sure the green people are so happy though \ud83d\udc4d\ud83e\udd2a\ud83e\udd2a\ud83e\udd73",
          "sentiment": 0.5,
          "engagement": "401",
          "price_at_post": "54.00",
          "thread_title": "Bliss",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E431AF8E-57C8-40B5-91C6-8D284968B368"
        },
        "ingested_at": "2026-01-29T12:41:41.866067+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261753-B2HS2L-79131501",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.913172",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "FWIW Google search What is the difference between event free and progression free survival AI Overview: Progression-Free Survival (PFS) measures the time from treatment initiation until objective tumor growth or death from any cause. Event-Free Survival (EFS) measures the time from randomization until a broader range of \"events,\" including disease progression, treatment failure, complications, or death. PFS focuses on tumor growth; EFS focuses on any negative outcome. Key Differences: Definition of Event: PFS is restricted to disease progression or death. EFS includes those, plus failure to proceed to planned surgery, relapse, or severe treatment complications. Context of Use: PFS is commonly used in advanced or metastatic cancer trials to evaluate treatment efficacy. EFS is frequently used in earlier-stage cancer trials, particularly in the neoadjuvant (pre-surgery) setting. Precision: PFS depends on the frequency of imaging scans to detect growth, while EFS is often defined by the time until a patient cannot proceed with their treatment plan. Essentially, PFS means the cancer has not worsened, whereas EFS means the patient has not experienced any negative, pre-defined event.",
          "sentiment": 0.0,
          "engagement": "6,000",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-29T12:41:41.866118+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261428-BuenaVis-43578226",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.913661",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "What is the current best progression free survival rate for TNBC? https://www.google.com/search?q=What+is+the+current+best+progression+free+survival+rate+for+TNBC%253F",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-29T12:41:41.866158+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261424-HarChris-40911762",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.914093",
        "source": "LSE_CHAT",
        "data": {
          "author": "HarChris",
          "content": "It's what happened to STS and might now happen with TNBC, might not of course, but if it did then it'll all fall to SGC to carry the load until FAP-EXD starts to produce meaningful data. __________________ In other words IF TNBC data doesn't deliver then SGC might have to carry the load until H2 2026? That's not bad as a worst case and it's very short term as it gets for biotech. And with the less risk averse and far more efficient BOIN design for 6103 we should start receiving compelling data rapidly if all is going well. It's close!",
          "sentiment": 0.0,
          "engagement": "15,865",
          "price_at_post": "54.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-29T12:41:41.866197+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261411-Thornogs-32747973",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.914533",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "No well spotted!  My bad.",
          "sentiment": 0.0,
          "engagement": "8,655",
          "price_at_post": "54.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-29T12:41:41.866235+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261409-BuenaVis-44546278",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.915065",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "I may be missing something here but trastuzumab deruxtecan (brand name Enhertu) and pertuzumab are both used to treat HER2-positive breast cancer.  So what has that got to do with TNBC which is an aggressive, fast-growing type of breast cancer that tests negative for three key receptors: estrogen (ER), progesterone (PR), and HER2?",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "54.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-29T12:41:41.866276+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261349-Thornogs-13020203",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.915517",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "'....FAP-DOX needs to beat.'",
          "sentiment": 0.0,
          "engagement": "8,655",
          "price_at_post": "54.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-29T12:41:41.866314+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261347-Thornogs--1227494",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.915945",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "But clearly relevent so clearly won't be mentioned by anyone else Watching? Obviously important if it's doubled the PFS times for TNBC, the bar has been raised as to what FAP-EXD needs to beat. It's what happened to STS and might now happen with TNBC, might not of course, but if it did then it'll all fall to SGC to carry the load until FAP-EXD starts to produce meaningful data.",
          "sentiment": 0.0,
          "engagement": "8,655",
          "price_at_post": "54.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-29T12:41:41.866354+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261347-pedrolan-25350684",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.837882",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Just a reminder that Thorn is not invested but spends his sad life on here posting negative comments about a company saving lives. What a guy!!!",
          "sentiment": 0.5,
          "engagement": "1,972",
          "price_at_post": "54.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-29T12:41:41.866393+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261339-Watching-92621300",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.838382",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "You Still have to focus on negatives. Thorny you are such a k n o bby \ud83e\udd21\ud83e\udd21",
          "sentiment": 0.0,
          "engagement": "9,213",
          "price_at_post": "54.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-29T12:41:41.866432+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261335-Thornogs--8879406",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.838824",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "It's perhaps double edged though? The AVA6000 STS trial was (allegedly) de-railed by a trial that showed longer, and better than expected, survival data. If there's a new 'Standard of Care' being announced for TNBC the bar might just have been raised on what FAP-DOX/TNBC needs to achieve to get a deal and get to market?",
          "sentiment": 0.0,
          "engagement": "8,655",
          "price_at_post": "55.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-29T12:41:41.866472+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261315-LovableL--2222971",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.839268",
        "source": "LSE_CHAT",
        "data": {
          "author": "LovableLumax",
          "content": "Https://x.com/onclive/status/2016451178872061994?s=46",
          "sentiment": 0.0,
          "engagement": "2,703",
          "price_at_post": "55.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-29T12:41:41.866512+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261053-Aldebara--4470010",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.839705",
        "source": "LSE_CHAT",
        "data": {
          "author": "Aldebaran",
          "content": "I think small caps are at the very start of a major bull run. Green portfolio everywhere across the board. Also note that even with hard times, avacta raised 16m through zeus at only 8% discount plus managed to delay and renegotiate the terms of the bond. No mean feat that and the macro picture for small caps has improved since then. As has our IP and data package plus the deadline for BP patent expiry has only become closer. Things nowhere near as desperate as this shhhhh it tee little market gives credit for. I mean avacta have developed the worlds first dual warhead peptide drug conjugate ffs . \ud83d\ude05",
          "sentiment": 0.0,
          "engagement": "3,894",
          "price_at_post": "55.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-29T12:41:41.866551+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261050-opti_mys--4876202",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.840239",
        "source": "LSE_CHAT",
        "data": {
          "author": "opti_mystic",
          "content": "I think that's optimistic Lovable being as the initial doses will be very low. It is a safety trial initially remember, but the trial design (BOIN) will allow for dose escalation quite quickly and also potentially skipping from say dose level one to does level 3. I think more realistically summer months we may start to see some useful efficacy. What they will know sooner is are there any problems/does it works as expected and designed. If no bad news by May/June I think we're on a winner. I expect it to work.",
          "sentiment": 0.0,
          "engagement": "296",
          "price_at_post": "55.50",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-01-29T12:41:41.866590+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261045-Sisyphus-16944749",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.840667",
        "source": "LSE_CHAT",
        "data": {
          "author": "SisyphusShorter",
          "content": "Out of coincidence it's been exactly a week since the last RNS regarding AVA6103. Could an announcement be due imminently?",
          "sentiment": 0.0,
          "engagement": "4",
          "price_at_post": "55.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-29T12:41:41.866629+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261014-HarChris--9000977",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.841093",
        "source": "LSE_CHAT",
        "data": {
          "author": "HarChris",
          "content": "I wonder if those solely focused on Avacta and thinking history always repeats are missing the fact that the AIM backdrop plays a major role here. And in that regard liquidity has returned to UK small caps with a vengeance, raises are happening without the sort of discounts seen in 2022/23/24/25, companies are seeing major share price appreciation actually hold rather than the wild swings of post Covid. It\u2019s a far healthier backdrop right now than at any point since I\u2019ve held Avacta shares.",
          "sentiment": 0.0,
          "engagement": "15,865",
          "price_at_post": "55.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-29T12:41:41.866668+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261003-harryhot--7341814",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.841536",
        "source": "LSE_CHAT",
        "data": {
          "author": "harryhotspur1311",
          "content": "I was hoping for the big erection shape although roundish bottoms are quite welcome as well!",
          "sentiment": 0.0,
          "engagement": "12",
          "price_at_post": "55.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-29T12:41:41.866708+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260958-A1invest-11960005",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.841950",
        "source": "LSE_CHAT",
        "data": {
          "author": "A1invest",
          "content": "Lets hope its a \"rounding bottom\" shape.  :)",
          "sentiment": 0.0,
          "engagement": "143",
          "price_at_post": "55.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-29T12:41:41.866747+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260953-pedrolan--3159138",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.842525",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Salty for sure",
          "sentiment": 0.0,
          "engagement": "1,972",
          "price_at_post": "55.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-29T12:41:41.866787+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260945-Thornogs-26597851",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.843025",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "\"Salt and vinegar on that sir?\"",
          "sentiment": 0.0,
          "engagement": "8,655",
          "price_at_post": "55.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-29T12:41:41.866827+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260944-Timster-81185255",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.843502",
        "source": "LSE_CHAT",
        "data": {
          "author": "Timster",
          "content": "Big fish, little fish, cardboard box....",
          "sentiment": 0.0,
          "engagement": "20,625",
          "price_at_post": "55.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-29T12:41:41.866866+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260941-harryhot-30961040",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.844130",
        "source": "LSE_CHAT",
        "data": {
          "author": "harryhotspur1311",
          "content": "Whenever the SP drops, the pessimists always quote \u2018the market knows\u2019 Perhaps this could work the other way around occasionally! Today, perhaps!",
          "sentiment": 0.0,
          "engagement": "12",
          "price_at_post": "56.00",
          "thread_title": "Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-29T12:41:41.866905+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260823-pedrolan--2230844",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.844561",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Ah yes, I knew I had been there but couldn't remember exactly which Lake \ud83e\udd23",
          "sentiment": 0.5,
          "engagement": "1,972",
          "price_at_post": "52.50",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-01-29T12:41:41.866944+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260726-Gingethe--6385439",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.844978",
        "source": "LSE_CHAT",
        "data": {
          "author": "GingetheWinge",
          "content": "Derwent valley dam in the Peak District.",
          "sentiment": 0.5,
          "engagement": "699",
          "price_at_post": "53.00",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-01-29T12:41:41.866982+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260713-LovableL-58845130",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.845409",
        "source": "LSE_CHAT",
        "data": {
          "author": "LovableLumax",
          "content": "I also suspect we will have a 6000 partner signed up once we have an approved accelerated pathway and registrations P2\\3 with FDA which is hopefully imminent",
          "sentiment": 0.0,
          "engagement": "2,703",
          "price_at_post": "53.00",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-01-29T12:41:41.867022+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260703-LovableL--5813062",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.845829",
        "source": "LSE_CHAT",
        "data": {
          "author": "LovableLumax",
          "content": "Given how potent the payload is and with the improved half-life and active in the TME for 5 days surely they'll see results as early as scan 1. That sounds rampy and too optimistic but look at the preclinical results. Things could really take off as early as the summer, or even before. Again, I suspect recruitment will be fairly rapid given FAP targeting with preCISION proven and preclinical results so investigators likely chomping at the bit.",
          "sentiment": 0.0,
          "engagement": "2,703",
          "price_at_post": "53.00",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-01-29T12:41:41.867062+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260659-nurseste--3244795",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.846277",
        "source": "LSE_CHAT",
        "data": {
          "author": "nursesteve",
          "content": "CC discussing FAP-Exd (AVA6103) - The profile of this second pre|CISION medicine in the preclinical setting is tremendous.  The sustained release mechanism developed by Avacta scientists results in a robust concentration of active drug in the tumor over five days with the disappearance from the bloodstream in only two hours. This is the exact profile needed to achieve better efficacy with this highly potent topo I inhibitor. Could payoff for LTH be this year?",
          "sentiment": 0.0,
          "engagement": "1,164",
          "price_at_post": "53.00",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-01-29T12:41:41.867111+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260006-D-Geeman-63511385",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.846690",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "An elderly character actor in our road, when I first arrived,  was in the movie \u2018The Dambusters\u2019, and in \u2018Bridge on the River Kwai\u2019. He used to tell some good stories of life on 1950\u2019s film sets. Dead for a while but he pops up on screen even now.",
          "sentiment": 0.0,
          "engagement": "5,844",
          "price_at_post": "52.50",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-01-29T12:41:41.867143+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20262319-pedrolan--8217015",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.847122",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Yes, it's an inspirational story. I think they tested it up in the Lake District",
          "sentiment": 0.5,
          "engagement": "1,972",
          "price_at_post": "52.50",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-01-29T12:41:41.867163+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20262113-Captains--4277855",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.847541",
        "source": "LSE_CHAT",
        "data": {
          "author": "Captainstanley.",
          "content": "I can't find that information anywhere Which Friday? Presumably you mean this week 29th Jan?",
          "sentiment": 0.0,
          "engagement": "467",
          "price_at_post": "52.50",
          "thread_title": "RE: SGC",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=5E3142A3-349A-43A2-B5B7-02836561174A"
        },
        "ingested_at": "2026-01-29T12:41:41.867188+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20262014-Flippine--7785395",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.847977",
        "source": "LSE_CHAT",
        "data": {
          "author": "Flippineck",
          "content": "I\u2019ve been thinking about the trials and tribulations of developing new inventions and ended up swotting up on Barnes Wallace, the inventor of the famous Bouncing Bomb. It seems initial proposals were dismissed by Bomber Command as being \u201c a mad-cap scheme\u201d. There were several critical failures in the development which had to be overcome. The shape of the bomb had to be changed, backspin had to be introduced, the weapon would shatter, sink or detonate prematurely or veer off course. Barnes Wallace persevered and it all came good in the end.",
          "sentiment": 0.0,
          "engagement": "417",
          "price_at_post": "52.50",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-01-29T12:41:41.867220+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261912-BuenaVis-43907073",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.848415",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Christina Coughlin became the CEO of Avacta on 1 May 2024. There is no need to dwell on anything or anyone before that date. CC has set out the company's objectives and timelines and has stuck to them, as much as is possible taking outside decision-making and events into account.  This adherence to the company's aims and plans comes about because she is a pharma executive with ample of experience of drug development and the way the FDA works.",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "52.50",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-01-29T12:41:41.867251+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261900-BuenaVis-25668122",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.848907",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "As Runner-Runner wrote... It's simple. 1. DO NOT ENGAGE 2. DO NOT ASK IT A QUESTION 3. DO NOT ANSWER ITS QUESTIONS 4. DO NOT MOAN ABOUT ITS POSTS 5. DO NOT ARGUE WITH IT 6. If you must do something. Mock it with reference only to its stupidity and nothing else. ------------------------------------------------------ If you're not part of the solution, you're part of the problem",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "52.50",
          "thread_title": "RE: Year end trading update :",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=CCFE6866-0D3C-4A1E-9659-9B2E552262F5"
        },
        "ingested_at": "2026-01-29T12:41:41.867284+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20262219-Thornogs-60499200",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.801399",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Anything new there? 'Expected' Q1? No, nothing new, just 'same old'.",
          "sentiment": 0.0,
          "engagement": "8,596",
          "price_at_post": "54.50",
          "thread_title": "RE: Bioconjugate Insights",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0DCD83D9-A17D-43E1-842E-1C922D520A76"
        },
        "ingested_at": "2026-01-29T12:41:41.867321+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20262212-avctIPma-34039622",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.801859",
        "source": "LSE_CHAT",
        "data": {
          "author": "avctIPmatters",
          "content": "Again courtesy of Stonks -  Finds  new coverage  Avacta related   many thanks . https://cdn.insights.bio/uploads/attachments/BCI%20Industry%20Insights.pdfAvacta Therapeutics reported new preclinical pharmacology data for FAP-Exd peptide drug conjugate [25] \"Avacta Therapeutics announced new preclinical pharmacology data for FAP-Exd (AVA6103), its second asset derived from the pre|CISION\u00ae tumor-activated delivery platform, which is expected to enter Phase 1 testing in Q1 2026. FAP-Exd is a fibroblast activation protein\u2013cleavable peptide-drug linking a proprietary peptide to a topoisomerase I inhibitor payload. The data demonstrated tumor-specific cytotoxicity, sustained intratumoral release of active exatecan with limited systemic exposure, and robust antitumor activity across multiple patient-derived xenograft models. Avacta also reported that artificial intelligence\u2013guided analysis was used to prioritize clinical indications based on co-expression of FAP and SLFN11.\" Gmcc",
          "sentiment": 0.0,
          "engagement": "720",
          "price_at_post": "54.50",
          "thread_title": "Bioconjugate Insights",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0DCD83D9-A17D-43E1-842E-1C922D520A76"
        },
        "ingested_at": "2026-01-29T12:41:41.867354+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20262210-Thornogs--1227443",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.802303",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Avacta does its thing regardless of what's posted here. Get over yourselves, self appointed \"Guardian's of the truth\"! And if you must wear your underpants on the outside do at least please ensure that  they're better laundered?",
          "sentiment": 0.0,
          "engagement": "8,596",
          "price_at_post": "54.50",
          "thread_title": "The reality?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=D8CC0643-0047-4DA0-A21A-3E0ECC3BD17C"
        },
        "ingested_at": "2026-01-29T12:41:41.867386+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20262154-BuenaVis--6299310",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.802718",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "I had Firefox nicely set up with AdBlock so that all ads were wiped out but had to 'repair' Firefox today (as tabs were crashing) and then reload an AdBlock extension but I now keep getting these annoying messages from LSE about ads that I never used to get.  Can't remember what I did before to permanently remove those messages.  Can anyone offer advice on how they've solved this?",
          "sentiment": 0.0,
          "engagement": "5,722",
          "price_at_post": "54.50",
          "thread_title": "Off-topic - removing ads on Firefox",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=9BE707F4-9555-444A-A3C8-1254E00A3443"
        },
        "ingested_at": "2026-01-29T12:41:41.867419+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20262109-Knotagai--8962522",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.803142",
        "source": "LSE_CHAT",
        "data": {
          "author": "Knotagain",
          "content": "All day every day...",
          "sentiment": 0.0,
          "engagement": "448",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-01-29T12:41:41.867458+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261944-Agenda10--8706449",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.803559",
        "source": "LSE_CHAT",
        "data": {
          "author": "Agenda101",
          "content": "Brilliant! The never ending Twats.. they are all green boxed here\u2026 But I\u2019m hearing you Sheepy! Exactly right.",
          "sentiment": 0.0,
          "engagement": "55",
          "price_at_post": "54.50",
          "thread_title": "RE: Frankly pathetic",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B36E2695-D07A-4E60-838B-02C995994856"
        },
        "ingested_at": "2026-01-29T12:41:41.867491+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261943-BuenaVis-52776211",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.803971",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Lighten up Thompi.  It's the best comedy show in town.",
          "sentiment": 0.0,
          "engagement": "5,722",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-01-29T12:41:41.867530+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261940-Thompi--3081922",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.804413",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thompi",
          "content": "Because, Touk, Thorn talks total twaddle and inundates this board with spam. It\u2019s made the board virtually unreadable. Even blocking him doesn\u2019t really help, because all I then see are green boxes and other people replying to his posts. I probably add to the noise at times too - but I\u2019ve genuinely had enough of one person commandeering the board with the same malicious rubbish, day after day. Post after post after post. It wears people down. It stops being discussion and just becomes disruption.",
          "sentiment": 0.0,
          "engagement": "1,355",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-01-29T12:41:41.867569+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261848-Toukanka--8422424",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.804832",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "Cj62 How can it be utter garbage when it\u2019s generally been predicting what is happening to Avacta. But the pond poms utter garbage of \u201ctakeover tomorrow \u201c, \u201cmarket thick as mince\u201d etc etc ad infinitum even though they\u2019ve been entirely wrong for years. Well that\u2019s fine clogging up the board with that garbage",
          "sentiment": 0.0,
          "engagement": "4,436",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-01-29T12:41:41.867609+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261845-BuenaVis-62231774",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.805254",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "6am to midnight but with a two hour evening break to neck a bottle of whisky.",
          "sentiment": 0.0,
          "engagement": "5,722",
          "price_at_post": "54.50",
          "thread_title": "RE: Frankly pathetic",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B36E2695-D07A-4E60-838B-02C995994856"
        },
        "ingested_at": "2026-01-29T12:41:41.867648+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261844-Toukanka--2325128",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.805661",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "You\u2019re right Thompi. You never do say much more than joining your mates and flinging the insults. Why not talk about Avacta rather the other posters on here?",
          "sentiment": 0.0,
          "engagement": "4,436",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-01-29T12:41:41.867689+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261841-sheppy--8332009",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.806079",
        "source": "LSE_CHAT",
        "data": {
          "author": "sheppy",
          "content": "Wyn, Thorn, Touk , DG same poster numerous aliases. Hourly paid hired help disrupter. Regardless of that what sort of sad, moronic halfwit would spend 7 days a week starting each day at 6 am and continuing after midnight posting negative comments about a share they are allegedly not invested in? Regardless of their reason what a total waste of one\u2019s life on this earth . What a pathetic pitiful existence arguing with anonymous people on an anonymous bb. I actually pity their sad, lonely unfulfilled existence. And before the poster tells me they live a very fulfilled life doing lots of other meaningful things ask yourself how this is possible with so many never ending  daily boring transparent attempts at disruption. Sad twat and a weirdo",
          "sentiment": 0.0,
          "engagement": "563",
          "price_at_post": "54.50",
          "thread_title": "Frankly pathetic",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B36E2695-D07A-4E60-838B-02C995994856"
        },
        "ingested_at": "2026-01-29T12:41:41.867728+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261831-cj62-36157687",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.806499",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "Anything you post Thorn is utter garbage. How many crayons have you done today ?",
          "sentiment": 0.0,
          "engagement": "4,270",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-01-29T12:41:41.867768+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261820-Thornogs--3237633",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.806924",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "And what did you say? Anything worth hearing? Anything about Avacta and what's going well and what isn't and thoughts about why? No, thought not. Shame.",
          "sentiment": 0.0,
          "engagement": "8,596",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-01-29T12:41:41.867807+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261755-Thompi--4019209",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.807357",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thompi",
          "content": "Pedro, if I add your 67 posts over the last 30 days to my 20, plus Tim\u2019s 43 and Watching\u2019s 39, the grand combined total is 169 posts. That\u2019s four people combined. Compared to Thorn\u2019s 253 posts on his own. The figures speak for themselves.",
          "sentiment": 0.0,
          "engagement": "1,355",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-01-29T12:41:41.867847+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261754-wyndrum--6271566",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.807774",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "And i see my requests to get NFT to respond have been deleted but the insults to me remain. But yes, its the LSE moderators allowing me to post that is the problem here. Where are you NFT, want to answer my queries so you can justify the remarks in your post?",
          "sentiment": 0.0,
          "engagement": "12,198",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-01-29T12:41:41.867886+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261737-pedrolan--4334698",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.808191",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Make that 29 to go",
          "sentiment": 0.0,
          "engagement": "1,948",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-01-29T12:41:41.867925+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261719-Thompi--7945697",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.808620",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thompi",
          "content": "Avacta posts over the last 30 days: 253 Thorn \ud83e\udd47 43 Timster 39 Watching Not much else to say really Thorn.",
          "sentiment": 0.0,
          "engagement": "1,355",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-01-29T12:41:41.867963+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261708-Thornogs-21866064",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.809052",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "And the two posters below your post Thompi? Watching 9,000 and Tim 20,000! All on only Avacta and all 100% content free 'jokes' or 'bile'. But to comment on that would be to show a consistent approach to this sort of thing wouldn't it? Be honest, it's not the number or posts, it's the fact that you might have to consider things that you don't want to consider. Fine, your choice, 5 years in and AVA6000 limping along to a possible low-ball deal and FAP-EXD entering the 'Last Chance Saloon' in the next 2-3 months. Everything that you've been predicting for the last 5 years, why would you need to hear a contrary opinion when you've clearly been smashing it all this time? Well up I dare say on your investment are we?",
          "sentiment": 0.0,
          "engagement": "8,596",
          "price_at_post": "54.00",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-01-29T12:41:41.868002+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261644-Thompi--8681002",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.809483",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thompi",
          "content": "To be fair Tim, Thorn\u2019s only posted 11 times so far today. He\u2019s got another 30 to go before he equals his personal best of 41 posts in 24 hours. By my reckoning, if he manages around 4.3 posts per hour between now and midnight (17:00\u201312:00am), he might just be in with a chance of beating it. Bless his selfless little heart.",
          "sentiment": 0.0,
          "engagement": "1,355",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-01-29T12:41:41.868041+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261537-Watching--7169922",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.809893",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "24/7. He keeps churning out verbal \ud83d\udca9",
          "sentiment": 0.0,
          "engagement": "9,201",
          "price_at_post": "54.50",
          "thread_title": "RE: CC interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=F5A9F3B7-45F7-4EC2-B1FD-1ACB3A2D2E18"
        },
        "ingested_at": "2026-01-29T12:41:41.868081+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261535-Timster--8962522",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.810318",
        "source": "LSE_CHAT",
        "data": {
          "author": "Timster",
          "content": "All day every day...",
          "sentiment": 0.0,
          "engagement": "20,620",
          "price_at_post": "54.50",
          "thread_title": "To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-01-29T12:41:41.868133+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261529-cj62-84685498",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.810731",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "Shall we have a 'Spot the idiot' competition? You win it thorn, no competition !!!",
          "sentiment": 0.0,
          "engagement": "4,270",
          "price_at_post": "54.50",
          "thread_title": "RE: CC interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=F5A9F3B7-45F7-4EC2-B1FD-1ACB3A2D2E18"
        },
        "ingested_at": "2026-01-29T12:41:41.868174+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261517-Thornogs--3435169",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.811159",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Of course we don't BV, and the industry experts who know these things currently value Avacta at 50 odd pence a share. NFT and the 28 odd who ticked up his posts think \u00a328 is more accurate. Shall we have a 'Spot the idiot' competition?",
          "sentiment": 0.0,
          "engagement": "8,596",
          "price_at_post": "54.50",
          "thread_title": "RE: CC interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=F5A9F3B7-45F7-4EC2-B1FD-1ACB3A2D2E18"
        },
        "ingested_at": "2026-01-29T12:41:41.868213+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261515-cj62--1342455",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.811569",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "That's theoretical of course. Thorn its like 99% of the other gibberish you post twat.",
          "sentiment": 0.0,
          "engagement": "4,270",
          "price_at_post": "54.50",
          "thread_title": "RE: CC interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=F5A9F3B7-45F7-4EC2-B1FD-1ACB3A2D2E18"
        },
        "ingested_at": "2026-01-29T12:41:41.868251+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20262313-aidanjc--8927964",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.524270",
        "source": "LSE_CHAT",
        "data": {
          "author": "aidanjc",
          "content": "Good point.  If cancer treatments improve that is a fantastic result. Its crept into my life a lot recently. Great to make a profit on the shares but improving outcomes for cancer patients is really important.",
          "sentiment": 0.0,
          "engagement": "6",
          "price_at_post": "51.50",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-01-31T00:40:42.739956+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20262051-avctIPma--5113510",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.524706",
        "source": "LSE_CHAT",
        "data": {
          "author": "avctIPmatters",
          "content": "Thanks for sharing  B2HS2L  -  Helps spread info on the platform  .",
          "sentiment": 0.0,
          "engagement": "728",
          "price_at_post": "51.50",
          "thread_title": "RE: CDD European Life Science Community Meeting",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=3A2F031D-C16F-4949-B22E-8512255BE282"
        },
        "ingested_at": "2026-01-31T00:40:42.739983+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20262049-avctIPma-25923542",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.525140",
        "source": "LSE_CHAT",
        "data": {
          "author": "avctIPmatters",
          "content": "Thanks for sharing  Thompi -  All helps spread   Avacta exposure .",
          "sentiment": 0.0,
          "engagement": "728",
          "price_at_post": "51.50",
          "thread_title": "RE: World CB & CDx Summit Europe",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=18E94451-D174-452E-BD8A-79154E17863F"
        },
        "ingested_at": "2026-01-31T00:40:42.740020+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20262022-Livedata--7717205",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.525565",
        "source": "LSE_CHAT",
        "data": {
          "author": "Livedataaccount",
          "content": "Ellen's great she will do a fantastic presentation",
          "sentiment": 0.0,
          "engagement": "2,957",
          "price_at_post": "51.50",
          "thread_title": "RE: CDD European Life Science Community Meeting",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=3A2F031D-C16F-4949-B22E-8512255BE282"
        },
        "ingested_at": "2026-01-31T00:40:42.740056+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20262016-B2HS2L--8957410",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.525997",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "Https://www.collaborativedrug.com/cdd-european-scientific-community-meeting-2026 Dr Ellen Watts, Avacta Therapeutics 25.02.2026  17:00-17:30: Delivering Targeted Therapies Using the pre|CISION\u00ae Platform. Last presentation of the day",
          "sentiment": 0.0,
          "engagement": "6,003",
          "price_at_post": "51.50",
          "thread_title": "CDD European Life Science Community Meeting",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=3A2F031D-C16F-4949-B22E-8512255BE282"
        },
        "ingested_at": "2026-01-31T00:40:42.740081+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261732-Timster--8574904",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.526420",
        "source": "LSE_CHAT",
        "data": {
          "author": "Timster",
          "content": "Good spot Thompi, thanks",
          "sentiment": 0.0,
          "engagement": "20,626",
          "price_at_post": "51.50",
          "thread_title": "RE: World CB & CDx Summit Europe",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=18E94451-D174-452E-BD8A-79154E17863F"
        },
        "ingested_at": "2026-01-31T00:40:42.740110+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261722-Thompi-66180586",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.526848",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thompi",
          "content": "Ruairidh Edwards will be speaking on 1 April at the 16th World Clinical Biomarkers & Companion Diagnostics Summit Europe. Presentation title: Establishing a Biomarker-Driven Approach to Guide Patient Selection for preCISION\u00ae Peptide-Drug Conjugates Using Tumour Targeting/Release and Payload Sensitivity Biomarkers. https://cdx-europe.com/full-event-guide/",
          "sentiment": 0.0,
          "engagement": "1,358",
          "price_at_post": "51.50",
          "thread_title": "World CB & CDx Summit Europe",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=18E94451-D174-452E-BD8A-79154E17863F"
        },
        "ingested_at": "2026-01-31T00:40:42.740130+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261707-Agenda10-40099385",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.527323",
        "source": "LSE_CHAT",
        "data": {
          "author": "Agenda101",
          "content": "No not engage ! It\u2019s working so let\u2019s continue to starve them of any engagement. As Runner-Runner wrote and BV reposted\u2026 It's simple. 1. DO NOT ENGAGE 2. DO NOT ASK IT A QUESTION 3. DO NOT ANSWER ITS QUESTIONS 4. DO NOT MOAN ABOUT ITS POSTS 5. DO NOT ARGUE WITH IT 6. If you must do something. Mock it with reference only to its stupidity and nothing else. ------------------------------------------------------ If you're not part of the solution, you're part of the problem",
          "sentiment": 0.0,
          "engagement": "72",
          "price_at_post": "52.50",
          "thread_title": "RE: Bone Marrow Toxicity, Brain malignancies?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=34DD9B68-3AA3-4F24-A8A5-8F742D7F4948"
        },
        "ingested_at": "2026-01-31T00:40:42.740148+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261704-Agenda10-23351467",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.527740",
        "source": "LSE_CHAT",
        "data": {
          "author": "Agenda101",
          "content": "\u201cI\u2019m committed for the next two years, but I anticipate that developments around licensing, manufacturing, and supply will begin to materialise well before then. From my perspective, the time to push ahead is now.\u201d",
          "sentiment": 0.0,
          "engagement": "72",
          "price_at_post": "51.50",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-01-31T00:40:42.740166+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261656-Thornogs-22212161",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.528205",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Well I didn't post! Not much said I see. More chat about FAP expressed on inflamed/fibrotic tissue other than cancer as a positive therapeutic opportunity with no one wondering if this self same tissue might cause problems should someone inject a FAP released 'Beast' into the circulation whilst trying to target a FAP related cancer.  Were that to happen in the FAP-EXD 1a Safety trial I think it would count as a Black Mark. BV and Syphysus indulged their in depth knowledge of molecular biology and the Blood Brain Barrier to 'deep dive' the potential to treat cerebral cancers, I do hope CC read those posts or perhaps one of you could send her an e mail explaining the possibilities? And the Market did what I thought it would do, go down, down the at the last come back up to almost, but not quite, where we opened. 1% down today, 3% this week and 10% down on the month. I see this continuing until the surprise deal mentioned earlier or being more realistic the next raise to fund the programme through 2026. Any thoughts on support/resistance levels Wyn? Happy to be out waiting for FAP-EXD and funding doubts to clear.",
          "sentiment": 0.0,
          "engagement": "8,666",
          "price_at_post": "51.50",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-01-31T00:40:42.740184+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261643-wyndrum--4835270",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.528628",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "I see \u201cthe don\u2019t engage\u201d policy didn\u2019t last long. You simply can\u2019t have a bb devoted to the actual topic and miss out on insulting others can you? Predictable and pathetic behaviour. Who knew?",
          "sentiment": 0.0,
          "engagement": "12,228",
          "price_at_post": "51.50",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-01-31T00:40:42.740202+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261640-D-Geeman--2662468",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.529049",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "'Chris, are you still interested in my buys and sells or would you prefer me not to bother?' Chris might not be interested Wyn, but I am... I dare say I'm not alone either.",
          "sentiment": 0.0,
          "engagement": "5,849",
          "price_at_post": "51.00",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-01-31T00:40:42.740220+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261639-Toukanka-85421524",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.529486",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "BV Are you a lawyer? We were led to believe that 6000 P1b would finish end of 25. So you don\u2019t regard having to go an extra cycle as missing a target. Or all the talk of multiple events before end 25 as not materialising. Anyhow at least some people on here are rooted in reality and believe CC when she says not to expect much before 2H26. Be. Patient",
          "sentiment": 0.0,
          "engagement": "4,454",
          "price_at_post": "51.00",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-01-31T00:40:42.740238+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261631-cj62--5289378",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.529902",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "Fine with me Chris. I would remind you however that it was you that asked I report my trades. You did report your last losing trade though did you, you prick",
          "sentiment": 0.0,
          "engagement": "4,282",
          "price_at_post": "51.50",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-01-31T00:40:42.740256+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261628-BuenaVis--7489762",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.530336",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Yes, that could be one possibility.",
          "sentiment": 0.0,
          "engagement": "5,775",
          "price_at_post": "51.50",
          "thread_title": "RE: Bone Marrow Toxicity, Brain malignancies?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=34DD9B68-3AA3-4F24-A8A5-8F742D7F4948"
        },
        "ingested_at": "2026-01-31T00:40:42.740274+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261622-wyndrum-27770064",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.530749",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "Fine with me Chris. I would remind you however that it was you that asked I report my trades. Anyway I\u2019m keen to see how this bb goes from here.",
          "sentiment": 0.0,
          "engagement": "12,228",
          "price_at_post": "51.50",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-01-31T00:40:42.740293+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261615-HarChris--3994767",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.531177",
        "source": "LSE_CHAT",
        "data": {
          "author": "HarChris",
          "content": "The last time I pointed out your losing trade you responded by saying you barely had anything on it\u2026 so nah, don\u2019t bother if you can just twist it how you want. And it clogs up the bb even more! How about not sharing any and trying not to care what an anonymous group of people think about your trading prowess?! That would be healthier!",
          "sentiment": 0.0,
          "engagement": "15,870",
          "price_at_post": "51.50",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-01-31T00:40:42.740311+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261613-Agenda10--7501487",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.531589",
        "source": "LSE_CHAT",
        "data": {
          "author": "Agenda101",
          "content": "None.. he\u2019s fishing don\u2019t reply!",
          "sentiment": 0.0,
          "engagement": "72",
          "price_at_post": "51.50",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-01-31T00:40:42.740330+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261547-BuenaVis--4131825",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.532000",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "@russell1 , what deadlines has Avacta missed since CC became CEO on 1 May 2024?",
          "sentiment": 0.0,
          "engagement": "5,775",
          "price_at_post": "51.00",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-01-31T00:40:42.740349+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261536-russell1-70764369",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.532426",
        "source": "LSE_CHAT",
        "data": {
          "author": "russell1",
          "content": "Well I'm not prepared to add any more money to my current loss situation so my only decision is whether to sell a proportion of my holding and hope I can buy back at a lower price if we (ever) get some worthwhile news or just leave it and hope! My expectation is that the price will just drift down until any news arrives but I have no expectation that this company will ever meet any of its reported deadlines.",
          "sentiment": -0.5,
          "engagement": "315",
          "price_at_post": "51.00",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-01-31T00:40:42.740368+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261529-Sisyphus--1225662",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.532837",
        "source": "LSE_CHAT",
        "data": {
          "author": "SisyphusShorter",
          "content": "Thanks BV, good to know. So in theory, a \"FAP-Temo\" agent would be roughly 460Da in size, provided the same Gen1 preCISION peptide is used. That puts it within the 400-600 threshold for BBB-crossing possibility (obviously notwithstanding lipophilicity, polarity and other parameters). That being said they could always cleave off a few residues to make a lightweight version for this specific indication.",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "51.00",
          "thread_title": "RE: Bone Marrow Toxicity, Brain malignancies?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=34DD9B68-3AA3-4F24-A8A5-8F742D7F4948"
        },
        "ingested_at": "2026-01-31T00:40:42.740387+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261509-Toukanka-28199741",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.533258",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "At last sensible posters instead of the usual carp \u201cfill yer boots you\u2019ll never again get the chance at this SP\u201d.  In truth we have a sideways drift until 6103 early clinical results are published in the Summer. Get over it and be patient.",
          "sentiment": 0.0,
          "engagement": "4,454",
          "price_at_post": "51.00",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-01-31T00:40:42.740405+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261432-wyndrum--4179704",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.533670",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "Chris, are you still interested in my buys and sells or would you prefer me not to bother?",
          "sentiment": 0.0,
          "engagement": "12,228",
          "price_at_post": "51.00",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-01-31T00:40:42.740424+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261413-Aston15--7186574",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.534076",
        "source": "LSE_CHAT",
        "data": {
          "author": "Aston15",
          "content": "I have brought enough now to be comfortable with the risk to reward ratio. 10% of my SIPP now in AVCT following another purchase this week. Many are expecting more than this, but my target remains a 5 billion valuation for the platform minimum. Happy to leave this to run now and hope the team delivers a positive outcome for both patients and shareholders.",
          "sentiment": 0.0,
          "engagement": "62",
          "price_at_post": "50.50",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-01-31T00:40:42.740442+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261410-B2HS2L--3832496",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.534502",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "Slide 16 & 18 of the Investormeet presentation 17.12.2025 contain info on tumor biopsies as articulated by Ruairidh Edwards, Translational Scientist. He's discussing phase 1b patients, possibly placing the recording of the interview before mid December.",
          "sentiment": 0.0,
          "engagement": "6,003",
          "price_at_post": "50.50",
          "thread_title": "RE: Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-01-31T00:40:42.740461+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261347-Vertizea--3232010",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.529148",
        "source": "LSE_CHAT",
        "data": {
          "author": "VertizeaSun",
          "content": "I think it links with CC's visit to Glasgow.....to visit the manufacturing site of AVA6103 and its \"first pour\".",
          "sentiment": 0.0,
          "engagement": "433",
          "price_at_post": "50.50",
          "thread_title": "RE: Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-01-31T00:40:42.740479+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261340-BuenaVis--7702142",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.529619",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Whilst the introduction by the host was current (post-IND announcement), CC seemed to be referencing passed events as being in the future and someone here suggested that the interview was recorded last year, in early December if I remember correctly.  I haven't listened to the interview again today but I do remember hearing bits that seemed out of step with today's situation.",
          "sentiment": 0.0,
          "engagement": "5,775",
          "price_at_post": "50.50",
          "thread_title": "RE: Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-01-31T00:40:42.740497+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261326-BuenaVis-55000483",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.530089",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Interesting and intelligent quesitions. As regards, fibrotic targets due to prior anthracycline treatment, it'll be interesting to see whether this side effect is reduced in previously untreated patients.  The breakdown of side effects vs prior treatment hasn't been presented yet but it is exacty the sort of detail I'm wanting to see (also, for example, side effects vs cancer indication/metastasis site).  Hopefully it will be included when the Phase 1 trial is written up in a peer-reviewed article, but there's always the AGM as an opportunity for asking detailed questions in person. As regards crossing the blood-brain barrier (BBB)... Temozolomide - molecular weight: 194.15 Da Doxorubicin - molecular weight: 543.52 Da Faridoxorubicin - molecular weight: 816.8 Da Faridoxorubicin without doxorubicin: 273.28 Da According to Gemini, \"Drugs that cross the BBB generally must be lipophilic (lipid-soluble), have a low molecular weight\u2014typically under 400\u2013600 Da\u2014and have a low polar surface area or few hydrogen bonds. They must avoid active efflux transport systems (like P-glycoprotein) and not be highly bound to plasma proteins.\"  So the requirements for an IV infusion drug are pretty stringent. However, there is an alternative route and that is, again according to Gemini, \"[administration] directly into the brain to bypass the BBB. This approach, known as local or regional drug delivery, is used to treat primary brain tumors (like glioblastoma) or brain metastases, allowing high concentrations of medication to reach the tumor without causing systemic toxicity.\"  I should think that the advantage of using pre|CISION for this is that, whilst the pre|CISION drug itself would be too big to cross OUT of the brain, the warhead, its metabolites and the leaving group from the pre|CISION substrate could all be below the size needed to cross out of the brain.  Anyway, CC wouldn't have specifically mentioned brain cancer if it weren't a possibility.",
          "sentiment": 0.0,
          "engagement": "5,775",
          "price_at_post": "50.50",
          "thread_title": "RE: Bone Marrow Toxicity, Brain malignancies?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=34DD9B68-3AA3-4F24-A8A5-8F742D7F4948"
        },
        "ingested_at": "2026-01-31T00:40:42.740516+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261318-IFA90--4412883",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.530517",
        "source": "LSE_CHAT",
        "data": {
          "author": "IFA90",
          "content": "I\u2019m not buying anymore. I\u2019ve increased my holding this week by selling a % and buying back c.10% cheaper. After 5 years it\u2019s entirely predictable, I just wish I\u2019d have realised that 3 years ago.",
          "sentiment": 0.0,
          "engagement": "409",
          "price_at_post": "50.50",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-01-31T00:40:42.740534+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261312-wyndrum-61360146",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.530949",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "Yes cj and I have just literally sold that holding and more as it looks to confused to me right now. Just so you know and can keep up I placed the sale evenly between Cpx and Xsg. Personally I would enjoy exploring and explaining my reasoning in a bit more depth but no need to is interested. ( and while you may all feel a bit more smug about this, it might be worth reflecting that I don\u2019t illicit the antagonist relationship here on other bb\u2019s. It begs the question is it me or you?)",
          "sentiment": 0.0,
          "engagement": "12,228",
          "price_at_post": "50.50",
          "thread_title": "RE: ADC 26",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=F3B63190-B417-42B7-9CC8-0ED98F4FBB92"
        },
        "ingested_at": "2026-01-31T00:40:42.740552+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261301-cj62--5317970",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.531376",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "\"Well the sp is 52p and now years later my analysis over a vey long period has proved correct and his wrong.\" but not recently you could have added- bought at 56.95 i believe. Yet still there are some that want me to be cancelled, yep you have that 100% correct as your narcissim knows no bounds",
          "sentiment": 0.0,
          "engagement": "4,282",
          "price_at_post": "50.50",
          "thread_title": "RE: ADC 26",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=F3B63190-B417-42B7-9CC8-0ED98F4FBB92"
        },
        "ingested_at": "2026-01-31T00:40:42.740570+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261254-Sisyphus-30001079",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.531796",
        "source": "LSE_CHAT",
        "data": {
          "author": "SisyphusShorter",
          "content": "So been looking at the phase 1 data for AVA6000 and also been listening to the podcast, thanks BV. Now I have two broad questions: One on bone/haem side effects, and one regarding primary brain cancers. Firstly, of the patients we have seen with bone marrow suppression, I know it's a known side effect of Dox, but I do wonder if prior primary therapies have induced a bit of fibrosis in the marrow, leading to FAP expression and thus Dox being released, leading to further bone marrow toxicity. That would imply that the side effects seen in the patients so far are less likely to emerge in a larger trial with a higher proportion of chemo-naive patients. Thoughts? Secondly, CC mentioned in the podcast that given that 90% of solid tumours express FAP, including brain, which she mentioned, and this begs the question whether or not the Peptide used in pre/CISION drug conjugates is small enough to pass the blood-brain-barrier, after all, that's how Temozolomide can do it's think for brain tumours. Again, thoughts?",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "50.50",
          "thread_title": "Bone Marrow Toxicity, Brain malignancies?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=34DD9B68-3AA3-4F24-A8A5-8F742D7F4948"
        },
        "ingested_at": "2026-01-31T00:40:42.740588+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261253-pedrolan-81019535",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.532225",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Yes, I bought some more the other week and am considering more now to get my average down further. If you believe in the medium term story here (with the bonus of a potential deal at any time) then it seems a bargain. Before any of the aliases bother to reply - I will not be responding to it - it will not be anything we have not all heard multiple times anyway.",
          "sentiment": 0.5,
          "engagement": "1,975",
          "price_at_post": "51.00",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-01-31T00:40:42.740607+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261252-BuenaVis-60401908",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.532633",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Another advantage of Avacta's PDCs is the h o m ogeneity of the dosage - exactly one warhead per drug molecule, or exactly two warheads per drug molecule for the dual payload drugs. In contrast, significant heterogeneity exists in ADCs as they are complex mixtures of varied molecular species rather than a single uniform compound. This includes differences in the drug-to-antibody ratio (DAR) and the conjugation sites on the antibody, leading to mixtures with 0 to 8+ payload molecules and various positional isomers.",
          "sentiment": 0.0,
          "engagement": "5,775",
          "price_at_post": "51.00",
          "thread_title": "RE: ADC 26",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=F3B63190-B417-42B7-9CC8-0ED98F4FBB92"
        },
        "ingested_at": "2026-01-31T00:40:42.740626+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261250-aidanjc--5123756",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.533041",
        "source": "LSE_CHAT",
        "data": {
          "author": "aidanjc",
          "content": "I've been a lth here having bought at several levels. Was hoping not to see us back around the 50p level. I've bought a few more. Anyone else buying. I'm hoping 50p will be the low tide mark...",
          "sentiment": 0.5,
          "engagement": "6",
          "price_at_post": "51.00",
          "thread_title": "Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-01-31T00:40:42.740644+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261246-wyndrum-29547928",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.533480",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "Also I don\u2019t care if you respond or not. I just hope it makes you think.also you will crack before we do. Not because it\u2019s a contest but simply we will ask questions or post opinions that as a bb you will naturally want to respond to. That\u2019s the whole purpose of a discussion bb. To discuss. And while there are a lot of recs to want us to be cancelled you will soon be bored with the lack of insight offered by the so called guardians of this bb. And never forget, it is exactly the same posters that by insulting us that then generate the board clogging are the ones piously demanding we be ignored. Just check sheppy watching bv and the rest for their overall contribution.",
          "sentiment": 0.0,
          "engagement": "12,228",
          "price_at_post": "51.00",
          "thread_title": "RE: ADC 26",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=F3B63190-B417-42B7-9CC8-0ED98F4FBB92"
        },
        "ingested_at": "2026-01-31T00:40:42.740662+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261243-Sisyphus--1225833",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.533883",
        "source": "LSE_CHAT",
        "data": {
          "author": "SisyphusShorter",
          "content": "Sorry, *Next* data release....",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "51.00",
          "thread_title": "RE: Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-01-31T00:40:42.740680+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261240-Sisyphus--8663293",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.534310",
        "source": "LSE_CHAT",
        "data": {
          "author": "SisyphusShorter",
          "content": "At 36:22 CC says, regarding tumour biopsies - \"...in our new data release which will be later this month...\" Make of that what you will..... GLA",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "51.00",
          "thread_title": "RE: Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-01-31T00:40:42.740699+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261232-wyndrum--7446972",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.534763",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "Oh, I remember, after this interview and the other stuff uncovered, what has the sp done? Why ,  How, can there be more sellers than buyers? Let\u2019s move on from the \u201csp doesn\u2019t matter \u201c. It\u2019s a facile statement which simply refuses to address a perfectly reasonable question. Yes the sp can drift up or down on no news but why can\u2019t we discuss it when there is a very positive release and it generates sells? By all means keep up this do not engage but myles tried this with me specifically on this bb with a little header to try and get me banned altogether. Well the sp is 52p and now years later my analysis over a vey long period has proved correct and his wrong. Yet still there are some that want me to be cancelled. You lot are either just plain weird or it is you that have an agenda. Just remember I have made money out of this stock and had you agreed with my view you would have too. The opposite would have happened if you followed bv and the rest. Yet you want me silenced. You might perhaps realise why I wonder what motivates the majority here.",
          "sentiment": 0.0,
          "engagement": "12,228",
          "price_at_post": "51.00",
          "thread_title": "RE: ADC 26",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=F3B63190-B417-42B7-9CC8-0ED98F4FBB92"
        },
        "ingested_at": "2026-01-31T00:40:42.740717+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261221-Watching-55943925",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.535189",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "To the Fudders they are trying so hard this morning ! It worked yesterday ! They are drying up \ud83e\udd21s",
          "sentiment": 0.0,
          "engagement": "9,215",
          "price_at_post": "51.00",
          "thread_title": "Do not respond",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=598797E4-B255-4509-971C-C103D6214E00"
        },
        "ingested_at": "2026-01-31T00:40:42.740735+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261143-wyndrum--2648178",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.535610",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "whatever you do, do not do not reply  or respond. you might want to take the ****, but resist. you might have the best put down ever! but do not repeat do not respond  got it? now what was i going to say\u2026. damn after all that i forgot \u2026.,",
          "sentiment": 0.0,
          "engagement": "12,228",
          "price_at_post": "52.00",
          "thread_title": "RE: ADC 26",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=F3B63190-B417-42B7-9CC8-0ED98F4FBB92"
        },
        "ingested_at": "2026-01-31T00:40:42.740753+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261014-HarryAng--6415846",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.536027",
        "source": "LSE_CHAT",
        "data": {
          "author": "HarryAngstrom",
          "content": "I meant PEAK SALES to Avacta... not TAM.",
          "sentiment": 0.0,
          "engagement": "9",
          "price_at_post": "52.50",
          "thread_title": "RE: Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-01-31T00:40:42.740771+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260955-D-Geeman-37829989",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.536554",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "'Today 09:44 Don't waste time responding if your handle is ........ D-Geeman ' You sound like a teenager with a statement like that B2HS2L. In this context that isn't a compliment.",
          "sentiment": 0.0,
          "engagement": "5,849",
          "price_at_post": "53.00",
          "thread_title": "RE: ADC 26",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=F3B63190-B417-42B7-9CC8-0ED98F4FBB92"
        },
        "ingested_at": "2026-01-31T00:40:42.740788+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260946-HarryAng--4577257",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.537041",
        "source": "LSE_CHAT",
        "data": {
          "author": "HarryAngstrom",
          "content": "This is a gigantic opportunity. TAM for Rhematoid Arthritis would be between $3.0 - $4.0 billion. And if they move into Fibrosis, the TAM there is between $7.0 - $10.0 billion. Once they prove they can deliver a toxin as potent as Exatecan using the FAP linker, using the same linker for milder anti-fibrotic or anti-inflammatory drugs is a low risk, high reward certainty.",
          "sentiment": 0.0,
          "engagement": "9",
          "price_at_post": "52.50",
          "thread_title": "RE: Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-01-31T00:40:42.740811+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260944-B2HS2L--5250424",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.537575",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "Don't waste time responding if your handle is wyndrum, Thornogson, Toukankahmoon or D-Geeman ********************************************************************************************************* Like my new header?  \ud83d\ude01\ud83d\ude09   I hope you create similar. In the event one company buys Avacta, all others will need to continue developing ADC's. They'll need to make improvements to compete as follows: 1 Reduce the time required to develop new drugs. 2 Improve the precision of targeting of warheads, so less drug is available systemically. 3 Improve the ease and speed of manufacturing 4 Find ways to reduce particle size 5 Find ways to deliver >1 drug at a time. Also - * Small molecule manufacturing and timeline/COGM (cost of goods manufactured) \"What that statement means and why that is important, is that the price tag for this drug (AVA6000), is one tenth of the price tag for an ADC drug. ADC's cost a lot of money in the clinic\"  CC 8.11.2024 I don't see why the statement isn't also true for AVA6103. ++++ A reminder from  Trinity Delta \u2013 Targeting the tumour microenvironment with pre|CISION - 18.11.2024 https://www.trinitydelta.org/research-notes/targeting-the-tumour-microenvironment-with-precision/ \"Avacta has so far FAP-enabled ten different warheads building up a database of multiple pre|CISION compounds that include c 40 capping groups (which alter the PK of the conjugate) and c 20   linkers (required for FAP cleavage with certain warheads and can be used to modify FAP affinity and activity). These have all been characterised through computational simulations to evaluate molecular binding and how they dock into the FAP structure. A key consideration is how close the warhead can get to the FAP cleavage sequence; this typically depends on the size of the molecule, and often defines whether a spacer group is required. Consideration is also given to how long the conjugate and the active warhead are likely to remain in the TME, and this informs whether PK alterations, achieved through an alternative capping group, are needed to either allow the sustained release of the warhead or to slow plasma clearance. Potential candidate molecules that meet the internal hurdle are also evaluated in vivo to investigate key PK parameters and cytotoxicity, with some selected for further characterisation in vitro and in vivo to establish preclinical efficacy and safety in a wide range of FAP tumour expression models with low serum FAP (including co-cultures of tumour cells and CAFs) to recapitulate the human TME.\" ++++ I'll bet there is more than ten warheads, forty capping groups and twenty linkers now!",
          "sentiment": 0.0,
          "engagement": "6,003",
          "price_at_post": "53.00",
          "thread_title": "RE: ADC 26",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=F3B63190-B417-42B7-9CC8-0ED98F4FBB92"
        },
        "ingested_at": "2026-01-31T00:40:42.740829+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260931-BuenaVis-33790686",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.537985",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Really does feel like adding Go Faster stripes at a horse fair.",
          "sentiment": 0.0,
          "engagement": "5,775",
          "price_at_post": "53.00",
          "thread_title": "RE: ADC 26",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=F3B63190-B417-42B7-9CC8-0ED98F4FBB92"
        },
        "ingested_at": "2026-01-31T00:40:42.740848+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260910-Yorkshir--7877295",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.538411",
        "source": "LSE_CHAT",
        "data": {
          "author": "Yorkshirepragma",
          "content": "CC refers to other applications \u2026Chronic Inflammation \u2018conversations\u2019 are interesting . One step at a time \u2026.",
          "sentiment": 0.0,
          "engagement": "1,804",
          "price_at_post": "53.00",
          "thread_title": "RE: Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-01-31T00:40:42.740866+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260845-Yorkshir--2791346",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.538852",
        "source": "LSE_CHAT",
        "data": {
          "author": "Yorkshirepragma",
          "content": "Fascinating similarity re Avactas current development processes. Tuesday 24th February 2026 The Next Generation of ADCs: Leveraging Novel Conjugation & Enhanced Antibody Engineering for the Future of Targeted Oncology Therapies 9:15 am Laying out the scope to differentiate ADC development through novel conjugation, antibody engineering, and target identification approaches to widen therapeutic index and bring patient benefit Incorporating in silico and AI tools to enhance the ADC discovery toolbox and deliver next-generation ADC engineering and design Highlighting future priorities for next-generation ADC development, including exploring the potential of radio conjugates",
          "sentiment": 0.0,
          "engagement": "1,804",
          "price_at_post": "53.00",
          "thread_title": "ADC 26",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=F3B63190-B417-42B7-9CC8-0ED98F4FBB92"
        },
        "ingested_at": "2026-01-31T00:40:42.740884+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260811-Agenda10--1196371",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.539272",
        "source": "LSE_CHAT",
        "data": {
          "author": "Agenda101",
          "content": "Cheers BV!",
          "sentiment": 0.0,
          "engagement": "72",
          "price_at_post": "53.00",
          "thread_title": "RE: Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-01-31T00:40:42.740902+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260754-cj62-91685090",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.539688",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "Who would be allowed access ?",
          "sentiment": 0.0,
          "engagement": "4,282",
          "price_at_post": "53.00",
          "thread_title": "Data Room",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=85F98FAE-01B2-48EC-B9D0-584FAD2B9731"
        },
        "ingested_at": "2026-01-31T00:40:42.740920+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260751-Thornogs-19017403",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.713580",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "This one and one after the close to comment on the top quality discussion and to check if we finished up or not.",
          "sentiment": 0.0,
          "engagement": "8,666",
          "price_at_post": "53.00",
          "thread_title": "2 post Friday.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=EDA1F112-F6D9-49A4-937D-081A93C2E757"
        },
        "ingested_at": "2026-01-31T00:40:42.740938+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260626-Gingethe--8511081",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.714067",
        "source": "LSE_CHAT",
        "data": {
          "author": "GingetheWinge",
          "content": "The FUDsters are thrashing like Terminator 2 in a smelting cauldron. It\u2019s working so let\u2019s continue to starve them of any engagement. As Runner-Runner wrote and BV reposted\u2026 It's simple. 1. DO NOT ENGAGE 2. DO NOT ASK IT A QUESTION 3. DO NOT ANSWER ITS QUESTIONS 4. DO NOT MOAN ABOUT ITS POSTS 5. DO NOT ARGUE WITH IT 6. If you must do something. Mock it with reference only to its stupidity and nothing else. ------------------------------------------------------ If you're not part of the solution, you're part of the problem",
          "sentiment": 0.5,
          "engagement": "700",
          "price_at_post": "53.00",
          "thread_title": "No not engage !",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=A348D8E1-4DC7-4D49-950E-08F79BC3A2D1"
        },
        "ingested_at": "2026-01-31T00:40:42.740956+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260138-BuenaVis--6175781",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.714500",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Even better link: https://www.youtube.com/watch?v=HWkh3OEFSds&t=1333s",
          "sentiment": 0.0,
          "engagement": "5,775",
          "price_at_post": "53.00",
          "thread_title": "RE: Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-01-31T00:40:42.740974+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260132-BuenaVis--6935910",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.714925",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "It's the Base to Base biotech podcast from a few days ago. Well worth a listen. Here's the link to the start of the CC interview: https://www.youtube.com/watch?v=HWkh3OEFSds&t=1290s",
          "sentiment": 0.0,
          "engagement": "5,775",
          "price_at_post": "53.00",
          "thread_title": "RE: Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-01-31T00:40:42.740992+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262331-D-Geeman--4808850",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.715361",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "Wasn\u2019t wyn comparing this BB to \u2018Lord of the Flies\u2019 classic story? Well for those who don\u2019t know the story I just caught a trailer for new BBC production starting soon; https://www.bbc.com/mediacentre/2026/lord-of-the-flies-trailer",
          "sentiment": 0.0,
          "engagement": "5,849",
          "price_at_post": "53.00",
          "thread_title": "RE: Avacta Therapeutics celebrates this",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=03B0B4A6-705E-45ED-983A-A89C321C0924"
        },
        "ingested_at": "2026-01-31T00:40:42.741010+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262302-alextak--9156869",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.715781",
        "source": "LSE_CHAT",
        "data": {
          "author": "alextak",
          "content": "Is it a new interview? .I'll listen to it tomorrow.",
          "sentiment": 0.0,
          "engagement": "540",
          "price_at_post": "53.00",
          "thread_title": "RE: Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-01-31T00:40:42.741028+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262258-alextak--2766927",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.716203",
        "source": "LSE_CHAT",
        "data": {
          "author": "alextak",
          "content": "Https://youtu.be/HWkh3OEFSds?si=0KezbLZbtRJA4N97",
          "sentiment": 0.0,
          "engagement": "540",
          "price_at_post": "53.00",
          "thread_title": "Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-01-31T00:40:42.741046+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262241-pedrolan--7192230",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.716624",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "When no-one engages that's what they end up with. Good work folks.",
          "sentiment": 0.5,
          "engagement": "1,975",
          "price_at_post": "53.00",
          "thread_title": "Voices in the wilderness",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=8AE5A358-4CCC-4E25-A8A9-D4C3BBC9FF5F"
        },
        "ingested_at": "2026-01-31T00:40:42.741063+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262222-Thornogs--1479250",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.717039",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Absolutely Pedro! All those who chance upon the LSE Avacta bulletin board and haven't been keeping up with the news, all of them? Exposure indeed, keep up the good work everybody!",
          "sentiment": 0.0,
          "engagement": "8,666",
          "price_at_post": "53.00",
          "thread_title": "RE: Avacta Therapeutics celebrates this",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=03B0B4A6-705E-45ED-983A-A89C321C0924"
        },
        "ingested_at": "2026-01-31T00:40:42.741081+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262202-pedrolan--2196930",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.717464",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "All great exposure. Thanks for posting \ud83d\udc4d\ud83c\udffb",
          "sentiment": 0.5,
          "engagement": "1,975",
          "price_at_post": "53.00",
          "thread_title": "RE: Avacta Therapeutics celebrates this",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=03B0B4A6-705E-45ED-983A-A89C321C0924"
        },
        "ingested_at": "2026-01-31T00:40:42.741107+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262145-Thornogs--3865863",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.717891",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Well there we have it Avcti, proof positive fof all those 'FUDsters' who have been saying otherwise all day! Avacta can produce FAP-EXD for the upcoming trial! What chance does 'FUD' have against this level of research and knowledge? Hang your heads in shame all those saying that it wasn't possible. Was anyone suggesting this?",
          "sentiment": 0.0,
          "engagement": "8,666",
          "price_at_post": "53.00",
          "thread_title": "RE: \" So excited to get the trial going soon. \"",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=C91568DF-F421-4695-901C-78161A0F4CD6"
        },
        "ingested_at": "2026-01-31T00:40:42.741127+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262110-avctIPma--4699638",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.718379",
        "source": "LSE_CHAT",
        "data": {
          "author": "avctIPmatters",
          "content": "FYI   Christina CoughlinChristina Coughlin \u2022 3rd+Verified \u2022 3rd+ Chief Executive Officer, AvactaChief Executive Officer, Avacta 53m \u2022  53 minutes ago \u2022 Visible to anyone on or off LinkedIn Follow We are thrilled to partner with our team at Curia - this partnership has enabled our team at hashtag#AVCT to move FAP-exatecan forward at record pace. So excited to get the trial going soon. This combined team reminds me of a favorite quote, \u201cNever doubt that a small group of thoughtful, committed citizens can change the world. Indeed, it is the only thing that ever has.\u201d \u2014Margaret Mead. hashtag#LetsDoThis hashtag#HopeWithoutCompromise CuriaCuria 104,425 followers104,425 followers 2h \u2022  2 hours ago \u2022 Visible to anyone on or off LinkedIn Follow Congratulations to Avacta Therapeutics on receiving U.S. Food and Drug Administration (FDA) clearance of the Investigational New Drug (IND) application for the Company\u2019s second program FAP-Exd (AVA6103). This peptide drug conjugate is based on the highly potent topoisomerase I inhibitor, exatecan. A Phase 1 clinical trial will enroll patients with solid tumors, pancreatic cancer, cervical cancer, gastric cancer and small cell lung cancer. CURIA STERILE DRUG PRODUCT business unit is proud to assist this cutting-edge oncology program with formulation development, analytical support and GMP clinical supply at our site in Glasgow. Read more about Avacta in the recent press release: https://hubs.li/Q040N2nz0",
          "sentiment": 0.0,
          "engagement": "728",
          "price_at_post": "53.00",
          "thread_title": "\" So excited to get the trial going soon. \"",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=C91568DF-F421-4695-901C-78161A0F4CD6"
        },
        "ingested_at": "2026-01-31T00:40:42.741145+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262104-wyndrum--2612814",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.718829",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "So you\u2019re right and I am wrong as you have said umpteen times  yet it is me who is the narcissist? You don\u2019t even know what the term means in detail yet bandi it about as a diagnosis of a stranger you know nothing about. Your arrogance in libelling me without any justification only amplifies my point. But in none of these umpteen times have you ever wondered why AVCT have failed to deliver the returns you expected when you first bought in ? No of course not. That would require self examination. Something you seem to lack but have no inhibition in accusing others of. The arrogance of the arguments directed at me are so cliched and bereft of any true accuracy that it is simply pathetic. What is so considerably worse is the recs they get. Not because it offends me more but rather of the evidence that so may can\u2019t reason for themselves and blithely agree. It\u2019s not a case of reading the room, more a case of group think. Under your reasoning we would all still think the earth was flat.",
          "sentiment": 0.0,
          "engagement": "12,228",
          "price_at_post": "53.00",
          "thread_title": "RE: Worldwide ADC Innovation & Collaboration   London",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=CB66756C-50A3-4D04-A499-ADC1B8951801"
        },
        "ingested_at": "2026-01-31T00:40:42.741163+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262104-Metatron-48045692",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.719249",
        "source": "LSE_CHAT",
        "data": {
          "author": "Metatron",
          "content": "Forgot.. dammit.. sawy \ud83e\udd14",
          "sentiment": 0.0,
          "engagement": "1,188",
          "price_at_post": "53.00",
          "thread_title": "RE: Worldwide ADC Innovation & Collaboration   London",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=CB66756C-50A3-4D04-A499-ADC1B8951801"
        },
        "ingested_at": "2026-01-31T00:40:42.741181+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262051-BuenaVis--8946779",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.719657",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Do not feed the troll. \ud83e\udd2a",
          "sentiment": 0.0,
          "engagement": "5,775",
          "price_at_post": "53.00",
          "thread_title": "RE: Worldwide ADC Innovation & Collaboration   London",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=CB66756C-50A3-4D04-A499-ADC1B8951801"
        },
        "ingested_at": "2026-01-31T00:40:42.741199+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262035-Metatron-58206235",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.720073",
        "source": "LSE_CHAT",
        "data": {
          "author": "Metatron",
          "content": "The problem is Wyndrone.. that you cannot read the room because you are a narcissist as I've explaind umpteen times. The recs are from other members who are just plain sick to death of you and your narcissistic droning behaviour.",
          "sentiment": 0.0,
          "engagement": "1,188",
          "price_at_post": "53.00",
          "thread_title": "RE: Worldwide ADC Innovation & Collaboration   London",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=CB66756C-50A3-4D04-A499-ADC1B8951801"
        },
        "ingested_at": "2026-01-31T00:40:42.741216+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262028-Metatron--3929745",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.720496",
        "source": "LSE_CHAT",
        "data": {
          "author": "Metatron",
          "content": "Looks like Thorndrone has repositioned itself as the ultimate purile commentator on the commentary? Looks more to me like the ultimate terd that just won't flush \ud83d\ude48\ud83d\udca9",
          "sentiment": 0.0,
          "engagement": "1,188",
          "price_at_post": "53.00",
          "thread_title": "RE: Avacta Therapeutics celebrates this",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=03B0B4A6-705E-45ED-983A-A89C321C0924"
        },
        "ingested_at": "2026-01-31T00:40:42.741234+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262028-wyndrum-40216466",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.720925",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "I think the problem is Chris is that while what you say is correct, it is the \u201canti-fudsters \u201c for want of a better expression, that quite deliberately push this debilitating and constant line at any opportunity. And like today, when nothing is going on, BV just stirs the pot. Yet every single time the cause of this futile exercise is laid at the door of the posters who are incessantly  attacked rather than the perpetrators . What\u2019s even more disturbing is the recs they get for doing it. This bb is simply one of the worst I have ever come across and we all contribute to that to some degree but it is the majority (when you look at the recs) here that revel in this disruptive behaviour and have little or no interest in resolving the situation for the better. Why can\u2019t I say after 5 years of a trial and a sp at near all time lows that maybe all is not what we were led to believe from the outset and can we look at what might be causing this without being asked to be ignored banned or wished an early death?",
          "sentiment": 0.0,
          "engagement": "12,228",
          "price_at_post": "53.00",
          "thread_title": "RE: Worldwide ADC Innovation & Collaboration   London",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=CB66756C-50A3-4D04-A499-ADC1B8951801"
        },
        "ingested_at": "2026-01-31T00:40:42.741252+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262015-stodgy88-73624125",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.721347",
        "source": "LSE_CHAT",
        "data": {
          "author": "stodgy88",
          "content": "LinkedIn.",
          "sentiment": 0.0,
          "engagement": "1,206",
          "price_at_post": "53.00",
          "thread_title": "RE: Avacta Therapeutics celebrates this",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=03B0B4A6-705E-45ED-983A-A89C321C0924"
        },
        "ingested_at": "2026-01-31T00:40:42.741270+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262014-stodgy88--2341864",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.721752",
        "source": "LSE_CHAT",
        "data": {
          "author": "stodgy88",
          "content": "This company as over  100,000 followers, so good exposure.",
          "sentiment": 0.0,
          "engagement": "1,206",
          "price_at_post": "53.00",
          "thread_title": "RE: Avacta Therapeutics celebrates this",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=03B0B4A6-705E-45ED-983A-A89C321C0924"
        },
        "ingested_at": "2026-01-31T00:40:42.741287+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262011-Thornogs--2611298",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.722182",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Quite Avcti, well done! Always good to be reminded of last week's RNS! In case any of ghd 'well infofmed' missed it eh?",
          "sentiment": 0.0,
          "engagement": "8,666",
          "price_at_post": "53.00",
          "thread_title": "RE: Avacta Therapeutics celebrates this",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=03B0B4A6-705E-45ED-983A-A89C321C0924"
        },
        "ingested_at": "2026-01-31T00:40:42.741305+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262010-HarChris-67918498",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.722603",
        "source": "LSE_CHAT",
        "data": {
          "author": "HarChris",
          "content": "There\u2019s a cycle of Thorn repeating the same points over and over again, the numerous posters who flood us with messages telling him to F off, begging others not to reply or to warn the bb of his dishonesty and then Wyn writing paragraphs of philosophy and psychology on the meaning of it all. That plays out at least four or five times a week! Almost identically. The odd post on Avacta gets a reply or two before the cycle kickstarts again. What a waste of time this BB is in quiet periods like this!",
          "sentiment": 0.0,
          "engagement": "15,870",
          "price_at_post": "53.00",
          "thread_title": "RE: Worldwide ADC Innovation & Collaboration   London",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=CB66756C-50A3-4D04-A499-ADC1B8951801"
        },
        "ingested_at": "2026-01-31T00:40:42.741323+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262004-avctIPma--4885111",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.723059",
        "source": "LSE_CHAT",
        "data": {
          "author": "avctIPmatters",
          "content": "Back to more worthwhile  conversation thanks Stonks -------------------------- Avacta Therapeutics celebrates this Curia 54m \u2022 Follow Congratulations to Avacta Therapeutics on receiving U.S. Food and Drug Administration (FDA) clearance of the Investigational New Drug (IND) application for the Company\u2019s second program FAP-Exd (AVA6103). This peptide drug conjugate is based on the highly potent topoisomerase I inhibitor, exatecan. A Phase 1 clinical trial will enroll patients with solid tumors, pancreatic cancer, cervical cancer, gastric cancer and small cell lung cancer. CURIA STERILE DRUG PRODUCT business unit is proud to assist this cutting-edge oncology program with formulation development, analytical support and GMP clinical supply at our site in Glasgow. Read more about Avacta in the recent press release: https://hubs.li/Q040N2nz0 \" Gmcc",
          "sentiment": 0.0,
          "engagement": "728",
          "price_at_post": "53.00",
          "thread_title": "Avacta Therapeutics celebrates this",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=03B0B4A6-705E-45ED-983A-A89C321C0924"
        },
        "ingested_at": "2026-01-31T00:40:42.741341+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261833-D-Geeman--6876813",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.723489",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "'and bucket to collect their donations for his roses.\u2019 'collect the dung & yes then spread the manure around the Roses' I understand that Watching does this too but with her Quality Street, not Roses.",
          "sentiment": 0.0,
          "engagement": "5,849",
          "price_at_post": "53.00",
          "thread_title": "RE: Worldwide ADC Innovation & Collaboration   London",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=CB66756C-50A3-4D04-A499-ADC1B8951801"
        },
        "ingested_at": "2026-01-31T00:40:42.741359+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261754-Thornogs-67529947",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.723915",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Now, now Wyn! Steady there. It's been decided that our constant 'FUD' detracts from thd ability of the 'well informed' posters to discuss Avzcta seriously. OK, so far it's just the usual nonsense but give thdm a chance I'm sure tomorrow they'll Smash It! Did we finish up by the way?",
          "sentiment": 0.0,
          "engagement": "8,666",
          "price_at_post": "53.00",
          "thread_title": "RE: Worldwide ADC Innovation & Collaboration   London",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=CB66756C-50A3-4D04-A499-ADC1B8951801"
        },
        "ingested_at": "2026-01-31T00:40:42.741376+00:00"
      },
      {
        "event_id": "SOCIAL-Today1236-Watching-32902935",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.595387",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "Let\u2019s have a day where know one engages with the Fudders A watch them argue with themselves \ud83d\ude0a",
          "sentiment": 0.0,
          "engagement": "9,213",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-01-31T00:40:42.741396+00:00"
      },
      {
        "event_id": "SOCIAL-Today1207-D-Geeman-56079218",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.595837",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "Evan Davis discussing mergers and acquisitions on Radio 4 right now.",
          "sentiment": 0.0,
          "engagement": "5,844",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-01-31T00:40:42.741414+00:00"
      },
      {
        "event_id": "SOCIAL-Today1050-D-Geeman--1486279",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.596300",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "Many of the most useful posts are green boxes to others. That's fine. I really don't care if **** doesn't read ****'s post as long as I can. Please, everyone who doesn't like ****'s posts filter and then the people who do read them can do so in peace.",
          "sentiment": 0.0,
          "engagement": "5,844",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-01-31T00:40:42.741432+00:00"
      },
      {
        "event_id": "SOCIAL-Today1034-Thornogs--7008142",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.596741",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Happy to sit on the sidelines to watch the emergence of all this deep research and intelligent discussion on the company's 'fundamentals'. Of course if it isn't accurate or realistic I presume there's the right to point this out? Otherwise it's just a meaningless Echo Chamber. Over to you, the self proclaimed 'well informed'. Let's see what quality posting looks like!",
          "sentiment": 0.0,
          "engagement": "8,655",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-01-31T00:40:42.741450+00:00"
      },
      {
        "event_id": "SOCIAL-Today1032-BuenaVis-12874342",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.597214",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "As Runner-Runner wrote... It's simple. 1. DO NOT ENGAGE 2. DO NOT ASK IT A QUESTION 3. DO NOT ANSWER ITS QUESTIONS 4. DO NOT MOAN ABOUT ITS POSTS 5. DO NOT ARGUE WITH IT 6. If you must do something. Mock it with reference only to its stupidity and nothing else. ------------------------------------------------------ If you're not part of the solution, you're part of the problem",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-01-31T00:40:42.741467+00:00"
      },
      {
        "event_id": "SOCIAL-Today1025-pedrolan--2265584",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.597761",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Ok, as one of the offenders ( I did it mainly to remind people of their/his agenda) I will pledge to now ignore them/him going forward. We really need everyone to do that though.",
          "sentiment": 0.5,
          "engagement": "1,972",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-01-31T00:40:42.741485+00:00"
      },
      {
        "event_id": "SOCIAL-Today1022-Aston15-78627087",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.598209",
        "source": "LSE_CHAT",
        "data": {
          "author": "Aston15",
          "content": "People do understand the only reason then come on here to spout sh*t is because others give them an audience? Its not difficult..  Green Box them and focus the chat on the company, not their trading agendas.",
          "sentiment": 0.0,
          "engagement": "61",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-01-31T00:40:42.741503+00:00"
      },
      {
        "event_id": "SOCIAL-Today1005-IFA90--6468508",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.598630",
        "source": "LSE_CHAT",
        "data": {
          "author": "IFA90",
          "content": "More posts than trades, never a good sign.",
          "sentiment": 0.0,
          "engagement": "408",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-01-31T00:40:42.741521+00:00"
      },
      {
        "event_id": "SOCIAL-Today0954-Aldebara--3060429",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.599061",
        "source": "LSE_CHAT",
        "data": {
          "author": "Aldebaran",
          "content": "Anyone engaging with them is part of the problem. I'll soon be adding them to my filter list if all the want to do is talk smack and try to score points against them. It's a waste of everyone's time, least not their own yet they persist. Sad. We could use this bb once again to discuss avacta but only if the engagement with FUDsters ends. Its nothing more than a digital playground otherwise. Filter. Them.",
          "sentiment": 0.0,
          "engagement": "3,894",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-01-31T00:40:42.741539+00:00"
      },
      {
        "event_id": "SOCIAL-Today0948-Watching-42450120",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.599520",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "Let\u2019s have a day where know one engages with the Fudders And watch them argue with there selves \ud83d\ude0a",
          "sentiment": 0.0,
          "engagement": "9,213",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-01-31T00:40:42.741557+00:00"
      },
      {
        "event_id": "SOCIAL-Today0932-Thornogs-11003354",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.599949",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "And on a day to day basis is there actually much new to talk about with Avacta? Tumbleweed City now until the next RNS, whatever that might be for.",
          "sentiment": 0.0,
          "engagement": "8,655",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-01-31T00:40:42.741575+00:00"
      },
      {
        "event_id": "SOCIAL-Today0924-wyndrum-53806189",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.600402",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "But Jane this was all caused by BV\u2019s non AVCT post. He deliberately provokes with his insults and lies. Non of this would have happened today without his non AVCT related post. Remember that would you",
          "sentiment": 0.0,
          "engagement": "12,217",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-01-31T00:40:42.741592+00:00"
      },
      {
        "event_id": "SOCIAL-Today0918-Watching--3746840",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.601027",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "Let\u2019s have a day where know one engages with the Fudders And watch them argue with themselves \ud83d\ude2c",
          "sentiment": 0.0,
          "engagement": "9,213",
          "price_at_post": "54.00",
          "thread_title": "Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-01-31T00:40:42.741610+00:00"
      },
      {
        "event_id": "SOCIAL-Today0917-pedrolan-50322080",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.601613",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "A seamless switch between users there Eggy Bravo",
          "sentiment": 0.0,
          "engagement": "1,972",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-31T00:40:42.741628+00:00"
      },
      {
        "event_id": "SOCIAL-Today0916-Thornogs--7494220",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.602292",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "To be fair Live account it's very easy to judge someone who repeatedly posts nonsense like you just have. And Pedro and BV joining in the: 'Look at us, we're idiots' gang.",
          "sentiment": 0.0,
          "engagement": "8,655",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-31T00:40:42.741646+00:00"
      },
      {
        "event_id": "SOCIAL-Today0902-wyndrum--1335200",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.603136",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "Sadly you have the memory of a goldfish but not its intellect. Again bv starts and contributes to the disruption. All we wait for now is the \u201cooh I can see all these green boxes\u201dposts add up my posts and add up all the rest and you quickly see who the paid disrupters are",
          "sentiment": 0.0,
          "engagement": "12,217",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-31T00:40:42.741664+00:00"
      },
      {
        "event_id": "SOCIAL-Today0859-BuenaVis-52539724",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.603939",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "\ud83e\udd14 Today's 'wyndrum' sounds even more petty and whiny than the 'Thornogson' account.",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-31T00:40:42.741681+00:00"
      },
      {
        "event_id": "SOCIAL-Today0858-pedrolan-61091843",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.604745",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "BV - he is doing it to fool us into thinking it is not one account. I nearly fell for it because I have the memory of a goldfish.",
          "sentiment": 0.5,
          "engagement": "1,972",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-31T00:40:42.741699+00:00"
      },
      {
        "event_id": "SOCIAL-Today0853-wyndrum-30595714",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.605571",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "It\u2019s snowing pretty hard here so it\u2019s not really the smoking gun you claim is it? Plus the fact you think I have multiple accounts only reinforces your mistaken analysis. (And see how many posts have been generated by bv These are the cause of the disruption. Not the posters who try to discuss the disconnect between AVCT results and the sp over the last 5 years",
          "sentiment": 0.0,
          "engagement": "12,217",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-31T00:40:42.741717+00:00"
      },
      {
        "event_id": "SOCIAL-Today0850-BuenaVis-90628000",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.606369",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Why is Thornogson/NDN/Eggy using the wyndrum account today?",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-31T00:40:42.741734+00:00"
      },
      {
        "event_id": "SOCIAL-Today0847-Livedata--9382436",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.607182",
        "source": "LSE_CHAT",
        "data": {
          "author": "Livedataaccount",
          "content": "With respect wyndrum its difficult not to judge someone who pretends to go on holiday and occasionally logs on with another alias replying to himself",
          "sentiment": 0.0,
          "engagement": "2,956",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-31T00:40:42.741752+00:00"
      },
      {
        "event_id": "SOCIAL-Today0835-BuenaVis-70402815",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.607959",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Wyn Shakespeare has swallowed a whole bag of question marks.",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-31T00:40:42.741770+00:00"
      },
      {
        "event_id": "SOCIAL-Today0831-pedrolan-53133828",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.608744",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Keep it up BV - people do need reminding. I see user Wyn Shakespeare is on the early shift.",
          "sentiment": 0.5,
          "engagement": "1,972",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-31T00:40:42.741788+00:00"
      },
      {
        "event_id": "SOCIAL-Today0826-wyndrum-70667060",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.609574",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "Thanks for reminding us dad, it must only be the 20th time you have posted this. Still at least your post s don\u2019t disrupt the board It\u2019s a great service you do, giving up your time to treat everyone here like morons by constantly reposting. Is it your new rule now that you must be shareholder to post and also be a genuine one at that? How do you intend to police your rules? Or is it just petty personal vendetta you are boring us all with?",
          "sentiment": 0.0,
          "engagement": "12,217",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-31T00:40:42.741805+00:00"
      },
      {
        "event_id": "SOCIAL-Today0750-BuenaVis--2400168",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.610363",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Just a reminder that Thornogson/NDN/Eggy isn't invested and is only here to argue, disrupt and try to waste our time.",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-31T00:40:42.741823+00:00"
      },
      {
        "event_id": "SOCIAL-Today0746-BuenaVis--7883747",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.904033",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Say what you see \ud83c\udf77\ud83c\udf77\ud83c\udf77",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "54.00",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-01-31T00:40:42.741840+00:00"
      },
      {
        "event_id": "SOCIAL-Today0733-Unbreade--1910350",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.904514",
        "source": "LSE_CHAT",
        "data": {
          "author": "Unbreaded",
          "content": "I love green boxes in the morning! Time for a coffee and catch up on the news.",
          "sentiment": 0.0,
          "engagement": "22",
          "price_at_post": "54.00",
          "thread_title": "Green Boes",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=F7E09828-40CF-45D7-8337-5F0A79C87685"
        },
        "ingested_at": "2026-01-31T00:40:42.741859+00:00"
      },
      {
        "event_id": "SOCIAL-Today0035-Thornogs--6083354",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.904967",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Sujood & Icecool. Similar content but I think ICE probably ahead on presentation. Both deeply underwater but talking a good game. Of course the SP matters, the only data that might be maturing is SGC 1b, which might secure a small deal. We've been told nothing about TNBC and STS is written off. We wait for FAP-EXD, we start again.",
          "sentiment": 0.0,
          "engagement": "8,655",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-31T00:40:42.741876+00:00"
      },
      {
        "event_id": "SOCIAL-Today0005-Toukanka--5802085",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.905422",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "Pivotal news in the Summer. Where have I heard that before? Oh yeah, it was me and I duly got panned by the Pom Pom girls for suggesting it would take thst long. \ud83e\udd23\ud83e\udd23\ud83e\udd23",
          "sentiment": 0.0,
          "engagement": "4,451",
          "price_at_post": "54.00",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-01-31T00:40:42.741894+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262359-Toukanka--6158422",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.905891",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "Work for ever????",
          "sentiment": 0.0,
          "engagement": "4,451",
          "price_at_post": "54.00",
          "thread_title": "RE: This will haunt you or please you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=8AE0FBBC-C14D-49F3-85C3-E6BED1BD66ED"
        },
        "ingested_at": "2026-01-31T00:40:42.741912+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262324-IFA90--1783373",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.906405",
        "source": "LSE_CHAT",
        "data": {
          "author": "IFA90",
          "content": "Thanks Andy",
          "sentiment": 0.0,
          "engagement": "408",
          "price_at_post": "54.00",
          "thread_title": "RE: This will haunt you or please you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=8AE0FBBC-C14D-49F3-85C3-E6BED1BD66ED"
        },
        "ingested_at": "2026-01-31T00:40:42.741930+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262322-BuenaVis-19660233",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.906824",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Thanks Thompi",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-31T00:40:42.741948+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262302-Sujood--6791022",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.907374",
        "source": "LSE_CHAT",
        "data": {
          "author": "Sujood",
          "content": "A multi billion dollar company in the making. It will haunt you if you dont position yourself Will please you, if you do the write thing. Learn about the company and do what you know is the right move to make. Nobody every wants to work forever. Keep this message We will talk again soon.",
          "sentiment": 0.5,
          "engagement": "1,260",
          "price_at_post": "54.00",
          "thread_title": "This will haunt you or please you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=8AE0FBBC-C14D-49F3-85C3-E6BED1BD66ED"
        },
        "ingested_at": "2026-01-31T00:40:42.741965+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262258-Icecool-17531335",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.907813",
        "source": "LSE_CHAT",
        "data": {
          "author": "Icecool",
          "content": "Commercial deals will come, and they\u2019ll be welcomed when they do. I\u2019m not in a rush though. If the data continues to strengthen and Avacta can leverage that science into materially better terms, I\u2019m perfectly happy for it to take longer. Time spent increasing leverage isn\u2019t wasted time, it\u2019s how you avoid bad deals and maximise value. \ud83d\ude0a Waiting could be the difference between a few billion and tens of billions. \ud83d\ude0a\ud83e\udd14",
          "sentiment": 0.0,
          "engagement": "8,824",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-31T00:40:42.741983+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262250-Thompi-23367673",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.908255",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thompi",
          "content": "You may find BV this tweet on X interesting on AVA6103 and BOIN design. AND https://x.com/sandyradders/status/2012950578595258664?s=61&t=BBb2UcjLDTXOFIzJM-vM6A",
          "sentiment": 0.0,
          "engagement": "1,357",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-31T00:40:42.742001+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262144-Knotagai-57765561",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.908887",
        "source": "LSE_CHAT",
        "data": {
          "author": "Knotagain",
          "content": "We're all fixated on the SP Icecool, it's just a matter of time frames. I've been invested for over five years and would love to see  some commercial news. Nothing wrong with that.",
          "sentiment": 0.0,
          "engagement": "451",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-31T00:40:42.742018+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262118-Icecool--4348281",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.909330",
        "source": "LSE_CHAT",
        "data": {
          "author": "Icecool",
          "content": "That\u2019s only a concern if you\u2019re fixated on the SP. AIM has never been able to price Avacta properly and it won\u2019t until there\u2019s either a takeover (and suspension) or a move to a serious exchange. The day to day price action is noise. What actually matters is what\u2019s happening behind the scenes with the science, the data, and the strategic discussions. That\u2019s where the real value is being built. \ud83d\udcaf\ud83d\udc4d",
          "sentiment": 0.0,
          "engagement": "8,824",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-31T00:40:42.742036+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262058-Knotagai-33940211",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.909883",
        "source": "LSE_CHAT",
        "data": {
          "author": "Knotagain",
          "content": "Totally agree Icecool, but only third party validation will move the share price. Hopefully it will happen sometime soon.",
          "sentiment": 0.0,
          "engagement": "451",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-31T00:40:42.742055+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262032-Icecool--6428649",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.910560",
        "source": "LSE_CHAT",
        "data": {
          "author": "Icecool",
          "content": "The FDA won\u2019t drag this out. AVA6000 proved the platform in humans, AVA6103 builds on that. Phase 1 is about safety and speed. This trial is designed to surface signals quickly with regulatory alignment, not waste years. AVA6000 data will have done a load of heavy lifting already.",
          "sentiment": 0.0,
          "engagement": "8,824",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-31T00:40:42.742073+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261954-BuenaVis--6230983",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.910984",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "I've got to say I was concerned that the AVA6103 trial with such a toxic agent as exatecan would start at a very low dose and take a long, long time if the step increases were to mimic those in the AVA6000 trial (seven dose levels! - three steps of 40 from 80 to 200, and then three 25% increases to 385) so very pleased to hear about all the benefits of the BOIN design.",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-31T00:40:42.742091+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261946-Icecool--2379572",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.911503",
        "source": "LSE_CHAT",
        "data": {
          "author": "Icecool",
          "content": "I would also point out that when Thorn bought in he\u2019s also a mega ramping twat!!! Flip/Flop. \ud83d\udcaf\ud83e\udd23\ud83e\udd23 best on filter \ud83d\udc4d",
          "sentiment": 0.0,
          "engagement": "8,824",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-31T00:40:42.742121+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261937-HarChris-60140226",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.912044",
        "source": "LSE_CHAT",
        "data": {
          "author": "HarChris",
          "content": "Going back to the trial design I thought this overview could be useful: Key Comparisons Accuracy in MTD Selection: BOIN generally outperforms 3+3 by more accurately identifying the true MTD. In simulations across various scenarios BOIN achieves a 12-16% higher percentage of correct selection (PCS) of the MTD, and in cases where the MTD is at higher doses, it can nearly triple the PCS compared to 3+3. Efficiency and Patient Allocation: BOIN is more efficient, often resulting in shorter trial durations and lower costs by adapting in real-time and allocating more patients to the MTD (especially at higher doses or with higher target DLT rates). The 3+3 design can prolong trials due to its conservative escalation and fixed cohort requirements, leading to fewer patients treated at effective doses. Safety and Risk Management: While 3+3 minimizes overdose risk by being overly cautious (e.g., lower chance of assigning >60% of patients above the MTD), it increases under-dosing, where many patients receive suboptimal doses. BOIN balances this better with built-in overdose controls and dynamic adjustments, reducing under-dosing without significantly raising overdose risks, thus improving ethical standards by minimising patient exposure to ineffective or overly toxic doses. Simplicity and Flexibility: Both are relatively easy to implement\u2014BOIN requires no complex programming or simulations beyond basic setup, making it accessible like 3+3. However, BOIN offers more flexibility, such as variable cohort sizes (e.g., 4 patients) and adjustable target toxicity rates, whereas 3+3 is fixed to cohorts of 3 (or 3+3) and standard targets. In summary, BOIN represents an evolution over 3+3, providing better performance across most metrics while maintaining ease of use. The 3+3 design is still widely used for its familiarity and safety focus in conservative settings but is increasingly seen as outdated for not fully utilising trial data.",
          "sentiment": 0.0,
          "engagement": "15,865",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-31T00:40:42.742140+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261812-Cashless--6680903",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.912567",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cashless",
          "content": "Been out all day, so just logged on.....and what a pleasure to see a sea of green and pretty much all informative posts...I LOVE GREEN...not sure the green people are so happy though \ud83d\udc4d\ud83e\udd2a\ud83e\udd2a\ud83e\udd73",
          "sentiment": 0.5,
          "engagement": "401",
          "price_at_post": "54.00",
          "thread_title": "Bliss",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E431AF8E-57C8-40B5-91C6-8D284968B368"
        },
        "ingested_at": "2026-01-31T00:40:42.742158+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261753-B2HS2L--1622857",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.913172",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "FWIW Google search What is the difference between event free and progression free survival AI Overview: Progression-Free Survival (PFS) measures the time from treatment initiation until objective tumor growth or death from any cause. Event-Free Survival (EFS) measures the time from randomization until a broader range of \"events,\" including disease progression, treatment failure, complications, or death. PFS focuses on tumor growth; EFS focuses on any negative outcome. Key Differences: Definition of Event: PFS is restricted to disease progression or death. EFS includes those, plus failure to proceed to planned surgery, relapse, or severe treatment complications. Context of Use: PFS is commonly used in advanced or metastatic cancer trials to evaluate treatment efficacy. EFS is frequently used in earlier-stage cancer trials, particularly in the neoadjuvant (pre-surgery) setting. Precision: PFS depends on the frequency of imaging scans to detect growth, while EFS is often defined by the time until a patient cannot proceed with their treatment plan. Essentially, PFS means the cancer has not worsened, whereas EFS means the patient has not experienced any negative, pre-defined event.",
          "sentiment": 0.0,
          "engagement": "6,000",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-31T00:40:42.742177+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261428-BuenaVis--4204877",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.913661",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "What is the current best progression free survival rate for TNBC? https://www.google.com/search?q=What+is+the+current+best+progression+free+survival+rate+for+TNBC%253F",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-31T00:40:42.742195+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261424-HarChris-32689181",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.914093",
        "source": "LSE_CHAT",
        "data": {
          "author": "HarChris",
          "content": "It's what happened to STS and might now happen with TNBC, might not of course, but if it did then it'll all fall to SGC to carry the load until FAP-EXD starts to produce meaningful data. __________________ In other words IF TNBC data doesn't deliver then SGC might have to carry the load until H2 2026? That's not bad as a worst case and it's very short term as it gets for biotech. And with the less risk averse and far more efficient BOIN design for 6103 we should start receiving compelling data rapidly if all is going well. It's close!",
          "sentiment": 0.0,
          "engagement": "15,865",
          "price_at_post": "54.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-31T00:40:42.742214+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261411-Thornogs--3507154",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.914533",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "No well spotted!  My bad.",
          "sentiment": 0.0,
          "engagement": "8,655",
          "price_at_post": "54.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-31T00:40:42.742377+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261409-BuenaVis-68146722",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.915065",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "I may be missing something here but trastuzumab deruxtecan (brand name Enhertu) and pertuzumab are both used to treat HER2-positive breast cancer.  So what has that got to do with TNBC which is an aggressive, fast-growing type of breast cancer that tests negative for three key receptors: estrogen (ER), progesterone (PR), and HER2?",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "54.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-31T00:40:42.742396+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261349-Thornogs--4031618",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.915517",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "'....FAP-DOX needs to beat.'",
          "sentiment": 0.0,
          "engagement": "8,655",
          "price_at_post": "54.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-31T00:40:42.742414+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261347-Thornogs-87203534",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.915945",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "But clearly relevent so clearly won't be mentioned by anyone else Watching? Obviously important if it's doubled the PFS times for TNBC, the bar has been raised as to what FAP-EXD needs to beat. It's what happened to STS and might now happen with TNBC, might not of course, but if it did then it'll all fall to SGC to carry the load until FAP-EXD starts to produce meaningful data.",
          "sentiment": 0.0,
          "engagement": "8,655",
          "price_at_post": "54.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-31T00:40:42.742433+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261347-pedrolan-48834800",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.837882",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Just a reminder that Thorn is not invested but spends his sad life on here posting negative comments about a company saving lives. What a guy!!!",
          "sentiment": 0.5,
          "engagement": "1,972",
          "price_at_post": "54.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-31T00:40:42.742451+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261339-Watching--8585044",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.838382",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "You Still have to focus on negatives. Thorny you are such a k n o bby \ud83e\udd21\ud83e\udd21",
          "sentiment": 0.0,
          "engagement": "9,213",
          "price_at_post": "54.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-31T00:40:42.742469+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261335-Thornogs--4533889",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.838824",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "It's perhaps double edged though? The AVA6000 STS trial was (allegedly) de-railed by a trial that showed longer, and better than expected, survival data. If there's a new 'Standard of Care' being announced for TNBC the bar might just have been raised on what FAP-DOX/TNBC needs to achieve to get a deal and get to market?",
          "sentiment": 0.0,
          "engagement": "8,655",
          "price_at_post": "55.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-31T00:40:42.742487+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261315-LovableL--7689951",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.839268",
        "source": "LSE_CHAT",
        "data": {
          "author": "LovableLumax",
          "content": "Https://x.com/onclive/status/2016451178872061994?s=46",
          "sentiment": 0.0,
          "engagement": "2,703",
          "price_at_post": "55.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-31T00:40:42.742506+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261053-Aldebara-46778268",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.839705",
        "source": "LSE_CHAT",
        "data": {
          "author": "Aldebaran",
          "content": "I think small caps are at the very start of a major bull run. Green portfolio everywhere across the board. Also note that even with hard times, avacta raised 16m through zeus at only 8% discount plus managed to delay and renegotiate the terms of the bond. No mean feat that and the macro picture for small caps has improved since then. As has our IP and data package plus the deadline for BP patent expiry has only become closer. Things nowhere near as desperate as this shhhhh it tee little market gives credit for. I mean avacta have developed the worlds first dual warhead peptide drug conjugate ffs . \ud83d\ude05",
          "sentiment": 0.0,
          "engagement": "3,894",
          "price_at_post": "55.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-31T00:40:42.742524+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261050-opti_mys--6566799",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.840239",
        "source": "LSE_CHAT",
        "data": {
          "author": "opti_mystic",
          "content": "I think that's optimistic Lovable being as the initial doses will be very low. It is a safety trial initially remember, but the trial design (BOIN) will allow for dose escalation quite quickly and also potentially skipping from say dose level one to does level 3. I think more realistically summer months we may start to see some useful efficacy. What they will know sooner is are there any problems/does it works as expected and designed. If no bad news by May/June I think we're on a winner. I expect it to work.",
          "sentiment": 0.0,
          "engagement": "296",
          "price_at_post": "55.50",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-01-31T00:40:42.742543+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261045-Sisyphus--1923319",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.840667",
        "source": "LSE_CHAT",
        "data": {
          "author": "SisyphusShorter",
          "content": "Out of coincidence it's been exactly a week since the last RNS regarding AVA6103. Could an announcement be due imminently?",
          "sentiment": 0.0,
          "engagement": "4",
          "price_at_post": "55.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-31T00:40:42.742561+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261014-HarChris-21804424",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.841093",
        "source": "LSE_CHAT",
        "data": {
          "author": "HarChris",
          "content": "I wonder if those solely focused on Avacta and thinking history always repeats are missing the fact that the AIM backdrop plays a major role here. And in that regard liquidity has returned to UK small caps with a vengeance, raises are happening without the sort of discounts seen in 2022/23/24/25, companies are seeing major share price appreciation actually hold rather than the wild swings of post Covid. It\u2019s a far healthier backdrop right now than at any point since I\u2019ve held Avacta shares.",
          "sentiment": 0.0,
          "engagement": "15,865",
          "price_at_post": "55.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-31T00:40:42.742579+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261003-harryhot--2491370",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.841536",
        "source": "LSE_CHAT",
        "data": {
          "author": "harryhotspur1311",
          "content": "I was hoping for the big erection shape although roundish bottoms are quite welcome as well!",
          "sentiment": 0.0,
          "engagement": "12",
          "price_at_post": "55.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-31T00:40:42.742598+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260958-A1invest-94469764",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.841950",
        "source": "LSE_CHAT",
        "data": {
          "author": "A1invest",
          "content": "Lets hope its a \"rounding bottom\" shape.  :)",
          "sentiment": 0.0,
          "engagement": "143",
          "price_at_post": "55.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-31T00:40:42.742616+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260953-pedrolan-46320113",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.842525",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Salty for sure",
          "sentiment": 0.0,
          "engagement": "1,972",
          "price_at_post": "55.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-31T00:40:42.742634+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260945-Thornogs-28987950",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.843025",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "\"Salt and vinegar on that sir?\"",
          "sentiment": 0.0,
          "engagement": "8,655",
          "price_at_post": "55.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-31T00:40:42.742652+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260944-Timster--1074393",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.843502",
        "source": "LSE_CHAT",
        "data": {
          "author": "Timster",
          "content": "Big fish, little fish, cardboard box....",
          "sentiment": 0.0,
          "engagement": "20,625",
          "price_at_post": "55.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-31T00:40:42.742670+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260941-harryhot-50407451",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.844130",
        "source": "LSE_CHAT",
        "data": {
          "author": "harryhotspur1311",
          "content": "Whenever the SP drops, the pessimists always quote \u2018the market knows\u2019 Perhaps this could work the other way around occasionally! Today, perhaps!",
          "sentiment": 0.0,
          "engagement": "12",
          "price_at_post": "56.00",
          "thread_title": "Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-01-31T00:40:42.742688+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260823-pedrolan--7650759",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.844561",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Ah yes, I knew I had been there but couldn't remember exactly which Lake \ud83e\udd23",
          "sentiment": 0.5,
          "engagement": "1,972",
          "price_at_post": "52.50",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-01-31T00:40:42.742706+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260726-Gingethe--2325539",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.844978",
        "source": "LSE_CHAT",
        "data": {
          "author": "GingetheWinge",
          "content": "Derwent valley dam in the Peak District.",
          "sentiment": 0.5,
          "engagement": "699",
          "price_at_post": "53.00",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-01-31T00:40:42.742724+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260713-LovableL--2620600",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.845409",
        "source": "LSE_CHAT",
        "data": {
          "author": "LovableLumax",
          "content": "I also suspect we will have a 6000 partner signed up once we have an approved accelerated pathway and registrations P2\\3 with FDA which is hopefully imminent",
          "sentiment": 0.0,
          "engagement": "2,703",
          "price_at_post": "53.00",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-01-31T00:40:42.742742+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260703-LovableL-50034887",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.845829",
        "source": "LSE_CHAT",
        "data": {
          "author": "LovableLumax",
          "content": "Given how potent the payload is and with the improved half-life and active in the TME for 5 days surely they'll see results as early as scan 1. That sounds rampy and too optimistic but look at the preclinical results. Things could really take off as early as the summer, or even before. Again, I suspect recruitment will be fairly rapid given FAP targeting with preCISION proven and preclinical results so investigators likely chomping at the bit.",
          "sentiment": 0.0,
          "engagement": "2,703",
          "price_at_post": "53.00",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-01-31T00:40:42.742760+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260659-nurseste-13919985",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.846277",
        "source": "LSE_CHAT",
        "data": {
          "author": "nursesteve",
          "content": "CC discussing FAP-Exd (AVA6103) - The profile of this second pre|CISION medicine in the preclinical setting is tremendous.  The sustained release mechanism developed by Avacta scientists results in a robust concentration of active drug in the tumor over five days with the disappearance from the bloodstream in only two hours. This is the exact profile needed to achieve better efficacy with this highly potent topo I inhibitor. Could payoff for LTH be this year?",
          "sentiment": 0.0,
          "engagement": "1,164",
          "price_at_post": "53.00",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-01-31T00:40:42.742779+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260006-D-Geeman--8680557",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.846690",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "An elderly character actor in our road, when I first arrived,  was in the movie \u2018The Dambusters\u2019, and in \u2018Bridge on the River Kwai\u2019. He used to tell some good stories of life on 1950\u2019s film sets. Dead for a while but he pops up on screen even now.",
          "sentiment": 0.0,
          "engagement": "5,844",
          "price_at_post": "52.50",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-01-31T00:40:42.742797+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20262319-pedrolan--5531431",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.847122",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Yes, it's an inspirational story. I think they tested it up in the Lake District",
          "sentiment": 0.5,
          "engagement": "1,972",
          "price_at_post": "52.50",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-01-31T00:40:42.742815+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20262113-Captains--4801503",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.847541",
        "source": "LSE_CHAT",
        "data": {
          "author": "Captainstanley.",
          "content": "I can't find that information anywhere Which Friday? Presumably you mean this week 29th Jan?",
          "sentiment": 0.0,
          "engagement": "467",
          "price_at_post": "52.50",
          "thread_title": "RE: SGC",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=5E3142A3-349A-43A2-B5B7-02836561174A"
        },
        "ingested_at": "2026-01-31T00:40:42.742833+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20262014-Flippine--2363517",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.847977",
        "source": "LSE_CHAT",
        "data": {
          "author": "Flippineck",
          "content": "I\u2019ve been thinking about the trials and tribulations of developing new inventions and ended up swotting up on Barnes Wallace, the inventor of the famous Bouncing Bomb. It seems initial proposals were dismissed by Bomber Command as being \u201c a mad-cap scheme\u201d. There were several critical failures in the development which had to be overcome. The shape of the bomb had to be changed, backspin had to be introduced, the weapon would shatter, sink or detonate prematurely or veer off course. Barnes Wallace persevered and it all came good in the end.",
          "sentiment": 0.0,
          "engagement": "417",
          "price_at_post": "52.50",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-01-31T00:40:42.742851+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261912-BuenaVis--5757477",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.848415",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Christina Coughlin became the CEO of Avacta on 1 May 2024. There is no need to dwell on anything or anyone before that date. CC has set out the company's objectives and timelines and has stuck to them, as much as is possible taking outside decision-making and events into account.  This adherence to the company's aims and plans comes about because she is a pharma executive with ample of experience of drug development and the way the FDA works.",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "52.50",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-01-31T00:40:42.742870+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261900-BuenaVis-12874342",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.848907",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "As Runner-Runner wrote... It's simple. 1. DO NOT ENGAGE 2. DO NOT ASK IT A QUESTION 3. DO NOT ANSWER ITS QUESTIONS 4. DO NOT MOAN ABOUT ITS POSTS 5. DO NOT ARGUE WITH IT 6. If you must do something. Mock it with reference only to its stupidity and nothing else. ------------------------------------------------------ If you're not part of the solution, you're part of the problem",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "52.50",
          "thread_title": "RE: Year end trading update :",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=CCFE6866-0D3C-4A1E-9659-9B2E552262F5"
        },
        "ingested_at": "2026-01-31T00:40:42.742888+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20262219-Thornogs--2309338",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.801399",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Anything new there? 'Expected' Q1? No, nothing new, just 'same old'.",
          "sentiment": 0.0,
          "engagement": "8,596",
          "price_at_post": "54.50",
          "thread_title": "RE: Bioconjugate Insights",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0DCD83D9-A17D-43E1-842E-1C922D520A76"
        },
        "ingested_at": "2026-01-31T00:40:42.742906+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20262212-avctIPma--1298723",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.801859",
        "source": "LSE_CHAT",
        "data": {
          "author": "avctIPmatters",
          "content": "Again courtesy of Stonks -  Finds  new coverage  Avacta related   many thanks . https://cdn.insights.bio/uploads/attachments/BCI%20Industry%20Insights.pdfAvacta Therapeutics reported new preclinical pharmacology data for FAP-Exd peptide drug conjugate [25] \"Avacta Therapeutics announced new preclinical pharmacology data for FAP-Exd (AVA6103), its second asset derived from the pre|CISION\u00ae tumor-activated delivery platform, which is expected to enter Phase 1 testing in Q1 2026. FAP-Exd is a fibroblast activation protein\u2013cleavable peptide-drug linking a proprietary peptide to a topoisomerase I inhibitor payload. The data demonstrated tumor-specific cytotoxicity, sustained intratumoral release of active exatecan with limited systemic exposure, and robust antitumor activity across multiple patient-derived xenograft models. Avacta also reported that artificial intelligence\u2013guided analysis was used to prioritize clinical indications based on co-expression of FAP and SLFN11.\" Gmcc",
          "sentiment": 0.0,
          "engagement": "720",
          "price_at_post": "54.50",
          "thread_title": "Bioconjugate Insights",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0DCD83D9-A17D-43E1-842E-1C922D520A76"
        },
        "ingested_at": "2026-01-31T00:40:42.742924+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20262210-Thornogs--6989083",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.802303",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Avacta does its thing regardless of what's posted here. Get over yourselves, self appointed \"Guardian's of the truth\"! And if you must wear your underpants on the outside do at least please ensure that  they're better laundered?",
          "sentiment": 0.0,
          "engagement": "8,596",
          "price_at_post": "54.50",
          "thread_title": "The reality?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=D8CC0643-0047-4DA0-A21A-3E0ECC3BD17C"
        },
        "ingested_at": "2026-01-31T00:40:42.742942+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20262154-BuenaVis-73855694",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.802718",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "I had Firefox nicely set up with AdBlock so that all ads were wiped out but had to 'repair' Firefox today (as tabs were crashing) and then reload an AdBlock extension but I now keep getting these annoying messages from LSE about ads that I never used to get.  Can't remember what I did before to permanently remove those messages.  Can anyone offer advice on how they've solved this?",
          "sentiment": 0.0,
          "engagement": "5,722",
          "price_at_post": "54.50",
          "thread_title": "Off-topic - removing ads on Firefox",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=9BE707F4-9555-444A-A3C8-1254E00A3443"
        },
        "ingested_at": "2026-01-31T00:40:42.742960+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20262109-Knotagai--3918411",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.803142",
        "source": "LSE_CHAT",
        "data": {
          "author": "Knotagain",
          "content": "All day every day...",
          "sentiment": 0.0,
          "engagement": "448",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-01-31T00:40:42.742978+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261944-Agenda10--9071982",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.803559",
        "source": "LSE_CHAT",
        "data": {
          "author": "Agenda101",
          "content": "Brilliant! The never ending Twats.. they are all green boxed here\u2026 But I\u2019m hearing you Sheepy! Exactly right.",
          "sentiment": 0.0,
          "engagement": "55",
          "price_at_post": "54.50",
          "thread_title": "RE: Frankly pathetic",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B36E2695-D07A-4E60-838B-02C995994856"
        },
        "ingested_at": "2026-01-31T00:40:42.742996+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261943-BuenaVis--5842581",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.803971",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Lighten up Thompi.  It's the best comedy show in town.",
          "sentiment": 0.0,
          "engagement": "5,722",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-01-31T00:40:42.743014+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261940-Thompi-21540944",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.804413",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thompi",
          "content": "Because, Touk, Thorn talks total twaddle and inundates this board with spam. It\u2019s made the board virtually unreadable. Even blocking him doesn\u2019t really help, because all I then see are green boxes and other people replying to his posts. I probably add to the noise at times too - but I\u2019ve genuinely had enough of one person commandeering the board with the same malicious rubbish, day after day. Post after post after post. It wears people down. It stops being discussion and just becomes disruption.",
          "sentiment": 0.0,
          "engagement": "1,355",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-01-31T00:40:42.743032+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261848-Toukanka--1550725",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.804832",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "Cj62 How can it be utter garbage when it\u2019s generally been predicting what is happening to Avacta. But the pond poms utter garbage of \u201ctakeover tomorrow \u201c, \u201cmarket thick as mince\u201d etc etc ad infinitum even though they\u2019ve been entirely wrong for years. Well that\u2019s fine clogging up the board with that garbage",
          "sentiment": 0.0,
          "engagement": "4,436",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-01-31T00:40:42.743050+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261845-BuenaVis--3938210",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.805254",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "6am to midnight but with a two hour evening break to neck a bottle of whisky.",
          "sentiment": 0.0,
          "engagement": "5,722",
          "price_at_post": "54.50",
          "thread_title": "RE: Frankly pathetic",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B36E2695-D07A-4E60-838B-02C995994856"
        },
        "ingested_at": "2026-01-31T00:40:42.743068+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261844-Toukanka-76560977",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.805661",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "You\u2019re right Thompi. You never do say much more than joining your mates and flinging the insults. Why not talk about Avacta rather the other posters on here?",
          "sentiment": 0.0,
          "engagement": "4,436",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-01-31T00:40:42.743087+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261841-sheppy--8608721",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.806079",
        "source": "LSE_CHAT",
        "data": {
          "author": "sheppy",
          "content": "Wyn, Thorn, Touk , DG same poster numerous aliases. Hourly paid hired help disrupter. Regardless of that what sort of sad, moronic halfwit would spend 7 days a week starting each day at 6 am and continuing after midnight posting negative comments about a share they are allegedly not invested in? Regardless of their reason what a total waste of one\u2019s life on this earth . What a pathetic pitiful existence arguing with anonymous people on an anonymous bb. I actually pity their sad, lonely unfulfilled existence. And before the poster tells me they live a very fulfilled life doing lots of other meaningful things ask yourself how this is possible with so many never ending  daily boring transparent attempts at disruption. Sad twat and a weirdo",
          "sentiment": 0.0,
          "engagement": "563",
          "price_at_post": "54.50",
          "thread_title": "Frankly pathetic",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B36E2695-D07A-4E60-838B-02C995994856"
        },
        "ingested_at": "2026-01-31T00:40:42.743115+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261831-cj62--1594820",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.806499",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "Anything you post Thorn is utter garbage. How many crayons have you done today ?",
          "sentiment": 0.0,
          "engagement": "4,270",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-01-31T00:40:42.743134+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261820-Thornogs-55270045",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.806924",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "And what did you say? Anything worth hearing? Anything about Avacta and what's going well and what isn't and thoughts about why? No, thought not. Shame.",
          "sentiment": 0.0,
          "engagement": "8,596",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-01-31T00:40:42.743152+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261755-Thompi-13780721",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.807357",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thompi",
          "content": "Pedro, if I add your 67 posts over the last 30 days to my 20, plus Tim\u2019s 43 and Watching\u2019s 39, the grand combined total is 169 posts. That\u2019s four people combined. Compared to Thorn\u2019s 253 posts on his own. The figures speak for themselves.",
          "sentiment": 0.0,
          "engagement": "1,355",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-01-31T00:40:42.743170+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261754-wyndrum--6586201",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.807774",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "And i see my requests to get NFT to respond have been deleted but the insults to me remain. But yes, its the LSE moderators allowing me to post that is the problem here. Where are you NFT, want to answer my queries so you can justify the remarks in your post?",
          "sentiment": 0.0,
          "engagement": "12,198",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-01-31T00:40:42.743188+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261737-pedrolan--2471371",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.808191",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Make that 29 to go",
          "sentiment": 0.0,
          "engagement": "1,948",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-01-31T00:40:42.743207+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261719-Thompi--5696904",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.808620",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thompi",
          "content": "Avacta posts over the last 30 days: 253 Thorn \ud83e\udd47 43 Timster 39 Watching Not much else to say really Thorn.",
          "sentiment": 0.0,
          "engagement": "1,355",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-01-31T00:40:42.743225+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261708-Thornogs-91516108",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.809052",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "And the two posters below your post Thompi? Watching 9,000 and Tim 20,000! All on only Avacta and all 100% content free 'jokes' or 'bile'. But to comment on that would be to show a consistent approach to this sort of thing wouldn't it? Be honest, it's not the number or posts, it's the fact that you might have to consider things that you don't want to consider. Fine, your choice, 5 years in and AVA6000 limping along to a possible low-ball deal and FAP-EXD entering the 'Last Chance Saloon' in the next 2-3 months. Everything that you've been predicting for the last 5 years, why would you need to hear a contrary opinion when you've clearly been smashing it all this time? Well up I dare say on your investment are we?",
          "sentiment": 0.0,
          "engagement": "8,596",
          "price_at_post": "54.00",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-01-31T00:40:42.743243+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261644-Thompi--8256173",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.809483",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thompi",
          "content": "To be fair Tim, Thorn\u2019s only posted 11 times so far today. He\u2019s got another 30 to go before he equals his personal best of 41 posts in 24 hours. By my reckoning, if he manages around 4.3 posts per hour between now and midnight (17:00\u201312:00am), he might just be in with a chance of beating it. Bless his selfless little heart.",
          "sentiment": 0.0,
          "engagement": "1,355",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-01-31T00:40:42.743261+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261537-Watching-14788139",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.809893",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "24/7. He keeps churning out verbal \ud83d\udca9",
          "sentiment": 0.0,
          "engagement": "9,201",
          "price_at_post": "54.50",
          "thread_title": "RE: CC interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=F5A9F3B7-45F7-4EC2-B1FD-1ACB3A2D2E18"
        },
        "ingested_at": "2026-01-31T00:40:42.743279+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261535-Timster--3918411",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.810318",
        "source": "LSE_CHAT",
        "data": {
          "author": "Timster",
          "content": "All day every day...",
          "sentiment": 0.0,
          "engagement": "20,620",
          "price_at_post": "54.50",
          "thread_title": "To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-01-31T00:40:42.743297+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261529-cj62--2451589",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.810731",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "Shall we have a 'Spot the idiot' competition? You win it thorn, no competition !!!",
          "sentiment": 0.0,
          "engagement": "4,270",
          "price_at_post": "54.50",
          "thread_title": "RE: CC interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=F5A9F3B7-45F7-4EC2-B1FD-1ACB3A2D2E18"
        },
        "ingested_at": "2026-01-31T00:40:42.743315+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261517-Thornogs--7300997",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.811159",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Of course we don't BV, and the industry experts who know these things currently value Avacta at 50 odd pence a share. NFT and the 28 odd who ticked up his posts think \u00a328 is more accurate. Shall we have a 'Spot the idiot' competition?",
          "sentiment": 0.0,
          "engagement": "8,596",
          "price_at_post": "54.50",
          "thread_title": "RE: CC interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=F5A9F3B7-45F7-4EC2-B1FD-1ACB3A2D2E18"
        },
        "ingested_at": "2026-01-31T00:40:42.743333+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261515-cj62-38623668",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.811569",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "That's theoretical of course. Thorn its like 99% of the other gibberish you post twat.",
          "sentiment": 0.0,
          "engagement": "4,270",
          "price_at_post": "54.50",
          "thread_title": "RE: CC interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=F5A9F3B7-45F7-4EC2-B1FD-1ACB3A2D2E18"
        },
        "ingested_at": "2026-01-31T00:40:42.743351+00:00"
      },
      {
        "event_id": "RNS-3rd Feb 2026-faridoxo",
        "event_type": "rns_announcement",
        "date": "2026-02-07T00:53:17.183031+00:00",
        "source": "LSE_RNS",
        "data": {
          "title": "Faridoxorubicin Program Clinical Updates",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/AVCT/faridoxorubicin-program-clinical-updates-6w3sndsec5rzjqb.html",
          "rns_number": "RNS Number : 4824R",
          "full_content": "3 Feb 2026 07:00\nRNS Number : 4824R\nAvacta Group PLC\n03 February 2026\nAvacta announces two key clinical updates to its faridoxorubicin program\nCardiac dosing limit removed and path forward to dose selection identified\nLONDON and PHILADELPHIA\n- February 3, 2026 - Avacta Therapeutics (AIM: AVCT, \"the Company\", \"Avacta\"), a clinical stage biopharmaceutical company developing pre|CISION\u00ae,\u00a0a tumor-activated oncology delivery platform, has published two key clinical updates to its faridoxorubicin (AVA6000) clinical program.\nAgreed updates to the trial protocol include the removal of the maximum dosing limit and to allow flexibility in dosing levels. These two developments underscore the growing confidence from investigators and regulators in the tolerability profile of faridoxorubicin and should support a smooth transition to future efficacy studies.\nThe historic maximum dosing limit which is based on the patient's exposure to released (free) doxorubicin, has been removed in the clinical trial following the collection of highly favorable safety data from the faridoxorubicin program and observation of patients receiving the highest cumulative doses for prolonged periods. Dosing in the Phase 1 clinical trial escalated to a dose of nearly 4x the conventional dose of doxorubicin and the maximum cumulative exposure of released doxorubicin was increased to 550 mg/m2 during the trial with no severe cardiac toxicity observed.\nOne of the key advantages of the pre|CISION\u00ae platform is that its unique delivery mechanism allows patients to receive the drug for longer and at higher doses due to improved tolerability, with the potential to extend the progression free survival endpoint in trials.\nThe Company's second significant update relates to the determination of the dose for the study in efficacy trials. The final cohorts of patients with the selected indications in Phase 1b will be enrolled, enabling two dose levels to be compared in order to determine the optimal biologic dose in future trials.\nUpdates to the clinical program will appear in the National Library of Medicine's clinicaltrials.gov entry for Faridoxorubicin (AVA6000) under the trial designation, ID Number NCT04969835.\nChristina Coughlin, CEO of Avacta Therapeutics commented,\n\"These two critical steps in the development of our faridoxorubicin (AVA6000) program and by extension the proprietary pre|CISION\u00ae platform demonstrate growing recognition by regulators of the safety of this platform.\n\"Highly favorable cardiac safety data for faridoxorubicin enable patients to be treated longer, as opposed to stopping the drug for a theoretical risk of cardiac toxicity which is the usual practice with doxorubicin therapy. Despite dosing to nearly 4x the standard dose of doxorubicin as well as to a higher lifetime maximum exposure, we have not seen a single case of severe cardiac toxicity.\nFurthermore, identifying the path forward to the selection of the optimal biologic dose will enable a smooth transition to efficacy studies with faridoxorubicin program and allows the Company to implement these approaches in the platform currently in Phase 1b, facilitating the development across pre|CISION\u00ae medicines.\"\n-Ends-\nFor further information from Avacta, please contact:\nAvacta Group plc\nChristina Coughlin, Chief Executive Officer\nhttps://avacta.com/\nvia ICR Healthcare\nStrand Hanson Limited (Nominated Adviser)\nJames Harris / Chris Raggett / James Dance\nwww.strandhanson.co.uk\nZeus (Broker)\nJames Hornigold / George Duxberry / Dominic King\nwww.zeuscapital.co.uk\nICR Healthcare\nMary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert\navacta@icrhealthcare.com\nInvestor Contact\nRenee Leck\nTHRUST Strategic Communications\nrenee@thrustsc.com\nMedia Contact\nCarly Scaduto\nTHRUST Strategic Communications\ncarly@thrustsc.com\nAbout Avacta\n-\nhttps://avacta.com/\nAvacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION\u00ae platform. pre|CISION\u00ae is a proprietary payload delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate highly potent payloads in the tumor microenvironment while sparing normal tissues.\nOur innovative pipeline consists of pre|CISION\u00ae peptide drug conjugates (PDC) or Affimer\u00ae drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates.\nThe pre|CISION\u00ae platform comprises an anticancer payload conjugated to a proprietary peptide that is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The pre|CISION\u00ae platform harnesses this tumor specific protease to cleave pre|CISION\u00ae peptide drug conjugates and pre|CISION\u00ae antibody/Affimer\u00ae drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity, allowing dosing ",
          "content_length": 5838
        },
        "ingested_at": "2026-02-07T00:53:17.183076+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20262318-Icecool-55358654",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.525582",
        "source": "LSE_CHAT",
        "data": {
          "author": "Icecool",
          "content": "Happy holidays everyone. \ud83d\ude09\ud83e\udd23\ud83d\ude2d",
          "sentiment": 0.0,
          "engagement": "8,855",
          "price_at_post": "60.50",
          "thread_title": "RE: From MM on X - If it offends - Tough",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=D20B314B-66BB-47B0-8ED4-D46B27E22B85"
        },
        "ingested_at": "2026-02-07T00:53:29.077490+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20262125-Livedata-85921862",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.526281",
        "source": "LSE_CHAT",
        "data": {
          "author": "Livedataaccount",
          "content": "who is offended not icecool being ****** again i hope",
          "sentiment": 0.0,
          "engagement": "2,969",
          "price_at_post": "60.50",
          "thread_title": "RE: From MM on X - If it offends - Tough",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=D20B314B-66BB-47B0-8ED4-D46B27E22B85"
        },
        "ingested_at": "2026-02-07T00:53:29.077530+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20262120-IFA90--4688551",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.526944",
        "source": "LSE_CHAT",
        "data": {
          "author": "IFA90",
          "content": "I\u2019m not offended. Xx",
          "sentiment": 0.0,
          "engagement": "415",
          "price_at_post": "60.50",
          "thread_title": "RE: From MM on X - If it offends - Tough",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=D20B314B-66BB-47B0-8ED4-D46B27E22B85"
        },
        "ingested_at": "2026-02-07T00:53:29.077567+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20262049-B2HS2L-72949661",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.527979",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "Https://x.com/BMHLTD/status/1736326494035603668 - Thanks BMH. December 2023 - Set of extracts from a Will Tap presentation. Will Tap discusses STS treatment improvement necessary. Now we have SGC first pass results, - AVA6000 more likely to be able to address items on Will Tap's STS wish list - with resulting FDA satisfaction.",
          "sentiment": 0.0,
          "engagement": "6,031",
          "price_at_post": "60.50",
          "thread_title": "Will Tap STS wish list",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=21C3C888-CE85-4F00-B718-E879BB3F5CC6"
        },
        "ingested_at": "2026-02-07T00:53:29.077603+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20262037-BuenaVis--5586682",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.528670",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Top publication, Scrip, so this is excellent exposure for CC and Avacta in their 'preview' of the year.",
          "sentiment": 0.0,
          "engagement": "5,826",
          "price_at_post": "60.50",
          "thread_title": "RE: Evolving Drug Conjugates",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B37AC3F0-A005-4580-9CCE-040AE6DF8EA7"
        },
        "ingested_at": "2026-02-07T00:53:29.077640+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261929-avctIPma-92212409",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.529343",
        "source": "LSE_CHAT",
        "data": {
          "author": "avctIPmatters",
          "content": "\"drive significant interest and global pharma partnerships.\"  sounds  good ! Gmcc",
          "sentiment": 0.0,
          "engagement": "740",
          "price_at_post": "60.50",
          "thread_title": "RE: Evolving Drug Conjugates",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B37AC3F0-A005-4580-9CCE-040AE6DF8EA7"
        },
        "ingested_at": "2026-02-07T00:53:29.077674+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261924-avctIPma--5314979",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.530056",
        "source": "LSE_CHAT",
        "data": {
          "author": "avctIPmatters",
          "content": "Thanks to Stonks ;   CC featured \"Scrip Asks... What Does 2026 Hold For Biopharma? Part 4: R&D Innovation\" https://insights.citeline.com/scrip/scrip-asks/scrip-asks-what-does-2026-hold-for-biopharma-part-4-rd-innovation-NDREFKFVB5DZPAQLA5CIZHE7OI/#oncology \"Evolving Drug Conjugates Drugs conjugated to antibodies and other carriers continue advancing through next-generation payload and linker innovation. \u201c2026 will be a pivotal year for dual payload drug conjugates, as the first wave of these therapies is expected to yield initial clinical data,\u201d predicted Christina Coughlin, CEO of Avacta Therapeutics. \u201cThe first dual payload peptide-drug conjugate was announced this year, and dozens of major pharma companies are advancing dual-payload programs targeting different resistance mechanisms. We expect the technology\u2019s ability to overcome drug resistance, enhance tumor selectivity and broaden the therapeutic window to drive significant interest and global pharma partnerships. This represents oncology\u2019s evolution from sequential combination dosing to precision dual-delivery, fundamentally reshaping how we approach tumor heterogeneity and resistance.\u201d Gmcc",
          "sentiment": 0.0,
          "engagement": "740",
          "price_at_post": "60.50",
          "thread_title": "Evolving Drug Conjugates",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B37AC3F0-A005-4580-9CCE-040AE6DF8EA7"
        },
        "ingested_at": "2026-02-07T00:53:29.077709+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261910-JES1889--8318794",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.530764",
        "source": "LSE_CHAT",
        "data": {
          "author": "JES1889",
          "content": "I think the other piece to consider here is that Avacta no longer seems to be a leaky ship. I now believe that (if and) when news drops it\u2019ll arrive without forewarning, like the FDA news this week. Whilst I see there being room for the share price to appreciate as this year progresses, on retail demand/expectations. I doubt that even positive data releases on TNBC and 6103 will see this head anywhere near true value. AIM and the UK investment community just find the scale too hard to contemplate. I\u2019ve seen comments about the current low share price and suggesting that potential bidders would start buying shares in the open market. There\u2019s no way that any party under NDA would be able to do that as they\u2019d be party to inside information and that would be covered by the Market Abuse Regulations. The NDA would almost certainly have some form of standstill clause prohibiting open market share purchases. I think the big news when it comes will come out of the blue.",
          "sentiment": 0.0,
          "engagement": "83",
          "price_at_post": "60.50",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-07T00:53:29.077744+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261857-Icecool-17391213",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.531439",
        "source": "LSE_CHAT",
        "data": {
          "author": "Icecool",
          "content": "Bella you assume the SP and deal value will be linked prior to any announcement. That might happen on the Nasdaq, however it certainly doesn\u2019t happen on AIM. The price will be negotiated on the technology, then and only then will the SP react accordingly.\ud83d\udcaf\ud83d\udc4d",
          "sentiment": 0.0,
          "engagement": "8,855",
          "price_at_post": "60.50",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-07T00:53:29.077778+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261334-Timster--2870896",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.532093",
        "source": "LSE_CHAT",
        "data": {
          "author": "Timster",
          "content": "Why would that offend?",
          "sentiment": 0.0,
          "engagement": "20,637",
          "price_at_post": "60.50",
          "thread_title": "RE: From MM on X - If it offends - Tough",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=D20B314B-66BB-47B0-8ED4-D46B27E22B85"
        },
        "ingested_at": "2026-02-07T00:53:29.077812+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261322-Toukanka-50605042",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.532773",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "All hail the uber ramper. But I agree with everything except I think his timeline is optimistic. I\u2019m still saying Summer for the pivotal moment - in that respect I am accepting CC\u2019s predictions.",
          "sentiment": 0.0,
          "engagement": "4,476",
          "price_at_post": "60.50",
          "thread_title": "RE: From MM on X - If it offends - Tough",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=D20B314B-66BB-47B0-8ED4-D46B27E22B85"
        },
        "ingested_at": "2026-02-07T00:53:29.077846+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261243-wyndrum--8721277",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.533481",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "Does that mean MM is NFT?",
          "sentiment": 0.0,
          "engagement": "12,250",
          "price_at_post": "60.50",
          "thread_title": "RE: From MM on X - If it offends - Tough",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=D20B314B-66BB-47B0-8ED4-D46B27E22B85"
        },
        "ingested_at": "2026-02-07T00:53:29.077881+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261226-cj62-68324982",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.534176",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "I have never been influenced by MM's ramblings but this actually echoes my sentiments exactly, our money is safe as I believe SGC alone makes this a very valuable company. We are now waiting on initial TNBC data prior to H2 which if successful will boost the valuation of Avacta considerably and to top that off ava6103 initial data i expect mid H2. Very exciting times indeed and hopefully well worth the wait.",
          "sentiment": 0.0,
          "engagement": "4,302",
          "price_at_post": "60.50",
          "thread_title": "RE: From MM on X - If it offends - Tough",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=D20B314B-66BB-47B0-8ED4-D46B27E22B85"
        },
        "ingested_at": "2026-02-07T00:53:29.077915+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261217-D-Geeman-84339337",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.534833",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "Vertizea, son, B2H just beat me to it. Whenever I have been influenced by MM in hindsight I should have done the opposite. Yet this does seem a very exciting time. 'If .... and b) the company can stay independent for a couple more years at least' could be the explanation of the contradiction in my response. I think I will keep some powder dry for the next year or so. Currently the 'powder' is in WG, waiting to be worth 30p. Would be comvenient if the various timings work out for me.",
          "sentiment": 0.0,
          "engagement": "5,868",
          "price_at_post": "60.50",
          "thread_title": "RE: From MM on X - If it offends - Tough",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=D20B314B-66BB-47B0-8ED4-D46B27E22B85"
        },
        "ingested_at": "2026-02-07T00:53:29.077949+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261206-B2HS2L-68922179",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.535518",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "Does that mean MM's out? Not offended. \ud83d\ude44 PS probably reducing.",
          "sentiment": 0.0,
          "engagement": "6,031",
          "price_at_post": "60.50",
          "thread_title": "RE: From MM on X - If it offends - Tough",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=D20B314B-66BB-47B0-8ED4-D46B27E22B85"
        },
        "ingested_at": "2026-02-07T00:53:29.077983+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261201-Vertizea--6680476",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.536296",
        "source": "LSE_CHAT",
        "data": {
          "author": "VertizeaSun",
          "content": "Myles McNulty @MylesMcNulty \u00b7 2h Replying to @RobDay80669068 Morning Robert, hope all's well. #AVCT's news on Tuesday was phenomenal. My understanding is that it's an unprecedented move by the FDA to remove the dosing limit for a modified-/reformulated-/pro-chemotherapy,  mid-Phase 1 trial. The rapid decline and fall of the UK investment community - in depth, breadth, intellectual curiosity and risk tolerance - is in my view providing one of the greatest asymmetrical bets of all time. #AVA6000 is an absolute shoe-in to get to market now. It much more than underpins Avacta's entire market cap. Management will know if #AVA6103 - 'the Beast' - is working in patients as they hope it will, by the end of next month. That single drug  has real potential to become the best selling drug in the history of pharma. It really is straightforward to explain and understand this. Personally, I give AVA6103 well over a >50% chance of success in clinic. If a) it is indeed a success in the clinic; and b) the company can stay independent for a couple more years at least; then the returns from the current 60p share price could be >100x. I have recently provided a real world example of these returns (see my last post on Avacta, comparing it with $RVMD). The next 6 months are by far the most important in Avacta's history. Good luck!",
          "sentiment": 0.0,
          "engagement": "440",
          "price_at_post": "60.50",
          "thread_title": "From MM on X - If it offends - Tough",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=D20B314B-66BB-47B0-8ED4-D46B27E22B85"
        },
        "ingested_at": "2026-02-07T00:53:29.078016+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261152-wyndrum--4666927",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.537031",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "Well done Bella, although you won't see this post because you are so clever with the filter button but I raised this most recently with NFT and he never responded to his valuation of $28b based on another company, even though I asked 3 times. Thats the problem with filters. I get filtering the sheppys and watchings of this world that offer absolutely nothing but when I am not defending myself against unsolicited slurs and random insult-only posts, I only talk about AVCT. You tend to eventually come to the same conclusions as me but it takes a while and of course that ground has already been covered. The thing I have noticed is that it does not take long at all to quickly scan any post to see if it has relevance or not and as a result no longer bother filtering anyone. And why? Just on the chance that they do in fact come across some good info or (heaven forfend), some helpful insight. But as I say this will just be another green box for you to never know what was said",
          "sentiment": 0.0,
          "engagement": "12,250",
          "price_at_post": "60.50",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-07T00:53:29.078050+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261143-Bella653--6963433",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.537707",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "Anyone quoting billion $ deals should also post the number of shares that were in issue and the SP prior to the deal...without this info you cannot compare apples with apples. I've checked some of these big deals only to find the SP increase was relatively small.",
          "sentiment": 0.0,
          "engagement": "6,756",
          "price_at_post": "60.50",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-07T00:53:29.078086+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261113-B2HS2L-53345095",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.538535",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "GSK's new CEO looking for $2B to $4B deals 'hiding in plain sight' This is the title of a Fierce Pharma document found on this link: https://www.fiercebiotech.com/biotech/gsks-new-ceo-looking-2-4b-deals-hiding-plain-sight +++ Luke Miels had only been at the helm of GSK for 20 days before he signed off on his first multibillion-dollar buyout, and the CEO is clear on what else will attract his interest. \u201cThe basic framework that we like for [business development] is in that 2-to-4 billion [dollar] range,\u201d Miels told journalists on a fourth-quarter earnings call this morning. \u201cTypically, we like a program where the science is reasonably established,\u201d he added. Miels\u2014who served as GSK\u2019s chief commercial officer before taking over from CEO Emma Walmsley in the new year\u2014pointed to a pattern in dealmaking set in 2022 by the $1.9 billion acquisition of Sierra Oncology for its near-approval cancer drug. GSK is especially interested in drugs where \u201cwe've got a degree of validation on the science, but there are liabilities with the existing products,\u201d he said. To demonstrate these criteria, Miels cited the $2.2 billion buyout of Rapt Therapeutics just days into his tenure as CEO. Rapt\u2019s IgE antibody ozureprubart protects against food allergy reactions by targeting the same epitope as Novartis and Roche\u2019s Xolair. Miels admitted that Xolair has \u201cabsolutely exploded in the U.S. for usage with severe allergies, particularly in kids.\u201d \u201cBut the problem is there's a very complicated dosing regimen, and these kids have to inject themselves every two weeks,\u201d he explained. \u201c[Ozureprubart] works exactly the same way as Xolair, except that you give it on a much lower frequency,\u201d Miels said. \ud83d\udc40 \u201cSo that's essentially the methodology we're going to follow with [business development]\u2014looking for assets [that are] well priced, not necessarily in the mainstream, hiding in plain sight,\u201d the CEO added. \u201cAnd we'll do that with a degree of frequency, which, again, will help us build out the late-stage portfolio.\u201d 1 The basic framework that we like for [business development] is in that 2-to-4 billion [dollar] range,\u201d  \u274c 2 \u201cTypically, we like a program where the science is reasonably established\u201d   \u2714\ufe0f 3 GSK is interested in drugs where \u201cwe've got a degree of validation on the science, but there are liabilities with the existing products\u201d \u2714\ufe0f 4  ...looking for assets [that are] well priced, not necessarily in the mainstream, hiding in plain sight\u201d \u274c see 1 - I'd take issue that multibillion assets don't usually exist in the mainstream, hiding in plain sight. I'd say all now know about Avacta and its products. Those specialising in cancer therapeutics HAVE to be interested or start making BIG advances soon in ADC cancer targeting. I think overall, GSK is looking for an opportunity that costs less than Avacta will sell for. - From the horses mouth.",
          "sentiment": 0.0,
          "engagement": "6,031",
          "price_at_post": "60.50",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-07T00:53:29.078135+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261101-Watching--4136035",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.539211",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "You don\u2019t always get the best deals with smaller companies .. J",
          "sentiment": 0.0,
          "engagement": "9,224",
          "price_at_post": "60.50",
          "thread_title": "RE: Trading 212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B38EA914-FA00-4B19-B293-5E96B62D2062"
        },
        "ingested_at": "2026-02-07T00:53:29.078176+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261055-Profchee-75650660",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.539863",
        "source": "LSE_CHAT",
        "data": {
          "author": "Profcheese",
          "content": "II also in the process of reducing their charges at the moment. It's a competitive world!",
          "sentiment": 0.0,
          "engagement": "539",
          "price_at_post": "60.50",
          "thread_title": "RE: Trading 212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B38EA914-FA00-4B19-B293-5E96B62D2062"
        },
        "ingested_at": "2026-02-07T00:53:29.078211+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261008-Watching-88883715",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.540533",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "IG t buying n selling is free if you have over \u00a330 k in there account",
          "sentiment": 0.0,
          "engagement": "9,224",
          "price_at_post": "60.50",
          "thread_title": "RE: Trading 212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B38EA914-FA00-4B19-B293-5E96B62D2062"
        },
        "ingested_at": "2026-02-07T00:53:29.078245+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261004-Bella653-90820497",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.541198",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "Have you compared the Bid and Ask prices ...many of these No Fee sites don't give the 'best' prices...",
          "sentiment": 0.0,
          "engagement": "6,756",
          "price_at_post": "60.50",
          "thread_title": "RE: Trading 212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B38EA914-FA00-4B19-B293-5E96B62D2062"
        },
        "ingested_at": "2026-02-07T00:53:29.078280+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20260955-wyndrum--6050819",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.541863",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "FWIW they were efficient in sorting out a pension for me too",
          "sentiment": 0.0,
          "engagement": "12,250",
          "price_at_post": "60.50",
          "thread_title": "RE: Trading 212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B38EA914-FA00-4B19-B293-5E96B62D2062"
        },
        "ingested_at": "2026-02-07T00:53:29.078315+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20260955-avctIPma--4462855",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.542723",
        "source": "LSE_CHAT",
        "data": {
          "author": "avctIPmatters",
          "content": "Recent CC quotes :  %   Chance of success  -  Surely Avacta platform that  can to enhance  existing drug treatments  requires  an IP value asset  re-set  . Certainly worth waiting  for  to see   which  BP  jumps first  . ---------------- \"@coughlin582: \u201cif there\u2019s an organ with a cancer, we can address it\u201d \"Christina Coughlin @coughlin582 \u00b7 Feb 4 Replying to @coughlin582 Love this! No would never give our secrets away here! The secret to the sustained release mechanism invented by our brilliant chemistry team is behind blob A and blob B. We call this the \u201cblob slide\u201d \u2026 #BestTeamEver\" Gmcc",
          "sentiment": 0.0,
          "engagement": "740",
          "price_at_post": "60.50",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-07T00:53:29.078349+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20260946-D-Geeman--2564850",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.174673",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "It's like Lidl V's Sainsbury's, but if Lidl stock everything you want then go for it. I found the message from HL regarding their charges, soon to be changed: 'Trading / Dealing Fees: We are reducing the amount you pay to buy or sell shares with us, from \u00a311.95 to \u00a36.95 per online trade** We\u2019re introducing a charge of \u00a31.95 per trade to buy or sell funds online' Account charges: We are reducing our account charges* from 0.45% to 0.35% per year on Stocks and Shares ISA and Self-Invested Personal Pension (SIPP) accounts For Fund and Share Accounts, we are reducing account charges for holding funds, from 0.45% to 0.35% per year and we are introducing a charge of 0.35% to hold shares New account charge limits for shares (includes investment trusts, Exchange Traded Funds (ETFs) and bonds): You will never pay more than \u00a3150 per year in account charges* for holding shares in each of our SIPP, Stocks and Shares ISA or our Fund and Share Accounts Compare current vs future charges",
          "sentiment": 0.0,
          "engagement": "5,868",
          "price_at_post": "60.50",
          "thread_title": "RE: Trading 212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38EA914-FA00-4B19-B293-5E96B62D2062"
        },
        "ingested_at": "2026-02-07T00:53:29.078383+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20260930-Watching-75672285",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.175455",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "A  big pharma   can\u2019t afford not to take us over Who ever bids first will know they will become the market leader over night  with our science ! Imo it\u2019s going to happen very very quickly in 2026 . Hold or. Top up if funds allow Gla . Jane",
          "sentiment": 0.0,
          "engagement": "9,224",
          "price_at_post": "60.50",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-07T00:53:29.078418+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20260918-cj62--3347335",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.176169",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "Incalculable!!!",
          "sentiment": 0.0,
          "engagement": "4,302",
          "price_at_post": "60.50",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-07T00:53:29.078454+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20260859-Wilson63-22102422",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.176882",
        "source": "LSE_CHAT",
        "data": {
          "author": "Wilson63",
          "content": "Post by Tvr5 on X read this and consider being used for just one of these examples and what a fair price would be for the company. https://x.com/TVR5AVCT/status/2019678221504291189",
          "sentiment": 0.0,
          "engagement": "8,808",
          "price_at_post": "60.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-07T00:53:29.078488+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20260847-jackeste-80983434",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.177597",
        "source": "LSE_CHAT",
        "data": {
          "author": "jackester",
          "content": "They definitely do deal in Avacta.",
          "sentiment": 0.0,
          "engagement": "311",
          "price_at_post": "60.00",
          "thread_title": "RE: Trading 212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38EA914-FA00-4B19-B293-5E96B62D2062"
        },
        "ingested_at": "2026-02-07T00:53:29.078523+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20260811-JFK8--4165451",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.178308",
        "source": "LSE_CHAT",
        "data": {
          "author": "JFK8",
          "content": "Opened an account and closed it 20 minutes later as they dont deal  AVCT shares .don't know if they do now though as it was a while ago",
          "sentiment": 0.0,
          "engagement": "3,057",
          "price_at_post": "60.00",
          "thread_title": "RE: Trading 212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38EA914-FA00-4B19-B293-5E96B62D2062"
        },
        "ingested_at": "2026-02-07T00:53:29.078557+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20260125-russell1--7626011",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.179005",
        "source": "LSE_CHAT",
        "data": {
          "author": "russell1",
          "content": "Thanks for the helpful replies.",
          "sentiment": -0.5,
          "engagement": "318",
          "price_at_post": "60.00",
          "thread_title": "RE: Trading 212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38EA914-FA00-4B19-B293-5E96B62D2062"
        },
        "ingested_at": "2026-02-07T00:53:29.078591+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20262323-Toukanka-87765728",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.179705",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "More desperate ramping",
          "sentiment": 0.0,
          "engagement": "4,476",
          "price_at_post": "60.00",
          "thread_title": "RE: TAKEOVER",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=DAF752F5-FA6F-49F9-BD50-F5C834118B9E"
        },
        "ingested_at": "2026-02-07T00:53:29.078626+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20262100-cj62-39066096",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.180428",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "Put your head above the parapet have we touk. RH will probably have less influence than you, you prick.",
          "sentiment": 0.0,
          "engagement": "4,302",
          "price_at_post": "60.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-07T00:53:29.078660+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20262049-D-Geeman--8334503",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.181255",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "AI Overview Trading 212 (T212) and Hargreaves Lansdown (HL) offer starkly different approaches to trading Tiziana Life Sciences Ltd (NASDAQ: TLSA), with T212 focusing on low-cost, app-based trading, while HL provides a more traditional, comprehensive service with higher fees . T212 is generally better for frequent, small-value, or beginner trading due to zero-commission fees, while HL is often preferred for larger, long-term holdings and pensions. Comparison: Tiziana Life Sciences (TLSA) Trading Trading 212 (T212): Cost: Zero-commission trading on stocks and ETFs, though a 0.15% FX fee applies to non-GBP transactions. Features: Offers fractional shares, allowing for small investments in TLSA. CFD Trading: Offers long/short CFD trading on TLSA with leverage. Downsides: Limited research tools and no tax advice; users have reported wide spreads during volatile times for small-cap stocks. Hargreaves Lansdown (HL): Cost: High dealing charges (e.g., \u00a311.95 per deal), which can be costly for small trades. Features: Provides extensive research, analysis, and higher-quality, live, or more transparent pricing. Suitability: Better suited for holding larger, long-term positions or in a SIPP (pension).",
          "sentiment": 0.0,
          "engagement": "5,868",
          "price_at_post": "60.00",
          "thread_title": "RE: Trading 212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38EA914-FA00-4B19-B293-5E96B62D2062"
        },
        "ingested_at": "2026-02-07T00:53:29.078695+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20262041-D-Geeman-16843753",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.181977",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "I also have shares in $TLSA (formerly Tiziana PLC) which moved to the Nasdaq. People on the board for $TLSA.US have often complained about other brokers (I THINK Halifax amongst others) not allowing trades and I think people with 212 had there accustem shares sold against their will when they were spun-off to OTC. If AVCT do go on to the Nas I shall be happy to be with HL but each to their own.",
          "sentiment": 0.0,
          "engagement": "5,868",
          "price_at_post": "60.00",
          "thread_title": "RE: Trading 212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38EA914-FA00-4B19-B293-5E96B62D2062"
        },
        "ingested_at": "2026-02-07T00:53:29.078729+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20262026-IFA90-50022503",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.182574",
        "source": "LSE_CHAT",
        "data": {
          "author": "IFA90",
          "content": "I\u2019m no trader so 212 works for me. I just transferred a handful of Avacta shares across, took about 10 days. I\u2019ll move the rest soon. You can\u2019t dummy quote but I don\u2019t see any other downsides.",
          "sentiment": 0.0,
          "engagement": "415",
          "price_at_post": "60.00",
          "thread_title": "RE: Trading 212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38EA914-FA00-4B19-B293-5E96B62D2062"
        },
        "ingested_at": "2026-02-07T00:53:29.078763+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20262025-Icecool--4123314",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.183017",
        "source": "LSE_CHAT",
        "data": {
          "author": "Icecool",
          "content": "I hear what you\u2019re saying, and I get the excitement, but this is where biotech reality usually kicks in. Big pharma almost never forces an early move before human data unless they\u2019re facing an immediate strategic threat. AVA6103 is IND-cleared, which is huge, but it\u2019s still pre-human efficacy. That\u2019s exciting, not yet unavoidable. They are already in the data room and Avacta has made it clear they want to see human data on AVA6103 before they deal on that asset, everyone has to respect that. Right now BP doesn\u2019t need to rush or upset anyone to protect its position. They can stay close, sit in the data room, structure options, or wait for Phase 1 signals before committing real money with Avacta approval. That\u2019s how this industry normally works. The idea that retail holders could be quietly shaken out on the cheap also feels unlikely. Any hint of opportunistic behaviour would harden positions very quickly, not soften them. What the board is doing makes sense, build leverage before the power dynamic flips. Once AVA6103 shows even early human efficacy, urgency changes overnight and the tone of conversations changes with it.",
          "sentiment": 0.0,
          "engagement": "8,855",
          "price_at_post": "60.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-07T00:53:29.078797+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20262022-cj62-56255551",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.183465",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "Well I'm hoping that maybe 2 or 3 BP would like it but if all is well with ava6103 maybe go down the ARM route. 6 months and we should know",
          "sentiment": 0.0,
          "engagement": "4,302",
          "price_at_post": "60.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-07T00:53:29.078838+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261948-B2HS2L--7592102",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.183925",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "'That is extremely unlikely in biotech. As big pharma prefer to negotiate clean and keep everyone on side.' I hear what you say and generally agree. However, an opportunity like this occurs very infrequently. A successful purchase - however that occurs - confers market disruption and after commercialisation, competitive advantage upon the purchaser, with others making do with ADC development or resuming the search for new tech. This situation can't be brushed under the carpet. It's not what we would want, but you can't help seeing BP may want a deal sooner rather than later for a myriad of reasons. Pi**ing off the BoD might have to happen if one, or more than one BP are so keen to 'own it', or likely - make sure other BP's don't get a bargain in their efforts to 'own it'. There are a large number of PI's who could be easily persuaded to part with their shares at prices BP would definitely find attractive. It remains to be seen where and when the first bid arrives. The BoD are planning for the long haul, but let's hope they achieve as much as humanly possible before BP calls time on Avacta's progress.",
          "sentiment": 0.0,
          "engagement": "6,031",
          "price_at_post": "60.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-07T00:53:29.078872+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261935-D-Geeman--3186919",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.184434",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "I opened a 212 account a few years ago but don't use it. With HL your purchase happens immediately but with 212 it can take a while and goes thru in dribs and drabs (while the price is changing). Aren't HL lowering their dealing charges in April? I got a message and believe they are dropping to around \u00a36 for everyone (maybe more for some?) Maybe 212 are ok for bigger shares.",
          "sentiment": 0.0,
          "engagement": "5,868",
          "price_at_post": "60.00",
          "thread_title": "RE: Trading 212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38EA914-FA00-4B19-B293-5E96B62D2062"
        },
        "ingested_at": "2026-02-07T00:53:29.078907+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261920-Codejunk-31600713",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.184970",
        "source": "LSE_CHAT",
        "data": {
          "author": "Codejunkie",
          "content": "Pharma don't generally do hostile takeovers. They just pay the right price for the IP and make sure staff transfer over Hostile takeovers lose key staff....",
          "sentiment": 0.0,
          "engagement": "2,668",
          "price_at_post": "60.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-07T00:53:29.078941+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261916-russell1-77232617",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.185404",
        "source": "LSE_CHAT",
        "data": {
          "author": "russell1",
          "content": "Does anybody hold their Avacta shares with Trading 212? If so, is it easy to deal and are the prices comparable to other platforms. I use HL but am thinking about moving away.",
          "sentiment": -0.5,
          "engagement": "318",
          "price_at_post": "60.00",
          "thread_title": "Trading 212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38EA914-FA00-4B19-B293-5E96B62D2062"
        },
        "ingested_at": "2026-02-07T00:53:29.078975+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261857-cj62-67912760",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.185820",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "Its OK saying Hughes won't allow a low bid to be decided by shareholders, but what about a hostile bid. Any bid will be decided by the shareholders RH will have no say.",
          "sentiment": 0.0,
          "engagement": "4,302",
          "price_at_post": "60.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-07T00:53:29.079009+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261849-Icecool-20611001",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.186361",
        "source": "LSE_CHAT",
        "data": {
          "author": "Icecool",
          "content": "\u201cIt\u2019s OK saying Hughes won't allow a low bid to be decided by shareholders, but what about a hostile bid.\u201d That is extremely unlikely in biotech. As big pharma prefer to negotiate clean and keep everyone on side.",
          "sentiment": 0.0,
          "engagement": "8,855",
          "price_at_post": "60.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-07T00:53:29.079043+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261842-B2HS2L-74304705",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.187281",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "Bella ...Is the BOD in it for the long haul or would they simply take a good offer so they can move on to pastures new? I'm no longer thinking so much about how long it's going to take Avacta to achieve A,B or C. The nearer timelines we know about, but my point is how long are BP going to allow us to plough our own furrow? The more IP we pile up the larger amount SB rightly thinks the company is worth. These companies (with larger manpower & resources) will probably not want to proceed at Avacta's pace. Some will want faster development, and want their competitive advantage, with the purchase of all we have, to begin sooner. Others can't face a bigger purchase if left too long. Some BP will have funds available at different times as their priorities such as other projects will need to be factored into their timescales. Its OK saying Hughes won't allow a low bid to be decided by shareholders, but what about a hostile bid. There is no accounting for such a bid with completely opaque timescales. This is a market disruptive project and to a certain extent interested parties will want to move possibly sooner than we would wish. I don't see Avacta finishing what they started, but what do I know?",
          "sentiment": 0.0,
          "engagement": "6,031",
          "price_at_post": "60.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-07T00:53:29.079077+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261755-Metatron-61220534",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.188128",
        "source": "LSE_CHAT",
        "data": {
          "author": "Metatron",
          "content": "That's the spirit Watching2!! poor old Winnypoos is banging his drum as fast as he can but.. can he stay in time? I've spent half my life with those and asking a drummer to think? that's sublime...",
          "sentiment": 0.0,
          "engagement": "1,192",
          "price_at_post": "60.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-07T00:53:29.079124+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261725-opti_mys--3627516",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.188933",
        "source": "LSE_CHAT",
        "data": {
          "author": "opti_mystic",
          "content": "With RH on the BoD there is zero chance of Avacta being sold on the cheap. They have to put serious offers to shareholders but I guess it depends how serious is defined. Offering half what the company is worth is not a serious offer in my view. They could down tools today and sell the IP and they'd get a lot more than the current market cap.",
          "sentiment": 0.0,
          "engagement": "307",
          "price_at_post": "60.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-07T00:53:29.079159+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261717-cj62--3456009",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.189693",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "There is 0% CoS attached to the sp and that includes ava 6 k. Presently it would stand at 5 - 11% after the recent rns",
          "sentiment": 0.0,
          "engagement": "4,302",
          "price_at_post": "60.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-07T00:53:29.079193+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261710-Watching-22540693",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.190157",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "Winne bot has broken  free ! Ignore !",
          "sentiment": 0.0,
          "engagement": "9,224",
          "price_at_post": "60.50",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-07T00:53:29.079227+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261613-wyndrum--4454930",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.032149",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "\"Buyers don\u2019t care about today\u2019s SP, they care about what this asset can generate over a decade.\" do you think ever, before you post? If a buyer thinks this will be huge multiple in value then they buy as cheaply as they can which today would be 60p? Otherwise one would assume they are waiting for something... i dunno....maybe data from a trial yet to start? Also in response to where shareholders might sell: The SP would not be say, 500p per share from here on speculation. It would be on the back of very good results and data. It would be that data that would influence as to weather or not it would be sensible to sell.",
          "sentiment": 0.0,
          "engagement": "12,250",
          "price_at_post": "60.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-07T00:53:29.079262+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261556-Icecool-29623925",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.032939",
        "source": "LSE_CHAT",
        "data": {
          "author": "Icecool",
          "content": "If AVA6103 does what it\u2019s designed to do in humans, this isn\u2019t a few billion story. On any sensible biotech valuation framework (see my case study \ud83e\udd23\ud83d\ude09), you\u2019re talking tens of billions, not pocket change. That\u2019s total value paid, not based on some AIM screen price that flickers day to day. That\u2019s why the share price right now is basically irrelevant. Buyers don\u2019t care about today\u2019s SP, they care about what this asset can generate over a decade. Thankfully it also explains the strategy perfectly. Avacta is keeping AVA6103 solo for now because proving it in humans is where the real value unlock happens. You don\u2019t sell something like this on promise alone, you sell it when the risk collapses and the leverage flips. That\u2019s the play here. Prove it works in people, then let the numbers do the talking.",
          "sentiment": 0.0,
          "engagement": "8,855",
          "price_at_post": "61.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-07T00:53:29.079297+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261528-Timster--6632263",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.033717",
        "source": "LSE_CHAT",
        "data": {
          "author": "Timster",
          "content": "If CC brings anything less than \u00a3200 ex chi-nah, she'd be having a laugh!",
          "sentiment": 0.0,
          "engagement": "20,637",
          "price_at_post": "61.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-07T00:53:29.079331+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261523-cj62--8708303",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.034552",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "Directors cannot quietly reject a serious offer that could reasonably be of interest to shareholders once it becomes concrete. Their duty is to: Act in shareholders\u2019 best interests and Not frustrate an offer without shareholder approval",
          "sentiment": 0.0,
          "engagement": "4,302",
          "price_at_post": "61.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-07T00:53:29.079365+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261523-HarChris-35292910",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.035361",
        "source": "LSE_CHAT",
        "data": {
          "author": "HarChris",
          "content": "575m total share count feels a more realistic figure to be working with when forecasting future takeover share price so \u00a33B would be more like \u00a35.25 a share.",
          "sentiment": 0.0,
          "engagement": "15,923",
          "price_at_post": "61.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-07T00:53:29.079399+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261512-Bella653--5706591",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.036083",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "The BIG Questions are... Is the BOD in it for the long haul or  would they simply take a good offer so they can move on to pastures new? and how much are they will to hold out for?",
          "sentiment": 0.0,
          "engagement": "6,756",
          "price_at_post": "61.50",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-07T00:53:29.079434+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261507-Bella653--5565144",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.036656",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "I don't think you'll get anywhere near your SP wishlist on a T/O deal as we stand right now. Deals and NASDAQ Listing will drive value but we need some big hitters in the Finance World like Healthcare Royalty to back Avacta and to negotiate the best T/O deal possible at the right time.",
          "sentiment": 0.0,
          "engagement": "6,756",
          "price_at_post": "61.50",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-07T00:53:29.079468+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261505-hamsters-24675897",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.037073",
        "source": "LSE_CHAT",
        "data": {
          "author": "hamsters18",
          "content": "What large buys?",
          "sentiment": 0.0,
          "engagement": "3,692",
          "price_at_post": "61.50",
          "thread_title": "RE: TAKEOVER",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=DAF752F5-FA6F-49F9-BD50-F5C834118B9E"
        },
        "ingested_at": "2026-02-07T00:53:29.079503+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261449-Deod123-74644806",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.037518",
        "source": "LSE_CHAT",
        "data": {
          "author": "Deod123",
          "content": "Large buys going through.someone is stake building",
          "sentiment": 0.0,
          "engagement": "68",
          "price_at_post": "61.00",
          "thread_title": "TAKEOVER",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=DAF752F5-FA6F-49F9-BD50-F5C834118B9E"
        },
        "ingested_at": "2026-02-07T00:53:29.079538+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261438-cj62-60161637",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.037940",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "\u00a3200 ex china  Not this LTH",
          "sentiment": 0.0,
          "engagement": "4,302",
          "price_at_post": "61.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-07T00:53:29.079571+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261431-Wilson63-11573100",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.038378",
        "source": "LSE_CHAT",
        "data": {
          "author": "Wilson63",
          "content": "I'm somewhat surprised a couple of regulars are going to sell out at fairly low numbers, if this continues to pass each obstacle it's a one and only lifetime chance imho, topping up monthly slow and steady.",
          "sentiment": 0.0,
          "engagement": "8,808",
          "price_at_post": "60.50",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-07T00:53:29.079605+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261323-BuenaVis-56646556",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.038809",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Yes, the pre|CISION pie can be cut many ways: by drugs, indications and territories, and all with or without exclusivity.  People might say that faridox, with its boring old doxorubicin, will be overtaken by newer, more powerful pre|CISION drugs but the fact is it is here and now and not far off its first approved indication, salivary gland cancer, if the data released so far is to be believed. So with all that, why would any company want to license it when there could be better options in the future?  Well, if the offer was a global exclusive licence to develop faridox for SGC, plus the option to have first dibs on any future Avacta pre|CISION drug for SGC, plus the rights to develop their own pre|CISION drugs for SGC\u2014essentially an exclusive licence agreement to control the global pre|CISION SGC market\u2014then that would surely be of great interest. If it's taking Simon a long time to get that first deal, well the licensing possibilities are nearly endless and newly revealed data and developments are moving the goal posts in Avacta's favour all the time as conclusive evidence proves the platform (I'll call it that now already).",
          "sentiment": 0.0,
          "engagement": "5,826",
          "price_at_post": "59.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-07T00:53:29.079641+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261300-Vertizea--8515276",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.039250",
        "source": "LSE_CHAT",
        "data": {
          "author": "VertizeaSun",
          "content": "\u00a32 billion to buy a serious geographic licence for pre|CISION and a couple of warheads  sounds about right......say the EU/EEA and ex-ROW. Simon Bennett is now in his third year and the fact he hasn't been fired will suggest he has something up his sleeve. \u00a32B will pay for future independence and a \u00a31 per share dividend. I think we'll know within a couple of months and perhaps sooner as CC is obviously in town (doing celebratory cake delivery) and probably here for a board meeting - where they'll be trying to digest the recent torrent of good news. They actually have a lot on their plate. But I'm having trouble digesting \"the removal of the maximum dosing limit\" ...... apparently the first time in history for a phase 1 trial compound so I'm quite happy to believe that eventually pre|CISION is going to be compared to the impact penicillin had on the world of medicine. And in the beginning that discovery had serious FUD. Bill Gates said that the world always over-estimates how much change can take place in six months, but under-estimates how much change will take place in six years.",
          "sentiment": 0.0,
          "engagement": "440",
          "price_at_post": "59.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-07T00:53:29.079676+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261259-Matml74--4462678",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.039673",
        "source": "LSE_CHAT",
        "data": {
          "author": "Matml74",
          "content": "Dolly, Watch the R&D spotlight episode on next generation Precision from 2024 and also the dual payload one from late 2025. These highlight the vast opportunity for Precision.",
          "sentiment": 0.0,
          "engagement": "2,547",
          "price_at_post": "59.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-07T00:53:29.079710+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261252-opti_mys-83111996",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.040082",
        "source": "LSE_CHAT",
        "data": {
          "author": "opti_mystic",
          "content": "Oh yea of little faith. \u00a310 is my absolute bare minimum from when I first invested. Due to progress on a number of fronts that has gone up. Somewhat disappointed that people would sell so cheaply. Hopefully the BoD know what the company is worth and will not put to shareholders derisory offers that significantly under values the company.",
          "sentiment": 0.0,
          "engagement": "307",
          "price_at_post": "59.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-07T00:53:29.079745+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261249-Dollyg--9741428",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.040506",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dollyg",
          "content": "Thank you",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "59.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-07T00:53:29.079779+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261239-yeboha-86681223",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.040920",
        "source": "LSE_CHAT",
        "data": {
          "author": "yeboha",
          "content": "Dolly if you do some research online you can see that many professionals in the field agree that it can be used on many drugs !",
          "sentiment": 0.0,
          "engagement": "963",
          "price_at_post": "59.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-07T00:53:29.079813+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261237-yeboha--7962755",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.041383",
        "source": "LSE_CHAT",
        "data": {
          "author": "yeboha",
          "content": "Avacta\u2019s pipeline includes several distinct pre|CISION\u00ae drug conjugates with different therapeutic payloads, not just a single product: AVA6000 (a doxorubicin-based peptide drug conjugate) has shown positive clinical progress. AVA6103 (exatecan-based PDC) is advancing toward clinical trial start. Dual-payload PDCs are being developed in preclinical stages, combining agents like microtubule inhibitors and DNA damage response modulators. Another pipeline program, AVA7100 (an Affimer\u00ae-based drug conjugate), is also in preclinical development with its own payload delivery design. \ud83d\udccc Why this matters: This demonstrates that Avacta\u2019s platform isn\u2019t limited to a single drug but is being developed as a modular engine for multiple therapeutic combinations and individual payloads",
          "sentiment": 0.0,
          "engagement": "963",
          "price_at_post": "59.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-07T00:53:29.079847+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261231-Dollyg-20134199",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.041792",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dollyg",
          "content": "Be good to get a medically qualified opinion of the ACTUAL potential of how many differing treatments this technology could affect.",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "59.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-07T00:53:29.079881+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261227-Livedata--5588627",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.042216",
        "source": "LSE_CHAT",
        "data": {
          "author": "Livedataaccount",
          "content": "Hi jane im out at 4 pounds if it gets there",
          "sentiment": 0.0,
          "engagement": "2,969",
          "price_at_post": "59.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-07T00:53:29.079915+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261225-yeboha--8825380",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.042623",
        "source": "LSE_CHAT",
        "data": {
          "author": "yeboha",
          "content": "Its funny we say this, being where the share price is but im so convinced about avacta and have been for years !",
          "sentiment": 0.0,
          "engagement": "963",
          "price_at_post": "59.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-07T00:53:29.079949+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261221-Watching-68613903",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.043037",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "Happy with \u00a37 pre share. But \u00a310 would be a nice surprise . Jane",
          "sentiment": 0.0,
          "engagement": "9,224",
          "price_at_post": "59.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-07T00:53:29.079984+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261213-Dollyg--4617679",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.043462",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dollyg",
          "content": "I read the \u00a33 billion figure was first mooted in 2023 and they seem to have come a long way since then in terms of efficacy. The concensus seens to be wait.",
          "sentiment": 0.5,
          "engagement": "8",
          "price_at_post": "59.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-07T00:53:29.080018+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261212-yeboha--3835975",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.043874",
        "source": "LSE_CHAT",
        "data": {
          "author": "yeboha",
          "content": "Thats roughly my thinking",
          "sentiment": 0.0,
          "engagement": "963",
          "price_at_post": "59.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-07T00:53:29.080052+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261209-BuenaVis-63867541",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.044290",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "$4bn would be 668p a share.  Not enough for me.  I'd be looking for at least 1,000p a share, a $6bn buyout.  At least.",
          "sentiment": 0.0,
          "engagement": "5,826",
          "price_at_post": "59.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-07T00:53:29.080086+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20262313-aidanjc--3062718",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.524270",
        "source": "LSE_CHAT",
        "data": {
          "author": "aidanjc",
          "content": "Good point.  If cancer treatments improve that is a fantastic result. Its crept into my life a lot recently. Great to make a profit on the shares but improving outcomes for cancer patients is really important.",
          "sentiment": 0.0,
          "engagement": "6",
          "price_at_post": "51.50",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-07T00:53:29.080137+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20262051-avctIPma--7143291",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.524706",
        "source": "LSE_CHAT",
        "data": {
          "author": "avctIPmatters",
          "content": "Thanks for sharing  B2HS2L  -  Helps spread info on the platform  .",
          "sentiment": 0.0,
          "engagement": "728",
          "price_at_post": "51.50",
          "thread_title": "RE: CDD European Life Science Community Meeting",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=3A2F031D-C16F-4949-B22E-8512255BE282"
        },
        "ingested_at": "2026-02-07T00:53:29.080173+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20262049-avctIPma-77223960",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.525140",
        "source": "LSE_CHAT",
        "data": {
          "author": "avctIPmatters",
          "content": "Thanks for sharing  Thompi -  All helps spread   Avacta exposure .",
          "sentiment": 0.0,
          "engagement": "728",
          "price_at_post": "51.50",
          "thread_title": "RE: World CB & CDx Summit Europe",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=18E94451-D174-452E-BD8A-79154E17863F"
        },
        "ingested_at": "2026-02-07T00:53:29.080208+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20262022-Livedata-88148055",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.525565",
        "source": "LSE_CHAT",
        "data": {
          "author": "Livedataaccount",
          "content": "Ellen's great she will do a fantastic presentation",
          "sentiment": 0.0,
          "engagement": "2,957",
          "price_at_post": "51.50",
          "thread_title": "RE: CDD European Life Science Community Meeting",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=3A2F031D-C16F-4949-B22E-8512255BE282"
        },
        "ingested_at": "2026-02-07T00:53:29.080243+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20262016-B2HS2L-72861532",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.525997",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "Https://www.collaborativedrug.com/cdd-european-scientific-community-meeting-2026 Dr Ellen Watts, Avacta Therapeutics 25.02.2026  17:00-17:30: Delivering Targeted Therapies Using the pre|CISION\u00ae Platform. Last presentation of the day",
          "sentiment": 0.0,
          "engagement": "6,003",
          "price_at_post": "51.50",
          "thread_title": "CDD European Life Science Community Meeting",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=3A2F031D-C16F-4949-B22E-8512255BE282"
        },
        "ingested_at": "2026-02-07T00:53:29.080278+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261732-Timster--5395275",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.526420",
        "source": "LSE_CHAT",
        "data": {
          "author": "Timster",
          "content": "Good spot Thompi, thanks",
          "sentiment": 0.0,
          "engagement": "20,626",
          "price_at_post": "51.50",
          "thread_title": "RE: World CB & CDx Summit Europe",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=18E94451-D174-452E-BD8A-79154E17863F"
        },
        "ingested_at": "2026-02-07T00:53:29.080311+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261722-Thompi-29440658",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.526848",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thompi",
          "content": "Ruairidh Edwards will be speaking on 1 April at the 16th World Clinical Biomarkers & Companion Diagnostics Summit Europe. Presentation title: Establishing a Biomarker-Driven Approach to Guide Patient Selection for preCISION\u00ae Peptide-Drug Conjugates Using Tumour Targeting/Release and Payload Sensitivity Biomarkers. https://cdx-europe.com/full-event-guide/",
          "sentiment": 0.0,
          "engagement": "1,358",
          "price_at_post": "51.50",
          "thread_title": "World CB & CDx Summit Europe",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=18E94451-D174-452E-BD8A-79154E17863F"
        },
        "ingested_at": "2026-02-07T00:53:29.080346+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261707-Agenda10-84027140",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.527323",
        "source": "LSE_CHAT",
        "data": {
          "author": "Agenda101",
          "content": "No not engage ! It\u2019s working so let\u2019s continue to starve them of any engagement. As Runner-Runner wrote and BV reposted\u2026 It's simple. 1. DO NOT ENGAGE 2. DO NOT ASK IT A QUESTION 3. DO NOT ANSWER ITS QUESTIONS 4. DO NOT MOAN ABOUT ITS POSTS 5. DO NOT ARGUE WITH IT 6. If you must do something. Mock it with reference only to its stupidity and nothing else. ------------------------------------------------------ If you're not part of the solution, you're part of the problem",
          "sentiment": 0.0,
          "engagement": "72",
          "price_at_post": "52.50",
          "thread_title": "RE: Bone Marrow Toxicity, Brain malignancies?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=34DD9B68-3AA3-4F24-A8A5-8F742D7F4948"
        },
        "ingested_at": "2026-02-07T00:53:29.080381+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261704-Agenda10--5396362",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.527740",
        "source": "LSE_CHAT",
        "data": {
          "author": "Agenda101",
          "content": "\u201cI\u2019m committed for the next two years, but I anticipate that developments around licensing, manufacturing, and supply will begin to materialise well before then. From my perspective, the time to push ahead is now.\u201d",
          "sentiment": 0.0,
          "engagement": "72",
          "price_at_post": "51.50",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-07T00:53:29.080416+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261656-Thornogs--3664560",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.528205",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Well I didn't post! Not much said I see. More chat about FAP expressed on inflamed/fibrotic tissue other than cancer as a positive therapeutic opportunity with no one wondering if this self same tissue might cause problems should someone inject a FAP released 'Beast' into the circulation whilst trying to target a FAP related cancer.  Were that to happen in the FAP-EXD 1a Safety trial I think it would count as a Black Mark. BV and Syphysus indulged their in depth knowledge of molecular biology and the Blood Brain Barrier to 'deep dive' the potential to treat cerebral cancers, I do hope CC read those posts or perhaps one of you could send her an e mail explaining the possibilities? And the Market did what I thought it would do, go down, down the at the last come back up to almost, but not quite, where we opened. 1% down today, 3% this week and 10% down on the month. I see this continuing until the surprise deal mentioned earlier or being more realistic the next raise to fund the programme through 2026. Any thoughts on support/resistance levels Wyn? Happy to be out waiting for FAP-EXD and funding doubts to clear.",
          "sentiment": 0.0,
          "engagement": "8,666",
          "price_at_post": "51.50",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-07T00:53:29.080452+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261643-wyndrum-78814079",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.528628",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "I see \u201cthe don\u2019t engage\u201d policy didn\u2019t last long. You simply can\u2019t have a bb devoted to the actual topic and miss out on insulting others can you? Predictable and pathetic behaviour. Who knew?",
          "sentiment": 0.0,
          "engagement": "12,228",
          "price_at_post": "51.50",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-07T00:53:29.080486+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261640-D-Geeman-45364316",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.529049",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "'Chris, are you still interested in my buys and sells or would you prefer me not to bother?' Chris might not be interested Wyn, but I am... I dare say I'm not alone either.",
          "sentiment": 0.0,
          "engagement": "5,849",
          "price_at_post": "51.00",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-07T00:53:29.080520+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261639-Toukanka-53734655",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.529486",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "BV Are you a lawyer? We were led to believe that 6000 P1b would finish end of 25. So you don\u2019t regard having to go an extra cycle as missing a target. Or all the talk of multiple events before end 25 as not materialising. Anyhow at least some people on here are rooted in reality and believe CC when she says not to expect much before 2H26. Be. Patient",
          "sentiment": 0.0,
          "engagement": "4,454",
          "price_at_post": "51.00",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-07T00:53:29.080556+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261631-cj62--6514262",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.529902",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "Fine with me Chris. I would remind you however that it was you that asked I report my trades. You did report your last losing trade though did you, you prick",
          "sentiment": 0.0,
          "engagement": "4,282",
          "price_at_post": "51.50",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-07T00:53:29.080590+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261628-BuenaVis--1734804",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.530336",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Yes, that could be one possibility.",
          "sentiment": 0.0,
          "engagement": "5,775",
          "price_at_post": "51.50",
          "thread_title": "RE: Bone Marrow Toxicity, Brain malignancies?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=34DD9B68-3AA3-4F24-A8A5-8F742D7F4948"
        },
        "ingested_at": "2026-02-07T00:53:29.080624+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261622-wyndrum-54822013",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.530749",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "Fine with me Chris. I would remind you however that it was you that asked I report my trades. Anyway I\u2019m keen to see how this bb goes from here.",
          "sentiment": 0.0,
          "engagement": "12,228",
          "price_at_post": "51.50",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-07T00:53:29.080659+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261615-HarChris--1565704",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.531177",
        "source": "LSE_CHAT",
        "data": {
          "author": "HarChris",
          "content": "The last time I pointed out your losing trade you responded by saying you barely had anything on it\u2026 so nah, don\u2019t bother if you can just twist it how you want. And it clogs up the bb even more! How about not sharing any and trying not to care what an anonymous group of people think about your trading prowess?! That would be healthier!",
          "sentiment": 0.0,
          "engagement": "15,870",
          "price_at_post": "51.50",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-07T00:53:29.080696+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261613-Agenda10-52076452",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.531589",
        "source": "LSE_CHAT",
        "data": {
          "author": "Agenda101",
          "content": "None.. he\u2019s fishing don\u2019t reply!",
          "sentiment": 0.0,
          "engagement": "72",
          "price_at_post": "51.50",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-07T00:53:29.080731+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261547-BuenaVis--1056328",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.532000",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "@russell1 , what deadlines has Avacta missed since CC became CEO on 1 May 2024?",
          "sentiment": 0.0,
          "engagement": "5,775",
          "price_at_post": "51.00",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-07T00:53:29.080766+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261536-russell1-92110298",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.532426",
        "source": "LSE_CHAT",
        "data": {
          "author": "russell1",
          "content": "Well I'm not prepared to add any more money to my current loss situation so my only decision is whether to sell a proportion of my holding and hope I can buy back at a lower price if we (ever) get some worthwhile news or just leave it and hope! My expectation is that the price will just drift down until any news arrives but I have no expectation that this company will ever meet any of its reported deadlines.",
          "sentiment": -0.5,
          "engagement": "315",
          "price_at_post": "51.00",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-07T00:53:29.080801+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261529-Sisyphus-26083925",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.532837",
        "source": "LSE_CHAT",
        "data": {
          "author": "SisyphusShorter",
          "content": "Thanks BV, good to know. So in theory, a \"FAP-Temo\" agent would be roughly 460Da in size, provided the same Gen1 preCISION peptide is used. That puts it within the 400-600 threshold for BBB-crossing possibility (obviously notwithstanding lipophilicity, polarity and other parameters). That being said they could always cleave off a few residues to make a lightweight version for this specific indication.",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "51.00",
          "thread_title": "RE: Bone Marrow Toxicity, Brain malignancies?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=34DD9B68-3AA3-4F24-A8A5-8F742D7F4948"
        },
        "ingested_at": "2026-02-07T00:53:29.080837+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261509-Toukanka-55118226",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.533258",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "At last sensible posters instead of the usual carp \u201cfill yer boots you\u2019ll never again get the chance at this SP\u201d.  In truth we have a sideways drift until 6103 early clinical results are published in the Summer. Get over it and be patient.",
          "sentiment": 0.0,
          "engagement": "4,454",
          "price_at_post": "51.00",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-07T00:53:29.080871+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261432-wyndrum--5955757",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.533670",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "Chris, are you still interested in my buys and sells or would you prefer me not to bother?",
          "sentiment": 0.0,
          "engagement": "12,228",
          "price_at_post": "51.00",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-07T00:53:29.080906+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261413-Aston15--9851853",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.534076",
        "source": "LSE_CHAT",
        "data": {
          "author": "Aston15",
          "content": "I have brought enough now to be comfortable with the risk to reward ratio. 10% of my SIPP now in AVCT following another purchase this week. Many are expecting more than this, but my target remains a 5 billion valuation for the platform minimum. Happy to leave this to run now and hope the team delivers a positive outcome for both patients and shareholders.",
          "sentiment": 0.0,
          "engagement": "62",
          "price_at_post": "50.50",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-07T00:53:29.080942+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261410-B2HS2L-19220983",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.534502",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "Slide 16 & 18 of the Investormeet presentation 17.12.2025 contain info on tumor biopsies as articulated by Ruairidh Edwards, Translational Scientist. He's discussing phase 1b patients, possibly placing the recording of the interview before mid December.",
          "sentiment": 0.0,
          "engagement": "6,003",
          "price_at_post": "50.50",
          "thread_title": "RE: Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-02-07T00:53:29.080978+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261347-Vertizea-75037465",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.529148",
        "source": "LSE_CHAT",
        "data": {
          "author": "VertizeaSun",
          "content": "I think it links with CC's visit to Glasgow.....to visit the manufacturing site of AVA6103 and its \"first pour\".",
          "sentiment": 0.0,
          "engagement": "433",
          "price_at_post": "50.50",
          "thread_title": "RE: Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-02-07T00:53:29.081012+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261340-BuenaVis--6238296",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.529619",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Whilst the introduction by the host was current (post-IND announcement), CC seemed to be referencing passed events as being in the future and someone here suggested that the interview was recorded last year, in early December if I remember correctly.  I haven't listened to the interview again today but I do remember hearing bits that seemed out of step with today's situation.",
          "sentiment": 0.0,
          "engagement": "5,775",
          "price_at_post": "50.50",
          "thread_title": "RE: Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-02-07T00:53:29.081048+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261326-BuenaVis-59200238",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.530089",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Interesting and intelligent quesitions. As regards, fibrotic targets due to prior anthracycline treatment, it'll be interesting to see whether this side effect is reduced in previously untreated patients.  The breakdown of side effects vs prior treatment hasn't been presented yet but it is exacty the sort of detail I'm wanting to see (also, for example, side effects vs cancer indication/metastasis site).  Hopefully it will be included when the Phase 1 trial is written up in a peer-reviewed article, but there's always the AGM as an opportunity for asking detailed questions in person. As regards crossing the blood-brain barrier (BBB)... Temozolomide - molecular weight: 194.15 Da Doxorubicin - molecular weight: 543.52 Da Faridoxorubicin - molecular weight: 816.8 Da Faridoxorubicin without doxorubicin: 273.28 Da According to Gemini, \"Drugs that cross the BBB generally must be lipophilic (lipid-soluble), have a low molecular weight\u2014typically under 400\u2013600 Da\u2014and have a low polar surface area or few hydrogen bonds. They must avoid active efflux transport systems (like P-glycoprotein) and not be highly bound to plasma proteins.\"  So the requirements for an IV infusion drug are pretty stringent. However, there is an alternative route and that is, again according to Gemini, \"[administration] directly into the brain to bypass the BBB. This approach, known as local or regional drug delivery, is used to treat primary brain tumors (like glioblastoma) or brain metastases, allowing high concentrations of medication to reach the tumor without causing systemic toxicity.\"  I should think that the advantage of using pre|CISION for this is that, whilst the pre|CISION drug itself would be too big to cross OUT of the brain, the warhead, its metabolites and the leaving group from the pre|CISION substrate could all be below the size needed to cross out of the brain.  Anyway, CC wouldn't have specifically mentioned brain cancer if it weren't a possibility.",
          "sentiment": 0.0,
          "engagement": "5,775",
          "price_at_post": "50.50",
          "thread_title": "RE: Bone Marrow Toxicity, Brain malignancies?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=34DD9B68-3AA3-4F24-A8A5-8F742D7F4948"
        },
        "ingested_at": "2026-02-07T00:53:29.081082+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261318-IFA90-20703762",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.530517",
        "source": "LSE_CHAT",
        "data": {
          "author": "IFA90",
          "content": "I\u2019m not buying anymore. I\u2019ve increased my holding this week by selling a % and buying back c.10% cheaper. After 5 years it\u2019s entirely predictable, I just wish I\u2019d have realised that 3 years ago.",
          "sentiment": 0.0,
          "engagement": "409",
          "price_at_post": "50.50",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-07T00:53:29.081140+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261312-wyndrum-67230262",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.530949",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "Yes cj and I have just literally sold that holding and more as it looks to confused to me right now. Just so you know and can keep up I placed the sale evenly between Cpx and Xsg. Personally I would enjoy exploring and explaining my reasoning in a bit more depth but no need to is interested. ( and while you may all feel a bit more smug about this, it might be worth reflecting that I don\u2019t illicit the antagonist relationship here on other bb\u2019s. It begs the question is it me or you?)",
          "sentiment": 0.0,
          "engagement": "12,228",
          "price_at_post": "50.50",
          "thread_title": "RE: ADC 26",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=F3B63190-B417-42B7-9CC8-0ED98F4FBB92"
        },
        "ingested_at": "2026-02-07T00:53:29.081175+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261301-cj62--7089578",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.531376",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "\"Well the sp is 52p and now years later my analysis over a vey long period has proved correct and his wrong.\" but not recently you could have added- bought at 56.95 i believe. Yet still there are some that want me to be cancelled, yep you have that 100% correct as your narcissim knows no bounds",
          "sentiment": 0.0,
          "engagement": "4,282",
          "price_at_post": "50.50",
          "thread_title": "RE: ADC 26",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=F3B63190-B417-42B7-9CC8-0ED98F4FBB92"
        },
        "ingested_at": "2026-02-07T00:53:29.081210+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261254-Sisyphus-65818128",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.531796",
        "source": "LSE_CHAT",
        "data": {
          "author": "SisyphusShorter",
          "content": "So been looking at the phase 1 data for AVA6000 and also been listening to the podcast, thanks BV. Now I have two broad questions: One on bone/haem side effects, and one regarding primary brain cancers. Firstly, of the patients we have seen with bone marrow suppression, I know it's a known side effect of Dox, but I do wonder if prior primary therapies have induced a bit of fibrosis in the marrow, leading to FAP expression and thus Dox being released, leading to further bone marrow toxicity. That would imply that the side effects seen in the patients so far are less likely to emerge in a larger trial with a higher proportion of chemo-naive patients. Thoughts? Secondly, CC mentioned in the podcast that given that 90% of solid tumours express FAP, including brain, which she mentioned, and this begs the question whether or not the Peptide used in pre/CISION drug conjugates is small enough to pass the blood-brain-barrier, after all, that's how Temozolomide can do it's think for brain tumours. Again, thoughts?",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "50.50",
          "thread_title": "Bone Marrow Toxicity, Brain malignancies?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=34DD9B68-3AA3-4F24-A8A5-8F742D7F4948"
        },
        "ingested_at": "2026-02-07T00:53:29.081246+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261253-pedrolan-17734245",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.532225",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Yes, I bought some more the other week and am considering more now to get my average down further. If you believe in the medium term story here (with the bonus of a potential deal at any time) then it seems a bargain. Before any of the aliases bother to reply - I will not be responding to it - it will not be anything we have not all heard multiple times anyway.",
          "sentiment": 0.5,
          "engagement": "1,975",
          "price_at_post": "51.00",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-07T00:53:29.081285+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261252-BuenaVis-73914058",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.532633",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Another advantage of Avacta's PDCs is the h o m ogeneity of the dosage - exactly one warhead per drug molecule, or exactly two warheads per drug molecule for the dual payload drugs. In contrast, significant heterogeneity exists in ADCs as they are complex mixtures of varied molecular species rather than a single uniform compound. This includes differences in the drug-to-antibody ratio (DAR) and the conjugation sites on the antibody, leading to mixtures with 0 to 8+ payload molecules and various positional isomers.",
          "sentiment": 0.0,
          "engagement": "5,775",
          "price_at_post": "51.00",
          "thread_title": "RE: ADC 26",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=F3B63190-B417-42B7-9CC8-0ED98F4FBB92"
        },
        "ingested_at": "2026-02-07T00:53:29.081320+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261250-aidanjc-87020053",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.533041",
        "source": "LSE_CHAT",
        "data": {
          "author": "aidanjc",
          "content": "I've been a lth here having bought at several levels. Was hoping not to see us back around the 50p level. I've bought a few more. Anyone else buying. I'm hoping 50p will be the low tide mark...",
          "sentiment": 0.5,
          "engagement": "6",
          "price_at_post": "51.00",
          "thread_title": "Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-07T00:53:29.081355+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261246-wyndrum-22800017",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.533480",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "Also I don\u2019t care if you respond or not. I just hope it makes you think.also you will crack before we do. Not because it\u2019s a contest but simply we will ask questions or post opinions that as a bb you will naturally want to respond to. That\u2019s the whole purpose of a discussion bb. To discuss. And while there are a lot of recs to want us to be cancelled you will soon be bored with the lack of insight offered by the so called guardians of this bb. And never forget, it is exactly the same posters that by insulting us that then generate the board clogging are the ones piously demanding we be ignored. Just check sheppy watching bv and the rest for their overall contribution.",
          "sentiment": 0.0,
          "engagement": "12,228",
          "price_at_post": "51.00",
          "thread_title": "RE: ADC 26",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=F3B63190-B417-42B7-9CC8-0ED98F4FBB92"
        },
        "ingested_at": "2026-02-07T00:53:29.081390+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261243-Sisyphus--8284214",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.533883",
        "source": "LSE_CHAT",
        "data": {
          "author": "SisyphusShorter",
          "content": "Sorry, *Next* data release....",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "51.00",
          "thread_title": "RE: Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-02-07T00:53:29.081425+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261240-Sisyphus--5326530",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.534310",
        "source": "LSE_CHAT",
        "data": {
          "author": "SisyphusShorter",
          "content": "At 36:22 CC says, regarding tumour biopsies - \"...in our new data release which will be later this month...\" Make of that what you will..... GLA",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "51.00",
          "thread_title": "RE: Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-02-07T00:53:29.081458+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261232-wyndrum--3988822",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.534763",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "Oh, I remember, after this interview and the other stuff uncovered, what has the sp done? Why ,  How, can there be more sellers than buyers? Let\u2019s move on from the \u201csp doesn\u2019t matter \u201c. It\u2019s a facile statement which simply refuses to address a perfectly reasonable question. Yes the sp can drift up or down on no news but why can\u2019t we discuss it when there is a very positive release and it generates sells? By all means keep up this do not engage but myles tried this with me specifically on this bb with a little header to try and get me banned altogether. Well the sp is 52p and now years later my analysis over a vey long period has proved correct and his wrong. Yet still there are some that want me to be cancelled. You lot are either just plain weird or it is you that have an agenda. Just remember I have made money out of this stock and had you agreed with my view you would have too. The opposite would have happened if you followed bv and the rest. Yet you want me silenced. You might perhaps realise why I wonder what motivates the majority here.",
          "sentiment": 0.0,
          "engagement": "12,228",
          "price_at_post": "51.00",
          "thread_title": "RE: ADC 26",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=F3B63190-B417-42B7-9CC8-0ED98F4FBB92"
        },
        "ingested_at": "2026-02-07T00:53:29.081492+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261221-Watching--6682918",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.535189",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "To the Fudders they are trying so hard this morning ! It worked yesterday ! They are drying up \ud83e\udd21s",
          "sentiment": 0.0,
          "engagement": "9,215",
          "price_at_post": "51.00",
          "thread_title": "Do not respond",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=598797E4-B255-4509-971C-C103D6214E00"
        },
        "ingested_at": "2026-02-07T00:53:29.081529+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261143-wyndrum--7978019",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.535610",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "whatever you do, do not do not reply  or respond. you might want to take the ****, but resist. you might have the best put down ever! but do not repeat do not respond  got it? now what was i going to say\u2026. damn after all that i forgot \u2026.,",
          "sentiment": 0.0,
          "engagement": "12,228",
          "price_at_post": "52.00",
          "thread_title": "RE: ADC 26",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=F3B63190-B417-42B7-9CC8-0ED98F4FBB92"
        },
        "ingested_at": "2026-02-07T00:53:29.081567+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261014-HarryAng--5327967",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.536027",
        "source": "LSE_CHAT",
        "data": {
          "author": "HarryAngstrom",
          "content": "I meant PEAK SALES to Avacta... not TAM.",
          "sentiment": 0.0,
          "engagement": "9",
          "price_at_post": "52.50",
          "thread_title": "RE: Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-02-07T00:53:29.081606+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260955-D-Geeman--1216038",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.536554",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "'Today 09:44 Don't waste time responding if your handle is ........ D-Geeman ' You sound like a teenager with a statement like that B2HS2L. In this context that isn't a compliment.",
          "sentiment": 0.0,
          "engagement": "5,849",
          "price_at_post": "53.00",
          "thread_title": "RE: ADC 26",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=F3B63190-B417-42B7-9CC8-0ED98F4FBB92"
        },
        "ingested_at": "2026-02-07T00:53:29.081644+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260946-HarryAng--6189423",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.537041",
        "source": "LSE_CHAT",
        "data": {
          "author": "HarryAngstrom",
          "content": "This is a gigantic opportunity. TAM for Rhematoid Arthritis would be between $3.0 - $4.0 billion. And if they move into Fibrosis, the TAM there is between $7.0 - $10.0 billion. Once they prove they can deliver a toxin as potent as Exatecan using the FAP linker, using the same linker for milder anti-fibrotic or anti-inflammatory drugs is a low risk, high reward certainty.",
          "sentiment": 0.0,
          "engagement": "9",
          "price_at_post": "52.50",
          "thread_title": "RE: Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-02-07T00:53:29.081682+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260944-B2HS2L--3525243",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.537575",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "Don't waste time responding if your handle is wyndrum, Thornogson, Toukankahmoon or D-Geeman ********************************************************************************************************* Like my new header?  \ud83d\ude01\ud83d\ude09   I hope you create similar. In the event one company buys Avacta, all others will need to continue developing ADC's. They'll need to make improvements to compete as follows: 1 Reduce the time required to develop new drugs. 2 Improve the precision of targeting of warheads, so less drug is available systemically. 3 Improve the ease and speed of manufacturing 4 Find ways to reduce particle size 5 Find ways to deliver >1 drug at a time. Also - * Small molecule manufacturing and timeline/COGM (cost of goods manufactured) \"What that statement means and why that is important, is that the price tag for this drug (AVA6000), is one tenth of the price tag for an ADC drug. ADC's cost a lot of money in the clinic\"  CC 8.11.2024 I don't see why the statement isn't also true for AVA6103. ++++ A reminder from  Trinity Delta \u2013 Targeting the tumour microenvironment with pre|CISION - 18.11.2024 https://www.trinitydelta.org/research-notes/targeting-the-tumour-microenvironment-with-precision/ \"Avacta has so far FAP-enabled ten different warheads building up a database of multiple pre|CISION compounds that include c 40 capping groups (which alter the PK of the conjugate) and c 20   linkers (required for FAP cleavage with certain warheads and can be used to modify FAP affinity and activity). These have all been characterised through computational simulations to evaluate molecular binding and how they dock into the FAP structure. A key consideration is how close the warhead can get to the FAP cleavage sequence; this typically depends on the size of the molecule, and often defines whether a spacer group is required. Consideration is also given to how long the conjugate and the active warhead are likely to remain in the TME, and this informs whether PK alterations, achieved through an alternative capping group, are needed to either allow the sustained release of the warhead or to slow plasma clearance. Potential candidate molecules that meet the internal hurdle are also evaluated in vivo to investigate key PK parameters and cytotoxicity, with some selected for further characterisation in vitro and in vivo to establish preclinical efficacy and safety in a wide range of FAP tumour expression models with low serum FAP (including co-cultures of tumour cells and CAFs) to recapitulate the human TME.\" ++++ I'll bet there is more than ten warheads, forty capping groups and twenty linkers now!",
          "sentiment": 0.0,
          "engagement": "6,003",
          "price_at_post": "53.00",
          "thread_title": "RE: ADC 26",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=F3B63190-B417-42B7-9CC8-0ED98F4FBB92"
        },
        "ingested_at": "2026-02-07T00:53:29.081720+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260931-BuenaVis-78309011",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.537985",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Really does feel like adding Go Faster stripes at a horse fair.",
          "sentiment": 0.0,
          "engagement": "5,775",
          "price_at_post": "53.00",
          "thread_title": "RE: ADC 26",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=F3B63190-B417-42B7-9CC8-0ED98F4FBB92"
        },
        "ingested_at": "2026-02-07T00:53:29.081757+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260910-Yorkshir--2491127",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.538411",
        "source": "LSE_CHAT",
        "data": {
          "author": "Yorkshirepragma",
          "content": "CC refers to other applications \u2026Chronic Inflammation \u2018conversations\u2019 are interesting . One step at a time \u2026.",
          "sentiment": 0.0,
          "engagement": "1,804",
          "price_at_post": "53.00",
          "thread_title": "RE: Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-02-07T00:53:29.081796+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260845-Yorkshir-48327046",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.538852",
        "source": "LSE_CHAT",
        "data": {
          "author": "Yorkshirepragma",
          "content": "Fascinating similarity re Avactas current development processes. Tuesday 24th February 2026 The Next Generation of ADCs: Leveraging Novel Conjugation & Enhanced Antibody Engineering for the Future of Targeted Oncology Therapies 9:15 am Laying out the scope to differentiate ADC development through novel conjugation, antibody engineering, and target identification approaches to widen therapeutic index and bring patient benefit Incorporating in silico and AI tools to enhance the ADC discovery toolbox and deliver next-generation ADC engineering and design Highlighting future priorities for next-generation ADC development, including exploring the potential of radio conjugates",
          "sentiment": 0.0,
          "engagement": "1,804",
          "price_at_post": "53.00",
          "thread_title": "ADC 26",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=F3B63190-B417-42B7-9CC8-0ED98F4FBB92"
        },
        "ingested_at": "2026-02-07T00:53:29.081835+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260811-Agenda10-90441450",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.539272",
        "source": "LSE_CHAT",
        "data": {
          "author": "Agenda101",
          "content": "Cheers BV!",
          "sentiment": 0.0,
          "engagement": "72",
          "price_at_post": "53.00",
          "thread_title": "RE: Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-02-07T00:53:29.081873+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260754-cj62-80634678",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.539688",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "Who would be allowed access ?",
          "sentiment": 0.0,
          "engagement": "4,282",
          "price_at_post": "53.00",
          "thread_title": "Data Room",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=85F98FAE-01B2-48EC-B9D0-584FAD2B9731"
        },
        "ingested_at": "2026-02-07T00:53:29.081911+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260751-Thornogs-71085239",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.713580",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "This one and one after the close to comment on the top quality discussion and to check if we finished up or not.",
          "sentiment": 0.0,
          "engagement": "8,666",
          "price_at_post": "53.00",
          "thread_title": "2 post Friday.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=EDA1F112-F6D9-49A4-937D-081A93C2E757"
        },
        "ingested_at": "2026-02-07T00:53:29.082191+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260626-Gingethe--3921242",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.714067",
        "source": "LSE_CHAT",
        "data": {
          "author": "GingetheWinge",
          "content": "The FUDsters are thrashing like Terminator 2 in a smelting cauldron. It\u2019s working so let\u2019s continue to starve them of any engagement. As Runner-Runner wrote and BV reposted\u2026 It's simple. 1. DO NOT ENGAGE 2. DO NOT ASK IT A QUESTION 3. DO NOT ANSWER ITS QUESTIONS 4. DO NOT MOAN ABOUT ITS POSTS 5. DO NOT ARGUE WITH IT 6. If you must do something. Mock it with reference only to its stupidity and nothing else. ------------------------------------------------------ If you're not part of the solution, you're part of the problem",
          "sentiment": 0.5,
          "engagement": "700",
          "price_at_post": "53.00",
          "thread_title": "No not engage !",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=A348D8E1-4DC7-4D49-950E-08F79BC3A2D1"
        },
        "ingested_at": "2026-02-07T00:53:29.082230+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260138-BuenaVis-59114715",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.714500",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Even better link: https://www.youtube.com/watch?v=HWkh3OEFSds&t=1333s",
          "sentiment": 0.0,
          "engagement": "5,775",
          "price_at_post": "53.00",
          "thread_title": "RE: Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-02-07T00:53:29.082268+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260132-BuenaVis--8736210",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.714925",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "It's the Base to Base biotech podcast from a few days ago. Well worth a listen. Here's the link to the start of the CC interview: https://www.youtube.com/watch?v=HWkh3OEFSds&t=1290s",
          "sentiment": 0.0,
          "engagement": "5,775",
          "price_at_post": "53.00",
          "thread_title": "RE: Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-02-07T00:53:29.082305+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262331-D-Geeman-35144483",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.715361",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "Wasn\u2019t wyn comparing this BB to \u2018Lord of the Flies\u2019 classic story? Well for those who don\u2019t know the story I just caught a trailer for new BBC production starting soon; https://www.bbc.com/mediacentre/2026/lord-of-the-flies-trailer",
          "sentiment": 0.0,
          "engagement": "5,849",
          "price_at_post": "53.00",
          "thread_title": "RE: Avacta Therapeutics celebrates this",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=03B0B4A6-705E-45ED-983A-A89C321C0924"
        },
        "ingested_at": "2026-02-07T00:53:29.082344+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262302-alextak-52028329",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.715781",
        "source": "LSE_CHAT",
        "data": {
          "author": "alextak",
          "content": "Is it a new interview? .I'll listen to it tomorrow.",
          "sentiment": 0.0,
          "engagement": "540",
          "price_at_post": "53.00",
          "thread_title": "RE: Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-02-07T00:53:29.082381+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262258-alextak-22474070",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.716203",
        "source": "LSE_CHAT",
        "data": {
          "author": "alextak",
          "content": "Https://youtu.be/HWkh3OEFSds?si=0KezbLZbtRJA4N97",
          "sentiment": 0.0,
          "engagement": "540",
          "price_at_post": "53.00",
          "thread_title": "Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-02-07T00:53:29.082419+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262241-pedrolan--1555738",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.716624",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "When no-one engages that's what they end up with. Good work folks.",
          "sentiment": 0.5,
          "engagement": "1,975",
          "price_at_post": "53.00",
          "thread_title": "Voices in the wilderness",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=8AE5A358-4CCC-4E25-A8A9-D4C3BBC9FF5F"
        },
        "ingested_at": "2026-02-07T00:53:29.082453+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262222-Thornogs-15751158",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.717039",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Absolutely Pedro! All those who chance upon the LSE Avacta bulletin board and haven't been keeping up with the news, all of them? Exposure indeed, keep up the good work everybody!",
          "sentiment": 0.0,
          "engagement": "8,666",
          "price_at_post": "53.00",
          "thread_title": "RE: Avacta Therapeutics celebrates this",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=03B0B4A6-705E-45ED-983A-A89C321C0924"
        },
        "ingested_at": "2026-02-07T00:53:29.082485+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262202-pedrolan--2708615",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.717464",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "All great exposure. Thanks for posting \ud83d\udc4d\ud83c\udffb",
          "sentiment": 0.5,
          "engagement": "1,975",
          "price_at_post": "53.00",
          "thread_title": "RE: Avacta Therapeutics celebrates this",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=03B0B4A6-705E-45ED-983A-A89C321C0924"
        },
        "ingested_at": "2026-02-07T00:53:29.082521+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262145-Thornogs--6500028",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.717891",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Well there we have it Avcti, proof positive fof all those 'FUDsters' who have been saying otherwise all day! Avacta can produce FAP-EXD for the upcoming trial! What chance does 'FUD' have against this level of research and knowledge? Hang your heads in shame all those saying that it wasn't possible. Was anyone suggesting this?",
          "sentiment": 0.0,
          "engagement": "8,666",
          "price_at_post": "53.00",
          "thread_title": "RE: \" So excited to get the trial going soon. \"",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=C91568DF-F421-4695-901C-78161A0F4CD6"
        },
        "ingested_at": "2026-02-07T00:53:29.082556+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262110-avctIPma--5861705",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.718379",
        "source": "LSE_CHAT",
        "data": {
          "author": "avctIPmatters",
          "content": "FYI   Christina CoughlinChristina Coughlin \u2022 3rd+Verified \u2022 3rd+ Chief Executive Officer, AvactaChief Executive Officer, Avacta 53m \u2022  53 minutes ago \u2022 Visible to anyone on or off LinkedIn Follow We are thrilled to partner with our team at Curia - this partnership has enabled our team at hashtag#AVCT to move FAP-exatecan forward at record pace. So excited to get the trial going soon. This combined team reminds me of a favorite quote, \u201cNever doubt that a small group of thoughtful, committed citizens can change the world. Indeed, it is the only thing that ever has.\u201d \u2014Margaret Mead. hashtag#LetsDoThis hashtag#HopeWithoutCompromise CuriaCuria 104,425 followers104,425 followers 2h \u2022  2 hours ago \u2022 Visible to anyone on or off LinkedIn Follow Congratulations to Avacta Therapeutics on receiving U.S. Food and Drug Administration (FDA) clearance of the Investigational New Drug (IND) application for the Company\u2019s second program FAP-Exd (AVA6103). This peptide drug conjugate is based on the highly potent topoisomerase I inhibitor, exatecan. A Phase 1 clinical trial will enroll patients with solid tumors, pancreatic cancer, cervical cancer, gastric cancer and small cell lung cancer. CURIA STERILE DRUG PRODUCT business unit is proud to assist this cutting-edge oncology program with formulation development, analytical support and GMP clinical supply at our site in Glasgow. Read more about Avacta in the recent press release: https://hubs.li/Q040N2nz0",
          "sentiment": 0.0,
          "engagement": "728",
          "price_at_post": "53.00",
          "thread_title": "\" So excited to get the trial going soon. \"",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=C91568DF-F421-4695-901C-78161A0F4CD6"
        },
        "ingested_at": "2026-02-07T00:53:29.082593+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262104-wyndrum-25012689",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.718829",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "So you\u2019re right and I am wrong as you have said umpteen times  yet it is me who is the narcissist? You don\u2019t even know what the term means in detail yet bandi it about as a diagnosis of a stranger you know nothing about. Your arrogance in libelling me without any justification only amplifies my point. But in none of these umpteen times have you ever wondered why AVCT have failed to deliver the returns you expected when you first bought in ? No of course not. That would require self examination. Something you seem to lack but have no inhibition in accusing others of. The arrogance of the arguments directed at me are so cliched and bereft of any true accuracy that it is simply pathetic. What is so considerably worse is the recs they get. Not because it offends me more but rather of the evidence that so may can\u2019t reason for themselves and blithely agree. It\u2019s not a case of reading the room, more a case of group think. Under your reasoning we would all still think the earth was flat.",
          "sentiment": 0.0,
          "engagement": "12,228",
          "price_at_post": "53.00",
          "thread_title": "RE: Worldwide ADC Innovation & Collaboration   London",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=CB66756C-50A3-4D04-A499-ADC1B8951801"
        },
        "ingested_at": "2026-02-07T00:53:29.082631+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262104-Metatron--1089633",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.719249",
        "source": "LSE_CHAT",
        "data": {
          "author": "Metatron",
          "content": "Forgot.. dammit.. sawy \ud83e\udd14",
          "sentiment": 0.0,
          "engagement": "1,188",
          "price_at_post": "53.00",
          "thread_title": "RE: Worldwide ADC Innovation & Collaboration   London",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=CB66756C-50A3-4D04-A499-ADC1B8951801"
        },
        "ingested_at": "2026-02-07T00:53:29.082669+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262051-BuenaVis-29919078",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.719657",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Do not feed the troll. \ud83e\udd2a",
          "sentiment": 0.0,
          "engagement": "5,775",
          "price_at_post": "53.00",
          "thread_title": "RE: Worldwide ADC Innovation & Collaboration   London",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=CB66756C-50A3-4D04-A499-ADC1B8951801"
        },
        "ingested_at": "2026-02-07T00:53:29.082708+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262035-Metatron-15339139",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.720073",
        "source": "LSE_CHAT",
        "data": {
          "author": "Metatron",
          "content": "The problem is Wyndrone.. that you cannot read the room because you are a narcissist as I've explaind umpteen times. The recs are from other members who are just plain sick to death of you and your narcissistic droning behaviour.",
          "sentiment": 0.0,
          "engagement": "1,188",
          "price_at_post": "53.00",
          "thread_title": "RE: Worldwide ADC Innovation & Collaboration   London",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=CB66756C-50A3-4D04-A499-ADC1B8951801"
        },
        "ingested_at": "2026-02-07T00:53:29.082746+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262028-Metatron-58901135",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.720496",
        "source": "LSE_CHAT",
        "data": {
          "author": "Metatron",
          "content": "Looks like Thorndrone has repositioned itself as the ultimate purile commentator on the commentary? Looks more to me like the ultimate terd that just won't flush \ud83d\ude48\ud83d\udca9",
          "sentiment": 0.0,
          "engagement": "1,188",
          "price_at_post": "53.00",
          "thread_title": "RE: Avacta Therapeutics celebrates this",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=03B0B4A6-705E-45ED-983A-A89C321C0924"
        },
        "ingested_at": "2026-02-07T00:53:29.082783+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262028-wyndrum-65893326",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.720925",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "I think the problem is Chris is that while what you say is correct, it is the \u201canti-fudsters \u201c for want of a better expression, that quite deliberately push this debilitating and constant line at any opportunity. And like today, when nothing is going on, BV just stirs the pot. Yet every single time the cause of this futile exercise is laid at the door of the posters who are incessantly  attacked rather than the perpetrators . What\u2019s even more disturbing is the recs they get for doing it. This bb is simply one of the worst I have ever come across and we all contribute to that to some degree but it is the majority (when you look at the recs) here that revel in this disruptive behaviour and have little or no interest in resolving the situation for the better. Why can\u2019t I say after 5 years of a trial and a sp at near all time lows that maybe all is not what we were led to believe from the outset and can we look at what might be causing this without being asked to be ignored banned or wished an early death?",
          "sentiment": 0.0,
          "engagement": "12,228",
          "price_at_post": "53.00",
          "thread_title": "RE: Worldwide ADC Innovation & Collaboration   London",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=CB66756C-50A3-4D04-A499-ADC1B8951801"
        },
        "ingested_at": "2026-02-07T00:53:29.082822+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262015-stodgy88-20706825",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.721347",
        "source": "LSE_CHAT",
        "data": {
          "author": "stodgy88",
          "content": "LinkedIn.",
          "sentiment": 0.0,
          "engagement": "1,206",
          "price_at_post": "53.00",
          "thread_title": "RE: Avacta Therapeutics celebrates this",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=03B0B4A6-705E-45ED-983A-A89C321C0924"
        },
        "ingested_at": "2026-02-07T00:53:29.082862+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262014-stodgy88-11662950",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.721752",
        "source": "LSE_CHAT",
        "data": {
          "author": "stodgy88",
          "content": "This company as over  100,000 followers, so good exposure.",
          "sentiment": 0.0,
          "engagement": "1,206",
          "price_at_post": "53.00",
          "thread_title": "RE: Avacta Therapeutics celebrates this",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=03B0B4A6-705E-45ED-983A-A89C321C0924"
        },
        "ingested_at": "2026-02-07T00:53:29.082901+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262011-Thornogs--6608698",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.722182",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Quite Avcti, well done! Always good to be reminded of last week's RNS! In case any of ghd 'well infofmed' missed it eh?",
          "sentiment": 0.0,
          "engagement": "8,666",
          "price_at_post": "53.00",
          "thread_title": "RE: Avacta Therapeutics celebrates this",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=03B0B4A6-705E-45ED-983A-A89C321C0924"
        },
        "ingested_at": "2026-02-07T00:53:29.082940+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262010-HarChris--2872643",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.722603",
        "source": "LSE_CHAT",
        "data": {
          "author": "HarChris",
          "content": "There\u2019s a cycle of Thorn repeating the same points over and over again, the numerous posters who flood us with messages telling him to F off, begging others not to reply or to warn the bb of his dishonesty and then Wyn writing paragraphs of philosophy and psychology on the meaning of it all. That plays out at least four or five times a week! Almost identically. The odd post on Avacta gets a reply or two before the cycle kickstarts again. What a waste of time this BB is in quiet periods like this!",
          "sentiment": 0.0,
          "engagement": "15,870",
          "price_at_post": "53.00",
          "thread_title": "RE: Worldwide ADC Innovation & Collaboration   London",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=CB66756C-50A3-4D04-A499-ADC1B8951801"
        },
        "ingested_at": "2026-02-07T00:53:29.082979+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262004-avctIPma--7471109",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.723059",
        "source": "LSE_CHAT",
        "data": {
          "author": "avctIPmatters",
          "content": "Back to more worthwhile  conversation thanks Stonks -------------------------- Avacta Therapeutics celebrates this Curia 54m \u2022 Follow Congratulations to Avacta Therapeutics on receiving U.S. Food and Drug Administration (FDA) clearance of the Investigational New Drug (IND) application for the Company\u2019s second program FAP-Exd (AVA6103). This peptide drug conjugate is based on the highly potent topoisomerase I inhibitor, exatecan. A Phase 1 clinical trial will enroll patients with solid tumors, pancreatic cancer, cervical cancer, gastric cancer and small cell lung cancer. CURIA STERILE DRUG PRODUCT business unit is proud to assist this cutting-edge oncology program with formulation development, analytical support and GMP clinical supply at our site in Glasgow. Read more about Avacta in the recent press release: https://hubs.li/Q040N2nz0 \" Gmcc",
          "sentiment": 0.0,
          "engagement": "728",
          "price_at_post": "53.00",
          "thread_title": "Avacta Therapeutics celebrates this",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=03B0B4A6-705E-45ED-983A-A89C321C0924"
        },
        "ingested_at": "2026-02-07T00:53:29.083017+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261833-D-Geeman-63345316",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.723489",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "'and bucket to collect their donations for his roses.\u2019 'collect the dung & yes then spread the manure around the Roses' I understand that Watching does this too but with her Quality Street, not Roses.",
          "sentiment": 0.0,
          "engagement": "5,849",
          "price_at_post": "53.00",
          "thread_title": "RE: Worldwide ADC Innovation & Collaboration   London",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=CB66756C-50A3-4D04-A499-ADC1B8951801"
        },
        "ingested_at": "2026-02-07T00:53:29.083056+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261754-Thornogs-75906327",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.723915",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Now, now Wyn! Steady there. It's been decided that our constant 'FUD' detracts from thd ability of the 'well informed' posters to discuss Avzcta seriously. OK, so far it's just the usual nonsense but give thdm a chance I'm sure tomorrow they'll Smash It! Did we finish up by the way?",
          "sentiment": 0.0,
          "engagement": "8,666",
          "price_at_post": "53.00",
          "thread_title": "RE: Worldwide ADC Innovation & Collaboration   London",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=CB66756C-50A3-4D04-A499-ADC1B8951801"
        },
        "ingested_at": "2026-02-07T00:53:29.083096+00:00"
      },
      {
        "event_id": "SOCIAL-Today1236-Watching--2972336",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.595387",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "Let\u2019s have a day where know one engages with the Fudders A watch them argue with themselves \ud83d\ude0a",
          "sentiment": 0.0,
          "engagement": "9,213",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-02-07T00:53:29.083156+00:00"
      },
      {
        "event_id": "SOCIAL-Today1207-D-Geeman-36196009",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.595837",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "Evan Davis discussing mergers and acquisitions on Radio 4 right now.",
          "sentiment": 0.0,
          "engagement": "5,844",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-02-07T00:53:29.083195+00:00"
      },
      {
        "event_id": "SOCIAL-Today1050-D-Geeman--1182557",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.596300",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "Many of the most useful posts are green boxes to others. That's fine. I really don't care if **** doesn't read ****'s post as long as I can. Please, everyone who doesn't like ****'s posts filter and then the people who do read them can do so in peace.",
          "sentiment": 0.0,
          "engagement": "5,844",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-02-07T00:53:29.083233+00:00"
      },
      {
        "event_id": "SOCIAL-Today1034-Thornogs-54011695",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.596741",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Happy to sit on the sidelines to watch the emergence of all this deep research and intelligent discussion on the company's 'fundamentals'. Of course if it isn't accurate or realistic I presume there's the right to point this out? Otherwise it's just a meaningless Echo Chamber. Over to you, the self proclaimed 'well informed'. Let's see what quality posting looks like!",
          "sentiment": 0.0,
          "engagement": "8,655",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-02-07T00:53:29.083273+00:00"
      },
      {
        "event_id": "SOCIAL-Today1032-BuenaVis--4999035",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.597214",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "As Runner-Runner wrote... It's simple. 1. DO NOT ENGAGE 2. DO NOT ASK IT A QUESTION 3. DO NOT ANSWER ITS QUESTIONS 4. DO NOT MOAN ABOUT ITS POSTS 5. DO NOT ARGUE WITH IT 6. If you must do something. Mock it with reference only to its stupidity and nothing else. ------------------------------------------------------ If you're not part of the solution, you're part of the problem",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-02-07T00:53:29.083311+00:00"
      },
      {
        "event_id": "SOCIAL-Today1025-pedrolan-55129519",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.597761",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Ok, as one of the offenders ( I did it mainly to remind people of their/his agenda) I will pledge to now ignore them/him going forward. We really need everyone to do that though.",
          "sentiment": 0.5,
          "engagement": "1,972",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-02-07T00:53:29.083349+00:00"
      },
      {
        "event_id": "SOCIAL-Today1022-Aston15--6286424",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.598209",
        "source": "LSE_CHAT",
        "data": {
          "author": "Aston15",
          "content": "People do understand the only reason then come on here to spout sh*t is because others give them an audience? Its not difficult..  Green Box them and focus the chat on the company, not their trading agendas.",
          "sentiment": 0.0,
          "engagement": "61",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-02-07T00:53:29.083387+00:00"
      },
      {
        "event_id": "SOCIAL-Today1005-IFA90-13148364",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.598630",
        "source": "LSE_CHAT",
        "data": {
          "author": "IFA90",
          "content": "More posts than trades, never a good sign.",
          "sentiment": 0.0,
          "engagement": "408",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-02-07T00:53:29.083425+00:00"
      },
      {
        "event_id": "SOCIAL-Today0954-Aldebara--7187409",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.599061",
        "source": "LSE_CHAT",
        "data": {
          "author": "Aldebaran",
          "content": "Anyone engaging with them is part of the problem. I'll soon be adding them to my filter list if all the want to do is talk smack and try to score points against them. It's a waste of everyone's time, least not their own yet they persist. Sad. We could use this bb once again to discuss avacta but only if the engagement with FUDsters ends. Its nothing more than a digital playground otherwise. Filter. Them.",
          "sentiment": 0.0,
          "engagement": "3,894",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-02-07T00:53:29.083464+00:00"
      },
      {
        "event_id": "SOCIAL-Today0948-Watching-71105509",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.599520",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "Let\u2019s have a day where know one engages with the Fudders And watch them argue with there selves \ud83d\ude0a",
          "sentiment": 0.0,
          "engagement": "9,213",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-02-07T00:53:29.083502+00:00"
      },
      {
        "event_id": "SOCIAL-Today0932-Thornogs-58109465",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.599949",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "And on a day to day basis is there actually much new to talk about with Avacta? Tumbleweed City now until the next RNS, whatever that might be for.",
          "sentiment": 0.0,
          "engagement": "8,655",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-02-07T00:53:29.083540+00:00"
      },
      {
        "event_id": "SOCIAL-Today0924-wyndrum--7838528",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.600402",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "But Jane this was all caused by BV\u2019s non AVCT post. He deliberately provokes with his insults and lies. Non of this would have happened today without his non AVCT related post. Remember that would you",
          "sentiment": 0.0,
          "engagement": "12,217",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-02-07T00:53:29.083579+00:00"
      },
      {
        "event_id": "SOCIAL-Today0918-Watching-10653123",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.601027",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "Let\u2019s have a day where know one engages with the Fudders And watch them argue with themselves \ud83d\ude2c",
          "sentiment": 0.0,
          "engagement": "9,213",
          "price_at_post": "54.00",
          "thread_title": "Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-02-07T00:53:29.083618+00:00"
      },
      {
        "event_id": "SOCIAL-Today0917-pedrolan--4319867",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.601613",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "A seamless switch between users there Eggy Bravo",
          "sentiment": 0.0,
          "engagement": "1,972",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-07T00:53:29.083656+00:00"
      },
      {
        "event_id": "SOCIAL-Today0916-Thornogs--4275444",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.602292",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "To be fair Live account it's very easy to judge someone who repeatedly posts nonsense like you just have. And Pedro and BV joining in the: 'Look at us, we're idiots' gang.",
          "sentiment": 0.0,
          "engagement": "8,655",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-07T00:53:29.083694+00:00"
      },
      {
        "event_id": "SOCIAL-Today0902-wyndrum-55405815",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.603136",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "Sadly you have the memory of a goldfish but not its intellect. Again bv starts and contributes to the disruption. All we wait for now is the \u201cooh I can see all these green boxes\u201dposts add up my posts and add up all the rest and you quickly see who the paid disrupters are",
          "sentiment": 0.0,
          "engagement": "12,217",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-07T00:53:29.083733+00:00"
      },
      {
        "event_id": "SOCIAL-Today0859-BuenaVis-20732112",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.603939",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "\ud83e\udd14 Today's 'wyndrum' sounds even more petty and whiny than the 'Thornogson' account.",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-07T00:53:29.083771+00:00"
      },
      {
        "event_id": "SOCIAL-Today0858-pedrolan-37334834",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.604745",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "BV - he is doing it to fool us into thinking it is not one account. I nearly fell for it because I have the memory of a goldfish.",
          "sentiment": 0.5,
          "engagement": "1,972",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-07T00:53:29.083810+00:00"
      },
      {
        "event_id": "SOCIAL-Today0853-wyndrum--1350544",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.605571",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "It\u2019s snowing pretty hard here so it\u2019s not really the smoking gun you claim is it? Plus the fact you think I have multiple accounts only reinforces your mistaken analysis. (And see how many posts have been generated by bv These are the cause of the disruption. Not the posters who try to discuss the disconnect between AVCT results and the sp over the last 5 years",
          "sentiment": 0.0,
          "engagement": "12,217",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-07T00:53:29.083848+00:00"
      },
      {
        "event_id": "SOCIAL-Today0850-BuenaVis-63058186",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.606369",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Why is Thornogson/NDN/Eggy using the wyndrum account today?",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-07T00:53:29.083886+00:00"
      },
      {
        "event_id": "SOCIAL-Today0847-Livedata-67981044",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.607182",
        "source": "LSE_CHAT",
        "data": {
          "author": "Livedataaccount",
          "content": "With respect wyndrum its difficult not to judge someone who pretends to go on holiday and occasionally logs on with another alias replying to himself",
          "sentiment": 0.0,
          "engagement": "2,956",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-07T00:53:29.083924+00:00"
      },
      {
        "event_id": "SOCIAL-Today0835-BuenaVis--7783306",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.607959",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Wyn Shakespeare has swallowed a whole bag of question marks.",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-07T00:53:29.083963+00:00"
      },
      {
        "event_id": "SOCIAL-Today0831-pedrolan-75988046",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.608744",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Keep it up BV - people do need reminding. I see user Wyn Shakespeare is on the early shift.",
          "sentiment": 0.5,
          "engagement": "1,972",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-07T00:53:29.084000+00:00"
      },
      {
        "event_id": "SOCIAL-Today0826-wyndrum--5058337",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.609574",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "Thanks for reminding us dad, it must only be the 20th time you have posted this. Still at least your post s don\u2019t disrupt the board It\u2019s a great service you do, giving up your time to treat everyone here like morons by constantly reposting. Is it your new rule now that you must be shareholder to post and also be a genuine one at that? How do you intend to police your rules? Or is it just petty personal vendetta you are boring us all with?",
          "sentiment": 0.0,
          "engagement": "12,217",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-07T00:53:29.084039+00:00"
      },
      {
        "event_id": "SOCIAL-Today0750-BuenaVis--6313130",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.610363",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Just a reminder that Thornogson/NDN/Eggy isn't invested and is only here to argue, disrupt and try to waste our time.",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-07T00:53:29.084077+00:00"
      },
      {
        "event_id": "SOCIAL-Today0746-BuenaVis-87104464",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.904033",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Say what you see \ud83c\udf77\ud83c\udf77\ud83c\udf77",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "54.00",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-02-07T00:53:29.084128+00:00"
      },
      {
        "event_id": "SOCIAL-Today0733-Unbreade-51306539",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.904514",
        "source": "LSE_CHAT",
        "data": {
          "author": "Unbreaded",
          "content": "I love green boxes in the morning! Time for a coffee and catch up on the news.",
          "sentiment": 0.0,
          "engagement": "22",
          "price_at_post": "54.00",
          "thread_title": "Green Boes",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=F7E09828-40CF-45D7-8337-5F0A79C87685"
        },
        "ingested_at": "2026-02-07T00:53:29.084167+00:00"
      },
      {
        "event_id": "SOCIAL-Today0035-Thornogs-16577153",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.904967",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Sujood & Icecool. Similar content but I think ICE probably ahead on presentation. Both deeply underwater but talking a good game. Of course the SP matters, the only data that might be maturing is SGC 1b, which might secure a small deal. We've been told nothing about TNBC and STS is written off. We wait for FAP-EXD, we start again.",
          "sentiment": 0.0,
          "engagement": "8,655",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-07T00:53:29.084207+00:00"
      },
      {
        "event_id": "SOCIAL-Today0005-Toukanka-77216340",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.905422",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "Pivotal news in the Summer. Where have I heard that before? Oh yeah, it was me and I duly got panned by the Pom Pom girls for suggesting it would take thst long. \ud83e\udd23\ud83e\udd23\ud83e\udd23",
          "sentiment": 0.0,
          "engagement": "4,451",
          "price_at_post": "54.00",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-02-07T00:53:29.084245+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262359-Toukanka--3992215",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.905891",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "Work for ever????",
          "sentiment": 0.0,
          "engagement": "4,451",
          "price_at_post": "54.00",
          "thread_title": "RE: This will haunt you or please you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=8AE0FBBC-C14D-49F3-85C3-E6BED1BD66ED"
        },
        "ingested_at": "2026-02-07T00:53:29.084285+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262324-IFA90--6562582",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.906405",
        "source": "LSE_CHAT",
        "data": {
          "author": "IFA90",
          "content": "Thanks Andy",
          "sentiment": 0.0,
          "engagement": "408",
          "price_at_post": "54.00",
          "thread_title": "RE: This will haunt you or please you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=8AE0FBBC-C14D-49F3-85C3-E6BED1BD66ED"
        },
        "ingested_at": "2026-02-07T00:53:29.084324+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262322-BuenaVis--7950788",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.906824",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Thanks Thompi",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-07T00:53:29.084363+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262302-Sujood-45626895",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.907374",
        "source": "LSE_CHAT",
        "data": {
          "author": "Sujood",
          "content": "A multi billion dollar company in the making. It will haunt you if you dont position yourself Will please you, if you do the write thing. Learn about the company and do what you know is the right move to make. Nobody every wants to work forever. Keep this message We will talk again soon.",
          "sentiment": 0.5,
          "engagement": "1,260",
          "price_at_post": "54.00",
          "thread_title": "This will haunt you or please you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=8AE0FBBC-C14D-49F3-85C3-E6BED1BD66ED"
        },
        "ingested_at": "2026-02-07T00:53:29.084402+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262258-Icecool-66081241",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.907813",
        "source": "LSE_CHAT",
        "data": {
          "author": "Icecool",
          "content": "Commercial deals will come, and they\u2019ll be welcomed when they do. I\u2019m not in a rush though. If the data continues to strengthen and Avacta can leverage that science into materially better terms, I\u2019m perfectly happy for it to take longer. Time spent increasing leverage isn\u2019t wasted time, it\u2019s how you avoid bad deals and maximise value. \ud83d\ude0a Waiting could be the difference between a few billion and tens of billions. \ud83d\ude0a\ud83e\udd14",
          "sentiment": 0.0,
          "engagement": "8,824",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-07T00:53:29.084442+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262250-Thompi-27051827",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.908255",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thompi",
          "content": "You may find BV this tweet on X interesting on AVA6103 and BOIN design. AND https://x.com/sandyradders/status/2012950578595258664?s=61&t=BBb2UcjLDTXOFIzJM-vM6A",
          "sentiment": 0.0,
          "engagement": "1,357",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-07T00:53:29.084481+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262144-Knotagai-28943652",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.908887",
        "source": "LSE_CHAT",
        "data": {
          "author": "Knotagain",
          "content": "We're all fixated on the SP Icecool, it's just a matter of time frames. I've been invested for over five years and would love to see  some commercial news. Nothing wrong with that.",
          "sentiment": 0.0,
          "engagement": "451",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-07T00:53:29.084520+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262118-Icecool-80431995",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.909330",
        "source": "LSE_CHAT",
        "data": {
          "author": "Icecool",
          "content": "That\u2019s only a concern if you\u2019re fixated on the SP. AIM has never been able to price Avacta properly and it won\u2019t until there\u2019s either a takeover (and suspension) or a move to a serious exchange. The day to day price action is noise. What actually matters is what\u2019s happening behind the scenes with the science, the data, and the strategic discussions. That\u2019s where the real value is being built. \ud83d\udcaf\ud83d\udc4d",
          "sentiment": 0.0,
          "engagement": "8,824",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-07T00:53:29.084558+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262058-Knotagai--7594563",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.909883",
        "source": "LSE_CHAT",
        "data": {
          "author": "Knotagain",
          "content": "Totally agree Icecool, but only third party validation will move the share price. Hopefully it will happen sometime soon.",
          "sentiment": 0.0,
          "engagement": "451",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-07T00:53:29.084598+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262032-Icecool--5958512",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.910560",
        "source": "LSE_CHAT",
        "data": {
          "author": "Icecool",
          "content": "The FDA won\u2019t drag this out. AVA6000 proved the platform in humans, AVA6103 builds on that. Phase 1 is about safety and speed. This trial is designed to surface signals quickly with regulatory alignment, not waste years. AVA6000 data will have done a load of heavy lifting already.",
          "sentiment": 0.0,
          "engagement": "8,824",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-07T00:53:29.084637+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261954-BuenaVis-48298338",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.910984",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "I've got to say I was concerned that the AVA6103 trial with such a toxic agent as exatecan would start at a very low dose and take a long, long time if the step increases were to mimic those in the AVA6000 trial (seven dose levels! - three steps of 40 from 80 to 200, and then three 25% increases to 385) so very pleased to hear about all the benefits of the BOIN design.",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-07T00:53:29.084676+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261946-Icecool--8553463",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.911503",
        "source": "LSE_CHAT",
        "data": {
          "author": "Icecool",
          "content": "I would also point out that when Thorn bought in he\u2019s also a mega ramping twat!!! Flip/Flop. \ud83d\udcaf\ud83e\udd23\ud83e\udd23 best on filter \ud83d\udc4d",
          "sentiment": 0.0,
          "engagement": "8,824",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-07T00:53:29.084714+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261937-HarChris--4371902",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.912044",
        "source": "LSE_CHAT",
        "data": {
          "author": "HarChris",
          "content": "Going back to the trial design I thought this overview could be useful: Key Comparisons Accuracy in MTD Selection: BOIN generally outperforms 3+3 by more accurately identifying the true MTD. In simulations across various scenarios BOIN achieves a 12-16% higher percentage of correct selection (PCS) of the MTD, and in cases where the MTD is at higher doses, it can nearly triple the PCS compared to 3+3. Efficiency and Patient Allocation: BOIN is more efficient, often resulting in shorter trial durations and lower costs by adapting in real-time and allocating more patients to the MTD (especially at higher doses or with higher target DLT rates). The 3+3 design can prolong trials due to its conservative escalation and fixed cohort requirements, leading to fewer patients treated at effective doses. Safety and Risk Management: While 3+3 minimizes overdose risk by being overly cautious (e.g., lower chance of assigning >60% of patients above the MTD), it increases under-dosing, where many patients receive suboptimal doses. BOIN balances this better with built-in overdose controls and dynamic adjustments, reducing under-dosing without significantly raising overdose risks, thus improving ethical standards by minimising patient exposure to ineffective or overly toxic doses. Simplicity and Flexibility: Both are relatively easy to implement\u2014BOIN requires no complex programming or simulations beyond basic setup, making it accessible like 3+3. However, BOIN offers more flexibility, such as variable cohort sizes (e.g., 4 patients) and adjustable target toxicity rates, whereas 3+3 is fixed to cohorts of 3 (or 3+3) and standard targets. In summary, BOIN represents an evolution over 3+3, providing better performance across most metrics while maintaining ease of use. The 3+3 design is still widely used for its familiarity and safety focus in conservative settings but is increasingly seen as outdated for not fully utilising trial data.",
          "sentiment": 0.0,
          "engagement": "15,865",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-07T00:53:29.084752+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261812-Cashless-80459589",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.912567",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cashless",
          "content": "Been out all day, so just logged on.....and what a pleasure to see a sea of green and pretty much all informative posts...I LOVE GREEN...not sure the green people are so happy though \ud83d\udc4d\ud83e\udd2a\ud83e\udd2a\ud83e\udd73",
          "sentiment": 0.5,
          "engagement": "401",
          "price_at_post": "54.00",
          "thread_title": "Bliss",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E431AF8E-57C8-40B5-91C6-8D284968B368"
        },
        "ingested_at": "2026-02-07T00:53:29.084790+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261753-B2HS2L-71701177",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.913172",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "FWIW Google search What is the difference between event free and progression free survival AI Overview: Progression-Free Survival (PFS) measures the time from treatment initiation until objective tumor growth or death from any cause. Event-Free Survival (EFS) measures the time from randomization until a broader range of \"events,\" including disease progression, treatment failure, complications, or death. PFS focuses on tumor growth; EFS focuses on any negative outcome. Key Differences: Definition of Event: PFS is restricted to disease progression or death. EFS includes those, plus failure to proceed to planned surgery, relapse, or severe treatment complications. Context of Use: PFS is commonly used in advanced or metastatic cancer trials to evaluate treatment efficacy. EFS is frequently used in earlier-stage cancer trials, particularly in the neoadjuvant (pre-surgery) setting. Precision: PFS depends on the frequency of imaging scans to detect growth, while EFS is often defined by the time until a patient cannot proceed with their treatment plan. Essentially, PFS means the cancer has not worsened, whereas EFS means the patient has not experienced any negative, pre-defined event.",
          "sentiment": 0.0,
          "engagement": "6,000",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-07T00:53:29.084828+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261428-BuenaVis-11570826",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.913661",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "What is the current best progression free survival rate for TNBC? https://www.google.com/search?q=What+is+the+current+best+progression+free+survival+rate+for+TNBC%253F",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-07T00:53:29.084866+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261424-HarChris--2797352",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.914093",
        "source": "LSE_CHAT",
        "data": {
          "author": "HarChris",
          "content": "It's what happened to STS and might now happen with TNBC, might not of course, but if it did then it'll all fall to SGC to carry the load until FAP-EXD starts to produce meaningful data. __________________ In other words IF TNBC data doesn't deliver then SGC might have to carry the load until H2 2026? That's not bad as a worst case and it's very short term as it gets for biotech. And with the less risk averse and far more efficient BOIN design for 6103 we should start receiving compelling data rapidly if all is going well. It's close!",
          "sentiment": 0.0,
          "engagement": "15,865",
          "price_at_post": "54.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-07T00:53:29.084903+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261411-Thornogs--6496437",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.914533",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "No well spotted!  My bad.",
          "sentiment": 0.0,
          "engagement": "8,655",
          "price_at_post": "54.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-07T00:53:29.084942+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261409-BuenaVis--2048180",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.915065",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "I may be missing something here but trastuzumab deruxtecan (brand name Enhertu) and pertuzumab are both used to treat HER2-positive breast cancer.  So what has that got to do with TNBC which is an aggressive, fast-growing type of breast cancer that tests negative for three key receptors: estrogen (ER), progesterone (PR), and HER2?",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "54.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-07T00:53:29.084981+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261349-Thornogs--2680142",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.915517",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "'....FAP-DOX needs to beat.'",
          "sentiment": 0.0,
          "engagement": "8,655",
          "price_at_post": "54.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-07T00:53:29.085019+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261347-Thornogs-11582241",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.915945",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "But clearly relevent so clearly won't be mentioned by anyone else Watching? Obviously important if it's doubled the PFS times for TNBC, the bar has been raised as to what FAP-EXD needs to beat. It's what happened to STS and might now happen with TNBC, might not of course, but if it did then it'll all fall to SGC to carry the load until FAP-EXD starts to produce meaningful data.",
          "sentiment": 0.0,
          "engagement": "8,655",
          "price_at_post": "54.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-07T00:53:29.085059+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261347-pedrolan-82834822",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.837882",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Just a reminder that Thorn is not invested but spends his sad life on here posting negative comments about a company saving lives. What a guy!!!",
          "sentiment": 0.5,
          "engagement": "1,972",
          "price_at_post": "54.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-07T00:53:29.085108+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261339-Watching--6477875",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.838382",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "You Still have to focus on negatives. Thorny you are such a k n o bby \ud83e\udd21\ud83e\udd21",
          "sentiment": 0.0,
          "engagement": "9,213",
          "price_at_post": "54.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-07T00:53:29.085151+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261335-Thornogs--5064353",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.838824",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "It's perhaps double edged though? The AVA6000 STS trial was (allegedly) de-railed by a trial that showed longer, and better than expected, survival data. If there's a new 'Standard of Care' being announced for TNBC the bar might just have been raised on what FAP-DOX/TNBC needs to achieve to get a deal and get to market?",
          "sentiment": 0.0,
          "engagement": "8,655",
          "price_at_post": "55.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-07T00:53:29.085190+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261315-LovableL--8943277",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.839268",
        "source": "LSE_CHAT",
        "data": {
          "author": "LovableLumax",
          "content": "Https://x.com/onclive/status/2016451178872061994?s=46",
          "sentiment": 0.0,
          "engagement": "2,703",
          "price_at_post": "55.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-07T00:53:29.085227+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261053-Aldebara--5873707",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.839705",
        "source": "LSE_CHAT",
        "data": {
          "author": "Aldebaran",
          "content": "I think small caps are at the very start of a major bull run. Green portfolio everywhere across the board. Also note that even with hard times, avacta raised 16m through zeus at only 8% discount plus managed to delay and renegotiate the terms of the bond. No mean feat that and the macro picture for small caps has improved since then. As has our IP and data package plus the deadline for BP patent expiry has only become closer. Things nowhere near as desperate as this shhhhh it tee little market gives credit for. I mean avacta have developed the worlds first dual warhead peptide drug conjugate ffs . \ud83d\ude05",
          "sentiment": 0.0,
          "engagement": "3,894",
          "price_at_post": "55.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-07T00:53:29.085266+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261050-opti_mys--4152810",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.840239",
        "source": "LSE_CHAT",
        "data": {
          "author": "opti_mystic",
          "content": "I think that's optimistic Lovable being as the initial doses will be very low. It is a safety trial initially remember, but the trial design (BOIN) will allow for dose escalation quite quickly and also potentially skipping from say dose level one to does level 3. I think more realistically summer months we may start to see some useful efficacy. What they will know sooner is are there any problems/does it works as expected and designed. If no bad news by May/June I think we're on a winner. I expect it to work.",
          "sentiment": 0.0,
          "engagement": "296",
          "price_at_post": "55.50",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-02-07T00:53:29.085305+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261045-Sisyphus-54357423",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.840667",
        "source": "LSE_CHAT",
        "data": {
          "author": "SisyphusShorter",
          "content": "Out of coincidence it's been exactly a week since the last RNS regarding AVA6103. Could an announcement be due imminently?",
          "sentiment": 0.0,
          "engagement": "4",
          "price_at_post": "55.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-07T00:53:29.085345+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261014-HarChris-17743638",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.841093",
        "source": "LSE_CHAT",
        "data": {
          "author": "HarChris",
          "content": "I wonder if those solely focused on Avacta and thinking history always repeats are missing the fact that the AIM backdrop plays a major role here. And in that regard liquidity has returned to UK small caps with a vengeance, raises are happening without the sort of discounts seen in 2022/23/24/25, companies are seeing major share price appreciation actually hold rather than the wild swings of post Covid. It\u2019s a far healthier backdrop right now than at any point since I\u2019ve held Avacta shares.",
          "sentiment": 0.0,
          "engagement": "15,865",
          "price_at_post": "55.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-07T00:53:29.085389+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261003-harryhot-25119862",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.841536",
        "source": "LSE_CHAT",
        "data": {
          "author": "harryhotspur1311",
          "content": "I was hoping for the big erection shape although roundish bottoms are quite welcome as well!",
          "sentiment": 0.0,
          "engagement": "12",
          "price_at_post": "55.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-07T00:53:29.085428+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260958-A1invest--6506786",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.841950",
        "source": "LSE_CHAT",
        "data": {
          "author": "A1invest",
          "content": "Lets hope its a \"rounding bottom\" shape.  :)",
          "sentiment": 0.0,
          "engagement": "143",
          "price_at_post": "55.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-07T00:53:29.085468+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260953-pedrolan--3688821",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.842525",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Salty for sure",
          "sentiment": 0.0,
          "engagement": "1,972",
          "price_at_post": "55.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-07T00:53:29.085507+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260945-Thornogs--4676644",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.843025",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "\"Salt and vinegar on that sir?\"",
          "sentiment": 0.0,
          "engagement": "8,655",
          "price_at_post": "55.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-07T00:53:29.085546+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260944-Timster-35573933",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.843502",
        "source": "LSE_CHAT",
        "data": {
          "author": "Timster",
          "content": "Big fish, little fish, cardboard box....",
          "sentiment": 0.0,
          "engagement": "20,625",
          "price_at_post": "55.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-07T00:53:29.085584+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260941-harryhot-10458799",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.844130",
        "source": "LSE_CHAT",
        "data": {
          "author": "harryhotspur1311",
          "content": "Whenever the SP drops, the pessimists always quote \u2018the market knows\u2019 Perhaps this could work the other way around occasionally! Today, perhaps!",
          "sentiment": 0.0,
          "engagement": "12",
          "price_at_post": "56.00",
          "thread_title": "Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-07T00:53:29.085624+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260823-pedrolan--4218869",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.844561",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Ah yes, I knew I had been there but couldn't remember exactly which Lake \ud83e\udd23",
          "sentiment": 0.5,
          "engagement": "1,972",
          "price_at_post": "52.50",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-02-07T00:53:29.085661+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260726-Gingethe-90142372",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.844978",
        "source": "LSE_CHAT",
        "data": {
          "author": "GingetheWinge",
          "content": "Derwent valley dam in the Peak District.",
          "sentiment": 0.5,
          "engagement": "699",
          "price_at_post": "53.00",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-02-07T00:53:29.085699+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260713-LovableL--7323217",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.845409",
        "source": "LSE_CHAT",
        "data": {
          "author": "LovableLumax",
          "content": "I also suspect we will have a 6000 partner signed up once we have an approved accelerated pathway and registrations P2\\3 with FDA which is hopefully imminent",
          "sentiment": 0.0,
          "engagement": "2,703",
          "price_at_post": "53.00",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-02-07T00:53:29.085739+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260703-LovableL--3321976",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.845829",
        "source": "LSE_CHAT",
        "data": {
          "author": "LovableLumax",
          "content": "Given how potent the payload is and with the improved half-life and active in the TME for 5 days surely they'll see results as early as scan 1. That sounds rampy and too optimistic but look at the preclinical results. Things could really take off as early as the summer, or even before. Again, I suspect recruitment will be fairly rapid given FAP targeting with preCISION proven and preclinical results so investigators likely chomping at the bit.",
          "sentiment": 0.0,
          "engagement": "2,703",
          "price_at_post": "53.00",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-02-07T00:53:29.085777+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260659-nurseste--8316014",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.846277",
        "source": "LSE_CHAT",
        "data": {
          "author": "nursesteve",
          "content": "CC discussing FAP-Exd (AVA6103) - The profile of this second pre|CISION medicine in the preclinical setting is tremendous.  The sustained release mechanism developed by Avacta scientists results in a robust concentration of active drug in the tumor over five days with the disappearance from the bloodstream in only two hours. This is the exact profile needed to achieve better efficacy with this highly potent topo I inhibitor. Could payoff for LTH be this year?",
          "sentiment": 0.0,
          "engagement": "1,164",
          "price_at_post": "53.00",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-02-07T00:53:29.085816+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260006-D-Geeman-31601960",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.846690",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "An elderly character actor in our road, when I first arrived,  was in the movie \u2018The Dambusters\u2019, and in \u2018Bridge on the River Kwai\u2019. He used to tell some good stories of life on 1950\u2019s film sets. Dead for a while but he pops up on screen even now.",
          "sentiment": 0.0,
          "engagement": "5,844",
          "price_at_post": "52.50",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-02-07T00:53:29.085854+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20262319-pedrolan--6108175",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.847122",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Yes, it's an inspirational story. I think they tested it up in the Lake District",
          "sentiment": 0.5,
          "engagement": "1,972",
          "price_at_post": "52.50",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-02-07T00:53:29.085893+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20262113-Captains-17218717",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.847541",
        "source": "LSE_CHAT",
        "data": {
          "author": "Captainstanley.",
          "content": "I can't find that information anywhere Which Friday? Presumably you mean this week 29th Jan?",
          "sentiment": 0.0,
          "engagement": "467",
          "price_at_post": "52.50",
          "thread_title": "RE: SGC",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=5E3142A3-349A-43A2-B5B7-02836561174A"
        },
        "ingested_at": "2026-02-07T00:53:29.085931+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20262014-Flippine-73805826",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.847977",
        "source": "LSE_CHAT",
        "data": {
          "author": "Flippineck",
          "content": "I\u2019ve been thinking about the trials and tribulations of developing new inventions and ended up swotting up on Barnes Wallace, the inventor of the famous Bouncing Bomb. It seems initial proposals were dismissed by Bomber Command as being \u201c a mad-cap scheme\u201d. There were several critical failures in the development which had to be overcome. The shape of the bomb had to be changed, backspin had to be introduced, the weapon would shatter, sink or detonate prematurely or veer off course. Barnes Wallace persevered and it all came good in the end.",
          "sentiment": 0.0,
          "engagement": "417",
          "price_at_post": "52.50",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-02-07T00:53:29.085971+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261912-BuenaVis-48532081",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.848415",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Christina Coughlin became the CEO of Avacta on 1 May 2024. There is no need to dwell on anything or anyone before that date. CC has set out the company's objectives and timelines and has stuck to them, as much as is possible taking outside decision-making and events into account.  This adherence to the company's aims and plans comes about because she is a pharma executive with ample of experience of drug development and the way the FDA works.",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "52.50",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-02-07T00:53:29.086009+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261900-BuenaVis--4999035",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.848907",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "As Runner-Runner wrote... It's simple. 1. DO NOT ENGAGE 2. DO NOT ASK IT A QUESTION 3. DO NOT ANSWER ITS QUESTIONS 4. DO NOT MOAN ABOUT ITS POSTS 5. DO NOT ARGUE WITH IT 6. If you must do something. Mock it with reference only to its stupidity and nothing else. ------------------------------------------------------ If you're not part of the solution, you're part of the problem",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "52.50",
          "thread_title": "RE: Year end trading update :",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=CCFE6866-0D3C-4A1E-9659-9B2E552262F5"
        },
        "ingested_at": "2026-02-07T00:53:29.086049+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20262219-Thornogs--3948950",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.801399",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Anything new there? 'Expected' Q1? No, nothing new, just 'same old'.",
          "sentiment": 0.0,
          "engagement": "8,596",
          "price_at_post": "54.50",
          "thread_title": "RE: Bioconjugate Insights",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0DCD83D9-A17D-43E1-842E-1C922D520A76"
        },
        "ingested_at": "2026-02-07T00:53:29.086087+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20262212-avctIPma--2397740",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.801859",
        "source": "LSE_CHAT",
        "data": {
          "author": "avctIPmatters",
          "content": "Again courtesy of Stonks -  Finds  new coverage  Avacta related   many thanks . https://cdn.insights.bio/uploads/attachments/BCI%20Industry%20Insights.pdfAvacta Therapeutics reported new preclinical pharmacology data for FAP-Exd peptide drug conjugate [25] \"Avacta Therapeutics announced new preclinical pharmacology data for FAP-Exd (AVA6103), its second asset derived from the pre|CISION\u00ae tumor-activated delivery platform, which is expected to enter Phase 1 testing in Q1 2026. FAP-Exd is a fibroblast activation protein\u2013cleavable peptide-drug linking a proprietary peptide to a topoisomerase I inhibitor payload. The data demonstrated tumor-specific cytotoxicity, sustained intratumoral release of active exatecan with limited systemic exposure, and robust antitumor activity across multiple patient-derived xenograft models. Avacta also reported that artificial intelligence\u2013guided analysis was used to prioritize clinical indications based on co-expression of FAP and SLFN11.\" Gmcc",
          "sentiment": 0.0,
          "engagement": "720",
          "price_at_post": "54.50",
          "thread_title": "Bioconjugate Insights",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0DCD83D9-A17D-43E1-842E-1C922D520A76"
        },
        "ingested_at": "2026-02-07T00:53:29.086138+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20262210-Thornogs--2465515",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.802303",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Avacta does its thing regardless of what's posted here. Get over yourselves, self appointed \"Guardian's of the truth\"! And if you must wear your underpants on the outside do at least please ensure that  they're better laundered?",
          "sentiment": 0.0,
          "engagement": "8,596",
          "price_at_post": "54.50",
          "thread_title": "The reality?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=D8CC0643-0047-4DA0-A21A-3E0ECC3BD17C"
        },
        "ingested_at": "2026-02-07T00:53:29.086177+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20262154-BuenaVis-23891103",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.802718",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "I had Firefox nicely set up with AdBlock so that all ads were wiped out but had to 'repair' Firefox today (as tabs were crashing) and then reload an AdBlock extension but I now keep getting these annoying messages from LSE about ads that I never used to get.  Can't remember what I did before to permanently remove those messages.  Can anyone offer advice on how they've solved this?",
          "sentiment": 0.0,
          "engagement": "5,722",
          "price_at_post": "54.50",
          "thread_title": "Off-topic - removing ads on Firefox",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=9BE707F4-9555-444A-A3C8-1254E00A3443"
        },
        "ingested_at": "2026-02-07T00:53:29.086215+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20262109-Knotagai--1472667",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.803142",
        "source": "LSE_CHAT",
        "data": {
          "author": "Knotagain",
          "content": "All day every day...",
          "sentiment": 0.0,
          "engagement": "448",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-02-07T00:53:29.086253+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261944-Agenda10--9794262",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.803559",
        "source": "LSE_CHAT",
        "data": {
          "author": "Agenda101",
          "content": "Brilliant! The never ending Twats.. they are all green boxed here\u2026 But I\u2019m hearing you Sheepy! Exactly right.",
          "sentiment": 0.0,
          "engagement": "55",
          "price_at_post": "54.50",
          "thread_title": "RE: Frankly pathetic",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B36E2695-D07A-4E60-838B-02C995994856"
        },
        "ingested_at": "2026-02-07T00:53:29.086292+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261943-BuenaVis--4993354",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.803971",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Lighten up Thompi.  It's the best comedy show in town.",
          "sentiment": 0.0,
          "engagement": "5,722",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-02-07T00:53:29.086330+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261940-Thompi--2086463",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.804413",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thompi",
          "content": "Because, Touk, Thorn talks total twaddle and inundates this board with spam. It\u2019s made the board virtually unreadable. Even blocking him doesn\u2019t really help, because all I then see are green boxes and other people replying to his posts. I probably add to the noise at times too - but I\u2019ve genuinely had enough of one person commandeering the board with the same malicious rubbish, day after day. Post after post after post. It wears people down. It stops being discussion and just becomes disruption.",
          "sentiment": 0.0,
          "engagement": "1,355",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-02-07T00:53:29.086369+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261848-Toukanka-37871561",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.804832",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "Cj62 How can it be utter garbage when it\u2019s generally been predicting what is happening to Avacta. But the pond poms utter garbage of \u201ctakeover tomorrow \u201c, \u201cmarket thick as mince\u201d etc etc ad infinitum even though they\u2019ve been entirely wrong for years. Well that\u2019s fine clogging up the board with that garbage",
          "sentiment": 0.0,
          "engagement": "4,436",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-02-07T00:53:29.086407+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261845-BuenaVis-23975319",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.805254",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "6am to midnight but with a two hour evening break to neck a bottle of whisky.",
          "sentiment": 0.0,
          "engagement": "5,722",
          "price_at_post": "54.50",
          "thread_title": "RE: Frankly pathetic",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B36E2695-D07A-4E60-838B-02C995994856"
        },
        "ingested_at": "2026-02-07T00:53:29.086445+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261844-Toukanka--3443626",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.805661",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "You\u2019re right Thompi. You never do say much more than joining your mates and flinging the insults. Why not talk about Avacta rather the other posters on here?",
          "sentiment": 0.0,
          "engagement": "4,436",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-02-07T00:53:29.086485+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261841-sheppy--4347770",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.806079",
        "source": "LSE_CHAT",
        "data": {
          "author": "sheppy",
          "content": "Wyn, Thorn, Touk , DG same poster numerous aliases. Hourly paid hired help disrupter. Regardless of that what sort of sad, moronic halfwit would spend 7 days a week starting each day at 6 am and continuing after midnight posting negative comments about a share they are allegedly not invested in? Regardless of their reason what a total waste of one\u2019s life on this earth . What a pathetic pitiful existence arguing with anonymous people on an anonymous bb. I actually pity their sad, lonely unfulfilled existence. And before the poster tells me they live a very fulfilled life doing lots of other meaningful things ask yourself how this is possible with so many never ending  daily boring transparent attempts at disruption. Sad twat and a weirdo",
          "sentiment": 0.0,
          "engagement": "563",
          "price_at_post": "54.50",
          "thread_title": "Frankly pathetic",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B36E2695-D07A-4E60-838B-02C995994856"
        },
        "ingested_at": "2026-02-07T00:53:29.086525+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261831-cj62--8399000",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.806499",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "Anything you post Thorn is utter garbage. How many crayons have you done today ?",
          "sentiment": 0.0,
          "engagement": "4,270",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-02-07T00:53:29.086564+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261820-Thornogs--6042066",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.806924",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "And what did you say? Anything worth hearing? Anything about Avacta and what's going well and what isn't and thoughts about why? No, thought not. Shame.",
          "sentiment": 0.0,
          "engagement": "8,596",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-02-07T00:53:29.086602+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261755-Thompi-33390837",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.807357",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thompi",
          "content": "Pedro, if I add your 67 posts over the last 30 days to my 20, plus Tim\u2019s 43 and Watching\u2019s 39, the grand combined total is 169 posts. That\u2019s four people combined. Compared to Thorn\u2019s 253 posts on his own. The figures speak for themselves.",
          "sentiment": 0.0,
          "engagement": "1,355",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-02-07T00:53:29.086640+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261754-wyndrum--5587841",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.807774",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "And i see my requests to get NFT to respond have been deleted but the insults to me remain. But yes, its the LSE moderators allowing me to post that is the problem here. Where are you NFT, want to answer my queries so you can justify the remarks in your post?",
          "sentiment": 0.0,
          "engagement": "12,198",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-02-07T00:53:29.086679+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261737-pedrolan--3929974",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.808191",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Make that 29 to go",
          "sentiment": 0.0,
          "engagement": "1,948",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-02-07T00:53:29.086719+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261719-Thompi-36425751",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.808620",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thompi",
          "content": "Avacta posts over the last 30 days: 253 Thorn \ud83e\udd47 43 Timster 39 Watching Not much else to say really Thorn.",
          "sentiment": 0.0,
          "engagement": "1,355",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-02-07T00:53:29.086757+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261708-Thornogs-67723353",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.809052",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "And the two posters below your post Thompi? Watching 9,000 and Tim 20,000! All on only Avacta and all 100% content free 'jokes' or 'bile'. But to comment on that would be to show a consistent approach to this sort of thing wouldn't it? Be honest, it's not the number or posts, it's the fact that you might have to consider things that you don't want to consider. Fine, your choice, 5 years in and AVA6000 limping along to a possible low-ball deal and FAP-EXD entering the 'Last Chance Saloon' in the next 2-3 months. Everything that you've been predicting for the last 5 years, why would you need to hear a contrary opinion when you've clearly been smashing it all this time? Well up I dare say on your investment are we?",
          "sentiment": 0.0,
          "engagement": "8,596",
          "price_at_post": "54.00",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-02-07T00:53:29.086796+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261644-Thompi-30586178",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.809483",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thompi",
          "content": "To be fair Tim, Thorn\u2019s only posted 11 times so far today. He\u2019s got another 30 to go before he equals his personal best of 41 posts in 24 hours. By my reckoning, if he manages around 4.3 posts per hour between now and midnight (17:00\u201312:00am), he might just be in with a chance of beating it. Bless his selfless little heart.",
          "sentiment": 0.0,
          "engagement": "1,355",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-02-07T00:53:29.086834+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261537-Watching--1728986",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.809893",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "24/7. He keeps churning out verbal \ud83d\udca9",
          "sentiment": 0.0,
          "engagement": "9,201",
          "price_at_post": "54.50",
          "thread_title": "RE: CC interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=F5A9F3B7-45F7-4EC2-B1FD-1ACB3A2D2E18"
        },
        "ingested_at": "2026-02-07T00:53:29.086874+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261535-Timster--1472667",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.810318",
        "source": "LSE_CHAT",
        "data": {
          "author": "Timster",
          "content": "All day every day...",
          "sentiment": 0.0,
          "engagement": "20,620",
          "price_at_post": "54.50",
          "thread_title": "To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-02-07T00:53:29.086913+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261529-cj62-84749191",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.810731",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "Shall we have a 'Spot the idiot' competition? You win it thorn, no competition !!!",
          "sentiment": 0.0,
          "engagement": "4,270",
          "price_at_post": "54.50",
          "thread_title": "RE: CC interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=F5A9F3B7-45F7-4EC2-B1FD-1ACB3A2D2E18"
        },
        "ingested_at": "2026-02-07T00:53:29.086951+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261517-Thornogs-41229971",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.811159",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Of course we don't BV, and the industry experts who know these things currently value Avacta at 50 odd pence a share. NFT and the 28 odd who ticked up his posts think \u00a328 is more accurate. Shall we have a 'Spot the idiot' competition?",
          "sentiment": 0.0,
          "engagement": "8,596",
          "price_at_post": "54.50",
          "thread_title": "RE: CC interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=F5A9F3B7-45F7-4EC2-B1FD-1ACB3A2D2E18"
        },
        "ingested_at": "2026-02-07T00:53:29.086990+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261515-cj62-77441289",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.811569",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "That's theoretical of course. Thorn its like 99% of the other gibberish you post twat.",
          "sentiment": 0.0,
          "engagement": "4,270",
          "price_at_post": "54.50",
          "thread_title": "RE: CC interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=F5A9F3B7-45F7-4EC2-B1FD-1ACB3A2D2E18"
        },
        "ingested_at": "2026-02-07T00:53:29.087028+00:00"
      },
      {
        "event_id": "RNS-9th Feb 2026-appointm",
        "event_type": "rns_announcement",
        "date": "2026-02-10T01:55:34.418392Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Appointment of CSO",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/AVCT/appointment-of-cso-wmdkzqhl1itcclu.html",
          "rns_number": "RNS Number : 1433S",
          "full_content": "9 Feb 2026 07:00\nRNS Number : 1433S\nAvacta Group PLC\n09 February 2026\nAvacta appoints Francis Wilson as Chief Scientific Officer\nLONDON and PHILADELPHIA\n- February 9, 2026 - Avacta Therapeutics (AIM: AVCT, \"the Company\", \"Avacta\"), a clinical stage biopharmaceutical company developing pre|CISION\u00ae,\u00a0a tumor-activated oncology delivery platform, has appointed Francis Wilson as its Chief Scientific Officer.\nSince joining Avacta in September 2022 as Vice President of Chemistry, Francis has demonstrated his extensive expertise and experience in the chemistry field, particularly in the development of the Company's pre|CISION\u00ae platform. Francis has been instrumental in the development of novel intellectual property around the pre|CISION\u00ae mechanism, notably the sustained release mechanism that forms the backbone of the FAP-Exd (AVA6103) program that is anticipated to begin clinical testing in the near term. He has also established himself as an industry leader in medicinal chemistry, a valued external speaker for the Company, and a strong team leader within the Avacta organization.\nBefore Avacta, Francis held various positions across the medicinal chemistry sector, including being a Research Scientist at Roche Discovery Welwyn from 1990-2001, Head of Chemistry at Xenova (2001-2003), Director of Chemistry at Cellzome (2003-2007) and Director of Chemistry at Summit Therapeutics (2007-2022) where he led multiple programs from discovery into clinical development.\nFrancis has a chemistry degree and holds a Doctor of Philosophy degree from Oxford University and is a Chartered Chemist and Fellow of the Royal Society of Chemistry.\nAlong with this leadership change, former CSO Michelle Morrow will be leaving Avacta to pursue another opportunity. The Company thanks her for her contributions and wishes her success in the future.\nChristina Coughlin, CEO of Avacta Therapeutics commented,\n\"\nFrancis is the ideal person to take us forward, both internally and across our industry, given his deep knowledge of the working of our unique pre|CISION\n\u00ae\nplatform. Francis has demonstrated his keen ability to foster an environment of innovation, and this has been instrumental in developing significant advances in the options for our pre|CISION\n\u00ae\nplatform to be used in the clinic. As Avacta enters a period of potentially significant preclinical development and intellectual property generation, we look forward to leveraging Francis' expertise and leadership in the drug development arena.\"\n\"In addition to his leadership internally, he has also been a key member of the team positioning our business across the international drug development sector. Francis is a well-known leader in medicinal chemistry externally and we are looking forward to forging the next chapter of pre|CISION\n\u00ae\nwith his scientific leadership and expertise. We also extend our well wishes to Michelle in the next chapter of her career and thank her for her contributions to Avacta.\"\nFrancis Wilson, CSO of Avacta added:\n\"I am thrilled to step into this role and look forward to partnering with Chris and the Management Team to move Avacta forward to our next chapter. Seeing AVA6103 - the molecule we invented - move to the clinic is a huge success for the Company. We will learn more about this program in the clinic and apply that as we continue to develop novel intellectual property around our highly successful pre|CISION\n\u00ae\nplatform.\"\n-Ends-\nFor further information from Avacta, please contact:\nAvacta Group plc\nChristina Coughlin, Chief Executive Officer\nhttps://avacta.com/\nvia Cohesion Bureau\nStrand Hanson Limited (Nominated Adviser)\nJames Harris / Chris Raggett / James Dance\nwww.strandhanson.co.uk\nZeus (Broker)\nJames Hornigold / George Duxberry / Dominic King\nwww.zeuscapital.co.uk\nCohesion Bureau (Communications)\nRichard Jarvis / Chris Maggos\navacta@cohesionbureau.com\nAbout Avacta\n-\nhttps://avacta.com/\nAvacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION\u00ae platform. pre|CISION\u00ae is a proprietary payload delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate highly potent payloads in the tumor microenvironment while sparing normal tissues.\nOur innovative pipeline consists of pre|CISION\u00ae peptide drug conjugates (PDC) or Affimer\u00ae drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates.\nThe pre|CISION\u00ae platform comprises an anticancer payload conjugated to a proprietary peptide that is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The pre|CISION\u00ae platform harnesses this tumor specific protease to cleave pre|CISION\u00ae peptide drug conjugates and pre|CISION\u00ae antibody/Affimer\u00ae drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor a",
          "content_length": 5898
        },
        "ingested_at": "2026-02-10T01:55:34.418442Z"
      },
      {
        "event_id": "SOCIAL-9Feb20262317-pedrolan-69296462",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.585477",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Folks, Touk is clearly Thorn. Look how he writes. Ignore him.",
          "sentiment": 0.0,
          "engagement": "1,988",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-10T01:55:46.153672+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20262306-Icecool-45531076",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.586081",
        "source": "LSE_CHAT",
        "data": {
          "author": "Icecool",
          "content": "You do talk a load of nonsense\u2026. \ud83e\udd26\u200d\u2642\ufe0f",
          "sentiment": 0.0,
          "engagement": "8,857",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-10T01:55:46.153710+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20262305-Toukanka-41181102",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.586694",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "At the end of the day, initial efficacy results will not be published before June IMO. And CC has said as much. She has also said that any acceptable deal is unlikely before those results are published. And there will be no takeover even if CJ62 forms a consortium of shareholders and tries to push it through at say \u00a31",
          "sentiment": 0.0,
          "engagement": "4,486",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-10T01:55:46.153748+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20262301-Toukanka--2142686",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.587310",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "Thompi FPI is not the same as FPD. But no point arguing. You all know better than CC.",
          "sentiment": 0.0,
          "engagement": "4,486",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-10T01:55:46.153785+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20262150-Thompi--2779976",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.587906",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thompi",
          "content": "Touk, for the record, this is what Chris said in the Base to Base interview released 23rd January, but probably recorded late last year: \u201cWe\u2019re really looking forward to getting the first sustained release [AVA6103] into the clinic. That one will start in March of next year. We\u2019re aiming for the first quarter for the first patient with that one.\u201d",
          "sentiment": 0.0,
          "engagement": "1,364",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-10T01:55:46.153818+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20262123-BuenaVis--5270264",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.588579",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "In clinical trials, FPI (First Patient In) marks the critical milestone when the very first participant is screened, enrolled, and officially enters the study, signifying the transition from planning to active execution. It validates site readiness, kicks off data collection, and is a major KPI for project timelines and investor confidence. Here are the key details regarding FPI: Key Aspects of FPI \u2022 Definition: It is the date the first human subject is qualified, accepted, and often dosed in a clinical trial. \u2022 Significance: It proves all regulatory approvals, document reviews, contracting, and site setups are complete. \u2022 Business Impact: FPI is a high-pressure corporate goal that affects company reputation, stock prices, and investor confidence. \u2022 Trial Flow: It moves the study from \"study start-up\" to \"execution/recruitment\" phase. Why FPI Matters \u2022 Timeline Driver: It sets the pace for the rest of the recruitment and trial timeline. \u2022 Success Indicator: Meeting the FPI goal on time usually means the study is on sound footing. \u2022 Risk: Rushing to hit FPI dates can sometimes lead to neglected study designs or premature starts. Sometimes, this milestone is also referred to as FPFV (First Patient First Visit), focusing on when data collection begins for that first subject.",
          "sentiment": 0.0,
          "engagement": "5,847",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-10T01:55:46.153849+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20262039-B2HS2L-11812659",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.589188",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "A couple of non-Avacta trials that mention FPI, state that FPI = first patient enrolment. Neither discuss enrolment details though.   \ud83e\udd23\ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "6,042",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-10T01:55:46.153879+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20262005-Gingethe--4226839",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.589761",
        "source": "LSE_CHAT",
        "data": {
          "author": "GingetheWinge",
          "content": "Every piece of Avacta communication. Q1 2026. That is fact. Your opinions are plucked out of your a r s e.",
          "sentiment": 0.5,
          "engagement": "705",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-10T01:55:46.153910+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261922-avctIPma--2286608",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.590377",
        "source": "LSE_CHAT",
        "data": {
          "author": "avctIPmatters",
          "content": "\"FPI stands for \"First Patient In\", which is a critical milestone in clinical trials. It marks the moment when the first participant is screened and enrolled into the trial, signaling the beginning of real-world data collection.\" Ref :   Slide 29 https://avacta.com/wp-content/uploads/2025/07/Avacta_Corp_23July2025.pdf \" Q1 2026   Phase 1 first patient in (FPI)\" Gmcc",
          "sentiment": 0.0,
          "engagement": "742",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-10T01:55:46.153940+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261913-BuenaVis--8736231",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.590980",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "The FDA has 30 calendar days to review an IND application after receiving it. https://drugdevelopment.web.unc.edu/u-s-investigational-new-drug-application-%e2%86%92-ind-application-process/ IND submitted mid/late December (as per the project plan in Spotlight 13) and approved by 20 January. The FDA will have been working closely with Avacta given the experience with faridox so that was a fast turnaround given the US government shutdown gping on at the time. - - - - - And ToucanOfDoom, stop purporting to know better than CC what the likely timescales are.",
          "sentiment": 0.0,
          "engagement": "5,847",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-10T01:55:46.153971+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261911-Toukanka--6250414",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.591588",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "CJ62 No, while posters on here continue to misconstrue communications from Avacta and purport to know better than CC what the likely timescales are, then I will continue to correct them. You and others stop posting baseless wishful thinking ramps on here and I will stop exposing them for what they are. Deal?",
          "sentiment": 0.0,
          "engagement": "4,486",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-10T01:55:46.154001+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261902-cj62-42201868",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.592186",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "Touk can you do a thorn and dissolve into the ether?",
          "sentiment": 0.0,
          "engagement": "4,304",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-10T01:55:46.154032+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261900-BuenaVis--6514336",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.592752",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Https://avacta.com/research-development-spotlight-series-episode-13/ @26:15 FPI late Q1/26",
          "sentiment": 0.0,
          "engagement": "5,847",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-10T01:55:46.154063+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261852-Vertizea-34611616",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.593353",
        "source": "LSE_CHAT",
        "data": {
          "author": "VertizeaSun",
          "content": "Thanks jmfw.....and I'll add the reminder that CC visited the AVA6103 manufacturing site (Glasgow) in early December. a necessary requirement if one knows that patient dosing is likely to begin sooner rather than later.",
          "sentiment": 0.0,
          "engagement": "446",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-10T01:55:46.154092+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261851-Toukanka--4444846",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.593952",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "No no no That is my point. Trial start does not mean first patient dosed. CC has outlined in a previous communication the lengthy steps between IND approval and first in patient dosed. My prediction is still for initial clinical results around June. No deals until at least tolerance shown to some degree and even then maybe not until initial signs of efficacy. And yes I do know that P1 is not designed to show efficacy.",
          "sentiment": 0.0,
          "engagement": "4,486",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-10T01:55:46.154151+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261837-jmfw-68727756",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.594558",
        "source": "LSE_CHAT",
        "data": {
          "author": "jmfw",
          "content": "Https://www.lse.co.uk/rns/AVCT/year-end-trading-update-63xrambu5i622u5.html Under heading:  Outlook for 2026",
          "sentiment": 0.0,
          "engagement": "418",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-10T01:55:46.154182+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261830-Toukanka--7874412",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.595177",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "Ginge That would be great. Can you provide a link to where that is stated please. I\u2019m not challenging you. Because that would be good if they start in March. Thanks",
          "sentiment": 0.0,
          "engagement": "4,486",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-10T01:55:46.154212+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261819-Bella653--2214063",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.595769",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "Scroll to end... https://www.forxtherapeutics.com/2025/12/forx-therapeutics-announces-usd-50m-series-a-financing-enabling-clinical-data-readout-for-potential-best-in-class-parg-inhibitor As I said, is this appointment about media or funding/partnering?",
          "sentiment": 0.0,
          "engagement": "6,761",
          "price_at_post": "60.50",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-10T01:55:46.154244+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261621-BuenaVis--8482408",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.596417",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Here are some links re Richard Jarvis at Novartis: Richard Jarvis history: https://rocketreach.co/richard-jarvis-email_238424640 Richard Jarvis at Jarvis Advisors: https://www.moneyhouse.ch/en/company/jarvis-advisors-gmbh-5842690731 (Binningen is on the edge of Basel, home of Novartis HQ) Richard Jarvis consultant: https://www.linkedin.com/posts/the-difference-collective_say-hello-to-collective-consultant-richard-activity-7389560479272259584-EiwK (with photo) Richard Jarvis at Cohesion Bureau: https://cohesionbureau.com/bureau/richard-jarvis (with photo) - - - - - And here is the Cohesion Bureau team at their various locations in Europe and the US: https://cohesionbureau.com/bureau",
          "sentiment": 0.0,
          "engagement": "5,847",
          "price_at_post": "60.50",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-10T01:55:46.154277+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261542-Gingethe-43001303",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.596992",
        "source": "LSE_CHAT",
        "data": {
          "author": "GingetheWinge",
          "content": "First patients are expected to receive AVA6103 before the end of March.",
          "sentiment": 0.5,
          "engagement": "705",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-10T01:55:46.154307+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261521-B2HS2L-57064785",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.597714",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "FWIW Chris Maggos Strategic Consulting and IR, PR & BD Services for Biotech / Medtech Experience Managing Director Cohesion Bureau \u00b7 Full-time Dec 2022 - Present \u00b7 3 yrs 3 mos Geneva, Switzerland \u00b7 Hybrid Our experienced multi-disciplinary U.S. and Pan-European team offers insightful strategic consulting and services to expedite your corporate growth. In addition to strategic consulting, we offer execution services for partnering, fundraising, investor and (social) media relations. We have a dedicated editorial unit producing corporate content, including, writing, graphic design, video and photography. We want to be your partner for growth. Our experienced multi-disciplinary U.S. and Pan-European team offers insightful strategic consulting and services to expedite your corporate growth. In addition to strategic consulting, we offer execution services for partnering, fundraising, investor and (social) media relations. We have a dedicated editorial unit producing corporate content, including, writing, graphic design, video and photography. We want to be your partner for growth. Managing Director BioConfidant S\u00e0rl Sep 2014 - Present \u00b7 11 yrs 6 mos Geneva, Switzerland BioConfidant offers strategic consulting on three closely related types of corporate activities: investor relations, public relations and business development (i.e. licensing and M&A). With our partners around Europe and in the U.S. we started Cohesion Bureau in 2022 to level the playing field for European startups and small-cap companies. We established and managed the European investor relations business of LifeSci Advisors from 2015-2021. We are passionate about developing relationships and collaborating with clients to earn the visibility and impact they need to succeed.",
          "sentiment": 0.0,
          "engagement": "6,042",
          "price_at_post": "60.50",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-10T01:55:46.154341+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261513-Livedata--6547264",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.598309",
        "source": "LSE_CHAT",
        "data": {
          "author": "Livedataaccount",
          "content": "With the location being switzerland one does imagine the cohesion team are in bed with some big players at roche and novartis",
          "sentiment": 0.0,
          "engagement": "2,974",
          "price_at_post": "61.50",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-10T01:55:46.154372+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261503-Timster-90047364",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.598888",
        "source": "LSE_CHAT",
        "data": {
          "author": "Timster",
          "content": "That's a serious accusation watching you WILL be hearing from my legal team, not as hidden as you think.......",
          "sentiment": 0.0,
          "engagement": "20,640",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-10T01:55:46.154403+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261503-avctIPma-12814742",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.599564",
        "source": "LSE_CHAT",
        "data": {
          "author": "avctIPmatters",
          "content": "\" Cohesion Bureau (Communications)  Richard Jarvis / Chris Maggos \" Interesting  connection  Richard Jarvis  has with  Novartis .   Avacta  has had lots of changes  recently  - Michelle Morrow  did  not last long  - guess  one less salary to pay & also streamlining communication costs. ------- \"Richard Jarvis Trustee Director Trustee Director Novartis UK Pension Trustee CompanyNovartis UK Pension Trustee Company 2014 - Present \u00b7 12 yrs 2 mos2014 to Present \u00b7 12 yrs 2 mos Grew funding position from <90% of liabilities to ~110% (buy-out basis) for ~7 000 members.Grew funding position from <90% of liabilities to ~110% (buy-out basis) for ~7 000 members. Novartis logo Head of Strategy & Financial Communications Head of Strategy & Financial Communications NovartisNovartis 2021 - 2025 \u00b7 4 yrs2021 to 2025 \u00b7 4 yrs Basel, SwitzerlandBasel, Switzerland Led global team of communications and media relations professionals, responsible for financial communications and global top tier media engagement.Led global team of communications and media relations professionals, responsible for financial communications and global top tier media engagement. Communications Strategy, Team Management and +6 skills\" Gmcc",
          "sentiment": 0.0,
          "engagement": "742",
          "price_at_post": "60.50",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-10T01:55:46.154434+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261502-Livedata-29819446",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.600169",
        "source": "LSE_CHAT",
        "data": {
          "author": "Livedataaccount",
          "content": "I always imagined timster was a belly dancer",
          "sentiment": 0.0,
          "engagement": "2,974",
          "price_at_post": "61.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-10T01:55:46.154465+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261458-Watching-43887983",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.363454",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "Timster are you still a children\u2019s entertainer ?",
          "sentiment": 0.0,
          "engagement": "9,229",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-10T01:55:46.154496+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261453-Timster--2603699",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.363899",
        "source": "LSE_CHAT",
        "data": {
          "author": "Timster",
          "content": "One of Francis's KPA's is to ensure LDA's requests for updates via the lse website are promptly answered. Id expect an update within 48hrs LDA",
          "sentiment": 0.0,
          "engagement": "20,640",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-10T01:55:46.154528+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261453-Toukanka--5553808",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.364338",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "Clear from what CC said in today\u2019s RNS that no one has been dosed with 6103 yet. Given the preparation work that needs to be carried out including pre screening, I previously predicted April earliest for dosing to start. (Based on 6100 timescales)",
          "sentiment": 0.0,
          "engagement": "4,486",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-10T01:55:46.154560+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261426-Livedata--1917536",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.364756",
        "source": "LSE_CHAT",
        "data": {
          "author": "Livedataaccount",
          "content": "Be good to get an update please on TNBC progress and 6103 dosing thank you in advance",
          "sentiment": 0.0,
          "engagement": "2,974",
          "price_at_post": "60.50",
          "thread_title": "Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-10T01:55:46.154592+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261324-B2HS2L--2421582",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.365200",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "If this was true in Nov 2024 (so for AVA6000), I would assume the situation is a little more rosy now. Possibly some starters for 10 here. https://www.trinitydelta.org/research-notes/targeting-the-tumour-microenvironment-with-precision/ A reminder from Trinity Delta \u2013 Targeting the tumour microenvironment with pre|CISION - 18.11.2024 \"Avacta has so far FAP-enabled ten different warheads building up a database of multiple pre|CISION compounds that include c 40 capping groups (which alter the PK of the conjugate) and c 20 linkers (required for FAP cleavage with certain warheads and can be used to modify FAP affinity and activity). These have all been characterised through computational simulations to evaluate molecular binding and how they dock into the FAP structure. A key consideration is how close the warhead can get to the FAP cleavage sequence; this typically depends on the size of the molecule, and often defines whether a spacer group is required. Consideration is also given to how long the conjugate and the active warhead are likely to remain in the TME, and this informs whether PK alterations, achieved through an alternative capping group, are needed to either allow the sustained release of the warhead or to slow plasma clearance.",
          "sentiment": 0.0,
          "engagement": "6,042",
          "price_at_post": "60.50",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=060607B8-56D7-4812-99EC-1BE5765F573F"
        },
        "ingested_at": "2026-02-10T01:55:46.154624+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261308-pedrolan-57034060",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.365614",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Yes and what a truly remarkable career he could have.",
          "sentiment": 0.5,
          "engagement": "1,988",
          "price_at_post": "60.50",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=060607B8-56D7-4812-99EC-1BE5765F573F"
        },
        "ingested_at": "2026-02-10T01:55:46.154654+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261300-BuenaVis-22416174",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.366018",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "As the mechanism of action\u2014the dipeptide and the cleavage\u2014is proven, it now comes down to designing each molecule's pharmacokinetics to fit the needs for the warhead.  And who better to lead that than a highy competent chemist at the top of his game?",
          "sentiment": 0.0,
          "engagement": "5,847",
          "price_at_post": "60.50",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=060607B8-56D7-4812-99EC-1BE5765F573F"
        },
        "ingested_at": "2026-02-10T01:55:46.154685+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261159-B2HS2L--1855771",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.366489",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "\"Francis - We will learn more about this program in the clinic and apply that as we continue to develop NOVEL INTELLECTUAL PROPERTY around our highly successful pre|CISION\u00ae platform.\" -  We look forward to plenty of new IP to come. 29.10.2025 CC: \"Much of the success and how we are going to be able to move the dual payload through is going to depend on our initial observations in the clinic with the exatacan molecule. Francis and Tom mentioned that a lot of what we are doing with the dual payload is based on the learnings in the lab with the exatecan molecule. We expect to learn a lot about the exatecan molecule as we move it into the clinic and that's going to inform a lot about the dual payload molecules. Clinic learnings in the first half of 2026, will inform how quickly we're going to move the dual payload through.\" Also \"if we do right and we do great things for patients, we will be doing great things for our shareholders.\" I hope they stack the new IP high. It will increase the bargaining value of the company. It doesn't sound like Francis is going to be straying far from the lab, unless other chemists are inbound, and Francis is the mentor.  \ud83d\udcab",
          "sentiment": 0.0,
          "engagement": "6,042",
          "price_at_post": "60.50",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=060607B8-56D7-4812-99EC-1BE5765F573F"
        },
        "ingested_at": "2026-02-10T01:55:46.154716+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261120-Timster-58396305",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.366896",
        "source": "LSE_CHAT",
        "data": {
          "author": "Timster",
          "content": "Biggest buy signal in recent days is when eggy threw in the towel and removed his account.",
          "sentiment": 0.0,
          "engagement": "20,640",
          "price_at_post": "61.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-10T01:55:46.154747+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261105-yeboha-86413218",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.367315",
        "source": "LSE_CHAT",
        "data": {
          "author": "yeboha",
          "content": "Great RNS yet again today ! All moving in the right direction !",
          "sentiment": 0.0,
          "engagement": "967",
          "price_at_post": "61.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-10T01:55:46.154778+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261054-D-Geeman--2608776",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.367735",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "Certainly Watching 2 raises the tone but is that why people read bulletin boards Ginge? Would you rather read a poster's record have have them be proved right again and again? Or, like W2's record.. Shall I raise the tone? \"\u00a3200 ex-chinah, nailed on!\" \"Later today! \" (Note to self; see, it's not difficult.)",
          "sentiment": 0.0,
          "engagement": "5,877",
          "price_at_post": "61.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-10T01:55:46.154809+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261048-Gingethe-43727844",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.368149",
        "source": "LSE_CHAT",
        "data": {
          "author": "GingetheWinge",
          "content": "Agreed. Always the usual suspects that lower the tone.",
          "sentiment": 0.5,
          "engagement": "705",
          "price_at_post": "61.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-10T01:55:46.154840+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261032-Watching-70574570",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.368583",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "Tidy the BB Ignore the muppets We now know ignore and they argue with themselves And eventually dry up ! Great appointment well done team  avacta !. Jane",
          "sentiment": 0.0,
          "engagement": "9,229",
          "price_at_post": "61.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-10T01:55:46.154870+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261017-D-Geeman--6424605",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.369068",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "Touk, Watching does their best... And not just on AVCT. 'Watching2 'Posted in: ENET Posts: 9,227 RE: Sidelines22 Nov 2023 09:59 Actually 1p is very unlikely Bottom has now been hit imo. Good averaging opportunity! Next rns will lift us' And in case you were wondering how this 'prediction'went, today's SP: Share Price Information for Ethernity Net (ENET) Share Price is delayed by 15 minutes Get Live Data 0.0048    0.0001 (2.13%) Bid: 0.0046 Ask: 0.005 Spread: 0.0004 (8.696%) Market Cap: \u00a348.00k Still, plenty of folk 'Rec'watching's posts so hats-off to Jane (unless you're still holding on to it Jane?) .",
          "sentiment": 0.0,
          "engagement": "5,877",
          "price_at_post": "61.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-10T01:55:46.154902+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261003-Livedata--9723754",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.369492",
        "source": "LSE_CHAT",
        "data": {
          "author": "Livedataaccount",
          "content": "Francis has been instrumental in ava6103 and ava6207 running a successful business is about retaining top talent and i have no doubt his IP is massive at Avacta it is a great appointment",
          "sentiment": 0.0,
          "engagement": "2,974",
          "price_at_post": "61.00",
          "thread_title": "New CSO",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=2EBFCF4C-4A4D-475C-BBFD-DB095DA011B8"
        },
        "ingested_at": "2026-02-10T01:55:46.154934+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260926-Harrogat--5238823",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.369903",
        "source": "LSE_CHAT",
        "data": {
          "author": "Harrogate4",
          "content": "Agreed -----did they ever do anything ---apart from taking their salaries of course?",
          "sentiment": 0.0,
          "engagement": "805",
          "price_at_post": "61.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-10T01:55:46.154965+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260923-Bella653--2691706",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.370320",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "So can we assume THRUST and ICR have been ditched now...if so good ridens...",
          "sentiment": 0.0,
          "engagement": "6,761",
          "price_at_post": "61.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-10T01:55:46.154996+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260921-Bella653-50857429",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.370735",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "Or.. 1.  Is Cohesion Bureau about attracting Pharma funding? Their website is terrible...Nothing comes up in the NEWS section!!!!! 2.  We are not in the Immunotherapy space we now need good Chemists.   I think CC mentioned this in one of her videos when she talked about the 'Chemistry' involved in developing new pipelines.",
          "sentiment": 0.0,
          "engagement": "6,761",
          "price_at_post": "61.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-10T01:55:46.155029+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260919-yeboha-14043351",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.371148",
        "source": "LSE_CHAT",
        "data": {
          "author": "yeboha",
          "content": "But then again i dont no if avacta want the take over, they certainly wont push for it !",
          "sentiment": 0.0,
          "engagement": "967",
          "price_at_post": "61.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-10T01:55:46.155062+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260918-yeboha--8414332",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.371554",
        "source": "LSE_CHAT",
        "data": {
          "author": "yeboha",
          "content": "Watching , i agree with you, everything seems to be lining up beautifully for the take over this year !",
          "sentiment": 0.5,
          "engagement": "967",
          "price_at_post": "61.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-10T01:55:46.155093+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260915-Toukanka--5721493",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.371960",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "Watching In your view each year for the past three years was the year we would be taken over\ud83e\udd21",
          "sentiment": 0.0,
          "engagement": "4,486",
          "price_at_post": "61.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-10T01:55:46.155140+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260908-Vertizea-10102070",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.372377",
        "source": "LSE_CHAT",
        "data": {
          "author": "VertizeaSun",
          "content": "T/O? I quite agree. Avacta's got the air of a company tidying up loose ends.",
          "sentiment": 0.0,
          "engagement": "446",
          "price_at_post": "61.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-10T01:55:46.155172+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260907-yeboha-37733200",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.372784",
        "source": "LSE_CHAT",
        "data": {
          "author": "yeboha",
          "content": "Great news! Francis has been appointed as the new chief scientific officer. Retaining him will be a massive advantage moving forward!",
          "sentiment": 0.5,
          "engagement": "967",
          "price_at_post": "61.00",
          "thread_title": "Important Appointment",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=8E658AE1-929D-4CD1-910B-CBDF7FD77692"
        },
        "ingested_at": "2026-02-10T01:55:46.155201+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260903-Watching--5776164",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.373199",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "Imo This year we will  will be taken over The glowing data  must be worth the risk to get in first gla Jane !",
          "sentiment": 0.0,
          "engagement": "9,229",
          "price_at_post": "61.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-10T01:55:46.155233+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260858-nurseste-40577735",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.373605",
        "source": "LSE_CHAT",
        "data": {
          "author": "nursesteve",
          "content": "It seems a bit strange from Simon being touted by Chris as being so busy to quietly being removed ?",
          "sentiment": 0.0,
          "engagement": "1,169",
          "price_at_post": "61.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-10T01:55:46.155264+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260849-BuenaVis-65403484",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.092369",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "We don't know what he was doing not why he's no longer on the team. He was another of Alan's hires that's now gone.",
          "sentiment": 0.0,
          "engagement": "5,847",
          "price_at_post": "62.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-10T01:55:46.155297+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260844-Watching-22836924",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.093088",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "Leaky ship ! Another hole plugged",
          "sentiment": 0.0,
          "engagement": "9,229",
          "price_at_post": "62.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=060607B8-56D7-4812-99EC-1BE5765F573F"
        },
        "ingested_at": "2026-02-10T01:55:46.155331+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260839-BuenaVis-18403100",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.093853",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "We'll know where and when in the fullness of time. https://www.linkedin.com/in/michelle-morrow-127605137",
          "sentiment": 0.0,
          "engagement": "5,847",
          "price_at_post": "62.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=060607B8-56D7-4812-99EC-1BE5765F573F"
        },
        "ingested_at": "2026-02-10T01:55:46.155363+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260837-nurseste-23920445",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.094563",
        "source": "LSE_CHAT",
        "data": {
          "author": "nursesteve",
          "content": "So Simon was busy doing??? \ud83e\udd14",
          "sentiment": 0.0,
          "engagement": "1,169",
          "price_at_post": "62.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-10T01:55:46.155395+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260837-cj62-30749950",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.095298",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "Probably caught with her hand in the cookie jar !!",
          "sentiment": 0.0,
          "engagement": "4,304",
          "price_at_post": "62.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=060607B8-56D7-4812-99EC-1BE5765F573F"
        },
        "ingested_at": "2026-02-10T01:55:46.155428+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260832-Harrogat--1601184",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.095975",
        "source": "LSE_CHAT",
        "data": {
          "author": "Harrogate4",
          "content": "Congratulations to Dr Francis Wilson, very well deserved in my view and a great choice by CC.",
          "sentiment": 0.0,
          "engagement": "805",
          "price_at_post": "62.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=060607B8-56D7-4812-99EC-1BE5765F573F"
        },
        "ingested_at": "2026-02-10T01:55:46.155460+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260818-Watching-84968667",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.096697",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "Perhaps it was requested by a big pharma as part of a agreement",
          "sentiment": 0.0,
          "engagement": "9,229",
          "price_at_post": "60.50",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=060607B8-56D7-4812-99EC-1BE5765F573F"
        },
        "ingested_at": "2026-02-10T01:55:46.155492+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260815-Prion25-30667897",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.097532",
        "source": "LSE_CHAT",
        "data": {
          "author": "Prion25",
          "content": "Michelle highly regarded in oncology biotech did a block buster drug with AZ  probably been headhunted by a prospective parter of Avacta or  big pharma competitors We won\u2019t know probably a NDA has been signed",
          "sentiment": 0.0,
          "engagement": "1,555",
          "price_at_post": "60.50",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=060607B8-56D7-4812-99EC-1BE5765F573F"
        },
        "ingested_at": "2026-02-10T01:55:46.155523+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260809-B2HS2L--3842870",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.098278",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "CC :  \"\"In addition to his leadership internally, he has also been a key member of the team positioning our business across the international drug development sector. Francis is a well-known leader in medicinal chemistry externally and we are looking forward to forging the next chapter of pre|CISION\u00ae with his scientific leadership and expertise. \" I think she wants him to become more of a Key Opinion Leader, - she uses 'leader' above - in spreading the pre-CISION gospel. To become more influential with respect to FDA / MHRA and the like. Michelle Morrow may have decided the grass was greener. \"former CSO Michelle Morrow will be leaving Avacta to pursue another opportunity\" - singular not plural. She must have done a lot of work to get AVA6103 successfully through the IND Application. (That's true for all staff). She knows what's inside the capping group and the linker group, - those two blue blobs (group A & group B) in blue in certain presentations.",
          "sentiment": 0.0,
          "engagement": "6,042",
          "price_at_post": "60.50",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=060607B8-56D7-4812-99EC-1BE5765F573F"
        },
        "ingested_at": "2026-02-10T01:55:46.155555+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260809-Colesy74-73017576",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.098949",
        "source": "LSE_CHAT",
        "data": {
          "author": "Colesy74",
          "content": "Https://youtu.be/kyQJRyoPzvw",
          "sentiment": 0.0,
          "engagement": "21",
          "price_at_post": "60.50",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-10T01:55:46.155585+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260737-Vertizea--4753099",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.099686",
        "source": "LSE_CHAT",
        "data": {
          "author": "VertizeaSun",
          "content": "Also....Simon Bennett was removed from Leadership page but Yulii Bogatyrenko remains.",
          "sentiment": 0.0,
          "engagement": "446",
          "price_at_post": "60.50",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-10T01:55:46.155617+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260727-dafad-50306393",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.100396",
        "source": "LSE_CHAT",
        "data": {
          "author": "dafad",
          "content": "They may have wanted someone of a higher calibre in the position as they develop the Platform",
          "sentiment": 0.0,
          "engagement": "2,416",
          "price_at_post": "60.50",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=060607B8-56D7-4812-99EC-1BE5765F573F"
        },
        "ingested_at": "2026-02-10T01:55:46.155647+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260723-Livedata-11895565",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.101080",
        "source": "LSE_CHAT",
        "data": {
          "author": "Livedataaccount",
          "content": "Who knows employees have many reasons for leaving job roles",
          "sentiment": 0.0,
          "engagement": "2,974",
          "price_at_post": "60.50",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=060607B8-56D7-4812-99EC-1BE5765F573F"
        },
        "ingested_at": "2026-02-10T01:55:46.155678+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260721-IFA90-77881001",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.101762",
        "source": "LSE_CHAT",
        "data": {
          "author": "IFA90",
          "content": "Why leave before the multi billion TO?",
          "sentiment": 0.0,
          "engagement": "416",
          "price_at_post": "60.50",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=060607B8-56D7-4812-99EC-1BE5765F573F"
        },
        "ingested_at": "2026-02-10T01:55:46.155709+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260721-BuenaVis--2408369",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.102469",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "A good decision. From CC's praise, he's likely been leading the science anyway.",
          "sentiment": 0.0,
          "engagement": "5,847",
          "price_at_post": "60.50",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=060607B8-56D7-4812-99EC-1BE5765F573F"
        },
        "ingested_at": "2026-02-10T01:55:46.155741+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260715-BuenaVis-78756424",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.103183",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Avacta's new comms organisation, based in Geneva: https://cohesionbureau.com/ It's All Change, every month, with Avacta!",
          "sentiment": 0.0,
          "engagement": "5,847",
          "price_at_post": "60.50",
          "thread_title": "Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-10T01:55:46.155773+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260705-JFK8--1244205",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.103866",
        "source": "LSE_CHAT",
        "data": {
          "author": "JFK8",
          "content": "New CSO to replace Michelle Morrow",
          "sentiment": 0.0,
          "engagement": "3,058",
          "price_at_post": "60.50",
          "thread_title": "RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=060607B8-56D7-4812-99EC-1BE5765F573F"
        },
        "ingested_at": "2026-02-10T01:55:46.155804+00:00"
      },
      {
        "event_id": "SOCIAL-8Feb20261320-BuenaVis--6379124",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.104577",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "The link didn't work so I ran that query in Grok.  Yes, the procedure is involved but so is standard doxorubicin I should think - valid prescription, qualified people, the \"Five Rights\", etc. but with the added safety measures need for radioactivity. I should think the patients have to be held in the hospital to be sure that the drug can be administered rather than have them just ambling in for the 3-weekly injection, the reason being timeliness, timeliness, timeliness... to Grok: \"What are the steps to get a radiopharmaceutical from production to patient?\" \"The journey of a radiopharmaceutical from production to patient administration is a highly time-sensitive, regulated supply chain due to the short half-lives of most radionuclides (often hours to days). This limits the window for manufacturing, quality control, transportation, and use. The process varies depending on the radionuclide (e.g., cyclotron-produced like F-18, Ga-68, or reactor-produced like Mo-99/Tc-99m, Lu-177) and whether the product is a ready-to-use diagnostic agent (e.g., FDG), a kit requiring on-site labeling, or a therapeutic agent.\" ...and so it goes on with the 11 stages and summarised under Key Challenges (Time pressure, Radiation safety, Regulatory compliance, Supply chain complexity)",
          "sentiment": 0.0,
          "engagement": "5,847",
          "price_at_post": "60.50",
          "thread_title": "RE: Watch Ely Lilly could make a move",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=4B1C735B-8BE4-4153-95B2-75A61E403C1D"
        },
        "ingested_at": "2026-02-10T01:55:46.155837+00:00"
      },
      {
        "event_id": "SOCIAL-8Feb20261235-B2HS2L--2315355",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.105340",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "Source Grok: \"what is the procedure to administer a dose of a radiopharmaceutical drug?\" https://x.com/i/grok?conversation=2020452204348313802 Intravenous administration of AVA6103 is going to be a doddle compared with radiopharmaceutical administration by a team of several. Time / expense to get radiopharmaceutical to hospital? If the decision to make funds available to dose a patient is made by a health insurance company, I don't think they would consider a radiopharmaceutical for long if a cheaper method of administration is available. PDC ADC - it has targeting issues. radiopharmaceutical - difficult / expensive to administer, too many specialists This is my list of most to least preferrable drug types for experts to consider using. Novartis must be \ud83d\udc40",
          "sentiment": 0.0,
          "engagement": "6,042",
          "price_at_post": "60.50",
          "thread_title": "RE: Watch Ely Lilly could make a move",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=4B1C735B-8BE4-4153-95B2-75A61E403C1D"
        },
        "ingested_at": "2026-02-10T01:55:46.155876+00:00"
      },
      {
        "event_id": "SOCIAL-8Feb20261107-GainsOnl-65058771",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.106009",
        "source": "LSE_CHAT",
        "data": {
          "author": "GainsOnly",
          "content": "This will be over 75p last placing price very soon DYOR",
          "sentiment": 0.0,
          "engagement": "10",
          "price_at_post": "60.50",
          "thread_title": "RE: Watch Ely Lilly could make a move",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=4B1C735B-8BE4-4153-95B2-75A61E403C1D"
        },
        "ingested_at": "2026-02-10T01:55:46.155908+00:00"
      },
      {
        "event_id": "SOCIAL-8Feb20261042-LiveLong--2897058",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.106802",
        "source": "LSE_CHAT",
        "data": {
          "author": "LiveLongnProsper",
          "content": "A few Exatecan products that AVA6103 might be compared against ..? Cybrexa \u2013 privately held, have CBX-12 a PDC, targeting pH (acidity), in phase 2. EMD Serono \u2013 Merck subsidiary, have M7437, ADC based, in phase 1 from Jan 2026. Innovent \u2013 now partnered with Takeda, have IBI343, ADC based, in phase 3 with FDA fast track. AVA6103, indeed the whole pre|CISION\u00ae platform, remains, as yet, \u2018unpartnered\u2019 (OK Lilly/CanSeek) - but not without \u2018friends\u2019 and \u2018admirers\u2019. What about BP then ..? We know that Daiichi Sankyo and AZN are massively committed to Enhertu\u00ae (trastuzumab deruxtecan), HER2 targeted ADC, and we know about \u2018patent cliffs\u2019.  DS / AZN currently pushing through a number of DXd products, perhaps most notably Datroway\u00ae (datopotamab deruxtecan), TROP2 targeted ADC in phase 3.  Daiichi have been working with Exatecan for over 20 years.  These guys need to protect their \u2018space\u2019. Merck (Keytruda) were apparently going to spend up to $32bn for Revolution \u2013 seems to be off now?  Guess they have ready cash then? Novartis have this massive \u2018hole\u2019 in their pipeline, i.e. no ADC\u2019s, but are doing FAP targeting for RLT.  They seem to have plenty of money also. \u2018Triggers\u2019 for Avacta acquisition ..? Positive AVA6000 TNBC readout?  PFS for SGC and AVA6000 becomes \u2018standard of care\u2019?  Early positive response to AVA6103? Or just a  \u2018pre-emptive strike\u2019? GLA",
          "sentiment": 0.0,
          "engagement": "1,836",
          "price_at_post": "60.50",
          "thread_title": "RE: Watch Ely Lilly could make a move",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=4B1C735B-8BE4-4153-95B2-75A61E403C1D"
        },
        "ingested_at": "2026-02-10T01:55:46.155940+00:00"
      },
      {
        "event_id": "SOCIAL-8Feb20260925-opti_mys--6540469",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.107491",
        "source": "LSE_CHAT",
        "data": {
          "author": "opti_mystic",
          "content": "Keytruda is out of Patent in 2028 when the immunology drug becomes an out of patent generic drug. Avacta could use it like we have Dox and Exatecan and we'd have chemo and immunology options.",
          "sentiment": 0.0,
          "engagement": "315",
          "price_at_post": "60.50",
          "thread_title": "RE: Watch Ely Lilly could make a move",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=4B1C735B-8BE4-4153-95B2-75A61E403C1D"
        },
        "ingested_at": "2026-02-10T01:55:46.155972+00:00"
      },
      {
        "event_id": "SOCIAL-8Feb20260859-Aldebara--7645891",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.108206",
        "source": "LSE_CHAT",
        "data": {
          "author": "Aldebaran",
          "content": "So we saying that lily and Novartis have eyes on either directly or indirectly. Would love to throw merck into the mix as well due to keytruda patent expiry. What about daiichi sankyo also. 4 way bidding war would be nice. All 4 could be made a reasonable case to be seriously interested in precision",
          "sentiment": 0.0,
          "engagement": "3,933",
          "price_at_post": "60.50",
          "thread_title": "RE: Watch Ely Lilly could make a move",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=4B1C735B-8BE4-4153-95B2-75A61E403C1D"
        },
        "ingested_at": "2026-02-10T01:55:46.156004+00:00"
      },
      {
        "event_id": "SOCIAL-8Feb20260852-Bella653--6654599",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.108890",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "'POINT Biopharma Inc Avacta has entered into a license agreement with POINT Biopharma Inc., (taken over by Eli Lilly in late 2023) a clinical-stage pharmaceutical company focused on the development and commercialisation of radioligand therapies for the treatment of cancer, to provide access to Avacta\u2019s pre|CISION\u00ae technology for the development of tumor-activated radiopharmaceuticals.' How much access are they now getting to PreCISION???",
          "sentiment": 0.0,
          "engagement": "6,761",
          "price_at_post": "60.50",
          "thread_title": "RE: Watch Ely Lilly could make a move",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=4B1C735B-8BE4-4153-95B2-75A61E403C1D"
        },
        "ingested_at": "2026-02-10T01:55:46.156036+00:00"
      },
      {
        "event_id": "SOCIAL-8Feb20260843-Bella653--6173799",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.109654",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "'Toxicity caused by off-target delivery is a longstanding concern of cancer therapies. Developed by Dr. William Bachovchin of Tufts University, POINT\u2019s CanSEEK\u2122 technology aims to minimize radiopharmaceutical toxicity caused by off-target delivery by only activating a radiopharmaceuticals' targeting moiety, such as its ligand, after it has encountered FAP-\u03b1 in the tumor microenvironment (TME). FAP-\u03b1 is highly expressed on a wide range of solid tumors, but in very low quantities or absent altogether in healthy tissues. The intent of CanSEEK\u2122 is to minimize the toxicity caused by off-target delivery. At first, CanSEEK\u2122 prevents the radiopharmaceutical from bonding to receptors on cells. When the radiopharmaceuticals enter the TME, the radiopharmaceuticals targeting moiety is re-activated, enabling it to once again bond to receptors on cancer cells. CanSEEK\u2122 has the potential to make treatments even more precise, expanding their therapeutic index, and enabling the use of new, more powerful medical isotopes.' \u200d",
          "sentiment": 0.0,
          "engagement": "6,761",
          "price_at_post": "60.50",
          "thread_title": "RE: Watch Ely Lilly could make a move",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=4B1C735B-8BE4-4153-95B2-75A61E403C1D"
        },
        "ingested_at": "2026-02-10T01:55:46.156067+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20262318-Icecool-57139809",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.525582",
        "source": "LSE_CHAT",
        "data": {
          "author": "Icecool",
          "content": "Happy holidays everyone. \ud83d\ude09\ud83e\udd23\ud83d\ude2d",
          "sentiment": 0.0,
          "engagement": "8,855",
          "price_at_post": "60.50",
          "thread_title": "RE: From MM on X - If it offends - Tough",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=D20B314B-66BB-47B0-8ED4-D46B27E22B85"
        },
        "ingested_at": "2026-02-10T01:55:46.156112+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20262125-Livedata--4352700",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.526281",
        "source": "LSE_CHAT",
        "data": {
          "author": "Livedataaccount",
          "content": "who is offended not icecool being ****** again i hope",
          "sentiment": 0.0,
          "engagement": "2,969",
          "price_at_post": "60.50",
          "thread_title": "RE: From MM on X - If it offends - Tough",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=D20B314B-66BB-47B0-8ED4-D46B27E22B85"
        },
        "ingested_at": "2026-02-10T01:55:46.156149+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20262120-IFA90-30892895",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.526944",
        "source": "LSE_CHAT",
        "data": {
          "author": "IFA90",
          "content": "I\u2019m not offended. Xx",
          "sentiment": 0.0,
          "engagement": "415",
          "price_at_post": "60.50",
          "thread_title": "RE: From MM on X - If it offends - Tough",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=D20B314B-66BB-47B0-8ED4-D46B27E22B85"
        },
        "ingested_at": "2026-02-10T01:55:46.156183+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20262049-B2HS2L--5087613",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.527979",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "Https://x.com/BMHLTD/status/1736326494035603668 - Thanks BMH. December 2023 - Set of extracts from a Will Tap presentation. Will Tap discusses STS treatment improvement necessary. Now we have SGC first pass results, - AVA6000 more likely to be able to address items on Will Tap's STS wish list - with resulting FDA satisfaction.",
          "sentiment": 0.0,
          "engagement": "6,031",
          "price_at_post": "60.50",
          "thread_title": "Will Tap STS wish list",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=21C3C888-CE85-4F00-B718-E879BB3F5CC6"
        },
        "ingested_at": "2026-02-10T01:55:46.156216+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20262037-BuenaVis--2677179",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.528670",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Top publication, Scrip, so this is excellent exposure for CC and Avacta in their 'preview' of the year.",
          "sentiment": 0.0,
          "engagement": "5,826",
          "price_at_post": "60.50",
          "thread_title": "RE: Evolving Drug Conjugates",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B37AC3F0-A005-4580-9CCE-040AE6DF8EA7"
        },
        "ingested_at": "2026-02-10T01:55:46.156248+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261929-avctIPma-37599981",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.529343",
        "source": "LSE_CHAT",
        "data": {
          "author": "avctIPmatters",
          "content": "\"drive significant interest and global pharma partnerships.\"  sounds  good ! Gmcc",
          "sentiment": 0.0,
          "engagement": "740",
          "price_at_post": "60.50",
          "thread_title": "RE: Evolving Drug Conjugates",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B37AC3F0-A005-4580-9CCE-040AE6DF8EA7"
        },
        "ingested_at": "2026-02-10T01:55:46.156279+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261924-avctIPma--6261798",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.530056",
        "source": "LSE_CHAT",
        "data": {
          "author": "avctIPmatters",
          "content": "Thanks to Stonks ;   CC featured \"Scrip Asks... What Does 2026 Hold For Biopharma? Part 4: R&D Innovation\" https://insights.citeline.com/scrip/scrip-asks/scrip-asks-what-does-2026-hold-for-biopharma-part-4-rd-innovation-NDREFKFVB5DZPAQLA5CIZHE7OI/#oncology \"Evolving Drug Conjugates Drugs conjugated to antibodies and other carriers continue advancing through next-generation payload and linker innovation. \u201c2026 will be a pivotal year for dual payload drug conjugates, as the first wave of these therapies is expected to yield initial clinical data,\u201d predicted Christina Coughlin, CEO of Avacta Therapeutics. \u201cThe first dual payload peptide-drug conjugate was announced this year, and dozens of major pharma companies are advancing dual-payload programs targeting different resistance mechanisms. We expect the technology\u2019s ability to overcome drug resistance, enhance tumor selectivity and broaden the therapeutic window to drive significant interest and global pharma partnerships. This represents oncology\u2019s evolution from sequential combination dosing to precision dual-delivery, fundamentally reshaping how we approach tumor heterogeneity and resistance.\u201d Gmcc",
          "sentiment": 0.0,
          "engagement": "740",
          "price_at_post": "60.50",
          "thread_title": "Evolving Drug Conjugates",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B37AC3F0-A005-4580-9CCE-040AE6DF8EA7"
        },
        "ingested_at": "2026-02-10T01:55:46.156311+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261910-JES1889--7453999",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.530764",
        "source": "LSE_CHAT",
        "data": {
          "author": "JES1889",
          "content": "I think the other piece to consider here is that Avacta no longer seems to be a leaky ship. I now believe that (if and) when news drops it\u2019ll arrive without forewarning, like the FDA news this week. Whilst I see there being room for the share price to appreciate as this year progresses, on retail demand/expectations. I doubt that even positive data releases on TNBC and 6103 will see this head anywhere near true value. AIM and the UK investment community just find the scale too hard to contemplate. I\u2019ve seen comments about the current low share price and suggesting that potential bidders would start buying shares in the open market. There\u2019s no way that any party under NDA would be able to do that as they\u2019d be party to inside information and that would be covered by the Market Abuse Regulations. The NDA would almost certainly have some form of standstill clause prohibiting open market share purchases. I think the big news when it comes will come out of the blue.",
          "sentiment": 0.0,
          "engagement": "83",
          "price_at_post": "60.50",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-10T01:55:46.156344+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261857-Icecool-40335218",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.531439",
        "source": "LSE_CHAT",
        "data": {
          "author": "Icecool",
          "content": "Bella you assume the SP and deal value will be linked prior to any announcement. That might happen on the Nasdaq, however it certainly doesn\u2019t happen on AIM. The price will be negotiated on the technology, then and only then will the SP react accordingly.\ud83d\udcaf\ud83d\udc4d",
          "sentiment": 0.0,
          "engagement": "8,855",
          "price_at_post": "60.50",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-10T01:55:46.156375+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261334-Timster-86252940",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.532093",
        "source": "LSE_CHAT",
        "data": {
          "author": "Timster",
          "content": "Why would that offend?",
          "sentiment": 0.0,
          "engagement": "20,637",
          "price_at_post": "60.50",
          "thread_title": "RE: From MM on X - If it offends - Tough",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=D20B314B-66BB-47B0-8ED4-D46B27E22B85"
        },
        "ingested_at": "2026-02-10T01:55:46.156408+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261322-Toukanka-24184861",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.532773",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "All hail the uber ramper. But I agree with everything except I think his timeline is optimistic. I\u2019m still saying Summer for the pivotal moment - in that respect I am accepting CC\u2019s predictions.",
          "sentiment": 0.0,
          "engagement": "4,476",
          "price_at_post": "60.50",
          "thread_title": "RE: From MM on X - If it offends - Tough",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=D20B314B-66BB-47B0-8ED4-D46B27E22B85"
        },
        "ingested_at": "2026-02-10T01:55:46.156440+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261243-wyndrum-14471036",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.533481",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "Does that mean MM is NFT?",
          "sentiment": 0.0,
          "engagement": "12,250",
          "price_at_post": "60.50",
          "thread_title": "RE: From MM on X - If it offends - Tough",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=D20B314B-66BB-47B0-8ED4-D46B27E22B85"
        },
        "ingested_at": "2026-02-10T01:55:46.156472+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261226-cj62--4220674",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.534176",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "I have never been influenced by MM's ramblings but this actually echoes my sentiments exactly, our money is safe as I believe SGC alone makes this a very valuable company. We are now waiting on initial TNBC data prior to H2 which if successful will boost the valuation of Avacta considerably and to top that off ava6103 initial data i expect mid H2. Very exciting times indeed and hopefully well worth the wait.",
          "sentiment": 0.0,
          "engagement": "4,302",
          "price_at_post": "60.50",
          "thread_title": "RE: From MM on X - If it offends - Tough",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=D20B314B-66BB-47B0-8ED4-D46B27E22B85"
        },
        "ingested_at": "2026-02-10T01:55:46.156503+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261217-D-Geeman--8522215",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.534833",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "Vertizea, son, B2H just beat me to it. Whenever I have been influenced by MM in hindsight I should have done the opposite. Yet this does seem a very exciting time. 'If .... and b) the company can stay independent for a couple more years at least' could be the explanation of the contradiction in my response. I think I will keep some powder dry for the next year or so. Currently the 'powder' is in WG, waiting to be worth 30p. Would be comvenient if the various timings work out for me.",
          "sentiment": 0.0,
          "engagement": "5,868",
          "price_at_post": "60.50",
          "thread_title": "RE: From MM on X - If it offends - Tough",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=D20B314B-66BB-47B0-8ED4-D46B27E22B85"
        },
        "ingested_at": "2026-02-10T01:55:46.156534+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261206-B2HS2L--8686956",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.535518",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "Does that mean MM's out? Not offended. \ud83d\ude44 PS probably reducing.",
          "sentiment": 0.0,
          "engagement": "6,031",
          "price_at_post": "60.50",
          "thread_title": "RE: From MM on X - If it offends - Tough",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=D20B314B-66BB-47B0-8ED4-D46B27E22B85"
        },
        "ingested_at": "2026-02-10T01:55:46.156567+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261201-Vertizea--1144307",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.536296",
        "source": "LSE_CHAT",
        "data": {
          "author": "VertizeaSun",
          "content": "Myles McNulty @MylesMcNulty \u00b7 2h Replying to @RobDay80669068 Morning Robert, hope all's well. #AVCT's news on Tuesday was phenomenal. My understanding is that it's an unprecedented move by the FDA to remove the dosing limit for a modified-/reformulated-/pro-chemotherapy,  mid-Phase 1 trial. The rapid decline and fall of the UK investment community - in depth, breadth, intellectual curiosity and risk tolerance - is in my view providing one of the greatest asymmetrical bets of all time. #AVA6000 is an absolute shoe-in to get to market now. It much more than underpins Avacta's entire market cap. Management will know if #AVA6103 - 'the Beast' - is working in patients as they hope it will, by the end of next month. That single drug  has real potential to become the best selling drug in the history of pharma. It really is straightforward to explain and understand this. Personally, I give AVA6103 well over a >50% chance of success in clinic. If a) it is indeed a success in the clinic; and b) the company can stay independent for a couple more years at least; then the returns from the current 60p share price could be >100x. I have recently provided a real world example of these returns (see my last post on Avacta, comparing it with $RVMD). The next 6 months are by far the most important in Avacta's history. Good luck!",
          "sentiment": 0.0,
          "engagement": "440",
          "price_at_post": "60.50",
          "thread_title": "From MM on X - If it offends - Tough",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=D20B314B-66BB-47B0-8ED4-D46B27E22B85"
        },
        "ingested_at": "2026-02-10T01:55:46.156600+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261152-wyndrum-43114377",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.537031",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "Well done Bella, although you won't see this post because you are so clever with the filter button but I raised this most recently with NFT and he never responded to his valuation of $28b based on another company, even though I asked 3 times. Thats the problem with filters. I get filtering the sheppys and watchings of this world that offer absolutely nothing but when I am not defending myself against unsolicited slurs and random insult-only posts, I only talk about AVCT. You tend to eventually come to the same conclusions as me but it takes a while and of course that ground has already been covered. The thing I have noticed is that it does not take long at all to quickly scan any post to see if it has relevance or not and as a result no longer bother filtering anyone. And why? Just on the chance that they do in fact come across some good info or (heaven forfend), some helpful insight. But as I say this will just be another green box for you to never know what was said",
          "sentiment": 0.0,
          "engagement": "12,250",
          "price_at_post": "60.50",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-10T01:55:46.156633+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261143-Bella653--2451128",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.537707",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "Anyone quoting billion $ deals should also post the number of shares that were in issue and the SP prior to the deal...without this info you cannot compare apples with apples. I've checked some of these big deals only to find the SP increase was relatively small.",
          "sentiment": 0.0,
          "engagement": "6,756",
          "price_at_post": "60.50",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-10T01:55:46.156665+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261113-B2HS2L--4555096",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.538535",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "GSK's new CEO looking for $2B to $4B deals 'hiding in plain sight' This is the title of a Fierce Pharma document found on this link: https://www.fiercebiotech.com/biotech/gsks-new-ceo-looking-2-4b-deals-hiding-plain-sight +++ Luke Miels had only been at the helm of GSK for 20 days before he signed off on his first multibillion-dollar buyout, and the CEO is clear on what else will attract his interest. \u201cThe basic framework that we like for [business development] is in that 2-to-4 billion [dollar] range,\u201d Miels told journalists on a fourth-quarter earnings call this morning. \u201cTypically, we like a program where the science is reasonably established,\u201d he added. Miels\u2014who served as GSK\u2019s chief commercial officer before taking over from CEO Emma Walmsley in the new year\u2014pointed to a pattern in dealmaking set in 2022 by the $1.9 billion acquisition of Sierra Oncology for its near-approval cancer drug. GSK is especially interested in drugs where \u201cwe've got a degree of validation on the science, but there are liabilities with the existing products,\u201d he said. To demonstrate these criteria, Miels cited the $2.2 billion buyout of Rapt Therapeutics just days into his tenure as CEO. Rapt\u2019s IgE antibody ozureprubart protects against food allergy reactions by targeting the same epitope as Novartis and Roche\u2019s Xolair. Miels admitted that Xolair has \u201cabsolutely exploded in the U.S. for usage with severe allergies, particularly in kids.\u201d \u201cBut the problem is there's a very complicated dosing regimen, and these kids have to inject themselves every two weeks,\u201d he explained. \u201c[Ozureprubart] works exactly the same way as Xolair, except that you give it on a much lower frequency,\u201d Miels said. \ud83d\udc40 \u201cSo that's essentially the methodology we're going to follow with [business development]\u2014looking for assets [that are] well priced, not necessarily in the mainstream, hiding in plain sight,\u201d the CEO added. \u201cAnd we'll do that with a degree of frequency, which, again, will help us build out the late-stage portfolio.\u201d 1 The basic framework that we like for [business development] is in that 2-to-4 billion [dollar] range,\u201d  \u274c 2 \u201cTypically, we like a program where the science is reasonably established\u201d   \u2714\ufe0f 3 GSK is interested in drugs where \u201cwe've got a degree of validation on the science, but there are liabilities with the existing products\u201d \u2714\ufe0f 4  ...looking for assets [that are] well priced, not necessarily in the mainstream, hiding in plain sight\u201d \u274c see 1 - I'd take issue that multibillion assets don't usually exist in the mainstream, hiding in plain sight. I'd say all now know about Avacta and its products. Those specialising in cancer therapeutics HAVE to be interested or start making BIG advances soon in ADC cancer targeting. I think overall, GSK is looking for an opportunity that costs less than Avacta will sell for. - From the horses mouth.",
          "sentiment": 0.0,
          "engagement": "6,031",
          "price_at_post": "60.50",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-10T01:55:46.156696+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261101-Watching-82952291",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.539211",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "You don\u2019t always get the best deals with smaller companies .. J",
          "sentiment": 0.0,
          "engagement": "9,224",
          "price_at_post": "60.50",
          "thread_title": "RE: Trading 212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B38EA914-FA00-4B19-B293-5E96B62D2062"
        },
        "ingested_at": "2026-02-10T01:55:46.156728+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261055-Profchee--5457536",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.539863",
        "source": "LSE_CHAT",
        "data": {
          "author": "Profcheese",
          "content": "II also in the process of reducing their charges at the moment. It's a competitive world!",
          "sentiment": 0.0,
          "engagement": "539",
          "price_at_post": "60.50",
          "thread_title": "RE: Trading 212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B38EA914-FA00-4B19-B293-5E96B62D2062"
        },
        "ingested_at": "2026-02-10T01:55:46.156761+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261008-Watching--8477052",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.540533",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "IG t buying n selling is free if you have over \u00a330 k in there account",
          "sentiment": 0.0,
          "engagement": "9,224",
          "price_at_post": "60.50",
          "thread_title": "RE: Trading 212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B38EA914-FA00-4B19-B293-5E96B62D2062"
        },
        "ingested_at": "2026-02-10T01:55:46.156792+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261004-Bella653--8388141",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.541198",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "Have you compared the Bid and Ask prices ...many of these No Fee sites don't give the 'best' prices...",
          "sentiment": 0.0,
          "engagement": "6,756",
          "price_at_post": "60.50",
          "thread_title": "RE: Trading 212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B38EA914-FA00-4B19-B293-5E96B62D2062"
        },
        "ingested_at": "2026-02-10T01:55:46.156825+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20260955-wyndrum-55173365",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.541863",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "FWIW they were efficient in sorting out a pension for me too",
          "sentiment": 0.0,
          "engagement": "12,250",
          "price_at_post": "60.50",
          "thread_title": "RE: Trading 212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B38EA914-FA00-4B19-B293-5E96B62D2062"
        },
        "ingested_at": "2026-02-10T01:55:46.156857+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20260955-avctIPma-77036858",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.542723",
        "source": "LSE_CHAT",
        "data": {
          "author": "avctIPmatters",
          "content": "Recent CC quotes :  %   Chance of success  -  Surely Avacta platform that  can to enhance  existing drug treatments  requires  an IP value asset  re-set  . Certainly worth waiting  for  to see   which  BP  jumps first  . ---------------- \"@coughlin582: \u201cif there\u2019s an organ with a cancer, we can address it\u201d \"Christina Coughlin @coughlin582 \u00b7 Feb 4 Replying to @coughlin582 Love this! No would never give our secrets away here! The secret to the sustained release mechanism invented by our brilliant chemistry team is behind blob A and blob B. We call this the \u201cblob slide\u201d \u2026 #BestTeamEver\" Gmcc",
          "sentiment": 0.0,
          "engagement": "740",
          "price_at_post": "60.50",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-10T01:55:46.156889+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20260946-D-Geeman-78259891",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.174673",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "It's like Lidl V's Sainsbury's, but if Lidl stock everything you want then go for it. I found the message from HL regarding their charges, soon to be changed: 'Trading / Dealing Fees: We are reducing the amount you pay to buy or sell shares with us, from \u00a311.95 to \u00a36.95 per online trade** We\u2019re introducing a charge of \u00a31.95 per trade to buy or sell funds online' Account charges: We are reducing our account charges* from 0.45% to 0.35% per year on Stocks and Shares ISA and Self-Invested Personal Pension (SIPP) accounts For Fund and Share Accounts, we are reducing account charges for holding funds, from 0.45% to 0.35% per year and we are introducing a charge of 0.35% to hold shares New account charge limits for shares (includes investment trusts, Exchange Traded Funds (ETFs) and bonds): You will never pay more than \u00a3150 per year in account charges* for holding shares in each of our SIPP, Stocks and Shares ISA or our Fund and Share Accounts Compare current vs future charges",
          "sentiment": 0.0,
          "engagement": "5,868",
          "price_at_post": "60.50",
          "thread_title": "RE: Trading 212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38EA914-FA00-4B19-B293-5E96B62D2062"
        },
        "ingested_at": "2026-02-10T01:55:46.156921+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20260930-Watching--8923166",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.175455",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "A  big pharma   can\u2019t afford not to take us over Who ever bids first will know they will become the market leader over night  with our science ! Imo it\u2019s going to happen very very quickly in 2026 . Hold or. Top up if funds allow Gla . Jane",
          "sentiment": 0.0,
          "engagement": "9,224",
          "price_at_post": "60.50",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-10T01:55:46.156954+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20260918-cj62-11129145",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.176169",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "Incalculable!!!",
          "sentiment": 0.0,
          "engagement": "4,302",
          "price_at_post": "60.50",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-10T01:55:46.156986+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20260859-Wilson63--4292053",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.176882",
        "source": "LSE_CHAT",
        "data": {
          "author": "Wilson63",
          "content": "Post by Tvr5 on X read this and consider being used for just one of these examples and what a fair price would be for the company. https://x.com/TVR5AVCT/status/2019678221504291189",
          "sentiment": 0.0,
          "engagement": "8,808",
          "price_at_post": "60.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-10T01:55:46.157018+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20260847-jackeste-74552631",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.177597",
        "source": "LSE_CHAT",
        "data": {
          "author": "jackester",
          "content": "They definitely do deal in Avacta.",
          "sentiment": 0.0,
          "engagement": "311",
          "price_at_post": "60.00",
          "thread_title": "RE: Trading 212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38EA914-FA00-4B19-B293-5E96B62D2062"
        },
        "ingested_at": "2026-02-10T01:55:46.157050+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20260811-JFK8-75653004",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.178308",
        "source": "LSE_CHAT",
        "data": {
          "author": "JFK8",
          "content": "Opened an account and closed it 20 minutes later as they dont deal  AVCT shares .don't know if they do now though as it was a while ago",
          "sentiment": 0.0,
          "engagement": "3,057",
          "price_at_post": "60.00",
          "thread_title": "RE: Trading 212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38EA914-FA00-4B19-B293-5E96B62D2062"
        },
        "ingested_at": "2026-02-10T01:55:46.157084+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20260125-russell1-75198284",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.179005",
        "source": "LSE_CHAT",
        "data": {
          "author": "russell1",
          "content": "Thanks for the helpful replies.",
          "sentiment": -0.5,
          "engagement": "318",
          "price_at_post": "60.00",
          "thread_title": "RE: Trading 212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38EA914-FA00-4B19-B293-5E96B62D2062"
        },
        "ingested_at": "2026-02-10T01:55:46.157132+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20262323-Toukanka--9448076",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.179705",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "More desperate ramping",
          "sentiment": 0.0,
          "engagement": "4,476",
          "price_at_post": "60.00",
          "thread_title": "RE: TAKEOVER",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=DAF752F5-FA6F-49F9-BD50-F5C834118B9E"
        },
        "ingested_at": "2026-02-10T01:55:46.157165+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20262100-cj62-27896987",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.180428",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "Put your head above the parapet have we touk. RH will probably have less influence than you, you prick.",
          "sentiment": 0.0,
          "engagement": "4,302",
          "price_at_post": "60.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-10T01:55:46.157196+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20262049-D-Geeman--8750521",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.181255",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "AI Overview Trading 212 (T212) and Hargreaves Lansdown (HL) offer starkly different approaches to trading Tiziana Life Sciences Ltd (NASDAQ: TLSA), with T212 focusing on low-cost, app-based trading, while HL provides a more traditional, comprehensive service with higher fees . T212 is generally better for frequent, small-value, or beginner trading due to zero-commission fees, while HL is often preferred for larger, long-term holdings and pensions. Comparison: Tiziana Life Sciences (TLSA) Trading Trading 212 (T212): Cost: Zero-commission trading on stocks and ETFs, though a 0.15% FX fee applies to non-GBP transactions. Features: Offers fractional shares, allowing for small investments in TLSA. CFD Trading: Offers long/short CFD trading on TLSA with leverage. Downsides: Limited research tools and no tax advice; users have reported wide spreads during volatile times for small-cap stocks. Hargreaves Lansdown (HL): Cost: High dealing charges (e.g., \u00a311.95 per deal), which can be costly for small trades. Features: Provides extensive research, analysis, and higher-quality, live, or more transparent pricing. Suitability: Better suited for holding larger, long-term positions or in a SIPP (pension).",
          "sentiment": 0.0,
          "engagement": "5,868",
          "price_at_post": "60.00",
          "thread_title": "RE: Trading 212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38EA914-FA00-4B19-B293-5E96B62D2062"
        },
        "ingested_at": "2026-02-10T01:55:46.157227+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20262041-D-Geeman-50989158",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.181977",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "I also have shares in $TLSA (formerly Tiziana PLC) which moved to the Nasdaq. People on the board for $TLSA.US have often complained about other brokers (I THINK Halifax amongst others) not allowing trades and I think people with 212 had there accustem shares sold against their will when they were spun-off to OTC. If AVCT do go on to the Nas I shall be happy to be with HL but each to their own.",
          "sentiment": 0.0,
          "engagement": "5,868",
          "price_at_post": "60.00",
          "thread_title": "RE: Trading 212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38EA914-FA00-4B19-B293-5E96B62D2062"
        },
        "ingested_at": "2026-02-10T01:55:46.157259+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20262026-IFA90-64437761",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.182574",
        "source": "LSE_CHAT",
        "data": {
          "author": "IFA90",
          "content": "I\u2019m no trader so 212 works for me. I just transferred a handful of Avacta shares across, took about 10 days. I\u2019ll move the rest soon. You can\u2019t dummy quote but I don\u2019t see any other downsides.",
          "sentiment": 0.0,
          "engagement": "415",
          "price_at_post": "60.00",
          "thread_title": "RE: Trading 212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38EA914-FA00-4B19-B293-5E96B62D2062"
        },
        "ingested_at": "2026-02-10T01:55:46.157291+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20262025-Icecool--4240825",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.183017",
        "source": "LSE_CHAT",
        "data": {
          "author": "Icecool",
          "content": "I hear what you\u2019re saying, and I get the excitement, but this is where biotech reality usually kicks in. Big pharma almost never forces an early move before human data unless they\u2019re facing an immediate strategic threat. AVA6103 is IND-cleared, which is huge, but it\u2019s still pre-human efficacy. That\u2019s exciting, not yet unavoidable. They are already in the data room and Avacta has made it clear they want to see human data on AVA6103 before they deal on that asset, everyone has to respect that. Right now BP doesn\u2019t need to rush or upset anyone to protect its position. They can stay close, sit in the data room, structure options, or wait for Phase 1 signals before committing real money with Avacta approval. That\u2019s how this industry normally works. The idea that retail holders could be quietly shaken out on the cheap also feels unlikely. Any hint of opportunistic behaviour would harden positions very quickly, not soften them. What the board is doing makes sense, build leverage before the power dynamic flips. Once AVA6103 shows even early human efficacy, urgency changes overnight and the tone of conversations changes with it.",
          "sentiment": 0.0,
          "engagement": "8,855",
          "price_at_post": "60.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-10T01:55:46.157322+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20262022-cj62-29833349",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.183465",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "Well I'm hoping that maybe 2 or 3 BP would like it but if all is well with ava6103 maybe go down the ARM route. 6 months and we should know",
          "sentiment": 0.0,
          "engagement": "4,302",
          "price_at_post": "60.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-10T01:55:46.157353+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261948-B2HS2L-77580819",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.183925",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "'That is extremely unlikely in biotech. As big pharma prefer to negotiate clean and keep everyone on side.' I hear what you say and generally agree. However, an opportunity like this occurs very infrequently. A successful purchase - however that occurs - confers market disruption and after commercialisation, competitive advantage upon the purchaser, with others making do with ADC development or resuming the search for new tech. This situation can't be brushed under the carpet. It's not what we would want, but you can't help seeing BP may want a deal sooner rather than later for a myriad of reasons. Pi**ing off the BoD might have to happen if one, or more than one BP are so keen to 'own it', or likely - make sure other BP's don't get a bargain in their efforts to 'own it'. There are a large number of PI's who could be easily persuaded to part with their shares at prices BP would definitely find attractive. It remains to be seen where and when the first bid arrives. The BoD are planning for the long haul, but let's hope they achieve as much as humanly possible before BP calls time on Avacta's progress.",
          "sentiment": 0.0,
          "engagement": "6,031",
          "price_at_post": "60.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-10T01:55:46.157385+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261935-D-Geeman--3686125",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.184434",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "I opened a 212 account a few years ago but don't use it. With HL your purchase happens immediately but with 212 it can take a while and goes thru in dribs and drabs (while the price is changing). Aren't HL lowering their dealing charges in April? I got a message and believe they are dropping to around \u00a36 for everyone (maybe more for some?) Maybe 212 are ok for bigger shares.",
          "sentiment": 0.0,
          "engagement": "5,868",
          "price_at_post": "60.00",
          "thread_title": "RE: Trading 212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38EA914-FA00-4B19-B293-5E96B62D2062"
        },
        "ingested_at": "2026-02-10T01:55:46.157418+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261920-Codejunk--7731590",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.184970",
        "source": "LSE_CHAT",
        "data": {
          "author": "Codejunkie",
          "content": "Pharma don't generally do hostile takeovers. They just pay the right price for the IP and make sure staff transfer over Hostile takeovers lose key staff....",
          "sentiment": 0.0,
          "engagement": "2,668",
          "price_at_post": "60.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-10T01:55:46.157451+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261916-russell1--8500754",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.185404",
        "source": "LSE_CHAT",
        "data": {
          "author": "russell1",
          "content": "Does anybody hold their Avacta shares with Trading 212? If so, is it easy to deal and are the prices comparable to other platforms. I use HL but am thinking about moving away.",
          "sentiment": -0.5,
          "engagement": "318",
          "price_at_post": "60.00",
          "thread_title": "Trading 212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38EA914-FA00-4B19-B293-5E96B62D2062"
        },
        "ingested_at": "2026-02-10T01:55:46.157483+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261857-cj62--7903020",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.185820",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "Its OK saying Hughes won't allow a low bid to be decided by shareholders, but what about a hostile bid. Any bid will be decided by the shareholders RH will have no say.",
          "sentiment": 0.0,
          "engagement": "4,302",
          "price_at_post": "60.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-10T01:55:46.157515+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261849-Icecool-23395895",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.186361",
        "source": "LSE_CHAT",
        "data": {
          "author": "Icecool",
          "content": "\u201cIt\u2019s OK saying Hughes won't allow a low bid to be decided by shareholders, but what about a hostile bid.\u201d That is extremely unlikely in biotech. As big pharma prefer to negotiate clean and keep everyone on side.",
          "sentiment": 0.0,
          "engagement": "8,855",
          "price_at_post": "60.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-10T01:55:46.157548+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261842-B2HS2L--2156212",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.187281",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "Bella ...Is the BOD in it for the long haul or would they simply take a good offer so they can move on to pastures new? I'm no longer thinking so much about how long it's going to take Avacta to achieve A,B or C. The nearer timelines we know about, but my point is how long are BP going to allow us to plough our own furrow? The more IP we pile up the larger amount SB rightly thinks the company is worth. These companies (with larger manpower & resources) will probably not want to proceed at Avacta's pace. Some will want faster development, and want their competitive advantage, with the purchase of all we have, to begin sooner. Others can't face a bigger purchase if left too long. Some BP will have funds available at different times as their priorities such as other projects will need to be factored into their timescales. Its OK saying Hughes won't allow a low bid to be decided by shareholders, but what about a hostile bid. There is no accounting for such a bid with completely opaque timescales. This is a market disruptive project and to a certain extent interested parties will want to move possibly sooner than we would wish. I don't see Avacta finishing what they started, but what do I know?",
          "sentiment": 0.0,
          "engagement": "6,031",
          "price_at_post": "60.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-10T01:55:46.157579+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261755-Metatron--8884980",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.188128",
        "source": "LSE_CHAT",
        "data": {
          "author": "Metatron",
          "content": "That's the spirit Watching2!! poor old Winnypoos is banging his drum as fast as he can but.. can he stay in time? I've spent half my life with those and asking a drummer to think? that's sublime...",
          "sentiment": 0.0,
          "engagement": "1,192",
          "price_at_post": "60.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-10T01:55:46.157611+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261725-opti_mys-74269711",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.188933",
        "source": "LSE_CHAT",
        "data": {
          "author": "opti_mystic",
          "content": "With RH on the BoD there is zero chance of Avacta being sold on the cheap. They have to put serious offers to shareholders but I guess it depends how serious is defined. Offering half what the company is worth is not a serious offer in my view. They could down tools today and sell the IP and they'd get a lot more than the current market cap.",
          "sentiment": 0.0,
          "engagement": "307",
          "price_at_post": "60.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-10T01:55:46.157643+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261717-cj62-77078701",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.189693",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "There is 0% CoS attached to the sp and that includes ava 6 k. Presently it would stand at 5 - 11% after the recent rns",
          "sentiment": 0.0,
          "engagement": "4,302",
          "price_at_post": "60.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-10T01:55:46.157674+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261710-Watching--7013306",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.190157",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "Winne bot has broken  free ! Ignore !",
          "sentiment": 0.0,
          "engagement": "9,224",
          "price_at_post": "60.50",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-10T01:55:46.157706+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261613-wyndrum-41493477",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.032149",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "\"Buyers don\u2019t care about today\u2019s SP, they care about what this asset can generate over a decade.\" do you think ever, before you post? If a buyer thinks this will be huge multiple in value then they buy as cheaply as they can which today would be 60p? Otherwise one would assume they are waiting for something... i dunno....maybe data from a trial yet to start? Also in response to where shareholders might sell: The SP would not be say, 500p per share from here on speculation. It would be on the back of very good results and data. It would be that data that would influence as to weather or not it would be sensible to sell.",
          "sentiment": 0.0,
          "engagement": "12,250",
          "price_at_post": "60.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-10T01:55:46.157737+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261556-Icecool-28634848",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.032939",
        "source": "LSE_CHAT",
        "data": {
          "author": "Icecool",
          "content": "If AVA6103 does what it\u2019s designed to do in humans, this isn\u2019t a few billion story. On any sensible biotech valuation framework (see my case study \ud83e\udd23\ud83d\ude09), you\u2019re talking tens of billions, not pocket change. That\u2019s total value paid, not based on some AIM screen price that flickers day to day. That\u2019s why the share price right now is basically irrelevant. Buyers don\u2019t care about today\u2019s SP, they care about what this asset can generate over a decade. Thankfully it also explains the strategy perfectly. Avacta is keeping AVA6103 solo for now because proving it in humans is where the real value unlock happens. You don\u2019t sell something like this on promise alone, you sell it when the risk collapses and the leverage flips. That\u2019s the play here. Prove it works in people, then let the numbers do the talking.",
          "sentiment": 0.0,
          "engagement": "8,855",
          "price_at_post": "61.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-10T01:55:46.157768+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261528-Timster--7621419",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.033717",
        "source": "LSE_CHAT",
        "data": {
          "author": "Timster",
          "content": "If CC brings anything less than \u00a3200 ex chi-nah, she'd be having a laugh!",
          "sentiment": 0.0,
          "engagement": "20,637",
          "price_at_post": "61.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-10T01:55:46.157800+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261523-cj62--2810965",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.034552",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "Directors cannot quietly reject a serious offer that could reasonably be of interest to shareholders once it becomes concrete. Their duty is to: Act in shareholders\u2019 best interests and Not frustrate an offer without shareholder approval",
          "sentiment": 0.0,
          "engagement": "4,302",
          "price_at_post": "61.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-10T01:55:46.157832+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261523-HarChris--4502656",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.035361",
        "source": "LSE_CHAT",
        "data": {
          "author": "HarChris",
          "content": "575m total share count feels a more realistic figure to be working with when forecasting future takeover share price so \u00a33B would be more like \u00a35.25 a share.",
          "sentiment": 0.0,
          "engagement": "15,923",
          "price_at_post": "61.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-10T01:55:46.157865+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261512-Bella653-74232959",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.036083",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "The BIG Questions are... Is the BOD in it for the long haul or  would they simply take a good offer so they can move on to pastures new? and how much are they will to hold out for?",
          "sentiment": 0.0,
          "engagement": "6,756",
          "price_at_post": "61.50",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-10T01:55:46.157899+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261507-Bella653-34097439",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.036656",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "I don't think you'll get anywhere near your SP wishlist on a T/O deal as we stand right now. Deals and NASDAQ Listing will drive value but we need some big hitters in the Finance World like Healthcare Royalty to back Avacta and to negotiate the best T/O deal possible at the right time.",
          "sentiment": 0.0,
          "engagement": "6,756",
          "price_at_post": "61.50",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-10T01:55:46.157931+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261505-hamsters-41545454",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.037073",
        "source": "LSE_CHAT",
        "data": {
          "author": "hamsters18",
          "content": "What large buys?",
          "sentiment": 0.0,
          "engagement": "3,692",
          "price_at_post": "61.50",
          "thread_title": "RE: TAKEOVER",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=DAF752F5-FA6F-49F9-BD50-F5C834118B9E"
        },
        "ingested_at": "2026-02-10T01:55:46.157964+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261449-Deod123--9159447",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.037518",
        "source": "LSE_CHAT",
        "data": {
          "author": "Deod123",
          "content": "Large buys going through.someone is stake building",
          "sentiment": 0.0,
          "engagement": "68",
          "price_at_post": "61.00",
          "thread_title": "TAKEOVER",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=DAF752F5-FA6F-49F9-BD50-F5C834118B9E"
        },
        "ingested_at": "2026-02-10T01:55:46.157996+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261438-cj62--4888222",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.037940",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "\u00a3200 ex china  Not this LTH",
          "sentiment": 0.0,
          "engagement": "4,302",
          "price_at_post": "61.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-10T01:55:46.158028+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261431-Wilson63--3275410",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.038378",
        "source": "LSE_CHAT",
        "data": {
          "author": "Wilson63",
          "content": "I'm somewhat surprised a couple of regulars are going to sell out at fairly low numbers, if this continues to pass each obstacle it's a one and only lifetime chance imho, topping up monthly slow and steady.",
          "sentiment": 0.0,
          "engagement": "8,808",
          "price_at_post": "60.50",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-10T01:55:46.158061+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261323-BuenaVis-68414929",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.038809",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Yes, the pre|CISION pie can be cut many ways: by drugs, indications and territories, and all with or without exclusivity.  People might say that faridox, with its boring old doxorubicin, will be overtaken by newer, more powerful pre|CISION drugs but the fact is it is here and now and not far off its first approved indication, salivary gland cancer, if the data released so far is to be believed. So with all that, why would any company want to license it when there could be better options in the future?  Well, if the offer was a global exclusive licence to develop faridox for SGC, plus the option to have first dibs on any future Avacta pre|CISION drug for SGC, plus the rights to develop their own pre|CISION drugs for SGC\u2014essentially an exclusive licence agreement to control the global pre|CISION SGC market\u2014then that would surely be of great interest. If it's taking Simon a long time to get that first deal, well the licensing possibilities are nearly endless and newly revealed data and developments are moving the goal posts in Avacta's favour all the time as conclusive evidence proves the platform (I'll call it that now already).",
          "sentiment": 0.0,
          "engagement": "5,826",
          "price_at_post": "59.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-10T01:55:46.158093+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261300-Vertizea--1961724",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.039250",
        "source": "LSE_CHAT",
        "data": {
          "author": "VertizeaSun",
          "content": "\u00a32 billion to buy a serious geographic licence for pre|CISION and a couple of warheads  sounds about right......say the EU/EEA and ex-ROW. Simon Bennett is now in his third year and the fact he hasn't been fired will suggest he has something up his sleeve. \u00a32B will pay for future independence and a \u00a31 per share dividend. I think we'll know within a couple of months and perhaps sooner as CC is obviously in town (doing celebratory cake delivery) and probably here for a board meeting - where they'll be trying to digest the recent torrent of good news. They actually have a lot on their plate. But I'm having trouble digesting \"the removal of the maximum dosing limit\" ...... apparently the first time in history for a phase 1 trial compound so I'm quite happy to believe that eventually pre|CISION is going to be compared to the impact penicillin had on the world of medicine. And in the beginning that discovery had serious FUD. Bill Gates said that the world always over-estimates how much change can take place in six months, but under-estimates how much change will take place in six years.",
          "sentiment": 0.0,
          "engagement": "440",
          "price_at_post": "59.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-10T01:55:46.158175+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261259-Matml74--4329047",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.039673",
        "source": "LSE_CHAT",
        "data": {
          "author": "Matml74",
          "content": "Dolly, Watch the R&D spotlight episode on next generation Precision from 2024 and also the dual payload one from late 2025. These highlight the vast opportunity for Precision.",
          "sentiment": 0.0,
          "engagement": "2,547",
          "price_at_post": "59.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-10T01:55:46.158208+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261252-opti_mys--4469962",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.040082",
        "source": "LSE_CHAT",
        "data": {
          "author": "opti_mystic",
          "content": "Oh yea of little faith. \u00a310 is my absolute bare minimum from when I first invested. Due to progress on a number of fronts that has gone up. Somewhat disappointed that people would sell so cheaply. Hopefully the BoD know what the company is worth and will not put to shareholders derisory offers that significantly under values the company.",
          "sentiment": 0.0,
          "engagement": "307",
          "price_at_post": "59.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-10T01:55:46.158240+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261249-Dollyg--5760220",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.040506",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dollyg",
          "content": "Thank you",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "59.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-10T01:55:46.158272+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261239-yeboha-36150305",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.040920",
        "source": "LSE_CHAT",
        "data": {
          "author": "yeboha",
          "content": "Dolly if you do some research online you can see that many professionals in the field agree that it can be used on many drugs !",
          "sentiment": 0.0,
          "engagement": "963",
          "price_at_post": "59.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-10T01:55:46.158304+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261237-yeboha--8449089",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.041383",
        "source": "LSE_CHAT",
        "data": {
          "author": "yeboha",
          "content": "Avacta\u2019s pipeline includes several distinct pre|CISION\u00ae drug conjugates with different therapeutic payloads, not just a single product: AVA6000 (a doxorubicin-based peptide drug conjugate) has shown positive clinical progress. AVA6103 (exatecan-based PDC) is advancing toward clinical trial start. Dual-payload PDCs are being developed in preclinical stages, combining agents like microtubule inhibitors and DNA damage response modulators. Another pipeline program, AVA7100 (an Affimer\u00ae-based drug conjugate), is also in preclinical development with its own payload delivery design. \ud83d\udccc Why this matters: This demonstrates that Avacta\u2019s platform isn\u2019t limited to a single drug but is being developed as a modular engine for multiple therapeutic combinations and individual payloads",
          "sentiment": 0.0,
          "engagement": "963",
          "price_at_post": "59.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-10T01:55:46.158337+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261231-Dollyg--4463357",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.041792",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dollyg",
          "content": "Be good to get a medically qualified opinion of the ACTUAL potential of how many differing treatments this technology could affect.",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "59.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-10T01:55:46.158371+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261227-Livedata-78387893",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.042216",
        "source": "LSE_CHAT",
        "data": {
          "author": "Livedataaccount",
          "content": "Hi jane im out at 4 pounds if it gets there",
          "sentiment": 0.0,
          "engagement": "2,969",
          "price_at_post": "59.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-10T01:55:46.158403+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261225-yeboha--5918730",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.042623",
        "source": "LSE_CHAT",
        "data": {
          "author": "yeboha",
          "content": "Its funny we say this, being where the share price is but im so convinced about avacta and have been for years !",
          "sentiment": 0.0,
          "engagement": "963",
          "price_at_post": "59.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-10T01:55:46.158433+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261221-Watching-84960436",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.043037",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "Happy with \u00a37 pre share. But \u00a310 would be a nice surprise . Jane",
          "sentiment": 0.0,
          "engagement": "9,224",
          "price_at_post": "59.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-10T01:55:46.158465+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261213-Dollyg-86059128",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.043462",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dollyg",
          "content": "I read the \u00a33 billion figure was first mooted in 2023 and they seem to have come a long way since then in terms of efficacy. The concensus seens to be wait.",
          "sentiment": 0.5,
          "engagement": "8",
          "price_at_post": "59.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-10T01:55:46.158496+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261212-yeboha-67250023",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.043874",
        "source": "LSE_CHAT",
        "data": {
          "author": "yeboha",
          "content": "Thats roughly my thinking",
          "sentiment": 0.0,
          "engagement": "963",
          "price_at_post": "59.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-10T01:55:46.158527+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261209-BuenaVis--8163790",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.044290",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "$4bn would be 668p a share.  Not enough for me.  I'd be looking for at least 1,000p a share, a $6bn buyout.  At least.",
          "sentiment": 0.0,
          "engagement": "5,826",
          "price_at_post": "59.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-10T01:55:46.158558+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20262313-aidanjc--2910865",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.524270",
        "source": "LSE_CHAT",
        "data": {
          "author": "aidanjc",
          "content": "Good point.  If cancer treatments improve that is a fantastic result. Its crept into my life a lot recently. Great to make a profit on the shares but improving outcomes for cancer patients is really important.",
          "sentiment": 0.0,
          "engagement": "6",
          "price_at_post": "51.50",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-10T01:55:46.158592+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20262051-avctIPma-37264448",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.524706",
        "source": "LSE_CHAT",
        "data": {
          "author": "avctIPmatters",
          "content": "Thanks for sharing  B2HS2L  -  Helps spread info on the platform  .",
          "sentiment": 0.0,
          "engagement": "728",
          "price_at_post": "51.50",
          "thread_title": "RE: CDD European Life Science Community Meeting",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=3A2F031D-C16F-4949-B22E-8512255BE282"
        },
        "ingested_at": "2026-02-10T01:55:46.158624+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20262049-avctIPma--3832473",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.525140",
        "source": "LSE_CHAT",
        "data": {
          "author": "avctIPmatters",
          "content": "Thanks for sharing  Thompi -  All helps spread   Avacta exposure .",
          "sentiment": 0.0,
          "engagement": "728",
          "price_at_post": "51.50",
          "thread_title": "RE: World CB & CDx Summit Europe",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=18E94451-D174-452E-BD8A-79154E17863F"
        },
        "ingested_at": "2026-02-10T01:55:46.158655+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20262022-Livedata-32625054",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.525565",
        "source": "LSE_CHAT",
        "data": {
          "author": "Livedataaccount",
          "content": "Ellen's great she will do a fantastic presentation",
          "sentiment": 0.0,
          "engagement": "2,957",
          "price_at_post": "51.50",
          "thread_title": "RE: CDD European Life Science Community Meeting",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=3A2F031D-C16F-4949-B22E-8512255BE282"
        },
        "ingested_at": "2026-02-10T01:55:46.158687+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20262016-B2HS2L--6906208",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.525997",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "Https://www.collaborativedrug.com/cdd-european-scientific-community-meeting-2026 Dr Ellen Watts, Avacta Therapeutics 25.02.2026  17:00-17:30: Delivering Targeted Therapies Using the pre|CISION\u00ae Platform. Last presentation of the day",
          "sentiment": 0.0,
          "engagement": "6,003",
          "price_at_post": "51.50",
          "thread_title": "CDD European Life Science Community Meeting",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=3A2F031D-C16F-4949-B22E-8512255BE282"
        },
        "ingested_at": "2026-02-10T01:55:46.158718+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261732-Timster-63508533",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.526420",
        "source": "LSE_CHAT",
        "data": {
          "author": "Timster",
          "content": "Good spot Thompi, thanks",
          "sentiment": 0.0,
          "engagement": "20,626",
          "price_at_post": "51.50",
          "thread_title": "RE: World CB & CDx Summit Europe",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=18E94451-D174-452E-BD8A-79154E17863F"
        },
        "ingested_at": "2026-02-10T01:55:46.158751+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261722-Thompi-38276347",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.526848",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thompi",
          "content": "Ruairidh Edwards will be speaking on 1 April at the 16th World Clinical Biomarkers & Companion Diagnostics Summit Europe. Presentation title: Establishing a Biomarker-Driven Approach to Guide Patient Selection for preCISION\u00ae Peptide-Drug Conjugates Using Tumour Targeting/Release and Payload Sensitivity Biomarkers. https://cdx-europe.com/full-event-guide/",
          "sentiment": 0.0,
          "engagement": "1,358",
          "price_at_post": "51.50",
          "thread_title": "World CB & CDx Summit Europe",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=18E94451-D174-452E-BD8A-79154E17863F"
        },
        "ingested_at": "2026-02-10T01:55:46.158784+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261707-Agenda10-29699119",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.527323",
        "source": "LSE_CHAT",
        "data": {
          "author": "Agenda101",
          "content": "No not engage ! It\u2019s working so let\u2019s continue to starve them of any engagement. As Runner-Runner wrote and BV reposted\u2026 It's simple. 1. DO NOT ENGAGE 2. DO NOT ASK IT A QUESTION 3. DO NOT ANSWER ITS QUESTIONS 4. DO NOT MOAN ABOUT ITS POSTS 5. DO NOT ARGUE WITH IT 6. If you must do something. Mock it with reference only to its stupidity and nothing else. ------------------------------------------------------ If you're not part of the solution, you're part of the problem",
          "sentiment": 0.0,
          "engagement": "72",
          "price_at_post": "52.50",
          "thread_title": "RE: Bone Marrow Toxicity, Brain malignancies?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=34DD9B68-3AA3-4F24-A8A5-8F742D7F4948"
        },
        "ingested_at": "2026-02-10T01:55:46.158817+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261704-Agenda10-21508118",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.527740",
        "source": "LSE_CHAT",
        "data": {
          "author": "Agenda101",
          "content": "\u201cI\u2019m committed for the next two years, but I anticipate that developments around licensing, manufacturing, and supply will begin to materialise well before then. From my perspective, the time to push ahead is now.\u201d",
          "sentiment": 0.0,
          "engagement": "72",
          "price_at_post": "51.50",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-10T01:55:46.158850+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261656-Thornogs--5771286",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.528205",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Well I didn't post! Not much said I see. More chat about FAP expressed on inflamed/fibrotic tissue other than cancer as a positive therapeutic opportunity with no one wondering if this self same tissue might cause problems should someone inject a FAP released 'Beast' into the circulation whilst trying to target a FAP related cancer.  Were that to happen in the FAP-EXD 1a Safety trial I think it would count as a Black Mark. BV and Syphysus indulged their in depth knowledge of molecular biology and the Blood Brain Barrier to 'deep dive' the potential to treat cerebral cancers, I do hope CC read those posts or perhaps one of you could send her an e mail explaining the possibilities? And the Market did what I thought it would do, go down, down the at the last come back up to almost, but not quite, where we opened. 1% down today, 3% this week and 10% down on the month. I see this continuing until the surprise deal mentioned earlier or being more realistic the next raise to fund the programme through 2026. Any thoughts on support/resistance levels Wyn? Happy to be out waiting for FAP-EXD and funding doubts to clear.",
          "sentiment": 0.0,
          "engagement": "8,666",
          "price_at_post": "51.50",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-10T01:55:46.158882+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261643-wyndrum-48613156",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.528628",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "I see \u201cthe don\u2019t engage\u201d policy didn\u2019t last long. You simply can\u2019t have a bb devoted to the actual topic and miss out on insulting others can you? Predictable and pathetic behaviour. Who knew?",
          "sentiment": 0.0,
          "engagement": "12,228",
          "price_at_post": "51.50",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-10T01:55:46.158915+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261640-D-Geeman-29292501",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.529049",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "'Chris, are you still interested in my buys and sells or would you prefer me not to bother?' Chris might not be interested Wyn, but I am... I dare say I'm not alone either.",
          "sentiment": 0.0,
          "engagement": "5,849",
          "price_at_post": "51.00",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-10T01:55:46.158948+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261639-Toukanka--6684202",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.529486",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "BV Are you a lawyer? We were led to believe that 6000 P1b would finish end of 25. So you don\u2019t regard having to go an extra cycle as missing a target. Or all the talk of multiple events before end 25 as not materialising. Anyhow at least some people on here are rooted in reality and believe CC when she says not to expect much before 2H26. Be. Patient",
          "sentiment": 0.0,
          "engagement": "4,454",
          "price_at_post": "51.00",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-10T01:55:46.158980+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261631-cj62-33059512",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.529902",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "Fine with me Chris. I would remind you however that it was you that asked I report my trades. You did report your last losing trade though did you, you prick",
          "sentiment": 0.0,
          "engagement": "4,282",
          "price_at_post": "51.50",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-10T01:55:46.159013+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261628-BuenaVis-18164307",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.530336",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Yes, that could be one possibility.",
          "sentiment": 0.0,
          "engagement": "5,775",
          "price_at_post": "51.50",
          "thread_title": "RE: Bone Marrow Toxicity, Brain malignancies?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=34DD9B68-3AA3-4F24-A8A5-8F742D7F4948"
        },
        "ingested_at": "2026-02-10T01:55:46.159046+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261622-wyndrum-75597441",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.530749",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "Fine with me Chris. I would remind you however that it was you that asked I report my trades. Anyway I\u2019m keen to see how this bb goes from here.",
          "sentiment": 0.0,
          "engagement": "12,228",
          "price_at_post": "51.50",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-10T01:55:46.159077+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261615-HarChris--4256484",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.531177",
        "source": "LSE_CHAT",
        "data": {
          "author": "HarChris",
          "content": "The last time I pointed out your losing trade you responded by saying you barely had anything on it\u2026 so nah, don\u2019t bother if you can just twist it how you want. And it clogs up the bb even more! How about not sharing any and trying not to care what an anonymous group of people think about your trading prowess?! That would be healthier!",
          "sentiment": 0.0,
          "engagement": "15,870",
          "price_at_post": "51.50",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-10T01:55:46.159122+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261613-Agenda10-68626717",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.531589",
        "source": "LSE_CHAT",
        "data": {
          "author": "Agenda101",
          "content": "None.. he\u2019s fishing don\u2019t reply!",
          "sentiment": 0.0,
          "engagement": "72",
          "price_at_post": "51.50",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-10T01:55:46.159157+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261547-BuenaVis--6083753",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.532000",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "@russell1 , what deadlines has Avacta missed since CC became CEO on 1 May 2024?",
          "sentiment": 0.0,
          "engagement": "5,775",
          "price_at_post": "51.00",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-10T01:55:46.159189+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261536-russell1-84505407",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.532426",
        "source": "LSE_CHAT",
        "data": {
          "author": "russell1",
          "content": "Well I'm not prepared to add any more money to my current loss situation so my only decision is whether to sell a proportion of my holding and hope I can buy back at a lower price if we (ever) get some worthwhile news or just leave it and hope! My expectation is that the price will just drift down until any news arrives but I have no expectation that this company will ever meet any of its reported deadlines.",
          "sentiment": -0.5,
          "engagement": "315",
          "price_at_post": "51.00",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-10T01:55:46.159221+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261529-Sisyphus--5822807",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.532837",
        "source": "LSE_CHAT",
        "data": {
          "author": "SisyphusShorter",
          "content": "Thanks BV, good to know. So in theory, a \"FAP-Temo\" agent would be roughly 460Da in size, provided the same Gen1 preCISION peptide is used. That puts it within the 400-600 threshold for BBB-crossing possibility (obviously notwithstanding lipophilicity, polarity and other parameters). That being said they could always cleave off a few residues to make a lightweight version for this specific indication.",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "51.00",
          "thread_title": "RE: Bone Marrow Toxicity, Brain malignancies?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=34DD9B68-3AA3-4F24-A8A5-8F742D7F4948"
        },
        "ingested_at": "2026-02-10T01:55:46.159254+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261509-Toukanka-53501341",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.533258",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "At last sensible posters instead of the usual carp \u201cfill yer boots you\u2019ll never again get the chance at this SP\u201d.  In truth we have a sideways drift until 6103 early clinical results are published in the Summer. Get over it and be patient.",
          "sentiment": 0.0,
          "engagement": "4,454",
          "price_at_post": "51.00",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-10T01:55:46.159287+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261432-wyndrum--3774274",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.533670",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "Chris, are you still interested in my buys and sells or would you prefer me not to bother?",
          "sentiment": 0.0,
          "engagement": "12,228",
          "price_at_post": "51.00",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-10T01:55:46.159318+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261413-Aston15-20548267",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.534076",
        "source": "LSE_CHAT",
        "data": {
          "author": "Aston15",
          "content": "I have brought enough now to be comfortable with the risk to reward ratio. 10% of my SIPP now in AVCT following another purchase this week. Many are expecting more than this, but my target remains a 5 billion valuation for the platform minimum. Happy to leave this to run now and hope the team delivers a positive outcome for both patients and shareholders.",
          "sentiment": 0.0,
          "engagement": "62",
          "price_at_post": "50.50",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-10T01:55:46.159348+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261410-B2HS2L--2832812",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.534502",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "Slide 16 & 18 of the Investormeet presentation 17.12.2025 contain info on tumor biopsies as articulated by Ruairidh Edwards, Translational Scientist. He's discussing phase 1b patients, possibly placing the recording of the interview before mid December.",
          "sentiment": 0.0,
          "engagement": "6,003",
          "price_at_post": "50.50",
          "thread_title": "RE: Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-02-10T01:55:46.159378+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261347-Vertizea-78157028",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.529148",
        "source": "LSE_CHAT",
        "data": {
          "author": "VertizeaSun",
          "content": "I think it links with CC's visit to Glasgow.....to visit the manufacturing site of AVA6103 and its \"first pour\".",
          "sentiment": 0.0,
          "engagement": "433",
          "price_at_post": "50.50",
          "thread_title": "RE: Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-02-10T01:55:46.159410+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261340-BuenaVis-71185975",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.529619",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Whilst the introduction by the host was current (post-IND announcement), CC seemed to be referencing passed events as being in the future and someone here suggested that the interview was recorded last year, in early December if I remember correctly.  I haven't listened to the interview again today but I do remember hearing bits that seemed out of step with today's situation.",
          "sentiment": 0.0,
          "engagement": "5,775",
          "price_at_post": "50.50",
          "thread_title": "RE: Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-02-10T01:55:46.159441+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261326-BuenaVis--5713033",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.530089",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Interesting and intelligent quesitions. As regards, fibrotic targets due to prior anthracycline treatment, it'll be interesting to see whether this side effect is reduced in previously untreated patients.  The breakdown of side effects vs prior treatment hasn't been presented yet but it is exacty the sort of detail I'm wanting to see (also, for example, side effects vs cancer indication/metastasis site).  Hopefully it will be included when the Phase 1 trial is written up in a peer-reviewed article, but there's always the AGM as an opportunity for asking detailed questions in person. As regards crossing the blood-brain barrier (BBB)... Temozolomide - molecular weight: 194.15 Da Doxorubicin - molecular weight: 543.52 Da Faridoxorubicin - molecular weight: 816.8 Da Faridoxorubicin without doxorubicin: 273.28 Da According to Gemini, \"Drugs that cross the BBB generally must be lipophilic (lipid-soluble), have a low molecular weight\u2014typically under 400\u2013600 Da\u2014and have a low polar surface area or few hydrogen bonds. They must avoid active efflux transport systems (like P-glycoprotein) and not be highly bound to plasma proteins.\"  So the requirements for an IV infusion drug are pretty stringent. However, there is an alternative route and that is, again according to Gemini, \"[administration] directly into the brain to bypass the BBB. This approach, known as local or regional drug delivery, is used to treat primary brain tumors (like glioblastoma) or brain metastases, allowing high concentrations of medication to reach the tumor without causing systemic toxicity.\"  I should think that the advantage of using pre|CISION for this is that, whilst the pre|CISION drug itself would be too big to cross OUT of the brain, the warhead, its metabolites and the leaving group from the pre|CISION substrate could all be below the size needed to cross out of the brain.  Anyway, CC wouldn't have specifically mentioned brain cancer if it weren't a possibility.",
          "sentiment": 0.0,
          "engagement": "5,775",
          "price_at_post": "50.50",
          "thread_title": "RE: Bone Marrow Toxicity, Brain malignancies?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=34DD9B68-3AA3-4F24-A8A5-8F742D7F4948"
        },
        "ingested_at": "2026-02-10T01:55:46.159474+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261318-IFA90-14187171",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.530517",
        "source": "LSE_CHAT",
        "data": {
          "author": "IFA90",
          "content": "I\u2019m not buying anymore. I\u2019ve increased my holding this week by selling a % and buying back c.10% cheaper. After 5 years it\u2019s entirely predictable, I just wish I\u2019d have realised that 3 years ago.",
          "sentiment": 0.0,
          "engagement": "409",
          "price_at_post": "50.50",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-10T01:55:46.159506+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261312-wyndrum-73460582",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.530949",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "Yes cj and I have just literally sold that holding and more as it looks to confused to me right now. Just so you know and can keep up I placed the sale evenly between Cpx and Xsg. Personally I would enjoy exploring and explaining my reasoning in a bit more depth but no need to is interested. ( and while you may all feel a bit more smug about this, it might be worth reflecting that I don\u2019t illicit the antagonist relationship here on other bb\u2019s. It begs the question is it me or you?)",
          "sentiment": 0.0,
          "engagement": "12,228",
          "price_at_post": "50.50",
          "thread_title": "RE: ADC 26",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=F3B63190-B417-42B7-9CC8-0ED98F4FBB92"
        },
        "ingested_at": "2026-02-10T01:55:46.159538+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261301-cj62--2785825",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.531376",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "\"Well the sp is 52p and now years later my analysis over a vey long period has proved correct and his wrong.\" but not recently you could have added- bought at 56.95 i believe. Yet still there are some that want me to be cancelled, yep you have that 100% correct as your narcissim knows no bounds",
          "sentiment": 0.0,
          "engagement": "4,282",
          "price_at_post": "50.50",
          "thread_title": "RE: ADC 26",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=F3B63190-B417-42B7-9CC8-0ED98F4FBB92"
        },
        "ingested_at": "2026-02-10T01:55:46.159570+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261254-Sisyphus-77202576",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.531796",
        "source": "LSE_CHAT",
        "data": {
          "author": "SisyphusShorter",
          "content": "So been looking at the phase 1 data for AVA6000 and also been listening to the podcast, thanks BV. Now I have two broad questions: One on bone/haem side effects, and one regarding primary brain cancers. Firstly, of the patients we have seen with bone marrow suppression, I know it's a known side effect of Dox, but I do wonder if prior primary therapies have induced a bit of fibrosis in the marrow, leading to FAP expression and thus Dox being released, leading to further bone marrow toxicity. That would imply that the side effects seen in the patients so far are less likely to emerge in a larger trial with a higher proportion of chemo-naive patients. Thoughts? Secondly, CC mentioned in the podcast that given that 90% of solid tumours express FAP, including brain, which she mentioned, and this begs the question whether or not the Peptide used in pre/CISION drug conjugates is small enough to pass the blood-brain-barrier, after all, that's how Temozolomide can do it's think for brain tumours. Again, thoughts?",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "50.50",
          "thread_title": "Bone Marrow Toxicity, Brain malignancies?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=34DD9B68-3AA3-4F24-A8A5-8F742D7F4948"
        },
        "ingested_at": "2026-02-10T01:55:46.159602+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261253-pedrolan-61695094",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.532225",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Yes, I bought some more the other week and am considering more now to get my average down further. If you believe in the medium term story here (with the bonus of a potential deal at any time) then it seems a bargain. Before any of the aliases bother to reply - I will not be responding to it - it will not be anything we have not all heard multiple times anyway.",
          "sentiment": 0.5,
          "engagement": "1,975",
          "price_at_post": "51.00",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-10T01:55:46.159634+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261252-BuenaVis--7231615",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.532633",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Another advantage of Avacta's PDCs is the h o m ogeneity of the dosage - exactly one warhead per drug molecule, or exactly two warheads per drug molecule for the dual payload drugs. In contrast, significant heterogeneity exists in ADCs as they are complex mixtures of varied molecular species rather than a single uniform compound. This includes differences in the drug-to-antibody ratio (DAR) and the conjugation sites on the antibody, leading to mixtures with 0 to 8+ payload molecules and various positional isomers.",
          "sentiment": 0.0,
          "engagement": "5,775",
          "price_at_post": "51.00",
          "thread_title": "RE: ADC 26",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=F3B63190-B417-42B7-9CC8-0ED98F4FBB92"
        },
        "ingested_at": "2026-02-10T01:55:46.159665+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261250-aidanjc--2581465",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.533041",
        "source": "LSE_CHAT",
        "data": {
          "author": "aidanjc",
          "content": "I've been a lth here having bought at several levels. Was hoping not to see us back around the 50p level. I've bought a few more. Anyone else buying. I'm hoping 50p will be the low tide mark...",
          "sentiment": 0.5,
          "engagement": "6",
          "price_at_post": "51.00",
          "thread_title": "Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-10T01:55:46.159696+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261246-wyndrum--1753427",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.533480",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "Also I don\u2019t care if you respond or not. I just hope it makes you think.also you will crack before we do. Not because it\u2019s a contest but simply we will ask questions or post opinions that as a bb you will naturally want to respond to. That\u2019s the whole purpose of a discussion bb. To discuss. And while there are a lot of recs to want us to be cancelled you will soon be bored with the lack of insight offered by the so called guardians of this bb. And never forget, it is exactly the same posters that by insulting us that then generate the board clogging are the ones piously demanding we be ignored. Just check sheppy watching bv and the rest for their overall contribution.",
          "sentiment": 0.0,
          "engagement": "12,228",
          "price_at_post": "51.00",
          "thread_title": "RE: ADC 26",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=F3B63190-B417-42B7-9CC8-0ED98F4FBB92"
        },
        "ingested_at": "2026-02-10T01:55:46.159727+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261243-Sisyphus-81075175",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.533883",
        "source": "LSE_CHAT",
        "data": {
          "author": "SisyphusShorter",
          "content": "Sorry, *Next* data release....",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "51.00",
          "thread_title": "RE: Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-02-10T01:55:46.159760+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261240-Sisyphus-21790776",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.534310",
        "source": "LSE_CHAT",
        "data": {
          "author": "SisyphusShorter",
          "content": "At 36:22 CC says, regarding tumour biopsies - \"...in our new data release which will be later this month...\" Make of that what you will..... GLA",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "51.00",
          "thread_title": "RE: Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-02-10T01:55:46.159792+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261232-wyndrum--6437938",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.534763",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "Oh, I remember, after this interview and the other stuff uncovered, what has the sp done? Why ,  How, can there be more sellers than buyers? Let\u2019s move on from the \u201csp doesn\u2019t matter \u201c. It\u2019s a facile statement which simply refuses to address a perfectly reasonable question. Yes the sp can drift up or down on no news but why can\u2019t we discuss it when there is a very positive release and it generates sells? By all means keep up this do not engage but myles tried this with me specifically on this bb with a little header to try and get me banned altogether. Well the sp is 52p and now years later my analysis over a vey long period has proved correct and his wrong. Yet still there are some that want me to be cancelled. You lot are either just plain weird or it is you that have an agenda. Just remember I have made money out of this stock and had you agreed with my view you would have too. The opposite would have happened if you followed bv and the rest. Yet you want me silenced. You might perhaps realise why I wonder what motivates the majority here.",
          "sentiment": 0.0,
          "engagement": "12,228",
          "price_at_post": "51.00",
          "thread_title": "RE: ADC 26",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=F3B63190-B417-42B7-9CC8-0ED98F4FBB92"
        },
        "ingested_at": "2026-02-10T01:55:46.159823+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261221-Watching-84841884",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.535189",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "To the Fudders they are trying so hard this morning ! It worked yesterday ! They are drying up \ud83e\udd21s",
          "sentiment": 0.0,
          "engagement": "9,215",
          "price_at_post": "51.00",
          "thread_title": "Do not respond",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=598797E4-B255-4509-971C-C103D6214E00"
        },
        "ingested_at": "2026-02-10T01:55:46.159855+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261143-wyndrum-85647133",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.535610",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "whatever you do, do not do not reply  or respond. you might want to take the ****, but resist. you might have the best put down ever! but do not repeat do not respond  got it? now what was i going to say\u2026. damn after all that i forgot \u2026.,",
          "sentiment": 0.0,
          "engagement": "12,228",
          "price_at_post": "52.00",
          "thread_title": "RE: ADC 26",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=F3B63190-B417-42B7-9CC8-0ED98F4FBB92"
        },
        "ingested_at": "2026-02-10T01:55:46.159887+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261014-HarryAng-50931094",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.536027",
        "source": "LSE_CHAT",
        "data": {
          "author": "HarryAngstrom",
          "content": "I meant PEAK SALES to Avacta... not TAM.",
          "sentiment": 0.0,
          "engagement": "9",
          "price_at_post": "52.50",
          "thread_title": "RE: Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-02-10T01:55:46.159919+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260955-D-Geeman--1196067",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.536554",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "'Today 09:44 Don't waste time responding if your handle is ........ D-Geeman ' You sound like a teenager with a statement like that B2HS2L. In this context that isn't a compliment.",
          "sentiment": 0.0,
          "engagement": "5,849",
          "price_at_post": "53.00",
          "thread_title": "RE: ADC 26",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=F3B63190-B417-42B7-9CC8-0ED98F4FBB92"
        },
        "ingested_at": "2026-02-10T01:55:46.159952+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260946-HarryAng-65277968",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.537041",
        "source": "LSE_CHAT",
        "data": {
          "author": "HarryAngstrom",
          "content": "This is a gigantic opportunity. TAM for Rhematoid Arthritis would be between $3.0 - $4.0 billion. And if they move into Fibrosis, the TAM there is between $7.0 - $10.0 billion. Once they prove they can deliver a toxin as potent as Exatecan using the FAP linker, using the same linker for milder anti-fibrotic or anti-inflammatory drugs is a low risk, high reward certainty.",
          "sentiment": 0.0,
          "engagement": "9",
          "price_at_post": "52.50",
          "thread_title": "RE: Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-02-10T01:55:46.159985+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260944-B2HS2L--6279236",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.537575",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "Don't waste time responding if your handle is wyndrum, Thornogson, Toukankahmoon or D-Geeman ********************************************************************************************************* Like my new header?  \ud83d\ude01\ud83d\ude09   I hope you create similar. In the event one company buys Avacta, all others will need to continue developing ADC's. They'll need to make improvements to compete as follows: 1 Reduce the time required to develop new drugs. 2 Improve the precision of targeting of warheads, so less drug is available systemically. 3 Improve the ease and speed of manufacturing 4 Find ways to reduce particle size 5 Find ways to deliver >1 drug at a time. Also - * Small molecule manufacturing and timeline/COGM (cost of goods manufactured) \"What that statement means and why that is important, is that the price tag for this drug (AVA6000), is one tenth of the price tag for an ADC drug. ADC's cost a lot of money in the clinic\"  CC 8.11.2024 I don't see why the statement isn't also true for AVA6103. ++++ A reminder from  Trinity Delta \u2013 Targeting the tumour microenvironment with pre|CISION - 18.11.2024 https://www.trinitydelta.org/research-notes/targeting-the-tumour-microenvironment-with-precision/ \"Avacta has so far FAP-enabled ten different warheads building up a database of multiple pre|CISION compounds that include c 40 capping groups (which alter the PK of the conjugate) and c 20   linkers (required for FAP cleavage with certain warheads and can be used to modify FAP affinity and activity). These have all been characterised through computational simulations to evaluate molecular binding and how they dock into the FAP structure. A key consideration is how close the warhead can get to the FAP cleavage sequence; this typically depends on the size of the molecule, and often defines whether a spacer group is required. Consideration is also given to how long the conjugate and the active warhead are likely to remain in the TME, and this informs whether PK alterations, achieved through an alternative capping group, are needed to either allow the sustained release of the warhead or to slow plasma clearance. Potential candidate molecules that meet the internal hurdle are also evaluated in vivo to investigate key PK parameters and cytotoxicity, with some selected for further characterisation in vitro and in vivo to establish preclinical efficacy and safety in a wide range of FAP tumour expression models with low serum FAP (including co-cultures of tumour cells and CAFs) to recapitulate the human TME.\" ++++ I'll bet there is more than ten warheads, forty capping groups and twenty linkers now!",
          "sentiment": 0.0,
          "engagement": "6,003",
          "price_at_post": "53.00",
          "thread_title": "RE: ADC 26",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=F3B63190-B417-42B7-9CC8-0ED98F4FBB92"
        },
        "ingested_at": "2026-02-10T01:55:46.160017+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260931-BuenaVis-26166819",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.537985",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Really does feel like adding Go Faster stripes at a horse fair.",
          "sentiment": 0.0,
          "engagement": "5,775",
          "price_at_post": "53.00",
          "thread_title": "RE: ADC 26",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=F3B63190-B417-42B7-9CC8-0ED98F4FBB92"
        },
        "ingested_at": "2026-02-10T01:55:46.160050+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260910-Yorkshir-84658563",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.538411",
        "source": "LSE_CHAT",
        "data": {
          "author": "Yorkshirepragma",
          "content": "CC refers to other applications \u2026Chronic Inflammation \u2018conversations\u2019 are interesting . One step at a time \u2026.",
          "sentiment": 0.0,
          "engagement": "1,804",
          "price_at_post": "53.00",
          "thread_title": "RE: Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-02-10T01:55:46.160088+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260845-Yorkshir-63492836",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.538852",
        "source": "LSE_CHAT",
        "data": {
          "author": "Yorkshirepragma",
          "content": "Fascinating similarity re Avactas current development processes. Tuesday 24th February 2026 The Next Generation of ADCs: Leveraging Novel Conjugation & Enhanced Antibody Engineering for the Future of Targeted Oncology Therapies 9:15 am Laying out the scope to differentiate ADC development through novel conjugation, antibody engineering, and target identification approaches to widen therapeutic index and bring patient benefit Incorporating in silico and AI tools to enhance the ADC discovery toolbox and deliver next-generation ADC engineering and design Highlighting future priorities for next-generation ADC development, including exploring the potential of radio conjugates",
          "sentiment": 0.0,
          "engagement": "1,804",
          "price_at_post": "53.00",
          "thread_title": "ADC 26",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=F3B63190-B417-42B7-9CC8-0ED98F4FBB92"
        },
        "ingested_at": "2026-02-10T01:55:46.160134+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260811-Agenda10-33166348",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.539272",
        "source": "LSE_CHAT",
        "data": {
          "author": "Agenda101",
          "content": "Cheers BV!",
          "sentiment": 0.0,
          "engagement": "72",
          "price_at_post": "53.00",
          "thread_title": "RE: Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-02-10T01:55:46.160165+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260754-cj62--4977376",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.539688",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "Who would be allowed access ?",
          "sentiment": 0.0,
          "engagement": "4,282",
          "price_at_post": "53.00",
          "thread_title": "Data Room",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=85F98FAE-01B2-48EC-B9D0-584FAD2B9731"
        },
        "ingested_at": "2026-02-10T01:55:46.160198+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260751-Thornogs--7555731",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.713580",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "This one and one after the close to comment on the top quality discussion and to check if we finished up or not.",
          "sentiment": 0.0,
          "engagement": "8,666",
          "price_at_post": "53.00",
          "thread_title": "2 post Friday.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=EDA1F112-F6D9-49A4-937D-081A93C2E757"
        },
        "ingested_at": "2026-02-10T01:55:46.160229+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260626-Gingethe-28943483",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.714067",
        "source": "LSE_CHAT",
        "data": {
          "author": "GingetheWinge",
          "content": "The FUDsters are thrashing like Terminator 2 in a smelting cauldron. It\u2019s working so let\u2019s continue to starve them of any engagement. As Runner-Runner wrote and BV reposted\u2026 It's simple. 1. DO NOT ENGAGE 2. DO NOT ASK IT A QUESTION 3. DO NOT ANSWER ITS QUESTIONS 4. DO NOT MOAN ABOUT ITS POSTS 5. DO NOT ARGUE WITH IT 6. If you must do something. Mock it with reference only to its stupidity and nothing else. ------------------------------------------------------ If you're not part of the solution, you're part of the problem",
          "sentiment": 0.5,
          "engagement": "700",
          "price_at_post": "53.00",
          "thread_title": "No not engage !",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=A348D8E1-4DC7-4D49-950E-08F79BC3A2D1"
        },
        "ingested_at": "2026-02-10T01:55:46.160261+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260138-BuenaVis-57500061",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.714500",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Even better link: https://www.youtube.com/watch?v=HWkh3OEFSds&t=1333s",
          "sentiment": 0.0,
          "engagement": "5,775",
          "price_at_post": "53.00",
          "thread_title": "RE: Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-02-10T01:55:46.160294+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260132-BuenaVis-72554801",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.714925",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "It's the Base to Base biotech podcast from a few days ago. Well worth a listen. Here's the link to the start of the CC interview: https://www.youtube.com/watch?v=HWkh3OEFSds&t=1290s",
          "sentiment": 0.0,
          "engagement": "5,775",
          "price_at_post": "53.00",
          "thread_title": "RE: Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-02-10T01:55:46.160327+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262331-D-Geeman--2453568",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.715361",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "Wasn\u2019t wyn comparing this BB to \u2018Lord of the Flies\u2019 classic story? Well for those who don\u2019t know the story I just caught a trailer for new BBC production starting soon; https://www.bbc.com/mediacentre/2026/lord-of-the-flies-trailer",
          "sentiment": 0.0,
          "engagement": "5,849",
          "price_at_post": "53.00",
          "thread_title": "RE: Avacta Therapeutics celebrates this",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=03B0B4A6-705E-45ED-983A-A89C321C0924"
        },
        "ingested_at": "2026-02-10T01:55:46.160357+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262302-alextak-36623014",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.715781",
        "source": "LSE_CHAT",
        "data": {
          "author": "alextak",
          "content": "Is it a new interview? .I'll listen to it tomorrow.",
          "sentiment": 0.0,
          "engagement": "540",
          "price_at_post": "53.00",
          "thread_title": "RE: Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-02-10T01:55:46.160387+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262258-alextak-44137891",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.716203",
        "source": "LSE_CHAT",
        "data": {
          "author": "alextak",
          "content": "Https://youtu.be/HWkh3OEFSds?si=0KezbLZbtRJA4N97",
          "sentiment": 0.0,
          "engagement": "540",
          "price_at_post": "53.00",
          "thread_title": "Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-02-10T01:55:46.160418+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262241-pedrolan--2797325",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.716624",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "When no-one engages that's what they end up with. Good work folks.",
          "sentiment": 0.5,
          "engagement": "1,975",
          "price_at_post": "53.00",
          "thread_title": "Voices in the wilderness",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=8AE5A358-4CCC-4E25-A8A9-D4C3BBC9FF5F"
        },
        "ingested_at": "2026-02-10T01:55:46.160450+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262222-Thornogs--7753564",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.717039",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Absolutely Pedro! All those who chance upon the LSE Avacta bulletin board and haven't been keeping up with the news, all of them? Exposure indeed, keep up the good work everybody!",
          "sentiment": 0.0,
          "engagement": "8,666",
          "price_at_post": "53.00",
          "thread_title": "RE: Avacta Therapeutics celebrates this",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=03B0B4A6-705E-45ED-983A-A89C321C0924"
        },
        "ingested_at": "2026-02-10T01:55:46.160482+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262202-pedrolan--2470019",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.717464",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "All great exposure. Thanks for posting \ud83d\udc4d\ud83c\udffb",
          "sentiment": 0.5,
          "engagement": "1,975",
          "price_at_post": "53.00",
          "thread_title": "RE: Avacta Therapeutics celebrates this",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=03B0B4A6-705E-45ED-983A-A89C321C0924"
        },
        "ingested_at": "2026-02-10T01:55:46.160513+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262145-Thornogs--7627601",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.717891",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Well there we have it Avcti, proof positive fof all those 'FUDsters' who have been saying otherwise all day! Avacta can produce FAP-EXD for the upcoming trial! What chance does 'FUD' have against this level of research and knowledge? Hang your heads in shame all those saying that it wasn't possible. Was anyone suggesting this?",
          "sentiment": 0.0,
          "engagement": "8,666",
          "price_at_post": "53.00",
          "thread_title": "RE: \" So excited to get the trial going soon. \"",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=C91568DF-F421-4695-901C-78161A0F4CD6"
        },
        "ingested_at": "2026-02-10T01:55:46.160545+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262110-avctIPma-76209025",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.718379",
        "source": "LSE_CHAT",
        "data": {
          "author": "avctIPmatters",
          "content": "FYI   Christina CoughlinChristina Coughlin \u2022 3rd+Verified \u2022 3rd+ Chief Executive Officer, AvactaChief Executive Officer, Avacta 53m \u2022  53 minutes ago \u2022 Visible to anyone on or off LinkedIn Follow We are thrilled to partner with our team at Curia - this partnership has enabled our team at hashtag#AVCT to move FAP-exatecan forward at record pace. So excited to get the trial going soon. This combined team reminds me of a favorite quote, \u201cNever doubt that a small group of thoughtful, committed citizens can change the world. Indeed, it is the only thing that ever has.\u201d \u2014Margaret Mead. hashtag#LetsDoThis hashtag#HopeWithoutCompromise CuriaCuria 104,425 followers104,425 followers 2h \u2022  2 hours ago \u2022 Visible to anyone on or off LinkedIn Follow Congratulations to Avacta Therapeutics on receiving U.S. Food and Drug Administration (FDA) clearance of the Investigational New Drug (IND) application for the Company\u2019s second program FAP-Exd (AVA6103). This peptide drug conjugate is based on the highly potent topoisomerase I inhibitor, exatecan. A Phase 1 clinical trial will enroll patients with solid tumors, pancreatic cancer, cervical cancer, gastric cancer and small cell lung cancer. CURIA STERILE DRUG PRODUCT business unit is proud to assist this cutting-edge oncology program with formulation development, analytical support and GMP clinical supply at our site in Glasgow. Read more about Avacta in the recent press release: https://hubs.li/Q040N2nz0",
          "sentiment": 0.0,
          "engagement": "728",
          "price_at_post": "53.00",
          "thread_title": "\" So excited to get the trial going soon. \"",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=C91568DF-F421-4695-901C-78161A0F4CD6"
        },
        "ingested_at": "2026-02-10T01:55:46.160576+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262104-wyndrum-25839694",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.718829",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "So you\u2019re right and I am wrong as you have said umpteen times  yet it is me who is the narcissist? You don\u2019t even know what the term means in detail yet bandi it about as a diagnosis of a stranger you know nothing about. Your arrogance in libelling me without any justification only amplifies my point. But in none of these umpteen times have you ever wondered why AVCT have failed to deliver the returns you expected when you first bought in ? No of course not. That would require self examination. Something you seem to lack but have no inhibition in accusing others of. The arrogance of the arguments directed at me are so cliched and bereft of any true accuracy that it is simply pathetic. What is so considerably worse is the recs they get. Not because it offends me more but rather of the evidence that so may can\u2019t reason for themselves and blithely agree. It\u2019s not a case of reading the room, more a case of group think. Under your reasoning we would all still think the earth was flat.",
          "sentiment": 0.0,
          "engagement": "12,228",
          "price_at_post": "53.00",
          "thread_title": "RE: Worldwide ADC Innovation & Collaboration   London",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=CB66756C-50A3-4D04-A499-ADC1B8951801"
        },
        "ingested_at": "2026-02-10T01:55:46.160608+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262104-Metatron--7778607",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.719249",
        "source": "LSE_CHAT",
        "data": {
          "author": "Metatron",
          "content": "Forgot.. dammit.. sawy \ud83e\udd14",
          "sentiment": 0.0,
          "engagement": "1,188",
          "price_at_post": "53.00",
          "thread_title": "RE: Worldwide ADC Innovation & Collaboration   London",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=CB66756C-50A3-4D04-A499-ADC1B8951801"
        },
        "ingested_at": "2026-02-10T01:55:46.160638+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262051-BuenaVis-34501332",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.719657",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Do not feed the troll. \ud83e\udd2a",
          "sentiment": 0.0,
          "engagement": "5,775",
          "price_at_post": "53.00",
          "thread_title": "RE: Worldwide ADC Innovation & Collaboration   London",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=CB66756C-50A3-4D04-A499-ADC1B8951801"
        },
        "ingested_at": "2026-02-10T01:55:46.160670+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262035-Metatron-49660701",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.720073",
        "source": "LSE_CHAT",
        "data": {
          "author": "Metatron",
          "content": "The problem is Wyndrone.. that you cannot read the room because you are a narcissist as I've explaind umpteen times. The recs are from other members who are just plain sick to death of you and your narcissistic droning behaviour.",
          "sentiment": 0.0,
          "engagement": "1,188",
          "price_at_post": "53.00",
          "thread_title": "RE: Worldwide ADC Innovation & Collaboration   London",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=CB66756C-50A3-4D04-A499-ADC1B8951801"
        },
        "ingested_at": "2026-02-10T01:55:46.160702+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262028-Metatron--6167191",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.720496",
        "source": "LSE_CHAT",
        "data": {
          "author": "Metatron",
          "content": "Looks like Thorndrone has repositioned itself as the ultimate purile commentator on the commentary? Looks more to me like the ultimate terd that just won't flush \ud83d\ude48\ud83d\udca9",
          "sentiment": 0.0,
          "engagement": "1,188",
          "price_at_post": "53.00",
          "thread_title": "RE: Avacta Therapeutics celebrates this",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=03B0B4A6-705E-45ED-983A-A89C321C0924"
        },
        "ingested_at": "2026-02-10T01:55:46.160732+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262028-wyndrum-76111328",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.720925",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "I think the problem is Chris is that while what you say is correct, it is the \u201canti-fudsters \u201c for want of a better expression, that quite deliberately push this debilitating and constant line at any opportunity. And like today, when nothing is going on, BV just stirs the pot. Yet every single time the cause of this futile exercise is laid at the door of the posters who are incessantly  attacked rather than the perpetrators . What\u2019s even more disturbing is the recs they get for doing it. This bb is simply one of the worst I have ever come across and we all contribute to that to some degree but it is the majority (when you look at the recs) here that revel in this disruptive behaviour and have little or no interest in resolving the situation for the better. Why can\u2019t I say after 5 years of a trial and a sp at near all time lows that maybe all is not what we were led to believe from the outset and can we look at what might be causing this without being asked to be ignored banned or wished an early death?",
          "sentiment": 0.0,
          "engagement": "12,228",
          "price_at_post": "53.00",
          "thread_title": "RE: Worldwide ADC Innovation & Collaboration   London",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=CB66756C-50A3-4D04-A499-ADC1B8951801"
        },
        "ingested_at": "2026-02-10T01:55:46.160762+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262015-stodgy88--3753995",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.721347",
        "source": "LSE_CHAT",
        "data": {
          "author": "stodgy88",
          "content": "LinkedIn.",
          "sentiment": 0.0,
          "engagement": "1,206",
          "price_at_post": "53.00",
          "thread_title": "RE: Avacta Therapeutics celebrates this",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=03B0B4A6-705E-45ED-983A-A89C321C0924"
        },
        "ingested_at": "2026-02-10T01:55:46.160794+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262014-stodgy88--1438234",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.721752",
        "source": "LSE_CHAT",
        "data": {
          "author": "stodgy88",
          "content": "This company as over  100,000 followers, so good exposure.",
          "sentiment": 0.0,
          "engagement": "1,206",
          "price_at_post": "53.00",
          "thread_title": "RE: Avacta Therapeutics celebrates this",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=03B0B4A6-705E-45ED-983A-A89C321C0924"
        },
        "ingested_at": "2026-02-10T01:55:46.160827+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262011-Thornogs-80698873",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.722182",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Quite Avcti, well done! Always good to be reminded of last week's RNS! In case any of ghd 'well infofmed' missed it eh?",
          "sentiment": 0.0,
          "engagement": "8,666",
          "price_at_post": "53.00",
          "thread_title": "RE: Avacta Therapeutics celebrates this",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=03B0B4A6-705E-45ED-983A-A89C321C0924"
        },
        "ingested_at": "2026-02-10T01:55:46.160858+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262010-HarChris--6602187",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.722603",
        "source": "LSE_CHAT",
        "data": {
          "author": "HarChris",
          "content": "There\u2019s a cycle of Thorn repeating the same points over and over again, the numerous posters who flood us with messages telling him to F off, begging others not to reply or to warn the bb of his dishonesty and then Wyn writing paragraphs of philosophy and psychology on the meaning of it all. That plays out at least four or five times a week! Almost identically. The odd post on Avacta gets a reply or two before the cycle kickstarts again. What a waste of time this BB is in quiet periods like this!",
          "sentiment": 0.0,
          "engagement": "15,870",
          "price_at_post": "53.00",
          "thread_title": "RE: Worldwide ADC Innovation & Collaboration   London",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=CB66756C-50A3-4D04-A499-ADC1B8951801"
        },
        "ingested_at": "2026-02-10T01:55:46.160890+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262004-avctIPma-22787831",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.723059",
        "source": "LSE_CHAT",
        "data": {
          "author": "avctIPmatters",
          "content": "Back to more worthwhile  conversation thanks Stonks -------------------------- Avacta Therapeutics celebrates this Curia 54m \u2022 Follow Congratulations to Avacta Therapeutics on receiving U.S. Food and Drug Administration (FDA) clearance of the Investigational New Drug (IND) application for the Company\u2019s second program FAP-Exd (AVA6103). This peptide drug conjugate is based on the highly potent topoisomerase I inhibitor, exatecan. A Phase 1 clinical trial will enroll patients with solid tumors, pancreatic cancer, cervical cancer, gastric cancer and small cell lung cancer. CURIA STERILE DRUG PRODUCT business unit is proud to assist this cutting-edge oncology program with formulation development, analytical support and GMP clinical supply at our site in Glasgow. Read more about Avacta in the recent press release: https://hubs.li/Q040N2nz0 \" Gmcc",
          "sentiment": 0.0,
          "engagement": "728",
          "price_at_post": "53.00",
          "thread_title": "Avacta Therapeutics celebrates this",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=03B0B4A6-705E-45ED-983A-A89C321C0924"
        },
        "ingested_at": "2026-02-10T01:55:46.160921+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261833-D-Geeman-39359922",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.723489",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "'and bucket to collect their donations for his roses.\u2019 'collect the dung & yes then spread the manure around the Roses' I understand that Watching does this too but with her Quality Street, not Roses.",
          "sentiment": 0.0,
          "engagement": "5,849",
          "price_at_post": "53.00",
          "thread_title": "RE: Worldwide ADC Innovation & Collaboration   London",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=CB66756C-50A3-4D04-A499-ADC1B8951801"
        },
        "ingested_at": "2026-02-10T01:55:46.160952+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261754-Thornogs-46691980",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.723915",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Now, now Wyn! Steady there. It's been decided that our constant 'FUD' detracts from thd ability of the 'well informed' posters to discuss Avzcta seriously. OK, so far it's just the usual nonsense but give thdm a chance I'm sure tomorrow they'll Smash It! Did we finish up by the way?",
          "sentiment": 0.0,
          "engagement": "8,666",
          "price_at_post": "53.00",
          "thread_title": "RE: Worldwide ADC Innovation & Collaboration   London",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=CB66756C-50A3-4D04-A499-ADC1B8951801"
        },
        "ingested_at": "2026-02-10T01:55:46.160984+00:00"
      },
      {
        "event_id": "SOCIAL-Today1236-Watching--6968522",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.595387",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "Let\u2019s have a day where know one engages with the Fudders A watch them argue with themselves \ud83d\ude0a",
          "sentiment": 0.0,
          "engagement": "9,213",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-02-10T01:55:46.161016+00:00"
      },
      {
        "event_id": "SOCIAL-Today1207-D-Geeman--7621996",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.595837",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "Evan Davis discussing mergers and acquisitions on Radio 4 right now.",
          "sentiment": 0.0,
          "engagement": "5,844",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-02-10T01:55:46.161048+00:00"
      },
      {
        "event_id": "SOCIAL-Today1050-D-Geeman-12692433",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.596300",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "Many of the most useful posts are green boxes to others. That's fine. I really don't care if **** doesn't read ****'s post as long as I can. Please, everyone who doesn't like ****'s posts filter and then the people who do read them can do so in peace.",
          "sentiment": 0.0,
          "engagement": "5,844",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-02-10T01:55:46.161080+00:00"
      },
      {
        "event_id": "SOCIAL-Today1034-Thornogs--7133216",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.596741",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Happy to sit on the sidelines to watch the emergence of all this deep research and intelligent discussion on the company's 'fundamentals'. Of course if it isn't accurate or realistic I presume there's the right to point this out? Otherwise it's just a meaningless Echo Chamber. Over to you, the self proclaimed 'well informed'. Let's see what quality posting looks like!",
          "sentiment": 0.0,
          "engagement": "8,655",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-02-10T01:55:46.161131+00:00"
      },
      {
        "event_id": "SOCIAL-Today1032-BuenaVis--3803731",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.597214",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "As Runner-Runner wrote... It's simple. 1. DO NOT ENGAGE 2. DO NOT ASK IT A QUESTION 3. DO NOT ANSWER ITS QUESTIONS 4. DO NOT MOAN ABOUT ITS POSTS 5. DO NOT ARGUE WITH IT 6. If you must do something. Mock it with reference only to its stupidity and nothing else. ------------------------------------------------------ If you're not part of the solution, you're part of the problem",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-02-10T01:55:46.161164+00:00"
      },
      {
        "event_id": "SOCIAL-Today1025-pedrolan--1541103",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.597761",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Ok, as one of the offenders ( I did it mainly to remind people of their/his agenda) I will pledge to now ignore them/him going forward. We really need everyone to do that though.",
          "sentiment": 0.5,
          "engagement": "1,972",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-02-10T01:55:46.161195+00:00"
      },
      {
        "event_id": "SOCIAL-Today1022-Aston15-77184307",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.598209",
        "source": "LSE_CHAT",
        "data": {
          "author": "Aston15",
          "content": "People do understand the only reason then come on here to spout sh*t is because others give them an audience? Its not difficult..  Green Box them and focus the chat on the company, not their trading agendas.",
          "sentiment": 0.0,
          "engagement": "61",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-02-10T01:55:46.161227+00:00"
      },
      {
        "event_id": "SOCIAL-Today1005-IFA90-12519428",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.598630",
        "source": "LSE_CHAT",
        "data": {
          "author": "IFA90",
          "content": "More posts than trades, never a good sign.",
          "sentiment": 0.0,
          "engagement": "408",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-02-10T01:55:46.161259+00:00"
      },
      {
        "event_id": "SOCIAL-Today0954-Aldebara--5224975",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.599061",
        "source": "LSE_CHAT",
        "data": {
          "author": "Aldebaran",
          "content": "Anyone engaging with them is part of the problem. I'll soon be adding them to my filter list if all the want to do is talk smack and try to score points against them. It's a waste of everyone's time, least not their own yet they persist. Sad. We could use this bb once again to discuss avacta but only if the engagement with FUDsters ends. Its nothing more than a digital playground otherwise. Filter. Them.",
          "sentiment": 0.0,
          "engagement": "3,894",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-02-10T01:55:46.161293+00:00"
      },
      {
        "event_id": "SOCIAL-Today0948-Watching--5775740",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.599520",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "Let\u2019s have a day where know one engages with the Fudders And watch them argue with there selves \ud83d\ude0a",
          "sentiment": 0.0,
          "engagement": "9,213",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-02-10T01:55:46.161325+00:00"
      },
      {
        "event_id": "SOCIAL-Today0932-Thornogs--7679062",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.599949",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "And on a day to day basis is there actually much new to talk about with Avacta? Tumbleweed City now until the next RNS, whatever that might be for.",
          "sentiment": 0.0,
          "engagement": "8,655",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-02-10T01:55:46.161356+00:00"
      },
      {
        "event_id": "SOCIAL-Today0924-wyndrum-32283674",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.600402",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "But Jane this was all caused by BV\u2019s non AVCT post. He deliberately provokes with his insults and lies. Non of this would have happened today without his non AVCT related post. Remember that would you",
          "sentiment": 0.0,
          "engagement": "12,217",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-02-10T01:55:46.161387+00:00"
      },
      {
        "event_id": "SOCIAL-Today0918-Watching--5444307",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.601027",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "Let\u2019s have a day where know one engages with the Fudders And watch them argue with themselves \ud83d\ude2c",
          "sentiment": 0.0,
          "engagement": "9,213",
          "price_at_post": "54.00",
          "thread_title": "Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-02-10T01:55:46.161418+00:00"
      },
      {
        "event_id": "SOCIAL-Today0917-pedrolan--4090215",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.601613",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "A seamless switch between users there Eggy Bravo",
          "sentiment": 0.0,
          "engagement": "1,972",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-10T01:55:46.161450+00:00"
      },
      {
        "event_id": "SOCIAL-Today0916-Thornogs--7059926",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.602292",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "To be fair Live account it's very easy to judge someone who repeatedly posts nonsense like you just have. And Pedro and BV joining in the: 'Look at us, we're idiots' gang.",
          "sentiment": 0.0,
          "engagement": "8,655",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-10T01:55:46.161480+00:00"
      },
      {
        "event_id": "SOCIAL-Today0902-wyndrum-36865007",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.603136",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "Sadly you have the memory of a goldfish but not its intellect. Again bv starts and contributes to the disruption. All we wait for now is the \u201cooh I can see all these green boxes\u201dposts add up my posts and add up all the rest and you quickly see who the paid disrupters are",
          "sentiment": 0.0,
          "engagement": "12,217",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-10T01:55:46.161510+00:00"
      },
      {
        "event_id": "SOCIAL-Today0859-BuenaVis-72145154",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.603939",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "\ud83e\udd14 Today's 'wyndrum' sounds even more petty and whiny than the 'Thornogson' account.",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-10T01:55:46.161541+00:00"
      },
      {
        "event_id": "SOCIAL-Today0858-pedrolan--1675635",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.604745",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "BV - he is doing it to fool us into thinking it is not one account. I nearly fell for it because I have the memory of a goldfish.",
          "sentiment": 0.5,
          "engagement": "1,972",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-10T01:55:46.161572+00:00"
      },
      {
        "event_id": "SOCIAL-Today0853-wyndrum--8492925",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.605571",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "It\u2019s snowing pretty hard here so it\u2019s not really the smoking gun you claim is it? Plus the fact you think I have multiple accounts only reinforces your mistaken analysis. (And see how many posts have been generated by bv These are the cause of the disruption. Not the posters who try to discuss the disconnect between AVCT results and the sp over the last 5 years",
          "sentiment": 0.0,
          "engagement": "12,217",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-10T01:55:46.161603+00:00"
      },
      {
        "event_id": "SOCIAL-Today0850-BuenaVis--7421516",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.606369",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Why is Thornogson/NDN/Eggy using the wyndrum account today?",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-10T01:55:46.161632+00:00"
      },
      {
        "event_id": "SOCIAL-Today0847-Livedata--3075318",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.607182",
        "source": "LSE_CHAT",
        "data": {
          "author": "Livedataaccount",
          "content": "With respect wyndrum its difficult not to judge someone who pretends to go on holiday and occasionally logs on with another alias replying to himself",
          "sentiment": 0.0,
          "engagement": "2,956",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-10T01:55:46.161662+00:00"
      },
      {
        "event_id": "SOCIAL-Today0835-BuenaVis-77318063",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.607959",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Wyn Shakespeare has swallowed a whole bag of question marks.",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-10T01:55:46.161694+00:00"
      },
      {
        "event_id": "SOCIAL-Today0831-pedrolan--6212211",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.608744",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Keep it up BV - people do need reminding. I see user Wyn Shakespeare is on the early shift.",
          "sentiment": 0.5,
          "engagement": "1,972",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-10T01:55:46.161725+00:00"
      },
      {
        "event_id": "SOCIAL-Today0826-wyndrum--5564307",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.609574",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "Thanks for reminding us dad, it must only be the 20th time you have posted this. Still at least your post s don\u2019t disrupt the board It\u2019s a great service you do, giving up your time to treat everyone here like morons by constantly reposting. Is it your new rule now that you must be shareholder to post and also be a genuine one at that? How do you intend to police your rules? Or is it just petty personal vendetta you are boring us all with?",
          "sentiment": 0.0,
          "engagement": "12,217",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-10T01:55:46.161756+00:00"
      },
      {
        "event_id": "SOCIAL-Today0750-BuenaVis-34412817",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.610363",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Just a reminder that Thornogson/NDN/Eggy isn't invested and is only here to argue, disrupt and try to waste our time.",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-10T01:55:46.161787+00:00"
      },
      {
        "event_id": "SOCIAL-Today0746-BuenaVis-46623910",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.904033",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Say what you see \ud83c\udf77\ud83c\udf77\ud83c\udf77",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "54.00",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-02-10T01:55:46.161819+00:00"
      },
      {
        "event_id": "SOCIAL-Today0733-Unbreade-75209636",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.904514",
        "source": "LSE_CHAT",
        "data": {
          "author": "Unbreaded",
          "content": "I love green boxes in the morning! Time for a coffee and catch up on the news.",
          "sentiment": 0.0,
          "engagement": "22",
          "price_at_post": "54.00",
          "thread_title": "Green Boes",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=F7E09828-40CF-45D7-8337-5F0A79C87685"
        },
        "ingested_at": "2026-02-10T01:55:46.161850+00:00"
      },
      {
        "event_id": "SOCIAL-Today0035-Thornogs--7131783",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.904967",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Sujood & Icecool. Similar content but I think ICE probably ahead on presentation. Both deeply underwater but talking a good game. Of course the SP matters, the only data that might be maturing is SGC 1b, which might secure a small deal. We've been told nothing about TNBC and STS is written off. We wait for FAP-EXD, we start again.",
          "sentiment": 0.0,
          "engagement": "8,655",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-10T01:55:46.161882+00:00"
      },
      {
        "event_id": "SOCIAL-Today0005-Toukanka-69462208",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.905422",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "Pivotal news in the Summer. Where have I heard that before? Oh yeah, it was me and I duly got panned by the Pom Pom girls for suggesting it would take thst long. \ud83e\udd23\ud83e\udd23\ud83e\udd23",
          "sentiment": 0.0,
          "engagement": "4,451",
          "price_at_post": "54.00",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-02-10T01:55:46.161915+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262359-Toukanka-41547606",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.905891",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "Work for ever????",
          "sentiment": 0.0,
          "engagement": "4,451",
          "price_at_post": "54.00",
          "thread_title": "RE: This will haunt you or please you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=8AE0FBBC-C14D-49F3-85C3-E6BED1BD66ED"
        },
        "ingested_at": "2026-02-10T01:55:46.161946+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262324-IFA90--8668608",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.906405",
        "source": "LSE_CHAT",
        "data": {
          "author": "IFA90",
          "content": "Thanks Andy",
          "sentiment": 0.0,
          "engagement": "408",
          "price_at_post": "54.00",
          "thread_title": "RE: This will haunt you or please you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=8AE0FBBC-C14D-49F3-85C3-E6BED1BD66ED"
        },
        "ingested_at": "2026-02-10T01:55:46.161979+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262322-BuenaVis--1126237",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.906824",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Thanks Thompi",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-10T01:55:46.162011+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262302-Sujood--6532307",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.907374",
        "source": "LSE_CHAT",
        "data": {
          "author": "Sujood",
          "content": "A multi billion dollar company in the making. It will haunt you if you dont position yourself Will please you, if you do the write thing. Learn about the company and do what you know is the right move to make. Nobody every wants to work forever. Keep this message We will talk again soon.",
          "sentiment": 0.5,
          "engagement": "1,260",
          "price_at_post": "54.00",
          "thread_title": "This will haunt you or please you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=8AE0FBBC-C14D-49F3-85C3-E6BED1BD66ED"
        },
        "ingested_at": "2026-02-10T01:55:46.162043+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262258-Icecool--2818249",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.907813",
        "source": "LSE_CHAT",
        "data": {
          "author": "Icecool",
          "content": "Commercial deals will come, and they\u2019ll be welcomed when they do. I\u2019m not in a rush though. If the data continues to strengthen and Avacta can leverage that science into materially better terms, I\u2019m perfectly happy for it to take longer. Time spent increasing leverage isn\u2019t wasted time, it\u2019s how you avoid bad deals and maximise value. \ud83d\ude0a Waiting could be the difference between a few billion and tens of billions. \ud83d\ude0a\ud83e\udd14",
          "sentiment": 0.0,
          "engagement": "8,824",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-10T01:55:46.162077+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262250-Thompi--6787336",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.908255",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thompi",
          "content": "You may find BV this tweet on X interesting on AVA6103 and BOIN design. AND https://x.com/sandyradders/status/2012950578595258664?s=61&t=BBb2UcjLDTXOFIzJM-vM6A",
          "sentiment": 0.0,
          "engagement": "1,357",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-10T01:55:46.162122+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262144-Knotagai-70906787",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.908887",
        "source": "LSE_CHAT",
        "data": {
          "author": "Knotagain",
          "content": "We're all fixated on the SP Icecool, it's just a matter of time frames. I've been invested for over five years and would love to see  some commercial news. Nothing wrong with that.",
          "sentiment": 0.0,
          "engagement": "451",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-10T01:55:46.162155+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262118-Icecool-34618602",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.909330",
        "source": "LSE_CHAT",
        "data": {
          "author": "Icecool",
          "content": "That\u2019s only a concern if you\u2019re fixated on the SP. AIM has never been able to price Avacta properly and it won\u2019t until there\u2019s either a takeover (and suspension) or a move to a serious exchange. The day to day price action is noise. What actually matters is what\u2019s happening behind the scenes with the science, the data, and the strategic discussions. That\u2019s where the real value is being built. \ud83d\udcaf\ud83d\udc4d",
          "sentiment": 0.0,
          "engagement": "8,824",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-10T01:55:46.162185+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262058-Knotagai-71687579",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.909883",
        "source": "LSE_CHAT",
        "data": {
          "author": "Knotagain",
          "content": "Totally agree Icecool, but only third party validation will move the share price. Hopefully it will happen sometime soon.",
          "sentiment": 0.0,
          "engagement": "451",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-10T01:55:46.162216+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262032-Icecool--7239622",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.910560",
        "source": "LSE_CHAT",
        "data": {
          "author": "Icecool",
          "content": "The FDA won\u2019t drag this out. AVA6000 proved the platform in humans, AVA6103 builds on that. Phase 1 is about safety and speed. This trial is designed to surface signals quickly with regulatory alignment, not waste years. AVA6000 data will have done a load of heavy lifting already.",
          "sentiment": 0.0,
          "engagement": "8,824",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-10T01:55:46.162248+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261954-BuenaVis--3918172",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.910984",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "I've got to say I was concerned that the AVA6103 trial with such a toxic agent as exatecan would start at a very low dose and take a long, long time if the step increases were to mimic those in the AVA6000 trial (seven dose levels! - three steps of 40 from 80 to 200, and then three 25% increases to 385) so very pleased to hear about all the benefits of the BOIN design.",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-10T01:55:46.162280+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261946-Icecool-17136398",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.911503",
        "source": "LSE_CHAT",
        "data": {
          "author": "Icecool",
          "content": "I would also point out that when Thorn bought in he\u2019s also a mega ramping twat!!! Flip/Flop. \ud83d\udcaf\ud83e\udd23\ud83e\udd23 best on filter \ud83d\udc4d",
          "sentiment": 0.0,
          "engagement": "8,824",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-10T01:55:46.162313+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261937-HarChris-84958923",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.912044",
        "source": "LSE_CHAT",
        "data": {
          "author": "HarChris",
          "content": "Going back to the trial design I thought this overview could be useful: Key Comparisons Accuracy in MTD Selection: BOIN generally outperforms 3+3 by more accurately identifying the true MTD. In simulations across various scenarios BOIN achieves a 12-16% higher percentage of correct selection (PCS) of the MTD, and in cases where the MTD is at higher doses, it can nearly triple the PCS compared to 3+3. Efficiency and Patient Allocation: BOIN is more efficient, often resulting in shorter trial durations and lower costs by adapting in real-time and allocating more patients to the MTD (especially at higher doses or with higher target DLT rates). The 3+3 design can prolong trials due to its conservative escalation and fixed cohort requirements, leading to fewer patients treated at effective doses. Safety and Risk Management: While 3+3 minimizes overdose risk by being overly cautious (e.g., lower chance of assigning >60% of patients above the MTD), it increases under-dosing, where many patients receive suboptimal doses. BOIN balances this better with built-in overdose controls and dynamic adjustments, reducing under-dosing without significantly raising overdose risks, thus improving ethical standards by minimising patient exposure to ineffective or overly toxic doses. Simplicity and Flexibility: Both are relatively easy to implement\u2014BOIN requires no complex programming or simulations beyond basic setup, making it accessible like 3+3. However, BOIN offers more flexibility, such as variable cohort sizes (e.g., 4 patients) and adjustable target toxicity rates, whereas 3+3 is fixed to cohorts of 3 (or 3+3) and standard targets. In summary, BOIN represents an evolution over 3+3, providing better performance across most metrics while maintaining ease of use. The 3+3 design is still widely used for its familiarity and safety focus in conservative settings but is increasingly seen as outdated for not fully utilising trial data.",
          "sentiment": 0.0,
          "engagement": "15,865",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-10T01:55:46.162345+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261812-Cashless-16089522",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.912567",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cashless",
          "content": "Been out all day, so just logged on.....and what a pleasure to see a sea of green and pretty much all informative posts...I LOVE GREEN...not sure the green people are so happy though \ud83d\udc4d\ud83e\udd2a\ud83e\udd2a\ud83e\udd73",
          "sentiment": 0.5,
          "engagement": "401",
          "price_at_post": "54.00",
          "thread_title": "Bliss",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E431AF8E-57C8-40B5-91C6-8D284968B368"
        },
        "ingested_at": "2026-02-10T01:55:46.162377+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261753-B2HS2L--3958694",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.913172",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "FWIW Google search What is the difference between event free and progression free survival AI Overview: Progression-Free Survival (PFS) measures the time from treatment initiation until objective tumor growth or death from any cause. Event-Free Survival (EFS) measures the time from randomization until a broader range of \"events,\" including disease progression, treatment failure, complications, or death. PFS focuses on tumor growth; EFS focuses on any negative outcome. Key Differences: Definition of Event: PFS is restricted to disease progression or death. EFS includes those, plus failure to proceed to planned surgery, relapse, or severe treatment complications. Context of Use: PFS is commonly used in advanced or metastatic cancer trials to evaluate treatment efficacy. EFS is frequently used in earlier-stage cancer trials, particularly in the neoadjuvant (pre-surgery) setting. Precision: PFS depends on the frequency of imaging scans to detect growth, while EFS is often defined by the time until a patient cannot proceed with their treatment plan. Essentially, PFS means the cancer has not worsened, whereas EFS means the patient has not experienced any negative, pre-defined event.",
          "sentiment": 0.0,
          "engagement": "6,000",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-10T01:55:46.162410+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261428-BuenaVis--3977118",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.913661",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "What is the current best progression free survival rate for TNBC? https://www.google.com/search?q=What+is+the+current+best+progression+free+survival+rate+for+TNBC%253F",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-10T01:55:46.162443+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261424-HarChris-61827957",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.914093",
        "source": "LSE_CHAT",
        "data": {
          "author": "HarChris",
          "content": "It's what happened to STS and might now happen with TNBC, might not of course, but if it did then it'll all fall to SGC to carry the load until FAP-EXD starts to produce meaningful data. __________________ In other words IF TNBC data doesn't deliver then SGC might have to carry the load until H2 2026? That's not bad as a worst case and it's very short term as it gets for biotech. And with the less risk averse and far more efficient BOIN design for 6103 we should start receiving compelling data rapidly if all is going well. It's close!",
          "sentiment": 0.0,
          "engagement": "15,865",
          "price_at_post": "54.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-10T01:55:46.162475+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261411-Thornogs-72328666",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.914533",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "No well spotted!  My bad.",
          "sentiment": 0.0,
          "engagement": "8,655",
          "price_at_post": "54.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-10T01:55:46.162508+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261409-BuenaVis-59927057",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.915065",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "I may be missing something here but trastuzumab deruxtecan (brand name Enhertu) and pertuzumab are both used to treat HER2-positive breast cancer.  So what has that got to do with TNBC which is an aggressive, fast-growing type of breast cancer that tests negative for three key receptors: estrogen (ER), progesterone (PR), and HER2?",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "54.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-10T01:55:46.162539+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261349-Thornogs--5150153",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.915517",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "'....FAP-DOX needs to beat.'",
          "sentiment": 0.0,
          "engagement": "8,655",
          "price_at_post": "54.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-10T01:55:46.162572+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261347-Thornogs--4619077",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.915945",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "But clearly relevent so clearly won't be mentioned by anyone else Watching? Obviously important if it's doubled the PFS times for TNBC, the bar has been raised as to what FAP-EXD needs to beat. It's what happened to STS and might now happen with TNBC, might not of course, but if it did then it'll all fall to SGC to carry the load until FAP-EXD starts to produce meaningful data.",
          "sentiment": 0.0,
          "engagement": "8,655",
          "price_at_post": "54.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-10T01:55:46.162604+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261347-pedrolan--6727585",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.837882",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Just a reminder that Thorn is not invested but spends his sad life on here posting negative comments about a company saving lives. What a guy!!!",
          "sentiment": 0.5,
          "engagement": "1,972",
          "price_at_post": "54.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-10T01:55:46.162635+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261339-Watching--2405689",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.838382",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "You Still have to focus on negatives. Thorny you are such a k n o bby \ud83e\udd21\ud83e\udd21",
          "sentiment": 0.0,
          "engagement": "9,213",
          "price_at_post": "54.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-10T01:55:46.162667+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261335-Thornogs--2253252",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.838824",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "It's perhaps double edged though? The AVA6000 STS trial was (allegedly) de-railed by a trial that showed longer, and better than expected, survival data. If there's a new 'Standard of Care' being announced for TNBC the bar might just have been raised on what FAP-DOX/TNBC needs to achieve to get a deal and get to market?",
          "sentiment": 0.0,
          "engagement": "8,655",
          "price_at_post": "55.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-10T01:55:46.162699+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261315-LovableL-13434659",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.839268",
        "source": "LSE_CHAT",
        "data": {
          "author": "LovableLumax",
          "content": "Https://x.com/onclive/status/2016451178872061994?s=46",
          "sentiment": 0.0,
          "engagement": "2,703",
          "price_at_post": "55.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-10T01:55:46.162730+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261053-Aldebara--1479046",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.839705",
        "source": "LSE_CHAT",
        "data": {
          "author": "Aldebaran",
          "content": "I think small caps are at the very start of a major bull run. Green portfolio everywhere across the board. Also note that even with hard times, avacta raised 16m through zeus at only 8% discount plus managed to delay and renegotiate the terms of the bond. No mean feat that and the macro picture for small caps has improved since then. As has our IP and data package plus the deadline for BP patent expiry has only become closer. Things nowhere near as desperate as this shhhhh it tee little market gives credit for. I mean avacta have developed the worlds first dual warhead peptide drug conjugate ffs . \ud83d\ude05",
          "sentiment": 0.0,
          "engagement": "3,894",
          "price_at_post": "55.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-10T01:55:46.162761+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261050-opti_mys-32961619",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.840239",
        "source": "LSE_CHAT",
        "data": {
          "author": "opti_mystic",
          "content": "I think that's optimistic Lovable being as the initial doses will be very low. It is a safety trial initially remember, but the trial design (BOIN) will allow for dose escalation quite quickly and also potentially skipping from say dose level one to does level 3. I think more realistically summer months we may start to see some useful efficacy. What they will know sooner is are there any problems/does it works as expected and designed. If no bad news by May/June I think we're on a winner. I expect it to work.",
          "sentiment": 0.0,
          "engagement": "296",
          "price_at_post": "55.50",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-02-10T01:55:46.162793+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261045-Sisyphus-14599036",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.840667",
        "source": "LSE_CHAT",
        "data": {
          "author": "SisyphusShorter",
          "content": "Out of coincidence it's been exactly a week since the last RNS regarding AVA6103. Could an announcement be due imminently?",
          "sentiment": 0.0,
          "engagement": "4",
          "price_at_post": "55.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-10T01:55:46.162826+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261014-HarChris-16934085",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.841093",
        "source": "LSE_CHAT",
        "data": {
          "author": "HarChris",
          "content": "I wonder if those solely focused on Avacta and thinking history always repeats are missing the fact that the AIM backdrop plays a major role here. And in that regard liquidity has returned to UK small caps with a vengeance, raises are happening without the sort of discounts seen in 2022/23/24/25, companies are seeing major share price appreciation actually hold rather than the wild swings of post Covid. It\u2019s a far healthier backdrop right now than at any point since I\u2019ve held Avacta shares.",
          "sentiment": 0.0,
          "engagement": "15,865",
          "price_at_post": "55.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-10T01:55:46.162859+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261003-harryhot-37977004",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.841536",
        "source": "LSE_CHAT",
        "data": {
          "author": "harryhotspur1311",
          "content": "I was hoping for the big erection shape although roundish bottoms are quite welcome as well!",
          "sentiment": 0.0,
          "engagement": "12",
          "price_at_post": "55.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-10T01:55:46.162891+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260958-A1invest--4099108",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.841950",
        "source": "LSE_CHAT",
        "data": {
          "author": "A1invest",
          "content": "Lets hope its a \"rounding bottom\" shape.  :)",
          "sentiment": 0.0,
          "engagement": "143",
          "price_at_post": "55.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-10T01:55:46.162924+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260953-pedrolan--2157780",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.842525",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Salty for sure",
          "sentiment": 0.0,
          "engagement": "1,972",
          "price_at_post": "55.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-10T01:55:46.162956+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260945-Thornogs--5274862",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.843025",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "\"Salt and vinegar on that sir?\"",
          "sentiment": 0.0,
          "engagement": "8,655",
          "price_at_post": "55.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-10T01:55:46.162988+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260944-Timster--8909488",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.843502",
        "source": "LSE_CHAT",
        "data": {
          "author": "Timster",
          "content": "Big fish, little fish, cardboard box....",
          "sentiment": 0.0,
          "engagement": "20,625",
          "price_at_post": "55.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-10T01:55:46.163020+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260941-harryhot-35293700",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.844130",
        "source": "LSE_CHAT",
        "data": {
          "author": "harryhotspur1311",
          "content": "Whenever the SP drops, the pessimists always quote \u2018the market knows\u2019 Perhaps this could work the other way around occasionally! Today, perhaps!",
          "sentiment": 0.0,
          "engagement": "12",
          "price_at_post": "56.00",
          "thread_title": "Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-10T01:55:46.163052+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260823-pedrolan-27071391",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.844561",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Ah yes, I knew I had been there but couldn't remember exactly which Lake \ud83e\udd23",
          "sentiment": 0.5,
          "engagement": "1,972",
          "price_at_post": "52.50",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-02-10T01:55:46.163082+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260726-Gingethe--6464129",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.844978",
        "source": "LSE_CHAT",
        "data": {
          "author": "GingetheWinge",
          "content": "Derwent valley dam in the Peak District.",
          "sentiment": 0.5,
          "engagement": "699",
          "price_at_post": "53.00",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-02-10T01:55:46.163135+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260713-LovableL--2051247",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.845409",
        "source": "LSE_CHAT",
        "data": {
          "author": "LovableLumax",
          "content": "I also suspect we will have a 6000 partner signed up once we have an approved accelerated pathway and registrations P2\\3 with FDA which is hopefully imminent",
          "sentiment": 0.0,
          "engagement": "2,703",
          "price_at_post": "53.00",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-02-10T01:55:46.163168+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260703-LovableL--8262554",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.845829",
        "source": "LSE_CHAT",
        "data": {
          "author": "LovableLumax",
          "content": "Given how potent the payload is and with the improved half-life and active in the TME for 5 days surely they'll see results as early as scan 1. That sounds rampy and too optimistic but look at the preclinical results. Things could really take off as early as the summer, or even before. Again, I suspect recruitment will be fairly rapid given FAP targeting with preCISION proven and preclinical results so investigators likely chomping at the bit.",
          "sentiment": 0.0,
          "engagement": "2,703",
          "price_at_post": "53.00",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-02-10T01:55:46.163202+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260659-nurseste-81006030",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.846277",
        "source": "LSE_CHAT",
        "data": {
          "author": "nursesteve",
          "content": "CC discussing FAP-Exd (AVA6103) - The profile of this second pre|CISION medicine in the preclinical setting is tremendous.  The sustained release mechanism developed by Avacta scientists results in a robust concentration of active drug in the tumor over five days with the disappearance from the bloodstream in only two hours. This is the exact profile needed to achieve better efficacy with this highly potent topo I inhibitor. Could payoff for LTH be this year?",
          "sentiment": 0.0,
          "engagement": "1,164",
          "price_at_post": "53.00",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-02-10T01:55:46.163235+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260006-D-Geeman--8339416",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.846690",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "An elderly character actor in our road, when I first arrived,  was in the movie \u2018The Dambusters\u2019, and in \u2018Bridge on the River Kwai\u2019. He used to tell some good stories of life on 1950\u2019s film sets. Dead for a while but he pops up on screen even now.",
          "sentiment": 0.0,
          "engagement": "5,844",
          "price_at_post": "52.50",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-02-10T01:55:46.163267+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20262319-pedrolan-53548568",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.847122",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Yes, it's an inspirational story. I think they tested it up in the Lake District",
          "sentiment": 0.5,
          "engagement": "1,972",
          "price_at_post": "52.50",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-02-10T01:55:46.163298+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20262113-Captains--4032680",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.847541",
        "source": "LSE_CHAT",
        "data": {
          "author": "Captainstanley.",
          "content": "I can't find that information anywhere Which Friday? Presumably you mean this week 29th Jan?",
          "sentiment": 0.0,
          "engagement": "467",
          "price_at_post": "52.50",
          "thread_title": "RE: SGC",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=5E3142A3-349A-43A2-B5B7-02836561174A"
        },
        "ingested_at": "2026-02-10T01:55:46.163330+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20262014-Flippine-37496796",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.847977",
        "source": "LSE_CHAT",
        "data": {
          "author": "Flippineck",
          "content": "I\u2019ve been thinking about the trials and tribulations of developing new inventions and ended up swotting up on Barnes Wallace, the inventor of the famous Bouncing Bomb. It seems initial proposals were dismissed by Bomber Command as being \u201c a mad-cap scheme\u201d. There were several critical failures in the development which had to be overcome. The shape of the bomb had to be changed, backspin had to be introduced, the weapon would shatter, sink or detonate prematurely or veer off course. Barnes Wallace persevered and it all came good in the end.",
          "sentiment": 0.0,
          "engagement": "417",
          "price_at_post": "52.50",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-02-10T01:55:46.163361+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261912-BuenaVis--2111376",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.848415",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Christina Coughlin became the CEO of Avacta on 1 May 2024. There is no need to dwell on anything or anyone before that date. CC has set out the company's objectives and timelines and has stuck to them, as much as is possible taking outside decision-making and events into account.  This adherence to the company's aims and plans comes about because she is a pharma executive with ample of experience of drug development and the way the FDA works.",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "52.50",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-02-10T01:55:46.163393+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261900-BuenaVis--3803731",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.848907",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "As Runner-Runner wrote... It's simple. 1. DO NOT ENGAGE 2. DO NOT ASK IT A QUESTION 3. DO NOT ANSWER ITS QUESTIONS 4. DO NOT MOAN ABOUT ITS POSTS 5. DO NOT ARGUE WITH IT 6. If you must do something. Mock it with reference only to its stupidity and nothing else. ------------------------------------------------------ If you're not part of the solution, you're part of the problem",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "52.50",
          "thread_title": "RE: Year end trading update :",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=CCFE6866-0D3C-4A1E-9659-9B2E552262F5"
        },
        "ingested_at": "2026-02-10T01:55:46.163425+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20262219-Thornogs--1681108",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.801399",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Anything new there? 'Expected' Q1? No, nothing new, just 'same old'.",
          "sentiment": 0.0,
          "engagement": "8,596",
          "price_at_post": "54.50",
          "thread_title": "RE: Bioconjugate Insights",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0DCD83D9-A17D-43E1-842E-1C922D520A76"
        },
        "ingested_at": "2026-02-10T01:55:46.163457+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20262212-avctIPma-55243405",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.801859",
        "source": "LSE_CHAT",
        "data": {
          "author": "avctIPmatters",
          "content": "Again courtesy of Stonks -  Finds  new coverage  Avacta related   many thanks . https://cdn.insights.bio/uploads/attachments/BCI%20Industry%20Insights.pdfAvacta Therapeutics reported new preclinical pharmacology data for FAP-Exd peptide drug conjugate [25] \"Avacta Therapeutics announced new preclinical pharmacology data for FAP-Exd (AVA6103), its second asset derived from the pre|CISION\u00ae tumor-activated delivery platform, which is expected to enter Phase 1 testing in Q1 2026. FAP-Exd is a fibroblast activation protein\u2013cleavable peptide-drug linking a proprietary peptide to a topoisomerase I inhibitor payload. The data demonstrated tumor-specific cytotoxicity, sustained intratumoral release of active exatecan with limited systemic exposure, and robust antitumor activity across multiple patient-derived xenograft models. Avacta also reported that artificial intelligence\u2013guided analysis was used to prioritize clinical indications based on co-expression of FAP and SLFN11.\" Gmcc",
          "sentiment": 0.0,
          "engagement": "720",
          "price_at_post": "54.50",
          "thread_title": "Bioconjugate Insights",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0DCD83D9-A17D-43E1-842E-1C922D520A76"
        },
        "ingested_at": "2026-02-10T01:55:46.163489+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20262210-Thornogs--4583287",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.802303",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Avacta does its thing regardless of what's posted here. Get over yourselves, self appointed \"Guardian's of the truth\"! And if you must wear your underpants on the outside do at least please ensure that  they're better laundered?",
          "sentiment": 0.0,
          "engagement": "8,596",
          "price_at_post": "54.50",
          "thread_title": "The reality?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=D8CC0643-0047-4DA0-A21A-3E0ECC3BD17C"
        },
        "ingested_at": "2026-02-10T01:55:46.163521+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20262154-BuenaVis-13657923",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.802718",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "I had Firefox nicely set up with AdBlock so that all ads were wiped out but had to 'repair' Firefox today (as tabs were crashing) and then reload an AdBlock extension but I now keep getting these annoying messages from LSE about ads that I never used to get.  Can't remember what I did before to permanently remove those messages.  Can anyone offer advice on how they've solved this?",
          "sentiment": 0.0,
          "engagement": "5,722",
          "price_at_post": "54.50",
          "thread_title": "Off-topic - removing ads on Firefox",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=9BE707F4-9555-444A-A3C8-1254E00A3443"
        },
        "ingested_at": "2026-02-10T01:55:46.163554+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20262109-Knotagai--3556535",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.803142",
        "source": "LSE_CHAT",
        "data": {
          "author": "Knotagain",
          "content": "All day every day...",
          "sentiment": 0.0,
          "engagement": "448",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-02-10T01:55:46.163587+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261944-Agenda10--6965314",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.803559",
        "source": "LSE_CHAT",
        "data": {
          "author": "Agenda101",
          "content": "Brilliant! The never ending Twats.. they are all green boxed here\u2026 But I\u2019m hearing you Sheepy! Exactly right.",
          "sentiment": 0.0,
          "engagement": "55",
          "price_at_post": "54.50",
          "thread_title": "RE: Frankly pathetic",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B36E2695-D07A-4E60-838B-02C995994856"
        },
        "ingested_at": "2026-02-10T01:55:46.163620+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261943-BuenaVis-20701014",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.803971",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Lighten up Thompi.  It's the best comedy show in town.",
          "sentiment": 0.0,
          "engagement": "5,722",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-02-10T01:55:46.163653+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261940-Thompi-13393200",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.804413",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thompi",
          "content": "Because, Touk, Thorn talks total twaddle and inundates this board with spam. It\u2019s made the board virtually unreadable. Even blocking him doesn\u2019t really help, because all I then see are green boxes and other people replying to his posts. I probably add to the noise at times too - but I\u2019ve genuinely had enough of one person commandeering the board with the same malicious rubbish, day after day. Post after post after post. It wears people down. It stops being discussion and just becomes disruption.",
          "sentiment": 0.0,
          "engagement": "1,355",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-02-10T01:55:46.163685+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261848-Toukanka--8336451",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.804832",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "Cj62 How can it be utter garbage when it\u2019s generally been predicting what is happening to Avacta. But the pond poms utter garbage of \u201ctakeover tomorrow \u201c, \u201cmarket thick as mince\u201d etc etc ad infinitum even though they\u2019ve been entirely wrong for years. Well that\u2019s fine clogging up the board with that garbage",
          "sentiment": 0.0,
          "engagement": "4,436",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-02-10T01:55:46.163718+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261845-BuenaVis-84302415",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.805254",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "6am to midnight but with a two hour evening break to neck a bottle of whisky.",
          "sentiment": 0.0,
          "engagement": "5,722",
          "price_at_post": "54.50",
          "thread_title": "RE: Frankly pathetic",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B36E2695-D07A-4E60-838B-02C995994856"
        },
        "ingested_at": "2026-02-10T01:55:46.163750+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261844-Toukanka--5693005",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.805661",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "You\u2019re right Thompi. You never do say much more than joining your mates and flinging the insults. Why not talk about Avacta rather the other posters on here?",
          "sentiment": 0.0,
          "engagement": "4,436",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-02-10T01:55:46.163781+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261841-sheppy-57381910",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.806079",
        "source": "LSE_CHAT",
        "data": {
          "author": "sheppy",
          "content": "Wyn, Thorn, Touk , DG same poster numerous aliases. Hourly paid hired help disrupter. Regardless of that what sort of sad, moronic halfwit would spend 7 days a week starting each day at 6 am and continuing after midnight posting negative comments about a share they are allegedly not invested in? Regardless of their reason what a total waste of one\u2019s life on this earth . What a pathetic pitiful existence arguing with anonymous people on an anonymous bb. I actually pity their sad, lonely unfulfilled existence. And before the poster tells me they live a very fulfilled life doing lots of other meaningful things ask yourself how this is possible with so many never ending  daily boring transparent attempts at disruption. Sad twat and a weirdo",
          "sentiment": 0.0,
          "engagement": "563",
          "price_at_post": "54.50",
          "thread_title": "Frankly pathetic",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B36E2695-D07A-4E60-838B-02C995994856"
        },
        "ingested_at": "2026-02-10T01:55:46.163813+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261831-cj62--2779667",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.806499",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "Anything you post Thorn is utter garbage. How many crayons have you done today ?",
          "sentiment": 0.0,
          "engagement": "4,270",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-02-10T01:55:46.163844+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261820-Thornogs-74108993",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.806924",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "And what did you say? Anything worth hearing? Anything about Avacta and what's going well and what isn't and thoughts about why? No, thought not. Shame.",
          "sentiment": 0.0,
          "engagement": "8,596",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-02-10T01:55:46.163876+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261755-Thompi--6758914",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.807357",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thompi",
          "content": "Pedro, if I add your 67 posts over the last 30 days to my 20, plus Tim\u2019s 43 and Watching\u2019s 39, the grand combined total is 169 posts. That\u2019s four people combined. Compared to Thorn\u2019s 253 posts on his own. The figures speak for themselves.",
          "sentiment": 0.0,
          "engagement": "1,355",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-02-10T01:55:46.163907+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261754-wyndrum--3181740",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.807774",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "And i see my requests to get NFT to respond have been deleted but the insults to me remain. But yes, its the LSE moderators allowing me to post that is the problem here. Where are you NFT, want to answer my queries so you can justify the remarks in your post?",
          "sentiment": 0.0,
          "engagement": "12,198",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-02-10T01:55:46.163940+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261737-pedrolan-32213456",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.808191",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Make that 29 to go",
          "sentiment": 0.0,
          "engagement": "1,948",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-02-10T01:55:46.163972+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261719-Thompi--8727455",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.808620",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thompi",
          "content": "Avacta posts over the last 30 days: 253 Thorn \ud83e\udd47 43 Timster 39 Watching Not much else to say really Thorn.",
          "sentiment": 0.0,
          "engagement": "1,355",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-02-10T01:55:46.164004+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261708-Thornogs-12527828",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.809052",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "And the two posters below your post Thompi? Watching 9,000 and Tim 20,000! All on only Avacta and all 100% content free 'jokes' or 'bile'. But to comment on that would be to show a consistent approach to this sort of thing wouldn't it? Be honest, it's not the number or posts, it's the fact that you might have to consider things that you don't want to consider. Fine, your choice, 5 years in and AVA6000 limping along to a possible low-ball deal and FAP-EXD entering the 'Last Chance Saloon' in the next 2-3 months. Everything that you've been predicting for the last 5 years, why would you need to hear a contrary opinion when you've clearly been smashing it all this time? Well up I dare say on your investment are we?",
          "sentiment": 0.0,
          "engagement": "8,596",
          "price_at_post": "54.00",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-02-10T01:55:46.164037+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261644-Thompi--6874147",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.809483",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thompi",
          "content": "To be fair Tim, Thorn\u2019s only posted 11 times so far today. He\u2019s got another 30 to go before he equals his personal best of 41 posts in 24 hours. By my reckoning, if he manages around 4.3 posts per hour between now and midnight (17:00\u201312:00am), he might just be in with a chance of beating it. Bless his selfless little heart.",
          "sentiment": 0.0,
          "engagement": "1,355",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-02-10T01:55:46.164068+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261537-Watching--7029393",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.809893",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "24/7. He keeps churning out verbal \ud83d\udca9",
          "sentiment": 0.0,
          "engagement": "9,201",
          "price_at_post": "54.50",
          "thread_title": "RE: CC interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=F5A9F3B7-45F7-4EC2-B1FD-1ACB3A2D2E18"
        },
        "ingested_at": "2026-02-10T01:55:46.164111+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261535-Timster--3556535",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.810318",
        "source": "LSE_CHAT",
        "data": {
          "author": "Timster",
          "content": "All day every day...",
          "sentiment": 0.0,
          "engagement": "20,620",
          "price_at_post": "54.50",
          "thread_title": "To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-02-10T01:55:46.164144+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261529-cj62-11228422",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.810731",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "Shall we have a 'Spot the idiot' competition? You win it thorn, no competition !!!",
          "sentiment": 0.0,
          "engagement": "4,270",
          "price_at_post": "54.50",
          "thread_title": "RE: CC interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=F5A9F3B7-45F7-4EC2-B1FD-1ACB3A2D2E18"
        },
        "ingested_at": "2026-02-10T01:55:46.164176+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261517-Thornogs-37687222",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.811159",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Of course we don't BV, and the industry experts who know these things currently value Avacta at 50 odd pence a share. NFT and the 28 odd who ticked up his posts think \u00a328 is more accurate. Shall we have a 'Spot the idiot' competition?",
          "sentiment": 0.0,
          "engagement": "8,596",
          "price_at_post": "54.50",
          "thread_title": "RE: CC interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=F5A9F3B7-45F7-4EC2-B1FD-1ACB3A2D2E18"
        },
        "ingested_at": "2026-02-10T01:55:46.164208+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261515-cj62-79861596",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.811569",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "That's theoretical of course. Thorn its like 99% of the other gibberish you post twat.",
          "sentiment": 0.0,
          "engagement": "4,270",
          "price_at_post": "54.50",
          "thread_title": "RE: CC interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=F5A9F3B7-45F7-4EC2-B1FD-1ACB3A2D2E18"
        },
        "ingested_at": "2026-02-10T01:55:46.164239+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20262211-B2HS2L--7876486",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.316988",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "Bella, I'm quoting company presentations and Trinity Delta. But I'll take any answer I can get from an Investor Relations company willing to respond to an Investor on behalf of Avacta. What a breath of fresh air that would be, and we could all organise a knee's up to celebrate responses.   Ha ha....dream on. Will advise any response, but it won't be this week I'm thinking.",
          "sentiment": 0.0,
          "engagement": "6,052",
          "price_at_post": "59.50",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0781AA9B-9049-48B9-B94C-F3239EA4AB66"
        },
        "ingested_at": "2026-02-11T01:19:44.512744+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20262058-D-Geeman-68192945",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.317461",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "\u2018 and Wynbore taken \u2019 Mel obvs missing Wyn after just a day or two. \ud83d\ude3f",
          "sentiment": 0.0,
          "engagement": "5,879",
          "price_at_post": "59.50",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0781AA9B-9049-48B9-B94C-F3239EA4AB66"
        },
        "ingested_at": "2026-02-11T01:19:44.512782+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20262040-Bella653--1894391",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.317882",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "Most likely you'll be referred to RNS updates.",
          "sentiment": 0.0,
          "engagement": "6,769",
          "price_at_post": "59.50",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0781AA9B-9049-48B9-B94C-F3239EA4AB66"
        },
        "ingested_at": "2026-02-11T01:19:44.512816+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20262038-Bella653-92193499",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.318312",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "B2...Afraid they won't be able to give you the answers you seek.",
          "sentiment": 0.0,
          "engagement": "6,769",
          "price_at_post": "59.50",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0781AA9B-9049-48B9-B94C-F3239EA4AB66"
        },
        "ingested_at": "2026-02-11T01:19:44.512850+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261947-Metatron--3073675",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.318724",
        "source": "LSE_CHAT",
        "data": {
          "author": "Metatron",
          "content": "Where have your mates gone Toukdroid? Thorn been banned? and Wynbore taken his bat and ball home? Pressures on you now.. need to raise your game? \ud83e\uddd0\ud83d\ude02\ud83d\ude44",
          "sentiment": 0.0,
          "engagement": "1,193",
          "price_at_post": "59.50",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0781AA9B-9049-48B9-B94C-F3239EA4AB66"
        },
        "ingested_at": "2026-02-11T01:19:44.512887+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261929-D-Geeman-15776775",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.319153",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "Faron, FARN, today. *Unless I'm missing something.",
          "sentiment": 0.0,
          "engagement": "5,879",
          "price_at_post": "59.50",
          "thread_title": "How *NOT* to organise a raise.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B74524AD-99F9-469D-8BB4-0B75886909B8"
        },
        "ingested_at": "2026-02-11T01:19:44.512919+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261806-cj62-92046882",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.319558",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "Thorn/ touk you continue to be an insufferable prick. As for the consortium you mention,at the present market cap, yes I probably could.",
          "sentiment": 0.0,
          "engagement": "4,305",
          "price_at_post": "59.50",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0781AA9B-9049-48B9-B94C-F3239EA4AB66"
        },
        "ingested_at": "2026-02-11T01:19:44.512950+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261757-Toukanka-71999175",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.319970",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "\u201c . As I mentioned, we'll have that,. Pipeline update, platform update, and so we're really excited about, the fourth quarter, for the company.\" Jeez I must have missed all those 4Q25 announcements",
          "sentiment": 0.0,
          "engagement": "4,490",
          "price_at_post": "59.50",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0781AA9B-9049-48B9-B94C-F3239EA4AB66"
        },
        "ingested_at": "2026-02-11T01:19:44.512983+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261717-Toukanka-16292957",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.320430",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "BenH It\u2019s ok Someone has deleted the post anyway",
          "sentiment": 0.0,
          "engagement": "4,490",
          "price_at_post": "59.50",
          "thread_title": "RE: Initial data seen under NDA 1st",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=DC4BE032-D599-4CC6-BFFD-F74DE0A45A33"
        },
        "ingested_at": "2026-02-11T01:19:44.513014+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261714-B2HS2L--1979823",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.320844",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "That's clear. What isn't clear is the nature of the phase 2 partnership sought by Avacta. 15:31",
          "sentiment": 0.0,
          "engagement": "6,052",
          "price_at_post": "59.50",
          "thread_title": "RE: Fairy docks ??????",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=8CFFD9D7-1C22-44FA-9FEA-90DC99BAA17F"
        },
        "ingested_at": "2026-02-11T01:19:44.513048+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261645-PL75--3599700",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.321279",
        "source": "LSE_CHAT",
        "data": {
          "author": "PL75",
          "content": "We have committed that we won't start the further development activities in the absence of a partnership. Why isn\u2019t that clear?",
          "sentiment": 0.0,
          "engagement": "11,226",
          "price_at_post": "59.50",
          "thread_title": "RE: Fairy docks ??????",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=8CFFD9D7-1C22-44FA-9FEA-90DC99BAA17F"
        },
        "ingested_at": "2026-02-11T01:19:44.513080+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261623-B2HS2L--1836435",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.321681",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "I'll keep checking my Spam directory for Cohesion's response..",
          "sentiment": 0.0,
          "engagement": "6,052",
          "price_at_post": "60.00",
          "thread_title": "RE: Fairy docks ??????",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=8CFFD9D7-1C22-44FA-9FEA-90DC99BAA17F"
        },
        "ingested_at": "2026-02-11T01:19:44.513134+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261613-pedrolan--2471508",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.322086",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "I was referring to the account that pulled you up and decided it needed a new thread to highlight it, for some reason!",
          "sentiment": 0.5,
          "engagement": "1,990",
          "price_at_post": "60.00",
          "thread_title": "RE: Fairy docks ??????",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=8CFFD9D7-1C22-44FA-9FEA-90DC99BAA17F"
        },
        "ingested_at": "2026-02-11T01:19:44.513171+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261606-B2HS2L--8539497",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.322501",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "I bet tonight's custard skin from your spotted dick that Sleeper account = avacta@cohesionbureau.com  \ud83d\ude09",
          "sentiment": 0.0,
          "engagement": "6,052",
          "price_at_post": "60.00",
          "thread_title": "RE: Fairy docks ??????",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=8CFFD9D7-1C22-44FA-9FEA-90DC99BAA17F"
        },
        "ingested_at": "2026-02-11T01:19:44.513209+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261605-BuenaVis--6039751",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.322907",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Should actually be ferry docks.",
          "sentiment": 0.0,
          "engagement": "5,848",
          "price_at_post": "60.00",
          "thread_title": "RE: Fairy docks ??????",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=8CFFD9D7-1C22-44FA-9FEA-90DC99BAA17F"
        },
        "ingested_at": "2026-02-11T01:19:44.513230+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261601-pedrolan--6843758",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.323320",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Sleeper account enabled",
          "sentiment": 0.5,
          "engagement": "1,990",
          "price_at_post": "59.50",
          "thread_title": "RE: Fairy docks ??????",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=8CFFD9D7-1C22-44FA-9FEA-90DC99BAA17F"
        },
        "ingested_at": "2026-02-11T01:19:44.513255+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261550-B2HS2L--3025178",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.323726",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "Should read 'faridoxorubicin' thanks Replacement email sent.",
          "sentiment": 0.0,
          "engagement": "6,052",
          "price_at_post": "59.50",
          "thread_title": "RE: Fairy docks ??????",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=8CFFD9D7-1C22-44FA-9FEA-90DC99BAA17F"
        },
        "ingested_at": "2026-02-11T01:19:44.513273+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261540-tiger29--7844683",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.324134",
        "source": "LSE_CHAT",
        "data": {
          "author": "tiger29",
          "content": "What are \"the fairy docks ?\"",
          "sentiment": 0.0,
          "engagement": "46",
          "price_at_post": "60.00",
          "thread_title": "Fairy docks ??????",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=8CFFD9D7-1C22-44FA-9FEA-90DC99BAA17F"
        },
        "ingested_at": "2026-02-11T01:19:44.513292+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261531-B2HS2L-12171195",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.324606",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "I've sent this to cohesion this afternoon, to see whether I get no response as per previous agencies. avacta@cohesionbureau.com Hi Cohesion Investor Relations, Many investors are unaware of the cost to Avacta of pursuing the upcoming phase 2/3 trial, for which the company currently seeks a partner. Does the company hope to 1 Have the partner cover 100% of the costs of the phase 2/3 trial. 2 Have the costs divided between Avacta and partner, dependent upon negotiations between parties. At the 30.09.2025 Investormeet presentation, a question was asked and insufficiently answered to get a response amenable to all. The question was: Q2 How much do you expect phase 2 for faridoxorubicin to cost Avacta? How will you fund this if a partnership doesn't materialise? The response from the CEO was: A2 \"So we're very confident in the maturing data in the phase 1B of, fairy docks and, we think that this will support the long-term value of this asset. Salivary gland cancers, you know, high unmet need and, we continue to, collect data, in the various cohorts. We have committed that we won't start the further development activities in the absence of a partnership. However, as I've said, the maturing data set in phase 1B is providing us with, ample confidence that precision is, working exactly as, we designed it to work. The development in the expansion cohorts is, well underway. We believe the preliminary data here will provide that natural inflection point for the program. It's gonna provide also clarity on accelerated approval pathways that we might be able to seek. And also there's, really an opportunity, for the overall market to, digest essentially the commercial potential for the program and the platform. As I mentioned, we'll have that,. Pipeline update, platform update, and so we're really excited about, the fourth quarter, for the company.\" It is assumed that this question was selected by Avacta to be asked in the presentation beforehand. Any information you can provide on this subject would be a great help Kind Regards Avacta shareholders",
          "sentiment": 0.0,
          "engagement": "6,052",
          "price_at_post": "60.00",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0781AA9B-9049-48B9-B94C-F3239EA4AB66"
        },
        "ingested_at": "2026-02-11T01:19:44.513310+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261449-B2HS2L-50592579",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.325021",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "IVM 30.09.25 - select Q/A tab. https://www.investormeetcompany.com/meetings/interim-results-491",
          "sentiment": 0.0,
          "engagement": "6,052",
          "price_at_post": "60.00",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0781AA9B-9049-48B9-B94C-F3239EA4AB66"
        },
        "ingested_at": "2026-02-11T01:19:44.513327+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261437-yeboha-86909663",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.325448",
        "source": "LSE_CHAT",
        "data": {
          "author": "yeboha",
          "content": "What was CC actual full reply to that question ????",
          "sentiment": 0.0,
          "engagement": "969",
          "price_at_post": "60.00",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0781AA9B-9049-48B9-B94C-F3239EA4AB66"
        },
        "ingested_at": "2026-02-11T01:19:44.513346+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261338-Bella653--4878862",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.325853",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "What plon\u00a3er put ghrough two 0 trades???\ud83d\ude02\ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "6,769",
          "price_at_post": "61.00",
          "thread_title": "Trades",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=F9CE2B15-57EB-41C4-816A-05159896BF66"
        },
        "ingested_at": "2026-02-11T01:19:44.513364+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261307-B2HS2L-48564434",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.326290",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "Update possibly end of March to coincide with the 1/4ly business update. (where have they gone BH?) Q2 How much do you expect phase 2 for faridoxorubicin to cost Avacta? How will you fund this if a partnership doesn't materialise? CC doesn't address the question very well, though other info appears. Note 26.06.2025 Trinity Delta: The foundational IP around the sustained release pre|CISION mechanism and the better appreciation of the scope of the pre|CISION platform gleaned from the Tempus collaboration provides multiple new opportunities for Avacta to unlock value through generating and developing a pipeline of highly novel tumour targeting drug conjugates, subject to securing additional funds. One potential funding pathway centres on business development, including securing: \u2022\tProduct-based partnerships: partnering or out-licensing deals with large pharma/biotech companies that have clinical and/or commercial expertise in certain therapeutic areas, or geographies, could help accelerate development of either existing or new product candidates. We note that Avacta is actively seeking a deal for AVA6000, ahead of starting Phase II development in H126",
          "sentiment": 0.0,
          "engagement": "6,052",
          "price_at_post": "61.00",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0781AA9B-9049-48B9-B94C-F3239EA4AB66"
        },
        "ingested_at": "2026-02-11T01:19:44.513382+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261246-opti_mys--2200843",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.326692",
        "source": "LSE_CHAT",
        "data": {
          "author": "opti_mystic",
          "content": "B2, the point of the partner for 6k phase 2 is that they the partner fund the trial, we won't be paying for it that is for sure. So they won't care about our finances. Presumably there will also be some sort of upfront payment too helping our finances. No partner no phase 2.",
          "sentiment": 0.0,
          "engagement": "317",
          "price_at_post": "61.00",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0781AA9B-9049-48B9-B94C-F3239EA4AB66"
        },
        "ingested_at": "2026-02-11T01:19:44.513400+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261238-B2HS2L-35792293",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.327228",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "Opti The company has said it will not take 6000 into phase 2/3 without a partner. 1 Depending on that deal, there may be cash available. 2 The state of AVCT finances might be cautionary for any AVA6000 partner. Would that partner be willing to proceed with Avacta unable to show sufficient longer term funding to proceed with phase 2/3, or unable to state when funding would become available? Sorting funding before finalising a partner would nullify such concerns. \"Avacta has strongly signalled a deal for that to fund 6103\". Avacta selling 6000 to fund 6103? IVM presentation 30.09.2025 Q2 How much do you expect phase 2 for faridoxorubicin to cost Avacta? How will you fund this if a partnership doesn't materialise? CC: \"So, we're very confident in the maturing data and the phase 1B of Faridoxorubicin and we think that this will support the long-term value of this asset. Salivary gland cancers, you know, high unmet need - and we continue to collect data in the various cohorts. We have committed that we won't start the further development activities in the absence of a partnership. However, as I've said, the maturing data set in phase 1B is providing us with ample confidence that precision is working exactly as we designed it to work. The development in the expansion cohorts is well underway. We believe the preliminary data here will provide that natural inflection point for the program. It's also going to provide clarity on accelerated approval pathways that we might be able to seek\"... ....Which will be of great interest to prospective partners. RNS'd FDA agreement that the dox lifetime limit to be removed on 03.02.2026. \"Agreed updates to the trial protocol include the removal of the maximum dosing limit and to allow flexibility in dosing levels. These two developments underscore the growing confidence from investigators and regulators in the tolerability profile of faridoxorubicin, and should support a smooth transition to future efficacy studies.\" \"The final cohorts of patients with the selected indications in Phase 1b will be enrolled, enabling two dose levels to be compared in order to determine the optimal biologic dose in future trials.\" +++ We await further details as to how the company enacts the FDA agreement, affecting past patients who have stopped faridox doses when they reached the lifetime limit. This is also true  for those patients on present cohorts who are still being dosed, but yet to reach the lifetime limit, as doses administered beyond 550 migs will affect the PFS calcs that are the end point of the trial. These patients now have the right to be treated beyond 550 migs... ...Again of interest to prospective partners. 6K Phase 1a data cutoff in 17 Dec 25 presentation was 15.09.2025 ie 4 months ago 6K Phase 1b data cutoff in 17 Dec 25 presentation was  15.10.2026 ie 3 months ago Update possibly end of March to coincide with the 1/4ly business update. (where have they g",
          "sentiment": 0.0,
          "engagement": "6,052",
          "price_at_post": "61.00",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0781AA9B-9049-48B9-B94C-F3239EA4AB66"
        },
        "ingested_at": "2026-02-11T01:19:44.513418+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261045-nurseste-87933491",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:41.202403",
        "source": "LSE_CHAT",
        "data": {
          "author": "nursesteve",
          "content": "A lot of people (inc big pharma) sitting on their hands just now. Volume is down but that can very soon change. GLA",
          "sentiment": 0.0,
          "engagement": "1,170",
          "price_at_post": "61.50",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=0781AA9B-9049-48B9-B94C-F3239EA4AB66"
        },
        "ingested_at": "2026-02-11T01:19:44.513436+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261043-Matml74--8036922",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:41.202838",
        "source": "LSE_CHAT",
        "data": {
          "author": "Matml74",
          "content": "They will also have very little cash left at that point (July/August). They won\u2019t run cash down to an only a few months worth so I would expect some form of funding to come forward in the next couple of months.",
          "sentiment": 0.0,
          "engagement": "2,551",
          "price_at_post": "61.50",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=0781AA9B-9049-48B9-B94C-F3239EA4AB66"
        },
        "ingested_at": "2026-02-11T01:19:44.513455+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261012-opti_mys-41835296",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:41.203267",
        "source": "LSE_CHAT",
        "data": {
          "author": "opti_mystic",
          "content": "The problem I see is that before BP spend a ton of cash they will want lots of data. They will have it with 6k by the end of June when TNBC data is released and it seems likely a deal for at least the three indications we know about would be the focus of that deal. Avacta has  strongly signalled a deal for that to fund 6103. However at a similar sort of time July/August they should have a very good idea on 6103 too with early data. Would waiting a little bit longer and buying the whole kit caboodle really make that much difference to BP who we all know have massive patent cliffs? Deal(s) are on the way for sure, the timing and size is the only uncertainty.",
          "sentiment": 0.0,
          "engagement": "317",
          "price_at_post": "61.50",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=0781AA9B-9049-48B9-B94C-F3239EA4AB66"
        },
        "ingested_at": "2026-02-11T01:19:44.513473+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20260946-Bella653-14955365",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:41.203675",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "Oops..funding not gunding...",
          "sentiment": 0.0,
          "engagement": "6,769",
          "price_at_post": "61.50",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=0781AA9B-9049-48B9-B94C-F3239EA4AB66"
        },
        "ingested_at": "2026-02-11T01:19:44.513491+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20260945-Bella653--1897686",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:41.204090",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "Morning LDA...yes it will...not worried just interesting how it's bumped 63 several time...bit of a glass ceiling right now... If a deal is to be struck before we need finance it's being worked on right now.  The new sppointment is very interesting and I think they will bring in the partnership with an upfront wad...and I wouldn't be surprised HR then come in with Royalty backed gunding.",
          "sentiment": 0.0,
          "engagement": "6,769",
          "price_at_post": "61.50",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=0781AA9B-9049-48B9-B94C-F3239EA4AB66"
        },
        "ingested_at": "2026-02-11T01:19:44.513509+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20260833-Livedata-42920505",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:41.204512",
        "source": "LSE_CHAT",
        "data": {
          "author": "Livedataaccount",
          "content": "Hey bella good morning it will come soon",
          "sentiment": 0.0,
          "engagement": "2,975",
          "price_at_post": "61.50",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=0781AA9B-9049-48B9-B94C-F3239EA4AB66"
        },
        "ingested_at": "2026-02-11T01:19:44.513527+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20260830-Bella653--8992229",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:41.204922",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "Wmsjames..'But signing a material deal purely off very early Phase 1 signals, before dose optimisation and without durability data, is still the exception rather than the rule.' They could sign an MOU type deal now with full deal based on certain outcomes/milestones.",
          "sentiment": 0.0,
          "engagement": "6,769",
          "price_at_post": "61.50",
          "thread_title": "RE: Initial data seen under NDA 1st",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=DC4BE032-D599-4CC6-BFFD-F74DE0A45A33"
        },
        "ingested_at": "2026-02-11T01:19:44.513545+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20260826-Bella653-31843660",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:41.205339",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "Need to break 63",
          "sentiment": 0.0,
          "engagement": "6,769",
          "price_at_post": "61.50",
          "thread_title": "SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=0781AA9B-9049-48B9-B94C-F3239EA4AB66"
        },
        "ingested_at": "2026-02-11T01:19:44.513563+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20260810-Bella653-89287167",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:41.205745",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "What about a Partnership for 6000 with Option to Licence one or more pipeline products...",
          "sentiment": 0.0,
          "engagement": "6,769",
          "price_at_post": "61.50",
          "thread_title": "RE: Initial data seen under NDA 1st",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=DC4BE032-D599-4CC6-BFFD-F74DE0A45A33"
        },
        "ingested_at": "2026-02-11T01:19:44.513599+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20260756-B2HS2L--7282226",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:41.206160",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "'6103 is actually validating 6000 which itself is derisking 6103.' I'll go for 6000 phase 1a results are being validated by 6000 phase 1b results in SGC so far. (Two other indications results not known yet).",
          "sentiment": 0.0,
          "engagement": "6,052",
          "price_at_post": "61.50",
          "thread_title": "RE: Initial data seen under NDA 1st",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=DC4BE032-D599-4CC6-BFFD-F74DE0A45A33"
        },
        "ingested_at": "2026-02-11T01:19:44.513620+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20260750-yeboha-79000340",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:41.206562",
        "source": "LSE_CHAT",
        "data": {
          "author": "yeboha",
          "content": "Remember, just ignore the same old FUD BRIGADE and they\u2019ll end up talking only among themselves! Yesterday\u2019s appointment was a great move by Avacta,  they are getting everything in order. Onwards and upwards!",
          "sentiment": 0.0,
          "engagement": "969",
          "price_at_post": "61.50",
          "thread_title": "Ignore the FUD BRIGADE",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B82AA1FD-8062-42D5-928C-4DE5C508547A"
        },
        "ingested_at": "2026-02-11T01:19:44.513639+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20260744-JamYeste-21117989",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:41.206972",
        "source": "LSE_CHAT",
        "data": {
          "author": "JamYesterday",
          "content": "100x more potent than Dox? Scary. So much depends on the next few months.",
          "sentiment": 0.0,
          "engagement": "560",
          "price_at_post": "61.50",
          "thread_title": "RE: Initial data seen under NDA 1st",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=DC4BE032-D599-4CC6-BFFD-F74DE0A45A33"
        },
        "ingested_at": "2026-02-11T01:19:44.513658+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20260734-Benharpe--6992793",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:41.207385",
        "source": "LSE_CHAT",
        "data": {
          "author": "Benharper",
          "content": "Every other poster isn\u2019t the same person Touk. In this post Alberbaran is being admittedly a bit optimistic regarding timelines. Wmsjames is being more circumspect. I personally think Wms is on the right track. Perhaps wait until last nights session has cleared your system before posting.",
          "sentiment": 0.0,
          "engagement": "746",
          "price_at_post": "61.50",
          "thread_title": "RE: Initial data seen under NDA 1st",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=DC4BE032-D599-4CC6-BFFD-F74DE0A45A33"
        },
        "ingested_at": "2026-02-11T01:19:44.513677+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20260659-Aldebara-49382519",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:41.207795",
        "source": "LSE_CHAT",
        "data": {
          "author": "Aldebaran",
          "content": "Im saying same thing that deal will be on faridoxorubicin based off the 4 years of dada we have for sts sgc and also breast cancer plus the work done on 3996 amd 6207 in pre clinical setting. Throw into the mix some initial data from 6103 and it becomes a self validating loop. 6103 is actually validating 6000 which itself is derisking 6103. Its highly unique. I am expecting 6103 data ans breast cancer data to lead to a deal or as some have said maybe even a direct take out approach. Could be well before market sets eyes on 6103 data... not giving the market and FUDsters chance to react and buy in \"cheap\". Before the deals land. Be a massive shame that but id get over it",
          "sentiment": 0.0,
          "engagement": "3,941",
          "price_at_post": "61.50",
          "thread_title": "RE: Initial data seen under NDA 1st",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=DC4BE032-D599-4CC6-BFFD-F74DE0A45A33"
        },
        "ingested_at": "2026-02-11T01:19:44.513701+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20260616-Wmsjames-15871550",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:41.208261",
        "source": "LSE_CHAT",
        "data": {
          "author": "Wmsjames",
          "content": "I\u2019m a bit more cautious on the timing. Yes, initial safety and tolerability signals are often seen early in Phase 1, sometimes within weeks of first dosing. But that doesn\u2019t automatically translate into actionable data for partners. Early signals are noisy, patient numbers are tiny, and dose escalation means you are often below biologically meaningful exposure in the first cohorts. On efficacy, even if there are early radiological hints, sponsors and pharma partners usually want: \u2022\tMultiple patients at or near the target dose \u2022\tConsistency across scans, not a single responder \u2022\tConfidence the signal isn\u2019t dose or patient specific That usually takes several months, not weeks. As for deals, could confidential discussions happen in parallel? Absolutely. Pharma will already understand the mechanism and will be tracking progress closely. But signing a material deal purely off very early Phase 1 signals, before dose optimisation and without durability data, is still the exception rather than the rule. So my view is: \u2022\tEarly internal confidence may build well before June \u2022\tMarket visible data likely takes longer \u2022\tAny deal would more likely be driven by confidence in the platform + AVA6000 validation, rather than a handful of first AVA6103 scans",
          "sentiment": 0.0,
          "engagement": "718",
          "price_at_post": "61.50",
          "thread_title": "RE: Initial data seen under NDA 1st",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=DC4BE032-D599-4CC6-BFFD-F74DE0A45A33"
        },
        "ingested_at": "2026-02-11T01:19:44.513734+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20260608-Aldebara-59820768",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:41.208683",
        "source": "LSE_CHAT",
        "data": {
          "author": "Aldebaran",
          "content": "Us plebs may have to wait until June earliest but how long before those under NDA such as presumably Novartis et al get to see it ? What do you think touk? 2nd question, how long before initial scans and tolerability is known after dosing. Initial i am saying. Given exetecan is what 20x more potent than irinotecan and 100x more potent than doxorubicin and more permeable than deruxtecan etc... ?? Personally I think within 1 months off dosing then the initial safety will be known and their could easily he signs of efficacy. This will be WAY before June and the point the market gets said data. Could a deal be signed off the back of this and the faridoxorubicin data to date before the market catches on, i think its possible. Highly possible actually. You and others? Thinking what?",
          "sentiment": 0.0,
          "engagement": "3,941",
          "price_at_post": "61.50",
          "thread_title": "Initial data seen under NDA 1st",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=DC4BE032-D599-4CC6-BFFD-F74DE0A45A33"
        },
        "ingested_at": "2026-02-11T01:19:44.513754+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20262317-pedrolan--8107755",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.585477",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Folks, Touk is clearly Thorn. Look how he writes. Ignore him.",
          "sentiment": 0.0,
          "engagement": "1,988",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-11T01:19:44.513774+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20262306-Icecool-89728192",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.586081",
        "source": "LSE_CHAT",
        "data": {
          "author": "Icecool",
          "content": "You do talk a load of nonsense\u2026. \ud83e\udd26\u200d\u2642\ufe0f",
          "sentiment": 0.0,
          "engagement": "8,857",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-11T01:19:44.513794+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20262305-Toukanka-54053481",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.586694",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "At the end of the day, initial efficacy results will not be published before June IMO. And CC has said as much. She has also said that any acceptable deal is unlikely before those results are published. And there will be no takeover even if CJ62 forms a consortium of shareholders and tries to push it through at say \u00a31",
          "sentiment": 0.0,
          "engagement": "4,486",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-11T01:19:44.513813+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20262301-Toukanka--2508390",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.587310",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "Thompi FPI is not the same as FPD. But no point arguing. You all know better than CC.",
          "sentiment": 0.0,
          "engagement": "4,486",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-11T01:19:44.513846+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20262150-Thompi--3994681",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.587906",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thompi",
          "content": "Touk, for the record, this is what Chris said in the Base to Base interview released 23rd January, but probably recorded late last year: \u201cWe\u2019re really looking forward to getting the first sustained release [AVA6103] into the clinic. That one will start in March of next year. We\u2019re aiming for the first quarter for the first patient with that one.\u201d",
          "sentiment": 0.0,
          "engagement": "1,364",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-11T01:19:44.513869+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20262123-BuenaVis-38598369",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.588579",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "In clinical trials, FPI (First Patient In) marks the critical milestone when the very first participant is screened, enrolled, and officially enters the study, signifying the transition from planning to active execution. It validates site readiness, kicks off data collection, and is a major KPI for project timelines and investor confidence. Here are the key details regarding FPI: Key Aspects of FPI \u2022 Definition: It is the date the first human subject is qualified, accepted, and often dosed in a clinical trial. \u2022 Significance: It proves all regulatory approvals, document reviews, contracting, and site setups are complete. \u2022 Business Impact: FPI is a high-pressure corporate goal that affects company reputation, stock prices, and investor confidence. \u2022 Trial Flow: It moves the study from \"study start-up\" to \"execution/recruitment\" phase. Why FPI Matters \u2022 Timeline Driver: It sets the pace for the rest of the recruitment and trial timeline. \u2022 Success Indicator: Meeting the FPI goal on time usually means the study is on sound footing. \u2022 Risk: Rushing to hit FPI dates can sometimes lead to neglected study designs or premature starts. Sometimes, this milestone is also referred to as FPFV (First Patient First Visit), focusing on when data collection begins for that first subject.",
          "sentiment": 0.0,
          "engagement": "5,847",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-11T01:19:44.513888+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20262039-B2HS2L-23097954",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.589188",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "A couple of non-Avacta trials that mention FPI, state that FPI = first patient enrolment. Neither discuss enrolment details though.   \ud83e\udd23\ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "6,042",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-11T01:19:44.513906+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20262005-Gingethe--6475419",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.589761",
        "source": "LSE_CHAT",
        "data": {
          "author": "GingetheWinge",
          "content": "Every piece of Avacta communication. Q1 2026. That is fact. Your opinions are plucked out of your a r s e.",
          "sentiment": 0.5,
          "engagement": "705",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-11T01:19:44.513925+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261922-avctIPma--4678284",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.590377",
        "source": "LSE_CHAT",
        "data": {
          "author": "avctIPmatters",
          "content": "\"FPI stands for \"First Patient In\", which is a critical milestone in clinical trials. It marks the moment when the first participant is screened and enrolled into the trial, signaling the beginning of real-world data collection.\" Ref :   Slide 29 https://avacta.com/wp-content/uploads/2025/07/Avacta_Corp_23July2025.pdf \" Q1 2026   Phase 1 first patient in (FPI)\" Gmcc",
          "sentiment": 0.0,
          "engagement": "742",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-11T01:19:44.513944+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261913-BuenaVis--8342674",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.590980",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "The FDA has 30 calendar days to review an IND application after receiving it. https://drugdevelopment.web.unc.edu/u-s-investigational-new-drug-application-%e2%86%92-ind-application-process/ IND submitted mid/late December (as per the project plan in Spotlight 13) and approved by 20 January. The FDA will have been working closely with Avacta given the experience with faridox so that was a fast turnaround given the US government shutdown gping on at the time. - - - - - And ToucanOfDoom, stop purporting to know better than CC what the likely timescales are.",
          "sentiment": 0.0,
          "engagement": "5,847",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-11T01:19:44.513976+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261911-Toukanka-39308376",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.591588",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "CJ62 No, while posters on here continue to misconstrue communications from Avacta and purport to know better than CC what the likely timescales are, then I will continue to correct them. You and others stop posting baseless wishful thinking ramps on here and I will stop exposing them for what they are. Deal?",
          "sentiment": 0.0,
          "engagement": "4,486",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-11T01:19:44.513998+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261902-cj62-21826987",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.592186",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "Touk can you do a thorn and dissolve into the ether?",
          "sentiment": 0.0,
          "engagement": "4,304",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-11T01:19:44.514017+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261900-BuenaVis-64182514",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.592752",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Https://avacta.com/research-development-spotlight-series-episode-13/ @26:15 FPI late Q1/26",
          "sentiment": 0.0,
          "engagement": "5,847",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-11T01:19:44.514036+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261852-Vertizea-14321081",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.593353",
        "source": "LSE_CHAT",
        "data": {
          "author": "VertizeaSun",
          "content": "Thanks jmfw.....and I'll add the reminder that CC visited the AVA6103 manufacturing site (Glasgow) in early December. a necessary requirement if one knows that patient dosing is likely to begin sooner rather than later.",
          "sentiment": 0.0,
          "engagement": "446",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-11T01:19:44.514054+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261851-Toukanka-84492525",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.593952",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "No no no That is my point. Trial start does not mean first patient dosed. CC has outlined in a previous communication the lengthy steps between IND approval and first in patient dosed. My prediction is still for initial clinical results around June. No deals until at least tolerance shown to some degree and even then maybe not until initial signs of efficacy. And yes I do know that P1 is not designed to show efficacy.",
          "sentiment": 0.0,
          "engagement": "4,486",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-11T01:19:44.514074+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261837-jmfw-24315913",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.594558",
        "source": "LSE_CHAT",
        "data": {
          "author": "jmfw",
          "content": "Https://www.lse.co.uk/rns/AVCT/year-end-trading-update-63xrambu5i622u5.html Under heading:  Outlook for 2026",
          "sentiment": 0.0,
          "engagement": "418",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-11T01:19:44.514121+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261830-Toukanka--1810561",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.595177",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "Ginge That would be great. Can you provide a link to where that is stated please. I\u2019m not challenging you. Because that would be good if they start in March. Thanks",
          "sentiment": 0.0,
          "engagement": "4,486",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-11T01:19:44.514142+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261819-Bella653--4091336",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.595769",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "Scroll to end... https://www.forxtherapeutics.com/2025/12/forx-therapeutics-announces-usd-50m-series-a-financing-enabling-clinical-data-readout-for-potential-best-in-class-parg-inhibitor As I said, is this appointment about media or funding/partnering?",
          "sentiment": 0.0,
          "engagement": "6,761",
          "price_at_post": "60.50",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-11T01:19:44.514161+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261621-BuenaVis--2269670",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.596417",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Here are some links re Richard Jarvis at Novartis: Richard Jarvis history: https://rocketreach.co/richard-jarvis-email_238424640 Richard Jarvis at Jarvis Advisors: https://www.moneyhouse.ch/en/company/jarvis-advisors-gmbh-5842690731 (Binningen is on the edge of Basel, home of Novartis HQ) Richard Jarvis consultant: https://www.linkedin.com/posts/the-difference-collective_say-hello-to-collective-consultant-richard-activity-7389560479272259584-EiwK (with photo) Richard Jarvis at Cohesion Bureau: https://cohesionbureau.com/bureau/richard-jarvis (with photo) - - - - - And here is the Cohesion Bureau team at their various locations in Europe and the US: https://cohesionbureau.com/bureau",
          "sentiment": 0.0,
          "engagement": "5,847",
          "price_at_post": "60.50",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-11T01:19:44.514180+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261542-Gingethe-72172957",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.596992",
        "source": "LSE_CHAT",
        "data": {
          "author": "GingetheWinge",
          "content": "First patients are expected to receive AVA6103 before the end of March.",
          "sentiment": 0.5,
          "engagement": "705",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-11T01:19:44.514198+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261521-B2HS2L-37543855",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.597714",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "FWIW Chris Maggos Strategic Consulting and IR, PR & BD Services for Biotech / Medtech Experience Managing Director Cohesion Bureau \u00b7 Full-time Dec 2022 - Present \u00b7 3 yrs 3 mos Geneva, Switzerland \u00b7 Hybrid Our experienced multi-disciplinary U.S. and Pan-European team offers insightful strategic consulting and services to expedite your corporate growth. In addition to strategic consulting, we offer execution services for partnering, fundraising, investor and (social) media relations. We have a dedicated editorial unit producing corporate content, including, writing, graphic design, video and photography. We want to be your partner for growth. Our experienced multi-disciplinary U.S. and Pan-European team offers insightful strategic consulting and services to expedite your corporate growth. In addition to strategic consulting, we offer execution services for partnering, fundraising, investor and (social) media relations. We have a dedicated editorial unit producing corporate content, including, writing, graphic design, video and photography. We want to be your partner for growth. Managing Director BioConfidant S\u00e0rl Sep 2014 - Present \u00b7 11 yrs 6 mos Geneva, Switzerland BioConfidant offers strategic consulting on three closely related types of corporate activities: investor relations, public relations and business development (i.e. licensing and M&A). With our partners around Europe and in the U.S. we started Cohesion Bureau in 2022 to level the playing field for European startups and small-cap companies. We established and managed the European investor relations business of LifeSci Advisors from 2015-2021. We are passionate about developing relationships and collaborating with clients to earn the visibility and impact they need to succeed.",
          "sentiment": 0.0,
          "engagement": "6,042",
          "price_at_post": "60.50",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-11T01:19:44.514217+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261513-Livedata--5612416",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.598309",
        "source": "LSE_CHAT",
        "data": {
          "author": "Livedataaccount",
          "content": "With the location being switzerland one does imagine the cohesion team are in bed with some big players at roche and novartis",
          "sentiment": 0.0,
          "engagement": "2,974",
          "price_at_post": "61.50",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-11T01:19:44.514245+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261503-Timster-49058565",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.598888",
        "source": "LSE_CHAT",
        "data": {
          "author": "Timster",
          "content": "That's a serious accusation watching you WILL be hearing from my legal team, not as hidden as you think.......",
          "sentiment": 0.0,
          "engagement": "20,640",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-11T01:19:44.514273+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261503-avctIPma--8399645",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.599564",
        "source": "LSE_CHAT",
        "data": {
          "author": "avctIPmatters",
          "content": "\" Cohesion Bureau (Communications)  Richard Jarvis / Chris Maggos \" Interesting  connection  Richard Jarvis  has with  Novartis .   Avacta  has had lots of changes  recently  - Michelle Morrow  did  not last long  - guess  one less salary to pay & also streamlining communication costs. ------- \"Richard Jarvis Trustee Director Trustee Director Novartis UK Pension Trustee CompanyNovartis UK Pension Trustee Company 2014 - Present \u00b7 12 yrs 2 mos2014 to Present \u00b7 12 yrs 2 mos Grew funding position from <90% of liabilities to ~110% (buy-out basis) for ~7 000 members.Grew funding position from <90% of liabilities to ~110% (buy-out basis) for ~7 000 members. Novartis logo Head of Strategy & Financial Communications Head of Strategy & Financial Communications NovartisNovartis 2021 - 2025 \u00b7 4 yrs2021 to 2025 \u00b7 4 yrs Basel, SwitzerlandBasel, Switzerland Led global team of communications and media relations professionals, responsible for financial communications and global top tier media engagement.Led global team of communications and media relations professionals, responsible for financial communications and global top tier media engagement. Communications Strategy, Team Management and +6 skills\" Gmcc",
          "sentiment": 0.0,
          "engagement": "742",
          "price_at_post": "60.50",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-11T01:19:44.514292+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261502-Livedata-81061968",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.600169",
        "source": "LSE_CHAT",
        "data": {
          "author": "Livedataaccount",
          "content": "I always imagined timster was a belly dancer",
          "sentiment": 0.0,
          "engagement": "2,974",
          "price_at_post": "61.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-11T01:19:44.514310+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261458-Watching--3400936",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.363454",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "Timster are you still a children\u2019s entertainer ?",
          "sentiment": 0.0,
          "engagement": "9,229",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-11T01:19:44.514329+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261453-Timster--4299293",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.363899",
        "source": "LSE_CHAT",
        "data": {
          "author": "Timster",
          "content": "One of Francis's KPA's is to ensure LDA's requests for updates via the lse website are promptly answered. Id expect an update within 48hrs LDA",
          "sentiment": 0.0,
          "engagement": "20,640",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-11T01:19:44.514348+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261453-Toukanka-62002804",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.364338",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "Clear from what CC said in today\u2019s RNS that no one has been dosed with 6103 yet. Given the preparation work that needs to be carried out including pre screening, I previously predicted April earliest for dosing to start. (Based on 6100 timescales)",
          "sentiment": 0.0,
          "engagement": "4,486",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-11T01:19:44.514379+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261426-Livedata-39843106",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.364756",
        "source": "LSE_CHAT",
        "data": {
          "author": "Livedataaccount",
          "content": "Be good to get an update please on TNBC progress and 6103 dosing thank you in advance",
          "sentiment": 0.0,
          "engagement": "2,974",
          "price_at_post": "60.50",
          "thread_title": "Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-11T01:19:44.514402+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261324-B2HS2L-17615538",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.365200",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "If this was true in Nov 2024 (so for AVA6000), I would assume the situation is a little more rosy now. Possibly some starters for 10 here. https://www.trinitydelta.org/research-notes/targeting-the-tumour-microenvironment-with-precision/ A reminder from Trinity Delta \u2013 Targeting the tumour microenvironment with pre|CISION - 18.11.2024 \"Avacta has so far FAP-enabled ten different warheads building up a database of multiple pre|CISION compounds that include c 40 capping groups (which alter the PK of the conjugate) and c 20 linkers (required for FAP cleavage with certain warheads and can be used to modify FAP affinity and activity). These have all been characterised through computational simulations to evaluate molecular binding and how they dock into the FAP structure. A key consideration is how close the warhead can get to the FAP cleavage sequence; this typically depends on the size of the molecule, and often defines whether a spacer group is required. Consideration is also given to how long the conjugate and the active warhead are likely to remain in the TME, and this informs whether PK alterations, achieved through an alternative capping group, are needed to either allow the sustained release of the warhead or to slow plasma clearance.",
          "sentiment": 0.0,
          "engagement": "6,042",
          "price_at_post": "60.50",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=060607B8-56D7-4812-99EC-1BE5765F573F"
        },
        "ingested_at": "2026-02-11T01:19:44.514421+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261308-pedrolan--1424102",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.365614",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Yes and what a truly remarkable career he could have.",
          "sentiment": 0.5,
          "engagement": "1,988",
          "price_at_post": "60.50",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=060607B8-56D7-4812-99EC-1BE5765F573F"
        },
        "ingested_at": "2026-02-11T01:19:44.514440+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261300-BuenaVis--2297131",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.366018",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "As the mechanism of action\u2014the dipeptide and the cleavage\u2014is proven, it now comes down to designing each molecule's pharmacokinetics to fit the needs for the warhead.  And who better to lead that than a highy competent chemist at the top of his game?",
          "sentiment": 0.0,
          "engagement": "5,847",
          "price_at_post": "60.50",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=060607B8-56D7-4812-99EC-1BE5765F573F"
        },
        "ingested_at": "2026-02-11T01:19:44.514458+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261159-B2HS2L--6945388",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.366489",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "\"Francis - We will learn more about this program in the clinic and apply that as we continue to develop NOVEL INTELLECTUAL PROPERTY around our highly successful pre|CISION\u00ae platform.\" -  We look forward to plenty of new IP to come. 29.10.2025 CC: \"Much of the success and how we are going to be able to move the dual payload through is going to depend on our initial observations in the clinic with the exatacan molecule. Francis and Tom mentioned that a lot of what we are doing with the dual payload is based on the learnings in the lab with the exatecan molecule. We expect to learn a lot about the exatecan molecule as we move it into the clinic and that's going to inform a lot about the dual payload molecules. Clinic learnings in the first half of 2026, will inform how quickly we're going to move the dual payload through.\" Also \"if we do right and we do great things for patients, we will be doing great things for our shareholders.\" I hope they stack the new IP high. It will increase the bargaining value of the company. It doesn't sound like Francis is going to be straying far from the lab, unless other chemists are inbound, and Francis is the mentor.  \ud83d\udcab",
          "sentiment": 0.0,
          "engagement": "6,042",
          "price_at_post": "60.50",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=060607B8-56D7-4812-99EC-1BE5765F573F"
        },
        "ingested_at": "2026-02-11T01:19:44.514477+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261120-Timster-57552624",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.366896",
        "source": "LSE_CHAT",
        "data": {
          "author": "Timster",
          "content": "Biggest buy signal in recent days is when eggy threw in the towel and removed his account.",
          "sentiment": 0.0,
          "engagement": "20,640",
          "price_at_post": "61.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-11T01:19:44.514506+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261105-yeboha--8001076",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.367315",
        "source": "LSE_CHAT",
        "data": {
          "author": "yeboha",
          "content": "Great RNS yet again today ! All moving in the right direction !",
          "sentiment": 0.0,
          "engagement": "967",
          "price_at_post": "61.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-11T01:19:44.514533+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261054-D-Geeman--3292391",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.367735",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "Certainly Watching 2 raises the tone but is that why people read bulletin boards Ginge? Would you rather read a poster's record have have them be proved right again and again? Or, like W2's record.. Shall I raise the tone? \"\u00a3200 ex-chinah, nailed on!\" \"Later today! \" (Note to self; see, it's not difficult.)",
          "sentiment": 0.0,
          "engagement": "5,877",
          "price_at_post": "61.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-11T01:19:44.514552+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261048-Gingethe-49966625",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.368149",
        "source": "LSE_CHAT",
        "data": {
          "author": "GingetheWinge",
          "content": "Agreed. Always the usual suspects that lower the tone.",
          "sentiment": 0.5,
          "engagement": "705",
          "price_at_post": "61.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-11T01:19:44.514571+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261032-Watching-14646237",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.368583",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "Tidy the BB Ignore the muppets We now know ignore and they argue with themselves And eventually dry up ! Great appointment well done team  avacta !. Jane",
          "sentiment": 0.0,
          "engagement": "9,229",
          "price_at_post": "61.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-11T01:19:44.514590+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261017-D-Geeman--3636110",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.369068",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "Touk, Watching does their best... And not just on AVCT. 'Watching2 'Posted in: ENET Posts: 9,227 RE: Sidelines22 Nov 2023 09:59 Actually 1p is very unlikely Bottom has now been hit imo. Good averaging opportunity! Next rns will lift us' And in case you were wondering how this 'prediction'went, today's SP: Share Price Information for Ethernity Net (ENET) Share Price is delayed by 15 minutes Get Live Data 0.0048    0.0001 (2.13%) Bid: 0.0046 Ask: 0.005 Spread: 0.0004 (8.696%) Market Cap: \u00a348.00k Still, plenty of folk 'Rec'watching's posts so hats-off to Jane (unless you're still holding on to it Jane?) .",
          "sentiment": 0.0,
          "engagement": "5,877",
          "price_at_post": "61.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-11T01:19:44.514608+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261003-Livedata--1491456",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.369492",
        "source": "LSE_CHAT",
        "data": {
          "author": "Livedataaccount",
          "content": "Francis has been instrumental in ava6103 and ava6207 running a successful business is about retaining top talent and i have no doubt his IP is massive at Avacta it is a great appointment",
          "sentiment": 0.0,
          "engagement": "2,974",
          "price_at_post": "61.00",
          "thread_title": "New CSO",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=2EBFCF4C-4A4D-475C-BBFD-DB095DA011B8"
        },
        "ingested_at": "2026-02-11T01:19:44.514639+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260926-Harrogat--1022087",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.369903",
        "source": "LSE_CHAT",
        "data": {
          "author": "Harrogate4",
          "content": "Agreed -----did they ever do anything ---apart from taking their salaries of course?",
          "sentiment": 0.0,
          "engagement": "805",
          "price_at_post": "61.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-11T01:19:44.514663+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260923-Bella653-39456612",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.370320",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "So can we assume THRUST and ICR have been ditched now...if so good ridens...",
          "sentiment": 0.0,
          "engagement": "6,761",
          "price_at_post": "61.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-11T01:19:44.514682+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260921-Bella653-38144612",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.370735",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "Or.. 1.  Is Cohesion Bureau about attracting Pharma funding? Their website is terrible...Nothing comes up in the NEWS section!!!!! 2.  We are not in the Immunotherapy space we now need good Chemists.   I think CC mentioned this in one of her videos when she talked about the 'Chemistry' involved in developing new pipelines.",
          "sentiment": 0.0,
          "engagement": "6,761",
          "price_at_post": "61.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-11T01:19:44.514701+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260919-yeboha--1149385",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.371148",
        "source": "LSE_CHAT",
        "data": {
          "author": "yeboha",
          "content": "But then again i dont no if avacta want the take over, they certainly wont push for it !",
          "sentiment": 0.0,
          "engagement": "967",
          "price_at_post": "61.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-11T01:19:44.514720+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260918-yeboha--7053952",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.371554",
        "source": "LSE_CHAT",
        "data": {
          "author": "yeboha",
          "content": "Watching , i agree with you, everything seems to be lining up beautifully for the take over this year !",
          "sentiment": 0.5,
          "engagement": "967",
          "price_at_post": "61.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-11T01:19:44.514738+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260915-Toukanka--1130834",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.371960",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "Watching In your view each year for the past three years was the year we would be taken over\ud83e\udd21",
          "sentiment": 0.0,
          "engagement": "4,486",
          "price_at_post": "61.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-11T01:19:44.514767+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260908-Vertizea-77160611",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.372377",
        "source": "LSE_CHAT",
        "data": {
          "author": "VertizeaSun",
          "content": "T/O? I quite agree. Avacta's got the air of a company tidying up loose ends.",
          "sentiment": 0.0,
          "engagement": "446",
          "price_at_post": "61.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-11T01:19:44.514793+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260907-yeboha-82115704",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.372784",
        "source": "LSE_CHAT",
        "data": {
          "author": "yeboha",
          "content": "Great news! Francis has been appointed as the new chief scientific officer. Retaining him will be a massive advantage moving forward!",
          "sentiment": 0.5,
          "engagement": "967",
          "price_at_post": "61.00",
          "thread_title": "Important Appointment",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=8E658AE1-929D-4CD1-910B-CBDF7FD77692"
        },
        "ingested_at": "2026-02-11T01:19:44.514812+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260903-Watching-28923829",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.373199",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "Imo This year we will  will be taken over The glowing data  must be worth the risk to get in first gla Jane !",
          "sentiment": 0.0,
          "engagement": "9,229",
          "price_at_post": "61.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-11T01:19:44.514833+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260858-nurseste--2998099",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.373605",
        "source": "LSE_CHAT",
        "data": {
          "author": "nursesteve",
          "content": "It seems a bit strange from Simon being touted by Chris as being so busy to quietly being removed ?",
          "sentiment": 0.0,
          "engagement": "1,169",
          "price_at_post": "61.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-11T01:19:44.514867+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260849-BuenaVis--8533467",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.092369",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "We don't know what he was doing not why he's no longer on the team. He was another of Alan's hires that's now gone.",
          "sentiment": 0.0,
          "engagement": "5,847",
          "price_at_post": "62.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-11T01:19:44.514903+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260844-Watching-63658285",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.093088",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "Leaky ship ! Another hole plugged",
          "sentiment": 0.0,
          "engagement": "9,229",
          "price_at_post": "62.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=060607B8-56D7-4812-99EC-1BE5765F573F"
        },
        "ingested_at": "2026-02-11T01:19:44.514941+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260839-BuenaVis-36455608",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.093853",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "We'll know where and when in the fullness of time. https://www.linkedin.com/in/michelle-morrow-127605137",
          "sentiment": 0.0,
          "engagement": "5,847",
          "price_at_post": "62.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=060607B8-56D7-4812-99EC-1BE5765F573F"
        },
        "ingested_at": "2026-02-11T01:19:44.514979+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260837-nurseste-97675556",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.094563",
        "source": "LSE_CHAT",
        "data": {
          "author": "nursesteve",
          "content": "So Simon was busy doing??? \ud83e\udd14",
          "sentiment": 0.0,
          "engagement": "1,169",
          "price_at_post": "62.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-11T01:19:44.515004+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260837-cj62--3937338",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.095298",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "Probably caught with her hand in the cookie jar !!",
          "sentiment": 0.0,
          "engagement": "4,304",
          "price_at_post": "62.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=060607B8-56D7-4812-99EC-1BE5765F573F"
        },
        "ingested_at": "2026-02-11T01:19:44.515034+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260832-Harrogat--2736651",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.095975",
        "source": "LSE_CHAT",
        "data": {
          "author": "Harrogate4",
          "content": "Congratulations to Dr Francis Wilson, very well deserved in my view and a great choice by CC.",
          "sentiment": 0.0,
          "engagement": "805",
          "price_at_post": "62.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=060607B8-56D7-4812-99EC-1BE5765F573F"
        },
        "ingested_at": "2026-02-11T01:19:44.515054+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260818-Watching-28427366",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.096697",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "Perhaps it was requested by a big pharma as part of a agreement",
          "sentiment": 0.0,
          "engagement": "9,229",
          "price_at_post": "60.50",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=060607B8-56D7-4812-99EC-1BE5765F573F"
        },
        "ingested_at": "2026-02-11T01:19:44.515073+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260815-Prion25-26061732",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.097532",
        "source": "LSE_CHAT",
        "data": {
          "author": "Prion25",
          "content": "Michelle highly regarded in oncology biotech did a block buster drug with AZ  probably been headhunted by a prospective parter of Avacta or  big pharma competitors We won\u2019t know probably a NDA has been signed",
          "sentiment": 0.0,
          "engagement": "1,555",
          "price_at_post": "60.50",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=060607B8-56D7-4812-99EC-1BE5765F573F"
        },
        "ingested_at": "2026-02-11T01:19:44.515092+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260809-B2HS2L-87083575",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.098278",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "CC :  \"\"In addition to his leadership internally, he has also been a key member of the team positioning our business across the international drug development sector. Francis is a well-known leader in medicinal chemistry externally and we are looking forward to forging the next chapter of pre|CISION\u00ae with his scientific leadership and expertise. \" I think she wants him to become more of a Key Opinion Leader, - she uses 'leader' above - in spreading the pre-CISION gospel. To become more influential with respect to FDA / MHRA and the like. Michelle Morrow may have decided the grass was greener. \"former CSO Michelle Morrow will be leaving Avacta to pursue another opportunity\" - singular not plural. She must have done a lot of work to get AVA6103 successfully through the IND Application. (That's true for all staff). She knows what's inside the capping group and the linker group, - those two blue blobs (group A & group B) in blue in certain presentations.",
          "sentiment": 0.0,
          "engagement": "6,042",
          "price_at_post": "60.50",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=060607B8-56D7-4812-99EC-1BE5765F573F"
        },
        "ingested_at": "2026-02-11T01:19:44.515128+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260809-Colesy74-90852540",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.098949",
        "source": "LSE_CHAT",
        "data": {
          "author": "Colesy74",
          "content": "Https://youtu.be/kyQJRyoPzvw",
          "sentiment": 0.0,
          "engagement": "21",
          "price_at_post": "60.50",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-11T01:19:44.515147+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260737-Vertizea--4869057",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.099686",
        "source": "LSE_CHAT",
        "data": {
          "author": "VertizeaSun",
          "content": "Also....Simon Bennett was removed from Leadership page but Yulii Bogatyrenko remains.",
          "sentiment": 0.0,
          "engagement": "446",
          "price_at_post": "60.50",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-11T01:19:44.515182+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260727-dafad--2616886",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.100396",
        "source": "LSE_CHAT",
        "data": {
          "author": "dafad",
          "content": "They may have wanted someone of a higher calibre in the position as they develop the Platform",
          "sentiment": 0.0,
          "engagement": "2,416",
          "price_at_post": "60.50",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=060607B8-56D7-4812-99EC-1BE5765F573F"
        },
        "ingested_at": "2026-02-11T01:19:44.515204+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260723-Livedata--1915356",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.101080",
        "source": "LSE_CHAT",
        "data": {
          "author": "Livedataaccount",
          "content": "Who knows employees have many reasons for leaving job roles",
          "sentiment": 0.0,
          "engagement": "2,974",
          "price_at_post": "60.50",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=060607B8-56D7-4812-99EC-1BE5765F573F"
        },
        "ingested_at": "2026-02-11T01:19:44.515223+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260721-IFA90--7249251",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.101762",
        "source": "LSE_CHAT",
        "data": {
          "author": "IFA90",
          "content": "Why leave before the multi billion TO?",
          "sentiment": 0.0,
          "engagement": "416",
          "price_at_post": "60.50",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=060607B8-56D7-4812-99EC-1BE5765F573F"
        },
        "ingested_at": "2026-02-11T01:19:44.515242+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260721-BuenaVis--4211474",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.102469",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "A good decision. From CC's praise, he's likely been leading the science anyway.",
          "sentiment": 0.0,
          "engagement": "5,847",
          "price_at_post": "60.50",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=060607B8-56D7-4812-99EC-1BE5765F573F"
        },
        "ingested_at": "2026-02-11T01:19:44.515261+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260715-BuenaVis--6573963",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.103183",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Avacta's new comms organisation, based in Geneva: https://cohesionbureau.com/ It's All Change, every month, with Avacta!",
          "sentiment": 0.0,
          "engagement": "5,847",
          "price_at_post": "60.50",
          "thread_title": "Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-11T01:19:44.515279+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260705-JFK8--7972028",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.103866",
        "source": "LSE_CHAT",
        "data": {
          "author": "JFK8",
          "content": "New CSO to replace Michelle Morrow",
          "sentiment": 0.0,
          "engagement": "3,058",
          "price_at_post": "60.50",
          "thread_title": "RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=060607B8-56D7-4812-99EC-1BE5765F573F"
        },
        "ingested_at": "2026-02-11T01:19:44.515313+00:00"
      },
      {
        "event_id": "SOCIAL-8Feb20261320-BuenaVis--2370137",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.104577",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "The link didn't work so I ran that query in Grok.  Yes, the procedure is involved but so is standard doxorubicin I should think - valid prescription, qualified people, the \"Five Rights\", etc. but with the added safety measures need for radioactivity. I should think the patients have to be held in the hospital to be sure that the drug can be administered rather than have them just ambling in for the 3-weekly injection, the reason being timeliness, timeliness, timeliness... to Grok: \"What are the steps to get a radiopharmaceutical from production to patient?\" \"The journey of a radiopharmaceutical from production to patient administration is a highly time-sensitive, regulated supply chain due to the short half-lives of most radionuclides (often hours to days). This limits the window for manufacturing, quality control, transportation, and use. The process varies depending on the radionuclide (e.g., cyclotron-produced like F-18, Ga-68, or reactor-produced like Mo-99/Tc-99m, Lu-177) and whether the product is a ready-to-use diagnostic agent (e.g., FDG), a kit requiring on-site labeling, or a therapeutic agent.\" ...and so it goes on with the 11 stages and summarised under Key Challenges (Time pressure, Radiation safety, Regulatory compliance, Supply chain complexity)",
          "sentiment": 0.0,
          "engagement": "5,847",
          "price_at_post": "60.50",
          "thread_title": "RE: Watch Ely Lilly could make a move",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=4B1C735B-8BE4-4153-95B2-75A61E403C1D"
        },
        "ingested_at": "2026-02-11T01:19:44.515335+00:00"
      },
      {
        "event_id": "SOCIAL-8Feb20261235-B2HS2L--1546268",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.105340",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "Source Grok: \"what is the procedure to administer a dose of a radiopharmaceutical drug?\" https://x.com/i/grok?conversation=2020452204348313802 Intravenous administration of AVA6103 is going to be a doddle compared with radiopharmaceutical administration by a team of several. Time / expense to get radiopharmaceutical to hospital? If the decision to make funds available to dose a patient is made by a health insurance company, I don't think they would consider a radiopharmaceutical for long if a cheaper method of administration is available. PDC ADC - it has targeting issues. radiopharmaceutical - difficult / expensive to administer, too many specialists This is my list of most to least preferrable drug types for experts to consider using. Novartis must be \ud83d\udc40",
          "sentiment": 0.0,
          "engagement": "6,042",
          "price_at_post": "60.50",
          "thread_title": "RE: Watch Ely Lilly could make a move",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=4B1C735B-8BE4-4153-95B2-75A61E403C1D"
        },
        "ingested_at": "2026-02-11T01:19:44.515353+00:00"
      },
      {
        "event_id": "SOCIAL-8Feb20261107-GainsOnl-20949724",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.106009",
        "source": "LSE_CHAT",
        "data": {
          "author": "GainsOnly",
          "content": "This will be over 75p last placing price very soon DYOR",
          "sentiment": 0.0,
          "engagement": "10",
          "price_at_post": "60.50",
          "thread_title": "RE: Watch Ely Lilly could make a move",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=4B1C735B-8BE4-4153-95B2-75A61E403C1D"
        },
        "ingested_at": "2026-02-11T01:19:44.515372+00:00"
      },
      {
        "event_id": "SOCIAL-8Feb20261042-LiveLong-23000454",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.106802",
        "source": "LSE_CHAT",
        "data": {
          "author": "LiveLongnProsper",
          "content": "A few Exatecan products that AVA6103 might be compared against ..? Cybrexa \u2013 privately held, have CBX-12 a PDC, targeting pH (acidity), in phase 2. EMD Serono \u2013 Merck subsidiary, have M7437, ADC based, in phase 1 from Jan 2026. Innovent \u2013 now partnered with Takeda, have IBI343, ADC based, in phase 3 with FDA fast track. AVA6103, indeed the whole pre|CISION\u00ae platform, remains, as yet, \u2018unpartnered\u2019 (OK Lilly/CanSeek) - but not without \u2018friends\u2019 and \u2018admirers\u2019. What about BP then ..? We know that Daiichi Sankyo and AZN are massively committed to Enhertu\u00ae (trastuzumab deruxtecan), HER2 targeted ADC, and we know about \u2018patent cliffs\u2019.  DS / AZN currently pushing through a number of DXd products, perhaps most notably Datroway\u00ae (datopotamab deruxtecan), TROP2 targeted ADC in phase 3.  Daiichi have been working with Exatecan for over 20 years.  These guys need to protect their \u2018space\u2019. Merck (Keytruda) were apparently going to spend up to $32bn for Revolution \u2013 seems to be off now?  Guess they have ready cash then? Novartis have this massive \u2018hole\u2019 in their pipeline, i.e. no ADC\u2019s, but are doing FAP targeting for RLT.  They seem to have plenty of money also. \u2018Triggers\u2019 for Avacta acquisition ..? Positive AVA6000 TNBC readout?  PFS for SGC and AVA6000 becomes \u2018standard of care\u2019?  Early positive response to AVA6103? Or just a  \u2018pre-emptive strike\u2019? GLA",
          "sentiment": 0.0,
          "engagement": "1,836",
          "price_at_post": "60.50",
          "thread_title": "RE: Watch Ely Lilly could make a move",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=4B1C735B-8BE4-4153-95B2-75A61E403C1D"
        },
        "ingested_at": "2026-02-11T01:19:44.515391+00:00"
      },
      {
        "event_id": "SOCIAL-8Feb20260925-opti_mys-42106985",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.107491",
        "source": "LSE_CHAT",
        "data": {
          "author": "opti_mystic",
          "content": "Keytruda is out of Patent in 2028 when the immunology drug becomes an out of patent generic drug. Avacta could use it like we have Dox and Exatecan and we'd have chemo and immunology options.",
          "sentiment": 0.0,
          "engagement": "315",
          "price_at_post": "60.50",
          "thread_title": "RE: Watch Ely Lilly could make a move",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=4B1C735B-8BE4-4153-95B2-75A61E403C1D"
        },
        "ingested_at": "2026-02-11T01:19:44.515410+00:00"
      },
      {
        "event_id": "SOCIAL-8Feb20260859-Aldebara-72040811",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.108206",
        "source": "LSE_CHAT",
        "data": {
          "author": "Aldebaran",
          "content": "So we saying that lily and Novartis have eyes on either directly or indirectly. Would love to throw merck into the mix as well due to keytruda patent expiry. What about daiichi sankyo also. 4 way bidding war would be nice. All 4 could be made a reasonable case to be seriously interested in precision",
          "sentiment": 0.0,
          "engagement": "3,933",
          "price_at_post": "60.50",
          "thread_title": "RE: Watch Ely Lilly could make a move",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=4B1C735B-8BE4-4153-95B2-75A61E403C1D"
        },
        "ingested_at": "2026-02-11T01:19:44.515445+00:00"
      },
      {
        "event_id": "SOCIAL-8Feb20260852-Bella653-17607103",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.108890",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "'POINT Biopharma Inc Avacta has entered into a license agreement with POINT Biopharma Inc., (taken over by Eli Lilly in late 2023) a clinical-stage pharmaceutical company focused on the development and commercialisation of radioligand therapies for the treatment of cancer, to provide access to Avacta\u2019s pre|CISION\u00ae technology for the development of tumor-activated radiopharmaceuticals.' How much access are they now getting to PreCISION???",
          "sentiment": 0.0,
          "engagement": "6,761",
          "price_at_post": "60.50",
          "thread_title": "RE: Watch Ely Lilly could make a move",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=4B1C735B-8BE4-4153-95B2-75A61E403C1D"
        },
        "ingested_at": "2026-02-11T01:19:44.515466+00:00"
      },
      {
        "event_id": "SOCIAL-8Feb20260843-Bella653-60329548",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.109654",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "'Toxicity caused by off-target delivery is a longstanding concern of cancer therapies. Developed by Dr. William Bachovchin of Tufts University, POINT\u2019s CanSEEK\u2122 technology aims to minimize radiopharmaceutical toxicity caused by off-target delivery by only activating a radiopharmaceuticals' targeting moiety, such as its ligand, after it has encountered FAP-\u03b1 in the tumor microenvironment (TME). FAP-\u03b1 is highly expressed on a wide range of solid tumors, but in very low quantities or absent altogether in healthy tissues. The intent of CanSEEK\u2122 is to minimize the toxicity caused by off-target delivery. At first, CanSEEK\u2122 prevents the radiopharmaceutical from bonding to receptors on cells. When the radiopharmaceuticals enter the TME, the radiopharmaceuticals targeting moiety is re-activated, enabling it to once again bond to receptors on cancer cells. CanSEEK\u2122 has the potential to make treatments even more precise, expanding their therapeutic index, and enabling the use of new, more powerful medical isotopes.' \u200d",
          "sentiment": 0.0,
          "engagement": "6,761",
          "price_at_post": "60.50",
          "thread_title": "RE: Watch Ely Lilly could make a move",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=4B1C735B-8BE4-4153-95B2-75A61E403C1D"
        },
        "ingested_at": "2026-02-11T01:19:44.515484+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20262318-Icecool-66580775",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.525582",
        "source": "LSE_CHAT",
        "data": {
          "author": "Icecool",
          "content": "Happy holidays everyone. \ud83d\ude09\ud83e\udd23\ud83d\ude2d",
          "sentiment": 0.0,
          "engagement": "8,855",
          "price_at_post": "60.50",
          "thread_title": "RE: From MM on X - If it offends - Tough",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=D20B314B-66BB-47B0-8ED4-D46B27E22B85"
        },
        "ingested_at": "2026-02-11T01:19:44.515503+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20262125-Livedata-58237633",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.526281",
        "source": "LSE_CHAT",
        "data": {
          "author": "Livedataaccount",
          "content": "who is offended not icecool being ****** again i hope",
          "sentiment": 0.0,
          "engagement": "2,969",
          "price_at_post": "60.50",
          "thread_title": "RE: From MM on X - If it offends - Tough",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=D20B314B-66BB-47B0-8ED4-D46B27E22B85"
        },
        "ingested_at": "2026-02-11T01:19:44.515521+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20262120-IFA90--2959052",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.526944",
        "source": "LSE_CHAT",
        "data": {
          "author": "IFA90",
          "content": "I\u2019m not offended. Xx",
          "sentiment": 0.0,
          "engagement": "415",
          "price_at_post": "60.50",
          "thread_title": "RE: From MM on X - If it offends - Tough",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=D20B314B-66BB-47B0-8ED4-D46B27E22B85"
        },
        "ingested_at": "2026-02-11T01:19:44.515540+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20262049-B2HS2L--7043987",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.527979",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "Https://x.com/BMHLTD/status/1736326494035603668 - Thanks BMH. December 2023 - Set of extracts from a Will Tap presentation. Will Tap discusses STS treatment improvement necessary. Now we have SGC first pass results, - AVA6000 more likely to be able to address items on Will Tap's STS wish list - with resulting FDA satisfaction.",
          "sentiment": 0.0,
          "engagement": "6,031",
          "price_at_post": "60.50",
          "thread_title": "Will Tap STS wish list",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=21C3C888-CE85-4F00-B718-E879BB3F5CC6"
        },
        "ingested_at": "2026-02-11T01:19:44.515575+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20262037-BuenaVis-22425249",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.528670",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Top publication, Scrip, so this is excellent exposure for CC and Avacta in their 'preview' of the year.",
          "sentiment": 0.0,
          "engagement": "5,826",
          "price_at_post": "60.50",
          "thread_title": "RE: Evolving Drug Conjugates",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B37AC3F0-A005-4580-9CCE-040AE6DF8EA7"
        },
        "ingested_at": "2026-02-11T01:19:44.515607+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261929-avctIPma-34256903",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.529343",
        "source": "LSE_CHAT",
        "data": {
          "author": "avctIPmatters",
          "content": "\"drive significant interest and global pharma partnerships.\"  sounds  good ! Gmcc",
          "sentiment": 0.0,
          "engagement": "740",
          "price_at_post": "60.50",
          "thread_title": "RE: Evolving Drug Conjugates",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B37AC3F0-A005-4580-9CCE-040AE6DF8EA7"
        },
        "ingested_at": "2026-02-11T01:19:44.515627+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261924-avctIPma--4201305",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.530056",
        "source": "LSE_CHAT",
        "data": {
          "author": "avctIPmatters",
          "content": "Thanks to Stonks ;   CC featured \"Scrip Asks... What Does 2026 Hold For Biopharma? Part 4: R&D Innovation\" https://insights.citeline.com/scrip/scrip-asks/scrip-asks-what-does-2026-hold-for-biopharma-part-4-rd-innovation-NDREFKFVB5DZPAQLA5CIZHE7OI/#oncology \"Evolving Drug Conjugates Drugs conjugated to antibodies and other carriers continue advancing through next-generation payload and linker innovation. \u201c2026 will be a pivotal year for dual payload drug conjugates, as the first wave of these therapies is expected to yield initial clinical data,\u201d predicted Christina Coughlin, CEO of Avacta Therapeutics. \u201cThe first dual payload peptide-drug conjugate was announced this year, and dozens of major pharma companies are advancing dual-payload programs targeting different resistance mechanisms. We expect the technology\u2019s ability to overcome drug resistance, enhance tumor selectivity and broaden the therapeutic window to drive significant interest and global pharma partnerships. This represents oncology\u2019s evolution from sequential combination dosing to precision dual-delivery, fundamentally reshaping how we approach tumor heterogeneity and resistance.\u201d Gmcc",
          "sentiment": 0.0,
          "engagement": "740",
          "price_at_post": "60.50",
          "thread_title": "Evolving Drug Conjugates",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B37AC3F0-A005-4580-9CCE-040AE6DF8EA7"
        },
        "ingested_at": "2026-02-11T01:19:44.515646+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261910-JES1889--2879003",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.530764",
        "source": "LSE_CHAT",
        "data": {
          "author": "JES1889",
          "content": "I think the other piece to consider here is that Avacta no longer seems to be a leaky ship. I now believe that (if and) when news drops it\u2019ll arrive without forewarning, like the FDA news this week. Whilst I see there being room for the share price to appreciate as this year progresses, on retail demand/expectations. I doubt that even positive data releases on TNBC and 6103 will see this head anywhere near true value. AIM and the UK investment community just find the scale too hard to contemplate. I\u2019ve seen comments about the current low share price and suggesting that potential bidders would start buying shares in the open market. There\u2019s no way that any party under NDA would be able to do that as they\u2019d be party to inside information and that would be covered by the Market Abuse Regulations. The NDA would almost certainly have some form of standstill clause prohibiting open market share purchases. I think the big news when it comes will come out of the blue.",
          "sentiment": 0.0,
          "engagement": "83",
          "price_at_post": "60.50",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T01:19:44.515664+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261857-Icecool-69480108",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.531439",
        "source": "LSE_CHAT",
        "data": {
          "author": "Icecool",
          "content": "Bella you assume the SP and deal value will be linked prior to any announcement. That might happen on the Nasdaq, however it certainly doesn\u2019t happen on AIM. The price will be negotiated on the technology, then and only then will the SP react accordingly.\ud83d\udcaf\ud83d\udc4d",
          "sentiment": 0.0,
          "engagement": "8,855",
          "price_at_post": "60.50",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T01:19:44.515683+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261334-Timster--3034545",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.532093",
        "source": "LSE_CHAT",
        "data": {
          "author": "Timster",
          "content": "Why would that offend?",
          "sentiment": 0.0,
          "engagement": "20,637",
          "price_at_post": "60.50",
          "thread_title": "RE: From MM on X - If it offends - Tough",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=D20B314B-66BB-47B0-8ED4-D46B27E22B85"
        },
        "ingested_at": "2026-02-11T01:19:44.515702+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261322-Toukanka--5154797",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.532773",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "All hail the uber ramper. But I agree with everything except I think his timeline is optimistic. I\u2019m still saying Summer for the pivotal moment - in that respect I am accepting CC\u2019s predictions.",
          "sentiment": 0.0,
          "engagement": "4,476",
          "price_at_post": "60.50",
          "thread_title": "RE: From MM on X - If it offends - Tough",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=D20B314B-66BB-47B0-8ED4-D46B27E22B85"
        },
        "ingested_at": "2026-02-11T01:19:44.515737+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261243-wyndrum-49889032",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.533481",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "Does that mean MM is NFT?",
          "sentiment": 0.0,
          "engagement": "12,250",
          "price_at_post": "60.50",
          "thread_title": "RE: From MM on X - If it offends - Tough",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=D20B314B-66BB-47B0-8ED4-D46B27E22B85"
        },
        "ingested_at": "2026-02-11T01:19:44.515759+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261226-cj62-19235865",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.534176",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "I have never been influenced by MM's ramblings but this actually echoes my sentiments exactly, our money is safe as I believe SGC alone makes this a very valuable company. We are now waiting on initial TNBC data prior to H2 which if successful will boost the valuation of Avacta considerably and to top that off ava6103 initial data i expect mid H2. Very exciting times indeed and hopefully well worth the wait.",
          "sentiment": 0.0,
          "engagement": "4,302",
          "price_at_post": "60.50",
          "thread_title": "RE: From MM on X - If it offends - Tough",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=D20B314B-66BB-47B0-8ED4-D46B27E22B85"
        },
        "ingested_at": "2026-02-11T01:19:44.515777+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261217-D-Geeman-74784520",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.534833",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "Vertizea, son, B2H just beat me to it. Whenever I have been influenced by MM in hindsight I should have done the opposite. Yet this does seem a very exciting time. 'If .... and b) the company can stay independent for a couple more years at least' could be the explanation of the contradiction in my response. I think I will keep some powder dry for the next year or so. Currently the 'powder' is in WG, waiting to be worth 30p. Would be comvenient if the various timings work out for me.",
          "sentiment": 0.0,
          "engagement": "5,868",
          "price_at_post": "60.50",
          "thread_title": "RE: From MM on X - If it offends - Tough",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=D20B314B-66BB-47B0-8ED4-D46B27E22B85"
        },
        "ingested_at": "2026-02-11T01:19:44.515796+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261206-B2HS2L-47075032",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.535518",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "Does that mean MM's out? Not offended. \ud83d\ude44 PS probably reducing.",
          "sentiment": 0.0,
          "engagement": "6,031",
          "price_at_post": "60.50",
          "thread_title": "RE: From MM on X - If it offends - Tough",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=D20B314B-66BB-47B0-8ED4-D46B27E22B85"
        },
        "ingested_at": "2026-02-11T01:19:44.515816+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261201-Vertizea-79385482",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.536296",
        "source": "LSE_CHAT",
        "data": {
          "author": "VertizeaSun",
          "content": "Myles McNulty @MylesMcNulty \u00b7 2h Replying to @RobDay80669068 Morning Robert, hope all's well. #AVCT's news on Tuesday was phenomenal. My understanding is that it's an unprecedented move by the FDA to remove the dosing limit for a modified-/reformulated-/pro-chemotherapy,  mid-Phase 1 trial. The rapid decline and fall of the UK investment community - in depth, breadth, intellectual curiosity and risk tolerance - is in my view providing one of the greatest asymmetrical bets of all time. #AVA6000 is an absolute shoe-in to get to market now. It much more than underpins Avacta's entire market cap. Management will know if #AVA6103 - 'the Beast' - is working in patients as they hope it will, by the end of next month. That single drug  has real potential to become the best selling drug in the history of pharma. It really is straightforward to explain and understand this. Personally, I give AVA6103 well over a >50% chance of success in clinic. If a) it is indeed a success in the clinic; and b) the company can stay independent for a couple more years at least; then the returns from the current 60p share price could be >100x. I have recently provided a real world example of these returns (see my last post on Avacta, comparing it with $RVMD). The next 6 months are by far the most important in Avacta's history. Good luck!",
          "sentiment": 0.0,
          "engagement": "440",
          "price_at_post": "60.50",
          "thread_title": "From MM on X - If it offends - Tough",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=D20B314B-66BB-47B0-8ED4-D46B27E22B85"
        },
        "ingested_at": "2026-02-11T01:19:44.515835+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261152-wyndrum-30755902",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.537031",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "Well done Bella, although you won't see this post because you are so clever with the filter button but I raised this most recently with NFT and he never responded to his valuation of $28b based on another company, even though I asked 3 times. Thats the problem with filters. I get filtering the sheppys and watchings of this world that offer absolutely nothing but when I am not defending myself against unsolicited slurs and random insult-only posts, I only talk about AVCT. You tend to eventually come to the same conclusions as me but it takes a while and of course that ground has already been covered. The thing I have noticed is that it does not take long at all to quickly scan any post to see if it has relevance or not and as a result no longer bother filtering anyone. And why? Just on the chance that they do in fact come across some good info or (heaven forfend), some helpful insight. But as I say this will just be another green box for you to never know what was said",
          "sentiment": 0.0,
          "engagement": "12,250",
          "price_at_post": "60.50",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T01:19:44.515869+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261143-Bella653--1596813",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.537707",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "Anyone quoting billion $ deals should also post the number of shares that were in issue and the SP prior to the deal...without this info you cannot compare apples with apples. I've checked some of these big deals only to find the SP increase was relatively small.",
          "sentiment": 0.0,
          "engagement": "6,756",
          "price_at_post": "60.50",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T01:19:44.515890+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261113-B2HS2L-85166846",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.538535",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "GSK's new CEO looking for $2B to $4B deals 'hiding in plain sight' This is the title of a Fierce Pharma document found on this link: https://www.fiercebiotech.com/biotech/gsks-new-ceo-looking-2-4b-deals-hiding-plain-sight +++ Luke Miels had only been at the helm of GSK for 20 days before he signed off on his first multibillion-dollar buyout, and the CEO is clear on what else will attract his interest. \u201cThe basic framework that we like for [business development] is in that 2-to-4 billion [dollar] range,\u201d Miels told journalists on a fourth-quarter earnings call this morning. \u201cTypically, we like a program where the science is reasonably established,\u201d he added. Miels\u2014who served as GSK\u2019s chief commercial officer before taking over from CEO Emma Walmsley in the new year\u2014pointed to a pattern in dealmaking set in 2022 by the $1.9 billion acquisition of Sierra Oncology for its near-approval cancer drug. GSK is especially interested in drugs where \u201cwe've got a degree of validation on the science, but there are liabilities with the existing products,\u201d he said. To demonstrate these criteria, Miels cited the $2.2 billion buyout of Rapt Therapeutics just days into his tenure as CEO. Rapt\u2019s IgE antibody ozureprubart protects against food allergy reactions by targeting the same epitope as Novartis and Roche\u2019s Xolair. Miels admitted that Xolair has \u201cabsolutely exploded in the U.S. for usage with severe allergies, particularly in kids.\u201d \u201cBut the problem is there's a very complicated dosing regimen, and these kids have to inject themselves every two weeks,\u201d he explained. \u201c[Ozureprubart] works exactly the same way as Xolair, except that you give it on a much lower frequency,\u201d Miels said. \ud83d\udc40 \u201cSo that's essentially the methodology we're going to follow with [business development]\u2014looking for assets [that are] well priced, not necessarily in the mainstream, hiding in plain sight,\u201d the CEO added. \u201cAnd we'll do that with a degree of frequency, which, again, will help us build out the late-stage portfolio.\u201d 1 The basic framework that we like for [business development] is in that 2-to-4 billion [dollar] range,\u201d  \u274c 2 \u201cTypically, we like a program where the science is reasonably established\u201d   \u2714\ufe0f 3 GSK is interested in drugs where \u201cwe've got a degree of validation on the science, but there are liabilities with the existing products\u201d \u2714\ufe0f 4  ...looking for assets [that are] well priced, not necessarily in the mainstream, hiding in plain sight\u201d \u274c see 1 - I'd take issue that multibillion assets don't usually exist in the mainstream, hiding in plain sight. I'd say all now know about Avacta and its products. Those specialising in cancer therapeutics HAVE to be interested or start making BIG advances soon in ADC cancer targeting. I think overall, GSK is looking for an opportunity that costs less than Avacta will sell for. - From the horses mouth.",
          "sentiment": 0.0,
          "engagement": "6,031",
          "price_at_post": "60.50",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T01:19:44.515909+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261101-Watching-49364652",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.539211",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "You don\u2019t always get the best deals with smaller companies .. J",
          "sentiment": 0.0,
          "engagement": "9,224",
          "price_at_post": "60.50",
          "thread_title": "RE: Trading 212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B38EA914-FA00-4B19-B293-5E96B62D2062"
        },
        "ingested_at": "2026-02-11T01:19:44.515928+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261055-Profchee-32724582",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.539863",
        "source": "LSE_CHAT",
        "data": {
          "author": "Profcheese",
          "content": "II also in the process of reducing their charges at the moment. It's a competitive world!",
          "sentiment": 0.0,
          "engagement": "539",
          "price_at_post": "60.50",
          "thread_title": "RE: Trading 212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B38EA914-FA00-4B19-B293-5E96B62D2062"
        },
        "ingested_at": "2026-02-11T01:19:44.515947+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261008-Watching-83116637",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.540533",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "IG t buying n selling is free if you have over \u00a330 k in there account",
          "sentiment": 0.0,
          "engagement": "9,224",
          "price_at_post": "60.50",
          "thread_title": "RE: Trading 212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B38EA914-FA00-4B19-B293-5E96B62D2062"
        },
        "ingested_at": "2026-02-11T01:19:44.515968+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261004-Bella653--7290407",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.541198",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "Have you compared the Bid and Ask prices ...many of these No Fee sites don't give the 'best' prices...",
          "sentiment": 0.0,
          "engagement": "6,756",
          "price_at_post": "60.50",
          "thread_title": "RE: Trading 212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B38EA914-FA00-4B19-B293-5E96B62D2062"
        },
        "ingested_at": "2026-02-11T01:19:44.516002+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20260955-wyndrum--3263513",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.541863",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "FWIW they were efficient in sorting out a pension for me too",
          "sentiment": 0.0,
          "engagement": "12,250",
          "price_at_post": "60.50",
          "thread_title": "RE: Trading 212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B38EA914-FA00-4B19-B293-5E96B62D2062"
        },
        "ingested_at": "2026-02-11T01:19:44.516022+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20260955-avctIPma-30083742",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.542723",
        "source": "LSE_CHAT",
        "data": {
          "author": "avctIPmatters",
          "content": "Recent CC quotes :  %   Chance of success  -  Surely Avacta platform that  can to enhance  existing drug treatments  requires  an IP value asset  re-set  . Certainly worth waiting  for  to see   which  BP  jumps first  . ---------------- \"@coughlin582: \u201cif there\u2019s an organ with a cancer, we can address it\u201d \"Christina Coughlin @coughlin582 \u00b7 Feb 4 Replying to @coughlin582 Love this! No would never give our secrets away here! The secret to the sustained release mechanism invented by our brilliant chemistry team is behind blob A and blob B. We call this the \u201cblob slide\u201d \u2026 #BestTeamEver\" Gmcc",
          "sentiment": 0.0,
          "engagement": "740",
          "price_at_post": "60.50",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T01:19:44.516041+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20260946-D-Geeman-99155679",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.174673",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "It's like Lidl V's Sainsbury's, but if Lidl stock everything you want then go for it. I found the message from HL regarding their charges, soon to be changed: 'Trading / Dealing Fees: We are reducing the amount you pay to buy or sell shares with us, from \u00a311.95 to \u00a36.95 per online trade** We\u2019re introducing a charge of \u00a31.95 per trade to buy or sell funds online' Account charges: We are reducing our account charges* from 0.45% to 0.35% per year on Stocks and Shares ISA and Self-Invested Personal Pension (SIPP) accounts For Fund and Share Accounts, we are reducing account charges for holding funds, from 0.45% to 0.35% per year and we are introducing a charge of 0.35% to hold shares New account charge limits for shares (includes investment trusts, Exchange Traded Funds (ETFs) and bonds): You will never pay more than \u00a3150 per year in account charges* for holding shares in each of our SIPP, Stocks and Shares ISA or our Fund and Share Accounts Compare current vs future charges",
          "sentiment": 0.0,
          "engagement": "5,868",
          "price_at_post": "60.50",
          "thread_title": "RE: Trading 212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38EA914-FA00-4B19-B293-5E96B62D2062"
        },
        "ingested_at": "2026-02-11T01:19:44.516060+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20260930-Watching-86883112",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.175455",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "A  big pharma   can\u2019t afford not to take us over Who ever bids first will know they will become the market leader over night  with our science ! Imo it\u2019s going to happen very very quickly in 2026 . Hold or. Top up if funds allow Gla . Jane",
          "sentiment": 0.0,
          "engagement": "9,224",
          "price_at_post": "60.50",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T01:19:44.516079+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20260918-cj62-49994052",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.176169",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "Incalculable!!!",
          "sentiment": 0.0,
          "engagement": "4,302",
          "price_at_post": "60.50",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T01:19:44.516110+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20260859-Wilson63-72714243",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.176882",
        "source": "LSE_CHAT",
        "data": {
          "author": "Wilson63",
          "content": "Post by Tvr5 on X read this and consider being used for just one of these examples and what a fair price would be for the company. https://x.com/TVR5AVCT/status/2019678221504291189",
          "sentiment": 0.0,
          "engagement": "8,808",
          "price_at_post": "60.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T01:19:44.516143+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20260847-jackeste--2480265",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.177597",
        "source": "LSE_CHAT",
        "data": {
          "author": "jackester",
          "content": "They definitely do deal in Avacta.",
          "sentiment": 0.0,
          "engagement": "311",
          "price_at_post": "60.00",
          "thread_title": "RE: Trading 212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38EA914-FA00-4B19-B293-5E96B62D2062"
        },
        "ingested_at": "2026-02-11T01:19:44.516162+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20260811-JFK8-44025783",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.178308",
        "source": "LSE_CHAT",
        "data": {
          "author": "JFK8",
          "content": "Opened an account and closed it 20 minutes later as they dont deal  AVCT shares .don't know if they do now though as it was a while ago",
          "sentiment": 0.0,
          "engagement": "3,057",
          "price_at_post": "60.00",
          "thread_title": "RE: Trading 212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38EA914-FA00-4B19-B293-5E96B62D2062"
        },
        "ingested_at": "2026-02-11T01:19:44.516182+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20260125-russell1--4136753",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.179005",
        "source": "LSE_CHAT",
        "data": {
          "author": "russell1",
          "content": "Thanks for the helpful replies.",
          "sentiment": -0.5,
          "engagement": "318",
          "price_at_post": "60.00",
          "thread_title": "RE: Trading 212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38EA914-FA00-4B19-B293-5E96B62D2062"
        },
        "ingested_at": "2026-02-11T01:19:44.516201+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20262323-Toukanka-40012493",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.179705",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "More desperate ramping",
          "sentiment": 0.0,
          "engagement": "4,476",
          "price_at_post": "60.00",
          "thread_title": "RE: TAKEOVER",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=DAF752F5-FA6F-49F9-BD50-F5C834118B9E"
        },
        "ingested_at": "2026-02-11T01:19:44.516220+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20262100-cj62-46925939",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.180428",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "Put your head above the parapet have we touk. RH will probably have less influence than you, you prick.",
          "sentiment": 0.0,
          "engagement": "4,302",
          "price_at_post": "60.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T01:19:44.516239+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20262049-D-Geeman--5884805",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.181255",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "AI Overview Trading 212 (T212) and Hargreaves Lansdown (HL) offer starkly different approaches to trading Tiziana Life Sciences Ltd (NASDAQ: TLSA), with T212 focusing on low-cost, app-based trading, while HL provides a more traditional, comprehensive service with higher fees . T212 is generally better for frequent, small-value, or beginner trading due to zero-commission fees, while HL is often preferred for larger, long-term holdings and pensions. Comparison: Tiziana Life Sciences (TLSA) Trading Trading 212 (T212): Cost: Zero-commission trading on stocks and ETFs, though a 0.15% FX fee applies to non-GBP transactions. Features: Offers fractional shares, allowing for small investments in TLSA. CFD Trading: Offers long/short CFD trading on TLSA with leverage. Downsides: Limited research tools and no tax advice; users have reported wide spreads during volatile times for small-cap stocks. Hargreaves Lansdown (HL): Cost: High dealing charges (e.g., \u00a311.95 per deal), which can be costly for small trades. Features: Provides extensive research, analysis, and higher-quality, live, or more transparent pricing. Suitability: Better suited for holding larger, long-term positions or in a SIPP (pension).",
          "sentiment": 0.0,
          "engagement": "5,868",
          "price_at_post": "60.00",
          "thread_title": "RE: Trading 212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38EA914-FA00-4B19-B293-5E96B62D2062"
        },
        "ingested_at": "2026-02-11T01:19:44.516273+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20262041-D-Geeman-78401299",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.181977",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "I also have shares in $TLSA (formerly Tiziana PLC) which moved to the Nasdaq. People on the board for $TLSA.US have often complained about other brokers (I THINK Halifax amongst others) not allowing trades and I think people with 212 had there accustem shares sold against their will when they were spun-off to OTC. If AVCT do go on to the Nas I shall be happy to be with HL but each to their own.",
          "sentiment": 0.0,
          "engagement": "5,868",
          "price_at_post": "60.00",
          "thread_title": "RE: Trading 212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38EA914-FA00-4B19-B293-5E96B62D2062"
        },
        "ingested_at": "2026-02-11T01:19:44.516294+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20262026-IFA90-56241309",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.182574",
        "source": "LSE_CHAT",
        "data": {
          "author": "IFA90",
          "content": "I\u2019m no trader so 212 works for me. I just transferred a handful of Avacta shares across, took about 10 days. I\u2019ll move the rest soon. You can\u2019t dummy quote but I don\u2019t see any other downsides.",
          "sentiment": 0.0,
          "engagement": "415",
          "price_at_post": "60.00",
          "thread_title": "RE: Trading 212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38EA914-FA00-4B19-B293-5E96B62D2062"
        },
        "ingested_at": "2026-02-11T01:19:44.516313+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20262025-Icecool-51149559",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.183017",
        "source": "LSE_CHAT",
        "data": {
          "author": "Icecool",
          "content": "I hear what you\u2019re saying, and I get the excitement, but this is where biotech reality usually kicks in. Big pharma almost never forces an early move before human data unless they\u2019re facing an immediate strategic threat. AVA6103 is IND-cleared, which is huge, but it\u2019s still pre-human efficacy. That\u2019s exciting, not yet unavoidable. They are already in the data room and Avacta has made it clear they want to see human data on AVA6103 before they deal on that asset, everyone has to respect that. Right now BP doesn\u2019t need to rush or upset anyone to protect its position. They can stay close, sit in the data room, structure options, or wait for Phase 1 signals before committing real money with Avacta approval. That\u2019s how this industry normally works. The idea that retail holders could be quietly shaken out on the cheap also feels unlikely. Any hint of opportunistic behaviour would harden positions very quickly, not soften them. What the board is doing makes sense, build leverage before the power dynamic flips. Once AVA6103 shows even early human efficacy, urgency changes overnight and the tone of conversations changes with it.",
          "sentiment": 0.0,
          "engagement": "8,855",
          "price_at_post": "60.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T01:19:44.516333+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20262022-cj62-13719511",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.183465",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "Well I'm hoping that maybe 2 or 3 BP would like it but if all is well with ava6103 maybe go down the ARM route. 6 months and we should know",
          "sentiment": 0.0,
          "engagement": "4,302",
          "price_at_post": "60.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T01:19:44.516351+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261948-B2HS2L-90539502",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.183925",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "'That is extremely unlikely in biotech. As big pharma prefer to negotiate clean and keep everyone on side.' I hear what you say and generally agree. However, an opportunity like this occurs very infrequently. A successful purchase - however that occurs - confers market disruption and after commercialisation, competitive advantage upon the purchaser, with others making do with ADC development or resuming the search for new tech. This situation can't be brushed under the carpet. It's not what we would want, but you can't help seeing BP may want a deal sooner rather than later for a myriad of reasons. Pi**ing off the BoD might have to happen if one, or more than one BP are so keen to 'own it', or likely - make sure other BP's don't get a bargain in their efforts to 'own it'. There are a large number of PI's who could be easily persuaded to part with their shares at prices BP would definitely find attractive. It remains to be seen where and when the first bid arrives. The BoD are planning for the long haul, but let's hope they achieve as much as humanly possible before BP calls time on Avacta's progress.",
          "sentiment": 0.0,
          "engagement": "6,031",
          "price_at_post": "60.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T01:19:44.516370+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261935-D-Geeman-65730123",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.184434",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "I opened a 212 account a few years ago but don't use it. With HL your purchase happens immediately but with 212 it can take a while and goes thru in dribs and drabs (while the price is changing). Aren't HL lowering their dealing charges in April? I got a message and believe they are dropping to around \u00a36 for everyone (maybe more for some?) Maybe 212 are ok for bigger shares.",
          "sentiment": 0.0,
          "engagement": "5,868",
          "price_at_post": "60.00",
          "thread_title": "RE: Trading 212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38EA914-FA00-4B19-B293-5E96B62D2062"
        },
        "ingested_at": "2026-02-11T01:19:44.516404+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261920-Codejunk-12812527",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.184970",
        "source": "LSE_CHAT",
        "data": {
          "author": "Codejunkie",
          "content": "Pharma don't generally do hostile takeovers. They just pay the right price for the IP and make sure staff transfer over Hostile takeovers lose key staff....",
          "sentiment": 0.0,
          "engagement": "2,668",
          "price_at_post": "60.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T01:19:44.516425+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261916-russell1--5958208",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.185404",
        "source": "LSE_CHAT",
        "data": {
          "author": "russell1",
          "content": "Does anybody hold their Avacta shares with Trading 212? If so, is it easy to deal and are the prices comparable to other platforms. I use HL but am thinking about moving away.",
          "sentiment": -0.5,
          "engagement": "318",
          "price_at_post": "60.00",
          "thread_title": "Trading 212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38EA914-FA00-4B19-B293-5E96B62D2062"
        },
        "ingested_at": "2026-02-11T01:19:44.516444+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261857-cj62--1433801",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.185820",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "Its OK saying Hughes won't allow a low bid to be decided by shareholders, but what about a hostile bid. Any bid will be decided by the shareholders RH will have no say.",
          "sentiment": 0.0,
          "engagement": "4,302",
          "price_at_post": "60.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T01:19:44.516462+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261849-Icecool-41209859",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.186361",
        "source": "LSE_CHAT",
        "data": {
          "author": "Icecool",
          "content": "\u201cIt\u2019s OK saying Hughes won't allow a low bid to be decided by shareholders, but what about a hostile bid.\u201d That is extremely unlikely in biotech. As big pharma prefer to negotiate clean and keep everyone on side.",
          "sentiment": 0.0,
          "engagement": "8,855",
          "price_at_post": "60.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T01:19:44.516481+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261842-B2HS2L--3068045",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.187281",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "Bella ...Is the BOD in it for the long haul or would they simply take a good offer so they can move on to pastures new? I'm no longer thinking so much about how long it's going to take Avacta to achieve A,B or C. The nearer timelines we know about, but my point is how long are BP going to allow us to plough our own furrow? The more IP we pile up the larger amount SB rightly thinks the company is worth. These companies (with larger manpower & resources) will probably not want to proceed at Avacta's pace. Some will want faster development, and want their competitive advantage, with the purchase of all we have, to begin sooner. Others can't face a bigger purchase if left too long. Some BP will have funds available at different times as their priorities such as other projects will need to be factored into their timescales. Its OK saying Hughes won't allow a low bid to be decided by shareholders, but what about a hostile bid. There is no accounting for such a bid with completely opaque timescales. This is a market disruptive project and to a certain extent interested parties will want to move possibly sooner than we would wish. I don't see Avacta finishing what they started, but what do I know?",
          "sentiment": 0.0,
          "engagement": "6,031",
          "price_at_post": "60.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T01:19:44.516501+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261755-Metatron-72380900",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.188128",
        "source": "LSE_CHAT",
        "data": {
          "author": "Metatron",
          "content": "That's the spirit Watching2!! poor old Winnypoos is banging his drum as fast as he can but.. can he stay in time? I've spent half my life with those and asking a drummer to think? that's sublime...",
          "sentiment": 0.0,
          "engagement": "1,192",
          "price_at_post": "60.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T01:19:44.516535+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261725-opti_mys-60835760",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.188933",
        "source": "LSE_CHAT",
        "data": {
          "author": "opti_mystic",
          "content": "With RH on the BoD there is zero chance of Avacta being sold on the cheap. They have to put serious offers to shareholders but I guess it depends how serious is defined. Offering half what the company is worth is not a serious offer in my view. They could down tools today and sell the IP and they'd get a lot more than the current market cap.",
          "sentiment": 0.0,
          "engagement": "307",
          "price_at_post": "60.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T01:19:44.516556+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261717-cj62--4406878",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.189693",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "There is 0% CoS attached to the sp and that includes ava 6 k. Presently it would stand at 5 - 11% after the recent rns",
          "sentiment": 0.0,
          "engagement": "4,302",
          "price_at_post": "60.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T01:19:44.516575+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261710-Watching-69522033",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.190157",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "Winne bot has broken  free ! Ignore !",
          "sentiment": 0.0,
          "engagement": "9,224",
          "price_at_post": "60.50",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T01:19:44.516595+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261613-wyndrum--2592893",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.032149",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "\"Buyers don\u2019t care about today\u2019s SP, they care about what this asset can generate over a decade.\" do you think ever, before you post? If a buyer thinks this will be huge multiple in value then they buy as cheaply as they can which today would be 60p? Otherwise one would assume they are waiting for something... i dunno....maybe data from a trial yet to start? Also in response to where shareholders might sell: The SP would not be say, 500p per share from here on speculation. It would be on the back of very good results and data. It would be that data that would influence as to weather or not it would be sensible to sell.",
          "sentiment": 0.0,
          "engagement": "12,250",
          "price_at_post": "60.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T01:19:44.516626+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261556-Icecool--1880654",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.032939",
        "source": "LSE_CHAT",
        "data": {
          "author": "Icecool",
          "content": "If AVA6103 does what it\u2019s designed to do in humans, this isn\u2019t a few billion story. On any sensible biotech valuation framework (see my case study \ud83e\udd23\ud83d\ude09), you\u2019re talking tens of billions, not pocket change. That\u2019s total value paid, not based on some AIM screen price that flickers day to day. That\u2019s why the share price right now is basically irrelevant. Buyers don\u2019t care about today\u2019s SP, they care about what this asset can generate over a decade. Thankfully it also explains the strategy perfectly. Avacta is keeping AVA6103 solo for now because proving it in humans is where the real value unlock happens. You don\u2019t sell something like this on promise alone, you sell it when the risk collapses and the leverage flips. That\u2019s the play here. Prove it works in people, then let the numbers do the talking.",
          "sentiment": 0.0,
          "engagement": "8,855",
          "price_at_post": "61.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T01:19:44.516659+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261528-Timster-41574805",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.033717",
        "source": "LSE_CHAT",
        "data": {
          "author": "Timster",
          "content": "If CC brings anything less than \u00a3200 ex chi-nah, she'd be having a laugh!",
          "sentiment": 0.0,
          "engagement": "20,637",
          "price_at_post": "61.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T01:19:44.516688+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261523-cj62--6458563",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.034552",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "Directors cannot quietly reject a serious offer that could reasonably be of interest to shareholders once it becomes concrete. Their duty is to: Act in shareholders\u2019 best interests and Not frustrate an offer without shareholder approval",
          "sentiment": 0.0,
          "engagement": "4,302",
          "price_at_post": "61.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T01:19:44.516720+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261523-HarChris--1628961",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.035361",
        "source": "LSE_CHAT",
        "data": {
          "author": "HarChris",
          "content": "575m total share count feels a more realistic figure to be working with when forecasting future takeover share price so \u00a33B would be more like \u00a35.25 a share.",
          "sentiment": 0.0,
          "engagement": "15,923",
          "price_at_post": "61.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T01:19:44.516752+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261512-Bella653--8711191",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.036083",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "The BIG Questions are... Is the BOD in it for the long haul or  would they simply take a good offer so they can move on to pastures new? and how much are they will to hold out for?",
          "sentiment": 0.0,
          "engagement": "6,756",
          "price_at_post": "61.50",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T01:19:44.516780+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261507-Bella653-79846520",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.036656",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "I don't think you'll get anywhere near your SP wishlist on a T/O deal as we stand right now. Deals and NASDAQ Listing will drive value but we need some big hitters in the Finance World like Healthcare Royalty to back Avacta and to negotiate the best T/O deal possible at the right time.",
          "sentiment": 0.0,
          "engagement": "6,756",
          "price_at_post": "61.50",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T01:19:44.516811+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261505-hamsters--4665355",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.037073",
        "source": "LSE_CHAT",
        "data": {
          "author": "hamsters18",
          "content": "What large buys?",
          "sentiment": 0.0,
          "engagement": "3,692",
          "price_at_post": "61.50",
          "thread_title": "RE: TAKEOVER",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=DAF752F5-FA6F-49F9-BD50-F5C834118B9E"
        },
        "ingested_at": "2026-02-11T01:19:44.516843+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261449-Deod123-53735015",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.037518",
        "source": "LSE_CHAT",
        "data": {
          "author": "Deod123",
          "content": "Large buys going through.someone is stake building",
          "sentiment": 0.0,
          "engagement": "68",
          "price_at_post": "61.00",
          "thread_title": "TAKEOVER",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=DAF752F5-FA6F-49F9-BD50-F5C834118B9E"
        },
        "ingested_at": "2026-02-11T01:19:44.516873+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261438-cj62--6673762",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.037940",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "\u00a3200 ex china  Not this LTH",
          "sentiment": 0.0,
          "engagement": "4,302",
          "price_at_post": "61.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T01:19:44.516910+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261431-Wilson63-16348150",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.038378",
        "source": "LSE_CHAT",
        "data": {
          "author": "Wilson63",
          "content": "I'm somewhat surprised a couple of regulars are going to sell out at fairly low numbers, if this continues to pass each obstacle it's a one and only lifetime chance imho, topping up monthly slow and steady.",
          "sentiment": 0.0,
          "engagement": "8,808",
          "price_at_post": "60.50",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T01:19:44.516950+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261323-BuenaVis--2861530",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.038809",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Yes, the pre|CISION pie can be cut many ways: by drugs, indications and territories, and all with or without exclusivity.  People might say that faridox, with its boring old doxorubicin, will be overtaken by newer, more powerful pre|CISION drugs but the fact is it is here and now and not far off its first approved indication, salivary gland cancer, if the data released so far is to be believed. So with all that, why would any company want to license it when there could be better options in the future?  Well, if the offer was a global exclusive licence to develop faridox for SGC, plus the option to have first dibs on any future Avacta pre|CISION drug for SGC, plus the rights to develop their own pre|CISION drugs for SGC\u2014essentially an exclusive licence agreement to control the global pre|CISION SGC market\u2014then that would surely be of great interest. If it's taking Simon a long time to get that first deal, well the licensing possibilities are nearly endless and newly revealed data and developments are moving the goal posts in Avacta's favour all the time as conclusive evidence proves the platform (I'll call it that now already).",
          "sentiment": 0.0,
          "engagement": "5,826",
          "price_at_post": "59.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T01:19:44.516985+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261300-Vertizea-30399080",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.039250",
        "source": "LSE_CHAT",
        "data": {
          "author": "VertizeaSun",
          "content": "\u00a32 billion to buy a serious geographic licence for pre|CISION and a couple of warheads  sounds about right......say the EU/EEA and ex-ROW. Simon Bennett is now in his third year and the fact he hasn't been fired will suggest he has something up his sleeve. \u00a32B will pay for future independence and a \u00a31 per share dividend. I think we'll know within a couple of months and perhaps sooner as CC is obviously in town (doing celebratory cake delivery) and probably here for a board meeting - where they'll be trying to digest the recent torrent of good news. They actually have a lot on their plate. But I'm having trouble digesting \"the removal of the maximum dosing limit\" ...... apparently the first time in history for a phase 1 trial compound so I'm quite happy to believe that eventually pre|CISION is going to be compared to the impact penicillin had on the world of medicine. And in the beginning that discovery had serious FUD. Bill Gates said that the world always over-estimates how much change can take place in six months, but under-estimates how much change will take place in six years.",
          "sentiment": 0.0,
          "engagement": "440",
          "price_at_post": "59.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T01:19:44.517005+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261259-Matml74--3887500",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.039673",
        "source": "LSE_CHAT",
        "data": {
          "author": "Matml74",
          "content": "Dolly, Watch the R&D spotlight episode on next generation Precision from 2024 and also the dual payload one from late 2025. These highlight the vast opportunity for Precision.",
          "sentiment": 0.0,
          "engagement": "2,547",
          "price_at_post": "59.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T01:19:44.517039+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261252-opti_mys--7309876",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.040082",
        "source": "LSE_CHAT",
        "data": {
          "author": "opti_mystic",
          "content": "Oh yea of little faith. \u00a310 is my absolute bare minimum from when I first invested. Due to progress on a number of fronts that has gone up. Somewhat disappointed that people would sell so cheaply. Hopefully the BoD know what the company is worth and will not put to shareholders derisory offers that significantly under values the company.",
          "sentiment": 0.0,
          "engagement": "307",
          "price_at_post": "59.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T01:19:44.517072+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261249-Dollyg--5562191",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.040506",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dollyg",
          "content": "Thank you",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "59.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T01:19:44.517092+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261239-yeboha-73579402",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.040920",
        "source": "LSE_CHAT",
        "data": {
          "author": "yeboha",
          "content": "Dolly if you do some research online you can see that many professionals in the field agree that it can be used on many drugs !",
          "sentiment": 0.0,
          "engagement": "963",
          "price_at_post": "59.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T01:19:44.517124+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261237-yeboha-15651176",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.041383",
        "source": "LSE_CHAT",
        "data": {
          "author": "yeboha",
          "content": "Avacta\u2019s pipeline includes several distinct pre|CISION\u00ae drug conjugates with different therapeutic payloads, not just a single product: AVA6000 (a doxorubicin-based peptide drug conjugate) has shown positive clinical progress. AVA6103 (exatecan-based PDC) is advancing toward clinical trial start. Dual-payload PDCs are being developed in preclinical stages, combining agents like microtubule inhibitors and DNA damage response modulators. Another pipeline program, AVA7100 (an Affimer\u00ae-based drug conjugate), is also in preclinical development with its own payload delivery design. \ud83d\udccc Why this matters: This demonstrates that Avacta\u2019s platform isn\u2019t limited to a single drug but is being developed as a modular engine for multiple therapeutic combinations and individual payloads",
          "sentiment": 0.0,
          "engagement": "963",
          "price_at_post": "59.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T01:19:44.517144+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261231-Dollyg--3123207",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.041792",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dollyg",
          "content": "Be good to get a medically qualified opinion of the ACTUAL potential of how many differing treatments this technology could affect.",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "59.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T01:19:44.517179+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261227-Livedata--8959248",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.042216",
        "source": "LSE_CHAT",
        "data": {
          "author": "Livedataaccount",
          "content": "Hi jane im out at 4 pounds if it gets there",
          "sentiment": 0.0,
          "engagement": "2,969",
          "price_at_post": "59.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T01:19:44.517200+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261225-yeboha-73204719",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.042623",
        "source": "LSE_CHAT",
        "data": {
          "author": "yeboha",
          "content": "Its funny we say this, being where the share price is but im so convinced about avacta and have been for years !",
          "sentiment": 0.0,
          "engagement": "963",
          "price_at_post": "59.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T01:19:44.517219+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261221-Watching-83134372",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.043037",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "Happy with \u00a37 pre share. But \u00a310 would be a nice surprise . Jane",
          "sentiment": 0.0,
          "engagement": "9,224",
          "price_at_post": "59.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T01:19:44.517238+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261213-Dollyg-58068287",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.043462",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dollyg",
          "content": "I read the \u00a33 billion figure was first mooted in 2023 and they seem to have come a long way since then in terms of efficacy. The concensus seens to be wait.",
          "sentiment": 0.5,
          "engagement": "8",
          "price_at_post": "59.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T01:19:44.517257+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261212-yeboha-54461473",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.043874",
        "source": "LSE_CHAT",
        "data": {
          "author": "yeboha",
          "content": "Thats roughly my thinking",
          "sentiment": 0.0,
          "engagement": "963",
          "price_at_post": "59.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T01:19:44.517276+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261209-BuenaVis--6551375",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.044290",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "$4bn would be 668p a share.  Not enough for me.  I'd be looking for at least 1,000p a share, a $6bn buyout.  At least.",
          "sentiment": 0.0,
          "engagement": "5,826",
          "price_at_post": "59.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T01:19:44.517311+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20262313-aidanjc--3184544",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.524270",
        "source": "LSE_CHAT",
        "data": {
          "author": "aidanjc",
          "content": "Good point.  If cancer treatments improve that is a fantastic result. Its crept into my life a lot recently. Great to make a profit on the shares but improving outcomes for cancer patients is really important.",
          "sentiment": 0.0,
          "engagement": "6",
          "price_at_post": "51.50",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-11T01:19:44.517332+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20262051-avctIPma-47518689",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.524706",
        "source": "LSE_CHAT",
        "data": {
          "author": "avctIPmatters",
          "content": "Thanks for sharing  B2HS2L  -  Helps spread info on the platform  .",
          "sentiment": 0.0,
          "engagement": "728",
          "price_at_post": "51.50",
          "thread_title": "RE: CDD European Life Science Community Meeting",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=3A2F031D-C16F-4949-B22E-8512255BE282"
        },
        "ingested_at": "2026-02-11T01:19:44.517351+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20262049-avctIPma--7014899",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.525140",
        "source": "LSE_CHAT",
        "data": {
          "author": "avctIPmatters",
          "content": "Thanks for sharing  Thompi -  All helps spread   Avacta exposure .",
          "sentiment": 0.0,
          "engagement": "728",
          "price_at_post": "51.50",
          "thread_title": "RE: World CB & CDx Summit Europe",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=18E94451-D174-452E-BD8A-79154E17863F"
        },
        "ingested_at": "2026-02-11T01:19:44.517370+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20262022-Livedata-33913612",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.525565",
        "source": "LSE_CHAT",
        "data": {
          "author": "Livedataaccount",
          "content": "Ellen's great she will do a fantastic presentation",
          "sentiment": 0.0,
          "engagement": "2,957",
          "price_at_post": "51.50",
          "thread_title": "RE: CDD European Life Science Community Meeting",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=3A2F031D-C16F-4949-B22E-8512255BE282"
        },
        "ingested_at": "2026-02-11T01:19:44.517389+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20262016-B2HS2L--8305230",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.525997",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "Https://www.collaborativedrug.com/cdd-european-scientific-community-meeting-2026 Dr Ellen Watts, Avacta Therapeutics 25.02.2026  17:00-17:30: Delivering Targeted Therapies Using the pre|CISION\u00ae Platform. Last presentation of the day",
          "sentiment": 0.0,
          "engagement": "6,003",
          "price_at_post": "51.50",
          "thread_title": "CDD European Life Science Community Meeting",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=3A2F031D-C16F-4949-B22E-8512255BE282"
        },
        "ingested_at": "2026-02-11T01:19:44.517409+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261732-Timster--2945364",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.526420",
        "source": "LSE_CHAT",
        "data": {
          "author": "Timster",
          "content": "Good spot Thompi, thanks",
          "sentiment": 0.0,
          "engagement": "20,626",
          "price_at_post": "51.50",
          "thread_title": "RE: World CB & CDx Summit Europe",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=18E94451-D174-452E-BD8A-79154E17863F"
        },
        "ingested_at": "2026-02-11T01:19:44.517442+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261722-Thompi-58776655",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.526848",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thompi",
          "content": "Ruairidh Edwards will be speaking on 1 April at the 16th World Clinical Biomarkers & Companion Diagnostics Summit Europe. Presentation title: Establishing a Biomarker-Driven Approach to Guide Patient Selection for preCISION\u00ae Peptide-Drug Conjugates Using Tumour Targeting/Release and Payload Sensitivity Biomarkers. https://cdx-europe.com/full-event-guide/",
          "sentiment": 0.0,
          "engagement": "1,358",
          "price_at_post": "51.50",
          "thread_title": "World CB & CDx Summit Europe",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=18E94451-D174-452E-BD8A-79154E17863F"
        },
        "ingested_at": "2026-02-11T01:19:44.517462+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261707-Agenda10-14234476",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.527323",
        "source": "LSE_CHAT",
        "data": {
          "author": "Agenda101",
          "content": "No not engage ! It\u2019s working so let\u2019s continue to starve them of any engagement. As Runner-Runner wrote and BV reposted\u2026 It's simple. 1. DO NOT ENGAGE 2. DO NOT ASK IT A QUESTION 3. DO NOT ANSWER ITS QUESTIONS 4. DO NOT MOAN ABOUT ITS POSTS 5. DO NOT ARGUE WITH IT 6. If you must do something. Mock it with reference only to its stupidity and nothing else. ------------------------------------------------------ If you're not part of the solution, you're part of the problem",
          "sentiment": 0.0,
          "engagement": "72",
          "price_at_post": "52.50",
          "thread_title": "RE: Bone Marrow Toxicity, Brain malignancies?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=34DD9B68-3AA3-4F24-A8A5-8F742D7F4948"
        },
        "ingested_at": "2026-02-11T01:19:44.517482+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261704-Agenda10-84285772",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.527740",
        "source": "LSE_CHAT",
        "data": {
          "author": "Agenda101",
          "content": "\u201cI\u2019m committed for the next two years, but I anticipate that developments around licensing, manufacturing, and supply will begin to materialise well before then. From my perspective, the time to push ahead is now.\u201d",
          "sentiment": 0.0,
          "engagement": "72",
          "price_at_post": "51.50",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-11T01:19:44.517500+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261656-Thornogs--4192018",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.528205",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Well I didn't post! Not much said I see. More chat about FAP expressed on inflamed/fibrotic tissue other than cancer as a positive therapeutic opportunity with no one wondering if this self same tissue might cause problems should someone inject a FAP released 'Beast' into the circulation whilst trying to target a FAP related cancer.  Were that to happen in the FAP-EXD 1a Safety trial I think it would count as a Black Mark. BV and Syphysus indulged their in depth knowledge of molecular biology and the Blood Brain Barrier to 'deep dive' the potential to treat cerebral cancers, I do hope CC read those posts or perhaps one of you could send her an e mail explaining the possibilities? And the Market did what I thought it would do, go down, down the at the last come back up to almost, but not quite, where we opened. 1% down today, 3% this week and 10% down on the month. I see this continuing until the surprise deal mentioned earlier or being more realistic the next raise to fund the programme through 2026. Any thoughts on support/resistance levels Wyn? Happy to be out waiting for FAP-EXD and funding doubts to clear.",
          "sentiment": 0.0,
          "engagement": "8,666",
          "price_at_post": "51.50",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-11T01:19:44.517519+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261643-wyndrum--3235146",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.528628",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "I see \u201cthe don\u2019t engage\u201d policy didn\u2019t last long. You simply can\u2019t have a bb devoted to the actual topic and miss out on insulting others can you? Predictable and pathetic behaviour. Who knew?",
          "sentiment": 0.0,
          "engagement": "12,228",
          "price_at_post": "51.50",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-11T01:19:44.517541+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261640-D-Geeman-58787360",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.529049",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "'Chris, are you still interested in my buys and sells or would you prefer me not to bother?' Chris might not be interested Wyn, but I am... I dare say I'm not alone either.",
          "sentiment": 0.0,
          "engagement": "5,849",
          "price_at_post": "51.00",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-11T01:19:44.517574+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261639-Toukanka-79984258",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.529486",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "BV Are you a lawyer? We were led to believe that 6000 P1b would finish end of 25. So you don\u2019t regard having to go an extra cycle as missing a target. Or all the talk of multiple events before end 25 as not materialising. Anyhow at least some people on here are rooted in reality and believe CC when she says not to expect much before 2H26. Be. Patient",
          "sentiment": 0.0,
          "engagement": "4,454",
          "price_at_post": "51.00",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-11T01:19:44.517593+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261631-cj62--3815118",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.529902",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "Fine with me Chris. I would remind you however that it was you that asked I report my trades. You did report your last losing trade though did you, you prick",
          "sentiment": 0.0,
          "engagement": "4,282",
          "price_at_post": "51.50",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-11T01:19:44.517613+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261628-BuenaVis-13622244",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.530336",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Yes, that could be one possibility.",
          "sentiment": 0.0,
          "engagement": "5,775",
          "price_at_post": "51.50",
          "thread_title": "RE: Bone Marrow Toxicity, Brain malignancies?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=34DD9B68-3AA3-4F24-A8A5-8F742D7F4948"
        },
        "ingested_at": "2026-02-11T01:19:44.517631+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261622-wyndrum-76692706",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.530749",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "Fine with me Chris. I would remind you however that it was you that asked I report my trades. Anyway I\u2019m keen to see how this bb goes from here.",
          "sentiment": 0.0,
          "engagement": "12,228",
          "price_at_post": "51.50",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-11T01:19:44.517650+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261615-HarChris-70766417",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.531177",
        "source": "LSE_CHAT",
        "data": {
          "author": "HarChris",
          "content": "The last time I pointed out your losing trade you responded by saying you barely had anything on it\u2026 so nah, don\u2019t bother if you can just twist it how you want. And it clogs up the bb even more! How about not sharing any and trying not to care what an anonymous group of people think about your trading prowess?! That would be healthier!",
          "sentiment": 0.0,
          "engagement": "15,870",
          "price_at_post": "51.50",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-11T01:19:44.517670+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261613-Agenda10--2239263",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.531589",
        "source": "LSE_CHAT",
        "data": {
          "author": "Agenda101",
          "content": "None.. he\u2019s fishing don\u2019t reply!",
          "sentiment": 0.0,
          "engagement": "72",
          "price_at_post": "51.50",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-11T01:19:44.517705+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261547-BuenaVis--7174053",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.532000",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "@russell1 , what deadlines has Avacta missed since CC became CEO on 1 May 2024?",
          "sentiment": 0.0,
          "engagement": "5,775",
          "price_at_post": "51.00",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-11T01:19:44.517725+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261536-russell1-12461229",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.532426",
        "source": "LSE_CHAT",
        "data": {
          "author": "russell1",
          "content": "Well I'm not prepared to add any more money to my current loss situation so my only decision is whether to sell a proportion of my holding and hope I can buy back at a lower price if we (ever) get some worthwhile news or just leave it and hope! My expectation is that the price will just drift down until any news arrives but I have no expectation that this company will ever meet any of its reported deadlines.",
          "sentiment": -0.5,
          "engagement": "315",
          "price_at_post": "51.00",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-11T01:19:44.517745+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261529-Sisyphus--4160302",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.532837",
        "source": "LSE_CHAT",
        "data": {
          "author": "SisyphusShorter",
          "content": "Thanks BV, good to know. So in theory, a \"FAP-Temo\" agent would be roughly 460Da in size, provided the same Gen1 preCISION peptide is used. That puts it within the 400-600 threshold for BBB-crossing possibility (obviously notwithstanding lipophilicity, polarity and other parameters). That being said they could always cleave off a few residues to make a lightweight version for this specific indication.",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "51.00",
          "thread_title": "RE: Bone Marrow Toxicity, Brain malignancies?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=34DD9B68-3AA3-4F24-A8A5-8F742D7F4948"
        },
        "ingested_at": "2026-02-11T01:19:44.517764+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261509-Toukanka-89998467",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.533258",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "At last sensible posters instead of the usual carp \u201cfill yer boots you\u2019ll never again get the chance at this SP\u201d.  In truth we have a sideways drift until 6103 early clinical results are published in the Summer. Get over it and be patient.",
          "sentiment": 0.0,
          "engagement": "4,454",
          "price_at_post": "51.00",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-11T01:19:44.517782+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261432-wyndrum-66762415",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.533670",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "Chris, are you still interested in my buys and sells or would you prefer me not to bother?",
          "sentiment": 0.0,
          "engagement": "12,228",
          "price_at_post": "51.00",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-11T01:19:44.517803+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261413-Aston15-76232755",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.534076",
        "source": "LSE_CHAT",
        "data": {
          "author": "Aston15",
          "content": "I have brought enough now to be comfortable with the risk to reward ratio. 10% of my SIPP now in AVCT following another purchase this week. Many are expecting more than this, but my target remains a 5 billion valuation for the platform minimum. Happy to leave this to run now and hope the team delivers a positive outcome for both patients and shareholders.",
          "sentiment": 0.0,
          "engagement": "62",
          "price_at_post": "50.50",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-11T01:19:44.517835+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261410-B2HS2L-87439923",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.534502",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "Slide 16 & 18 of the Investormeet presentation 17.12.2025 contain info on tumor biopsies as articulated by Ruairidh Edwards, Translational Scientist. He's discussing phase 1b patients, possibly placing the recording of the interview before mid December.",
          "sentiment": 0.0,
          "engagement": "6,003",
          "price_at_post": "50.50",
          "thread_title": "RE: Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-02-11T01:19:44.517855+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261347-Vertizea--6075208",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.529148",
        "source": "LSE_CHAT",
        "data": {
          "author": "VertizeaSun",
          "content": "I think it links with CC's visit to Glasgow.....to visit the manufacturing site of AVA6103 and its \"first pour\".",
          "sentiment": 0.0,
          "engagement": "433",
          "price_at_post": "50.50",
          "thread_title": "RE: Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-02-11T01:19:44.517875+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261340-BuenaVis-37677428",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.529619",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Whilst the introduction by the host was current (post-IND announcement), CC seemed to be referencing passed events as being in the future and someone here suggested that the interview was recorded last year, in early December if I remember correctly.  I haven't listened to the interview again today but I do remember hearing bits that seemed out of step with today's situation.",
          "sentiment": 0.0,
          "engagement": "5,775",
          "price_at_post": "50.50",
          "thread_title": "RE: Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-02-11T01:19:44.517893+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261326-BuenaVis--2242266",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.530089",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Interesting and intelligent quesitions. As regards, fibrotic targets due to prior anthracycline treatment, it'll be interesting to see whether this side effect is reduced in previously untreated patients.  The breakdown of side effects vs prior treatment hasn't been presented yet but it is exacty the sort of detail I'm wanting to see (also, for example, side effects vs cancer indication/metastasis site).  Hopefully it will be included when the Phase 1 trial is written up in a peer-reviewed article, but there's always the AGM as an opportunity for asking detailed questions in person. As regards crossing the blood-brain barrier (BBB)... Temozolomide - molecular weight: 194.15 Da Doxorubicin - molecular weight: 543.52 Da Faridoxorubicin - molecular weight: 816.8 Da Faridoxorubicin without doxorubicin: 273.28 Da According to Gemini, \"Drugs that cross the BBB generally must be lipophilic (lipid-soluble), have a low molecular weight\u2014typically under 400\u2013600 Da\u2014and have a low polar surface area or few hydrogen bonds. They must avoid active efflux transport systems (like P-glycoprotein) and not be highly bound to plasma proteins.\"  So the requirements for an IV infusion drug are pretty stringent. However, there is an alternative route and that is, again according to Gemini, \"[administration] directly into the brain to bypass the BBB. This approach, known as local or regional drug delivery, is used to treat primary brain tumors (like glioblastoma) or brain metastases, allowing high concentrations of medication to reach the tumor without causing systemic toxicity.\"  I should think that the advantage of using pre|CISION for this is that, whilst the pre|CISION drug itself would be too big to cross OUT of the brain, the warhead, its metabolites and the leaving group from the pre|CISION substrate could all be below the size needed to cross out of the brain.  Anyway, CC wouldn't have specifically mentioned brain cancer if it weren't a possibility.",
          "sentiment": 0.0,
          "engagement": "5,775",
          "price_at_post": "50.50",
          "thread_title": "RE: Bone Marrow Toxicity, Brain malignancies?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=34DD9B68-3AA3-4F24-A8A5-8F742D7F4948"
        },
        "ingested_at": "2026-02-11T01:19:44.517912+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261318-IFA90--5028517",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.530517",
        "source": "LSE_CHAT",
        "data": {
          "author": "IFA90",
          "content": "I\u2019m not buying anymore. I\u2019ve increased my holding this week by selling a % and buying back c.10% cheaper. After 5 years it\u2019s entirely predictable, I just wish I\u2019d have realised that 3 years ago.",
          "sentiment": 0.0,
          "engagement": "409",
          "price_at_post": "50.50",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-11T01:19:44.517932+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261312-wyndrum--3360174",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.530949",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "Yes cj and I have just literally sold that holding and more as it looks to confused to me right now. Just so you know and can keep up I placed the sale evenly between Cpx and Xsg. Personally I would enjoy exploring and explaining my reasoning in a bit more depth but no need to is interested. ( and while you may all feel a bit more smug about this, it might be worth reflecting that I don\u2019t illicit the antagonist relationship here on other bb\u2019s. It begs the question is it me or you?)",
          "sentiment": 0.0,
          "engagement": "12,228",
          "price_at_post": "50.50",
          "thread_title": "RE: ADC 26",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=F3B63190-B417-42B7-9CC8-0ED98F4FBB92"
        },
        "ingested_at": "2026-02-11T01:19:44.517969+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261301-cj62--7430119",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.531376",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "\"Well the sp is 52p and now years later my analysis over a vey long period has proved correct and his wrong.\" but not recently you could have added- bought at 56.95 i believe. Yet still there are some that want me to be cancelled, yep you have that 100% correct as your narcissim knows no bounds",
          "sentiment": 0.0,
          "engagement": "4,282",
          "price_at_post": "50.50",
          "thread_title": "RE: ADC 26",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=F3B63190-B417-42B7-9CC8-0ED98F4FBB92"
        },
        "ingested_at": "2026-02-11T01:19:44.518002+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261254-Sisyphus-26927967",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.531796",
        "source": "LSE_CHAT",
        "data": {
          "author": "SisyphusShorter",
          "content": "So been looking at the phase 1 data for AVA6000 and also been listening to the podcast, thanks BV. Now I have two broad questions: One on bone/haem side effects, and one regarding primary brain cancers. Firstly, of the patients we have seen with bone marrow suppression, I know it's a known side effect of Dox, but I do wonder if prior primary therapies have induced a bit of fibrosis in the marrow, leading to FAP expression and thus Dox being released, leading to further bone marrow toxicity. That would imply that the side effects seen in the patients so far are less likely to emerge in a larger trial with a higher proportion of chemo-naive patients. Thoughts? Secondly, CC mentioned in the podcast that given that 90% of solid tumours express FAP, including brain, which she mentioned, and this begs the question whether or not the Peptide used in pre/CISION drug conjugates is small enough to pass the blood-brain-barrier, after all, that's how Temozolomide can do it's think for brain tumours. Again, thoughts?",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "50.50",
          "thread_title": "Bone Marrow Toxicity, Brain malignancies?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=34DD9B68-3AA3-4F24-A8A5-8F742D7F4948"
        },
        "ingested_at": "2026-02-11T01:19:44.518034+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261253-pedrolan--2112681",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.532225",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Yes, I bought some more the other week and am considering more now to get my average down further. If you believe in the medium term story here (with the bonus of a potential deal at any time) then it seems a bargain. Before any of the aliases bother to reply - I will not be responding to it - it will not be anything we have not all heard multiple times anyway.",
          "sentiment": 0.5,
          "engagement": "1,975",
          "price_at_post": "51.00",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-11T01:19:44.518064+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261252-BuenaVis--5808619",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.532633",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Another advantage of Avacta's PDCs is the h o m ogeneity of the dosage - exactly one warhead per drug molecule, or exactly two warheads per drug molecule for the dual payload drugs. In contrast, significant heterogeneity exists in ADCs as they are complex mixtures of varied molecular species rather than a single uniform compound. This includes differences in the drug-to-antibody ratio (DAR) and the conjugation sites on the antibody, leading to mixtures with 0 to 8+ payload molecules and various positional isomers.",
          "sentiment": 0.0,
          "engagement": "5,775",
          "price_at_post": "51.00",
          "thread_title": "RE: ADC 26",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=F3B63190-B417-42B7-9CC8-0ED98F4FBB92"
        },
        "ingested_at": "2026-02-11T01:19:44.518094+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261250-aidanjc-25699905",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.533041",
        "source": "LSE_CHAT",
        "data": {
          "author": "aidanjc",
          "content": "I've been a lth here having bought at several levels. Was hoping not to see us back around the 50p level. I've bought a few more. Anyone else buying. I'm hoping 50p will be the low tide mark...",
          "sentiment": 0.5,
          "engagement": "6",
          "price_at_post": "51.00",
          "thread_title": "Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-11T01:19:44.518136+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261246-wyndrum--5970438",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.533480",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "Also I don\u2019t care if you respond or not. I just hope it makes you think.also you will crack before we do. Not because it\u2019s a contest but simply we will ask questions or post opinions that as a bb you will naturally want to respond to. That\u2019s the whole purpose of a discussion bb. To discuss. And while there are a lot of recs to want us to be cancelled you will soon be bored with the lack of insight offered by the so called guardians of this bb. And never forget, it is exactly the same posters that by insulting us that then generate the board clogging are the ones piously demanding we be ignored. Just check sheppy watching bv and the rest for their overall contribution.",
          "sentiment": 0.0,
          "engagement": "12,228",
          "price_at_post": "51.00",
          "thread_title": "RE: ADC 26",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=F3B63190-B417-42B7-9CC8-0ED98F4FBB92"
        },
        "ingested_at": "2026-02-11T01:19:44.518163+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261243-Sisyphus-82373515",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.533883",
        "source": "LSE_CHAT",
        "data": {
          "author": "SisyphusShorter",
          "content": "Sorry, *Next* data release....",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "51.00",
          "thread_title": "RE: Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-02-11T01:19:44.518198+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261240-Sisyphus--7932671",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.534310",
        "source": "LSE_CHAT",
        "data": {
          "author": "SisyphusShorter",
          "content": "At 36:22 CC says, regarding tumour biopsies - \"...in our new data release which will be later this month...\" Make of that what you will..... GLA",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "51.00",
          "thread_title": "RE: Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-02-11T01:19:44.518236+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261232-wyndrum-83947636",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.534763",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "Oh, I remember, after this interview and the other stuff uncovered, what has the sp done? Why ,  How, can there be more sellers than buyers? Let\u2019s move on from the \u201csp doesn\u2019t matter \u201c. It\u2019s a facile statement which simply refuses to address a perfectly reasonable question. Yes the sp can drift up or down on no news but why can\u2019t we discuss it when there is a very positive release and it generates sells? By all means keep up this do not engage but myles tried this with me specifically on this bb with a little header to try and get me banned altogether. Well the sp is 52p and now years later my analysis over a vey long period has proved correct and his wrong. Yet still there are some that want me to be cancelled. You lot are either just plain weird or it is you that have an agenda. Just remember I have made money out of this stock and had you agreed with my view you would have too. The opposite would have happened if you followed bv and the rest. Yet you want me silenced. You might perhaps realise why I wonder what motivates the majority here.",
          "sentiment": 0.0,
          "engagement": "12,228",
          "price_at_post": "51.00",
          "thread_title": "RE: ADC 26",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=F3B63190-B417-42B7-9CC8-0ED98F4FBB92"
        },
        "ingested_at": "2026-02-11T01:19:44.518274+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261221-Watching--4106451",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.535189",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "To the Fudders they are trying so hard this morning ! It worked yesterday ! They are drying up \ud83e\udd21s",
          "sentiment": 0.0,
          "engagement": "9,215",
          "price_at_post": "51.00",
          "thread_title": "Do not respond",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=598797E4-B255-4509-971C-C103D6214E00"
        },
        "ingested_at": "2026-02-11T01:19:44.518313+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261143-wyndrum-17214523",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.535610",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "whatever you do, do not do not reply  or respond. you might want to take the ****, but resist. you might have the best put down ever! but do not repeat do not respond  got it? now what was i going to say\u2026. damn after all that i forgot \u2026.,",
          "sentiment": 0.0,
          "engagement": "12,228",
          "price_at_post": "52.00",
          "thread_title": "RE: ADC 26",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=F3B63190-B417-42B7-9CC8-0ED98F4FBB92"
        },
        "ingested_at": "2026-02-11T01:19:44.518352+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261014-HarryAng--6367215",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.536027",
        "source": "LSE_CHAT",
        "data": {
          "author": "HarryAngstrom",
          "content": "I meant PEAK SALES to Avacta... not TAM.",
          "sentiment": 0.0,
          "engagement": "9",
          "price_at_post": "52.50",
          "thread_title": "RE: Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-02-11T01:19:44.518390+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260955-D-Geeman--8548866",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.536554",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "'Today 09:44 Don't waste time responding if your handle is ........ D-Geeman ' You sound like a teenager with a statement like that B2HS2L. In this context that isn't a compliment.",
          "sentiment": 0.0,
          "engagement": "5,849",
          "price_at_post": "53.00",
          "thread_title": "RE: ADC 26",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=F3B63190-B417-42B7-9CC8-0ED98F4FBB92"
        },
        "ingested_at": "2026-02-11T01:19:44.518428+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260946-HarryAng--7007185",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.537041",
        "source": "LSE_CHAT",
        "data": {
          "author": "HarryAngstrom",
          "content": "This is a gigantic opportunity. TAM for Rhematoid Arthritis would be between $3.0 - $4.0 billion. And if they move into Fibrosis, the TAM there is between $7.0 - $10.0 billion. Once they prove they can deliver a toxin as potent as Exatecan using the FAP linker, using the same linker for milder anti-fibrotic or anti-inflammatory drugs is a low risk, high reward certainty.",
          "sentiment": 0.0,
          "engagement": "9",
          "price_at_post": "52.50",
          "thread_title": "RE: Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-02-11T01:19:44.518468+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260944-B2HS2L--3562673",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.537575",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "Don't waste time responding if your handle is wyndrum, Thornogson, Toukankahmoon or D-Geeman ********************************************************************************************************* Like my new header?  \ud83d\ude01\ud83d\ude09   I hope you create similar. In the event one company buys Avacta, all others will need to continue developing ADC's. They'll need to make improvements to compete as follows: 1 Reduce the time required to develop new drugs. 2 Improve the precision of targeting of warheads, so less drug is available systemically. 3 Improve the ease and speed of manufacturing 4 Find ways to reduce particle size 5 Find ways to deliver >1 drug at a time. Also - * Small molecule manufacturing and timeline/COGM (cost of goods manufactured) \"What that statement means and why that is important, is that the price tag for this drug (AVA6000), is one tenth of the price tag for an ADC drug. ADC's cost a lot of money in the clinic\"  CC 8.11.2024 I don't see why the statement isn't also true for AVA6103. ++++ A reminder from  Trinity Delta \u2013 Targeting the tumour microenvironment with pre|CISION - 18.11.2024 https://www.trinitydelta.org/research-notes/targeting-the-tumour-microenvironment-with-precision/ \"Avacta has so far FAP-enabled ten different warheads building up a database of multiple pre|CISION compounds that include c 40 capping groups (which alter the PK of the conjugate) and c 20   linkers (required for FAP cleavage with certain warheads and can be used to modify FAP affinity and activity). These have all been characterised through computational simulations to evaluate molecular binding and how they dock into the FAP structure. A key consideration is how close the warhead can get to the FAP cleavage sequence; this typically depends on the size of the molecule, and often defines whether a spacer group is required. Consideration is also given to how long the conjugate and the active warhead are likely to remain in the TME, and this informs whether PK alterations, achieved through an alternative capping group, are needed to either allow the sustained release of the warhead or to slow plasma clearance. Potential candidate molecules that meet the internal hurdle are also evaluated in vivo to investigate key PK parameters and cytotoxicity, with some selected for further characterisation in vitro and in vivo to establish preclinical efficacy and safety in a wide range of FAP tumour expression models with low serum FAP (including co-cultures of tumour cells and CAFs) to recapitulate the human TME.\" ++++ I'll bet there is more than ten warheads, forty capping groups and twenty linkers now!",
          "sentiment": 0.0,
          "engagement": "6,003",
          "price_at_post": "53.00",
          "thread_title": "RE: ADC 26",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=F3B63190-B417-42B7-9CC8-0ED98F4FBB92"
        },
        "ingested_at": "2026-02-11T01:19:44.518506+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260931-BuenaVis-78719035",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.537985",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Really does feel like adding Go Faster stripes at a horse fair.",
          "sentiment": 0.0,
          "engagement": "5,775",
          "price_at_post": "53.00",
          "thread_title": "RE: ADC 26",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=F3B63190-B417-42B7-9CC8-0ED98F4FBB92"
        },
        "ingested_at": "2026-02-11T01:19:44.518544+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260910-Yorkshir-36701096",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.538411",
        "source": "LSE_CHAT",
        "data": {
          "author": "Yorkshirepragma",
          "content": "CC refers to other applications \u2026Chronic Inflammation \u2018conversations\u2019 are interesting . One step at a time \u2026.",
          "sentiment": 0.0,
          "engagement": "1,804",
          "price_at_post": "53.00",
          "thread_title": "RE: Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-02-11T01:19:44.518584+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260845-Yorkshir-47139443",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.538852",
        "source": "LSE_CHAT",
        "data": {
          "author": "Yorkshirepragma",
          "content": "Fascinating similarity re Avactas current development processes. Tuesday 24th February 2026 The Next Generation of ADCs: Leveraging Novel Conjugation & Enhanced Antibody Engineering for the Future of Targeted Oncology Therapies 9:15 am Laying out the scope to differentiate ADC development through novel conjugation, antibody engineering, and target identification approaches to widen therapeutic index and bring patient benefit Incorporating in silico and AI tools to enhance the ADC discovery toolbox and deliver next-generation ADC engineering and design Highlighting future priorities for next-generation ADC development, including exploring the potential of radio conjugates",
          "sentiment": 0.0,
          "engagement": "1,804",
          "price_at_post": "53.00",
          "thread_title": "ADC 26",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=F3B63190-B417-42B7-9CC8-0ED98F4FBB92"
        },
        "ingested_at": "2026-02-11T01:19:44.518624+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260811-Agenda10-59502620",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.539272",
        "source": "LSE_CHAT",
        "data": {
          "author": "Agenda101",
          "content": "Cheers BV!",
          "sentiment": 0.0,
          "engagement": "72",
          "price_at_post": "53.00",
          "thread_title": "RE: Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-02-11T01:19:44.518663+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260754-cj62-67824916",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.539688",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "Who would be allowed access ?",
          "sentiment": 0.0,
          "engagement": "4,282",
          "price_at_post": "53.00",
          "thread_title": "Data Room",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=85F98FAE-01B2-48EC-B9D0-584FAD2B9731"
        },
        "ingested_at": "2026-02-11T01:19:44.518687+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260751-Thornogs-80355102",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.713580",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "This one and one after the close to comment on the top quality discussion and to check if we finished up or not.",
          "sentiment": 0.0,
          "engagement": "8,666",
          "price_at_post": "53.00",
          "thread_title": "2 post Friday.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=EDA1F112-F6D9-49A4-937D-081A93C2E757"
        },
        "ingested_at": "2026-02-11T01:19:44.518712+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260626-Gingethe-71006850",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.714067",
        "source": "LSE_CHAT",
        "data": {
          "author": "GingetheWinge",
          "content": "The FUDsters are thrashing like Terminator 2 in a smelting cauldron. It\u2019s working so let\u2019s continue to starve them of any engagement. As Runner-Runner wrote and BV reposted\u2026 It's simple. 1. DO NOT ENGAGE 2. DO NOT ASK IT A QUESTION 3. DO NOT ANSWER ITS QUESTIONS 4. DO NOT MOAN ABOUT ITS POSTS 5. DO NOT ARGUE WITH IT 6. If you must do something. Mock it with reference only to its stupidity and nothing else. ------------------------------------------------------ If you're not part of the solution, you're part of the problem",
          "sentiment": 0.5,
          "engagement": "700",
          "price_at_post": "53.00",
          "thread_title": "No not engage !",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=A348D8E1-4DC7-4D49-950E-08F79BC3A2D1"
        },
        "ingested_at": "2026-02-11T01:19:44.518751+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260138-BuenaVis-17057485",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.714500",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Even better link: https://www.youtube.com/watch?v=HWkh3OEFSds&t=1333s",
          "sentiment": 0.0,
          "engagement": "5,775",
          "price_at_post": "53.00",
          "thread_title": "RE: Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-02-11T01:19:44.518783+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260132-BuenaVis-46646555",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.714925",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "It's the Base to Base biotech podcast from a few days ago. Well worth a listen. Here's the link to the start of the CC interview: https://www.youtube.com/watch?v=HWkh3OEFSds&t=1290s",
          "sentiment": 0.0,
          "engagement": "5,775",
          "price_at_post": "53.00",
          "thread_title": "RE: Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-02-11T01:19:44.518802+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262331-D-Geeman-79441578",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.715361",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "Wasn\u2019t wyn comparing this BB to \u2018Lord of the Flies\u2019 classic story? Well for those who don\u2019t know the story I just caught a trailer for new BBC production starting soon; https://www.bbc.com/mediacentre/2026/lord-of-the-flies-trailer",
          "sentiment": 0.0,
          "engagement": "5,849",
          "price_at_post": "53.00",
          "thread_title": "RE: Avacta Therapeutics celebrates this",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=03B0B4A6-705E-45ED-983A-A89C321C0924"
        },
        "ingested_at": "2026-02-11T01:19:44.518836+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262302-alextak--5188216",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.715781",
        "source": "LSE_CHAT",
        "data": {
          "author": "alextak",
          "content": "Is it a new interview? .I'll listen to it tomorrow.",
          "sentiment": 0.0,
          "engagement": "540",
          "price_at_post": "53.00",
          "thread_title": "RE: Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-02-11T01:19:44.518875+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262258-alextak-66101425",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.716203",
        "source": "LSE_CHAT",
        "data": {
          "author": "alextak",
          "content": "Https://youtu.be/HWkh3OEFSds?si=0KezbLZbtRJA4N97",
          "sentiment": 0.0,
          "engagement": "540",
          "price_at_post": "53.00",
          "thread_title": "Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-02-11T01:19:44.518897+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262241-pedrolan-64882069",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.716624",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "When no-one engages that's what they end up with. Good work folks.",
          "sentiment": 0.5,
          "engagement": "1,975",
          "price_at_post": "53.00",
          "thread_title": "Voices in the wilderness",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=8AE5A358-4CCC-4E25-A8A9-D4C3BBC9FF5F"
        },
        "ingested_at": "2026-02-11T01:19:44.518925+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262222-Thornogs--3168512",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.717039",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Absolutely Pedro! All those who chance upon the LSE Avacta bulletin board and haven't been keeping up with the news, all of them? Exposure indeed, keep up the good work everybody!",
          "sentiment": 0.0,
          "engagement": "8,666",
          "price_at_post": "53.00",
          "thread_title": "RE: Avacta Therapeutics celebrates this",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=03B0B4A6-705E-45ED-983A-A89C321C0924"
        },
        "ingested_at": "2026-02-11T01:19:44.518962+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262202-pedrolan--1810260",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.717464",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "All great exposure. Thanks for posting \ud83d\udc4d\ud83c\udffb",
          "sentiment": 0.5,
          "engagement": "1,975",
          "price_at_post": "53.00",
          "thread_title": "RE: Avacta Therapeutics celebrates this",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=03B0B4A6-705E-45ED-983A-A89C321C0924"
        },
        "ingested_at": "2026-02-11T01:19:44.518982+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262145-Thornogs-41849125",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.717891",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Well there we have it Avcti, proof positive fof all those 'FUDsters' who have been saying otherwise all day! Avacta can produce FAP-EXD for the upcoming trial! What chance does 'FUD' have against this level of research and knowledge? Hang your heads in shame all those saying that it wasn't possible. Was anyone suggesting this?",
          "sentiment": 0.0,
          "engagement": "8,666",
          "price_at_post": "53.00",
          "thread_title": "RE: \" So excited to get the trial going soon. \"",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=C91568DF-F421-4695-901C-78161A0F4CD6"
        },
        "ingested_at": "2026-02-11T01:19:44.519001+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262110-avctIPma-41744629",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.718379",
        "source": "LSE_CHAT",
        "data": {
          "author": "avctIPmatters",
          "content": "FYI   Christina CoughlinChristina Coughlin \u2022 3rd+Verified \u2022 3rd+ Chief Executive Officer, AvactaChief Executive Officer, Avacta 53m \u2022  53 minutes ago \u2022 Visible to anyone on or off LinkedIn Follow We are thrilled to partner with our team at Curia - this partnership has enabled our team at hashtag#AVCT to move FAP-exatecan forward at record pace. So excited to get the trial going soon. This combined team reminds me of a favorite quote, \u201cNever doubt that a small group of thoughtful, committed citizens can change the world. Indeed, it is the only thing that ever has.\u201d \u2014Margaret Mead. hashtag#LetsDoThis hashtag#HopeWithoutCompromise CuriaCuria 104,425 followers104,425 followers 2h \u2022  2 hours ago \u2022 Visible to anyone on or off LinkedIn Follow Congratulations to Avacta Therapeutics on receiving U.S. Food and Drug Administration (FDA) clearance of the Investigational New Drug (IND) application for the Company\u2019s second program FAP-Exd (AVA6103). This peptide drug conjugate is based on the highly potent topoisomerase I inhibitor, exatecan. A Phase 1 clinical trial will enroll patients with solid tumors, pancreatic cancer, cervical cancer, gastric cancer and small cell lung cancer. CURIA STERILE DRUG PRODUCT business unit is proud to assist this cutting-edge oncology program with formulation development, analytical support and GMP clinical supply at our site in Glasgow. Read more about Avacta in the recent press release: https://hubs.li/Q040N2nz0",
          "sentiment": 0.0,
          "engagement": "728",
          "price_at_post": "53.00",
          "thread_title": "\" So excited to get the trial going soon. \"",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=C91568DF-F421-4695-901C-78161A0F4CD6"
        },
        "ingested_at": "2026-02-11T01:19:44.519020+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262104-wyndrum--1865713",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.718829",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "So you\u2019re right and I am wrong as you have said umpteen times  yet it is me who is the narcissist? You don\u2019t even know what the term means in detail yet bandi it about as a diagnosis of a stranger you know nothing about. Your arrogance in libelling me without any justification only amplifies my point. But in none of these umpteen times have you ever wondered why AVCT have failed to deliver the returns you expected when you first bought in ? No of course not. That would require self examination. Something you seem to lack but have no inhibition in accusing others of. The arrogance of the arguments directed at me are so cliched and bereft of any true accuracy that it is simply pathetic. What is so considerably worse is the recs they get. Not because it offends me more but rather of the evidence that so may can\u2019t reason for themselves and blithely agree. It\u2019s not a case of reading the room, more a case of group think. Under your reasoning we would all still think the earth was flat.",
          "sentiment": 0.0,
          "engagement": "12,228",
          "price_at_post": "53.00",
          "thread_title": "RE: Worldwide ADC Innovation & Collaboration   London",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=CB66756C-50A3-4D04-A499-ADC1B8951801"
        },
        "ingested_at": "2026-02-11T01:19:44.519052+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262104-Metatron--5537218",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.719249",
        "source": "LSE_CHAT",
        "data": {
          "author": "Metatron",
          "content": "Forgot.. dammit.. sawy \ud83e\udd14",
          "sentiment": 0.0,
          "engagement": "1,188",
          "price_at_post": "53.00",
          "thread_title": "RE: Worldwide ADC Innovation & Collaboration   London",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=CB66756C-50A3-4D04-A499-ADC1B8951801"
        },
        "ingested_at": "2026-02-11T01:19:44.519075+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262051-BuenaVis--1384204",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.719657",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Do not feed the troll. \ud83e\udd2a",
          "sentiment": 0.0,
          "engagement": "5,775",
          "price_at_post": "53.00",
          "thread_title": "RE: Worldwide ADC Innovation & Collaboration   London",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=CB66756C-50A3-4D04-A499-ADC1B8951801"
        },
        "ingested_at": "2026-02-11T01:19:44.519094+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262035-Metatron--5973233",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.720073",
        "source": "LSE_CHAT",
        "data": {
          "author": "Metatron",
          "content": "The problem is Wyndrone.. that you cannot read the room because you are a narcissist as I've explaind umpteen times. The recs are from other members who are just plain sick to death of you and your narcissistic droning behaviour.",
          "sentiment": 0.0,
          "engagement": "1,188",
          "price_at_post": "53.00",
          "thread_title": "RE: Worldwide ADC Innovation & Collaboration   London",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=CB66756C-50A3-4D04-A499-ADC1B8951801"
        },
        "ingested_at": "2026-02-11T01:19:44.519131+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262028-Metatron--5763495",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.720496",
        "source": "LSE_CHAT",
        "data": {
          "author": "Metatron",
          "content": "Looks like Thorndrone has repositioned itself as the ultimate purile commentator on the commentary? Looks more to me like the ultimate terd that just won't flush \ud83d\ude48\ud83d\udca9",
          "sentiment": 0.0,
          "engagement": "1,188",
          "price_at_post": "53.00",
          "thread_title": "RE: Avacta Therapeutics celebrates this",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=03B0B4A6-705E-45ED-983A-A89C321C0924"
        },
        "ingested_at": "2026-02-11T01:19:44.519150+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262028-wyndrum--5400503",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.720925",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "I think the problem is Chris is that while what you say is correct, it is the \u201canti-fudsters \u201c for want of a better expression, that quite deliberately push this debilitating and constant line at any opportunity. And like today, when nothing is going on, BV just stirs the pot. Yet every single time the cause of this futile exercise is laid at the door of the posters who are incessantly  attacked rather than the perpetrators . What\u2019s even more disturbing is the recs they get for doing it. This bb is simply one of the worst I have ever come across and we all contribute to that to some degree but it is the majority (when you look at the recs) here that revel in this disruptive behaviour and have little or no interest in resolving the situation for the better. Why can\u2019t I say after 5 years of a trial and a sp at near all time lows that maybe all is not what we were led to believe from the outset and can we look at what might be causing this without being asked to be ignored banned or wished an early death?",
          "sentiment": 0.0,
          "engagement": "12,228",
          "price_at_post": "53.00",
          "thread_title": "RE: Worldwide ADC Innovation & Collaboration   London",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=CB66756C-50A3-4D04-A499-ADC1B8951801"
        },
        "ingested_at": "2026-02-11T01:19:44.519170+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262015-stodgy88-87125421",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.721347",
        "source": "LSE_CHAT",
        "data": {
          "author": "stodgy88",
          "content": "LinkedIn.",
          "sentiment": 0.0,
          "engagement": "1,206",
          "price_at_post": "53.00",
          "thread_title": "RE: Avacta Therapeutics celebrates this",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=03B0B4A6-705E-45ED-983A-A89C321C0924"
        },
        "ingested_at": "2026-02-11T01:19:44.519205+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262014-stodgy88-82166812",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.721752",
        "source": "LSE_CHAT",
        "data": {
          "author": "stodgy88",
          "content": "This company as over  100,000 followers, so good exposure.",
          "sentiment": 0.0,
          "engagement": "1,206",
          "price_at_post": "53.00",
          "thread_title": "RE: Avacta Therapeutics celebrates this",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=03B0B4A6-705E-45ED-983A-A89C321C0924"
        },
        "ingested_at": "2026-02-11T01:19:44.519226+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262011-Thornogs--1503700",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.722182",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Quite Avcti, well done! Always good to be reminded of last week's RNS! In case any of ghd 'well infofmed' missed it eh?",
          "sentiment": 0.0,
          "engagement": "8,666",
          "price_at_post": "53.00",
          "thread_title": "RE: Avacta Therapeutics celebrates this",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=03B0B4A6-705E-45ED-983A-A89C321C0924"
        },
        "ingested_at": "2026-02-11T01:19:44.519246+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262010-HarChris-76638665",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.722603",
        "source": "LSE_CHAT",
        "data": {
          "author": "HarChris",
          "content": "There\u2019s a cycle of Thorn repeating the same points over and over again, the numerous posters who flood us with messages telling him to F off, begging others not to reply or to warn the bb of his dishonesty and then Wyn writing paragraphs of philosophy and psychology on the meaning of it all. That plays out at least four or five times a week! Almost identically. The odd post on Avacta gets a reply or two before the cycle kickstarts again. What a waste of time this BB is in quiet periods like this!",
          "sentiment": 0.0,
          "engagement": "15,870",
          "price_at_post": "53.00",
          "thread_title": "RE: Worldwide ADC Innovation & Collaboration   London",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=CB66756C-50A3-4D04-A499-ADC1B8951801"
        },
        "ingested_at": "2026-02-11T01:19:44.519265+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262004-avctIPma--8483862",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.723059",
        "source": "LSE_CHAT",
        "data": {
          "author": "avctIPmatters",
          "content": "Back to more worthwhile  conversation thanks Stonks -------------------------- Avacta Therapeutics celebrates this Curia 54m \u2022 Follow Congratulations to Avacta Therapeutics on receiving U.S. Food and Drug Administration (FDA) clearance of the Investigational New Drug (IND) application for the Company\u2019s second program FAP-Exd (AVA6103). This peptide drug conjugate is based on the highly potent topoisomerase I inhibitor, exatecan. A Phase 1 clinical trial will enroll patients with solid tumors, pancreatic cancer, cervical cancer, gastric cancer and small cell lung cancer. CURIA STERILE DRUG PRODUCT business unit is proud to assist this cutting-edge oncology program with formulation development, analytical support and GMP clinical supply at our site in Glasgow. Read more about Avacta in the recent press release: https://hubs.li/Q040N2nz0 \" Gmcc",
          "sentiment": 0.0,
          "engagement": "728",
          "price_at_post": "53.00",
          "thread_title": "Avacta Therapeutics celebrates this",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=03B0B4A6-705E-45ED-983A-A89C321C0924"
        },
        "ingested_at": "2026-02-11T01:19:44.519284+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261833-D-Geeman--2740185",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.723489",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "'and bucket to collect their donations for his roses.\u2019 'collect the dung & yes then spread the manure around the Roses' I understand that Watching does this too but with her Quality Street, not Roses.",
          "sentiment": 0.0,
          "engagement": "5,849",
          "price_at_post": "53.00",
          "thread_title": "RE: Worldwide ADC Innovation & Collaboration   London",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=CB66756C-50A3-4D04-A499-ADC1B8951801"
        },
        "ingested_at": "2026-02-11T01:19:44.519305+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261754-Thornogs--8963968",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.723915",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Now, now Wyn! Steady there. It's been decided that our constant 'FUD' detracts from thd ability of the 'well informed' posters to discuss Avzcta seriously. OK, so far it's just the usual nonsense but give thdm a chance I'm sure tomorrow they'll Smash It! Did we finish up by the way?",
          "sentiment": 0.0,
          "engagement": "8,666",
          "price_at_post": "53.00",
          "thread_title": "RE: Worldwide ADC Innovation & Collaboration   London",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=CB66756C-50A3-4D04-A499-ADC1B8951801"
        },
        "ingested_at": "2026-02-11T01:19:44.519338+00:00"
      },
      {
        "event_id": "SOCIAL-Today1236-Watching-47978326",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.595387",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "Let\u2019s have a day where know one engages with the Fudders A watch them argue with themselves \ud83d\ude0a",
          "sentiment": 0.0,
          "engagement": "9,213",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-02-11T01:19:44.519358+00:00"
      },
      {
        "event_id": "SOCIAL-Today1207-D-Geeman--1263536",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.595837",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "Evan Davis discussing mergers and acquisitions on Radio 4 right now.",
          "sentiment": 0.0,
          "engagement": "5,844",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-02-11T01:19:44.519377+00:00"
      },
      {
        "event_id": "SOCIAL-Today1050-D-Geeman-30388242",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.596300",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "Many of the most useful posts are green boxes to others. That's fine. I really don't care if **** doesn't read ****'s post as long as I can. Please, everyone who doesn't like ****'s posts filter and then the people who do read them can do so in peace.",
          "sentiment": 0.0,
          "engagement": "5,844",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-02-11T01:19:44.519397+00:00"
      },
      {
        "event_id": "SOCIAL-Today1034-Thornogs--4195922",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.596741",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Happy to sit on the sidelines to watch the emergence of all this deep research and intelligent discussion on the company's 'fundamentals'. Of course if it isn't accurate or realistic I presume there's the right to point this out? Otherwise it's just a meaningless Echo Chamber. Over to you, the self proclaimed 'well informed'. Let's see what quality posting looks like!",
          "sentiment": 0.0,
          "engagement": "8,655",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-02-11T01:19:44.519416+00:00"
      },
      {
        "event_id": "SOCIAL-Today1032-BuenaVis-60194886",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.597214",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "As Runner-Runner wrote... It's simple. 1. DO NOT ENGAGE 2. DO NOT ASK IT A QUESTION 3. DO NOT ANSWER ITS QUESTIONS 4. DO NOT MOAN ABOUT ITS POSTS 5. DO NOT ARGUE WITH IT 6. If you must do something. Mock it with reference only to its stupidity and nothing else. ------------------------------------------------------ If you're not part of the solution, you're part of the problem",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-02-11T01:19:44.519438+00:00"
      },
      {
        "event_id": "SOCIAL-Today1025-pedrolan-72566564",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.597761",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Ok, as one of the offenders ( I did it mainly to remind people of their/his agenda) I will pledge to now ignore them/him going forward. We really need everyone to do that though.",
          "sentiment": 0.5,
          "engagement": "1,972",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-02-11T01:19:44.519470+00:00"
      },
      {
        "event_id": "SOCIAL-Today1022-Aston15-62717785",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.598209",
        "source": "LSE_CHAT",
        "data": {
          "author": "Aston15",
          "content": "People do understand the only reason then come on here to spout sh*t is because others give them an audience? Its not difficult..  Green Box them and focus the chat on the company, not their trading agendas.",
          "sentiment": 0.0,
          "engagement": "61",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-02-11T01:19:44.519490+00:00"
      },
      {
        "event_id": "SOCIAL-Today1005-IFA90--4806682",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.598630",
        "source": "LSE_CHAT",
        "data": {
          "author": "IFA90",
          "content": "More posts than trades, never a good sign.",
          "sentiment": 0.0,
          "engagement": "408",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-02-11T01:19:44.519508+00:00"
      },
      {
        "event_id": "SOCIAL-Today0954-Aldebara-48884474",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.599061",
        "source": "LSE_CHAT",
        "data": {
          "author": "Aldebaran",
          "content": "Anyone engaging with them is part of the problem. I'll soon be adding them to my filter list if all the want to do is talk smack and try to score points against them. It's a waste of everyone's time, least not their own yet they persist. Sad. We could use this bb once again to discuss avacta but only if the engagement with FUDsters ends. Its nothing more than a digital playground otherwise. Filter. Them.",
          "sentiment": 0.0,
          "engagement": "3,894",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-02-11T01:19:44.519527+00:00"
      },
      {
        "event_id": "SOCIAL-Today0948-Watching-86786936",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.599520",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "Let\u2019s have a day where know one engages with the Fudders And watch them argue with there selves \ud83d\ude0a",
          "sentiment": 0.0,
          "engagement": "9,213",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-02-11T01:19:44.519546+00:00"
      },
      {
        "event_id": "SOCIAL-Today0932-Thornogs-32310347",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.599949",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "And on a day to day basis is there actually much new to talk about with Avacta? Tumbleweed City now until the next RNS, whatever that might be for.",
          "sentiment": 0.0,
          "engagement": "8,655",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-02-11T01:19:44.519568+00:00"
      },
      {
        "event_id": "SOCIAL-Today0924-wyndrum-75506712",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.600402",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "But Jane this was all caused by BV\u2019s non AVCT post. He deliberately provokes with his insults and lies. Non of this would have happened today without his non AVCT related post. Remember that would you",
          "sentiment": 0.0,
          "engagement": "12,217",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-02-11T01:19:44.519745+00:00"
      },
      {
        "event_id": "SOCIAL-Today0918-Watching--3030158",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.601027",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "Let\u2019s have a day where know one engages with the Fudders And watch them argue with themselves \ud83d\ude2c",
          "sentiment": 0.0,
          "engagement": "9,213",
          "price_at_post": "54.00",
          "thread_title": "Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-02-11T01:19:44.519764+00:00"
      },
      {
        "event_id": "SOCIAL-Today0917-pedrolan--4671067",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.601613",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "A seamless switch between users there Eggy Bravo",
          "sentiment": 0.0,
          "engagement": "1,972",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T01:19:44.519783+00:00"
      },
      {
        "event_id": "SOCIAL-Today0916-Thornogs-76544649",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.602292",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "To be fair Live account it's very easy to judge someone who repeatedly posts nonsense like you just have. And Pedro and BV joining in the: 'Look at us, we're idiots' gang.",
          "sentiment": 0.0,
          "engagement": "8,655",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T01:19:44.519802+00:00"
      },
      {
        "event_id": "SOCIAL-Today0902-wyndrum--1077680",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.603136",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "Sadly you have the memory of a goldfish but not its intellect. Again bv starts and contributes to the disruption. All we wait for now is the \u201cooh I can see all these green boxes\u201dposts add up my posts and add up all the rest and you quickly see who the paid disrupters are",
          "sentiment": 0.0,
          "engagement": "12,217",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T01:19:44.519821+00:00"
      },
      {
        "event_id": "SOCIAL-Today0859-BuenaVis--3144905",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.603939",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "\ud83e\udd14 Today's 'wyndrum' sounds even more petty and whiny than the 'Thornogson' account.",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T01:19:44.519848+00:00"
      },
      {
        "event_id": "SOCIAL-Today0858-pedrolan-83710740",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.604745",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "BV - he is doing it to fool us into thinking it is not one account. I nearly fell for it because I have the memory of a goldfish.",
          "sentiment": 0.5,
          "engagement": "1,972",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T01:19:44.519875+00:00"
      },
      {
        "event_id": "SOCIAL-Today0853-wyndrum-21753003",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.605571",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "It\u2019s snowing pretty hard here so it\u2019s not really the smoking gun you claim is it? Plus the fact you think I have multiple accounts only reinforces your mistaken analysis. (And see how many posts have been generated by bv These are the cause of the disruption. Not the posters who try to discuss the disconnect between AVCT results and the sp over the last 5 years",
          "sentiment": 0.0,
          "engagement": "12,217",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T01:19:44.519894+00:00"
      },
      {
        "event_id": "SOCIAL-Today0850-BuenaVis-38615352",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.606369",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Why is Thornogson/NDN/Eggy using the wyndrum account today?",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T01:19:44.519912+00:00"
      },
      {
        "event_id": "SOCIAL-Today0847-Livedata-27425521",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.607182",
        "source": "LSE_CHAT",
        "data": {
          "author": "Livedataaccount",
          "content": "With respect wyndrum its difficult not to judge someone who pretends to go on holiday and occasionally logs on with another alias replying to himself",
          "sentiment": 0.0,
          "engagement": "2,956",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T01:19:44.519931+00:00"
      },
      {
        "event_id": "SOCIAL-Today0835-BuenaVis-22400107",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.607959",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Wyn Shakespeare has swallowed a whole bag of question marks.",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T01:19:44.519949+00:00"
      },
      {
        "event_id": "SOCIAL-Today0831-pedrolan-14371352",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.608744",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Keep it up BV - people do need reminding. I see user Wyn Shakespeare is on the early shift.",
          "sentiment": 0.5,
          "engagement": "1,972",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T01:19:44.519976+00:00"
      },
      {
        "event_id": "SOCIAL-Today0826-wyndrum--2610535",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.609574",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "Thanks for reminding us dad, it must only be the 20th time you have posted this. Still at least your post s don\u2019t disrupt the board It\u2019s a great service you do, giving up your time to treat everyone here like morons by constantly reposting. Is it your new rule now that you must be shareholder to post and also be a genuine one at that? How do you intend to police your rules? Or is it just petty personal vendetta you are boring us all with?",
          "sentiment": 0.0,
          "engagement": "12,217",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T01:19:44.520004+00:00"
      },
      {
        "event_id": "SOCIAL-Today0750-BuenaVis-74417918",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.610363",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Just a reminder that Thornogson/NDN/Eggy isn't invested and is only here to argue, disrupt and try to waste our time.",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T01:19:44.520023+00:00"
      },
      {
        "event_id": "SOCIAL-Today0746-BuenaVis--6255498",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.904033",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Say what you see \ud83c\udf77\ud83c\udf77\ud83c\udf77",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "54.00",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-02-11T01:19:44.520041+00:00"
      },
      {
        "event_id": "SOCIAL-Today0733-Unbreade--3400822",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.904514",
        "source": "LSE_CHAT",
        "data": {
          "author": "Unbreaded",
          "content": "I love green boxes in the morning! Time for a coffee and catch up on the news.",
          "sentiment": 0.0,
          "engagement": "22",
          "price_at_post": "54.00",
          "thread_title": "Green Boes",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=F7E09828-40CF-45D7-8337-5F0A79C87685"
        },
        "ingested_at": "2026-02-11T01:19:44.520059+00:00"
      },
      {
        "event_id": "SOCIAL-Today0035-Thornogs--1003376",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.904967",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Sujood & Icecool. Similar content but I think ICE probably ahead on presentation. Both deeply underwater but talking a good game. Of course the SP matters, the only data that might be maturing is SGC 1b, which might secure a small deal. We've been told nothing about TNBC and STS is written off. We wait for FAP-EXD, we start again.",
          "sentiment": 0.0,
          "engagement": "8,655",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T01:19:44.520077+00:00"
      },
      {
        "event_id": "SOCIAL-Today0005-Toukanka--3242548",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.905422",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "Pivotal news in the Summer. Where have I heard that before? Oh yeah, it was me and I duly got panned by the Pom Pom girls for suggesting it would take thst long. \ud83e\udd23\ud83e\udd23\ud83e\udd23",
          "sentiment": 0.0,
          "engagement": "4,451",
          "price_at_post": "54.00",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-02-11T01:19:44.520106+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262359-Toukanka-88523954",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.905891",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "Work for ever????",
          "sentiment": 0.0,
          "engagement": "4,451",
          "price_at_post": "54.00",
          "thread_title": "RE: This will haunt you or please you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=8AE0FBBC-C14D-49F3-85C3-E6BED1BD66ED"
        },
        "ingested_at": "2026-02-11T01:19:44.520139+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262324-IFA90--1286604",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.906405",
        "source": "LSE_CHAT",
        "data": {
          "author": "IFA90",
          "content": "Thanks Andy",
          "sentiment": 0.0,
          "engagement": "408",
          "price_at_post": "54.00",
          "thread_title": "RE: This will haunt you or please you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=8AE0FBBC-C14D-49F3-85C3-E6BED1BD66ED"
        },
        "ingested_at": "2026-02-11T01:19:44.520159+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262322-BuenaVis--5581137",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.906824",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Thanks Thompi",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T01:19:44.520177+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262302-Sujood--6237302",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.907374",
        "source": "LSE_CHAT",
        "data": {
          "author": "Sujood",
          "content": "A multi billion dollar company in the making. It will haunt you if you dont position yourself Will please you, if you do the write thing. Learn about the company and do what you know is the right move to make. Nobody every wants to work forever. Keep this message We will talk again soon.",
          "sentiment": 0.5,
          "engagement": "1,260",
          "price_at_post": "54.00",
          "thread_title": "This will haunt you or please you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=8AE0FBBC-C14D-49F3-85C3-E6BED1BD66ED"
        },
        "ingested_at": "2026-02-11T01:19:44.520196+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262258-Icecool-85914547",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.907813",
        "source": "LSE_CHAT",
        "data": {
          "author": "Icecool",
          "content": "Commercial deals will come, and they\u2019ll be welcomed when they do. I\u2019m not in a rush though. If the data continues to strengthen and Avacta can leverage that science into materially better terms, I\u2019m perfectly happy for it to take longer. Time spent increasing leverage isn\u2019t wasted time, it\u2019s how you avoid bad deals and maximise value. \ud83d\ude0a Waiting could be the difference between a few billion and tens of billions. \ud83d\ude0a\ud83e\udd14",
          "sentiment": 0.0,
          "engagement": "8,824",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T01:19:44.520214+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262250-Thompi-85682135",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.908255",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thompi",
          "content": "You may find BV this tweet on X interesting on AVA6103 and BOIN design. AND https://x.com/sandyradders/status/2012950578595258664?s=61&t=BBb2UcjLDTXOFIzJM-vM6A",
          "sentiment": 0.0,
          "engagement": "1,357",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T01:19:44.520233+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262144-Knotagai-28750272",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.908887",
        "source": "LSE_CHAT",
        "data": {
          "author": "Knotagain",
          "content": "We're all fixated on the SP Icecool, it's just a matter of time frames. I've been invested for over five years and would love to see  some commercial news. Nothing wrong with that.",
          "sentiment": 0.0,
          "engagement": "451",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T01:19:44.520262+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262118-Icecool-36417862",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.909330",
        "source": "LSE_CHAT",
        "data": {
          "author": "Icecool",
          "content": "That\u2019s only a concern if you\u2019re fixated on the SP. AIM has never been able to price Avacta properly and it won\u2019t until there\u2019s either a takeover (and suspension) or a move to a serious exchange. The day to day price action is noise. What actually matters is what\u2019s happening behind the scenes with the science, the data, and the strategic discussions. That\u2019s where the real value is being built. \ud83d\udcaf\ud83d\udc4d",
          "sentiment": 0.0,
          "engagement": "8,824",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T01:19:44.520288+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262058-Knotagai-31459725",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.909883",
        "source": "LSE_CHAT",
        "data": {
          "author": "Knotagain",
          "content": "Totally agree Icecool, but only third party validation will move the share price. Hopefully it will happen sometime soon.",
          "sentiment": 0.0,
          "engagement": "451",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T01:19:44.520307+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262032-Icecool-22247322",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.910560",
        "source": "LSE_CHAT",
        "data": {
          "author": "Icecool",
          "content": "The FDA won\u2019t drag this out. AVA6000 proved the platform in humans, AVA6103 builds on that. Phase 1 is about safety and speed. This trial is designed to surface signals quickly with regulatory alignment, not waste years. AVA6000 data will have done a load of heavy lifting already.",
          "sentiment": 0.0,
          "engagement": "8,824",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T01:19:44.520326+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261954-BuenaVis-58404006",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.910984",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "I've got to say I was concerned that the AVA6103 trial with such a toxic agent as exatecan would start at a very low dose and take a long, long time if the step increases were to mimic those in the AVA6000 trial (seven dose levels! - three steps of 40 from 80 to 200, and then three 25% increases to 385) so very pleased to hear about all the benefits of the BOIN design.",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T01:19:44.520345+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261946-Icecool--8482088",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.911503",
        "source": "LSE_CHAT",
        "data": {
          "author": "Icecool",
          "content": "I would also point out that when Thorn bought in he\u2019s also a mega ramping twat!!! Flip/Flop. \ud83d\udcaf\ud83e\udd23\ud83e\udd23 best on filter \ud83d\udc4d",
          "sentiment": 0.0,
          "engagement": "8,824",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T01:19:44.520363+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261937-HarChris--6055199",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.912044",
        "source": "LSE_CHAT",
        "data": {
          "author": "HarChris",
          "content": "Going back to the trial design I thought this overview could be useful: Key Comparisons Accuracy in MTD Selection: BOIN generally outperforms 3+3 by more accurately identifying the true MTD. In simulations across various scenarios BOIN achieves a 12-16% higher percentage of correct selection (PCS) of the MTD, and in cases where the MTD is at higher doses, it can nearly triple the PCS compared to 3+3. Efficiency and Patient Allocation: BOIN is more efficient, often resulting in shorter trial durations and lower costs by adapting in real-time and allocating more patients to the MTD (especially at higher doses or with higher target DLT rates). The 3+3 design can prolong trials due to its conservative escalation and fixed cohort requirements, leading to fewer patients treated at effective doses. Safety and Risk Management: While 3+3 minimizes overdose risk by being overly cautious (e.g., lower chance of assigning >60% of patients above the MTD), it increases under-dosing, where many patients receive suboptimal doses. BOIN balances this better with built-in overdose controls and dynamic adjustments, reducing under-dosing without significantly raising overdose risks, thus improving ethical standards by minimising patient exposure to ineffective or overly toxic doses. Simplicity and Flexibility: Both are relatively easy to implement\u2014BOIN requires no complex programming or simulations beyond basic setup, making it accessible like 3+3. However, BOIN offers more flexibility, such as variable cohort sizes (e.g., 4 patients) and adjustable target toxicity rates, whereas 3+3 is fixed to cohorts of 3 (or 3+3) and standard targets. In summary, BOIN represents an evolution over 3+3, providing better performance across most metrics while maintaining ease of use. The 3+3 design is still widely used for its familiarity and safety focus in conservative settings but is increasingly seen as outdated for not fully utilising trial data.",
          "sentiment": 0.0,
          "engagement": "15,865",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T01:19:44.520388+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261812-Cashless-41291277",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.912567",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cashless",
          "content": "Been out all day, so just logged on.....and what a pleasure to see a sea of green and pretty much all informative posts...I LOVE GREEN...not sure the green people are so happy though \ud83d\udc4d\ud83e\udd2a\ud83e\udd2a\ud83e\udd73",
          "sentiment": 0.5,
          "engagement": "401",
          "price_at_post": "54.00",
          "thread_title": "Bliss",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E431AF8E-57C8-40B5-91C6-8D284968B368"
        },
        "ingested_at": "2026-02-11T01:19:44.520417+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261753-B2HS2L--8835982",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.913172",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "FWIW Google search What is the difference between event free and progression free survival AI Overview: Progression-Free Survival (PFS) measures the time from treatment initiation until objective tumor growth or death from any cause. Event-Free Survival (EFS) measures the time from randomization until a broader range of \"events,\" including disease progression, treatment failure, complications, or death. PFS focuses on tumor growth; EFS focuses on any negative outcome. Key Differences: Definition of Event: PFS is restricted to disease progression or death. EFS includes those, plus failure to proceed to planned surgery, relapse, or severe treatment complications. Context of Use: PFS is commonly used in advanced or metastatic cancer trials to evaluate treatment efficacy. EFS is frequently used in earlier-stage cancer trials, particularly in the neoadjuvant (pre-surgery) setting. Precision: PFS depends on the frequency of imaging scans to detect growth, while EFS is often defined by the time until a patient cannot proceed with their treatment plan. Essentially, PFS means the cancer has not worsened, whereas EFS means the patient has not experienced any negative, pre-defined event.",
          "sentiment": 0.0,
          "engagement": "6,000",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T01:19:44.520436+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261428-BuenaVis--6998324",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.913661",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "What is the current best progression free survival rate for TNBC? https://www.google.com/search?q=What+is+the+current+best+progression+free+survival+rate+for+TNBC%253F",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T01:19:44.520454+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261424-HarChris-46375425",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.914093",
        "source": "LSE_CHAT",
        "data": {
          "author": "HarChris",
          "content": "It's what happened to STS and might now happen with TNBC, might not of course, but if it did then it'll all fall to SGC to carry the load until FAP-EXD starts to produce meaningful data. __________________ In other words IF TNBC data doesn't deliver then SGC might have to carry the load until H2 2026? That's not bad as a worst case and it's very short term as it gets for biotech. And with the less risk averse and far more efficient BOIN design for 6103 we should start receiving compelling data rapidly if all is going well. It's close!",
          "sentiment": 0.0,
          "engagement": "15,865",
          "price_at_post": "54.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T01:19:44.520473+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261411-Thornogs-26250052",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.914533",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "No well spotted!  My bad.",
          "sentiment": 0.0,
          "engagement": "8,655",
          "price_at_post": "54.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T01:19:44.520491+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261409-BuenaVis-66699482",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.915065",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "I may be missing something here but trastuzumab deruxtecan (brand name Enhertu) and pertuzumab are both used to treat HER2-positive breast cancer.  So what has that got to do with TNBC which is an aggressive, fast-growing type of breast cancer that tests negative for three key receptors: estrogen (ER), progesterone (PR), and HER2?",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "54.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T01:19:44.520515+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261349-Thornogs--3249862",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.915517",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "'....FAP-DOX needs to beat.'",
          "sentiment": 0.0,
          "engagement": "8,655",
          "price_at_post": "54.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T01:19:44.520546+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261347-Thornogs--3462575",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.915945",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "But clearly relevent so clearly won't be mentioned by anyone else Watching? Obviously important if it's doubled the PFS times for TNBC, the bar has been raised as to what FAP-EXD needs to beat. It's what happened to STS and might now happen with TNBC, might not of course, but if it did then it'll all fall to SGC to carry the load until FAP-EXD starts to produce meaningful data.",
          "sentiment": 0.0,
          "engagement": "8,655",
          "price_at_post": "54.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T01:19:44.520565+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261347-pedrolan--6171892",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.837882",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Just a reminder that Thorn is not invested but spends his sad life on here posting negative comments about a company saving lives. What a guy!!!",
          "sentiment": 0.5,
          "engagement": "1,972",
          "price_at_post": "54.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T01:19:44.520583+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261339-Watching-20815324",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.838382",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "You Still have to focus on negatives. Thorny you are such a k n o bby \ud83e\udd21\ud83e\udd21",
          "sentiment": 0.0,
          "engagement": "9,213",
          "price_at_post": "54.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T01:19:44.520602+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261335-Thornogs-86640310",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.838824",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "It's perhaps double edged though? The AVA6000 STS trial was (allegedly) de-railed by a trial that showed longer, and better than expected, survival data. If there's a new 'Standard of Care' being announced for TNBC the bar might just have been raised on what FAP-DOX/TNBC needs to achieve to get a deal and get to market?",
          "sentiment": 0.0,
          "engagement": "8,655",
          "price_at_post": "55.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T01:19:44.520620+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261315-LovableL-88817552",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.839268",
        "source": "LSE_CHAT",
        "data": {
          "author": "LovableLumax",
          "content": "Https://x.com/onclive/status/2016451178872061994?s=46",
          "sentiment": 0.0,
          "engagement": "2,703",
          "price_at_post": "55.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T01:19:44.520641+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261053-Aldebara--2546430",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.839705",
        "source": "LSE_CHAT",
        "data": {
          "author": "Aldebaran",
          "content": "I think small caps are at the very start of a major bull run. Green portfolio everywhere across the board. Also note that even with hard times, avacta raised 16m through zeus at only 8% discount plus managed to delay and renegotiate the terms of the bond. No mean feat that and the macro picture for small caps has improved since then. As has our IP and data package plus the deadline for BP patent expiry has only become closer. Things nowhere near as desperate as this shhhhh it tee little market gives credit for. I mean avacta have developed the worlds first dual warhead peptide drug conjugate ffs . \ud83d\ude05",
          "sentiment": 0.0,
          "engagement": "3,894",
          "price_at_post": "55.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T01:19:44.520674+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261050-opti_mys--7029414",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.840239",
        "source": "LSE_CHAT",
        "data": {
          "author": "opti_mystic",
          "content": "I think that's optimistic Lovable being as the initial doses will be very low. It is a safety trial initially remember, but the trial design (BOIN) will allow for dose escalation quite quickly and also potentially skipping from say dose level one to does level 3. I think more realistically summer months we may start to see some useful efficacy. What they will know sooner is are there any problems/does it works as expected and designed. If no bad news by May/June I think we're on a winner. I expect it to work.",
          "sentiment": 0.0,
          "engagement": "296",
          "price_at_post": "55.50",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-02-11T01:19:44.520694+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261045-Sisyphus-58061445",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.840667",
        "source": "LSE_CHAT",
        "data": {
          "author": "SisyphusShorter",
          "content": "Out of coincidence it's been exactly a week since the last RNS regarding AVA6103. Could an announcement be due imminently?",
          "sentiment": 0.0,
          "engagement": "4",
          "price_at_post": "55.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T01:19:44.520712+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261014-HarChris--4041373",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.841093",
        "source": "LSE_CHAT",
        "data": {
          "author": "HarChris",
          "content": "I wonder if those solely focused on Avacta and thinking history always repeats are missing the fact that the AIM backdrop plays a major role here. And in that regard liquidity has returned to UK small caps with a vengeance, raises are happening without the sort of discounts seen in 2022/23/24/25, companies are seeing major share price appreciation actually hold rather than the wild swings of post Covid. It\u2019s a far healthier backdrop right now than at any point since I\u2019ve held Avacta shares.",
          "sentiment": 0.0,
          "engagement": "15,865",
          "price_at_post": "55.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T01:19:44.520730+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261003-harryhot-58873857",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.841536",
        "source": "LSE_CHAT",
        "data": {
          "author": "harryhotspur1311",
          "content": "I was hoping for the big erection shape although roundish bottoms are quite welcome as well!",
          "sentiment": 0.0,
          "engagement": "12",
          "price_at_post": "55.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T01:19:44.520749+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260958-A1invest-26155420",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.841950",
        "source": "LSE_CHAT",
        "data": {
          "author": "A1invest",
          "content": "Lets hope its a \"rounding bottom\" shape.  :)",
          "sentiment": 0.0,
          "engagement": "143",
          "price_at_post": "55.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T01:19:44.520767+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260953-pedrolan-47563574",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.842525",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Salty for sure",
          "sentiment": 0.0,
          "engagement": "1,972",
          "price_at_post": "55.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T01:19:44.520803+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260945-Thornogs-10312628",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.843025",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "\"Salt and vinegar on that sir?\"",
          "sentiment": 0.0,
          "engagement": "8,655",
          "price_at_post": "55.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T01:19:44.520823+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260944-Timster--4431768",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.843502",
        "source": "LSE_CHAT",
        "data": {
          "author": "Timster",
          "content": "Big fish, little fish, cardboard box....",
          "sentiment": 0.0,
          "engagement": "20,625",
          "price_at_post": "55.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T01:19:44.520842+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260941-harryhot--1932423",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.844130",
        "source": "LSE_CHAT",
        "data": {
          "author": "harryhotspur1311",
          "content": "Whenever the SP drops, the pessimists always quote \u2018the market knows\u2019 Perhaps this could work the other way around occasionally! Today, perhaps!",
          "sentiment": 0.0,
          "engagement": "12",
          "price_at_post": "56.00",
          "thread_title": "Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T01:19:44.520860+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260823-pedrolan--3820698",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.844561",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Ah yes, I knew I had been there but couldn't remember exactly which Lake \ud83e\udd23",
          "sentiment": 0.5,
          "engagement": "1,972",
          "price_at_post": "52.50",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-02-11T01:19:44.520878+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260726-Gingethe-14220609",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.844978",
        "source": "LSE_CHAT",
        "data": {
          "author": "GingetheWinge",
          "content": "Derwent valley dam in the Peak District.",
          "sentiment": 0.5,
          "engagement": "699",
          "price_at_post": "53.00",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-02-11T01:19:44.520896+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260713-LovableL--3191192",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.845409",
        "source": "LSE_CHAT",
        "data": {
          "author": "LovableLumax",
          "content": "I also suspect we will have a 6000 partner signed up once we have an approved accelerated pathway and registrations P2\\3 with FDA which is hopefully imminent",
          "sentiment": 0.0,
          "engagement": "2,703",
          "price_at_post": "53.00",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-02-11T01:19:44.520931+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260703-LovableL-18340731",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.845829",
        "source": "LSE_CHAT",
        "data": {
          "author": "LovableLumax",
          "content": "Given how potent the payload is and with the improved half-life and active in the TME for 5 days surely they'll see results as early as scan 1. That sounds rampy and too optimistic but look at the preclinical results. Things could really take off as early as the summer, or even before. Again, I suspect recruitment will be fairly rapid given FAP targeting with preCISION proven and preclinical results so investigators likely chomping at the bit.",
          "sentiment": 0.0,
          "engagement": "2,703",
          "price_at_post": "53.00",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-02-11T01:19:44.520952+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260659-nurseste-99923001",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.846277",
        "source": "LSE_CHAT",
        "data": {
          "author": "nursesteve",
          "content": "CC discussing FAP-Exd (AVA6103) - The profile of this second pre|CISION medicine in the preclinical setting is tremendous.  The sustained release mechanism developed by Avacta scientists results in a robust concentration of active drug in the tumor over five days with the disappearance from the bloodstream in only two hours. This is the exact profile needed to achieve better efficacy with this highly potent topo I inhibitor. Could payoff for LTH be this year?",
          "sentiment": 0.0,
          "engagement": "1,164",
          "price_at_post": "53.00",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-02-11T01:19:44.520971+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260006-D-Geeman--5334499",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.846690",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "An elderly character actor in our road, when I first arrived,  was in the movie \u2018The Dambusters\u2019, and in \u2018Bridge on the River Kwai\u2019. He used to tell some good stories of life on 1950\u2019s film sets. Dead for a while but he pops up on screen even now.",
          "sentiment": 0.0,
          "engagement": "5,844",
          "price_at_post": "52.50",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-02-11T01:19:44.520989+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20262319-pedrolan--4830850",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.847122",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Yes, it's an inspirational story. I think they tested it up in the Lake District",
          "sentiment": 0.5,
          "engagement": "1,972",
          "price_at_post": "52.50",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-02-11T01:19:44.521007+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20262113-Captains-24531092",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.847541",
        "source": "LSE_CHAT",
        "data": {
          "author": "Captainstanley.",
          "content": "I can't find that information anywhere Which Friday? Presumably you mean this week 29th Jan?",
          "sentiment": 0.0,
          "engagement": "467",
          "price_at_post": "52.50",
          "thread_title": "RE: SGC",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=5E3142A3-349A-43A2-B5B7-02836561174A"
        },
        "ingested_at": "2026-02-11T01:19:44.521025+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20262014-Flippine--2088855",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.847977",
        "source": "LSE_CHAT",
        "data": {
          "author": "Flippineck",
          "content": "I\u2019ve been thinking about the trials and tribulations of developing new inventions and ended up swotting up on Barnes Wallace, the inventor of the famous Bouncing Bomb. It seems initial proposals were dismissed by Bomber Command as being \u201c a mad-cap scheme\u201d. There were several critical failures in the development which had to be overcome. The shape of the bomb had to be changed, backspin had to be introduced, the weapon would shatter, sink or detonate prematurely or veer off course. Barnes Wallace persevered and it all came good in the end.",
          "sentiment": 0.0,
          "engagement": "417",
          "price_at_post": "52.50",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-02-11T01:19:44.521057+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261912-BuenaVis--6357386",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.848415",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Christina Coughlin became the CEO of Avacta on 1 May 2024. There is no need to dwell on anything or anyone before that date. CC has set out the company's objectives and timelines and has stuck to them, as much as is possible taking outside decision-making and events into account.  This adherence to the company's aims and plans comes about because she is a pharma executive with ample of experience of drug development and the way the FDA works.",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "52.50",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-02-11T01:19:44.521088+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261900-BuenaVis-60194886",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.848907",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "As Runner-Runner wrote... It's simple. 1. DO NOT ENGAGE 2. DO NOT ASK IT A QUESTION 3. DO NOT ANSWER ITS QUESTIONS 4. DO NOT MOAN ABOUT ITS POSTS 5. DO NOT ARGUE WITH IT 6. If you must do something. Mock it with reference only to its stupidity and nothing else. ------------------------------------------------------ If you're not part of the solution, you're part of the problem",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "52.50",
          "thread_title": "RE: Year end trading update :",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=CCFE6866-0D3C-4A1E-9659-9B2E552262F5"
        },
        "ingested_at": "2026-02-11T01:19:44.521123+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20262219-Thornogs-72175014",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.801399",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Anything new there? 'Expected' Q1? No, nothing new, just 'same old'.",
          "sentiment": 0.0,
          "engagement": "8,596",
          "price_at_post": "54.50",
          "thread_title": "RE: Bioconjugate Insights",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0DCD83D9-A17D-43E1-842E-1C922D520A76"
        },
        "ingested_at": "2026-02-11T01:19:44.521142+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20262212-avctIPma-24615635",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.801859",
        "source": "LSE_CHAT",
        "data": {
          "author": "avctIPmatters",
          "content": "Again courtesy of Stonks -  Finds  new coverage  Avacta related   many thanks . https://cdn.insights.bio/uploads/attachments/BCI%20Industry%20Insights.pdfAvacta Therapeutics reported new preclinical pharmacology data for FAP-Exd peptide drug conjugate [25] \"Avacta Therapeutics announced new preclinical pharmacology data for FAP-Exd (AVA6103), its second asset derived from the pre|CISION\u00ae tumor-activated delivery platform, which is expected to enter Phase 1 testing in Q1 2026. FAP-Exd is a fibroblast activation protein\u2013cleavable peptide-drug linking a proprietary peptide to a topoisomerase I inhibitor payload. The data demonstrated tumor-specific cytotoxicity, sustained intratumoral release of active exatecan with limited systemic exposure, and robust antitumor activity across multiple patient-derived xenograft models. Avacta also reported that artificial intelligence\u2013guided analysis was used to prioritize clinical indications based on co-expression of FAP and SLFN11.\" Gmcc",
          "sentiment": 0.0,
          "engagement": "720",
          "price_at_post": "54.50",
          "thread_title": "Bioconjugate Insights",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0DCD83D9-A17D-43E1-842E-1C922D520A76"
        },
        "ingested_at": "2026-02-11T01:19:44.521160+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20262210-Thornogs-43090804",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.802303",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Avacta does its thing regardless of what's posted here. Get over yourselves, self appointed \"Guardian's of the truth\"! And if you must wear your underpants on the outside do at least please ensure that  they're better laundered?",
          "sentiment": 0.0,
          "engagement": "8,596",
          "price_at_post": "54.50",
          "thread_title": "The reality?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=D8CC0643-0047-4DA0-A21A-3E0ECC3BD17C"
        },
        "ingested_at": "2026-02-11T01:19:44.521182+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20262154-BuenaVis--6351259",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.802718",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "I had Firefox nicely set up with AdBlock so that all ads were wiped out but had to 'repair' Firefox today (as tabs were crashing) and then reload an AdBlock extension but I now keep getting these annoying messages from LSE about ads that I never used to get.  Can't remember what I did before to permanently remove those messages.  Can anyone offer advice on how they've solved this?",
          "sentiment": 0.0,
          "engagement": "5,722",
          "price_at_post": "54.50",
          "thread_title": "Off-topic - removing ads on Firefox",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=9BE707F4-9555-444A-A3C8-1254E00A3443"
        },
        "ingested_at": "2026-02-11T01:19:44.521215+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20262109-Knotagai-67613416",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.803142",
        "source": "LSE_CHAT",
        "data": {
          "author": "Knotagain",
          "content": "All day every day...",
          "sentiment": 0.0,
          "engagement": "448",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-02-11T01:19:44.521234+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261944-Agenda10-79219734",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.803559",
        "source": "LSE_CHAT",
        "data": {
          "author": "Agenda101",
          "content": "Brilliant! The never ending Twats.. they are all green boxed here\u2026 But I\u2019m hearing you Sheepy! Exactly right.",
          "sentiment": 0.0,
          "engagement": "55",
          "price_at_post": "54.50",
          "thread_title": "RE: Frankly pathetic",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B36E2695-D07A-4E60-838B-02C995994856"
        },
        "ingested_at": "2026-02-11T01:19:44.521253+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261943-BuenaVis--7520304",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.803971",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Lighten up Thompi.  It's the best comedy show in town.",
          "sentiment": 0.0,
          "engagement": "5,722",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-02-11T01:19:44.521271+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261940-Thompi-15414865",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.804413",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thompi",
          "content": "Because, Touk, Thorn talks total twaddle and inundates this board with spam. It\u2019s made the board virtually unreadable. Even blocking him doesn\u2019t really help, because all I then see are green boxes and other people replying to his posts. I probably add to the noise at times too - but I\u2019ve genuinely had enough of one person commandeering the board with the same malicious rubbish, day after day. Post after post after post. It wears people down. It stops being discussion and just becomes disruption.",
          "sentiment": 0.0,
          "engagement": "1,355",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-02-11T01:19:44.521289+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261848-Toukanka-42609667",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.804832",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "Cj62 How can it be utter garbage when it\u2019s generally been predicting what is happening to Avacta. But the pond poms utter garbage of \u201ctakeover tomorrow \u201c, \u201cmarket thick as mince\u201d etc etc ad infinitum even though they\u2019ve been entirely wrong for years. Well that\u2019s fine clogging up the board with that garbage",
          "sentiment": 0.0,
          "engagement": "4,436",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-02-11T01:19:44.521309+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261845-BuenaVis--6667483",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.805254",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "6am to midnight but with a two hour evening break to neck a bottle of whisky.",
          "sentiment": 0.0,
          "engagement": "5,722",
          "price_at_post": "54.50",
          "thread_title": "RE: Frankly pathetic",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B36E2695-D07A-4E60-838B-02C995994856"
        },
        "ingested_at": "2026-02-11T01:19:44.521344+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261844-Toukanka--7029462",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.805661",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "You\u2019re right Thompi. You never do say much more than joining your mates and flinging the insults. Why not talk about Avacta rather the other posters on here?",
          "sentiment": 0.0,
          "engagement": "4,436",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-02-11T01:19:44.521364+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261841-sheppy--2195525",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.806079",
        "source": "LSE_CHAT",
        "data": {
          "author": "sheppy",
          "content": "Wyn, Thorn, Touk , DG same poster numerous aliases. Hourly paid hired help disrupter. Regardless of that what sort of sad, moronic halfwit would spend 7 days a week starting each day at 6 am and continuing after midnight posting negative comments about a share they are allegedly not invested in? Regardless of their reason what a total waste of one\u2019s life on this earth . What a pathetic pitiful existence arguing with anonymous people on an anonymous bb. I actually pity their sad, lonely unfulfilled existence. And before the poster tells me they live a very fulfilled life doing lots of other meaningful things ask yourself how this is possible with so many never ending  daily boring transparent attempts at disruption. Sad twat and a weirdo",
          "sentiment": 0.0,
          "engagement": "563",
          "price_at_post": "54.50",
          "thread_title": "Frankly pathetic",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B36E2695-D07A-4E60-838B-02C995994856"
        },
        "ingested_at": "2026-02-11T01:19:44.521383+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261831-cj62--2536610",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.806499",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "Anything you post Thorn is utter garbage. How many crayons have you done today ?",
          "sentiment": 0.0,
          "engagement": "4,270",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-02-11T01:19:44.521401+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261820-Thornogs-63667867",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.806924",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "And what did you say? Anything worth hearing? Anything about Avacta and what's going well and what isn't and thoughts about why? No, thought not. Shame.",
          "sentiment": 0.0,
          "engagement": "8,596",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-02-11T01:19:44.521420+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261755-Thompi-53235625",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.807357",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thompi",
          "content": "Pedro, if I add your 67 posts over the last 30 days to my 20, plus Tim\u2019s 43 and Watching\u2019s 39, the grand combined total is 169 posts. That\u2019s four people combined. Compared to Thorn\u2019s 253 posts on his own. The figures speak for themselves.",
          "sentiment": 0.0,
          "engagement": "1,355",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-02-11T01:19:44.521447+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261754-wyndrum--5481759",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.807774",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "And i see my requests to get NFT to respond have been deleted but the insults to me remain. But yes, its the LSE moderators allowing me to post that is the problem here. Where are you NFT, want to answer my queries so you can justify the remarks in your post?",
          "sentiment": 0.0,
          "engagement": "12,198",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-02-11T01:19:44.521480+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261737-pedrolan-80224620",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.808191",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Make that 29 to go",
          "sentiment": 0.0,
          "engagement": "1,948",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-02-11T01:19:44.521499+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261719-Thompi-20554757",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.808620",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thompi",
          "content": "Avacta posts over the last 30 days: 253 Thorn \ud83e\udd47 43 Timster 39 Watching Not much else to say really Thorn.",
          "sentiment": 0.0,
          "engagement": "1,355",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-02-11T01:19:44.521517+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261708-Thornogs-54759486",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.809052",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "And the two posters below your post Thompi? Watching 9,000 and Tim 20,000! All on only Avacta and all 100% content free 'jokes' or 'bile'. But to comment on that would be to show a consistent approach to this sort of thing wouldn't it? Be honest, it's not the number or posts, it's the fact that you might have to consider things that you don't want to consider. Fine, your choice, 5 years in and AVA6000 limping along to a possible low-ball deal and FAP-EXD entering the 'Last Chance Saloon' in the next 2-3 months. Everything that you've been predicting for the last 5 years, why would you need to hear a contrary opinion when you've clearly been smashing it all this time? Well up I dare say on your investment are we?",
          "sentiment": 0.0,
          "engagement": "8,596",
          "price_at_post": "54.00",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-02-11T01:19:44.521536+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261644-Thompi-75476877",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.809483",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thompi",
          "content": "To be fair Tim, Thorn\u2019s only posted 11 times so far today. He\u2019s got another 30 to go before he equals his personal best of 41 posts in 24 hours. By my reckoning, if he manages around 4.3 posts per hour between now and midnight (17:00\u201312:00am), he might just be in with a chance of beating it. Bless his selfless little heart.",
          "sentiment": 0.0,
          "engagement": "1,355",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-02-11T01:19:44.521555+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261537-Watching-50323658",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.809893",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "24/7. He keeps churning out verbal \ud83d\udca9",
          "sentiment": 0.0,
          "engagement": "9,201",
          "price_at_post": "54.50",
          "thread_title": "RE: CC interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=F5A9F3B7-45F7-4EC2-B1FD-1ACB3A2D2E18"
        },
        "ingested_at": "2026-02-11T01:19:44.521576+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261535-Timster-67613416",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.810318",
        "source": "LSE_CHAT",
        "data": {
          "author": "Timster",
          "content": "All day every day...",
          "sentiment": 0.0,
          "engagement": "20,620",
          "price_at_post": "54.50",
          "thread_title": "To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-02-11T01:19:44.521609+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261529-cj62--2104729",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.810731",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "Shall we have a 'Spot the idiot' competition? You win it thorn, no competition !!!",
          "sentiment": 0.0,
          "engagement": "4,270",
          "price_at_post": "54.50",
          "thread_title": "RE: CC interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=F5A9F3B7-45F7-4EC2-B1FD-1ACB3A2D2E18"
        },
        "ingested_at": "2026-02-11T01:19:44.521628+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261517-Thornogs-58146499",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.811159",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Of course we don't BV, and the industry experts who know these things currently value Avacta at 50 odd pence a share. NFT and the 28 odd who ticked up his posts think \u00a328 is more accurate. Shall we have a 'Spot the idiot' competition?",
          "sentiment": 0.0,
          "engagement": "8,596",
          "price_at_post": "54.50",
          "thread_title": "RE: CC interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=F5A9F3B7-45F7-4EC2-B1FD-1ACB3A2D2E18"
        },
        "ingested_at": "2026-02-11T01:19:44.521647+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261515-cj62--9218563",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.811569",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "That's theoretical of course. Thorn its like 99% of the other gibberish you post twat.",
          "sentiment": 0.0,
          "engagement": "4,270",
          "price_at_post": "54.50",
          "thread_title": "RE: CC interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=F5A9F3B7-45F7-4EC2-B1FD-1ACB3A2D2E18"
        },
        "ingested_at": "2026-02-11T01:19:44.521666+00:00"
      },
      {
        "event_id": "SOCIAL-Today1337-wyndrum--1478550",
        "event_type": "social_post",
        "date": "2026-02-11T14:17:05.527997",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "Yeah, funny when there is new news (and it\u2019s positive) there is less to comment on. Please stop posting on whether you think I am in or out . You have always been wrong. My holdings have never influenced my views. The reason I have posted less is because the usual disrupters have stopped targeting me with lies and insults. If you could just keep your posts to AVCT and leave me out of it then that would help further.",
          "sentiment": 0.0,
          "engagement": "12,256",
          "price_at_post": "60.00",
          "thread_title": "RE: Banned",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AA63DAAF-42CA-42B0-A114-E3945671F7FA"
        },
        "ingested_at": "2026-02-11T14:17:13.146333+00:00"
      },
      {
        "event_id": "SOCIAL-Today1226-Saint68-26499211",
        "event_type": "social_post",
        "date": "2026-02-11T14:17:05.528446",
        "source": "LSE_CHAT",
        "data": {
          "author": "Saint68",
          "content": "Who cares - he's not posting so all good.",
          "sentiment": 0.0,
          "engagement": "2,194",
          "price_at_post": "60.00",
          "thread_title": "RE: Banned",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AA63DAAF-42CA-42B0-A114-E3945671F7FA"
        },
        "ingested_at": "2026-02-11T14:17:13.146368+00:00"
      },
      {
        "event_id": "SOCIAL-Today1220-pedrolan--8511324",
        "event_type": "social_post",
        "date": "2026-02-11T14:17:05.528858",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "I take it as a good sign the board is quiet here. Of course there will be a big element of that down to the omission of Thorn, Now apologies in advance and I don't want to set the hare running but do we know he deleted his account or was he banned? Does anyone know for sure? It did seem to be around the time he was re-exposed as Eggy but it is possible that was a coincidence.",
          "sentiment": 0.5,
          "engagement": "1,993",
          "price_at_post": "60.00",
          "thread_title": "RE: Banned",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AA63DAAF-42CA-42B0-A114-E3945671F7FA"
        },
        "ingested_at": "2026-02-11T14:17:13.146389+00:00"
      },
      {
        "event_id": "SOCIAL-Today1200-Icecool-40197810",
        "event_type": "social_post",
        "date": "2026-02-11T14:17:05.529302",
        "source": "LSE_CHAT",
        "data": {
          "author": "Icecool",
          "content": "There\u2019s not much to debate right now to be honest. Windy\u2019s suddenly gone quiet now he\u2019s back in, funny how that works \ud83d\ude44\ud83e\udd23\ud83d\ude2d. When he\u2019s out it\u2019s doom and gloom, when he\u2019s in it\u2019s silence. Standard behaviour. Most of the board actually seems pretty calm. Everyone knows the next real catalyst is TNBC data. That\u2019s what matters. And Thorn disappearing the moment the lifetime dose cap was removed!! That tells its own story. The whole half life cumulative toxicity argument was the backbone of that narrative. Once regulators lifted the cap, that line of attack collapsed overnight. The drug just gained a structural advantage. You don\u2019t quietly delete your account if that doesn\u2019t sting. \ud83e\udd23\ud83e\udd23\ud83e\udd23 Now we wait for data. Everything else is just noise in the meantime. \ud83d\udcaf\ud83d\udc4d",
          "sentiment": 0.0,
          "engagement": "8,858",
          "price_at_post": "60.00",
          "thread_title": "RE: Banned",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AA63DAAF-42CA-42B0-A114-E3945671F7FA"
        },
        "ingested_at": "2026-02-11T14:17:13.146409+00:00"
      },
      {
        "event_id": "SOCIAL-Today1157-BuenaVis-46203650",
        "event_type": "social_post",
        "date": "2026-02-11T14:17:05.529711",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "\"[U]p to $2.4 billion in cash, inclusive of an upfront payment and subsequent payments upon achievement of certain clinical development milestones\" so enough for a scone today and gallons and gallons of jam tomorrow, if they're lucky. Nothing in clinical development: https://www.ornatx.com/our-pipeline/",
          "sentiment": 0.0,
          "engagement": "5,849",
          "price_at_post": "60.00",
          "thread_title": "RE: ELY LILLY",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B6F8359B-09F7-4910-B7F8-547334C64F27"
        },
        "ingested_at": "2026-02-11T14:17:13.146428+00:00"
      },
      {
        "event_id": "SOCIAL-Today1146-D0berman--5360726",
        "event_type": "social_post",
        "date": "2026-02-11T14:17:05.530123",
        "source": "LSE_CHAT",
        "data": {
          "author": "D0berman",
          "content": "Bloody Hell!! Who's been banned, it's so quiet!!",
          "sentiment": 0.0,
          "engagement": "1,024",
          "price_at_post": "60.00",
          "thread_title": "Banned",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AA63DAAF-42CA-42B0-A114-E3945671F7FA"
        },
        "ingested_at": "2026-02-11T14:17:13.146445+00:00"
      },
      {
        "event_id": "SOCIAL-Today0904-Harrogat--7906998",
        "event_type": "social_post",
        "date": "2026-02-11T14:17:05.530532",
        "source": "LSE_CHAT",
        "data": {
          "author": "Harrogate4",
          "content": "One day Rodders ----that could be us.",
          "sentiment": 0.0,
          "engagement": "807",
          "price_at_post": "60.50",
          "thread_title": "RE: ELY LILLY",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B6F8359B-09F7-4910-B7F8-547334C64F27"
        },
        "ingested_at": "2026-02-11T14:17:13.146477+00:00"
      },
      {
        "event_id": "SOCIAL-Today0812-Bella653--1446904",
        "event_type": "social_post",
        "date": "2026-02-11T14:17:05.530927",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "Https://investor.lilly.com/news-releases/news-release-details/lilly-acquire-orna-therapeutics-advance-cell-therapies",
          "sentiment": 0.0,
          "engagement": "6,770",
          "price_at_post": "59.50",
          "thread_title": "ELY LILLY",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B6F8359B-09F7-4910-B7F8-547334C64F27"
        },
        "ingested_at": "2026-02-11T14:17:13.146512+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20262211-B2HS2L-51178386",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.316988",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "Bella, I'm quoting company presentations and Trinity Delta. But I'll take any answer I can get from an Investor Relations company willing to respond to an Investor on behalf of Avacta. What a breath of fresh air that would be, and we could all organise a knee's up to celebrate responses.   Ha ha....dream on. Will advise any response, but it won't be this week I'm thinking.",
          "sentiment": 0.0,
          "engagement": "6,052",
          "price_at_post": "59.50",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0781AA9B-9049-48B9-B94C-F3239EA4AB66"
        },
        "ingested_at": "2026-02-11T14:17:13.146547+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20262058-D-Geeman-37588185",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.317461",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "\u2018 and Wynbore taken \u2019 Mel obvs missing Wyn after just a day or two. \ud83d\ude3f",
          "sentiment": 0.0,
          "engagement": "5,879",
          "price_at_post": "59.50",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0781AA9B-9049-48B9-B94C-F3239EA4AB66"
        },
        "ingested_at": "2026-02-11T14:17:13.146576+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20262040-Bella653-80868459",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.317882",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "Most likely you'll be referred to RNS updates.",
          "sentiment": 0.0,
          "engagement": "6,769",
          "price_at_post": "59.50",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0781AA9B-9049-48B9-B94C-F3239EA4AB66"
        },
        "ingested_at": "2026-02-11T14:17:13.146594+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20262038-Bella653-74115467",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.318312",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "B2...Afraid they won't be able to give you the answers you seek.",
          "sentiment": 0.0,
          "engagement": "6,769",
          "price_at_post": "59.50",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0781AA9B-9049-48B9-B94C-F3239EA4AB66"
        },
        "ingested_at": "2026-02-11T14:17:13.146630+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261947-Metatron-16210326",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.318724",
        "source": "LSE_CHAT",
        "data": {
          "author": "Metatron",
          "content": "Where have your mates gone Toukdroid? Thorn been banned? and Wynbore taken his bat and ball home? Pressures on you now.. need to raise your game? \ud83e\uddd0\ud83d\ude02\ud83d\ude44",
          "sentiment": 0.0,
          "engagement": "1,193",
          "price_at_post": "59.50",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0781AA9B-9049-48B9-B94C-F3239EA4AB66"
        },
        "ingested_at": "2026-02-11T14:17:13.146649+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261929-D-Geeman--4384207",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.319153",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "Faron, FARN, today. *Unless I'm missing something.",
          "sentiment": 0.0,
          "engagement": "5,879",
          "price_at_post": "59.50",
          "thread_title": "How *NOT* to organise a raise.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B74524AD-99F9-469D-8BB4-0B75886909B8"
        },
        "ingested_at": "2026-02-11T14:17:13.146667+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261806-cj62--6425164",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.319558",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "Thorn/ touk you continue to be an insufferable prick. As for the consortium you mention,at the present market cap, yes I probably could.",
          "sentiment": 0.0,
          "engagement": "4,305",
          "price_at_post": "59.50",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0781AA9B-9049-48B9-B94C-F3239EA4AB66"
        },
        "ingested_at": "2026-02-11T14:17:13.146685+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261757-Toukanka--8897562",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.319970",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "\u201c . As I mentioned, we'll have that,. Pipeline update, platform update, and so we're really excited about, the fourth quarter, for the company.\" Jeez I must have missed all those 4Q25 announcements",
          "sentiment": 0.0,
          "engagement": "4,490",
          "price_at_post": "59.50",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0781AA9B-9049-48B9-B94C-F3239EA4AB66"
        },
        "ingested_at": "2026-02-11T14:17:13.146703+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261717-Toukanka-70428967",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.320430",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "BenH It\u2019s ok Someone has deleted the post anyway",
          "sentiment": 0.0,
          "engagement": "4,490",
          "price_at_post": "59.50",
          "thread_title": "RE: Initial data seen under NDA 1st",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=DC4BE032-D599-4CC6-BFFD-F74DE0A45A33"
        },
        "ingested_at": "2026-02-11T14:17:13.146720+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261714-B2HS2L-22947853",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.320844",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "That's clear. What isn't clear is the nature of the phase 2 partnership sought by Avacta. 15:31",
          "sentiment": 0.0,
          "engagement": "6,052",
          "price_at_post": "59.50",
          "thread_title": "RE: Fairy docks ??????",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=8CFFD9D7-1C22-44FA-9FEA-90DC99BAA17F"
        },
        "ingested_at": "2026-02-11T14:17:13.146738+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261645-PL75--5669738",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.321279",
        "source": "LSE_CHAT",
        "data": {
          "author": "PL75",
          "content": "We have committed that we won't start the further development activities in the absence of a partnership. Why isn\u2019t that clear?",
          "sentiment": 0.0,
          "engagement": "11,226",
          "price_at_post": "59.50",
          "thread_title": "RE: Fairy docks ??????",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=8CFFD9D7-1C22-44FA-9FEA-90DC99BAA17F"
        },
        "ingested_at": "2026-02-11T14:17:13.146757+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261623-B2HS2L-79098104",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.321681",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "I'll keep checking my Spam directory for Cohesion's response..",
          "sentiment": 0.0,
          "engagement": "6,052",
          "price_at_post": "60.00",
          "thread_title": "RE: Fairy docks ??????",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=8CFFD9D7-1C22-44FA-9FEA-90DC99BAA17F"
        },
        "ingested_at": "2026-02-11T14:17:13.146775+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261613-pedrolan--9636997",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.322086",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "I was referring to the account that pulled you up and decided it needed a new thread to highlight it, for some reason!",
          "sentiment": 0.5,
          "engagement": "1,990",
          "price_at_post": "60.00",
          "thread_title": "RE: Fairy docks ??????",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=8CFFD9D7-1C22-44FA-9FEA-90DC99BAA17F"
        },
        "ingested_at": "2026-02-11T14:17:13.146799+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261606-B2HS2L--6148808",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.322501",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "I bet tonight's custard skin from your spotted dick that Sleeper account = avacta@cohesionbureau.com  \ud83d\ude09",
          "sentiment": 0.0,
          "engagement": "6,052",
          "price_at_post": "60.00",
          "thread_title": "RE: Fairy docks ??????",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=8CFFD9D7-1C22-44FA-9FEA-90DC99BAA17F"
        },
        "ingested_at": "2026-02-11T14:17:13.146819+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261605-BuenaVis--2210362",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.322907",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Should actually be ferry docks.",
          "sentiment": 0.0,
          "engagement": "5,848",
          "price_at_post": "60.00",
          "thread_title": "RE: Fairy docks ??????",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=8CFFD9D7-1C22-44FA-9FEA-90DC99BAA17F"
        },
        "ingested_at": "2026-02-11T14:17:13.146837+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261601-pedrolan--3623345",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.323320",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Sleeper account enabled",
          "sentiment": 0.5,
          "engagement": "1,990",
          "price_at_post": "59.50",
          "thread_title": "RE: Fairy docks ??????",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=8CFFD9D7-1C22-44FA-9FEA-90DC99BAA17F"
        },
        "ingested_at": "2026-02-11T14:17:13.146855+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261550-B2HS2L-27972970",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.323726",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "Should read 'faridoxorubicin' thanks Replacement email sent.",
          "sentiment": 0.0,
          "engagement": "6,052",
          "price_at_post": "59.50",
          "thread_title": "RE: Fairy docks ??????",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=8CFFD9D7-1C22-44FA-9FEA-90DC99BAA17F"
        },
        "ingested_at": "2026-02-11T14:17:13.146873+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261540-tiger29-41699515",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.324134",
        "source": "LSE_CHAT",
        "data": {
          "author": "tiger29",
          "content": "What are \"the fairy docks ?\"",
          "sentiment": 0.0,
          "engagement": "46",
          "price_at_post": "60.00",
          "thread_title": "Fairy docks ??????",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=8CFFD9D7-1C22-44FA-9FEA-90DC99BAA17F"
        },
        "ingested_at": "2026-02-11T14:17:13.146890+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261531-B2HS2L--1808789",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.324606",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "I've sent this to cohesion this afternoon, to see whether I get no response as per previous agencies. avacta@cohesionbureau.com Hi Cohesion Investor Relations, Many investors are unaware of the cost to Avacta of pursuing the upcoming phase 2/3 trial, for which the company currently seeks a partner. Does the company hope to 1 Have the partner cover 100% of the costs of the phase 2/3 trial. 2 Have the costs divided between Avacta and partner, dependent upon negotiations between parties. At the 30.09.2025 Investormeet presentation, a question was asked and insufficiently answered to get a response amenable to all. The question was: Q2 How much do you expect phase 2 for faridoxorubicin to cost Avacta? How will you fund this if a partnership doesn't materialise? The response from the CEO was: A2 \"So we're very confident in the maturing data in the phase 1B of, fairy docks and, we think that this will support the long-term value of this asset. Salivary gland cancers, you know, high unmet need and, we continue to, collect data, in the various cohorts. We have committed that we won't start the further development activities in the absence of a partnership. However, as I've said, the maturing data set in phase 1B is providing us with, ample confidence that precision is, working exactly as, we designed it to work. The development in the expansion cohorts is, well underway. We believe the preliminary data here will provide that natural inflection point for the program. It's gonna provide also clarity on accelerated approval pathways that we might be able to seek. And also there's, really an opportunity, for the overall market to, digest essentially the commercial potential for the program and the platform. As I mentioned, we'll have that,. Pipeline update, platform update, and so we're really excited about, the fourth quarter, for the company.\" It is assumed that this question was selected by Avacta to be asked in the presentation beforehand. Any information you can provide on this subject would be a great help Kind Regards Avacta shareholders",
          "sentiment": 0.0,
          "engagement": "6,052",
          "price_at_post": "60.00",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0781AA9B-9049-48B9-B94C-F3239EA4AB66"
        },
        "ingested_at": "2026-02-11T14:17:13.146909+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261449-B2HS2L--6020123",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.325021",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "IVM 30.09.25 - select Q/A tab. https://www.investormeetcompany.com/meetings/interim-results-491",
          "sentiment": 0.0,
          "engagement": "6,052",
          "price_at_post": "60.00",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0781AA9B-9049-48B9-B94C-F3239EA4AB66"
        },
        "ingested_at": "2026-02-11T14:17:13.146926+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261437-yeboha--8655065",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.325448",
        "source": "LSE_CHAT",
        "data": {
          "author": "yeboha",
          "content": "What was CC actual full reply to that question ????",
          "sentiment": 0.0,
          "engagement": "969",
          "price_at_post": "60.00",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0781AA9B-9049-48B9-B94C-F3239EA4AB66"
        },
        "ingested_at": "2026-02-11T14:17:13.146944+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261338-Bella653--7284288",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.325853",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "What plon\u00a3er put ghrough two 0 trades???\ud83d\ude02\ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "6,769",
          "price_at_post": "61.00",
          "thread_title": "Trades",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=F9CE2B15-57EB-41C4-816A-05159896BF66"
        },
        "ingested_at": "2026-02-11T14:17:13.146962+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261307-B2HS2L-64907676",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.326290",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "Update possibly end of March to coincide with the 1/4ly business update. (where have they gone BH?) Q2 How much do you expect phase 2 for faridoxorubicin to cost Avacta? How will you fund this if a partnership doesn't materialise? CC doesn't address the question very well, though other info appears. Note 26.06.2025 Trinity Delta: The foundational IP around the sustained release pre|CISION mechanism and the better appreciation of the scope of the pre|CISION platform gleaned from the Tempus collaboration provides multiple new opportunities for Avacta to unlock value through generating and developing a pipeline of highly novel tumour targeting drug conjugates, subject to securing additional funds. One potential funding pathway centres on business development, including securing: \u2022\tProduct-based partnerships: partnering or out-licensing deals with large pharma/biotech companies that have clinical and/or commercial expertise in certain therapeutic areas, or geographies, could help accelerate development of either existing or new product candidates. We note that Avacta is actively seeking a deal for AVA6000, ahead of starting Phase II development in H126",
          "sentiment": 0.0,
          "engagement": "6,052",
          "price_at_post": "61.00",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0781AA9B-9049-48B9-B94C-F3239EA4AB66"
        },
        "ingested_at": "2026-02-11T14:17:13.146981+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261246-opti_mys-75091763",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.326692",
        "source": "LSE_CHAT",
        "data": {
          "author": "opti_mystic",
          "content": "B2, the point of the partner for 6k phase 2 is that they the partner fund the trial, we won't be paying for it that is for sure. So they won't care about our finances. Presumably there will also be some sort of upfront payment too helping our finances. No partner no phase 2.",
          "sentiment": 0.0,
          "engagement": "317",
          "price_at_post": "61.00",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0781AA9B-9049-48B9-B94C-F3239EA4AB66"
        },
        "ingested_at": "2026-02-11T14:17:13.146999+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261238-B2HS2L-44572808",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.327228",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "Opti The company has said it will not take 6000 into phase 2/3 without a partner. 1 Depending on that deal, there may be cash available. 2 The state of AVCT finances might be cautionary for any AVA6000 partner. Would that partner be willing to proceed with Avacta unable to show sufficient longer term funding to proceed with phase 2/3, or unable to state when funding would become available? Sorting funding before finalising a partner would nullify such concerns. \"Avacta has strongly signalled a deal for that to fund 6103\". Avacta selling 6000 to fund 6103? IVM presentation 30.09.2025 Q2 How much do you expect phase 2 for faridoxorubicin to cost Avacta? How will you fund this if a partnership doesn't materialise? CC: \"So, we're very confident in the maturing data and the phase 1B of Faridoxorubicin and we think that this will support the long-term value of this asset. Salivary gland cancers, you know, high unmet need - and we continue to collect data in the various cohorts. We have committed that we won't start the further development activities in the absence of a partnership. However, as I've said, the maturing data set in phase 1B is providing us with ample confidence that precision is working exactly as we designed it to work. The development in the expansion cohorts is well underway. We believe the preliminary data here will provide that natural inflection point for the program. It's also going to provide clarity on accelerated approval pathways that we might be able to seek\"... ....Which will be of great interest to prospective partners. RNS'd FDA agreement that the dox lifetime limit to be removed on 03.02.2026. \"Agreed updates to the trial protocol include the removal of the maximum dosing limit and to allow flexibility in dosing levels. These two developments underscore the growing confidence from investigators and regulators in the tolerability profile of faridoxorubicin, and should support a smooth transition to future efficacy studies.\" \"The final cohorts of patients with the selected indications in Phase 1b will be enrolled, enabling two dose levels to be compared in order to determine the optimal biologic dose in future trials.\" +++ We await further details as to how the company enacts the FDA agreement, affecting past patients who have stopped faridox doses when they reached the lifetime limit. This is also true  for those patients on present cohorts who are still being dosed, but yet to reach the lifetime limit, as doses administered beyond 550 migs will affect the PFS calcs that are the end point of the trial. These patients now have the right to be treated beyond 550 migs... ...Again of interest to prospective partners. 6K Phase 1a data cutoff in 17 Dec 25 presentation was 15.09.2025 ie 4 months ago 6K Phase 1b data cutoff in 17 Dec 25 presentation was  15.10.2026 ie 3 months ago Update possibly end of March to coincide with the 1/4ly business update. (where have they g",
          "sentiment": 0.0,
          "engagement": "6,052",
          "price_at_post": "61.00",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0781AA9B-9049-48B9-B94C-F3239EA4AB66"
        },
        "ingested_at": "2026-02-11T14:17:13.147017+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261045-nurseste--7034413",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:41.202403",
        "source": "LSE_CHAT",
        "data": {
          "author": "nursesteve",
          "content": "A lot of people (inc big pharma) sitting on their hands just now. Volume is down but that can very soon change. GLA",
          "sentiment": 0.0,
          "engagement": "1,170",
          "price_at_post": "61.50",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=0781AA9B-9049-48B9-B94C-F3239EA4AB66"
        },
        "ingested_at": "2026-02-11T14:17:13.147035+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261043-Matml74--1527726",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:41.202838",
        "source": "LSE_CHAT",
        "data": {
          "author": "Matml74",
          "content": "They will also have very little cash left at that point (July/August). They won\u2019t run cash down to an only a few months worth so I would expect some form of funding to come forward in the next couple of months.",
          "sentiment": 0.0,
          "engagement": "2,551",
          "price_at_post": "61.50",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=0781AA9B-9049-48B9-B94C-F3239EA4AB66"
        },
        "ingested_at": "2026-02-11T14:17:13.147053+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261012-opti_mys--2136797",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:41.203267",
        "source": "LSE_CHAT",
        "data": {
          "author": "opti_mystic",
          "content": "The problem I see is that before BP spend a ton of cash they will want lots of data. They will have it with 6k by the end of June when TNBC data is released and it seems likely a deal for at least the three indications we know about would be the focus of that deal. Avacta has  strongly signalled a deal for that to fund 6103. However at a similar sort of time July/August they should have a very good idea on 6103 too with early data. Would waiting a little bit longer and buying the whole kit caboodle really make that much difference to BP who we all know have massive patent cliffs? Deal(s) are on the way for sure, the timing and size is the only uncertainty.",
          "sentiment": 0.0,
          "engagement": "317",
          "price_at_post": "61.50",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=0781AA9B-9049-48B9-B94C-F3239EA4AB66"
        },
        "ingested_at": "2026-02-11T14:17:13.147071+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20260946-Bella653-33877915",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:41.203675",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "Oops..funding not gunding...",
          "sentiment": 0.0,
          "engagement": "6,769",
          "price_at_post": "61.50",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=0781AA9B-9049-48B9-B94C-F3239EA4AB66"
        },
        "ingested_at": "2026-02-11T14:17:13.147089+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20260945-Bella653--4362283",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:41.204090",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "Morning LDA...yes it will...not worried just interesting how it's bumped 63 several time...bit of a glass ceiling right now... If a deal is to be struck before we need finance it's being worked on right now.  The new sppointment is very interesting and I think they will bring in the partnership with an upfront wad...and I wouldn't be surprised HR then come in with Royalty backed gunding.",
          "sentiment": 0.0,
          "engagement": "6,769",
          "price_at_post": "61.50",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=0781AA9B-9049-48B9-B94C-F3239EA4AB66"
        },
        "ingested_at": "2026-02-11T14:17:13.147124+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20260833-Livedata-36209005",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:41.204512",
        "source": "LSE_CHAT",
        "data": {
          "author": "Livedataaccount",
          "content": "Hey bella good morning it will come soon",
          "sentiment": 0.0,
          "engagement": "2,975",
          "price_at_post": "61.50",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=0781AA9B-9049-48B9-B94C-F3239EA4AB66"
        },
        "ingested_at": "2026-02-11T14:17:13.147143+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20260830-Bella653--5700786",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:41.204922",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "Wmsjames..'But signing a material deal purely off very early Phase 1 signals, before dose optimisation and without durability data, is still the exception rather than the rule.' They could sign an MOU type deal now with full deal based on certain outcomes/milestones.",
          "sentiment": 0.0,
          "engagement": "6,769",
          "price_at_post": "61.50",
          "thread_title": "RE: Initial data seen under NDA 1st",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=DC4BE032-D599-4CC6-BFFD-F74DE0A45A33"
        },
        "ingested_at": "2026-02-11T14:17:13.147161+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20260826-Bella653--2802410",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:41.205339",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "Need to break 63",
          "sentiment": 0.0,
          "engagement": "6,769",
          "price_at_post": "61.50",
          "thread_title": "SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=0781AA9B-9049-48B9-B94C-F3239EA4AB66"
        },
        "ingested_at": "2026-02-11T14:17:13.147179+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20260810-Bella653--1497169",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:41.205745",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "What about a Partnership for 6000 with Option to Licence one or more pipeline products...",
          "sentiment": 0.0,
          "engagement": "6,769",
          "price_at_post": "61.50",
          "thread_title": "RE: Initial data seen under NDA 1st",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=DC4BE032-D599-4CC6-BFFD-F74DE0A45A33"
        },
        "ingested_at": "2026-02-11T14:17:13.147198+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20260756-B2HS2L-33048597",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:41.206160",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "'6103 is actually validating 6000 which itself is derisking 6103.' I'll go for 6000 phase 1a results are being validated by 6000 phase 1b results in SGC so far. (Two other indications results not known yet).",
          "sentiment": 0.0,
          "engagement": "6,052",
          "price_at_post": "61.50",
          "thread_title": "RE: Initial data seen under NDA 1st",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=DC4BE032-D599-4CC6-BFFD-F74DE0A45A33"
        },
        "ingested_at": "2026-02-11T14:17:13.147216+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20260750-yeboha-17071332",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:41.206562",
        "source": "LSE_CHAT",
        "data": {
          "author": "yeboha",
          "content": "Remember, just ignore the same old FUD BRIGADE and they\u2019ll end up talking only among themselves! Yesterday\u2019s appointment was a great move by Avacta,  they are getting everything in order. Onwards and upwards!",
          "sentiment": 0.0,
          "engagement": "969",
          "price_at_post": "61.50",
          "thread_title": "Ignore the FUD BRIGADE",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B82AA1FD-8062-42D5-928C-4DE5C508547A"
        },
        "ingested_at": "2026-02-11T14:17:13.147233+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20260744-JamYeste-63728409",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:41.206972",
        "source": "LSE_CHAT",
        "data": {
          "author": "JamYesterday",
          "content": "100x more potent than Dox? Scary. So much depends on the next few months.",
          "sentiment": 0.0,
          "engagement": "560",
          "price_at_post": "61.50",
          "thread_title": "RE: Initial data seen under NDA 1st",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=DC4BE032-D599-4CC6-BFFD-F74DE0A45A33"
        },
        "ingested_at": "2026-02-11T14:17:13.147252+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20260734-Benharpe--2679647",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:41.207385",
        "source": "LSE_CHAT",
        "data": {
          "author": "Benharper",
          "content": "Every other poster isn\u2019t the same person Touk. In this post Alberbaran is being admittedly a bit optimistic regarding timelines. Wmsjames is being more circumspect. I personally think Wms is on the right track. Perhaps wait until last nights session has cleared your system before posting.",
          "sentiment": 0.0,
          "engagement": "746",
          "price_at_post": "61.50",
          "thread_title": "RE: Initial data seen under NDA 1st",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=DC4BE032-D599-4CC6-BFFD-F74DE0A45A33"
        },
        "ingested_at": "2026-02-11T14:17:13.147270+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20260659-Aldebara-19700415",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:41.207795",
        "source": "LSE_CHAT",
        "data": {
          "author": "Aldebaran",
          "content": "Im saying same thing that deal will be on faridoxorubicin based off the 4 years of dada we have for sts sgc and also breast cancer plus the work done on 3996 amd 6207 in pre clinical setting. Throw into the mix some initial data from 6103 and it becomes a self validating loop. 6103 is actually validating 6000 which itself is derisking 6103. Its highly unique. I am expecting 6103 data ans breast cancer data to lead to a deal or as some have said maybe even a direct take out approach. Could be well before market sets eyes on 6103 data... not giving the market and FUDsters chance to react and buy in \"cheap\". Before the deals land. Be a massive shame that but id get over it",
          "sentiment": 0.0,
          "engagement": "3,941",
          "price_at_post": "61.50",
          "thread_title": "RE: Initial data seen under NDA 1st",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=DC4BE032-D599-4CC6-BFFD-F74DE0A45A33"
        },
        "ingested_at": "2026-02-11T14:17:13.147289+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20260616-Wmsjames--4829322",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:41.208261",
        "source": "LSE_CHAT",
        "data": {
          "author": "Wmsjames",
          "content": "I\u2019m a bit more cautious on the timing. Yes, initial safety and tolerability signals are often seen early in Phase 1, sometimes within weeks of first dosing. But that doesn\u2019t automatically translate into actionable data for partners. Early signals are noisy, patient numbers are tiny, and dose escalation means you are often below biologically meaningful exposure in the first cohorts. On efficacy, even if there are early radiological hints, sponsors and pharma partners usually want: \u2022\tMultiple patients at or near the target dose \u2022\tConsistency across scans, not a single responder \u2022\tConfidence the signal isn\u2019t dose or patient specific That usually takes several months, not weeks. As for deals, could confidential discussions happen in parallel? Absolutely. Pharma will already understand the mechanism and will be tracking progress closely. But signing a material deal purely off very early Phase 1 signals, before dose optimisation and without durability data, is still the exception rather than the rule. So my view is: \u2022\tEarly internal confidence may build well before June \u2022\tMarket visible data likely takes longer \u2022\tAny deal would more likely be driven by confidence in the platform + AVA6000 validation, rather than a handful of first AVA6103 scans",
          "sentiment": 0.0,
          "engagement": "718",
          "price_at_post": "61.50",
          "thread_title": "RE: Initial data seen under NDA 1st",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=DC4BE032-D599-4CC6-BFFD-F74DE0A45A33"
        },
        "ingested_at": "2026-02-11T14:17:13.147307+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20260608-Aldebara--5656765",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:41.208683",
        "source": "LSE_CHAT",
        "data": {
          "author": "Aldebaran",
          "content": "Us plebs may have to wait until June earliest but how long before those under NDA such as presumably Novartis et al get to see it ? What do you think touk? 2nd question, how long before initial scans and tolerability is known after dosing. Initial i am saying. Given exetecan is what 20x more potent than irinotecan and 100x more potent than doxorubicin and more permeable than deruxtecan etc... ?? Personally I think within 1 months off dosing then the initial safety will be known and their could easily he signs of efficacy. This will be WAY before June and the point the market gets said data. Could a deal be signed off the back of this and the faridoxorubicin data to date before the market catches on, i think its possible. Highly possible actually. You and others? Thinking what?",
          "sentiment": 0.0,
          "engagement": "3,941",
          "price_at_post": "61.50",
          "thread_title": "Initial data seen under NDA 1st",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=DC4BE032-D599-4CC6-BFFD-F74DE0A45A33"
        },
        "ingested_at": "2026-02-11T14:17:13.147325+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20262317-pedrolan--8129109",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.585477",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Folks, Touk is clearly Thorn. Look how he writes. Ignore him.",
          "sentiment": 0.0,
          "engagement": "1,988",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-11T14:17:13.147344+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20262306-Icecool--5435193",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.586081",
        "source": "LSE_CHAT",
        "data": {
          "author": "Icecool",
          "content": "You do talk a load of nonsense\u2026. \ud83e\udd26\u200d\u2642\ufe0f",
          "sentiment": 0.0,
          "engagement": "8,857",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-11T14:17:13.147362+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20262305-Toukanka-75642087",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.586694",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "At the end of the day, initial efficacy results will not be published before June IMO. And CC has said as much. She has also said that any acceptable deal is unlikely before those results are published. And there will be no takeover even if CJ62 forms a consortium of shareholders and tries to push it through at say \u00a31",
          "sentiment": 0.0,
          "engagement": "4,486",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-11T14:17:13.147381+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20262301-Toukanka--5335433",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.587310",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "Thompi FPI is not the same as FPD. But no point arguing. You all know better than CC.",
          "sentiment": 0.0,
          "engagement": "4,486",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-11T14:17:13.147399+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20262150-Thompi--7874928",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.587906",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thompi",
          "content": "Touk, for the record, this is what Chris said in the Base to Base interview released 23rd January, but probably recorded late last year: \u201cWe\u2019re really looking forward to getting the first sustained release [AVA6103] into the clinic. That one will start in March of next year. We\u2019re aiming for the first quarter for the first patient with that one.\u201d",
          "sentiment": 0.0,
          "engagement": "1,364",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-11T14:17:13.147417+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20262123-BuenaVis-56985310",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.588579",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "In clinical trials, FPI (First Patient In) marks the critical milestone when the very first participant is screened, enrolled, and officially enters the study, signifying the transition from planning to active execution. It validates site readiness, kicks off data collection, and is a major KPI for project timelines and investor confidence. Here are the key details regarding FPI: Key Aspects of FPI \u2022 Definition: It is the date the first human subject is qualified, accepted, and often dosed in a clinical trial. \u2022 Significance: It proves all regulatory approvals, document reviews, contracting, and site setups are complete. \u2022 Business Impact: FPI is a high-pressure corporate goal that affects company reputation, stock prices, and investor confidence. \u2022 Trial Flow: It moves the study from \"study start-up\" to \"execution/recruitment\" phase. Why FPI Matters \u2022 Timeline Driver: It sets the pace for the rest of the recruitment and trial timeline. \u2022 Success Indicator: Meeting the FPI goal on time usually means the study is on sound footing. \u2022 Risk: Rushing to hit FPI dates can sometimes lead to neglected study designs or premature starts. Sometimes, this milestone is also referred to as FPFV (First Patient First Visit), focusing on when data collection begins for that first subject.",
          "sentiment": 0.0,
          "engagement": "5,847",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-11T14:17:13.147435+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20262039-B2HS2L--8814810",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.589188",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "A couple of non-Avacta trials that mention FPI, state that FPI = first patient enrolment. Neither discuss enrolment details though.   \ud83e\udd23\ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "6,042",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-11T14:17:13.147453+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20262005-Gingethe-19319219",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.589761",
        "source": "LSE_CHAT",
        "data": {
          "author": "GingetheWinge",
          "content": "Every piece of Avacta communication. Q1 2026. That is fact. Your opinions are plucked out of your a r s e.",
          "sentiment": 0.5,
          "engagement": "705",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-11T14:17:13.147471+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261922-avctIPma--4497170",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.590377",
        "source": "LSE_CHAT",
        "data": {
          "author": "avctIPmatters",
          "content": "\"FPI stands for \"First Patient In\", which is a critical milestone in clinical trials. It marks the moment when the first participant is screened and enrolled into the trial, signaling the beginning of real-world data collection.\" Ref :   Slide 29 https://avacta.com/wp-content/uploads/2025/07/Avacta_Corp_23July2025.pdf \" Q1 2026   Phase 1 first patient in (FPI)\" Gmcc",
          "sentiment": 0.0,
          "engagement": "742",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-11T14:17:13.147489+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261913-BuenaVis--3848363",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.590980",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "The FDA has 30 calendar days to review an IND application after receiving it. https://drugdevelopment.web.unc.edu/u-s-investigational-new-drug-application-%e2%86%92-ind-application-process/ IND submitted mid/late December (as per the project plan in Spotlight 13) and approved by 20 January. The FDA will have been working closely with Avacta given the experience with faridox so that was a fast turnaround given the US government shutdown gping on at the time. - - - - - And ToucanOfDoom, stop purporting to know better than CC what the likely timescales are.",
          "sentiment": 0.0,
          "engagement": "5,847",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-11T14:17:13.147507+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261911-Toukanka-61032905",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.591588",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "CJ62 No, while posters on here continue to misconstrue communications from Avacta and purport to know better than CC what the likely timescales are, then I will continue to correct them. You and others stop posting baseless wishful thinking ramps on here and I will stop exposing them for what they are. Deal?",
          "sentiment": 0.0,
          "engagement": "4,486",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-11T14:17:13.147525+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261902-cj62-22094478",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.592186",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "Touk can you do a thorn and dissolve into the ether?",
          "sentiment": 0.0,
          "engagement": "4,304",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-11T14:17:13.147542+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261900-BuenaVis--4478560",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.592752",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Https://avacta.com/research-development-spotlight-series-episode-13/ @26:15 FPI late Q1/26",
          "sentiment": 0.0,
          "engagement": "5,847",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-11T14:17:13.147560+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261852-Vertizea-89371878",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.593353",
        "source": "LSE_CHAT",
        "data": {
          "author": "VertizeaSun",
          "content": "Thanks jmfw.....and I'll add the reminder that CC visited the AVA6103 manufacturing site (Glasgow) in early December. a necessary requirement if one knows that patient dosing is likely to begin sooner rather than later.",
          "sentiment": 0.0,
          "engagement": "446",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-11T14:17:13.147578+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261851-Toukanka-49722668",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.593952",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "No no no That is my point. Trial start does not mean first patient dosed. CC has outlined in a previous communication the lengthy steps between IND approval and first in patient dosed. My prediction is still for initial clinical results around June. No deals until at least tolerance shown to some degree and even then maybe not until initial signs of efficacy. And yes I do know that P1 is not designed to show efficacy.",
          "sentiment": 0.0,
          "engagement": "4,486",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-11T14:17:13.147596+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261837-jmfw--1844588",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.594558",
        "source": "LSE_CHAT",
        "data": {
          "author": "jmfw",
          "content": "Https://www.lse.co.uk/rns/AVCT/year-end-trading-update-63xrambu5i622u5.html Under heading:  Outlook for 2026",
          "sentiment": 0.0,
          "engagement": "418",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-11T14:17:13.147613+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261830-Toukanka--5651602",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.595177",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "Ginge That would be great. Can you provide a link to where that is stated please. I\u2019m not challenging you. Because that would be good if they start in March. Thanks",
          "sentiment": 0.0,
          "engagement": "4,486",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-11T14:17:13.147631+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261819-Bella653--2825803",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.595769",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "Scroll to end... https://www.forxtherapeutics.com/2025/12/forx-therapeutics-announces-usd-50m-series-a-financing-enabling-clinical-data-readout-for-potential-best-in-class-parg-inhibitor As I said, is this appointment about media or funding/partnering?",
          "sentiment": 0.0,
          "engagement": "6,761",
          "price_at_post": "60.50",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-11T14:17:13.147649+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261621-BuenaVis-49711111",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.596417",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Here are some links re Richard Jarvis at Novartis: Richard Jarvis history: https://rocketreach.co/richard-jarvis-email_238424640 Richard Jarvis at Jarvis Advisors: https://www.moneyhouse.ch/en/company/jarvis-advisors-gmbh-5842690731 (Binningen is on the edge of Basel, home of Novartis HQ) Richard Jarvis consultant: https://www.linkedin.com/posts/the-difference-collective_say-hello-to-collective-consultant-richard-activity-7389560479272259584-EiwK (with photo) Richard Jarvis at Cohesion Bureau: https://cohesionbureau.com/bureau/richard-jarvis (with photo) - - - - - And here is the Cohesion Bureau team at their various locations in Europe and the US: https://cohesionbureau.com/bureau",
          "sentiment": 0.0,
          "engagement": "5,847",
          "price_at_post": "60.50",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-11T14:17:13.147666+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261542-Gingethe--4848059",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.596992",
        "source": "LSE_CHAT",
        "data": {
          "author": "GingetheWinge",
          "content": "First patients are expected to receive AVA6103 before the end of March.",
          "sentiment": 0.5,
          "engagement": "705",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-11T14:17:13.147684+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261521-B2HS2L--7665298",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.597714",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "FWIW Chris Maggos Strategic Consulting and IR, PR & BD Services for Biotech / Medtech Experience Managing Director Cohesion Bureau \u00b7 Full-time Dec 2022 - Present \u00b7 3 yrs 3 mos Geneva, Switzerland \u00b7 Hybrid Our experienced multi-disciplinary U.S. and Pan-European team offers insightful strategic consulting and services to expedite your corporate growth. In addition to strategic consulting, we offer execution services for partnering, fundraising, investor and (social) media relations. We have a dedicated editorial unit producing corporate content, including, writing, graphic design, video and photography. We want to be your partner for growth. Our experienced multi-disciplinary U.S. and Pan-European team offers insightful strategic consulting and services to expedite your corporate growth. In addition to strategic consulting, we offer execution services for partnering, fundraising, investor and (social) media relations. We have a dedicated editorial unit producing corporate content, including, writing, graphic design, video and photography. We want to be your partner for growth. Managing Director BioConfidant S\u00e0rl Sep 2014 - Present \u00b7 11 yrs 6 mos Geneva, Switzerland BioConfidant offers strategic consulting on three closely related types of corporate activities: investor relations, public relations and business development (i.e. licensing and M&A). With our partners around Europe and in the U.S. we started Cohesion Bureau in 2022 to level the playing field for European startups and small-cap companies. We established and managed the European investor relations business of LifeSci Advisors from 2015-2021. We are passionate about developing relationships and collaborating with clients to earn the visibility and impact they need to succeed.",
          "sentiment": 0.0,
          "engagement": "6,042",
          "price_at_post": "60.50",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-11T14:17:13.147702+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261513-Livedata-65986037",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.598309",
        "source": "LSE_CHAT",
        "data": {
          "author": "Livedataaccount",
          "content": "With the location being switzerland one does imagine the cohesion team are in bed with some big players at roche and novartis",
          "sentiment": 0.0,
          "engagement": "2,974",
          "price_at_post": "61.50",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-11T14:17:13.147720+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261503-Timster-30392407",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.598888",
        "source": "LSE_CHAT",
        "data": {
          "author": "Timster",
          "content": "That's a serious accusation watching you WILL be hearing from my legal team, not as hidden as you think.......",
          "sentiment": 0.0,
          "engagement": "20,640",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-11T14:17:13.147738+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261503-avctIPma-53063489",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.599564",
        "source": "LSE_CHAT",
        "data": {
          "author": "avctIPmatters",
          "content": "\" Cohesion Bureau (Communications)  Richard Jarvis / Chris Maggos \" Interesting  connection  Richard Jarvis  has with  Novartis .   Avacta  has had lots of changes  recently  - Michelle Morrow  did  not last long  - guess  one less salary to pay & also streamlining communication costs. ------- \"Richard Jarvis Trustee Director Trustee Director Novartis UK Pension Trustee CompanyNovartis UK Pension Trustee Company 2014 - Present \u00b7 12 yrs 2 mos2014 to Present \u00b7 12 yrs 2 mos Grew funding position from <90% of liabilities to ~110% (buy-out basis) for ~7 000 members.Grew funding position from <90% of liabilities to ~110% (buy-out basis) for ~7 000 members. Novartis logo Head of Strategy & Financial Communications Head of Strategy & Financial Communications NovartisNovartis 2021 - 2025 \u00b7 4 yrs2021 to 2025 \u00b7 4 yrs Basel, SwitzerlandBasel, Switzerland Led global team of communications and media relations professionals, responsible for financial communications and global top tier media engagement.Led global team of communications and media relations professionals, responsible for financial communications and global top tier media engagement. Communications Strategy, Team Management and +6 skills\" Gmcc",
          "sentiment": 0.0,
          "engagement": "742",
          "price_at_post": "60.50",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-11T14:17:13.147756+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261502-Livedata--1300153",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.600169",
        "source": "LSE_CHAT",
        "data": {
          "author": "Livedataaccount",
          "content": "I always imagined timster was a belly dancer",
          "sentiment": 0.0,
          "engagement": "2,974",
          "price_at_post": "61.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-11T14:17:13.147773+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261458-Watching--3579032",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.363454",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "Timster are you still a children\u2019s entertainer ?",
          "sentiment": 0.0,
          "engagement": "9,229",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-11T14:17:13.147792+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261453-Timster-15514980",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.363899",
        "source": "LSE_CHAT",
        "data": {
          "author": "Timster",
          "content": "One of Francis's KPA's is to ensure LDA's requests for updates via the lse website are promptly answered. Id expect an update within 48hrs LDA",
          "sentiment": 0.0,
          "engagement": "20,640",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-11T14:17:13.147809+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261453-Toukanka--3872432",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.364338",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "Clear from what CC said in today\u2019s RNS that no one has been dosed with 6103 yet. Given the preparation work that needs to be carried out including pre screening, I previously predicted April earliest for dosing to start. (Based on 6100 timescales)",
          "sentiment": 0.0,
          "engagement": "4,486",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-11T14:17:13.147827+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261426-Livedata--8469696",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.364756",
        "source": "LSE_CHAT",
        "data": {
          "author": "Livedataaccount",
          "content": "Be good to get an update please on TNBC progress and 6103 dosing thank you in advance",
          "sentiment": 0.0,
          "engagement": "2,974",
          "price_at_post": "60.50",
          "thread_title": "Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-11T14:17:13.147845+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261324-B2HS2L-86877788",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.365200",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "If this was true in Nov 2024 (so for AVA6000), I would assume the situation is a little more rosy now. Possibly some starters for 10 here. https://www.trinitydelta.org/research-notes/targeting-the-tumour-microenvironment-with-precision/ A reminder from Trinity Delta \u2013 Targeting the tumour microenvironment with pre|CISION - 18.11.2024 \"Avacta has so far FAP-enabled ten different warheads building up a database of multiple pre|CISION compounds that include c 40 capping groups (which alter the PK of the conjugate) and c 20 linkers (required for FAP cleavage with certain warheads and can be used to modify FAP affinity and activity). These have all been characterised through computational simulations to evaluate molecular binding and how they dock into the FAP structure. A key consideration is how close the warhead can get to the FAP cleavage sequence; this typically depends on the size of the molecule, and often defines whether a spacer group is required. Consideration is also given to how long the conjugate and the active warhead are likely to remain in the TME, and this informs whether PK alterations, achieved through an alternative capping group, are needed to either allow the sustained release of the warhead or to slow plasma clearance.",
          "sentiment": 0.0,
          "engagement": "6,042",
          "price_at_post": "60.50",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=060607B8-56D7-4812-99EC-1BE5765F573F"
        },
        "ingested_at": "2026-02-11T14:17:13.147862+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261308-pedrolan-64493982",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.365614",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Yes and what a truly remarkable career he could have.",
          "sentiment": 0.5,
          "engagement": "1,988",
          "price_at_post": "60.50",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=060607B8-56D7-4812-99EC-1BE5765F573F"
        },
        "ingested_at": "2026-02-11T14:17:13.147880+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261300-BuenaVis-53503416",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.366018",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "As the mechanism of action\u2014the dipeptide and the cleavage\u2014is proven, it now comes down to designing each molecule's pharmacokinetics to fit the needs for the warhead.  And who better to lead that than a highy competent chemist at the top of his game?",
          "sentiment": 0.0,
          "engagement": "5,847",
          "price_at_post": "60.50",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=060607B8-56D7-4812-99EC-1BE5765F573F"
        },
        "ingested_at": "2026-02-11T14:17:13.147898+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261159-B2HS2L-85622687",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.366489",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "\"Francis - We will learn more about this program in the clinic and apply that as we continue to develop NOVEL INTELLECTUAL PROPERTY around our highly successful pre|CISION\u00ae platform.\" -  We look forward to plenty of new IP to come. 29.10.2025 CC: \"Much of the success and how we are going to be able to move the dual payload through is going to depend on our initial observations in the clinic with the exatacan molecule. Francis and Tom mentioned that a lot of what we are doing with the dual payload is based on the learnings in the lab with the exatecan molecule. We expect to learn a lot about the exatecan molecule as we move it into the clinic and that's going to inform a lot about the dual payload molecules. Clinic learnings in the first half of 2026, will inform how quickly we're going to move the dual payload through.\" Also \"if we do right and we do great things for patients, we will be doing great things for our shareholders.\" I hope they stack the new IP high. It will increase the bargaining value of the company. It doesn't sound like Francis is going to be straying far from the lab, unless other chemists are inbound, and Francis is the mentor.  \ud83d\udcab",
          "sentiment": 0.0,
          "engagement": "6,042",
          "price_at_post": "60.50",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=060607B8-56D7-4812-99EC-1BE5765F573F"
        },
        "ingested_at": "2026-02-11T14:17:13.147916+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261120-Timster-59051880",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.366896",
        "source": "LSE_CHAT",
        "data": {
          "author": "Timster",
          "content": "Biggest buy signal in recent days is when eggy threw in the towel and removed his account.",
          "sentiment": 0.0,
          "engagement": "20,640",
          "price_at_post": "61.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-11T14:17:13.147933+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261105-yeboha-45269883",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.367315",
        "source": "LSE_CHAT",
        "data": {
          "author": "yeboha",
          "content": "Great RNS yet again today ! All moving in the right direction !",
          "sentiment": 0.0,
          "engagement": "967",
          "price_at_post": "61.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-11T14:17:13.147951+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261054-D-Geeman-78006360",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.367735",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "Certainly Watching 2 raises the tone but is that why people read bulletin boards Ginge? Would you rather read a poster's record have have them be proved right again and again? Or, like W2's record.. Shall I raise the tone? \"\u00a3200 ex-chinah, nailed on!\" \"Later today! \" (Note to self; see, it's not difficult.)",
          "sentiment": 0.0,
          "engagement": "5,877",
          "price_at_post": "61.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-11T14:17:13.147969+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261048-Gingethe-34766127",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.368149",
        "source": "LSE_CHAT",
        "data": {
          "author": "GingetheWinge",
          "content": "Agreed. Always the usual suspects that lower the tone.",
          "sentiment": 0.5,
          "engagement": "705",
          "price_at_post": "61.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-11T14:17:13.147986+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261032-Watching-14551740",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.368583",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "Tidy the BB Ignore the muppets We now know ignore and they argue with themselves And eventually dry up ! Great appointment well done team  avacta !. Jane",
          "sentiment": 0.0,
          "engagement": "9,229",
          "price_at_post": "61.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-11T14:17:13.148004+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261017-D-Geeman-85091182",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.369068",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "Touk, Watching does their best... And not just on AVCT. 'Watching2 'Posted in: ENET Posts: 9,227 RE: Sidelines22 Nov 2023 09:59 Actually 1p is very unlikely Bottom has now been hit imo. Good averaging opportunity! Next rns will lift us' And in case you were wondering how this 'prediction'went, today's SP: Share Price Information for Ethernity Net (ENET) Share Price is delayed by 15 minutes Get Live Data 0.0048    0.0001 (2.13%) Bid: 0.0046 Ask: 0.005 Spread: 0.0004 (8.696%) Market Cap: \u00a348.00k Still, plenty of folk 'Rec'watching's posts so hats-off to Jane (unless you're still holding on to it Jane?) .",
          "sentiment": 0.0,
          "engagement": "5,877",
          "price_at_post": "61.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-11T14:17:13.148022+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261003-Livedata--8080594",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.369492",
        "source": "LSE_CHAT",
        "data": {
          "author": "Livedataaccount",
          "content": "Francis has been instrumental in ava6103 and ava6207 running a successful business is about retaining top talent and i have no doubt his IP is massive at Avacta it is a great appointment",
          "sentiment": 0.0,
          "engagement": "2,974",
          "price_at_post": "61.00",
          "thread_title": "New CSO",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=2EBFCF4C-4A4D-475C-BBFD-DB095DA011B8"
        },
        "ingested_at": "2026-02-11T14:17:13.148040+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260926-Harrogat-39249637",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.369903",
        "source": "LSE_CHAT",
        "data": {
          "author": "Harrogate4",
          "content": "Agreed -----did they ever do anything ---apart from taking their salaries of course?",
          "sentiment": 0.0,
          "engagement": "805",
          "price_at_post": "61.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-11T14:17:13.148066+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260923-Bella653--7927494",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.370320",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "So can we assume THRUST and ICR have been ditched now...if so good ridens...",
          "sentiment": 0.0,
          "engagement": "6,761",
          "price_at_post": "61.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-11T14:17:13.148084+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260921-Bella653-23010380",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.370735",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "Or.. 1.  Is Cohesion Bureau about attracting Pharma funding? Their website is terrible...Nothing comes up in the NEWS section!!!!! 2.  We are not in the Immunotherapy space we now need good Chemists.   I think CC mentioned this in one of her videos when she talked about the 'Chemistry' involved in developing new pipelines.",
          "sentiment": 0.0,
          "engagement": "6,761",
          "price_at_post": "61.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-11T14:17:13.148122+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260919-yeboha--1964874",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.371148",
        "source": "LSE_CHAT",
        "data": {
          "author": "yeboha",
          "content": "But then again i dont no if avacta want the take over, they certainly wont push for it !",
          "sentiment": 0.0,
          "engagement": "967",
          "price_at_post": "61.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-11T14:17:13.148144+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260918-yeboha--6504095",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.371554",
        "source": "LSE_CHAT",
        "data": {
          "author": "yeboha",
          "content": "Watching , i agree with you, everything seems to be lining up beautifully for the take over this year !",
          "sentiment": 0.5,
          "engagement": "967",
          "price_at_post": "61.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-11T14:17:13.148162+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260915-Toukanka--5805531",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.371960",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "Watching In your view each year for the past three years was the year we would be taken over\ud83e\udd21",
          "sentiment": 0.0,
          "engagement": "4,486",
          "price_at_post": "61.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-11T14:17:13.148180+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260908-Vertizea-89183206",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.372377",
        "source": "LSE_CHAT",
        "data": {
          "author": "VertizeaSun",
          "content": "T/O? I quite agree. Avacta's got the air of a company tidying up loose ends.",
          "sentiment": 0.0,
          "engagement": "446",
          "price_at_post": "61.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-11T14:17:13.148198+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260907-yeboha-43469812",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.372784",
        "source": "LSE_CHAT",
        "data": {
          "author": "yeboha",
          "content": "Great news! Francis has been appointed as the new chief scientific officer. Retaining him will be a massive advantage moving forward!",
          "sentiment": 0.5,
          "engagement": "967",
          "price_at_post": "61.00",
          "thread_title": "Important Appointment",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=8E658AE1-929D-4CD1-910B-CBDF7FD77692"
        },
        "ingested_at": "2026-02-11T14:17:13.148216+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260903-Watching-50926203",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.373199",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "Imo This year we will  will be taken over The glowing data  must be worth the risk to get in first gla Jane !",
          "sentiment": 0.0,
          "engagement": "9,229",
          "price_at_post": "61.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-11T14:17:13.148234+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260858-nurseste-79047319",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.373605",
        "source": "LSE_CHAT",
        "data": {
          "author": "nursesteve",
          "content": "It seems a bit strange from Simon being touted by Chris as being so busy to quietly being removed ?",
          "sentiment": 0.0,
          "engagement": "1,169",
          "price_at_post": "61.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-11T14:17:13.148258+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260849-BuenaVis-84448301",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.092369",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "We don't know what he was doing not why he's no longer on the team. He was another of Alan's hires that's now gone.",
          "sentiment": 0.0,
          "engagement": "5,847",
          "price_at_post": "62.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-11T14:17:13.148277+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260844-Watching-85213910",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.093088",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "Leaky ship ! Another hole plugged",
          "sentiment": 0.0,
          "engagement": "9,229",
          "price_at_post": "62.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=060607B8-56D7-4812-99EC-1BE5765F573F"
        },
        "ingested_at": "2026-02-11T14:17:13.148296+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260839-BuenaVis-42982987",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.093853",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "We'll know where and when in the fullness of time. https://www.linkedin.com/in/michelle-morrow-127605137",
          "sentiment": 0.0,
          "engagement": "5,847",
          "price_at_post": "62.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=060607B8-56D7-4812-99EC-1BE5765F573F"
        },
        "ingested_at": "2026-02-11T14:17:13.148313+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260837-nurseste-18408798",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.094563",
        "source": "LSE_CHAT",
        "data": {
          "author": "nursesteve",
          "content": "So Simon was busy doing??? \ud83e\udd14",
          "sentiment": 0.0,
          "engagement": "1,169",
          "price_at_post": "62.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-11T14:17:13.148331+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260837-cj62--6122918",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.095298",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "Probably caught with her hand in the cookie jar !!",
          "sentiment": 0.0,
          "engagement": "4,304",
          "price_at_post": "62.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=060607B8-56D7-4812-99EC-1BE5765F573F"
        },
        "ingested_at": "2026-02-11T14:17:13.148349+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260832-Harrogat-89984726",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.095975",
        "source": "LSE_CHAT",
        "data": {
          "author": "Harrogate4",
          "content": "Congratulations to Dr Francis Wilson, very well deserved in my view and a great choice by CC.",
          "sentiment": 0.0,
          "engagement": "805",
          "price_at_post": "62.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=060607B8-56D7-4812-99EC-1BE5765F573F"
        },
        "ingested_at": "2026-02-11T14:17:13.148366+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260818-Watching--1207682",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.096697",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "Perhaps it was requested by a big pharma as part of a agreement",
          "sentiment": 0.0,
          "engagement": "9,229",
          "price_at_post": "60.50",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=060607B8-56D7-4812-99EC-1BE5765F573F"
        },
        "ingested_at": "2026-02-11T14:17:13.148384+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260815-Prion25-61087210",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.097532",
        "source": "LSE_CHAT",
        "data": {
          "author": "Prion25",
          "content": "Michelle highly regarded in oncology biotech did a block buster drug with AZ  probably been headhunted by a prospective parter of Avacta or  big pharma competitors We won\u2019t know probably a NDA has been signed",
          "sentiment": 0.0,
          "engagement": "1,555",
          "price_at_post": "60.50",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=060607B8-56D7-4812-99EC-1BE5765F573F"
        },
        "ingested_at": "2026-02-11T14:17:13.148402+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260809-B2HS2L-79817576",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.098278",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "CC :  \"\"In addition to his leadership internally, he has also been a key member of the team positioning our business across the international drug development sector. Francis is a well-known leader in medicinal chemistry externally and we are looking forward to forging the next chapter of pre|CISION\u00ae with his scientific leadership and expertise. \" I think she wants him to become more of a Key Opinion Leader, - she uses 'leader' above - in spreading the pre-CISION gospel. To become more influential with respect to FDA / MHRA and the like. Michelle Morrow may have decided the grass was greener. \"former CSO Michelle Morrow will be leaving Avacta to pursue another opportunity\" - singular not plural. She must have done a lot of work to get AVA6103 successfully through the IND Application. (That's true for all staff). She knows what's inside the capping group and the linker group, - those two blue blobs (group A & group B) in blue in certain presentations.",
          "sentiment": 0.0,
          "engagement": "6,042",
          "price_at_post": "60.50",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=060607B8-56D7-4812-99EC-1BE5765F573F"
        },
        "ingested_at": "2026-02-11T14:17:13.148420+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260809-Colesy74--4784104",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.098949",
        "source": "LSE_CHAT",
        "data": {
          "author": "Colesy74",
          "content": "Https://youtu.be/kyQJRyoPzvw",
          "sentiment": 0.0,
          "engagement": "21",
          "price_at_post": "60.50",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-11T14:17:13.148438+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260737-Vertizea-90881566",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.099686",
        "source": "LSE_CHAT",
        "data": {
          "author": "VertizeaSun",
          "content": "Also....Simon Bennett was removed from Leadership page but Yulii Bogatyrenko remains.",
          "sentiment": 0.0,
          "engagement": "446",
          "price_at_post": "60.50",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-11T14:17:13.148456+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260727-dafad-53329373",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.100396",
        "source": "LSE_CHAT",
        "data": {
          "author": "dafad",
          "content": "They may have wanted someone of a higher calibre in the position as they develop the Platform",
          "sentiment": 0.0,
          "engagement": "2,416",
          "price_at_post": "60.50",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=060607B8-56D7-4812-99EC-1BE5765F573F"
        },
        "ingested_at": "2026-02-11T14:17:13.148473+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260723-Livedata-43467016",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.101080",
        "source": "LSE_CHAT",
        "data": {
          "author": "Livedataaccount",
          "content": "Who knows employees have many reasons for leaving job roles",
          "sentiment": 0.0,
          "engagement": "2,974",
          "price_at_post": "60.50",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=060607B8-56D7-4812-99EC-1BE5765F573F"
        },
        "ingested_at": "2026-02-11T14:17:13.148491+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260721-IFA90-27731152",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.101762",
        "source": "LSE_CHAT",
        "data": {
          "author": "IFA90",
          "content": "Why leave before the multi billion TO?",
          "sentiment": 0.0,
          "engagement": "416",
          "price_at_post": "60.50",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=060607B8-56D7-4812-99EC-1BE5765F573F"
        },
        "ingested_at": "2026-02-11T14:17:13.148509+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260721-BuenaVis-88055851",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.102469",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "A good decision. From CC's praise, he's likely been leading the science anyway.",
          "sentiment": 0.0,
          "engagement": "5,847",
          "price_at_post": "60.50",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=060607B8-56D7-4812-99EC-1BE5765F573F"
        },
        "ingested_at": "2026-02-11T14:17:13.148527+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260715-BuenaVis-87537871",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.103183",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Avacta's new comms organisation, based in Geneva: https://cohesionbureau.com/ It's All Change, every month, with Avacta!",
          "sentiment": 0.0,
          "engagement": "5,847",
          "price_at_post": "60.50",
          "thread_title": "Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-11T14:17:13.148544+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260705-JFK8-38443653",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.103866",
        "source": "LSE_CHAT",
        "data": {
          "author": "JFK8",
          "content": "New CSO to replace Michelle Morrow",
          "sentiment": 0.0,
          "engagement": "3,058",
          "price_at_post": "60.50",
          "thread_title": "RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=060607B8-56D7-4812-99EC-1BE5765F573F"
        },
        "ingested_at": "2026-02-11T14:17:13.148562+00:00"
      },
      {
        "event_id": "SOCIAL-8Feb20261320-BuenaVis-15335588",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.104577",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "The link didn't work so I ran that query in Grok.  Yes, the procedure is involved but so is standard doxorubicin I should think - valid prescription, qualified people, the \"Five Rights\", etc. but with the added safety measures need for radioactivity. I should think the patients have to be held in the hospital to be sure that the drug can be administered rather than have them just ambling in for the 3-weekly injection, the reason being timeliness, timeliness, timeliness... to Grok: \"What are the steps to get a radiopharmaceutical from production to patient?\" \"The journey of a radiopharmaceutical from production to patient administration is a highly time-sensitive, regulated supply chain due to the short half-lives of most radionuclides (often hours to days). This limits the window for manufacturing, quality control, transportation, and use. The process varies depending on the radionuclide (e.g., cyclotron-produced like F-18, Ga-68, or reactor-produced like Mo-99/Tc-99m, Lu-177) and whether the product is a ready-to-use diagnostic agent (e.g., FDG), a kit requiring on-site labeling, or a therapeutic agent.\" ...and so it goes on with the 11 stages and summarised under Key Challenges (Time pressure, Radiation safety, Regulatory compliance, Supply chain complexity)",
          "sentiment": 0.0,
          "engagement": "5,847",
          "price_at_post": "60.50",
          "thread_title": "RE: Watch Ely Lilly could make a move",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=4B1C735B-8BE4-4153-95B2-75A61E403C1D"
        },
        "ingested_at": "2026-02-11T14:17:13.148580+00:00"
      },
      {
        "event_id": "SOCIAL-8Feb20261235-B2HS2L-25648567",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.105340",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "Source Grok: \"what is the procedure to administer a dose of a radiopharmaceutical drug?\" https://x.com/i/grok?conversation=2020452204348313802 Intravenous administration of AVA6103 is going to be a doddle compared with radiopharmaceutical administration by a team of several. Time / expense to get radiopharmaceutical to hospital? If the decision to make funds available to dose a patient is made by a health insurance company, I don't think they would consider a radiopharmaceutical for long if a cheaper method of administration is available. PDC ADC - it has targeting issues. radiopharmaceutical - difficult / expensive to administer, too many specialists This is my list of most to least preferrable drug types for experts to consider using. Novartis must be \ud83d\udc40",
          "sentiment": 0.0,
          "engagement": "6,042",
          "price_at_post": "60.50",
          "thread_title": "RE: Watch Ely Lilly could make a move",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=4B1C735B-8BE4-4153-95B2-75A61E403C1D"
        },
        "ingested_at": "2026-02-11T14:17:13.148597+00:00"
      },
      {
        "event_id": "SOCIAL-8Feb20261107-GainsOnl-34793742",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.106009",
        "source": "LSE_CHAT",
        "data": {
          "author": "GainsOnly",
          "content": "This will be over 75p last placing price very soon DYOR",
          "sentiment": 0.0,
          "engagement": "10",
          "price_at_post": "60.50",
          "thread_title": "RE: Watch Ely Lilly could make a move",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=4B1C735B-8BE4-4153-95B2-75A61E403C1D"
        },
        "ingested_at": "2026-02-11T14:17:13.148615+00:00"
      },
      {
        "event_id": "SOCIAL-8Feb20261042-LiveLong--3025827",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.106802",
        "source": "LSE_CHAT",
        "data": {
          "author": "LiveLongnProsper",
          "content": "A few Exatecan products that AVA6103 might be compared against ..? Cybrexa \u2013 privately held, have CBX-12 a PDC, targeting pH (acidity), in phase 2. EMD Serono \u2013 Merck subsidiary, have M7437, ADC based, in phase 1 from Jan 2026. Innovent \u2013 now partnered with Takeda, have IBI343, ADC based, in phase 3 with FDA fast track. AVA6103, indeed the whole pre|CISION\u00ae platform, remains, as yet, \u2018unpartnered\u2019 (OK Lilly/CanSeek) - but not without \u2018friends\u2019 and \u2018admirers\u2019. What about BP then ..? We know that Daiichi Sankyo and AZN are massively committed to Enhertu\u00ae (trastuzumab deruxtecan), HER2 targeted ADC, and we know about \u2018patent cliffs\u2019.  DS / AZN currently pushing through a number of DXd products, perhaps most notably Datroway\u00ae (datopotamab deruxtecan), TROP2 targeted ADC in phase 3.  Daiichi have been working with Exatecan for over 20 years.  These guys need to protect their \u2018space\u2019. Merck (Keytruda) were apparently going to spend up to $32bn for Revolution \u2013 seems to be off now?  Guess they have ready cash then? Novartis have this massive \u2018hole\u2019 in their pipeline, i.e. no ADC\u2019s, but are doing FAP targeting for RLT.  They seem to have plenty of money also. \u2018Triggers\u2019 for Avacta acquisition ..? Positive AVA6000 TNBC readout?  PFS for SGC and AVA6000 becomes \u2018standard of care\u2019?  Early positive response to AVA6103? Or just a  \u2018pre-emptive strike\u2019? GLA",
          "sentiment": 0.0,
          "engagement": "1,836",
          "price_at_post": "60.50",
          "thread_title": "RE: Watch Ely Lilly could make a move",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=4B1C735B-8BE4-4153-95B2-75A61E403C1D"
        },
        "ingested_at": "2026-02-11T14:17:13.148633+00:00"
      },
      {
        "event_id": "SOCIAL-8Feb20260925-opti_mys-44711861",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.107491",
        "source": "LSE_CHAT",
        "data": {
          "author": "opti_mystic",
          "content": "Keytruda is out of Patent in 2028 when the immunology drug becomes an out of patent generic drug. Avacta could use it like we have Dox and Exatecan and we'd have chemo and immunology options.",
          "sentiment": 0.0,
          "engagement": "315",
          "price_at_post": "60.50",
          "thread_title": "RE: Watch Ely Lilly could make a move",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=4B1C735B-8BE4-4153-95B2-75A61E403C1D"
        },
        "ingested_at": "2026-02-11T14:17:13.148651+00:00"
      },
      {
        "event_id": "SOCIAL-8Feb20260859-Aldebara--7989010",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.108206",
        "source": "LSE_CHAT",
        "data": {
          "author": "Aldebaran",
          "content": "So we saying that lily and Novartis have eyes on either directly or indirectly. Would love to throw merck into the mix as well due to keytruda patent expiry. What about daiichi sankyo also. 4 way bidding war would be nice. All 4 could be made a reasonable case to be seriously interested in precision",
          "sentiment": 0.0,
          "engagement": "3,933",
          "price_at_post": "60.50",
          "thread_title": "RE: Watch Ely Lilly could make a move",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=4B1C735B-8BE4-4153-95B2-75A61E403C1D"
        },
        "ingested_at": "2026-02-11T14:17:13.148670+00:00"
      },
      {
        "event_id": "SOCIAL-8Feb20260852-Bella653--6238511",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.108890",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "'POINT Biopharma Inc Avacta has entered into a license agreement with POINT Biopharma Inc., (taken over by Eli Lilly in late 2023) a clinical-stage pharmaceutical company focused on the development and commercialisation of radioligand therapies for the treatment of cancer, to provide access to Avacta\u2019s pre|CISION\u00ae technology for the development of tumor-activated radiopharmaceuticals.' How much access are they now getting to PreCISION???",
          "sentiment": 0.0,
          "engagement": "6,761",
          "price_at_post": "60.50",
          "thread_title": "RE: Watch Ely Lilly could make a move",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=4B1C735B-8BE4-4153-95B2-75A61E403C1D"
        },
        "ingested_at": "2026-02-11T14:17:13.148688+00:00"
      },
      {
        "event_id": "SOCIAL-8Feb20260843-Bella653-74643865",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.109654",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "'Toxicity caused by off-target delivery is a longstanding concern of cancer therapies. Developed by Dr. William Bachovchin of Tufts University, POINT\u2019s CanSEEK\u2122 technology aims to minimize radiopharmaceutical toxicity caused by off-target delivery by only activating a radiopharmaceuticals' targeting moiety, such as its ligand, after it has encountered FAP-\u03b1 in the tumor microenvironment (TME). FAP-\u03b1 is highly expressed on a wide range of solid tumors, but in very low quantities or absent altogether in healthy tissues. The intent of CanSEEK\u2122 is to minimize the toxicity caused by off-target delivery. At first, CanSEEK\u2122 prevents the radiopharmaceutical from bonding to receptors on cells. When the radiopharmaceuticals enter the TME, the radiopharmaceuticals targeting moiety is re-activated, enabling it to once again bond to receptors on cancer cells. CanSEEK\u2122 has the potential to make treatments even more precise, expanding their therapeutic index, and enabling the use of new, more powerful medical isotopes.' \u200d",
          "sentiment": 0.0,
          "engagement": "6,761",
          "price_at_post": "60.50",
          "thread_title": "RE: Watch Ely Lilly could make a move",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=4B1C735B-8BE4-4153-95B2-75A61E403C1D"
        },
        "ingested_at": "2026-02-11T14:17:13.148706+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20262318-Icecool--8374579",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.525582",
        "source": "LSE_CHAT",
        "data": {
          "author": "Icecool",
          "content": "Happy holidays everyone. \ud83d\ude09\ud83e\udd23\ud83d\ude2d",
          "sentiment": 0.0,
          "engagement": "8,855",
          "price_at_post": "60.50",
          "thread_title": "RE: From MM on X - If it offends - Tough",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=D20B314B-66BB-47B0-8ED4-D46B27E22B85"
        },
        "ingested_at": "2026-02-11T14:17:13.148724+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20262125-Livedata--5668192",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.526281",
        "source": "LSE_CHAT",
        "data": {
          "author": "Livedataaccount",
          "content": "who is offended not icecool being ****** again i hope",
          "sentiment": 0.0,
          "engagement": "2,969",
          "price_at_post": "60.50",
          "thread_title": "RE: From MM on X - If it offends - Tough",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=D20B314B-66BB-47B0-8ED4-D46B27E22B85"
        },
        "ingested_at": "2026-02-11T14:17:13.148742+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20262120-IFA90-54897985",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.526944",
        "source": "LSE_CHAT",
        "data": {
          "author": "IFA90",
          "content": "I\u2019m not offended. Xx",
          "sentiment": 0.0,
          "engagement": "415",
          "price_at_post": "60.50",
          "thread_title": "RE: From MM on X - If it offends - Tough",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=D20B314B-66BB-47B0-8ED4-D46B27E22B85"
        },
        "ingested_at": "2026-02-11T14:17:13.148760+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20262049-B2HS2L--7550543",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.527979",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "Https://x.com/BMHLTD/status/1736326494035603668 - Thanks BMH. December 2023 - Set of extracts from a Will Tap presentation. Will Tap discusses STS treatment improvement necessary. Now we have SGC first pass results, - AVA6000 more likely to be able to address items on Will Tap's STS wish list - with resulting FDA satisfaction.",
          "sentiment": 0.0,
          "engagement": "6,031",
          "price_at_post": "60.50",
          "thread_title": "Will Tap STS wish list",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=21C3C888-CE85-4F00-B718-E879BB3F5CC6"
        },
        "ingested_at": "2026-02-11T14:17:13.148778+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20262037-BuenaVis--9756628",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.528670",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Top publication, Scrip, so this is excellent exposure for CC and Avacta in their 'preview' of the year.",
          "sentiment": 0.0,
          "engagement": "5,826",
          "price_at_post": "60.50",
          "thread_title": "RE: Evolving Drug Conjugates",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B37AC3F0-A005-4580-9CCE-040AE6DF8EA7"
        },
        "ingested_at": "2026-02-11T14:17:13.148795+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261929-avctIPma--7407692",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.529343",
        "source": "LSE_CHAT",
        "data": {
          "author": "avctIPmatters",
          "content": "\"drive significant interest and global pharma partnerships.\"  sounds  good ! Gmcc",
          "sentiment": 0.0,
          "engagement": "740",
          "price_at_post": "60.50",
          "thread_title": "RE: Evolving Drug Conjugates",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B37AC3F0-A005-4580-9CCE-040AE6DF8EA7"
        },
        "ingested_at": "2026-02-11T14:17:13.148813+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261924-avctIPma--6847684",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.530056",
        "source": "LSE_CHAT",
        "data": {
          "author": "avctIPmatters",
          "content": "Thanks to Stonks ;   CC featured \"Scrip Asks... What Does 2026 Hold For Biopharma? Part 4: R&D Innovation\" https://insights.citeline.com/scrip/scrip-asks/scrip-asks-what-does-2026-hold-for-biopharma-part-4-rd-innovation-NDREFKFVB5DZPAQLA5CIZHE7OI/#oncology \"Evolving Drug Conjugates Drugs conjugated to antibodies and other carriers continue advancing through next-generation payload and linker innovation. \u201c2026 will be a pivotal year for dual payload drug conjugates, as the first wave of these therapies is expected to yield initial clinical data,\u201d predicted Christina Coughlin, CEO of Avacta Therapeutics. \u201cThe first dual payload peptide-drug conjugate was announced this year, and dozens of major pharma companies are advancing dual-payload programs targeting different resistance mechanisms. We expect the technology\u2019s ability to overcome drug resistance, enhance tumor selectivity and broaden the therapeutic window to drive significant interest and global pharma partnerships. This represents oncology\u2019s evolution from sequential combination dosing to precision dual-delivery, fundamentally reshaping how we approach tumor heterogeneity and resistance.\u201d Gmcc",
          "sentiment": 0.0,
          "engagement": "740",
          "price_at_post": "60.50",
          "thread_title": "Evolving Drug Conjugates",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B37AC3F0-A005-4580-9CCE-040AE6DF8EA7"
        },
        "ingested_at": "2026-02-11T14:17:13.148831+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261910-JES1889-30249318",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.530764",
        "source": "LSE_CHAT",
        "data": {
          "author": "JES1889",
          "content": "I think the other piece to consider here is that Avacta no longer seems to be a leaky ship. I now believe that (if and) when news drops it\u2019ll arrive without forewarning, like the FDA news this week. Whilst I see there being room for the share price to appreciate as this year progresses, on retail demand/expectations. I doubt that even positive data releases on TNBC and 6103 will see this head anywhere near true value. AIM and the UK investment community just find the scale too hard to contemplate. I\u2019ve seen comments about the current low share price and suggesting that potential bidders would start buying shares in the open market. There\u2019s no way that any party under NDA would be able to do that as they\u2019d be party to inside information and that would be covered by the Market Abuse Regulations. The NDA would almost certainly have some form of standstill clause prohibiting open market share purchases. I think the big news when it comes will come out of the blue.",
          "sentiment": 0.0,
          "engagement": "83",
          "price_at_post": "60.50",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T14:17:13.148848+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261857-Icecool-55430835",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.531439",
        "source": "LSE_CHAT",
        "data": {
          "author": "Icecool",
          "content": "Bella you assume the SP and deal value will be linked prior to any announcement. That might happen on the Nasdaq, however it certainly doesn\u2019t happen on AIM. The price will be negotiated on the technology, then and only then will the SP react accordingly.\ud83d\udcaf\ud83d\udc4d",
          "sentiment": 0.0,
          "engagement": "8,855",
          "price_at_post": "60.50",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T14:17:13.148865+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261334-Timster--7612429",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.532093",
        "source": "LSE_CHAT",
        "data": {
          "author": "Timster",
          "content": "Why would that offend?",
          "sentiment": 0.0,
          "engagement": "20,637",
          "price_at_post": "60.50",
          "thread_title": "RE: From MM on X - If it offends - Tough",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=D20B314B-66BB-47B0-8ED4-D46B27E22B85"
        },
        "ingested_at": "2026-02-11T14:17:13.148883+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261322-Toukanka-58945169",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.532773",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "All hail the uber ramper. But I agree with everything except I think his timeline is optimistic. I\u2019m still saying Summer for the pivotal moment - in that respect I am accepting CC\u2019s predictions.",
          "sentiment": 0.0,
          "engagement": "4,476",
          "price_at_post": "60.50",
          "thread_title": "RE: From MM on X - If it offends - Tough",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=D20B314B-66BB-47B0-8ED4-D46B27E22B85"
        },
        "ingested_at": "2026-02-11T14:17:13.148901+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261243-wyndrum-70847645",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.533481",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "Does that mean MM is NFT?",
          "sentiment": 0.0,
          "engagement": "12,250",
          "price_at_post": "60.50",
          "thread_title": "RE: From MM on X - If it offends - Tough",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=D20B314B-66BB-47B0-8ED4-D46B27E22B85"
        },
        "ingested_at": "2026-02-11T14:17:13.148918+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261226-cj62-70734365",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.534176",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "I have never been influenced by MM's ramblings but this actually echoes my sentiments exactly, our money is safe as I believe SGC alone makes this a very valuable company. We are now waiting on initial TNBC data prior to H2 which if successful will boost the valuation of Avacta considerably and to top that off ava6103 initial data i expect mid H2. Very exciting times indeed and hopefully well worth the wait.",
          "sentiment": 0.0,
          "engagement": "4,302",
          "price_at_post": "60.50",
          "thread_title": "RE: From MM on X - If it offends - Tough",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=D20B314B-66BB-47B0-8ED4-D46B27E22B85"
        },
        "ingested_at": "2026-02-11T14:17:13.148936+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261217-D-Geeman--2485647",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.534833",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "Vertizea, son, B2H just beat me to it. Whenever I have been influenced by MM in hindsight I should have done the opposite. Yet this does seem a very exciting time. 'If .... and b) the company can stay independent for a couple more years at least' could be the explanation of the contradiction in my response. I think I will keep some powder dry for the next year or so. Currently the 'powder' is in WG, waiting to be worth 30p. Would be comvenient if the various timings work out for me.",
          "sentiment": 0.0,
          "engagement": "5,868",
          "price_at_post": "60.50",
          "thread_title": "RE: From MM on X - If it offends - Tough",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=D20B314B-66BB-47B0-8ED4-D46B27E22B85"
        },
        "ingested_at": "2026-02-11T14:17:13.148959+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261206-B2HS2L-13887346",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.535518",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "Does that mean MM's out? Not offended. \ud83d\ude44 PS probably reducing.",
          "sentiment": 0.0,
          "engagement": "6,031",
          "price_at_post": "60.50",
          "thread_title": "RE: From MM on X - If it offends - Tough",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=D20B314B-66BB-47B0-8ED4-D46B27E22B85"
        },
        "ingested_at": "2026-02-11T14:17:13.148979+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261201-Vertizea--6426742",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.536296",
        "source": "LSE_CHAT",
        "data": {
          "author": "VertizeaSun",
          "content": "Myles McNulty @MylesMcNulty \u00b7 2h Replying to @RobDay80669068 Morning Robert, hope all's well. #AVCT's news on Tuesday was phenomenal. My understanding is that it's an unprecedented move by the FDA to remove the dosing limit for a modified-/reformulated-/pro-chemotherapy,  mid-Phase 1 trial. The rapid decline and fall of the UK investment community - in depth, breadth, intellectual curiosity and risk tolerance - is in my view providing one of the greatest asymmetrical bets of all time. #AVA6000 is an absolute shoe-in to get to market now. It much more than underpins Avacta's entire market cap. Management will know if #AVA6103 - 'the Beast' - is working in patients as they hope it will, by the end of next month. That single drug  has real potential to become the best selling drug in the history of pharma. It really is straightforward to explain and understand this. Personally, I give AVA6103 well over a >50% chance of success in clinic. If a) it is indeed a success in the clinic; and b) the company can stay independent for a couple more years at least; then the returns from the current 60p share price could be >100x. I have recently provided a real world example of these returns (see my last post on Avacta, comparing it with $RVMD). The next 6 months are by far the most important in Avacta's history. Good luck!",
          "sentiment": 0.0,
          "engagement": "440",
          "price_at_post": "60.50",
          "thread_title": "From MM on X - If it offends - Tough",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=D20B314B-66BB-47B0-8ED4-D46B27E22B85"
        },
        "ingested_at": "2026-02-11T14:17:13.148997+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261152-wyndrum--1810053",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.537031",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "Well done Bella, although you won't see this post because you are so clever with the filter button but I raised this most recently with NFT and he never responded to his valuation of $28b based on another company, even though I asked 3 times. Thats the problem with filters. I get filtering the sheppys and watchings of this world that offer absolutely nothing but when I am not defending myself against unsolicited slurs and random insult-only posts, I only talk about AVCT. You tend to eventually come to the same conclusions as me but it takes a while and of course that ground has already been covered. The thing I have noticed is that it does not take long at all to quickly scan any post to see if it has relevance or not and as a result no longer bother filtering anyone. And why? Just on the chance that they do in fact come across some good info or (heaven forfend), some helpful insight. But as I say this will just be another green box for you to never know what was said",
          "sentiment": 0.0,
          "engagement": "12,250",
          "price_at_post": "60.50",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T14:17:13.149015+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261143-Bella653-95520298",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.537707",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "Anyone quoting billion $ deals should also post the number of shares that were in issue and the SP prior to the deal...without this info you cannot compare apples with apples. I've checked some of these big deals only to find the SP increase was relatively small.",
          "sentiment": 0.0,
          "engagement": "6,756",
          "price_at_post": "60.50",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T14:17:13.149033+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261113-B2HS2L--3278449",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.538535",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "GSK's new CEO looking for $2B to $4B deals 'hiding in plain sight' This is the title of a Fierce Pharma document found on this link: https://www.fiercebiotech.com/biotech/gsks-new-ceo-looking-2-4b-deals-hiding-plain-sight +++ Luke Miels had only been at the helm of GSK for 20 days before he signed off on his first multibillion-dollar buyout, and the CEO is clear on what else will attract his interest. \u201cThe basic framework that we like for [business development] is in that 2-to-4 billion [dollar] range,\u201d Miels told journalists on a fourth-quarter earnings call this morning. \u201cTypically, we like a program where the science is reasonably established,\u201d he added. Miels\u2014who served as GSK\u2019s chief commercial officer before taking over from CEO Emma Walmsley in the new year\u2014pointed to a pattern in dealmaking set in 2022 by the $1.9 billion acquisition of Sierra Oncology for its near-approval cancer drug. GSK is especially interested in drugs where \u201cwe've got a degree of validation on the science, but there are liabilities with the existing products,\u201d he said. To demonstrate these criteria, Miels cited the $2.2 billion buyout of Rapt Therapeutics just days into his tenure as CEO. Rapt\u2019s IgE antibody ozureprubart protects against food allergy reactions by targeting the same epitope as Novartis and Roche\u2019s Xolair. Miels admitted that Xolair has \u201cabsolutely exploded in the U.S. for usage with severe allergies, particularly in kids.\u201d \u201cBut the problem is there's a very complicated dosing regimen, and these kids have to inject themselves every two weeks,\u201d he explained. \u201c[Ozureprubart] works exactly the same way as Xolair, except that you give it on a much lower frequency,\u201d Miels said. \ud83d\udc40 \u201cSo that's essentially the methodology we're going to follow with [business development]\u2014looking for assets [that are] well priced, not necessarily in the mainstream, hiding in plain sight,\u201d the CEO added. \u201cAnd we'll do that with a degree of frequency, which, again, will help us build out the late-stage portfolio.\u201d 1 The basic framework that we like for [business development] is in that 2-to-4 billion [dollar] range,\u201d  \u274c 2 \u201cTypically, we like a program where the science is reasonably established\u201d   \u2714\ufe0f 3 GSK is interested in drugs where \u201cwe've got a degree of validation on the science, but there are liabilities with the existing products\u201d \u2714\ufe0f 4  ...looking for assets [that are] well priced, not necessarily in the mainstream, hiding in plain sight\u201d \u274c see 1 - I'd take issue that multibillion assets don't usually exist in the mainstream, hiding in plain sight. I'd say all now know about Avacta and its products. Those specialising in cancer therapeutics HAVE to be interested or start making BIG advances soon in ADC cancer targeting. I think overall, GSK is looking for an opportunity that costs less than Avacta will sell for. - From the horses mouth.",
          "sentiment": 0.0,
          "engagement": "6,031",
          "price_at_post": "60.50",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T14:17:13.149050+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261101-Watching-59119145",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.539211",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "You don\u2019t always get the best deals with smaller companies .. J",
          "sentiment": 0.0,
          "engagement": "9,224",
          "price_at_post": "60.50",
          "thread_title": "RE: Trading 212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B38EA914-FA00-4B19-B293-5E96B62D2062"
        },
        "ingested_at": "2026-02-11T14:17:13.149068+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261055-Profchee-15764933",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.539863",
        "source": "LSE_CHAT",
        "data": {
          "author": "Profcheese",
          "content": "II also in the process of reducing their charges at the moment. It's a competitive world!",
          "sentiment": 0.0,
          "engagement": "539",
          "price_at_post": "60.50",
          "thread_title": "RE: Trading 212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B38EA914-FA00-4B19-B293-5E96B62D2062"
        },
        "ingested_at": "2026-02-11T14:17:13.149086+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261008-Watching--7448487",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.540533",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "IG t buying n selling is free if you have over \u00a330 k in there account",
          "sentiment": 0.0,
          "engagement": "9,224",
          "price_at_post": "60.50",
          "thread_title": "RE: Trading 212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B38EA914-FA00-4B19-B293-5E96B62D2062"
        },
        "ingested_at": "2026-02-11T14:17:13.149120+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261004-Bella653-21224790",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.541198",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "Have you compared the Bid and Ask prices ...many of these No Fee sites don't give the 'best' prices...",
          "sentiment": 0.0,
          "engagement": "6,756",
          "price_at_post": "60.50",
          "thread_title": "RE: Trading 212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B38EA914-FA00-4B19-B293-5E96B62D2062"
        },
        "ingested_at": "2026-02-11T14:17:13.149139+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20260955-wyndrum-77242964",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.541863",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "FWIW they were efficient in sorting out a pension for me too",
          "sentiment": 0.0,
          "engagement": "12,250",
          "price_at_post": "60.50",
          "thread_title": "RE: Trading 212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B38EA914-FA00-4B19-B293-5E96B62D2062"
        },
        "ingested_at": "2026-02-11T14:17:13.149157+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20260955-avctIPma-12846740",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.542723",
        "source": "LSE_CHAT",
        "data": {
          "author": "avctIPmatters",
          "content": "Recent CC quotes :  %   Chance of success  -  Surely Avacta platform that  can to enhance  existing drug treatments  requires  an IP value asset  re-set  . Certainly worth waiting  for  to see   which  BP  jumps first  . ---------------- \"@coughlin582: \u201cif there\u2019s an organ with a cancer, we can address it\u201d \"Christina Coughlin @coughlin582 \u00b7 Feb 4 Replying to @coughlin582 Love this! No would never give our secrets away here! The secret to the sustained release mechanism invented by our brilliant chemistry team is behind blob A and blob B. We call this the \u201cblob slide\u201d \u2026 #BestTeamEver\" Gmcc",
          "sentiment": 0.0,
          "engagement": "740",
          "price_at_post": "60.50",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T14:17:13.149176+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20260946-D-Geeman--5003805",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.174673",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "It's like Lidl V's Sainsbury's, but if Lidl stock everything you want then go for it. I found the message from HL regarding their charges, soon to be changed: 'Trading / Dealing Fees: We are reducing the amount you pay to buy or sell shares with us, from \u00a311.95 to \u00a36.95 per online trade** We\u2019re introducing a charge of \u00a31.95 per trade to buy or sell funds online' Account charges: We are reducing our account charges* from 0.45% to 0.35% per year on Stocks and Shares ISA and Self-Invested Personal Pension (SIPP) accounts For Fund and Share Accounts, we are reducing account charges for holding funds, from 0.45% to 0.35% per year and we are introducing a charge of 0.35% to hold shares New account charge limits for shares (includes investment trusts, Exchange Traded Funds (ETFs) and bonds): You will never pay more than \u00a3150 per year in account charges* for holding shares in each of our SIPP, Stocks and Shares ISA or our Fund and Share Accounts Compare current vs future charges",
          "sentiment": 0.0,
          "engagement": "5,868",
          "price_at_post": "60.50",
          "thread_title": "RE: Trading 212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38EA914-FA00-4B19-B293-5E96B62D2062"
        },
        "ingested_at": "2026-02-11T14:17:13.149194+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20260930-Watching-22877833",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.175455",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "A  big pharma   can\u2019t afford not to take us over Who ever bids first will know they will become the market leader over night  with our science ! Imo it\u2019s going to happen very very quickly in 2026 . Hold or. Top up if funds allow Gla . Jane",
          "sentiment": 0.0,
          "engagement": "9,224",
          "price_at_post": "60.50",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T14:17:13.149212+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20260918-cj62--3282452",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.176169",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "Incalculable!!!",
          "sentiment": 0.0,
          "engagement": "4,302",
          "price_at_post": "60.50",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T14:17:13.149229+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20260859-Wilson63--7849268",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.176882",
        "source": "LSE_CHAT",
        "data": {
          "author": "Wilson63",
          "content": "Post by Tvr5 on X read this and consider being used for just one of these examples and what a fair price would be for the company. https://x.com/TVR5AVCT/status/2019678221504291189",
          "sentiment": 0.0,
          "engagement": "8,808",
          "price_at_post": "60.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T14:17:13.149248+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20260847-jackeste--2983053",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.177597",
        "source": "LSE_CHAT",
        "data": {
          "author": "jackester",
          "content": "They definitely do deal in Avacta.",
          "sentiment": 0.0,
          "engagement": "311",
          "price_at_post": "60.00",
          "thread_title": "RE: Trading 212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38EA914-FA00-4B19-B293-5E96B62D2062"
        },
        "ingested_at": "2026-02-11T14:17:13.149266+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20260811-JFK8-19762849",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.178308",
        "source": "LSE_CHAT",
        "data": {
          "author": "JFK8",
          "content": "Opened an account and closed it 20 minutes later as they dont deal  AVCT shares .don't know if they do now though as it was a while ago",
          "sentiment": 0.0,
          "engagement": "3,057",
          "price_at_post": "60.00",
          "thread_title": "RE: Trading 212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38EA914-FA00-4B19-B293-5E96B62D2062"
        },
        "ingested_at": "2026-02-11T14:17:13.149284+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20260125-russell1-61917876",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.179005",
        "source": "LSE_CHAT",
        "data": {
          "author": "russell1",
          "content": "Thanks for the helpful replies.",
          "sentiment": -0.5,
          "engagement": "318",
          "price_at_post": "60.00",
          "thread_title": "RE: Trading 212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38EA914-FA00-4B19-B293-5E96B62D2062"
        },
        "ingested_at": "2026-02-11T14:17:13.149302+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20262323-Toukanka--4938002",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.179705",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "More desperate ramping",
          "sentiment": 0.0,
          "engagement": "4,476",
          "price_at_post": "60.00",
          "thread_title": "RE: TAKEOVER",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=DAF752F5-FA6F-49F9-BD50-F5C834118B9E"
        },
        "ingested_at": "2026-02-11T14:17:13.149320+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20262100-cj62--2586319",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.180428",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "Put your head above the parapet have we touk. RH will probably have less influence than you, you prick.",
          "sentiment": 0.0,
          "engagement": "4,302",
          "price_at_post": "60.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T14:17:13.149339+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20262049-D-Geeman--4081826",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.181255",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "AI Overview Trading 212 (T212) and Hargreaves Lansdown (HL) offer starkly different approaches to trading Tiziana Life Sciences Ltd (NASDAQ: TLSA), with T212 focusing on low-cost, app-based trading, while HL provides a more traditional, comprehensive service with higher fees . T212 is generally better for frequent, small-value, or beginner trading due to zero-commission fees, while HL is often preferred for larger, long-term holdings and pensions. Comparison: Tiziana Life Sciences (TLSA) Trading Trading 212 (T212): Cost: Zero-commission trading on stocks and ETFs, though a 0.15% FX fee applies to non-GBP transactions. Features: Offers fractional shares, allowing for small investments in TLSA. CFD Trading: Offers long/short CFD trading on TLSA with leverage. Downsides: Limited research tools and no tax advice; users have reported wide spreads during volatile times for small-cap stocks. Hargreaves Lansdown (HL): Cost: High dealing charges (e.g., \u00a311.95 per deal), which can be costly for small trades. Features: Provides extensive research, analysis, and higher-quality, live, or more transparent pricing. Suitability: Better suited for holding larger, long-term positions or in a SIPP (pension).",
          "sentiment": 0.0,
          "engagement": "5,868",
          "price_at_post": "60.00",
          "thread_title": "RE: Trading 212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38EA914-FA00-4B19-B293-5E96B62D2062"
        },
        "ingested_at": "2026-02-11T14:17:13.149357+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20262041-D-Geeman-18971994",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.181977",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "I also have shares in $TLSA (formerly Tiziana PLC) which moved to the Nasdaq. People on the board for $TLSA.US have often complained about other brokers (I THINK Halifax amongst others) not allowing trades and I think people with 212 had there accustem shares sold against their will when they were spun-off to OTC. If AVCT do go on to the Nas I shall be happy to be with HL but each to their own.",
          "sentiment": 0.0,
          "engagement": "5,868",
          "price_at_post": "60.00",
          "thread_title": "RE: Trading 212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38EA914-FA00-4B19-B293-5E96B62D2062"
        },
        "ingested_at": "2026-02-11T14:17:13.149375+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20262026-IFA90-90166206",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.182574",
        "source": "LSE_CHAT",
        "data": {
          "author": "IFA90",
          "content": "I\u2019m no trader so 212 works for me. I just transferred a handful of Avacta shares across, took about 10 days. I\u2019ll move the rest soon. You can\u2019t dummy quote but I don\u2019t see any other downsides.",
          "sentiment": 0.0,
          "engagement": "415",
          "price_at_post": "60.00",
          "thread_title": "RE: Trading 212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38EA914-FA00-4B19-B293-5E96B62D2062"
        },
        "ingested_at": "2026-02-11T14:17:13.149393+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20262025-Icecool-25649696",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.183017",
        "source": "LSE_CHAT",
        "data": {
          "author": "Icecool",
          "content": "I hear what you\u2019re saying, and I get the excitement, but this is where biotech reality usually kicks in. Big pharma almost never forces an early move before human data unless they\u2019re facing an immediate strategic threat. AVA6103 is IND-cleared, which is huge, but it\u2019s still pre-human efficacy. That\u2019s exciting, not yet unavoidable. They are already in the data room and Avacta has made it clear they want to see human data on AVA6103 before they deal on that asset, everyone has to respect that. Right now BP doesn\u2019t need to rush or upset anyone to protect its position. They can stay close, sit in the data room, structure options, or wait for Phase 1 signals before committing real money with Avacta approval. That\u2019s how this industry normally works. The idea that retail holders could be quietly shaken out on the cheap also feels unlikely. Any hint of opportunistic behaviour would harden positions very quickly, not soften them. What the board is doing makes sense, build leverage before the power dynamic flips. Once AVA6103 shows even early human efficacy, urgency changes overnight and the tone of conversations changes with it.",
          "sentiment": 0.0,
          "engagement": "8,855",
          "price_at_post": "60.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T14:17:13.149411+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20262022-cj62--5262862",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.183465",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "Well I'm hoping that maybe 2 or 3 BP would like it but if all is well with ava6103 maybe go down the ARM route. 6 months and we should know",
          "sentiment": 0.0,
          "engagement": "4,302",
          "price_at_post": "60.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T14:17:13.149429+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261948-B2HS2L-80838450",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.183925",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "'That is extremely unlikely in biotech. As big pharma prefer to negotiate clean and keep everyone on side.' I hear what you say and generally agree. However, an opportunity like this occurs very infrequently. A successful purchase - however that occurs - confers market disruption and after commercialisation, competitive advantage upon the purchaser, with others making do with ADC development or resuming the search for new tech. This situation can't be brushed under the carpet. It's not what we would want, but you can't help seeing BP may want a deal sooner rather than later for a myriad of reasons. Pi**ing off the BoD might have to happen if one, or more than one BP are so keen to 'own it', or likely - make sure other BP's don't get a bargain in their efforts to 'own it'. There are a large number of PI's who could be easily persuaded to part with their shares at prices BP would definitely find attractive. It remains to be seen where and when the first bid arrives. The BoD are planning for the long haul, but let's hope they achieve as much as humanly possible before BP calls time on Avacta's progress.",
          "sentiment": 0.0,
          "engagement": "6,031",
          "price_at_post": "60.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T14:17:13.149447+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261935-D-Geeman-32356359",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.184434",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "I opened a 212 account a few years ago but don't use it. With HL your purchase happens immediately but with 212 it can take a while and goes thru in dribs and drabs (while the price is changing). Aren't HL lowering their dealing charges in April? I got a message and believe they are dropping to around \u00a36 for everyone (maybe more for some?) Maybe 212 are ok for bigger shares.",
          "sentiment": 0.0,
          "engagement": "5,868",
          "price_at_post": "60.00",
          "thread_title": "RE: Trading 212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38EA914-FA00-4B19-B293-5E96B62D2062"
        },
        "ingested_at": "2026-02-11T14:17:13.149465+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261920-Codejunk--3900099",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.184970",
        "source": "LSE_CHAT",
        "data": {
          "author": "Codejunkie",
          "content": "Pharma don't generally do hostile takeovers. They just pay the right price for the IP and make sure staff transfer over Hostile takeovers lose key staff....",
          "sentiment": 0.0,
          "engagement": "2,668",
          "price_at_post": "60.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T14:17:13.149483+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261916-russell1--2469957",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.185404",
        "source": "LSE_CHAT",
        "data": {
          "author": "russell1",
          "content": "Does anybody hold their Avacta shares with Trading 212? If so, is it easy to deal and are the prices comparable to other platforms. I use HL but am thinking about moving away.",
          "sentiment": -0.5,
          "engagement": "318",
          "price_at_post": "60.00",
          "thread_title": "Trading 212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38EA914-FA00-4B19-B293-5E96B62D2062"
        },
        "ingested_at": "2026-02-11T14:17:13.149501+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261857-cj62-75204591",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.185820",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "Its OK saying Hughes won't allow a low bid to be decided by shareholders, but what about a hostile bid. Any bid will be decided by the shareholders RH will have no say.",
          "sentiment": 0.0,
          "engagement": "4,302",
          "price_at_post": "60.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T14:17:13.149518+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261849-Icecool-77511936",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.186361",
        "source": "LSE_CHAT",
        "data": {
          "author": "Icecool",
          "content": "\u201cIt\u2019s OK saying Hughes won't allow a low bid to be decided by shareholders, but what about a hostile bid.\u201d That is extremely unlikely in biotech. As big pharma prefer to negotiate clean and keep everyone on side.",
          "sentiment": 0.0,
          "engagement": "8,855",
          "price_at_post": "60.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T14:17:13.149536+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261842-B2HS2L--3915998",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.187281",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "Bella ...Is the BOD in it for the long haul or would they simply take a good offer so they can move on to pastures new? I'm no longer thinking so much about how long it's going to take Avacta to achieve A,B or C. The nearer timelines we know about, but my point is how long are BP going to allow us to plough our own furrow? The more IP we pile up the larger amount SB rightly thinks the company is worth. These companies (with larger manpower & resources) will probably not want to proceed at Avacta's pace. Some will want faster development, and want their competitive advantage, with the purchase of all we have, to begin sooner. Others can't face a bigger purchase if left too long. Some BP will have funds available at different times as their priorities such as other projects will need to be factored into their timescales. Its OK saying Hughes won't allow a low bid to be decided by shareholders, but what about a hostile bid. There is no accounting for such a bid with completely opaque timescales. This is a market disruptive project and to a certain extent interested parties will want to move possibly sooner than we would wish. I don't see Avacta finishing what they started, but what do I know?",
          "sentiment": 0.0,
          "engagement": "6,031",
          "price_at_post": "60.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T14:17:13.149554+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261755-Metatron--8625944",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.188128",
        "source": "LSE_CHAT",
        "data": {
          "author": "Metatron",
          "content": "That's the spirit Watching2!! poor old Winnypoos is banging his drum as fast as he can but.. can he stay in time? I've spent half my life with those and asking a drummer to think? that's sublime...",
          "sentiment": 0.0,
          "engagement": "1,192",
          "price_at_post": "60.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T14:17:13.149571+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261725-opti_mys--8787194",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.188933",
        "source": "LSE_CHAT",
        "data": {
          "author": "opti_mystic",
          "content": "With RH on the BoD there is zero chance of Avacta being sold on the cheap. They have to put serious offers to shareholders but I guess it depends how serious is defined. Offering half what the company is worth is not a serious offer in my view. They could down tools today and sell the IP and they'd get a lot more than the current market cap.",
          "sentiment": 0.0,
          "engagement": "307",
          "price_at_post": "60.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T14:17:13.149596+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261717-cj62--7802757",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.189693",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "There is 0% CoS attached to the sp and that includes ava 6 k. Presently it would stand at 5 - 11% after the recent rns",
          "sentiment": 0.0,
          "engagement": "4,302",
          "price_at_post": "60.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T14:17:13.149615+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261710-Watching-22877766",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.190157",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "Winne bot has broken  free ! Ignore !",
          "sentiment": 0.0,
          "engagement": "9,224",
          "price_at_post": "60.50",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T14:17:13.149633+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261613-wyndrum-60433698",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.032149",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "\"Buyers don\u2019t care about today\u2019s SP, they care about what this asset can generate over a decade.\" do you think ever, before you post? If a buyer thinks this will be huge multiple in value then they buy as cheaply as they can which today would be 60p? Otherwise one would assume they are waiting for something... i dunno....maybe data from a trial yet to start? Also in response to where shareholders might sell: The SP would not be say, 500p per share from here on speculation. It would be on the back of very good results and data. It would be that data that would influence as to weather or not it would be sensible to sell.",
          "sentiment": 0.0,
          "engagement": "12,250",
          "price_at_post": "60.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T14:17:13.149651+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261556-Icecool--3428084",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.032939",
        "source": "LSE_CHAT",
        "data": {
          "author": "Icecool",
          "content": "If AVA6103 does what it\u2019s designed to do in humans, this isn\u2019t a few billion story. On any sensible biotech valuation framework (see my case study \ud83e\udd23\ud83d\ude09), you\u2019re talking tens of billions, not pocket change. That\u2019s total value paid, not based on some AIM screen price that flickers day to day. That\u2019s why the share price right now is basically irrelevant. Buyers don\u2019t care about today\u2019s SP, they care about what this asset can generate over a decade. Thankfully it also explains the strategy perfectly. Avacta is keeping AVA6103 solo for now because proving it in humans is where the real value unlock happens. You don\u2019t sell something like this on promise alone, you sell it when the risk collapses and the leverage flips. That\u2019s the play here. Prove it works in people, then let the numbers do the talking.",
          "sentiment": 0.0,
          "engagement": "8,855",
          "price_at_post": "61.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T14:17:13.149669+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261528-Timster-24493842",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.033717",
        "source": "LSE_CHAT",
        "data": {
          "author": "Timster",
          "content": "If CC brings anything less than \u00a3200 ex chi-nah, she'd be having a laugh!",
          "sentiment": 0.0,
          "engagement": "20,637",
          "price_at_post": "61.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T14:17:13.149691+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261523-cj62--5163206",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.034552",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "Directors cannot quietly reject a serious offer that could reasonably be of interest to shareholders once it becomes concrete. Their duty is to: Act in shareholders\u2019 best interests and Not frustrate an offer without shareholder approval",
          "sentiment": 0.0,
          "engagement": "4,302",
          "price_at_post": "61.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T14:17:13.149710+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261523-HarChris--8741012",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.035361",
        "source": "LSE_CHAT",
        "data": {
          "author": "HarChris",
          "content": "575m total share count feels a more realistic figure to be working with when forecasting future takeover share price so \u00a33B would be more like \u00a35.25 a share.",
          "sentiment": 0.0,
          "engagement": "15,923",
          "price_at_post": "61.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T14:17:13.149728+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261512-Bella653-78910968",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.036083",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "The BIG Questions are... Is the BOD in it for the long haul or  would they simply take a good offer so they can move on to pastures new? and how much are they will to hold out for?",
          "sentiment": 0.0,
          "engagement": "6,756",
          "price_at_post": "61.50",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T14:17:13.149746+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261507-Bella653--3766729",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.036656",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "I don't think you'll get anywhere near your SP wishlist on a T/O deal as we stand right now. Deals and NASDAQ Listing will drive value but we need some big hitters in the Finance World like Healthcare Royalty to back Avacta and to negotiate the best T/O deal possible at the right time.",
          "sentiment": 0.0,
          "engagement": "6,756",
          "price_at_post": "61.50",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T14:17:13.149764+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261505-hamsters-53237628",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.037073",
        "source": "LSE_CHAT",
        "data": {
          "author": "hamsters18",
          "content": "What large buys?",
          "sentiment": 0.0,
          "engagement": "3,692",
          "price_at_post": "61.50",
          "thread_title": "RE: TAKEOVER",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=DAF752F5-FA6F-49F9-BD50-F5C834118B9E"
        },
        "ingested_at": "2026-02-11T14:17:13.149782+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261449-Deod123--9137822",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.037518",
        "source": "LSE_CHAT",
        "data": {
          "author": "Deod123",
          "content": "Large buys going through.someone is stake building",
          "sentiment": 0.0,
          "engagement": "68",
          "price_at_post": "61.00",
          "thread_title": "TAKEOVER",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=DAF752F5-FA6F-49F9-BD50-F5C834118B9E"
        },
        "ingested_at": "2026-02-11T14:17:13.149800+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261438-cj62-48645617",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.037940",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "\u00a3200 ex china  Not this LTH",
          "sentiment": 0.0,
          "engagement": "4,302",
          "price_at_post": "61.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T14:17:13.149817+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261431-Wilson63--9123227",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.038378",
        "source": "LSE_CHAT",
        "data": {
          "author": "Wilson63",
          "content": "I'm somewhat surprised a couple of regulars are going to sell out at fairly low numbers, if this continues to pass each obstacle it's a one and only lifetime chance imho, topping up monthly slow and steady.",
          "sentiment": 0.0,
          "engagement": "8,808",
          "price_at_post": "60.50",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T14:17:13.149836+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261323-BuenaVis-93964297",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.038809",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Yes, the pre|CISION pie can be cut many ways: by drugs, indications and territories, and all with or without exclusivity.  People might say that faridox, with its boring old doxorubicin, will be overtaken by newer, more powerful pre|CISION drugs but the fact is it is here and now and not far off its first approved indication, salivary gland cancer, if the data released so far is to be believed. So with all that, why would any company want to license it when there could be better options in the future?  Well, if the offer was a global exclusive licence to develop faridox for SGC, plus the option to have first dibs on any future Avacta pre|CISION drug for SGC, plus the rights to develop their own pre|CISION drugs for SGC\u2014essentially an exclusive licence agreement to control the global pre|CISION SGC market\u2014then that would surely be of great interest. If it's taking Simon a long time to get that first deal, well the licensing possibilities are nearly endless and newly revealed data and developments are moving the goal posts in Avacta's favour all the time as conclusive evidence proves the platform (I'll call it that now already).",
          "sentiment": 0.0,
          "engagement": "5,826",
          "price_at_post": "59.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T14:17:13.149853+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261300-Vertizea--5039202",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.039250",
        "source": "LSE_CHAT",
        "data": {
          "author": "VertizeaSun",
          "content": "\u00a32 billion to buy a serious geographic licence for pre|CISION and a couple of warheads  sounds about right......say the EU/EEA and ex-ROW. Simon Bennett is now in his third year and the fact he hasn't been fired will suggest he has something up his sleeve. \u00a32B will pay for future independence and a \u00a31 per share dividend. I think we'll know within a couple of months and perhaps sooner as CC is obviously in town (doing celebratory cake delivery) and probably here for a board meeting - where they'll be trying to digest the recent torrent of good news. They actually have a lot on their plate. But I'm having trouble digesting \"the removal of the maximum dosing limit\" ...... apparently the first time in history for a phase 1 trial compound so I'm quite happy to believe that eventually pre|CISION is going to be compared to the impact penicillin had on the world of medicine. And in the beginning that discovery had serious FUD. Bill Gates said that the world always over-estimates how much change can take place in six months, but under-estimates how much change will take place in six years.",
          "sentiment": 0.0,
          "engagement": "440",
          "price_at_post": "59.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T14:17:13.149876+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261259-Matml74--6655369",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.039673",
        "source": "LSE_CHAT",
        "data": {
          "author": "Matml74",
          "content": "Dolly, Watch the R&D spotlight episode on next generation Precision from 2024 and also the dual payload one from late 2025. These highlight the vast opportunity for Precision.",
          "sentiment": 0.0,
          "engagement": "2,547",
          "price_at_post": "59.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T14:17:13.149896+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261252-opti_mys--6476822",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.040082",
        "source": "LSE_CHAT",
        "data": {
          "author": "opti_mystic",
          "content": "Oh yea of little faith. \u00a310 is my absolute bare minimum from when I first invested. Due to progress on a number of fronts that has gone up. Somewhat disappointed that people would sell so cheaply. Hopefully the BoD know what the company is worth and will not put to shareholders derisory offers that significantly under values the company.",
          "sentiment": 0.0,
          "engagement": "307",
          "price_at_post": "59.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T14:17:13.149914+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261249-Dollyg--5449625",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.040506",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dollyg",
          "content": "Thank you",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "59.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T14:17:13.149938+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261239-yeboha--2754329",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.040920",
        "source": "LSE_CHAT",
        "data": {
          "author": "yeboha",
          "content": "Dolly if you do some research online you can see that many professionals in the field agree that it can be used on many drugs !",
          "sentiment": 0.0,
          "engagement": "963",
          "price_at_post": "59.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T14:17:13.149956+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261237-yeboha--7021280",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.041383",
        "source": "LSE_CHAT",
        "data": {
          "author": "yeboha",
          "content": "Avacta\u2019s pipeline includes several distinct pre|CISION\u00ae drug conjugates with different therapeutic payloads, not just a single product: AVA6000 (a doxorubicin-based peptide drug conjugate) has shown positive clinical progress. AVA6103 (exatecan-based PDC) is advancing toward clinical trial start. Dual-payload PDCs are being developed in preclinical stages, combining agents like microtubule inhibitors and DNA damage response modulators. Another pipeline program, AVA7100 (an Affimer\u00ae-based drug conjugate), is also in preclinical development with its own payload delivery design. \ud83d\udccc Why this matters: This demonstrates that Avacta\u2019s platform isn\u2019t limited to a single drug but is being developed as a modular engine for multiple therapeutic combinations and individual payloads",
          "sentiment": 0.0,
          "engagement": "963",
          "price_at_post": "59.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T14:17:13.149974+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261231-Dollyg-72787930",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.041792",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dollyg",
          "content": "Be good to get a medically qualified opinion of the ACTUAL potential of how many differing treatments this technology could affect.",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "59.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T14:17:13.149992+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261227-Livedata--5276411",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.042216",
        "source": "LSE_CHAT",
        "data": {
          "author": "Livedataaccount",
          "content": "Hi jane im out at 4 pounds if it gets there",
          "sentiment": 0.0,
          "engagement": "2,969",
          "price_at_post": "59.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T14:17:13.150018+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261225-yeboha-39544964",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.042623",
        "source": "LSE_CHAT",
        "data": {
          "author": "yeboha",
          "content": "Its funny we say this, being where the share price is but im so convinced about avacta and have been for years !",
          "sentiment": 0.0,
          "engagement": "963",
          "price_at_post": "59.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T14:17:13.150037+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261221-Watching--7708200",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.043037",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "Happy with \u00a37 pre share. But \u00a310 would be a nice surprise . Jane",
          "sentiment": 0.0,
          "engagement": "9,224",
          "price_at_post": "59.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T14:17:13.150055+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261213-Dollyg-17099262",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.043462",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dollyg",
          "content": "I read the \u00a33 billion figure was first mooted in 2023 and they seem to have come a long way since then in terms of efficacy. The concensus seens to be wait.",
          "sentiment": 0.5,
          "engagement": "8",
          "price_at_post": "59.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T14:17:13.150083+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261212-yeboha-44984905",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.043874",
        "source": "LSE_CHAT",
        "data": {
          "author": "yeboha",
          "content": "Thats roughly my thinking",
          "sentiment": 0.0,
          "engagement": "963",
          "price_at_post": "59.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T14:17:13.150111+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261209-BuenaVis--5083001",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.044290",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "$4bn would be 668p a share.  Not enough for me.  I'd be looking for at least 1,000p a share, a $6bn buyout.  At least.",
          "sentiment": 0.0,
          "engagement": "5,826",
          "price_at_post": "59.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T14:17:13.150129+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20262313-aidanjc-40145061",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.524270",
        "source": "LSE_CHAT",
        "data": {
          "author": "aidanjc",
          "content": "Good point.  If cancer treatments improve that is a fantastic result. Its crept into my life a lot recently. Great to make a profit on the shares but improving outcomes for cancer patients is really important.",
          "sentiment": 0.0,
          "engagement": "6",
          "price_at_post": "51.50",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-11T14:17:13.150148+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20262051-avctIPma-42029146",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.524706",
        "source": "LSE_CHAT",
        "data": {
          "author": "avctIPmatters",
          "content": "Thanks for sharing  B2HS2L  -  Helps spread info on the platform  .",
          "sentiment": 0.0,
          "engagement": "728",
          "price_at_post": "51.50",
          "thread_title": "RE: CDD European Life Science Community Meeting",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=3A2F031D-C16F-4949-B22E-8512255BE282"
        },
        "ingested_at": "2026-02-11T14:17:13.150166+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20262049-avctIPma-75953649",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.525140",
        "source": "LSE_CHAT",
        "data": {
          "author": "avctIPmatters",
          "content": "Thanks for sharing  Thompi -  All helps spread   Avacta exposure .",
          "sentiment": 0.0,
          "engagement": "728",
          "price_at_post": "51.50",
          "thread_title": "RE: World CB & CDx Summit Europe",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=18E94451-D174-452E-BD8A-79154E17863F"
        },
        "ingested_at": "2026-02-11T14:17:13.150184+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20262022-Livedata--3829244",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.525565",
        "source": "LSE_CHAT",
        "data": {
          "author": "Livedataaccount",
          "content": "Ellen's great she will do a fantastic presentation",
          "sentiment": 0.0,
          "engagement": "2,957",
          "price_at_post": "51.50",
          "thread_title": "RE: CDD European Life Science Community Meeting",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=3A2F031D-C16F-4949-B22E-8512255BE282"
        },
        "ingested_at": "2026-02-11T14:17:13.150202+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20262016-B2HS2L-58940434",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.525997",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "Https://www.collaborativedrug.com/cdd-european-scientific-community-meeting-2026 Dr Ellen Watts, Avacta Therapeutics 25.02.2026  17:00-17:30: Delivering Targeted Therapies Using the pre|CISION\u00ae Platform. Last presentation of the day",
          "sentiment": 0.0,
          "engagement": "6,003",
          "price_at_post": "51.50",
          "thread_title": "CDD European Life Science Community Meeting",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=3A2F031D-C16F-4949-B22E-8512255BE282"
        },
        "ingested_at": "2026-02-11T14:17:13.150220+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261732-Timster-60199600",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.526420",
        "source": "LSE_CHAT",
        "data": {
          "author": "Timster",
          "content": "Good spot Thompi, thanks",
          "sentiment": 0.0,
          "engagement": "20,626",
          "price_at_post": "51.50",
          "thread_title": "RE: World CB & CDx Summit Europe",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=18E94451-D174-452E-BD8A-79154E17863F"
        },
        "ingested_at": "2026-02-11T14:17:13.150238+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261722-Thompi--4829451",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.526848",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thompi",
          "content": "Ruairidh Edwards will be speaking on 1 April at the 16th World Clinical Biomarkers & Companion Diagnostics Summit Europe. Presentation title: Establishing a Biomarker-Driven Approach to Guide Patient Selection for preCISION\u00ae Peptide-Drug Conjugates Using Tumour Targeting/Release and Payload Sensitivity Biomarkers. https://cdx-europe.com/full-event-guide/",
          "sentiment": 0.0,
          "engagement": "1,358",
          "price_at_post": "51.50",
          "thread_title": "World CB & CDx Summit Europe",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=18E94451-D174-452E-BD8A-79154E17863F"
        },
        "ingested_at": "2026-02-11T14:17:13.150256+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261707-Agenda10-30026316",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.527323",
        "source": "LSE_CHAT",
        "data": {
          "author": "Agenda101",
          "content": "No not engage ! It\u2019s working so let\u2019s continue to starve them of any engagement. As Runner-Runner wrote and BV reposted\u2026 It's simple. 1. DO NOT ENGAGE 2. DO NOT ASK IT A QUESTION 3. DO NOT ANSWER ITS QUESTIONS 4. DO NOT MOAN ABOUT ITS POSTS 5. DO NOT ARGUE WITH IT 6. If you must do something. Mock it with reference only to its stupidity and nothing else. ------------------------------------------------------ If you're not part of the solution, you're part of the problem",
          "sentiment": 0.0,
          "engagement": "72",
          "price_at_post": "52.50",
          "thread_title": "RE: Bone Marrow Toxicity, Brain malignancies?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=34DD9B68-3AA3-4F24-A8A5-8F742D7F4948"
        },
        "ingested_at": "2026-02-11T14:17:13.150280+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261704-Agenda10-87254312",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.527740",
        "source": "LSE_CHAT",
        "data": {
          "author": "Agenda101",
          "content": "\u201cI\u2019m committed for the next two years, but I anticipate that developments around licensing, manufacturing, and supply will begin to materialise well before then. From my perspective, the time to push ahead is now.\u201d",
          "sentiment": 0.0,
          "engagement": "72",
          "price_at_post": "51.50",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-11T14:17:13.150298+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261656-Thornogs-79458981",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.528205",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Well I didn't post! Not much said I see. More chat about FAP expressed on inflamed/fibrotic tissue other than cancer as a positive therapeutic opportunity with no one wondering if this self same tissue might cause problems should someone inject a FAP released 'Beast' into the circulation whilst trying to target a FAP related cancer.  Were that to happen in the FAP-EXD 1a Safety trial I think it would count as a Black Mark. BV and Syphysus indulged their in depth knowledge of molecular biology and the Blood Brain Barrier to 'deep dive' the potential to treat cerebral cancers, I do hope CC read those posts or perhaps one of you could send her an e mail explaining the possibilities? And the Market did what I thought it would do, go down, down the at the last come back up to almost, but not quite, where we opened. 1% down today, 3% this week and 10% down on the month. I see this continuing until the surprise deal mentioned earlier or being more realistic the next raise to fund the programme through 2026. Any thoughts on support/resistance levels Wyn? Happy to be out waiting for FAP-EXD and funding doubts to clear.",
          "sentiment": 0.0,
          "engagement": "8,666",
          "price_at_post": "51.50",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-11T14:17:13.150316+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261643-wyndrum-64951066",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.528628",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "I see \u201cthe don\u2019t engage\u201d policy didn\u2019t last long. You simply can\u2019t have a bb devoted to the actual topic and miss out on insulting others can you? Predictable and pathetic behaviour. Who knew?",
          "sentiment": 0.0,
          "engagement": "12,228",
          "price_at_post": "51.50",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-11T14:17:13.150335+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261640-D-Geeman-12603773",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.529049",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "'Chris, are you still interested in my buys and sells or would you prefer me not to bother?' Chris might not be interested Wyn, but I am... I dare say I'm not alone either.",
          "sentiment": 0.0,
          "engagement": "5,849",
          "price_at_post": "51.00",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-11T14:17:13.150352+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261639-Toukanka--2395019",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.529486",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "BV Are you a lawyer? We were led to believe that 6000 P1b would finish end of 25. So you don\u2019t regard having to go an extra cycle as missing a target. Or all the talk of multiple events before end 25 as not materialising. Anyhow at least some people on here are rooted in reality and believe CC when she says not to expect much before 2H26. Be. Patient",
          "sentiment": 0.0,
          "engagement": "4,454",
          "price_at_post": "51.00",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-11T14:17:13.150377+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261631-cj62-57205646",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.529902",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "Fine with me Chris. I would remind you however that it was you that asked I report my trades. You did report your last losing trade though did you, you prick",
          "sentiment": 0.0,
          "engagement": "4,282",
          "price_at_post": "51.50",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-11T14:17:13.150395+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261628-BuenaVis--3560344",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.530336",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Yes, that could be one possibility.",
          "sentiment": 0.0,
          "engagement": "5,775",
          "price_at_post": "51.50",
          "thread_title": "RE: Bone Marrow Toxicity, Brain malignancies?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=34DD9B68-3AA3-4F24-A8A5-8F742D7F4948"
        },
        "ingested_at": "2026-02-11T14:17:13.150414+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261622-wyndrum-57292393",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.530749",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "Fine with me Chris. I would remind you however that it was you that asked I report my trades. Anyway I\u2019m keen to see how this bb goes from here.",
          "sentiment": 0.0,
          "engagement": "12,228",
          "price_at_post": "51.50",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-11T14:17:13.150432+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261615-HarChris--7044991",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.531177",
        "source": "LSE_CHAT",
        "data": {
          "author": "HarChris",
          "content": "The last time I pointed out your losing trade you responded by saying you barely had anything on it\u2026 so nah, don\u2019t bother if you can just twist it how you want. And it clogs up the bb even more! How about not sharing any and trying not to care what an anonymous group of people think about your trading prowess?! That would be healthier!",
          "sentiment": 0.0,
          "engagement": "15,870",
          "price_at_post": "51.50",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-11T14:17:13.150458+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261613-Agenda10-76475423",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.531589",
        "source": "LSE_CHAT",
        "data": {
          "author": "Agenda101",
          "content": "None.. he\u2019s fishing don\u2019t reply!",
          "sentiment": 0.0,
          "engagement": "72",
          "price_at_post": "51.50",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-11T14:17:13.150478+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261547-BuenaVis-81962082",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.532000",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "@russell1 , what deadlines has Avacta missed since CC became CEO on 1 May 2024?",
          "sentiment": 0.0,
          "engagement": "5,775",
          "price_at_post": "51.00",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-11T14:17:13.150496+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261536-russell1-12726561",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.532426",
        "source": "LSE_CHAT",
        "data": {
          "author": "russell1",
          "content": "Well I'm not prepared to add any more money to my current loss situation so my only decision is whether to sell a proportion of my holding and hope I can buy back at a lower price if we (ever) get some worthwhile news or just leave it and hope! My expectation is that the price will just drift down until any news arrives but I have no expectation that this company will ever meet any of its reported deadlines.",
          "sentiment": -0.5,
          "engagement": "315",
          "price_at_post": "51.00",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-11T14:17:13.150514+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261529-Sisyphus-52821892",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.532837",
        "source": "LSE_CHAT",
        "data": {
          "author": "SisyphusShorter",
          "content": "Thanks BV, good to know. So in theory, a \"FAP-Temo\" agent would be roughly 460Da in size, provided the same Gen1 preCISION peptide is used. That puts it within the 400-600 threshold for BBB-crossing possibility (obviously notwithstanding lipophilicity, polarity and other parameters). That being said they could always cleave off a few residues to make a lightweight version for this specific indication.",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "51.00",
          "thread_title": "RE: Bone Marrow Toxicity, Brain malignancies?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=34DD9B68-3AA3-4F24-A8A5-8F742D7F4948"
        },
        "ingested_at": "2026-02-11T14:17:13.150532+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261509-Toukanka-16120477",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.533258",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "At last sensible posters instead of the usual carp \u201cfill yer boots you\u2019ll never again get the chance at this SP\u201d.  In truth we have a sideways drift until 6103 early clinical results are published in the Summer. Get over it and be patient.",
          "sentiment": 0.0,
          "engagement": "4,454",
          "price_at_post": "51.00",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-11T14:17:13.150549+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261432-wyndrum--8328756",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.533670",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "Chris, are you still interested in my buys and sells or would you prefer me not to bother?",
          "sentiment": 0.0,
          "engagement": "12,228",
          "price_at_post": "51.00",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-11T14:17:13.150573+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261413-Aston15-41228563",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.534076",
        "source": "LSE_CHAT",
        "data": {
          "author": "Aston15",
          "content": "I have brought enough now to be comfortable with the risk to reward ratio. 10% of my SIPP now in AVCT following another purchase this week. Many are expecting more than this, but my target remains a 5 billion valuation for the platform minimum. Happy to leave this to run now and hope the team delivers a positive outcome for both patients and shareholders.",
          "sentiment": 0.0,
          "engagement": "62",
          "price_at_post": "50.50",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-11T14:17:13.150592+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261410-B2HS2L-63140081",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.534502",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "Slide 16 & 18 of the Investormeet presentation 17.12.2025 contain info on tumor biopsies as articulated by Ruairidh Edwards, Translational Scientist. He's discussing phase 1b patients, possibly placing the recording of the interview before mid December.",
          "sentiment": 0.0,
          "engagement": "6,003",
          "price_at_post": "50.50",
          "thread_title": "RE: Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-02-11T14:17:13.150609+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261347-Vertizea--3675179",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.529148",
        "source": "LSE_CHAT",
        "data": {
          "author": "VertizeaSun",
          "content": "I think it links with CC's visit to Glasgow.....to visit the manufacturing site of AVA6103 and its \"first pour\".",
          "sentiment": 0.0,
          "engagement": "433",
          "price_at_post": "50.50",
          "thread_title": "RE: Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-02-11T14:17:13.150627+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261340-BuenaVis--1332465",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.529619",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Whilst the introduction by the host was current (post-IND announcement), CC seemed to be referencing passed events as being in the future and someone here suggested that the interview was recorded last year, in early December if I remember correctly.  I haven't listened to the interview again today but I do remember hearing bits that seemed out of step with today's situation.",
          "sentiment": 0.0,
          "engagement": "5,775",
          "price_at_post": "50.50",
          "thread_title": "RE: Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-02-11T14:17:13.150650+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261326-BuenaVis--6512659",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.530089",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Interesting and intelligent quesitions. As regards, fibrotic targets due to prior anthracycline treatment, it'll be interesting to see whether this side effect is reduced in previously untreated patients.  The breakdown of side effects vs prior treatment hasn't been presented yet but it is exacty the sort of detail I'm wanting to see (also, for example, side effects vs cancer indication/metastasis site).  Hopefully it will be included when the Phase 1 trial is written up in a peer-reviewed article, but there's always the AGM as an opportunity for asking detailed questions in person. As regards crossing the blood-brain barrier (BBB)... Temozolomide - molecular weight: 194.15 Da Doxorubicin - molecular weight: 543.52 Da Faridoxorubicin - molecular weight: 816.8 Da Faridoxorubicin without doxorubicin: 273.28 Da According to Gemini, \"Drugs that cross the BBB generally must be lipophilic (lipid-soluble), have a low molecular weight\u2014typically under 400\u2013600 Da\u2014and have a low polar surface area or few hydrogen bonds. They must avoid active efflux transport systems (like P-glycoprotein) and not be highly bound to plasma proteins.\"  So the requirements for an IV infusion drug are pretty stringent. However, there is an alternative route and that is, again according to Gemini, \"[administration] directly into the brain to bypass the BBB. This approach, known as local or regional drug delivery, is used to treat primary brain tumors (like glioblastoma) or brain metastases, allowing high concentrations of medication to reach the tumor without causing systemic toxicity.\"  I should think that the advantage of using pre|CISION for this is that, whilst the pre|CISION drug itself would be too big to cross OUT of the brain, the warhead, its metabolites and the leaving group from the pre|CISION substrate could all be below the size needed to cross out of the brain.  Anyway, CC wouldn't have specifically mentioned brain cancer if it weren't a possibility.",
          "sentiment": 0.0,
          "engagement": "5,775",
          "price_at_post": "50.50",
          "thread_title": "RE: Bone Marrow Toxicity, Brain malignancies?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=34DD9B68-3AA3-4F24-A8A5-8F742D7F4948"
        },
        "ingested_at": "2026-02-11T14:17:13.150669+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261318-IFA90--2127986",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.530517",
        "source": "LSE_CHAT",
        "data": {
          "author": "IFA90",
          "content": "I\u2019m not buying anymore. I\u2019ve increased my holding this week by selling a % and buying back c.10% cheaper. After 5 years it\u2019s entirely predictable, I just wish I\u2019d have realised that 3 years ago.",
          "sentiment": 0.0,
          "engagement": "409",
          "price_at_post": "50.50",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-11T14:17:13.150687+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261312-wyndrum--8470112",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.530949",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "Yes cj and I have just literally sold that holding and more as it looks to confused to me right now. Just so you know and can keep up I placed the sale evenly between Cpx and Xsg. Personally I would enjoy exploring and explaining my reasoning in a bit more depth but no need to is interested. ( and while you may all feel a bit more smug about this, it might be worth reflecting that I don\u2019t illicit the antagonist relationship here on other bb\u2019s. It begs the question is it me or you?)",
          "sentiment": 0.0,
          "engagement": "12,228",
          "price_at_post": "50.50",
          "thread_title": "RE: ADC 26",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=F3B63190-B417-42B7-9CC8-0ED98F4FBB92"
        },
        "ingested_at": "2026-02-11T14:17:13.150705+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261301-cj62-81081020",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.531376",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "\"Well the sp is 52p and now years later my analysis over a vey long period has proved correct and his wrong.\" but not recently you could have added- bought at 56.95 i believe. Yet still there are some that want me to be cancelled, yep you have that 100% correct as your narcissim knows no bounds",
          "sentiment": 0.0,
          "engagement": "4,282",
          "price_at_post": "50.50",
          "thread_title": "RE: ADC 26",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=F3B63190-B417-42B7-9CC8-0ED98F4FBB92"
        },
        "ingested_at": "2026-02-11T14:17:13.150723+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261254-Sisyphus--6763830",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.531796",
        "source": "LSE_CHAT",
        "data": {
          "author": "SisyphusShorter",
          "content": "So been looking at the phase 1 data for AVA6000 and also been listening to the podcast, thanks BV. Now I have two broad questions: One on bone/haem side effects, and one regarding primary brain cancers. Firstly, of the patients we have seen with bone marrow suppression, I know it's a known side effect of Dox, but I do wonder if prior primary therapies have induced a bit of fibrosis in the marrow, leading to FAP expression and thus Dox being released, leading to further bone marrow toxicity. That would imply that the side effects seen in the patients so far are less likely to emerge in a larger trial with a higher proportion of chemo-naive patients. Thoughts? Secondly, CC mentioned in the podcast that given that 90% of solid tumours express FAP, including brain, which she mentioned, and this begs the question whether or not the Peptide used in pre/CISION drug conjugates is small enough to pass the blood-brain-barrier, after all, that's how Temozolomide can do it's think for brain tumours. Again, thoughts?",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "50.50",
          "thread_title": "Bone Marrow Toxicity, Brain malignancies?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=34DD9B68-3AA3-4F24-A8A5-8F742D7F4948"
        },
        "ingested_at": "2026-02-11T14:17:13.150742+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261253-pedrolan-10464839",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.532225",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Yes, I bought some more the other week and am considering more now to get my average down further. If you believe in the medium term story here (with the bonus of a potential deal at any time) then it seems a bargain. Before any of the aliases bother to reply - I will not be responding to it - it will not be anything we have not all heard multiple times anyway.",
          "sentiment": 0.5,
          "engagement": "1,975",
          "price_at_post": "51.00",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-11T14:17:13.150760+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261252-BuenaVis-24212298",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.532633",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Another advantage of Avacta's PDCs is the h o m ogeneity of the dosage - exactly one warhead per drug molecule, or exactly two warheads per drug molecule for the dual payload drugs. In contrast, significant heterogeneity exists in ADCs as they are complex mixtures of varied molecular species rather than a single uniform compound. This includes differences in the drug-to-antibody ratio (DAR) and the conjugation sites on the antibody, leading to mixtures with 0 to 8+ payload molecules and various positional isomers.",
          "sentiment": 0.0,
          "engagement": "5,775",
          "price_at_post": "51.00",
          "thread_title": "RE: ADC 26",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=F3B63190-B417-42B7-9CC8-0ED98F4FBB92"
        },
        "ingested_at": "2026-02-11T14:17:13.150778+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261250-aidanjc--7866468",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.533041",
        "source": "LSE_CHAT",
        "data": {
          "author": "aidanjc",
          "content": "I've been a lth here having bought at several levels. Was hoping not to see us back around the 50p level. I've bought a few more. Anyone else buying. I'm hoping 50p will be the low tide mark...",
          "sentiment": 0.5,
          "engagement": "6",
          "price_at_post": "51.00",
          "thread_title": "Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-11T14:17:13.150795+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261246-wyndrum-37816227",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.533480",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "Also I don\u2019t care if you respond or not. I just hope it makes you think.also you will crack before we do. Not because it\u2019s a contest but simply we will ask questions or post opinions that as a bb you will naturally want to respond to. That\u2019s the whole purpose of a discussion bb. To discuss. And while there are a lot of recs to want us to be cancelled you will soon be bored with the lack of insight offered by the so called guardians of this bb. And never forget, it is exactly the same posters that by insulting us that then generate the board clogging are the ones piously demanding we be ignored. Just check sheppy watching bv and the rest for their overall contribution.",
          "sentiment": 0.0,
          "engagement": "12,228",
          "price_at_post": "51.00",
          "thread_title": "RE: ADC 26",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=F3B63190-B417-42B7-9CC8-0ED98F4FBB92"
        },
        "ingested_at": "2026-02-11T14:17:13.150813+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261243-Sisyphus--3440795",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.533883",
        "source": "LSE_CHAT",
        "data": {
          "author": "SisyphusShorter",
          "content": "Sorry, *Next* data release....",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "51.00",
          "thread_title": "RE: Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-02-11T14:17:13.150837+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261240-Sisyphus-10255339",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.534310",
        "source": "LSE_CHAT",
        "data": {
          "author": "SisyphusShorter",
          "content": "At 36:22 CC says, regarding tumour biopsies - \"...in our new data release which will be later this month...\" Make of that what you will..... GLA",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "51.00",
          "thread_title": "RE: Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-02-11T14:17:13.150855+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261232-wyndrum--1245779",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.534763",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "Oh, I remember, after this interview and the other stuff uncovered, what has the sp done? Why ,  How, can there be more sellers than buyers? Let\u2019s move on from the \u201csp doesn\u2019t matter \u201c. It\u2019s a facile statement which simply refuses to address a perfectly reasonable question. Yes the sp can drift up or down on no news but why can\u2019t we discuss it when there is a very positive release and it generates sells? By all means keep up this do not engage but myles tried this with me specifically on this bb with a little header to try and get me banned altogether. Well the sp is 52p and now years later my analysis over a vey long period has proved correct and his wrong. Yet still there are some that want me to be cancelled. You lot are either just plain weird or it is you that have an agenda. Just remember I have made money out of this stock and had you agreed with my view you would have too. The opposite would have happened if you followed bv and the rest. Yet you want me silenced. You might perhaps realise why I wonder what motivates the majority here.",
          "sentiment": 0.0,
          "engagement": "12,228",
          "price_at_post": "51.00",
          "thread_title": "RE: ADC 26",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=F3B63190-B417-42B7-9CC8-0ED98F4FBB92"
        },
        "ingested_at": "2026-02-11T14:17:13.150873+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261221-Watching-71402840",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.535189",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "To the Fudders they are trying so hard this morning ! It worked yesterday ! They are drying up \ud83e\udd21s",
          "sentiment": 0.0,
          "engagement": "9,215",
          "price_at_post": "51.00",
          "thread_title": "Do not respond",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=598797E4-B255-4509-971C-C103D6214E00"
        },
        "ingested_at": "2026-02-11T14:17:13.150897+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261143-wyndrum--2218968",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.535610",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "whatever you do, do not do not reply  or respond. you might want to take the ****, but resist. you might have the best put down ever! but do not repeat do not respond  got it? now what was i going to say\u2026. damn after all that i forgot \u2026.,",
          "sentiment": 0.0,
          "engagement": "12,228",
          "price_at_post": "52.00",
          "thread_title": "RE: ADC 26",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=F3B63190-B417-42B7-9CC8-0ED98F4FBB92"
        },
        "ingested_at": "2026-02-11T14:17:13.150915+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261014-HarryAng--5159061",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.536027",
        "source": "LSE_CHAT",
        "data": {
          "author": "HarryAngstrom",
          "content": "I meant PEAK SALES to Avacta... not TAM.",
          "sentiment": 0.0,
          "engagement": "9",
          "price_at_post": "52.50",
          "thread_title": "RE: Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-02-11T14:17:13.150933+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260955-D-Geeman--5139260",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.536554",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "'Today 09:44 Don't waste time responding if your handle is ........ D-Geeman ' You sound like a teenager with a statement like that B2HS2L. In this context that isn't a compliment.",
          "sentiment": 0.0,
          "engagement": "5,849",
          "price_at_post": "53.00",
          "thread_title": "RE: ADC 26",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=F3B63190-B417-42B7-9CC8-0ED98F4FBB92"
        },
        "ingested_at": "2026-02-11T14:17:13.150951+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260946-HarryAng-38788797",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.537041",
        "source": "LSE_CHAT",
        "data": {
          "author": "HarryAngstrom",
          "content": "This is a gigantic opportunity. TAM for Rhematoid Arthritis would be between $3.0 - $4.0 billion. And if they move into Fibrosis, the TAM there is between $7.0 - $10.0 billion. Once they prove they can deliver a toxin as potent as Exatecan using the FAP linker, using the same linker for milder anti-fibrotic or anti-inflammatory drugs is a low risk, high reward certainty.",
          "sentiment": 0.0,
          "engagement": "9",
          "price_at_post": "52.50",
          "thread_title": "RE: Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-02-11T14:17:13.150969+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260944-B2HS2L--3507798",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.537575",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "Don't waste time responding if your handle is wyndrum, Thornogson, Toukankahmoon or D-Geeman ********************************************************************************************************* Like my new header?  \ud83d\ude01\ud83d\ude09   I hope you create similar. In the event one company buys Avacta, all others will need to continue developing ADC's. They'll need to make improvements to compete as follows: 1 Reduce the time required to develop new drugs. 2 Improve the precision of targeting of warheads, so less drug is available systemically. 3 Improve the ease and speed of manufacturing 4 Find ways to reduce particle size 5 Find ways to deliver >1 drug at a time. Also - * Small molecule manufacturing and timeline/COGM (cost of goods manufactured) \"What that statement means and why that is important, is that the price tag for this drug (AVA6000), is one tenth of the price tag for an ADC drug. ADC's cost a lot of money in the clinic\"  CC 8.11.2024 I don't see why the statement isn't also true for AVA6103. ++++ A reminder from  Trinity Delta \u2013 Targeting the tumour microenvironment with pre|CISION - 18.11.2024 https://www.trinitydelta.org/research-notes/targeting-the-tumour-microenvironment-with-precision/ \"Avacta has so far FAP-enabled ten different warheads building up a database of multiple pre|CISION compounds that include c 40 capping groups (which alter the PK of the conjugate) and c 20   linkers (required for FAP cleavage with certain warheads and can be used to modify FAP affinity and activity). These have all been characterised through computational simulations to evaluate molecular binding and how they dock into the FAP structure. A key consideration is how close the warhead can get to the FAP cleavage sequence; this typically depends on the size of the molecule, and often defines whether a spacer group is required. Consideration is also given to how long the conjugate and the active warhead are likely to remain in the TME, and this informs whether PK alterations, achieved through an alternative capping group, are needed to either allow the sustained release of the warhead or to slow plasma clearance. Potential candidate molecules that meet the internal hurdle are also evaluated in vivo to investigate key PK parameters and cytotoxicity, with some selected for further characterisation in vitro and in vivo to establish preclinical efficacy and safety in a wide range of FAP tumour expression models with low serum FAP (including co-cultures of tumour cells and CAFs) to recapitulate the human TME.\" ++++ I'll bet there is more than ten warheads, forty capping groups and twenty linkers now!",
          "sentiment": 0.0,
          "engagement": "6,003",
          "price_at_post": "53.00",
          "thread_title": "RE: ADC 26",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=F3B63190-B417-42B7-9CC8-0ED98F4FBB92"
        },
        "ingested_at": "2026-02-11T14:17:13.150987+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260931-BuenaVis--1810785",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.537985",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Really does feel like adding Go Faster stripes at a horse fair.",
          "sentiment": 0.0,
          "engagement": "5,775",
          "price_at_post": "53.00",
          "thread_title": "RE: ADC 26",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=F3B63190-B417-42B7-9CC8-0ED98F4FBB92"
        },
        "ingested_at": "2026-02-11T14:17:13.151005+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260910-Yorkshir-84071741",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.538411",
        "source": "LSE_CHAT",
        "data": {
          "author": "Yorkshirepragma",
          "content": "CC refers to other applications \u2026Chronic Inflammation \u2018conversations\u2019 are interesting . One step at a time \u2026.",
          "sentiment": 0.0,
          "engagement": "1,804",
          "price_at_post": "53.00",
          "thread_title": "RE: Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-02-11T14:17:13.151028+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260845-Yorkshir--3759978",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.538852",
        "source": "LSE_CHAT",
        "data": {
          "author": "Yorkshirepragma",
          "content": "Fascinating similarity re Avactas current development processes. Tuesday 24th February 2026 The Next Generation of ADCs: Leveraging Novel Conjugation & Enhanced Antibody Engineering for the Future of Targeted Oncology Therapies 9:15 am Laying out the scope to differentiate ADC development through novel conjugation, antibody engineering, and target identification approaches to widen therapeutic index and bring patient benefit Incorporating in silico and AI tools to enhance the ADC discovery toolbox and deliver next-generation ADC engineering and design Highlighting future priorities for next-generation ADC development, including exploring the potential of radio conjugates",
          "sentiment": 0.0,
          "engagement": "1,804",
          "price_at_post": "53.00",
          "thread_title": "ADC 26",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=F3B63190-B417-42B7-9CC8-0ED98F4FBB92"
        },
        "ingested_at": "2026-02-11T14:17:13.151046+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260811-Agenda10--4785443",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.539272",
        "source": "LSE_CHAT",
        "data": {
          "author": "Agenda101",
          "content": "Cheers BV!",
          "sentiment": 0.0,
          "engagement": "72",
          "price_at_post": "53.00",
          "thread_title": "RE: Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-02-11T14:17:13.151070+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260754-cj62-29208632",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.539688",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "Who would be allowed access ?",
          "sentiment": 0.0,
          "engagement": "4,282",
          "price_at_post": "53.00",
          "thread_title": "Data Room",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=85F98FAE-01B2-48EC-B9D0-584FAD2B9731"
        },
        "ingested_at": "2026-02-11T14:17:13.151089+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260751-Thornogs--4710885",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.713580",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "This one and one after the close to comment on the top quality discussion and to check if we finished up or not.",
          "sentiment": 0.0,
          "engagement": "8,666",
          "price_at_post": "53.00",
          "thread_title": "2 post Friday.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=EDA1F112-F6D9-49A4-937D-081A93C2E757"
        },
        "ingested_at": "2026-02-11T14:17:13.151116+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260626-Gingethe--2062077",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.714067",
        "source": "LSE_CHAT",
        "data": {
          "author": "GingetheWinge",
          "content": "The FUDsters are thrashing like Terminator 2 in a smelting cauldron. It\u2019s working so let\u2019s continue to starve them of any engagement. As Runner-Runner wrote and BV reposted\u2026 It's simple. 1. DO NOT ENGAGE 2. DO NOT ASK IT A QUESTION 3. DO NOT ANSWER ITS QUESTIONS 4. DO NOT MOAN ABOUT ITS POSTS 5. DO NOT ARGUE WITH IT 6. If you must do something. Mock it with reference only to its stupidity and nothing else. ------------------------------------------------------ If you're not part of the solution, you're part of the problem",
          "sentiment": 0.5,
          "engagement": "700",
          "price_at_post": "53.00",
          "thread_title": "No not engage !",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=A348D8E1-4DC7-4D49-950E-08F79BC3A2D1"
        },
        "ingested_at": "2026-02-11T14:17:13.151134+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260138-BuenaVis--2908016",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.714500",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Even better link: https://www.youtube.com/watch?v=HWkh3OEFSds&t=1333s",
          "sentiment": 0.0,
          "engagement": "5,775",
          "price_at_post": "53.00",
          "thread_title": "RE: Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-02-11T14:17:13.151152+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260132-BuenaVis--5635489",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.714925",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "It's the Base to Base biotech podcast from a few days ago. Well worth a listen. Here's the link to the start of the CC interview: https://www.youtube.com/watch?v=HWkh3OEFSds&t=1290s",
          "sentiment": 0.0,
          "engagement": "5,775",
          "price_at_post": "53.00",
          "thread_title": "RE: Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-02-11T14:17:13.151170+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262331-D-Geeman--2884595",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.715361",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "Wasn\u2019t wyn comparing this BB to \u2018Lord of the Flies\u2019 classic story? Well for those who don\u2019t know the story I just caught a trailer for new BBC production starting soon; https://www.bbc.com/mediacentre/2026/lord-of-the-flies-trailer",
          "sentiment": 0.0,
          "engagement": "5,849",
          "price_at_post": "53.00",
          "thread_title": "RE: Avacta Therapeutics celebrates this",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=03B0B4A6-705E-45ED-983A-A89C321C0924"
        },
        "ingested_at": "2026-02-11T14:17:13.151188+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262302-alextak-74105829",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.715781",
        "source": "LSE_CHAT",
        "data": {
          "author": "alextak",
          "content": "Is it a new interview? .I'll listen to it tomorrow.",
          "sentiment": 0.0,
          "engagement": "540",
          "price_at_post": "53.00",
          "thread_title": "RE: Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-02-11T14:17:13.151211+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262258-alextak-23654812",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.716203",
        "source": "LSE_CHAT",
        "data": {
          "author": "alextak",
          "content": "Https://youtu.be/HWkh3OEFSds?si=0KezbLZbtRJA4N97",
          "sentiment": 0.0,
          "engagement": "540",
          "price_at_post": "53.00",
          "thread_title": "Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-02-11T14:17:13.151230+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262241-pedrolan-32454737",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.716624",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "When no-one engages that's what they end up with. Good work folks.",
          "sentiment": 0.5,
          "engagement": "1,975",
          "price_at_post": "53.00",
          "thread_title": "Voices in the wilderness",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=8AE5A358-4CCC-4E25-A8A9-D4C3BBC9FF5F"
        },
        "ingested_at": "2026-02-11T14:17:13.151248+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262222-Thornogs-20447806",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.717039",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Absolutely Pedro! All those who chance upon the LSE Avacta bulletin board and haven't been keeping up with the news, all of them? Exposure indeed, keep up the good work everybody!",
          "sentiment": 0.0,
          "engagement": "8,666",
          "price_at_post": "53.00",
          "thread_title": "RE: Avacta Therapeutics celebrates this",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=03B0B4A6-705E-45ED-983A-A89C321C0924"
        },
        "ingested_at": "2026-02-11T14:17:13.151266+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262202-pedrolan--5038992",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.717464",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "All great exposure. Thanks for posting \ud83d\udc4d\ud83c\udffb",
          "sentiment": 0.5,
          "engagement": "1,975",
          "price_at_post": "53.00",
          "thread_title": "RE: Avacta Therapeutics celebrates this",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=03B0B4A6-705E-45ED-983A-A89C321C0924"
        },
        "ingested_at": "2026-02-11T14:17:13.151284+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262145-Thornogs-43242774",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.717891",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Well there we have it Avcti, proof positive fof all those 'FUDsters' who have been saying otherwise all day! Avacta can produce FAP-EXD for the upcoming trial! What chance does 'FUD' have against this level of research and knowledge? Hang your heads in shame all those saying that it wasn't possible. Was anyone suggesting this?",
          "sentiment": 0.0,
          "engagement": "8,666",
          "price_at_post": "53.00",
          "thread_title": "RE: \" So excited to get the trial going soon. \"",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=C91568DF-F421-4695-901C-78161A0F4CD6"
        },
        "ingested_at": "2026-02-11T14:17:13.151301+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262110-avctIPma--5773811",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.718379",
        "source": "LSE_CHAT",
        "data": {
          "author": "avctIPmatters",
          "content": "FYI   Christina CoughlinChristina Coughlin \u2022 3rd+Verified \u2022 3rd+ Chief Executive Officer, AvactaChief Executive Officer, Avacta 53m \u2022  53 minutes ago \u2022 Visible to anyone on or off LinkedIn Follow We are thrilled to partner with our team at Curia - this partnership has enabled our team at hashtag#AVCT to move FAP-exatecan forward at record pace. So excited to get the trial going soon. This combined team reminds me of a favorite quote, \u201cNever doubt that a small group of thoughtful, committed citizens can change the world. Indeed, it is the only thing that ever has.\u201d \u2014Margaret Mead. hashtag#LetsDoThis hashtag#HopeWithoutCompromise CuriaCuria 104,425 followers104,425 followers 2h \u2022  2 hours ago \u2022 Visible to anyone on or off LinkedIn Follow Congratulations to Avacta Therapeutics on receiving U.S. Food and Drug Administration (FDA) clearance of the Investigational New Drug (IND) application for the Company\u2019s second program FAP-Exd (AVA6103). This peptide drug conjugate is based on the highly potent topoisomerase I inhibitor, exatecan. A Phase 1 clinical trial will enroll patients with solid tumors, pancreatic cancer, cervical cancer, gastric cancer and small cell lung cancer. CURIA STERILE DRUG PRODUCT business unit is proud to assist this cutting-edge oncology program with formulation development, analytical support and GMP clinical supply at our site in Glasgow. Read more about Avacta in the recent press release: https://hubs.li/Q040N2nz0",
          "sentiment": 0.0,
          "engagement": "728",
          "price_at_post": "53.00",
          "thread_title": "\" So excited to get the trial going soon. \"",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=C91568DF-F421-4695-901C-78161A0F4CD6"
        },
        "ingested_at": "2026-02-11T14:17:13.151319+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262104-wyndrum--5434909",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.718829",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "So you\u2019re right and I am wrong as you have said umpteen times  yet it is me who is the narcissist? You don\u2019t even know what the term means in detail yet bandi it about as a diagnosis of a stranger you know nothing about. Your arrogance in libelling me without any justification only amplifies my point. But in none of these umpteen times have you ever wondered why AVCT have failed to deliver the returns you expected when you first bought in ? No of course not. That would require self examination. Something you seem to lack but have no inhibition in accusing others of. The arrogance of the arguments directed at me are so cliched and bereft of any true accuracy that it is simply pathetic. What is so considerably worse is the recs they get. Not because it offends me more but rather of the evidence that so may can\u2019t reason for themselves and blithely agree. It\u2019s not a case of reading the room, more a case of group think. Under your reasoning we would all still think the earth was flat.",
          "sentiment": 0.0,
          "engagement": "12,228",
          "price_at_post": "53.00",
          "thread_title": "RE: Worldwide ADC Innovation & Collaboration   London",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=CB66756C-50A3-4D04-A499-ADC1B8951801"
        },
        "ingested_at": "2026-02-11T14:17:13.151337+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262104-Metatron--5617149",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.719249",
        "source": "LSE_CHAT",
        "data": {
          "author": "Metatron",
          "content": "Forgot.. dammit.. sawy \ud83e\udd14",
          "sentiment": 0.0,
          "engagement": "1,188",
          "price_at_post": "53.00",
          "thread_title": "RE: Worldwide ADC Innovation & Collaboration   London",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=CB66756C-50A3-4D04-A499-ADC1B8951801"
        },
        "ingested_at": "2026-02-11T14:17:13.151355+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262051-BuenaVis-51217124",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.719657",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Do not feed the troll. \ud83e\udd2a",
          "sentiment": 0.0,
          "engagement": "5,775",
          "price_at_post": "53.00",
          "thread_title": "RE: Worldwide ADC Innovation & Collaboration   London",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=CB66756C-50A3-4D04-A499-ADC1B8951801"
        },
        "ingested_at": "2026-02-11T14:17:13.151373+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262035-Metatron-46850957",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.720073",
        "source": "LSE_CHAT",
        "data": {
          "author": "Metatron",
          "content": "The problem is Wyndrone.. that you cannot read the room because you are a narcissist as I've explaind umpteen times. The recs are from other members who are just plain sick to death of you and your narcissistic droning behaviour.",
          "sentiment": 0.0,
          "engagement": "1,188",
          "price_at_post": "53.00",
          "thread_title": "RE: Worldwide ADC Innovation & Collaboration   London",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=CB66756C-50A3-4D04-A499-ADC1B8951801"
        },
        "ingested_at": "2026-02-11T14:17:13.151396+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262028-Metatron-49744899",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.720496",
        "source": "LSE_CHAT",
        "data": {
          "author": "Metatron",
          "content": "Looks like Thorndrone has repositioned itself as the ultimate purile commentator on the commentary? Looks more to me like the ultimate terd that just won't flush \ud83d\ude48\ud83d\udca9",
          "sentiment": 0.0,
          "engagement": "1,188",
          "price_at_post": "53.00",
          "thread_title": "RE: Avacta Therapeutics celebrates this",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=03B0B4A6-705E-45ED-983A-A89C321C0924"
        },
        "ingested_at": "2026-02-11T14:17:13.151415+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262028-wyndrum--1472636",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.720925",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "I think the problem is Chris is that while what you say is correct, it is the \u201canti-fudsters \u201c for want of a better expression, that quite deliberately push this debilitating and constant line at any opportunity. And like today, when nothing is going on, BV just stirs the pot. Yet every single time the cause of this futile exercise is laid at the door of the posters who are incessantly  attacked rather than the perpetrators . What\u2019s even more disturbing is the recs they get for doing it. This bb is simply one of the worst I have ever come across and we all contribute to that to some degree but it is the majority (when you look at the recs) here that revel in this disruptive behaviour and have little or no interest in resolving the situation for the better. Why can\u2019t I say after 5 years of a trial and a sp at near all time lows that maybe all is not what we were led to believe from the outset and can we look at what might be causing this without being asked to be ignored banned or wished an early death?",
          "sentiment": 0.0,
          "engagement": "12,228",
          "price_at_post": "53.00",
          "thread_title": "RE: Worldwide ADC Innovation & Collaboration   London",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=CB66756C-50A3-4D04-A499-ADC1B8951801"
        },
        "ingested_at": "2026-02-11T14:17:13.151439+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262015-stodgy88-88047217",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.721347",
        "source": "LSE_CHAT",
        "data": {
          "author": "stodgy88",
          "content": "LinkedIn.",
          "sentiment": 0.0,
          "engagement": "1,206",
          "price_at_post": "53.00",
          "thread_title": "RE: Avacta Therapeutics celebrates this",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=03B0B4A6-705E-45ED-983A-A89C321C0924"
        },
        "ingested_at": "2026-02-11T14:17:13.151457+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262014-stodgy88--6944492",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.721752",
        "source": "LSE_CHAT",
        "data": {
          "author": "stodgy88",
          "content": "This company as over  100,000 followers, so good exposure.",
          "sentiment": 0.0,
          "engagement": "1,206",
          "price_at_post": "53.00",
          "thread_title": "RE: Avacta Therapeutics celebrates this",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=03B0B4A6-705E-45ED-983A-A89C321C0924"
        },
        "ingested_at": "2026-02-11T14:17:13.151476+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262011-Thornogs--8499050",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.722182",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Quite Avcti, well done! Always good to be reminded of last week's RNS! In case any of ghd 'well infofmed' missed it eh?",
          "sentiment": 0.0,
          "engagement": "8,666",
          "price_at_post": "53.00",
          "thread_title": "RE: Avacta Therapeutics celebrates this",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=03B0B4A6-705E-45ED-983A-A89C321C0924"
        },
        "ingested_at": "2026-02-11T14:17:13.151493+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262010-HarChris-28981774",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.722603",
        "source": "LSE_CHAT",
        "data": {
          "author": "HarChris",
          "content": "There\u2019s a cycle of Thorn repeating the same points over and over again, the numerous posters who flood us with messages telling him to F off, begging others not to reply or to warn the bb of his dishonesty and then Wyn writing paragraphs of philosophy and psychology on the meaning of it all. That plays out at least four or five times a week! Almost identically. The odd post on Avacta gets a reply or two before the cycle kickstarts again. What a waste of time this BB is in quiet periods like this!",
          "sentiment": 0.0,
          "engagement": "15,870",
          "price_at_post": "53.00",
          "thread_title": "RE: Worldwide ADC Innovation & Collaboration   London",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=CB66756C-50A3-4D04-A499-ADC1B8951801"
        },
        "ingested_at": "2026-02-11T14:17:13.151511+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262004-avctIPma--1450100",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.723059",
        "source": "LSE_CHAT",
        "data": {
          "author": "avctIPmatters",
          "content": "Back to more worthwhile  conversation thanks Stonks -------------------------- Avacta Therapeutics celebrates this Curia 54m \u2022 Follow Congratulations to Avacta Therapeutics on receiving U.S. Food and Drug Administration (FDA) clearance of the Investigational New Drug (IND) application for the Company\u2019s second program FAP-Exd (AVA6103). This peptide drug conjugate is based on the highly potent topoisomerase I inhibitor, exatecan. A Phase 1 clinical trial will enroll patients with solid tumors, pancreatic cancer, cervical cancer, gastric cancer and small cell lung cancer. CURIA STERILE DRUG PRODUCT business unit is proud to assist this cutting-edge oncology program with formulation development, analytical support and GMP clinical supply at our site in Glasgow. Read more about Avacta in the recent press release: https://hubs.li/Q040N2nz0 \" Gmcc",
          "sentiment": 0.0,
          "engagement": "728",
          "price_at_post": "53.00",
          "thread_title": "Avacta Therapeutics celebrates this",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=03B0B4A6-705E-45ED-983A-A89C321C0924"
        },
        "ingested_at": "2026-02-11T14:17:13.151529+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261833-D-Geeman-13143580",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.723489",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "'and bucket to collect their donations for his roses.\u2019 'collect the dung & yes then spread the manure around the Roses' I understand that Watching does this too but with her Quality Street, not Roses.",
          "sentiment": 0.0,
          "engagement": "5,849",
          "price_at_post": "53.00",
          "thread_title": "RE: Worldwide ADC Innovation & Collaboration   London",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=CB66756C-50A3-4D04-A499-ADC1B8951801"
        },
        "ingested_at": "2026-02-11T14:17:13.151546+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261754-Thornogs-69614698",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.723915",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Now, now Wyn! Steady there. It's been decided that our constant 'FUD' detracts from thd ability of the 'well informed' posters to discuss Avzcta seriously. OK, so far it's just the usual nonsense but give thdm a chance I'm sure tomorrow they'll Smash It! Did we finish up by the way?",
          "sentiment": 0.0,
          "engagement": "8,666",
          "price_at_post": "53.00",
          "thread_title": "RE: Worldwide ADC Innovation & Collaboration   London",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=CB66756C-50A3-4D04-A499-ADC1B8951801"
        },
        "ingested_at": "2026-02-11T14:17:13.151570+00:00"
      },
      {
        "event_id": "SOCIAL-Today1236-Watching--3609003",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.595387",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "Let\u2019s have a day where know one engages with the Fudders A watch them argue with themselves \ud83d\ude0a",
          "sentiment": 0.0,
          "engagement": "9,213",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-02-11T14:17:13.151594+00:00"
      },
      {
        "event_id": "SOCIAL-Today1207-D-Geeman--9555673",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.595837",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "Evan Davis discussing mergers and acquisitions on Radio 4 right now.",
          "sentiment": 0.0,
          "engagement": "5,844",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-02-11T14:17:13.151611+00:00"
      },
      {
        "event_id": "SOCIAL-Today1050-D-Geeman--3387886",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.596300",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "Many of the most useful posts are green boxes to others. That's fine. I really don't care if **** doesn't read ****'s post as long as I can. Please, everyone who doesn't like ****'s posts filter and then the people who do read them can do so in peace.",
          "sentiment": 0.0,
          "engagement": "5,844",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-02-11T14:17:13.151629+00:00"
      },
      {
        "event_id": "SOCIAL-Today1034-Thornogs--8772370",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.596741",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Happy to sit on the sidelines to watch the emergence of all this deep research and intelligent discussion on the company's 'fundamentals'. Of course if it isn't accurate or realistic I presume there's the right to point this out? Otherwise it's just a meaningless Echo Chamber. Over to you, the self proclaimed 'well informed'. Let's see what quality posting looks like!",
          "sentiment": 0.0,
          "engagement": "8,655",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-02-11T14:17:13.151647+00:00"
      },
      {
        "event_id": "SOCIAL-Today1032-BuenaVis--1603412",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.597214",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "As Runner-Runner wrote... It's simple. 1. DO NOT ENGAGE 2. DO NOT ASK IT A QUESTION 3. DO NOT ANSWER ITS QUESTIONS 4. DO NOT MOAN ABOUT ITS POSTS 5. DO NOT ARGUE WITH IT 6. If you must do something. Mock it with reference only to its stupidity and nothing else. ------------------------------------------------------ If you're not part of the solution, you're part of the problem",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-02-11T14:17:13.151665+00:00"
      },
      {
        "event_id": "SOCIAL-Today1025-pedrolan--5490188",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.597761",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Ok, as one of the offenders ( I did it mainly to remind people of their/his agenda) I will pledge to now ignore them/him going forward. We really need everyone to do that though.",
          "sentiment": 0.5,
          "engagement": "1,972",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-02-11T14:17:13.151682+00:00"
      },
      {
        "event_id": "SOCIAL-Today1022-Aston15--7793942",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.598209",
        "source": "LSE_CHAT",
        "data": {
          "author": "Aston15",
          "content": "People do understand the only reason then come on here to spout sh*t is because others give them an audience? Its not difficult..  Green Box them and focus the chat on the company, not their trading agendas.",
          "sentiment": 0.0,
          "engagement": "61",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-02-11T14:17:13.151701+00:00"
      },
      {
        "event_id": "SOCIAL-Today1005-IFA90-89664687",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.598630",
        "source": "LSE_CHAT",
        "data": {
          "author": "IFA90",
          "content": "More posts than trades, never a good sign.",
          "sentiment": 0.0,
          "engagement": "408",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-02-11T14:17:13.151820+00:00"
      },
      {
        "event_id": "SOCIAL-Today0954-Aldebara--8531483",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.599061",
        "source": "LSE_CHAT",
        "data": {
          "author": "Aldebaran",
          "content": "Anyone engaging with them is part of the problem. I'll soon be adding them to my filter list if all the want to do is talk smack and try to score points against them. It's a waste of everyone's time, least not their own yet they persist. Sad. We could use this bb once again to discuss avacta but only if the engagement with FUDsters ends. Its nothing more than a digital playground otherwise. Filter. Them.",
          "sentiment": 0.0,
          "engagement": "3,894",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-02-11T14:17:13.151839+00:00"
      },
      {
        "event_id": "SOCIAL-Today0948-Watching--4034863",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.599520",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "Let\u2019s have a day where know one engages with the Fudders And watch them argue with there selves \ud83d\ude0a",
          "sentiment": 0.0,
          "engagement": "9,213",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-02-11T14:17:13.151857+00:00"
      },
      {
        "event_id": "SOCIAL-Today0932-Thornogs--1794183",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.599949",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "And on a day to day basis is there actually much new to talk about with Avacta? Tumbleweed City now until the next RNS, whatever that might be for.",
          "sentiment": 0.0,
          "engagement": "8,655",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-02-11T14:17:13.151875+00:00"
      },
      {
        "event_id": "SOCIAL-Today0924-wyndrum--6113888",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.600402",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "But Jane this was all caused by BV\u2019s non AVCT post. He deliberately provokes with his insults and lies. Non of this would have happened today without his non AVCT related post. Remember that would you",
          "sentiment": 0.0,
          "engagement": "12,217",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-02-11T14:17:13.151900+00:00"
      },
      {
        "event_id": "SOCIAL-Today0918-Watching-45821084",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.601027",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "Let\u2019s have a day where know one engages with the Fudders And watch them argue with themselves \ud83d\ude2c",
          "sentiment": 0.0,
          "engagement": "9,213",
          "price_at_post": "54.00",
          "thread_title": "Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-02-11T14:17:13.151918+00:00"
      },
      {
        "event_id": "SOCIAL-Today0917-pedrolan--4909048",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.601613",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "A seamless switch between users there Eggy Bravo",
          "sentiment": 0.0,
          "engagement": "1,972",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T14:17:13.151935+00:00"
      },
      {
        "event_id": "SOCIAL-Today0916-Thornogs-86196546",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.602292",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "To be fair Live account it's very easy to judge someone who repeatedly posts nonsense like you just have. And Pedro and BV joining in the: 'Look at us, we're idiots' gang.",
          "sentiment": 0.0,
          "engagement": "8,655",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T14:17:13.151953+00:00"
      },
      {
        "event_id": "SOCIAL-Today0902-wyndrum-65992914",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.603136",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "Sadly you have the memory of a goldfish but not its intellect. Again bv starts and contributes to the disruption. All we wait for now is the \u201cooh I can see all these green boxes\u201dposts add up my posts and add up all the rest and you quickly see who the paid disrupters are",
          "sentiment": 0.0,
          "engagement": "12,217",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T14:17:13.151971+00:00"
      },
      {
        "event_id": "SOCIAL-Today0859-BuenaVis-76479060",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.603939",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "\ud83e\udd14 Today's 'wyndrum' sounds even more petty and whiny than the 'Thornogson' account.",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T14:17:13.151989+00:00"
      },
      {
        "event_id": "SOCIAL-Today0858-pedrolan-91610866",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.604745",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "BV - he is doing it to fool us into thinking it is not one account. I nearly fell for it because I have the memory of a goldfish.",
          "sentiment": 0.5,
          "engagement": "1,972",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T14:17:13.152006+00:00"
      },
      {
        "event_id": "SOCIAL-Today0853-wyndrum-42617837",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.605571",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "It\u2019s snowing pretty hard here so it\u2019s not really the smoking gun you claim is it? Plus the fact you think I have multiple accounts only reinforces your mistaken analysis. (And see how many posts have been generated by bv These are the cause of the disruption. Not the posters who try to discuss the disconnect between AVCT results and the sp over the last 5 years",
          "sentiment": 0.0,
          "engagement": "12,217",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T14:17:13.152024+00:00"
      },
      {
        "event_id": "SOCIAL-Today0850-BuenaVis-47497404",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.606369",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Why is Thornogson/NDN/Eggy using the wyndrum account today?",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T14:17:13.152042+00:00"
      },
      {
        "event_id": "SOCIAL-Today0847-Livedata-38149461",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.607182",
        "source": "LSE_CHAT",
        "data": {
          "author": "Livedataaccount",
          "content": "With respect wyndrum its difficult not to judge someone who pretends to go on holiday and occasionally logs on with another alias replying to himself",
          "sentiment": 0.0,
          "engagement": "2,956",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T14:17:13.152064+00:00"
      },
      {
        "event_id": "SOCIAL-Today0835-BuenaVis--8253553",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.607959",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Wyn Shakespeare has swallowed a whole bag of question marks.",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T14:17:13.152083+00:00"
      },
      {
        "event_id": "SOCIAL-Today0831-pedrolan-29634916",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.608744",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Keep it up BV - people do need reminding. I see user Wyn Shakespeare is on the early shift.",
          "sentiment": 0.5,
          "engagement": "1,972",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T14:17:13.152109+00:00"
      },
      {
        "event_id": "SOCIAL-Today0826-wyndrum-32414429",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.609574",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "Thanks for reminding us dad, it must only be the 20th time you have posted this. Still at least your post s don\u2019t disrupt the board It\u2019s a great service you do, giving up your time to treat everyone here like morons by constantly reposting. Is it your new rule now that you must be shareholder to post and also be a genuine one at that? How do you intend to police your rules? Or is it just petty personal vendetta you are boring us all with?",
          "sentiment": 0.0,
          "engagement": "12,217",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T14:17:13.152134+00:00"
      },
      {
        "event_id": "SOCIAL-Today0750-BuenaVis--8052450",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.610363",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Just a reminder that Thornogson/NDN/Eggy isn't invested and is only here to argue, disrupt and try to waste our time.",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T14:17:13.152161+00:00"
      },
      {
        "event_id": "SOCIAL-Today0746-BuenaVis--7059878",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.904033",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Say what you see \ud83c\udf77\ud83c\udf77\ud83c\udf77",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "54.00",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-02-11T14:17:13.152179+00:00"
      },
      {
        "event_id": "SOCIAL-Today0733-Unbreade--4926834",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.904514",
        "source": "LSE_CHAT",
        "data": {
          "author": "Unbreaded",
          "content": "I love green boxes in the morning! Time for a coffee and catch up on the news.",
          "sentiment": 0.0,
          "engagement": "22",
          "price_at_post": "54.00",
          "thread_title": "Green Boes",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=F7E09828-40CF-45D7-8337-5F0A79C87685"
        },
        "ingested_at": "2026-02-11T14:17:13.152197+00:00"
      },
      {
        "event_id": "SOCIAL-Today0035-Thornogs--3601487",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.904967",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Sujood & Icecool. Similar content but I think ICE probably ahead on presentation. Both deeply underwater but talking a good game. Of course the SP matters, the only data that might be maturing is SGC 1b, which might secure a small deal. We've been told nothing about TNBC and STS is written off. We wait for FAP-EXD, we start again.",
          "sentiment": 0.0,
          "engagement": "8,655",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T14:17:13.152215+00:00"
      },
      {
        "event_id": "SOCIAL-Today0005-Toukanka--4516945",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.905422",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "Pivotal news in the Summer. Where have I heard that before? Oh yeah, it was me and I duly got panned by the Pom Pom girls for suggesting it would take thst long. \ud83e\udd23\ud83e\udd23\ud83e\udd23",
          "sentiment": 0.0,
          "engagement": "4,451",
          "price_at_post": "54.00",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-02-11T14:17:13.152233+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262359-Toukanka-35127795",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.905891",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "Work for ever????",
          "sentiment": 0.0,
          "engagement": "4,451",
          "price_at_post": "54.00",
          "thread_title": "RE: This will haunt you or please you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=8AE0FBBC-C14D-49F3-85C3-E6BED1BD66ED"
        },
        "ingested_at": "2026-02-11T14:17:13.152251+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262324-IFA90-71143053",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.906405",
        "source": "LSE_CHAT",
        "data": {
          "author": "IFA90",
          "content": "Thanks Andy",
          "sentiment": 0.0,
          "engagement": "408",
          "price_at_post": "54.00",
          "thread_title": "RE: This will haunt you or please you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=8AE0FBBC-C14D-49F3-85C3-E6BED1BD66ED"
        },
        "ingested_at": "2026-02-11T14:17:13.152274+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262322-BuenaVis--5721090",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.906824",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Thanks Thompi",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T14:17:13.152293+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262302-Sujood--5821193",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.907374",
        "source": "LSE_CHAT",
        "data": {
          "author": "Sujood",
          "content": "A multi billion dollar company in the making. It will haunt you if you dont position yourself Will please you, if you do the write thing. Learn about the company and do what you know is the right move to make. Nobody every wants to work forever. Keep this message We will talk again soon.",
          "sentiment": 0.5,
          "engagement": "1,260",
          "price_at_post": "54.00",
          "thread_title": "This will haunt you or please you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=8AE0FBBC-C14D-49F3-85C3-E6BED1BD66ED"
        },
        "ingested_at": "2026-02-11T14:17:13.152311+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262258-Icecool-86882927",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.907813",
        "source": "LSE_CHAT",
        "data": {
          "author": "Icecool",
          "content": "Commercial deals will come, and they\u2019ll be welcomed when they do. I\u2019m not in a rush though. If the data continues to strengthen and Avacta can leverage that science into materially better terms, I\u2019m perfectly happy for it to take longer. Time spent increasing leverage isn\u2019t wasted time, it\u2019s how you avoid bad deals and maximise value. \ud83d\ude0a Waiting could be the difference between a few billion and tens of billions. \ud83d\ude0a\ud83e\udd14",
          "sentiment": 0.0,
          "engagement": "8,824",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T14:17:13.152329+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262250-Thompi-13801484",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.908255",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thompi",
          "content": "You may find BV this tweet on X interesting on AVA6103 and BOIN design. AND https://x.com/sandyradders/status/2012950578595258664?s=61&t=BBb2UcjLDTXOFIzJM-vM6A",
          "sentiment": 0.0,
          "engagement": "1,357",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T14:17:13.152348+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262144-Knotagai--4582455",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.908887",
        "source": "LSE_CHAT",
        "data": {
          "author": "Knotagain",
          "content": "We're all fixated on the SP Icecool, it's just a matter of time frames. I've been invested for over five years and would love to see  some commercial news. Nothing wrong with that.",
          "sentiment": 0.0,
          "engagement": "451",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T14:17:13.152366+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262118-Icecool--8454028",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.909330",
        "source": "LSE_CHAT",
        "data": {
          "author": "Icecool",
          "content": "That\u2019s only a concern if you\u2019re fixated on the SP. AIM has never been able to price Avacta properly and it won\u2019t until there\u2019s either a takeover (and suspension) or a move to a serious exchange. The day to day price action is noise. What actually matters is what\u2019s happening behind the scenes with the science, the data, and the strategic discussions. That\u2019s where the real value is being built. \ud83d\udcaf\ud83d\udc4d",
          "sentiment": 0.0,
          "engagement": "8,824",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T14:17:13.152383+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262058-Knotagai-59793754",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.909883",
        "source": "LSE_CHAT",
        "data": {
          "author": "Knotagain",
          "content": "Totally agree Icecool, but only third party validation will move the share price. Hopefully it will happen sometime soon.",
          "sentiment": 0.0,
          "engagement": "451",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T14:17:13.152401+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262032-Icecool--1268974",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.910560",
        "source": "LSE_CHAT",
        "data": {
          "author": "Icecool",
          "content": "The FDA won\u2019t drag this out. AVA6000 proved the platform in humans, AVA6103 builds on that. Phase 1 is about safety and speed. This trial is designed to surface signals quickly with regulatory alignment, not waste years. AVA6000 data will have done a load of heavy lifting already.",
          "sentiment": 0.0,
          "engagement": "8,824",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T14:17:13.152419+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261954-BuenaVis--9825186",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.910984",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "I've got to say I was concerned that the AVA6103 trial with such a toxic agent as exatecan would start at a very low dose and take a long, long time if the step increases were to mimic those in the AVA6000 trial (seven dose levels! - three steps of 40 from 80 to 200, and then three 25% increases to 385) so very pleased to hear about all the benefits of the BOIN design.",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T14:17:13.152437+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261946-Icecool-21387265",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.911503",
        "source": "LSE_CHAT",
        "data": {
          "author": "Icecool",
          "content": "I would also point out that when Thorn bought in he\u2019s also a mega ramping twat!!! Flip/Flop. \ud83d\udcaf\ud83e\udd23\ud83e\udd23 best on filter \ud83d\udc4d",
          "sentiment": 0.0,
          "engagement": "8,824",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T14:17:13.152461+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261937-HarChris-86316577",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.912044",
        "source": "LSE_CHAT",
        "data": {
          "author": "HarChris",
          "content": "Going back to the trial design I thought this overview could be useful: Key Comparisons Accuracy in MTD Selection: BOIN generally outperforms 3+3 by more accurately identifying the true MTD. In simulations across various scenarios BOIN achieves a 12-16% higher percentage of correct selection (PCS) of the MTD, and in cases where the MTD is at higher doses, it can nearly triple the PCS compared to 3+3. Efficiency and Patient Allocation: BOIN is more efficient, often resulting in shorter trial durations and lower costs by adapting in real-time and allocating more patients to the MTD (especially at higher doses or with higher target DLT rates). The 3+3 design can prolong trials due to its conservative escalation and fixed cohort requirements, leading to fewer patients treated at effective doses. Safety and Risk Management: While 3+3 minimizes overdose risk by being overly cautious (e.g., lower chance of assigning >60% of patients above the MTD), it increases under-dosing, where many patients receive suboptimal doses. BOIN balances this better with built-in overdose controls and dynamic adjustments, reducing under-dosing without significantly raising overdose risks, thus improving ethical standards by minimising patient exposure to ineffective or overly toxic doses. Simplicity and Flexibility: Both are relatively easy to implement\u2014BOIN requires no complex programming or simulations beyond basic setup, making it accessible like 3+3. However, BOIN offers more flexibility, such as variable cohort sizes (e.g., 4 patients) and adjustable target toxicity rates, whereas 3+3 is fixed to cohorts of 3 (or 3+3) and standard targets. In summary, BOIN represents an evolution over 3+3, providing better performance across most metrics while maintaining ease of use. The 3+3 design is still widely used for its familiarity and safety focus in conservative settings but is increasingly seen as outdated for not fully utilising trial data.",
          "sentiment": 0.0,
          "engagement": "15,865",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T14:17:13.152479+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261812-Cashless--5262080",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.912567",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cashless",
          "content": "Been out all day, so just logged on.....and what a pleasure to see a sea of green and pretty much all informative posts...I LOVE GREEN...not sure the green people are so happy though \ud83d\udc4d\ud83e\udd2a\ud83e\udd2a\ud83e\udd73",
          "sentiment": 0.5,
          "engagement": "401",
          "price_at_post": "54.00",
          "thread_title": "Bliss",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E431AF8E-57C8-40B5-91C6-8D284968B368"
        },
        "ingested_at": "2026-02-11T14:17:13.152497+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261753-B2HS2L--9279866",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.913172",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "FWIW Google search What is the difference between event free and progression free survival AI Overview: Progression-Free Survival (PFS) measures the time from treatment initiation until objective tumor growth or death from any cause. Event-Free Survival (EFS) measures the time from randomization until a broader range of \"events,\" including disease progression, treatment failure, complications, or death. PFS focuses on tumor growth; EFS focuses on any negative outcome. Key Differences: Definition of Event: PFS is restricted to disease progression or death. EFS includes those, plus failure to proceed to planned surgery, relapse, or severe treatment complications. Context of Use: PFS is commonly used in advanced or metastatic cancer trials to evaluate treatment efficacy. EFS is frequently used in earlier-stage cancer trials, particularly in the neoadjuvant (pre-surgery) setting. Precision: PFS depends on the frequency of imaging scans to detect growth, while EFS is often defined by the time until a patient cannot proceed with their treatment plan. Essentially, PFS means the cancer has not worsened, whereas EFS means the patient has not experienced any negative, pre-defined event.",
          "sentiment": 0.0,
          "engagement": "6,000",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T14:17:13.152515+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261428-BuenaVis-73030553",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.913661",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "What is the current best progression free survival rate for TNBC? https://www.google.com/search?q=What+is+the+current+best+progression+free+survival+rate+for+TNBC%253F",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T14:17:13.152533+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261424-HarChris-59453105",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.914093",
        "source": "LSE_CHAT",
        "data": {
          "author": "HarChris",
          "content": "It's what happened to STS and might now happen with TNBC, might not of course, but if it did then it'll all fall to SGC to carry the load until FAP-EXD starts to produce meaningful data. __________________ In other words IF TNBC data doesn't deliver then SGC might have to carry the load until H2 2026? That's not bad as a worst case and it's very short term as it gets for biotech. And with the less risk averse and far more efficient BOIN design for 6103 we should start receiving compelling data rapidly if all is going well. It's close!",
          "sentiment": 0.0,
          "engagement": "15,865",
          "price_at_post": "54.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T14:17:13.152551+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261411-Thornogs--4898151",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.914533",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "No well spotted!  My bad.",
          "sentiment": 0.0,
          "engagement": "8,655",
          "price_at_post": "54.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T14:17:13.152568+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261409-BuenaVis--4406665",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.915065",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "I may be missing something here but trastuzumab deruxtecan (brand name Enhertu) and pertuzumab are both used to treat HER2-positive breast cancer.  So what has that got to do with TNBC which is an aggressive, fast-growing type of breast cancer that tests negative for three key receptors: estrogen (ER), progesterone (PR), and HER2?",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "54.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T14:17:13.152586+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261349-Thornogs-25102981",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.915517",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "'....FAP-DOX needs to beat.'",
          "sentiment": 0.0,
          "engagement": "8,655",
          "price_at_post": "54.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T14:17:13.152603+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261347-Thornogs-86063768",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.915945",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "But clearly relevent so clearly won't be mentioned by anyone else Watching? Obviously important if it's doubled the PFS times for TNBC, the bar has been raised as to what FAP-EXD needs to beat. It's what happened to STS and might now happen with TNBC, might not of course, but if it did then it'll all fall to SGC to carry the load until FAP-EXD starts to produce meaningful data.",
          "sentiment": 0.0,
          "engagement": "8,655",
          "price_at_post": "54.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T14:17:13.152626+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261347-pedrolan--8304320",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.837882",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Just a reminder that Thorn is not invested but spends his sad life on here posting negative comments about a company saving lives. What a guy!!!",
          "sentiment": 0.5,
          "engagement": "1,972",
          "price_at_post": "54.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T14:17:13.152650+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261339-Watching-14998542",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.838382",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "You Still have to focus on negatives. Thorny you are such a k n o bby \ud83e\udd21\ud83e\udd21",
          "sentiment": 0.0,
          "engagement": "9,213",
          "price_at_post": "54.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T14:17:13.152674+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261335-Thornogs-71168410",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.838824",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "It's perhaps double edged though? The AVA6000 STS trial was (allegedly) de-railed by a trial that showed longer, and better than expected, survival data. If there's a new 'Standard of Care' being announced for TNBC the bar might just have been raised on what FAP-DOX/TNBC needs to achieve to get a deal and get to market?",
          "sentiment": 0.0,
          "engagement": "8,655",
          "price_at_post": "55.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T14:17:13.152692+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261315-LovableL--3050757",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.839268",
        "source": "LSE_CHAT",
        "data": {
          "author": "LovableLumax",
          "content": "Https://x.com/onclive/status/2016451178872061994?s=46",
          "sentiment": 0.0,
          "engagement": "2,703",
          "price_at_post": "55.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T14:17:13.152710+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261053-Aldebara-71810612",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.839705",
        "source": "LSE_CHAT",
        "data": {
          "author": "Aldebaran",
          "content": "I think small caps are at the very start of a major bull run. Green portfolio everywhere across the board. Also note that even with hard times, avacta raised 16m through zeus at only 8% discount plus managed to delay and renegotiate the terms of the bond. No mean feat that and the macro picture for small caps has improved since then. As has our IP and data package plus the deadline for BP patent expiry has only become closer. Things nowhere near as desperate as this shhhhh it tee little market gives credit for. I mean avacta have developed the worlds first dual warhead peptide drug conjugate ffs . \ud83d\ude05",
          "sentiment": 0.0,
          "engagement": "3,894",
          "price_at_post": "55.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T14:17:13.152728+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261050-opti_mys--4252617",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.840239",
        "source": "LSE_CHAT",
        "data": {
          "author": "opti_mystic",
          "content": "I think that's optimistic Lovable being as the initial doses will be very low. It is a safety trial initially remember, but the trial design (BOIN) will allow for dose escalation quite quickly and also potentially skipping from say dose level one to does level 3. I think more realistically summer months we may start to see some useful efficacy. What they will know sooner is are there any problems/does it works as expected and designed. If no bad news by May/June I think we're on a winner. I expect it to work.",
          "sentiment": 0.0,
          "engagement": "296",
          "price_at_post": "55.50",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-02-11T14:17:13.152746+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261045-Sisyphus--2890518",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.840667",
        "source": "LSE_CHAT",
        "data": {
          "author": "SisyphusShorter",
          "content": "Out of coincidence it's been exactly a week since the last RNS regarding AVA6103. Could an announcement be due imminently?",
          "sentiment": 0.0,
          "engagement": "4",
          "price_at_post": "55.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T14:17:13.152764+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261014-HarChris--5765579",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.841093",
        "source": "LSE_CHAT",
        "data": {
          "author": "HarChris",
          "content": "I wonder if those solely focused on Avacta and thinking history always repeats are missing the fact that the AIM backdrop plays a major role here. And in that regard liquidity has returned to UK small caps with a vengeance, raises are happening without the sort of discounts seen in 2022/23/24/25, companies are seeing major share price appreciation actually hold rather than the wild swings of post Covid. It\u2019s a far healthier backdrop right now than at any point since I\u2019ve held Avacta shares.",
          "sentiment": 0.0,
          "engagement": "15,865",
          "price_at_post": "55.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T14:17:13.152782+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261003-harryhot--4002911",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.841536",
        "source": "LSE_CHAT",
        "data": {
          "author": "harryhotspur1311",
          "content": "I was hoping for the big erection shape although roundish bottoms are quite welcome as well!",
          "sentiment": 0.0,
          "engagement": "12",
          "price_at_post": "55.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T14:17:13.152799+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260958-A1invest-14138153",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.841950",
        "source": "LSE_CHAT",
        "data": {
          "author": "A1invest",
          "content": "Lets hope its a \"rounding bottom\" shape.  :)",
          "sentiment": 0.0,
          "engagement": "143",
          "price_at_post": "55.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T14:17:13.152822+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260953-pedrolan-78675128",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.842525",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Salty for sure",
          "sentiment": 0.0,
          "engagement": "1,972",
          "price_at_post": "55.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T14:17:13.152841+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260945-Thornogs--4316812",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.843025",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "\"Salt and vinegar on that sir?\"",
          "sentiment": 0.0,
          "engagement": "8,655",
          "price_at_post": "55.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T14:17:13.152859+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260944-Timster-36220048",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.843502",
        "source": "LSE_CHAT",
        "data": {
          "author": "Timster",
          "content": "Big fish, little fish, cardboard box....",
          "sentiment": 0.0,
          "engagement": "20,625",
          "price_at_post": "55.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T14:17:13.152877+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260941-harryhot-19987151",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.844130",
        "source": "LSE_CHAT",
        "data": {
          "author": "harryhotspur1311",
          "content": "Whenever the SP drops, the pessimists always quote \u2018the market knows\u2019 Perhaps this could work the other way around occasionally! Today, perhaps!",
          "sentiment": 0.0,
          "engagement": "12",
          "price_at_post": "56.00",
          "thread_title": "Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T14:17:13.152895+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260823-pedrolan-25352816",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.844561",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Ah yes, I knew I had been there but couldn't remember exactly which Lake \ud83e\udd23",
          "sentiment": 0.5,
          "engagement": "1,972",
          "price_at_post": "52.50",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-02-11T14:17:13.152913+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260726-Gingethe-72789632",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.844978",
        "source": "LSE_CHAT",
        "data": {
          "author": "GingetheWinge",
          "content": "Derwent valley dam in the Peak District.",
          "sentiment": 0.5,
          "engagement": "699",
          "price_at_post": "53.00",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-02-11T14:17:13.152930+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260713-LovableL--4823584",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.845409",
        "source": "LSE_CHAT",
        "data": {
          "author": "LovableLumax",
          "content": "I also suspect we will have a 6000 partner signed up once we have an approved accelerated pathway and registrations P2\\3 with FDA which is hopefully imminent",
          "sentiment": 0.0,
          "engagement": "2,703",
          "price_at_post": "53.00",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-02-11T14:17:13.152948+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260703-LovableL-51921029",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.845829",
        "source": "LSE_CHAT",
        "data": {
          "author": "LovableLumax",
          "content": "Given how potent the payload is and with the improved half-life and active in the TME for 5 days surely they'll see results as early as scan 1. That sounds rampy and too optimistic but look at the preclinical results. Things could really take off as early as the summer, or even before. Again, I suspect recruitment will be fairly rapid given FAP targeting with preCISION proven and preclinical results so investigators likely chomping at the bit.",
          "sentiment": 0.0,
          "engagement": "2,703",
          "price_at_post": "53.00",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-02-11T14:17:13.152966+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260659-nurseste-12049974",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.846277",
        "source": "LSE_CHAT",
        "data": {
          "author": "nursesteve",
          "content": "CC discussing FAP-Exd (AVA6103) - The profile of this second pre|CISION medicine in the preclinical setting is tremendous.  The sustained release mechanism developed by Avacta scientists results in a robust concentration of active drug in the tumor over five days with the disappearance from the bloodstream in only two hours. This is the exact profile needed to achieve better efficacy with this highly potent topo I inhibitor. Could payoff for LTH be this year?",
          "sentiment": 0.0,
          "engagement": "1,164",
          "price_at_post": "53.00",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-02-11T14:17:13.152984+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260006-D-Geeman-56005172",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.846690",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "An elderly character actor in our road, when I first arrived,  was in the movie \u2018The Dambusters\u2019, and in \u2018Bridge on the River Kwai\u2019. He used to tell some good stories of life on 1950\u2019s film sets. Dead for a while but he pops up on screen even now.",
          "sentiment": 0.0,
          "engagement": "5,844",
          "price_at_post": "52.50",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-02-11T14:17:13.153007+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20262319-pedrolan--5670694",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.847122",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Yes, it's an inspirational story. I think they tested it up in the Lake District",
          "sentiment": 0.5,
          "engagement": "1,972",
          "price_at_post": "52.50",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-02-11T14:17:13.153026+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20262113-Captains--5075450",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.847541",
        "source": "LSE_CHAT",
        "data": {
          "author": "Captainstanley.",
          "content": "I can't find that information anywhere Which Friday? Presumably you mean this week 29th Jan?",
          "sentiment": 0.0,
          "engagement": "467",
          "price_at_post": "52.50",
          "thread_title": "RE: SGC",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=5E3142A3-349A-43A2-B5B7-02836561174A"
        },
        "ingested_at": "2026-02-11T14:17:13.153044+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20262014-Flippine-19419897",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.847977",
        "source": "LSE_CHAT",
        "data": {
          "author": "Flippineck",
          "content": "I\u2019ve been thinking about the trials and tribulations of developing new inventions and ended up swotting up on Barnes Wallace, the inventor of the famous Bouncing Bomb. It seems initial proposals were dismissed by Bomber Command as being \u201c a mad-cap scheme\u201d. There were several critical failures in the development which had to be overcome. The shape of the bomb had to be changed, backspin had to be introduced, the weapon would shatter, sink or detonate prematurely or veer off course. Barnes Wallace persevered and it all came good in the end.",
          "sentiment": 0.0,
          "engagement": "417",
          "price_at_post": "52.50",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-02-11T14:17:13.153067+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261912-BuenaVis-81858188",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.848415",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Christina Coughlin became the CEO of Avacta on 1 May 2024. There is no need to dwell on anything or anyone before that date. CC has set out the company's objectives and timelines and has stuck to them, as much as is possible taking outside decision-making and events into account.  This adherence to the company's aims and plans comes about because she is a pharma executive with ample of experience of drug development and the way the FDA works.",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "52.50",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-02-11T14:17:13.153086+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261900-BuenaVis--1603412",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.848907",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "As Runner-Runner wrote... It's simple. 1. DO NOT ENGAGE 2. DO NOT ASK IT A QUESTION 3. DO NOT ANSWER ITS QUESTIONS 4. DO NOT MOAN ABOUT ITS POSTS 5. DO NOT ARGUE WITH IT 6. If you must do something. Mock it with reference only to its stupidity and nothing else. ------------------------------------------------------ If you're not part of the solution, you're part of the problem",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "52.50",
          "thread_title": "RE: Year end trading update :",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=CCFE6866-0D3C-4A1E-9659-9B2E552262F5"
        },
        "ingested_at": "2026-02-11T14:17:13.153112+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20262219-Thornogs--7759358",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.801399",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Anything new there? 'Expected' Q1? No, nothing new, just 'same old'.",
          "sentiment": 0.0,
          "engagement": "8,596",
          "price_at_post": "54.50",
          "thread_title": "RE: Bioconjugate Insights",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0DCD83D9-A17D-43E1-842E-1C922D520A76"
        },
        "ingested_at": "2026-02-11T14:17:13.153136+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20262212-avctIPma-42310184",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.801859",
        "source": "LSE_CHAT",
        "data": {
          "author": "avctIPmatters",
          "content": "Again courtesy of Stonks -  Finds  new coverage  Avacta related   many thanks . https://cdn.insights.bio/uploads/attachments/BCI%20Industry%20Insights.pdfAvacta Therapeutics reported new preclinical pharmacology data for FAP-Exd peptide drug conjugate [25] \"Avacta Therapeutics announced new preclinical pharmacology data for FAP-Exd (AVA6103), its second asset derived from the pre|CISION\u00ae tumor-activated delivery platform, which is expected to enter Phase 1 testing in Q1 2026. FAP-Exd is a fibroblast activation protein\u2013cleavable peptide-drug linking a proprietary peptide to a topoisomerase I inhibitor payload. The data demonstrated tumor-specific cytotoxicity, sustained intratumoral release of active exatecan with limited systemic exposure, and robust antitumor activity across multiple patient-derived xenograft models. Avacta also reported that artificial intelligence\u2013guided analysis was used to prioritize clinical indications based on co-expression of FAP and SLFN11.\" Gmcc",
          "sentiment": 0.0,
          "engagement": "720",
          "price_at_post": "54.50",
          "thread_title": "Bioconjugate Insights",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0DCD83D9-A17D-43E1-842E-1C922D520A76"
        },
        "ingested_at": "2026-02-11T14:17:13.153154+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20262210-Thornogs--5552331",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.802303",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Avacta does its thing regardless of what's posted here. Get over yourselves, self appointed \"Guardian's of the truth\"! And if you must wear your underpants on the outside do at least please ensure that  they're better laundered?",
          "sentiment": 0.0,
          "engagement": "8,596",
          "price_at_post": "54.50",
          "thread_title": "The reality?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=D8CC0643-0047-4DA0-A21A-3E0ECC3BD17C"
        },
        "ingested_at": "2026-02-11T14:17:13.153172+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20262154-BuenaVis--5934322",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.802718",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "I had Firefox nicely set up with AdBlock so that all ads were wiped out but had to 'repair' Firefox today (as tabs were crashing) and then reload an AdBlock extension but I now keep getting these annoying messages from LSE about ads that I never used to get.  Can't remember what I did before to permanently remove those messages.  Can anyone offer advice on how they've solved this?",
          "sentiment": 0.0,
          "engagement": "5,722",
          "price_at_post": "54.50",
          "thread_title": "Off-topic - removing ads on Firefox",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=9BE707F4-9555-444A-A3C8-1254E00A3443"
        },
        "ingested_at": "2026-02-11T14:17:13.153190+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20262109-Knotagai--3187019",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.803142",
        "source": "LSE_CHAT",
        "data": {
          "author": "Knotagain",
          "content": "All day every day...",
          "sentiment": 0.0,
          "engagement": "448",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-02-11T14:17:13.153213+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261944-Agenda10-79388776",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.803559",
        "source": "LSE_CHAT",
        "data": {
          "author": "Agenda101",
          "content": "Brilliant! The never ending Twats.. they are all green boxed here\u2026 But I\u2019m hearing you Sheepy! Exactly right.",
          "sentiment": 0.0,
          "engagement": "55",
          "price_at_post": "54.50",
          "thread_title": "RE: Frankly pathetic",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B36E2695-D07A-4E60-838B-02C995994856"
        },
        "ingested_at": "2026-02-11T14:17:13.153231+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261943-BuenaVis-41151265",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.803971",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Lighten up Thompi.  It's the best comedy show in town.",
          "sentiment": 0.0,
          "engagement": "5,722",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-02-11T14:17:13.153249+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261940-Thompi--6767215",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.804413",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thompi",
          "content": "Because, Touk, Thorn talks total twaddle and inundates this board with spam. It\u2019s made the board virtually unreadable. Even blocking him doesn\u2019t really help, because all I then see are green boxes and other people replying to his posts. I probably add to the noise at times too - but I\u2019ve genuinely had enough of one person commandeering the board with the same malicious rubbish, day after day. Post after post after post. It wears people down. It stops being discussion and just becomes disruption.",
          "sentiment": 0.0,
          "engagement": "1,355",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-02-11T14:17:13.153267+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261848-Toukanka-72413469",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.804832",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "Cj62 How can it be utter garbage when it\u2019s generally been predicting what is happening to Avacta. But the pond poms utter garbage of \u201ctakeover tomorrow \u201c, \u201cmarket thick as mince\u201d etc etc ad infinitum even though they\u2019ve been entirely wrong for years. Well that\u2019s fine clogging up the board with that garbage",
          "sentiment": 0.0,
          "engagement": "4,436",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-02-11T14:17:13.153285+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261845-BuenaVis--3922782",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.805254",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "6am to midnight but with a two hour evening break to neck a bottle of whisky.",
          "sentiment": 0.0,
          "engagement": "5,722",
          "price_at_post": "54.50",
          "thread_title": "RE: Frankly pathetic",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B36E2695-D07A-4E60-838B-02C995994856"
        },
        "ingested_at": "2026-02-11T14:17:13.153302+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261844-Toukanka--3915231",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.805661",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "You\u2019re right Thompi. You never do say much more than joining your mates and flinging the insults. Why not talk about Avacta rather the other posters on here?",
          "sentiment": 0.0,
          "engagement": "4,436",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-02-11T14:17:13.153320+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261841-sheppy--3167109",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.806079",
        "source": "LSE_CHAT",
        "data": {
          "author": "sheppy",
          "content": "Wyn, Thorn, Touk , DG same poster numerous aliases. Hourly paid hired help disrupter. Regardless of that what sort of sad, moronic halfwit would spend 7 days a week starting each day at 6 am and continuing after midnight posting negative comments about a share they are allegedly not invested in? Regardless of their reason what a total waste of one\u2019s life on this earth . What a pathetic pitiful existence arguing with anonymous people on an anonymous bb. I actually pity their sad, lonely unfulfilled existence. And before the poster tells me they live a very fulfilled life doing lots of other meaningful things ask yourself how this is possible with so many never ending  daily boring transparent attempts at disruption. Sad twat and a weirdo",
          "sentiment": 0.0,
          "engagement": "563",
          "price_at_post": "54.50",
          "thread_title": "Frankly pathetic",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B36E2695-D07A-4E60-838B-02C995994856"
        },
        "ingested_at": "2026-02-11T14:17:13.153338+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261831-cj62--6451011",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.806499",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "Anything you post Thorn is utter garbage. How many crayons have you done today ?",
          "sentiment": 0.0,
          "engagement": "4,270",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-02-11T14:17:13.153356+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261820-Thornogs-61692101",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.806924",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "And what did you say? Anything worth hearing? Anything about Avacta and what's going well and what isn't and thoughts about why? No, thought not. Shame.",
          "sentiment": 0.0,
          "engagement": "8,596",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-02-11T14:17:13.153374+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261755-Thompi--8953962",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.807357",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thompi",
          "content": "Pedro, if I add your 67 posts over the last 30 days to my 20, plus Tim\u2019s 43 and Watching\u2019s 39, the grand combined total is 169 posts. That\u2019s four people combined. Compared to Thorn\u2019s 253 posts on his own. The figures speak for themselves.",
          "sentiment": 0.0,
          "engagement": "1,355",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-02-11T14:17:13.153398+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261754-wyndrum-60123406",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.807774",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "And i see my requests to get NFT to respond have been deleted but the insults to me remain. But yes, its the LSE moderators allowing me to post that is the problem here. Where are you NFT, want to answer my queries so you can justify the remarks in your post?",
          "sentiment": 0.0,
          "engagement": "12,198",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-02-11T14:17:13.153416+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261737-pedrolan--4339183",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.808191",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Make that 29 to go",
          "sentiment": 0.0,
          "engagement": "1,948",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-02-11T14:17:13.153434+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261719-Thompi-29140107",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.808620",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thompi",
          "content": "Avacta posts over the last 30 days: 253 Thorn \ud83e\udd47 43 Timster 39 Watching Not much else to say really Thorn.",
          "sentiment": 0.0,
          "engagement": "1,355",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-02-11T14:17:13.153458+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261708-Thornogs-86952728",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.809052",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "And the two posters below your post Thompi? Watching 9,000 and Tim 20,000! All on only Avacta and all 100% content free 'jokes' or 'bile'. But to comment on that would be to show a consistent approach to this sort of thing wouldn't it? Be honest, it's not the number or posts, it's the fact that you might have to consider things that you don't want to consider. Fine, your choice, 5 years in and AVA6000 limping along to a possible low-ball deal and FAP-EXD entering the 'Last Chance Saloon' in the next 2-3 months. Everything that you've been predicting for the last 5 years, why would you need to hear a contrary opinion when you've clearly been smashing it all this time? Well up I dare say on your investment are we?",
          "sentiment": 0.0,
          "engagement": "8,596",
          "price_at_post": "54.00",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-02-11T14:17:13.153476+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261644-Thompi--4058935",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.809483",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thompi",
          "content": "To be fair Tim, Thorn\u2019s only posted 11 times so far today. He\u2019s got another 30 to go before he equals his personal best of 41 posts in 24 hours. By my reckoning, if he manages around 4.3 posts per hour between now and midnight (17:00\u201312:00am), he might just be in with a chance of beating it. Bless his selfless little heart.",
          "sentiment": 0.0,
          "engagement": "1,355",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-02-11T14:17:13.153494+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261537-Watching--8388075",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.809893",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "24/7. He keeps churning out verbal \ud83d\udca9",
          "sentiment": 0.0,
          "engagement": "9,201",
          "price_at_post": "54.50",
          "thread_title": "RE: CC interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=F5A9F3B7-45F7-4EC2-B1FD-1ACB3A2D2E18"
        },
        "ingested_at": "2026-02-11T14:17:13.153511+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261535-Timster--3187019",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.810318",
        "source": "LSE_CHAT",
        "data": {
          "author": "Timster",
          "content": "All day every day...",
          "sentiment": 0.0,
          "engagement": "20,620",
          "price_at_post": "54.50",
          "thread_title": "To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-02-11T14:17:13.153529+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261529-cj62--2619129",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.810731",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "Shall we have a 'Spot the idiot' competition? You win it thorn, no competition !!!",
          "sentiment": 0.0,
          "engagement": "4,270",
          "price_at_post": "54.50",
          "thread_title": "RE: CC interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=F5A9F3B7-45F7-4EC2-B1FD-1ACB3A2D2E18"
        },
        "ingested_at": "2026-02-11T14:17:13.153547+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261517-Thornogs--1664114",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.811159",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Of course we don't BV, and the industry experts who know these things currently value Avacta at 50 odd pence a share. NFT and the 28 odd who ticked up his posts think \u00a328 is more accurate. Shall we have a 'Spot the idiot' competition?",
          "sentiment": 0.0,
          "engagement": "8,596",
          "price_at_post": "54.50",
          "thread_title": "RE: CC interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=F5A9F3B7-45F7-4EC2-B1FD-1ACB3A2D2E18"
        },
        "ingested_at": "2026-02-11T14:17:13.153569+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261515-cj62-14159589",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.811569",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "That's theoretical of course. Thorn its like 99% of the other gibberish you post twat.",
          "sentiment": 0.0,
          "engagement": "4,270",
          "price_at_post": "54.50",
          "thread_title": "RE: CC interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=F5A9F3B7-45F7-4EC2-B1FD-1ACB3A2D2E18"
        },
        "ingested_at": "2026-02-11T14:17:13.153589+00:00"
      },
      {
        "event_id": "SOCIAL-Today1908-avctIPma-76890597",
        "event_type": "social_post",
        "date": "2026-02-11T19:45:39.604715",
        "source": "LSE_CHAT",
        "data": {
          "author": "avctIPmatters",
          "content": "FYI   :  Balanced  update   does not provide any valuations  . Good recognition  \"Regulatory willingness to remove a dosing cap is not routine. It implies confidence in emerging safety signals and may simplify dose optimization in later-phase trials. For investors, this shifts AVA6000 from proof-of-concept toward clinical differentiation territory.   \" \" Avacta Therapeutics (AIM: AVCT) elevates Francis Wilson to CSO as faridoxorubicin dosing cap is removed Avacta Therapeutics lifts AVA6000 dosing cap and appoints a new Chief Scientific Officer. Explore what this means for pre|CISION and investors.\" https://business-news-today.com/avacta-therapeutics-aim-avct-elevates-francis-wilson-to-cso-as-faridoxorubicin-dosing-cap-is-removed/ Gmcc",
          "sentiment": 0.0,
          "engagement": "743",
          "price_at_post": "60.00",
          "thread_title": "Business-News-Today  Avacta update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=10807794-7C19-49BB-A5D5-EFA3C7D9C99E"
        },
        "ingested_at": "2026-02-11T19:45:46.481022+00:00"
      },
      {
        "event_id": "SOCIAL-Today1854-Livedata-22728770",
        "event_type": "social_post",
        "date": "2026-02-11T19:45:39.605151",
        "source": "LSE_CHAT",
        "data": {
          "author": "Livedataaccount",
          "content": "Some great comments here and I expect an update tomorrow",
          "sentiment": 0.0,
          "engagement": "2,976",
          "price_at_post": "60.00",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-11T19:45:46.481052+00:00"
      },
      {
        "event_id": "SOCIAL-Today1737-yeboha-80000808",
        "event_type": "social_post",
        "date": "2026-02-11T19:45:39.605551",
        "source": "LSE_CHAT",
        "data": {
          "author": "yeboha",
          "content": "I've never heard such nonsense from Wyn. If we had any negative news, you would be here nonstop! Not that we've had any negative news for quite some time!",
          "sentiment": 0.0,
          "engagement": "970",
          "price_at_post": "60.00",
          "thread_title": "RE: Banned",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AA63DAAF-42CA-42B0-A114-E3945671F7FA"
        },
        "ingested_at": "2026-02-11T19:45:46.481071+00:00"
      },
      {
        "event_id": "SOCIAL-Today1722-B2HS2L-15126774",
        "event_type": "social_post",
        "date": "2026-02-11T19:45:39.605983",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "From 21.01.2026 RNS - Dr Alexander Spira: Virginia Cancer Specialists \"I am thrilled to work with Avacta on this exciting new drug. The ability to concentrate a potent topoisomerase I inhibitor directly in the tumor while protecting normal tissues from harmful effects is the next stage of how we should be treating cancer. We are looking forward to participating in this second pre|CISION\u00ae Phase 1 trial and helping the Company to drive this pioneering technology forward.\" Here is VCS's patient enrolment video. https://virginiacancerspecialists.com/available-clinical-trials-at-virginia-cancer-specialists/ Introduces the newly diagnosed through the concept of finding a suitable cancer trial via VCS services. VCS acts as a portal introducing screened patients to those companies looking for willing trialists. Recommend the whole video, but it's long winded, (ie not rushed for those recently diagnosed). Slides 9,13 & 14 were most relevant for me.",
          "sentiment": 0.0,
          "engagement": "6,053",
          "price_at_post": "60.00",
          "thread_title": "Virginia Cancer Specialists",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=766DA308-297F-48F1-90EB-342F09A35ECD"
        },
        "ingested_at": "2026-02-11T19:45:46.481090+00:00"
      },
      {
        "event_id": "SOCIAL-Today1337-wyndrum-63315019",
        "event_type": "social_post",
        "date": "2026-02-11T14:17:05.527997",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "Yeah, funny when there is new news (and it\u2019s positive) there is less to comment on. Please stop posting on whether you think I am in or out . You have always been wrong. My holdings have never influenced my views. The reason I have posted less is because the usual disrupters have stopped targeting me with lies and insults. If you could just keep your posts to AVCT and leave me out of it then that would help further.",
          "sentiment": 0.0,
          "engagement": "12,256",
          "price_at_post": "60.00",
          "thread_title": "RE: Banned",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AA63DAAF-42CA-42B0-A114-E3945671F7FA"
        },
        "ingested_at": "2026-02-11T19:45:46.481128+00:00"
      },
      {
        "event_id": "SOCIAL-Today1226-Saint68-59726891",
        "event_type": "social_post",
        "date": "2026-02-11T14:17:05.528446",
        "source": "LSE_CHAT",
        "data": {
          "author": "Saint68",
          "content": "Who cares - he's not posting so all good.",
          "sentiment": 0.0,
          "engagement": "2,194",
          "price_at_post": "60.00",
          "thread_title": "RE: Banned",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AA63DAAF-42CA-42B0-A114-E3945671F7FA"
        },
        "ingested_at": "2026-02-11T19:45:46.481147+00:00"
      },
      {
        "event_id": "SOCIAL-Today1220-pedrolan-97252395",
        "event_type": "social_post",
        "date": "2026-02-11T14:17:05.528858",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "I take it as a good sign the board is quiet here. Of course there will be a big element of that down to the omission of Thorn, Now apologies in advance and I don't want to set the hare running but do we know he deleted his account or was he banned? Does anyone know for sure? It did seem to be around the time he was re-exposed as Eggy but it is possible that was a coincidence.",
          "sentiment": 0.5,
          "engagement": "1,993",
          "price_at_post": "60.00",
          "thread_title": "RE: Banned",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AA63DAAF-42CA-42B0-A114-E3945671F7FA"
        },
        "ingested_at": "2026-02-11T19:45:46.481167+00:00"
      },
      {
        "event_id": "SOCIAL-Today1200-Icecool-90420885",
        "event_type": "social_post",
        "date": "2026-02-11T14:17:05.529302",
        "source": "LSE_CHAT",
        "data": {
          "author": "Icecool",
          "content": "There\u2019s not much to debate right now to be honest. Windy\u2019s suddenly gone quiet now he\u2019s back in, funny how that works \ud83d\ude44\ud83e\udd23\ud83d\ude2d. When he\u2019s out it\u2019s doom and gloom, when he\u2019s in it\u2019s silence. Standard behaviour. Most of the board actually seems pretty calm. Everyone knows the next real catalyst is TNBC data. That\u2019s what matters. And Thorn disappearing the moment the lifetime dose cap was removed!! That tells its own story. The whole half life cumulative toxicity argument was the backbone of that narrative. Once regulators lifted the cap, that line of attack collapsed overnight. The drug just gained a structural advantage. You don\u2019t quietly delete your account if that doesn\u2019t sting. \ud83e\udd23\ud83e\udd23\ud83e\udd23 Now we wait for data. Everything else is just noise in the meantime. \ud83d\udcaf\ud83d\udc4d",
          "sentiment": 0.0,
          "engagement": "8,858",
          "price_at_post": "60.00",
          "thread_title": "RE: Banned",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AA63DAAF-42CA-42B0-A114-E3945671F7FA"
        },
        "ingested_at": "2026-02-11T19:45:46.481196+00:00"
      },
      {
        "event_id": "SOCIAL-Today1157-BuenaVis--7487579",
        "event_type": "social_post",
        "date": "2026-02-11T14:17:05.529711",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "\"[U]p to $2.4 billion in cash, inclusive of an upfront payment and subsequent payments upon achievement of certain clinical development milestones\" so enough for a scone today and gallons and gallons of jam tomorrow, if they're lucky. Nothing in clinical development: https://www.ornatx.com/our-pipeline/",
          "sentiment": 0.0,
          "engagement": "5,849",
          "price_at_post": "60.00",
          "thread_title": "RE: ELY LILLY",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B6F8359B-09F7-4910-B7F8-547334C64F27"
        },
        "ingested_at": "2026-02-11T19:45:46.481231+00:00"
      },
      {
        "event_id": "SOCIAL-Today1146-D0berman--1598276",
        "event_type": "social_post",
        "date": "2026-02-11T14:17:05.530123",
        "source": "LSE_CHAT",
        "data": {
          "author": "D0berman",
          "content": "Bloody Hell!! Who's been banned, it's so quiet!!",
          "sentiment": 0.0,
          "engagement": "1,024",
          "price_at_post": "60.00",
          "thread_title": "Banned",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AA63DAAF-42CA-42B0-A114-E3945671F7FA"
        },
        "ingested_at": "2026-02-11T19:45:46.481265+00:00"
      },
      {
        "event_id": "SOCIAL-Today0904-Harrogat--4751624",
        "event_type": "social_post",
        "date": "2026-02-11T14:17:05.530532",
        "source": "LSE_CHAT",
        "data": {
          "author": "Harrogate4",
          "content": "One day Rodders ----that could be us.",
          "sentiment": 0.0,
          "engagement": "807",
          "price_at_post": "60.50",
          "thread_title": "RE: ELY LILLY",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B6F8359B-09F7-4910-B7F8-547334C64F27"
        },
        "ingested_at": "2026-02-11T19:45:46.481299+00:00"
      },
      {
        "event_id": "SOCIAL-Today0812-Bella653--7507521",
        "event_type": "social_post",
        "date": "2026-02-11T14:17:05.530927",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "Https://investor.lilly.com/news-releases/news-release-details/lilly-acquire-orna-therapeutics-advance-cell-therapies",
          "sentiment": 0.0,
          "engagement": "6,770",
          "price_at_post": "59.50",
          "thread_title": "ELY LILLY",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B6F8359B-09F7-4910-B7F8-547334C64F27"
        },
        "ingested_at": "2026-02-11T19:45:46.481334+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20262211-B2HS2L--5493897",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.316988",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "Bella, I'm quoting company presentations and Trinity Delta. But I'll take any answer I can get from an Investor Relations company willing to respond to an Investor on behalf of Avacta. What a breath of fresh air that would be, and we could all organise a knee's up to celebrate responses.   Ha ha....dream on. Will advise any response, but it won't be this week I'm thinking.",
          "sentiment": 0.0,
          "engagement": "6,052",
          "price_at_post": "59.50",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0781AA9B-9049-48B9-B94C-F3239EA4AB66"
        },
        "ingested_at": "2026-02-11T19:45:46.481370+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20262058-D-Geeman--4854769",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.317461",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "\u2018 and Wynbore taken \u2019 Mel obvs missing Wyn after just a day or two. \ud83d\ude3f",
          "sentiment": 0.0,
          "engagement": "5,879",
          "price_at_post": "59.50",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0781AA9B-9049-48B9-B94C-F3239EA4AB66"
        },
        "ingested_at": "2026-02-11T19:45:46.481392+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20262040-Bella653--6054150",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.317882",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "Most likely you'll be referred to RNS updates.",
          "sentiment": 0.0,
          "engagement": "6,769",
          "price_at_post": "59.50",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0781AA9B-9049-48B9-B94C-F3239EA4AB66"
        },
        "ingested_at": "2026-02-11T19:45:46.481411+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20262038-Bella653--2090213",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.318312",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "B2...Afraid they won't be able to give you the answers you seek.",
          "sentiment": 0.0,
          "engagement": "6,769",
          "price_at_post": "59.50",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0781AA9B-9049-48B9-B94C-F3239EA4AB66"
        },
        "ingested_at": "2026-02-11T19:45:46.481429+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261947-Metatron-19109980",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.318724",
        "source": "LSE_CHAT",
        "data": {
          "author": "Metatron",
          "content": "Where have your mates gone Toukdroid? Thorn been banned? and Wynbore taken his bat and ball home? Pressures on you now.. need to raise your game? \ud83e\uddd0\ud83d\ude02\ud83d\ude44",
          "sentiment": 0.0,
          "engagement": "1,193",
          "price_at_post": "59.50",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0781AA9B-9049-48B9-B94C-F3239EA4AB66"
        },
        "ingested_at": "2026-02-11T19:45:46.481448+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261929-D-Geeman--7515882",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.319153",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "Faron, FARN, today. *Unless I'm missing something.",
          "sentiment": 0.0,
          "engagement": "5,879",
          "price_at_post": "59.50",
          "thread_title": "How *NOT* to organise a raise.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B74524AD-99F9-469D-8BB4-0B75886909B8"
        },
        "ingested_at": "2026-02-11T19:45:46.481466+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261806-cj62--1925798",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.319558",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "Thorn/ touk you continue to be an insufferable prick. As for the consortium you mention,at the present market cap, yes I probably could.",
          "sentiment": 0.0,
          "engagement": "4,305",
          "price_at_post": "59.50",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0781AA9B-9049-48B9-B94C-F3239EA4AB66"
        },
        "ingested_at": "2026-02-11T19:45:46.481485+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261757-Toukanka--9225349",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.319970",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "\u201c . As I mentioned, we'll have that,. Pipeline update, platform update, and so we're really excited about, the fourth quarter, for the company.\" Jeez I must have missed all those 4Q25 announcements",
          "sentiment": 0.0,
          "engagement": "4,490",
          "price_at_post": "59.50",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0781AA9B-9049-48B9-B94C-F3239EA4AB66"
        },
        "ingested_at": "2026-02-11T19:45:46.481503+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261717-Toukanka--8504898",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.320430",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "BenH It\u2019s ok Someone has deleted the post anyway",
          "sentiment": 0.0,
          "engagement": "4,490",
          "price_at_post": "59.50",
          "thread_title": "RE: Initial data seen under NDA 1st",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=DC4BE032-D599-4CC6-BFFD-F74DE0A45A33"
        },
        "ingested_at": "2026-02-11T19:45:46.481522+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261714-B2HS2L-28265327",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.320844",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "That's clear. What isn't clear is the nature of the phase 2 partnership sought by Avacta. 15:31",
          "sentiment": 0.0,
          "engagement": "6,052",
          "price_at_post": "59.50",
          "thread_title": "RE: Fairy docks ??????",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=8CFFD9D7-1C22-44FA-9FEA-90DC99BAA17F"
        },
        "ingested_at": "2026-02-11T19:45:46.481540+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261645-PL75--9147038",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.321279",
        "source": "LSE_CHAT",
        "data": {
          "author": "PL75",
          "content": "We have committed that we won't start the further development activities in the absence of a partnership. Why isn\u2019t that clear?",
          "sentiment": 0.0,
          "engagement": "11,226",
          "price_at_post": "59.50",
          "thread_title": "RE: Fairy docks ??????",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=8CFFD9D7-1C22-44FA-9FEA-90DC99BAA17F"
        },
        "ingested_at": "2026-02-11T19:45:46.481559+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261623-B2HS2L-90868920",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.321681",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "I'll keep checking my Spam directory for Cohesion's response..",
          "sentiment": 0.0,
          "engagement": "6,052",
          "price_at_post": "60.00",
          "thread_title": "RE: Fairy docks ??????",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=8CFFD9D7-1C22-44FA-9FEA-90DC99BAA17F"
        },
        "ingested_at": "2026-02-11T19:45:46.481577+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261613-pedrolan--7371792",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.322086",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "I was referring to the account that pulled you up and decided it needed a new thread to highlight it, for some reason!",
          "sentiment": 0.5,
          "engagement": "1,990",
          "price_at_post": "60.00",
          "thread_title": "RE: Fairy docks ??????",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=8CFFD9D7-1C22-44FA-9FEA-90DC99BAA17F"
        },
        "ingested_at": "2026-02-11T19:45:46.481597+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261606-B2HS2L--8553527",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.322501",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "I bet tonight's custard skin from your spotted dick that Sleeper account = avacta@cohesionbureau.com  \ud83d\ude09",
          "sentiment": 0.0,
          "engagement": "6,052",
          "price_at_post": "60.00",
          "thread_title": "RE: Fairy docks ??????",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=8CFFD9D7-1C22-44FA-9FEA-90DC99BAA17F"
        },
        "ingested_at": "2026-02-11T19:45:46.481615+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261605-BuenaVis-60195383",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.322907",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Should actually be ferry docks.",
          "sentiment": 0.0,
          "engagement": "5,848",
          "price_at_post": "60.00",
          "thread_title": "RE: Fairy docks ??????",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=8CFFD9D7-1C22-44FA-9FEA-90DC99BAA17F"
        },
        "ingested_at": "2026-02-11T19:45:46.481634+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261601-pedrolan-38925717",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.323320",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Sleeper account enabled",
          "sentiment": 0.5,
          "engagement": "1,990",
          "price_at_post": "59.50",
          "thread_title": "RE: Fairy docks ??????",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=8CFFD9D7-1C22-44FA-9FEA-90DC99BAA17F"
        },
        "ingested_at": "2026-02-11T19:45:46.481653+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261550-B2HS2L--1342617",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.323726",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "Should read 'faridoxorubicin' thanks Replacement email sent.",
          "sentiment": 0.0,
          "engagement": "6,052",
          "price_at_post": "59.50",
          "thread_title": "RE: Fairy docks ??????",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=8CFFD9D7-1C22-44FA-9FEA-90DC99BAA17F"
        },
        "ingested_at": "2026-02-11T19:45:46.481671+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261540-tiger29-78803094",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.324134",
        "source": "LSE_CHAT",
        "data": {
          "author": "tiger29",
          "content": "What are \"the fairy docks ?\"",
          "sentiment": 0.0,
          "engagement": "46",
          "price_at_post": "60.00",
          "thread_title": "Fairy docks ??????",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=8CFFD9D7-1C22-44FA-9FEA-90DC99BAA17F"
        },
        "ingested_at": "2026-02-11T19:45:46.481689+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261531-B2HS2L-29839675",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.324606",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "I've sent this to cohesion this afternoon, to see whether I get no response as per previous agencies. avacta@cohesionbureau.com Hi Cohesion Investor Relations, Many investors are unaware of the cost to Avacta of pursuing the upcoming phase 2/3 trial, for which the company currently seeks a partner. Does the company hope to 1 Have the partner cover 100% of the costs of the phase 2/3 trial. 2 Have the costs divided between Avacta and partner, dependent upon negotiations between parties. At the 30.09.2025 Investormeet presentation, a question was asked and insufficiently answered to get a response amenable to all. The question was: Q2 How much do you expect phase 2 for faridoxorubicin to cost Avacta? How will you fund this if a partnership doesn't materialise? The response from the CEO was: A2 \"So we're very confident in the maturing data in the phase 1B of, fairy docks and, we think that this will support the long-term value of this asset. Salivary gland cancers, you know, high unmet need and, we continue to, collect data, in the various cohorts. We have committed that we won't start the further development activities in the absence of a partnership. However, as I've said, the maturing data set in phase 1B is providing us with, ample confidence that precision is, working exactly as, we designed it to work. The development in the expansion cohorts is, well underway. We believe the preliminary data here will provide that natural inflection point for the program. It's gonna provide also clarity on accelerated approval pathways that we might be able to seek. And also there's, really an opportunity, for the overall market to, digest essentially the commercial potential for the program and the platform. As I mentioned, we'll have that,. Pipeline update, platform update, and so we're really excited about, the fourth quarter, for the company.\" It is assumed that this question was selected by Avacta to be asked in the presentation beforehand. Any information you can provide on this subject would be a great help Kind Regards Avacta shareholders",
          "sentiment": 0.0,
          "engagement": "6,052",
          "price_at_post": "60.00",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0781AA9B-9049-48B9-B94C-F3239EA4AB66"
        },
        "ingested_at": "2026-02-11T19:45:46.481707+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261449-B2HS2L--4336447",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.325021",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "IVM 30.09.25 - select Q/A tab. https://www.investormeetcompany.com/meetings/interim-results-491",
          "sentiment": 0.0,
          "engagement": "6,052",
          "price_at_post": "60.00",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0781AA9B-9049-48B9-B94C-F3239EA4AB66"
        },
        "ingested_at": "2026-02-11T19:45:46.481725+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261437-yeboha-53328026",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.325448",
        "source": "LSE_CHAT",
        "data": {
          "author": "yeboha",
          "content": "What was CC actual full reply to that question ????",
          "sentiment": 0.0,
          "engagement": "969",
          "price_at_post": "60.00",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0781AA9B-9049-48B9-B94C-F3239EA4AB66"
        },
        "ingested_at": "2026-02-11T19:45:46.481744+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261338-Bella653-36663983",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.325853",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "What plon\u00a3er put ghrough two 0 trades???\ud83d\ude02\ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "6,769",
          "price_at_post": "61.00",
          "thread_title": "Trades",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=F9CE2B15-57EB-41C4-816A-05159896BF66"
        },
        "ingested_at": "2026-02-11T19:45:46.481762+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261307-B2HS2L--5504975",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.326290",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "Update possibly end of March to coincide with the 1/4ly business update. (where have they gone BH?) Q2 How much do you expect phase 2 for faridoxorubicin to cost Avacta? How will you fund this if a partnership doesn't materialise? CC doesn't address the question very well, though other info appears. Note 26.06.2025 Trinity Delta: The foundational IP around the sustained release pre|CISION mechanism and the better appreciation of the scope of the pre|CISION platform gleaned from the Tempus collaboration provides multiple new opportunities for Avacta to unlock value through generating and developing a pipeline of highly novel tumour targeting drug conjugates, subject to securing additional funds. One potential funding pathway centres on business development, including securing: \u2022\tProduct-based partnerships: partnering or out-licensing deals with large pharma/biotech companies that have clinical and/or commercial expertise in certain therapeutic areas, or geographies, could help accelerate development of either existing or new product candidates. We note that Avacta is actively seeking a deal for AVA6000, ahead of starting Phase II development in H126",
          "sentiment": 0.0,
          "engagement": "6,052",
          "price_at_post": "61.00",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0781AA9B-9049-48B9-B94C-F3239EA4AB66"
        },
        "ingested_at": "2026-02-11T19:45:46.481780+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261246-opti_mys--9253912",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.326692",
        "source": "LSE_CHAT",
        "data": {
          "author": "opti_mystic",
          "content": "B2, the point of the partner for 6k phase 2 is that they the partner fund the trial, we won't be paying for it that is for sure. So they won't care about our finances. Presumably there will also be some sort of upfront payment too helping our finances. No partner no phase 2.",
          "sentiment": 0.0,
          "engagement": "317",
          "price_at_post": "61.00",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0781AA9B-9049-48B9-B94C-F3239EA4AB66"
        },
        "ingested_at": "2026-02-11T19:45:46.481799+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261238-B2HS2L--7037370",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.327228",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "Opti The company has said it will not take 6000 into phase 2/3 without a partner. 1 Depending on that deal, there may be cash available. 2 The state of AVCT finances might be cautionary for any AVA6000 partner. Would that partner be willing to proceed with Avacta unable to show sufficient longer term funding to proceed with phase 2/3, or unable to state when funding would become available? Sorting funding before finalising a partner would nullify such concerns. \"Avacta has strongly signalled a deal for that to fund 6103\". Avacta selling 6000 to fund 6103? IVM presentation 30.09.2025 Q2 How much do you expect phase 2 for faridoxorubicin to cost Avacta? How will you fund this if a partnership doesn't materialise? CC: \"So, we're very confident in the maturing data and the phase 1B of Faridoxorubicin and we think that this will support the long-term value of this asset. Salivary gland cancers, you know, high unmet need - and we continue to collect data in the various cohorts. We have committed that we won't start the further development activities in the absence of a partnership. However, as I've said, the maturing data set in phase 1B is providing us with ample confidence that precision is working exactly as we designed it to work. The development in the expansion cohorts is well underway. We believe the preliminary data here will provide that natural inflection point for the program. It's also going to provide clarity on accelerated approval pathways that we might be able to seek\"... ....Which will be of great interest to prospective partners. RNS'd FDA agreement that the dox lifetime limit to be removed on 03.02.2026. \"Agreed updates to the trial protocol include the removal of the maximum dosing limit and to allow flexibility in dosing levels. These two developments underscore the growing confidence from investigators and regulators in the tolerability profile of faridoxorubicin, and should support a smooth transition to future efficacy studies.\" \"The final cohorts of patients with the selected indications in Phase 1b will be enrolled, enabling two dose levels to be compared in order to determine the optimal biologic dose in future trials.\" +++ We await further details as to how the company enacts the FDA agreement, affecting past patients who have stopped faridox doses when they reached the lifetime limit. This is also true  for those patients on present cohorts who are still being dosed, but yet to reach the lifetime limit, as doses administered beyond 550 migs will affect the PFS calcs that are the end point of the trial. These patients now have the right to be treated beyond 550 migs... ...Again of interest to prospective partners. 6K Phase 1a data cutoff in 17 Dec 25 presentation was 15.09.2025 ie 4 months ago 6K Phase 1b data cutoff in 17 Dec 25 presentation was  15.10.2026 ie 3 months ago Update possibly end of March to coincide with the 1/4ly business update. (where have they g",
          "sentiment": 0.0,
          "engagement": "6,052",
          "price_at_post": "61.00",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0781AA9B-9049-48B9-B94C-F3239EA4AB66"
        },
        "ingested_at": "2026-02-11T19:45:46.481817+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261045-nurseste-30797931",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:41.202403",
        "source": "LSE_CHAT",
        "data": {
          "author": "nursesteve",
          "content": "A lot of people (inc big pharma) sitting on their hands just now. Volume is down but that can very soon change. GLA",
          "sentiment": 0.0,
          "engagement": "1,170",
          "price_at_post": "61.50",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=0781AA9B-9049-48B9-B94C-F3239EA4AB66"
        },
        "ingested_at": "2026-02-11T19:45:46.481836+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261043-Matml74-11320874",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:41.202838",
        "source": "LSE_CHAT",
        "data": {
          "author": "Matml74",
          "content": "They will also have very little cash left at that point (July/August). They won\u2019t run cash down to an only a few months worth so I would expect some form of funding to come forward in the next couple of months.",
          "sentiment": 0.0,
          "engagement": "2,551",
          "price_at_post": "61.50",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=0781AA9B-9049-48B9-B94C-F3239EA4AB66"
        },
        "ingested_at": "2026-02-11T19:45:46.481855+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261012-opti_mys-44019908",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:41.203267",
        "source": "LSE_CHAT",
        "data": {
          "author": "opti_mystic",
          "content": "The problem I see is that before BP spend a ton of cash they will want lots of data. They will have it with 6k by the end of June when TNBC data is released and it seems likely a deal for at least the three indications we know about would be the focus of that deal. Avacta has  strongly signalled a deal for that to fund 6103. However at a similar sort of time July/August they should have a very good idea on 6103 too with early data. Would waiting a little bit longer and buying the whole kit caboodle really make that much difference to BP who we all know have massive patent cliffs? Deal(s) are on the way for sure, the timing and size is the only uncertainty.",
          "sentiment": 0.0,
          "engagement": "317",
          "price_at_post": "61.50",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=0781AA9B-9049-48B9-B94C-F3239EA4AB66"
        },
        "ingested_at": "2026-02-11T19:45:46.481873+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20260946-Bella653-18328164",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:41.203675",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "Oops..funding not gunding...",
          "sentiment": 0.0,
          "engagement": "6,769",
          "price_at_post": "61.50",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=0781AA9B-9049-48B9-B94C-F3239EA4AB66"
        },
        "ingested_at": "2026-02-11T19:45:46.481892+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20260945-Bella653-36063361",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:41.204090",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "Morning LDA...yes it will...not worried just interesting how it's bumped 63 several time...bit of a glass ceiling right now... If a deal is to be struck before we need finance it's being worked on right now.  The new sppointment is very interesting and I think they will bring in the partnership with an upfront wad...and I wouldn't be surprised HR then come in with Royalty backed gunding.",
          "sentiment": 0.0,
          "engagement": "6,769",
          "price_at_post": "61.50",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=0781AA9B-9049-48B9-B94C-F3239EA4AB66"
        },
        "ingested_at": "2026-02-11T19:45:46.481910+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20260833-Livedata-62853644",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:41.204512",
        "source": "LSE_CHAT",
        "data": {
          "author": "Livedataaccount",
          "content": "Hey bella good morning it will come soon",
          "sentiment": 0.0,
          "engagement": "2,975",
          "price_at_post": "61.50",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=0781AA9B-9049-48B9-B94C-F3239EA4AB66"
        },
        "ingested_at": "2026-02-11T19:45:46.481929+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20260830-Bella653--7018471",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:41.204922",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "Wmsjames..'But signing a material deal purely off very early Phase 1 signals, before dose optimisation and without durability data, is still the exception rather than the rule.' They could sign an MOU type deal now with full deal based on certain outcomes/milestones.",
          "sentiment": 0.0,
          "engagement": "6,769",
          "price_at_post": "61.50",
          "thread_title": "RE: Initial data seen under NDA 1st",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=DC4BE032-D599-4CC6-BFFD-F74DE0A45A33"
        },
        "ingested_at": "2026-02-11T19:45:46.481947+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20260826-Bella653--1046007",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:41.205339",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "Need to break 63",
          "sentiment": 0.0,
          "engagement": "6,769",
          "price_at_post": "61.50",
          "thread_title": "SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=0781AA9B-9049-48B9-B94C-F3239EA4AB66"
        },
        "ingested_at": "2026-02-11T19:45:46.481966+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20260810-Bella653--4519564",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:41.205745",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "What about a Partnership for 6000 with Option to Licence one or more pipeline products...",
          "sentiment": 0.0,
          "engagement": "6,769",
          "price_at_post": "61.50",
          "thread_title": "RE: Initial data seen under NDA 1st",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=DC4BE032-D599-4CC6-BFFD-F74DE0A45A33"
        },
        "ingested_at": "2026-02-11T19:45:46.481984+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20260756-B2HS2L-57170167",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:41.206160",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "'6103 is actually validating 6000 which itself is derisking 6103.' I'll go for 6000 phase 1a results are being validated by 6000 phase 1b results in SGC so far. (Two other indications results not known yet).",
          "sentiment": 0.0,
          "engagement": "6,052",
          "price_at_post": "61.50",
          "thread_title": "RE: Initial data seen under NDA 1st",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=DC4BE032-D599-4CC6-BFFD-F74DE0A45A33"
        },
        "ingested_at": "2026-02-11T19:45:46.482002+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20260750-yeboha--5544984",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:41.206562",
        "source": "LSE_CHAT",
        "data": {
          "author": "yeboha",
          "content": "Remember, just ignore the same old FUD BRIGADE and they\u2019ll end up talking only among themselves! Yesterday\u2019s appointment was a great move by Avacta,  they are getting everything in order. Onwards and upwards!",
          "sentiment": 0.0,
          "engagement": "969",
          "price_at_post": "61.50",
          "thread_title": "Ignore the FUD BRIGADE",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B82AA1FD-8062-42D5-928C-4DE5C508547A"
        },
        "ingested_at": "2026-02-11T19:45:46.482029+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20260744-JamYeste--6041954",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:41.206972",
        "source": "LSE_CHAT",
        "data": {
          "author": "JamYesterday",
          "content": "100x more potent than Dox? Scary. So much depends on the next few months.",
          "sentiment": 0.0,
          "engagement": "560",
          "price_at_post": "61.50",
          "thread_title": "RE: Initial data seen under NDA 1st",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=DC4BE032-D599-4CC6-BFFD-F74DE0A45A33"
        },
        "ingested_at": "2026-02-11T19:45:46.482048+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20260734-Benharpe-52452271",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:41.207385",
        "source": "LSE_CHAT",
        "data": {
          "author": "Benharper",
          "content": "Every other poster isn\u2019t the same person Touk. In this post Alberbaran is being admittedly a bit optimistic regarding timelines. Wmsjames is being more circumspect. I personally think Wms is on the right track. Perhaps wait until last nights session has cleared your system before posting.",
          "sentiment": 0.0,
          "engagement": "746",
          "price_at_post": "61.50",
          "thread_title": "RE: Initial data seen under NDA 1st",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=DC4BE032-D599-4CC6-BFFD-F74DE0A45A33"
        },
        "ingested_at": "2026-02-11T19:45:46.482067+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20260659-Aldebara--6043197",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:41.207795",
        "source": "LSE_CHAT",
        "data": {
          "author": "Aldebaran",
          "content": "Im saying same thing that deal will be on faridoxorubicin based off the 4 years of dada we have for sts sgc and also breast cancer plus the work done on 3996 amd 6207 in pre clinical setting. Throw into the mix some initial data from 6103 and it becomes a self validating loop. 6103 is actually validating 6000 which itself is derisking 6103. Its highly unique. I am expecting 6103 data ans breast cancer data to lead to a deal or as some have said maybe even a direct take out approach. Could be well before market sets eyes on 6103 data... not giving the market and FUDsters chance to react and buy in \"cheap\". Before the deals land. Be a massive shame that but id get over it",
          "sentiment": 0.0,
          "engagement": "3,941",
          "price_at_post": "61.50",
          "thread_title": "RE: Initial data seen under NDA 1st",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=DC4BE032-D599-4CC6-BFFD-F74DE0A45A33"
        },
        "ingested_at": "2026-02-11T19:45:46.482085+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20260616-Wmsjames-54529566",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:41.208261",
        "source": "LSE_CHAT",
        "data": {
          "author": "Wmsjames",
          "content": "I\u2019m a bit more cautious on the timing. Yes, initial safety and tolerability signals are often seen early in Phase 1, sometimes within weeks of first dosing. But that doesn\u2019t automatically translate into actionable data for partners. Early signals are noisy, patient numbers are tiny, and dose escalation means you are often below biologically meaningful exposure in the first cohorts. On efficacy, even if there are early radiological hints, sponsors and pharma partners usually want: \u2022\tMultiple patients at or near the target dose \u2022\tConsistency across scans, not a single responder \u2022\tConfidence the signal isn\u2019t dose or patient specific That usually takes several months, not weeks. As for deals, could confidential discussions happen in parallel? Absolutely. Pharma will already understand the mechanism and will be tracking progress closely. But signing a material deal purely off very early Phase 1 signals, before dose optimisation and without durability data, is still the exception rather than the rule. So my view is: \u2022\tEarly internal confidence may build well before June \u2022\tMarket visible data likely takes longer \u2022\tAny deal would more likely be driven by confidence in the platform + AVA6000 validation, rather than a handful of first AVA6103 scans",
          "sentiment": 0.0,
          "engagement": "718",
          "price_at_post": "61.50",
          "thread_title": "RE: Initial data seen under NDA 1st",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=DC4BE032-D599-4CC6-BFFD-F74DE0A45A33"
        },
        "ingested_at": "2026-02-11T19:45:46.482124+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20260608-Aldebara--5035362",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:41.208683",
        "source": "LSE_CHAT",
        "data": {
          "author": "Aldebaran",
          "content": "Us plebs may have to wait until June earliest but how long before those under NDA such as presumably Novartis et al get to see it ? What do you think touk? 2nd question, how long before initial scans and tolerability is known after dosing. Initial i am saying. Given exetecan is what 20x more potent than irinotecan and 100x more potent than doxorubicin and more permeable than deruxtecan etc... ?? Personally I think within 1 months off dosing then the initial safety will be known and their could easily he signs of efficacy. This will be WAY before June and the point the market gets said data. Could a deal be signed off the back of this and the faridoxorubicin data to date before the market catches on, i think its possible. Highly possible actually. You and others? Thinking what?",
          "sentiment": 0.0,
          "engagement": "3,941",
          "price_at_post": "61.50",
          "thread_title": "Initial data seen under NDA 1st",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=DC4BE032-D599-4CC6-BFFD-F74DE0A45A33"
        },
        "ingested_at": "2026-02-11T19:45:46.482146+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20262317-pedrolan-59633540",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.585477",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Folks, Touk is clearly Thorn. Look how he writes. Ignore him.",
          "sentiment": 0.0,
          "engagement": "1,988",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-11T19:45:46.482165+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20262306-Icecool-30129107",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.586081",
        "source": "LSE_CHAT",
        "data": {
          "author": "Icecool",
          "content": "You do talk a load of nonsense\u2026. \ud83e\udd26\u200d\u2642\ufe0f",
          "sentiment": 0.0,
          "engagement": "8,857",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-11T19:45:46.482184+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20262305-Toukanka--6402704",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.586694",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "At the end of the day, initial efficacy results will not be published before June IMO. And CC has said as much. She has also said that any acceptable deal is unlikely before those results are published. And there will be no takeover even if CJ62 forms a consortium of shareholders and tries to push it through at say \u00a31",
          "sentiment": 0.0,
          "engagement": "4,486",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-11T19:45:46.482203+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20262301-Toukanka--2476708",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.587310",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "Thompi FPI is not the same as FPD. But no point arguing. You all know better than CC.",
          "sentiment": 0.0,
          "engagement": "4,486",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-11T19:45:46.482222+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20262150-Thompi--1679653",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.587906",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thompi",
          "content": "Touk, for the record, this is what Chris said in the Base to Base interview released 23rd January, but probably recorded late last year: \u201cWe\u2019re really looking forward to getting the first sustained release [AVA6103] into the clinic. That one will start in March of next year. We\u2019re aiming for the first quarter for the first patient with that one.\u201d",
          "sentiment": 0.0,
          "engagement": "1,364",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-11T19:45:46.482240+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20262123-BuenaVis-88061964",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.588579",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "In clinical trials, FPI (First Patient In) marks the critical milestone when the very first participant is screened, enrolled, and officially enters the study, signifying the transition from planning to active execution. It validates site readiness, kicks off data collection, and is a major KPI for project timelines and investor confidence. Here are the key details regarding FPI: Key Aspects of FPI \u2022 Definition: It is the date the first human subject is qualified, accepted, and often dosed in a clinical trial. \u2022 Significance: It proves all regulatory approvals, document reviews, contracting, and site setups are complete. \u2022 Business Impact: FPI is a high-pressure corporate goal that affects company reputation, stock prices, and investor confidence. \u2022 Trial Flow: It moves the study from \"study start-up\" to \"execution/recruitment\" phase. Why FPI Matters \u2022 Timeline Driver: It sets the pace for the rest of the recruitment and trial timeline. \u2022 Success Indicator: Meeting the FPI goal on time usually means the study is on sound footing. \u2022 Risk: Rushing to hit FPI dates can sometimes lead to neglected study designs or premature starts. Sometimes, this milestone is also referred to as FPFV (First Patient First Visit), focusing on when data collection begins for that first subject.",
          "sentiment": 0.0,
          "engagement": "5,847",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-11T19:45:46.482259+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20262039-B2HS2L--7165654",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.589188",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "A couple of non-Avacta trials that mention FPI, state that FPI = first patient enrolment. Neither discuss enrolment details though.   \ud83e\udd23\ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "6,042",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-11T19:45:46.482277+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20262005-Gingethe--8295483",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.589761",
        "source": "LSE_CHAT",
        "data": {
          "author": "GingetheWinge",
          "content": "Every piece of Avacta communication. Q1 2026. That is fact. Your opinions are plucked out of your a r s e.",
          "sentiment": 0.5,
          "engagement": "705",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-11T19:45:46.482296+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261922-avctIPma-26848179",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.590377",
        "source": "LSE_CHAT",
        "data": {
          "author": "avctIPmatters",
          "content": "\"FPI stands for \"First Patient In\", which is a critical milestone in clinical trials. It marks the moment when the first participant is screened and enrolled into the trial, signaling the beginning of real-world data collection.\" Ref :   Slide 29 https://avacta.com/wp-content/uploads/2025/07/Avacta_Corp_23July2025.pdf \" Q1 2026   Phase 1 first patient in (FPI)\" Gmcc",
          "sentiment": 0.0,
          "engagement": "742",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-11T19:45:46.482315+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261913-BuenaVis-88795045",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.590980",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "The FDA has 30 calendar days to review an IND application after receiving it. https://drugdevelopment.web.unc.edu/u-s-investigational-new-drug-application-%e2%86%92-ind-application-process/ IND submitted mid/late December (as per the project plan in Spotlight 13) and approved by 20 January. The FDA will have been working closely with Avacta given the experience with faridox so that was a fast turnaround given the US government shutdown gping on at the time. - - - - - And ToucanOfDoom, stop purporting to know better than CC what the likely timescales are.",
          "sentiment": 0.0,
          "engagement": "5,847",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-11T19:45:46.482334+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261911-Toukanka--2030599",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.591588",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "CJ62 No, while posters on here continue to misconstrue communications from Avacta and purport to know better than CC what the likely timescales are, then I will continue to correct them. You and others stop posting baseless wishful thinking ramps on here and I will stop exposing them for what they are. Deal?",
          "sentiment": 0.0,
          "engagement": "4,486",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-11T19:45:46.482353+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261902-cj62--2439971",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.592186",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "Touk can you do a thorn and dissolve into the ether?",
          "sentiment": 0.0,
          "engagement": "4,304",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-11T19:45:46.482371+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261900-BuenaVis--7987617",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.592752",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Https://avacta.com/research-development-spotlight-series-episode-13/ @26:15 FPI late Q1/26",
          "sentiment": 0.0,
          "engagement": "5,847",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-11T19:45:46.482390+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261852-Vertizea-72243313",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.593353",
        "source": "LSE_CHAT",
        "data": {
          "author": "VertizeaSun",
          "content": "Thanks jmfw.....and I'll add the reminder that CC visited the AVA6103 manufacturing site (Glasgow) in early December. a necessary requirement if one knows that patient dosing is likely to begin sooner rather than later.",
          "sentiment": 0.0,
          "engagement": "446",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-11T19:45:46.482409+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261851-Toukanka--2403492",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.593952",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "No no no That is my point. Trial start does not mean first patient dosed. CC has outlined in a previous communication the lengthy steps between IND approval and first in patient dosed. My prediction is still for initial clinical results around June. No deals until at least tolerance shown to some degree and even then maybe not until initial signs of efficacy. And yes I do know that P1 is not designed to show efficacy.",
          "sentiment": 0.0,
          "engagement": "4,486",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-11T19:45:46.482427+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261837-jmfw--7990932",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.594558",
        "source": "LSE_CHAT",
        "data": {
          "author": "jmfw",
          "content": "Https://www.lse.co.uk/rns/AVCT/year-end-trading-update-63xrambu5i622u5.html Under heading:  Outlook for 2026",
          "sentiment": 0.0,
          "engagement": "418",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-11T19:45:46.482445+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261830-Toukanka-80398622",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.595177",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "Ginge That would be great. Can you provide a link to where that is stated please. I\u2019m not challenging you. Because that would be good if they start in March. Thanks",
          "sentiment": 0.0,
          "engagement": "4,486",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-11T19:45:46.482464+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261819-Bella653-78768485",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.595769",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "Scroll to end... https://www.forxtherapeutics.com/2025/12/forx-therapeutics-announces-usd-50m-series-a-financing-enabling-clinical-data-readout-for-potential-best-in-class-parg-inhibitor As I said, is this appointment about media or funding/partnering?",
          "sentiment": 0.0,
          "engagement": "6,761",
          "price_at_post": "60.50",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-11T19:45:46.482482+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261621-BuenaVis--3806974",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.596417",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Here are some links re Richard Jarvis at Novartis: Richard Jarvis history: https://rocketreach.co/richard-jarvis-email_238424640 Richard Jarvis at Jarvis Advisors: https://www.moneyhouse.ch/en/company/jarvis-advisors-gmbh-5842690731 (Binningen is on the edge of Basel, home of Novartis HQ) Richard Jarvis consultant: https://www.linkedin.com/posts/the-difference-collective_say-hello-to-collective-consultant-richard-activity-7389560479272259584-EiwK (with photo) Richard Jarvis at Cohesion Bureau: https://cohesionbureau.com/bureau/richard-jarvis (with photo) - - - - - And here is the Cohesion Bureau team at their various locations in Europe and the US: https://cohesionbureau.com/bureau",
          "sentiment": 0.0,
          "engagement": "5,847",
          "price_at_post": "60.50",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-11T19:45:46.482501+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261542-Gingethe-62659373",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.596992",
        "source": "LSE_CHAT",
        "data": {
          "author": "GingetheWinge",
          "content": "First patients are expected to receive AVA6103 before the end of March.",
          "sentiment": 0.5,
          "engagement": "705",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-11T19:45:46.482519+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261521-B2HS2L-54511188",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.597714",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "FWIW Chris Maggos Strategic Consulting and IR, PR & BD Services for Biotech / Medtech Experience Managing Director Cohesion Bureau \u00b7 Full-time Dec 2022 - Present \u00b7 3 yrs 3 mos Geneva, Switzerland \u00b7 Hybrid Our experienced multi-disciplinary U.S. and Pan-European team offers insightful strategic consulting and services to expedite your corporate growth. In addition to strategic consulting, we offer execution services for partnering, fundraising, investor and (social) media relations. We have a dedicated editorial unit producing corporate content, including, writing, graphic design, video and photography. We want to be your partner for growth. Our experienced multi-disciplinary U.S. and Pan-European team offers insightful strategic consulting and services to expedite your corporate growth. In addition to strategic consulting, we offer execution services for partnering, fundraising, investor and (social) media relations. We have a dedicated editorial unit producing corporate content, including, writing, graphic design, video and photography. We want to be your partner for growth. Managing Director BioConfidant S\u00e0rl Sep 2014 - Present \u00b7 11 yrs 6 mos Geneva, Switzerland BioConfidant offers strategic consulting on three closely related types of corporate activities: investor relations, public relations and business development (i.e. licensing and M&A). With our partners around Europe and in the U.S. we started Cohesion Bureau in 2022 to level the playing field for European startups and small-cap companies. We established and managed the European investor relations business of LifeSci Advisors from 2015-2021. We are passionate about developing relationships and collaborating with clients to earn the visibility and impact they need to succeed.",
          "sentiment": 0.0,
          "engagement": "6,042",
          "price_at_post": "60.50",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-11T19:45:46.482537+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261513-Livedata--1426658",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.598309",
        "source": "LSE_CHAT",
        "data": {
          "author": "Livedataaccount",
          "content": "With the location being switzerland one does imagine the cohesion team are in bed with some big players at roche and novartis",
          "sentiment": 0.0,
          "engagement": "2,974",
          "price_at_post": "61.50",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-11T19:45:46.482555+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261503-Timster--2717249",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.598888",
        "source": "LSE_CHAT",
        "data": {
          "author": "Timster",
          "content": "That's a serious accusation watching you WILL be hearing from my legal team, not as hidden as you think.......",
          "sentiment": 0.0,
          "engagement": "20,640",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-11T19:45:46.482574+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261503-avctIPma-67311507",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.599564",
        "source": "LSE_CHAT",
        "data": {
          "author": "avctIPmatters",
          "content": "\" Cohesion Bureau (Communications)  Richard Jarvis / Chris Maggos \" Interesting  connection  Richard Jarvis  has with  Novartis .   Avacta  has had lots of changes  recently  - Michelle Morrow  did  not last long  - guess  one less salary to pay & also streamlining communication costs. ------- \"Richard Jarvis Trustee Director Trustee Director Novartis UK Pension Trustee CompanyNovartis UK Pension Trustee Company 2014 - Present \u00b7 12 yrs 2 mos2014 to Present \u00b7 12 yrs 2 mos Grew funding position from <90% of liabilities to ~110% (buy-out basis) for ~7 000 members.Grew funding position from <90% of liabilities to ~110% (buy-out basis) for ~7 000 members. Novartis logo Head of Strategy & Financial Communications Head of Strategy & Financial Communications NovartisNovartis 2021 - 2025 \u00b7 4 yrs2021 to 2025 \u00b7 4 yrs Basel, SwitzerlandBasel, Switzerland Led global team of communications and media relations professionals, responsible for financial communications and global top tier media engagement.Led global team of communications and media relations professionals, responsible for financial communications and global top tier media engagement. Communications Strategy, Team Management and +6 skills\" Gmcc",
          "sentiment": 0.0,
          "engagement": "742",
          "price_at_post": "60.50",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-11T19:45:46.482592+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261502-Livedata--4686313",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.600169",
        "source": "LSE_CHAT",
        "data": {
          "author": "Livedataaccount",
          "content": "I always imagined timster was a belly dancer",
          "sentiment": 0.0,
          "engagement": "2,974",
          "price_at_post": "61.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-11T19:45:46.482610+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261458-Watching-78930206",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.363454",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "Timster are you still a children\u2019s entertainer ?",
          "sentiment": 0.0,
          "engagement": "9,229",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-11T19:45:46.482629+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261453-Timster-26491411",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.363899",
        "source": "LSE_CHAT",
        "data": {
          "author": "Timster",
          "content": "One of Francis's KPA's is to ensure LDA's requests for updates via the lse website are promptly answered. Id expect an update within 48hrs LDA",
          "sentiment": 0.0,
          "engagement": "20,640",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-11T19:45:46.482647+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261453-Toukanka-78935883",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.364338",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "Clear from what CC said in today\u2019s RNS that no one has been dosed with 6103 yet. Given the preparation work that needs to be carried out including pre screening, I previously predicted April earliest for dosing to start. (Based on 6100 timescales)",
          "sentiment": 0.0,
          "engagement": "4,486",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-11T19:45:46.482665+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261426-Livedata--4188638",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.364756",
        "source": "LSE_CHAT",
        "data": {
          "author": "Livedataaccount",
          "content": "Be good to get an update please on TNBC progress and 6103 dosing thank you in advance",
          "sentiment": 0.0,
          "engagement": "2,974",
          "price_at_post": "60.50",
          "thread_title": "Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-11T19:45:46.482683+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261324-B2HS2L--1660869",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.365200",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "If this was true in Nov 2024 (so for AVA6000), I would assume the situation is a little more rosy now. Possibly some starters for 10 here. https://www.trinitydelta.org/research-notes/targeting-the-tumour-microenvironment-with-precision/ A reminder from Trinity Delta \u2013 Targeting the tumour microenvironment with pre|CISION - 18.11.2024 \"Avacta has so far FAP-enabled ten different warheads building up a database of multiple pre|CISION compounds that include c 40 capping groups (which alter the PK of the conjugate) and c 20 linkers (required for FAP cleavage with certain warheads and can be used to modify FAP affinity and activity). These have all been characterised through computational simulations to evaluate molecular binding and how they dock into the FAP structure. A key consideration is how close the warhead can get to the FAP cleavage sequence; this typically depends on the size of the molecule, and often defines whether a spacer group is required. Consideration is also given to how long the conjugate and the active warhead are likely to remain in the TME, and this informs whether PK alterations, achieved through an alternative capping group, are needed to either allow the sustained release of the warhead or to slow plasma clearance.",
          "sentiment": 0.0,
          "engagement": "6,042",
          "price_at_post": "60.50",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=060607B8-56D7-4812-99EC-1BE5765F573F"
        },
        "ingested_at": "2026-02-11T19:45:46.482702+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261308-pedrolan-82307309",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.365614",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Yes and what a truly remarkable career he could have.",
          "sentiment": 0.5,
          "engagement": "1,988",
          "price_at_post": "60.50",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=060607B8-56D7-4812-99EC-1BE5765F573F"
        },
        "ingested_at": "2026-02-11T19:45:46.482720+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261300-BuenaVis--6800329",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.366018",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "As the mechanism of action\u2014the dipeptide and the cleavage\u2014is proven, it now comes down to designing each molecule's pharmacokinetics to fit the needs for the warhead.  And who better to lead that than a highy competent chemist at the top of his game?",
          "sentiment": 0.0,
          "engagement": "5,847",
          "price_at_post": "60.50",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=060607B8-56D7-4812-99EC-1BE5765F573F"
        },
        "ingested_at": "2026-02-11T19:45:46.482738+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261159-B2HS2L-71341754",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.366489",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "\"Francis - We will learn more about this program in the clinic and apply that as we continue to develop NOVEL INTELLECTUAL PROPERTY around our highly successful pre|CISION\u00ae platform.\" -  We look forward to plenty of new IP to come. 29.10.2025 CC: \"Much of the success and how we are going to be able to move the dual payload through is going to depend on our initial observations in the clinic with the exatacan molecule. Francis and Tom mentioned that a lot of what we are doing with the dual payload is based on the learnings in the lab with the exatecan molecule. We expect to learn a lot about the exatecan molecule as we move it into the clinic and that's going to inform a lot about the dual payload molecules. Clinic learnings in the first half of 2026, will inform how quickly we're going to move the dual payload through.\" Also \"if we do right and we do great things for patients, we will be doing great things for our shareholders.\" I hope they stack the new IP high. It will increase the bargaining value of the company. It doesn't sound like Francis is going to be straying far from the lab, unless other chemists are inbound, and Francis is the mentor.  \ud83d\udcab",
          "sentiment": 0.0,
          "engagement": "6,042",
          "price_at_post": "60.50",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=060607B8-56D7-4812-99EC-1BE5765F573F"
        },
        "ingested_at": "2026-02-11T19:45:46.482756+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261120-Timster-84391766",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.366896",
        "source": "LSE_CHAT",
        "data": {
          "author": "Timster",
          "content": "Biggest buy signal in recent days is when eggy threw in the towel and removed his account.",
          "sentiment": 0.0,
          "engagement": "20,640",
          "price_at_post": "61.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-11T19:45:46.482774+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261105-yeboha--2907257",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.367315",
        "source": "LSE_CHAT",
        "data": {
          "author": "yeboha",
          "content": "Great RNS yet again today ! All moving in the right direction !",
          "sentiment": 0.0,
          "engagement": "967",
          "price_at_post": "61.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-11T19:45:46.482792+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261054-D-Geeman--4659249",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.367735",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "Certainly Watching 2 raises the tone but is that why people read bulletin boards Ginge? Would you rather read a poster's record have have them be proved right again and again? Or, like W2's record.. Shall I raise the tone? \"\u00a3200 ex-chinah, nailed on!\" \"Later today! \" (Note to self; see, it's not difficult.)",
          "sentiment": 0.0,
          "engagement": "5,877",
          "price_at_post": "61.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-11T19:45:46.482811+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261048-Gingethe--2942806",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.368149",
        "source": "LSE_CHAT",
        "data": {
          "author": "GingetheWinge",
          "content": "Agreed. Always the usual suspects that lower the tone.",
          "sentiment": 0.5,
          "engagement": "705",
          "price_at_post": "61.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-11T19:45:46.482829+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261032-Watching-46005442",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.368583",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "Tidy the BB Ignore the muppets We now know ignore and they argue with themselves And eventually dry up ! Great appointment well done team  avacta !. Jane",
          "sentiment": 0.0,
          "engagement": "9,229",
          "price_at_post": "61.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-11T19:45:46.482847+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261017-D-Geeman-80223400",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.369068",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "Touk, Watching does their best... And not just on AVCT. 'Watching2 'Posted in: ENET Posts: 9,227 RE: Sidelines22 Nov 2023 09:59 Actually 1p is very unlikely Bottom has now been hit imo. Good averaging opportunity! Next rns will lift us' And in case you were wondering how this 'prediction'went, today's SP: Share Price Information for Ethernity Net (ENET) Share Price is delayed by 15 minutes Get Live Data 0.0048    0.0001 (2.13%) Bid: 0.0046 Ask: 0.005 Spread: 0.0004 (8.696%) Market Cap: \u00a348.00k Still, plenty of folk 'Rec'watching's posts so hats-off to Jane (unless you're still holding on to it Jane?) .",
          "sentiment": 0.0,
          "engagement": "5,877",
          "price_at_post": "61.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-11T19:45:46.482865+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261003-Livedata--6726760",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.369492",
        "source": "LSE_CHAT",
        "data": {
          "author": "Livedataaccount",
          "content": "Francis has been instrumental in ava6103 and ava6207 running a successful business is about retaining top talent and i have no doubt his IP is massive at Avacta it is a great appointment",
          "sentiment": 0.0,
          "engagement": "2,974",
          "price_at_post": "61.00",
          "thread_title": "New CSO",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=2EBFCF4C-4A4D-475C-BBFD-DB095DA011B8"
        },
        "ingested_at": "2026-02-11T19:45:46.482884+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260926-Harrogat-19569437",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.369903",
        "source": "LSE_CHAT",
        "data": {
          "author": "Harrogate4",
          "content": "Agreed -----did they ever do anything ---apart from taking their salaries of course?",
          "sentiment": 0.0,
          "engagement": "805",
          "price_at_post": "61.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-11T19:45:46.482902+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260923-Bella653-10525166",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.370320",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "So can we assume THRUST and ICR have been ditched now...if so good ridens...",
          "sentiment": 0.0,
          "engagement": "6,761",
          "price_at_post": "61.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-11T19:45:46.482920+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260921-Bella653-10303052",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.370735",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "Or.. 1.  Is Cohesion Bureau about attracting Pharma funding? Their website is terrible...Nothing comes up in the NEWS section!!!!! 2.  We are not in the Immunotherapy space we now need good Chemists.   I think CC mentioned this in one of her videos when she talked about the 'Chemistry' involved in developing new pipelines.",
          "sentiment": 0.0,
          "engagement": "6,761",
          "price_at_post": "61.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-11T19:45:46.482938+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260919-yeboha-63417678",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.371148",
        "source": "LSE_CHAT",
        "data": {
          "author": "yeboha",
          "content": "But then again i dont no if avacta want the take over, they certainly wont push for it !",
          "sentiment": 0.0,
          "engagement": "967",
          "price_at_post": "61.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-11T19:45:46.482957+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260918-yeboha-25400733",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.371554",
        "source": "LSE_CHAT",
        "data": {
          "author": "yeboha",
          "content": "Watching , i agree with you, everything seems to be lining up beautifully for the take over this year !",
          "sentiment": 0.5,
          "engagement": "967",
          "price_at_post": "61.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-11T19:45:46.482974+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260915-Toukanka--6627621",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.371960",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "Watching In your view each year for the past three years was the year we would be taken over\ud83e\udd21",
          "sentiment": 0.0,
          "engagement": "4,486",
          "price_at_post": "61.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-11T19:45:46.482993+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260908-Vertizea-32262006",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.372377",
        "source": "LSE_CHAT",
        "data": {
          "author": "VertizeaSun",
          "content": "T/O? I quite agree. Avacta's got the air of a company tidying up loose ends.",
          "sentiment": 0.0,
          "engagement": "446",
          "price_at_post": "61.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-11T19:45:46.483011+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260907-yeboha--4193760",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.372784",
        "source": "LSE_CHAT",
        "data": {
          "author": "yeboha",
          "content": "Great news! Francis has been appointed as the new chief scientific officer. Retaining him will be a massive advantage moving forward!",
          "sentiment": 0.5,
          "engagement": "967",
          "price_at_post": "61.00",
          "thread_title": "Important Appointment",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=8E658AE1-929D-4CD1-910B-CBDF7FD77692"
        },
        "ingested_at": "2026-02-11T19:45:46.483029+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260903-Watching-17005794",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.373199",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "Imo This year we will  will be taken over The glowing data  must be worth the risk to get in first gla Jane !",
          "sentiment": 0.0,
          "engagement": "9,229",
          "price_at_post": "61.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-11T19:45:46.483047+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260858-nurseste-16821099",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.373605",
        "source": "LSE_CHAT",
        "data": {
          "author": "nursesteve",
          "content": "It seems a bit strange from Simon being touted by Chris as being so busy to quietly being removed ?",
          "sentiment": 0.0,
          "engagement": "1,169",
          "price_at_post": "61.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-11T19:45:46.483065+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260849-BuenaVis-19913502",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.092369",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "We don't know what he was doing not why he's no longer on the team. He was another of Alan's hires that's now gone.",
          "sentiment": 0.0,
          "engagement": "5,847",
          "price_at_post": "62.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-11T19:45:46.483083+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260844-Watching-13513217",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.093088",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "Leaky ship ! Another hole plugged",
          "sentiment": 0.0,
          "engagement": "9,229",
          "price_at_post": "62.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=060607B8-56D7-4812-99EC-1BE5765F573F"
        },
        "ingested_at": "2026-02-11T19:45:46.483115+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260839-BuenaVis-74931923",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.093853",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "We'll know where and when in the fullness of time. https://www.linkedin.com/in/michelle-morrow-127605137",
          "sentiment": 0.0,
          "engagement": "5,847",
          "price_at_post": "62.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=060607B8-56D7-4812-99EC-1BE5765F573F"
        },
        "ingested_at": "2026-02-11T19:45:46.483136+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260837-nurseste--5179275",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.094563",
        "source": "LSE_CHAT",
        "data": {
          "author": "nursesteve",
          "content": "So Simon was busy doing??? \ud83e\udd14",
          "sentiment": 0.0,
          "engagement": "1,169",
          "price_at_post": "62.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-11T19:45:46.483154+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260837-cj62--6158829",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.095298",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "Probably caught with her hand in the cookie jar !!",
          "sentiment": 0.0,
          "engagement": "4,304",
          "price_at_post": "62.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=060607B8-56D7-4812-99EC-1BE5765F573F"
        },
        "ingested_at": "2026-02-11T19:45:46.483173+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260832-Harrogat-31308339",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.095975",
        "source": "LSE_CHAT",
        "data": {
          "author": "Harrogate4",
          "content": "Congratulations to Dr Francis Wilson, very well deserved in my view and a great choice by CC.",
          "sentiment": 0.0,
          "engagement": "805",
          "price_at_post": "62.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=060607B8-56D7-4812-99EC-1BE5765F573F"
        },
        "ingested_at": "2026-02-11T19:45:46.483191+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260818-Watching-47487002",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.096697",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "Perhaps it was requested by a big pharma as part of a agreement",
          "sentiment": 0.0,
          "engagement": "9,229",
          "price_at_post": "60.50",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=060607B8-56D7-4812-99EC-1BE5765F573F"
        },
        "ingested_at": "2026-02-11T19:45:46.483210+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260815-Prion25-53423200",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.097532",
        "source": "LSE_CHAT",
        "data": {
          "author": "Prion25",
          "content": "Michelle highly regarded in oncology biotech did a block buster drug with AZ  probably been headhunted by a prospective parter of Avacta or  big pharma competitors We won\u2019t know probably a NDA has been signed",
          "sentiment": 0.0,
          "engagement": "1,555",
          "price_at_post": "60.50",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=060607B8-56D7-4812-99EC-1BE5765F573F"
        },
        "ingested_at": "2026-02-11T19:45:46.483228+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260809-B2HS2L-56937813",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.098278",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "CC :  \"\"In addition to his leadership internally, he has also been a key member of the team positioning our business across the international drug development sector. Francis is a well-known leader in medicinal chemistry externally and we are looking forward to forging the next chapter of pre|CISION\u00ae with his scientific leadership and expertise. \" I think she wants him to become more of a Key Opinion Leader, - she uses 'leader' above - in spreading the pre-CISION gospel. To become more influential with respect to FDA / MHRA and the like. Michelle Morrow may have decided the grass was greener. \"former CSO Michelle Morrow will be leaving Avacta to pursue another opportunity\" - singular not plural. She must have done a lot of work to get AVA6103 successfully through the IND Application. (That's true for all staff). She knows what's inside the capping group and the linker group, - those two blue blobs (group A & group B) in blue in certain presentations.",
          "sentiment": 0.0,
          "engagement": "6,042",
          "price_at_post": "60.50",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=060607B8-56D7-4812-99EC-1BE5765F573F"
        },
        "ingested_at": "2026-02-11T19:45:46.483247+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260809-Colesy74-38896053",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.098949",
        "source": "LSE_CHAT",
        "data": {
          "author": "Colesy74",
          "content": "Https://youtu.be/kyQJRyoPzvw",
          "sentiment": 0.0,
          "engagement": "21",
          "price_at_post": "60.50",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-11T19:45:46.483265+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260737-Vertizea--1191164",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.099686",
        "source": "LSE_CHAT",
        "data": {
          "author": "VertizeaSun",
          "content": "Also....Simon Bennett was removed from Leadership page but Yulii Bogatyrenko remains.",
          "sentiment": 0.0,
          "engagement": "446",
          "price_at_post": "60.50",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-11T19:45:46.483283+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260727-dafad-28846413",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.100396",
        "source": "LSE_CHAT",
        "data": {
          "author": "dafad",
          "content": "They may have wanted someone of a higher calibre in the position as they develop the Platform",
          "sentiment": 0.0,
          "engagement": "2,416",
          "price_at_post": "60.50",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=060607B8-56D7-4812-99EC-1BE5765F573F"
        },
        "ingested_at": "2026-02-11T19:45:46.483302+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260723-Livedata-14015599",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.101080",
        "source": "LSE_CHAT",
        "data": {
          "author": "Livedataaccount",
          "content": "Who knows employees have many reasons for leaving job roles",
          "sentiment": 0.0,
          "engagement": "2,974",
          "price_at_post": "60.50",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=060607B8-56D7-4812-99EC-1BE5765F573F"
        },
        "ingested_at": "2026-02-11T19:45:46.483320+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260721-IFA90--7520895",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.101762",
        "source": "LSE_CHAT",
        "data": {
          "author": "IFA90",
          "content": "Why leave before the multi billion TO?",
          "sentiment": 0.0,
          "engagement": "416",
          "price_at_post": "60.50",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=060607B8-56D7-4812-99EC-1BE5765F573F"
        },
        "ingested_at": "2026-02-11T19:45:46.483338+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260721-BuenaVis--6057696",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.102469",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "A good decision. From CC's praise, he's likely been leading the science anyway.",
          "sentiment": 0.0,
          "engagement": "5,847",
          "price_at_post": "60.50",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=060607B8-56D7-4812-99EC-1BE5765F573F"
        },
        "ingested_at": "2026-02-11T19:45:46.483357+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260715-BuenaVis-81388091",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.103183",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Avacta's new comms organisation, based in Geneva: https://cohesionbureau.com/ It's All Change, every month, with Avacta!",
          "sentiment": 0.0,
          "engagement": "5,847",
          "price_at_post": "60.50",
          "thread_title": "Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-11T19:45:46.483374+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260705-JFK8-45044843",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.103866",
        "source": "LSE_CHAT",
        "data": {
          "author": "JFK8",
          "content": "New CSO to replace Michelle Morrow",
          "sentiment": 0.0,
          "engagement": "3,058",
          "price_at_post": "60.50",
          "thread_title": "RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=060607B8-56D7-4812-99EC-1BE5765F573F"
        },
        "ingested_at": "2026-02-11T19:45:46.483392+00:00"
      },
      {
        "event_id": "SOCIAL-8Feb20261320-BuenaVis--4998856",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.104577",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "The link didn't work so I ran that query in Grok.  Yes, the procedure is involved but so is standard doxorubicin I should think - valid prescription, qualified people, the \"Five Rights\", etc. but with the added safety measures need for radioactivity. I should think the patients have to be held in the hospital to be sure that the drug can be administered rather than have them just ambling in for the 3-weekly injection, the reason being timeliness, timeliness, timeliness... to Grok: \"What are the steps to get a radiopharmaceutical from production to patient?\" \"The journey of a radiopharmaceutical from production to patient administration is a highly time-sensitive, regulated supply chain due to the short half-lives of most radionuclides (often hours to days). This limits the window for manufacturing, quality control, transportation, and use. The process varies depending on the radionuclide (e.g., cyclotron-produced like F-18, Ga-68, or reactor-produced like Mo-99/Tc-99m, Lu-177) and whether the product is a ready-to-use diagnostic agent (e.g., FDG), a kit requiring on-site labeling, or a therapeutic agent.\" ...and so it goes on with the 11 stages and summarised under Key Challenges (Time pressure, Radiation safety, Regulatory compliance, Supply chain complexity)",
          "sentiment": 0.0,
          "engagement": "5,847",
          "price_at_post": "60.50",
          "thread_title": "RE: Watch Ely Lilly could make a move",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=4B1C735B-8BE4-4153-95B2-75A61E403C1D"
        },
        "ingested_at": "2026-02-11T19:45:46.483410+00:00"
      },
      {
        "event_id": "SOCIAL-8Feb20261235-B2HS2L-17387524",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.105340",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "Source Grok: \"what is the procedure to administer a dose of a radiopharmaceutical drug?\" https://x.com/i/grok?conversation=2020452204348313802 Intravenous administration of AVA6103 is going to be a doddle compared with radiopharmaceutical administration by a team of several. Time / expense to get radiopharmaceutical to hospital? If the decision to make funds available to dose a patient is made by a health insurance company, I don't think they would consider a radiopharmaceutical for long if a cheaper method of administration is available. PDC ADC - it has targeting issues. radiopharmaceutical - difficult / expensive to administer, too many specialists This is my list of most to least preferrable drug types for experts to consider using. Novartis must be \ud83d\udc40",
          "sentiment": 0.0,
          "engagement": "6,042",
          "price_at_post": "60.50",
          "thread_title": "RE: Watch Ely Lilly could make a move",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=4B1C735B-8BE4-4153-95B2-75A61E403C1D"
        },
        "ingested_at": "2026-02-11T19:45:46.483428+00:00"
      },
      {
        "event_id": "SOCIAL-8Feb20261107-GainsOnl-61960428",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.106009",
        "source": "LSE_CHAT",
        "data": {
          "author": "GainsOnly",
          "content": "This will be over 75p last placing price very soon DYOR",
          "sentiment": 0.0,
          "engagement": "10",
          "price_at_post": "60.50",
          "thread_title": "RE: Watch Ely Lilly could make a move",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=4B1C735B-8BE4-4153-95B2-75A61E403C1D"
        },
        "ingested_at": "2026-02-11T19:45:46.483446+00:00"
      },
      {
        "event_id": "SOCIAL-8Feb20261042-LiveLong-24013217",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.106802",
        "source": "LSE_CHAT",
        "data": {
          "author": "LiveLongnProsper",
          "content": "A few Exatecan products that AVA6103 might be compared against ..? Cybrexa \u2013 privately held, have CBX-12 a PDC, targeting pH (acidity), in phase 2. EMD Serono \u2013 Merck subsidiary, have M7437, ADC based, in phase 1 from Jan 2026. Innovent \u2013 now partnered with Takeda, have IBI343, ADC based, in phase 3 with FDA fast track. AVA6103, indeed the whole pre|CISION\u00ae platform, remains, as yet, \u2018unpartnered\u2019 (OK Lilly/CanSeek) - but not without \u2018friends\u2019 and \u2018admirers\u2019. What about BP then ..? We know that Daiichi Sankyo and AZN are massively committed to Enhertu\u00ae (trastuzumab deruxtecan), HER2 targeted ADC, and we know about \u2018patent cliffs\u2019.  DS / AZN currently pushing through a number of DXd products, perhaps most notably Datroway\u00ae (datopotamab deruxtecan), TROP2 targeted ADC in phase 3.  Daiichi have been working with Exatecan for over 20 years.  These guys need to protect their \u2018space\u2019. Merck (Keytruda) were apparently going to spend up to $32bn for Revolution \u2013 seems to be off now?  Guess they have ready cash then? Novartis have this massive \u2018hole\u2019 in their pipeline, i.e. no ADC\u2019s, but are doing FAP targeting for RLT.  They seem to have plenty of money also. \u2018Triggers\u2019 for Avacta acquisition ..? Positive AVA6000 TNBC readout?  PFS for SGC and AVA6000 becomes \u2018standard of care\u2019?  Early positive response to AVA6103? Or just a  \u2018pre-emptive strike\u2019? GLA",
          "sentiment": 0.0,
          "engagement": "1,836",
          "price_at_post": "60.50",
          "thread_title": "RE: Watch Ely Lilly could make a move",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=4B1C735B-8BE4-4153-95B2-75A61E403C1D"
        },
        "ingested_at": "2026-02-11T19:45:46.483464+00:00"
      },
      {
        "event_id": "SOCIAL-8Feb20260925-opti_mys--7552256",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.107491",
        "source": "LSE_CHAT",
        "data": {
          "author": "opti_mystic",
          "content": "Keytruda is out of Patent in 2028 when the immunology drug becomes an out of patent generic drug. Avacta could use it like we have Dox and Exatecan and we'd have chemo and immunology options.",
          "sentiment": 0.0,
          "engagement": "315",
          "price_at_post": "60.50",
          "thread_title": "RE: Watch Ely Lilly could make a move",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=4B1C735B-8BE4-4153-95B2-75A61E403C1D"
        },
        "ingested_at": "2026-02-11T19:45:46.483482+00:00"
      },
      {
        "event_id": "SOCIAL-8Feb20260859-Aldebara-43131142",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.108206",
        "source": "LSE_CHAT",
        "data": {
          "author": "Aldebaran",
          "content": "So we saying that lily and Novartis have eyes on either directly or indirectly. Would love to throw merck into the mix as well due to keytruda patent expiry. What about daiichi sankyo also. 4 way bidding war would be nice. All 4 could be made a reasonable case to be seriously interested in precision",
          "sentiment": 0.0,
          "engagement": "3,933",
          "price_at_post": "60.50",
          "thread_title": "RE: Watch Ely Lilly could make a move",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=4B1C735B-8BE4-4153-95B2-75A61E403C1D"
        },
        "ingested_at": "2026-02-11T19:45:46.483500+00:00"
      },
      {
        "event_id": "SOCIAL-8Feb20260852-Bella653-81801383",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.108890",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "'POINT Biopharma Inc Avacta has entered into a license agreement with POINT Biopharma Inc., (taken over by Eli Lilly in late 2023) a clinical-stage pharmaceutical company focused on the development and commercialisation of radioligand therapies for the treatment of cancer, to provide access to Avacta\u2019s pre|CISION\u00ae technology for the development of tumor-activated radiopharmaceuticals.' How much access are they now getting to PreCISION???",
          "sentiment": 0.0,
          "engagement": "6,761",
          "price_at_post": "60.50",
          "thread_title": "RE: Watch Ely Lilly could make a move",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=4B1C735B-8BE4-4153-95B2-75A61E403C1D"
        },
        "ingested_at": "2026-02-11T19:45:46.483519+00:00"
      },
      {
        "event_id": "SOCIAL-8Feb20260843-Bella653-53175594",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.109654",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "'Toxicity caused by off-target delivery is a longstanding concern of cancer therapies. Developed by Dr. William Bachovchin of Tufts University, POINT\u2019s CanSEEK\u2122 technology aims to minimize radiopharmaceutical toxicity caused by off-target delivery by only activating a radiopharmaceuticals' targeting moiety, such as its ligand, after it has encountered FAP-\u03b1 in the tumor microenvironment (TME). FAP-\u03b1 is highly expressed on a wide range of solid tumors, but in very low quantities or absent altogether in healthy tissues. The intent of CanSEEK\u2122 is to minimize the toxicity caused by off-target delivery. At first, CanSEEK\u2122 prevents the radiopharmaceutical from bonding to receptors on cells. When the radiopharmaceuticals enter the TME, the radiopharmaceuticals targeting moiety is re-activated, enabling it to once again bond to receptors on cancer cells. CanSEEK\u2122 has the potential to make treatments even more precise, expanding their therapeutic index, and enabling the use of new, more powerful medical isotopes.' \u200d",
          "sentiment": 0.0,
          "engagement": "6,761",
          "price_at_post": "60.50",
          "thread_title": "RE: Watch Ely Lilly could make a move",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=4B1C735B-8BE4-4153-95B2-75A61E403C1D"
        },
        "ingested_at": "2026-02-11T19:45:46.483537+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20262318-Icecool--6961242",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.525582",
        "source": "LSE_CHAT",
        "data": {
          "author": "Icecool",
          "content": "Happy holidays everyone. \ud83d\ude09\ud83e\udd23\ud83d\ude2d",
          "sentiment": 0.0,
          "engagement": "8,855",
          "price_at_post": "60.50",
          "thread_title": "RE: From MM on X - If it offends - Tough",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=D20B314B-66BB-47B0-8ED4-D46B27E22B85"
        },
        "ingested_at": "2026-02-11T19:45:46.483555+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20262125-Livedata--4434538",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.526281",
        "source": "LSE_CHAT",
        "data": {
          "author": "Livedataaccount",
          "content": "who is offended not icecool being ****** again i hope",
          "sentiment": 0.0,
          "engagement": "2,969",
          "price_at_post": "60.50",
          "thread_title": "RE: From MM on X - If it offends - Tough",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=D20B314B-66BB-47B0-8ED4-D46B27E22B85"
        },
        "ingested_at": "2026-02-11T19:45:46.483573+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20262120-IFA90-69792454",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.526944",
        "source": "LSE_CHAT",
        "data": {
          "author": "IFA90",
          "content": "I\u2019m not offended. Xx",
          "sentiment": 0.0,
          "engagement": "415",
          "price_at_post": "60.50",
          "thread_title": "RE: From MM on X - If it offends - Tough",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=D20B314B-66BB-47B0-8ED4-D46B27E22B85"
        },
        "ingested_at": "2026-02-11T19:45:46.483592+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20262049-B2HS2L--1421740",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.527979",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "Https://x.com/BMHLTD/status/1736326494035603668 - Thanks BMH. December 2023 - Set of extracts from a Will Tap presentation. Will Tap discusses STS treatment improvement necessary. Now we have SGC first pass results, - AVA6000 more likely to be able to address items on Will Tap's STS wish list - with resulting FDA satisfaction.",
          "sentiment": 0.0,
          "engagement": "6,031",
          "price_at_post": "60.50",
          "thread_title": "Will Tap STS wish list",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=21C3C888-CE85-4F00-B718-E879BB3F5CC6"
        },
        "ingested_at": "2026-02-11T19:45:46.483610+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20262037-BuenaVis--5471367",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.528670",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Top publication, Scrip, so this is excellent exposure for CC and Avacta in their 'preview' of the year.",
          "sentiment": 0.0,
          "engagement": "5,826",
          "price_at_post": "60.50",
          "thread_title": "RE: Evolving Drug Conjugates",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B37AC3F0-A005-4580-9CCE-040AE6DF8EA7"
        },
        "ingested_at": "2026-02-11T19:45:46.483629+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261929-avctIPma--5216003",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.529343",
        "source": "LSE_CHAT",
        "data": {
          "author": "avctIPmatters",
          "content": "\"drive significant interest and global pharma partnerships.\"  sounds  good ! Gmcc",
          "sentiment": 0.0,
          "engagement": "740",
          "price_at_post": "60.50",
          "thread_title": "RE: Evolving Drug Conjugates",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B37AC3F0-A005-4580-9CCE-040AE6DF8EA7"
        },
        "ingested_at": "2026-02-11T19:45:46.483647+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261924-avctIPma--7916942",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.530056",
        "source": "LSE_CHAT",
        "data": {
          "author": "avctIPmatters",
          "content": "Thanks to Stonks ;   CC featured \"Scrip Asks... What Does 2026 Hold For Biopharma? Part 4: R&D Innovation\" https://insights.citeline.com/scrip/scrip-asks/scrip-asks-what-does-2026-hold-for-biopharma-part-4-rd-innovation-NDREFKFVB5DZPAQLA5CIZHE7OI/#oncology \"Evolving Drug Conjugates Drugs conjugated to antibodies and other carriers continue advancing through next-generation payload and linker innovation. \u201c2026 will be a pivotal year for dual payload drug conjugates, as the first wave of these therapies is expected to yield initial clinical data,\u201d predicted Christina Coughlin, CEO of Avacta Therapeutics. \u201cThe first dual payload peptide-drug conjugate was announced this year, and dozens of major pharma companies are advancing dual-payload programs targeting different resistance mechanisms. We expect the technology\u2019s ability to overcome drug resistance, enhance tumor selectivity and broaden the therapeutic window to drive significant interest and global pharma partnerships. This represents oncology\u2019s evolution from sequential combination dosing to precision dual-delivery, fundamentally reshaping how we approach tumor heterogeneity and resistance.\u201d Gmcc",
          "sentiment": 0.0,
          "engagement": "740",
          "price_at_post": "60.50",
          "thread_title": "Evolving Drug Conjugates",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B37AC3F0-A005-4580-9CCE-040AE6DF8EA7"
        },
        "ingested_at": "2026-02-11T19:45:46.483665+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261910-JES1889--8367857",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.530764",
        "source": "LSE_CHAT",
        "data": {
          "author": "JES1889",
          "content": "I think the other piece to consider here is that Avacta no longer seems to be a leaky ship. I now believe that (if and) when news drops it\u2019ll arrive without forewarning, like the FDA news this week. Whilst I see there being room for the share price to appreciate as this year progresses, on retail demand/expectations. I doubt that even positive data releases on TNBC and 6103 will see this head anywhere near true value. AIM and the UK investment community just find the scale too hard to contemplate. I\u2019ve seen comments about the current low share price and suggesting that potential bidders would start buying shares in the open market. There\u2019s no way that any party under NDA would be able to do that as they\u2019d be party to inside information and that would be covered by the Market Abuse Regulations. The NDA would almost certainly have some form of standstill clause prohibiting open market share purchases. I think the big news when it comes will come out of the blue.",
          "sentiment": 0.0,
          "engagement": "83",
          "price_at_post": "60.50",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T19:45:46.483683+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261857-Icecool-31588598",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.531439",
        "source": "LSE_CHAT",
        "data": {
          "author": "Icecool",
          "content": "Bella you assume the SP and deal value will be linked prior to any announcement. That might happen on the Nasdaq, however it certainly doesn\u2019t happen on AIM. The price will be negotiated on the technology, then and only then will the SP react accordingly.\ud83d\udcaf\ud83d\udc4d",
          "sentiment": 0.0,
          "engagement": "8,855",
          "price_at_post": "60.50",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T19:45:46.483701+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261334-Timster-71566779",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.532093",
        "source": "LSE_CHAT",
        "data": {
          "author": "Timster",
          "content": "Why would that offend?",
          "sentiment": 0.0,
          "engagement": "20,637",
          "price_at_post": "60.50",
          "thread_title": "RE: From MM on X - If it offends - Tough",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=D20B314B-66BB-47B0-8ED4-D46B27E22B85"
        },
        "ingested_at": "2026-02-11T19:45:46.483720+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261322-Toukanka-79739626",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.532773",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "All hail the uber ramper. But I agree with everything except I think his timeline is optimistic. I\u2019m still saying Summer for the pivotal moment - in that respect I am accepting CC\u2019s predictions.",
          "sentiment": 0.0,
          "engagement": "4,476",
          "price_at_post": "60.50",
          "thread_title": "RE: From MM on X - If it offends - Tough",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=D20B314B-66BB-47B0-8ED4-D46B27E22B85"
        },
        "ingested_at": "2026-02-11T19:45:46.483738+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261243-wyndrum-88525321",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.533481",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "Does that mean MM is NFT?",
          "sentiment": 0.0,
          "engagement": "12,250",
          "price_at_post": "60.50",
          "thread_title": "RE: From MM on X - If it offends - Tough",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=D20B314B-66BB-47B0-8ED4-D46B27E22B85"
        },
        "ingested_at": "2026-02-11T19:45:46.483757+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261226-cj62-80129976",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.534176",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "I have never been influenced by MM's ramblings but this actually echoes my sentiments exactly, our money is safe as I believe SGC alone makes this a very valuable company. We are now waiting on initial TNBC data prior to H2 which if successful will boost the valuation of Avacta considerably and to top that off ava6103 initial data i expect mid H2. Very exciting times indeed and hopefully well worth the wait.",
          "sentiment": 0.0,
          "engagement": "4,302",
          "price_at_post": "60.50",
          "thread_title": "RE: From MM on X - If it offends - Tough",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=D20B314B-66BB-47B0-8ED4-D46B27E22B85"
        },
        "ingested_at": "2026-02-11T19:45:46.483775+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261217-D-Geeman-72746555",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.534833",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "Vertizea, son, B2H just beat me to it. Whenever I have been influenced by MM in hindsight I should have done the opposite. Yet this does seem a very exciting time. 'If .... and b) the company can stay independent for a couple more years at least' could be the explanation of the contradiction in my response. I think I will keep some powder dry for the next year or so. Currently the 'powder' is in WG, waiting to be worth 30p. Would be comvenient if the various timings work out for me.",
          "sentiment": 0.0,
          "engagement": "5,868",
          "price_at_post": "60.50",
          "thread_title": "RE: From MM on X - If it offends - Tough",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=D20B314B-66BB-47B0-8ED4-D46B27E22B85"
        },
        "ingested_at": "2026-02-11T19:45:46.483793+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261206-B2HS2L-29975539",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.535518",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "Does that mean MM's out? Not offended. \ud83d\ude44 PS probably reducing.",
          "sentiment": 0.0,
          "engagement": "6,031",
          "price_at_post": "60.50",
          "thread_title": "RE: From MM on X - If it offends - Tough",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=D20B314B-66BB-47B0-8ED4-D46B27E22B85"
        },
        "ingested_at": "2026-02-11T19:45:46.483812+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261201-Vertizea--4012720",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.536296",
        "source": "LSE_CHAT",
        "data": {
          "author": "VertizeaSun",
          "content": "Myles McNulty @MylesMcNulty \u00b7 2h Replying to @RobDay80669068 Morning Robert, hope all's well. #AVCT's news on Tuesday was phenomenal. My understanding is that it's an unprecedented move by the FDA to remove the dosing limit for a modified-/reformulated-/pro-chemotherapy,  mid-Phase 1 trial. The rapid decline and fall of the UK investment community - in depth, breadth, intellectual curiosity and risk tolerance - is in my view providing one of the greatest asymmetrical bets of all time. #AVA6000 is an absolute shoe-in to get to market now. It much more than underpins Avacta's entire market cap. Management will know if #AVA6103 - 'the Beast' - is working in patients as they hope it will, by the end of next month. That single drug  has real potential to become the best selling drug in the history of pharma. It really is straightforward to explain and understand this. Personally, I give AVA6103 well over a >50% chance of success in clinic. If a) it is indeed a success in the clinic; and b) the company can stay independent for a couple more years at least; then the returns from the current 60p share price could be >100x. I have recently provided a real world example of these returns (see my last post on Avacta, comparing it with $RVMD). The next 6 months are by far the most important in Avacta's history. Good luck!",
          "sentiment": 0.0,
          "engagement": "440",
          "price_at_post": "60.50",
          "thread_title": "From MM on X - If it offends - Tough",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=D20B314B-66BB-47B0-8ED4-D46B27E22B85"
        },
        "ingested_at": "2026-02-11T19:45:46.483831+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261152-wyndrum--4365152",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.537031",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "Well done Bella, although you won't see this post because you are so clever with the filter button but I raised this most recently with NFT and he never responded to his valuation of $28b based on another company, even though I asked 3 times. Thats the problem with filters. I get filtering the sheppys and watchings of this world that offer absolutely nothing but when I am not defending myself against unsolicited slurs and random insult-only posts, I only talk about AVCT. You tend to eventually come to the same conclusions as me but it takes a while and of course that ground has already been covered. The thing I have noticed is that it does not take long at all to quickly scan any post to see if it has relevance or not and as a result no longer bother filtering anyone. And why? Just on the chance that they do in fact come across some good info or (heaven forfend), some helpful insight. But as I say this will just be another green box for you to never know what was said",
          "sentiment": 0.0,
          "engagement": "12,250",
          "price_at_post": "60.50",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T19:45:46.483850+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261143-Bella653--3672626",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.537707",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "Anyone quoting billion $ deals should also post the number of shares that were in issue and the SP prior to the deal...without this info you cannot compare apples with apples. I've checked some of these big deals only to find the SP increase was relatively small.",
          "sentiment": 0.0,
          "engagement": "6,756",
          "price_at_post": "60.50",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T19:45:46.483868+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261113-B2HS2L--1753837",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.538535",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "GSK's new CEO looking for $2B to $4B deals 'hiding in plain sight' This is the title of a Fierce Pharma document found on this link: https://www.fiercebiotech.com/biotech/gsks-new-ceo-looking-2-4b-deals-hiding-plain-sight +++ Luke Miels had only been at the helm of GSK for 20 days before he signed off on his first multibillion-dollar buyout, and the CEO is clear on what else will attract his interest. \u201cThe basic framework that we like for [business development] is in that 2-to-4 billion [dollar] range,\u201d Miels told journalists on a fourth-quarter earnings call this morning. \u201cTypically, we like a program where the science is reasonably established,\u201d he added. Miels\u2014who served as GSK\u2019s chief commercial officer before taking over from CEO Emma Walmsley in the new year\u2014pointed to a pattern in dealmaking set in 2022 by the $1.9 billion acquisition of Sierra Oncology for its near-approval cancer drug. GSK is especially interested in drugs where \u201cwe've got a degree of validation on the science, but there are liabilities with the existing products,\u201d he said. To demonstrate these criteria, Miels cited the $2.2 billion buyout of Rapt Therapeutics just days into his tenure as CEO. Rapt\u2019s IgE antibody ozureprubart protects against food allergy reactions by targeting the same epitope as Novartis and Roche\u2019s Xolair. Miels admitted that Xolair has \u201cabsolutely exploded in the U.S. for usage with severe allergies, particularly in kids.\u201d \u201cBut the problem is there's a very complicated dosing regimen, and these kids have to inject themselves every two weeks,\u201d he explained. \u201c[Ozureprubart] works exactly the same way as Xolair, except that you give it on a much lower frequency,\u201d Miels said. \ud83d\udc40 \u201cSo that's essentially the methodology we're going to follow with [business development]\u2014looking for assets [that are] well priced, not necessarily in the mainstream, hiding in plain sight,\u201d the CEO added. \u201cAnd we'll do that with a degree of frequency, which, again, will help us build out the late-stage portfolio.\u201d 1 The basic framework that we like for [business development] is in that 2-to-4 billion [dollar] range,\u201d  \u274c 2 \u201cTypically, we like a program where the science is reasonably established\u201d   \u2714\ufe0f 3 GSK is interested in drugs where \u201cwe've got a degree of validation on the science, but there are liabilities with the existing products\u201d \u2714\ufe0f 4  ...looking for assets [that are] well priced, not necessarily in the mainstream, hiding in plain sight\u201d \u274c see 1 - I'd take issue that multibillion assets don't usually exist in the mainstream, hiding in plain sight. I'd say all now know about Avacta and its products. Those specialising in cancer therapeutics HAVE to be interested or start making BIG advances soon in ADC cancer targeting. I think overall, GSK is looking for an opportunity that costs less than Avacta will sell for. - From the horses mouth.",
          "sentiment": 0.0,
          "engagement": "6,031",
          "price_at_post": "60.50",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T19:45:46.483887+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261101-Watching-56584040",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.539211",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "You don\u2019t always get the best deals with smaller companies .. J",
          "sentiment": 0.0,
          "engagement": "9,224",
          "price_at_post": "60.50",
          "thread_title": "RE: Trading 212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B38EA914-FA00-4B19-B293-5E96B62D2062"
        },
        "ingested_at": "2026-02-11T19:45:46.483905+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261055-Profchee--1308363",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.539863",
        "source": "LSE_CHAT",
        "data": {
          "author": "Profcheese",
          "content": "II also in the process of reducing their charges at the moment. It's a competitive world!",
          "sentiment": 0.0,
          "engagement": "539",
          "price_at_post": "60.50",
          "thread_title": "RE: Trading 212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B38EA914-FA00-4B19-B293-5E96B62D2062"
        },
        "ingested_at": "2026-02-11T19:45:46.483923+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261008-Watching-16292023",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.540533",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "IG t buying n selling is free if you have over \u00a330 k in there account",
          "sentiment": 0.0,
          "engagement": "9,224",
          "price_at_post": "60.50",
          "thread_title": "RE: Trading 212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B38EA914-FA00-4B19-B293-5E96B62D2062"
        },
        "ingested_at": "2026-02-11T19:45:46.483941+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261004-Bella653--6005067",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.541198",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "Have you compared the Bid and Ask prices ...many of these No Fee sites don't give the 'best' prices...",
          "sentiment": 0.0,
          "engagement": "6,756",
          "price_at_post": "60.50",
          "thread_title": "RE: Trading 212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B38EA914-FA00-4B19-B293-5E96B62D2062"
        },
        "ingested_at": "2026-02-11T19:45:46.483959+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20260955-wyndrum--3812410",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.541863",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "FWIW they were efficient in sorting out a pension for me too",
          "sentiment": 0.0,
          "engagement": "12,250",
          "price_at_post": "60.50",
          "thread_title": "RE: Trading 212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B38EA914-FA00-4B19-B293-5E96B62D2062"
        },
        "ingested_at": "2026-02-11T19:45:46.483978+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20260955-avctIPma-34832009",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.542723",
        "source": "LSE_CHAT",
        "data": {
          "author": "avctIPmatters",
          "content": "Recent CC quotes :  %   Chance of success  -  Surely Avacta platform that  can to enhance  existing drug treatments  requires  an IP value asset  re-set  . Certainly worth waiting  for  to see   which  BP  jumps first  . ---------------- \"@coughlin582: \u201cif there\u2019s an organ with a cancer, we can address it\u201d \"Christina Coughlin @coughlin582 \u00b7 Feb 4 Replying to @coughlin582 Love this! No would never give our secrets away here! The secret to the sustained release mechanism invented by our brilliant chemistry team is behind blob A and blob B. We call this the \u201cblob slide\u201d \u2026 #BestTeamEver\" Gmcc",
          "sentiment": 0.0,
          "engagement": "740",
          "price_at_post": "60.50",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T19:45:46.483996+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20260946-D-Geeman-37784143",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.174673",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "It's like Lidl V's Sainsbury's, but if Lidl stock everything you want then go for it. I found the message from HL regarding their charges, soon to be changed: 'Trading / Dealing Fees: We are reducing the amount you pay to buy or sell shares with us, from \u00a311.95 to \u00a36.95 per online trade** We\u2019re introducing a charge of \u00a31.95 per trade to buy or sell funds online' Account charges: We are reducing our account charges* from 0.45% to 0.35% per year on Stocks and Shares ISA and Self-Invested Personal Pension (SIPP) accounts For Fund and Share Accounts, we are reducing account charges for holding funds, from 0.45% to 0.35% per year and we are introducing a charge of 0.35% to hold shares New account charge limits for shares (includes investment trusts, Exchange Traded Funds (ETFs) and bonds): You will never pay more than \u00a3150 per year in account charges* for holding shares in each of our SIPP, Stocks and Shares ISA or our Fund and Share Accounts Compare current vs future charges",
          "sentiment": 0.0,
          "engagement": "5,868",
          "price_at_post": "60.50",
          "thread_title": "RE: Trading 212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38EA914-FA00-4B19-B293-5E96B62D2062"
        },
        "ingested_at": "2026-02-11T19:45:46.484015+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20260930-Watching-53688137",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.175455",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "A  big pharma   can\u2019t afford not to take us over Who ever bids first will know they will become the market leader over night  with our science ! Imo it\u2019s going to happen very very quickly in 2026 . Hold or. Top up if funds allow Gla . Jane",
          "sentiment": 0.0,
          "engagement": "9,224",
          "price_at_post": "60.50",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T19:45:46.484033+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20260918-cj62--6156853",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.176169",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "Incalculable!!!",
          "sentiment": 0.0,
          "engagement": "4,302",
          "price_at_post": "60.50",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T19:45:46.484051+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20260859-Wilson63-72169429",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.176882",
        "source": "LSE_CHAT",
        "data": {
          "author": "Wilson63",
          "content": "Post by Tvr5 on X read this and consider being used for just one of these examples and what a fair price would be for the company. https://x.com/TVR5AVCT/status/2019678221504291189",
          "sentiment": 0.0,
          "engagement": "8,808",
          "price_at_post": "60.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T19:45:46.484070+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20260847-jackeste-67889762",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.177597",
        "source": "LSE_CHAT",
        "data": {
          "author": "jackester",
          "content": "They definitely do deal in Avacta.",
          "sentiment": 0.0,
          "engagement": "311",
          "price_at_post": "60.00",
          "thread_title": "RE: Trading 212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38EA914-FA00-4B19-B293-5E96B62D2062"
        },
        "ingested_at": "2026-02-11T19:45:46.484089+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20260811-JFK8--2583923",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.178308",
        "source": "LSE_CHAT",
        "data": {
          "author": "JFK8",
          "content": "Opened an account and closed it 20 minutes later as they dont deal  AVCT shares .don't know if they do now though as it was a while ago",
          "sentiment": 0.0,
          "engagement": "3,057",
          "price_at_post": "60.00",
          "thread_title": "RE: Trading 212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38EA914-FA00-4B19-B293-5E96B62D2062"
        },
        "ingested_at": "2026-02-11T19:45:46.484125+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20260125-russell1-69556383",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.179005",
        "source": "LSE_CHAT",
        "data": {
          "author": "russell1",
          "content": "Thanks for the helpful replies.",
          "sentiment": -0.5,
          "engagement": "318",
          "price_at_post": "60.00",
          "thread_title": "RE: Trading 212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38EA914-FA00-4B19-B293-5E96B62D2062"
        },
        "ingested_at": "2026-02-11T19:45:46.484144+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20262323-Toukanka-16545677",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.179705",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "More desperate ramping",
          "sentiment": 0.0,
          "engagement": "4,476",
          "price_at_post": "60.00",
          "thread_title": "RE: TAKEOVER",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=DAF752F5-FA6F-49F9-BD50-F5C834118B9E"
        },
        "ingested_at": "2026-02-11T19:45:46.484162+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20262100-cj62--4772092",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.180428",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "Put your head above the parapet have we touk. RH will probably have less influence than you, you prick.",
          "sentiment": 0.0,
          "engagement": "4,302",
          "price_at_post": "60.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T19:45:46.484180+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20262049-D-Geeman--5649478",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.181255",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "AI Overview Trading 212 (T212) and Hargreaves Lansdown (HL) offer starkly different approaches to trading Tiziana Life Sciences Ltd (NASDAQ: TLSA), with T212 focusing on low-cost, app-based trading, while HL provides a more traditional, comprehensive service with higher fees . T212 is generally better for frequent, small-value, or beginner trading due to zero-commission fees, while HL is often preferred for larger, long-term holdings and pensions. Comparison: Tiziana Life Sciences (TLSA) Trading Trading 212 (T212): Cost: Zero-commission trading on stocks and ETFs, though a 0.15% FX fee applies to non-GBP transactions. Features: Offers fractional shares, allowing for small investments in TLSA. CFD Trading: Offers long/short CFD trading on TLSA with leverage. Downsides: Limited research tools and no tax advice; users have reported wide spreads during volatile times for small-cap stocks. Hargreaves Lansdown (HL): Cost: High dealing charges (e.g., \u00a311.95 per deal), which can be costly for small trades. Features: Provides extensive research, analysis, and higher-quality, live, or more transparent pricing. Suitability: Better suited for holding larger, long-term positions or in a SIPP (pension).",
          "sentiment": 0.0,
          "engagement": "5,868",
          "price_at_post": "60.00",
          "thread_title": "RE: Trading 212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38EA914-FA00-4B19-B293-5E96B62D2062"
        },
        "ingested_at": "2026-02-11T19:45:46.484199+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20262041-D-Geeman--6347142",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.181977",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "I also have shares in $TLSA (formerly Tiziana PLC) which moved to the Nasdaq. People on the board for $TLSA.US have often complained about other brokers (I THINK Halifax amongst others) not allowing trades and I think people with 212 had there accustem shares sold against their will when they were spun-off to OTC. If AVCT do go on to the Nas I shall be happy to be with HL but each to their own.",
          "sentiment": 0.0,
          "engagement": "5,868",
          "price_at_post": "60.00",
          "thread_title": "RE: Trading 212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38EA914-FA00-4B19-B293-5E96B62D2062"
        },
        "ingested_at": "2026-02-11T19:45:46.484217+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20262026-IFA90-56936521",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.182574",
        "source": "LSE_CHAT",
        "data": {
          "author": "IFA90",
          "content": "I\u2019m no trader so 212 works for me. I just transferred a handful of Avacta shares across, took about 10 days. I\u2019ll move the rest soon. You can\u2019t dummy quote but I don\u2019t see any other downsides.",
          "sentiment": 0.0,
          "engagement": "415",
          "price_at_post": "60.00",
          "thread_title": "RE: Trading 212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38EA914-FA00-4B19-B293-5E96B62D2062"
        },
        "ingested_at": "2026-02-11T19:45:46.484236+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20262025-Icecool--1063959",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.183017",
        "source": "LSE_CHAT",
        "data": {
          "author": "Icecool",
          "content": "I hear what you\u2019re saying, and I get the excitement, but this is where biotech reality usually kicks in. Big pharma almost never forces an early move before human data unless they\u2019re facing an immediate strategic threat. AVA6103 is IND-cleared, which is huge, but it\u2019s still pre-human efficacy. That\u2019s exciting, not yet unavoidable. They are already in the data room and Avacta has made it clear they want to see human data on AVA6103 before they deal on that asset, everyone has to respect that. Right now BP doesn\u2019t need to rush or upset anyone to protect its position. They can stay close, sit in the data room, structure options, or wait for Phase 1 signals before committing real money with Avacta approval. That\u2019s how this industry normally works. The idea that retail holders could be quietly shaken out on the cheap also feels unlikely. Any hint of opportunistic behaviour would harden positions very quickly, not soften them. What the board is doing makes sense, build leverage before the power dynamic flips. Once AVA6103 shows even early human efficacy, urgency changes overnight and the tone of conversations changes with it.",
          "sentiment": 0.0,
          "engagement": "8,855",
          "price_at_post": "60.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T19:45:46.484253+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20262022-cj62-87233411",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.183465",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "Well I'm hoping that maybe 2 or 3 BP would like it but if all is well with ava6103 maybe go down the ARM route. 6 months and we should know",
          "sentiment": 0.0,
          "engagement": "4,302",
          "price_at_post": "60.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T19:45:46.484272+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261948-B2HS2L--4221595",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.183925",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "'That is extremely unlikely in biotech. As big pharma prefer to negotiate clean and keep everyone on side.' I hear what you say and generally agree. However, an opportunity like this occurs very infrequently. A successful purchase - however that occurs - confers market disruption and after commercialisation, competitive advantage upon the purchaser, with others making do with ADC development or resuming the search for new tech. This situation can't be brushed under the carpet. It's not what we would want, but you can't help seeing BP may want a deal sooner rather than later for a myriad of reasons. Pi**ing off the BoD might have to happen if one, or more than one BP are so keen to 'own it', or likely - make sure other BP's don't get a bargain in their efforts to 'own it'. There are a large number of PI's who could be easily persuaded to part with their shares at prices BP would definitely find attractive. It remains to be seen where and when the first bid arrives. The BoD are planning for the long haul, but let's hope they achieve as much as humanly possible before BP calls time on Avacta's progress.",
          "sentiment": 0.0,
          "engagement": "6,031",
          "price_at_post": "60.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T19:45:46.484290+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261935-D-Geeman--5425405",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.184434",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "I opened a 212 account a few years ago but don't use it. With HL your purchase happens immediately but with 212 it can take a while and goes thru in dribs and drabs (while the price is changing). Aren't HL lowering their dealing charges in April? I got a message and believe they are dropping to around \u00a36 for everyone (maybe more for some?) Maybe 212 are ok for bigger shares.",
          "sentiment": 0.0,
          "engagement": "5,868",
          "price_at_post": "60.00",
          "thread_title": "RE: Trading 212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38EA914-FA00-4B19-B293-5E96B62D2062"
        },
        "ingested_at": "2026-02-11T19:45:46.484309+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261920-Codejunk--3448245",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.184970",
        "source": "LSE_CHAT",
        "data": {
          "author": "Codejunkie",
          "content": "Pharma don't generally do hostile takeovers. They just pay the right price for the IP and make sure staff transfer over Hostile takeovers lose key staff....",
          "sentiment": 0.0,
          "engagement": "2,668",
          "price_at_post": "60.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T19:45:46.484327+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261916-russell1--2176570",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.185404",
        "source": "LSE_CHAT",
        "data": {
          "author": "russell1",
          "content": "Does anybody hold their Avacta shares with Trading 212? If so, is it easy to deal and are the prices comparable to other platforms. I use HL but am thinking about moving away.",
          "sentiment": -0.5,
          "engagement": "318",
          "price_at_post": "60.00",
          "thread_title": "Trading 212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38EA914-FA00-4B19-B293-5E96B62D2062"
        },
        "ingested_at": "2026-02-11T19:45:46.484345+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261857-cj62--7133561",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.185820",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "Its OK saying Hughes won't allow a low bid to be decided by shareholders, but what about a hostile bid. Any bid will be decided by the shareholders RH will have no say.",
          "sentiment": 0.0,
          "engagement": "4,302",
          "price_at_post": "60.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T19:45:46.484364+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261849-Icecool--8090886",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.186361",
        "source": "LSE_CHAT",
        "data": {
          "author": "Icecool",
          "content": "\u201cIt\u2019s OK saying Hughes won't allow a low bid to be decided by shareholders, but what about a hostile bid.\u201d That is extremely unlikely in biotech. As big pharma prefer to negotiate clean and keep everyone on side.",
          "sentiment": 0.0,
          "engagement": "8,855",
          "price_at_post": "60.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T19:45:46.484381+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261842-B2HS2L--5477538",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.187281",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "Bella ...Is the BOD in it for the long haul or would they simply take a good offer so they can move on to pastures new? I'm no longer thinking so much about how long it's going to take Avacta to achieve A,B or C. The nearer timelines we know about, but my point is how long are BP going to allow us to plough our own furrow? The more IP we pile up the larger amount SB rightly thinks the company is worth. These companies (with larger manpower & resources) will probably not want to proceed at Avacta's pace. Some will want faster development, and want their competitive advantage, with the purchase of all we have, to begin sooner. Others can't face a bigger purchase if left too long. Some BP will have funds available at different times as their priorities such as other projects will need to be factored into their timescales. Its OK saying Hughes won't allow a low bid to be decided by shareholders, but what about a hostile bid. There is no accounting for such a bid with completely opaque timescales. This is a market disruptive project and to a certain extent interested parties will want to move possibly sooner than we would wish. I don't see Avacta finishing what they started, but what do I know?",
          "sentiment": 0.0,
          "engagement": "6,031",
          "price_at_post": "60.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T19:45:46.484399+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261755-Metatron--8426012",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.188128",
        "source": "LSE_CHAT",
        "data": {
          "author": "Metatron",
          "content": "That's the spirit Watching2!! poor old Winnypoos is banging his drum as fast as he can but.. can he stay in time? I've spent half my life with those and asking a drummer to think? that's sublime...",
          "sentiment": 0.0,
          "engagement": "1,192",
          "price_at_post": "60.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T19:45:46.484418+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261725-opti_mys--1702397",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.188933",
        "source": "LSE_CHAT",
        "data": {
          "author": "opti_mystic",
          "content": "With RH on the BoD there is zero chance of Avacta being sold on the cheap. They have to put serious offers to shareholders but I guess it depends how serious is defined. Offering half what the company is worth is not a serious offer in my view. They could down tools today and sell the IP and they'd get a lot more than the current market cap.",
          "sentiment": 0.0,
          "engagement": "307",
          "price_at_post": "60.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T19:45:46.484437+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261717-cj62--1201272",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.189693",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "There is 0% CoS attached to the sp and that includes ava 6 k. Presently it would stand at 5 - 11% after the recent rns",
          "sentiment": 0.0,
          "engagement": "4,302",
          "price_at_post": "60.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T19:45:46.484455+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261710-Watching-47679468",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.190157",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "Winne bot has broken  free ! Ignore !",
          "sentiment": 0.0,
          "engagement": "9,224",
          "price_at_post": "60.50",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T19:45:46.484473+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261613-wyndrum--4168006",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.032149",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "\"Buyers don\u2019t care about today\u2019s SP, they care about what this asset can generate over a decade.\" do you think ever, before you post? If a buyer thinks this will be huge multiple in value then they buy as cheaply as they can which today would be 60p? Otherwise one would assume they are waiting for something... i dunno....maybe data from a trial yet to start? Also in response to where shareholders might sell: The SP would not be say, 500p per share from here on speculation. It would be on the back of very good results and data. It would be that data that would influence as to weather or not it would be sensible to sell.",
          "sentiment": 0.0,
          "engagement": "12,250",
          "price_at_post": "60.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T19:45:46.484492+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261556-Icecool--4519857",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.032939",
        "source": "LSE_CHAT",
        "data": {
          "author": "Icecool",
          "content": "If AVA6103 does what it\u2019s designed to do in humans, this isn\u2019t a few billion story. On any sensible biotech valuation framework (see my case study \ud83e\udd23\ud83d\ude09), you\u2019re talking tens of billions, not pocket change. That\u2019s total value paid, not based on some AIM screen price that flickers day to day. That\u2019s why the share price right now is basically irrelevant. Buyers don\u2019t care about today\u2019s SP, they care about what this asset can generate over a decade. Thankfully it also explains the strategy perfectly. Avacta is keeping AVA6103 solo for now because proving it in humans is where the real value unlock happens. You don\u2019t sell something like this on promise alone, you sell it when the risk collapses and the leverage flips. That\u2019s the play here. Prove it works in people, then let the numbers do the talking.",
          "sentiment": 0.0,
          "engagement": "8,855",
          "price_at_post": "61.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T19:45:46.484510+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261528-Timster--6767327",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.033717",
        "source": "LSE_CHAT",
        "data": {
          "author": "Timster",
          "content": "If CC brings anything less than \u00a3200 ex chi-nah, she'd be having a laugh!",
          "sentiment": 0.0,
          "engagement": "20,637",
          "price_at_post": "61.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T19:45:46.484529+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261523-cj62--5888272",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.034552",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "Directors cannot quietly reject a serious offer that could reasonably be of interest to shareholders once it becomes concrete. Their duty is to: Act in shareholders\u2019 best interests and Not frustrate an offer without shareholder approval",
          "sentiment": 0.0,
          "engagement": "4,302",
          "price_at_post": "61.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T19:45:46.484547+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261523-HarChris--4937697",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.035361",
        "source": "LSE_CHAT",
        "data": {
          "author": "HarChris",
          "content": "575m total share count feels a more realistic figure to be working with when forecasting future takeover share price so \u00a33B would be more like \u00a35.25 a share.",
          "sentiment": 0.0,
          "engagement": "15,923",
          "price_at_post": "61.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T19:45:46.484565+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261512-Bella653-40185945",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.036083",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "The BIG Questions are... Is the BOD in it for the long haul or  would they simply take a good offer so they can move on to pastures new? and how much are they will to hold out for?",
          "sentiment": 0.0,
          "engagement": "6,756",
          "price_at_post": "61.50",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T19:45:46.484583+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261507-Bella653--5484486",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.036656",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "I don't think you'll get anywhere near your SP wishlist on a T/O deal as we stand right now. Deals and NASDAQ Listing will drive value but we need some big hitters in the Finance World like Healthcare Royalty to back Avacta and to negotiate the best T/O deal possible at the right time.",
          "sentiment": 0.0,
          "engagement": "6,756",
          "price_at_post": "61.50",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T19:45:46.484601+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261505-hamsters-15579784",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.037073",
        "source": "LSE_CHAT",
        "data": {
          "author": "hamsters18",
          "content": "What large buys?",
          "sentiment": 0.0,
          "engagement": "3,692",
          "price_at_post": "61.50",
          "thread_title": "RE: TAKEOVER",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=DAF752F5-FA6F-49F9-BD50-F5C834118B9E"
        },
        "ingested_at": "2026-02-11T19:45:46.484619+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261449-Deod123--6722851",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.037518",
        "source": "LSE_CHAT",
        "data": {
          "author": "Deod123",
          "content": "Large buys going through.someone is stake building",
          "sentiment": 0.0,
          "engagement": "68",
          "price_at_post": "61.00",
          "thread_title": "TAKEOVER",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=DAF752F5-FA6F-49F9-BD50-F5C834118B9E"
        },
        "ingested_at": "2026-02-11T19:45:46.484637+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261438-cj62--8897491",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.037940",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "\u00a3200 ex china  Not this LTH",
          "sentiment": 0.0,
          "engagement": "4,302",
          "price_at_post": "61.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T19:45:46.484655+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261431-Wilson63--6575635",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.038378",
        "source": "LSE_CHAT",
        "data": {
          "author": "Wilson63",
          "content": "I'm somewhat surprised a couple of regulars are going to sell out at fairly low numbers, if this continues to pass each obstacle it's a one and only lifetime chance imho, topping up monthly slow and steady.",
          "sentiment": 0.0,
          "engagement": "8,808",
          "price_at_post": "60.50",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T19:45:46.484673+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261323-BuenaVis--3725949",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.038809",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Yes, the pre|CISION pie can be cut many ways: by drugs, indications and territories, and all with or without exclusivity.  People might say that faridox, with its boring old doxorubicin, will be overtaken by newer, more powerful pre|CISION drugs but the fact is it is here and now and not far off its first approved indication, salivary gland cancer, if the data released so far is to be believed. So with all that, why would any company want to license it when there could be better options in the future?  Well, if the offer was a global exclusive licence to develop faridox for SGC, plus the option to have first dibs on any future Avacta pre|CISION drug for SGC, plus the rights to develop their own pre|CISION drugs for SGC\u2014essentially an exclusive licence agreement to control the global pre|CISION SGC market\u2014then that would surely be of great interest. If it's taking Simon a long time to get that first deal, well the licensing possibilities are nearly endless and newly revealed data and developments are moving the goal posts in Avacta's favour all the time as conclusive evidence proves the platform (I'll call it that now already).",
          "sentiment": 0.0,
          "engagement": "5,826",
          "price_at_post": "59.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T19:45:46.484691+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261300-Vertizea-99749913",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.039250",
        "source": "LSE_CHAT",
        "data": {
          "author": "VertizeaSun",
          "content": "\u00a32 billion to buy a serious geographic licence for pre|CISION and a couple of warheads  sounds about right......say the EU/EEA and ex-ROW. Simon Bennett is now in his third year and the fact he hasn't been fired will suggest he has something up his sleeve. \u00a32B will pay for future independence and a \u00a31 per share dividend. I think we'll know within a couple of months and perhaps sooner as CC is obviously in town (doing celebratory cake delivery) and probably here for a board meeting - where they'll be trying to digest the recent torrent of good news. They actually have a lot on their plate. But I'm having trouble digesting \"the removal of the maximum dosing limit\" ...... apparently the first time in history for a phase 1 trial compound so I'm quite happy to believe that eventually pre|CISION is going to be compared to the impact penicillin had on the world of medicine. And in the beginning that discovery had serious FUD. Bill Gates said that the world always over-estimates how much change can take place in six months, but under-estimates how much change will take place in six years.",
          "sentiment": 0.0,
          "engagement": "440",
          "price_at_post": "59.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T19:45:46.484709+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261259-Matml74--9139727",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.039673",
        "source": "LSE_CHAT",
        "data": {
          "author": "Matml74",
          "content": "Dolly, Watch the R&D spotlight episode on next generation Precision from 2024 and also the dual payload one from late 2025. These highlight the vast opportunity for Precision.",
          "sentiment": 0.0,
          "engagement": "2,547",
          "price_at_post": "59.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T19:45:46.484727+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261252-opti_mys-44225194",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.040082",
        "source": "LSE_CHAT",
        "data": {
          "author": "opti_mystic",
          "content": "Oh yea of little faith. \u00a310 is my absolute bare minimum from when I first invested. Due to progress on a number of fronts that has gone up. Somewhat disappointed that people would sell so cheaply. Hopefully the BoD know what the company is worth and will not put to shareholders derisory offers that significantly under values the company.",
          "sentiment": 0.0,
          "engagement": "307",
          "price_at_post": "59.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T19:45:46.484745+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261249-Dollyg--4143128",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.040506",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dollyg",
          "content": "Thank you",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "59.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T19:45:46.484763+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261239-yeboha--7861752",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.040920",
        "source": "LSE_CHAT",
        "data": {
          "author": "yeboha",
          "content": "Dolly if you do some research online you can see that many professionals in the field agree that it can be used on many drugs !",
          "sentiment": 0.0,
          "engagement": "963",
          "price_at_post": "59.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T19:45:46.484781+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261237-yeboha-70379182",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.041383",
        "source": "LSE_CHAT",
        "data": {
          "author": "yeboha",
          "content": "Avacta\u2019s pipeline includes several distinct pre|CISION\u00ae drug conjugates with different therapeutic payloads, not just a single product: AVA6000 (a doxorubicin-based peptide drug conjugate) has shown positive clinical progress. AVA6103 (exatecan-based PDC) is advancing toward clinical trial start. Dual-payload PDCs are being developed in preclinical stages, combining agents like microtubule inhibitors and DNA damage response modulators. Another pipeline program, AVA7100 (an Affimer\u00ae-based drug conjugate), is also in preclinical development with its own payload delivery design. \ud83d\udccc Why this matters: This demonstrates that Avacta\u2019s platform isn\u2019t limited to a single drug but is being developed as a modular engine for multiple therapeutic combinations and individual payloads",
          "sentiment": 0.0,
          "engagement": "963",
          "price_at_post": "59.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T19:45:46.484799+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261231-Dollyg-45307592",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.041792",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dollyg",
          "content": "Be good to get a medically qualified opinion of the ACTUAL potential of how many differing treatments this technology could affect.",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "59.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T19:45:46.484817+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261227-Livedata-79208315",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.042216",
        "source": "LSE_CHAT",
        "data": {
          "author": "Livedataaccount",
          "content": "Hi jane im out at 4 pounds if it gets there",
          "sentiment": 0.0,
          "engagement": "2,969",
          "price_at_post": "59.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T19:45:46.484835+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261225-yeboha--4441947",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.042623",
        "source": "LSE_CHAT",
        "data": {
          "author": "yeboha",
          "content": "Its funny we say this, being where the share price is but im so convinced about avacta and have been for years !",
          "sentiment": 0.0,
          "engagement": "963",
          "price_at_post": "59.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T19:45:46.484853+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261221-Watching-75618298",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.043037",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "Happy with \u00a37 pre share. But \u00a310 would be a nice surprise . Jane",
          "sentiment": 0.0,
          "engagement": "9,224",
          "price_at_post": "59.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T19:45:46.484871+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261213-Dollyg--6825274",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.043462",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dollyg",
          "content": "I read the \u00a33 billion figure was first mooted in 2023 and they seem to have come a long way since then in terms of efficacy. The concensus seens to be wait.",
          "sentiment": 0.5,
          "engagement": "8",
          "price_at_post": "59.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T19:45:46.484889+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261212-yeboha-93053066",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.043874",
        "source": "LSE_CHAT",
        "data": {
          "author": "yeboha",
          "content": "Thats roughly my thinking",
          "sentiment": 0.0,
          "engagement": "963",
          "price_at_post": "59.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T19:45:46.484907+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261209-BuenaVis--3951235",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.044290",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "$4bn would be 668p a share.  Not enough for me.  I'd be looking for at least 1,000p a share, a $6bn buyout.  At least.",
          "sentiment": 0.0,
          "engagement": "5,826",
          "price_at_post": "59.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-11T19:45:46.484924+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20262313-aidanjc-82907666",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.524270",
        "source": "LSE_CHAT",
        "data": {
          "author": "aidanjc",
          "content": "Good point.  If cancer treatments improve that is a fantastic result. Its crept into my life a lot recently. Great to make a profit on the shares but improving outcomes for cancer patients is really important.",
          "sentiment": 0.0,
          "engagement": "6",
          "price_at_post": "51.50",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-11T19:45:46.484942+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20262051-avctIPma-10473546",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.524706",
        "source": "LSE_CHAT",
        "data": {
          "author": "avctIPmatters",
          "content": "Thanks for sharing  B2HS2L  -  Helps spread info on the platform  .",
          "sentiment": 0.0,
          "engagement": "728",
          "price_at_post": "51.50",
          "thread_title": "RE: CDD European Life Science Community Meeting",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=3A2F031D-C16F-4949-B22E-8512255BE282"
        },
        "ingested_at": "2026-02-11T19:45:46.484961+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20262049-avctIPma--2605614",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.525140",
        "source": "LSE_CHAT",
        "data": {
          "author": "avctIPmatters",
          "content": "Thanks for sharing  Thompi -  All helps spread   Avacta exposure .",
          "sentiment": 0.0,
          "engagement": "728",
          "price_at_post": "51.50",
          "thread_title": "RE: World CB & CDx Summit Europe",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=18E94451-D174-452E-BD8A-79154E17863F"
        },
        "ingested_at": "2026-02-11T19:45:46.484978+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20262022-Livedata-42999798",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.525565",
        "source": "LSE_CHAT",
        "data": {
          "author": "Livedataaccount",
          "content": "Ellen's great she will do a fantastic presentation",
          "sentiment": 0.0,
          "engagement": "2,957",
          "price_at_post": "51.50",
          "thread_title": "RE: CDD European Life Science Community Meeting",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=3A2F031D-C16F-4949-B22E-8512255BE282"
        },
        "ingested_at": "2026-02-11T19:45:46.484996+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20262016-B2HS2L-56696935",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.525997",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "Https://www.collaborativedrug.com/cdd-european-scientific-community-meeting-2026 Dr Ellen Watts, Avacta Therapeutics 25.02.2026  17:00-17:30: Delivering Targeted Therapies Using the pre|CISION\u00ae Platform. Last presentation of the day",
          "sentiment": 0.0,
          "engagement": "6,003",
          "price_at_post": "51.50",
          "thread_title": "CDD European Life Science Community Meeting",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=3A2F031D-C16F-4949-B22E-8512255BE282"
        },
        "ingested_at": "2026-02-11T19:45:46.485014+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261732-Timster--8723187",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.526420",
        "source": "LSE_CHAT",
        "data": {
          "author": "Timster",
          "content": "Good spot Thompi, thanks",
          "sentiment": 0.0,
          "engagement": "20,626",
          "price_at_post": "51.50",
          "thread_title": "RE: World CB & CDx Summit Europe",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=18E94451-D174-452E-BD8A-79154E17863F"
        },
        "ingested_at": "2026-02-11T19:45:46.485032+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261722-Thompi-78926700",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.526848",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thompi",
          "content": "Ruairidh Edwards will be speaking on 1 April at the 16th World Clinical Biomarkers & Companion Diagnostics Summit Europe. Presentation title: Establishing a Biomarker-Driven Approach to Guide Patient Selection for preCISION\u00ae Peptide-Drug Conjugates Using Tumour Targeting/Release and Payload Sensitivity Biomarkers. https://cdx-europe.com/full-event-guide/",
          "sentiment": 0.0,
          "engagement": "1,358",
          "price_at_post": "51.50",
          "thread_title": "World CB & CDx Summit Europe",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=18E94451-D174-452E-BD8A-79154E17863F"
        },
        "ingested_at": "2026-02-11T19:45:46.485050+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261707-Agenda10--1627514",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.527323",
        "source": "LSE_CHAT",
        "data": {
          "author": "Agenda101",
          "content": "No not engage ! It\u2019s working so let\u2019s continue to starve them of any engagement. As Runner-Runner wrote and BV reposted\u2026 It's simple. 1. DO NOT ENGAGE 2. DO NOT ASK IT A QUESTION 3. DO NOT ANSWER ITS QUESTIONS 4. DO NOT MOAN ABOUT ITS POSTS 5. DO NOT ARGUE WITH IT 6. If you must do something. Mock it with reference only to its stupidity and nothing else. ------------------------------------------------------ If you're not part of the solution, you're part of the problem",
          "sentiment": 0.0,
          "engagement": "72",
          "price_at_post": "52.50",
          "thread_title": "RE: Bone Marrow Toxicity, Brain malignancies?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=34DD9B68-3AA3-4F24-A8A5-8F742D7F4948"
        },
        "ingested_at": "2026-02-11T19:45:46.485068+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261704-Agenda10-39974965",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.527740",
        "source": "LSE_CHAT",
        "data": {
          "author": "Agenda101",
          "content": "\u201cI\u2019m committed for the next two years, but I anticipate that developments around licensing, manufacturing, and supply will begin to materialise well before then. From my perspective, the time to push ahead is now.\u201d",
          "sentiment": 0.0,
          "engagement": "72",
          "price_at_post": "51.50",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-11T19:45:46.485085+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261656-Thornogs--6327204",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.528205",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Well I didn't post! Not much said I see. More chat about FAP expressed on inflamed/fibrotic tissue other than cancer as a positive therapeutic opportunity with no one wondering if this self same tissue might cause problems should someone inject a FAP released 'Beast' into the circulation whilst trying to target a FAP related cancer.  Were that to happen in the FAP-EXD 1a Safety trial I think it would count as a Black Mark. BV and Syphysus indulged their in depth knowledge of molecular biology and the Blood Brain Barrier to 'deep dive' the potential to treat cerebral cancers, I do hope CC read those posts or perhaps one of you could send her an e mail explaining the possibilities? And the Market did what I thought it would do, go down, down the at the last come back up to almost, but not quite, where we opened. 1% down today, 3% this week and 10% down on the month. I see this continuing until the surprise deal mentioned earlier or being more realistic the next raise to fund the programme through 2026. Any thoughts on support/resistance levels Wyn? Happy to be out waiting for FAP-EXD and funding doubts to clear.",
          "sentiment": 0.0,
          "engagement": "8,666",
          "price_at_post": "51.50",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-11T19:45:46.485119+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261643-wyndrum-89300900",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.528628",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "I see \u201cthe don\u2019t engage\u201d policy didn\u2019t last long. You simply can\u2019t have a bb devoted to the actual topic and miss out on insulting others can you? Predictable and pathetic behaviour. Who knew?",
          "sentiment": 0.0,
          "engagement": "12,228",
          "price_at_post": "51.50",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-11T19:45:46.485138+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261640-D-Geeman--7306542",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.529049",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "'Chris, are you still interested in my buys and sells or would you prefer me not to bother?' Chris might not be interested Wyn, but I am... I dare say I'm not alone either.",
          "sentiment": 0.0,
          "engagement": "5,849",
          "price_at_post": "51.00",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-11T19:45:46.485156+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261639-Toukanka--5096460",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.529486",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "BV Are you a lawyer? We were led to believe that 6000 P1b would finish end of 25. So you don\u2019t regard having to go an extra cycle as missing a target. Or all the talk of multiple events before end 25 as not materialising. Anyhow at least some people on here are rooted in reality and believe CC when she says not to expect much before 2H26. Be. Patient",
          "sentiment": 0.0,
          "engagement": "4,454",
          "price_at_post": "51.00",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-11T19:45:46.485175+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261631-cj62--5871615",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.529902",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "Fine with me Chris. I would remind you however that it was you that asked I report my trades. You did report your last losing trade though did you, you prick",
          "sentiment": 0.0,
          "engagement": "4,282",
          "price_at_post": "51.50",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-11T19:45:46.485193+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261628-BuenaVis--5823821",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.530336",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Yes, that could be one possibility.",
          "sentiment": 0.0,
          "engagement": "5,775",
          "price_at_post": "51.50",
          "thread_title": "RE: Bone Marrow Toxicity, Brain malignancies?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=34DD9B68-3AA3-4F24-A8A5-8F742D7F4948"
        },
        "ingested_at": "2026-02-11T19:45:46.485211+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261622-wyndrum-29933887",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.530749",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "Fine with me Chris. I would remind you however that it was you that asked I report my trades. Anyway I\u2019m keen to see how this bb goes from here.",
          "sentiment": 0.0,
          "engagement": "12,228",
          "price_at_post": "51.50",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-11T19:45:46.485229+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261615-HarChris-86181020",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.531177",
        "source": "LSE_CHAT",
        "data": {
          "author": "HarChris",
          "content": "The last time I pointed out your losing trade you responded by saying you barely had anything on it\u2026 so nah, don\u2019t bother if you can just twist it how you want. And it clogs up the bb even more! How about not sharing any and trying not to care what an anonymous group of people think about your trading prowess?! That would be healthier!",
          "sentiment": 0.0,
          "engagement": "15,870",
          "price_at_post": "51.50",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-11T19:45:46.485248+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261613-Agenda10-83567112",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.531589",
        "source": "LSE_CHAT",
        "data": {
          "author": "Agenda101",
          "content": "None.. he\u2019s fishing don\u2019t reply!",
          "sentiment": 0.0,
          "engagement": "72",
          "price_at_post": "51.50",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-11T19:45:46.485266+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261547-BuenaVis-24511431",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.532000",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "@russell1 , what deadlines has Avacta missed since CC became CEO on 1 May 2024?",
          "sentiment": 0.0,
          "engagement": "5,775",
          "price_at_post": "51.00",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-11T19:45:46.485285+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261536-russell1--8386015",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.532426",
        "source": "LSE_CHAT",
        "data": {
          "author": "russell1",
          "content": "Well I'm not prepared to add any more money to my current loss situation so my only decision is whether to sell a proportion of my holding and hope I can buy back at a lower price if we (ever) get some worthwhile news or just leave it and hope! My expectation is that the price will just drift down until any news arrives but I have no expectation that this company will ever meet any of its reported deadlines.",
          "sentiment": -0.5,
          "engagement": "315",
          "price_at_post": "51.00",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-11T19:45:46.485303+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261529-Sisyphus-88381489",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.532837",
        "source": "LSE_CHAT",
        "data": {
          "author": "SisyphusShorter",
          "content": "Thanks BV, good to know. So in theory, a \"FAP-Temo\" agent would be roughly 460Da in size, provided the same Gen1 preCISION peptide is used. That puts it within the 400-600 threshold for BBB-crossing possibility (obviously notwithstanding lipophilicity, polarity and other parameters). That being said they could always cleave off a few residues to make a lightweight version for this specific indication.",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "51.00",
          "thread_title": "RE: Bone Marrow Toxicity, Brain malignancies?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=34DD9B68-3AA3-4F24-A8A5-8F742D7F4948"
        },
        "ingested_at": "2026-02-11T19:45:46.485322+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261509-Toukanka-29938939",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.533258",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "At last sensible posters instead of the usual carp \u201cfill yer boots you\u2019ll never again get the chance at this SP\u201d.  In truth we have a sideways drift until 6103 early clinical results are published in the Summer. Get over it and be patient.",
          "sentiment": 0.0,
          "engagement": "4,454",
          "price_at_post": "51.00",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-11T19:45:46.485340+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261432-wyndrum--7874181",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.533670",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "Chris, are you still interested in my buys and sells or would you prefer me not to bother?",
          "sentiment": 0.0,
          "engagement": "12,228",
          "price_at_post": "51.00",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-11T19:45:46.485358+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261413-Aston15--8879263",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.534076",
        "source": "LSE_CHAT",
        "data": {
          "author": "Aston15",
          "content": "I have brought enough now to be comfortable with the risk to reward ratio. 10% of my SIPP now in AVCT following another purchase this week. Many are expecting more than this, but my target remains a 5 billion valuation for the platform minimum. Happy to leave this to run now and hope the team delivers a positive outcome for both patients and shareholders.",
          "sentiment": 0.0,
          "engagement": "62",
          "price_at_post": "50.50",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-11T19:45:46.485376+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261410-B2HS2L--8008877",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.534502",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "Slide 16 & 18 of the Investormeet presentation 17.12.2025 contain info on tumor biopsies as articulated by Ruairidh Edwards, Translational Scientist. He's discussing phase 1b patients, possibly placing the recording of the interview before mid December.",
          "sentiment": 0.0,
          "engagement": "6,003",
          "price_at_post": "50.50",
          "thread_title": "RE: Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-02-11T19:45:46.485394+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261347-Vertizea-44355322",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.529148",
        "source": "LSE_CHAT",
        "data": {
          "author": "VertizeaSun",
          "content": "I think it links with CC's visit to Glasgow.....to visit the manufacturing site of AVA6103 and its \"first pour\".",
          "sentiment": 0.0,
          "engagement": "433",
          "price_at_post": "50.50",
          "thread_title": "RE: Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-02-11T19:45:46.485413+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261340-BuenaVis--2396940",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.529619",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Whilst the introduction by the host was current (post-IND announcement), CC seemed to be referencing passed events as being in the future and someone here suggested that the interview was recorded last year, in early December if I remember correctly.  I haven't listened to the interview again today but I do remember hearing bits that seemed out of step with today's situation.",
          "sentiment": 0.0,
          "engagement": "5,775",
          "price_at_post": "50.50",
          "thread_title": "RE: Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-02-11T19:45:46.485431+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261326-BuenaVis--2467035",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.530089",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Interesting and intelligent quesitions. As regards, fibrotic targets due to prior anthracycline treatment, it'll be interesting to see whether this side effect is reduced in previously untreated patients.  The breakdown of side effects vs prior treatment hasn't been presented yet but it is exacty the sort of detail I'm wanting to see (also, for example, side effects vs cancer indication/metastasis site).  Hopefully it will be included when the Phase 1 trial is written up in a peer-reviewed article, but there's always the AGM as an opportunity for asking detailed questions in person. As regards crossing the blood-brain barrier (BBB)... Temozolomide - molecular weight: 194.15 Da Doxorubicin - molecular weight: 543.52 Da Faridoxorubicin - molecular weight: 816.8 Da Faridoxorubicin without doxorubicin: 273.28 Da According to Gemini, \"Drugs that cross the BBB generally must be lipophilic (lipid-soluble), have a low molecular weight\u2014typically under 400\u2013600 Da\u2014and have a low polar surface area or few hydrogen bonds. They must avoid active efflux transport systems (like P-glycoprotein) and not be highly bound to plasma proteins.\"  So the requirements for an IV infusion drug are pretty stringent. However, there is an alternative route and that is, again according to Gemini, \"[administration] directly into the brain to bypass the BBB. This approach, known as local or regional drug delivery, is used to treat primary brain tumors (like glioblastoma) or brain metastases, allowing high concentrations of medication to reach the tumor without causing systemic toxicity.\"  I should think that the advantage of using pre|CISION for this is that, whilst the pre|CISION drug itself would be too big to cross OUT of the brain, the warhead, its metabolites and the leaving group from the pre|CISION substrate could all be below the size needed to cross out of the brain.  Anyway, CC wouldn't have specifically mentioned brain cancer if it weren't a possibility.",
          "sentiment": 0.0,
          "engagement": "5,775",
          "price_at_post": "50.50",
          "thread_title": "RE: Bone Marrow Toxicity, Brain malignancies?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=34DD9B68-3AA3-4F24-A8A5-8F742D7F4948"
        },
        "ingested_at": "2026-02-11T19:45:46.485449+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261318-IFA90--2442107",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.530517",
        "source": "LSE_CHAT",
        "data": {
          "author": "IFA90",
          "content": "I\u2019m not buying anymore. I\u2019ve increased my holding this week by selling a % and buying back c.10% cheaper. After 5 years it\u2019s entirely predictable, I just wish I\u2019d have realised that 3 years ago.",
          "sentiment": 0.0,
          "engagement": "409",
          "price_at_post": "50.50",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-11T19:45:46.485467+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261312-wyndrum--8300281",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.530949",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "Yes cj and I have just literally sold that holding and more as it looks to confused to me right now. Just so you know and can keep up I placed the sale evenly between Cpx and Xsg. Personally I would enjoy exploring and explaining my reasoning in a bit more depth but no need to is interested. ( and while you may all feel a bit more smug about this, it might be worth reflecting that I don\u2019t illicit the antagonist relationship here on other bb\u2019s. It begs the question is it me or you?)",
          "sentiment": 0.0,
          "engagement": "12,228",
          "price_at_post": "50.50",
          "thread_title": "RE: ADC 26",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=F3B63190-B417-42B7-9CC8-0ED98F4FBB92"
        },
        "ingested_at": "2026-02-11T19:45:46.485485+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261301-cj62--1314928",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.531376",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "\"Well the sp is 52p and now years later my analysis over a vey long period has proved correct and his wrong.\" but not recently you could have added- bought at 56.95 i believe. Yet still there are some that want me to be cancelled, yep you have that 100% correct as your narcissim knows no bounds",
          "sentiment": 0.0,
          "engagement": "4,282",
          "price_at_post": "50.50",
          "thread_title": "RE: ADC 26",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=F3B63190-B417-42B7-9CC8-0ED98F4FBB92"
        },
        "ingested_at": "2026-02-11T19:45:46.487289+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261254-Sisyphus--7569530",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.531796",
        "source": "LSE_CHAT",
        "data": {
          "author": "SisyphusShorter",
          "content": "So been looking at the phase 1 data for AVA6000 and also been listening to the podcast, thanks BV. Now I have two broad questions: One on bone/haem side effects, and one regarding primary brain cancers. Firstly, of the patients we have seen with bone marrow suppression, I know it's a known side effect of Dox, but I do wonder if prior primary therapies have induced a bit of fibrosis in the marrow, leading to FAP expression and thus Dox being released, leading to further bone marrow toxicity. That would imply that the side effects seen in the patients so far are less likely to emerge in a larger trial with a higher proportion of chemo-naive patients. Thoughts? Secondly, CC mentioned in the podcast that given that 90% of solid tumours express FAP, including brain, which she mentioned, and this begs the question whether or not the Peptide used in pre/CISION drug conjugates is small enough to pass the blood-brain-barrier, after all, that's how Temozolomide can do it's think for brain tumours. Again, thoughts?",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "50.50",
          "thread_title": "Bone Marrow Toxicity, Brain malignancies?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=34DD9B68-3AA3-4F24-A8A5-8F742D7F4948"
        },
        "ingested_at": "2026-02-11T19:45:46.487318+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261253-pedrolan--7454883",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.532225",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Yes, I bought some more the other week and am considering more now to get my average down further. If you believe in the medium term story here (with the bonus of a potential deal at any time) then it seems a bargain. Before any of the aliases bother to reply - I will not be responding to it - it will not be anything we have not all heard multiple times anyway.",
          "sentiment": 0.5,
          "engagement": "1,975",
          "price_at_post": "51.00",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-11T19:45:46.487337+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261252-BuenaVis--5560763",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.532633",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Another advantage of Avacta's PDCs is the h o m ogeneity of the dosage - exactly one warhead per drug molecule, or exactly two warheads per drug molecule for the dual payload drugs. In contrast, significant heterogeneity exists in ADCs as they are complex mixtures of varied molecular species rather than a single uniform compound. This includes differences in the drug-to-antibody ratio (DAR) and the conjugation sites on the antibody, leading to mixtures with 0 to 8+ payload molecules and various positional isomers.",
          "sentiment": 0.0,
          "engagement": "5,775",
          "price_at_post": "51.00",
          "thread_title": "RE: ADC 26",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=F3B63190-B417-42B7-9CC8-0ED98F4FBB92"
        },
        "ingested_at": "2026-02-11T19:45:46.487356+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261250-aidanjc--4300945",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.533041",
        "source": "LSE_CHAT",
        "data": {
          "author": "aidanjc",
          "content": "I've been a lth here having bought at several levels. Was hoping not to see us back around the 50p level. I've bought a few more. Anyone else buying. I'm hoping 50p will be the low tide mark...",
          "sentiment": 0.5,
          "engagement": "6",
          "price_at_post": "51.00",
          "thread_title": "Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-11T19:45:46.487375+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261246-wyndrum-34215551",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.533480",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "Also I don\u2019t care if you respond or not. I just hope it makes you think.also you will crack before we do. Not because it\u2019s a contest but simply we will ask questions or post opinions that as a bb you will naturally want to respond to. That\u2019s the whole purpose of a discussion bb. To discuss. And while there are a lot of recs to want us to be cancelled you will soon be bored with the lack of insight offered by the so called guardians of this bb. And never forget, it is exactly the same posters that by insulting us that then generate the board clogging are the ones piously demanding we be ignored. Just check sheppy watching bv and the rest for their overall contribution.",
          "sentiment": 0.0,
          "engagement": "12,228",
          "price_at_post": "51.00",
          "thread_title": "RE: ADC 26",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=F3B63190-B417-42B7-9CC8-0ED98F4FBB92"
        },
        "ingested_at": "2026-02-11T19:45:46.487393+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261243-Sisyphus--7287324",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.533883",
        "source": "LSE_CHAT",
        "data": {
          "author": "SisyphusShorter",
          "content": "Sorry, *Next* data release....",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "51.00",
          "thread_title": "RE: Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-02-11T19:45:46.487412+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261240-Sisyphus--5217810",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.534310",
        "source": "LSE_CHAT",
        "data": {
          "author": "SisyphusShorter",
          "content": "At 36:22 CC says, regarding tumour biopsies - \"...in our new data release which will be later this month...\" Make of that what you will..... GLA",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "51.00",
          "thread_title": "RE: Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-02-11T19:45:46.487430+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261232-wyndrum--1627799",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.534763",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "Oh, I remember, after this interview and the other stuff uncovered, what has the sp done? Why ,  How, can there be more sellers than buyers? Let\u2019s move on from the \u201csp doesn\u2019t matter \u201c. It\u2019s a facile statement which simply refuses to address a perfectly reasonable question. Yes the sp can drift up or down on no news but why can\u2019t we discuss it when there is a very positive release and it generates sells? By all means keep up this do not engage but myles tried this with me specifically on this bb with a little header to try and get me banned altogether. Well the sp is 52p and now years later my analysis over a vey long period has proved correct and his wrong. Yet still there are some that want me to be cancelled. You lot are either just plain weird or it is you that have an agenda. Just remember I have made money out of this stock and had you agreed with my view you would have too. The opposite would have happened if you followed bv and the rest. Yet you want me silenced. You might perhaps realise why I wonder what motivates the majority here.",
          "sentiment": 0.0,
          "engagement": "12,228",
          "price_at_post": "51.00",
          "thread_title": "RE: ADC 26",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=F3B63190-B417-42B7-9CC8-0ED98F4FBB92"
        },
        "ingested_at": "2026-02-11T19:45:46.487449+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261221-Watching-57255275",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.535189",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "To the Fudders they are trying so hard this morning ! It worked yesterday ! They are drying up \ud83e\udd21s",
          "sentiment": 0.0,
          "engagement": "9,215",
          "price_at_post": "51.00",
          "thread_title": "Do not respond",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=598797E4-B255-4509-971C-C103D6214E00"
        },
        "ingested_at": "2026-02-11T19:45:46.487467+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261143-wyndrum--2507042",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.535610",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "whatever you do, do not do not reply  or respond. you might want to take the ****, but resist. you might have the best put down ever! but do not repeat do not respond  got it? now what was i going to say\u2026. damn after all that i forgot \u2026.,",
          "sentiment": 0.0,
          "engagement": "12,228",
          "price_at_post": "52.00",
          "thread_title": "RE: ADC 26",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=F3B63190-B417-42B7-9CC8-0ED98F4FBB92"
        },
        "ingested_at": "2026-02-11T19:45:46.487485+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261014-HarryAng--4693959",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.536027",
        "source": "LSE_CHAT",
        "data": {
          "author": "HarryAngstrom",
          "content": "I meant PEAK SALES to Avacta... not TAM.",
          "sentiment": 0.0,
          "engagement": "9",
          "price_at_post": "52.50",
          "thread_title": "RE: Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-02-11T19:45:46.487503+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260955-D-Geeman--4709036",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.536554",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "'Today 09:44 Don't waste time responding if your handle is ........ D-Geeman ' You sound like a teenager with a statement like that B2HS2L. In this context that isn't a compliment.",
          "sentiment": 0.0,
          "engagement": "5,849",
          "price_at_post": "53.00",
          "thread_title": "RE: ADC 26",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=F3B63190-B417-42B7-9CC8-0ED98F4FBB92"
        },
        "ingested_at": "2026-02-11T19:45:46.487521+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260946-HarryAng-92190244",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.537041",
        "source": "LSE_CHAT",
        "data": {
          "author": "HarryAngstrom",
          "content": "This is a gigantic opportunity. TAM for Rhematoid Arthritis would be between $3.0 - $4.0 billion. And if they move into Fibrosis, the TAM there is between $7.0 - $10.0 billion. Once they prove they can deliver a toxin as potent as Exatecan using the FAP linker, using the same linker for milder anti-fibrotic or anti-inflammatory drugs is a low risk, high reward certainty.",
          "sentiment": 0.0,
          "engagement": "9",
          "price_at_post": "52.50",
          "thread_title": "RE: Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-02-11T19:45:46.487539+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260944-B2HS2L--5091818",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.537575",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "Don't waste time responding if your handle is wyndrum, Thornogson, Toukankahmoon or D-Geeman ********************************************************************************************************* Like my new header?  \ud83d\ude01\ud83d\ude09   I hope you create similar. In the event one company buys Avacta, all others will need to continue developing ADC's. They'll need to make improvements to compete as follows: 1 Reduce the time required to develop new drugs. 2 Improve the precision of targeting of warheads, so less drug is available systemically. 3 Improve the ease and speed of manufacturing 4 Find ways to reduce particle size 5 Find ways to deliver >1 drug at a time. Also - * Small molecule manufacturing and timeline/COGM (cost of goods manufactured) \"What that statement means and why that is important, is that the price tag for this drug (AVA6000), is one tenth of the price tag for an ADC drug. ADC's cost a lot of money in the clinic\"  CC 8.11.2024 I don't see why the statement isn't also true for AVA6103. ++++ A reminder from  Trinity Delta \u2013 Targeting the tumour microenvironment with pre|CISION - 18.11.2024 https://www.trinitydelta.org/research-notes/targeting-the-tumour-microenvironment-with-precision/ \"Avacta has so far FAP-enabled ten different warheads building up a database of multiple pre|CISION compounds that include c 40 capping groups (which alter the PK of the conjugate) and c 20   linkers (required for FAP cleavage with certain warheads and can be used to modify FAP affinity and activity). These have all been characterised through computational simulations to evaluate molecular binding and how they dock into the FAP structure. A key consideration is how close the warhead can get to the FAP cleavage sequence; this typically depends on the size of the molecule, and often defines whether a spacer group is required. Consideration is also given to how long the conjugate and the active warhead are likely to remain in the TME, and this informs whether PK alterations, achieved through an alternative capping group, are needed to either allow the sustained release of the warhead or to slow plasma clearance. Potential candidate molecules that meet the internal hurdle are also evaluated in vivo to investigate key PK parameters and cytotoxicity, with some selected for further characterisation in vitro and in vivo to establish preclinical efficacy and safety in a wide range of FAP tumour expression models with low serum FAP (including co-cultures of tumour cells and CAFs) to recapitulate the human TME.\" ++++ I'll bet there is more than ten warheads, forty capping groups and twenty linkers now!",
          "sentiment": 0.0,
          "engagement": "6,003",
          "price_at_post": "53.00",
          "thread_title": "RE: ADC 26",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=F3B63190-B417-42B7-9CC8-0ED98F4FBB92"
        },
        "ingested_at": "2026-02-11T19:45:46.487557+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260931-BuenaVis-90750551",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.537985",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Really does feel like adding Go Faster stripes at a horse fair.",
          "sentiment": 0.0,
          "engagement": "5,775",
          "price_at_post": "53.00",
          "thread_title": "RE: ADC 26",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=F3B63190-B417-42B7-9CC8-0ED98F4FBB92"
        },
        "ingested_at": "2026-02-11T19:45:46.487575+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260910-Yorkshir-62978782",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.538411",
        "source": "LSE_CHAT",
        "data": {
          "author": "Yorkshirepragma",
          "content": "CC refers to other applications \u2026Chronic Inflammation \u2018conversations\u2019 are interesting . One step at a time \u2026.",
          "sentiment": 0.0,
          "engagement": "1,804",
          "price_at_post": "53.00",
          "thread_title": "RE: Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-02-11T19:45:46.487593+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260845-Yorkshir-48149332",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.538852",
        "source": "LSE_CHAT",
        "data": {
          "author": "Yorkshirepragma",
          "content": "Fascinating similarity re Avactas current development processes. Tuesday 24th February 2026 The Next Generation of ADCs: Leveraging Novel Conjugation & Enhanced Antibody Engineering for the Future of Targeted Oncology Therapies 9:15 am Laying out the scope to differentiate ADC development through novel conjugation, antibody engineering, and target identification approaches to widen therapeutic index and bring patient benefit Incorporating in silico and AI tools to enhance the ADC discovery toolbox and deliver next-generation ADC engineering and design Highlighting future priorities for next-generation ADC development, including exploring the potential of radio conjugates",
          "sentiment": 0.0,
          "engagement": "1,804",
          "price_at_post": "53.00",
          "thread_title": "ADC 26",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=F3B63190-B417-42B7-9CC8-0ED98F4FBB92"
        },
        "ingested_at": "2026-02-11T19:45:46.487612+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260811-Agenda10-26373526",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.539272",
        "source": "LSE_CHAT",
        "data": {
          "author": "Agenda101",
          "content": "Cheers BV!",
          "sentiment": 0.0,
          "engagement": "72",
          "price_at_post": "53.00",
          "thread_title": "RE: Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-02-11T19:45:46.487630+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260754-cj62--3994598",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.539688",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "Who would be allowed access ?",
          "sentiment": 0.0,
          "engagement": "4,282",
          "price_at_post": "53.00",
          "thread_title": "Data Room",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=85F98FAE-01B2-48EC-B9D0-584FAD2B9731"
        },
        "ingested_at": "2026-02-11T19:45:46.487649+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260751-Thornogs--1257725",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.713580",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "This one and one after the close to comment on the top quality discussion and to check if we finished up or not.",
          "sentiment": 0.0,
          "engagement": "8,666",
          "price_at_post": "53.00",
          "thread_title": "2 post Friday.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=EDA1F112-F6D9-49A4-937D-081A93C2E757"
        },
        "ingested_at": "2026-02-11T19:45:46.487667+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260626-Gingethe--6544886",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.714067",
        "source": "LSE_CHAT",
        "data": {
          "author": "GingetheWinge",
          "content": "The FUDsters are thrashing like Terminator 2 in a smelting cauldron. It\u2019s working so let\u2019s continue to starve them of any engagement. As Runner-Runner wrote and BV reposted\u2026 It's simple. 1. DO NOT ENGAGE 2. DO NOT ASK IT A QUESTION 3. DO NOT ANSWER ITS QUESTIONS 4. DO NOT MOAN ABOUT ITS POSTS 5. DO NOT ARGUE WITH IT 6. If you must do something. Mock it with reference only to its stupidity and nothing else. ------------------------------------------------------ If you're not part of the solution, you're part of the problem",
          "sentiment": 0.5,
          "engagement": "700",
          "price_at_post": "53.00",
          "thread_title": "No not engage !",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=A348D8E1-4DC7-4D49-950E-08F79BC3A2D1"
        },
        "ingested_at": "2026-02-11T19:45:46.487685+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260138-BuenaVis-36154427",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.714500",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Even better link: https://www.youtube.com/watch?v=HWkh3OEFSds&t=1333s",
          "sentiment": 0.0,
          "engagement": "5,775",
          "price_at_post": "53.00",
          "thread_title": "RE: Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-02-11T19:45:46.487704+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260132-BuenaVis-20461538",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.714925",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "It's the Base to Base biotech podcast from a few days ago. Well worth a listen. Here's the link to the start of the CC interview: https://www.youtube.com/watch?v=HWkh3OEFSds&t=1290s",
          "sentiment": 0.0,
          "engagement": "5,775",
          "price_at_post": "53.00",
          "thread_title": "RE: Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-02-11T19:45:46.487722+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262331-D-Geeman-47901963",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.715361",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "Wasn\u2019t wyn comparing this BB to \u2018Lord of the Flies\u2019 classic story? Well for those who don\u2019t know the story I just caught a trailer for new BBC production starting soon; https://www.bbc.com/mediacentre/2026/lord-of-the-flies-trailer",
          "sentiment": 0.0,
          "engagement": "5,849",
          "price_at_post": "53.00",
          "thread_title": "RE: Avacta Therapeutics celebrates this",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=03B0B4A6-705E-45ED-983A-A89C321C0924"
        },
        "ingested_at": "2026-02-11T19:45:46.487740+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262302-alextak--7072633",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.715781",
        "source": "LSE_CHAT",
        "data": {
          "author": "alextak",
          "content": "Is it a new interview? .I'll listen to it tomorrow.",
          "sentiment": 0.0,
          "engagement": "540",
          "price_at_post": "53.00",
          "thread_title": "RE: Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-02-11T19:45:46.487758+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262258-alextak-27011007",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.716203",
        "source": "LSE_CHAT",
        "data": {
          "author": "alextak",
          "content": "Https://youtu.be/HWkh3OEFSds?si=0KezbLZbtRJA4N97",
          "sentiment": 0.0,
          "engagement": "540",
          "price_at_post": "53.00",
          "thread_title": "Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-02-11T19:45:46.487776+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262241-pedrolan-19712095",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.716624",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "When no-one engages that's what they end up with. Good work folks.",
          "sentiment": 0.5,
          "engagement": "1,975",
          "price_at_post": "53.00",
          "thread_title": "Voices in the wilderness",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=8AE5A358-4CCC-4E25-A8A9-D4C3BBC9FF5F"
        },
        "ingested_at": "2026-02-11T19:45:46.487794+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262222-Thornogs-50817748",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.717039",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Absolutely Pedro! All those who chance upon the LSE Avacta bulletin board and haven't been keeping up with the news, all of them? Exposure indeed, keep up the good work everybody!",
          "sentiment": 0.0,
          "engagement": "8,666",
          "price_at_post": "53.00",
          "thread_title": "RE: Avacta Therapeutics celebrates this",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=03B0B4A6-705E-45ED-983A-A89C321C0924"
        },
        "ingested_at": "2026-02-11T19:45:46.487812+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262202-pedrolan-47846788",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.717464",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "All great exposure. Thanks for posting \ud83d\udc4d\ud83c\udffb",
          "sentiment": 0.5,
          "engagement": "1,975",
          "price_at_post": "53.00",
          "thread_title": "RE: Avacta Therapeutics celebrates this",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=03B0B4A6-705E-45ED-983A-A89C321C0924"
        },
        "ingested_at": "2026-02-11T19:45:46.487830+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262145-Thornogs--7863758",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.717891",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Well there we have it Avcti, proof positive fof all those 'FUDsters' who have been saying otherwise all day! Avacta can produce FAP-EXD for the upcoming trial! What chance does 'FUD' have against this level of research and knowledge? Hang your heads in shame all those saying that it wasn't possible. Was anyone suggesting this?",
          "sentiment": 0.0,
          "engagement": "8,666",
          "price_at_post": "53.00",
          "thread_title": "RE: \" So excited to get the trial going soon. \"",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=C91568DF-F421-4695-901C-78161A0F4CD6"
        },
        "ingested_at": "2026-02-11T19:45:46.487848+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262110-avctIPma-47991813",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.718379",
        "source": "LSE_CHAT",
        "data": {
          "author": "avctIPmatters",
          "content": "FYI   Christina CoughlinChristina Coughlin \u2022 3rd+Verified \u2022 3rd+ Chief Executive Officer, AvactaChief Executive Officer, Avacta 53m \u2022  53 minutes ago \u2022 Visible to anyone on or off LinkedIn Follow We are thrilled to partner with our team at Curia - this partnership has enabled our team at hashtag#AVCT to move FAP-exatecan forward at record pace. So excited to get the trial going soon. This combined team reminds me of a favorite quote, \u201cNever doubt that a small group of thoughtful, committed citizens can change the world. Indeed, it is the only thing that ever has.\u201d \u2014Margaret Mead. hashtag#LetsDoThis hashtag#HopeWithoutCompromise CuriaCuria 104,425 followers104,425 followers 2h \u2022  2 hours ago \u2022 Visible to anyone on or off LinkedIn Follow Congratulations to Avacta Therapeutics on receiving U.S. Food and Drug Administration (FDA) clearance of the Investigational New Drug (IND) application for the Company\u2019s second program FAP-Exd (AVA6103). This peptide drug conjugate is based on the highly potent topoisomerase I inhibitor, exatecan. A Phase 1 clinical trial will enroll patients with solid tumors, pancreatic cancer, cervical cancer, gastric cancer and small cell lung cancer. CURIA STERILE DRUG PRODUCT business unit is proud to assist this cutting-edge oncology program with formulation development, analytical support and GMP clinical supply at our site in Glasgow. Read more about Avacta in the recent press release: https://hubs.li/Q040N2nz0",
          "sentiment": 0.0,
          "engagement": "728",
          "price_at_post": "53.00",
          "thread_title": "\" So excited to get the trial going soon. \"",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=C91568DF-F421-4695-901C-78161A0F4CD6"
        },
        "ingested_at": "2026-02-11T19:45:46.487866+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262104-wyndrum-77025102",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.718829",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "So you\u2019re right and I am wrong as you have said umpteen times  yet it is me who is the narcissist? You don\u2019t even know what the term means in detail yet bandi it about as a diagnosis of a stranger you know nothing about. Your arrogance in libelling me without any justification only amplifies my point. But in none of these umpteen times have you ever wondered why AVCT have failed to deliver the returns you expected when you first bought in ? No of course not. That would require self examination. Something you seem to lack but have no inhibition in accusing others of. The arrogance of the arguments directed at me are so cliched and bereft of any true accuracy that it is simply pathetic. What is so considerably worse is the recs they get. Not because it offends me more but rather of the evidence that so may can\u2019t reason for themselves and blithely agree. It\u2019s not a case of reading the room, more a case of group think. Under your reasoning we would all still think the earth was flat.",
          "sentiment": 0.0,
          "engagement": "12,228",
          "price_at_post": "53.00",
          "thread_title": "RE: Worldwide ADC Innovation & Collaboration   London",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=CB66756C-50A3-4D04-A499-ADC1B8951801"
        },
        "ingested_at": "2026-02-11T19:45:46.487884+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262104-Metatron-14947498",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.719249",
        "source": "LSE_CHAT",
        "data": {
          "author": "Metatron",
          "content": "Forgot.. dammit.. sawy \ud83e\udd14",
          "sentiment": 0.0,
          "engagement": "1,188",
          "price_at_post": "53.00",
          "thread_title": "RE: Worldwide ADC Innovation & Collaboration   London",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=CB66756C-50A3-4D04-A499-ADC1B8951801"
        },
        "ingested_at": "2026-02-11T19:45:46.487902+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262051-BuenaVis-38670914",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.719657",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Do not feed the troll. \ud83e\udd2a",
          "sentiment": 0.0,
          "engagement": "5,775",
          "price_at_post": "53.00",
          "thread_title": "RE: Worldwide ADC Innovation & Collaboration   London",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=CB66756C-50A3-4D04-A499-ADC1B8951801"
        },
        "ingested_at": "2026-02-11T19:45:46.487921+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262035-Metatron-44469372",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.720073",
        "source": "LSE_CHAT",
        "data": {
          "author": "Metatron",
          "content": "The problem is Wyndrone.. that you cannot read the room because you are a narcissist as I've explaind umpteen times. The recs are from other members who are just plain sick to death of you and your narcissistic droning behaviour.",
          "sentiment": 0.0,
          "engagement": "1,188",
          "price_at_post": "53.00",
          "thread_title": "RE: Worldwide ADC Innovation & Collaboration   London",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=CB66756C-50A3-4D04-A499-ADC1B8951801"
        },
        "ingested_at": "2026-02-11T19:45:46.487939+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262028-Metatron--7932154",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.720496",
        "source": "LSE_CHAT",
        "data": {
          "author": "Metatron",
          "content": "Looks like Thorndrone has repositioned itself as the ultimate purile commentator on the commentary? Looks more to me like the ultimate terd that just won't flush \ud83d\ude48\ud83d\udca9",
          "sentiment": 0.0,
          "engagement": "1,188",
          "price_at_post": "53.00",
          "thread_title": "RE: Avacta Therapeutics celebrates this",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=03B0B4A6-705E-45ED-983A-A89C321C0924"
        },
        "ingested_at": "2026-02-11T19:45:46.487957+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262028-wyndrum--8004373",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.720925",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "I think the problem is Chris is that while what you say is correct, it is the \u201canti-fudsters \u201c for want of a better expression, that quite deliberately push this debilitating and constant line at any opportunity. And like today, when nothing is going on, BV just stirs the pot. Yet every single time the cause of this futile exercise is laid at the door of the posters who are incessantly  attacked rather than the perpetrators . What\u2019s even more disturbing is the recs they get for doing it. This bb is simply one of the worst I have ever come across and we all contribute to that to some degree but it is the majority (when you look at the recs) here that revel in this disruptive behaviour and have little or no interest in resolving the situation for the better. Why can\u2019t I say after 5 years of a trial and a sp at near all time lows that maybe all is not what we were led to believe from the outset and can we look at what might be causing this without being asked to be ignored banned or wished an early death?",
          "sentiment": 0.0,
          "engagement": "12,228",
          "price_at_post": "53.00",
          "thread_title": "RE: Worldwide ADC Innovation & Collaboration   London",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=CB66756C-50A3-4D04-A499-ADC1B8951801"
        },
        "ingested_at": "2026-02-11T19:45:46.487976+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262015-stodgy88--8715423",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.721347",
        "source": "LSE_CHAT",
        "data": {
          "author": "stodgy88",
          "content": "LinkedIn.",
          "sentiment": 0.0,
          "engagement": "1,206",
          "price_at_post": "53.00",
          "thread_title": "RE: Avacta Therapeutics celebrates this",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=03B0B4A6-705E-45ED-983A-A89C321C0924"
        },
        "ingested_at": "2026-02-11T19:45:46.487994+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262014-stodgy88--8276152",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.721752",
        "source": "LSE_CHAT",
        "data": {
          "author": "stodgy88",
          "content": "This company as over  100,000 followers, so good exposure.",
          "sentiment": 0.0,
          "engagement": "1,206",
          "price_at_post": "53.00",
          "thread_title": "RE: Avacta Therapeutics celebrates this",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=03B0B4A6-705E-45ED-983A-A89C321C0924"
        },
        "ingested_at": "2026-02-11T19:45:46.488011+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262011-Thornogs-47835239",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.722182",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Quite Avcti, well done! Always good to be reminded of last week's RNS! In case any of ghd 'well infofmed' missed it eh?",
          "sentiment": 0.0,
          "engagement": "8,666",
          "price_at_post": "53.00",
          "thread_title": "RE: Avacta Therapeutics celebrates this",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=03B0B4A6-705E-45ED-983A-A89C321C0924"
        },
        "ingested_at": "2026-02-11T19:45:46.488030+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262010-HarChris-41958497",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.722603",
        "source": "LSE_CHAT",
        "data": {
          "author": "HarChris",
          "content": "There\u2019s a cycle of Thorn repeating the same points over and over again, the numerous posters who flood us with messages telling him to F off, begging others not to reply or to warn the bb of his dishonesty and then Wyn writing paragraphs of philosophy and psychology on the meaning of it all. That plays out at least four or five times a week! Almost identically. The odd post on Avacta gets a reply or two before the cycle kickstarts again. What a waste of time this BB is in quiet periods like this!",
          "sentiment": 0.0,
          "engagement": "15,870",
          "price_at_post": "53.00",
          "thread_title": "RE: Worldwide ADC Innovation & Collaboration   London",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=CB66756C-50A3-4D04-A499-ADC1B8951801"
        },
        "ingested_at": "2026-02-11T19:45:46.488047+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262004-avctIPma-89556027",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.723059",
        "source": "LSE_CHAT",
        "data": {
          "author": "avctIPmatters",
          "content": "Back to more worthwhile  conversation thanks Stonks -------------------------- Avacta Therapeutics celebrates this Curia 54m \u2022 Follow Congratulations to Avacta Therapeutics on receiving U.S. Food and Drug Administration (FDA) clearance of the Investigational New Drug (IND) application for the Company\u2019s second program FAP-Exd (AVA6103). This peptide drug conjugate is based on the highly potent topoisomerase I inhibitor, exatecan. A Phase 1 clinical trial will enroll patients with solid tumors, pancreatic cancer, cervical cancer, gastric cancer and small cell lung cancer. CURIA STERILE DRUG PRODUCT business unit is proud to assist this cutting-edge oncology program with formulation development, analytical support and GMP clinical supply at our site in Glasgow. Read more about Avacta in the recent press release: https://hubs.li/Q040N2nz0 \" Gmcc",
          "sentiment": 0.0,
          "engagement": "728",
          "price_at_post": "53.00",
          "thread_title": "Avacta Therapeutics celebrates this",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=03B0B4A6-705E-45ED-983A-A89C321C0924"
        },
        "ingested_at": "2026-02-11T19:45:46.488066+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261833-D-Geeman-79953998",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.723489",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "'and bucket to collect their donations for his roses.\u2019 'collect the dung & yes then spread the manure around the Roses' I understand that Watching does this too but with her Quality Street, not Roses.",
          "sentiment": 0.0,
          "engagement": "5,849",
          "price_at_post": "53.00",
          "thread_title": "RE: Worldwide ADC Innovation & Collaboration   London",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=CB66756C-50A3-4D04-A499-ADC1B8951801"
        },
        "ingested_at": "2026-02-11T19:45:46.488084+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261754-Thornogs-67898115",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.723915",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Now, now Wyn! Steady there. It's been decided that our constant 'FUD' detracts from thd ability of the 'well informed' posters to discuss Avzcta seriously. OK, so far it's just the usual nonsense but give thdm a chance I'm sure tomorrow they'll Smash It! Did we finish up by the way?",
          "sentiment": 0.0,
          "engagement": "8,666",
          "price_at_post": "53.00",
          "thread_title": "RE: Worldwide ADC Innovation & Collaboration   London",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=CB66756C-50A3-4D04-A499-ADC1B8951801"
        },
        "ingested_at": "2026-02-11T19:45:46.488112+00:00"
      },
      {
        "event_id": "SOCIAL-Today1236-Watching-40795749",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.595387",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "Let\u2019s have a day where know one engages with the Fudders A watch them argue with themselves \ud83d\ude0a",
          "sentiment": 0.0,
          "engagement": "9,213",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-02-11T19:45:46.488131+00:00"
      },
      {
        "event_id": "SOCIAL-Today1207-D-Geeman-50799247",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.595837",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "Evan Davis discussing mergers and acquisitions on Radio 4 right now.",
          "sentiment": 0.0,
          "engagement": "5,844",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-02-11T19:45:46.488149+00:00"
      },
      {
        "event_id": "SOCIAL-Today1050-D-Geeman--7330528",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.596300",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "Many of the most useful posts are green boxes to others. That's fine. I really don't care if **** doesn't read ****'s post as long as I can. Please, everyone who doesn't like ****'s posts filter and then the people who do read them can do so in peace.",
          "sentiment": 0.0,
          "engagement": "5,844",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-02-11T19:45:46.488167+00:00"
      },
      {
        "event_id": "SOCIAL-Today1034-Thornogs-71823889",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.596741",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Happy to sit on the sidelines to watch the emergence of all this deep research and intelligent discussion on the company's 'fundamentals'. Of course if it isn't accurate or realistic I presume there's the right to point this out? Otherwise it's just a meaningless Echo Chamber. Over to you, the self proclaimed 'well informed'. Let's see what quality posting looks like!",
          "sentiment": 0.0,
          "engagement": "8,655",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-02-11T19:45:46.488185+00:00"
      },
      {
        "event_id": "SOCIAL-Today1032-BuenaVis--1491434",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.597214",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "As Runner-Runner wrote... It's simple. 1. DO NOT ENGAGE 2. DO NOT ASK IT A QUESTION 3. DO NOT ANSWER ITS QUESTIONS 4. DO NOT MOAN ABOUT ITS POSTS 5. DO NOT ARGUE WITH IT 6. If you must do something. Mock it with reference only to its stupidity and nothing else. ------------------------------------------------------ If you're not part of the solution, you're part of the problem",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-02-11T19:45:46.488203+00:00"
      },
      {
        "event_id": "SOCIAL-Today1025-pedrolan--1226761",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.597761",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Ok, as one of the offenders ( I did it mainly to remind people of their/his agenda) I will pledge to now ignore them/him going forward. We really need everyone to do that though.",
          "sentiment": 0.5,
          "engagement": "1,972",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-02-11T19:45:46.488220+00:00"
      },
      {
        "event_id": "SOCIAL-Today1022-Aston15-84515599",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.598209",
        "source": "LSE_CHAT",
        "data": {
          "author": "Aston15",
          "content": "People do understand the only reason then come on here to spout sh*t is because others give them an audience? Its not difficult..  Green Box them and focus the chat on the company, not their trading agendas.",
          "sentiment": 0.0,
          "engagement": "61",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-02-11T19:45:46.488238+00:00"
      },
      {
        "event_id": "SOCIAL-Today1005-IFA90-72118801",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.598630",
        "source": "LSE_CHAT",
        "data": {
          "author": "IFA90",
          "content": "More posts than trades, never a good sign.",
          "sentiment": 0.0,
          "engagement": "408",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-02-11T19:45:46.488257+00:00"
      },
      {
        "event_id": "SOCIAL-Today0954-Aldebara--8827573",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.599061",
        "source": "LSE_CHAT",
        "data": {
          "author": "Aldebaran",
          "content": "Anyone engaging with them is part of the problem. I'll soon be adding them to my filter list if all the want to do is talk smack and try to score points against them. It's a waste of everyone's time, least not their own yet they persist. Sad. We could use this bb once again to discuss avacta but only if the engagement with FUDsters ends. Its nothing more than a digital playground otherwise. Filter. Them.",
          "sentiment": 0.0,
          "engagement": "3,894",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-02-11T19:45:46.488275+00:00"
      },
      {
        "event_id": "SOCIAL-Today0948-Watching-89890799",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.599520",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "Let\u2019s have a day where know one engages with the Fudders And watch them argue with there selves \ud83d\ude0a",
          "sentiment": 0.0,
          "engagement": "9,213",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-02-11T19:45:46.488292+00:00"
      },
      {
        "event_id": "SOCIAL-Today0932-Thornogs--8353755",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.599949",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "And on a day to day basis is there actually much new to talk about with Avacta? Tumbleweed City now until the next RNS, whatever that might be for.",
          "sentiment": 0.0,
          "engagement": "8,655",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-02-11T19:45:46.488310+00:00"
      },
      {
        "event_id": "SOCIAL-Today0924-wyndrum-90926277",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.600402",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "But Jane this was all caused by BV\u2019s non AVCT post. He deliberately provokes with his insults and lies. Non of this would have happened today without his non AVCT related post. Remember that would you",
          "sentiment": 0.0,
          "engagement": "12,217",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-02-11T19:45:46.488328+00:00"
      },
      {
        "event_id": "SOCIAL-Today0918-Watching--8795380",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.601027",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "Let\u2019s have a day where know one engages with the Fudders And watch them argue with themselves \ud83d\ude2c",
          "sentiment": 0.0,
          "engagement": "9,213",
          "price_at_post": "54.00",
          "thread_title": "Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-02-11T19:45:46.488346+00:00"
      },
      {
        "event_id": "SOCIAL-Today0917-pedrolan--4483643",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.601613",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "A seamless switch between users there Eggy Bravo",
          "sentiment": 0.0,
          "engagement": "1,972",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T19:45:46.488364+00:00"
      },
      {
        "event_id": "SOCIAL-Today0916-Thornogs--1212311",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.602292",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "To be fair Live account it's very easy to judge someone who repeatedly posts nonsense like you just have. And Pedro and BV joining in the: 'Look at us, we're idiots' gang.",
          "sentiment": 0.0,
          "engagement": "8,655",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T19:45:46.488382+00:00"
      },
      {
        "event_id": "SOCIAL-Today0902-wyndrum--4947523",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.603136",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "Sadly you have the memory of a goldfish but not its intellect. Again bv starts and contributes to the disruption. All we wait for now is the \u201cooh I can see all these green boxes\u201dposts add up my posts and add up all the rest and you quickly see who the paid disrupters are",
          "sentiment": 0.0,
          "engagement": "12,217",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T19:45:46.488400+00:00"
      },
      {
        "event_id": "SOCIAL-Today0859-BuenaVis--7012886",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.603939",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "\ud83e\udd14 Today's 'wyndrum' sounds even more petty and whiny than the 'Thornogson' account.",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T19:45:46.488418+00:00"
      },
      {
        "event_id": "SOCIAL-Today0858-pedrolan--4258789",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.604745",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "BV - he is doing it to fool us into thinking it is not one account. I nearly fell for it because I have the memory of a goldfish.",
          "sentiment": 0.5,
          "engagement": "1,972",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T19:45:46.488436+00:00"
      },
      {
        "event_id": "SOCIAL-Today0853-wyndrum-64828360",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.605571",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "It\u2019s snowing pretty hard here so it\u2019s not really the smoking gun you claim is it? Plus the fact you think I have multiple accounts only reinforces your mistaken analysis. (And see how many posts have been generated by bv These are the cause of the disruption. Not the posters who try to discuss the disconnect between AVCT results and the sp over the last 5 years",
          "sentiment": 0.0,
          "engagement": "12,217",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T19:45:46.488455+00:00"
      },
      {
        "event_id": "SOCIAL-Today0850-BuenaVis--5854002",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.606369",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Why is Thornogson/NDN/Eggy using the wyndrum account today?",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T19:45:46.488473+00:00"
      },
      {
        "event_id": "SOCIAL-Today0847-Livedata--5723270",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.607182",
        "source": "LSE_CHAT",
        "data": {
          "author": "Livedataaccount",
          "content": "With respect wyndrum its difficult not to judge someone who pretends to go on holiday and occasionally logs on with another alias replying to himself",
          "sentiment": 0.0,
          "engagement": "2,956",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T19:45:46.488491+00:00"
      },
      {
        "event_id": "SOCIAL-Today0835-BuenaVis--8164934",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.607959",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Wyn Shakespeare has swallowed a whole bag of question marks.",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T19:45:46.488509+00:00"
      },
      {
        "event_id": "SOCIAL-Today0831-pedrolan-74542897",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.608744",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Keep it up BV - people do need reminding. I see user Wyn Shakespeare is on the early shift.",
          "sentiment": 0.5,
          "engagement": "1,972",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T19:45:46.488527+00:00"
      },
      {
        "event_id": "SOCIAL-Today0826-wyndrum--1415472",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.609574",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "Thanks for reminding us dad, it must only be the 20th time you have posted this. Still at least your post s don\u2019t disrupt the board It\u2019s a great service you do, giving up your time to treat everyone here like morons by constantly reposting. Is it your new rule now that you must be shareholder to post and also be a genuine one at that? How do you intend to police your rules? Or is it just petty personal vendetta you are boring us all with?",
          "sentiment": 0.0,
          "engagement": "12,217",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T19:45:46.488544+00:00"
      },
      {
        "event_id": "SOCIAL-Today0750-BuenaVis-53974156",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.610363",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Just a reminder that Thornogson/NDN/Eggy isn't invested and is only here to argue, disrupt and try to waste our time.",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T19:45:46.488562+00:00"
      },
      {
        "event_id": "SOCIAL-Today0746-BuenaVis-17390940",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.904033",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Say what you see \ud83c\udf77\ud83c\udf77\ud83c\udf77",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "54.00",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-02-11T19:45:46.488587+00:00"
      },
      {
        "event_id": "SOCIAL-Today0733-Unbreade-57113115",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.904514",
        "source": "LSE_CHAT",
        "data": {
          "author": "Unbreaded",
          "content": "I love green boxes in the morning! Time for a coffee and catch up on the news.",
          "sentiment": 0.0,
          "engagement": "22",
          "price_at_post": "54.00",
          "thread_title": "Green Boes",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=F7E09828-40CF-45D7-8337-5F0A79C87685"
        },
        "ingested_at": "2026-02-11T19:45:46.488606+00:00"
      },
      {
        "event_id": "SOCIAL-Today0035-Thornogs-61517617",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.904967",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Sujood & Icecool. Similar content but I think ICE probably ahead on presentation. Both deeply underwater but talking a good game. Of course the SP matters, the only data that might be maturing is SGC 1b, which might secure a small deal. We've been told nothing about TNBC and STS is written off. We wait for FAP-EXD, we start again.",
          "sentiment": 0.0,
          "engagement": "8,655",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T19:45:46.488624+00:00"
      },
      {
        "event_id": "SOCIAL-Today0005-Toukanka--6814696",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.905422",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "Pivotal news in the Summer. Where have I heard that before? Oh yeah, it was me and I duly got panned by the Pom Pom girls for suggesting it would take thst long. \ud83e\udd23\ud83e\udd23\ud83e\udd23",
          "sentiment": 0.0,
          "engagement": "4,451",
          "price_at_post": "54.00",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-02-11T19:45:46.488642+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262359-Toukanka-65821766",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.905891",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "Work for ever????",
          "sentiment": 0.0,
          "engagement": "4,451",
          "price_at_post": "54.00",
          "thread_title": "RE: This will haunt you or please you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=8AE0FBBC-C14D-49F3-85C3-E6BED1BD66ED"
        },
        "ingested_at": "2026-02-11T19:45:46.488661+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262324-IFA90--1266466",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.906405",
        "source": "LSE_CHAT",
        "data": {
          "author": "IFA90",
          "content": "Thanks Andy",
          "sentiment": 0.0,
          "engagement": "408",
          "price_at_post": "54.00",
          "thread_title": "RE: This will haunt you or please you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=8AE0FBBC-C14D-49F3-85C3-E6BED1BD66ED"
        },
        "ingested_at": "2026-02-11T19:45:46.488679+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262322-BuenaVis-75182389",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.906824",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Thanks Thompi",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T19:45:46.488698+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262302-Sujood--9088473",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.907374",
        "source": "LSE_CHAT",
        "data": {
          "author": "Sujood",
          "content": "A multi billion dollar company in the making. It will haunt you if you dont position yourself Will please you, if you do the write thing. Learn about the company and do what you know is the right move to make. Nobody every wants to work forever. Keep this message We will talk again soon.",
          "sentiment": 0.5,
          "engagement": "1,260",
          "price_at_post": "54.00",
          "thread_title": "This will haunt you or please you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=8AE0FBBC-C14D-49F3-85C3-E6BED1BD66ED"
        },
        "ingested_at": "2026-02-11T19:45:46.488716+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262258-Icecool--8932265",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.907813",
        "source": "LSE_CHAT",
        "data": {
          "author": "Icecool",
          "content": "Commercial deals will come, and they\u2019ll be welcomed when they do. I\u2019m not in a rush though. If the data continues to strengthen and Avacta can leverage that science into materially better terms, I\u2019m perfectly happy for it to take longer. Time spent increasing leverage isn\u2019t wasted time, it\u2019s how you avoid bad deals and maximise value. \ud83d\ude0a Waiting could be the difference between a few billion and tens of billions. \ud83d\ude0a\ud83e\udd14",
          "sentiment": 0.0,
          "engagement": "8,824",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T19:45:46.488734+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262250-Thompi--9201897",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.908255",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thompi",
          "content": "You may find BV this tweet on X interesting on AVA6103 and BOIN design. AND https://x.com/sandyradders/status/2012950578595258664?s=61&t=BBb2UcjLDTXOFIzJM-vM6A",
          "sentiment": 0.0,
          "engagement": "1,357",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T19:45:46.488753+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262144-Knotagai--1199736",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.908887",
        "source": "LSE_CHAT",
        "data": {
          "author": "Knotagain",
          "content": "We're all fixated on the SP Icecool, it's just a matter of time frames. I've been invested for over five years and would love to see  some commercial news. Nothing wrong with that.",
          "sentiment": 0.0,
          "engagement": "451",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T19:45:46.488771+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262118-Icecool-36828114",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.909330",
        "source": "LSE_CHAT",
        "data": {
          "author": "Icecool",
          "content": "That\u2019s only a concern if you\u2019re fixated on the SP. AIM has never been able to price Avacta properly and it won\u2019t until there\u2019s either a takeover (and suspension) or a move to a serious exchange. The day to day price action is noise. What actually matters is what\u2019s happening behind the scenes with the science, the data, and the strategic discussions. That\u2019s where the real value is being built. \ud83d\udcaf\ud83d\udc4d",
          "sentiment": 0.0,
          "engagement": "8,824",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T19:45:46.488789+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262058-Knotagai--1830811",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.909883",
        "source": "LSE_CHAT",
        "data": {
          "author": "Knotagain",
          "content": "Totally agree Icecool, but only third party validation will move the share price. Hopefully it will happen sometime soon.",
          "sentiment": 0.0,
          "engagement": "451",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T19:45:46.488808+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262032-Icecool-23636423",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.910560",
        "source": "LSE_CHAT",
        "data": {
          "author": "Icecool",
          "content": "The FDA won\u2019t drag this out. AVA6000 proved the platform in humans, AVA6103 builds on that. Phase 1 is about safety and speed. This trial is designed to surface signals quickly with regulatory alignment, not waste years. AVA6000 data will have done a load of heavy lifting already.",
          "sentiment": 0.0,
          "engagement": "8,824",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T19:45:46.488826+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261954-BuenaVis-19641170",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.910984",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "I've got to say I was concerned that the AVA6103 trial with such a toxic agent as exatecan would start at a very low dose and take a long, long time if the step increases were to mimic those in the AVA6000 trial (seven dose levels! - three steps of 40 from 80 to 200, and then three 25% increases to 385) so very pleased to hear about all the benefits of the BOIN design.",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T19:45:46.488844+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261946-Icecool-38564869",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.911503",
        "source": "LSE_CHAT",
        "data": {
          "author": "Icecool",
          "content": "I would also point out that when Thorn bought in he\u2019s also a mega ramping twat!!! Flip/Flop. \ud83d\udcaf\ud83e\udd23\ud83e\udd23 best on filter \ud83d\udc4d",
          "sentiment": 0.0,
          "engagement": "8,824",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T19:45:46.488863+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261937-HarChris-55787894",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.912044",
        "source": "LSE_CHAT",
        "data": {
          "author": "HarChris",
          "content": "Going back to the trial design I thought this overview could be useful: Key Comparisons Accuracy in MTD Selection: BOIN generally outperforms 3+3 by more accurately identifying the true MTD. In simulations across various scenarios BOIN achieves a 12-16% higher percentage of correct selection (PCS) of the MTD, and in cases where the MTD is at higher doses, it can nearly triple the PCS compared to 3+3. Efficiency and Patient Allocation: BOIN is more efficient, often resulting in shorter trial durations and lower costs by adapting in real-time and allocating more patients to the MTD (especially at higher doses or with higher target DLT rates). The 3+3 design can prolong trials due to its conservative escalation and fixed cohort requirements, leading to fewer patients treated at effective doses. Safety and Risk Management: While 3+3 minimizes overdose risk by being overly cautious (e.g., lower chance of assigning >60% of patients above the MTD), it increases under-dosing, where many patients receive suboptimal doses. BOIN balances this better with built-in overdose controls and dynamic adjustments, reducing under-dosing without significantly raising overdose risks, thus improving ethical standards by minimising patient exposure to ineffective or overly toxic doses. Simplicity and Flexibility: Both are relatively easy to implement\u2014BOIN requires no complex programming or simulations beyond basic setup, making it accessible like 3+3. However, BOIN offers more flexibility, such as variable cohort sizes (e.g., 4 patients) and adjustable target toxicity rates, whereas 3+3 is fixed to cohorts of 3 (or 3+3) and standard targets. In summary, BOIN represents an evolution over 3+3, providing better performance across most metrics while maintaining ease of use. The 3+3 design is still widely used for its familiarity and safety focus in conservative settings but is increasingly seen as outdated for not fully utilising trial data.",
          "sentiment": 0.0,
          "engagement": "15,865",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T19:45:46.488881+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261812-Cashless-66023834",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.912567",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cashless",
          "content": "Been out all day, so just logged on.....and what a pleasure to see a sea of green and pretty much all informative posts...I LOVE GREEN...not sure the green people are so happy though \ud83d\udc4d\ud83e\udd2a\ud83e\udd2a\ud83e\udd73",
          "sentiment": 0.5,
          "engagement": "401",
          "price_at_post": "54.00",
          "thread_title": "Bliss",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E431AF8E-57C8-40B5-91C6-8D284968B368"
        },
        "ingested_at": "2026-02-11T19:45:46.488899+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261753-B2HS2L--5354592",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.913172",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "FWIW Google search What is the difference between event free and progression free survival AI Overview: Progression-Free Survival (PFS) measures the time from treatment initiation until objective tumor growth or death from any cause. Event-Free Survival (EFS) measures the time from randomization until a broader range of \"events,\" including disease progression, treatment failure, complications, or death. PFS focuses on tumor growth; EFS focuses on any negative outcome. Key Differences: Definition of Event: PFS is restricted to disease progression or death. EFS includes those, plus failure to proceed to planned surgery, relapse, or severe treatment complications. Context of Use: PFS is commonly used in advanced or metastatic cancer trials to evaluate treatment efficacy. EFS is frequently used in earlier-stage cancer trials, particularly in the neoadjuvant (pre-surgery) setting. Precision: PFS depends on the frequency of imaging scans to detect growth, while EFS is often defined by the time until a patient cannot proceed with their treatment plan. Essentially, PFS means the cancer has not worsened, whereas EFS means the patient has not experienced any negative, pre-defined event.",
          "sentiment": 0.0,
          "engagement": "6,000",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T19:45:46.488918+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261428-BuenaVis-70958032",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.913661",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "What is the current best progression free survival rate for TNBC? https://www.google.com/search?q=What+is+the+current+best+progression+free+survival+rate+for+TNBC%253F",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T19:45:46.488936+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261424-HarChris--2490797",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.914093",
        "source": "LSE_CHAT",
        "data": {
          "author": "HarChris",
          "content": "It's what happened to STS and might now happen with TNBC, might not of course, but if it did then it'll all fall to SGC to carry the load until FAP-EXD starts to produce meaningful data. __________________ In other words IF TNBC data doesn't deliver then SGC might have to carry the load until H2 2026? That's not bad as a worst case and it's very short term as it gets for biotech. And with the less risk averse and far more efficient BOIN design for 6103 we should start receiving compelling data rapidly if all is going well. It's close!",
          "sentiment": 0.0,
          "engagement": "15,865",
          "price_at_post": "54.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T19:45:46.488955+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261411-Thornogs-10758698",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.914533",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "No well spotted!  My bad.",
          "sentiment": 0.0,
          "engagement": "8,655",
          "price_at_post": "54.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T19:45:46.488973+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261409-BuenaVis--7679442",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.915065",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "I may be missing something here but trastuzumab deruxtecan (brand name Enhertu) and pertuzumab are both used to treat HER2-positive breast cancer.  So what has that got to do with TNBC which is an aggressive, fast-growing type of breast cancer that tests negative for three key receptors: estrogen (ER), progesterone (PR), and HER2?",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "54.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T19:45:46.488992+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261349-Thornogs--3298262",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.915517",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "'....FAP-DOX needs to beat.'",
          "sentiment": 0.0,
          "engagement": "8,655",
          "price_at_post": "54.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T19:45:46.489009+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261347-Thornogs--6490076",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.915945",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "But clearly relevent so clearly won't be mentioned by anyone else Watching? Obviously important if it's doubled the PFS times for TNBC, the bar has been raised as to what FAP-EXD needs to beat. It's what happened to STS and might now happen with TNBC, might not of course, but if it did then it'll all fall to SGC to carry the load until FAP-EXD starts to produce meaningful data.",
          "sentiment": 0.0,
          "engagement": "8,655",
          "price_at_post": "54.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T19:45:46.489028+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261347-pedrolan-90365036",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.837882",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Just a reminder that Thorn is not invested but spends his sad life on here posting negative comments about a company saving lives. What a guy!!!",
          "sentiment": 0.5,
          "engagement": "1,972",
          "price_at_post": "54.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T19:45:46.489046+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261339-Watching-35795205",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.838382",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "You Still have to focus on negatives. Thorny you are such a k n o bby \ud83e\udd21\ud83e\udd21",
          "sentiment": 0.0,
          "engagement": "9,213",
          "price_at_post": "54.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T19:45:46.489065+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261335-Thornogs-45536728",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.838824",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "It's perhaps double edged though? The AVA6000 STS trial was (allegedly) de-railed by a trial that showed longer, and better than expected, survival data. If there's a new 'Standard of Care' being announced for TNBC the bar might just have been raised on what FAP-DOX/TNBC needs to achieve to get a deal and get to market?",
          "sentiment": 0.0,
          "engagement": "8,655",
          "price_at_post": "55.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T19:45:46.489083+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261315-LovableL-46785398",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.839268",
        "source": "LSE_CHAT",
        "data": {
          "author": "LovableLumax",
          "content": "Https://x.com/onclive/status/2016451178872061994?s=46",
          "sentiment": 0.0,
          "engagement": "2,703",
          "price_at_post": "55.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T19:45:46.489109+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261053-Aldebara--7362213",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.839705",
        "source": "LSE_CHAT",
        "data": {
          "author": "Aldebaran",
          "content": "I think small caps are at the very start of a major bull run. Green portfolio everywhere across the board. Also note that even with hard times, avacta raised 16m through zeus at only 8% discount plus managed to delay and renegotiate the terms of the bond. No mean feat that and the macro picture for small caps has improved since then. As has our IP and data package plus the deadline for BP patent expiry has only become closer. Things nowhere near as desperate as this shhhhh it tee little market gives credit for. I mean avacta have developed the worlds first dual warhead peptide drug conjugate ffs . \ud83d\ude05",
          "sentiment": 0.0,
          "engagement": "3,894",
          "price_at_post": "55.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T19:45:46.489128+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261050-opti_mys--5648581",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.840239",
        "source": "LSE_CHAT",
        "data": {
          "author": "opti_mystic",
          "content": "I think that's optimistic Lovable being as the initial doses will be very low. It is a safety trial initially remember, but the trial design (BOIN) will allow for dose escalation quite quickly and also potentially skipping from say dose level one to does level 3. I think more realistically summer months we may start to see some useful efficacy. What they will know sooner is are there any problems/does it works as expected and designed. If no bad news by May/June I think we're on a winner. I expect it to work.",
          "sentiment": 0.0,
          "engagement": "296",
          "price_at_post": "55.50",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-02-11T19:45:46.489147+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261045-Sisyphus--5986348",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.840667",
        "source": "LSE_CHAT",
        "data": {
          "author": "SisyphusShorter",
          "content": "Out of coincidence it's been exactly a week since the last RNS regarding AVA6103. Could an announcement be due imminently?",
          "sentiment": 0.0,
          "engagement": "4",
          "price_at_post": "55.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T19:45:46.489165+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261014-HarChris-82610208",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.841093",
        "source": "LSE_CHAT",
        "data": {
          "author": "HarChris",
          "content": "I wonder if those solely focused on Avacta and thinking history always repeats are missing the fact that the AIM backdrop plays a major role here. And in that regard liquidity has returned to UK small caps with a vengeance, raises are happening without the sort of discounts seen in 2022/23/24/25, companies are seeing major share price appreciation actually hold rather than the wild swings of post Covid. It\u2019s a far healthier backdrop right now than at any point since I\u2019ve held Avacta shares.",
          "sentiment": 0.0,
          "engagement": "15,865",
          "price_at_post": "55.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T19:45:46.489184+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261003-harryhot-77788542",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.841536",
        "source": "LSE_CHAT",
        "data": {
          "author": "harryhotspur1311",
          "content": "I was hoping for the big erection shape although roundish bottoms are quite welcome as well!",
          "sentiment": 0.0,
          "engagement": "12",
          "price_at_post": "55.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T19:45:46.489202+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260958-A1invest-32879147",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.841950",
        "source": "LSE_CHAT",
        "data": {
          "author": "A1invest",
          "content": "Lets hope its a \"rounding bottom\" shape.  :)",
          "sentiment": 0.0,
          "engagement": "143",
          "price_at_post": "55.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T19:45:46.489221+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260953-pedrolan-19524832",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.842525",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Salty for sure",
          "sentiment": 0.0,
          "engagement": "1,972",
          "price_at_post": "55.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T19:45:46.489239+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260945-Thornogs-14556455",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.843025",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "\"Salt and vinegar on that sir?\"",
          "sentiment": 0.0,
          "engagement": "8,655",
          "price_at_post": "55.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T19:45:46.489257+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260944-Timster-25414276",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.843502",
        "source": "LSE_CHAT",
        "data": {
          "author": "Timster",
          "content": "Big fish, little fish, cardboard box....",
          "sentiment": 0.0,
          "engagement": "20,625",
          "price_at_post": "55.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T19:45:46.489275+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260941-harryhot--8241976",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.844130",
        "source": "LSE_CHAT",
        "data": {
          "author": "harryhotspur1311",
          "content": "Whenever the SP drops, the pessimists always quote \u2018the market knows\u2019 Perhaps this could work the other way around occasionally! Today, perhaps!",
          "sentiment": 0.0,
          "engagement": "12",
          "price_at_post": "56.00",
          "thread_title": "Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-11T19:45:46.489294+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260823-pedrolan--4683602",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.844561",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Ah yes, I knew I had been there but couldn't remember exactly which Lake \ud83e\udd23",
          "sentiment": 0.5,
          "engagement": "1,972",
          "price_at_post": "52.50",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-02-11T19:45:46.489312+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260726-Gingethe-75028228",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.844978",
        "source": "LSE_CHAT",
        "data": {
          "author": "GingetheWinge",
          "content": "Derwent valley dam in the Peak District.",
          "sentiment": 0.5,
          "engagement": "699",
          "price_at_post": "53.00",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-02-11T19:45:46.489330+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260713-LovableL-85946624",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.845409",
        "source": "LSE_CHAT",
        "data": {
          "author": "LovableLumax",
          "content": "I also suspect we will have a 6000 partner signed up once we have an approved accelerated pathway and registrations P2\\3 with FDA which is hopefully imminent",
          "sentiment": 0.0,
          "engagement": "2,703",
          "price_at_post": "53.00",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-02-11T19:45:46.489348+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260703-LovableL--6824318",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.845829",
        "source": "LSE_CHAT",
        "data": {
          "author": "LovableLumax",
          "content": "Given how potent the payload is and with the improved half-life and active in the TME for 5 days surely they'll see results as early as scan 1. That sounds rampy and too optimistic but look at the preclinical results. Things could really take off as early as the summer, or even before. Again, I suspect recruitment will be fairly rapid given FAP targeting with preCISION proven and preclinical results so investigators likely chomping at the bit.",
          "sentiment": 0.0,
          "engagement": "2,703",
          "price_at_post": "53.00",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-02-11T19:45:46.489367+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260659-nurseste-13355543",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.846277",
        "source": "LSE_CHAT",
        "data": {
          "author": "nursesteve",
          "content": "CC discussing FAP-Exd (AVA6103) - The profile of this second pre|CISION medicine in the preclinical setting is tremendous.  The sustained release mechanism developed by Avacta scientists results in a robust concentration of active drug in the tumor over five days with the disappearance from the bloodstream in only two hours. This is the exact profile needed to achieve better efficacy with this highly potent topo I inhibitor. Could payoff for LTH be this year?",
          "sentiment": 0.0,
          "engagement": "1,164",
          "price_at_post": "53.00",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-02-11T19:45:46.489385+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260006-D-Geeman--9099312",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.846690",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "An elderly character actor in our road, when I first arrived,  was in the movie \u2018The Dambusters\u2019, and in \u2018Bridge on the River Kwai\u2019. He used to tell some good stories of life on 1950\u2019s film sets. Dead for a while but he pops up on screen even now.",
          "sentiment": 0.0,
          "engagement": "5,844",
          "price_at_post": "52.50",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-02-11T19:45:46.489403+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20262319-pedrolan--1476108",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.847122",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Yes, it's an inspirational story. I think they tested it up in the Lake District",
          "sentiment": 0.5,
          "engagement": "1,972",
          "price_at_post": "52.50",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-02-11T19:45:46.489421+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20262113-Captains-79656055",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.847541",
        "source": "LSE_CHAT",
        "data": {
          "author": "Captainstanley.",
          "content": "I can't find that information anywhere Which Friday? Presumably you mean this week 29th Jan?",
          "sentiment": 0.0,
          "engagement": "467",
          "price_at_post": "52.50",
          "thread_title": "RE: SGC",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=5E3142A3-349A-43A2-B5B7-02836561174A"
        },
        "ingested_at": "2026-02-11T19:45:46.489439+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20262014-Flippine--4284134",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.847977",
        "source": "LSE_CHAT",
        "data": {
          "author": "Flippineck",
          "content": "I\u2019ve been thinking about the trials and tribulations of developing new inventions and ended up swotting up on Barnes Wallace, the inventor of the famous Bouncing Bomb. It seems initial proposals were dismissed by Bomber Command as being \u201c a mad-cap scheme\u201d. There were several critical failures in the development which had to be overcome. The shape of the bomb had to be changed, backspin had to be introduced, the weapon would shatter, sink or detonate prematurely or veer off course. Barnes Wallace persevered and it all came good in the end.",
          "sentiment": 0.0,
          "engagement": "417",
          "price_at_post": "52.50",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-02-11T19:45:46.489457+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261912-BuenaVis--6283976",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.848415",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Christina Coughlin became the CEO of Avacta on 1 May 2024. There is no need to dwell on anything or anyone before that date. CC has set out the company's objectives and timelines and has stuck to them, as much as is possible taking outside decision-making and events into account.  This adherence to the company's aims and plans comes about because she is a pharma executive with ample of experience of drug development and the way the FDA works.",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "52.50",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-02-11T19:45:46.489475+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261900-BuenaVis--1491434",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.848907",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "As Runner-Runner wrote... It's simple. 1. DO NOT ENGAGE 2. DO NOT ASK IT A QUESTION 3. DO NOT ANSWER ITS QUESTIONS 4. DO NOT MOAN ABOUT ITS POSTS 5. DO NOT ARGUE WITH IT 6. If you must do something. Mock it with reference only to its stupidity and nothing else. ------------------------------------------------------ If you're not part of the solution, you're part of the problem",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "52.50",
          "thread_title": "RE: Year end trading update :",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=CCFE6866-0D3C-4A1E-9659-9B2E552262F5"
        },
        "ingested_at": "2026-02-11T19:45:46.489493+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20262219-Thornogs--4798979",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.801399",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Anything new there? 'Expected' Q1? No, nothing new, just 'same old'.",
          "sentiment": 0.0,
          "engagement": "8,596",
          "price_at_post": "54.50",
          "thread_title": "RE: Bioconjugate Insights",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0DCD83D9-A17D-43E1-842E-1C922D520A76"
        },
        "ingested_at": "2026-02-11T19:45:46.489511+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20262212-avctIPma-13175719",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.801859",
        "source": "LSE_CHAT",
        "data": {
          "author": "avctIPmatters",
          "content": "Again courtesy of Stonks -  Finds  new coverage  Avacta related   many thanks . https://cdn.insights.bio/uploads/attachments/BCI%20Industry%20Insights.pdfAvacta Therapeutics reported new preclinical pharmacology data for FAP-Exd peptide drug conjugate [25] \"Avacta Therapeutics announced new preclinical pharmacology data for FAP-Exd (AVA6103), its second asset derived from the pre|CISION\u00ae tumor-activated delivery platform, which is expected to enter Phase 1 testing in Q1 2026. FAP-Exd is a fibroblast activation protein\u2013cleavable peptide-drug linking a proprietary peptide to a topoisomerase I inhibitor payload. The data demonstrated tumor-specific cytotoxicity, sustained intratumoral release of active exatecan with limited systemic exposure, and robust antitumor activity across multiple patient-derived xenograft models. Avacta also reported that artificial intelligence\u2013guided analysis was used to prioritize clinical indications based on co-expression of FAP and SLFN11.\" Gmcc",
          "sentiment": 0.0,
          "engagement": "720",
          "price_at_post": "54.50",
          "thread_title": "Bioconjugate Insights",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0DCD83D9-A17D-43E1-842E-1C922D520A76"
        },
        "ingested_at": "2026-02-11T19:45:46.489530+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20262210-Thornogs-72069878",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.802303",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Avacta does its thing regardless of what's posted here. Get over yourselves, self appointed \"Guardian's of the truth\"! And if you must wear your underpants on the outside do at least please ensure that  they're better laundered?",
          "sentiment": 0.0,
          "engagement": "8,596",
          "price_at_post": "54.50",
          "thread_title": "The reality?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=D8CC0643-0047-4DA0-A21A-3E0ECC3BD17C"
        },
        "ingested_at": "2026-02-11T19:45:46.489548+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20262154-BuenaVis-71801676",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.802718",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "I had Firefox nicely set up with AdBlock so that all ads were wiped out but had to 'repair' Firefox today (as tabs were crashing) and then reload an AdBlock extension but I now keep getting these annoying messages from LSE about ads that I never used to get.  Can't remember what I did before to permanently remove those messages.  Can anyone offer advice on how they've solved this?",
          "sentiment": 0.0,
          "engagement": "5,722",
          "price_at_post": "54.50",
          "thread_title": "Off-topic - removing ads on Firefox",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=9BE707F4-9555-444A-A3C8-1254E00A3443"
        },
        "ingested_at": "2026-02-11T19:45:46.489565+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20262109-Knotagai-12455499",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.803142",
        "source": "LSE_CHAT",
        "data": {
          "author": "Knotagain",
          "content": "All day every day...",
          "sentiment": 0.0,
          "engagement": "448",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-02-11T19:45:46.489583+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261944-Agenda10-74171117",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.803559",
        "source": "LSE_CHAT",
        "data": {
          "author": "Agenda101",
          "content": "Brilliant! The never ending Twats.. they are all green boxed here\u2026 But I\u2019m hearing you Sheepy! Exactly right.",
          "sentiment": 0.0,
          "engagement": "55",
          "price_at_post": "54.50",
          "thread_title": "RE: Frankly pathetic",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B36E2695-D07A-4E60-838B-02C995994856"
        },
        "ingested_at": "2026-02-11T19:45:46.489601+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261943-BuenaVis--8037826",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.803971",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Lighten up Thompi.  It's the best comedy show in town.",
          "sentiment": 0.0,
          "engagement": "5,722",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-02-11T19:45:46.489619+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261940-Thompi-90176563",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.804413",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thompi",
          "content": "Because, Touk, Thorn talks total twaddle and inundates this board with spam. It\u2019s made the board virtually unreadable. Even blocking him doesn\u2019t really help, because all I then see are green boxes and other people replying to his posts. I probably add to the noise at times too - but I\u2019ve genuinely had enough of one person commandeering the board with the same malicious rubbish, day after day. Post after post after post. It wears people down. It stops being discussion and just becomes disruption.",
          "sentiment": 0.0,
          "engagement": "1,355",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-02-11T19:45:46.489637+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261848-Toukanka-27757925",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.804832",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "Cj62 How can it be utter garbage when it\u2019s generally been predicting what is happening to Avacta. But the pond poms utter garbage of \u201ctakeover tomorrow \u201c, \u201cmarket thick as mince\u201d etc etc ad infinitum even though they\u2019ve been entirely wrong for years. Well that\u2019s fine clogging up the board with that garbage",
          "sentiment": 0.0,
          "engagement": "4,436",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-02-11T19:45:46.489655+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261845-BuenaVis-89724616",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.805254",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "6am to midnight but with a two hour evening break to neck a bottle of whisky.",
          "sentiment": 0.0,
          "engagement": "5,722",
          "price_at_post": "54.50",
          "thread_title": "RE: Frankly pathetic",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B36E2695-D07A-4E60-838B-02C995994856"
        },
        "ingested_at": "2026-02-11T19:45:46.489673+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261844-Toukanka--5854753",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.805661",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "You\u2019re right Thompi. You never do say much more than joining your mates and flinging the insults. Why not talk about Avacta rather the other posters on here?",
          "sentiment": 0.0,
          "engagement": "4,436",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-02-11T19:45:46.489691+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261841-sheppy-29255584",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.806079",
        "source": "LSE_CHAT",
        "data": {
          "author": "sheppy",
          "content": "Wyn, Thorn, Touk , DG same poster numerous aliases. Hourly paid hired help disrupter. Regardless of that what sort of sad, moronic halfwit would spend 7 days a week starting each day at 6 am and continuing after midnight posting negative comments about a share they are allegedly not invested in? Regardless of their reason what a total waste of one\u2019s life on this earth . What a pathetic pitiful existence arguing with anonymous people on an anonymous bb. I actually pity their sad, lonely unfulfilled existence. And before the poster tells me they live a very fulfilled life doing lots of other meaningful things ask yourself how this is possible with so many never ending  daily boring transparent attempts at disruption. Sad twat and a weirdo",
          "sentiment": 0.0,
          "engagement": "563",
          "price_at_post": "54.50",
          "thread_title": "Frankly pathetic",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B36E2695-D07A-4E60-838B-02C995994856"
        },
        "ingested_at": "2026-02-11T19:45:46.489709+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261831-cj62--3694716",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.806499",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "Anything you post Thorn is utter garbage. How many crayons have you done today ?",
          "sentiment": 0.0,
          "engagement": "4,270",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-02-11T19:45:46.489727+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261820-Thornogs-42262216",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.806924",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "And what did you say? Anything worth hearing? Anything about Avacta and what's going well and what isn't and thoughts about why? No, thought not. Shame.",
          "sentiment": 0.0,
          "engagement": "8,596",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-02-11T19:45:46.489745+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261755-Thompi-20368481",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.807357",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thompi",
          "content": "Pedro, if I add your 67 posts over the last 30 days to my 20, plus Tim\u2019s 43 and Watching\u2019s 39, the grand combined total is 169 posts. That\u2019s four people combined. Compared to Thorn\u2019s 253 posts on his own. The figures speak for themselves.",
          "sentiment": 0.0,
          "engagement": "1,355",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-02-11T19:45:46.489763+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261754-wyndrum--1061660",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.807774",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "And i see my requests to get NFT to respond have been deleted but the insults to me remain. But yes, its the LSE moderators allowing me to post that is the problem here. Where are you NFT, want to answer my queries so you can justify the remarks in your post?",
          "sentiment": 0.0,
          "engagement": "12,198",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-02-11T19:45:46.489782+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261737-pedrolan--8775049",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.808191",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Make that 29 to go",
          "sentiment": 0.0,
          "engagement": "1,948",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-02-11T19:45:46.489800+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261719-Thompi-47526799",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.808620",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thompi",
          "content": "Avacta posts over the last 30 days: 253 Thorn \ud83e\udd47 43 Timster 39 Watching Not much else to say really Thorn.",
          "sentiment": 0.0,
          "engagement": "1,355",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-02-11T19:45:46.489818+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261708-Thornogs--5123619",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.809052",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "And the two posters below your post Thompi? Watching 9,000 and Tim 20,000! All on only Avacta and all 100% content free 'jokes' or 'bile'. But to comment on that would be to show a consistent approach to this sort of thing wouldn't it? Be honest, it's not the number or posts, it's the fact that you might have to consider things that you don't want to consider. Fine, your choice, 5 years in and AVA6000 limping along to a possible low-ball deal and FAP-EXD entering the 'Last Chance Saloon' in the next 2-3 months. Everything that you've been predicting for the last 5 years, why would you need to hear a contrary opinion when you've clearly been smashing it all this time? Well up I dare say on your investment are we?",
          "sentiment": 0.0,
          "engagement": "8,596",
          "price_at_post": "54.00",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-02-11T19:45:46.489836+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261644-Thompi--7455800",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.809483",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thompi",
          "content": "To be fair Tim, Thorn\u2019s only posted 11 times so far today. He\u2019s got another 30 to go before he equals his personal best of 41 posts in 24 hours. By my reckoning, if he manages around 4.3 posts per hour between now and midnight (17:00\u201312:00am), he might just be in with a chance of beating it. Bless his selfless little heart.",
          "sentiment": 0.0,
          "engagement": "1,355",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-02-11T19:45:46.489854+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261537-Watching-71903151",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.809893",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "24/7. He keeps churning out verbal \ud83d\udca9",
          "sentiment": 0.0,
          "engagement": "9,201",
          "price_at_post": "54.50",
          "thread_title": "RE: CC interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=F5A9F3B7-45F7-4EC2-B1FD-1ACB3A2D2E18"
        },
        "ingested_at": "2026-02-11T19:45:46.489872+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261535-Timster-12455499",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.810318",
        "source": "LSE_CHAT",
        "data": {
          "author": "Timster",
          "content": "All day every day...",
          "sentiment": 0.0,
          "engagement": "20,620",
          "price_at_post": "54.50",
          "thread_title": "To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-02-11T19:45:46.489890+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261529-cj62--5246288",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.810731",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "Shall we have a 'Spot the idiot' competition? You win it thorn, no competition !!!",
          "sentiment": 0.0,
          "engagement": "4,270",
          "price_at_post": "54.50",
          "thread_title": "RE: CC interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=F5A9F3B7-45F7-4EC2-B1FD-1ACB3A2D2E18"
        },
        "ingested_at": "2026-02-11T19:45:46.489908+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261517-Thornogs-88493090",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.811159",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Of course we don't BV, and the industry experts who know these things currently value Avacta at 50 odd pence a share. NFT and the 28 odd who ticked up his posts think \u00a328 is more accurate. Shall we have a 'Spot the idiot' competition?",
          "sentiment": 0.0,
          "engagement": "8,596",
          "price_at_post": "54.50",
          "thread_title": "RE: CC interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=F5A9F3B7-45F7-4EC2-B1FD-1ACB3A2D2E18"
        },
        "ingested_at": "2026-02-11T19:45:46.489925+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261515-cj62--5987349",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.811569",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "That's theoretical of course. Thorn its like 99% of the other gibberish you post twat.",
          "sentiment": 0.0,
          "engagement": "4,270",
          "price_at_post": "54.50",
          "thread_title": "RE: CC interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=F5A9F3B7-45F7-4EC2-B1FD-1ACB3A2D2E18"
        },
        "ingested_at": "2026-02-11T19:45:46.489944+00:00"
      },
      {
        "event_id": "SOCIAL-Today1729-Toukanka-83609287",
        "event_type": "social_post",
        "date": "2026-02-12T21:57:47.646808",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "BV Don\u2019t belittle yourself. I am as sure as there is going to be a TO tomorrow that CC has jumped at your advice. In other news: the next edition of this should finally put to bed the bickering on timescales. I do hope it comes out asap. BV perhaps you could send CC another email and encourage her to get a move on. Thanks",
          "sentiment": 0.0,
          "engagement": "4,491",
          "price_at_post": "58.50",
          "thread_title": "RE: New Avacta podcast series",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=80481A38-380A-4D87-A08C-4237BB1744A3"
        },
        "ingested_at": "2026-02-12T21:57:56.477275+00:00"
      },
      {
        "event_id": "SOCIAL-Today1706-BuenaVis--3584907",
        "event_type": "social_post",
        "date": "2026-02-12T21:57:47.647284",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Glad to see this series appearing.  I found the discussion very interesting and informative.  I did email CC last Wednesday requesting an explainer about how patient safety can be ensured at the start and during trials (starting dose level; identifyng contraindicatory\u2014raised FAP\u2014conditions; and, for faridox, monitoring cardiotoxicity/cardio-function now that the lifetime limit has been removed).  Pretty sure this series was devised before my email, but hope that it will cover these aspects as they are of extreme importance to Avacta\u2014you don't want patients dying from our drug on trial as that would be a nail in the platform's coffin, and no amount of spanner work would remedy that.",
          "sentiment": 0.0,
          "engagement": "5,852",
          "price_at_post": "59.00",
          "thread_title": "RE: New Avacta podcast series",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=80481A38-380A-4D87-A08C-4237BB1744A3"
        },
        "ingested_at": "2026-02-12T21:57:56.477320+00:00"
      },
      {
        "event_id": "SOCIAL-Today1657-HarChris--8389333",
        "event_type": "social_post",
        "date": "2026-02-12T21:57:47.647697",
        "source": "LSE_CHAT",
        "data": {
          "author": "HarChris",
          "content": "There hasn\u2019t even been an RNS, are you just imagining them up now to have a moan?",
          "sentiment": 0.0,
          "engagement": "15,964",
          "price_at_post": "58.50",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=7B5AA42A-0EBE-4975-8AEE-555D9A5D3DA4"
        },
        "ingested_at": "2026-02-12T21:57:56.477345+00:00"
      },
      {
        "event_id": "SOCIAL-Today1633-yeboha--3539886",
        "event_type": "social_post",
        "date": "2026-02-12T21:57:47.648127",
        "source": "LSE_CHAT",
        "data": {
          "author": "yeboha",
          "content": "They will not sell on the cheap , havent you worked that out yet ! If you cant take the heat , get out of the kitchen !",
          "sentiment": 0.0,
          "engagement": "972",
          "price_at_post": "58.50",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=7B5AA42A-0EBE-4975-8AEE-555D9A5D3DA4"
        },
        "ingested_at": "2026-02-12T21:57:56.477364+00:00"
      },
      {
        "event_id": "SOCIAL-Today1624-Viking.R-85449536",
        "event_type": "social_post",
        "date": "2026-02-12T21:57:47.648542",
        "source": "LSE_CHAT",
        "data": {
          "author": "Viking.Raider",
          "content": "Same old news jam tomorrow they won\u2019t sell there to comfortable to get the big salary, Just  get it sold and we can move on and hopefully make so money elsewhere.",
          "sentiment": 0.0,
          "engagement": "422",
          "price_at_post": "58.50",
          "thread_title": "RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=7B5AA42A-0EBE-4975-8AEE-555D9A5D3DA4"
        },
        "ingested_at": "2026-02-12T21:57:56.477382+00:00"
      },
      {
        "event_id": "SOCIAL-Today1619-cj62--8907567",
        "event_type": "social_post",
        "date": "2026-02-12T21:57:47.648956",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "That's a lot of episode to fit in between now and August or maybe before. Something will need to be resolved in the 2/3 months though",
          "sentiment": 0.0,
          "engagement": "4,306",
          "price_at_post": "58.00",
          "thread_title": "RE: Avacta Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=E39FA2AF-8504-49A9-B9E4-FE96F677D53F"
        },
        "ingested_at": "2026-02-12T21:57:56.477399+00:00"
      },
      {
        "event_id": "SOCIAL-Today1619-BuenaVis-29220775",
        "event_type": "social_post",
        "date": "2026-02-12T21:57:47.649378",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "'Nuts and Bolts' hmm... Beware oncologists carrying spanners!",
          "sentiment": 0.0,
          "engagement": "5,852",
          "price_at_post": "58.00",
          "thread_title": "RE: New Avacta podcast series",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=80481A38-380A-4D87-A08C-4237BB1744A3"
        },
        "ingested_at": "2026-02-12T21:57:56.477417+00:00"
      },
      {
        "event_id": "SOCIAL-Today1601-Runner-R-79181946",
        "event_type": "social_post",
        "date": "2026-02-12T21:57:47.649778",
        "source": "LSE_CHAT",
        "data": {
          "author": "Runner-Runner",
          "content": "Episode 1356 - How the first deal was delivered.",
          "sentiment": 0.0,
          "engagement": "704",
          "price_at_post": "58.00",
          "thread_title": "RE: Avacta Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=E39FA2AF-8504-49A9-B9E4-FE96F677D53F"
        },
        "ingested_at": "2026-02-12T21:57:56.477446+00:00"
      },
      {
        "event_id": "SOCIAL-Today1551-Livedata-82141966",
        "event_type": "social_post",
        "date": "2026-02-12T21:57:47.650200",
        "source": "LSE_CHAT",
        "data": {
          "author": "Livedataaccount",
          "content": "Watched it x2 speed now have to wait for episode 2 with dave to find out about dosing",
          "sentiment": 0.0,
          "engagement": "2,978",
          "price_at_post": "58.00",
          "thread_title": "RE: Avacta Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=E39FA2AF-8504-49A9-B9E4-FE96F677D53F"
        },
        "ingested_at": "2026-02-12T21:57:56.477478+00:00"
      },
      {
        "event_id": "SOCIAL-Today1548-yeboha--8606560",
        "event_type": "social_post",
        "date": "2026-02-12T21:57:47.650610",
        "source": "LSE_CHAT",
        "data": {
          "author": "yeboha",
          "content": "I watched it and found it very interesting !",
          "sentiment": 0.0,
          "engagement": "972",
          "price_at_post": "58.00",
          "thread_title": "RE: Avacta Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=E39FA2AF-8504-49A9-B9E4-FE96F677D53F"
        },
        "ingested_at": "2026-02-12T21:57:56.477512+00:00"
      },
      {
        "event_id": "SOCIAL-Today1538-IFA90-81931581",
        "event_type": "social_post",
        "date": "2026-02-12T21:57:47.651081",
        "source": "LSE_CHAT",
        "data": {
          "author": "IFA90",
          "content": "They\u2019ll do anything but sign a deal FFS.",
          "sentiment": 0.0,
          "engagement": "419",
          "price_at_post": "58.00",
          "thread_title": "Avacta Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=E39FA2AF-8504-49A9-B9E4-FE96F677D53F"
        },
        "ingested_at": "2026-02-12T21:57:56.477544+00:00"
      },
      {
        "event_id": "SOCIAL-Today1532-LikeOrig-48526899",
        "event_type": "social_post",
        "date": "2026-02-12T21:57:47.651513",
        "source": "LSE_CHAT",
        "data": {
          "author": "LikeOriginal",
          "content": "New drug development podcast series on investormeetcompany. https://www.investormeetcompany.com/updates/avacta-academy-series-1/show",
          "sentiment": 0.0,
          "engagement": "19",
          "price_at_post": "58.00",
          "thread_title": "New Avacta podcast series",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=80481A38-380A-4D87-A08C-4237BB1744A3"
        },
        "ingested_at": "2026-02-12T21:57:56.477577+00:00"
      },
      {
        "event_id": "SOCIAL-Today1314-Timster--9220392",
        "event_type": "social_post",
        "date": "2026-02-12T21:57:47.651993",
        "source": "LSE_CHAT",
        "data": {
          "author": "Timster",
          "content": "Can't believe Avacta are ignoring your update request LDA, it's a disgrace",
          "sentiment": 0.0,
          "engagement": "20,641",
          "price_at_post": "59.00",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-12T21:57:56.477597+00:00"
      },
      {
        "event_id": "SOCIAL-Today1128-B2HS2L--2765880",
        "event_type": "social_post",
        "date": "2026-02-12T21:57:47.652495",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "A king wanted to go fishing and he asked the royal weather forecaster for the weather for the day. The palace meteorologist assured him that there was no chance of rain. So the king and the queen went fishing... On the way he met a man with a fishing pole riding on a donkey, and he asked the man if the fish were biting. The fisherman said, \"Your Majesty, you should return to the palace! In just a short time I expect a huge rain storm.\" The king replied: \"I hold the palace meteorologist in high regard. He is an educated and experienced professional. Besides, I pay him very high wages. He gave me a very different forecast. I trust him.\" So the king continued on his way, however, in a short time a torrential rain flooded the fields, and the King and Queen were totally soaked. The king returned to the palace and fired the meteorologist. Then he summoned the fisherman and offered him the prestigious position of royal forecaster. The fisherman said, \"Your Majesty, I do not know anything about forecasting. I obtain my information from my donkey. If my donkey's ears droop, it means with certainty that... it will rain.\" So the king hired the donkey. And thus began the practice of hiring dumb asses to work in influential positions of government..",
          "sentiment": 0.0,
          "engagement": "6,055",
          "price_at_post": "59.00",
          "thread_title": "Off topic",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=E8A3A1A8-BE7E-4395-AAA2-7940E7B2F5AD"
        },
        "ingested_at": "2026-02-12T21:57:56.477614+00:00"
      },
      {
        "event_id": "SOCIAL-Today1029-HarChris--1537779",
        "event_type": "social_post",
        "date": "2026-02-12T21:57:47.652892",
        "source": "LSE_CHAT",
        "data": {
          "author": "HarChris",
          "content": "Maybe you should send all the institutions of the world a strongly worded letter?",
          "sentiment": 0.0,
          "engagement": "15,964",
          "price_at_post": "60.00",
          "thread_title": "RE: Stake building",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=8AC31BCC-F765-4AD9-BEB9-86976AA474EE"
        },
        "ingested_at": "2026-02-12T21:57:56.477632+00:00"
      },
      {
        "event_id": "SOCIAL-Today1011-IFA90--1620014",
        "event_type": "social_post",
        "date": "2026-02-12T21:57:47.653376",
        "source": "LSE_CHAT",
        "data": {
          "author": "IFA90",
          "content": "Perhaps they should hire a BDM to generate interest. I hear Simon Bennett is available.",
          "sentiment": 0.0,
          "engagement": "419",
          "price_at_post": "60.00",
          "thread_title": "RE: Stake building",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=8AC31BCC-F765-4AD9-BEB9-86976AA474EE"
        },
        "ingested_at": "2026-02-12T21:57:56.477650+00:00"
      },
      {
        "event_id": "SOCIAL-Today0833-Livedata-66255218",
        "event_type": "social_post",
        "date": "2026-02-12T21:57:47.653826",
        "source": "LSE_CHAT",
        "data": {
          "author": "Livedataaccount",
          "content": "Avacta really needs some to build a stake simply no volume at all",
          "sentiment": 0.0,
          "engagement": "2,978",
          "price_at_post": "60.00",
          "thread_title": "Stake building",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=8AC31BCC-F765-4AD9-BEB9-86976AA474EE"
        },
        "ingested_at": "2026-02-12T21:57:56.477667+00:00"
      },
      {
        "event_id": "SOCIAL-Today0006-B2HS2L-68648871",
        "event_type": "social_post",
        "date": "2026-02-12T21:57:47.654334",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "Key takeaways on what this means for Avacta Therapeutics, competitors, and the oncology delivery sector Elevating Francis Wilson to Chief Scientific Officer signals chemistry-led platform consolidation rather than commercial pivot. * platform consolidation is assured when it hosts 6000 and 6103, and 6207 being designed for same platform. Removal of the cardiac dosing cap for faridoxorubicin suggests growing regulatory confidence in tolerability data. * thereby providing industry validation, (regulatory validation\ud83d\udc40), for preCISION & 6000. Dosing to nearly four times conventional doxorubicin without severe cardiac toxicity challenges a long-standing anthracycline constraint. * Safe high dosage capability recognised by FDA. Flexible dosing and biologic dose comparison in Phase 1b clarify the path toward efficacy-focused trials. * A recognition that with three indications being trialled, flexibility should provide for optimum dosing identification The pre|CISION platform is increasingly positioned as a multi-asset delivery engine rather than a single-drug program. * Taken as read by shareholders and Avacta, but hopefully will be evident to all should successful 6103 trial results be published. Competitive differentiation will depend on demonstrable efficacy gains, not safety improvements alone. * Cardiac safety improvements evident. - Improved chemo targeting leading to much reduced side effects. Manufacturing, activation variability, and capital requirements remain execution risks. * No shortage of plans to spend on R&D are evident. Shareholders awaiting visibility of funding source(s). Upcoming Phase 1b data and AVA6103 clinical entry represent key near-term valuation catalysts. * Not to speak of removal of the cardiac dosing cap and new flexible dosing permissions. Investor re-rating is more likely after efficacy data than on safety updates alone. * \ud83d\udc4d The oncology delivery landscape may shift if tumor-activated prodrugs consistently expand therapeutic windows across payload classes. * Oncology delivery landscape may have already shifted as evidenced by BP discussing IP cliff removal, with preCISION delivery of cash cow drugs.",
          "sentiment": 0.0,
          "engagement": "6,055",
          "price_at_post": "60.00",
          "thread_title": "RE: Business-News-Today  Avacta update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=10807794-7C19-49BB-A5D5-EFA3C7D9C99E"
        },
        "ingested_at": "2026-02-12T21:57:56.477684+00:00"
      },
      {
        "event_id": "SOCIAL-11Feb20262143-IFA90-26818600",
        "event_type": "social_post",
        "date": "2026-02-12T21:57:47.654734",
        "source": "LSE_CHAT",
        "data": {
          "author": "IFA90",
          "content": "Alan loves a Thursday RNS.",
          "sentiment": 0.0,
          "engagement": "419",
          "price_at_post": "60.00",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-12T21:57:56.477702+00:00"
      },
      {
        "event_id": "SOCIAL-11Feb20262004-BuenaVis-58659924",
        "event_type": "social_post",
        "date": "2026-02-12T21:57:47.655146",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Good find. It's a seemingly intelligent (AI-generated?) summary of the importance of February's announcements.  Where it fails however is in not looking beyond those announcements to other important information being provided by Avacta such as the collaboration with Tempus AI to identify susceptible indications, the ease of manufacture and cost advantages of the pre|CISION prodrugs, and the inhouse expertise in designing pre|CISION substrates to achieve desired pharmacokinetics.  These very largely reduce the identified rsks.  The only material risk that I can see are whether AVA6103 in humans will repeat the excellent characteristics of AVA6000, namely inert in the bloodstream, cleaved in the TME with minimal off-target toxicity, and inert/non-toxic byproducts - the capping group and self-immolative linker.",
          "sentiment": 0.0,
          "engagement": "5,852",
          "price_at_post": "60.00",
          "thread_title": "RE: Business-News-Today  Avacta update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=10807794-7C19-49BB-A5D5-EFA3C7D9C99E"
        },
        "ingested_at": "2026-02-12T21:57:56.477720+00:00"
      },
      {
        "event_id": "SOCIAL-11Feb20261908-avctIPma--8952594",
        "event_type": "social_post",
        "date": "2026-02-12T21:57:47.655565",
        "source": "LSE_CHAT",
        "data": {
          "author": "avctIPmatters",
          "content": "FYI   :  Balanced  update   does not provide any valuations  . Good recognition  \"Regulatory willingness to remove a dosing cap is not routine. It implies confidence in emerging safety signals and may simplify dose optimization in later-phase trials. For investors, this shifts AVA6000 from proof-of-concept toward clinical differentiation territory.   \" \" Avacta Therapeutics (AIM: AVCT) elevates Francis Wilson to CSO as faridoxorubicin dosing cap is removed Avacta Therapeutics lifts AVA6000 dosing cap and appoints a new Chief Scientific Officer. Explore what this means for pre|CISION and investors.\" https://business-news-today.com/avacta-therapeutics-aim-avct-elevates-francis-wilson-to-cso-as-faridoxorubicin-dosing-cap-is-removed/ Gmcc",
          "sentiment": 0.0,
          "engagement": "743",
          "price_at_post": "60.00",
          "thread_title": "Business-News-Today  Avacta update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=10807794-7C19-49BB-A5D5-EFA3C7D9C99E"
        },
        "ingested_at": "2026-02-12T21:57:56.477737+00:00"
      },
      {
        "event_id": "SOCIAL-11Feb20261854-Livedata--4677055",
        "event_type": "social_post",
        "date": "2026-02-12T21:57:47.655969",
        "source": "LSE_CHAT",
        "data": {
          "author": "Livedataaccount",
          "content": "Some great comments here and I expect an update tomorrow",
          "sentiment": 0.0,
          "engagement": "2,978",
          "price_at_post": "60.00",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-12T21:57:56.477756+00:00"
      },
      {
        "event_id": "SOCIAL-11Feb20261737-yeboha--1273581",
        "event_type": "social_post",
        "date": "2026-02-12T21:57:47.656378",
        "source": "LSE_CHAT",
        "data": {
          "author": "yeboha",
          "content": "I've never heard such nonsense from Wyn. If we had any negative news, you would be here nonstop! Not that we've had any negative news for quite some time!",
          "sentiment": 0.0,
          "engagement": "972",
          "price_at_post": "60.00",
          "thread_title": "RE: Banned",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AA63DAAF-42CA-42B0-A114-E3945671F7FA"
        },
        "ingested_at": "2026-02-12T21:57:56.477774+00:00"
      },
      {
        "event_id": "SOCIAL-11Feb20261722-B2HS2L--1241004",
        "event_type": "social_post",
        "date": "2026-02-12T21:57:47.656819",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "From 21.01.2026 RNS - Dr Alexander Spira: Virginia Cancer Specialists \"I am thrilled to work with Avacta on this exciting new drug. The ability to concentrate a potent topoisomerase I inhibitor directly in the tumor while protecting normal tissues from harmful effects is the next stage of how we should be treating cancer. We are looking forward to participating in this second pre|CISION\u00ae Phase 1 trial and helping the Company to drive this pioneering technology forward.\" Here is VCS's patient enrolment video. https://virginiacancerspecialists.com/available-clinical-trials-at-virginia-cancer-specialists/ Introduces the newly diagnosed through the concept of finding a suitable cancer trial via VCS services. VCS acts as a portal introducing screened patients to those companies looking for willing trialists. Recommend the whole video, but it's long winded, (ie not rushed for those recently diagnosed). Slides 9,13 & 14 were most relevant for me.",
          "sentiment": 0.0,
          "engagement": "6,055",
          "price_at_post": "60.00",
          "thread_title": "Virginia Cancer Specialists",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=766DA308-297F-48F1-90EB-342F09A35ECD"
        },
        "ingested_at": "2026-02-12T21:57:56.477791+00:00"
      },
      {
        "event_id": "SOCIAL-11Feb20261337-wyndrum-57955480",
        "event_type": "social_post",
        "date": "2026-02-12T21:57:47.657242",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "Yeah, funny when there is new news (and it\u2019s positive) there is less to comment on. Please stop posting on whether you think I am in or out . You have always been wrong. My holdings have never influenced my views. The reason I have posted less is because the usual disrupters have stopped targeting me with lies and insults. If you could just keep your posts to AVCT and leave me out of it then that would help further.",
          "sentiment": 0.0,
          "engagement": "12,257",
          "price_at_post": "60.00",
          "thread_title": "RE: Banned",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AA63DAAF-42CA-42B0-A114-E3945671F7FA"
        },
        "ingested_at": "2026-02-12T21:57:56.477809+00:00"
      },
      {
        "event_id": "SOCIAL-11Feb20261226-Saint68-25164363",
        "event_type": "social_post",
        "date": "2026-02-12T21:57:51.360723",
        "source": "LSE_CHAT",
        "data": {
          "author": "Saint68",
          "content": "Who cares - he's not posting so all good.",
          "sentiment": 0.0,
          "engagement": "2,194",
          "price_at_post": "60.00",
          "thread_title": "RE: Banned",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AA63DAAF-42CA-42B0-A114-E3945671F7FA"
        },
        "ingested_at": "2026-02-12T21:57:56.477826+00:00"
      },
      {
        "event_id": "SOCIAL-11Feb20261220-pedrolan-17127747",
        "event_type": "social_post",
        "date": "2026-02-12T21:57:51.361278",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "I take it as a good sign the board is quiet here. Of course there will be a big element of that down to the omission of Thorn, Now apologies in advance and I don't want to set the hare running but do we know he deleted his account or was he banned? Does anyone know for sure? It did seem to be around the time he was re-exposed as Eggy but it is possible that was a coincidence.",
          "sentiment": 0.5,
          "engagement": "1,993",
          "price_at_post": "60.00",
          "thread_title": "RE: Banned",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AA63DAAF-42CA-42B0-A114-E3945671F7FA"
        },
        "ingested_at": "2026-02-12T21:57:56.477844+00:00"
      },
      {
        "event_id": "SOCIAL-11Feb20261200-Icecool--8237373",
        "event_type": "social_post",
        "date": "2026-02-12T21:57:51.361821",
        "source": "LSE_CHAT",
        "data": {
          "author": "Icecool",
          "content": "There\u2019s not much to debate right now to be honest. Windy\u2019s suddenly gone quiet now he\u2019s back in, funny how that works \ud83d\ude44\ud83e\udd23\ud83d\ude2d. When he\u2019s out it\u2019s doom and gloom, when he\u2019s in it\u2019s silence. Standard behaviour. Most of the board actually seems pretty calm. Everyone knows the next real catalyst is TNBC data. That\u2019s what matters. And Thorn disappearing the moment the lifetime dose cap was removed!! That tells its own story. The whole half life cumulative toxicity argument was the backbone of that narrative. Once regulators lifted the cap, that line of attack collapsed overnight. The drug just gained a structural advantage. You don\u2019t quietly delete your account if that doesn\u2019t sting. \ud83e\udd23\ud83e\udd23\ud83e\udd23 Now we wait for data. Everything else is just noise in the meantime. \ud83d\udcaf\ud83d\udc4d",
          "sentiment": 0.0,
          "engagement": "8,858",
          "price_at_post": "60.00",
          "thread_title": "RE: Banned",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AA63DAAF-42CA-42B0-A114-E3945671F7FA"
        },
        "ingested_at": "2026-02-12T21:57:56.477861+00:00"
      },
      {
        "event_id": "SOCIAL-11Feb20261157-BuenaVis--6313327",
        "event_type": "social_post",
        "date": "2026-02-12T21:57:51.362274",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "\"[U]p to $2.4 billion in cash, inclusive of an upfront payment and subsequent payments upon achievement of certain clinical development milestones\" so enough for a scone today and gallons and gallons of jam tomorrow, if they're lucky. Nothing in clinical development: https://www.ornatx.com/our-pipeline/",
          "sentiment": 0.0,
          "engagement": "5,852",
          "price_at_post": "60.00",
          "thread_title": "RE: ELY LILLY",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B6F8359B-09F7-4910-B7F8-547334C64F27"
        },
        "ingested_at": "2026-02-12T21:57:56.477879+00:00"
      },
      {
        "event_id": "SOCIAL-11Feb20261146-D0berman--1200629",
        "event_type": "social_post",
        "date": "2026-02-12T21:57:51.362685",
        "source": "LSE_CHAT",
        "data": {
          "author": "D0berman",
          "content": "Bloody Hell!! Who's been banned, it's so quiet!!",
          "sentiment": 0.0,
          "engagement": "1,024",
          "price_at_post": "60.00",
          "thread_title": "Banned",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AA63DAAF-42CA-42B0-A114-E3945671F7FA"
        },
        "ingested_at": "2026-02-12T21:57:56.477896+00:00"
      },
      {
        "event_id": "SOCIAL-11Feb20260904-Harrogat-72119994",
        "event_type": "social_post",
        "date": "2026-02-12T21:57:51.363092",
        "source": "LSE_CHAT",
        "data": {
          "author": "Harrogate4",
          "content": "One day Rodders ----that could be us.",
          "sentiment": 0.0,
          "engagement": "808",
          "price_at_post": "60.50",
          "thread_title": "RE: ELY LILLY",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B6F8359B-09F7-4910-B7F8-547334C64F27"
        },
        "ingested_at": "2026-02-12T21:57:56.477914+00:00"
      },
      {
        "event_id": "SOCIAL-11Feb20260812-Bella653-73498243",
        "event_type": "social_post",
        "date": "2026-02-12T21:57:51.363521",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "Https://investor.lilly.com/news-releases/news-release-details/lilly-acquire-orna-therapeutics-advance-cell-therapies",
          "sentiment": 0.0,
          "engagement": "6,770",
          "price_at_post": "59.50",
          "thread_title": "ELY LILLY",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B6F8359B-09F7-4910-B7F8-547334C64F27"
        },
        "ingested_at": "2026-02-12T21:57:56.477931+00:00"
      },
      {
        "event_id": "SOCIAL-Today1908-avctIPma--8952594",
        "event_type": "social_post",
        "date": "2026-02-11T19:45:39.604715",
        "source": "LSE_CHAT",
        "data": {
          "author": "avctIPmatters",
          "content": "FYI   :  Balanced  update   does not provide any valuations  . Good recognition  \"Regulatory willingness to remove a dosing cap is not routine. It implies confidence in emerging safety signals and may simplify dose optimization in later-phase trials. For investors, this shifts AVA6000 from proof-of-concept toward clinical differentiation territory.   \" \" Avacta Therapeutics (AIM: AVCT) elevates Francis Wilson to CSO as faridoxorubicin dosing cap is removed Avacta Therapeutics lifts AVA6000 dosing cap and appoints a new Chief Scientific Officer. Explore what this means for pre|CISION and investors.\" https://business-news-today.com/avacta-therapeutics-aim-avct-elevates-francis-wilson-to-cso-as-faridoxorubicin-dosing-cap-is-removed/ Gmcc",
          "sentiment": 0.0,
          "engagement": "743",
          "price_at_post": "60.00",
          "thread_title": "Business-News-Today  Avacta update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=10807794-7C19-49BB-A5D5-EFA3C7D9C99E"
        },
        "ingested_at": "2026-02-12T21:57:56.477960+00:00"
      },
      {
        "event_id": "SOCIAL-Today1854-Livedata--4677055",
        "event_type": "social_post",
        "date": "2026-02-11T19:45:39.605151",
        "source": "LSE_CHAT",
        "data": {
          "author": "Livedataaccount",
          "content": "Some great comments here and I expect an update tomorrow",
          "sentiment": 0.0,
          "engagement": "2,976",
          "price_at_post": "60.00",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-12T21:57:56.477988+00:00"
      },
      {
        "event_id": "SOCIAL-Today1737-yeboha--1273581",
        "event_type": "social_post",
        "date": "2026-02-11T19:45:39.605551",
        "source": "LSE_CHAT",
        "data": {
          "author": "yeboha",
          "content": "I've never heard such nonsense from Wyn. If we had any negative news, you would be here nonstop! Not that we've had any negative news for quite some time!",
          "sentiment": 0.0,
          "engagement": "970",
          "price_at_post": "60.00",
          "thread_title": "RE: Banned",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AA63DAAF-42CA-42B0-A114-E3945671F7FA"
        },
        "ingested_at": "2026-02-12T21:57:56.478006+00:00"
      },
      {
        "event_id": "SOCIAL-Today1722-B2HS2L--1241004",
        "event_type": "social_post",
        "date": "2026-02-11T19:45:39.605983",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "From 21.01.2026 RNS - Dr Alexander Spira: Virginia Cancer Specialists \"I am thrilled to work with Avacta on this exciting new drug. The ability to concentrate a potent topoisomerase I inhibitor directly in the tumor while protecting normal tissues from harmful effects is the next stage of how we should be treating cancer. We are looking forward to participating in this second pre|CISION\u00ae Phase 1 trial and helping the Company to drive this pioneering technology forward.\" Here is VCS's patient enrolment video. https://virginiacancerspecialists.com/available-clinical-trials-at-virginia-cancer-specialists/ Introduces the newly diagnosed through the concept of finding a suitable cancer trial via VCS services. VCS acts as a portal introducing screened patients to those companies looking for willing trialists. Recommend the whole video, but it's long winded, (ie not rushed for those recently diagnosed). Slides 9,13 & 14 were most relevant for me.",
          "sentiment": 0.0,
          "engagement": "6,053",
          "price_at_post": "60.00",
          "thread_title": "Virginia Cancer Specialists",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=766DA308-297F-48F1-90EB-342F09A35ECD"
        },
        "ingested_at": "2026-02-12T21:57:56.478023+00:00"
      },
      {
        "event_id": "SOCIAL-Today1337-wyndrum-57955480",
        "event_type": "social_post",
        "date": "2026-02-11T14:17:05.527997",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "Yeah, funny when there is new news (and it\u2019s positive) there is less to comment on. Please stop posting on whether you think I am in or out . You have always been wrong. My holdings have never influenced my views. The reason I have posted less is because the usual disrupters have stopped targeting me with lies and insults. If you could just keep your posts to AVCT and leave me out of it then that would help further.",
          "sentiment": 0.0,
          "engagement": "12,256",
          "price_at_post": "60.00",
          "thread_title": "RE: Banned",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AA63DAAF-42CA-42B0-A114-E3945671F7FA"
        },
        "ingested_at": "2026-02-12T21:57:56.478041+00:00"
      },
      {
        "event_id": "SOCIAL-Today1226-Saint68-25164363",
        "event_type": "social_post",
        "date": "2026-02-11T14:17:05.528446",
        "source": "LSE_CHAT",
        "data": {
          "author": "Saint68",
          "content": "Who cares - he's not posting so all good.",
          "sentiment": 0.0,
          "engagement": "2,194",
          "price_at_post": "60.00",
          "thread_title": "RE: Banned",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AA63DAAF-42CA-42B0-A114-E3945671F7FA"
        },
        "ingested_at": "2026-02-12T21:57:56.478059+00:00"
      },
      {
        "event_id": "SOCIAL-Today1220-pedrolan-17127747",
        "event_type": "social_post",
        "date": "2026-02-11T14:17:05.528858",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "I take it as a good sign the board is quiet here. Of course there will be a big element of that down to the omission of Thorn, Now apologies in advance and I don't want to set the hare running but do we know he deleted his account or was he banned? Does anyone know for sure? It did seem to be around the time he was re-exposed as Eggy but it is possible that was a coincidence.",
          "sentiment": 0.5,
          "engagement": "1,993",
          "price_at_post": "60.00",
          "thread_title": "RE: Banned",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AA63DAAF-42CA-42B0-A114-E3945671F7FA"
        },
        "ingested_at": "2026-02-12T21:57:56.478077+00:00"
      },
      {
        "event_id": "SOCIAL-Today1200-Icecool--8237373",
        "event_type": "social_post",
        "date": "2026-02-11T14:17:05.529302",
        "source": "LSE_CHAT",
        "data": {
          "author": "Icecool",
          "content": "There\u2019s not much to debate right now to be honest. Windy\u2019s suddenly gone quiet now he\u2019s back in, funny how that works \ud83d\ude44\ud83e\udd23\ud83d\ude2d. When he\u2019s out it\u2019s doom and gloom, when he\u2019s in it\u2019s silence. Standard behaviour. Most of the board actually seems pretty calm. Everyone knows the next real catalyst is TNBC data. That\u2019s what matters. And Thorn disappearing the moment the lifetime dose cap was removed!! That tells its own story. The whole half life cumulative toxicity argument was the backbone of that narrative. Once regulators lifted the cap, that line of attack collapsed overnight. The drug just gained a structural advantage. You don\u2019t quietly delete your account if that doesn\u2019t sting. \ud83e\udd23\ud83e\udd23\ud83e\udd23 Now we wait for data. Everything else is just noise in the meantime. \ud83d\udcaf\ud83d\udc4d",
          "sentiment": 0.0,
          "engagement": "8,858",
          "price_at_post": "60.00",
          "thread_title": "RE: Banned",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AA63DAAF-42CA-42B0-A114-E3945671F7FA"
        },
        "ingested_at": "2026-02-12T21:57:56.478109+00:00"
      },
      {
        "event_id": "SOCIAL-Today1157-BuenaVis--6313327",
        "event_type": "social_post",
        "date": "2026-02-11T14:17:05.529711",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "\"[U]p to $2.4 billion in cash, inclusive of an upfront payment and subsequent payments upon achievement of certain clinical development milestones\" so enough for a scone today and gallons and gallons of jam tomorrow, if they're lucky. Nothing in clinical development: https://www.ornatx.com/our-pipeline/",
          "sentiment": 0.0,
          "engagement": "5,849",
          "price_at_post": "60.00",
          "thread_title": "RE: ELY LILLY",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B6F8359B-09F7-4910-B7F8-547334C64F27"
        },
        "ingested_at": "2026-02-12T21:57:56.478147+00:00"
      },
      {
        "event_id": "SOCIAL-Today1146-D0berman--1200629",
        "event_type": "social_post",
        "date": "2026-02-11T14:17:05.530123",
        "source": "LSE_CHAT",
        "data": {
          "author": "D0berman",
          "content": "Bloody Hell!! Who's been banned, it's so quiet!!",
          "sentiment": 0.0,
          "engagement": "1,024",
          "price_at_post": "60.00",
          "thread_title": "Banned",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AA63DAAF-42CA-42B0-A114-E3945671F7FA"
        },
        "ingested_at": "2026-02-12T21:57:56.478166+00:00"
      },
      {
        "event_id": "SOCIAL-Today0904-Harrogat-72119994",
        "event_type": "social_post",
        "date": "2026-02-11T14:17:05.530532",
        "source": "LSE_CHAT",
        "data": {
          "author": "Harrogate4",
          "content": "One day Rodders ----that could be us.",
          "sentiment": 0.0,
          "engagement": "807",
          "price_at_post": "60.50",
          "thread_title": "RE: ELY LILLY",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B6F8359B-09F7-4910-B7F8-547334C64F27"
        },
        "ingested_at": "2026-02-12T21:57:56.478184+00:00"
      },
      {
        "event_id": "SOCIAL-Today0812-Bella653-73498243",
        "event_type": "social_post",
        "date": "2026-02-11T14:17:05.530927",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "Https://investor.lilly.com/news-releases/news-release-details/lilly-acquire-orna-therapeutics-advance-cell-therapies",
          "sentiment": 0.0,
          "engagement": "6,770",
          "price_at_post": "59.50",
          "thread_title": "ELY LILLY",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B6F8359B-09F7-4910-B7F8-547334C64F27"
        },
        "ingested_at": "2026-02-12T21:57:56.478202+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20262211-B2HS2L-90068380",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.316988",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "Bella, I'm quoting company presentations and Trinity Delta. But I'll take any answer I can get from an Investor Relations company willing to respond to an Investor on behalf of Avacta. What a breath of fresh air that would be, and we could all organise a knee's up to celebrate responses.   Ha ha....dream on. Will advise any response, but it won't be this week I'm thinking.",
          "sentiment": 0.0,
          "engagement": "6,052",
          "price_at_post": "59.50",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0781AA9B-9049-48B9-B94C-F3239EA4AB66"
        },
        "ingested_at": "2026-02-12T21:57:56.478221+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20262058-D-Geeman-88268318",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.317461",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "\u2018 and Wynbore taken \u2019 Mel obvs missing Wyn after just a day or two. \ud83d\ude3f",
          "sentiment": 0.0,
          "engagement": "5,879",
          "price_at_post": "59.50",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0781AA9B-9049-48B9-B94C-F3239EA4AB66"
        },
        "ingested_at": "2026-02-12T21:57:56.478239+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20262040-Bella653--4775516",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.317882",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "Most likely you'll be referred to RNS updates.",
          "sentiment": 0.0,
          "engagement": "6,769",
          "price_at_post": "59.50",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0781AA9B-9049-48B9-B94C-F3239EA4AB66"
        },
        "ingested_at": "2026-02-12T21:57:56.478258+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20262038-Bella653-15931636",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.318312",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "B2...Afraid they won't be able to give you the answers you seek.",
          "sentiment": 0.0,
          "engagement": "6,769",
          "price_at_post": "59.50",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0781AA9B-9049-48B9-B94C-F3239EA4AB66"
        },
        "ingested_at": "2026-02-12T21:57:56.478291+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261947-Metatron-48350380",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.318724",
        "source": "LSE_CHAT",
        "data": {
          "author": "Metatron",
          "content": "Where have your mates gone Toukdroid? Thorn been banned? and Wynbore taken his bat and ball home? Pressures on you now.. need to raise your game? \ud83e\uddd0\ud83d\ude02\ud83d\ude44",
          "sentiment": 0.0,
          "engagement": "1,193",
          "price_at_post": "59.50",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0781AA9B-9049-48B9-B94C-F3239EA4AB66"
        },
        "ingested_at": "2026-02-12T21:57:56.478315+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261929-D-Geeman-39712784",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.319153",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "Faron, FARN, today. *Unless I'm missing something.",
          "sentiment": 0.0,
          "engagement": "5,879",
          "price_at_post": "59.50",
          "thread_title": "How *NOT* to organise a raise.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B74524AD-99F9-469D-8BB4-0B75886909B8"
        },
        "ingested_at": "2026-02-12T21:57:56.478334+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261806-cj62--8100090",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.319558",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "Thorn/ touk you continue to be an insufferable prick. As for the consortium you mention,at the present market cap, yes I probably could.",
          "sentiment": 0.0,
          "engagement": "4,305",
          "price_at_post": "59.50",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0781AA9B-9049-48B9-B94C-F3239EA4AB66"
        },
        "ingested_at": "2026-02-12T21:57:56.478352+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261757-Toukanka-79787436",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.319970",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "\u201c . As I mentioned, we'll have that,. Pipeline update, platform update, and so we're really excited about, the fourth quarter, for the company.\" Jeez I must have missed all those 4Q25 announcements",
          "sentiment": 0.0,
          "engagement": "4,490",
          "price_at_post": "59.50",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0781AA9B-9049-48B9-B94C-F3239EA4AB66"
        },
        "ingested_at": "2026-02-12T21:57:56.478370+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261717-Toukanka--2724389",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.320430",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "BenH It\u2019s ok Someone has deleted the post anyway",
          "sentiment": 0.0,
          "engagement": "4,490",
          "price_at_post": "59.50",
          "thread_title": "RE: Initial data seen under NDA 1st",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=DC4BE032-D599-4CC6-BFFD-F74DE0A45A33"
        },
        "ingested_at": "2026-02-12T21:57:56.478388+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261714-B2HS2L--6056947",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.320844",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "That's clear. What isn't clear is the nature of the phase 2 partnership sought by Avacta. 15:31",
          "sentiment": 0.0,
          "engagement": "6,052",
          "price_at_post": "59.50",
          "thread_title": "RE: Fairy docks ??????",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=8CFFD9D7-1C22-44FA-9FEA-90DC99BAA17F"
        },
        "ingested_at": "2026-02-12T21:57:56.478418+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261645-PL75--7180160",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.321279",
        "source": "LSE_CHAT",
        "data": {
          "author": "PL75",
          "content": "We have committed that we won't start the further development activities in the absence of a partnership. Why isn\u2019t that clear?",
          "sentiment": 0.0,
          "engagement": "11,226",
          "price_at_post": "59.50",
          "thread_title": "RE: Fairy docks ??????",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=8CFFD9D7-1C22-44FA-9FEA-90DC99BAA17F"
        },
        "ingested_at": "2026-02-12T21:57:56.478442+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261623-B2HS2L-17149431",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.321681",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "I'll keep checking my Spam directory for Cohesion's response..",
          "sentiment": 0.0,
          "engagement": "6,052",
          "price_at_post": "60.00",
          "thread_title": "RE: Fairy docks ??????",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=8CFFD9D7-1C22-44FA-9FEA-90DC99BAA17F"
        },
        "ingested_at": "2026-02-12T21:57:56.478460+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261613-pedrolan-22397787",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.322086",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "I was referring to the account that pulled you up and decided it needed a new thread to highlight it, for some reason!",
          "sentiment": 0.5,
          "engagement": "1,990",
          "price_at_post": "60.00",
          "thread_title": "RE: Fairy docks ??????",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=8CFFD9D7-1C22-44FA-9FEA-90DC99BAA17F"
        },
        "ingested_at": "2026-02-12T21:57:56.478478+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261606-B2HS2L-24015354",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.322501",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "I bet tonight's custard skin from your spotted dick that Sleeper account = avacta@cohesionbureau.com  \ud83d\ude09",
          "sentiment": 0.0,
          "engagement": "6,052",
          "price_at_post": "60.00",
          "thread_title": "RE: Fairy docks ??????",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=8CFFD9D7-1C22-44FA-9FEA-90DC99BAA17F"
        },
        "ingested_at": "2026-02-12T21:57:56.478496+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261605-BuenaVis-33995252",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.322907",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Should actually be ferry docks.",
          "sentiment": 0.0,
          "engagement": "5,848",
          "price_at_post": "60.00",
          "thread_title": "RE: Fairy docks ??????",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=8CFFD9D7-1C22-44FA-9FEA-90DC99BAA17F"
        },
        "ingested_at": "2026-02-12T21:57:56.478515+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261601-pedrolan-48465408",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.323320",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Sleeper account enabled",
          "sentiment": 0.5,
          "engagement": "1,990",
          "price_at_post": "59.50",
          "thread_title": "RE: Fairy docks ??????",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=8CFFD9D7-1C22-44FA-9FEA-90DC99BAA17F"
        },
        "ingested_at": "2026-02-12T21:57:56.478534+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261550-B2HS2L-57254478",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.323726",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "Should read 'faridoxorubicin' thanks Replacement email sent.",
          "sentiment": 0.0,
          "engagement": "6,052",
          "price_at_post": "59.50",
          "thread_title": "RE: Fairy docks ??????",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=8CFFD9D7-1C22-44FA-9FEA-90DC99BAA17F"
        },
        "ingested_at": "2026-02-12T21:57:56.478567+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261540-tiger29--8639298",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.324134",
        "source": "LSE_CHAT",
        "data": {
          "author": "tiger29",
          "content": "What are \"the fairy docks ?\"",
          "sentiment": 0.0,
          "engagement": "46",
          "price_at_post": "60.00",
          "thread_title": "Fairy docks ??????",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=8CFFD9D7-1C22-44FA-9FEA-90DC99BAA17F"
        },
        "ingested_at": "2026-02-12T21:57:56.478586+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261531-B2HS2L--1358336",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.324606",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "I've sent this to cohesion this afternoon, to see whether I get no response as per previous agencies. avacta@cohesionbureau.com Hi Cohesion Investor Relations, Many investors are unaware of the cost to Avacta of pursuing the upcoming phase 2/3 trial, for which the company currently seeks a partner. Does the company hope to 1 Have the partner cover 100% of the costs of the phase 2/3 trial. 2 Have the costs divided between Avacta and partner, dependent upon negotiations between parties. At the 30.09.2025 Investormeet presentation, a question was asked and insufficiently answered to get a response amenable to all. The question was: Q2 How much do you expect phase 2 for faridoxorubicin to cost Avacta? How will you fund this if a partnership doesn't materialise? The response from the CEO was: A2 \"So we're very confident in the maturing data in the phase 1B of, fairy docks and, we think that this will support the long-term value of this asset. Salivary gland cancers, you know, high unmet need and, we continue to, collect data, in the various cohorts. We have committed that we won't start the further development activities in the absence of a partnership. However, as I've said, the maturing data set in phase 1B is providing us with, ample confidence that precision is, working exactly as, we designed it to work. The development in the expansion cohorts is, well underway. We believe the preliminary data here will provide that natural inflection point for the program. It's gonna provide also clarity on accelerated approval pathways that we might be able to seek. And also there's, really an opportunity, for the overall market to, digest essentially the commercial potential for the program and the platform. As I mentioned, we'll have that,. Pipeline update, platform update, and so we're really excited about, the fourth quarter, for the company.\" It is assumed that this question was selected by Avacta to be asked in the presentation beforehand. Any information you can provide on this subject would be a great help Kind Regards Avacta shareholders",
          "sentiment": 0.0,
          "engagement": "6,052",
          "price_at_post": "60.00",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0781AA9B-9049-48B9-B94C-F3239EA4AB66"
        },
        "ingested_at": "2026-02-12T21:57:56.478604+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261449-B2HS2L--1899082",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.325021",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "IVM 30.09.25 - select Q/A tab. https://www.investormeetcompany.com/meetings/interim-results-491",
          "sentiment": 0.0,
          "engagement": "6,052",
          "price_at_post": "60.00",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0781AA9B-9049-48B9-B94C-F3239EA4AB66"
        },
        "ingested_at": "2026-02-12T21:57:56.478622+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261437-yeboha--3451810",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.325448",
        "source": "LSE_CHAT",
        "data": {
          "author": "yeboha",
          "content": "What was CC actual full reply to that question ????",
          "sentiment": 0.0,
          "engagement": "969",
          "price_at_post": "60.00",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0781AA9B-9049-48B9-B94C-F3239EA4AB66"
        },
        "ingested_at": "2026-02-12T21:57:56.478640+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261338-Bella653--3175843",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.325853",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "What plon\u00a3er put ghrough two 0 trades???\ud83d\ude02\ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "6,769",
          "price_at_post": "61.00",
          "thread_title": "Trades",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=F9CE2B15-57EB-41C4-816A-05159896BF66"
        },
        "ingested_at": "2026-02-12T21:57:56.478659+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261307-B2HS2L--8149095",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.326290",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "Update possibly end of March to coincide with the 1/4ly business update. (where have they gone BH?) Q2 How much do you expect phase 2 for faridoxorubicin to cost Avacta? How will you fund this if a partnership doesn't materialise? CC doesn't address the question very well, though other info appears. Note 26.06.2025 Trinity Delta: The foundational IP around the sustained release pre|CISION mechanism and the better appreciation of the scope of the pre|CISION platform gleaned from the Tempus collaboration provides multiple new opportunities for Avacta to unlock value through generating and developing a pipeline of highly novel tumour targeting drug conjugates, subject to securing additional funds. One potential funding pathway centres on business development, including securing: \u2022\tProduct-based partnerships: partnering or out-licensing deals with large pharma/biotech companies that have clinical and/or commercial expertise in certain therapeutic areas, or geographies, could help accelerate development of either existing or new product candidates. We note that Avacta is actively seeking a deal for AVA6000, ahead of starting Phase II development in H126",
          "sentiment": 0.0,
          "engagement": "6,052",
          "price_at_post": "61.00",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0781AA9B-9049-48B9-B94C-F3239EA4AB66"
        },
        "ingested_at": "2026-02-12T21:57:56.478689+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261246-opti_mys--5765494",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.326692",
        "source": "LSE_CHAT",
        "data": {
          "author": "opti_mystic",
          "content": "B2, the point of the partner for 6k phase 2 is that they the partner fund the trial, we won't be paying for it that is for sure. So they won't care about our finances. Presumably there will also be some sort of upfront payment too helping our finances. No partner no phase 2.",
          "sentiment": 0.0,
          "engagement": "317",
          "price_at_post": "61.00",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0781AA9B-9049-48B9-B94C-F3239EA4AB66"
        },
        "ingested_at": "2026-02-12T21:57:56.478713+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261238-B2HS2L--6928396",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:38.327228",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "Opti The company has said it will not take 6000 into phase 2/3 without a partner. 1 Depending on that deal, there may be cash available. 2 The state of AVCT finances might be cautionary for any AVA6000 partner. Would that partner be willing to proceed with Avacta unable to show sufficient longer term funding to proceed with phase 2/3, or unable to state when funding would become available? Sorting funding before finalising a partner would nullify such concerns. \"Avacta has strongly signalled a deal for that to fund 6103\". Avacta selling 6000 to fund 6103? IVM presentation 30.09.2025 Q2 How much do you expect phase 2 for faridoxorubicin to cost Avacta? How will you fund this if a partnership doesn't materialise? CC: \"So, we're very confident in the maturing data and the phase 1B of Faridoxorubicin and we think that this will support the long-term value of this asset. Salivary gland cancers, you know, high unmet need - and we continue to collect data in the various cohorts. We have committed that we won't start the further development activities in the absence of a partnership. However, as I've said, the maturing data set in phase 1B is providing us with ample confidence that precision is working exactly as we designed it to work. The development in the expansion cohorts is well underway. We believe the preliminary data here will provide that natural inflection point for the program. It's also going to provide clarity on accelerated approval pathways that we might be able to seek\"... ....Which will be of great interest to prospective partners. RNS'd FDA agreement that the dox lifetime limit to be removed on 03.02.2026. \"Agreed updates to the trial protocol include the removal of the maximum dosing limit and to allow flexibility in dosing levels. These two developments underscore the growing confidence from investigators and regulators in the tolerability profile of faridoxorubicin, and should support a smooth transition to future efficacy studies.\" \"The final cohorts of patients with the selected indications in Phase 1b will be enrolled, enabling two dose levels to be compared in order to determine the optimal biologic dose in future trials.\" +++ We await further details as to how the company enacts the FDA agreement, affecting past patients who have stopped faridox doses when they reached the lifetime limit. This is also true  for those patients on present cohorts who are still being dosed, but yet to reach the lifetime limit, as doses administered beyond 550 migs will affect the PFS calcs that are the end point of the trial. These patients now have the right to be treated beyond 550 migs... ...Again of interest to prospective partners. 6K Phase 1a data cutoff in 17 Dec 25 presentation was 15.09.2025 ie 4 months ago 6K Phase 1b data cutoff in 17 Dec 25 presentation was  15.10.2026 ie 3 months ago Update possibly end of March to coincide with the 1/4ly business update. (where have they g",
          "sentiment": 0.0,
          "engagement": "6,052",
          "price_at_post": "61.00",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0781AA9B-9049-48B9-B94C-F3239EA4AB66"
        },
        "ingested_at": "2026-02-12T21:57:56.478731+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261045-nurseste-29576910",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:41.202403",
        "source": "LSE_CHAT",
        "data": {
          "author": "nursesteve",
          "content": "A lot of people (inc big pharma) sitting on their hands just now. Volume is down but that can very soon change. GLA",
          "sentiment": 0.0,
          "engagement": "1,170",
          "price_at_post": "61.50",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=0781AA9B-9049-48B9-B94C-F3239EA4AB66"
        },
        "ingested_at": "2026-02-12T21:57:56.478749+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261043-Matml74--1897620",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:41.202838",
        "source": "LSE_CHAT",
        "data": {
          "author": "Matml74",
          "content": "They will also have very little cash left at that point (July/August). They won\u2019t run cash down to an only a few months worth so I would expect some form of funding to come forward in the next couple of months.",
          "sentiment": 0.0,
          "engagement": "2,551",
          "price_at_post": "61.50",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=0781AA9B-9049-48B9-B94C-F3239EA4AB66"
        },
        "ingested_at": "2026-02-12T21:57:56.478767+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20261012-opti_mys--4282273",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:41.203267",
        "source": "LSE_CHAT",
        "data": {
          "author": "opti_mystic",
          "content": "The problem I see is that before BP spend a ton of cash they will want lots of data. They will have it with 6k by the end of June when TNBC data is released and it seems likely a deal for at least the three indications we know about would be the focus of that deal. Avacta has  strongly signalled a deal for that to fund 6103. However at a similar sort of time July/August they should have a very good idea on 6103 too with early data. Would waiting a little bit longer and buying the whole kit caboodle really make that much difference to BP who we all know have massive patent cliffs? Deal(s) are on the way for sure, the timing and size is the only uncertainty.",
          "sentiment": 0.0,
          "engagement": "317",
          "price_at_post": "61.50",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=0781AA9B-9049-48B9-B94C-F3239EA4AB66"
        },
        "ingested_at": "2026-02-12T21:57:56.478785+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20260946-Bella653-78389018",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:41.203675",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "Oops..funding not gunding...",
          "sentiment": 0.0,
          "engagement": "6,769",
          "price_at_post": "61.50",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=0781AA9B-9049-48B9-B94C-F3239EA4AB66"
        },
        "ingested_at": "2026-02-12T21:57:56.478803+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20260945-Bella653--4434479",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:41.204090",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "Morning LDA...yes it will...not worried just interesting how it's bumped 63 several time...bit of a glass ceiling right now... If a deal is to be struck before we need finance it's being worked on right now.  The new sppointment is very interesting and I think they will bring in the partnership with an upfront wad...and I wouldn't be surprised HR then come in with Royalty backed gunding.",
          "sentiment": 0.0,
          "engagement": "6,769",
          "price_at_post": "61.50",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=0781AA9B-9049-48B9-B94C-F3239EA4AB66"
        },
        "ingested_at": "2026-02-12T21:57:56.478821+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20260833-Livedata--3566299",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:41.204512",
        "source": "LSE_CHAT",
        "data": {
          "author": "Livedataaccount",
          "content": "Hey bella good morning it will come soon",
          "sentiment": 0.0,
          "engagement": "2,975",
          "price_at_post": "61.50",
          "thread_title": "RE: SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=0781AA9B-9049-48B9-B94C-F3239EA4AB66"
        },
        "ingested_at": "2026-02-12T21:57:56.478840+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20260830-Bella653-76076242",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:41.204922",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "Wmsjames..'But signing a material deal purely off very early Phase 1 signals, before dose optimisation and without durability data, is still the exception rather than the rule.' They could sign an MOU type deal now with full deal based on certain outcomes/milestones.",
          "sentiment": 0.0,
          "engagement": "6,769",
          "price_at_post": "61.50",
          "thread_title": "RE: Initial data seen under NDA 1st",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=DC4BE032-D599-4CC6-BFFD-F74DE0A45A33"
        },
        "ingested_at": "2026-02-12T21:57:56.478857+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20260826-Bella653-81634305",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:41.205339",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "Need to break 63",
          "sentiment": 0.0,
          "engagement": "6,769",
          "price_at_post": "61.50",
          "thread_title": "SP",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=0781AA9B-9049-48B9-B94C-F3239EA4AB66"
        },
        "ingested_at": "2026-02-12T21:57:56.478876+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20260810-Bella653-61066080",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:41.205745",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "What about a Partnership for 6000 with Option to Licence one or more pipeline products...",
          "sentiment": 0.0,
          "engagement": "6,769",
          "price_at_post": "61.50",
          "thread_title": "RE: Initial data seen under NDA 1st",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=DC4BE032-D599-4CC6-BFFD-F74DE0A45A33"
        },
        "ingested_at": "2026-02-12T21:57:56.478894+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20260756-B2HS2L-77284670",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:41.206160",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "'6103 is actually validating 6000 which itself is derisking 6103.' I'll go for 6000 phase 1a results are being validated by 6000 phase 1b results in SGC so far. (Two other indications results not known yet).",
          "sentiment": 0.0,
          "engagement": "6,052",
          "price_at_post": "61.50",
          "thread_title": "RE: Initial data seen under NDA 1st",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=DC4BE032-D599-4CC6-BFFD-F74DE0A45A33"
        },
        "ingested_at": "2026-02-12T21:57:56.478912+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20260750-yeboha--1262226",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:41.206562",
        "source": "LSE_CHAT",
        "data": {
          "author": "yeboha",
          "content": "Remember, just ignore the same old FUD BRIGADE and they\u2019ll end up talking only among themselves! Yesterday\u2019s appointment was a great move by Avacta,  they are getting everything in order. Onwards and upwards!",
          "sentiment": 0.0,
          "engagement": "969",
          "price_at_post": "61.50",
          "thread_title": "Ignore the FUD BRIGADE",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B82AA1FD-8062-42D5-928C-4DE5C508547A"
        },
        "ingested_at": "2026-02-12T21:57:56.478930+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20260744-JamYeste--4844677",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:41.206972",
        "source": "LSE_CHAT",
        "data": {
          "author": "JamYesterday",
          "content": "100x more potent than Dox? Scary. So much depends on the next few months.",
          "sentiment": 0.0,
          "engagement": "560",
          "price_at_post": "61.50",
          "thread_title": "RE: Initial data seen under NDA 1st",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=DC4BE032-D599-4CC6-BFFD-F74DE0A45A33"
        },
        "ingested_at": "2026-02-12T21:57:56.478949+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20260734-Benharpe--1529138",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:41.207385",
        "source": "LSE_CHAT",
        "data": {
          "author": "Benharper",
          "content": "Every other poster isn\u2019t the same person Touk. In this post Alberbaran is being admittedly a bit optimistic regarding timelines. Wmsjames is being more circumspect. I personally think Wms is on the right track. Perhaps wait until last nights session has cleared your system before posting.",
          "sentiment": 0.0,
          "engagement": "746",
          "price_at_post": "61.50",
          "thread_title": "RE: Initial data seen under NDA 1st",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=DC4BE032-D599-4CC6-BFFD-F74DE0A45A33"
        },
        "ingested_at": "2026-02-12T21:57:56.478967+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20260659-Aldebara-82731147",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:41.207795",
        "source": "LSE_CHAT",
        "data": {
          "author": "Aldebaran",
          "content": "Im saying same thing that deal will be on faridoxorubicin based off the 4 years of dada we have for sts sgc and also breast cancer plus the work done on 3996 amd 6207 in pre clinical setting. Throw into the mix some initial data from 6103 and it becomes a self validating loop. 6103 is actually validating 6000 which itself is derisking 6103. Its highly unique. I am expecting 6103 data ans breast cancer data to lead to a deal or as some have said maybe even a direct take out approach. Could be well before market sets eyes on 6103 data... not giving the market and FUDsters chance to react and buy in \"cheap\". Before the deals land. Be a massive shame that but id get over it",
          "sentiment": 0.0,
          "engagement": "3,941",
          "price_at_post": "61.50",
          "thread_title": "RE: Initial data seen under NDA 1st",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=DC4BE032-D599-4CC6-BFFD-F74DE0A45A33"
        },
        "ingested_at": "2026-02-12T21:57:56.478985+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20260616-Wmsjames-39747426",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:41.208261",
        "source": "LSE_CHAT",
        "data": {
          "author": "Wmsjames",
          "content": "I\u2019m a bit more cautious on the timing. Yes, initial safety and tolerability signals are often seen early in Phase 1, sometimes within weeks of first dosing. But that doesn\u2019t automatically translate into actionable data for partners. Early signals are noisy, patient numbers are tiny, and dose escalation means you are often below biologically meaningful exposure in the first cohorts. On efficacy, even if there are early radiological hints, sponsors and pharma partners usually want: \u2022\tMultiple patients at or near the target dose \u2022\tConsistency across scans, not a single responder \u2022\tConfidence the signal isn\u2019t dose or patient specific That usually takes several months, not weeks. As for deals, could confidential discussions happen in parallel? Absolutely. Pharma will already understand the mechanism and will be tracking progress closely. But signing a material deal purely off very early Phase 1 signals, before dose optimisation and without durability data, is still the exception rather than the rule. So my view is: \u2022\tEarly internal confidence may build well before June \u2022\tMarket visible data likely takes longer \u2022\tAny deal would more likely be driven by confidence in the platform + AVA6000 validation, rather than a handful of first AVA6103 scans",
          "sentiment": 0.0,
          "engagement": "718",
          "price_at_post": "61.50",
          "thread_title": "RE: Initial data seen under NDA 1st",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=DC4BE032-D599-4CC6-BFFD-F74DE0A45A33"
        },
        "ingested_at": "2026-02-12T21:57:56.479003+00:00"
      },
      {
        "event_id": "SOCIAL-10Feb20260608-Aldebara--4257395",
        "event_type": "social_post",
        "date": "2026-02-11T01:19:41.208683",
        "source": "LSE_CHAT",
        "data": {
          "author": "Aldebaran",
          "content": "Us plebs may have to wait until June earliest but how long before those under NDA such as presumably Novartis et al get to see it ? What do you think touk? 2nd question, how long before initial scans and tolerability is known after dosing. Initial i am saying. Given exetecan is what 20x more potent than irinotecan and 100x more potent than doxorubicin and more permeable than deruxtecan etc... ?? Personally I think within 1 months off dosing then the initial safety will be known and their could easily he signs of efficacy. This will be WAY before June and the point the market gets said data. Could a deal be signed off the back of this and the faridoxorubicin data to date before the market catches on, i think its possible. Highly possible actually. You and others? Thinking what?",
          "sentiment": 0.0,
          "engagement": "3,941",
          "price_at_post": "61.50",
          "thread_title": "Initial data seen under NDA 1st",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=DC4BE032-D599-4CC6-BFFD-F74DE0A45A33"
        },
        "ingested_at": "2026-02-12T21:57:56.479020+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20262317-pedrolan--1165645",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.585477",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Folks, Touk is clearly Thorn. Look how he writes. Ignore him.",
          "sentiment": 0.0,
          "engagement": "1,988",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-12T21:57:56.479039+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20262306-Icecool--8577807",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.586081",
        "source": "LSE_CHAT",
        "data": {
          "author": "Icecool",
          "content": "You do talk a load of nonsense\u2026. \ud83e\udd26\u200d\u2642\ufe0f",
          "sentiment": 0.0,
          "engagement": "8,857",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-12T21:57:56.479057+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20262305-Toukanka--1907677",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.586694",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "At the end of the day, initial efficacy results will not be published before June IMO. And CC has said as much. She has also said that any acceptable deal is unlikely before those results are published. And there will be no takeover even if CJ62 forms a consortium of shareholders and tries to push it through at say \u00a31",
          "sentiment": 0.0,
          "engagement": "4,486",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-12T21:57:56.479075+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20262301-Toukanka-49383649",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.587310",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "Thompi FPI is not the same as FPD. But no point arguing. You all know better than CC.",
          "sentiment": 0.0,
          "engagement": "4,486",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-12T21:57:56.479093+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20262150-Thompi--4395646",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.587906",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thompi",
          "content": "Touk, for the record, this is what Chris said in the Base to Base interview released 23rd January, but probably recorded late last year: \u201cWe\u2019re really looking forward to getting the first sustained release [AVA6103] into the clinic. That one will start in March of next year. We\u2019re aiming for the first quarter for the first patient with that one.\u201d",
          "sentiment": 0.0,
          "engagement": "1,364",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-12T21:57:56.479128+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20262123-BuenaVis--7782095",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.588579",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "In clinical trials, FPI (First Patient In) marks the critical milestone when the very first participant is screened, enrolled, and officially enters the study, signifying the transition from planning to active execution. It validates site readiness, kicks off data collection, and is a major KPI for project timelines and investor confidence. Here are the key details regarding FPI: Key Aspects of FPI \u2022 Definition: It is the date the first human subject is qualified, accepted, and often dosed in a clinical trial. \u2022 Significance: It proves all regulatory approvals, document reviews, contracting, and site setups are complete. \u2022 Business Impact: FPI is a high-pressure corporate goal that affects company reputation, stock prices, and investor confidence. \u2022 Trial Flow: It moves the study from \"study start-up\" to \"execution/recruitment\" phase. Why FPI Matters \u2022 Timeline Driver: It sets the pace for the rest of the recruitment and trial timeline. \u2022 Success Indicator: Meeting the FPI goal on time usually means the study is on sound footing. \u2022 Risk: Rushing to hit FPI dates can sometimes lead to neglected study designs or premature starts. Sometimes, this milestone is also referred to as FPFV (First Patient First Visit), focusing on when data collection begins for that first subject.",
          "sentiment": 0.0,
          "engagement": "5,847",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-12T21:57:56.479147+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20262039-B2HS2L--3366770",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.589188",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "A couple of non-Avacta trials that mention FPI, state that FPI = first patient enrolment. Neither discuss enrolment details though.   \ud83e\udd23\ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "6,042",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-12T21:57:56.479165+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20262005-Gingethe-84354947",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.589761",
        "source": "LSE_CHAT",
        "data": {
          "author": "GingetheWinge",
          "content": "Every piece of Avacta communication. Q1 2026. That is fact. Your opinions are plucked out of your a r s e.",
          "sentiment": 0.5,
          "engagement": "705",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-12T21:57:56.479183+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261922-avctIPma-45337221",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.590377",
        "source": "LSE_CHAT",
        "data": {
          "author": "avctIPmatters",
          "content": "\"FPI stands for \"First Patient In\", which is a critical milestone in clinical trials. It marks the moment when the first participant is screened and enrolled into the trial, signaling the beginning of real-world data collection.\" Ref :   Slide 29 https://avacta.com/wp-content/uploads/2025/07/Avacta_Corp_23July2025.pdf \" Q1 2026   Phase 1 first patient in (FPI)\" Gmcc",
          "sentiment": 0.0,
          "engagement": "742",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-12T21:57:56.479201+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261913-BuenaVis-91030129",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.590980",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "The FDA has 30 calendar days to review an IND application after receiving it. https://drugdevelopment.web.unc.edu/u-s-investigational-new-drug-application-%e2%86%92-ind-application-process/ IND submitted mid/late December (as per the project plan in Spotlight 13) and approved by 20 January. The FDA will have been working closely with Avacta given the experience with faridox so that was a fast turnaround given the US government shutdown gping on at the time. - - - - - And ToucanOfDoom, stop purporting to know better than CC what the likely timescales are.",
          "sentiment": 0.0,
          "engagement": "5,847",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-12T21:57:56.479220+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261911-Toukanka--4629577",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.591588",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "CJ62 No, while posters on here continue to misconstrue communications from Avacta and purport to know better than CC what the likely timescales are, then I will continue to correct them. You and others stop posting baseless wishful thinking ramps on here and I will stop exposing them for what they are. Deal?",
          "sentiment": 0.0,
          "engagement": "4,486",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-12T21:57:56.479238+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261902-cj62-65802107",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.592186",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "Touk can you do a thorn and dissolve into the ether?",
          "sentiment": 0.0,
          "engagement": "4,304",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-12T21:57:56.479256+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261900-BuenaVis-26909859",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.592752",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Https://avacta.com/research-development-spotlight-series-episode-13/ @26:15 FPI late Q1/26",
          "sentiment": 0.0,
          "engagement": "5,847",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-12T21:57:56.479274+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261852-Vertizea--8967258",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.593353",
        "source": "LSE_CHAT",
        "data": {
          "author": "VertizeaSun",
          "content": "Thanks jmfw.....and I'll add the reminder that CC visited the AVA6103 manufacturing site (Glasgow) in early December. a necessary requirement if one knows that patient dosing is likely to begin sooner rather than later.",
          "sentiment": 0.0,
          "engagement": "446",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-12T21:57:56.479292+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261851-Toukanka-18682507",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.593952",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "No no no That is my point. Trial start does not mean first patient dosed. CC has outlined in a previous communication the lengthy steps between IND approval and first in patient dosed. My prediction is still for initial clinical results around June. No deals until at least tolerance shown to some degree and even then maybe not until initial signs of efficacy. And yes I do know that P1 is not designed to show efficacy.",
          "sentiment": 0.0,
          "engagement": "4,486",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-12T21:57:56.479310+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261837-jmfw-55817091",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.594558",
        "source": "LSE_CHAT",
        "data": {
          "author": "jmfw",
          "content": "Https://www.lse.co.uk/rns/AVCT/year-end-trading-update-63xrambu5i622u5.html Under heading:  Outlook for 2026",
          "sentiment": 0.0,
          "engagement": "418",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-12T21:57:56.479329+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261830-Toukanka--7754029",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.595177",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "Ginge That would be great. Can you provide a link to where that is stated please. I\u2019m not challenging you. Because that would be good if they start in March. Thanks",
          "sentiment": 0.0,
          "engagement": "4,486",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-12T21:57:56.479346+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261819-Bella653--1864183",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.595769",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "Scroll to end... https://www.forxtherapeutics.com/2025/12/forx-therapeutics-announces-usd-50m-series-a-financing-enabling-clinical-data-readout-for-potential-best-in-class-parg-inhibitor As I said, is this appointment about media or funding/partnering?",
          "sentiment": 0.0,
          "engagement": "6,761",
          "price_at_post": "60.50",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-12T21:57:56.479364+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261621-BuenaVis--6597522",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.596417",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Here are some links re Richard Jarvis at Novartis: Richard Jarvis history: https://rocketreach.co/richard-jarvis-email_238424640 Richard Jarvis at Jarvis Advisors: https://www.moneyhouse.ch/en/company/jarvis-advisors-gmbh-5842690731 (Binningen is on the edge of Basel, home of Novartis HQ) Richard Jarvis consultant: https://www.linkedin.com/posts/the-difference-collective_say-hello-to-collective-consultant-richard-activity-7389560479272259584-EiwK (with photo) Richard Jarvis at Cohesion Bureau: https://cohesionbureau.com/bureau/richard-jarvis (with photo) - - - - - And here is the Cohesion Bureau team at their various locations in Europe and the US: https://cohesionbureau.com/bureau",
          "sentiment": 0.0,
          "engagement": "5,847",
          "price_at_post": "60.50",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-12T21:57:56.479383+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261542-Gingethe--4066315",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.596992",
        "source": "LSE_CHAT",
        "data": {
          "author": "GingetheWinge",
          "content": "First patients are expected to receive AVA6103 before the end of March.",
          "sentiment": 0.5,
          "engagement": "705",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-12T21:57:56.479401+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261521-B2HS2L-16942742",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.597714",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "FWIW Chris Maggos Strategic Consulting and IR, PR & BD Services for Biotech / Medtech Experience Managing Director Cohesion Bureau \u00b7 Full-time Dec 2022 - Present \u00b7 3 yrs 3 mos Geneva, Switzerland \u00b7 Hybrid Our experienced multi-disciplinary U.S. and Pan-European team offers insightful strategic consulting and services to expedite your corporate growth. In addition to strategic consulting, we offer execution services for partnering, fundraising, investor and (social) media relations. We have a dedicated editorial unit producing corporate content, including, writing, graphic design, video and photography. We want to be your partner for growth. Our experienced multi-disciplinary U.S. and Pan-European team offers insightful strategic consulting and services to expedite your corporate growth. In addition to strategic consulting, we offer execution services for partnering, fundraising, investor and (social) media relations. We have a dedicated editorial unit producing corporate content, including, writing, graphic design, video and photography. We want to be your partner for growth. Managing Director BioConfidant S\u00e0rl Sep 2014 - Present \u00b7 11 yrs 6 mos Geneva, Switzerland BioConfidant offers strategic consulting on three closely related types of corporate activities: investor relations, public relations and business development (i.e. licensing and M&A). With our partners around Europe and in the U.S. we started Cohesion Bureau in 2022 to level the playing field for European startups and small-cap companies. We established and managed the European investor relations business of LifeSci Advisors from 2015-2021. We are passionate about developing relationships and collaborating with clients to earn the visibility and impact they need to succeed.",
          "sentiment": 0.0,
          "engagement": "6,042",
          "price_at_post": "60.50",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-12T21:57:56.479418+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261513-Livedata-77385285",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.598309",
        "source": "LSE_CHAT",
        "data": {
          "author": "Livedataaccount",
          "content": "With the location being switzerland one does imagine the cohesion team are in bed with some big players at roche and novartis",
          "sentiment": 0.0,
          "engagement": "2,974",
          "price_at_post": "61.50",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-12T21:57:56.479436+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261503-Timster--9196945",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.598888",
        "source": "LSE_CHAT",
        "data": {
          "author": "Timster",
          "content": "That's a serious accusation watching you WILL be hearing from my legal team, not as hidden as you think.......",
          "sentiment": 0.0,
          "engagement": "20,640",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-12T21:57:56.479454+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261503-avctIPma--2468171",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.599564",
        "source": "LSE_CHAT",
        "data": {
          "author": "avctIPmatters",
          "content": "\" Cohesion Bureau (Communications)  Richard Jarvis / Chris Maggos \" Interesting  connection  Richard Jarvis  has with  Novartis .   Avacta  has had lots of changes  recently  - Michelle Morrow  did  not last long  - guess  one less salary to pay & also streamlining communication costs. ------- \"Richard Jarvis Trustee Director Trustee Director Novartis UK Pension Trustee CompanyNovartis UK Pension Trustee Company 2014 - Present \u00b7 12 yrs 2 mos2014 to Present \u00b7 12 yrs 2 mos Grew funding position from <90% of liabilities to ~110% (buy-out basis) for ~7 000 members.Grew funding position from <90% of liabilities to ~110% (buy-out basis) for ~7 000 members. Novartis logo Head of Strategy & Financial Communications Head of Strategy & Financial Communications NovartisNovartis 2021 - 2025 \u00b7 4 yrs2021 to 2025 \u00b7 4 yrs Basel, SwitzerlandBasel, Switzerland Led global team of communications and media relations professionals, responsible for financial communications and global top tier media engagement.Led global team of communications and media relations professionals, responsible for financial communications and global top tier media engagement. Communications Strategy, Team Management and +6 skills\" Gmcc",
          "sentiment": 0.0,
          "engagement": "742",
          "price_at_post": "60.50",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-12T21:57:56.479472+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261502-Livedata--4856317",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:38.600169",
        "source": "LSE_CHAT",
        "data": {
          "author": "Livedataaccount",
          "content": "I always imagined timster was a belly dancer",
          "sentiment": 0.0,
          "engagement": "2,974",
          "price_at_post": "61.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-12T21:57:56.479490+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261458-Watching--2265731",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.363454",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "Timster are you still a children\u2019s entertainer ?",
          "sentiment": 0.0,
          "engagement": "9,229",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-12T21:57:56.479507+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261453-Timster--2561425",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.363899",
        "source": "LSE_CHAT",
        "data": {
          "author": "Timster",
          "content": "One of Francis's KPA's is to ensure LDA's requests for updates via the lse website are promptly answered. Id expect an update within 48hrs LDA",
          "sentiment": 0.0,
          "engagement": "20,640",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-12T21:57:56.479526+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261453-Toukanka-85039450",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.364338",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "Clear from what CC said in today\u2019s RNS that no one has been dosed with 6103 yet. Given the preparation work that needs to be carried out including pre screening, I previously predicted April earliest for dosing to start. (Based on 6100 timescales)",
          "sentiment": 0.0,
          "engagement": "4,486",
          "price_at_post": "60.50",
          "thread_title": "RE: Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-12T21:57:56.479544+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261426-Livedata-11827848",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.364756",
        "source": "LSE_CHAT",
        "data": {
          "author": "Livedataaccount",
          "content": "Be good to get an update please on TNBC progress and 6103 dosing thank you in advance",
          "sentiment": 0.0,
          "engagement": "2,974",
          "price_at_post": "60.50",
          "thread_title": "Update",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AECF81E6-F56B-4DAD-8250-3FEF1001DDBD"
        },
        "ingested_at": "2026-02-12T21:57:56.479562+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261324-B2HS2L-85425551",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.365200",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "If this was true in Nov 2024 (so for AVA6000), I would assume the situation is a little more rosy now. Possibly some starters for 10 here. https://www.trinitydelta.org/research-notes/targeting-the-tumour-microenvironment-with-precision/ A reminder from Trinity Delta \u2013 Targeting the tumour microenvironment with pre|CISION - 18.11.2024 \"Avacta has so far FAP-enabled ten different warheads building up a database of multiple pre|CISION compounds that include c 40 capping groups (which alter the PK of the conjugate) and c 20 linkers (required for FAP cleavage with certain warheads and can be used to modify FAP affinity and activity). These have all been characterised through computational simulations to evaluate molecular binding and how they dock into the FAP structure. A key consideration is how close the warhead can get to the FAP cleavage sequence; this typically depends on the size of the molecule, and often defines whether a spacer group is required. Consideration is also given to how long the conjugate and the active warhead are likely to remain in the TME, and this informs whether PK alterations, achieved through an alternative capping group, are needed to either allow the sustained release of the warhead or to slow plasma clearance.",
          "sentiment": 0.0,
          "engagement": "6,042",
          "price_at_post": "60.50",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=060607B8-56D7-4812-99EC-1BE5765F573F"
        },
        "ingested_at": "2026-02-12T21:57:56.481190+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261308-pedrolan-57389406",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.365614",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Yes and what a truly remarkable career he could have.",
          "sentiment": 0.5,
          "engagement": "1,988",
          "price_at_post": "60.50",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=060607B8-56D7-4812-99EC-1BE5765F573F"
        },
        "ingested_at": "2026-02-12T21:57:56.481245+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261300-BuenaVis-60211376",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.366018",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "As the mechanism of action\u2014the dipeptide and the cleavage\u2014is proven, it now comes down to designing each molecule's pharmacokinetics to fit the needs for the warhead.  And who better to lead that than a highy competent chemist at the top of his game?",
          "sentiment": 0.0,
          "engagement": "5,847",
          "price_at_post": "60.50",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=060607B8-56D7-4812-99EC-1BE5765F573F"
        },
        "ingested_at": "2026-02-12T21:57:56.481283+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261159-B2HS2L--3795827",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.366489",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "\"Francis - We will learn more about this program in the clinic and apply that as we continue to develop NOVEL INTELLECTUAL PROPERTY around our highly successful pre|CISION\u00ae platform.\" -  We look forward to plenty of new IP to come. 29.10.2025 CC: \"Much of the success and how we are going to be able to move the dual payload through is going to depend on our initial observations in the clinic with the exatacan molecule. Francis and Tom mentioned that a lot of what we are doing with the dual payload is based on the learnings in the lab with the exatecan molecule. We expect to learn a lot about the exatecan molecule as we move it into the clinic and that's going to inform a lot about the dual payload molecules. Clinic learnings in the first half of 2026, will inform how quickly we're going to move the dual payload through.\" Also \"if we do right and we do great things for patients, we will be doing great things for our shareholders.\" I hope they stack the new IP high. It will increase the bargaining value of the company. It doesn't sound like Francis is going to be straying far from the lab, unless other chemists are inbound, and Francis is the mentor.  \ud83d\udcab",
          "sentiment": 0.0,
          "engagement": "6,042",
          "price_at_post": "60.50",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=060607B8-56D7-4812-99EC-1BE5765F573F"
        },
        "ingested_at": "2026-02-12T21:57:56.481303+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261120-Timster--4799454",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.366896",
        "source": "LSE_CHAT",
        "data": {
          "author": "Timster",
          "content": "Biggest buy signal in recent days is when eggy threw in the towel and removed his account.",
          "sentiment": 0.0,
          "engagement": "20,640",
          "price_at_post": "61.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-12T21:57:56.481322+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261105-yeboha--6959440",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.367315",
        "source": "LSE_CHAT",
        "data": {
          "author": "yeboha",
          "content": "Great RNS yet again today ! All moving in the right direction !",
          "sentiment": 0.0,
          "engagement": "967",
          "price_at_post": "61.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-12T21:57:56.481340+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261054-D-Geeman-73164271",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.367735",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "Certainly Watching 2 raises the tone but is that why people read bulletin boards Ginge? Would you rather read a poster's record have have them be proved right again and again? Or, like W2's record.. Shall I raise the tone? \"\u00a3200 ex-chinah, nailed on!\" \"Later today! \" (Note to self; see, it's not difficult.)",
          "sentiment": 0.0,
          "engagement": "5,877",
          "price_at_post": "61.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-12T21:57:56.481360+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261048-Gingethe--4383674",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.368149",
        "source": "LSE_CHAT",
        "data": {
          "author": "GingetheWinge",
          "content": "Agreed. Always the usual suspects that lower the tone.",
          "sentiment": 0.5,
          "engagement": "705",
          "price_at_post": "61.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-12T21:57:56.481394+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261032-Watching--1040972",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.368583",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "Tidy the BB Ignore the muppets We now know ignore and they argue with themselves And eventually dry up ! Great appointment well done team  avacta !. Jane",
          "sentiment": 0.0,
          "engagement": "9,229",
          "price_at_post": "61.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-12T21:57:56.481426+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261017-D-Geeman-11241182",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.369068",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "Touk, Watching does their best... And not just on AVCT. 'Watching2 'Posted in: ENET Posts: 9,227 RE: Sidelines22 Nov 2023 09:59 Actually 1p is very unlikely Bottom has now been hit imo. Good averaging opportunity! Next rns will lift us' And in case you were wondering how this 'prediction'went, today's SP: Share Price Information for Ethernity Net (ENET) Share Price is delayed by 15 minutes Get Live Data 0.0048    0.0001 (2.13%) Bid: 0.0046 Ask: 0.005 Spread: 0.0004 (8.696%) Market Cap: \u00a348.00k Still, plenty of folk 'Rec'watching's posts so hats-off to Jane (unless you're still holding on to it Jane?) .",
          "sentiment": 0.0,
          "engagement": "5,877",
          "price_at_post": "61.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-12T21:57:56.481457+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261003-Livedata-15438540",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.369492",
        "source": "LSE_CHAT",
        "data": {
          "author": "Livedataaccount",
          "content": "Francis has been instrumental in ava6103 and ava6207 running a successful business is about retaining top talent and i have no doubt his IP is massive at Avacta it is a great appointment",
          "sentiment": 0.0,
          "engagement": "2,974",
          "price_at_post": "61.00",
          "thread_title": "New CSO",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=2EBFCF4C-4A4D-475C-BBFD-DB095DA011B8"
        },
        "ingested_at": "2026-02-12T21:57:56.481489+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260926-Harrogat-49981981",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.369903",
        "source": "LSE_CHAT",
        "data": {
          "author": "Harrogate4",
          "content": "Agreed -----did they ever do anything ---apart from taking their salaries of course?",
          "sentiment": 0.0,
          "engagement": "805",
          "price_at_post": "61.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-12T21:57:56.481523+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260923-Bella653--5050085",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.370320",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "So can we assume THRUST and ICR have been ditched now...if so good ridens...",
          "sentiment": 0.0,
          "engagement": "6,761",
          "price_at_post": "61.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-12T21:57:56.481546+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260921-Bella653-17439194",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.370735",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "Or.. 1.  Is Cohesion Bureau about attracting Pharma funding? Their website is terrible...Nothing comes up in the NEWS section!!!!! 2.  We are not in the Immunotherapy space we now need good Chemists.   I think CC mentioned this in one of her videos when she talked about the 'Chemistry' involved in developing new pipelines.",
          "sentiment": 0.0,
          "engagement": "6,761",
          "price_at_post": "61.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-12T21:57:56.481565+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260919-yeboha--7323769",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.371148",
        "source": "LSE_CHAT",
        "data": {
          "author": "yeboha",
          "content": "But then again i dont no if avacta want the take over, they certainly wont push for it !",
          "sentiment": 0.0,
          "engagement": "967",
          "price_at_post": "61.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-12T21:57:56.481583+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260918-yeboha--6273319",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.371554",
        "source": "LSE_CHAT",
        "data": {
          "author": "yeboha",
          "content": "Watching , i agree with you, everything seems to be lining up beautifully for the take over this year !",
          "sentiment": 0.5,
          "engagement": "967",
          "price_at_post": "61.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-12T21:57:56.481601+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260915-Toukanka--8146344",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.371960",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "Watching In your view each year for the past three years was the year we would be taken over\ud83e\udd21",
          "sentiment": 0.0,
          "engagement": "4,486",
          "price_at_post": "61.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-12T21:57:56.481620+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260908-Vertizea-40267960",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.372377",
        "source": "LSE_CHAT",
        "data": {
          "author": "VertizeaSun",
          "content": "T/O? I quite agree. Avacta's got the air of a company tidying up loose ends.",
          "sentiment": 0.0,
          "engagement": "446",
          "price_at_post": "61.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-12T21:57:56.481638+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260907-yeboha-49493443",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.372784",
        "source": "LSE_CHAT",
        "data": {
          "author": "yeboha",
          "content": "Great news! Francis has been appointed as the new chief scientific officer. Retaining him will be a massive advantage moving forward!",
          "sentiment": 0.5,
          "engagement": "967",
          "price_at_post": "61.00",
          "thread_title": "Important Appointment",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=8E658AE1-929D-4CD1-910B-CBDF7FD77692"
        },
        "ingested_at": "2026-02-12T21:57:56.481656+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260903-Watching--4211634",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.373199",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "Imo This year we will  will be taken over The glowing data  must be worth the risk to get in first gla Jane !",
          "sentiment": 0.0,
          "engagement": "9,229",
          "price_at_post": "61.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-12T21:57:56.481685+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260858-nurseste-44474215",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:43.373605",
        "source": "LSE_CHAT",
        "data": {
          "author": "nursesteve",
          "content": "It seems a bit strange from Simon being touted by Chris as being so busy to quietly being removed ?",
          "sentiment": 0.0,
          "engagement": "1,169",
          "price_at_post": "61.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-12T21:57:56.481716+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260849-BuenaVis--2457358",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.092369",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "We don't know what he was doing not why he's no longer on the team. He was another of Alan's hires that's now gone.",
          "sentiment": 0.0,
          "engagement": "5,847",
          "price_at_post": "62.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-12T21:57:56.481748+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260844-Watching-84679798",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.093088",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "Leaky ship ! Another hole plugged",
          "sentiment": 0.0,
          "engagement": "9,229",
          "price_at_post": "62.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=060607B8-56D7-4812-99EC-1BE5765F573F"
        },
        "ingested_at": "2026-02-12T21:57:56.481779+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260839-BuenaVis-18474003",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.093853",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "We'll know where and when in the fullness of time. https://www.linkedin.com/in/michelle-morrow-127605137",
          "sentiment": 0.0,
          "engagement": "5,847",
          "price_at_post": "62.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=060607B8-56D7-4812-99EC-1BE5765F573F"
        },
        "ingested_at": "2026-02-12T21:57:56.481799+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260837-nurseste-82016695",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.094563",
        "source": "LSE_CHAT",
        "data": {
          "author": "nursesteve",
          "content": "So Simon was busy doing??? \ud83e\udd14",
          "sentiment": 0.0,
          "engagement": "1,169",
          "price_at_post": "62.00",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-12T21:57:56.481817+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260837-cj62--6896959",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.095298",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "Probably caught with her hand in the cookie jar !!",
          "sentiment": 0.0,
          "engagement": "4,304",
          "price_at_post": "62.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=060607B8-56D7-4812-99EC-1BE5765F573F"
        },
        "ingested_at": "2026-02-12T21:57:56.481835+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260832-Harrogat-28161232",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.095975",
        "source": "LSE_CHAT",
        "data": {
          "author": "Harrogate4",
          "content": "Congratulations to Dr Francis Wilson, very well deserved in my view and a great choice by CC.",
          "sentiment": 0.0,
          "engagement": "805",
          "price_at_post": "62.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=060607B8-56D7-4812-99EC-1BE5765F573F"
        },
        "ingested_at": "2026-02-12T21:57:56.481854+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260818-Watching--1755916",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.096697",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "Perhaps it was requested by a big pharma as part of a agreement",
          "sentiment": 0.0,
          "engagement": "9,229",
          "price_at_post": "60.50",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=060607B8-56D7-4812-99EC-1BE5765F573F"
        },
        "ingested_at": "2026-02-12T21:57:56.481889+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260815-Prion25-78418364",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.097532",
        "source": "LSE_CHAT",
        "data": {
          "author": "Prion25",
          "content": "Michelle highly regarded in oncology biotech did a block buster drug with AZ  probably been headhunted by a prospective parter of Avacta or  big pharma competitors We won\u2019t know probably a NDA has been signed",
          "sentiment": 0.0,
          "engagement": "1,555",
          "price_at_post": "60.50",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=060607B8-56D7-4812-99EC-1BE5765F573F"
        },
        "ingested_at": "2026-02-12T21:57:56.481913+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260809-B2HS2L-25373251",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.098278",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "CC :  \"\"In addition to his leadership internally, he has also been a key member of the team positioning our business across the international drug development sector. Francis is a well-known leader in medicinal chemistry externally and we are looking forward to forging the next chapter of pre|CISION\u00ae with his scientific leadership and expertise. \" I think she wants him to become more of a Key Opinion Leader, - she uses 'leader' above - in spreading the pre-CISION gospel. To become more influential with respect to FDA / MHRA and the like. Michelle Morrow may have decided the grass was greener. \"former CSO Michelle Morrow will be leaving Avacta to pursue another opportunity\" - singular not plural. She must have done a lot of work to get AVA6103 successfully through the IND Application. (That's true for all staff). She knows what's inside the capping group and the linker group, - those two blue blobs (group A & group B) in blue in certain presentations.",
          "sentiment": 0.0,
          "engagement": "6,042",
          "price_at_post": "60.50",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=060607B8-56D7-4812-99EC-1BE5765F573F"
        },
        "ingested_at": "2026-02-12T21:57:56.481931+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260809-Colesy74-88748027",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.098949",
        "source": "LSE_CHAT",
        "data": {
          "author": "Colesy74",
          "content": "Https://youtu.be/kyQJRyoPzvw",
          "sentiment": 0.0,
          "engagement": "21",
          "price_at_post": "60.50",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-12T21:57:56.481950+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260737-Vertizea--7474600",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.099686",
        "source": "LSE_CHAT",
        "data": {
          "author": "VertizeaSun",
          "content": "Also....Simon Bennett was removed from Leadership page but Yulii Bogatyrenko remains.",
          "sentiment": 0.0,
          "engagement": "446",
          "price_at_post": "60.50",
          "thread_title": "RE: Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-12T21:57:56.481968+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260727-dafad--1204197",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.100396",
        "source": "LSE_CHAT",
        "data": {
          "author": "dafad",
          "content": "They may have wanted someone of a higher calibre in the position as they develop the Platform",
          "sentiment": 0.0,
          "engagement": "2,416",
          "price_at_post": "60.50",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=060607B8-56D7-4812-99EC-1BE5765F573F"
        },
        "ingested_at": "2026-02-12T21:57:56.481987+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260723-Livedata--2069547",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.101080",
        "source": "LSE_CHAT",
        "data": {
          "author": "Livedataaccount",
          "content": "Who knows employees have many reasons for leaving job roles",
          "sentiment": 0.0,
          "engagement": "2,974",
          "price_at_post": "60.50",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=060607B8-56D7-4812-99EC-1BE5765F573F"
        },
        "ingested_at": "2026-02-12T21:57:56.482008+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260721-IFA90-40276056",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.101762",
        "source": "LSE_CHAT",
        "data": {
          "author": "IFA90",
          "content": "Why leave before the multi billion TO?",
          "sentiment": 0.0,
          "engagement": "416",
          "price_at_post": "60.50",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=060607B8-56D7-4812-99EC-1BE5765F573F"
        },
        "ingested_at": "2026-02-12T21:57:56.482041+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260721-BuenaVis-61160613",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.102469",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "A good decision. From CC's praise, he's likely been leading the science anyway.",
          "sentiment": 0.0,
          "engagement": "5,847",
          "price_at_post": "60.50",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=060607B8-56D7-4812-99EC-1BE5765F573F"
        },
        "ingested_at": "2026-02-12T21:57:56.482060+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260715-BuenaVis-21674176",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.103183",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Avacta's new comms organisation, based in Geneva: https://cohesionbureau.com/ It's All Change, every month, with Avacta!",
          "sentiment": 0.0,
          "engagement": "5,847",
          "price_at_post": "60.50",
          "thread_title": "Communications Bureau",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38029F2-7256-433F-AB0C-2497509B6802"
        },
        "ingested_at": "2026-02-12T21:57:56.482078+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20260705-JFK8-50132453",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.103866",
        "source": "LSE_CHAT",
        "data": {
          "author": "JFK8",
          "content": "New CSO to replace Michelle Morrow",
          "sentiment": 0.0,
          "engagement": "3,058",
          "price_at_post": "60.50",
          "thread_title": "RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=060607B8-56D7-4812-99EC-1BE5765F573F"
        },
        "ingested_at": "2026-02-12T21:57:56.482110+00:00"
      },
      {
        "event_id": "SOCIAL-8Feb20261320-BuenaVis-29013500",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.104577",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "The link didn't work so I ran that query in Grok.  Yes, the procedure is involved but so is standard doxorubicin I should think - valid prescription, qualified people, the \"Five Rights\", etc. but with the added safety measures need for radioactivity. I should think the patients have to be held in the hospital to be sure that the drug can be administered rather than have them just ambling in for the 3-weekly injection, the reason being timeliness, timeliness, timeliness... to Grok: \"What are the steps to get a radiopharmaceutical from production to patient?\" \"The journey of a radiopharmaceutical from production to patient administration is a highly time-sensitive, regulated supply chain due to the short half-lives of most radionuclides (often hours to days). This limits the window for manufacturing, quality control, transportation, and use. The process varies depending on the radionuclide (e.g., cyclotron-produced like F-18, Ga-68, or reactor-produced like Mo-99/Tc-99m, Lu-177) and whether the product is a ready-to-use diagnostic agent (e.g., FDG), a kit requiring on-site labeling, or a therapeutic agent.\" ...and so it goes on with the 11 stages and summarised under Key Challenges (Time pressure, Radiation safety, Regulatory compliance, Supply chain complexity)",
          "sentiment": 0.0,
          "engagement": "5,847",
          "price_at_post": "60.50",
          "thread_title": "RE: Watch Ely Lilly could make a move",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=4B1C735B-8BE4-4153-95B2-75A61E403C1D"
        },
        "ingested_at": "2026-02-12T21:57:56.482132+00:00"
      },
      {
        "event_id": "SOCIAL-8Feb20261235-B2HS2L-48091109",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.105340",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "Source Grok: \"what is the procedure to administer a dose of a radiopharmaceutical drug?\" https://x.com/i/grok?conversation=2020452204348313802 Intravenous administration of AVA6103 is going to be a doddle compared with radiopharmaceutical administration by a team of several. Time / expense to get radiopharmaceutical to hospital? If the decision to make funds available to dose a patient is made by a health insurance company, I don't think they would consider a radiopharmaceutical for long if a cheaper method of administration is available. PDC ADC - it has targeting issues. radiopharmaceutical - difficult / expensive to administer, too many specialists This is my list of most to least preferrable drug types for experts to consider using. Novartis must be \ud83d\udc40",
          "sentiment": 0.0,
          "engagement": "6,042",
          "price_at_post": "60.50",
          "thread_title": "RE: Watch Ely Lilly could make a move",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=4B1C735B-8BE4-4153-95B2-75A61E403C1D"
        },
        "ingested_at": "2026-02-12T21:57:56.482151+00:00"
      },
      {
        "event_id": "SOCIAL-8Feb20261107-GainsOnl--4413306",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.106009",
        "source": "LSE_CHAT",
        "data": {
          "author": "GainsOnly",
          "content": "This will be over 75p last placing price very soon DYOR",
          "sentiment": 0.0,
          "engagement": "10",
          "price_at_post": "60.50",
          "thread_title": "RE: Watch Ely Lilly could make a move",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=4B1C735B-8BE4-4153-95B2-75A61E403C1D"
        },
        "ingested_at": "2026-02-12T21:57:56.482179+00:00"
      },
      {
        "event_id": "SOCIAL-8Feb20261042-LiveLong-85314975",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.106802",
        "source": "LSE_CHAT",
        "data": {
          "author": "LiveLongnProsper",
          "content": "A few Exatecan products that AVA6103 might be compared against ..? Cybrexa \u2013 privately held, have CBX-12 a PDC, targeting pH (acidity), in phase 2. EMD Serono \u2013 Merck subsidiary, have M7437, ADC based, in phase 1 from Jan 2026. Innovent \u2013 now partnered with Takeda, have IBI343, ADC based, in phase 3 with FDA fast track. AVA6103, indeed the whole pre|CISION\u00ae platform, remains, as yet, \u2018unpartnered\u2019 (OK Lilly/CanSeek) - but not without \u2018friends\u2019 and \u2018admirers\u2019. What about BP then ..? We know that Daiichi Sankyo and AZN are massively committed to Enhertu\u00ae (trastuzumab deruxtecan), HER2 targeted ADC, and we know about \u2018patent cliffs\u2019.  DS / AZN currently pushing through a number of DXd products, perhaps most notably Datroway\u00ae (datopotamab deruxtecan), TROP2 targeted ADC in phase 3.  Daiichi have been working with Exatecan for over 20 years.  These guys need to protect their \u2018space\u2019. Merck (Keytruda) were apparently going to spend up to $32bn for Revolution \u2013 seems to be off now?  Guess they have ready cash then? Novartis have this massive \u2018hole\u2019 in their pipeline, i.e. no ADC\u2019s, but are doing FAP targeting for RLT.  They seem to have plenty of money also. \u2018Triggers\u2019 for Avacta acquisition ..? Positive AVA6000 TNBC readout?  PFS for SGC and AVA6000 becomes \u2018standard of care\u2019?  Early positive response to AVA6103? Or just a  \u2018pre-emptive strike\u2019? GLA",
          "sentiment": 0.0,
          "engagement": "1,836",
          "price_at_post": "60.50",
          "thread_title": "RE: Watch Ely Lilly could make a move",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=4B1C735B-8BE4-4153-95B2-75A61E403C1D"
        },
        "ingested_at": "2026-02-12T21:57:56.482216+00:00"
      },
      {
        "event_id": "SOCIAL-8Feb20260925-opti_mys-43345761",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.107491",
        "source": "LSE_CHAT",
        "data": {
          "author": "opti_mystic",
          "content": "Keytruda is out of Patent in 2028 when the immunology drug becomes an out of patent generic drug. Avacta could use it like we have Dox and Exatecan and we'd have chemo and immunology options.",
          "sentiment": 0.0,
          "engagement": "315",
          "price_at_post": "60.50",
          "thread_title": "RE: Watch Ely Lilly could make a move",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=4B1C735B-8BE4-4153-95B2-75A61E403C1D"
        },
        "ingested_at": "2026-02-12T21:57:56.482239+00:00"
      },
      {
        "event_id": "SOCIAL-8Feb20260859-Aldebara--5161685",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.108206",
        "source": "LSE_CHAT",
        "data": {
          "author": "Aldebaran",
          "content": "So we saying that lily and Novartis have eyes on either directly or indirectly. Would love to throw merck into the mix as well due to keytruda patent expiry. What about daiichi sankyo also. 4 way bidding war would be nice. All 4 could be made a reasonable case to be seriously interested in precision",
          "sentiment": 0.0,
          "engagement": "3,933",
          "price_at_post": "60.50",
          "thread_title": "RE: Watch Ely Lilly could make a move",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=4B1C735B-8BE4-4153-95B2-75A61E403C1D"
        },
        "ingested_at": "2026-02-12T21:57:56.482258+00:00"
      },
      {
        "event_id": "SOCIAL-8Feb20260852-Bella653-28629733",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.108890",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "'POINT Biopharma Inc Avacta has entered into a license agreement with POINT Biopharma Inc., (taken over by Eli Lilly in late 2023) a clinical-stage pharmaceutical company focused on the development and commercialisation of radioligand therapies for the treatment of cancer, to provide access to Avacta\u2019s pre|CISION\u00ae technology for the development of tumor-activated radiopharmaceuticals.' How much access are they now getting to PreCISION???",
          "sentiment": 0.0,
          "engagement": "6,761",
          "price_at_post": "60.50",
          "thread_title": "RE: Watch Ely Lilly could make a move",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=4B1C735B-8BE4-4153-95B2-75A61E403C1D"
        },
        "ingested_at": "2026-02-12T21:57:56.482276+00:00"
      },
      {
        "event_id": "SOCIAL-8Feb20260843-Bella653--9070427",
        "event_type": "social_post",
        "date": "2026-02-10T01:55:46.109654",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "'Toxicity caused by off-target delivery is a longstanding concern of cancer therapies. Developed by Dr. William Bachovchin of Tufts University, POINT\u2019s CanSEEK\u2122 technology aims to minimize radiopharmaceutical toxicity caused by off-target delivery by only activating a radiopharmaceuticals' targeting moiety, such as its ligand, after it has encountered FAP-\u03b1 in the tumor microenvironment (TME). FAP-\u03b1 is highly expressed on a wide range of solid tumors, but in very low quantities or absent altogether in healthy tissues. The intent of CanSEEK\u2122 is to minimize the toxicity caused by off-target delivery. At first, CanSEEK\u2122 prevents the radiopharmaceutical from bonding to receptors on cells. When the radiopharmaceuticals enter the TME, the radiopharmaceuticals targeting moiety is re-activated, enabling it to once again bond to receptors on cancer cells. CanSEEK\u2122 has the potential to make treatments even more precise, expanding their therapeutic index, and enabling the use of new, more powerful medical isotopes.' \u200d",
          "sentiment": 0.0,
          "engagement": "6,761",
          "price_at_post": "60.50",
          "thread_title": "RE: Watch Ely Lilly could make a move",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=4B1C735B-8BE4-4153-95B2-75A61E403C1D"
        },
        "ingested_at": "2026-02-12T21:57:56.482294+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20262318-Icecool-60729544",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.525582",
        "source": "LSE_CHAT",
        "data": {
          "author": "Icecool",
          "content": "Happy holidays everyone. \ud83d\ude09\ud83e\udd23\ud83d\ude2d",
          "sentiment": 0.0,
          "engagement": "8,855",
          "price_at_post": "60.50",
          "thread_title": "RE: From MM on X - If it offends - Tough",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=D20B314B-66BB-47B0-8ED4-D46B27E22B85"
        },
        "ingested_at": "2026-02-12T21:57:56.482313+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20262125-Livedata--2979799",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.526281",
        "source": "LSE_CHAT",
        "data": {
          "author": "Livedataaccount",
          "content": "who is offended not icecool being ****** again i hope",
          "sentiment": 0.0,
          "engagement": "2,969",
          "price_at_post": "60.50",
          "thread_title": "RE: From MM on X - If it offends - Tough",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=D20B314B-66BB-47B0-8ED4-D46B27E22B85"
        },
        "ingested_at": "2026-02-12T21:57:56.482336+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20262120-IFA90--1877160",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.526944",
        "source": "LSE_CHAT",
        "data": {
          "author": "IFA90",
          "content": "I\u2019m not offended. Xx",
          "sentiment": 0.0,
          "engagement": "415",
          "price_at_post": "60.50",
          "thread_title": "RE: From MM on X - If it offends - Tough",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=D20B314B-66BB-47B0-8ED4-D46B27E22B85"
        },
        "ingested_at": "2026-02-12T21:57:56.482371+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20262049-B2HS2L-88027553",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.527979",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "Https://x.com/BMHLTD/status/1736326494035603668 - Thanks BMH. December 2023 - Set of extracts from a Will Tap presentation. Will Tap discusses STS treatment improvement necessary. Now we have SGC first pass results, - AVA6000 more likely to be able to address items on Will Tap's STS wish list - with resulting FDA satisfaction.",
          "sentiment": 0.0,
          "engagement": "6,031",
          "price_at_post": "60.50",
          "thread_title": "Will Tap STS wish list",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=21C3C888-CE85-4F00-B718-E879BB3F5CC6"
        },
        "ingested_at": "2026-02-12T21:57:56.482404+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20262037-BuenaVis-82900062",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.528670",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Top publication, Scrip, so this is excellent exposure for CC and Avacta in their 'preview' of the year.",
          "sentiment": 0.0,
          "engagement": "5,826",
          "price_at_post": "60.50",
          "thread_title": "RE: Evolving Drug Conjugates",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B37AC3F0-A005-4580-9CCE-040AE6DF8EA7"
        },
        "ingested_at": "2026-02-12T21:57:56.482437+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261929-avctIPma-14164557",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.529343",
        "source": "LSE_CHAT",
        "data": {
          "author": "avctIPmatters",
          "content": "\"drive significant interest and global pharma partnerships.\"  sounds  good ! Gmcc",
          "sentiment": 0.0,
          "engagement": "740",
          "price_at_post": "60.50",
          "thread_title": "RE: Evolving Drug Conjugates",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B37AC3F0-A005-4580-9CCE-040AE6DF8EA7"
        },
        "ingested_at": "2026-02-12T21:57:56.482469+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261924-avctIPma--2298354",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.530056",
        "source": "LSE_CHAT",
        "data": {
          "author": "avctIPmatters",
          "content": "Thanks to Stonks ;   CC featured \"Scrip Asks... What Does 2026 Hold For Biopharma? Part 4: R&D Innovation\" https://insights.citeline.com/scrip/scrip-asks/scrip-asks-what-does-2026-hold-for-biopharma-part-4-rd-innovation-NDREFKFVB5DZPAQLA5CIZHE7OI/#oncology \"Evolving Drug Conjugates Drugs conjugated to antibodies and other carriers continue advancing through next-generation payload and linker innovation. \u201c2026 will be a pivotal year for dual payload drug conjugates, as the first wave of these therapies is expected to yield initial clinical data,\u201d predicted Christina Coughlin, CEO of Avacta Therapeutics. \u201cThe first dual payload peptide-drug conjugate was announced this year, and dozens of major pharma companies are advancing dual-payload programs targeting different resistance mechanisms. We expect the technology\u2019s ability to overcome drug resistance, enhance tumor selectivity and broaden the therapeutic window to drive significant interest and global pharma partnerships. This represents oncology\u2019s evolution from sequential combination dosing to precision dual-delivery, fundamentally reshaping how we approach tumor heterogeneity and resistance.\u201d Gmcc",
          "sentiment": 0.0,
          "engagement": "740",
          "price_at_post": "60.50",
          "thread_title": "Evolving Drug Conjugates",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B37AC3F0-A005-4580-9CCE-040AE6DF8EA7"
        },
        "ingested_at": "2026-02-12T21:57:56.482503+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261910-JES1889--8240634",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.530764",
        "source": "LSE_CHAT",
        "data": {
          "author": "JES1889",
          "content": "I think the other piece to consider here is that Avacta no longer seems to be a leaky ship. I now believe that (if and) when news drops it\u2019ll arrive without forewarning, like the FDA news this week. Whilst I see there being room for the share price to appreciate as this year progresses, on retail demand/expectations. I doubt that even positive data releases on TNBC and 6103 will see this head anywhere near true value. AIM and the UK investment community just find the scale too hard to contemplate. I\u2019ve seen comments about the current low share price and suggesting that potential bidders would start buying shares in the open market. There\u2019s no way that any party under NDA would be able to do that as they\u2019d be party to inside information and that would be covered by the Market Abuse Regulations. The NDA would almost certainly have some form of standstill clause prohibiting open market share purchases. I think the big news when it comes will come out of the blue.",
          "sentiment": 0.0,
          "engagement": "83",
          "price_at_post": "60.50",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-12T21:57:56.482538+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261857-Icecool--6001828",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.531439",
        "source": "LSE_CHAT",
        "data": {
          "author": "Icecool",
          "content": "Bella you assume the SP and deal value will be linked prior to any announcement. That might happen on the Nasdaq, however it certainly doesn\u2019t happen on AIM. The price will be negotiated on the technology, then and only then will the SP react accordingly.\ud83d\udcaf\ud83d\udc4d",
          "sentiment": 0.0,
          "engagement": "8,855",
          "price_at_post": "60.50",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-12T21:57:56.482573+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261334-Timster--3398450",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.532093",
        "source": "LSE_CHAT",
        "data": {
          "author": "Timster",
          "content": "Why would that offend?",
          "sentiment": 0.0,
          "engagement": "20,637",
          "price_at_post": "60.50",
          "thread_title": "RE: From MM on X - If it offends - Tough",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=D20B314B-66BB-47B0-8ED4-D46B27E22B85"
        },
        "ingested_at": "2026-02-12T21:57:56.482608+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261322-Toukanka-76186284",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.532773",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "All hail the uber ramper. But I agree with everything except I think his timeline is optimistic. I\u2019m still saying Summer for the pivotal moment - in that respect I am accepting CC\u2019s predictions.",
          "sentiment": 0.0,
          "engagement": "4,476",
          "price_at_post": "60.50",
          "thread_title": "RE: From MM on X - If it offends - Tough",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=D20B314B-66BB-47B0-8ED4-D46B27E22B85"
        },
        "ingested_at": "2026-02-12T21:57:56.482642+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261243-wyndrum-29196351",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.533481",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "Does that mean MM is NFT?",
          "sentiment": 0.0,
          "engagement": "12,250",
          "price_at_post": "60.50",
          "thread_title": "RE: From MM on X - If it offends - Tough",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=D20B314B-66BB-47B0-8ED4-D46B27E22B85"
        },
        "ingested_at": "2026-02-12T21:57:56.482675+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261226-cj62--3483748",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.534176",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "I have never been influenced by MM's ramblings but this actually echoes my sentiments exactly, our money is safe as I believe SGC alone makes this a very valuable company. We are now waiting on initial TNBC data prior to H2 which if successful will boost the valuation of Avacta considerably and to top that off ava6103 initial data i expect mid H2. Very exciting times indeed and hopefully well worth the wait.",
          "sentiment": 0.0,
          "engagement": "4,302",
          "price_at_post": "60.50",
          "thread_title": "RE: From MM on X - If it offends - Tough",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=D20B314B-66BB-47B0-8ED4-D46B27E22B85"
        },
        "ingested_at": "2026-02-12T21:57:56.482708+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261217-D-Geeman-39152392",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.534833",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "Vertizea, son, B2H just beat me to it. Whenever I have been influenced by MM in hindsight I should have done the opposite. Yet this does seem a very exciting time. 'If .... and b) the company can stay independent for a couple more years at least' could be the explanation of the contradiction in my response. I think I will keep some powder dry for the next year or so. Currently the 'powder' is in WG, waiting to be worth 30p. Would be comvenient if the various timings work out for me.",
          "sentiment": 0.0,
          "engagement": "5,868",
          "price_at_post": "60.50",
          "thread_title": "RE: From MM on X - If it offends - Tough",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=D20B314B-66BB-47B0-8ED4-D46B27E22B85"
        },
        "ingested_at": "2026-02-12T21:57:56.482741+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261206-B2HS2L--6046882",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.535518",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "Does that mean MM's out? Not offended. \ud83d\ude44 PS probably reducing.",
          "sentiment": 0.0,
          "engagement": "6,031",
          "price_at_post": "60.50",
          "thread_title": "RE: From MM on X - If it offends - Tough",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=D20B314B-66BB-47B0-8ED4-D46B27E22B85"
        },
        "ingested_at": "2026-02-12T21:57:56.482775+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261201-Vertizea-50637743",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.536296",
        "source": "LSE_CHAT",
        "data": {
          "author": "VertizeaSun",
          "content": "Myles McNulty @MylesMcNulty \u00b7 2h Replying to @RobDay80669068 Morning Robert, hope all's well. #AVCT's news on Tuesday was phenomenal. My understanding is that it's an unprecedented move by the FDA to remove the dosing limit for a modified-/reformulated-/pro-chemotherapy,  mid-Phase 1 trial. The rapid decline and fall of the UK investment community - in depth, breadth, intellectual curiosity and risk tolerance - is in my view providing one of the greatest asymmetrical bets of all time. #AVA6000 is an absolute shoe-in to get to market now. It much more than underpins Avacta's entire market cap. Management will know if #AVA6103 - 'the Beast' - is working in patients as they hope it will, by the end of next month. That single drug  has real potential to become the best selling drug in the history of pharma. It really is straightforward to explain and understand this. Personally, I give AVA6103 well over a >50% chance of success in clinic. If a) it is indeed a success in the clinic; and b) the company can stay independent for a couple more years at least; then the returns from the current 60p share price could be >100x. I have recently provided a real world example of these returns (see my last post on Avacta, comparing it with $RVMD). The next 6 months are by far the most important in Avacta's history. Good luck!",
          "sentiment": 0.0,
          "engagement": "440",
          "price_at_post": "60.50",
          "thread_title": "From MM on X - If it offends - Tough",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=D20B314B-66BB-47B0-8ED4-D46B27E22B85"
        },
        "ingested_at": "2026-02-12T21:57:56.482808+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261152-wyndrum-90113031",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.537031",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "Well done Bella, although you won't see this post because you are so clever with the filter button but I raised this most recently with NFT and he never responded to his valuation of $28b based on another company, even though I asked 3 times. Thats the problem with filters. I get filtering the sheppys and watchings of this world that offer absolutely nothing but when I am not defending myself against unsolicited slurs and random insult-only posts, I only talk about AVCT. You tend to eventually come to the same conclusions as me but it takes a while and of course that ground has already been covered. The thing I have noticed is that it does not take long at all to quickly scan any post to see if it has relevance or not and as a result no longer bother filtering anyone. And why? Just on the chance that they do in fact come across some good info or (heaven forfend), some helpful insight. But as I say this will just be another green box for you to never know what was said",
          "sentiment": 0.0,
          "engagement": "12,250",
          "price_at_post": "60.50",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-12T21:57:56.482843+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261143-Bella653--4923054",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.537707",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "Anyone quoting billion $ deals should also post the number of shares that were in issue and the SP prior to the deal...without this info you cannot compare apples with apples. I've checked some of these big deals only to find the SP increase was relatively small.",
          "sentiment": 0.0,
          "engagement": "6,756",
          "price_at_post": "60.50",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-12T21:57:56.482879+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261113-B2HS2L-53321023",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.538535",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "GSK's new CEO looking for $2B to $4B deals 'hiding in plain sight' This is the title of a Fierce Pharma document found on this link: https://www.fiercebiotech.com/biotech/gsks-new-ceo-looking-2-4b-deals-hiding-plain-sight +++ Luke Miels had only been at the helm of GSK for 20 days before he signed off on his first multibillion-dollar buyout, and the CEO is clear on what else will attract his interest. \u201cThe basic framework that we like for [business development] is in that 2-to-4 billion [dollar] range,\u201d Miels told journalists on a fourth-quarter earnings call this morning. \u201cTypically, we like a program where the science is reasonably established,\u201d he added. Miels\u2014who served as GSK\u2019s chief commercial officer before taking over from CEO Emma Walmsley in the new year\u2014pointed to a pattern in dealmaking set in 2022 by the $1.9 billion acquisition of Sierra Oncology for its near-approval cancer drug. GSK is especially interested in drugs where \u201cwe've got a degree of validation on the science, but there are liabilities with the existing products,\u201d he said. To demonstrate these criteria, Miels cited the $2.2 billion buyout of Rapt Therapeutics just days into his tenure as CEO. Rapt\u2019s IgE antibody ozureprubart protects against food allergy reactions by targeting the same epitope as Novartis and Roche\u2019s Xolair. Miels admitted that Xolair has \u201cabsolutely exploded in the U.S. for usage with severe allergies, particularly in kids.\u201d \u201cBut the problem is there's a very complicated dosing regimen, and these kids have to inject themselves every two weeks,\u201d he explained. \u201c[Ozureprubart] works exactly the same way as Xolair, except that you give it on a much lower frequency,\u201d Miels said. \ud83d\udc40 \u201cSo that's essentially the methodology we're going to follow with [business development]\u2014looking for assets [that are] well priced, not necessarily in the mainstream, hiding in plain sight,\u201d the CEO added. \u201cAnd we'll do that with a degree of frequency, which, again, will help us build out the late-stage portfolio.\u201d 1 The basic framework that we like for [business development] is in that 2-to-4 billion [dollar] range,\u201d  \u274c 2 \u201cTypically, we like a program where the science is reasonably established\u201d   \u2714\ufe0f 3 GSK is interested in drugs where \u201cwe've got a degree of validation on the science, but there are liabilities with the existing products\u201d \u2714\ufe0f 4  ...looking for assets [that are] well priced, not necessarily in the mainstream, hiding in plain sight\u201d \u274c see 1 - I'd take issue that multibillion assets don't usually exist in the mainstream, hiding in plain sight. I'd say all now know about Avacta and its products. Those specialising in cancer therapeutics HAVE to be interested or start making BIG advances soon in ADC cancer targeting. I think overall, GSK is looking for an opportunity that costs less than Avacta will sell for. - From the horses mouth.",
          "sentiment": 0.0,
          "engagement": "6,031",
          "price_at_post": "60.50",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-12T21:57:56.482899+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261101-Watching--7171201",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.539211",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "You don\u2019t always get the best deals with smaller companies .. J",
          "sentiment": 0.0,
          "engagement": "9,224",
          "price_at_post": "60.50",
          "thread_title": "RE: Trading 212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B38EA914-FA00-4B19-B293-5E96B62D2062"
        },
        "ingested_at": "2026-02-12T21:57:56.482917+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261055-Profchee-35691140",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.539863",
        "source": "LSE_CHAT",
        "data": {
          "author": "Profcheese",
          "content": "II also in the process of reducing their charges at the moment. It's a competitive world!",
          "sentiment": 0.0,
          "engagement": "539",
          "price_at_post": "60.50",
          "thread_title": "RE: Trading 212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B38EA914-FA00-4B19-B293-5E96B62D2062"
        },
        "ingested_at": "2026-02-12T21:57:56.482936+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261008-Watching-45026746",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.540533",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "IG t buying n selling is free if you have over \u00a330 k in there account",
          "sentiment": 0.0,
          "engagement": "9,224",
          "price_at_post": "60.50",
          "thread_title": "RE: Trading 212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B38EA914-FA00-4B19-B293-5E96B62D2062"
        },
        "ingested_at": "2026-02-12T21:57:56.482954+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261004-Bella653-57647176",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.541198",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "Have you compared the Bid and Ask prices ...many of these No Fee sites don't give the 'best' prices...",
          "sentiment": 0.0,
          "engagement": "6,756",
          "price_at_post": "60.50",
          "thread_title": "RE: Trading 212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B38EA914-FA00-4B19-B293-5E96B62D2062"
        },
        "ingested_at": "2026-02-12T21:57:56.482972+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20260955-wyndrum-96726800",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.541863",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "FWIW they were efficient in sorting out a pension for me too",
          "sentiment": 0.0,
          "engagement": "12,250",
          "price_at_post": "60.50",
          "thread_title": "RE: Trading 212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B38EA914-FA00-4B19-B293-5E96B62D2062"
        },
        "ingested_at": "2026-02-12T21:57:56.482990+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20260955-avctIPma--3065827",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:20.542723",
        "source": "LSE_CHAT",
        "data": {
          "author": "avctIPmatters",
          "content": "Recent CC quotes :  %   Chance of success  -  Surely Avacta platform that  can to enhance  existing drug treatments  requires  an IP value asset  re-set  . Certainly worth waiting  for  to see   which  BP  jumps first  . ---------------- \"@coughlin582: \u201cif there\u2019s an organ with a cancer, we can address it\u201d \"Christina Coughlin @coughlin582 \u00b7 Feb 4 Replying to @coughlin582 Love this! No would never give our secrets away here! The secret to the sustained release mechanism invented by our brilliant chemistry team is behind blob A and blob B. We call this the \u201cblob slide\u201d \u2026 #BestTeamEver\" Gmcc",
          "sentiment": 0.0,
          "engagement": "740",
          "price_at_post": "60.50",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-12T21:57:56.483008+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20260946-D-Geeman-23836548",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.174673",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "It's like Lidl V's Sainsbury's, but if Lidl stock everything you want then go for it. I found the message from HL regarding their charges, soon to be changed: 'Trading / Dealing Fees: We are reducing the amount you pay to buy or sell shares with us, from \u00a311.95 to \u00a36.95 per online trade** We\u2019re introducing a charge of \u00a31.95 per trade to buy or sell funds online' Account charges: We are reducing our account charges* from 0.45% to 0.35% per year on Stocks and Shares ISA and Self-Invested Personal Pension (SIPP) accounts For Fund and Share Accounts, we are reducing account charges for holding funds, from 0.45% to 0.35% per year and we are introducing a charge of 0.35% to hold shares New account charge limits for shares (includes investment trusts, Exchange Traded Funds (ETFs) and bonds): You will never pay more than \u00a3150 per year in account charges* for holding shares in each of our SIPP, Stocks and Shares ISA or our Fund and Share Accounts Compare current vs future charges",
          "sentiment": 0.0,
          "engagement": "5,868",
          "price_at_post": "60.50",
          "thread_title": "RE: Trading 212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38EA914-FA00-4B19-B293-5E96B62D2062"
        },
        "ingested_at": "2026-02-12T21:57:56.483026+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20260930-Watching-13712868",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.175455",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "A  big pharma   can\u2019t afford not to take us over Who ever bids first will know they will become the market leader over night  with our science ! Imo it\u2019s going to happen very very quickly in 2026 . Hold or. Top up if funds allow Gla . Jane",
          "sentiment": 0.0,
          "engagement": "9,224",
          "price_at_post": "60.50",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-12T21:57:56.483044+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20260918-cj62-59981115",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.176169",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "Incalculable!!!",
          "sentiment": 0.0,
          "engagement": "4,302",
          "price_at_post": "60.50",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-12T21:57:56.483062+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20260859-Wilson63--8271949",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.176882",
        "source": "LSE_CHAT",
        "data": {
          "author": "Wilson63",
          "content": "Post by Tvr5 on X read this and consider being used for just one of these examples and what a fair price would be for the company. https://x.com/TVR5AVCT/status/2019678221504291189",
          "sentiment": 0.0,
          "engagement": "8,808",
          "price_at_post": "60.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-12T21:57:56.483080+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20260847-jackeste-32995754",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.177597",
        "source": "LSE_CHAT",
        "data": {
          "author": "jackester",
          "content": "They definitely do deal in Avacta.",
          "sentiment": 0.0,
          "engagement": "311",
          "price_at_post": "60.00",
          "thread_title": "RE: Trading 212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38EA914-FA00-4B19-B293-5E96B62D2062"
        },
        "ingested_at": "2026-02-12T21:57:56.483112+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20260811-JFK8-47221210",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.178308",
        "source": "LSE_CHAT",
        "data": {
          "author": "JFK8",
          "content": "Opened an account and closed it 20 minutes later as they dont deal  AVCT shares .don't know if they do now though as it was a while ago",
          "sentiment": 0.0,
          "engagement": "3,057",
          "price_at_post": "60.00",
          "thread_title": "RE: Trading 212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38EA914-FA00-4B19-B293-5E96B62D2062"
        },
        "ingested_at": "2026-02-12T21:57:56.483134+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20260125-russell1-80328254",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.179005",
        "source": "LSE_CHAT",
        "data": {
          "author": "russell1",
          "content": "Thanks for the helpful replies.",
          "sentiment": -0.5,
          "engagement": "318",
          "price_at_post": "60.00",
          "thread_title": "RE: Trading 212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38EA914-FA00-4B19-B293-5E96B62D2062"
        },
        "ingested_at": "2026-02-12T21:57:56.483152+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20262323-Toukanka-59158638",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.179705",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "More desperate ramping",
          "sentiment": 0.0,
          "engagement": "4,476",
          "price_at_post": "60.00",
          "thread_title": "RE: TAKEOVER",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=DAF752F5-FA6F-49F9-BD50-F5C834118B9E"
        },
        "ingested_at": "2026-02-12T21:57:56.483170+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20262100-cj62-71090381",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.180428",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "Put your head above the parapet have we touk. RH will probably have less influence than you, you prick.",
          "sentiment": 0.0,
          "engagement": "4,302",
          "price_at_post": "60.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-12T21:57:56.483188+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20262049-D-Geeman--5718319",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.181255",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "AI Overview Trading 212 (T212) and Hargreaves Lansdown (HL) offer starkly different approaches to trading Tiziana Life Sciences Ltd (NASDAQ: TLSA), with T212 focusing on low-cost, app-based trading, while HL provides a more traditional, comprehensive service with higher fees . T212 is generally better for frequent, small-value, or beginner trading due to zero-commission fees, while HL is often preferred for larger, long-term holdings and pensions. Comparison: Tiziana Life Sciences (TLSA) Trading Trading 212 (T212): Cost: Zero-commission trading on stocks and ETFs, though a 0.15% FX fee applies to non-GBP transactions. Features: Offers fractional shares, allowing for small investments in TLSA. CFD Trading: Offers long/short CFD trading on TLSA with leverage. Downsides: Limited research tools and no tax advice; users have reported wide spreads during volatile times for small-cap stocks. Hargreaves Lansdown (HL): Cost: High dealing charges (e.g., \u00a311.95 per deal), which can be costly for small trades. Features: Provides extensive research, analysis, and higher-quality, live, or more transparent pricing. Suitability: Better suited for holding larger, long-term positions or in a SIPP (pension).",
          "sentiment": 0.0,
          "engagement": "5,868",
          "price_at_post": "60.00",
          "thread_title": "RE: Trading 212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38EA914-FA00-4B19-B293-5E96B62D2062"
        },
        "ingested_at": "2026-02-12T21:57:56.483207+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20262041-D-Geeman--7043399",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.181977",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "I also have shares in $TLSA (formerly Tiziana PLC) which moved to the Nasdaq. People on the board for $TLSA.US have often complained about other brokers (I THINK Halifax amongst others) not allowing trades and I think people with 212 had there accustem shares sold against their will when they were spun-off to OTC. If AVCT do go on to the Nas I shall be happy to be with HL but each to their own.",
          "sentiment": 0.0,
          "engagement": "5,868",
          "price_at_post": "60.00",
          "thread_title": "RE: Trading 212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38EA914-FA00-4B19-B293-5E96B62D2062"
        },
        "ingested_at": "2026-02-12T21:57:56.483225+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20262026-IFA90-67203280",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.182574",
        "source": "LSE_CHAT",
        "data": {
          "author": "IFA90",
          "content": "I\u2019m no trader so 212 works for me. I just transferred a handful of Avacta shares across, took about 10 days. I\u2019ll move the rest soon. You can\u2019t dummy quote but I don\u2019t see any other downsides.",
          "sentiment": 0.0,
          "engagement": "415",
          "price_at_post": "60.00",
          "thread_title": "RE: Trading 212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38EA914-FA00-4B19-B293-5E96B62D2062"
        },
        "ingested_at": "2026-02-12T21:57:56.483243+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20262025-Icecool--6685518",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.183017",
        "source": "LSE_CHAT",
        "data": {
          "author": "Icecool",
          "content": "I hear what you\u2019re saying, and I get the excitement, but this is where biotech reality usually kicks in. Big pharma almost never forces an early move before human data unless they\u2019re facing an immediate strategic threat. AVA6103 is IND-cleared, which is huge, but it\u2019s still pre-human efficacy. That\u2019s exciting, not yet unavoidable. They are already in the data room and Avacta has made it clear they want to see human data on AVA6103 before they deal on that asset, everyone has to respect that. Right now BP doesn\u2019t need to rush or upset anyone to protect its position. They can stay close, sit in the data room, structure options, or wait for Phase 1 signals before committing real money with Avacta approval. That\u2019s how this industry normally works. The idea that retail holders could be quietly shaken out on the cheap also feels unlikely. Any hint of opportunistic behaviour would harden positions very quickly, not soften them. What the board is doing makes sense, build leverage before the power dynamic flips. Once AVA6103 shows even early human efficacy, urgency changes overnight and the tone of conversations changes with it.",
          "sentiment": 0.0,
          "engagement": "8,855",
          "price_at_post": "60.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-12T21:57:56.483262+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20262022-cj62-27282395",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.183465",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "Well I'm hoping that maybe 2 or 3 BP would like it but if all is well with ava6103 maybe go down the ARM route. 6 months and we should know",
          "sentiment": 0.0,
          "engagement": "4,302",
          "price_at_post": "60.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-12T21:57:56.483280+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261948-B2HS2L--1054024",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.183925",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "'That is extremely unlikely in biotech. As big pharma prefer to negotiate clean and keep everyone on side.' I hear what you say and generally agree. However, an opportunity like this occurs very infrequently. A successful purchase - however that occurs - confers market disruption and after commercialisation, competitive advantage upon the purchaser, with others making do with ADC development or resuming the search for new tech. This situation can't be brushed under the carpet. It's not what we would want, but you can't help seeing BP may want a deal sooner rather than later for a myriad of reasons. Pi**ing off the BoD might have to happen if one, or more than one BP are so keen to 'own it', or likely - make sure other BP's don't get a bargain in their efforts to 'own it'. There are a large number of PI's who could be easily persuaded to part with their shares at prices BP would definitely find attractive. It remains to be seen where and when the first bid arrives. The BoD are planning for the long haul, but let's hope they achieve as much as humanly possible before BP calls time on Avacta's progress.",
          "sentiment": 0.0,
          "engagement": "6,031",
          "price_at_post": "60.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-12T21:57:56.483298+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261935-D-Geeman--3810626",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.184434",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "I opened a 212 account a few years ago but don't use it. With HL your purchase happens immediately but with 212 it can take a while and goes thru in dribs and drabs (while the price is changing). Aren't HL lowering their dealing charges in April? I got a message and believe they are dropping to around \u00a36 for everyone (maybe more for some?) Maybe 212 are ok for bigger shares.",
          "sentiment": 0.0,
          "engagement": "5,868",
          "price_at_post": "60.00",
          "thread_title": "RE: Trading 212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38EA914-FA00-4B19-B293-5E96B62D2062"
        },
        "ingested_at": "2026-02-12T21:57:56.483316+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261920-Codejunk--2816078",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.184970",
        "source": "LSE_CHAT",
        "data": {
          "author": "Codejunkie",
          "content": "Pharma don't generally do hostile takeovers. They just pay the right price for the IP and make sure staff transfer over Hostile takeovers lose key staff....",
          "sentiment": 0.0,
          "engagement": "2,668",
          "price_at_post": "60.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-12T21:57:56.483334+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261916-russell1--2621237",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.185404",
        "source": "LSE_CHAT",
        "data": {
          "author": "russell1",
          "content": "Does anybody hold their Avacta shares with Trading 212? If so, is it easy to deal and are the prices comparable to other platforms. I use HL but am thinking about moving away.",
          "sentiment": -0.5,
          "engagement": "318",
          "price_at_post": "60.00",
          "thread_title": "Trading 212",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=B38EA914-FA00-4B19-B293-5E96B62D2062"
        },
        "ingested_at": "2026-02-12T21:57:56.483352+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261857-cj62-56533229",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.185820",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "Its OK saying Hughes won't allow a low bid to be decided by shareholders, but what about a hostile bid. Any bid will be decided by the shareholders RH will have no say.",
          "sentiment": 0.0,
          "engagement": "4,302",
          "price_at_post": "60.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-12T21:57:56.483371+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261849-Icecool--1852521",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.186361",
        "source": "LSE_CHAT",
        "data": {
          "author": "Icecool",
          "content": "\u201cIt\u2019s OK saying Hughes won't allow a low bid to be decided by shareholders, but what about a hostile bid.\u201d That is extremely unlikely in biotech. As big pharma prefer to negotiate clean and keep everyone on side.",
          "sentiment": 0.0,
          "engagement": "8,855",
          "price_at_post": "60.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-12T21:57:56.483389+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261842-B2HS2L--2395003",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.187281",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "Bella ...Is the BOD in it for the long haul or would they simply take a good offer so they can move on to pastures new? I'm no longer thinking so much about how long it's going to take Avacta to achieve A,B or C. The nearer timelines we know about, but my point is how long are BP going to allow us to plough our own furrow? The more IP we pile up the larger amount SB rightly thinks the company is worth. These companies (with larger manpower & resources) will probably not want to proceed at Avacta's pace. Some will want faster development, and want their competitive advantage, with the purchase of all we have, to begin sooner. Others can't face a bigger purchase if left too long. Some BP will have funds available at different times as their priorities such as other projects will need to be factored into their timescales. Its OK saying Hughes won't allow a low bid to be decided by shareholders, but what about a hostile bid. There is no accounting for such a bid with completely opaque timescales. This is a market disruptive project and to a certain extent interested parties will want to move possibly sooner than we would wish. I don't see Avacta finishing what they started, but what do I know?",
          "sentiment": 0.0,
          "engagement": "6,031",
          "price_at_post": "60.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-12T21:57:56.483408+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261755-Metatron--7154333",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.188128",
        "source": "LSE_CHAT",
        "data": {
          "author": "Metatron",
          "content": "That's the spirit Watching2!! poor old Winnypoos is banging his drum as fast as he can but.. can he stay in time? I've spent half my life with those and asking a drummer to think? that's sublime...",
          "sentiment": 0.0,
          "engagement": "1,192",
          "price_at_post": "60.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-12T21:57:56.483426+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261725-opti_mys--6507147",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.188933",
        "source": "LSE_CHAT",
        "data": {
          "author": "opti_mystic",
          "content": "With RH on the BoD there is zero chance of Avacta being sold on the cheap. They have to put serious offers to shareholders but I guess it depends how serious is defined. Offering half what the company is worth is not a serious offer in my view. They could down tools today and sell the IP and they'd get a lot more than the current market cap.",
          "sentiment": 0.0,
          "engagement": "307",
          "price_at_post": "60.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-12T21:57:56.483444+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261717-cj62-47152855",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.189693",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "There is 0% CoS attached to the sp and that includes ava 6 k. Presently it would stand at 5 - 11% after the recent rns",
          "sentiment": 0.0,
          "engagement": "4,302",
          "price_at_post": "60.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-12T21:57:56.483463+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261710-Watching--2621368",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:24.190157",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "Winne bot has broken  free ! Ignore !",
          "sentiment": 0.0,
          "engagement": "9,224",
          "price_at_post": "60.50",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-12T21:57:56.483481+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261613-wyndrum-58829804",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.032149",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "\"Buyers don\u2019t care about today\u2019s SP, they care about what this asset can generate over a decade.\" do you think ever, before you post? If a buyer thinks this will be huge multiple in value then they buy as cheaply as they can which today would be 60p? Otherwise one would assume they are waiting for something... i dunno....maybe data from a trial yet to start? Also in response to where shareholders might sell: The SP would not be say, 500p per share from here on speculation. It would be on the back of very good results and data. It would be that data that would influence as to weather or not it would be sensible to sell.",
          "sentiment": 0.0,
          "engagement": "12,250",
          "price_at_post": "60.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-12T21:57:56.483499+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261556-Icecool-31938217",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.032939",
        "source": "LSE_CHAT",
        "data": {
          "author": "Icecool",
          "content": "If AVA6103 does what it\u2019s designed to do in humans, this isn\u2019t a few billion story. On any sensible biotech valuation framework (see my case study \ud83e\udd23\ud83d\ude09), you\u2019re talking tens of billions, not pocket change. That\u2019s total value paid, not based on some AIM screen price that flickers day to day. That\u2019s why the share price right now is basically irrelevant. Buyers don\u2019t care about today\u2019s SP, they care about what this asset can generate over a decade. Thankfully it also explains the strategy perfectly. Avacta is keeping AVA6103 solo for now because proving it in humans is where the real value unlock happens. You don\u2019t sell something like this on promise alone, you sell it when the risk collapses and the leverage flips. That\u2019s the play here. Prove it works in people, then let the numbers do the talking.",
          "sentiment": 0.0,
          "engagement": "8,855",
          "price_at_post": "61.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-12T21:57:56.483517+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261528-Timster-12910800",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.033717",
        "source": "LSE_CHAT",
        "data": {
          "author": "Timster",
          "content": "If CC brings anything less than \u00a3200 ex chi-nah, she'd be having a laugh!",
          "sentiment": 0.0,
          "engagement": "20,637",
          "price_at_post": "61.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-12T21:57:56.483535+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261523-cj62--2619483",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.034552",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "Directors cannot quietly reject a serious offer that could reasonably be of interest to shareholders once it becomes concrete. Their duty is to: Act in shareholders\u2019 best interests and Not frustrate an offer without shareholder approval",
          "sentiment": 0.0,
          "engagement": "4,302",
          "price_at_post": "61.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-12T21:57:56.483564+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261523-HarChris--7165790",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.035361",
        "source": "LSE_CHAT",
        "data": {
          "author": "HarChris",
          "content": "575m total share count feels a more realistic figure to be working with when forecasting future takeover share price so \u00a33B would be more like \u00a35.25 a share.",
          "sentiment": 0.0,
          "engagement": "15,923",
          "price_at_post": "61.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-12T21:57:56.483583+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261512-Bella653--4740263",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.036083",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "The BIG Questions are... Is the BOD in it for the long haul or  would they simply take a good offer so they can move on to pastures new? and how much are they will to hold out for?",
          "sentiment": 0.0,
          "engagement": "6,756",
          "price_at_post": "61.50",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-12T21:57:56.483601+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261507-Bella653--1179557",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.036656",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bella6532",
          "content": "I don't think you'll get anywhere near your SP wishlist on a T/O deal as we stand right now. Deals and NASDAQ Listing will drive value but we need some big hitters in the Finance World like Healthcare Royalty to back Avacta and to negotiate the best T/O deal possible at the right time.",
          "sentiment": 0.0,
          "engagement": "6,756",
          "price_at_post": "61.50",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-12T21:57:56.483620+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261505-hamsters-46505628",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.037073",
        "source": "LSE_CHAT",
        "data": {
          "author": "hamsters18",
          "content": "What large buys?",
          "sentiment": 0.0,
          "engagement": "3,692",
          "price_at_post": "61.50",
          "thread_title": "RE: TAKEOVER",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=DAF752F5-FA6F-49F9-BD50-F5C834118B9E"
        },
        "ingested_at": "2026-02-12T21:57:56.483653+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261449-Deod123--8222236",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.037518",
        "source": "LSE_CHAT",
        "data": {
          "author": "Deod123",
          "content": "Large buys going through.someone is stake building",
          "sentiment": 0.0,
          "engagement": "68",
          "price_at_post": "61.00",
          "thread_title": "TAKEOVER",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=DAF752F5-FA6F-49F9-BD50-F5C834118B9E"
        },
        "ingested_at": "2026-02-12T21:57:56.483686+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261438-cj62--2477863",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.037940",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "\u00a3200 ex china  Not this LTH",
          "sentiment": 0.0,
          "engagement": "4,302",
          "price_at_post": "61.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-12T21:57:56.483718+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261431-Wilson63--6973626",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.038378",
        "source": "LSE_CHAT",
        "data": {
          "author": "Wilson63",
          "content": "I'm somewhat surprised a couple of regulars are going to sell out at fairly low numbers, if this continues to pass each obstacle it's a one and only lifetime chance imho, topping up monthly slow and steady.",
          "sentiment": 0.0,
          "engagement": "8,808",
          "price_at_post": "60.50",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-12T21:57:56.483751+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261323-BuenaVis--1789332",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.038809",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Yes, the pre|CISION pie can be cut many ways: by drugs, indications and territories, and all with or without exclusivity.  People might say that faridox, with its boring old doxorubicin, will be overtaken by newer, more powerful pre|CISION drugs but the fact is it is here and now and not far off its first approved indication, salivary gland cancer, if the data released so far is to be believed. So with all that, why would any company want to license it when there could be better options in the future?  Well, if the offer was a global exclusive licence to develop faridox for SGC, plus the option to have first dibs on any future Avacta pre|CISION drug for SGC, plus the rights to develop their own pre|CISION drugs for SGC\u2014essentially an exclusive licence agreement to control the global pre|CISION SGC market\u2014then that would surely be of great interest. If it's taking Simon a long time to get that first deal, well the licensing possibilities are nearly endless and newly revealed data and developments are moving the goal posts in Avacta's favour all the time as conclusive evidence proves the platform (I'll call it that now already).",
          "sentiment": 0.0,
          "engagement": "5,826",
          "price_at_post": "59.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-12T21:57:56.483786+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261300-Vertizea--3821527",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.039250",
        "source": "LSE_CHAT",
        "data": {
          "author": "VertizeaSun",
          "content": "\u00a32 billion to buy a serious geographic licence for pre|CISION and a couple of warheads  sounds about right......say the EU/EEA and ex-ROW. Simon Bennett is now in his third year and the fact he hasn't been fired will suggest he has something up his sleeve. \u00a32B will pay for future independence and a \u00a31 per share dividend. I think we'll know within a couple of months and perhaps sooner as CC is obviously in town (doing celebratory cake delivery) and probably here for a board meeting - where they'll be trying to digest the recent torrent of good news. They actually have a lot on their plate. But I'm having trouble digesting \"the removal of the maximum dosing limit\" ...... apparently the first time in history for a phase 1 trial compound so I'm quite happy to believe that eventually pre|CISION is going to be compared to the impact penicillin had on the world of medicine. And in the beginning that discovery had serious FUD. Bill Gates said that the world always over-estimates how much change can take place in six months, but under-estimates how much change will take place in six years.",
          "sentiment": 0.0,
          "engagement": "440",
          "price_at_post": "59.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-12T21:57:56.483809+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261259-Matml74--2579826",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.039673",
        "source": "LSE_CHAT",
        "data": {
          "author": "Matml74",
          "content": "Dolly, Watch the R&D spotlight episode on next generation Precision from 2024 and also the dual payload one from late 2025. These highlight the vast opportunity for Precision.",
          "sentiment": 0.0,
          "engagement": "2,547",
          "price_at_post": "59.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-12T21:57:56.483827+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261252-opti_mys--9529423",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.040082",
        "source": "LSE_CHAT",
        "data": {
          "author": "opti_mystic",
          "content": "Oh yea of little faith. \u00a310 is my absolute bare minimum from when I first invested. Due to progress on a number of fronts that has gone up. Somewhat disappointed that people would sell so cheaply. Hopefully the BoD know what the company is worth and will not put to shareholders derisory offers that significantly under values the company.",
          "sentiment": 0.0,
          "engagement": "307",
          "price_at_post": "59.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-12T21:57:56.483845+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261249-Dollyg--7644657",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.040506",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dollyg",
          "content": "Thank you",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "59.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-12T21:57:56.483864+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261239-yeboha-64858310",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.040920",
        "source": "LSE_CHAT",
        "data": {
          "author": "yeboha",
          "content": "Dolly if you do some research online you can see that many professionals in the field agree that it can be used on many drugs !",
          "sentiment": 0.0,
          "engagement": "963",
          "price_at_post": "59.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-12T21:57:56.483882+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261237-yeboha-66576287",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.041383",
        "source": "LSE_CHAT",
        "data": {
          "author": "yeboha",
          "content": "Avacta\u2019s pipeline includes several distinct pre|CISION\u00ae drug conjugates with different therapeutic payloads, not just a single product: AVA6000 (a doxorubicin-based peptide drug conjugate) has shown positive clinical progress. AVA6103 (exatecan-based PDC) is advancing toward clinical trial start. Dual-payload PDCs are being developed in preclinical stages, combining agents like microtubule inhibitors and DNA damage response modulators. Another pipeline program, AVA7100 (an Affimer\u00ae-based drug conjugate), is also in preclinical development with its own payload delivery design. \ud83d\udccc Why this matters: This demonstrates that Avacta\u2019s platform isn\u2019t limited to a single drug but is being developed as a modular engine for multiple therapeutic combinations and individual payloads",
          "sentiment": 0.0,
          "engagement": "963",
          "price_at_post": "59.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-12T21:57:56.483899+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261231-Dollyg--7639797",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.041792",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dollyg",
          "content": "Be good to get a medically qualified opinion of the ACTUAL potential of how many differing treatments this technology could affect.",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "59.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-12T21:57:56.483932+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261227-Livedata--9167179",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.042216",
        "source": "LSE_CHAT",
        "data": {
          "author": "Livedataaccount",
          "content": "Hi jane im out at 4 pounds if it gets there",
          "sentiment": 0.0,
          "engagement": "2,969",
          "price_at_post": "59.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-12T21:57:56.483967+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261225-yeboha--7068589",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.042623",
        "source": "LSE_CHAT",
        "data": {
          "author": "yeboha",
          "content": "Its funny we say this, being where the share price is but im so convinced about avacta and have been for years !",
          "sentiment": 0.0,
          "engagement": "963",
          "price_at_post": "59.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-12T21:57:56.484001+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261221-Watching-50287405",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.043037",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "Happy with \u00a37 pre share. But \u00a310 would be a nice surprise . Jane",
          "sentiment": 0.0,
          "engagement": "9,224",
          "price_at_post": "59.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-12T21:57:56.484039+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261213-Dollyg-57453012",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.043462",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dollyg",
          "content": "I read the \u00a33 billion figure was first mooted in 2023 and they seem to have come a long way since then in terms of efficacy. The concensus seens to be wait.",
          "sentiment": 0.5,
          "engagement": "8",
          "price_at_post": "59.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-12T21:57:56.484072+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261212-yeboha--5962085",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.043874",
        "source": "LSE_CHAT",
        "data": {
          "author": "yeboha",
          "content": "Thats roughly my thinking",
          "sentiment": 0.0,
          "engagement": "963",
          "price_at_post": "59.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-12T21:57:56.484119+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261209-BuenaVis-73698368",
        "event_type": "social_post",
        "date": "2026-02-07T00:53:29.044290",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "$4bn would be 668p a share.  Not enough for me.  I'd be looking for at least 1,000p a share, a $6bn buyout.  At least.",
          "sentiment": 0.0,
          "engagement": "5,826",
          "price_at_post": "59.00",
          "thread_title": "RE: Could Avacta Be On There Shopping List ??",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=AFA39E85-54FB-47BD-BDC9-3E682CADD78F"
        },
        "ingested_at": "2026-02-12T21:57:56.484156+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20262313-aidanjc-90713615",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.524270",
        "source": "LSE_CHAT",
        "data": {
          "author": "aidanjc",
          "content": "Good point.  If cancer treatments improve that is a fantastic result. Its crept into my life a lot recently. Great to make a profit on the shares but improving outcomes for cancer patients is really important.",
          "sentiment": 0.0,
          "engagement": "6",
          "price_at_post": "51.50",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-12T21:57:56.484189+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20262051-avctIPma-15740320",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.524706",
        "source": "LSE_CHAT",
        "data": {
          "author": "avctIPmatters",
          "content": "Thanks for sharing  B2HS2L  -  Helps spread info on the platform  .",
          "sentiment": 0.0,
          "engagement": "728",
          "price_at_post": "51.50",
          "thread_title": "RE: CDD European Life Science Community Meeting",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=3A2F031D-C16F-4949-B22E-8512255BE282"
        },
        "ingested_at": "2026-02-12T21:57:56.484208+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20262049-avctIPma--6454154",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.525140",
        "source": "LSE_CHAT",
        "data": {
          "author": "avctIPmatters",
          "content": "Thanks for sharing  Thompi -  All helps spread   Avacta exposure .",
          "sentiment": 0.0,
          "engagement": "728",
          "price_at_post": "51.50",
          "thread_title": "RE: World CB & CDx Summit Europe",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=18E94451-D174-452E-BD8A-79154E17863F"
        },
        "ingested_at": "2026-02-12T21:57:56.484227+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20262022-Livedata--3011248",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.525565",
        "source": "LSE_CHAT",
        "data": {
          "author": "Livedataaccount",
          "content": "Ellen's great she will do a fantastic presentation",
          "sentiment": 0.0,
          "engagement": "2,957",
          "price_at_post": "51.50",
          "thread_title": "RE: CDD European Life Science Community Meeting",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=3A2F031D-C16F-4949-B22E-8512255BE282"
        },
        "ingested_at": "2026-02-12T21:57:56.484245+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20262016-B2HS2L-87164591",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.525997",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "Https://www.collaborativedrug.com/cdd-european-scientific-community-meeting-2026 Dr Ellen Watts, Avacta Therapeutics 25.02.2026  17:00-17:30: Delivering Targeted Therapies Using the pre|CISION\u00ae Platform. Last presentation of the day",
          "sentiment": 0.0,
          "engagement": "6,003",
          "price_at_post": "51.50",
          "thread_title": "CDD European Life Science Community Meeting",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=3A2F031D-C16F-4949-B22E-8512255BE282"
        },
        "ingested_at": "2026-02-12T21:57:56.484263+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261732-Timster-15840505",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.526420",
        "source": "LSE_CHAT",
        "data": {
          "author": "Timster",
          "content": "Good spot Thompi, thanks",
          "sentiment": 0.0,
          "engagement": "20,626",
          "price_at_post": "51.50",
          "thread_title": "RE: World CB & CDx Summit Europe",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=18E94451-D174-452E-BD8A-79154E17863F"
        },
        "ingested_at": "2026-02-12T21:57:56.484281+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261722-Thompi--1166931",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.526848",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thompi",
          "content": "Ruairidh Edwards will be speaking on 1 April at the 16th World Clinical Biomarkers & Companion Diagnostics Summit Europe. Presentation title: Establishing a Biomarker-Driven Approach to Guide Patient Selection for preCISION\u00ae Peptide-Drug Conjugates Using Tumour Targeting/Release and Payload Sensitivity Biomarkers. https://cdx-europe.com/full-event-guide/",
          "sentiment": 0.0,
          "engagement": "1,358",
          "price_at_post": "51.50",
          "thread_title": "World CB & CDx Summit Europe",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=18E94451-D174-452E-BD8A-79154E17863F"
        },
        "ingested_at": "2026-02-12T21:57:56.484300+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261707-Agenda10-49114263",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.527323",
        "source": "LSE_CHAT",
        "data": {
          "author": "Agenda101",
          "content": "No not engage ! It\u2019s working so let\u2019s continue to starve them of any engagement. As Runner-Runner wrote and BV reposted\u2026 It's simple. 1. DO NOT ENGAGE 2. DO NOT ASK IT A QUESTION 3. DO NOT ANSWER ITS QUESTIONS 4. DO NOT MOAN ABOUT ITS POSTS 5. DO NOT ARGUE WITH IT 6. If you must do something. Mock it with reference only to its stupidity and nothing else. ------------------------------------------------------ If you're not part of the solution, you're part of the problem",
          "sentiment": 0.0,
          "engagement": "72",
          "price_at_post": "52.50",
          "thread_title": "RE: Bone Marrow Toxicity, Brain malignancies?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=34DD9B68-3AA3-4F24-A8A5-8F742D7F4948"
        },
        "ingested_at": "2026-02-12T21:57:56.484319+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261704-Agenda10--3675162",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.527740",
        "source": "LSE_CHAT",
        "data": {
          "author": "Agenda101",
          "content": "\u201cI\u2019m committed for the next two years, but I anticipate that developments around licensing, manufacturing, and supply will begin to materialise well before then. From my perspective, the time to push ahead is now.\u201d",
          "sentiment": 0.0,
          "engagement": "72",
          "price_at_post": "51.50",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-12T21:57:56.484337+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261656-Thornogs--7102480",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.528205",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Well I didn't post! Not much said I see. More chat about FAP expressed on inflamed/fibrotic tissue other than cancer as a positive therapeutic opportunity with no one wondering if this self same tissue might cause problems should someone inject a FAP released 'Beast' into the circulation whilst trying to target a FAP related cancer.  Were that to happen in the FAP-EXD 1a Safety trial I think it would count as a Black Mark. BV and Syphysus indulged their in depth knowledge of molecular biology and the Blood Brain Barrier to 'deep dive' the potential to treat cerebral cancers, I do hope CC read those posts or perhaps one of you could send her an e mail explaining the possibilities? And the Market did what I thought it would do, go down, down the at the last come back up to almost, but not quite, where we opened. 1% down today, 3% this week and 10% down on the month. I see this continuing until the surprise deal mentioned earlier or being more realistic the next raise to fund the programme through 2026. Any thoughts on support/resistance levels Wyn? Happy to be out waiting for FAP-EXD and funding doubts to clear.",
          "sentiment": 0.0,
          "engagement": "8,666",
          "price_at_post": "51.50",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-12T21:57:56.484356+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261643-wyndrum-63273701",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.528628",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "I see \u201cthe don\u2019t engage\u201d policy didn\u2019t last long. You simply can\u2019t have a bb devoted to the actual topic and miss out on insulting others can you? Predictable and pathetic behaviour. Who knew?",
          "sentiment": 0.0,
          "engagement": "12,228",
          "price_at_post": "51.50",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-12T21:57:56.484375+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261640-D-Geeman-82898298",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.529049",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "'Chris, are you still interested in my buys and sells or would you prefer me not to bother?' Chris might not be interested Wyn, but I am... I dare say I'm not alone either.",
          "sentiment": 0.0,
          "engagement": "5,849",
          "price_at_post": "51.00",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-12T21:57:56.484393+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261639-Toukanka-57527835",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.529486",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "BV Are you a lawyer? We were led to believe that 6000 P1b would finish end of 25. So you don\u2019t regard having to go an extra cycle as missing a target. Or all the talk of multiple events before end 25 as not materialising. Anyhow at least some people on here are rooted in reality and believe CC when she says not to expect much before 2H26. Be. Patient",
          "sentiment": 0.0,
          "engagement": "4,454",
          "price_at_post": "51.00",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-12T21:57:56.484411+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261631-cj62-16712523",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.529902",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "Fine with me Chris. I would remind you however that it was you that asked I report my trades. You did report your last losing trade though did you, you prick",
          "sentiment": 0.0,
          "engagement": "4,282",
          "price_at_post": "51.50",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-12T21:57:56.484430+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261628-BuenaVis-59546982",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.530336",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Yes, that could be one possibility.",
          "sentiment": 0.0,
          "engagement": "5,775",
          "price_at_post": "51.50",
          "thread_title": "RE: Bone Marrow Toxicity, Brain malignancies?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=34DD9B68-3AA3-4F24-A8A5-8F742D7F4948"
        },
        "ingested_at": "2026-02-12T21:57:56.484448+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261622-wyndrum--1548591",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.530749",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "Fine with me Chris. I would remind you however that it was you that asked I report my trades. Anyway I\u2019m keen to see how this bb goes from here.",
          "sentiment": 0.0,
          "engagement": "12,228",
          "price_at_post": "51.50",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-12T21:57:56.484466+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261615-HarChris--2560003",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.531177",
        "source": "LSE_CHAT",
        "data": {
          "author": "HarChris",
          "content": "The last time I pointed out your losing trade you responded by saying you barely had anything on it\u2026 so nah, don\u2019t bother if you can just twist it how you want. And it clogs up the bb even more! How about not sharing any and trying not to care what an anonymous group of people think about your trading prowess?! That would be healthier!",
          "sentiment": 0.0,
          "engagement": "15,870",
          "price_at_post": "51.50",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-12T21:57:56.484485+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261613-Agenda10--5632382",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.531589",
        "source": "LSE_CHAT",
        "data": {
          "author": "Agenda101",
          "content": "None.. he\u2019s fishing don\u2019t reply!",
          "sentiment": 0.0,
          "engagement": "72",
          "price_at_post": "51.50",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-12T21:57:56.484502+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261547-BuenaVis--3328679",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.532000",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "@russell1 , what deadlines has Avacta missed since CC became CEO on 1 May 2024?",
          "sentiment": 0.0,
          "engagement": "5,775",
          "price_at_post": "51.00",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-12T21:57:56.484520+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261536-russell1--2304438",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.532426",
        "source": "LSE_CHAT",
        "data": {
          "author": "russell1",
          "content": "Well I'm not prepared to add any more money to my current loss situation so my only decision is whether to sell a proportion of my holding and hope I can buy back at a lower price if we (ever) get some worthwhile news or just leave it and hope! My expectation is that the price will just drift down until any news arrives but I have no expectation that this company will ever meet any of its reported deadlines.",
          "sentiment": -0.5,
          "engagement": "315",
          "price_at_post": "51.00",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-12T21:57:56.484538+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261529-Sisyphus--2121893",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.532837",
        "source": "LSE_CHAT",
        "data": {
          "author": "SisyphusShorter",
          "content": "Thanks BV, good to know. So in theory, a \"FAP-Temo\" agent would be roughly 460Da in size, provided the same Gen1 preCISION peptide is used. That puts it within the 400-600 threshold for BBB-crossing possibility (obviously notwithstanding lipophilicity, polarity and other parameters). That being said they could always cleave off a few residues to make a lightweight version for this specific indication.",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "51.00",
          "thread_title": "RE: Bone Marrow Toxicity, Brain malignancies?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=34DD9B68-3AA3-4F24-A8A5-8F742D7F4948"
        },
        "ingested_at": "2026-02-12T21:57:56.484556+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261509-Toukanka--7321760",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.533258",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "At last sensible posters instead of the usual carp \u201cfill yer boots you\u2019ll never again get the chance at this SP\u201d.  In truth we have a sideways drift until 6103 early clinical results are published in the Summer. Get over it and be patient.",
          "sentiment": 0.0,
          "engagement": "4,454",
          "price_at_post": "51.00",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-12T21:57:56.484574+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261432-wyndrum-31125904",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.533670",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "Chris, are you still interested in my buys and sells or would you prefer me not to bother?",
          "sentiment": 0.0,
          "engagement": "12,228",
          "price_at_post": "51.00",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-12T21:57:56.484592+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261413-Aston15--1996729",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.534076",
        "source": "LSE_CHAT",
        "data": {
          "author": "Aston15",
          "content": "I have brought enough now to be comfortable with the risk to reward ratio. 10% of my SIPP now in AVCT following another purchase this week. Many are expecting more than this, but my target remains a 5 billion valuation for the platform minimum. Happy to leave this to run now and hope the team delivers a positive outcome for both patients and shareholders.",
          "sentiment": 0.0,
          "engagement": "62",
          "price_at_post": "50.50",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-12T21:57:56.484611+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261410-B2HS2L-14558585",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:35.534502",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "Slide 16 & 18 of the Investormeet presentation 17.12.2025 contain info on tumor biopsies as articulated by Ruairidh Edwards, Translational Scientist. He's discussing phase 1b patients, possibly placing the recording of the interview before mid December.",
          "sentiment": 0.0,
          "engagement": "6,003",
          "price_at_post": "50.50",
          "thread_title": "RE: Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-02-12T21:57:56.484629+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261347-Vertizea-69169929",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.529148",
        "source": "LSE_CHAT",
        "data": {
          "author": "VertizeaSun",
          "content": "I think it links with CC's visit to Glasgow.....to visit the manufacturing site of AVA6103 and its \"first pour\".",
          "sentiment": 0.0,
          "engagement": "433",
          "price_at_post": "50.50",
          "thread_title": "RE: Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-02-12T21:57:56.484647+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261340-BuenaVis--4484545",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.529619",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Whilst the introduction by the host was current (post-IND announcement), CC seemed to be referencing passed events as being in the future and someone here suggested that the interview was recorded last year, in early December if I remember correctly.  I haven't listened to the interview again today but I do remember hearing bits that seemed out of step with today's situation.",
          "sentiment": 0.0,
          "engagement": "5,775",
          "price_at_post": "50.50",
          "thread_title": "RE: Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-02-12T21:57:56.484665+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261326-BuenaVis-70445020",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.530089",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Interesting and intelligent quesitions. As regards, fibrotic targets due to prior anthracycline treatment, it'll be interesting to see whether this side effect is reduced in previously untreated patients.  The breakdown of side effects vs prior treatment hasn't been presented yet but it is exacty the sort of detail I'm wanting to see (also, for example, side effects vs cancer indication/metastasis site).  Hopefully it will be included when the Phase 1 trial is written up in a peer-reviewed article, but there's always the AGM as an opportunity for asking detailed questions in person. As regards crossing the blood-brain barrier (BBB)... Temozolomide - molecular weight: 194.15 Da Doxorubicin - molecular weight: 543.52 Da Faridoxorubicin - molecular weight: 816.8 Da Faridoxorubicin without doxorubicin: 273.28 Da According to Gemini, \"Drugs that cross the BBB generally must be lipophilic (lipid-soluble), have a low molecular weight\u2014typically under 400\u2013600 Da\u2014and have a low polar surface area or few hydrogen bonds. They must avoid active efflux transport systems (like P-glycoprotein) and not be highly bound to plasma proteins.\"  So the requirements for an IV infusion drug are pretty stringent. However, there is an alternative route and that is, again according to Gemini, \"[administration] directly into the brain to bypass the BBB. This approach, known as local or regional drug delivery, is used to treat primary brain tumors (like glioblastoma) or brain metastases, allowing high concentrations of medication to reach the tumor without causing systemic toxicity.\"  I should think that the advantage of using pre|CISION for this is that, whilst the pre|CISION drug itself would be too big to cross OUT of the brain, the warhead, its metabolites and the leaving group from the pre|CISION substrate could all be below the size needed to cross out of the brain.  Anyway, CC wouldn't have specifically mentioned brain cancer if it weren't a possibility.",
          "sentiment": 0.0,
          "engagement": "5,775",
          "price_at_post": "50.50",
          "thread_title": "RE: Bone Marrow Toxicity, Brain malignancies?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=34DD9B68-3AA3-4F24-A8A5-8F742D7F4948"
        },
        "ingested_at": "2026-02-12T21:57:56.484683+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261318-IFA90--5099475",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.530517",
        "source": "LSE_CHAT",
        "data": {
          "author": "IFA90",
          "content": "I\u2019m not buying anymore. I\u2019ve increased my holding this week by selling a % and buying back c.10% cheaper. After 5 years it\u2019s entirely predictable, I just wish I\u2019d have realised that 3 years ago.",
          "sentiment": 0.0,
          "engagement": "409",
          "price_at_post": "50.50",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-12T21:57:56.484701+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261312-wyndrum--2378269",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.530949",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "Yes cj and I have just literally sold that holding and more as it looks to confused to me right now. Just so you know and can keep up I placed the sale evenly between Cpx and Xsg. Personally I would enjoy exploring and explaining my reasoning in a bit more depth but no need to is interested. ( and while you may all feel a bit more smug about this, it might be worth reflecting that I don\u2019t illicit the antagonist relationship here on other bb\u2019s. It begs the question is it me or you?)",
          "sentiment": 0.0,
          "engagement": "12,228",
          "price_at_post": "50.50",
          "thread_title": "RE: ADC 26",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=F3B63190-B417-42B7-9CC8-0ED98F4FBB92"
        },
        "ingested_at": "2026-02-12T21:57:56.484718+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261301-cj62-24513392",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.531376",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "\"Well the sp is 52p and now years later my analysis over a vey long period has proved correct and his wrong.\" but not recently you could have added- bought at 56.95 i believe. Yet still there are some that want me to be cancelled, yep you have that 100% correct as your narcissim knows no bounds",
          "sentiment": 0.0,
          "engagement": "4,282",
          "price_at_post": "50.50",
          "thread_title": "RE: ADC 26",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=F3B63190-B417-42B7-9CC8-0ED98F4FBB92"
        },
        "ingested_at": "2026-02-12T21:57:56.484736+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261254-Sisyphus-88440504",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.531796",
        "source": "LSE_CHAT",
        "data": {
          "author": "SisyphusShorter",
          "content": "So been looking at the phase 1 data for AVA6000 and also been listening to the podcast, thanks BV. Now I have two broad questions: One on bone/haem side effects, and one regarding primary brain cancers. Firstly, of the patients we have seen with bone marrow suppression, I know it's a known side effect of Dox, but I do wonder if prior primary therapies have induced a bit of fibrosis in the marrow, leading to FAP expression and thus Dox being released, leading to further bone marrow toxicity. That would imply that the side effects seen in the patients so far are less likely to emerge in a larger trial with a higher proportion of chemo-naive patients. Thoughts? Secondly, CC mentioned in the podcast that given that 90% of solid tumours express FAP, including brain, which she mentioned, and this begs the question whether or not the Peptide used in pre/CISION drug conjugates is small enough to pass the blood-brain-barrier, after all, that's how Temozolomide can do it's think for brain tumours. Again, thoughts?",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "50.50",
          "thread_title": "Bone Marrow Toxicity, Brain malignancies?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=34DD9B68-3AA3-4F24-A8A5-8F742D7F4948"
        },
        "ingested_at": "2026-02-12T21:57:56.484754+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261253-pedrolan-88687589",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.532225",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Yes, I bought some more the other week and am considering more now to get my average down further. If you believe in the medium term story here (with the bonus of a potential deal at any time) then it seems a bargain. Before any of the aliases bother to reply - I will not be responding to it - it will not be anything we have not all heard multiple times anyway.",
          "sentiment": 0.5,
          "engagement": "1,975",
          "price_at_post": "51.00",
          "thread_title": "RE: Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-12T21:57:56.484772+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261252-BuenaVis-66960837",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.532633",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Another advantage of Avacta's PDCs is the h o m ogeneity of the dosage - exactly one warhead per drug molecule, or exactly two warheads per drug molecule for the dual payload drugs. In contrast, significant heterogeneity exists in ADCs as they are complex mixtures of varied molecular species rather than a single uniform compound. This includes differences in the drug-to-antibody ratio (DAR) and the conjugation sites on the antibody, leading to mixtures with 0 to 8+ payload molecules and various positional isomers.",
          "sentiment": 0.0,
          "engagement": "5,775",
          "price_at_post": "51.00",
          "thread_title": "RE: ADC 26",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=F3B63190-B417-42B7-9CC8-0ED98F4FBB92"
        },
        "ingested_at": "2026-02-12T21:57:56.484789+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261250-aidanjc--5464501",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.533041",
        "source": "LSE_CHAT",
        "data": {
          "author": "aidanjc",
          "content": "I've been a lth here having bought at several levels. Was hoping not to see us back around the 50p level. I've bought a few more. Anyone else buying. I'm hoping 50p will be the low tide mark...",
          "sentiment": 0.5,
          "engagement": "6",
          "price_at_post": "51.00",
          "thread_title": "Anyone buying at this level?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=6E88B10D-0251-463F-B2DA-3263632F7632"
        },
        "ingested_at": "2026-02-12T21:57:56.484807+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261246-wyndrum--1374924",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.533480",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "Also I don\u2019t care if you respond or not. I just hope it makes you think.also you will crack before we do. Not because it\u2019s a contest but simply we will ask questions or post opinions that as a bb you will naturally want to respond to. That\u2019s the whole purpose of a discussion bb. To discuss. And while there are a lot of recs to want us to be cancelled you will soon be bored with the lack of insight offered by the so called guardians of this bb. And never forget, it is exactly the same posters that by insulting us that then generate the board clogging are the ones piously demanding we be ignored. Just check sheppy watching bv and the rest for their overall contribution.",
          "sentiment": 0.0,
          "engagement": "12,228",
          "price_at_post": "51.00",
          "thread_title": "RE: ADC 26",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=F3B63190-B417-42B7-9CC8-0ED98F4FBB92"
        },
        "ingested_at": "2026-02-12T21:57:56.484825+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261243-Sisyphus--9602864",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.533883",
        "source": "LSE_CHAT",
        "data": {
          "author": "SisyphusShorter",
          "content": "Sorry, *Next* data release....",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "51.00",
          "thread_title": "RE: Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-02-12T21:57:56.484843+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261240-Sisyphus--6954893",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.534310",
        "source": "LSE_CHAT",
        "data": {
          "author": "SisyphusShorter",
          "content": "At 36:22 CC says, regarding tumour biopsies - \"...in our new data release which will be later this month...\" Make of that what you will..... GLA",
          "sentiment": 0.0,
          "engagement": "8",
          "price_at_post": "51.00",
          "thread_title": "RE: Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-02-12T21:57:56.484861+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261232-wyndrum--8567319",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.534763",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "Oh, I remember, after this interview and the other stuff uncovered, what has the sp done? Why ,  How, can there be more sellers than buyers? Let\u2019s move on from the \u201csp doesn\u2019t matter \u201c. It\u2019s a facile statement which simply refuses to address a perfectly reasonable question. Yes the sp can drift up or down on no news but why can\u2019t we discuss it when there is a very positive release and it generates sells? By all means keep up this do not engage but myles tried this with me specifically on this bb with a little header to try and get me banned altogether. Well the sp is 52p and now years later my analysis over a vey long period has proved correct and his wrong. Yet still there are some that want me to be cancelled. You lot are either just plain weird or it is you that have an agenda. Just remember I have made money out of this stock and had you agreed with my view you would have too. The opposite would have happened if you followed bv and the rest. Yet you want me silenced. You might perhaps realise why I wonder what motivates the majority here.",
          "sentiment": 0.0,
          "engagement": "12,228",
          "price_at_post": "51.00",
          "thread_title": "RE: ADC 26",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=F3B63190-B417-42B7-9CC8-0ED98F4FBB92"
        },
        "ingested_at": "2026-02-12T21:57:56.484879+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261221-Watching--9005122",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.535189",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "To the Fudders they are trying so hard this morning ! It worked yesterday ! They are drying up \ud83e\udd21s",
          "sentiment": 0.0,
          "engagement": "9,215",
          "price_at_post": "51.00",
          "thread_title": "Do not respond",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=598797E4-B255-4509-971C-C103D6214E00"
        },
        "ingested_at": "2026-02-12T21:57:56.484897+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261143-wyndrum-66236737",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.535610",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "whatever you do, do not do not reply  or respond. you might want to take the ****, but resist. you might have the best put down ever! but do not repeat do not respond  got it? now what was i going to say\u2026. damn after all that i forgot \u2026.,",
          "sentiment": 0.0,
          "engagement": "12,228",
          "price_at_post": "52.00",
          "thread_title": "RE: ADC 26",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=F3B63190-B417-42B7-9CC8-0ED98F4FBB92"
        },
        "ingested_at": "2026-02-12T21:57:56.484915+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20261014-HarryAng--5194312",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.536027",
        "source": "LSE_CHAT",
        "data": {
          "author": "HarryAngstrom",
          "content": "I meant PEAK SALES to Avacta... not TAM.",
          "sentiment": 0.0,
          "engagement": "9",
          "price_at_post": "52.50",
          "thread_title": "RE: Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-02-12T21:57:56.484934+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260955-D-Geeman--7986110",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.536554",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "'Today 09:44 Don't waste time responding if your handle is ........ D-Geeman ' You sound like a teenager with a statement like that B2HS2L. In this context that isn't a compliment.",
          "sentiment": 0.0,
          "engagement": "5,849",
          "price_at_post": "53.00",
          "thread_title": "RE: ADC 26",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=F3B63190-B417-42B7-9CC8-0ED98F4FBB92"
        },
        "ingested_at": "2026-02-12T21:57:56.484952+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260946-HarryAng--3939342",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.537041",
        "source": "LSE_CHAT",
        "data": {
          "author": "HarryAngstrom",
          "content": "This is a gigantic opportunity. TAM for Rhematoid Arthritis would be between $3.0 - $4.0 billion. And if they move into Fibrosis, the TAM there is between $7.0 - $10.0 billion. Once they prove they can deliver a toxin as potent as Exatecan using the FAP linker, using the same linker for milder anti-fibrotic or anti-inflammatory drugs is a low risk, high reward certainty.",
          "sentiment": 0.0,
          "engagement": "9",
          "price_at_post": "52.50",
          "thread_title": "RE: Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-02-12T21:57:56.484969+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260944-B2HS2L--7767435",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.537575",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "Don't waste time responding if your handle is wyndrum, Thornogson, Toukankahmoon or D-Geeman ********************************************************************************************************* Like my new header?  \ud83d\ude01\ud83d\ude09   I hope you create similar. In the event one company buys Avacta, all others will need to continue developing ADC's. They'll need to make improvements to compete as follows: 1 Reduce the time required to develop new drugs. 2 Improve the precision of targeting of warheads, so less drug is available systemically. 3 Improve the ease and speed of manufacturing 4 Find ways to reduce particle size 5 Find ways to deliver >1 drug at a time. Also - * Small molecule manufacturing and timeline/COGM (cost of goods manufactured) \"What that statement means and why that is important, is that the price tag for this drug (AVA6000), is one tenth of the price tag for an ADC drug. ADC's cost a lot of money in the clinic\"  CC 8.11.2024 I don't see why the statement isn't also true for AVA6103. ++++ A reminder from  Trinity Delta \u2013 Targeting the tumour microenvironment with pre|CISION - 18.11.2024 https://www.trinitydelta.org/research-notes/targeting-the-tumour-microenvironment-with-precision/ \"Avacta has so far FAP-enabled ten different warheads building up a database of multiple pre|CISION compounds that include c 40 capping groups (which alter the PK of the conjugate) and c 20   linkers (required for FAP cleavage with certain warheads and can be used to modify FAP affinity and activity). These have all been characterised through computational simulations to evaluate molecular binding and how they dock into the FAP structure. A key consideration is how close the warhead can get to the FAP cleavage sequence; this typically depends on the size of the molecule, and often defines whether a spacer group is required. Consideration is also given to how long the conjugate and the active warhead are likely to remain in the TME, and this informs whether PK alterations, achieved through an alternative capping group, are needed to either allow the sustained release of the warhead or to slow plasma clearance. Potential candidate molecules that meet the internal hurdle are also evaluated in vivo to investigate key PK parameters and cytotoxicity, with some selected for further characterisation in vitro and in vivo to establish preclinical efficacy and safety in a wide range of FAP tumour expression models with low serum FAP (including co-cultures of tumour cells and CAFs) to recapitulate the human TME.\" ++++ I'll bet there is more than ten warheads, forty capping groups and twenty linkers now!",
          "sentiment": 0.0,
          "engagement": "6,003",
          "price_at_post": "53.00",
          "thread_title": "RE: ADC 26",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=F3B63190-B417-42B7-9CC8-0ED98F4FBB92"
        },
        "ingested_at": "2026-02-12T21:57:56.484987+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260931-BuenaVis-33150258",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.537985",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Really does feel like adding Go Faster stripes at a horse fair.",
          "sentiment": 0.0,
          "engagement": "5,775",
          "price_at_post": "53.00",
          "thread_title": "RE: ADC 26",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=F3B63190-B417-42B7-9CC8-0ED98F4FBB92"
        },
        "ingested_at": "2026-02-12T21:57:56.485005+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260910-Yorkshir--4977049",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.538411",
        "source": "LSE_CHAT",
        "data": {
          "author": "Yorkshirepragma",
          "content": "CC refers to other applications \u2026Chronic Inflammation \u2018conversations\u2019 are interesting . One step at a time \u2026.",
          "sentiment": 0.0,
          "engagement": "1,804",
          "price_at_post": "53.00",
          "thread_title": "RE: Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-02-12T21:57:56.485024+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260845-Yorkshir-61979970",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.538852",
        "source": "LSE_CHAT",
        "data": {
          "author": "Yorkshirepragma",
          "content": "Fascinating similarity re Avactas current development processes. Tuesday 24th February 2026 The Next Generation of ADCs: Leveraging Novel Conjugation & Enhanced Antibody Engineering for the Future of Targeted Oncology Therapies 9:15 am Laying out the scope to differentiate ADC development through novel conjugation, antibody engineering, and target identification approaches to widen therapeutic index and bring patient benefit Incorporating in silico and AI tools to enhance the ADC discovery toolbox and deliver next-generation ADC engineering and design Highlighting future priorities for next-generation ADC development, including exploring the potential of radio conjugates",
          "sentiment": 0.0,
          "engagement": "1,804",
          "price_at_post": "53.00",
          "thread_title": "ADC 26",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=F3B63190-B417-42B7-9CC8-0ED98F4FBB92"
        },
        "ingested_at": "2026-02-12T21:57:56.485042+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260811-Agenda10--4845677",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.539272",
        "source": "LSE_CHAT",
        "data": {
          "author": "Agenda101",
          "content": "Cheers BV!",
          "sentiment": 0.0,
          "engagement": "72",
          "price_at_post": "53.00",
          "thread_title": "RE: Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-02-12T21:57:56.485061+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260754-cj62--4800786",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:38.539688",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "Who would be allowed access ?",
          "sentiment": 0.0,
          "engagement": "4,282",
          "price_at_post": "53.00",
          "thread_title": "Data Room",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=85F98FAE-01B2-48EC-B9D0-584FAD2B9731"
        },
        "ingested_at": "2026-02-12T21:57:56.485079+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260751-Thornogs-75078153",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.713580",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "This one and one after the close to comment on the top quality discussion and to check if we finished up or not.",
          "sentiment": 0.0,
          "engagement": "8,666",
          "price_at_post": "53.00",
          "thread_title": "2 post Friday.",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=EDA1F112-F6D9-49A4-937D-081A93C2E757"
        },
        "ingested_at": "2026-02-12T21:57:56.485108+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260626-Gingethe--6164280",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.714067",
        "source": "LSE_CHAT",
        "data": {
          "author": "GingetheWinge",
          "content": "The FUDsters are thrashing like Terminator 2 in a smelting cauldron. It\u2019s working so let\u2019s continue to starve them of any engagement. As Runner-Runner wrote and BV reposted\u2026 It's simple. 1. DO NOT ENGAGE 2. DO NOT ASK IT A QUESTION 3. DO NOT ANSWER ITS QUESTIONS 4. DO NOT MOAN ABOUT ITS POSTS 5. DO NOT ARGUE WITH IT 6. If you must do something. Mock it with reference only to its stupidity and nothing else. ------------------------------------------------------ If you're not part of the solution, you're part of the problem",
          "sentiment": 0.5,
          "engagement": "700",
          "price_at_post": "53.00",
          "thread_title": "No not engage !",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=A348D8E1-4DC7-4D49-950E-08F79BC3A2D1"
        },
        "ingested_at": "2026-02-12T21:57:56.485136+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260138-BuenaVis--4876454",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.714500",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Even better link: https://www.youtube.com/watch?v=HWkh3OEFSds&t=1333s",
          "sentiment": 0.0,
          "engagement": "5,775",
          "price_at_post": "53.00",
          "thread_title": "RE: Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-02-12T21:57:56.485154+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260132-BuenaVis-81206812",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.714925",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "It's the Base to Base biotech podcast from a few days ago. Well worth a listen. Here's the link to the start of the CC interview: https://www.youtube.com/watch?v=HWkh3OEFSds&t=1290s",
          "sentiment": 0.0,
          "engagement": "5,775",
          "price_at_post": "53.00",
          "thread_title": "RE: Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-02-12T21:57:56.485172+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262331-D-Geeman-85108518",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.715361",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "Wasn\u2019t wyn comparing this BB to \u2018Lord of the Flies\u2019 classic story? Well for those who don\u2019t know the story I just caught a trailer for new BBC production starting soon; https://www.bbc.com/mediacentre/2026/lord-of-the-flies-trailer",
          "sentiment": 0.0,
          "engagement": "5,849",
          "price_at_post": "53.00",
          "thread_title": "RE: Avacta Therapeutics celebrates this",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=03B0B4A6-705E-45ED-983A-A89C321C0924"
        },
        "ingested_at": "2026-02-12T21:57:56.485190+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262302-alextak-99490969",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.715781",
        "source": "LSE_CHAT",
        "data": {
          "author": "alextak",
          "content": "Is it a new interview? .I'll listen to it tomorrow.",
          "sentiment": 0.0,
          "engagement": "540",
          "price_at_post": "53.00",
          "thread_title": "RE: Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-02-12T21:57:56.485208+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262258-alextak--3843319",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.716203",
        "source": "LSE_CHAT",
        "data": {
          "author": "alextak",
          "content": "Https://youtu.be/HWkh3OEFSds?si=0KezbLZbtRJA4N97",
          "sentiment": 0.0,
          "engagement": "540",
          "price_at_post": "53.00",
          "thread_title": "Biotech Podcast",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E827EC5F-7795-4CC9-89D6-AF5CD8F0C254"
        },
        "ingested_at": "2026-02-12T21:57:56.485227+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262241-pedrolan-49255462",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.716624",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "When no-one engages that's what they end up with. Good work folks.",
          "sentiment": 0.5,
          "engagement": "1,975",
          "price_at_post": "53.00",
          "thread_title": "Voices in the wilderness",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=8AE5A358-4CCC-4E25-A8A9-D4C3BBC9FF5F"
        },
        "ingested_at": "2026-02-12T21:57:56.485244+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262222-Thornogs-22823979",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.717039",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Absolutely Pedro! All those who chance upon the LSE Avacta bulletin board and haven't been keeping up with the news, all of them? Exposure indeed, keep up the good work everybody!",
          "sentiment": 0.0,
          "engagement": "8,666",
          "price_at_post": "53.00",
          "thread_title": "RE: Avacta Therapeutics celebrates this",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=03B0B4A6-705E-45ED-983A-A89C321C0924"
        },
        "ingested_at": "2026-02-12T21:57:56.485263+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262202-pedrolan-38183260",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.717464",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "All great exposure. Thanks for posting \ud83d\udc4d\ud83c\udffb",
          "sentiment": 0.5,
          "engagement": "1,975",
          "price_at_post": "53.00",
          "thread_title": "RE: Avacta Therapeutics celebrates this",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=03B0B4A6-705E-45ED-983A-A89C321C0924"
        },
        "ingested_at": "2026-02-12T21:57:56.485280+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262145-Thornogs-87599947",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.717891",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Well there we have it Avcti, proof positive fof all those 'FUDsters' who have been saying otherwise all day! Avacta can produce FAP-EXD for the upcoming trial! What chance does 'FUD' have against this level of research and knowledge? Hang your heads in shame all those saying that it wasn't possible. Was anyone suggesting this?",
          "sentiment": 0.0,
          "engagement": "8,666",
          "price_at_post": "53.00",
          "thread_title": "RE: \" So excited to get the trial going soon. \"",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=C91568DF-F421-4695-901C-78161A0F4CD6"
        },
        "ingested_at": "2026-02-12T21:57:56.485299+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262110-avctIPma--7499470",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.718379",
        "source": "LSE_CHAT",
        "data": {
          "author": "avctIPmatters",
          "content": "FYI   Christina CoughlinChristina Coughlin \u2022 3rd+Verified \u2022 3rd+ Chief Executive Officer, AvactaChief Executive Officer, Avacta 53m \u2022  53 minutes ago \u2022 Visible to anyone on or off LinkedIn Follow We are thrilled to partner with our team at Curia - this partnership has enabled our team at hashtag#AVCT to move FAP-exatecan forward at record pace. So excited to get the trial going soon. This combined team reminds me of a favorite quote, \u201cNever doubt that a small group of thoughtful, committed citizens can change the world. Indeed, it is the only thing that ever has.\u201d \u2014Margaret Mead. hashtag#LetsDoThis hashtag#HopeWithoutCompromise CuriaCuria 104,425 followers104,425 followers 2h \u2022  2 hours ago \u2022 Visible to anyone on or off LinkedIn Follow Congratulations to Avacta Therapeutics on receiving U.S. Food and Drug Administration (FDA) clearance of the Investigational New Drug (IND) application for the Company\u2019s second program FAP-Exd (AVA6103). This peptide drug conjugate is based on the highly potent topoisomerase I inhibitor, exatecan. A Phase 1 clinical trial will enroll patients with solid tumors, pancreatic cancer, cervical cancer, gastric cancer and small cell lung cancer. CURIA STERILE DRUG PRODUCT business unit is proud to assist this cutting-edge oncology program with formulation development, analytical support and GMP clinical supply at our site in Glasgow. Read more about Avacta in the recent press release: https://hubs.li/Q040N2nz0",
          "sentiment": 0.0,
          "engagement": "728",
          "price_at_post": "53.00",
          "thread_title": "\" So excited to get the trial going soon. \"",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=C91568DF-F421-4695-901C-78161A0F4CD6"
        },
        "ingested_at": "2026-02-12T21:57:56.485317+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262104-wyndrum-74155512",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.718829",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "So you\u2019re right and I am wrong as you have said umpteen times  yet it is me who is the narcissist? You don\u2019t even know what the term means in detail yet bandi it about as a diagnosis of a stranger you know nothing about. Your arrogance in libelling me without any justification only amplifies my point. But in none of these umpteen times have you ever wondered why AVCT have failed to deliver the returns you expected when you first bought in ? No of course not. That would require self examination. Something you seem to lack but have no inhibition in accusing others of. The arrogance of the arguments directed at me are so cliched and bereft of any true accuracy that it is simply pathetic. What is so considerably worse is the recs they get. Not because it offends me more but rather of the evidence that so may can\u2019t reason for themselves and blithely agree. It\u2019s not a case of reading the room, more a case of group think. Under your reasoning we would all still think the earth was flat.",
          "sentiment": 0.0,
          "engagement": "12,228",
          "price_at_post": "53.00",
          "thread_title": "RE: Worldwide ADC Innovation & Collaboration   London",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=CB66756C-50A3-4D04-A499-ADC1B8951801"
        },
        "ingested_at": "2026-02-12T21:57:56.485335+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262104-Metatron-41720291",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.719249",
        "source": "LSE_CHAT",
        "data": {
          "author": "Metatron",
          "content": "Forgot.. dammit.. sawy \ud83e\udd14",
          "sentiment": 0.0,
          "engagement": "1,188",
          "price_at_post": "53.00",
          "thread_title": "RE: Worldwide ADC Innovation & Collaboration   London",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=CB66756C-50A3-4D04-A499-ADC1B8951801"
        },
        "ingested_at": "2026-02-12T21:57:56.485353+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262051-BuenaVis--1471594",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.719657",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Do not feed the troll. \ud83e\udd2a",
          "sentiment": 0.0,
          "engagement": "5,775",
          "price_at_post": "53.00",
          "thread_title": "RE: Worldwide ADC Innovation & Collaboration   London",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=CB66756C-50A3-4D04-A499-ADC1B8951801"
        },
        "ingested_at": "2026-02-12T21:57:56.485371+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262035-Metatron-10406823",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.720073",
        "source": "LSE_CHAT",
        "data": {
          "author": "Metatron",
          "content": "The problem is Wyndrone.. that you cannot read the room because you are a narcissist as I've explaind umpteen times. The recs are from other members who are just plain sick to death of you and your narcissistic droning behaviour.",
          "sentiment": 0.0,
          "engagement": "1,188",
          "price_at_post": "53.00",
          "thread_title": "RE: Worldwide ADC Innovation & Collaboration   London",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=CB66756C-50A3-4D04-A499-ADC1B8951801"
        },
        "ingested_at": "2026-02-12T21:57:56.485390+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262028-Metatron--4327010",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.720496",
        "source": "LSE_CHAT",
        "data": {
          "author": "Metatron",
          "content": "Looks like Thorndrone has repositioned itself as the ultimate purile commentator on the commentary? Looks more to me like the ultimate terd that just won't flush \ud83d\ude48\ud83d\udca9",
          "sentiment": 0.0,
          "engagement": "1,188",
          "price_at_post": "53.00",
          "thread_title": "RE: Avacta Therapeutics celebrates this",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=03B0B4A6-705E-45ED-983A-A89C321C0924"
        },
        "ingested_at": "2026-02-12T21:57:56.485408+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262028-wyndrum-24590590",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.720925",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "I think the problem is Chris is that while what you say is correct, it is the \u201canti-fudsters \u201c for want of a better expression, that quite deliberately push this debilitating and constant line at any opportunity. And like today, when nothing is going on, BV just stirs the pot. Yet every single time the cause of this futile exercise is laid at the door of the posters who are incessantly  attacked rather than the perpetrators . What\u2019s even more disturbing is the recs they get for doing it. This bb is simply one of the worst I have ever come across and we all contribute to that to some degree but it is the majority (when you look at the recs) here that revel in this disruptive behaviour and have little or no interest in resolving the situation for the better. Why can\u2019t I say after 5 years of a trial and a sp at near all time lows that maybe all is not what we were led to believe from the outset and can we look at what might be causing this without being asked to be ignored banned or wished an early death?",
          "sentiment": 0.0,
          "engagement": "12,228",
          "price_at_post": "53.00",
          "thread_title": "RE: Worldwide ADC Innovation & Collaboration   London",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=CB66756C-50A3-4D04-A499-ADC1B8951801"
        },
        "ingested_at": "2026-02-12T21:57:56.485426+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262015-stodgy88--5906589",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.721347",
        "source": "LSE_CHAT",
        "data": {
          "author": "stodgy88",
          "content": "LinkedIn.",
          "sentiment": 0.0,
          "engagement": "1,206",
          "price_at_post": "53.00",
          "thread_title": "RE: Avacta Therapeutics celebrates this",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=03B0B4A6-705E-45ED-983A-A89C321C0924"
        },
        "ingested_at": "2026-02-12T21:57:56.485444+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262014-stodgy88-47838953",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.721752",
        "source": "LSE_CHAT",
        "data": {
          "author": "stodgy88",
          "content": "This company as over  100,000 followers, so good exposure.",
          "sentiment": 0.0,
          "engagement": "1,206",
          "price_at_post": "53.00",
          "thread_title": "RE: Avacta Therapeutics celebrates this",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=03B0B4A6-705E-45ED-983A-A89C321C0924"
        },
        "ingested_at": "2026-02-12T21:57:56.485462+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262011-Thornogs-33096609",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.722182",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Quite Avcti, well done! Always good to be reminded of last week's RNS! In case any of ghd 'well infofmed' missed it eh?",
          "sentiment": 0.0,
          "engagement": "8,666",
          "price_at_post": "53.00",
          "thread_title": "RE: Avacta Therapeutics celebrates this",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=03B0B4A6-705E-45ED-983A-A89C321C0924"
        },
        "ingested_at": "2026-02-12T21:57:56.485480+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262010-HarChris-49281014",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.722603",
        "source": "LSE_CHAT",
        "data": {
          "author": "HarChris",
          "content": "There\u2019s a cycle of Thorn repeating the same points over and over again, the numerous posters who flood us with messages telling him to F off, begging others not to reply or to warn the bb of his dishonesty and then Wyn writing paragraphs of philosophy and psychology on the meaning of it all. That plays out at least four or five times a week! Almost identically. The odd post on Avacta gets a reply or two before the cycle kickstarts again. What a waste of time this BB is in quiet periods like this!",
          "sentiment": 0.0,
          "engagement": "15,870",
          "price_at_post": "53.00",
          "thread_title": "RE: Worldwide ADC Innovation & Collaboration   London",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=CB66756C-50A3-4D04-A499-ADC1B8951801"
        },
        "ingested_at": "2026-02-12T21:57:56.485498+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20262004-avctIPma-50100302",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.723059",
        "source": "LSE_CHAT",
        "data": {
          "author": "avctIPmatters",
          "content": "Back to more worthwhile  conversation thanks Stonks -------------------------- Avacta Therapeutics celebrates this Curia 54m \u2022 Follow Congratulations to Avacta Therapeutics on receiving U.S. Food and Drug Administration (FDA) clearance of the Investigational New Drug (IND) application for the Company\u2019s second program FAP-Exd (AVA6103). This peptide drug conjugate is based on the highly potent topoisomerase I inhibitor, exatecan. A Phase 1 clinical trial will enroll patients with solid tumors, pancreatic cancer, cervical cancer, gastric cancer and small cell lung cancer. CURIA STERILE DRUG PRODUCT business unit is proud to assist this cutting-edge oncology program with formulation development, analytical support and GMP clinical supply at our site in Glasgow. Read more about Avacta in the recent press release: https://hubs.li/Q040N2nz0 \" Gmcc",
          "sentiment": 0.0,
          "engagement": "728",
          "price_at_post": "53.00",
          "thread_title": "Avacta Therapeutics celebrates this",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=03B0B4A6-705E-45ED-983A-A89C321C0924"
        },
        "ingested_at": "2026-02-12T21:57:56.485516+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261833-D-Geeman-21947200",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.723489",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "'and bucket to collect their donations for his roses.\u2019 'collect the dung & yes then spread the manure around the Roses' I understand that Watching does this too but with her Quality Street, not Roses.",
          "sentiment": 0.0,
          "engagement": "5,849",
          "price_at_post": "53.00",
          "thread_title": "RE: Worldwide ADC Innovation & Collaboration   London",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=CB66756C-50A3-4D04-A499-ADC1B8951801"
        },
        "ingested_at": "2026-02-12T21:57:56.485535+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20261754-Thornogs-87075537",
        "event_type": "social_post",
        "date": "2026-01-31T00:40:42.723915",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Now, now Wyn! Steady there. It's been decided that our constant 'FUD' detracts from thd ability of the 'well informed' posters to discuss Avzcta seriously. OK, so far it's just the usual nonsense but give thdm a chance I'm sure tomorrow they'll Smash It! Did we finish up by the way?",
          "sentiment": 0.0,
          "engagement": "8,666",
          "price_at_post": "53.00",
          "thread_title": "RE: Worldwide ADC Innovation & Collaboration   London",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=CB66756C-50A3-4D04-A499-ADC1B8951801"
        },
        "ingested_at": "2026-02-12T21:57:56.485553+00:00"
      },
      {
        "event_id": "SOCIAL-Today1236-Watching-75152923",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.595387",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "Let\u2019s have a day where know one engages with the Fudders A watch them argue with themselves \ud83d\ude0a",
          "sentiment": 0.0,
          "engagement": "9,213",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-02-12T21:57:56.485571+00:00"
      },
      {
        "event_id": "SOCIAL-Today1207-D-Geeman-40123755",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.595837",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "Evan Davis discussing mergers and acquisitions on Radio 4 right now.",
          "sentiment": 0.0,
          "engagement": "5,844",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-02-12T21:57:56.485588+00:00"
      },
      {
        "event_id": "SOCIAL-Today1050-D-Geeman-76525177",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.596300",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "Many of the most useful posts are green boxes to others. That's fine. I really don't care if **** doesn't read ****'s post as long as I can. Please, everyone who doesn't like ****'s posts filter and then the people who do read them can do so in peace.",
          "sentiment": 0.0,
          "engagement": "5,844",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-02-12T21:57:56.485606+00:00"
      },
      {
        "event_id": "SOCIAL-Today1034-Thornogs-51987529",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.596741",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Happy to sit on the sidelines to watch the emergence of all this deep research and intelligent discussion on the company's 'fundamentals'. Of course if it isn't accurate or realistic I presume there's the right to point this out? Otherwise it's just a meaningless Echo Chamber. Over to you, the self proclaimed 'well informed'. Let's see what quality posting looks like!",
          "sentiment": 0.0,
          "engagement": "8,655",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-02-12T21:57:56.485624+00:00"
      },
      {
        "event_id": "SOCIAL-Today1032-BuenaVis--8861258",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.597214",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "As Runner-Runner wrote... It's simple. 1. DO NOT ENGAGE 2. DO NOT ASK IT A QUESTION 3. DO NOT ANSWER ITS QUESTIONS 4. DO NOT MOAN ABOUT ITS POSTS 5. DO NOT ARGUE WITH IT 6. If you must do something. Mock it with reference only to its stupidity and nothing else. ------------------------------------------------------ If you're not part of the solution, you're part of the problem",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-02-12T21:57:56.485642+00:00"
      },
      {
        "event_id": "SOCIAL-Today1025-pedrolan--7539991",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.597761",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Ok, as one of the offenders ( I did it mainly to remind people of their/his agenda) I will pledge to now ignore them/him going forward. We really need everyone to do that though.",
          "sentiment": 0.5,
          "engagement": "1,972",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-02-12T21:57:56.485660+00:00"
      },
      {
        "event_id": "SOCIAL-Today1022-Aston15-25428763",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.598209",
        "source": "LSE_CHAT",
        "data": {
          "author": "Aston15",
          "content": "People do understand the only reason then come on here to spout sh*t is because others give them an audience? Its not difficult..  Green Box them and focus the chat on the company, not their trading agendas.",
          "sentiment": 0.0,
          "engagement": "61",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-02-12T21:57:56.485679+00:00"
      },
      {
        "event_id": "SOCIAL-Today1005-IFA90-50594982",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.598630",
        "source": "LSE_CHAT",
        "data": {
          "author": "IFA90",
          "content": "More posts than trades, never a good sign.",
          "sentiment": 0.0,
          "engagement": "408",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-02-12T21:57:56.485697+00:00"
      },
      {
        "event_id": "SOCIAL-Today0954-Aldebara-25408285",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.599061",
        "source": "LSE_CHAT",
        "data": {
          "author": "Aldebaran",
          "content": "Anyone engaging with them is part of the problem. I'll soon be adding them to my filter list if all the want to do is talk smack and try to score points against them. It's a waste of everyone's time, least not their own yet they persist. Sad. We could use this bb once again to discuss avacta but only if the engagement with FUDsters ends. Its nothing more than a digital playground otherwise. Filter. Them.",
          "sentiment": 0.0,
          "engagement": "3,894",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-02-12T21:57:56.485715+00:00"
      },
      {
        "event_id": "SOCIAL-Today0948-Watching-59403176",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.599520",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "Let\u2019s have a day where know one engages with the Fudders And watch them argue with there selves \ud83d\ude0a",
          "sentiment": 0.0,
          "engagement": "9,213",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-02-12T21:57:56.485733+00:00"
      },
      {
        "event_id": "SOCIAL-Today0932-Thornogs--7096394",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.599949",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "And on a day to day basis is there actually much new to talk about with Avacta? Tumbleweed City now until the next RNS, whatever that might be for.",
          "sentiment": 0.0,
          "engagement": "8,655",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-02-12T21:57:56.485751+00:00"
      },
      {
        "event_id": "SOCIAL-Today0924-wyndrum--1493485",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.600402",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "But Jane this was all caused by BV\u2019s non AVCT post. He deliberately provokes with his insults and lies. Non of this would have happened today without his non AVCT related post. Remember that would you",
          "sentiment": 0.0,
          "engagement": "12,217",
          "price_at_post": "54.00",
          "thread_title": "RE: Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-02-12T21:57:56.485769+00:00"
      },
      {
        "event_id": "SOCIAL-Today0918-Watching-17032035",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.601027",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "Let\u2019s have a day where know one engages with the Fudders And watch them argue with themselves \ud83d\ude2c",
          "sentiment": 0.0,
          "engagement": "9,213",
          "price_at_post": "54.00",
          "thread_title": "Do not engage",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=6CA6D871-5A29-4DE7-80D2-49A6C69A9D17"
        },
        "ingested_at": "2026-02-12T21:57:56.485788+00:00"
      },
      {
        "event_id": "SOCIAL-Today0917-pedrolan-41885718",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.601613",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "A seamless switch between users there Eggy Bravo",
          "sentiment": 0.0,
          "engagement": "1,972",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-12T21:57:56.485806+00:00"
      },
      {
        "event_id": "SOCIAL-Today0916-Thornogs-34575559",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.602292",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "To be fair Live account it's very easy to judge someone who repeatedly posts nonsense like you just have. And Pedro and BV joining in the: 'Look at us, we're idiots' gang.",
          "sentiment": 0.0,
          "engagement": "8,655",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-12T21:57:56.485823+00:00"
      },
      {
        "event_id": "SOCIAL-Today0902-wyndrum-10040425",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.603136",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "Sadly you have the memory of a goldfish but not its intellect. Again bv starts and contributes to the disruption. All we wait for now is the \u201cooh I can see all these green boxes\u201dposts add up my posts and add up all the rest and you quickly see who the paid disrupters are",
          "sentiment": 0.0,
          "engagement": "12,217",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-12T21:57:56.485842+00:00"
      },
      {
        "event_id": "SOCIAL-Today0859-BuenaVis--7120936",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.603939",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "\ud83e\udd14 Today's 'wyndrum' sounds even more petty and whiny than the 'Thornogson' account.",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-12T21:57:56.485859+00:00"
      },
      {
        "event_id": "SOCIAL-Today0858-pedrolan--7103691",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.604745",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "BV - he is doing it to fool us into thinking it is not one account. I nearly fell for it because I have the memory of a goldfish.",
          "sentiment": 0.5,
          "engagement": "1,972",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-12T21:57:56.485877+00:00"
      },
      {
        "event_id": "SOCIAL-Today0853-wyndrum--7240706",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.605571",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "It\u2019s snowing pretty hard here so it\u2019s not really the smoking gun you claim is it? Plus the fact you think I have multiple accounts only reinforces your mistaken analysis. (And see how many posts have been generated by bv These are the cause of the disruption. Not the posters who try to discuss the disconnect between AVCT results and the sp over the last 5 years",
          "sentiment": 0.0,
          "engagement": "12,217",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-12T21:57:56.485896+00:00"
      },
      {
        "event_id": "SOCIAL-Today0850-BuenaVis--3995310",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.606369",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Why is Thornogson/NDN/Eggy using the wyndrum account today?",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-12T21:57:56.485914+00:00"
      },
      {
        "event_id": "SOCIAL-Today0847-Livedata-39294853",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.607182",
        "source": "LSE_CHAT",
        "data": {
          "author": "Livedataaccount",
          "content": "With respect wyndrum its difficult not to judge someone who pretends to go on holiday and occasionally logs on with another alias replying to himself",
          "sentiment": 0.0,
          "engagement": "2,956",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-12T21:57:56.485931+00:00"
      },
      {
        "event_id": "SOCIAL-Today0835-BuenaVis-34226245",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.607959",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Wyn Shakespeare has swallowed a whole bag of question marks.",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-12T21:57:56.485949+00:00"
      },
      {
        "event_id": "SOCIAL-Today0831-pedrolan--4377863",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.608744",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Keep it up BV - people do need reminding. I see user Wyn Shakespeare is on the early shift.",
          "sentiment": 0.5,
          "engagement": "1,972",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-12T21:57:56.485967+00:00"
      },
      {
        "event_id": "SOCIAL-Today0826-wyndrum--6459749",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.609574",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "Thanks for reminding us dad, it must only be the 20th time you have posted this. Still at least your post s don\u2019t disrupt the board It\u2019s a great service you do, giving up your time to treat everyone here like morons by constantly reposting. Is it your new rule now that you must be shareholder to post and also be a genuine one at that? How do you intend to police your rules? Or is it just petty personal vendetta you are boring us all with?",
          "sentiment": 0.0,
          "engagement": "12,217",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-12T21:57:56.485986+00:00"
      },
      {
        "event_id": "SOCIAL-Today0750-BuenaVis-92016242",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:32.610363",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Just a reminder that Thornogson/NDN/Eggy isn't invested and is only here to argue, disrupt and try to waste our time.",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-12T21:57:56.486004+00:00"
      },
      {
        "event_id": "SOCIAL-Today0746-BuenaVis-19366561",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.904033",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Say what you see \ud83c\udf77\ud83c\udf77\ud83c\udf77",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "54.00",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-02-12T21:57:56.486021+00:00"
      },
      {
        "event_id": "SOCIAL-Today0733-Unbreade--4999289",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.904514",
        "source": "LSE_CHAT",
        "data": {
          "author": "Unbreaded",
          "content": "I love green boxes in the morning! Time for a coffee and catch up on the news.",
          "sentiment": 0.0,
          "engagement": "22",
          "price_at_post": "54.00",
          "thread_title": "Green Boes",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=F7E09828-40CF-45D7-8337-5F0A79C87685"
        },
        "ingested_at": "2026-02-12T21:57:56.486039+00:00"
      },
      {
        "event_id": "SOCIAL-Today0035-Thornogs--4898490",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.904967",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Sujood & Icecool. Similar content but I think ICE probably ahead on presentation. Both deeply underwater but talking a good game. Of course the SP matters, the only data that might be maturing is SGC 1b, which might secure a small deal. We've been told nothing about TNBC and STS is written off. We wait for FAP-EXD, we start again.",
          "sentiment": 0.0,
          "engagement": "8,655",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-12T21:57:56.486057+00:00"
      },
      {
        "event_id": "SOCIAL-Today0005-Toukanka-90281199",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.905422",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "Pivotal news in the Summer. Where have I heard that before? Oh yeah, it was me and I duly got panned by the Pom Pom girls for suggesting it would take thst long. \ud83e\udd23\ud83e\udd23\ud83e\udd23",
          "sentiment": 0.0,
          "engagement": "4,451",
          "price_at_post": "54.00",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-02-12T21:57:56.486075+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262359-Toukanka-18887063",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.905891",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "Work for ever????",
          "sentiment": 0.0,
          "engagement": "4,451",
          "price_at_post": "54.00",
          "thread_title": "RE: This will haunt you or please you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=8AE0FBBC-C14D-49F3-85C3-E6BED1BD66ED"
        },
        "ingested_at": "2026-02-12T21:57:56.486093+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262324-IFA90-54595858",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.906405",
        "source": "LSE_CHAT",
        "data": {
          "author": "IFA90",
          "content": "Thanks Andy",
          "sentiment": 0.0,
          "engagement": "408",
          "price_at_post": "54.00",
          "thread_title": "RE: This will haunt you or please you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=8AE0FBBC-C14D-49F3-85C3-E6BED1BD66ED"
        },
        "ingested_at": "2026-02-12T21:57:56.486129+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262322-BuenaVis-84751740",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.906824",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Thanks Thompi",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-12T21:57:56.486148+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262302-Sujood--5228015",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.907374",
        "source": "LSE_CHAT",
        "data": {
          "author": "Sujood",
          "content": "A multi billion dollar company in the making. It will haunt you if you dont position yourself Will please you, if you do the write thing. Learn about the company and do what you know is the right move to make. Nobody every wants to work forever. Keep this message We will talk again soon.",
          "sentiment": 0.5,
          "engagement": "1,260",
          "price_at_post": "54.00",
          "thread_title": "This will haunt you or please you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=8AE0FBBC-C14D-49F3-85C3-E6BED1BD66ED"
        },
        "ingested_at": "2026-02-12T21:57:56.486166+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262258-Icecool--8113660",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.907813",
        "source": "LSE_CHAT",
        "data": {
          "author": "Icecool",
          "content": "Commercial deals will come, and they\u2019ll be welcomed when they do. I\u2019m not in a rush though. If the data continues to strengthen and Avacta can leverage that science into materially better terms, I\u2019m perfectly happy for it to take longer. Time spent increasing leverage isn\u2019t wasted time, it\u2019s how you avoid bad deals and maximise value. \ud83d\ude0a Waiting could be the difference between a few billion and tens of billions. \ud83d\ude0a\ud83e\udd14",
          "sentiment": 0.0,
          "engagement": "8,824",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-12T21:57:56.486185+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262250-Thompi--1599374",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.908255",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thompi",
          "content": "You may find BV this tweet on X interesting on AVA6103 and BOIN design. AND https://x.com/sandyradders/status/2012950578595258664?s=61&t=BBb2UcjLDTXOFIzJM-vM6A",
          "sentiment": 0.0,
          "engagement": "1,357",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-12T21:57:56.486203+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262144-Knotagai--8260966",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.908887",
        "source": "LSE_CHAT",
        "data": {
          "author": "Knotagain",
          "content": "We're all fixated on the SP Icecool, it's just a matter of time frames. I've been invested for over five years and would love to see  some commercial news. Nothing wrong with that.",
          "sentiment": 0.0,
          "engagement": "451",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-12T21:57:56.486221+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262118-Icecool--5833761",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.909330",
        "source": "LSE_CHAT",
        "data": {
          "author": "Icecool",
          "content": "That\u2019s only a concern if you\u2019re fixated on the SP. AIM has never been able to price Avacta properly and it won\u2019t until there\u2019s either a takeover (and suspension) or a move to a serious exchange. The day to day price action is noise. What actually matters is what\u2019s happening behind the scenes with the science, the data, and the strategic discussions. That\u2019s where the real value is being built. \ud83d\udcaf\ud83d\udc4d",
          "sentiment": 0.0,
          "engagement": "8,824",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-12T21:57:56.486241+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262058-Knotagai-55618075",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.909883",
        "source": "LSE_CHAT",
        "data": {
          "author": "Knotagain",
          "content": "Totally agree Icecool, but only third party validation will move the share price. Hopefully it will happen sometime soon.",
          "sentiment": 0.0,
          "engagement": "451",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-12T21:57:56.486259+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20262032-Icecool-31223033",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.910560",
        "source": "LSE_CHAT",
        "data": {
          "author": "Icecool",
          "content": "The FDA won\u2019t drag this out. AVA6000 proved the platform in humans, AVA6103 builds on that. Phase 1 is about safety and speed. This trial is designed to surface signals quickly with regulatory alignment, not waste years. AVA6000 data will have done a load of heavy lifting already.",
          "sentiment": 0.0,
          "engagement": "8,824",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-12T21:57:56.486277+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261954-BuenaVis-58929427",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.910984",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "I've got to say I was concerned that the AVA6103 trial with such a toxic agent as exatecan would start at a very low dose and take a long, long time if the step increases were to mimic those in the AVA6000 trial (seven dose levels! - three steps of 40 from 80 to 200, and then three 25% increases to 385) so very pleased to hear about all the benefits of the BOIN design.",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-12T21:57:56.486296+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261946-Icecool--2765744",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.911503",
        "source": "LSE_CHAT",
        "data": {
          "author": "Icecool",
          "content": "I would also point out that when Thorn bought in he\u2019s also a mega ramping twat!!! Flip/Flop. \ud83d\udcaf\ud83e\udd23\ud83e\udd23 best on filter \ud83d\udc4d",
          "sentiment": 0.0,
          "engagement": "8,824",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-12T21:57:56.486314+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261937-HarChris-27682749",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.912044",
        "source": "LSE_CHAT",
        "data": {
          "author": "HarChris",
          "content": "Going back to the trial design I thought this overview could be useful: Key Comparisons Accuracy in MTD Selection: BOIN generally outperforms 3+3 by more accurately identifying the true MTD. In simulations across various scenarios BOIN achieves a 12-16% higher percentage of correct selection (PCS) of the MTD, and in cases where the MTD is at higher doses, it can nearly triple the PCS compared to 3+3. Efficiency and Patient Allocation: BOIN is more efficient, often resulting in shorter trial durations and lower costs by adapting in real-time and allocating more patients to the MTD (especially at higher doses or with higher target DLT rates). The 3+3 design can prolong trials due to its conservative escalation and fixed cohort requirements, leading to fewer patients treated at effective doses. Safety and Risk Management: While 3+3 minimizes overdose risk by being overly cautious (e.g., lower chance of assigning >60% of patients above the MTD), it increases under-dosing, where many patients receive suboptimal doses. BOIN balances this better with built-in overdose controls and dynamic adjustments, reducing under-dosing without significantly raising overdose risks, thus improving ethical standards by minimising patient exposure to ineffective or overly toxic doses. Simplicity and Flexibility: Both are relatively easy to implement\u2014BOIN requires no complex programming or simulations beyond basic setup, making it accessible like 3+3. However, BOIN offers more flexibility, such as variable cohort sizes (e.g., 4 patients) and adjustable target toxicity rates, whereas 3+3 is fixed to cohorts of 3 (or 3+3) and standard targets. In summary, BOIN represents an evolution over 3+3, providing better performance across most metrics while maintaining ease of use. The 3+3 design is still widely used for its familiarity and safety focus in conservative settings but is increasingly seen as outdated for not fully utilising trial data.",
          "sentiment": 0.0,
          "engagement": "15,865",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-12T21:57:56.486333+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261812-Cashless-69327171",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.912567",
        "source": "LSE_CHAT",
        "data": {
          "author": "Cashless",
          "content": "Been out all day, so just logged on.....and what a pleasure to see a sea of green and pretty much all informative posts...I LOVE GREEN...not sure the green people are so happy though \ud83d\udc4d\ud83e\udd2a\ud83e\udd2a\ud83e\udd73",
          "sentiment": 0.5,
          "engagement": "401",
          "price_at_post": "54.00",
          "thread_title": "Bliss",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=E431AF8E-57C8-40B5-91C6-8D284968B368"
        },
        "ingested_at": "2026-02-12T21:57:56.486351+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261753-B2HS2L--8659563",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.913172",
        "source": "LSE_CHAT",
        "data": {
          "author": "B2HS2L",
          "content": "FWIW Google search What is the difference between event free and progression free survival AI Overview: Progression-Free Survival (PFS) measures the time from treatment initiation until objective tumor growth or death from any cause. Event-Free Survival (EFS) measures the time from randomization until a broader range of \"events,\" including disease progression, treatment failure, complications, or death. PFS focuses on tumor growth; EFS focuses on any negative outcome. Key Differences: Definition of Event: PFS is restricted to disease progression or death. EFS includes those, plus failure to proceed to planned surgery, relapse, or severe treatment complications. Context of Use: PFS is commonly used in advanced or metastatic cancer trials to evaluate treatment efficacy. EFS is frequently used in earlier-stage cancer trials, particularly in the neoadjuvant (pre-surgery) setting. Precision: PFS depends on the frequency of imaging scans to detect growth, while EFS is often defined by the time until a patient cannot proceed with their treatment plan. Essentially, PFS means the cancer has not worsened, whereas EFS means the patient has not experienced any negative, pre-defined event.",
          "sentiment": 0.0,
          "engagement": "6,000",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-12T21:57:56.486369+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261428-BuenaVis-33961197",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.913661",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "What is the current best progression free survival rate for TNBC? https://www.google.com/search?q=What+is+the+current+best+progression+free+survival+rate+for+TNBC%253F",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "54.00",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-12T21:57:56.486387+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261424-HarChris-69928548",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.914093",
        "source": "LSE_CHAT",
        "data": {
          "author": "HarChris",
          "content": "It's what happened to STS and might now happen with TNBC, might not of course, but if it did then it'll all fall to SGC to carry the load until FAP-EXD starts to produce meaningful data. __________________ In other words IF TNBC data doesn't deliver then SGC might have to carry the load until H2 2026? That's not bad as a worst case and it's very short term as it gets for biotech. And with the less risk averse and far more efficient BOIN design for 6103 we should start receiving compelling data rapidly if all is going well. It's close!",
          "sentiment": 0.0,
          "engagement": "15,865",
          "price_at_post": "54.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-12T21:57:56.486406+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261411-Thornogs--4064159",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.914533",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "No well spotted!  My bad.",
          "sentiment": 0.0,
          "engagement": "8,655",
          "price_at_post": "54.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-12T21:57:56.486423+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261409-BuenaVis-25541768",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.915065",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "I may be missing something here but trastuzumab deruxtecan (brand name Enhertu) and pertuzumab are both used to treat HER2-positive breast cancer.  So what has that got to do with TNBC which is an aggressive, fast-growing type of breast cancer that tests negative for three key receptors: estrogen (ER), progesterone (PR), and HER2?",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "54.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-12T21:57:56.486441+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261349-Thornogs-91788560",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.915517",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "'....FAP-DOX needs to beat.'",
          "sentiment": 0.0,
          "engagement": "8,655",
          "price_at_post": "54.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-12T21:57:56.486459+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261347-Thornogs-42781100",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:37.915945",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "But clearly relevent so clearly won't be mentioned by anyone else Watching? Obviously important if it's doubled the PFS times for TNBC, the bar has been raised as to what FAP-EXD needs to beat. It's what happened to STS and might now happen with TNBC, might not of course, but if it did then it'll all fall to SGC to carry the load until FAP-EXD starts to produce meaningful data.",
          "sentiment": 0.0,
          "engagement": "8,655",
          "price_at_post": "54.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-12T21:57:56.486477+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261347-pedrolan-60740658",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.837882",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Just a reminder that Thorn is not invested but spends his sad life on here posting negative comments about a company saving lives. What a guy!!!",
          "sentiment": 0.5,
          "engagement": "1,972",
          "price_at_post": "54.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-12T21:57:56.486495+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261339-Watching-75064457",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.838382",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "You Still have to focus on negatives. Thorny you are such a k n o bby \ud83e\udd21\ud83e\udd21",
          "sentiment": 0.0,
          "engagement": "9,213",
          "price_at_post": "54.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-12T21:57:56.486514+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261335-Thornogs-44818644",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.838824",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "It's perhaps double edged though? The AVA6000 STS trial was (allegedly) de-railed by a trial that showed longer, and better than expected, survival data. If there's a new 'Standard of Care' being announced for TNBC the bar might just have been raised on what FAP-DOX/TNBC needs to achieve to get a deal and get to market?",
          "sentiment": 0.0,
          "engagement": "8,655",
          "price_at_post": "55.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-12T21:57:56.486532+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261315-LovableL-62495879",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.839268",
        "source": "LSE_CHAT",
        "data": {
          "author": "LovableLumax",
          "content": "Https://x.com/onclive/status/2016451178872061994?s=46",
          "sentiment": 0.0,
          "engagement": "2,703",
          "price_at_post": "55.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-12T21:57:56.486550+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261053-Aldebara--6069804",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.839705",
        "source": "LSE_CHAT",
        "data": {
          "author": "Aldebaran",
          "content": "I think small caps are at the very start of a major bull run. Green portfolio everywhere across the board. Also note that even with hard times, avacta raised 16m through zeus at only 8% discount plus managed to delay and renegotiate the terms of the bond. No mean feat that and the macro picture for small caps has improved since then. As has our IP and data package plus the deadline for BP patent expiry has only become closer. Things nowhere near as desperate as this shhhhh it tee little market gives credit for. I mean avacta have developed the worlds first dual warhead peptide drug conjugate ffs . \ud83d\ude05",
          "sentiment": 0.0,
          "engagement": "3,894",
          "price_at_post": "55.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-12T21:57:56.486568+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261050-opti_mys--8026401",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.840239",
        "source": "LSE_CHAT",
        "data": {
          "author": "opti_mystic",
          "content": "I think that's optimistic Lovable being as the initial doses will be very low. It is a safety trial initially remember, but the trial design (BOIN) will allow for dose escalation quite quickly and also potentially skipping from say dose level one to does level 3. I think more realistically summer months we may start to see some useful efficacy. What they will know sooner is are there any problems/does it works as expected and designed. If no bad news by May/June I think we're on a winner. I expect it to work.",
          "sentiment": 0.0,
          "engagement": "296",
          "price_at_post": "55.50",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-02-12T21:57:56.486587+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261045-Sisyphus-88835539",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.840667",
        "source": "LSE_CHAT",
        "data": {
          "author": "SisyphusShorter",
          "content": "Out of coincidence it's been exactly a week since the last RNS regarding AVA6103. Could an announcement be due imminently?",
          "sentiment": 0.0,
          "engagement": "4",
          "price_at_post": "55.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-12T21:57:56.486605+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261014-HarChris-64050679",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.841093",
        "source": "LSE_CHAT",
        "data": {
          "author": "HarChris",
          "content": "I wonder if those solely focused on Avacta and thinking history always repeats are missing the fact that the AIM backdrop plays a major role here. And in that regard liquidity has returned to UK small caps with a vengeance, raises are happening without the sort of discounts seen in 2022/23/24/25, companies are seeing major share price appreciation actually hold rather than the wild swings of post Covid. It\u2019s a far healthier backdrop right now than at any point since I\u2019ve held Avacta shares.",
          "sentiment": 0.0,
          "engagement": "15,865",
          "price_at_post": "55.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-12T21:57:56.486623+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261003-harryhot-58632834",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.841536",
        "source": "LSE_CHAT",
        "data": {
          "author": "harryhotspur1311",
          "content": "I was hoping for the big erection shape although roundish bottoms are quite welcome as well!",
          "sentiment": 0.0,
          "engagement": "12",
          "price_at_post": "55.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-12T21:57:56.486642+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260958-A1invest-59094007",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.841950",
        "source": "LSE_CHAT",
        "data": {
          "author": "A1invest",
          "content": "Lets hope its a \"rounding bottom\" shape.  :)",
          "sentiment": 0.0,
          "engagement": "143",
          "price_at_post": "55.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-12T21:57:56.486660+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260953-pedrolan--9029398",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.842525",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Salty for sure",
          "sentiment": 0.0,
          "engagement": "1,972",
          "price_at_post": "55.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-12T21:57:56.486678+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260945-Thornogs--8119423",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.843025",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "\"Salt and vinegar on that sir?\"",
          "sentiment": 0.0,
          "engagement": "8,655",
          "price_at_post": "55.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-12T21:57:56.486696+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260944-Timster-75464660",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.843502",
        "source": "LSE_CHAT",
        "data": {
          "author": "Timster",
          "content": "Big fish, little fish, cardboard box....",
          "sentiment": 0.0,
          "engagement": "20,625",
          "price_at_post": "55.50",
          "thread_title": "RE: Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-12T21:57:56.486714+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260941-harryhot--5763333",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.844130",
        "source": "LSE_CHAT",
        "data": {
          "author": "harryhotspur1311",
          "content": "Whenever the SP drops, the pessimists always quote \u2018the market knows\u2019 Perhaps this could work the other way around occasionally! Today, perhaps!",
          "sentiment": 0.0,
          "engagement": "12",
          "price_at_post": "56.00",
          "thread_title": "Some big shapes this morning\u2026..at last!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=247E997E-ED32-479E-9488-96FD0904953B"
        },
        "ingested_at": "2026-02-12T21:57:56.486732+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260823-pedrolan-26542153",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.844561",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Ah yes, I knew I had been there but couldn't remember exactly which Lake \ud83e\udd23",
          "sentiment": 0.5,
          "engagement": "1,972",
          "price_at_post": "52.50",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-02-12T21:57:56.486750+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260726-Gingethe--1793100",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.844978",
        "source": "LSE_CHAT",
        "data": {
          "author": "GingetheWinge",
          "content": "Derwent valley dam in the Peak District.",
          "sentiment": 0.5,
          "engagement": "699",
          "price_at_post": "53.00",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-02-12T21:57:56.486768+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260713-LovableL-77385207",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.845409",
        "source": "LSE_CHAT",
        "data": {
          "author": "LovableLumax",
          "content": "I also suspect we will have a 6000 partner signed up once we have an approved accelerated pathway and registrations P2\\3 with FDA which is hopefully imminent",
          "sentiment": 0.0,
          "engagement": "2,703",
          "price_at_post": "53.00",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-02-12T21:57:56.486787+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260703-LovableL--2932437",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.845829",
        "source": "LSE_CHAT",
        "data": {
          "author": "LovableLumax",
          "content": "Given how potent the payload is and with the improved half-life and active in the TME for 5 days surely they'll see results as early as scan 1. That sounds rampy and too optimistic but look at the preclinical results. Things could really take off as early as the summer, or even before. Again, I suspect recruitment will be fairly rapid given FAP targeting with preCISION proven and preclinical results so investigators likely chomping at the bit.",
          "sentiment": 0.0,
          "engagement": "2,703",
          "price_at_post": "53.00",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-02-12T21:57:56.486805+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260659-nurseste--6966963",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.846277",
        "source": "LSE_CHAT",
        "data": {
          "author": "nursesteve",
          "content": "CC discussing FAP-Exd (AVA6103) - The profile of this second pre|CISION medicine in the preclinical setting is tremendous.  The sustained release mechanism developed by Avacta scientists results in a robust concentration of active drug in the tumor over five days with the disappearance from the bloodstream in only two hours. This is the exact profile needed to achieve better efficacy with this highly potent topo I inhibitor. Could payoff for LTH be this year?",
          "sentiment": 0.0,
          "engagement": "1,164",
          "price_at_post": "53.00",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-02-12T21:57:56.486823+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260006-D-Geeman--2797902",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.846690",
        "source": "LSE_CHAT",
        "data": {
          "author": "D-Geeman",
          "content": "An elderly character actor in our road, when I first arrived,  was in the movie \u2018The Dambusters\u2019, and in \u2018Bridge on the River Kwai\u2019. He used to tell some good stories of life on 1950\u2019s film sets. Dead for a while but he pops up on screen even now.",
          "sentiment": 0.0,
          "engagement": "5,844",
          "price_at_post": "52.50",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-02-12T21:57:56.486841+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20262319-pedrolan-43948709",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.847122",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Yes, it's an inspirational story. I think they tested it up in the Lake District",
          "sentiment": 0.5,
          "engagement": "1,972",
          "price_at_post": "52.50",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-02-12T21:57:56.486859+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20262113-Captains--7785789",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.847541",
        "source": "LSE_CHAT",
        "data": {
          "author": "Captainstanley.",
          "content": "I can't find that information anywhere Which Friday? Presumably you mean this week 29th Jan?",
          "sentiment": 0.0,
          "engagement": "467",
          "price_at_post": "52.50",
          "thread_title": "RE: SGC",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=5E3142A3-349A-43A2-B5B7-02836561174A"
        },
        "ingested_at": "2026-02-12T21:57:56.486877+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20262014-Flippine--2124037",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.847977",
        "source": "LSE_CHAT",
        "data": {
          "author": "Flippineck",
          "content": "I\u2019ve been thinking about the trials and tribulations of developing new inventions and ended up swotting up on Barnes Wallace, the inventor of the famous Bouncing Bomb. It seems initial proposals were dismissed by Bomber Command as being \u201c a mad-cap scheme\u201d. There were several critical failures in the development which had to be overcome. The shape of the bomb had to be changed, backspin had to be introduced, the weapon would shatter, sink or detonate prematurely or veer off course. Barnes Wallace persevered and it all came good in the end.",
          "sentiment": 0.0,
          "engagement": "417",
          "price_at_post": "52.50",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-02-12T21:57:56.486895+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261912-BuenaVis-58304820",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.848415",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Christina Coughlin became the CEO of Avacta on 1 May 2024. There is no need to dwell on anything or anyone before that date. CC has set out the company's objectives and timelines and has stuck to them, as much as is possible taking outside decision-making and events into account.  This adherence to the company's aims and plans comes about because she is a pharma executive with ample of experience of drug development and the way the FDA works.",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "52.50",
          "thread_title": "RE: Avacta -  re-inventing  itself",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=D3FD9CFE-9EEC-40CC-9167-65CB380D8D74"
        },
        "ingested_at": "2026-02-12T21:57:56.486914+00:00"
      },
      {
        "event_id": "SOCIAL-27Jan20261900-BuenaVis--8861258",
        "event_type": "social_post",
        "date": "2026-01-29T12:41:41.848907",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "As Runner-Runner wrote... It's simple. 1. DO NOT ENGAGE 2. DO NOT ASK IT A QUESTION 3. DO NOT ANSWER ITS QUESTIONS 4. DO NOT MOAN ABOUT ITS POSTS 5. DO NOT ARGUE WITH IT 6. If you must do something. Mock it with reference only to its stupidity and nothing else. ------------------------------------------------------ If you're not part of the solution, you're part of the problem",
          "sentiment": 0.0,
          "engagement": "5,764",
          "price_at_post": "52.50",
          "thread_title": "RE: Year end trading update :",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&share=AVCT&thread=CCFE6866-0D3C-4A1E-9659-9B2E552262F5"
        },
        "ingested_at": "2026-02-12T21:57:56.486932+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20262219-Thornogs--5133878",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.801399",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Anything new there? 'Expected' Q1? No, nothing new, just 'same old'.",
          "sentiment": 0.0,
          "engagement": "8,596",
          "price_at_post": "54.50",
          "thread_title": "RE: Bioconjugate Insights",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0DCD83D9-A17D-43E1-842E-1C922D520A76"
        },
        "ingested_at": "2026-02-12T21:57:56.486950+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20262212-avctIPma--5307308",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.801859",
        "source": "LSE_CHAT",
        "data": {
          "author": "avctIPmatters",
          "content": "Again courtesy of Stonks -  Finds  new coverage  Avacta related   many thanks . https://cdn.insights.bio/uploads/attachments/BCI%20Industry%20Insights.pdfAvacta Therapeutics reported new preclinical pharmacology data for FAP-Exd peptide drug conjugate [25] \"Avacta Therapeutics announced new preclinical pharmacology data for FAP-Exd (AVA6103), its second asset derived from the pre|CISION\u00ae tumor-activated delivery platform, which is expected to enter Phase 1 testing in Q1 2026. FAP-Exd is a fibroblast activation protein\u2013cleavable peptide-drug linking a proprietary peptide to a topoisomerase I inhibitor payload. The data demonstrated tumor-specific cytotoxicity, sustained intratumoral release of active exatecan with limited systemic exposure, and robust antitumor activity across multiple patient-derived xenograft models. Avacta also reported that artificial intelligence\u2013guided analysis was used to prioritize clinical indications based on co-expression of FAP and SLFN11.\" Gmcc",
          "sentiment": 0.0,
          "engagement": "720",
          "price_at_post": "54.50",
          "thread_title": "Bioconjugate Insights",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0DCD83D9-A17D-43E1-842E-1C922D520A76"
        },
        "ingested_at": "2026-02-12T21:57:56.486969+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20262210-Thornogs-77884893",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.802303",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Avacta does its thing regardless of what's posted here. Get over yourselves, self appointed \"Guardian's of the truth\"! And if you must wear your underpants on the outside do at least please ensure that  they're better laundered?",
          "sentiment": 0.0,
          "engagement": "8,596",
          "price_at_post": "54.50",
          "thread_title": "The reality?",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=D8CC0643-0047-4DA0-A21A-3E0ECC3BD17C"
        },
        "ingested_at": "2026-02-12T21:57:56.486987+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20262154-BuenaVis--9228164",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.802718",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "I had Firefox nicely set up with AdBlock so that all ads were wiped out but had to 'repair' Firefox today (as tabs were crashing) and then reload an AdBlock extension but I now keep getting these annoying messages from LSE about ads that I never used to get.  Can't remember what I did before to permanently remove those messages.  Can anyone offer advice on how they've solved this?",
          "sentiment": 0.0,
          "engagement": "5,722",
          "price_at_post": "54.50",
          "thread_title": "Off-topic - removing ads on Firefox",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=9BE707F4-9555-444A-A3C8-1254E00A3443"
        },
        "ingested_at": "2026-02-12T21:57:56.487004+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20262109-Knotagai-12060600",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.803142",
        "source": "LSE_CHAT",
        "data": {
          "author": "Knotagain",
          "content": "All day every day...",
          "sentiment": 0.0,
          "engagement": "448",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-02-12T21:57:56.487023+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261944-Agenda10-62697663",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.803559",
        "source": "LSE_CHAT",
        "data": {
          "author": "Agenda101",
          "content": "Brilliant! The never ending Twats.. they are all green boxed here\u2026 But I\u2019m hearing you Sheepy! Exactly right.",
          "sentiment": 0.0,
          "engagement": "55",
          "price_at_post": "54.50",
          "thread_title": "RE: Frankly pathetic",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B36E2695-D07A-4E60-838B-02C995994856"
        },
        "ingested_at": "2026-02-12T21:57:56.487041+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261943-BuenaVis-73755013",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.803971",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "Lighten up Thompi.  It's the best comedy show in town.",
          "sentiment": 0.0,
          "engagement": "5,722",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-02-12T21:57:56.487059+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261940-Thompi--7998203",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.804413",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thompi",
          "content": "Because, Touk, Thorn talks total twaddle and inundates this board with spam. It\u2019s made the board virtually unreadable. Even blocking him doesn\u2019t really help, because all I then see are green boxes and other people replying to his posts. I probably add to the noise at times too - but I\u2019ve genuinely had enough of one person commandeering the board with the same malicious rubbish, day after day. Post after post after post. It wears people down. It stops being discussion and just becomes disruption.",
          "sentiment": 0.0,
          "engagement": "1,355",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-02-12T21:57:56.487078+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261848-Toukanka-37301745",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.804832",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "Cj62 How can it be utter garbage when it\u2019s generally been predicting what is happening to Avacta. But the pond poms utter garbage of \u201ctakeover tomorrow \u201c, \u201cmarket thick as mince\u201d etc etc ad infinitum even though they\u2019ve been entirely wrong for years. Well that\u2019s fine clogging up the board with that garbage",
          "sentiment": 0.0,
          "engagement": "4,436",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-02-12T21:57:56.487104+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261845-BuenaVis-36193607",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.805254",
        "source": "LSE_CHAT",
        "data": {
          "author": "BuenaVista",
          "content": "6am to midnight but with a two hour evening break to neck a bottle of whisky.",
          "sentiment": 0.0,
          "engagement": "5,722",
          "price_at_post": "54.50",
          "thread_title": "RE: Frankly pathetic",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B36E2695-D07A-4E60-838B-02C995994856"
        },
        "ingested_at": "2026-02-12T21:57:56.487136+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261844-Toukanka-73893121",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.805661",
        "source": "LSE_CHAT",
        "data": {
          "author": "Toukankahmoon",
          "content": "You\u2019re right Thompi. You never do say much more than joining your mates and flinging the insults. Why not talk about Avacta rather the other posters on here?",
          "sentiment": 0.0,
          "engagement": "4,436",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-02-12T21:57:56.487155+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261841-sheppy--7225909",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.806079",
        "source": "LSE_CHAT",
        "data": {
          "author": "sheppy",
          "content": "Wyn, Thorn, Touk , DG same poster numerous aliases. Hourly paid hired help disrupter. Regardless of that what sort of sad, moronic halfwit would spend 7 days a week starting each day at 6 am and continuing after midnight posting negative comments about a share they are allegedly not invested in? Regardless of their reason what a total waste of one\u2019s life on this earth . What a pathetic pitiful existence arguing with anonymous people on an anonymous bb. I actually pity their sad, lonely unfulfilled existence. And before the poster tells me they live a very fulfilled life doing lots of other meaningful things ask yourself how this is possible with so many never ending  daily boring transparent attempts at disruption. Sad twat and a weirdo",
          "sentiment": 0.0,
          "engagement": "563",
          "price_at_post": "54.50",
          "thread_title": "Frankly pathetic",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=B36E2695-D07A-4E60-838B-02C995994856"
        },
        "ingested_at": "2026-02-12T21:57:56.487173+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261831-cj62--8612246",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.806499",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "Anything you post Thorn is utter garbage. How many crayons have you done today ?",
          "sentiment": 0.0,
          "engagement": "4,270",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-02-12T21:57:56.487191+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261820-Thornogs--1530678",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.806924",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "And what did you say? Anything worth hearing? Anything about Avacta and what's going well and what isn't and thoughts about why? No, thought not. Shame.",
          "sentiment": 0.0,
          "engagement": "8,596",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-02-12T21:57:56.487210+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261755-Thompi-46028515",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.807357",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thompi",
          "content": "Pedro, if I add your 67 posts over the last 30 days to my 20, plus Tim\u2019s 43 and Watching\u2019s 39, the grand combined total is 169 posts. That\u2019s four people combined. Compared to Thorn\u2019s 253 posts on his own. The figures speak for themselves.",
          "sentiment": 0.0,
          "engagement": "1,355",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-02-12T21:57:56.487228+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261754-wyndrum-20468335",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.807774",
        "source": "LSE_CHAT",
        "data": {
          "author": "wyndrum",
          "content": "And i see my requests to get NFT to respond have been deleted but the insults to me remain. But yes, its the LSE moderators allowing me to post that is the problem here. Where are you NFT, want to answer my queries so you can justify the remarks in your post?",
          "sentiment": 0.0,
          "engagement": "12,198",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-02-12T21:57:56.487247+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261737-pedrolan-66288184",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.808191",
        "source": "LSE_CHAT",
        "data": {
          "author": "pedrolancaster",
          "content": "Make that 29 to go",
          "sentiment": 0.0,
          "engagement": "1,948",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-02-12T21:57:56.487266+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261719-Thompi-87716438",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.808620",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thompi",
          "content": "Avacta posts over the last 30 days: 253 Thorn \ud83e\udd47 43 Timster 39 Watching Not much else to say really Thorn.",
          "sentiment": 0.0,
          "engagement": "1,355",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-02-12T21:57:56.487284+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261708-Thornogs-13563229",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.809052",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "And the two posters below your post Thompi? Watching 9,000 and Tim 20,000! All on only Avacta and all 100% content free 'jokes' or 'bile'. But to comment on that would be to show a consistent approach to this sort of thing wouldn't it? Be honest, it's not the number or posts, it's the fact that you might have to consider things that you don't want to consider. Fine, your choice, 5 years in and AVA6000 limping along to a possible low-ball deal and FAP-EXD entering the 'Last Chance Saloon' in the next 2-3 months. Everything that you've been predicting for the last 5 years, why would you need to hear a contrary opinion when you've clearly been smashing it all this time? Well up I dare say on your investment are we?",
          "sentiment": 0.0,
          "engagement": "8,596",
          "price_at_post": "54.00",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-02-12T21:57:56.487302+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261644-Thompi-80992053",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.809483",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thompi",
          "content": "To be fair Tim, Thorn\u2019s only posted 11 times so far today. He\u2019s got another 30 to go before he equals his personal best of 41 posts in 24 hours. By my reckoning, if he manages around 4.3 posts per hour between now and midnight (17:00\u201312:00am), he might just be in with a chance of beating it. Bless his selfless little heart.",
          "sentiment": 0.0,
          "engagement": "1,355",
          "price_at_post": "54.50",
          "thread_title": "RE: To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-02-12T21:57:56.487320+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261537-Watching-13298222",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.809893",
        "source": "LSE_CHAT",
        "data": {
          "author": "Watching2",
          "content": "24/7. He keeps churning out verbal \ud83d\udca9",
          "sentiment": 0.0,
          "engagement": "9,201",
          "price_at_post": "54.50",
          "thread_title": "RE: CC interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=F5A9F3B7-45F7-4EC2-B1FD-1ACB3A2D2E18"
        },
        "ingested_at": "2026-02-12T21:57:56.487339+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261535-Timster-12060600",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.810318",
        "source": "LSE_CHAT",
        "data": {
          "author": "Timster",
          "content": "All day every day...",
          "sentiment": 0.0,
          "engagement": "20,620",
          "price_at_post": "54.50",
          "thread_title": "To me.... To you",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=0CB8CB58-8A53-4243-86D8-2ED658317655"
        },
        "ingested_at": "2026-02-12T21:57:56.487357+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261529-cj62--4886568",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.810731",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "Shall we have a 'Spot the idiot' competition? You win it thorn, no competition !!!",
          "sentiment": 0.0,
          "engagement": "4,270",
          "price_at_post": "54.50",
          "thread_title": "RE: CC interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=F5A9F3B7-45F7-4EC2-B1FD-1ACB3A2D2E18"
        },
        "ingested_at": "2026-02-12T21:57:56.487376+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261517-Thornogs-35143582",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.811159",
        "source": "LSE_CHAT",
        "data": {
          "author": "Thornogson",
          "content": "Of course we don't BV, and the industry experts who know these things currently value Avacta at 50 odd pence a share. NFT and the 28 odd who ticked up his posts think \u00a328 is more accurate. Shall we have a 'Spot the idiot' competition?",
          "sentiment": 0.0,
          "engagement": "8,596",
          "price_at_post": "54.50",
          "thread_title": "RE: CC interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=F5A9F3B7-45F7-4EC2-B1FD-1ACB3A2D2E18"
        },
        "ingested_at": "2026-02-12T21:57:56.487394+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261515-cj62-40949442",
        "event_type": "social_post",
        "date": "2026-01-24T02:51:17.811569",
        "source": "LSE_CHAT",
        "data": {
          "author": "cj62",
          "content": "That's theoretical of course. Thorn its like 99% of the other gibberish you post twat.",
          "sentiment": 0.0,
          "engagement": "4,270",
          "price_at_post": "54.50",
          "thread_title": "RE: CC interview",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=AVCT&thread=F5A9F3B7-45F7-4EC2-B1FD-1ACB3A2D2E18"
        },
        "ingested_at": "2026-02-12T21:57:56.487412+00:00"
      }
    ],
    "catalyst_dates": {
      "proxy_date": "2023-02-08"
    }
  },
  "ai_insights": {
    "available": false,
    "reason": "LLM module not loaded or analysis failed"
  },
  "crashdash": {
    "industry_intelligence": {
      "category": "BIOTECH_PHARMA",
      "name": "Biotech & Pharma",
      "icon": "\ud83e\uddec",
      "color": "#10b981",
      "crash_patterns": [
        "Clinical trial failures (Phase 1/2/3)",
        "FDA/EMA rejection or delay",
        "Safety concerns or adverse events",
        "Patent expiry or IP challenges",
        "Funding gaps (cash runway concerns)"
      ],
      "recovery_paths": [
        "Positive trial data (efficacy endpoints met)",
        "Regulatory approvals (FDA/EMA)",
        "Partnership deals (big pharma licensing)",
        "Orphan drug designation or fast track",
        "New trial initiations (pipeline expansion)"
      ],
      "active_patterns": [
        "Clinical trial failures (Phase 1/2/3)",
        "FDA/EMA rejection or delay",
        "Patent expiry or IP challenges"
      ],
      "relevant_rns_count": 2,
      "key_metrics": [
        "Clinical stage (preclinical, Phase 1/2/3, commercialized)",
        "Cash runway (months until next funding)",
        "Addressable market size (indication)",
        "Trial enrollment progress",
        "Intellectual property strength"
      ]
    },
    "panic_analysis": {
      "panic_score": 39.8,
      "signal": "MILD_CONCERN",
      "interpretation": "\ud83d\udfe2 Normal volatility - not a crash signal",
      "breakdown": {
        "price_destruction": 13.8,
        "volume_death": 10,
        "social_silence": 6,
        "news_sentiment": 10
      },
      "is_opportunity": false,
      "opportunity_reason": "\ud83d\ude10 Normal market conditions - no crash signal"
    },
    "fear_vs_facts": {
      "fear_points": [],
      "facts_points": [
        "\ud83d\udcc8 Historical upside: 263% proven capacity",
        "\ud83d\udd04 Pattern reliability: 8 previous rallies"
      ],
      "verdict": "\u2705 Facts align with low fear - Normal risk/reward"
    },
    "crashhunter_signals": [
      {
        "type": "BUILDING",
        "icon": "\ud83d\udcca",
        "text": "Building",
        "color": "#10b981"
      },
      {
        "type": "MODERATE_QUALITY",
        "icon": "\ud83c\udf1f",
        "text": "APEX 61",
        "color": "#3b82f6"
      }
    ],
    "catalyst_pipeline": [
      {
        "type": "rns",
        "date": "Unknown",
        "title": "Appointment of CSO",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "rns",
        "date": "Unknown",
        "title": "Faridoxorubicin Program Clinical Updates",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "rns",
        "date": "Unknown",
        "title": "FDA Clearance of IND Application for AVA6103",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "rns",
        "date": "Unknown",
        "title": "Year-end trading update",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "rns",
        "date": "Unknown",
        "title": "Appointment of Nominated Adviser & TVR",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "expected",
        "date": "Expected soon",
        "title": "Watch for: Funding announcement or operational update",
        "status": "pending",
        "icon": "\ud83d\udd2e"
      },
      {
        "type": "expected",
        "date": "Expected soon",
        "title": "Watch for: Volume expansion confirmation",
        "status": "pending",
        "icon": "\ud83d\udd2e"
      }
    ],
    "decision_matrix": {
      "decision": "WATCH",
      "reason": "\u23f3 Monitor for timing regime change or panic escalation",
      "checklist": [
        {
          "criterion": "Panic Score",
          "value": "40/100",
          "pass": false,
          "icon": "\ud83d\udfe2"
        },
        {
          "criterion": "Timing Regime",
          "value": "EARLY_BUILD",
          "pass": true,
          "icon": "\u2705"
        },
        {
          "criterion": "APEX Quality",
          "value": "61/100",
          "pass": true,
          "icon": "\u2b50"
        },
        {
          "criterion": "Data Confidence",
          "value": "50/100",
          "pass": true,
          "icon": "\ud83c\udfaf"
        },
        {
          "criterion": "Industry Pattern",
          "value": "3 active",
          "pass": true,
          "icon": "\ud83e\uddec"
        }
      ],
      "pass_rate": "4/5"
    },
    "contrarian_panic": {
      "total_score": 12,
      "band": "\u26aa LOW COMPRESSION (Early/Weak)",
      "components": {
        "compression": {
          "score": 3,
          "max": 40,
          "signals_30d": 1,
          "signals_60d": 1,
          "signals_90d": 1,
          "signals_per_week": 0.08,
          "total_signals": 1,
          "rsi_extreme_count": 0,
          "rsi_ultra_count": 0,
          "escalation_count": 0,
          "density_score": 3,
          "rsi_score": 0,
          "escalation_score": 0,
          "description": "0.1 signals/week | Early stage"
        },
        "intensification": {
          "score": 0,
          "max": 20,
          "pattern": "SINGLE_SIGNAL",
          "escalating": false
        },
        "volume_death": {
          "score": 0,
          "max": 15,
          "relative_volume": 1.94,
          "description": "Normal volume"
        },
        "pop_potential": {
          "score": 9,
          "max": 15,
          "best_historical_rally": 262.9,
          "avg_rally": 262.9,
          "signal_count": 1,
          "description": "Moderate performer (263%)"
        },
        "accumulation": {
          "score": 0,
          "max": 10,
          "has_accumulation": false,
          "bars_since_accum": 0,
          "description": "No accumulation detected"
        }
      },
      "ticker": "AVCT.L",
      "signal_date": "2022-02-14",
      "total_signals_history": 1
    }
  },
  "scoring_breakdown": {
    "apex_factors": [
      "Technical quality: +11 (AI_Technical_Score=9.0/20)",
      "Drawdown reversion potential: +17 (Drawdown_Pct=82.5%)",
      "Volume confirmation: +6 (Relative_Volume=1.9)",
      "Pattern reliability: +15 (Rally_Count=8.0)",
      "Upside history: +12 (best_rally_pct=263%)"
    ],
    "technical_score": {
      "points": 11,
      "ai_score": 9.0,
      "reason": "AI Technical Score 9.0/20 translates to 11/25 points"
    },
    "drawdown_score": {
      "points": 17,
      "drawdown_pct": 82.52,
      "reason": "Drawdown of 82.5% gives 17/20 points"
    },
    "volume_score": {
      "points": 6,
      "rel_volume": 1.94,
      "reason": "Relative volume 1.94x gives 6 points"
    },
    "pattern_score": {
      "points": 15,
      "rally_count": 8.0,
      "reason": "8.0 historical rallies gives 15/15 points"
    },
    "upside_score": {
      "points": 12,
      "best_rally_pct": 262.86,
      "reason": "Best rally of 263% gives 12/20 points"
    },
    "penalties": {
      "total": 0,
      "items": []
    }
  },
  "reasons_buy_sell": {
    "reasons_to_buy": [
      {
        "reason": "Early stage positioning offers best R:R if catalysts appear",
        "tag": "MED",
        "evidence": [
          "timing_regime=EARLY_BUILD",
          "current_return_pct=4.1%"
        ]
      },
      {
        "reason": "Proven winner - previously hit lock-in target",
        "tag": "MED",
        "evidence": [
          "lock_in_reached=True"
        ]
      }
    ],
    "reasons_to_sell": [
      {
        "reason": "Stale signal - not for active trading",
        "tag": "HIGH",
        "evidence": [
          "status=historical",
          "signal_date=2022-02-14"
        ]
      }
    ]
  },
  "trade_plan": {
    "trader_plan": {
      "style": "Watch / Starter",
      "action": "Wait for base + catalyst confirmation; starter position only",
      "sizing": "0-1% until CONFIRMED",
      "risk": "Invalidation = breaks recent lows / dilution / suspension",
      "profit_taking": "Scale out 25% at +15%, 25% at +50%, runner above"
    },
    "investor_plan": {
      "allowed": false,
      "thesis_conditions": "Unlock after AI triangulation + CONFIRMED timing",
      "hold_window": "N/A",
      "risk_management": "N/A"
    }
  },
  "exhaustion": {
    "regime": "EARLY_BUILD",
    "run_multiple": 0.02,
    "current_run_pct": 4.13,
    "avg_historical_run_pct": 262.86
  },
  "history_snapshot": {
    "previous_report_date": null,
    "score_change": null,
    "confidence_change": null,
    "new_events_count": 0,
    "new_rns_titles": []
  },
  "commentary": {
    "executive_summary": "This report runs in HISTORICAL-ONLY mode: triangulation (RNS/social/trends) not loaded. The setup shows EARLY_BUILD timing with 61/100 APEX score. Historical data shows 8 rallies averaging 263% upside. Current position: +4.1%. Your edge comes from waiting for AI Engine confirmation instead of blind entry.",
    "bull_case": [
      "Reliable pattern (8 previous rallies)",
      "Early regime often offers best risk/reward"
    ],
    "bear_case": [
      "Monitor for breakdown signals"
    ],
    "timing_translation": "Early accumulation phase. Watch for confirmation before committing size.",
    "confidence_explained": "Confidence 50/100 reflects full data quality with triangulation loaded."
  },
  "data_quality": {
    "sources_present": {
      "snapshot_json": false,
      "daily_enrichment_row": true,
      "historical_profile": true,
      "metadata": true,
      "triangulation_events": true,
      "ai_insights": false
    },
    "missing_data": [
      "AI insights from Groq LLM"
    ],
    "confidence_impact": "HIGH",
    "disclaimer": "Data provided as-is. Not financial advice. AIM micro-caps carry significant volatility risk."
  }
}